Cosmeceuticals and Cosmetic Ingredients 

Notice

Medicine  is  an  ever-changing  science.  As  new  research  and  clinical  experience  broaden  our  knowledge, 
changes in treatment and drug therapy are required. The authors and the publisher of this work have checked 
with sources believed to be reliable in their efforts to provide information that is complete and generally in 
accord with the standards accepted at the time of publication. However, in view of the possibility of human 
error or changes in medical sciences, neither the authors nor the publisher nor any other party who has been 
involved in the preparation or publication of this work warrants that the information contained herein is in 
every respect accurate or complete, and they disclaim all responsibility for any errors or omissions or for the 
results obtained from use of the information contained in this work. Readers are encouraged to confirm the 
information contained herein with other sources. For example and in particular, readers are advised to check 
the product information sheet included in the package of each drug they plan to administer to be certain that 
the information contained in this work is accurate and that changes have not been made in the recommended 
dose  or  in  the  contraindications  for  administration.  This  recommendation  is  of  particular  importance  in 
connection with new or infrequently used drugs.

Cosmeceuticals and Cosmetic Ingredients 

FIRST EdITIon

Leslie Baumann, MD
CEO, Baumann Cosmetic and Research Institute 
Miami, FL

Medical

New York    Chicago    San Francisco    Athens    London    Madrid    Mexico City
Milan    New Delhi    Singapore    Sydney    Toronto

Copyright © 2015 by McGraw-Hill Education. All rights reserved. Except as permitted under the United States Copyright Act of 1976, no part 
of this publication may be reproduced or distributed in any form or by any means, or stored in a database or retrieval system, without the prior 
written permission of the publisher, with the exception that the program listings may be entered, stored, and executed in a computer system, 
but they may not be reproduced for publication.

ISBN: 978-0-07-179399-5

MHID: 0-07-179399-2

The material in this eBook also appears in the print version of this title: ISBN: 978-0-07-179398-8,
MHID: 0-07-179398-4.

eBook conversion by codeMantra
Version 1.0

All trademarks are trademarks of their respective owners. Rather than put a trademark symbol after every occurrence of a trademarked name, 
we use names in an editorial fashion only, and to the benefit of the trademark owner, with no intention of infringement of the trademark. Where 
such designations appear in this book, they have been printed with initial caps.

McGraw-Hill Education eBooks are available at special quantity discounts to use as premiums and sales promotions or for use in corporate 
training programs. To contact a representative, please visit the Contact Us page at www.mhprofessional.com.

TERMS OF USE

This is a copyrighted work and McGraw-Hill Education and its licensors reserve all rights in and to the work. Use of this work is subject 
to these terms. Except as permitted under the Copyright Act of 1976 and the right to store and retrieve one copy of the work, you may not  
decompile,  disassemble,  reverse  engineer,  reproduce,  modify,  create  derivative  works  based  upon,  transmit,  distribute,  disseminate,  sell, 
publish  or  sublicense  the  work  or  any  part  of  it  without  McGraw-Hill  Education’s  prior  consent.  You  may  use  the  work  for  your  own  
noncommercial and personal use; any other use of the work is strictly prohibited. Your right to use the work may be terminated if you fail to 
comply with these terms.

THE  WORK  IS  PROVIDED  “AS  IS.”  McGRAW-HILL  EDUCATION  AND  ITS  LICENSORS  MAKE  NO  GUARANTEES  OR  
WARRANTIES  AS  TO  THE  ACCURACY,  ADEQUACY  OR  COMPLETENESS  OF  OR  RESULTS  TO  BE  OBTAINED  FROM  
USING THE WORK, INCLUDING ANY INFORMATION THAT CAN BE ACCESSED THROUGH THE WORK VIA HYPERLINK OR 
OTHERWISE, AND    EXPRESSLY  DISCLAIM ANY WARRANTY,  EXPRESS  OR  IMPLIED,  INCLUDING  BUT  NOT  LIMITED TO  
IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. McGraw-Hill Education and its 
licensors  do  not  warrant  or  guarantee  that  the  functions  contained  in  the  work  will  meet  your  requirements  or  that  its  operation  will  be  
uninterrupted or error free. Neither McGraw-Hill Education nor its licensors shall be liable to you or anyone else for any inaccuracy, error 
or omission, regardless of cause, in the work or for any damages resulting therefrom. McGraw-Hill Education has no responsibility for the 
content of any information accessed through the work. Under no circumstances shall McGraw-Hill Education and/or its licensors be liable for 
any indirect, incidental, special, punitive, consequential or similar damages that result from the use of or inability to use the work, even if any 
of them has been advised of the possibility of such damages. This limitation of liability shall apply to any claim or cause whatsoever whether 
such claim or cause arises in contract, tort or otherwise.

This  book  is  dedicated  to  Edmund  Weisberg,  my  Managing  Editor  for  over  a  decade 
 and a half.

This page intentionally left blank 

Contents

Preface   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xi
Acknowledgments   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiii

PART I:  Principles of Skin Care

Chapter 1.  The Importance of Skin Type: The Baumann Skin Type System   . . . . . . . . . . . . . . . . . . . . . . . . . . . . .1
Chapter 2.  Basic Cosmetic Chemistry   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5
Chapter 3.  Organic Ingredient Labeling   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .8
Chapter 4.  Cosmeceutical Marketing Claims   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .11
Chapter 5.  Epidermis and Dermis   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16

PART II:  The Ingredients

Section A:  Cleansing Agents   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

Chapter 6.  Overview of Cleansing Agents  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .19

Section B:   Moisturizing Agents   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21

Chapter 7.  Moisturizing Agents   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .21

Chapter 8.  Occlusives   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22

Chapter 9.  Oils   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .23

Chapter 10.  Argan Oil   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .25

Chapter 11.  Borage Seed Oil   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .28

Chapter 12.  Jojoba Oil   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .31

Chapter 13.  Mineral Oil   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .34

Chapter 14.  Olive Oil   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .37

Chapter 15.  Safflower Oil   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .41

Chapter 16.  Tamanu Oil   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .44

Chapter 17.  Petrolatum   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .48

Chapter 18.  Dimethicone and Silicones   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .51

Section C:  Barrier Repair Ingredients   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54

Chapter 19.  Barrier Repair Ingredients   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .54
Chapter 20.  Ceramides   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .57

Chapter 21.  Cholesterol   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .64

Chapter 22.  Lanolin   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .68

Chapter 23.  Stearic Acid   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .70

Chapter 24.  Humectants    . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .73

Chapter 25.  Glycerin   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .74

Chapter 26.  Hyaluronic Acid   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .77
Chapter 27.  Vitamin B5 (Pantothenic Acid/Dexpanthenol)   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .81
Chapter 28.  Urea   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .84

Chapter 29.  Aquaporin    . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .87

Chapter 30.  Ajuga Turkestanica   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .88

vii

viii 

  C o n t e n t s

Chapter 31.  Natural Moisturizing Factor   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .91

Section D: Skin Lightening Agents   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92

Chapter 32.  Overview of the Pigmentation Process   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .92

Chapter 33.  Overview of Melanin Production   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .93

Chapter 34.  Aloesin   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .95

Chapter 35.  Arbutin   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .97

Chapter 36.  Hydroquinone   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .100

Chapter 37.  Kojic Acid   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .105

Chapter 38.  Emblica Extract   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .108

Chapter 39.  Mulberry Extract   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .113

Chapter 40.  Vitamin C (Ascorbic Acid)   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .117

Chapter 41.  Cucumber   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .120

Chapter 42.  Lignin Peroxidase   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .123

Chapter 43.  Overview of the PAR-2 Receptor   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .125

Chapter 44.  Niacinamide   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .126

Chapter 45.  Soy   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .129

Section E: Antioxidants   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 135

Chapter 46.  Antioxidants   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .135

Chapter 47.  Green Tea   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .137

Chapter 48.  Rosa Damascena   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .145

Chapter 49.  Pycnogenol   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .148

Chapter 50.  Resveratrol   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .152

Chapter 51.  Flaxseed Oil   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .160

Chapter 52.  Phloretin   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .163

Chapter 53.  Caffeic Acid   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .166

Chapter 54.  Ferulic Acid   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .171

Section F: Vitamins   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176

Chapter 55.  Ascorbic Acid (Vitamin C)   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .176

Chapter 56.  Tocopherol (Vitamin E)   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .182

Section G: Other Ingredients   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
Chapter 57.  Coenzyme Q10   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .188
Chapter 58.  Coffeeberry   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .194

Chapter 59.  Ginger   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .198

Chapter 60.  Honey/Propolis/Royal Jelly   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .203

Chapter 61.  Idebenone   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .213
Chapter 62.  Melatonin   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .217

Chapter 63.  Peppermint   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .223

Section H: Anti-Inflammatory Agents   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227

Chapter 64.  Anti-Inflammatory Agents   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .227

Chapter 65.  Aloe Vera   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .229

Chapter 66.  Feverfew   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .238

Chapter 67.  Licorice Extract   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .244

Chapter 68.  Colloidal Oatmeal   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .253

Chapter 69.  Turmeric   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .257

Chapter 70.  Chamomile   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .265

Chapter 71.  Calendula   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .271

 
 
 
C o n t e n t s  

ix

Chapter 72.  Edelweiss   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .276

Chapter 73.  Lavandula   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .279

Chapter 74.  Horse Chestnut   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .284

Section I: Antiacne Ingredients    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 288

Chapter 75.  Overview of Acne   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .288

Chapter 76.  Benzoyl Peroxide  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .292

Chapter 77.  Tea Tree Oil   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .297

Chapter 78.  Salicylic Acid   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .301

Chapter 79.  Retinol, Retinyl Esters, and Retinoic Acid   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .306

Chapter 80.  Silver   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .311

Section J: Antiaging Ingredients    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  . 317

Chapter 81.  Overview of Aging   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .317

Chapter 82.  Hydroxy Acids    . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .322

Chapter 83.  Retinoids (Retinol)   . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .328

Index    .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .  .335

 
 
 
 
This page intentionally left blank 

Preface

This book was inspired by a passion for skin care, science, the 
history of the cosmeceutical industry, and almost two decades 
of  treating  patients  with  cosmeceutical  products.  Its  goal  is  to 
help  the  reader  understand  the  history  of  cosmeceutical 
ingredients, the science behind them, as well as the challenges 
of using them in a skin care regimen, and learn how to choose 
what  type  of  ingredients  are  appropriate  for  various  Baumann 
Skin  Types®.  This  book  is  meant  to  dispel  myths  and 
misperceptions  about  what  certain  ingredients  can  and  cannot 
do. It provides an unbiased, brand-agnostic approach to the sub-
ject. (I work for almost all of the companies and I do not have 
my own skin care line.) It will explain the various studies on the 
ingredients  and  provide  detailed  references  so  that  the  reader 
can go back and read the original study if they have doubts. It is 
divided into sections to help the reader classify ingredients in a 
simple manner; however, some ingredients work for more than 
one purpose. For this reason, we have provided two “Table of 
Contents”:  One  is  by  type  of  ingredient  such  as  cleanser, 
moisturizer, or antiaging agent, and the second is in alphabetical 
order  by  ingredient.  As  I  am  a  dermatologist  and  not  a 
formulator,  this  book  does  not  attempt  to  teach  you  how  to 
formulate skin care products, but instead helps you know what 
ingredients should work for various types of skin and why. In 
other words, we provide the ingredients, but we do not provide 
the  recipe.  In  order  to  understand  how  this  book  came  about 
and the passion that went into writing it, one must understand 
the history of my career as a cosmetic dermatologist. 

In  1997,  when  I  was  asked  by  William  Eaglstein,  MD, 
Chairman of the prestigious Department of Dermatology at the 
University  of  Miami,  to  become  the  Director  of  the  country’s 
first  Division  of  Cosmetic  Dermatology,  I  was  skeptical  at 
first. At that time, Botox and hyaluronic acid dermal fillers like 
Restylane  and  Juvéderm  had  not  yet  been  approved  by  the 
FDA  and  there  was  not  much  scientific  research  supporting 
skin care products (with the notable exception of the individ-
ual work by Drs. Albert Kligman, Jim Leyden, Sheldon Pinnell, 
and  Eugene  Van  Scott).  Dr.  Eaglstein  and  my  other  mentor,  
Dr. Francisco Kerdel, knew of my passion for skin care science 
and my love of the history of the cosmetic skin care industry. I 
collected  vintage  cosmetic  advertisements,  face  powders, 
soaps,  and  even  an  old  tin  of  Burt’s  Bees  furniture  polish.  I 
cherished books written by industry pioneers such as Helena 
Rubenstein,  Elizabeth  Arden,  Mary  Kay,  Estée  Lauder,  and 
Charles  Revson.  I  was  30  years  old,  with  lots  of  energy,  and 
was willing to accept the challenge. Drs. Eaglstein and Kerdel 
explained  that  they  had  heard  about  a  new  product  called 
“Botox” and thought “it might cause changes in the dermatology 
industry,  and  increase  interest  in  in-office  cosmetic  procedures 
and skin care.”

To put it into perspective, “skin care lectures” at that time 
consisted  of  subjective  opinions  and  little  data.  Companies 
just were not spending money and effort on researching their 
products  for  efficacy,  and  few  dermatologists  sold  skin  care 

products.  Rodan  and  Fields  had  recently  launched  Proactiv 
and  changed  the  way  people  thought  about  acne  treatments 
and proved that there was money to be made in the acne skin 
care business. I decided to join those rising to the challenge of 
raising the bar of cosmetic science and founded the Division 
of  Cosmetic  Dermatology.  Soon  thereafter,  our  department 
became the leading center for cosmetic dermatology research, 
performing  the  research  trials  that  led  to  FDA  approval  of 
Botox,  Dysport,  Hylaform,  Juvéderm,  Sculptra,  Voluma,  Tri-
Luma,  and  many  other  products  and  procedures.  I  began 
studying  cosmetic  skin  care  products  for  over  50  companies 
such as Elizabeth Arden, Unilever (Ponds and Dove), Johnson 
and  Johnson  (Neutrogena,  Aveeno,  Roc),  and  L’Oréal  and 
served  on  numerous  advisory  boards  and  committees.  My 
vintage  compact  collection  grew  as  did  my  experience  and 
knowledge.

In 2001, I began writing a monthly column called “Cosme-
ceutical Critique” on cosmetic ingredients for Skin and Allergy 
News, a journal for dermatologists. I still write this column and 
it can be found online. In 2002, I published the first textbook 
devoted  to  cosmetic  dermatology,  Cosmetic  Dermatology: 
Principles  and  Practice  (McGraw-Hill),  which  has  been  trans-
lated  into  several  languages  and  is  the  bestselling  cosmetic 
dermatology book in the world. In 2004–2005, I developed a 
skin  typing  system  used  to  divide  patients  into  16  unique 
“Baumann  Skin  Types®”  that  are  used  to  properly  match 
ingredients and products to skin type. This system resulted in 
a  New  York  Times  bestselling  book  The  Skin  Type  Solution 
(Bantam, 2005) and a PBS Special of the same name in 2010. 
During this time, I ran a busy cosmetic dermatology clinic and 
saw  6,000  to  7,000  Botox  and  filler  patients  a  year  –  all  of 
whom  were  put  on  customized  skin  care  regimens  using  the 
skin typing system. Doctors around the world began using the 
Baumann Skin Typing System in their practices and giving us 
data  and  feedback.  The  skin  typing  system  is  described  in 
Chapter  1  of  this  book  and  in  several  leading  textbooks  and 
multiple publications in the fields of dermatology, plastic sur-
gery, and facial plastic surgery.

In 2009, my team developed www.virtualtrialfacility.com, 
a website that allows people to register to try various skin care 
products and provide an unbiased opinion. This online survey 
system,  my  live  clinical  research  trials,  and  my  busy  clinical 
practice, allowed me to test different ingredients on the vari-
ous  Baumann  Skin  Types  and  identify  which  ingredients 
worked best in each setting. I was able to test and “type” tens 
of  thousands  of  skin  care  products  around  the  world.  The 
“SkinIQ” quiz that was developed in 2003–2005 was tested on 
hundreds  of  thousands  of  people  online  and  in  dermatologic 
practices  around  the  world.  In  2009–2010,  we  found  that 
when  the  Baumann  Skin  Typing  System  was  used  in  derma-
tology practices to prescribe skin care products, product return 
rates  were  significantly  lowered  and  patient  outcomes  were 
improved.

xi

xii 

  P r e f a Ce

By 2012, my Yahoo blog at www.skinguru.com had over  
3  million  readers  –  many  of  whose  comments  revealed  that 
there  was  still  much  misinformation  about  skin  care  science 
and  people  just  did  not  know  who  or  what  to  believe.  It 
seemed  that  all  of  the  “experts”  had  something  to  sell,  and 
even dermatologists were getting confused. I realized that der-
matologists  did  not  have  the  time  in  their  busy  schedules  to 
adequately  educate  their  patients  on  the  multiple  important 
details  of  skin  care.  That  year,  we  launched  STS  Franchise 
System,  LLC,  a  turn-key  skin  care  retail  solution  for  medical 
practices  that  identifies  and  tests  products  from  around  the 
world and matches them to the 16 Baumann Skin Types.

All  of  these  activities  and  experiences  led  to  the  knowl-
edge that there is no unbiased encyclopedic reference of cos-
meceutical  ingredients  that  helps  aestheticians,  skin  care 
specialists, and doctors properly match cosmeceutical ingredi-
ents to skin type. 

After 14 years of writing my monthly column on cosmeceu-
tical  ingredients  for  dermatologists  and  researching  skin  care 

products  for  the  STS  Franchise  system,  I  decided  to  put  all  of 
my ingredient knowledge together in one place. Thanks to my 
managing  editor  Edmund  Weisberg,  we  were  able  to  rewrite 
and  update  the  “Cosmeceutical  Critique”  columns,  add  new 
chapters, and organize them into a manageable structure. This 
project  has  been  a  labor  of  love  and  the  book  is  much  longer 
than originally planned because I just could not stop adding in-
gredients.  I  had  to  choose  my  favorite  ingredients  because  of 
space constraints, so not all ingredients are included. I hope that 
whether you are a doctor, aesthetician, nurse, cosmetic scientist, 
skin care retailer, or a lover of skin care technology and science 
that this book will help you understand the fascinating science 
of cosmeceuticals. We have set up a YouTube channel at you-
tube.com/ingredientbook  and  will  post  videos  to  supplement 
some of the information in this book and keep you up to date. 

My goal with this book is to empower you to understand 
cosmeceutical  science  so  that  you  can  decipher  marketing 
claims  and  make  better  skin  care  decisions  for  your  patients, 
your clients, your family, and yourself. 

 
 
 
Acknowledgments

I met Edmund in the late 1990s when he was an editor for my 
monthly column at the dermatology magazine Skin and Aging. 
We developed a great rapport and enjoyed working together. 
One  day  he  suggested  that  I  write  a  textbook  on  cosmetic 
dermatology. I had no idea how to do a book proposal and he 
generously  offered  to  help  me.  We  decided  to  send  the 
proposal to McGraw-Hill because they were the publisher of 
all  of  the  great  medical  books,  such  as  Harrison’s  Principles  of 
in  General 
Internal  Medicine  and  Fitzpatrick’s  Dermatology 
Medicine. We were thrilled to get a book deal with them and 
wrote and published the first edition of Cosmetic Dermatology 
in  2002.  It  rapidly  became  a  bestseller.  Somewhere  during 
that  time,  I  was  asked  to  write  a  column  in  Skin  and  Allergy 
News  and  I  asked  Edmund  to  become  my  editor.  We  have 
worked  together  for  over  15  years  now  on  various  projects 
including  the  “Cosmeceutical  Critique”  column  that  led  to 
this  book.  We  are  currently  working  on  the  3rd  edition  of 

Cosmetic Dermatology – which remains the bestselling cosmetic 
dermatology textbook in the world. We share a love of litera-
ture, food, and chocolate and have become good friends. Al-
though  Edmund’s  title  is  Managing  Editor,  his  role  was  far 
more.  He  functioned  as  a  research  assistant,  cowriter,  and 
psychologist  throughout  the  process.  Although  this  book  is 
finished,  I  anticipate  continuing  working  with  Edmund  for 
years to come. 

Thank you Edmund – you are one of the easiest people to 
work  with  that  I  have  ever  met.  You  are  reliable,  organized, 
funny, and if you get stressed out – I never see it. It is so funny 
when  you  make  fun  of  my  misspellings  and  typos  and  turn 
them into jokes. Your limericks keep me laughing and your en-
thusiasm  keeps  me  writing.  We  are  a  great  team  and  I  look 
forward to many more years of working together.

Leslie Baumann 

xiii

This page intentionally left blank 

Cosmeceuticals and Cosmetic Ingredients

This page intentionally left blank 

C H A P T E R  1  ■   T H E   I M P O R TA N C E   O F   S K I N  T Y P E : T H E   B A U M A N N   S K I N  T Y P E   S Y S T E M  

1

C H A P T E R   1

The Importance of Skin Type: The Baumann 
Skin Type System

The  Baumann  Skin  Type  System  (BSTS)  is  a  skin-type 
classification system comprised of 16 distinct skin phenotypes. 
This approach to categorizing skin type was developed in 2004 
by dermatologist Leslie Baumann, M.D., to subdivide research 
participants  into  specific  distinct  phenotypes  in  order  to 
facilitate data collection and analysis as well as subject recruit-
ment. The 16 Baumann Skin Types have been used in genetic 
research aimed at identifying the genes that contribute to skin 
characteristics  such  as  dryness,  oiliness,  aging,  pigmentation, 
and sensitivity. The BSTS optimizes communication between 
researchers,  dermatologists,  cosmetic  scientists,  aestheticians, 
advertisers,  consumers,  and  educators.  The  classification 
system  has  been  adopted  by  aestheticians,  dermatologists, 
consumers,  and  retailers  worldwide  to  match  cosmeceutical 
ingredients and skin care product recommendations to specific 
skin types. It is applicable to all ethnicities, ages, and genders.
The Baumann Skin Type (BST) is determined by a scientifi-
cally validated questionnaire, known as the Baumann Skin Type 
Indicator  (BSTI).  In  the  United  States,  the  16  Baumann  Skin 
Types have been the subject of the New York Times bestselling 
book The  Skin  Type  Solution (Bantam 2005, 2010) and a public 
television  special  Skin  Type  Solutions  with  Dr.  Leslie  Baumann 
(2010, 2011). The Skin Type Solution has also been published in 
other countries including Australia, the United Kingdom, Brazil, 
Turkey, China, Vietnam, and South Korea.

BST  can  change  with  the  use  of  a  new  skin  care  regimen, 
advancing age, travel or a move to a different geographic location, 
or a change in hormone status. It is recommended that patients 
retake  the  BSTI  when  one  of  these  changes  has  occurred  or 
when  one’s  current  skin  care  regimen  does  not  seem  to  be 
working.

 THE PARAMETERS

The  BSTS  is  based  on  the  identification  and  combination  of 
four main skin characteristics or parameters that apply to facial 
skin:

1.  Dry versus Oily

2.  Sensitive versus Resistant

OSPW

OSPT

OSNW

OSNT

ORPW

ORPT

ORNW

ORNT

DSPW

DSPT

DSNW

DSNT

DRPW

DRPT

DRNW

DRNT

▶

FIGURE 1-1  The 16 Baumann skin types.

and  challenges,  and  dictate  the  courses  of  prevention  and 
treatment.  It  is  crucial  to  take  all  four  of  the  factors  into 
consideration when evaluating facial skin. 

Color Dot System
In order to simplify the BSTS, a color dot system was devel-
oped  that  assigns  a  color  and  number  to  each  skin  type. 
Consumers,  cosmetic  companies,  and  retailers  can  use  this 
color  dot  system  to  effectively  communicate  using  mobile 
applications, web sites, product labels, shelf displays, or other 
visual aids (Figure 1-2).

Weight and Severity of the Parameters
Each of these four parameters is weighted to indicate the sever-
ity of each of the relevant skin issues. The calculations used to 
determine these scores and the resulting skin type are proprie-
tary and were developed after years of research, and are also 
beyond the scope of this chapter. Suffice it to say that the BSTI 
questionnaire that determines skin type is preferentially tallied 
by a computer program that takes several factors into account. 
A complicated mathematical formula is used in the process to 
analyze the BSTI scores and to determine the BST designations. 

3.  Pigmented  (uneven  skin  toned)  versus  Non-pigmented 

(even toned)

4.  Wrinkle prone versus Tight (non-wrinkle prone).

One option from each of these parameters is assigned to the 
BST; therefore, 16 possible skin types emerge from the four skin-
type parameters (Figure 1-1). For example, one BST is DSPW or 
dry, sensitive, pigmented, and wrinkled while another is ORNT 
or  oily,  resistant,  non-pigmented,  and  tight.  The  16  skin 
phenotypes are much more than just different combinations of 
basic skin characteristics. The individual parameters interact and 
express  themselves  in  16  unique  skin  “syndromes”  that 
predispose  certain  skin  types  to  specific  dermatological  issues 

 SKIN HYDRATION: DRY (D) VERSUS OILY (O)
In the BSTS, the D or O designation is designed for simplicity 
of  use.  However,  the  designation  of  D  versus  O  is  actually 
much more complex than it seems at first glance.

Score Numbering of the Dry and Oily Skin Types
A dry skin type is assigned a 1-4 numerical value depending on 
the  way  the  questions  are  answered  in  the  questionnaire.  A 
higher  number  indicates  severe  dryness  and  a  lower  number 
indicates slight dryness. A D3, for example, is much dryer than 
a D2. Similarly, an oily skin type is also assigned a 1-4 numerical 

 
2 

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

1

5

9

DSPT

OSPT

2

6

DSNT

OSNT

3

7

DSPW

OSPW

4

8

DSNW

OSNW

ORPT

10

ORNT

11

ORPW

12

ORNW

13

DRPT

14

DRNT

15

DRPW

16

DRNW

▶

FIGURE 1-2  Each Baumann skin type is assigned a color and a number.

value.  Accordingly,  a  higher  number  indicates  severe  oiliness 
and a lower number indicates slight oiliness. An O3, for exam-
ple, is much oilier than an O2.

Dry Skin
Dry skin is characterized by the lack of moisture in the stratum 
corneum (SC). Water is the major plasticizer of the skin, and 
when levels are low, cracks and fissures occur.1 The increase in 
transepidermal water loss (TEWL) that leads to dry skin results 
when  a  defect  in  the  permeability  barrier  allows  excessive 
water to be evaporated off of the skin and lost to the atmos-
phere. Dry skin is a result of decreased water content in the SC, 
which  leads  to  abnormal  desquamation  of  corneocytes  and, 
eventually, to skin roughness.2 For the skin to appear and feel 
normal,  the  water  content  of  the  SC  must  be  greater  than 
10 percent.3 When the water level in skin is less than 10 percent, 
study  subjects  experience  symptoms  that  we  specifically  ask 
about  in  the  BSTI.  Questions  about  these  symptoms  were 
developed and shown to correlate with TEWL in skin.4

Many factors play a role in skin hydration. Sebum produc-
tion  is  an  important  one,  but  certainly  not  the  determining 
factor of dry skin. Sebum creates a lipid-based occlusive film on 
the skin, which has an effect on skin hydration by preventing 
water  evaporation  from  the  skin.5  However,  those  with 
decreased  sebum  production  will  not  be  designated  as  a  “D” 
(dry) skin type if TEWL and skin water content are within nor-
mal limits.

Oily Skin
Diet, stress, and hormones play a role in sebum production, but 
there is a significant genetic link,6 and twin studies have shown 
that  identical  twins  have  similar  sebum  secretion  rates.  In 
humid climates, the sebum is more fluid and subjects perceive 
sebum secretion to be greater even if it is not. Studies have also 
shown that subjects are unable to correctly estimate the amount 
of sebum secretion on their skin in many cases.7 To validate the 
BSTI, studies were performed to evaluate questions answered 
by subjects about their perception of skin oiliness in order to 
identify  which  questions  correlated  with  actual  measured 
sebum secretions using a Sebumeter®. It was found that certain 
combinations of questions could correctly determine whether a 
subject was a low, medium, or high producer of facial sebum.8 
Greatly increased sebum production causes an oily skin pheno-
type that is designated as an “O” for “oily” in the BSTS. 

Combination Skin
There are two main types of combination skin: 1) skin that is dry 
for parts of the year and oily during other parts of the year; and 
2) skin that is oily in the T-zone and dry on the sides of the face.

SEASONAL SKIN  Skin that is dry for one part of the year and 
oily during another part of the year likely has a defect in TEWL 
that worsens in low-humidity conditions such as winter. Such 
skin requires heavier moisturizer use in winter or in a dry cli-
mate. This skin type is the most impacted by geographic and 
weather changes and will likely require two skin regimens, one 
for humid climates, and one for dry climates and during winter. 
Individuals  with  such  skin  will  test  differently  on  the  BSTI 
depending on the climate in which they are when taking the 
questionnaire.  They  may  be  O  types  in  the  summer  and  D 
types  in  the  winter.  For  this  reason,  when  the  questions  are 
answered on the BSTI, they should be answered according to 
how the skin is behaving at the time the BSTI is taken.

T-ZONE SKIN  Skin that is oily in the T-zone and dry on the sides 
has decreased TEWL that is offset in the T-zone by increased 
sebum  production.  Individuals  with  such  skin  need  cleansers 
that will strip excess oil from the T-zone combined with mois-
turizers that will improve the skin barrier without being occlu-
sive.  This  type  of  combination  skin  type  usually  remains  the 
same until middle age, when hormone activity changes.

Combination skin types will be designated as O or D depend-
ing on which deficiencies are found by the BSTI questionnaire. 
In some cases, the T-zone type of combination skin would ben-
efit by applying moisturizers only to the dry parts of the skin, 
avoiding the T-zone.

Normal Skin
Normal  skin  types  are  designated  as O1 in the  BSTS. Normal 
skin displays a normal baseline level of sebum secretion and an 
intact skin barrier with normal TEWL. Therefore, it does not 
receive the dry designation, but instead receives the designation 
of “O1” to illustrate the normal function of the sebum glands. 
Conversely, skin with below normal sebum secretion, an intact 
skin barrier, and normal TEWL receives a designation of “D1.” 
Individuals with such skin may believe they have normal skin 
but in reality external moisturizing agents would be beneficial 
to  them  to  compensate  for  the  lack  of  sebum  production,  so 
they are designated as a dry type.

 
C H A P T E R  1  ■   T H E   I M P O R TA N C E   O F   S K I N  T Y P E : T H E   B A U M A N N   S K I N  T Y P E   S Y S T E M 

3

 SKIN SENSITIVITY: SENSITIVE (S) 
VERSUS RESISTANT (R)

Resistant Skin
Resistant skin has a strong SC that confers protection to skin 
cells,  keeping  allergens  and  other  irritating  substances  out.  It 
rarely develops erythema unless sunburned, and rarely devel-
ops acne. Those with resistant facial skin can usually use any 
skin care product without developing a rash, acne, or a stinging 
sensation. However, resistant skin may also be impervious to 
penetration of active ingredients so that it is more difficult to 
see beneficial effects from less concentrated products.

SCORE NUMBERING OF RESISTANT SKIN  Resistant skin is not 
weighted like sensitive skin. That is, a person either has resist-
ant skin or not. In the BSTS, resistant skin is defined as skin that 
does not show signs of inflammation. Resistant skin that also 
exhibits D2 or D3 characteristics would be suspected to have an 
impaired skin barrier, but because inflammation is absent, the 
skin type is considered resistant. Either the skin’s dryness is not 
caused by an impaired barrier, but by a defect in natural mois-
turizing factor, aquaporin, or a yet to be discovered ailment, or 
the  skin  has  some  sort  of  mechanism(s)  protecting  it  from 
inflammation. Regardless of the reason, the skin would be con-
sidered  resistant  to  inflammation.  On  the  other  hand,  if  the 
skin exhibits O2 or O3 characteristics and is resistant, then the 
person has protective mechanisms against acne. For some rea-
son,  this  person  either  has  less  Propionibacterium  acnes  in  the 
presence of copious sebum, or has an internal protective mech-
anism  against  acne  in  the  presence  of  bacteria  and  sebum. 
Absence of acne, rosacea, stinging sensations, and dermatitis in 
combination  with  other  characteristics  gives  important  clues 
about underlying mechanisms that determine skin type.

Sensitive Skin
In  the  early  1990s,  more  than  40  percent  of  patients  were 
claiming to have sensitive skin,9 with healthy, premenopausal 
women presenting with this complaint more often than other 
demographic  groups.  However,  the  number  of  people 
presenting  with  such  complaints  has  steadily  increased, 
particularly among men,10 in the last two decades. In addition, 
a majority of women in the United States, Europe, and Japan 
are thought to believe that they have sensitive skin.11 In fact, a 
2009  study  with  1,039  subjects  revealed  a  68.4  percent 
prevalence  of  self-reported  sensitive  skin,  with  no  gender 
differences observed.10 Finding the best skin care product for a 
particular manifestation of sensitive skin is complicated by the 
fact that there are five very different subtypes of sensitive skin:

1.  acne subtype

2.  rosacea subtype

3.  stinging subtype 

4.  allergic subtype

5.  seborrheic dermatitis.

It  is  important  to  note  that  inflammation  is  the  common 
denominator among all sensitive skin subtypes. Sunburn suscep-
tibility is not considered a factor in the sensitive skin designation 
in this skin-typing system.

SCORE  NUMBERING  OF  THE  SENSITIVE  SKIN  TYPES  The  S 
score is calculated differently than the other parameters. Each 

subtype  of  sensitive  skin  contributes  a  number  to  the  score. 
For example, an individual with acne would be designated as 
S1 while an individual with stinging would be S3. Combinations 
are possible, so, for example, an individual with acne, rosacea, 
and stinging would be S1S2S3. These numbers do not indicate 
severity;  however,  a  subject  with  more  than  one  subtype 
would  suffer  from  more  skin  problems  than  a  subject  with 
only one subtype.

 COMBINING THE D/O AND S/R 
PARAMETERS

Eczema
Patients with an impaired skin barrier, manifested by dry skin, 
are more likely to suffer from eczema, which is now known to 
be a genetic defect of filaggrin. Those with eczema often test 
out  as  having  a  DS4  or  DS3S4  skin  type.  Subjects  that  do  not 
have  eczema  but  experience  allergic  reactions  to  allergens 
placed on the skin often also have dry skin because they have 
an impaired barrier.12 These skin types are designated as DS4.

Acne
People with OR types may have a pimple here and there, but 
do not suffer frequently from acne. For this reason, we know 
that oil alone is not enough to cause acne. Other factors such as 
genetic predisposition, high volume of P. acnes, and abnormal 
keratinization must be present. Although most S1 types are also 
classified as oily (OS1), there are some acne sufferers that have 
dry  skin  (DS1).  Individuals  with  DS1  skin  have  very  different 
skin care needs than acne sufferers with oily skin (OS1). This is 
one of many reasons that all four of the BSTS parameters must 
be identified before a skin care regimen is prescribed.

Rosacea
S3  types  experience  stinging  of  the  skin.  Those  with  rosacea 
(S2),  and  dry  skin  (D)  often  experience  stinging.  Therefore, 
DS2S3 is a common skin type for those with rosacea.

 SKIN PIGMENTATION: PIGMENTED (P) 
VERSUS NON-PIGMENTED (N)

This parameter measures the proclivity to develop unwanted 
solar-induced dark patches on the face, known as melasma or 
solar  lentigos.  These  can  be  prevented  and  treated  with  skin 
care products and procedures. While intrinsic or genetic factors 
contribute  to  uneven  pigmentation,  extrinsic  factors  such  as 
ultraviolet light and heat play an important role. 

Score Numbering of the Pigmented Skin Types
A pigmented skin type may be assigned a 1-4 numerical value 
depending on how likely the skin is to develop skin pigmentation 
issues  such  as  postinflammatory  hyperpigmentation  or  mel-
asma.  This  score  can  be  used  to  screen  candidates  for 
dermatologic procedures in order to predetermine their risk for 
dyspigmentation after a procedure. The higher number indicates 
a higher risk for dyschromia and the lower number indicates less 
risk. An individual designated P4, for example, would not be a 
good candidate for laser resurfacing procedures. The designation 
P for pigmented is often used without a number when used for 

 
4 

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

the purpose of recommending skin care. Individuals with P skin 
types will benefit from skin-lightening ingredients.

prone  to  rosacea,  stinging,  and  wrinkles).  The  letters  are  an 
extremely  accurate  way  to  categorize  skin  types  in  order  to 
properly prescribe treatments and follow results.

 SKIN ELASTICITY: WRINKLED (W) 
VERSUS TIGHT (T)

This parameter is affected by age and ethnicity in addition to 
lifestyle habits; however, this is the only BSTS parameter over 
which  an  individual  has  significant  control.  That  is,  while  a 
person  cannot  alter  the  genetic  component  of  skin  aging,  an 
individual can certainly change her/his behavior to reduce the 
risk  of  incurring  exposure  to  and  manifesting  the  signs  of 
extrinsic aging, which is due to external factors such as smok-
ing, excessive use of alcohol, poor nutrition, and, most impor-
tantly,  sun  exposure.  In  fact,  80  percent  of  facial  aging  is 
ascribed to sun exposure.13

 COMBINING THE P/N AND W/T 
PARAMETERS

Photoaging
The  pigmented  lesions  caused  by  sun  exposure  are  typically 
associated with other signs of skin aging such as wrinkles, so a 
person with a P skin type and a significant history of sun expo-
sure  often  falls  into  the  W  category.  Photoaged  skin  would 
likely be designated as a PW type.

 COMBINING THE PARAMETERS TO 
DESIGNATE BAUMANN SKIN TYPE

BST is calculated by a software program that assigns one letter 
from each parameter and, if applicable, a sensitive subtype, as 
described  above.  One  example  of  the  former  designation  is 
DRPW  (dry,  resistant,  pigmented,  and  wrinkle  prone),  while 
DS2S3NW is an example of the latter (dry, non-pigmented type 

 DETERMINING THE BAUMANN SKIN TYPE
The  BSTI  questionnaire  is  the  only  validated  method  to  deter-  
mine  BST.  It  is  constantly  updated  as  new  data  are  considered 
and  the  software  increases  in  sophistication.  The  most  recent  
version of the BSTI is available at www.skintypesolutions.com.

REFERENCES

1.  Takahashi  J,  Kawasaki  K,  Tanaka  M,  et  al.  The  mechanism  of 
stratum  corneum  plasticization  with  water.  In:  Marks  R,  Payne 
PA, eds. Bioengineering and the Skin. Lancaster: Cardiff MTP Press 
Limited; 1980:67–73.

2.  Wildnauer RH, Bothwell JW, Douglass AB. Stratum corneum bio-
mechanical properties. I. Influence of relative humidity on normal 
and  extracted  human  stratum  corneum.  J  Invest  Dermatol. 
1971;56:72.

3.  Draelos  ZD.  Therapeutic  moisturizers.  Dermatol  Clin. 

2000;18:597.

4.  Data on file Baumann Cosmetic and Research Institute (a).
5.  Orton DI, Wilkinson, JD. Cosmetic allergy: Incidence, diagnosis, 

and management. Am J Clin Dermatol. 2004;5:327.

6.  Mehta SS, Reddy BS. Cosmetic dermatitis – Current perspectives. 

Int J Dermatol. 2003;42:533.

7.  Youn SW, Kim SJ, Hwang IA, et al. Evaluation of facial skin type 
by  sebum  secretion:  discrepancies  between  subjective  descrip-
tions and sebum secretion. Skin Res Technol. 2002;8:168.
8.  Data on file Baumann Cosmetic and Research Institute (b).
9.  Jackson  EM.  The  science  of  cosmetics.  Am  J  Contact  Dermat. 

1993;4:108.

10.  Farage MA. How do perceptions of sensitive skin differ at differ-
ent anatomical sites? An epidemiological study. Clin Exp Dermatol. 
2009;34(8):e521.

11.  Kligman  A.  Human  models  for  characterizing  “Sensitive  Skin.” 

Cosm Derm. 2001;14:15.

12.  Jovanovic  M,  Poljacki  M,  Duran  V,  et  al.  Contact  allergy  to 
Compositae plants in patients with atopic dermatitis. Med Pregl. 
2004;57:209.

13.  Uitto  J.  Understanding  premature  skin  aging.  N  Engl  J  Med. 

1997;337:1463.

 
C H A P T E R  2  ■   B A S I C   CO S M E T I C   C H E M I S T RY  

5

C H A P T E R   2

Basic Cosmetic Chemistry

There are entire books, courses, and academic societies dedi-
cated to cosmetic chemistry. This chapter is intended to cover 
the basics only. Understanding these few basic chemistry items 
is crucial in order to decipher the language used in reference to 
personal care products.

 COSMETIC INGREDIENT NOMENCLATURE

The cosmetic industry uses nomenclature that differs from that 
established  by  the  International  Union  of  Pure  and  Applied 
Chemistry (IUPAC), which is taught in organic chemistry. The 
Cosmetic  Toiletry  and  Fragrance  Association,  which  changed 
its name to the Personal Care Products Council in 2007, com-
piled  a  standardized  list  of  ingredients  and  published  it  in 
1973.1  This  system  is  now  known  as  the  International 
Nomenclature of Cosmetic Ingredients (INCI). A comprehen-
sive description of this system appears in Chapter 4 of Beginning 
Cosmetic  Chemistry.2  Understanding  the  stem  terms  facilitates 
reading product labels. For the most up-to-date information on 
INCI  nomenclature,  visit  the  website  for  the  Personal  Care 
Products  Council  (http://www.personalcarecouncil.org/).  In 
some cases, the nomenclature varies between the United States 
(US) and the European Union (EU). Botanical ingredients (those 
derived from plants), in particular, are labeled differently in the 
US and the EU. In the EU, the Latin binomial (genus and spe-
cies names) is used, while in the US the name includes the Latin 
binominal, the common name of the plant, the plant part, and 
the type of preparation. Oatmeal extract is a good example to 
illustrate the divergent approaches to classification. In the EU, 
the INCI name for oatmeal extract is Avena Sativa. In the US, 
the INCI name is Avena Sativa (Oat) Kernel Extract. The big-
gest differences between names in the US and EU seem to be 
found  in  the  names  of  botanicals,  colorants,  denatured  alco-
hols, fragrances, and flavors.3

 SIGNIFICANCE OF THE pH

Measurements of pH are used both in formulating and testing 
product  stability.  The  pH  of  skin  or  hair  is  also  a  necessary 
consideration in cosmetic chemistry. pH is the measure of the 
activity of the hydrogen atom.

Measure of the activity of the hydrogen atom:

pH log (a )

=Η +

= −

10

log

10





1
a

H

+





The higher the pH, the more basic or alkaline is the solution; 
the lower the pH, the more acidic the solution. The irritation or 
stinging induced by a product is often directly related to how 
low the pH is.

Obviously, pH is an important consideration when formulat- 
ing  personal  care  products.  It  affects  shelf  stability,  bacterial 
growth,  how  well  ingredients  combine,  and  how  the  product 
interacts with skin or hair. Measurements of pH can be used to 
reflect the stability of a product. For example, if components in 

the  product  hydrolyze,  free  acid  would  be  released,  which 
would  lower  the  pH  of  the  formulation  and  provide  evidence 
that ingredient degradation has occurred. Changes in pH during 
shelf life can promote bacterial and fungal growth in the formu-
lation. The pH of exfoliating skin care products such as hydroxy 
acids  affects  their  efficacy.  Acid  products  with  a  lower  pH  are 
more likely to cause exfoliation than a neutral pH preparation. 
(Water, for example, has a pH of 7.) The pH of a formulation can 
also play a role in the penetration of cosmetic ingredients into 
the  stratum  corneum.  It  is  well  known  that  ascorbic  acid 
penetrates best at a pH of 2.0.4

 ACID DISSOCIATION CONSTANT, 
Ka AND pKa-

The pKa of a substance is a quantitative measure of the strength 
of an acid in solution and it measures the capacity of that sub-
stance to donate protons. If HA is an acid, it can dissociate into 
its conjugate base (A-) and a hydrogen ion (H+). H+ is essen-
tially a proton.

The generic acid HA dissociates into A- and H+.

HA ⇌ A– + H+

The larger the value of the pKa, the less dissociation occurs; 
therefore,  a  weak  acid  has  a  high  pKa.  A  strong  acid  has  a  
pKa ≤ to -2.

The  equations  used  to  calculate  the  Ka and  the  more  com-

monly used pKa:

The dissociation constant called the Ka is written in mol/L:

aK =

+
−
[A ][H ]
[HA]

It is more common to use a logarithmic measure of the acid 

dissolution constant called the pKa:

pKa = -log 10Ka

Another way to think about the acid dissociation constant is 
that the pKa is the pH at which the level of free acid is the same 
as the level of the salt form of the acid. When the pH is less than 
the pKa, the free acid form predominates; when the pH is greater 
than the pKa, the salt form predominates.

The  concept  of  pKa  is  important  in  formulating  cosmetic 
products. It is particularly pertinent when talking about products 
with exfoliating or peeling capabilities such as  a -hydroxy acid 
(AHA) or b -hydroxy acid (BHA). In order to use AHAs and BHA 
properly, one must understand the pKa and how the pH of a peel 
affects its efficacy. In the case of peeling agents, the acid form of 
the cosmetic ingredient is the “active form” in the peel because it 
provokes  exfoliation.  The  proper  balance  of  the  salt  and  acid 
forms  is  necessary  in  order  to  yield  an  efficacious  peel  with 
minimal irritation. The pKa for salicylic acid is 2.97 while 3.83 is 
the pKa for the array of AHAs.5,6 Because the pKa of BHA differs 
from that of the AHA family, it is difficult to formulate an AHA 
and BHA combination product that can achieve an optimal pH. 

 
6 

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

For example, in a combination AHA–BHA product with a pH of 
3.5,  the  AHA  acid  form  would  predominate  but  the  BHA  salt 
form  would  predominate.  The  effects  of  BHA  would  be  ren-
dered suboptimal.

 MAILLARD REACTION OR GLYCATION

The Maillard reaction is a chemical reaction between an amino 
acid  and  a  sugar  that  is  also  known  as  glycation.  It  usually 
requires heat. Louis-Camille Maillard first described this reac-
tion in 1912 when he observed that amino acids can react with 
sugar  to  create  brown  or  golden  brown  compounds.  The 
Maillard  reaction  is  a  well-known  phenomenon  in  cooking 
because it changes the flavors in food. Caramelizing sugar or 
onions, browning a turkey, and baking cookies all involve this 
process. In the personal care product world, the Maillard reac-
tion is demonstrated in the darkening of skin that occurs with 
sunless  tanning  products  that  contain  dihydroxyacetone 
(DHA). Scientists did not recognize the importance of glycation 
in health until the 1980s. Currently, many antiaging products 
are  designed  to  prevent  this  response  because  the  Maillard 
reaction can lead to protein crosslinks thought to contribute to 
aging and cancer in the skin and other organs.

Chemistry of the Maillard Reaction
In the Maillard reaction, heat and other circumstances cause a 
molecule of sugar to open its structure and glue itself (glycate) to 
a  protein  molecule.  This  sugar  +  protein  molecule  is  called  a 
Schiff base (Figure 2-1). The Schiff base is unstable and rapidly 
degrades to a more stable structure called an Amadori product. 
Amadori  products  can  cause  proteins  to  crosslink  each  other, 
which is the source of the problem. These crosslinked proteins 
are called advanced glycation endproducts or AGEs (Figure 2-2). 
Free  radicals  enhance  this  process  resulting  in  an  increased 
amount  of  dangerous  AGEs.  Many  have  touted  the  use  of 
antioxidants  as  a  method  of  preventing  AGEs.  Although 
antioxidants are beneficial for many reasons, they do not seem 
helpful  in  preventing  the  glycation  process  primarily  because 
once  the  Schiff  base  is  formed,  it  is  highly  unstable.  Using 
antioxidants may result in blocking one pathway, but the Schiff 
base  is  free  to  move  down  another  pathway  still  amassing 
harmful AGEs.

Glucose

Protein

Schiff base

1
Hours

2
Days

Amadori
product

3
Weeks

Crosslinked
proteins

HC

O

H2

C

OH

NH2

+

HC

N

CH2

N
H

HC OH

OC

N

N

AGE
crosslink

▶ FIGURE 2-1  The Schiff base is the intermediate product formed when 
the Maillard Reaction occurs.

+

Glycation and Disease
Most of the research on glycation has been conducted to determine 
how diabetes affects the body. Diabetics have increased sugar in 
their  blood,  which  leads  to  damaging  protein  crosslinks  that 
manifest  as  coronary  artery  disease,  poor  circulation,  and  vision 
problems. This is the reason that the focus of diabetes treatment is 
to lower blood sugar levels using insulin and other medications. 
When  doctors  check  how  well  a  patient  is  keeping  their  blood 
sugar down, they order a test called hemoglobin A1c or HbA1c. 
This test measures the levels of glycated hemoglobin, which is an 
Amadori byproduct of sugar binding the hemoglobin in blood.

AGE crosslinks bind vital proteins such as elastin, which is 
needed  to  give  skin  and  organs  elasticity  and  the  ability  to 
bounce  back.  When  the  AGE  crosslinks  damage  elastin,  the 
arteries  lose  elasticity,  which  is  one  cause  of  high  blood 
pressure.  The  ability  of  the  heart  to  pump  blood  is  also 
impaired.  AGEs  can  damage  the  nerves,  kidneys,  and  many 
other organs. They also hinder many types of proteins including 
collagen. It is important to know that sugars are not the only 
etiologic elements in glycation. Fats such as triglycerides also 
lead to AGEs. For this reason, healthy diets should be relatively 
low in saturated fat and carbohydrates (sugars).

Glycation and Skin Aging
Two  main  proteins,  collagen  and  elastin,  which  are  found  in 
the dermal layer of the skin, play a major role in skin appear-
ance. Collagen imparts strength to the skin, and elastin, flexibil-
ity. Glycosylated collagen and elastin are believed to play a role 
in  the  appearance  of  aged  skin  because  glycation  causes 
crosslinks in these fibers that alter their function (Figure 2-3). 7 
The importance of these components is discussed at length in 
Chapter 5, Epidermis and Dermis.

 REACTIVE OXYGEN SpECIES   
AND FREE RADICALS

Reactive  oxygen  species,  also  called  free  radicals,  are  chemi-
cally reactive molecules containing oxygen. Stable oxygen has 
an  even  number  of  electrons.  When  something  consumes  or 
removes one of the electrons from oxygen (such as ultraviolet 
exposure), oxygen is left with an unpaired electron that renders 
it reactive. “Free radicals” are another name for oxygen that has 
an  uneven  number  of  electrons;  thus,  they  are  inherently 
unstable.  Free  radicals  steal  electrons  from  other  cellular 
components  to  regain  an  even  number  of  electrons.  It  is  the 
instability  of  the  odd  number  of  electrons  that  makes  free 
radicals  harmful.  Free  radicals  can  take  electrons  from  DNA, 
lipids in cell membranes (such as low-density lipoproteins, also 

Glucose

Collagen
fibers

Glucosepane
crosslink

(Several steps)

Collagen fibers

Protein molecules

Sugar molecules

Glycated protein

▶ FIGURE 2-2  Advanced glycation endproducts (AGEs).

▶ FIGURE 2-3  Glycation produces crosslinks in collagen fibers.

 
known as LDL or “bad cholesterol”), proteins, and other vital 
structures, leaving them impaired. Free radicals can be caused 
by  ultraviolet  exposure,  cigarette  smoking,  normal  cellular 
processes  such  as  oxidative  phosphorylation,  as  well  as 
sunscreens  and  other  chemicals  upon  decomposition. 
Antioxidants supply free radicals with the electrons they crave, 
thereby  neutralizing  them  or  rendering  them  harmless  (see 
Chapter 46, Antioxidants).

 CONCLUSION

Knowing this basic chemistry will enhance your understanding 
of the discussions throughout this book. While some sections 
may  refer  to  the  traditional  uses  of  barely  processed  ingredi-
ents,  the  ultimate  focus  here  will  be  on  topical  formulations 
used  or  potentially  useful  in  the  modern  dermatologic  arma-
mentarium.

SUGGESTED  READING

Schueller  R,  Romanowski  P.  Beginning  Cosmetic  Chemistry.  2nd  ed. 
Allured Publishing, 2003.
Barel AO, Paye M, Maibach HI, eds. Handbook of Cosmetic Science and 
Technology. 3rd ed. INFRMA-HC; 2009.
Moore RJ, Wilkinson JB. Harry’s Cosmeticology, 7th ed. Chemical 
Publishing Company; 1982.

C H A P T E R  2  ■   B A S I C   CO S M E T I C   C H E M I S T RY  

7

WEbSITES

Society  of  Cosmetic  Chemists:  http://www.scconline.org 
/website/index.shtml
Personal Care Products Council: http://www.personalcarecouncil.org/

REFERENCES

1.  Personal  Care  Products  Council:  A  Centennial  History  of  the 
Personal Care Products Council. http://www.personalcarecouncil 
.org/about-us/history?page=2.  Washington,  DC  2012.  Accessed 
July 29, 2012.

2.  Schueller R, Romanowski P. Cosmetic ingredient nomenclature. 
In:  Beginning  Cosmetic  Chemistry:  An  Overview  for  Chemists, 
Formulators, Suppliers and Others Interested in the Cosmetic Industry. 
2nd ed. Carol Stream, IL: Allured Publishing; 2003:21–27.

3.  Schueller  R,  Romanowski  P.  INCI  names:  Differences  between 
the US and the EU. In: Beginning Cosmetic Chemistry: An Overview 
for  Chemists,  Formulators,  Suppliers  and  Others  Interested  in  the 
Cosmetic  Industry.  2nd  ed.  Carol  Stream,  IL,  Allured  Publishing; 
2003:29–34.

4.  Pinnell  SR,  Yang  H,  Omar  M,  et  al.  Topical  L-ascorbic  acid: 
Percutaneous absorption studies. Dermatol Surg. 2001;27:137.
5.  Davies M, Marks R. Studies on the effect of salicylic acid on nor-

mal skin. Br J Dermatol. 1976;95:187.

6.  Kligman  A.  A  comparative  evaluation  of  a  novel  low-strength 
salicylic  acid  cream  and  glycolic  acid  products  on  human  skin. 
Cosmet Dermatol Suppl. 1997;10:11.

7.  Pageon  H,  Bakala  H,  Monnier  VM,  et  al.  Collagen  glycation 
triggers  the  formation  of  aged  skin  in  vitro.  Eur  J  Dermatol. 
2007;17:12.

 
8 

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   3

Organic Ingredient Labeling

As  pressure  grows  on  cosmetics  companies  to  use  more 
environmentally-friendly ingredients and packaging, we are seeing 
a  profound  increase  in  organic/natural  claims  on  “green”  beauty 
products.  Terms  such  as  “active  naturals,”  “botanical,”  “natural,” 
“green,” and “organic” are bandied about regularly; however, these 
terms  are  meaningless  without  standard  consensus  definitions. 
Of these categories, only the term “organic” has a set of require-
ments  associated  with  its  labeling.  Unfortunately,  standards  and 
definitions in the United States (US) and other countries vary.

 “ORGANIC” ORIGIN

The  term  “organic”  was  coined  in  1940  by  J.I.  Rodale,  who 
founded  the  Rodale  book  and  magazine  publishing  empire 
with  the  publication  Organic  Farming  and  Gardening.  In  1992, 
the US Department of Agriculture (USDA) created the National 
Organic  Program  (NOP)  and  approved  the  Organic  Label 
within  its  accompanying  standards;  however,  this  “organic 
seal” is applied mainly to agricultural foods and practices. It is 
often  used  on  personal  care  products,  although  it  primarily 
takes into account the practices of growing the ingredients for 
food, so it is not always suitable for personal care products that 
contain  modified  agricultural  materials  and  multicomponent 
packaging. For example, the seal does not mean that the pack-
aging of the skin care product is recyclable.

 ORGANIC REGULATION

There was no recognized “organic” label for personal skin care 
products  until  May  2002.  The  USDA  made  it  clear  then  in  a 
policy statement about the NOP that manufacturers of nonfood 
products (such as personal care products) containing agricultural 
ingredients were eligible to seek certification under the NOP. This 
allowed producers of nonfood items to display the iconic round, 
green “USDA Organic” seal to attest to “authentic” organic claims 
on their labels. However, in April 2004, the USDA issued a sur-
prising “Guidance Statement” reversing this position, indicating 
that producers of personal care products would not be eligible to 
seek  certification  and  had  to  cease  use  of  their  green  symbol. 
There  was  vacillation  on  this  decision  for  many  months  until 
August 2005 when the Organic Consumers Association (OCA), 
representing more than 500,000 members, won a major victory in 
a lawsuit against the USDA again allowing nonfood products to 
be certified with the organic seal. This NOP Standard offers three 
different  kinds  of  organic  certification:  If  a  product  contains 
100 percent organic ingredients, it can be labeled as 100 percent 
organic and use the seal on the front of the package; if a product 
contains  95  percent  organic  ingredients,  it  can  be  labeled  as 
“organic” and use the seal on the front of the package; if a product 
contains between 70 and 94 percent organic ingredients, it can be 
labeled as “made with (name of) organic ingredient” and the seal 
may not be used on the package. The nonorganic ingredients in 
the remaining 5 to 30 percent must also be  screened to  ensure 
that they conform to organic food standards.

 THE RULES OF ORGANIC PRODUCTION

In organic farming, of food crops or those intended for topical 
products,  farmers  avoid  the  use  of  synthetic  pesticides,  hor-
mones,  genetically  modified  crops,  and  chemical  products. 
Organic  farming  also  follows  traditional  agricultural  practices 
that enrich the soil, use resources in an environmentally sound 
manner, and treat livestock humanely. Specifically, a grower of 
organic ingredients must meet these baseline criteria in order 
for the products to be certified as organic:

1.  Abstain  from  the  application  of  prohibited  materials 
(including  synthetic  fertilizers,  pesticides,  and  sewage 
sludge) for three years prior to certification and then con-
tinually throughout their organic license.

2.  Prohibit the use of genetically modified organisms, irradia-

tion, and petrochemical solvents.

3.  Employ  positive  soil  building,  conservation,  manure 

management, and crop rotation practices.

4.  Avoid  contamination  during  the  processing  of  organic 

products.

5.  Keep records of all operations (courtesy of OCA).

 REGULATORY BODIES FOR PERSONAL 
CARE PRODUCTS

For  personal  care  products,  the  USDA  seal  is  the  one  we  see 
most commonly in the US, but because it applies to food prod-
ucts, many new standards have been created. However, no one 
standard  has  been  agreed  upon  at  a  national  level  in  the  US. 
Standards and regulations also vary from country to country. In 
addition, some regulatory bodies are for-profit businesses that 
will  certify  products  for  a  fee.  Obviously,  this  presents  an 
inherent bias.

In  Europe,  one  organization  that  offers  certification  is  the 
European  Cosmetics  Standards  Working  Group’s  Cosmetics 
Organic Standard (COSMOS). This group formed nearly 10 years 
ago,  officially  launched  COSMOS  in  2008,  and  released  their 
certification  standards  in  February  2011.  COSMOS  is  an 
amalgamation of several other European associations, including 
BIOFORUM from Belgium, Cosmebio and Ecocert from France, 
Bundesverband der Industrie- und Handelsunternehmen (BDIH) 
from  Germany,  Associazione  Italiana  Agricoltura  Biologica 
(AIAB)  and  Istituto  per  la  Certificazione  Etica  e  Ambientale 
(ICEA)  from  Italy,  and  the  Soil  Association  from  the  United 
Kingdom.  These  seven  organizations  represent  manufacturer 
associations,  standards  and  certifying  bodies,  and  consumer 
groups working in the field of organic and natural cosmetic prod-
ucts that have united to form COSMOS. For more information, 
visit http://www.cosmos-standard.org/.

Another popular certifying organization for natural and organic 
cosmetics is Na True from Belgium (www.natrue.org). Na True 
and COSMOS seem to be the most popular certifying bodies in 
the US currently. Not surprisingly, this is a competitive field right 

 
now and all organizations with an interest in labeling skin care 
products want to be recognized as the one defining the standards 
for natural and organic cosmetics. Other certifying bodies in the 
US include the National Sanitation Foundation (NSF International), 
which  developed  the  American  National  Standards  Institute 
(ANSI) 305 criteria (similar to Na True criteria) and OASIS, which 
was created by a coalition of beauty product manufacturers. Each 
certifying  body  has  its  own  standards  for  what  constitutes 
“organic.” There is a discrepancy among them about such guide-
lines. For example, each standard differs in allowed preservatives, 
calculations for extracts, processing aids, etc.

 ORGANIC TOPICAL PRODUCTS

While there are no long-term studies documenting the effects 
of using topical organic products or ingredients, consumers of 
organic products are typically as interested in what products do 
not contain as in what they do contain. The organic label intends 
to  assure  that  the  key  cleansing  and  conditioning  ingredients 
are derived from organically grown plant products, rather than 
conventionally  grown  plants,  synthetic  chemicals,  or  petro-
leum byproducts. In addition, topical organic products exclude 
or  minimize  any  ingredients  that  could  be  considered  poten-
tially harmful to people, animals, waterways, or the environ-
ment.  The  rules  about  which  ingredients  can  and  cannot  be 
included vary from regulatory body to regulatory body.

 “NATURAL” INGREDIENTS

Natural Standard for Personal Care Products
It is important to note that a product that is touted as “natural” 
is not necessarily organic. There is much confusion about what 
the  term  “natural”  means.  The  Natural  Products  Association 
(NPA),  a  nonprofit  organization  founded  in  1936  as  the 
American Health Foods Association that has since undergone 
several name changes, represents the interests of manufacturers 
and consumers in marketing and certifying products that are at 
least 95 percent natural. The NPA’s “Natural Seal” can be dis-
played  on  products  that  meet  this  95  percent  science-based 
standard  (95  percent  natural  ingredients  or  ingredients  from 
natural sources, not counting water) as certified by independ-
ent third-party auditors. Although the NPA issues guidelines on 
whether or not a product can be deemed “natural,” there is no 
governmental requirement to have this certification in order to 
use  the  term  “natural”  on  the  product  label.  The  NPA  seal 
should be thought of as a guideline to help conscientious con-
sumers choose products that meet certain standards. The NPA 
seal  certifies  that  a  company  has  met  standards  pertaining  to 
natural  ingredients,  safety,  sustainability,  and  responsibility. 
The Natural Standard for Personal Care Products requires that 
companies  be  transparent,  fully  disclosing  their  ingredients 
accurately and truthfully. They should strive to maximize their 
use  of  recyclable  and  postconsumer  recycled  content  in 
packaging. No animal testing in the development of the product 
is allowed. For more information and a list of ingredients that 
can be included in products, visit http://www.npainfo.org.

Active Naturals
“Active naturals” is a term popularized by the skin care product 
manufacturer Aveeno to describe ingredients that are found in 
nature but that have been enhanced in the laboratory. A good 

C H A P T E R  3  ■   O R G A N I C   I N G R E D I E N T   L A B E L I N G  

9

example  is  feverfew,  which  naturally  contains  the  sesquiter-
pene lactone parthenolide. Topical applications of formulations 
containing  parthenolide  can  lead  to  skin  irritation;  blisters  in 
the  mouth  can  develop  when  parthenolide  is  taken  orally. 
Aveeno  products  contain  feverfew  that  has  had  the  parthe-
nolide  component  removed.  The  “active  soy”  preparations 
found in Neutrogena and Aveeno products were developed in a 
similar manner. They contain soy that has had the estrogenic 
components  removed.  These  products,  while  containing  a 
form of natural ingredients, would not be eligible for the NPA 
certification  because  the  constituents  were  adulterated  in  the 
laboratory to increase efficacy.

 PITFALLS OF ORGANIC AND NATURAL 
PRODUCTS

Although natural and organic products are thought to be safer 
for the environment, they come with their own share of prob-
lems.  For  instance,  many  natural  and  organic  brands  contain 
certain fragrances and essential oils that can cause dermatitis. 
Oil of bergamot, and balsam of Peru are both highly allergenic, 
so even an organic product containing them could irritate sensi-
tive  individuals.  Organic  products  containing  strong  essential 
oils  like  peppermint  or  rosemary  can  also  irritate  or  inflame 
sensitive  skin.  Chamomile,  generally  considered  a  gentle  and 
soothing herb, can induce allergies in some people (who may 
also  tend  to  be  allergic  to  ragweed).  Some  natural  products 
contain  a  “perfume  mix”  to  mask  their  odor.  Components  of 
the  perfume  mix  are  rarely  listed  on  the  product  label  since 
each company uses its own proprietary blend. Even a product 
listed as 95 percent organic could contain a perfume mix that 
might induce allergic reactions in some people. Organic prod-
ucts  follow  the  International  Fragrance  Association  (IFRA) 
restrictions that limit the kinds of fragrances used, so they are 
no  more  likely  to  cause  fragrance  allergy  than  synthetic 
products.

Manufacturers of organic and natural products have a tough 
challenge to face. These products are very appealing to bacteria 
and fungi and the kinds of preservatives that can be used in a 
product labeled as natural or organic are limited. For example, 
parabens are a very effective preservative ingredient shunned in 
the  natural/organic  product  world  and  certainly  omitted  from 
the  list  of  approved  ingredients  by  the  NPA.  The  more  earth-
friendly types of preservatives can, in fact, cause a skin allergy in 
the  user.  Companies  struggle  to  find  environmentally-friendly 
preservatives.  At  this  time,  phenoxyethanol  is  the  most  com-
monly used preservative in organic and natural products.

 THE PRECAUTIONARY PRINCIPLE

Sometimes  certain  ingredients  are  excluded  from  products 
based on research. In other cases, exclusions are based on the 
“precautionary  principle,”  which  holds that until the cumula-
tive impacts and exposures to a broad range of ingredients can 
be fully assessed, it is best to err on the side of caution and limit 
use.  For  example,  though  many  chemical  ingredients  used  in 
cosmetics are widely considered safe for use, some safety fac-
tors  have  not  been  fully  studied.  It  is  virtually  impossible  to 
assess the cumulative effects of repeated exposures from multiple 
sources.  This  is  important  because  consumers,  especially 
women,  use  several  skin,  hair,  and  beauty  products  per  day. 
The ingredients in these products could potentially interact, or 
lead to a higher combined rate of exposure to certain ingredients 

 
10 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

than  is  usually  evaluated  by  studying  the  safety  of  a  single 
ingredient in the laboratory. Further, to accurately establish the 
baseline of the chemical exposures people can safely tolerate, it 
would be necessary to account for all chemical exposures from 
food, urban smog, industrial waste, and other sources.

Many  consumers  who  choose  organic  foods  and  topical 
products  prefer  to  limit  chemical  exposures  as  a  precaution. 
Use of natural products is recommended for pregnant or breast-
feeding  women,  young  children,  and  others  concerned  about 
the impact that the creation and disposal of personal care prod-
ucts can have on the environment.

 THE FUTURE OF ORGANICS

Very few product lines can meet the standards of these regula-
tory organizations (or, more accurately, self-regulatory organi-
zations, as they are not governmental bodies with enforcement 
authority)  because  it  is  expensive  and  time  consuming  to 

achieve and maintain this standard. Luckily, there are success-
ful brands that are forging the path for advances in this area, 
and raising the standards of natural products. Burt’s Bees, for 
example,  is  a  company  that  certifies  to  the  NPA  Natural 
Personal Care standard and has the top selling lip balm stock-
keeping  unit  (SKU)  across  all  categories  (not  just  the  natural 
categories).  Other  companies  that  make  natural  products 
include Jurlique, Dr. Hauschka, Suki, Sophyto, Toms, Organix, 
Alba, Jason, Avalon, Kiss My Face, Weleda, Pangea Organics, 
and Natural Gate.

It is important to remember that the terms “organic,” “natu-
ral,” or “sustainable” do not imply efficacy. None of the organic 
or natural certifications require efficacy data, so many of these 
products  have  not  undergone  the  strict  scrutiny  of  scientific 
investigation to evaluate efficacy. It is understandable that these 
companies  are  slower  to  perform  clinical  trials  because  the 
research  process  is  expensive  and  they  have  already  incurred 
such costs to meet the organic/natural standards. However, it is 
my hope that as sales increase, so will the scientific data.

 
C H A P T E R  4  ■   CO S M E C E U T I C A L   M A R K E T I N G   C L A I M S  

11

C H A P T E R   4

Cosmeceutical Marketing Claims

More than a quarter of a century since Albert Kligman, M.D., 
Ph.D., introduced the term “cosmeceutical,” the existence of 
this group of compounds has never been officially or legally 
recognized, leaving this category of products largely unregu-
lated.1  The  United  States  Food  and  Drug  Administration 
(USFDA)  classifies  personal  care  products  as  a  drug,  cos-
metic, or both [e.g., antidandruff shampoos or moisturizers 
with  sun  protection  factor  (SPF)].  Cosmeceutical  products, 
which are personal care products that may actually yield a 
biologic impact, fall between the cracks of these incomplete 
designations. 

Most  manufacturers  of  cosmeceutical  formulations  have 
established the clinical merit of their products despite the lack of 
official  oversight,  but  some  doubt  is  inevitable  given  the 
regulatory  loophole,  particularly  when  companies  make 
extraordinary  claims.  Manufacturers  typically  test  main 
ingredients and finished products in small in vivo trials, but rarely 
if ever publish results in the peer-reviewed literature.

Even  though  cosmeceuticals  are  not  regulated  by  the  FDA, 
there  are  standards  and  guidelines  for  good  practices  in  many 
cases.  Manufacturers  that  try  to  skirt  this  self-policing  system 
risk a greater likelihood that their product(s) will not succeed. It 
is important for practitioners and consumers alike to be familiar 
with  these  standards.  That  is,  claims  made  on  cosmeceutical 
products  routinely  use  the  same  terms  or  expressions  none  of 
which  are  made  patently  clear  but  are  somewhat  consistently 
used  across  manufacturers.  Given  the  absence  of  regulatory 
oversight of these products, this chapter will read between the 
lines and explain the language used in cosmeceutical marketing 
claims. These terms and expressions are defined below, and fur-
ther described according to the typical data used to support their 
marketing.

 ADVERTISING OMISSIONS

Allergen-free
No standard definition has been established for “allergen-free” 
either,  and  no  testing  is  required  of  companies.  More  often 
than not, “allergen-free” indicates that the product includes no 
fragrances on the European Union’s “List of Substances Which 
Cosmetic  Products  Must  Not  Contain  Except  Subject  to 
Restrictions and Conditions Laid Down” or other compounds 
typically  identified  as  allergens.  Some  manufacturers  use 
human repeated insult patch testing (HRIPT) for allergy testing.

Hypoallergenic
Each  manufacturer  defines  this  term  in  its  own  way,  often 
using it liberally, as no standard definition of hypoallergenicity 
has been established. HRIPT of about 100 to 200 subjects and 
cumulative  irritation  testing  (smaller  panel)  are  the  common 
methods of evaluation. Occasionally, photoreactivity testing is 
conducted, depending on the product type.

Unscented/Fragrance-free
When a product lacks common fragrance ingredients, particu-
larly  those  most  often  linked  to  allergic  sensitivity,  or  a 
traditional fragrance intended to impart scent to a product, its 
manufacturer  can  label  the  formulation  as  fragrance-free. 
However, the appearance of the expression “fragrance-free” on 
a  product  does  not  necessarily  mean  that  a  fragrance  is  not 
included. Companies sometimes include fragrance subcompo-
nents or botanicals to render a cosmetic or preservative effect 
that,  concomitantly,  delivers  a  scent  or  pleasant  aroma  to  a 
formulation. If the primary reason for including the “fragrance” 
is not related to scent, such as acting as a preservative, then the 
manufacturer  is  not  required  to  label  the  ingredient  as  a 
fragrance but can label the product as fragrance-free.

It is also worth noting that some ingredients, including pre-
servatives  like  phenoxyethanol  (the  most  often  used  one  in 
organic and natural products), background wax odors from long 
chain/paraffins, or unfragranced sunscreens, are not considered 
fragrances, but do impart an odor and can provoke reactions in 
individuals sensitive or allergic to fragrance. 

Formulations labeled as “unscented” typically have no detect-
able  odor,  but  the  product  may  have  a  “masking”  fragrance 
included  to  disguise  background  odor.  Therefore,  “unscented” 
does not necessarily translate to no added fragrance. In an age in 
which  companies  have  been  compelled  into  advertising  the 
absence of the preservative parabens, consumers have come to 
expect that if an ingredient is excluded from a product, it really is 
excluded. That said, this lack of clarity in advertising is likely not 
problematic for any but the most sensitive individuals. It is none-
theless important to understand how the process works.

 ORGANIC OR NATURAL

In the last two decades, interest has increased greatly regarding 
the use of what consumers perceive to be the healthiest quality 
ingredients  in  skin  care  products,  not  to  mention  food  and 
clothing.  Manufacturers  have  responded  to  the  call  by  using 
terms and expressions  such as  “organic,” “natural,” “naturally 
derived,”  and  “botanical”  on  their  product  label  claims. 
Consumers are left to puzzle as to exactly what these descrip-
tions mean (see Chapter 3, Organic Ingredient Labeling, for a 
more detailed explanation).

Organic
In 2005, the US Department of Agriculture (USDA) issued new 
organic  standards  for  skin  care  products.  According  to  these 
guidelines, a product labeled as “organic” must contain at least 
95  percent  organic  ingredients;  one  said  to  be  “made  with 
organic ingredients” must be composed of at least 75 and up to 
94  percent  organic  ingredients.  These  standards  are  based  on 
organic food standards, and prohibit the use of synthetic pre-
servatives  and  most  chemical  processing  of  ingredients. 
Consequently,  organic  skin  care  products  are  derived  from 

 
12 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

organically  grown  plant  products,  not  conventionally  grown 
plants, synthetic chemicals, or petroleum byproducts. To meet 
these  standards,  producers  also  exclude  or  minimize  ingredi-
ents  considered  potentially  deleterious  to  people,  animals, 
waterways, or the environment.

only the ingredient or the actual final formulation that is clinically 
“proven.” Furthermore, the advertising regulation does not apply 
to  package  labeling.  If  only  the  ingredient  rather  than  the  final 
formulation was tested, the wording usually is carefully crafted 
(e.g., “with an ingredient that has been clinically proven to X”).

Natural, Naturally Derived, Botanical
Products labeled as “natural” may or may not be organic. Such 
products contain ingredients derived from plants but can also 
contain chemicals added to act as preservatives or to improve 
its  texture.  In  the  next  step  further  removed  from  what  con-
sumers  might  envision  is  natural  are  the  so-called  “naturally 
derived” ingredients, which find their origins in plants but are 
enhanced in the laboratory. None of these terms have any legal 
meaning. “Botanical” refers to products that were made from or 
contain some plant constituents. This in no way means that the 
product is exclusively made from plant components. Consumers 
can  easily  be  misled  in  this  regard  or  by  the  fact  that  while 
there  are  several  effective  botanical  products  on  the  market, 
generic  versions  with  similar  ingredients  and  packaging  may 
not be as effective. The order of ingredients, pH, and tempera-
ture when ingredients were added are all patented trade secrets 
that influence the effectiveness of a product.

 TESTING AND APPROVAL

Clinically Tested
Typically, these products have indeed been investigated through 
some  form  of  clinical  testing,  but  the  test  could  be  a  simple 
48-hour patch test for irritancy. There are no rules about how 
many subjects or the type of trial required for a formulation to 
be  considered  “clinically  tested,”  and  it  is  not  always  clear 
whether  the  finished  formulation  was  tested  or  only  compo-
nents. When a product is described as “clinically tested,” each 
word is carefully chosen (e.g., clinically tested “technology” or 
clinically tested “formula”) to offer clarity to the attentive reader.
Clinical  testing  is  distinct  from  more  ordinary  “consumer” 
testing, which could include focus groups and simple patient use 
questionnaires.  Clinical  tests  are  typically  run  with  scientific/
medical experts, using an approved protocol, specified statistical 
analysis, and enough subjects to provide statistical significance, 
based  on  the  study  design.  The  new  sunscreen  monograph 
allows for as few as 10 subjects per panel for SPF. Other types of 
assessments (moisturization, antiacne, etc.) would typically use 
more subjects, perhaps from 30 to 100.

Clinically Proven
“Proven,” according to the National Advertising Division of the 
Council of Better Business Bureaus (NAD), requires two similar 
well-controlled clinical studies to make this claim. This is the 
standard  for  the  major  television  networks  with  regard  to 
broadcast  advertising  of  a  product.  The  Office  of  Broadcast 
Standards  and  Practices  reviews  ads  and  the  data  to  support 
any  claims  before  accepting  them  for  broadcast.  If  there  has 
been just one study, the wording might be limited to clinically 
“shown” or “tested.” Sometimes, one study on the “technology” 
and  another  study  on  the  final  formulation  will  satisfy  the 
network’s requirements for “clinically proven.”

Despite attempts at rigor, the “clinically proven” claim can be 
unclear for consumers, as they are unable to determine if it was 

Dermatologist Tested
This claim conjures images of a dermatologist applying a lotion 
to the face, assessing it as cosmetically acceptable, and subse-
quently  approving  the  formulation.  While  “dermatologist 
tested”  generally  means  much  more  than  this,  the  claim  is 
highly variable. Often if a formulation is “dermatologist tested,” 
a dermatologist has reviewed the clinical study and signed off 
on  it,  but  s/he  may  have  simply  reviewed  the  formula  or  a 
study  report.  The  doctor  may  or  may  not  be  involved  in  the 
conduct of the study and/or analysis of results.

Nonetheless,  this  claim  is  usually  based  on  a  specific  clinical 
trial with a protocol, and the final formula sold in stores has been 
tested. Panel size depends on the company, but the general rule is 
a  minimum  of  30  subjects  for  claims  of  efficacy.  In  this  case,  a 
certified dermatologist signs off and oversees the testing. However, 
this is not required to make the claim “dermatologist tested.”

Dermatologist Approved
This claim only requires one dermatologist to approve the prod-
uct in some fashion, perhaps based on an assessment of safety, 
efficacy, or just a brief review of ingredients. Typically, a small 
company  doing  infomercials  may  just  use  one  dermatologist, 
who may also be its consultant or a stockholder in the company. 
Larger  companies  typically  sample  four  or  five  independent 
dermatologists  with  data  to  be  reviewed,  depending  on  the 
claim  and  the  size  of  the  company.  This  wording  is  not  as 
common as “dermatologist recommended,” which is typically 
based on a questionnaire that is sent to many dermatologists.

The Role of Monographs
A  monograph  is  a  statement  detailing  the  kind  and  amount  of 
active  ingredients  that,  when  used  at  the  concentration  range 
stipulated,  can  be  included  in  product  claims.  Claim  language 
preapproved  by  the  FDA  is  allowed  on  a  product  monograph 
without supplying additional data. Generally, manufacturers are 
required  to  follow  the  wording  used  in  the  monograph  for  its 
claims. However, companies can provide additional claims (e.g., 
“moisturizes,” “cleans,” “brightens”) for products not sold over the 
counter.  To  better  illustrate  this  point,  consider  acne  products. 
Companies  must  have  an  approved  monograph  listing  active 
ingredients,  such  as  benzoyl  peroxide,  salicylic  acid,  or  sulfur, 
within  the  approved  range.  Companies  are  not  required  to  test 
this formulation for effectiveness in treating acne as long as they 
meet the range requirement. However, they are not permitted to 
combine acne actives or other monograph actives. In other words, 
a formulation may not contain benzoyl peroxide and ultraviolet 
screens and then claim that it treats acne and imparts an SPF factor 
without undergoing FDA review and approval.2

 PROBLEMS WITH PROPRIETARY DATA

Even  though  companies  may  perform  extensive  research  on 
their cosmeceutical products, their findings most often remain 
unpublished.  Consequently,  dermatologists  cannot  easily 
access  this  scientific  evidence  to  evaluate  the  efficacy  of  the 

 
C H A P T E R  4  ■   C O S M E C E U T I C A L   M A R K E T I N G   C L A I M S 

13

myriad marketed products. Bereft of such evidence, physicians, 
who  are  taught  to  practice  evidence-based  medicine,  have 
scant reason to believe that any of these products are actually 
effective. Therefore, the medical establishment dismisses such 
products  as  useless  even  though  some  of  these  formulations 
may potentially offer benefits to patients. Essentially, internal 
company research that is kept under proprietary wraps thwarts 
the peer-review process. Peer review has long been considered 
necessary to validate the research findings of scientists. Without 
the peer review of research findings, the scientific community 
as  well  as  the  public-at-large  is  left  with  no  reasons  to  have 
confidence in study results.

 APPEARANCE CLAIMS

Each  company  has  its  own  research  standards  and  some 
companies do not do any research at all to support its claims 
because  research  trials  are  not  required  by  the  FDA  or  FTC. 
Some cosmetic companies try the study product on five of its 
employees,  all  who  know  the  identity  of  the  cream  and  are 
obligated  to  their  employers.  This  of  course  is  not  the  ideal 
study design but is frequently used. Many companies perform 
“research trials” in-house, do not share the design and results of 
the  trials,  and  do  not  attempt  to  publish  the  results.  Other 
companies use an independent dermatologist to assess subjects 
in an open-label trial (the subject and the investigator know the 
identity of the study product). It is much preferred that the trial 
be a double-blinded vehicle-controlled trial.

Although some trusted manufacturers exist in the cosmeceu-
tical  realm  and  a  number  of  formulations  have  proven  their 
clinical merit, the lack of official oversight, the proprietary nature 
of the formulations, and the disincentive for research data leaves 
room  for  doubt  about  the  efficacy  claims  of  personal  care 
products.  Some  reputable  formulators  test  both  the  main 
ingredients and finished products through in vivo (in living human 
skin) trials, but most rely on the ingredient manufacturers in vitro 
(in  test  tubes  or  cell  cultures)  investigations  of  the  individual 
ingredient and not the final formulation. It is almost impossible 
for  consumers  to  know  the  specifics  of  the  research  study 
design by reading a product label but a few clues may reside in 
the language used. The following terms and expressions do not 
have regulated or legal definitions but are thought to convey the 
common connotations below:

Antiaging
Claims  that  a  product  confers  an  antiaging  benefit  are  often 
based on an ingredient claim. Often included in this claim is a 
grading  by  consumers  or  experts.  SPF  is  known  to  gauge  the 
ability of a product to prevent photodamage and premature pho-
toaging, and new label revisions allow SPF products to make this 
claim. However, manufacturers of antiaging products often tout 
the “antiaging” effects of their formulations based on ingredients 
other than UV screens. For example, AHAs and vitamin A deriv-
atives are popular ingredients in “antiaging” products.

ple, can make scientific claims of “increasing collagen produc-
tion”  or  stimulating  fibroblasts  to  produce  collagen.  To  avoid 
that  issue,  companies  will  instead  say  “improves  the  appear-
ance of wrinkles” and avoid the biological explanation of why 
the improvement occurred.

Brightening
The meaning of brightening is unclear but it seems to pertain to 
light reflection off of the skin’s surface. This is also referred to as 
radiance or clarity. Decreasing melanin levels in the skin lead to 
“brightening” because melanin absorbs light. When there is less 
melanin, the skin reflects more light, making it appear brighter or 
more radiant. Often visual elements are placed in the formula-
tions  to  reflect  light  and  cause  brightening.  For  this  reason, 
brightening  can  be  noticed  instantly  upon  application  of  the 
product.  There  are  multiple  approaches  for  assessing 
“brightening”  effects.  This  is  typically  performed  via  clinical 
evaluation,  with  dermatologists  grading  brightness  on  a  scale 
(e.g., from very dull/not bright to very bright/no dullness) over 
the course of treatment. Results may also be obtained through 
measurement of luminosity image analysis such as photographs.

Deep Cleaning
This claim is made, but with no accompanying standard defini-
tion.  That  said,  several  approaches  have  been  suggested.  A 
standard compound can be applied to the skin and allowed to 
equilibrate,  followed  by  a  standardized  washing  procedure. 
Typically,  a  new  cleansing  product  (or  device)  is  compared  to 
either one or all of the following: a competitor, water alone, bar 
soap, or an older formulation (device). The amount of residual 
material  can  be  quantified  using  laboratory  instruments.  For 
instance, tape stripping is used to measure depth, and a sebumeter 
is used to demonstrate sebum reduction. Determining “cleanli-
ness” may also be performed by consumers or expert graders.

Firming
Expert  assessment  and/or  subject  self-assessments  are  the 
foundation  used  to  buttress  a  firming  claim.  Although  some 
instrumental  measurements  have  been  applied  (currently 
limited to ballistometry), few publications are available on this 
method and its validity is questionable. Occasionally, a firming 
claim is based on the inclusion of an ingredient with no actual 
testing performed.

Lifting
Three  main  methods  are  used  to  exhibit  “lifting”:  bioinstru-
ments (change in volume based on imaging software), expert 
graders, or consumer questionnaires. Live grading can be con-
ducted split-face, if subjects are symmetrical, or three-dimen-
sional  imaging  can  be  used  for  grading  of  lifting.  Sometimes 
calculations  can  be  performed  on  the  images  to  measure  in 
millimeters the appearance of visible lifting.

“. . . Appearance of Wrinkles”
For  cosmetic  products,  this  claim  is  typically  supported  by  a 
dermatologist’s in vivo or photographic assessment of subjects 
at  the  end  of  the  trial  compared  to  baseline.  In  some  cases, 
bioinstruments (e.g., fringe projection, image analysis) are used 
or a consumer study with questionnaire is used to support this 
claim. Normally, only a drug product, like tretinoin, for exam-

Lightening
Lightening  means  a  decrease  in  the  amount  of  melanin  or 
brown in the skin. Lightening can be assessed with any combi-
nation or single method of evaluation, including bioinstrumen-
tation, clinical expert assessment, or consumer questionnaire. 
Clinical studies typically include dermatologist assessments of 
overall  skin  fairness,  overall  evenness,  and  instrumental 

 
14 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

measurements  such  as  L*a*b*  values  from  chromameters. 
Image  analysis  for  pigmented  spots  can  be  done  on 
high-resolution  images,  and  dark  marks  can  be  followed  for 
size  and  intensity  compared  to  nearby  skin.  Photographic 
assessment is commonly used.

Noncomedogenic
There  is  no  standard  definition  associated  with  this  claim. 
However, industry practice suggests the use of comedogenicity 
patch testing on the upper back in 10 to 20 subjects, based on 
the modified Kligman method in which cyanoacrylate follicular 
biopsies are then reviewed under a microscope.

instead, they are required to clearly state the results that con-
sumers should usually expect.3,4

In addition, the revised guides added new examples to show 
that payments or free products exchanged between advertisers 
and  endorsers  must  be  divulged  (e.g.,  bloggers  paid  to  write  a 
review or celebrity endorsements on a talk show). Similarly, if a 
company refers in an advertisement to the findings of a research 
organization  that  conducted  research  sponsored  by  the  com-
pany, the advertisement must reveal the connection between the 
advertiser and the research organization.

The FTC guidelines are nonbinding administrative interpre-
tations of the law intended to help advertisers comply with the 
FTC Act.

Plumping
Lip cosmetics often make this claim. Companies may use der-
matologist  assessments  (from  one  to  three  physicians)  of  lip 
volume,  plumpness,  color,  or  shape.  Subject  self-assessment 
may  also  be  used  by  companies,  as  subjects  sometimes  say 
they can “feel” the plumpness. This claim is also based on the 
use of digital imaging and grading by experts; advanced three-
dimensional imaging techniques can even allow quantification 
of volume changes. Plumping may simply be a claim based on 
the  incorporation  of  ingredients  that  engender  an  increase  in 
blood flow, thus temporarily expanding the size of the lips.

Pore Reducing
The observation of a pore size reduction may be made by derma-
tologist  reviewers/graders  in  person  or  through  before/after 
photograph comparisons. Images can also be evaluated with bioin-
strumentation (e.g., the software in the Visia system by Canfield) 
that measures pore size changes. More often, though, effects on 
pore size are self-assessed by subjects and graded on a questionnaire.

Smoothing
Smoothing can be measured in many ways. It may be as simple 
as  a  claim  based  on  feedback  from  consumers  or  subjects.  A 
dermatologist  may  assess  texture  tactilely;  improvements  in 
tactile roughness would support a smoothing claim. Rarely, three- 
dimensional imaging or replicas are used to support this claim. 

Volumizing
This is a common claim associated with eye cosmetics because 
any coating on the eyelash will expand the volume based on 
the  volume  equation  πr2h.  Thus,  a  doubling  of  the  hair  shaft 
radius will quadruple the volume (i.e., a 400 percent increase in 
the volume of the lash). Typically, photo assessments are com-
pleted, but there are no regulations on the number of subjects 
needed to claim that a product confers a plumping effect. 

 CAVEAT EMPTOR: BUYER BEWARE

Cosmetic  company  insiders  have  noted,  somewhat  cynically, 
that  the  most  reliable  claim  on  a  package  is  the  product  size, 
since this can be objectively measured. All other claims can be 
exaggerated  based  on  limited  or  non-product-specific  data  or 
even, rarely, nothing at all. Even when a company tests a prod-
uct, the study may be conducted under unrealistic conditions or 
with such tight controls that a consumer’s actual use pattern will 
not likely yield similar results. For example, a manufacturer may 
claim that its product improves wrinkles after 51 percent of con-
sumers report a self-assessed benefit, which, of course, translates 
to roughly a 50/50 chance of a given consumer deriving a benefit.
Nevertheless,  well-formulated  products  can  elicit  benefits. 
“Clinically proven” claims, supported by research studies with 
independent dermatologists, are reliable indicators of potential 
product efficacy. Another strong indicator of likely benefits from 
products are television ads on the three major networks. A tele-
vision ad on one of the traditional major networks that refers to 
a product as “clinically proven” is also a good indication of prod-
uct effectiveness. Such claims are most likely to be brandished 
by brand name products with strong research and development 
divisions.  Consumers  should  be  wary  of  generic  store  brands 
that urge comparisons to other products. Manufacturers of these 
products  are  trying  to  piggyback  off  of  the  reputation  of  the 
“innovator”  and  are  unlikely  to  have  conducted  any  studies. 
Generic products may contain the same ingredients as another 
brand, but are unlikely to be identical to the original products. 
The  generic  version  can  only  be  thought  to  deliver  the  same 
efficacy if its final formulation has been clinically proven.

It may take extra work, but for reliability, consumers should be 
advised  to  consider  the  history  and  reputation  of  the  company 
selling the product and note the efficacy claimed as well as any new 
reports on the product or manufacturer. Larger companies generally 
will conduct clinical research and testing aimed at verifying claims, 
since their competitors are likely to challenge any false advertising. 
Smaller companies are less likely to be scrutinized; therefore, they 
can more easily operate under the radar and perhaps get away with 
making more unfounded or less scrupulous claims.

 FTC GUIDELINES ON PRODUCT 
ENDORSEMENTS AND TESTIMONIALS

 CONCLUSION

In  2009,  the  Federal  Trade  Commission  (FTC)  updated  its 
“Guides Concerning the Use of Endorsements and Testimonials 
in  Advertising,”  which  covers  endorsements  by  consumers, 
experts, organizations, and celebrities, as well as the disclosure 
of  important  connections  between  advertisers  and  endorsers. 
The previous version of the guidelines was published in 1980.3 
Advertisers can no longer issue a “results not typical” disclaimer; 

It is prudent for consumers to always remember that compa-
nies are in business to make profits for their shareholders. This 
is more likely if a quality product is proffered, but that is not 
always  the  case.  With  lax  or  a  lack  of  regulations  regarding 
various product claims, there are many opportunities for cos-
meceutical  manufacturers  to  make  misleading  or  false  claims 
while also making money. Claims are not often clearly defined 

 
C H A P T E R  4  ■   CO S M E C E U T I C A L   M A R K E T I N G   C L A I M S  

15

or objectively determined. An objective, standardized approach 
to  product  assessment  would  best  serve  patients  and  derma-
tologists  alike.  This  murky  information  void  is  especially 
important to consider when discussing in-office physician dis-
pensing of products. Such doctors should certainly understand 
the science of formulations and their claims and be very clear 
with their patients, keeping the best interest of patients at the 
forefront of the process. Preserving patient trust and the sanc-
tity of the physician–patient relationship should be placed on 
the same level as patient welfare as the highest priorities. 

REFERENCES

1.  Kligman  A.  Cosmeceuticals:  do  we  need  a  new  category?  In: 
Elsner  P,  Maibach  H,  eds.  Cosmeceuticals.  New  York:  Marcel 
Dekker Inc.;2000:1.

2.  Kessler  DA.  Rules  and  regulations,  acne.  Fed  Reg.  1991; 

56(159):41020.

3.  FTC  Publishes  Final  Guides  Governing  Endorsements, 
Testimonials. http://www.ftc.gov/opa/2009/10/endortest.shtm.
4.  Federal Trade Commission 16 CFR Part 255. Guides Concerning 
the  Use  of  Endorsements  and  Testimonials  in  Advertising. 
October 15, 2009;74:198.

 
16 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   5

Epidermis And Dermis

The appearance of the skin is affected by both the outer layer 
of the skin, the epidermis, and the middle layer of the skin, the 
dermis. The deepest layer is composed of a subcutaneous fat 
layer. The thickness and contour of the fat layer can also affect 
the  appearance  of  the  skin.  The  fat  layer  and  muscle  layer 
below  it  are  too  deep  to  be  influenced  by  topical  skin  care 
agents so they will not be discussed in this book. Instead, the 
epidermis and dermis will be explored. (For a more in-depth 
review of basic skin science, see Cosmetic Dermatology: Principles 
and  Practice,  2nd  edition,  Chapters  1–8.)  The  epidermis  and 
dermis contain many types of cells. Only the ones known to 
play  an  important  role  in  skin  care  will  be  discussed  here 
(Figure 5-1). 

 KERATINOCY TES

Keratinocytes  constitute  the  outer  layer  of  skin  called  the 
epidermis.  The  epidermis  is  very  important  in  skin  appear-
ance  because  it  provides  protection,  keeping  skin  hydrated 
while  preventing  the  penetration  of  caustic  agents,  and 
significantly  contributes  to  skin  radiance,  evenness  of  color, 
and smoothness.

The epidermis is made up of layers of keratinocyte cells that 
resemble a brick wall. The youngest cells are found at the base 
and are called the basal layer. The stem cells also reside in the 
basal  layer.  The  next  layer  contains  spiny  attachments  that 
tightly hold the keratinocyte cells together to give skin strength. 
This layer is called the spinous layer. The next layer of cells is 
very productive, synthesizing fats, proteins, and sugars as well 
as  other  cellular  components  in  “factories”  inside  the  cells. 
When  viewed  through  a  microscope  these  factories  (cellular 
organelles)  appear  as  multicolored  granules.  For  this  reason, 
this important layer is called the granular layer. After the granu-
lar layer, the cells begin to lose activity, the granules disappear, 
and the cells flatten out. This layer of flattened inactive cells is 
the most outer layer and is termed the stratum corneum (SC). 

▶

FIGURE 5-1  Cross-section of skin as seen from a microscope.

▶
FIGURE 5-2  Normal epidermis showing the cuboidal basal cells, the 
spinous layer, granular layer, and stratum corneum. The top layer of the SC 
is exhibiting the process of desquamation.

The outermost cells are known as squamous cells from the Latin 
squama meaning “scale.” They are “dead” or apoptotic and flake 
off into the environment. At some point in the SC the attach-
ments that hold these squamous cells together loosen, allowing 
the cells to fall from the surface in an action known as desqua-
mation,  from  the  Latin  desquamare  meaning  “to  scrape  the 
scales off” (Figure 5-2).

Aged  skin  is  thinner  and  more  fragile  than  young  skin 
because the middle dermal layer thins with age. In contrast, 
the top layer, the epidermis, is often thickened in aged skin. 
The  thickened  epidermis  is  caused  by  an  excess  of 
keratinocyte  cells  in  the  SC.  This  occurs  because  the 
keratinocytes  normally  migrate  toward  the  skin’s  surface, 
and as the keratinocytes die, they accumulate at the surface 
of the skin. Normally, naturally occurring enzymes degrade 
the  connections  between  the  SC  cells,  releasing  them  from 
the  cells  below  and  allowing  them  to  desquamate.  Older, 
aged skin or dehydrated skin lacks these enzymes. The result 
is a buildup of dead squamous skin cells on the surface of the 
skin  (Figure  5-3).  This  amassing  of  dead  cells  prevents  the 
skin from reflecting light. People often complain that the skin 
looks  “dull  and  tired.”  People  with  darker  skin  types  often 
describe  their  dry  or  aged  skin  as  “ashy”  in  appearance 
(Figure 5-4). Cosmetic products can be used to make the skin 
look  smoother  and  more  radiant  (see  Video  1  for  a  more 
detailed explanation). 

Keratinocytes can lose the ability to undergo apoptosis (pro-
grammed  cell  death)  and  become  cancerous.  They  begin  to 
replicate  and  produce  multiple  copies  of  themselves.  When 
superficial keratinocyte cells become cancerous, it is known as 
squamous  cell  carcinoma  (SCC).  When  the  deeper,  or  basal, 
keratinocytes  become  cancerous,  this  is  known  as  basal  cell 
carcinoma (BCC). SCCs and BCCs are more common in people 
with a history of significant sun exposure. SCCs and BCCs are 
usually treated surgically, which can lead to scarring. There is 
some evidence that antioxidants and retinoids may play a role 
in the prevention of SCCs and BCCs.1,2

 
C H A P T E R  5  ■   E P I D E R M I S   A N D   D E R M I S 

17

excreted  from  the  fibroblasts  in  a  ready-to-go  form  that 
provides  a  scaffolding  or  structural  framework  that  confers 
strength to the skin (Video 2). Aged skin contains less of types 
I and III collagen than young skin.5 Several ingredients such as 
retinoids, glycolic acid, and ascorbic acid have been shown to 
increase the production of collagen. Lasers, light devices, and 
injectable HA products have also been shown to stimulate col-
lagen production.6–9

Elastin
An essential component of the extracellular matrix of connective 
tissue, elastin is made up of two main constituents: fibrillin and 
tropoelastin.10 These are secreted separately from the fibroblast. 
The skin must assemble them once they are secreted. Once these 
are  assembled,  the  mature  elastin  fibril  is  rendered  elastic  and 
gives the skin its ability to bounce back. The complex assembly 
process makes it hard for the skin to produce functional elastin 
after puberty. This is why older skin sags and does not bounce 
back. Aged skin contains less functional elastin than young skin. 
At this point, no topical or injectable products have convincingly 
been able to induce skin to synthesize functional elastin.

Hyaluronic Acid
The most abundant glycosaminoglycans in the dermis, HA is a 
sugar that binds 1,000 times its weight in water. HA allows the 
joints to flow properly and helps the skin attract and hold onto 
water, giving the dermis its volume. In addition, HA plays an 
important role in cell growth, membrane receptor function, and 
cellular adhesion. Older people have less HA in their joints and 
skin. This is why a baby’s skin is plump while an older person’s 
skin  is  not.  HA  is  the  ingredient  in  dermal  fillers  such  as 
Restylane and Juvéderm.

 CONCLUSION

Aged  skin  has  fewer  fibroblasts  than  young  skin.  Topical 
cosmeceuticals  have  been  developed  to  stimulate  fibroblast 
production.  To  date,  however,  cosmeceuticals  have  only  been 
successful  in  spurring  fibroblasts  to  produce  collagen.  Elastin  is 
associated with such a complex assembly process that no known 
topical  formulations  have  been  developed  that  undoubtedly 
increase the levels of functional elastin. There is some evidence 
that glucosamine supplementation can increase the production of 
HA  but  the  evidence  is  weak.11,12  Topical  retinoids  have  been 
proven to increase HA production, though.13 Many skin care prod-
ucts contain collagen, elastin, or HA in the preparation; however, 
these  large  structures  do  not  penetrate  into  the  dermis  and  are 
unable to replace lost collagen, elastin, and HA in the aged dermis 
despite the claims made by cosmetic product manufacturers.

Most  products  on  the  market,  including  cleansers,  scrubs, 
antiaging  products,  and  moisturizers,  actually  act  on  the 
epidermis  and  are  unable  to  penetrate  down  into  the  dermis. 
These products can help temporarily improve cutaneous appear-
ance  by  hydrating  the  skin,  which  diminishes  fine  lines  and 
removes  the  desquamating  keratinocytes.  This  smoothes  the 
surface  of  the  skin,  allowing  it  to  better  reflect  light  and  look 
“radiant.” These  products  can  also  decrease skin pigmentation 
leading  to  a  more  even  skin  tone.  Only  a  few  ingredients  are 
known  to  penetrate  into  and  cause  a  long-lasting  biological 
change in the dermis. Ingredients known to easily penetrate into 
the dermis include hormones such as estrogen, retinoids such as 
tretinoin, some growth factors, and immune response modifiers 

FIGURE 5-3  The upper layer of keratinocytes cling together creating 

▶
heaps and valleys that form scales and make skin look dull and ashy.

▶

FIGURE 5-4  Darker, ashy, dry skin.

 FIBROBLASTS

Fibroblasts make up the middle layer of the skin that lies over the 
muscle and fat layer. Fibroblasts are very important in skin aging 
because  they  are  the  cells  that  produce  collagen,  elastin,  and 
hyaluronic  acid  (HA),  which  are  all  known  to  affect  the  skin’s 
appearance. The fibroblast cell is responsible for the skin’s thickness, 
volume, elasticity, and strength. This is because the fibroblast cell 
contains the “factory” or cellular organelles that produce key com-
ponents of the skin: collagen, elastin, and HA.

Collagen
The main component of connective tissue, collagen is a family 
of  proteins  with  a  distinctive  triple-helix  structure.  Of  the 
18 types of collagen, 11 are found in the dermis.3 Type I is the 
most abundant protein in humans and types I, III, and VII are 
the  most  important  forms  of  collagen  in  skin.4  Collagen  is 

 
18 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

such  as  imiquimod.  Proving  that  an  ingredient  penetrates  into 
the dermis and causes a biologic change is a tricky proposition 
for a cosmetic company because of the way that cosmetic ingre-
dients  are  regulated  as  compared  to  ingredients  labeled  as 
drugs.14 If an ingredient is shown to penetrate into the dermis 
and  produce  a  biologic  change,  then  the  Food  and  Drug 
Administration requires that the formulation enter the drug reg-
ulatory pathway, which is very expensive, can take years, and 
results in a product that is available only by prescription. For this 
reason, cosmetic companies are actually encouraged or incentiv-
ized not to do research, so that their product can be labeled as a 
“cosmetic”  and  be  made  available  over  the  counter  without 
required  research  trials.  For  more  information  about  cosmetic 
claims, see Chapter 4, Cosmeceutical Marketing Claims.

REFERENCES

1.  Sander CS, Chang H, Hamm F, et al. Role of oxidative stress and 
the  antioxidant  network  in  cutaneous  carcinogenesis.  Int  J 
Dermatol. 2004;43:326.

2.  De  Graaf  YG,  Euvrard  S,  Bouwes  Bavinck  JN.  Systemic  and 
topical  retinoids  in  the  management  of  skin  cancer  in  organ 
transplant recipients. Dermatol Surg. 2004;30(4 Pt 2):656.

3.  Bornstein P, Sage H. Structurally distinct collagen types. Annu Rev 

Biochem. 1980;49:957.

4.  Di Lullo GA, Sweeney SM, Korkko J, et al. Mapping the ligand-
binding  sites  and  disease-associated  mutations  on  the  most 
abundant  protein  in  the  human,  type  I  collagen.  J  Biol  Chem. 
2002;277:4223.

5.  Nelson B, Majmudar G, Griffiths C, et al. Clinical improvement 
following  dermabrasion  of  photoaged  skin  correlates  with 
synthesis of collagen I. Arch Derm. 1994;130:1136.

6.  Skinner SM, Gage JP, Wilce PA, et al. A preliminary study of the 
effects of laser radiation on collagen metabolism in cell structure. 
Aust Dent J. 1996;41:188.

7.  Orringer  JS,  Kang  S,  Johnson  TM,  et  al.  Connective  tissue 
remodeling  induced  by  carbon  dioxide  laser  resurfacing  of 
photodamaged human skin. Arch Dermatol. 2004;140:1326.

8.  Weiss  RA,  Weiss  MA,  Beasley  KL.  Rejuvenation  of  photoaged 
skin: 5 years results with intense pulsed light of the face, neck, 
and chest. Dermatol Surg. 2002;28:1115.

9.  Wang F, Garza LA, Kang S, et al. In vivo stimulation of de novo 
collagen  production  caused  by  cross-linked  hyaluronic  acid 
dermal  filler  injections  in  photodamaged  human  skin.  Arch 
Dermatol. 2007;143:155.

10.  Rosenbloom J, Abrams WR. Elastin and the microfibrillar appara-
tus.  In:  Royce  PM,  Steinmann  B,  eds.  Connective  Tissue  and  Its 
Heritable Disorders: Molecular, Genetic, and Medical Aspects. 2nd ed. 
Hoboken, NJ: Wiley-Liss; 2002:249–269.

11.  Bissett DL. Glucosamine: An ingredient with skin and other ben-

efits. J Cosmet Dermatol. 2006;5:309.

12.  Murad  H,  Tabibian  MP.  The  effect  of  an  oral  supplement 
containing glucosamine, amino acids, minerals, and antioxidants 
on  cutaneous  aging:  A  preliminary  study.  J  Dermatolog  Treat. 
2001;12:47.

13.  Tammi R, Tammi M. Influence of retinoic acid on the ultrastruc-
ture and hyaluronic acid synthesis of adult human epidermis in 
whole skin organ culture. J Cell Physiol. 1986;126:389.

14.  Weisberg  E,  Baumann  L.  Cosmetic  and  drug  regulation.  In: 
Baumann  L,  Saghari    S,  Weisberg  E,  eds.  Cosmetic  Dermatology: 
Principles  and  Practice.  2nd  ed.  New  York:  McGraw-Hill; 
2009:241.

 
C H A P T E R  6  ■   O V E R V I E W   O F   C L E A N S I N G   AG E N T S  

19

SECTION

A

Cleansing Agents

C H A P T E R   6

Overview of Cleansing Agents

The primary purpose of cleansing is to remove oil, bacteria, 
sweat, dirt, and desquamated skin cells from the face and 
body. However, cleansers can react with lipids and proteins 
on  the  skin  and  incite  keratinocytes  to  release  cytokines, 
all  of  which  can  irritate  or  damage  the  skin’s  surface.1,2 
Surface-active substances, known as surfactants, work by 
reducing  the  surface  tension  on  the  skin  and  emulsifying 
dirt.3  There  are  various  kinds  of  surfactants  found  in 
cleansers.

 CATIONIC (POSITIVELY CHARGED) 
SURFACTANTS

Cationic  surfactants  have  lower  detergent  properties  than 
anionic surfactants and are very irritating, but are typically used 
because  of  their  antimicrobial  properties.  These  surfactants 
often lead to the hand dermatitis seen in frequent hand washers. 
Cetrimide,  chlorhexidine,  and  benzalkonium  chloride  are 
examples of cationic surfactants.

 ANIONIC (NEGATIVELY CHARGED) 
SURFACTANTS

Anionic  surfactants  form  generous  foam  and  have  the 
highest  cleansing  power.  Consequently,  these  compounds 
are  often  found  as  the  primary  surfactants  in  cleansers 
(Table  6-1).  “Soap”  contains  the  anionic  surfactant  alkyl 
carboxylate. These anionic agents are potent irritants to 
the skin,4 and have been found to cause harmful swelling 
of  cell  membranes.5,6  The  well-known  anionic  agent  (a 
type of alkyl sulfate) sodium lauryl sulfate (SLS), which 
strips lipids from the skin, is so irritating that it is used 
in the research setting to impair the skin barrier in order 
to  test  “barrier  repair  products.”  Sodium  laureth  sulfate 
(or sodium lauryl ether sulfate, also known as SLES) has 
good  cleansing  power  but  is  less  likely  to  provoke 
irritation than SLS.

TABLE 6-1 
Anionic Agents used in Surfactants
Acyl glycinates
Acylglutamates
Alkyl acyl isethionates
Alkyl carboxylates
Alkyl ether sulfates
Alkyl ethoxy sulfates
Alkyl phosphates
Alkyl sulfates
Alkyl sulfonates
Alkyl sulfosuccinates
Alkyl taurates

 AMPHOTERIC SURFACTANTS

Amphoteric surfactants exhibit changing properties depending 
on  the  pH  of  the  solution.  Amphoterics  are  popular  because 
they lather well, exhibit good cleansing power and compatibility 
with  different  pHs,  display  moderate  antimicrobial  activity, 
and cause minimal irritation. Examples include cocamidopropyl 
betaine, cocoamphoacetate, and cocoamphodiacetate.

 NONIONIC SURFACTANTS

Nonionic  agents  have  no  electric  charge.  They  are  expensive 
and demonstrate poor cleansing characteristics but are believed 
to  cause  less  irritation  than  anionic  or  cationic  cleansers. 
Nonionic agents have been found to disrupt the skin barrier by 
solubilizing fatty acids and cholesterol.2 Examples of nonionic 
surfactants include cocoglucoside, lauryl glucoside, decylgluco-
side, and coconut diethanolamine (cocamide DEA).

 IRRITANCY

Several factors influence the irritancy potential of cleansers including 
the  amount  of  time  left  on  the  skin,  rinsability,  pH,  and  the 
susceptibility of the skin to irritation. (Individuals with a Baumann 
Skin Type designated as S4 are more susceptible to irritation because 
their  skin  barrier  is  impaired.)  The  surfactant  type  is  the  main 
influence on irritancy. Surfactants with C10–C14 chain lengths are 
the most aggressive because they are the most active in solution.

 NEWER CLASSES OF CLEANSERS

Attempts  to  diminish  the  irritancy  of  soaps  through  the 
addition of secondary components have led to the development 
of  newer  classes  of  cleansers  such  as  superfatted  soaps, 

 
20 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

transparent  soaps,  and  combination  bars  (combars).  Bars 
composed of synthetic surfactants are often referred to as “syndet 
bars.” These surfactants have a neutral pH, and include ingredients 
such as alkyl glyceryl ether sulfonate, a -olefin sulfonates, betaines, 
sulfosuccinates,  sodium  cocoyl  monoglyceride  sulfate,  and 
sodium cocoyl isethionate. Organic preparations are also available 
and include ingredients such as saponins and sucrose laurate.

 NATURAL INGREDIENTS IN CLEANSERS

Saponins  are  a  large  family  of  structurally-related  compounds 
derived  from  plants.  The  word  “saponin”  originates  from  the 
plant  genus  Saponaria.  Many  saponins  manifest  foaming 
characteristics  that  make  them  a  good  option  for  natural  or 
organic  cleansers.  Saponins  are  composed  of  a  steroid  or 
triterpenoid  aglycone  (sapogenin)  linked  to  one  or  more 
oligosaccharide  moieties  by  glycosidic  linkage.7  The  foaming 
action of saponins emerge by dint of the combination of the non-
polar sapogenin and the water-soluble side chain. The Sapindus 
mukorossi (soapnut) plant has been used as a natural cleanser and 
displayed antimicrobial activity in one study.8–11 Camellia oleifera 
has  been  shown  to  exhibit  notable  detergent  abilities.7  Several 
plants contain saponins, including alfalfa foliage, peas, chickpeas, 
horse chestnut trees, soybeans, and daisies. Desert plants, includ-
ing  Yucca  schidigera  and  Quillaja  saponaria,  are  good  sources  of 
saponins and are found in natural cleansers on the market.

 CLEANSER CHOICE

The choice of cleanser is pivotal for individuals that suffer from 
excessively  oily  or  dry  skin.  Oily  skin  benefits  from  foaming 
cleansers that can strip unwanted sebum lipids from the skin, 

while people with dry skin are better served with lipid-sparing 
gentle cleansers such as milks and creams.

REFERENCES

1.  Bárány E, Lindberg M, Lodén M. Biophysical characterization of 
skin damage and recovery after exposure to different surfactants. 
Contact Dermatitis. 1999;40:98.

2.  Ananthapadmanabhan  KP,  Moore  DJ,  Subramanyan  K,  et  al. 
Cleansing  without  compromise:  the  impact  of  cleansers  on  the 
skin barrier and the technology of mild cleansing. Dermatol Ther. 
2004;17(Suppl 1):16.

3.  Corazza M, Lauriola MM, Zappaterra M, et al. Surfactants, skin 
cleansing protagonists. J Eur Acad Dermatol Venereol. 2010;24:1.
4.  Effendy  I,  Maibach  HI.  Surfactants  and  experimental  irritant 

contact dermatitis. Contact Dermatitis. 1995;33:217.

5.  Wilhelm  KP,  Freitag  G,  Wolff  HH.  Surfactant-induced  skin 
irritation and skin repair. Evaluation of the acute human irritation 
model  by  noninvasive  techniques.  J  Am  Acad  Dermatol. 
1994;30:944.

6.  Froebe  CL,  Simion  FA,  Rhein  LD,  et  al.  Stratum  corneum  lipid 
removal by surfactants: Relation to in vivo irritation. Dermatologica. 
1990;181:277.

7.  Chen  YF,  Yang  CH,  Chang  MS,  et  al.  Foam  properties  and 
detergent  abilities  of  the  saponins  from  Camellia  oleifera.  Int  J 
Mol Sci. 2010;11:4417.

8.  Aneja  KR,  Joshi  R,  Sharma  C.  In  vitro  antimicrobial  activity  of 
Sapindus mukorossi and Emblica officinalis against dental caries 
pathogens. Ethnobotanical Leaflets. 2010;14:402.

9.  Kamra DN, Patra AK, Chatterjee PN, et al. Effect of plant extracts 
on methanogenesis and microbial profile of the rumen of buffalo: 
A brief overview. Austral J Exp Agric. 2008;48:175.

10.  Patra AK, Saxena J. The effect and mode of action of saponins on 
the  microbial  populations  and  fermentation  in  the  rumen  and 
ruminant production. Nutr Res Rev. 2009;22:204.

11.  Rakesh  M,  Ashok  K,  Kumar  S,  et  al.  Formulation  of  herbal 
shampoos  from  Asparagus  racemosus,  Acacia  concin,  Sapindus 
mukorosii. Int J Pharm Sci Rev Res. 2010;4:39.

 
C H A P T E R  7  ■   M O I S T U R I Z I N G   AG E N T S  

21

SECTION

B

Moisturizing Agents

C H A P T E R   7

Moisturizing Agents

In the 1950s, Blank demonstrated that low moisture content of 
the  skin  is  a  prime  factor  in  dry  skin  conditions.1  It  is  now 
known  that  the  symptoms  of  dry  skin  can  be  treated  by 
increasing  the  hydration  state  of  the  stratum  corneum  with 
occlusive  or  humectant  ingredients;  smoothing  the  rough 
surface  with  an  emollient;  restoring  the  integrity  of  the  skin 
barrier;  increasing  natural  moisturizing  factor  (NMF)  or  the 
activity  of  aquaporin;  and  controlling  the  calcium  gradient. 
Choosing the correct cleanser is also crucial in the treatment of 
dry skin (see Chapter 6, Overview of Cleansing Agents).

Various types of moisturizers are combined to form the best 
strategy  for  treating  the  underlying  issues  leading  to  dry  skin. 
Several factors should be taken into account when choosing the 
type of moisturizing ingredients. The first is the Baumann Skin 
Type (BST) (see Chapter 1, The Importance of Skin Type: The 
Baumann Skin Type System). The level of dryness determined 
by the Baumann Skin Typing System (BSTS), designated by D1 
D2 D3, gives information about the severity of skin dryness. A 
higher D score such as D3 indicates that more than one defect is 
contributing to skin dryness and that multiple strategies should 
be chosen. If the BST also includes type 4 sensitive (S4) skin, then 
there is evidence that the skin barrier is severely impaired and the 
barrier repair strategy should take top priority. If the Baumann 
Skin  Type  Indicator  (BSTI)  questionnaire  that  determines  BST 
detects  signs  of  increased  sebum  secretion,  then  an  occlusive 
moisturizer  would  be  unnecessary  because  sebum  is  a  great 
occlusive  moisturizer.  Individuals  who  have  dry  skin  with 
increased sebum secretion likely have defects such as impaired 
aquaporin function, decreased NMF, altered calcium channels, or 
they may be using barrier-disturbing cleansers that are leading to 
the dry skin. Noting the humidity level of the environment prior 
to  choosing  a  moisturizer  is  important  because  humectant 
ingredients  work  better  in  a  humid  environment.  Knowing 
habits such as increased sun exposure (which lowers NMF) and 

prolonged immersion in water (which disturbs the skin barrier) 
can also give clues about the causes of dry skin.

The  ingredients  in  this  chapter  are  divided  into  subsections 
according to their mechanism of action. Some ingredients have 
more than one mechanism of action. In that case, they will be 
discussed in the subsection that displays the unique characteristics 
of that ingredient and distinguishes it from others. For example, 
glycerin is a well-known and very effective humectant, but it has 
the unique property of being able to pass through the aquaporin 
channels so it will be discussed in the aquaporin subsection. The 
mechanisms will be briefly explained at the beginning of each 
subsection. For more detailed information on the causes of dry 
skin, see Cosmetic Dermatology: Principles and Practice, 2nd edition, 
McGraw-Hill (2009).

Emollients are substances added to cosmetics to soften and 
smooth the skin and are composed mainly of lipids and oil. They 
act by filling the spaces between desquamating corneocytes to 
create a smooth surface. Emollients provide increased cohesion 
of cells causing a flattening of the curled edges of the individual 
corneocytes and a smoother surface with less friction and greater 
light refraction. Most emollients function as occlusives but some 
exhibit humectant activity; therefore, they will be discussed in 
the corresponding subsections of this chapter. Lanolin, mineral 
oil,  shea  butter,  safflower  oil,  and  petrolatum  are  examples  of 
occlusive ingredients that also confer an emollient effect. Long 
chain saturated fatty acids and fatty alcohols are often used as 
emollients,  such  as  stearic,  linoleic,  linolenic,  oleic,  and  lauric 
acids.

REFERENCE

1.  Blank  IH.  Factors  which  influence  the  water  content  of  the 

stratum corneum. J Invest Dermatol. 1952;18:433.

 
22 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   8

Occlusives

Occlusive agents are usually oily substances that coat the stratum 
corneum (SC) rendering an emollient effect as well as the ability 
to decrease transepidermal water loss (TEWL). Two of the best 
occlusive  ingredients  currently  available  are  petrolatum  and 
mineral  oil.  Petrolatum,  for  example,  has  a  water  vapor  loss 
resistance 170 times that of olive oil.1 However, petrolatum and 
mineral  oil  have  a  greasy  feeling  on  the  skin,  leaving  them 
cosmetically  undesirable,  and  have  further  lost  popularity 
because of the greater awareness of the environmental effects of 
processing  these  products.  Other  synthetic  agents  commonly 
used as occlusive ingredients include paraffin, squalene, dimethi-
cone, and propylene glycol.2 Lanolin is an example of a natural 
occlusive  ingredient.  Organic  occlusive  ingredients  have  also 
become  increasingly  popular  and  include  argan  oil,  beeswax, 
borage seed oil, safflower oil, olive oil, jojoba oil, and tamanu oil. 
Occlusive  ingredients  seem  to  be  most  effective  when  placed 
over damp skin and are only effective while present on the skin 
because  once  removed,  TEWL  returns  to  the  normal  level. 
Occlusives are usually combined with humectant ingredients.

 INFLUENCES ON THE OCCLUSIVE EFFECT3
In  order  for  an  ingredient  to  impart  an  occlusive  effect,  the 
molecules in that ingredient must be able to align to form a tight 
barrier (or palisade). Short straight chains of the same length are 
the most efficient at aligning in this manner. When a product 
contains  various  compounds  with  diverse  types  of  chains  or 
with  different  chain  lengths,  it  is  inherently  a  less  effective 
occlusive than an agent with a consistent type of molecule with 
a  straight  chain.  An  example  of  a  well-structured  occlusive  is 
mineral oil, which contains straight alkyl chains but of varying 
lengths. This contributes to its ability to form a tight palisade on 
the  skin  and  exhibit  a  strong  occlusive  effect  (Figure  8-1).  
If mineral oil had straight alkyl chains of the same length, its 
occlusive  effect  would  be  even  stronger.  In  contrast,  the 
molecules in botanical oils can be extremely diverse, making it 
difficult for the molecules to tightly align. For this reason, many 
botanical oils make poor occlusive agents.

Another factor that determines occlusive ability is ingredient 
substantivity, or the ability of the ingredients to stay on the skin’s 
surface. If the molecules rapidly penetrate into the SC, then the 
result is a weaker palisade or occlusive effect, which is known as 
lower substantivity. Therefore, ingredients with larger molecules 
and  a  comparatively  lower  capacity  to  penetrate  the  SC,  thus 
higher  substantivity,  may  display  greater  occlusive  activity. 
Viscosity can also affect occlusive ability. For example, petrolatum 
has  a  higher  viscosity  than  mineral  oil  and  is  a  much  better 
occlusive.  In  many  cases,  such  as  petrolatum,  high  viscosity 
corresponds with low spreadability. Therefore, ingredients with 
a very high viscosity may offer less cosmetic appeal to consumers 
because of their decreased spreadability. Viscosity also influences 
the  occlusive  effect  insofar  as  in  less  viscous  formulations,  the 
ingredient diffuses laterally allowing the palisade to break down, 
which  results  in  a  less  occlusive  effect.  The  viscosity  of  a 
completed  formulation  can  be  adjusted  with  the  addition  of 

Water vapor permeability of dif ferent
emollients (conditions: 25°C, 35% rel. humidity, 24 hours)

Emollient

Water vapor
permeability (%)

Control

1. Isopropyl myristate

2. Ethyl oleate
3. Isopropyl palmitate
4. lsopropyl stearate
5. 2-ethyl-hexyl cocoate

6. 2-ethyl-hexyl palmitate

7. Decyl oleate
8. 2-ethyl-hexyl tallowate

9. 2-ethyl-hexyl stearate

10. Oleyl oleate

11. 2-octyl-dodecyl myristate

12. Oleyl erucate

13. 2-octyl-dodecyl palmitate

14. 2-octyl-dodecyl stearate

15. Mineral oil

6.63

3.04

2.84
2.73

2.43

2.07

1.66

1.54

1.51

1.47

1.21

0.94

0.93

0.85

0.78

0.30

▶
FIGURE 8-1 Various ingredients were studied for effects on TEWL and 
mineral oil was found to be superior to the others tested. Reprinted with 
permission from Rawlings AV, Lombardi KJ. A review on the extensive skin 
benefits of mineral oil. Int J Cosmet Sci 2012;34:511.

hyaluronic acid, sugars, and various polymers that may positively 
or negatively impact the efficacy of the final product.

The  concentration  of  ingredients  also  plays  an  important 
role in occlusive ability. There must be enough of the occlusive 
ingredient in a formula for it to be an active occlusive. Many 
cosmetic emollients are not included in a sufficient concentration 
to  be  effective.  Other  reasons  that  occlusives  would  lose 
efficacy  include:  they  are  not  viscous  enough  to  exhibit  an 
adequate  degree  of  substantivity;  their  components  are  not 
regularly shaped well enough to form a tight palisade; or their 
activity is diminished by other ingredients in the formulation. 
Therefore, when evaluating the occlusive aspects of a product, 
it  is  necessary  to  consider  the  final  viscosity  and  physical 
characteristics of the formula and the interactions of major and 
minor ingredients.

REFERENCES

1.  Spruitt  D.  The  interference  of  some  substances  with  the  water 

vapor loss of human skin. Dermatologica. 1971;142:89.

2.  Draelos Z. Moisturizers. In: Atlas of Cosmetic Dermatology. New York 

Churchill Livingstone; 2000:83.

3.  Rawlings AV, Lombard KJ. A review on the extensive skin bene-

fits of mineral oil. Int J Cosmet Sci. 2012;34:511.

 
C H A P T E R   9

Oils

Oil  is  a  substance  that  is  liquid  at  room  temperature  and 
insoluble  in  water.  Synthetic  oils  include  mineral  oil  and 
petrolatum, which are derived from the distillation of petroleum 
in the production of gasoline. Vegetable oils are pressed out of 
seeds, and essential oils are steamed from several plant parts, 
including  stems,  leaves,  and  roots.  The  Cosmetic  Ingredient 
Review  (CIR)  categorizes  vegetable  oils  in  the  larger  class  of 
edible  oils.  Edible  oils,  such  as  peanut  oil,  are  refined  in  a 
process  that  removes  proteins  that  can  cause  sensitization  in 
allergic  individuals.1  Manufacturers  of  animal-derived  oils, 
such  as  lanolin,  have  to  follow  strictly  certified  processes  in 
order to eliminate any risk of infectious agents. 

 TriglycEridEs

Most  oils  and  fats  are  triglycerides,  which  are  composed  of 
glycerol and fatty acids. Natural triglycerides  contain  the  five 
most  common  fatty  acids  in  various  proportions:  palmitic, 
stearic, oleic, linoleic, and linolenic acids.

 FaT Ty a cids

Oils contain a large variety of fatty acids, with stearic, oleic, 
and linoleic acids among the most abundant.2 The fatty acid 
profile  for  a  certain  oil  helps  to  determine  the  oil’s 
characteristics with respect to skin feel,  substantivity, occlu-
sive  ability,  penetration,  biologic  activity,  and  stability. 
Stability  is  influenced  by  susceptibility  to  oxidation:  fatty 
acids with a higher degree of unsaturation are oxidized more 
easily. Essential fatty acids (EFAs) are those that the body can-
not synthesize and, therefore, must be obtained topically or in 
the diet. Vegetable and fish oils contain EFAs such as ω-6 and 
ω-3  fatty  acids.  EFAs  influence  skin  barrier  function,  mem-
brane fluidity, cell signaling, and the inflammatory eicosanoid 
pathway.  Nonessential  fatty  acids  and  EFAs  play  important 
roles in skin function.

Linoleic Acid
Linoleic acid is an EFA. Several edible oils contain linoleic acid. 
Linoleic acid is an unsaturated ω-6 fatty acid present in many 
oils including sunflower and safflower (Table 9-1). In addition 
to  providing  structural  lipids  needed  for  barrier  integrity,  lin-
oleic acid is used by the body to produce γ-linolenic acid (GLA). 
GLA is a polyunsaturated essential cis-fatty acid important in 
the  production  of  prostaglandins;  therefore,  it  plays  a  role  in 
the inflammatory process.

Oleic Acid
Oleic  acid  is  technically  not  an  EFA  because  the  body  can 
produce a small amount; however, it is a very important fatty 
acid for the skin. Oleic acid has a polar head group attached to 
a  long  alkyl  chain.3,4  This  structure  allows  it  to  disrupt  the 

C H A P T E R  9  ■   O I L S  

23

TABLE 9-1
Oils That Contain Linoleic Acid

OILS
Black currant
Borage
Chestnut
Coconut
Corn
Cotton seed
Evening primrose
Grape seed
Hemp
Macadamia
Olive
Palm
Peanut
Pistachio
Poppy seed
Rice bran
Safflower
Sesame
Soybean
Sunflower
Walnut
Wheat germ

barrier by inserting its alkyl chains into ceramides. In turn, this 
sets the stage for a phase separation to occur, leading to pools 
of oleic acid in the membrane, which is more fluid and easier 
for  molecules  to  diffuse  through  than  intact  ceramides.5  The 
result  is  barrier  disruption  and  increased  penetration  of 
molecules. Oleic acid is found in high amounts in olive oil.

Stearic Acid
Stearic acid is made by the body, and therefore is not an EFA. It 
is very commonly seen in skin care products (see Chapter 23, 
Stearic Acid).

 EdiblE  Oils VErsus MinEral Oils

Edible oils contain a wide variety of chemical components, such 
as unsaturated, aromatic groups and polyphenols, which affect 
its activity whereas mineral oil contains mainly straight-chain 
hydrocarbons. Edible oils can be used to deliver a specific effect 
or activity, such as anti-inflammatory or antioxidant, while min-
eral oils, which are inert, only provide an occlusive, softening 
effect.  Some  edible  oils  increase  penetration  of  ingredients  in 
other  topically  applied  products  while  mineral  oils  seem  to 
decrease penetration of ingredients.6 Edible oils, including those 
in cosmetics,7 may contain harmful aflatoxins that occur when 
the  crops  have  an  infestation  of  a  type  of  fungus  known  as 
Aspergillum.8  Aflatoxins  are  toxic  and  carcinogenic.  In  fact, 

 
24 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

aflatoxins have been used to induce skin cancer in the research 
setting.9 High temperature and high humidity favor the growth 
of Aspergillum. The United States Food and Drug Administration 
(USFDA)  has  developed  standards  to  protect  crops  from  afla-
toxin  contamination,  but  not  all  countries  have  adopted  this 
approach.10 The risk of aflatoxins is an example that lends cre-
dence to the statement that “natural” products are not necessar-
ily safer than synthetic products.11

 saFET y

Essential Oils
Essential oils have increased in popularity. However, it is crucial 
to  realize  that  these  products  can  act  as  allergens.12  Massage 
therapists  and  others  who  are  routinely  exposed  to  essential 
oils are at risk for developing an allergy to the topically applied 
oil that can translate to an allergy to that oil in food products.13 
The CIR report in December 2010 stated that edible oils are 
believed to be safe for use on the skin. Those with an allergy to 
a food are most likely allergic to the proteins in the food. This 
protein does not partition into the refined oil; therefore, someone 
with a peanut allergy likely will not react to peanut oil. Oils that 
have  been  associated  with  causing  a  contact  allergy  include 
soybean, sunflower seed, olive, avocado, sesame seed, cashew, 
and macadamia.14

 TuMOrigEnEsis

Published data provide substantial evidence that some vehicles, 
particularly  the  lighter  oils,  enhance  penetration  of  ultraviolet 
radiation (UVR) into mouse skin, leading to a greater cutaneous 
response—sometimes nearly doubling the effectiveness of a UVR 
dose.15  Heavier  formulations,  such  as  petrolatum  and  lanolin, 
were shown by Kligman and Kligman to prevent tumorigenesis.16 
Lu et al. demonstrated that certain moisturizing creams enhanced 
tumorigenesis in mice, but a formulation that excluded mineral 
oil did not.17 It seems apparent that all oils have light-reflective 
properties and can allow more light to be absorbed into the skin; 
however, it is unknown at this time exactly what roles various 
oils  play,  if  any,  in  skin  cancer  formation.  Animal  and  human 
studies of mineral oil are conflicting. Botanical oils that contain 
antioxidants, for example, may be able to neutralize any damage 
caused by increased absorption of UV light.18

rEFErEncEs

1.  Yunginger JW, Calobrisi SD. Investigation of the allergenicity of a 
refined  peanut-oil-containing  topical  dermatologic  agent  in 
persons who are sensitive to peanuts. Cutis. 2001;68:153.

2.  Lodén M. Role of topical emollients and moisturizers in the treat-
ment of dry skin barrier disorders. Am J Clin Dermatol. 2003;4:771.
3.  Naik A, Pechtold LA, Potts RO, et al. Mechanism of oleic acid-
induced  skin  penetration  enhancement  in  vivo  in  humans.  
J Control Release. 1995;37:299.

4.  Ongpipattanakul  B,  Burnette  RR,  Potts  RO,  et  al.  Evidence  that 
oleic  acid  exists  in  a  separate  phase  within  stratum  corneum 
lipids. Pharm Res. 1991;8:350.

5.  Hadgraft  J.  Modulation  of  the  barrier  function  of  the  skin.  Skin 

Pharmacol Appl Skin Physiol. 2001;14(Suppl 1):72.

6.  Sahlin A, Edlund F, Lodén M. A double-blind and controlled study 
on  the  influence  of  the  vehicle  on  the  skin  susceptibility  to 
stinging from lactic acid. Int J Cosmet Sci. 2007;29:385.

7.  Mahoney N, Molyneux RJ. Rapid analytical method for the deter-
mination  of  aflatoxins  in  plant-derived  dietary  supplement  and 
cosmetic oils. J Agric Food Chem. 2010;58:4065.

8.  Cavaliere C, Foglia P, Guarino C, et al. Determination of aflatoxins 
in olive oil by liquid chromatography-tandem mass spectrometry. 
Anal Chim Acta. 2007;596:141.

9.  Rastogi S, Shukla Y, Paul BN, et al. Protective effect of Ocimum 
sanctum  on  3-methylcholanthrene,  7,12-dimethylbenz(a)
anthracene and aflatoxin B1 induced skin tumorigenesis in mice. 
Toxicol Appl Pharmacol. 2007;224:228.

10.  el-Dessouki  S.  Aflatoxins  in  cosmetics  containing  substrates  for 

aflatoxin-producing fungi. Food Chem Toxicol. 1992;30:993.

11.  Antignac E, Nohynek GJ, Re T, et al. Safety of botanical ingredi-
ents  in  personal  care  products/cosmetics.  Food  Chem  Toxicol. 
2011;49:324.

12.  Boonchai W, Iamtharachai P, Sunthonpalin P. Occupational allergic 
contact dermatitis from essential oils in aromatherapists. Contact 
Dermatitis. 2007;56:181.

13.  Bleasel  N,  Tate  B,  Rademaker  M.  Allergic  contact  dermatitis 
following  exposure  to  essential  oils.  Australas  J  Dermatol. 
2002;43:211.

14.  Cosmetic  Ingredient  Review:  Draft  report  of  the  plant-derived 
edible  oil  group.  http://www.cir-safety.org/sites/default/files/117 
_draft_oils.pdf. Washington, DC 2010. Accessed October 17, 2012.
15.  Forbes PD. Moisturizers, vehicle effects, and photocarcinogenesis. 

J Invest Dermatol. 2009;129:261.

16.  Kligman  LH,  Kligman  AM.  Petrolatum  and  other  hydrophobic 
emollients  reduce  UVB-induced  damage.  J  Dermatolog  Treat. 
1992;3:3.

17.  Lu  YP,  Lou  YR,  Xie  JG,  et  al.  Tumorigenic  effect  of  some 
commonly  used  moisturizing  creams  when  applied  topically 
to  UVB-pretreated  high-risk  mice.  J  Invest  Dermatol. 
2009;129:468.

18.  Perchellet  JP,  Perchellet  EM,  Belman  S.  Inhibition  of  DMBA-
induced mouse skin tumorigenesis by garlic oil and inhibition of 
two tumor-promotion stages by garlic and onion oils. Nutr Cancer. 
1990;14:183.

 
C H A P T E R   1 0

Argan Oil

C H A P T E R  10  ■   A R G A N   O I L  

25

Activities:

Prostaglandin inhibition, antioxidant, barrier disruption 
and barrier repair, penetration enhancer

Important Chemical Components:
Major: Oleic acid, linoleic acid, palmitic acid, stearic acid1
Minor:  Polyphenols  (caffeic  acid,  vanillic  acid,  syringic 
acid, ferulic acid, tyrosol, catechol, resorcinol, (-)-epicat-
echin, (+)-catechin, p-hydroxybenzoic)
Sterols (stigmasta-8,22-diene-3-ol, spinasterol, schottenol, 
stigmasta, 7-24-diene-3-ol)
Tocopherols (α-, β-, γ-, and δ-tocopherols)
Squalene, carotenes, and triterpene alcohols1–4

Origin Classification:

This ingredient is considered natural. Organic forms are 
available.

Personal Care Category:

Antioxidant, moisturizing, anti-inflammatory

Recommended for the following Baumann Skin 
Types: 

All dry types and sensitive types will benefit from this 
ingredient  but  it  is  best  for  DRNW,  DRPW,  DSNT, 
DSNW, DSPT, and DSPW.

 SOURCE

Argan oil is derived from the fruit of Argania spinosa, which is a 
slow-growing tree native to the arid climate of southwestern 
Morocco (where it is the third most common tree regionally) as 
well  as  the  Algerian  province  of  Tindouf  in  the  western 
Mediterranean area.5,6

 HISTORY

For more than 800 years, native Moroccans and explorers to the 
region  have  cited  the  health  benefits  of  argan  oil  consumption 
and  topical  use.2  Traditionally,  the  vegetable  oil  has  been 
prescribed  for  reputed  cosmetic,  bactericidal,  and  fungicidal 
properties and as a treatment for infertility and heart disease.4,6 
Argan oil has been used as a treatment for acne, dry skin, dry hair, 
hair loss, psoriasis, wrinkles, skin inflammation, and joint pain.6,7

 CHEMISTRY

The ω-9 monounsaturated fatty acid known as oleic acid makes 
up a large proportion of the oil (43–49 percent) and has been found 
to be a penetration enhancer by disturbing the skin barrier.8,9 An 
ω-6  polyunsaturated  fatty  acid  known  as  linoleic  acid  (29–36 
percent of the oil) is integral in the biosynthesis of inflammatory 
prostaglandins  through  the  arachidonic  acid  pathway.4,10  The 

TABLE 10-1
Pros and Cons of Argan Oil

Pros
Polyphenol content supports antioxidant 

Cons
Oily, heavy texture

reputation

Use of argan forestry reforestation to 

stem desertification in Northern Africa

Very expensive, so often used in small 
amounts

Anecdotal experience has shown its 
usefulness in rosacea

presence of linoleic acid may help prevent or decrease inflamma-
tion.  Linoleic  acid  is  also  a  component  of  ceramide  1  linoleate, 
which is decreased in dry skin. Topical application of linoleic acid 
can  increase  ceramide  1  linoleate  levels  in  skin,  thus  reducing 
xerosis.11 Argan oil also contains the saturated fatty acids palmitic 
acid (11–15 percent) and stearic acid (4–7 percent).5

Though  argan  oil  is  mainly  composed  of  unsaturated  fatty 
acids (80 percent), the unsaponifiable fraction (1 percent) is rife 
with  antioxidants,  including  sterols,  saponins,  and  polyphe-
nols.1,2,4,12  It  is  the  polyphenolic  constituents,  mainly 
γ-tocopherol, that are thought to be primarily responsible for the 
antioxidant effects (Table 10-1).1,2,12,13

Olive and argan oils have been compared because of their simi-
lar  roles  in  regional  diets  and  their  purported  medical  benefits. 
Though olive oil has been far more extensively studied, it is worth 
noting that both vegetable oils have oleic and linoleic acids as their 
primary  constituents;  both  are  also  rich in  vitamin E. However, 
argan oil contains two to three times the amount of tocopherol. 
The main form of vitamin E in olive oil is α-tocopherol. Argan oil 
contains  γ-tocopherol,  which  is  considered  the  most  efficient 
among the tocopherols at scavenging free radicals.1,5,14

 ORAL USES

Argan oil is available in edible and cosmetic grades. Argan fruit 
kernels are roasted in the preparation of edible argan oil. Virgin 
argan oil is higher in total antioxidant capacity than other vegetable 
oils.3 Edible argan oil is known to have a taste similar to hazelnut. 
Argan oil used for cosmetic purposes is gold in color and has no 
taste. Given its abundant supply of fatty acids, phenolic constitu-
ents, squalene, sterols, and tocopherols, argan oil is also thought to 
be an important factor in enhancing the anticancer influences of 
the Moroccan diet.12 Drissi and other colleagues involved in much 
of the published research on argan oil recently studied the effects 
of  its  regular  consumption  on  the  lipid  profile  and  antioxidant 
status  in  healthy  Moroccan  subjects  (62  consumers  and  34  
nonconsumers, of whom 76 were women and 20 were men). The 
researchers  found  that  plasma  low-density  lipoprotein  (LDL)  
cholesterol  levels  were  lower  in  participants  who  regularly  
consumed virgin argan oil and their diets contained higher levels 
of polyunsaturated fats, as compared to the nonconsumers. They 
also  investigated  the  in  vitro  effects  of  the  tocopherols,  sterols,  
and  polyphenols  in  the  herbal  extract  on  LDL  peroxidation,  
finding  plasma  lipoperoxides  lower  and  the  molar  ratio  of 

 
26 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

α-tocopherol/total cholesterol and concentration of α-tocopherol 
higher in the consumer group as compared to nonconsumers. LDL 
oxidation was found to be similar in the two groups, despite the 
fact that consumers had higher plasma antioxidant concentrations 
and  lower  lipoperoxide  levels.  The  investigators  concluded  that 
their findings clearly established the antioxidant and cholesterol-
lowering activity imparted by the regular consumption of virgin 
argan oil, suggesting the viability of this natural extract as a dietary 
adjunct for lowering the risk of cardiovascular events.15

 TOPICAL USES

Unroasted  kernels  are  used  to  produce  cosmetic-grade  argan 
oil.  Cosmetic  argan  oil  is  used  in  moisturizing  creams,  body 
lotions, and shampoos. Although argan oil contains components 
that have antioxidant and anti-inflammatory features and there 
are many patents on the use of argan oil in skin care, there is a 
paucity of published research studies looking at the effects of 
argan oil-containing skin care products on aging, inflamed, or 
dry skin. In one study, Dobrev assessed the efficacy of a sebum 
control  cream  composed  of  saw  palmetto  extract,  sesame 
seeds, and argan oil in 20 healthy volunteers, 16 with oily skin 
and 4 with combination skin. During the two test months in 
the winter, the test formulation was applied twice daily to the 
face over four weeks. The volunteers were assessed clinically 
and by instrumental measurement before and after the study 
period.  Questionnaires  were  completed  by  participants  for  a 
subjective  evaluation  of  efficacy,  tolerance,  and  cosmetic 
qualities.  Objective  measurements  were  made  using  a 
Sebumeter, Sebufix, Visioscope and Surface Evaluation of the 
Living Skin (SELS) software. Results indicated that all volunteers 
tolerated the product. In 95 percent of the participants, a visible 
sebum-regulating  or  antisebum  efficacy  was  observed.  In 
addition,  clinical  evaluation  scores,  casual  sebum  levels,  and 
areas  covered  by  oily  spots  declined  significantly  after  one 
month of treatment. Dobrev concluded that this argan oil-con-
taining formulation was efficacious in mitigating the greasiness 
and  ameliorating  the  appearance  of  oily  facial  skin.16  The 
mechanism  of  the  effects  on  sebum  production  is  perplexing 
and questionable without further research looking at argan oil 
alone. In addition, this sole open-label study does not support 
the  use  of  argan  oil  as  an  antiaging  or  anti-inflammatory 
product, as it is most frequently employed. There are no other 
published studies on topical argan oil listed in PubMed.

The presence of camphor and 1,8-cineole in the fruit pulp of 
the fruit of A. spinosa has led some researchers to conclude that 
there is potential of the essential oil for use as an insect repellent.17 
In spite of the dearth of research, anecdotal evidence abounds 
and argan oil is an expensive and popular cosmetic product.

The  best  use  for  argan  oil  is  as  a  moisturizing  anti- 
inflammatory serum. Although the oleic acid components can 
harm  the  skin  barrier,  this  can  allow  penetration  of  other 
ingredients such as linoleic acid, which can help the skin form 
hydrating  ceramides.  The  disruption  of  the  barrier  caused  by 
oleic acid is likely counteracted by the occlusive properties of 
the  oil  that  help  prevent  transepidermal  water  loss  (TEWL) 
from  the  skin.  In  addition,  linoleic  acid  may  help  increase 
ceramide  1,  which  in  turn  strengthens  the  skin  barrier.  More 
importantly,  the  linoleic  acid  in  argan  oil  helps  prevent  the 
production  of  inflammatory  prostaglandins.  The  polyphenols 
in this compound have an anti-inflammatory and antioxidant 
effect as well (see Chapter 46, Antioxidants, and Chapter 64, 
Anti-Inflammatory Agents).

 SAFETY ISSUES

Argan oil has been used safely by the Amazigh population of 
southern  Morocco  for  centuries  as  part  of  their  diet  and  as  a 
topical cosmetic agent for just as long. It is not believed to be 
associated  with  acute  or  chronic  toxicity.  One  case  of 
anaphylaxis was reported in 2010.18

 ENVIRONMENTAL IMPACT

The  argan  tree  is  endangered  by  the  harsh  environment  and 
overexploitation.2 It was protected first by Moroccan law, then 
in  1998  by  the  United  Nations  Educational  Scientific  and 
Cultural Organization (UNESCO), and the tree was added to 
the  World  Heritage  List  in  1999  and  designated  as  a 
bioreserve.5,19 The trees are important to the region because the 
roots  help  prevent  encroachment  of  the  Sahara  desert,  the 
locals use the fruits, leaves, and wood for their own needs, and 
the oil extracted from the tree is used in cooking and sold for 
use  in  skin  and  hair  care  products  providing  much  needed 
income for the local Berber women. A third of Morocco’s argan 
forest has disappeared in the last 100 years. A local economic 
interest  group  for  the  development,  preservation,  and 
valorization of the forest has been created and collaborations 
have  been  formed  to  harvest  argan  oil  in  a  sustainable 
fashion.5,20 The “argan forest” in Morocco is considered to be a 
crucial  factor  in  stemming  desertification,  with  sustainable 
development of the forest dating to 1995.

 FORMULATION CONSIDERATIONS

Virgin  edible  and  beauty  oils  are  produced  only  in  Morocco, 
but industrially prepared cosmetic argan oil, which uses solvent 
extraction  of  imported  kernels,  occurs  primarily  in  Europe.5 
Cosmetic  argan  oil  is  limited  to  inclusion  in  moisturizers, 
shampoos, and other cosmetic products.5

 USAGE CONSIDERATIONS

Virgin edible argan oil has a longer shelf-life than virgin beauty 
argan oil. At 77°F (25°C), the edible variety can last as long as 
two years, whereas the topical oil has a notably brief shelf-life 
of three to four months.5,21

 SIGNIFICANT BACKGROUND

Once prevalent in North Africa, the A. spinosa tree is cultivated 
only in Morocco presently,20 and is considered to be endangered, 
so its oil, which is labor-intensive to obtain, is becoming more 
valuable, increasing the risk of overexploitation of the trees.

There  is  little  research  on  this  botanical  compound,  but  the 
preponderance  of  recent  investigations  has  focused  on  the 
cardiovascular benefits of virgin argan oil consumption. Specifically, 
antiatherogenic,  cholesterol-lowering,  antiproliferative,  and 
antioxidant benefits have been observed.22–26

Argan  oil  may  qualify  as  one  of  the  latest  in  a  long  line  of 
“flavors-of-the-month” in terms of so-called “miracle” ingredients 
in the beauty industry. It is quite popular in France, Japan, as well 
as  North  America,  and  English  and  French  tourists  have  been 
known for several years to return with argan oil from vacations 
in  Morocco.1,19  In  fact,  argan  oil  was  identified  as  the  world’s 
most  expensive  oil  in  2009  and  ranked  by  the  public  relations 

 
firm Pierce Mattei as the number one cosmetic ingredient.2 As a 
cosmetic agent, argan oil is touted for hydrating and revitalizing 
the skin, treating acne, and making the hair shine. The reputed 
therapeutic  activities  of  topical  argan  oil  are  characterized  as 
antiacne,  antisebum,  antiaging,  moisturizing,  and  wound 
healing,  but  such  claims  are  based  on  traditional  uses  and  are 
associated with minimal scientific evidence.5

 CONCLUSION

The  body  of  published  research,  particularly  clinical  data,  on 
argan oil is scant. However, in the author’s experience, it is very 
useful  in  rosacea  and  reduces  redness  better  than  licorice 
extract,  feverfew,  and  prescription  azelaic  acid  and 
metronidazole.  Further  study  is  warranted,  and  randomized 
controlled trials are necessary to establish the efficacy of the use 
of argan oil in inflammatory disorders such as rosacea. Argan 
oil  is  expensive  and  most  products  currently  on  the  market 
contain such a small amount of the oil that efficacy is doubtful.

REFERENCES

1.  Charrouf Z, Guillaume D. Should the amazigh diet (regular and 
moderate  argan-oil  consumption)  have  a  beneficial  impact  on 
human health? Crit Rev Food Sci Nutr. 2010;50:473.

2.  Monfalouti  HE,  Guillaume  D,  Denhez  C,  et  al.  Therapeutic 
potential of argan oil: a review. J Pharm Pharmacol. 2010;62:1669.
3.  Cabrera-Vique  C,  Marfil  R,  Giménez  R,  et  al.  Bioactive  com-
pounds and nutritional significance of virgin argan oil – An edible 
oil with potential as a functional food. Nutr Rev. 2012;70:266.
4.  Cherki M, Berrougui H, Drissi A, et al. Argan oil: Which benefits 

on cardiovascular diseases? Pharmacol Res. 2006;54:1.

5.  Guillaume  D,  Charrouf  Z.  Argan  oil.  Monograph.  Altern  Med  

Rev. 2011;16:275.

6.  Charrouf Z, Guillaume D. Ethnoeconomical, ethnomedical, and 
phytochemical  study  of  Argania  spinosa  (L.)  Skeels.  J 
Ethnopharmacol. 1999;67:7.

7.  El Babili F, Bouajila J, Fouraste I, et al. Chemical study, antimalarial 
and  antioxidant,  and  cytotoxicity  to  human  breast  cancer  cells 
(MCF7) of Argania spinosa. Phytomedicine. 2010;17:157.

8.  Naik A, Pechtold LA, Potts RO, et al. Mechanism of oleic acid-
induced  skin  penetration  enhancement  in  vivo  in  humans.  
J Control Release. 1995;37:299.

9.  Tanojo H, Bosvan Geest A, Bouwstra JA et al. In vitro human skin 
barrier  perturbation  by  oleic  acid:  Thermal  analysis  and  freeze 
fracture  electron  microscopy  studies.  Thermochimica  Acta. 
1997;293:77.

C H A P T E R  10  ■   A R G A N   O I L  

27

10.  Das UN. Essential fatty acid metabolism in patients with essential 
hypertension,  diabetes  mellitus  and  coronary  heart  disease. 
Prostaglandins Leukot Essent Fatty Acids. 1995;52:387.

11.  Conti A, Rogers J, Verdejo P, et al. Seasonal influences on stratum 
corneum  ceramide  1  fatty  acids  and  the  influence  of  topical 
essential fatty acids. Int J Cosmet Sci. 1996;18:1.

12.  Khallouki F, Younos C, Soulimani R, et al. Consumption of argan 
oil (Morocco) with its unique profile of fatty acids, tocopherols, 
squalene, sterols and phenolic compounds should confer valuable 
cancer chemopreventive effects. Eur J Cancer Prev. 2003;12:67.
13.  Amzal H, Alaoui K, Tok S, et al. Protective effect of saponins from 
Argania spinosa against free radical-induced oxidative haemolysis. 
Fitoterapia. 2008;79:337.

14.  Jiang Q, Christen S, Shigenaga MK, et al. Gamma-tocopherol, the 
major form of vitamin E in the US diet, deserves more attention. 
Am J Clin Nutr. 2001;74:714.

15.  Drissi  A,  Girona  J,  Cherki  M,  et  al.  Evidence  of  hypolipemiant 
and  antioxidant  properties  of  argan  oil  derived  from  the  argan 
tree (Argania spinosa). Clin Nutr. 2004;23:1159.

16.  Dobrev  H.  Clinical  and  instrumental  study  of  the  efficacy  of  a 

new sebum control cream. J Cosmet Dermatol. 2007;6:113.

17.  Harhar  H,  Gharby  S,  Ghanmi  M,  et  al.  Composition  of  the 
essential oil of Argania spinosa (Sapotaceae) fruit pulp. Nat Prod 
Commun. 2010;5:935.

18.  Astier C, Benchad Yel A, Moneret-Vautrin DA, et al. Anaphylaxis 

to argan oil. Allergy. 2010;65:662.

19.  Larocca A. Liquid Gold in Morocco. The New York Times, Travel, 
November  18,  2007.  http://travel.nytimes.com/2007/11/18/
travel/tmagazine/14get-sourcing-caps.html.  Accessed  June  13, 
2008.

20.  Stussi I, Henry F, Moser P, et al. Argania spinosa – How ecological 
farming,  fair  trade  and  sustainability  can  drive  the  research  for 
new cosmetic active ingredients. SÖFW-Journal. 2005;131:35.
21.  Harhar  H,  Gharby  S,  Kartah  BE,  et  al.  Long  argan  fruit  drying 
time  is  detrimental  for  argan  oil  quality.  Nat  Prod  Commun. 
2010;5:1799.

22.  Derouiche A, Cherki M, Drissi A, et al. Nutritional intervention 
study with argan oil in man: Effects on lipids and apolipoproteins. 
Ann Nutr Metab. 2005;49:196.

23.  Cherki M, Derouiche A, Drissi A, et al. Consumption of argan oil 
may  have  an  antiatherogenic  effect  by  improving  paraoxonase 
activities  and  antioxidant  status:  Intervention  study  in  healthy 
men. Nutr Metab Cardiovasc Dis. 2005;15:352.

24.  Samane S, Noël J, Charrouf Z, et al. Insulin-sensitizing and anti-
proliferative effects of Argania spinosa seed extracts. Evid Based 
Complement Alternat Med. 2006;3:317.

25.  Drissi  A,  Bennani  H,  Giton,  F,  et  al.  Tocopherols  and  saponins 
derived from Argania spinosa exert an antiproliferative effect on 
human prostate cancer. Cancer Invest. 2006;24:588.

26.  Bennani H, Drissi A, Giton F, et al. Antiproliferative effect of poly-
phenols and sterols of virgin argan oil on human prostate cancer 
cell lines. Cancer Detect Prev. 2007;31:64.

 
28 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   1 1

Borage Seed Oil

Activities:

Blocks  formation  of  leukotrienes,  increases  production 
of ceramide 1

Important Chemical Components:
γ-linolenic acid (GLA), which ranges from 20 to 27 percent 
in borage oil1
α-linolenic acid (10 percent)
Palmitic, stearic, oleic, linoleic, eicosenoic, and erucic acids

Origin Classification:
This ingredient is considered natural. Organic forms are 
available. 

Personal Care Category:

Lipophilic,  occlusive,  emollient,  anti-inflammatory, 
hydrating

Recommended  for  the  following  Baumann  Skin 
Types:

 All dry and sensitive types benefit from this ingredient. 
It  is  best  for  DSNT,  DSPT,  DSNW,  and  DSPW.  This 
ingredient may feel too greasy to individuals with oily 
skin types.

 SOURCE

Borage  (Borago  officinalis)  is  an  annual  herb  native  to  Syria 
and  grown  now  throughout  the  Mediterranean  region, 
Middle  East,  North  Africa,  Europe,  and  South  America 
(Figure  11-1).  Derived  from  the  seeds  of  the  plant,  borage 
seed oil is used in medical practice for its anti-inflammatory 
activity  in  the  treatment  of  atopic  dermatitis,  rheumatoid 
arthritis, and other conditions.

▶

FIGURE 11-1  Borago officinalis.

 HISTORY

B.  officinalis,  a  wildflower  also  known  as  “starflower”  for  its 
star-shaped  bright  blue  flowers,  is  a  tall  (average  of  1.5  feet) 
herb used for over 1,500 years.2 References to borage date back 
to  the  Roman  historian  Pliny  the  Elder  and  the  Greek  poet 
Homer, who cited the elixir “nepenthe,” which is now believed 
to  have  been  derived  from  borage  leaves  steeped  in  wine.3  
A  medicinal  tea  made  of  borage  leaves  was  frequently 
consumed in the Middle Ages.2

 CHEMISTRY

Although  human skin  cannot  synthesize  GLA,  it  is  produced 
elsewhere in the body but only in the presence of the fatty acid 
linoleic acid (LA). This is one of the main reasons why LA is a 
desirable  ingredient  in  skin  care  products  as  well  as  oral 
supplements. LA also helps the body produce ceramide 1 (see 
Chapter  7,  Moisturizing  Agents).  Because  LA  is  not  synthe-
sized  by  the  body,  it  must  be  consumed  through  the  diet  or 
absorbed topically. It is abundant in a wide range of vegetables, 
nuts, and seed oils. 

The enzyme δ-6 desaturase (D6D), which is found in many cell 
types including fibroblasts and sebocytes, plays the crucial role of 
converting LA into GLA. GLA is subsequently metabolized into 
prostaglandin E1 (PGE1), which exhibits anti-inflammatory activ-
ity and aids in regulating transepidermal water loss (TEWL) and 
protecting the skin.4 Borage seed oil has been shown to have two 
to three times more GLA than evening primrose oil, which itself is 
known to be a rich source of the essential acid.5,6

 ORAL USES

Borage seed oil has been used for years to treat inflammatory 
conditions and dry skin (Table 11-1). Twenty years ago, Miller 
et al. fed guinea pigs borage oil containing 25 percent GLA or a 
control diet containing safflower oil (less than 0.5 percent GLA) 
for eight weeks. The goal of this study was to ascertain whether 
GLA  could  modulate  cutaneous  eicosanoids,  which  play  an 
important role in inflammation. Examination of epidermal skin 
samples from the borage-treated animals revealed a significant 
increase  in  GLA  and  its  product  dihomo-γ-linolenic  acid 

TABLE 11-1
Pros and Cons of Borage Seed Oil

Pros
Potent anti-inflammatory agent
Did not cause allergy in Cosmetic Ingredient 

Review studies

May help increase ceramide production
May help rosacea and other inflammatory skin 

conditions

Does not inactivate retinoids or other ingredients

Cons
Greasy feel

 
(DGLA). A marked rise in the DGLA metabolites 15-hydroxy 
fatty acid (15-OH-20:3n-6) and (PGE1), both of which exhibit 
anti-inflammatory potential, was also seen in the borage oil-fed 
guinea pigs. The investigators concluded that increased dietary 
GLA  had  the  potential  to  produce  local  anti-inflammatory 
metabolites,  thus  warranting  use  to  treat  inflammatory  skin 
disorders.7

Three years later, Miller et al. supplemented the diets of nor-
mal  guinea  pigs  with  either  fish  oil  or  GLA-rich  borage  oil,  to 
determine the epidermal effects. Fish oil is rich in the ω-3 fatty 
acids  eicosapentaenoic  acid  (EPA)  and  docosahexaenoic  acid 
(DHA). The researchers found that fish oil and borage oil both 
inhibited  production  of  leukotriene,  which  is  a  product  of  the 
arachidonic  acid  inflammatory  cascade  (see  Chapter  64,  Anti-
inflammatory Agents). They concluded that the reported benefi-
cial effects of fish and borage oils in treating chronic inflammatory 
skin  disorders  may  be  at  least  partly  ascribed  to  the  decreased 
production of leukotrienes.8

In 2000, Brosche and Platt assessed the effects of borage oil 
consumption on various skin parameters in 29 healthy elderly 
people  (mean  age  68.6  years).  The  subjects  received  a  daily 
dose of borage oil in gelatin capsules for two months. A mean 
decrease of 10.8 percent was seen in TEWL. Although no sig-
nificant changes in skin hydration were measured, the percent-
age of subjects that complained of dry skin dropped from 42 to 
14 percent and complaints of itch dropped from 34 percent to 
none after treatment. The researchers concluded that consump-
tion of borage oil improved the skin function of their healthy 
elderly  study  participants.9  This  study  was  not  placebo  con-
trolled and changes in actual skin hydration were not seen in 
the measurements.

In  early  2009,  investigators  tested  the  cutaneous  effects  of 
flaxseed oil and borage oil supplementation versus a medium-
chain  fatty  acid  placebo  in  a  12-week  study  of  two  groups  of 
women. The flaxseed oil and borage seed oil groups experienced 
a decline in skin reddening and blood flow over the study. Skin 
hydration  was  increased  in  all  groups,  including  the  placebo 
group. After six weeks of supplementation, a 10 percent decrease 
in TEWL was noted in both the flaxseed and borage seed groups, 
with  an  additional  reduction  in  TEWL  after  12  weeks  in  the 
flaxseed  group.  Investigators  found  that  skin  roughness  and 
scaling diminished significantly at week 12 as compared to base-
line in both the flaxseed and borage seed groups.10

In 1999, Henz et al. conducted a 24-week double-blind, multi-
center study with 160 adults with stable, moderately severe atopic 
eczema randomized to take daily a 500 mg borage oil capsule or a 
placebo.  The  researchers  noted,  though,  that  GLA  metabolites 
increased  in  the  borage  oil-treated  patients  in  this  group,  and 
serum IgE appeared to subside, and there was no improvement in 
eczema.11 It is important to note that since the time of this trial, it 
has been discovered that eczema is caused by a genetic defect in 
filaggrin with a resulting decrease in natural  moisturizing  factor 
(NMF). Borage seed oil does not have any known effects on NMF, 
so studies looking at borage seed oil in subjects with eczema were 
really evaluating effects on inflammation rather than changes in 
the underlying problem of decreased NMF.

As an oral supplement, borage seed oil is believed to be use-
ful  in  reducing  skin  inflammation  and  erythema.  It  may  help 
improve the skin barrier and decrease TEWL by increasing cera-
mide  levels.  Studies  have  been  conducted  looking  at  borage 
seed oil in rheumatoid arthritis, where it seems to have an anti-
inflammatory effect. 12 Borage seed oil may inhibit platelet func-
tion13 and slow blood clotting, which would increase the risk of 
bruising.

C H A P T E R  11  ■   B O R AG E   S E E D   O I L  

29

 TOPICAL USES

In 1993, Tollesson and Frithz studied the significance of TEWL 
and stratum corneum water content in disease and recovery in 
37 patients with clinically diagnosed infantile seborrheic derma-
titis and found that within 3 to 4 weeks of daily topical application 
of borage oil, all patients were symptom-free. The investigators 
concluded that GLA is key to maintaining normal TEWL and as a 
treatment for infantile seborrheic dermatitis.14,15 It is likely that the 
anti-inflammatory  properties  of  GLA  rendered  this  treatment 
effective in seborrheic dermatitis.

The topical use of borage oil has demonstrated efficacy in the 
treatment  of  childhood  eczema  in  small  studies.  In  one  study, 
the symptoms of childhood atopic dermatitis were relieved by 
undershirts  coated  with  borage  oil.16–18  Borage  seed  oil  cannot 
replace the missing NMF in eczema, but the hydrating and anti-
inflammatory effects would explain the benefits seen in eczema. 
There are no published large, double-blinded, placebo-controlled 
trials looking at the effects of borage seed oil in non-eczematous 
dry skin or in inflammatory disorders like rosacea.

 SAFETY ISSUES

No safety issues were found with borage seed oil in the plant-
derived oils report by the Cosmetic Ingredient Review (CIR) on 
December 14, 2010.19 The CIR report states that patch testing 
done  by  TKL  labs  and  Clinique  labs  showed  no  irritation 
potential  with  topical  borage  seed  oil.20  WebMD  states  that 
borage seed oil is possibly safe for most adults and children as 
long  as  it  is  free  of  dangerous  chemicals  called  pyrrolizidine 
alkaloids (PAs).They suggest that one should only use products 
that are certified and labeled PA-free.

 ENVIRONMENTAL IMPACT

There  are  no  known  challenges  or  significant  effects  on  the 
environment imposed by borage plant cultivation.

 FORMULATION CONSIDERATIONS

Cold  pressing  borage  oil  extraction  does  not  harm  the  final 
product  quality,  but  its  yield  is  lower  than  the  yield  of  tradi-
tional  oil  extraction  processes  by  solvent  application.  Using 
enzymes  with  pectinase  and  cellulase  activities  prior  to  the 
pressing stage can increase oil extraction yield.21 Borage can be 
formulated  with  hydroxy  acids  and  retinol  and  is  thought  to 
decrease  the  irritation  that  occurs  from  these  compounds.  A 
patent was filed on this by Chesebrough-Ponds in 1996. They 
stated that a preferred carrier is siloxane.

 USAGE CONSIDERATIONS

Borage seed oil does not inactivate retinoids, antioxidants, or 
acids.  Its  effect  on  the  absorption  of  other  ingredients  is 
unknown at this time.

 SIGNIFICANT BACKGROUND

The use of borage oil has also been demonstrated as beneficial 
in treating rheumatoid arthritis, as indicated by recent double-
blind  studies.22  It  is  believed  that  the  GLA  portion  of  borage 
oil raises PGE1 levels that, in turn, augment cAMP levels, which 

 
30 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

inhibit  the  production  of  tumor  necrosis  factor-α,  a  central 
mediator in rheumatoid arthritis and other inflammatory pro-
cesses.23 Reviews of electronic database records by Cameron et 
al. in 2009 and 2011 of randomized controlled trials of herbal 
interventions to treat rheumatoid arthritis found moderate data 
that GLA-containing oils such as borage seed oil confer symp-
tom relief.24,25

A 2010 review found 12 clinically controlled trials of oral or 
topical borage oil for the treatment of atopic dermatitis and one 
preventive  trial.  Though  most  were  randomized  and  double-
blind, they were typically small and otherwise limited methodo-
logically, according to Foster et al. The results were mixed, with 
the effects of borage seed oil found to be significant in five stud-
ies, insignificant in five others, and inconclusive in two, though 
most studies indicated that at least a modest benefit was deliv-
ered by borage oil. Further, Foster and colleagues concluded that 
the studies suggested that a clinical effect from oral supplemen-
tation with borage seed oil is unlikely but may help a small per-
centage of patients with less severe atopic dermatitis.5 Many of 
these trials were conducted before the filaggrin defect was iden-
tified as a cause of atopic dermatitis. It is likely that borage seed 
oil imparts a beneficial effect on non-eczematous dry skin, but 
the study data do not support this conclusion at this time.

 CONCLUSION

As  the  greatest  natural  source  of  GLA,  borage  seed  oil  is  an 
important ingredient for dry and inflamed skin types. Increasing 
evidence suggests that GLA-rich borage seed oil delivers anti-
inflammatory activity in the treatment of various medical con-
ditions, including several cutaneous ones. Anecdotal evidence 
suggests that borage seed oil would be useful in the treatment 
of eczema and rosacea. It likely has a hydrating effect by help-
ing  increase  ceramide  production  and  serving  as  an  occlusive 
moisturizer; however, it does not repair the filaggrin defect in 
atopic dermatitis. Borage seed oil and GLA have been demon-
strated to be effective through oral supplementation and topi-
cal administration. Much more research is necessary, though, 
to  determine  the  extent  to  which  borage  seed  oil  can  serve 
more than an adjuvant therapeutic role.

REFERENCES

5.  Foster  RH,  Hardy  G,  Alany  RG.  Borage  oil  in  the  treatment  of 

atopic dermatitis. Nutrition. 2010;26:708.

6.  Melnik B, Plewig G. Atopic dermatitis and disturbances of essen-
tial fatty acid and prostaglandin E metabolism. J Am Acad Dermatol. 
1991;25:859.

7.  Miller CC, Ziboh VA. Gammalinolenic acid-enriched diet alters 
cutaneous  eicosanoids.  Biochem  Biophys  Res  Commun. 
1988;154:967.

8.  Miller  CC,  Tang  W,  Ziboh  VA,  et  al.  Dietary  supplementation 
with ethyl ester concentrates of fish oil (n-3) and borage oil (n-6) 
polyunsaturated fatty acids induces epidermal generation of local 
putative  anti-inflammatory  metabolites.  J  Invest  Dermatol. 
1991;96:98.

9.  Brosche T, Platt D. Effect of borage oil consumption on fatty acid 
metabolism,  transepidermal  water  loss  and  skin  parameters  in 
elderly people. Arch Gerontol Geriatr. 2000;30:139.

10.  De Spirt S, Stahl W, Tronnier H, et al. Intervention with flaxseed 
and borage oil supplements modulates skin condition in women. 
Br J Nutr. 2009;101:440.

11.  Henz BM, Jablonska S, van de Kerkhof PC, et al. Double-blind, 
multicentre analysis of the efficacy of borage oil in patients with 
atopic eczema. Br J Dermatol. 1999;140:685.

12.  Macfarlane GJ, El-Metwally A, De Silva V, et al. Evidence for the 
efficacy of complementary and alternative medicines in the man-
agement  of  rheumatoid  arthritis:  A  systematic  review. 
Rheumatology (Oxford). 2011;50:1672.

13.  Barre DE, Holub BJ. The effect of borage oil consumption on the 
composition  of  individual  phospholipids  in  human  platelets. 
Lipids. 1992;27:315.

14.  Tollesson A, Frithz A. Transepidermal water loss and water con-
tent  in  the  stratum  corneum  in  infantile  seborrheic  dermatitis. 
Acta Derm Venereol. 1993;73:18.

15.  Tollesson A, Frithz A. Borage oil, an effective new treatment for 
infantile seborrhoeic dermatitis. Br J Dermatol. 1993;129:95.
16.  Kanehara S, Ohtani T, Uede K, et al. Undershirts coated with bor-
age  oil  alleviate  the  symptoms  of  atopic  dermatitis  in  children. 
Eur J Dermatol. 2007;17:448.

17.  Kanehara S, Ohtani T, Uede K, et al. Clinical effects of undershirts 
coated  with  borage  oil  on  children  with  atopic  dermatitis:  A 
double-blind,  placebo-controlled  clinical  trial.  J  Dermatol. 
2007;34:811.

18.  Yates JE, Phifer JB, Flake D. Clinical inquiries. Do nonmedicated 
topicals relieve childhood eczema? J Fam Pract. 2009;58:280.
19.  WebMD.  Borage  overview  information.  http://www.webmd 
.com/vitamins-supplements/ingredientmono-596-BORAGE.aspx?
activeIngredientId=596&activeIngredientName=BORAGE. 
Accessed October 2, 2012.

20.  Cosmetic  Ingredient  Review:  Draft  report  of  the  plant-derived 
edible  oil  group.  http://www.cir-safety.org/sites/default/files/117 
_draft_oils.pdf. Washington, DC 2010. Accessed October 2, 2012.

21.  Soto CG, Chamy R, Zúñiga ME. Effect of enzymatic application 
on  borage  (Borago  officinalis)  oil  extraction  by  cold  pressing.  
J Chem Eng Jpn. 2004;37:326.

22.  Belch JJ, Hill A. Evening primrose oil and borage oil in rheumato-

1.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

logic conditions. Am J Clin Nutr. 2000;71:352S.

Medicine. Rochester, VT: Healing Arts Press; 2003:56.

2.  Grieve M. A Modern Herbal. Vol 1. New York: Dover Publications; 

1971:119.

3.  Foster S. An Illustrated Guide to 101 Medicinal Herbs: Their History, 
Use,  Recommended  Dosages,  and  Cautions.  Loveland,  CO: 
Interweave Press; 1998:38.

4.  Ziboh  VA,  Miller  C.  Essential  fatty  acids  and  polyunsaturated 
fatty  acids:  significance  in  cutaneous  biology.  Annu  Rev  Nutr. 
1990;10:433.

23.  Kast RE. Borage oil reduction of rheumatoid arthritis activity may 
be mediated by increased cAMP that suppresses tumor necrosis 
factor-alpha. Int Immunopharmacol. 2001;1:2197.

24.  Cameron M, Gagnier JJ, Chrubasik S. Herbal therapy for treating 
rheumatoid  arthritis.  Cochrane  Database  Syst  Rev. 
2011;2:CD002948.

25.  Cameron M, Gagnier JJ, Little CV, et al. Evidence of effectiveness 
of herbal products in the treatment of arthritis. Part 2: Rheumatoid 
arthritis. Phytother Res. 2009;23:1647.

 
C H A P T E R   1 2

Jojoba Oil

C H A P T E R  12  ■   J O J O B A   O I L  

31

Activities:

Anti-inflammatory, humectant, antiviral, antiacne, anal-
gesic,  antibacterial,  antioxidant,  antiparasitic,  and 
antipyretic1–4

Important Chemical Components:

Triglycerides
Fatty acids (including linoleic, linolenic, oleic and arachi-
donic)
Triterpene  alcohols 
24-methylenecyclobartenol)
4-demethylsterols (campesterol, stigmasterol, sitosterol, 
isofucosterol)
4-methylsterols  (obtusifoliol,  gramisterol,  cycloeucale-
nol, citrostadeienol)5

(cycloartenol,  cyclobranol, 

Origin Classification:

This ingredient is considered natural. Organic forms are 
available. The natural form may undergo processing and 
there are also synthetic forms of jojoba oil.

Personal Care Category: 

Emollient, occlusive

Recommended for the following Baumann Skin 
Types: 

This ingredient is ideal for dry and sensitive types but is 
not recommended for acne types. Oily types may find it 
too  sticky.  Recommended  for  DRNT,  DRNW,  DRPT, 
DRPW, DSNT, DSNW, DSPT, and DSPW.

 SOURCE

The jojoba (pronounced ho-ho-ba) plant (Simmondsia chinensis or 
Buxus chinensis) is a hardy perennial shrub endemic to the arid 
Sonoran  Desert  of  northwest  Mexico  and  adjacent  areas  in 
Arizona and southern California that grows up to 15 feet. The 
seeds  of  the  plant,  which  are  laden  with  a  light  yellow/gold, 
odorless  liquid  wax,  were  used  by  Native  Americans  for  cos-
metic and medical purposes to treat various conditions, including 
sores and wounds, sunburn, dry skin, hair loss, headaches, and 
renal colic.2,5,6 Cosmetic products may contain various ingredi-
ent  forms  of  this  plant  including  S.  chinensis  (jojoba)  seed  oil,  
S. chinensis seed, and S. chinensis butter. Further processing yields 
other ingredients including: hydrogenated jojoba oil, hydrolyzed 
jojoba esters, isomerized jojoba oil, jojoba esters, and jojoba alco-
hol. Synthetic jojoba oil also is used in cosmetics. Jojoba seed oil 
is the most widely used type of S. chinensis derivative.

 HISTORY

This evergreen plant, also known as goat nut, deer nut, pignut, 
wild hazel, quinine nut, coffeeberry, or gray box bush, can live 
up to 200 years. Native Americans are known to have eaten the 

smooth-skinned, odorless, oil-rich nuts or seeds of the jojoba. 
The oil from jojoba nuts or seeds has been used for centuries to 
promote hair growth and alleviate skin conditions. 

As for modern medical applications, as early as 30 years ago, 
observers noted the increased use of the liquid wax derived from 
jojoba seeds in skin care formulations.7 It is the oil of the plant (or 
liquid  wax  in  this  particular  case),  composed  of  straight  chain 
monoesters of alcohols and fatty acids, that is of particular interest 
in  the  modern  skin  care  industry  as  jojoba  is  one  of  the  many 
popular botanical products available in cosmetics and cosmeceuti-
cals.  Indeed,  jojoba  is  now  cultivated  for  commercial  purposes, 
including therapeutic options in Australia, Israel, several African 
countries,  including  Egypt,  and  India  as  well  as  throughout  the 
Americas  (including  the  United  States,  Mexico,  Argentina,  and 
Brazil).2,6,8–10

 CHEMISTRY

Jojoba  oil  is  derived  by  cold-pressing  the  seeds.1  As  noted 
above, it is actually a polyunsaturated liquid wax. Very similar 
in consistency to human sebum, jojoba oil is considered to be a 
natural moisturizer and thought to be highly conditioning, sof-
tening, and healing for skin. 

 ORAL USES

Jojoba seed extract is the source of simmondsin, a key dietary sup-
plement  used  for  weight  loss.  The  meal  that  remains  from  the 
jojoba oil extraction process is approximately 30 percent protein 
and  exhibits  a  significant  appetite  suppressant  effect.11  In  2006, 
Boozer and Herron tested the botanical ingredient over 8 weeks in 
lean Sprague-Dawley male rats and 16 weeks in obese rats and 
found  dose-response  effects  in  lowering  food  consumption  and 
body weight at concentrations of 0.15 and 0.25 percent. Jojoba oil 
is not typically consumed in the diet as it is poorly digested.5,12,13

 TOPICAL USES

In skin care products, jojoba oil is typically used as a humectant 
(Table 12-1). It also delivers a protective film over the skin that 
aids in retaining moisture, thus imparting occlusive properties.14 
The  skin’s  natural  sebum  is  readily  compatible  with  the  wide 

TABLE 12-1
Pros and Cons of Jojoba Oil

Pros
Displays anti-inflammatory and humectant 

qualities

Stable
Easy to formulate
Increased antioxidant value when combined 

with tocopherol

Safe

Cons
While results are promising, more research 
is necessary to establish a significant role 
in the dermatologic armamentarium

Expensive
Comedogenic (some forms)

 
32 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

range of fatty acids (e.g., oleic, linoleic, linolenic, and arachidonic) 
and triglycerides that are key components of jojoba oil.5,15 Some 
authors speculate that its efficacy as a nongreasy lubricant gives 
the oil, pure or in hydrogenated form, potential to be effective in 
various formulations (i.e., creams, lotions, soaps, lipsticks, etc.) 
intended for topical application on the skin or hair.3 Jojoba oil 
has been found to confer a wide range of significant beneficial 
properties as an analgesic, antibacterial, anti-inflammatory, anti-
oxidant, antiparasitic, and antipyretic agent.1,3

Human Studies
The inclusion of hydrolyzed jojoba esters in skin, hair, and nail 
products has been demonstrated to enhance cutaneous hydra-
tion and sensation for users.9 In fact, jojoba has been reported 
to  penetrate  the  outer  layer  of  the  stratum  corneum  and 
enhance hydration.10 In 2008, Meyer et al. conducted a small 
pilot study of nine healthy women (between 22 and 55 years of 
age;  six  Caucasian,  two  Hispanic,  one  African  American)  to 
establish  “proof  of  concept”  that  the  combination  of  hydro-
lyzed  jojoba  esters  (K-20W)  and  glycerol  renders  an  additive 
skin moisturizing effect. The formulation was topically applied 
to the lower leg and investigators made baseline assessments as 
well as at eight and 24 hours after application. They found that 
transepidermal  water  loss  values  were  significantly  lower  in 
association  with  the  combination  formula  (containing  
3.75 percent glycerol and 1.25 percent hydrolyzed jojoba esters) 
than with glycerol alone eight and 24 hours after treatment.9

In  2012,  Meier  et  al.  conducted  an  open,  prospective, 
observational  pilot  study  of  194  subjects  (192  female,  2  male) 
with  acne-prone  skin  with  lesions  in  which  participants 
completed questionnaires after using clay jojoba facial masks for 
six  weeks  (applying  them  two  to  three  times  weekly).  The 
investigators noted that of the 133 individuals who also returned 
complete  lesion  counts,  a  54  percent  mean  reduction  in  total 
lesions  was  calculated.  Significant  reductions  in  inflammatory 
and noninflammatory lesions from baseline were observed. The 
researchers concluded that clay jojoba facial masks exhibit the 
potential to successfully treat mild acne.16

 SAFETY ISSUES

The Cosmetic Ingredient Review (CIR) safety report states that 
studies of the oral and topical forms of jojoba oil on animals were 
nontoxic  in  their  effects.17  It  is  important  to  realize  that  any 
plant-derived  material  can  contain  pesticide  residues  and/or 
heavy  metals.  The  CIR  stated,  “The  cosmetic  industry  should 
continue  to  limit  pesticide  and  heavy  metal  impurities  in  the 
plant-derived ingredients before blending into cosmetic formula-
tions.” S. chinensis seed oil was neither a significant dermal irri-
tant nor a sensitizer, according to the clinical test results reported 
in  the  CIR.  In  repeat  insult  patch  tests,  jojoba  alcohol,  jojoba 
esters,  and  hydrolyzed  jojoba  esters  were  not  irritating  during 
induction or sensitizing at challenge. Neither S. chinensis seed oil 
nor jojoba alcohol were phototoxic. None of the tested ingredi-
ents were genotoxic and there were no structural alerts for carci-
nogenicity. Some forms of jojoba can aggravate acne. S. chinensis 
seed wax was moderately comedogenic in tests using rabbits and 
jojoba esters were non-comedogenic to slightly comedogenic.

 ENVIRONMENTAL IMPACT

Jojoba oil first gained industry interest and support for its via-
bility as a replacement for sperm whale oil, the use of which 
was banned by the US government in the early 1970s as a result 

of the Endangered Species Act. It has been the primary natural 
source of wax esters for commercial use since then.18 No sig-
nificant environmental impact from jojoba harvesting has been 
reported.  S.  chinensis  is  a  hardy,  long-living  perennial  that 
revives or recovers well after fires.

 FORMULATION CONSIDERATIONS

Jojoba oil is the primary biological source of wax esters, which 
have  considerable  commercial  applications  despite  its  high 
cost. In fact, the cost has prompted research into less expensive 
jojoba  oil  alternatives  to  be  bioengineered using recombinant 
microorganisms.18 S. chinensis seed oil forms stable emulsions 
in water with small particles,19 and the emulsion of jojoba seed 
oil and water used for microcapsulization was found to be sta-
ble after freeze-drying and storage at room temperature for a 
year.20 Seed oil is not easily oxidized and remains chemically 
unchanged for years.17

 USAGE CONSIDERATIONS

Jojoba  seed  oil  has  been  reported  to  readily  penetrate  nude 
mouse skin and to increase penetration of other agents such 
as  aminophylline  in  clinical  tests.17  Its  oxidative  stability 
index  decreases  when  exposed  to  zinc  oxides  and  salicylic 
acid  but  increases  with  tocopherols,  titanium  dioxide,  and 
kojic acid.17

 SIGNIFICANT BACKGROUND

In Vitro
In 2010, Yarmolinsky et al. investigated the in vitro activity of 
purified  fractions  and  aquatic  and  ethanol  leaf  extracts  of 
Callissia fragrans and S. chinensis against herpetic viruses. They 
found  that  S.  chinensis  potently  suppressed  all  of  the  herpetic 
viruses studied.8

In 2011, Ranzato et al. assessed,  in  vitro, the wound healing 
characteristics of jojoba liquid wax on HaCaT keratinocytes and 
human  dermal  fibroblasts.  Cytotoxicity  assays  and  scratch 
wound experiments respectively revealed that jojoba liquid wax 
displayed  low  toxicity  while  significantly  accelerating  wound 
closure. Jojoba was also determined to have promoted collagen I 
production  in  fibroblasts.  Investigators  concluded  that  jojoba 
liquid wax warrants consideration for a role in treatment options 
in the clinical environment.6

Animal Studies
In 2005, Habashy et al. used several experimental animal mod-
els to evaluate the anti-inflammatory potential of jojoba liquid 
wax. Their findings demonstrated that the botanical derivative 
diminished  carrageenan-induced  rat  paw  edema  as  well  as 
prostaglandin  E2  (PGE2)  in  inflammatory  exudates;  reduced 
croton oil-induced rat ear edema as well as neutrophil infiltra-
tion; improved histopathological alterations caused by croton 
oil;  and  decreased  nitric  oxide  levels  and  tumor  necrosis 
factor-α release. The investigators concluded that jojoba liquid 
wax  exerted  dynamic  anti-inflammatory  activity,  without 
clearly  identifying  the  components  of  the  plant  directly 
involved.2

 
 CONCLUSION

The  various  forms  of  jojoba  are  mainly  used  to  confer  anti-
inflammatory properties to cosmetics and cosmeceuticals. No 
studies could be found that looked at use in eczema or rosacea. 
The acne study discussed above likely revealed benefits due to 
the  moisturizing  and  anti-inflammatory  effects  of  jojoba  but 
studies  have  demonstrated  that  moisturization  alone  can 
improve acne. Because S. chinensis seed wax has been shown to 
be comedogenic, jojoba would not be the best topical choice to 
relieve the inflammatory aspect of acne. The versatile botanical 
extract jojoba oil has not been shown to be harmful or to elicit 
significant adverse effects and is not phototoxic. Much research, 
in the form of randomized, placebo-controlled clinical trials, is 
necessary  to  compare  jojoba-containing  products  with  other 
formulations established as effective anti-inflammatory agents.

REFERENCES

1.  Aburjai  T,  Natsheh  FM.  Plants  used  in  cosmetics.  Phytother  Res. 

2003;17:987.

2.  Habashy RR, Abdel-Naim AB, Khalifa AE, et al. Anti-inflammatory 
effects  of  jojoba  liquid  wax  in  experimental  models.  Pharmacol 
Res. 2005;51:95.

3.  Arquette DJ, Bailyn EM, Palenske J, et al. Non-comedogenic and 
hypoallergenic properties of jojoba oil and hydrogenated jojoba 
oil. J Cosm Sci. 1998;49:377.

4.  Kampf  A,  Gringberg  S,  Galuun  A.  Oxidative  stability  of  jojoba 

wax. J Am Oil Chem Soc. 1986;63:246.

5.  Van Boven M, Daenens P, Maes K, et al. Content and composition 
of  free  sterols  and  free  fatty  alcohols  in  jojoba  oil.  J  Agric  Food 
Chem. 1997;45:1180.

6.  Ranzato E, Martinotti S, Burlando B. Wound healing properties 
of  jojoba  liquid  wax:  an  in  vitro  study.  J  Ethnopharmacol. 
2011;134:443.

7.  Yaron A, Samoiloff V, Benzioni A. Absorption and distribution of 

orally administered jojoba wax in mice. Lipids. 1982;17:169.

C H A P T E R  12  ■   J O J O B A   O I L  

33

8.  Yarmolinksy L, Zaccai M, Ben-Shabat S, et al. Anti-herpetic activ-
ity of Callissia fragrans and Simmondsia chinensis leaf extracts in 
vitro. Open Virol J. 2010;4:57.

9.  Meyer  J,  Marshall  B,  Gacula  M  Jr,  et  al.  Evaluation  of  additive 
effects  of  hydrolyzed  jojoba  (Simmondsia  chinensis)  esters  and 
glycerol: a preliminary study. J Cosmet Dermatol. 2008;7:268.
10.  Cummings  M,  Reinhart  J,  Lockhart  L.  Penetration  effects  of 

Jojoba. Cosmet Toilet. 2000;115:73.

11.  Boozer CN, Herron AJ. Simmondsin for weight loss in rats. Int J 

Obes (Lond). 2006;30:1143.

12.  Verschuren PM, Nutgeren DH. Evaluation of jojoba oil as a low-
energy  fat.  2.  Intestinal  transit  time,  stomach  emptying  and 
digestibility  in  short-term  feeding  studies  in  rats.  Food  Chem 
Toxicol. 1989;27:45.

13.  Heise C, Decombaz J, Anantharaman K. Energy value of JO for 

the growing rat. Int J Vitam Nutr Res. 1982;52:216.

14.  Dweck AC. Skin treatment with plants of the Americas. Cosmet 

Toiletries. 1997;112:47.

15.  Van Boven M, Holser RA, Cokelaere M, et al. Characterization of 
triglycerides  isolated  from  jojoba  oil.  J  Am  Oil  Chem  Soc. 
2000;77:1325.

16.  Meier L, Stange R, Michalsen A, et al. Clay jojoba oil facial mask 
for lesioned skin and mild acne – Results of a prospective, obser-
vational pilot study. Forsch Komplementmed. 2012;19:75.

17.  Cosmetic  Ingredient  Review.  Final  report  of  the  Cosmetic 
Ingredient Review Expert Panel: Safety assessment of Simmondsia 
chinensis  (jojoba)  seed  oil,  Simmondsia  chinensis  (jojoba)  seed 
wax, hydrogenated jojoba oil, hydrolyzed jojoba esters, isomer-
ized jojoba oil, jojoba esters, Simmondsia chinensis (jojoba) but-
ter, jojoba alcohol, and synthetic jojoba oil. http://www.cir-safety 
.org/sites/default/files/115_buff3f_suppl.pdf.  Washington,  DC 
2008. Accessed October 5, 2012.

18.  Kalscheuer R, Stöveken T, Luftmann H, et al. Neutral lipid bio-
synthesis in engineered Escherichia coli: jojoba oil-like wax esters 
and fatty acid butyl esters. Appl Environ Microbiol. 2006;72:1373.
19.  Chung  H,  Kim  TW,  Kwon  M,  et  al.  Oil  components  modulate 
physical characteristics and function of the natural oil emulsions 
as drug or gene delivery system. J Controlled Release. 2001;71:339.
20.  Esquisabel  A,  Hernandez  RM,  Igartua  M,  et  al.  Preparation  and 
stability of agarose microcapsules containing BCG. J Microencapsul. 
2002;19:237.

 
34  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   1 3

Mineral Oil

Activities:

Inert substance

Important Chemical Components:
Highly refined saturated hydrocarbons1 such as:
paraffins
naphthenes (cycloalkanes)

Origin Classification:

Mineral oil is derived from petroleum, and is considered 
synthetic because solvents and other chemicals are used 
during the refining process.

Personal Care Category:

Emollient, occlusive

Recommended for the following Baumann Skin 
Types: 

Best for dry skin types because oily ones will not like the 
greasiness. Does not have any anti-inflammatory prop-
erties. Best for DRNT, DRNW, DRPT, and DRPW.

 SOURCE

Mineral oil (also known as liquid petrolatum, heavy mineral 
oil, light mineral oil, liquid paraffin, mineral oil mist, paraffin 
oil,  paraffinum  liquidum,  petrolatum  liquid,  petroleum  oil, 
white  mineral  oil,  and  white  oil)1  is  a  complex  mixture  of 
highly  refined  saturated  hydrocarbons  derived  from  the 
distillation  of  petroleum  in  the  production  of  gasoline.2 
Along with petrolatum, lanolin, and silicones, mineral oil is 
among  the  most  effective  of  occlusive  ingredients  used  in 
skin care products (Table 13-1).3 As such, it is a popular cos-
metic ingredient in moisturizers, creams, and baby lotions. 

 HISTORY

The  use  of  petrolatum  dates  back  to  its  discovery  in  1872  by 
Robert  A.  Chesebrough.4  The  cosmetic  use  of  mineral  oil 
followed  shortly  thereafter,  incorporated  in  such  agents  since 
the 1880s, and remains one of the most frequently used oils in 
skin  care  formulations.2  A  notable  study  in  the  more  recent 
history  of  mineral  oil  showed,  in  1989,  that  an  emulsion 

TABLE 13-1
Pros and Cons of Mineral Oil

Pros
One of the most effective occlusive 

Cons
Requires repeated applications

ingredients

Inexpensive
Stable

May increase susceptibility to UV damage
Inert, so it confers no biologic activity 

Greasy

containing mineral oil was more effective than various linoleic 
acid  emulsions  in  reducing  skin  vapor  loss  in  volunteers  who 
received topical applications of sodium lauryl sulfate solution.5

 CHEMISTRY

Mineral oil is a byproduct of the process of converting petroleum to 
gasoline. Petroleum itself is composed of fossil plankton and algae-
derived substances largely made up of hydrocarbons.1 It is refined 
using solvents and other methods to produce mineral oil. Refined 
mineral  oil  is  composed  of  two  hydrocarbon  types:  paraffinics, 
which  are  branched-chain  alkanes,  and  naphthenics,  which  are 
alkanes  containing  one  or  more  saturated  cyclic  structures.1  The 
ratio of paraffinics to naphthenics and their respective molecular 
weight  determines  the  physical  properties  of  the  resulting  oil. 
Mineral oils are classified by their viscosities. “Light” mineral oil has 
low viscosity. “Heavy” mineral oil has a high viscosity.

Mineral oil is known to have strong occlusive properties, and is 
one of the best occlusive ingredients known (second to petrolatum). 
It is able to form a tight barrier that prevents the passage of other 
molecules because it has straight alkyl chains that easily align to 
form the occlusive palisade. The highly variable chain length of 
the alkyl chains keeps mineral oil from being a perfect occlusive, 
because  short  straight  chains  of  the  same  length  represent  the 
ideal  structure  for  an  occlusive  ingredient  (see  Chapter  8, 
Occlusives). As compared to heavy mineral oil, light mineral oil 
contains more cyclic (saturated) molecules that prevent the con-
sistent build-up of the palisade; therefore, heavy mineral oil is a 
better occlusive than light mineral oil.1

 ORAL USES

Cosmetic mineral oil is not to be taken internally. A food grade 
mineral oil exists, but is beyond the scope of this chapter.

 TOPICAL USES

In  1989,  investigators  found  that  a  topical  emulsion  containing 
mineral oil was more effective than several linoleic acid emulsions 
in diminishing skin vapor loss in volunteers with an iatrogenically-
induced  impaired  skin  barrier.5  Since  then,  many  studies  have 
demonstrated the occlusive and skin-softening benefits of min-
eral oil.6,7 One reason that mineral oil is such a good occlusive is 
that  it  is  poorly  absorbed  into  the  skin;8,9  therefore,  it  exhibits 
high  substantivity,  which  is  one  of  the  hallmarks  of  a  good 
occlusive  ingredient.  Conversely,  when  mineral  oil  is  placed  in 
water  dispersions,  such  as  when  used  as  a  bath  oil,  it  is  better 
absorbed into the skin than vegetable oils. This absorptive ability 
varies with oil concentration and bath water temperature.10 The 
viscosity of the mineral oil also affects its occlusive abilities.

Mineral oil can decrease the penetration of other ingredients. 
Sahlin et al. showed that increasing the concentration of mineral 
oil from 10 to 50 percent in formulations containing the same 
concentration of lactic acid tended to decrease the stinging effect 
of lactic acid. They surmised that this was because the increased 

 
concentrations of mineral oil diminished the penetration of lactic 
acid.11

When used for its primary purpose, as a moisturizer, mineral 
oil  has  been  shown  to  be  safe  and  effective.  In  2004,  a  rand-
omized double-blind controlled trial demonstrated that mineral 
oil and extra virgin coconut oil were equally efficacious and safe 
as  moisturizers  in  treating  mild-to-moderate  dry  skin  in  
34 patients, with surface lipid levels and skin hydration signifi-
cantly enhanced in both groups.12

 SAFETY ISSUES

Because of its source, several criticisms have emerged regarding 
mineral oil. The mineral oil used in cosmetic products, USP or BP 
grade, is highly refined and purified but industrial grade petro-
leum may contain benzene and has been associated with forma-
tion  of  cancer.13  In  fact,  a  1997  epidemiologic  review  of  the 
relationship between mineral oil exposure and cancer revealed 
several associations,14 but these were cases of protracted expo-
sure  to  industrial  grade  mineral  oil.  Cosmetic  grade  mineral  oil 
has never been associated with cancer etiology. 

Mineral  oil  has  also  been  blamed  for  causing  blocked  pores 
(comedones) and acne and playing a role in the etiology of “acne 
cosmetica.”  In  1989,  Fulton  published  a  list  of  comedogenic 
ingredients that included mineral oil.15 Conflicting results were 
published by Mills and Kligman, who found no comedogenicity 
in human and rabbit models.16 A 2005 study suggested that even 
though  industrial  grade  mineral  oil  may  be  comedogenic,  cos-
metic grade mineral oil is not.2 Certainly the viscosity and purity 
of the mineral oil, the study subject susceptibility, and combina-
tion with other ingredients and products could affect the results 
of these studies. Actual use patterns and environmental factors 
could also influence the incidence of comedogenicity (e.g., ambi-
ent  humidity;  light  exposure;  stress  levels;  combination  with 
other products, drugs, or devices; and diet).

Mineral  oil  has  strong  light-reflective  properties  and  allows 
more  light  to  be  absorbed  into  skin.1  Studies  in  humans  have 
shown that typical moisturizers containing 10 percent mineral 
oil or glycerol make the skin slightly more sensitive to turning 
red upon ultraviolet (UV) light exposure. One study showed that 
these moisturizers decreased the minimal erythema dose of skin 
to UVB irradiation by 5 to 7.6 percent.17

 ENVIRONMENTAL IMPACT

Mineral  oil,  or  liquid  petrolatum,  as  stated  above,  is  derived 
from the distillation of petroleum in the production of gasoline. 
Many consumers who favor organic products may opt against 
mineral oil because of the deleterious effects of its production 
process on the environment. It is important to remember that 
mineral oil is a byproduct and not the primary goal of the petro-
leum extraction process. Many benefits are derived, clearly, but 
the cost/benefit debate on this issue is beyond the purview of 
this  text.  Mineral  oil  is  certainly  not  considered  a  natural  or 
organic product and its disposal in the environment and disper-
sal in the human body have not been examined. Similarly, the 
long-term outcomes or effects of mineral oil have not been com-
pared with the long-term outcomes from the use of natural oils.

 FORMULATION CONSIDERATIONS

Mineral oil is inert and thus insensitive to light and resistant to 
oxidation, which gives it a long shelf life.1,4

C H A P T E R  13  ■   M I N E R A L   O I L  

35

 USAGE CONSIDERATIONS

Mineral oil may decrease the skin penetration of other ingredients.

 SIGNIFICANT BACKGROUND

Mineral  oil  became  a  popular  addition  to  skin  care  products 
because the low cost, bulk availability, reproducible quality, as 
well as affluence and influence of the petrochemical industry all 
played a role in increasing the usage of this raw material.18 The 
mild backlash against mineral oil preceded the current environ-
mental  reawakening  by  several  decades.  That  is,  mineral  oil 
was one of the products associated with “acne cosmetica,” an 
expression  that  emerged  in  the  early  1970s  to  describe 
cosmetics-related acne breakouts. Notably, mineral oil was not 
found to be as comedogenic as some other agents, but Fulton 
did identify mineral oil as one of the culprits in his study using 
rabbits.15 However, Mills and Kligman had previously found no 
comedogenic association for mineral oil in rabbit and human 
models.16  The  DiNardo  report  in  2005  finally  brought  some 
resolution  to  this  subject,  concluding  that  mineral  oil  is  not 
comedogenic.2

 CONCLUSION

Mineral oil is one of the most effective occlusive ingredients in 
moisturizers. There is some question about the safety of min-
eral oil in those with significant sun exposure and more studies 
are needed to determine the safety of its use during UV light 
exposure.  The  occlusive  properties  of  mineral  oil  lead  to  the 
retention  of  stratum  corneum  water  content  by  reducing  or 
preventing  TEWL  in  people  with  dry  skin.  Individuals  with 
sensitive  skin  also  benefit  from  using  mineral  oil.  Although 
popular claims suggest that mineral oil clogs pores or contrib-
utes  to  acne,  there  is  no  evidence  to  support  such  myths. 
Repeated application is necessary to provide or maintain cuta-
neous benefits.

REFERENCES

1.  Rawlings AV, Lombard KJ. A review on the extensive skin bene-

fits of mineral oil. Int J Cosmet Sci. 2012; 34:511.

2.  DiNardo  JC.  Is  mineral  oil  comedogenic?  J  Cosmet  Dermatol. 

2005;4:2.

3.  Kraft JN, Lynde CW. Moisturizers: What they are and a practical 

approach to product selection. Skin Therapy Lett. 2005;10:1.

4.  Lodén M. Role of topical emollients and moisturizers in the treat-
ment of dry skin barrier disorders. Am J Clin Dermatol. 2003;4:771.
5.  Blanken R, van Vilsteren MJ, Tupker RA, et al. Effect of mineral oil 
and linoleic-acid-containing emulsions on the skin vapour loss of 
sodium-lauryl-sulphate-induced  irritant  skin  reactions.  Contact 
Dermatitis. 1989;20:93.

6.  Overgaard Olsen L, Jemec GB. The influence of water, glycerin, 
paraffin  oil  and  ethanol  on  skin  mechanics.  Acta  Derm  Venereol. 
1993;73:404.

7.  Maes D, Short J, Turek BA, et al. In vivo measuring of skin soft-
ness using the Gas Bearing Electrodynamometer. Int J Cosmet Sci. 
1983;5:189.

8.  Brown EB, Diembeck W, Hoppe U, et al. Fate of topical hydrocar-

bons in the skin. J Soc Cosmet Chem. 1995;46:1.

9.  Stamatas GN, de Sterke J, Hauser M, et al. Lipid uptake and skin 
occlusion following topical application of oils on adult and infant 
skin. J Dermatol Sci. 2008;50:135.

10.  Taylor EA. Oil adsorption: A new method to determine the affin-
ity  of  skin  to  adsorb  oil  from  aqueous  dispersions  of  water-
dispensable oil preparations. J Invest Dermatol. 1961;37:69.

11.  Sahlin A, Edlund F, Lodén M. A double-blind and controlled study 
on the influence of the vehicle on the skin susceptibility to sting-
ing from lactic acid. Int J Cosmet Sci. 2007;29:385.

 
36 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

12.  Agero AL, Verallo-Rowell VM. A randomized double-blind con-
trolled trial comparing extra virgin coconut oil with mineral oil as 
a moisturizer for mild to moderate xerosis. Dermatitis. 2004;15:109.
13.  Cruickshank CN, Squire JR. Skin cancer in the engineering indus-

try from the use of mineral oil. Br J Ind Med. 1950;7:1.

14.  Tolbert PE. Oils and cancer. Cancer Causes Control. 1997;8:386.
15.  Fulton  JE.  Comedogenicity  and  irritancy  of  commonly  used 
ingredients in skin care products. J Soc Cosmet Chem. 1989;40:321.

16.  Mills OH Jr, Kligman AM. A human model for assessing comedo-

genic substances. Arch Dermatol. 1982;118:903.

17.  Forbes PD. Moisturizers, vehicle effects, and photocarcinogene-

sis. J Invest Dermatol. 2009;129:261.

18.  Barton S. Formulation of skin moisturizers. In: Leyden J, Rawlings 
A,  (eds),  Skin  Moisturization.  New  York:  Marcel  Dekker  Inc.; 
2002:552.

 
C H A P T E R   1 4

Olive Oil

C H A P T E R  14  ■   O L I V E   O I L  

37

Activities:

Anti-inflammatory, antioxidant

Important Chemical Components:

Polyphenols
squalene
fatty acids (predominantly oleic acid with some stearic 
and linoleic)
triglycerides
tocopherols
carotenoids
sterols (mainly b -sitosterol, avenasterol, and campesterol)
chlorophylls1–3

Origin Classification:

This ingredient is natural, but organic forms are available.

for  athletes,  anointing  oil,  salve  for  soothing  wounds  –  by 
ancient  Egyptians  and  Romans.  In  an  interesting  historical 
study,  Nomikos  et  al.  used  a  comprehensive  study  of  Greek 
and world literature, including works attributed to Hippocrates 
and  Aristotle,  as  a  portal  through  which  to  assess  the  use  of 
olive oil for the prevention and treatment of sports injuries in 
the ancient world. They found that olive oil was used in mas-
sage to diminish muscle fatigue, eliminate lactic acid, and pro-
mote  flexibility,  thus  possibly  preventing  the  occurrence  of 
injury.  The  authors  also  noted  that  the  ancient  world  openly 
acknowledged the therapeutic use of oils, which were distrib-
uted freely to athletes at sporting events.6

In contemporary times, the topical application of olive oil has 
reportedly been successful in treating xerosis, rosacea, psoriasis, 
atopic  dermatitis,  contact  dermatitis  (especially  in  the  diaper 
area), eczema (including severe cases on the hands and feet), seb-
orrhea, and various inflammations, burns and other skin damage.1

Personal Care Category: 

Occlusive and emollient, anti-inflammatory, antioxidant

 CHEMISTRY

Recommended for the following Baumann Skin 
Types:

DRNW, DRNT, DRPT, and DRPW

 SOURCE

Olive oil is derived from the olive tree (Olea europaea) and has 
long been considered one of the most significant of the natural 
essential oils. In the Mediterranean diet, known as one of the 
world’s healthiest diets, it is the primary source of fat. It was 
also used for dermatologic purposes among ancient Egyptians, 
Greeks, and Romans.

Olive oil is an effective hydrating agent and has been shown 
to confer anti-inflammatory and anticarcinogenic properties.1,4,5 
In fact, topically applied olive oil has been reportedly used suc-
cessfully to treat xerosis, pruritus, rosacea, psoriasis, atopic der-
matitis,  contact  dermatitis  (particularly  in  the  diaper  area), 
eczema  (including  severe  cases  on  the  hands  and  feet),  sebor-
rhea, and various inflammations, burns and other skin damage.1 
In terms of additional potential cutaneous applications, olive oil 
has demonstrated promise as a photoprotective agent.5

 HISTORY

Olive  oil  has  been  used  for  dermatologic  purposes  for  thou-
sands of years, since the times of the ancient Egyptians, Greeks, 
and Romans. A staple of the Mediterranean diet, known to be 
one of the healthiest around the world, olive oil has long been 
considered one of the most important of the natural essential 
oils. For as long as it has been a component in the human diet, 
people have also used olive oil for its beneficial effects on the 
skin. Ancient Greeks bathed with olive oil,1 and the essential 
oil was also used in various ways – food, cosmetic, massage oil 

Various potent compounds, many of which display antioxidant 
properties, are found in olive oil, including polyphenols, squalene, 
fatty acids (notably oleic acid), triglycerides, tocopherols, carote-
noids,  sterols,  and  chlorophylls  (Table  14-1).1,7  The  primary 
phenolic  compounds  found  in  olive  oil  are  simple  phenols 
(hydroxytyrosol and tyrosol), secoiridoids (oleuropein, the agly-
cone  of  ligstroside,  and  their  respective  decarboxylated  dialde-
hyde  derivatives),  and  the  lignans  [(+)-]-acetoxypinoresinol  and 
pinoresinol.8 The polar fraction of olive oil is composed primarily 
of the polyphenols oleuropein, tyrosol, hydroxytyrosol, and caf-
feic acid.9 The antioxidant characteristics of these phenolic com-
pounds are well established.7 Studies have also demonstrated that 
these polyphenolic compounds in olive oil yield protective effects 
against inflammation.1,4 (See the introduction to the Polyphenols 
section.) Lignans are also considered strong antioxidants.10

The main components of the unsaponifiable fraction of virgin 
olive oil include erythrodiol, b -sitosterol, and squalene. Olive oil 
contains much more squalene than other edible oils.5,11,12 Assays 
evaluating the unsaponifiable and polar fractions of olive oil have 
revealed anti-inflammatory effects exhibited by both groups.9

 ORAL USES

Olive oil is one of the primary and most nutritional cooking oils 
in current use. Olives and olive oil contain high levels of mono-
unsaturated fats, which are believed to be important in amelio-
rating xerosis.

TABLE 14-1
Pros and Cons of Olive Oil

Pros
Readily available
Rich in antioxidants

Cons
May impair skin barrier
Greasy feel

 
38 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

In 2001, Moreno et al. examined the effect of a diet rich in 
olive oil on key inflammation mediators, specifically oxida-
tive  stress  and  prostaglandin  production.  The  investigators 
compared the effects on rats of an olive oil-rich diet to those 
of corn-oil rich and fish oil-rich diets. Both olive and fish oils 
were found to reduce arachidonic acid (AA) release and the 
ensuing synthesis of AA metabolites, but olive oil was more 
efficient in reducing oxidative stress. Prostaglandin E2 levels 
were found to be lower in the rats fed the olive oil or fish oil 
diets  as  compared  to  the  corn  oil  diet.13  A  different  2001 
study, by Purba et al., also found that the high consumption 
of  olive  oil,  along  with  vegetables  and  legumes,  imparted 
protection  against  actinic  damage.14  Indeed,  the  high 
consumption  of  extra  virgin  olive  oil,  which  is  laden  with 
antioxidants  from  these  polyphenols  as  well  as  other  com-
pounds,  is  thought  to  protect  against  oxidative  stress  and 
some of its manifestations, such as skin and other cancers as 
well as aging.8

Of note, the study by Purba et al. implied that diets high in 
monounsaturated acids may raise the levels of monounsaturated 
fatty  acids  in  the  epidermis,  which  resist  oxidative  damage, 
unlike  epidermal  polyunsaturated  fatty  acids,  which  are  more 
vulnerable to oxidation.15 They theorized that this may explain 
their  observed  association  between  monounsaturated  olive  oil 
and less wrinkling as well as the higher level of wrinkling linked 
to the consumption of polyunsaturated margarine.14

In 2012, Latreille et al. conducted a cross-sectional survey of 
1,264  women  and  1,655  men  between  the  ages  of  45  and  
60 years to ascertain a link between the risk of photoaging and 
monounsaturated fatty acids intake. Using estimates of dietary 
monounsaturated fatty acid consumption in at least ten 24-hour 
diet records completed during the first 2.5 years of the follow-up 
period,  and  baseline  facial  skin  photoaging  assessments  by 
trained  investigators,  the  researchers  found  that  higher  con-
sumption of olive oil, in both sexes, was linked to lower risk of 
severe photoaging.16

 TOPICAL USES

Olive oil is currently used in topical applications for the treat-
ment  of  several  skin  conditions,  including  xerosis,  pruritus, 
and  inflammation  as  well  as  disorders  such  as  rosacea.  A 
study by de la Puerta et al. in 2000 of the effects of topically 
applied virgin olive oil on edema in mice induced by AA or 
12-O-tetradecanoylphorbol  acetate  (TPA)  revealed  that  the 
unsaponifiable fraction of the oil more strongly inhibited AA, 
and oleuropein was found to be a strong inhibitor among the 
polar  components.  The  researchers  concluded  that  the  anti-
inflammatory  activity  attributed  to  both  groups  of  com-
pounds  may  be  important  in  delivering  the  health  benefits 
ascribed to virgin olive oil.9 The polyphenolic components of 
olive  oil  have  been  shown  in  other  studies  to  play  a  role  in 
protecting against inflammation,1,4 which is a key mediator in 
dermatologic disorders, not to mention other conditions. 

In a 2012 randomized controlled clinical trial of 100 nullipa-
rous pregnant women conducted at various health care centers 
and  hospitals  affiliated  with  Tehran  University  of  Medical 
Sciences,  Soltanipoor  et  al.  evaluated  the  effects  of  olive  oil  in 
preventing  striae  gravidarum  (stretch  marks).  The  treatment 
group, to which 50 women were randomized, received 1 cc of 
topical olive oil for twice daily gentle application to abdominal 
skin, not massaging it into the skin until after delivery. The control 

group  of  50  women  received  no  treatment.  The  investigators  
did  not  find  a  statistically  significant  difference  between  the 
groups, though they noted that olive oil lowered the incidence 
of severe striae gravidarum but was associated with an increase 
in the incidence of mild striae.17

Although  olive  oil  is  increasingly  considered  an  anti-
inflammatory agent, it is also considered to be a weak irritant. 
There have been occasional reports of adverse side effects to its 
topical use, and it is considered unsuitable or contraindicated in 
patients with venous insufficiency and related eczema on the 
lower  extremities.18  In  a  recent  study,  Danby  et  al.  recruited  
19 adults with and without a history of atopic dermatitis (AD) 
into  two  randomized  forearm-controlled mechanistic studies. 
One  group  was  instructed  to  apply,  twice  daily,  six  drops  of 
olive  oil  to  one  forearm  for  five  weeks.  Over  a  four-week 
period, the second group applied, twice daily, the same amount 
of olive oil to one forearm along with six drops of sunflower 
seed  oil.  The  investigators  found  that  olive  oil  precipitated  a 
decline in stratum corneum (SC) integrity as well as well mild 
erythema in the subjects regardless of AD history. Conversely, 
sunflower seed oil supported SC integrity, improved hydration, 
and  did  not  provoke  erythema.  In  light  of  these  results,  the 
investigators concluded that olive oil exhibits the potential to 
aggravate AD and they recommend against its use for dry skin 
or infant massage.19

 SAFETY ISSUES

Olive oil is generally recognized as safe, but as a weak irritant.18 
It has a high content of oleic acid, which likely accounts for the 
“decrease in SC integrity” reported in studies.

 ENVIRONMENTAL IMPACT

As in the case with any plant that is cultivated for food and 
industrial uses, positive and negative effects on the environ-
ment are not uncommon. Considerable care must be taken 
to  ensure  environmental  sustainability,  which  has  become 
increasingly  important  to  growers  particularly  in  the 
European  Union  and  the  four  main  olive-producing  coun-
tries (i.e., Greece, Italy, Spain, and Portugal).20 Optimal dis-
posal of olive mill waste water is a key consideration.21 It is 
also necessary to monitor the impact on olive cultivation of 
European  Union  subsidies  leading  to  the  intensification  of 
olive production.22

 FORMULATION CONSIDERATIONS

Olive  oil  is  lipophilic.  It  can  be  successfully  made  into  stable 
oil-in-water emulsions or used as a pure oil.23

 USAGE CONSIDERATIONS

Olive oil has significant amounts of oleic acid, which has been 
shown  to  increase  skin  penetration  by  disturbing  the  bar-
rier.24,25 Its use may increase penetration of other ingredients. 
Extra virgin olive oil is the product obtained from the first olive 
pressings  and  is  much  higher  in  polyphenols  than  the  oil 
obtained during further pressings.

 
 SIGNIFICANT BACKGROUND

Olive oil has been found to be an important ingredient in some 
botanical combination therapies and for various conditions.

Combination Therapy
In multiple studies, Al-Waili has shown that a honey, olive oil, 
and beeswax mixture (1:1:1) can be used effectively for multiple 
conditions,  including  AD,  diaper  dermatitis,  psoriasis,  anal  fis-
sures, and fungal as well as bacterial infections. In 2003, Al-Waili 
performed  a  partially  controlled,  single-blind  study  to  evaluate 
the effects of the mixture on 21 patients with AD and 18 patients 
with  psoriasis.  Most  of  the  AD  patients  exhibited  significant 
improvement in the evaluated symptoms (i.e., erythema, scaling, 
lichenification,  excoriation,  indurations,  oozing,  and  pruritus) 
after two weeks as did a majority of the psoriasis patients (i.e., 
redness,  scaling,  thickening,  and  pruritus).26  In  2004,  Al-Waili 
tested the same ointment in 37 patients as treatment for the cuta-
neous  fungal  infections  pityriasis  versicolor,  tinea  cruris,  tinea 
corporis, and tinea faciei. Three daily applications on the lesions 
for up to four weeks resulted in observed clinical responses (i.e., 
reductions  in  erythema,  scaling,  and  itching)  in  86  percent  of 
pityriasis versicolor patients, 78 percent of tinea cruris patients, 
and 75 percent of tinea corporis patients, with mycological reso-
lution achieved in a significant percentage of patients (75 percent, 
71 percent, and 62 percent of patients with pityriasis versicolor, 
tinea cruris, and tinea corporis, respectively).27

In 2005, Al-Waili evaluated the effects of the honey/olive oil/
beeswax  mixture  on  the  growth  of  Staphylococcus  aureus  and 
Candida albicans isolated from humans and found that while the 
mixture  as  well  as  honey  alone  were  effective  in  inhibiting 
bacterial  growth,  mild-to-moderate  growth  occurred  on  media 
containing olive oil or beeswax.28 Also that year, Al-Waili assessed 
the mixture for its effects on 12 infants with diaper dermatitis. 
Four daily treatments for seven days yielded significant declines 
in mean lesion scores. Further,  Candida albicans was isolated in 
four patients before treatment began, but only two patients after 
the one week of treatment, leading to Al-Waili’s conclusion that 
the  honey/olive/beeswax  ointment  is  safe  as  well  as  clinically 
and mycologically effective for treating diaper dermatitis.29 The 
ointment was found to be clinically effective in a pilot study to 
treat anal fissures and hemorrhoids in 2006.30

In 2008, Kiechl-Kohlendorfer et al. reported on their rand-
omized  controlled  trial  to  test  the  cutaneous  effects  of  two 
topical  ointments  on  the  skin  of  173  premature  infants  con-
ducted  between  October  2004  and  November  2006. 
Researchers  prospectively  enrolled  the  infants  (between  25 
and 36 weeks of gestation) admitted into a neonatal intensive 
care  unit,  and  randomly  scheduled  them  for  daily  treatment 
with  a  water-in-oil  emollient  cream,  an  olive  oil  cream  
(70 percent lanolin, 30 percent olive oil), or a control ointment. 
Statistically  less  dermatitis  was  noted  in  the  infants  treated 
with the olive oil cream after four weeks as compared to the 
emollient cream and control.31

In 2012, Panahi et al. conducted a randomized double-blind 
clinical trial in 67 Iranian injured war veterans to determine the 
clinical efficacy of a topical cream combining Aloe vera and olive 
oil  in  comparison  to  b-methasone  0.1  percent  cream.  Thirty-
one out of 34 subjects randomized to the botanical combina-
tion completed the regimen of twice daily application for six 
weeks  and  32  out  of  the  33  randomized  to  b -methasone 

C H A P T E R  14  ■   O L I V E   O I L  

39

finished  the  trial.  A  pruritic  score  questionnaire  and  visual 
analog scale were used for assessment. Significant decreases in 
pruritus frequency, burning, scaling, and xerosis by the end of 
the trial were seen in both groups. The rate of amelioration in 
pruritus severity was comparable between the groups; reduc-
tions  in  fissures  and  excoriations  were  observed  only  in  the  
A.  vera/olive  oil  group.  The  investigators  concluded  that  the 
botanical cream was as effective as b-methasone 0.1 percent in 
treating sulfur mustard-induced chronic skin complications and 
displays potential as a therapeutic option for such patients.32

Antifungal Activity
In  2006,  Battinelli  et  al.  found  that  the aliphatic aldehydes in 
olives  [hexanal,  nonanal,  (E)-2-hexenal,  (E)-2-heptenal,  (E)-2-
octenal, and (E)-2-nonenal] exhibited antifungal effects against 
T. mentagrophytes and M. canis and concentration-dependently 
inhibited elastase activity.33

Cancer
Data  over  the  last  decade  suggest  the  potential  of  anticarcino-
genic properties in olive oil. In 2000, the topical application of 
olive oil following ultraviolet (UVB) exposure was found to be 
effective  against  photocarcinogenesis  in  mouse  skin  models.5 
That same year, Ichihashi et al. found that topically applied extra 
virgin olive oil may diminish the formation of the free radical-
induced 8-hydroxy-deoxyguanosine (8-OHdG), which is known 
to be involved in gene mutation, and thus has the potential to 
slow the development of UV-induced skin cancer in humans as 
it appears to do in mice.34 In a more recent study in humans on 
the effects of various topical agents on the transmission of UVB 
radiation therapy, Fetil et al. found that olive oil did not affect the 
minimal  erythema  dose  and  was  therefore  appropriate  to  use 
before phototherapy.35 Olive oil may also exhibit activity against 
UVA. Hydroxytyrosol, one of the key polyphenolic components 
of the polar fraction of olive oil, has displayed a capacity to sup-
press cell proliferation in human leukemia (HL60) cells,36 and to 
prevent UVA-induced protein damage in melanoma cells.37

 CONCLUSION

Various compounds in olive oil with known antioxidant activ-
ity, as well as evidence suggesting anti-inflammatory and anti-
carcinogenic  properties,  suggest  reasons  to  consider  further 
research to establish what appears to be an important ingredi-
ent in skin care formulations. That said, the salutary effects of 
dietary  olive  oil  are  much  better  researched  and  understood. 
There is a paucity of evidence, particularly from randomized, 
double-blind, controlled trials, establishing the efficacy of topi-
cally applied olive oil. While there appears to be emerging data 
suggesting a role for olive oil in the topical dermatologic arma-
mentarium,  particularly  in  relation  to  photoprotective,  anti-
inflammatory,  and  antioxidant  activity,  more  research  is 
necessary to elucidate whether the increasing inclusion of olive 
oil in over-the-counter products is warranted and, if so, whether 
the botanical can be harnessed for more effective use in derma-
tologic treatments. The high amounts of oleic acid in olive oil 
can disturb the skin barrier, which would affect the efficacy of 
olive oil in dry skin conditions. It seems certain that the utility 
of  olive  oil  in  treating  dry  skin  conditions  depends  upon  the 
other ingredients with which it is combined.

 
40 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

REFERENCES

1.  Aburjai  T,  Natsheh  FM.  Plants  used  in  cosmetics.  Phytother  Res. 

2003;17:987.

2.  Charrouf Z, Guillaume D. Should the amazigh diet (regular and 
moderate  argan-oil  consumption)  have  a  beneficial  impact  on 
human health? Crit Rev Food Sci Nutr. 2010;50:473.

3.  Cunha SS, Fernandes JO, Oliveira MB. Quantification of free and 
esterified sterols in Portuguese olive oils by solid-phase extraction 
and  gas  chromatography-mass  spectrometry.  J  Chromatogr  A. 
2006;1128:220.

4.  Martínez-Domínguez E, de la Puerta R, Ruiz-Gutiérrez V. Protective 
effects upon experimental inflammation models of a polyphenol-
supplemented virgin olive oil diet. Inflamm Res. 2001;50:102.

5.  Budiyanto A, Ahmed NU, Wu A, et al. Protective effect of topi-
cally applied olive oil against photocarcinogenesis following UVB 
exposure of mice. Carcinogenesis. 2000;21:2085.

6.  Nomikos NN, Nomikos GN, Kores DS. The use of deep friction 
massage with olive oil as a means of prevention and treatment of 
sports injuries in ancient times. Arch Med Sci. 2010;6:642.

7.  de la Puerta R, Martínez Domínguez ME, Ruíz-Gutíerrez V, et al. 
Effects  of  virgin  olive  oil  phenolics  on  scavenging  of  reactive 
nitrogen  species  and  upon  nitrergic  neurotransmission.  Life  Sci. 
2001;69:1213.

8.  Owen RW, Giacosa A, Hull WE, et al. Olive-oil consumption and 
health: the possible role of antioxidants. Lancet Oncol. 2000;1:107.
9.  de la Puerta R, Martínez-Domínguez E, Ruíz-Gutiérrez V. Effect of 
minor components of virgin olive oil on topical anti-inflammatory 
assays. Z Naturforsch C. 2000;55:814.

10.  Owen RW, Mier W, Giacosa A, et al. Identification of lignans as 
major components in the phenolic fraction of olive oil. Clin Chem. 
2000;46:976.

11.  Newmark HL. Squalene, olive oil, and cancer risk: A review and 

hypothesis. Cancer Epidemiol Biomarkers Prev. 1997;6:1101.

12.  Kohno Y, Egawa Y, Itoh S, et al. Kinetic study of quenching reac-
tion of singlet oxygen and scavenging reaction of free radical by 
squalene in n-butanol. Biochim Biophys Acta. 1995;1256:52.

13.  Moreno JJ, Carbonell T, Sánchez T, et al. Olive oil decreases both 
oxidative stress and the production of arachidonic acid metabo-
lites  by  the  prostaglandin  G/H  synthase  pathway  in  rat  mac-
rophages. J Nutr. 2001;131:2145.

14.  Purba  MB,  Kouris-Blazos  A,  Wattanapenpaiboon  N,  et  al.  Skin 
wrinkling: Can food make a difference? J Am Coll Nutr. 2001;20:71.
15.  Baumann LS, Weisberg EM. Olive oil in botanical cosmeceuticals. 
In:  Preedy  VR,  Weston  R,  (eds),  Olives  and  Olive  Oil  in  Health  
and  Disease  Prevention.  New  York:  Academic  Press;  2010: 
1117-1124.

16.  Latreille J, Kesse-Guyot E, Malvy D, et al. Dietary monounsatu-
rated  fatty  acids  intake  and  risk  of  skin  photoaging.  PLoS  One. 
2012;7:e44490.

17.  Soltanipoor F, Delaram M, Taavoni S, et al. The effect of olive oil 
on  prevention  of  striae  gravidarum:  A  randomized  controlled 
clinical trial. Complement Ther Med. 2012;20:263.

18.  Kränke B, Komericki P, Aberer W. Olive oil – Contact sensitizer or 

irritant? Contact Dermatitis. 1997;36:5.

19.  Danby SG, Alenezi T, Sultan A, et al. Effect of olive and sunflower 
seed oil on the adult skin barrier: implications for neonatal skin 
care. Pediatr Dermatol. 2013; 30:42.

20.  Camarsa  G,  Gardner  S,  Jones  W,  et  al.  LIFE  (“The  Financial 
Instrument  for  the  Environment”)  among  the  olives:  Good 

practice  in  improving  environmental  performance  in  the  olive 
sector. In: Martin H, ed. Brussels: European Union; 2010.

21.  Topi D, Thomaj F, Beqiraj I, et al. The environmental implications 
from olive industry in Albania. BALWOIS (Water Observation and 
Information System for Balkan Countries). 28 May–2 June 2012.

22.  Allen HD, Randall RE, Amable GS, et al. The impact of changing 
olive cultivation practices on the ground flora of olive groves in 
the  Messara  and  Psiloritis  regions,  Crete,  Greece.  Land  Degrad 
Develop. 2006;17:249.

23.  Smaoui S, Ben Hlima H, Jarraya R, et al. Cosmetic emulsion from 
virgin  olive  oil:  Formulation  and  bio-physical  evaluation.  Afr  J 
Biotechnol. 2012;11:9664.

24.  Naik A, Pechtold LA, Potts RO, et al. Mechanism of oleic acid-
induced  skin  penetration  enhancement  in  vivo  in  humans.  
J Control Release. 1995;37:299.

25.  Ongpipattanakul  B,  Burnette  RR,  Potts  RO,  et  al.  Evidence  that 
oleic  acid  exists  in  a  separate  phase  within  stratum  corneum 
lipids. Pharm Res. 1991;8:350.

26.  Al-Waili NS. Topical application of natural honey, beeswax and 
olive oil mixture for atopic dermatitis or psoriasis: Partially con-
trolled, single-blinded study. Complement Ther Med. 2003;11:226.

27.  Al-Waili  NS.  An  alternative  treatment  for  pityriasis  versicolor, 
tinea  cruris, tinea  corporis  and  tinea  faciei  with  topical  applica-
tion of honey, olive oil and beeswax mixture: an open pilot study. 
Complement Ther Med. 2004;12:45.

28.  Al-Waili  NS.  Mixture  of  honey,  beeswax  and  olive  oil  inhibits 
growth of Staphylococcus aureus and Candida albicans. Arch Med 
Res. 2005;36:10.

29.  Al-Waili NS. Clinical and mycological benefits of topical applica-
tion  of  honey,  olive  oil  and  beeswax  in  diaper  dermatitis.  Clin 
Microbiol Infect. 2005;11:160.

30.  Al-Waili NS, Saloom KS, Al-Waili TN, et al. The safety and effi-
cacy of a mixture of honey, olive oil, and beeswax for the man-
agement  of  hemorrhoids  and  anal  fissure:  A  pilot  study. 
ScientificWorldJournal. 2006;6:1998.

31.  Kiechl-Kohlendorfer U, Berger C, Inzinger R. The effect of daily 
treatment with an olive oil/lanolin emollient on skin integrity in 
preterm  infants:  a  randomized  controlled  trial.  Pediatr  Dermatol. 
2008;25:174.

32.  Panahi Y, Davoudi SM, Sahebkar A, et al. Efficacy of Aloe vera/
olive  oil  cream  versus  betamethasone  cream  for  chronic  skin 
lesions following sulfur mustard exposure: A randomized double-
blind clinical trial. Cutan Ocu Toxicol. 2012;31:95.

33.  Battinelli L, Daniele C, Cristiani M, et al. In vitro antifungal and 
anti-elastase  activity  of  some  aliphatic  aldehydes  from  Olea  
europaea L. fruit. Phytomedicine. 2006;13:558.

34.  Ichihashi M, Ahmed NU, Budiyanto A, et al. Preventive effect of 
antioxidant on ultraviolet-induced skin cancer in mice. J Dermatol 
Sci. 2000;23(Suppl 1):S45.

35.  Fetil E, Akarsu S, Ilknur T, et al. Effects of some emollients on the 
transmission  of  ultraviolet.  Photodermatol  Photoimmunol  Photomed. 
2006;22:137.

36.  Fabiani R, De Bartolomeo A, Rosignoli P, et al. Cancer chemo-
prevention  by  hydroxytyrosol  isolated  from  virgin  olive  oil 
through  G1  cell  cycle  arrest  and  apoptosis.  Eur  J  Cancer  Prev. 
2002;11:351.

37.  D’Angelo  S,  Ingrosso  D,  Migliardi  V,  et  al.  Hydroxytyrosol,  a 
natural  antioxidant  from  olive  oil,  prevents  protein  damage 
induced  by  long-wave  ultraviolet  radiation  in  melanoma  cells. 
Free Radic Biol Med. 2005;38:908.

 
C H A P T E R   1 5

Safflower Oil

C H A P T E R  15  ■   S A F F L O W E R   O I L 

41

Activities:

Anti-inflammatory,  hydrating,  increases  ceramide  1 
production

Important Chemical Components:

Linoleic acid
Oleic acid
Palmitic acid
Arachidonic acid (trace amounts)
Polyphenols1

Origin Classification:

This ingredient is considered natural. Organic forms are 
available.

Personal Care Category:

Occlusive, barrier repair

Recommended for the following Baumann Skin 
Types:

It is useful in dry and inflamed skin types (S2, S3, S4) but 
should not be used in S1 (acne type) sensitive skin. Best 
for DRNT, DRPT, DRNW, DRPW, DSNT, DSPT, DSNW, 
and DSNT.

 SOURCE

Safflower (Carthamus tinctorius) is a thistle-like annual plant with 
many branches that belongs to the Asteraceae or Compositae 
family.  Plants  range  in  height  from  1  to  almost  5  feet  with 
yellow,  orange,  or  red  flowers.  Safflower  oil  is  obtained  by 
pressing the seeds of the plant. The fatty acid composition of 
safflower  oil  can  be  experimentally  manipulated  and  varies 
depending on the geographical location of the plants.2

 HISTORY

Safflower is one of the oldest cultivated crops, its use dating back 
4,000  years  to  ancient  Egypt,  though  its  native  country  is  not 
known.3,4 The plant was traditionally grown for its seeds, which 
were used in foods and folk medicine. The plant is now globally 
cultivated, in regions with long dry seasons, for its vegetable oil. 
The  oil  has  been  found  to  exert  notable  health  benefits  when 
consumed through the diet and also when used in topical formu-
lations. The flower of C. tinctorius has been used for laxative and 
diaphoretic  purposes  as  well  as  for  skin  eruptions,  fevers,  and 
measles in children.3 In traditional Chinese medicine (TCM), C. 
tinctorius  has  been  associated  with  uterostimulant  activity.5  In 
addition, there is a lengthy history of safflower seed use in the 
clinical setting in Korea to prevent osteoporosis, to foster bone 
development, and to treat rheumatism.6

 CHEMISTRY

Linoleic  acid  (LA)  is  a  primary  constituent  of  safflower  seeds 
and  the  ingredient  typically  cited  for  providing  its  cutaneous 
benefits ( Table 15-1). In fact, safflower oil is one of the richest 
sources of LA, which is essential for the endogenous produc-
tion  of  ceramides,  important  components  of  the  epidermal 
layer that play a crucial role in barrier function and cutaneous 
water retention. LA is not produced by the body and, therefore, 
must be obtained through the diet. LA applied to skin has been 
shown to strengthen the skin barrier and lower transepidermal 
water loss.7

LA is also a critical component in the systemic synthesis of 
γ -linolenic acid (GLA), which plays an important role in the con-
trol of inflammation. See Chapter 11, Borage Seed Oil, for the 
significance  of  LA  metabolism  in  the  production  of  inflamma-
tory  eicosanoids  (i.e.,  prostaglandins,  thromboxanes,  and 
leukotrienes).

 ORAL USES

Odorless  and  tasteless  safflower  oil  is  one  of  several  plant-
based oils available on the market. It is also marketed in dietary 
supplement  capsule  form.  Safflower  oil  is  used  clinically  as  a 
source  for  LA  and  has  been  used  to  treat  essential  fatty  acid 
deficiency (EFAD), Friedreich’s ataxia, and hangovers.2

Diabetes
Safflower oil has been found to impart dietary benefits to dia-
betic  pregnant  rats  and  their  embryos,  preventing  diabetes-
induced  developmental  harm  during  early  organogenesis.8 
Supplementation has also been demonstrated to prevent exces-
sive activity by matrix metalloproteinases (specifically MMP-2 
and MMP-9) in the placenta of diabetic rats.9 In addition, in a 
recent  study,  safflower  oil  and  folic  acid  supplementations 
were  demonstrated  to  interact,  protecting  rat  embryos  from 
diabetes-induced  harm  through  diminished  proinflammatory 
mediators.10

TABLE 15-1
Pros and Cons of Safflower Oil

Pros
Rich in linoleic acid
Stable unless prolonged exposure to air
Nontoxic 

Anti-inflammatory properties
Penetrates into skin
Useful for rosacea
Does not inactivate other ingredients

Cons
Mildly comedogenic
Minimal data on efficacy
Greasy, so individuals with oily skin will 

not like it

 
42 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Menopause
In addition, Asp et al. recently completed a randomized, double-
blinded crossover study of 55 postmenopausal women with type 
2 diabetes (with 35 completing the study), which revealed that the 
daily  consumption  of  8  g  of  safflower  oil  improved  glycemia, 
inflammation, and blood lipids.11 A study by Kim et al. in 2002 in 
female  Sprague-Dawley  rats  provided  evidence  that  safflower 
seeds exert protection against bone loss due to estrogen deficiency.6

 TOPICAL USES

When  applied  topically,  safflower  oil  is  absorbed  into  skin  as 
evidenced by studies on rodents with EFAD.7 Safflower oil is incor-
porated  in  moisturizing  agents  for  its  emollient,  occlusive,  and 
anti-inflammatory properties. Its high concentration of LA, and its 
stability make it an important ingredient in personal care products. 
LA  gives  safflower  oil  its  anti-inflammatory  properties.12,13  Pure 
safflower oil is a mild-to-moderate comedogenic agent,2 so it is not 
the best choice of products for acne patients.

Inflammation/Tumorigenesis
In  an  early  study  on  the  antiproliferative  potential  of  C. 
tinctorius extracts, Yasukawa et al., in 1996, applied the tumor-
promoting  agent  12-O-tetradecanoylphorbol-13-acetate 
(TPA) to the ears of mice (1 μg/ear) to induce inflammation. 
The investigators then isolated erythro-alkane-6,8-diols from 
the flowers of C. tinctorius and applied the extract to the same 
area.  They  reported  that  the  alkane-6,8-diols  suppressed 
inflammation  and  significantly  inhibited  TPA-induced  skin 
tumor formation in mice.14

Pigmentation
In  2004,  Roh  et  al.  investigated  potential  melanogenesis-sup-
pressing  activity  of  safflower  seeds  to  develop  a  novel  skin-
whitening  agent.  They  reported  that  an  80  percent  aqueous 
methanol extract and ethyl acetate fraction from the seeds sig-
nificantly inhibited mushroom tyrosinase, and identified three 
active constituents [N-feruloylserotonin, N-(p-coumaroyl)sero-
tonin,  and  acacetin].  Of  these,  N-feruloylserotonin  and  N-(p-
coumaroyl)serotonin were found to more potently suppress the 
melanin synthesis of Streptomyces bikiniensis and B16 melanoma 
cells than arbutin, a well-known inhibitor of melanogenesis.15 
There  are  no  published  in  vivo  studies  on  the  use  of  topical  
safflower oil in pigmentation disorders.

 SAFETY ISSUES

Safflower oil is nontoxic when ingested. There are no reports 
of significant adverse side effects to its topical usage. Given its 
membership in the Asteraceae or Compositae family, known 
to be associated with contact dermatitis, topical safflower oil 
should be considered to have the potential to elicit such a reac-
tion.  Safflower  oil  comes  from  the  seeds  of  plants;  therefore, 
contamination from pesticides could occur. Although aflatoxin 
contamination  of  safflower  seeds  has  been  reported  in  India, 
this is unlikely in seeds from plants grown in the United States.2 
Undiluted  safflower  oil  can  cause  skin  irritation  as  seen  in 
repeat open patch tests, but contact dermatitis to products con-
taining  safflower  oil  is  very  unlikely.2  Safflower  oil  does  not 
appear  to  be  phototoxic.2  The  Cosmetic  Ingredient  Review 
panel considers safflower oil to be a safe ingredient.2

 ENVIRONMENTAL IMPACT

Safflower is cultivated in several countries, but is considered a 
minor crop. Its environmental impact is minimal. The plant is 
susceptible to frost and to developing fungal diseases in rainy 
conditions.16

 FORMULATION CONSIDERATIONS

Safflower oil is liquid at room temperature and soluble in fats 
and  oil  solvents.  It  is  relatively  resistant  to  oxidation  unless 
exposure to air has been prolonged, in which case the product 
becomes thickened and rancid. The stability of safflower oil or 
its resistance to oxidation increases as its oleic acid concentration 
increases.

 USAGE CONSIDERATIONS

Safflower oil may affect penetration of other ingredients both 
positively  and  negatively  depending  on  its  fatty  acid 
composition and concentration.

 SIGNIFICANT BACKGROUND

In 2005, Solanki et al. conducted a short randomized controlled 
study in a tertiary care neonatal intensive care unit of a large 
teaching hospital to assess the transcutaneous absorption of oil 
traditionally used in massage of newborns and to compare the 
effects of safflower oil and coconut oil on fatty acid profiles of 
massaged  babies.  The  investigators  randomly  assigned  120 
babies  to  three  groups  –  safflower  oil,  coconut  oil,  or  no  oil 
controls (40 in each group). Oil (5 mL) was massaged four times 
daily  for  five  days.  Triglyceride  levels  were  significantly  ele-
vated in all groups, though much more so in the non-control 
groups.  Significant  increases  in  essential  fatty  acids  (linolenic 
and arachidonic) were seen in the safflower oil group and simi-
lar  increases  in  saturated  fats  were  seen  in  the  coconut  oil 
group, with changes more evident in term babies. The research-
ers concluded that topically applied oil is absorbed in neonates 
and is likely available nutritionally. Consequently, they deemed 
the  fatty  acid  constituents  of  the  massage  oils  significant  in 
potentially  impacting  the  fatty  acid  profiles  of  patients.17 
Safflower oil is rich in essential fatty acids and coconut oil is 
rife with saturated fat.

 CONCLUSION

Safflower oil, rich in linoleic acid, can be used to strengthen the 
skin  barrier,  hydrate  skin  through  occlusion,  and  decrease 
inflammation. It is used topically and as a dietary supplement. 
There are many studies in the literature investigating the ben-
efits of linoleic acid on skin but there is a paucity of trials look-
ing at safflower oil to treat dry, irritated skin. However, in the 
author’s experience, it joins borage seed oil and argan oil as the 
best  oils  to  use  for  dry  and  inflamed  skin  including  rosacea. 
More controlled studies are needed to examine its role in rosa-
cea and other disorders that cause skin redness. Although some 
trials described above considered safflower oil as an anticancer 
treatment,  the  larger  dietary  trials  have  been  inconclusive.2 
Only one trial in the literature discussed the tyrosinase inhibi-
tory effect of safflower oil, so this claim is poorly founded and 
not supported by data.

 
REFERENCES

1.  Cho SH, Lee HR, Kim TH, et al. Effects of defatted safflower seed 
extract and phenolic compounds in diet on plasma and liver lipid 
in  ovariectomized  rats  fed  high-cholesterol  diets.  J  Nutr  Sci 
Vitaminol (Tokyo). 2004;50:32.

2.  Elder RL. Final report on the safety assessment of safflower oil.  

Int J Toxicol. 1985;4:171.

3.  Grieve M. A Modern Herbal. Vol 1. New York Dover Publications; 

1971:698.

4.  Smith Joseph R. Safflower. Champaign, IL: AOCS Press; 1996:2.
5.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy:  Modern 

Herbal Medicine. London: Churchill Livingstone; 2000:240.

6.  Kim HJ, Bae YC, Park RW, et al. Bone-protecting effect of safflower 

seeds in ovariectomized rats. Calcif Tissue Int. 2002;71:88.

7.  Hartop PJ, Prottey C. Changes in transepidermal water loss and 
the composition of epidermal lecithin after applications of pure 
fatty acid triglycerides to skin of essential fatty acid-deficient rats. 
Br J Dermatol. 1976;95:255.

8.  Higa R, White V, Martínez N, et al. Safflower and olive oil dietary 
treatments rescue aberrant embryonic arachidonic acid and nitric 
oxide  metabolism  and  prevent  diabetic  embryopathy  in  rats. 
Mol Hum Reprod. 2010;16:286.

9.  Martinez N, Sosa M, Higa R, et al. Dietary treatments enriched in 
olive and safflower oils regulate seric and placental matrix metal-
loproteinases in maternal diabetes. Placenta. 2012;33:8.

C H A P T E R  15  ■   S A F F LO W E R   O I L  

43

10.  Higa R, Kurtz M, Mazzucco MB, et al. Folic acid and safflower 
oil  supplementation  interacts  and  protects  embryos  from 
maternal  diabetes-induced  damage.  Mol  Hum  Reprod.  2012; 
18:253.

11.  Asp ML, Collene AL, Norris LE, et al. Time-dependent effects of 
safflower  oil  to  improve  glycemia,  inflammation  and  blood 
lipids in obese, post-menopausal women with Type 2 diabetes: 
a  randomized,  double-masked,  crossover  study.  Clin  Nutr. 
2011;30:443.

12.  Letawe  C,  Boone  M,  Piérard  GE.  Digital  image  analysis  of  the 
effect of topically applied linoleic acid on acne microcomedones. 
Clin Exp Dermatol. 1998;23:56.

13.  Darmstadt GL, Mao-Qiang M, Chi E, et al. Impact of topical oils 
on  the  skin  barrier:  Possible  implications  for  neonatal  health  in 
developing countries. Acta Paediatr. 2002;91:546.

14.  Yasukawa  K,  Akihisa  T,  Kasahara  Y,  et  al.  Inhibitory  effect  of 
alkane-6,8-diols,  the  components  of  safflower,  on  tumor 
promotion  by  12-O-tetradecanoylphorbol-13-acetate  in  two-
stage carcinogenesis in mouse skin. Oncology. 1996;53:133.
15.  Roh  JS,  Han  JY,  Kim  JH,  et  al.  Inhibitory  effects  of  active  com-
pounds  isolated  from  safflower  (Carthamus  tinctorius  L.)  seeds 
for melanogenesis. Biol Pharm Bull. 2004;27:1976.

16.  Smith Joseph R. Safflower. Champaign, IL: AOCS Press; 1996:2.
17.  Solanki K, Matnani M, Kale M, et al. Transcutaneous absorption 
of  topically  massaged  oil  in  neonates.  Indian  Pediatr.  2005; 
42:998.

 
44 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   1 6

Tamanu Oil

Activities:

Anti-inflammatory,  analgesic,  antibacterial,  antioxidant, 
antiviral, ultraviolet (UV) radiation absorption, anticancer

Important Chemical Components:

Major: Dipyranocoumarins (including 4-phenylcoumarins, 
calanolides, inocalophyllins); 
Oleic acid
Linoleic acid
Palmitic acid
Stearic acid 
Glycolipids, phospholipids;
Inophyllum B and P;
Phytosterols (β-sitosterol, stigmasterol, campesterol)
Tocotrienols (δ-tocotrienol, γ-tocotrienol)1–4
Terpenoids
Minor:  Triterpenes  (friedelin,  friedelan-3-β-ol),  steroids, 
benzodipyranones, xanthones, flavonoids, tocopherols5–7

Origin Classification:

This ingredient is considered natural. Organic forms are 
available.

Personal Care Category:

Anti-inflammatory, occlusive, emollient, sun protective, 
antioxidant, scar treatment, and first aid for burns

Recommended for the following Baumann Skin 
Types:

Perfect for dry, sensitive S1 (acne) type skin. May be too 
greasy  for  individuals  with  oily  skin  types.  Best  for 
DSNT, DSNW, DSPT, and DSPW.

 SOURCE

Calophyllum  inophyllum,  a  member  of  the  mangosteen  family 
(Clusiaceae, also known as Guttiferae), is a large, nondeciduous 
tree  native  to  Africa,  South  India,  Southeast  Asia,  Polynesia, 
the Philippines, and Australia.1 C. inophyllum ranges from nearly 
25  to  75  feet  high  and  is  found  in  the  high  plateaus  of 
Madagascar  as  well  as  the  shores  throughout  the  Philippines 
and  India,  and  is  characterized  as  a  tropical  evergreen  shrub 
that grows along the southern coast of Taiwan.4,6–8 It is rumored 
that the trees that grow along the coastal shore provide a better 
oil  for  use  in  cosmetics  than  the  inland  trees,  but  there  have 
been no scientific studies to support this claim.9

C. inophyllum is now cultivated in much of the tropical world. 
The  oil  derived  from  this  abundant  plant,  known  by  a  wide 
variety of names, including Alexandrian laurel, Domba oil, beach 
mahogany,  beauty  leaf,  beach  calophyllum,  dilo,  and  kamani, 
but perhaps best known by the French Polynesian term tamanu, 
is a cold-pressed vegetable oil extracted from the fruit and seeds 
of  the  plant.  The  leaves,  bark,  and  seeds  (almonds)  of  
C.  inophyllum  are  widely  used  in  traditional  medicine  in  most 

Pacific  islands  as  well  as  the  regions  mentioned  above.10  The 
fruits contain a nut kernel, which has little oil. However, if it is 
dried on racks for a month, a chocolate brown, rich oil forms. 
Mechanical pressing results in a greenish yellow oil, similar to 
olive oil, with an aromatic odor and an insipid taste.

 HISTORY

C. inophyllum has been used for hundreds of years in cuisine and 
as an ornamental plant because of its beauty and sweet fragrance. 
Its name comes from Greek – kalos (beautiful) and phullon (leaf). 
The wood is hard and is used in construction and canoe building. 
The seeds are the source of the oil, which is used for cosmetic 
and  medicinal  purposes  and  was  once  used  as  a  lamp  oil. 
Polynesians  considered  tamanu  trees  as  sacred,8  and  the  wood 
was used to carve idols. The trees were planted inside the royal 
marae (sacred areas) and it was believed that the gods would hide 
in tamanu trees and watch human sacrifices without being seen. 
The leaves and wood of the trees have been used for various 
purposes but it is the oil that is used for cosmetic and dermato-
logic  purposes.8,10  Ocular  burn  and  cutaneous  wound  healing 
are  distinct  conditions  for  which  the  oil  of  C.  inophyllum  has 
long been used in traditional folk medicine.8,11 Several medical 
conditions have also been treated with C. inophyllum in tradi-
tional  Chinese  medicine  (TCM),  including  skin  infections, 
wounds,  inflammation,  rheumatism,  leprous  nephritis,  pain, 
and  eye  disorders.6  C.  inophyllum  was  used  for  centuries  in 
Madagascar to treat skin infections, facial neuralgia, hair loss, 
and wounds; in modern times, the herb has been used there to 
treat abrasions, burns, impetigo, insect bites, rashes, psoriasis, 
and as an antirheumatic agent.7,8,12 Tamanu oil is also consid-
ered a historical beauty secret of the women of Tahiti.8

 CHEMISTRY

The C. inophyllum constituents to which wound-healing activity 
have been attributed include calophyllolide, calophyllic acid, and 
inophyllum as well as various polyphenols, many of which exert 
antioxidant effects.8 C. inophyllum also contains δ-tocotrienol, a 
form of vitamin E that acts as an antioxidant.1,2 Calophyllolide 
and calophyllic acid are coumarin derivatives found in tamanu 
oil with antibacterial and anti-inflammatory properties. A wide 
variety of phospholipids are found in the oil (Table 16-1).13–15

 ORAL USES

Tamanu oil is for external use only, though the oleoresin of the 
oil can be taken orally for pulmonary conditions.8

 TOPICAL USES

Although  the  bark  and  leaves  have  been  used  topically,  this 
chapter  will  be  confined  to  the  uses  of  the  oil.  Several  health 
benefits have been attributed to tamanu oil and the ingredient is 
found in an increasing number of topical products. It is thought 
to  impart  anti-inflammatory,  antioxidant,  antibacterial,  antivi-
ral,  and  photoprotective  activity  (Table  16-2).  Although  the 

 
TABLE 16-1
Lipid Contents of Tamanu Oil13–15

Lipid Compositon of tamanu oil
The oil of tamanu contains basic classes of lipids (fats), enumerated below.

General lipid Composition
Neutral lipids
Glycolipids
Phospholipids

Neutral lipids
Monoacylglycerols
sn -1,3 – Diaglycerides
sn -1,2 (2,3) – Diaglycerides
Free fatty acids
Triacylglycerols
Sterols, sterolesters, and hydrocarbons

GlyColipids
Monogalactosyldiacylglycerol
Acylated sterolglucoside
Monogalactosylmonoacylglycerol
Acylmonogalactosyldiacylglycerol

Phospholipids
Phosphatidylethanolamine
Phosphatidylcholine
Phosphatidic acid
Phosphatidylserine
Lysophosphatidylcholine

Source: References 2, 15, 22.

TABLE 16-2
Pros and Cons of Tamanu Oil

pros
Provides UV protection

Anti-inflammatory and antimicrobial
Possible benefit in wound healing
May play a role in the treatment of 

acne in dry skin patients

  92.0%
  6.4%
  1.6%

  1.8%
  2.4%
  2.6%
  7.4%
82.3%
  3.5%

11.4%
13.1%
22.2%
53.3%

46.3%
33.8%
   8.1%
   6.1%
5.7%

Cons
Insufficient research to establish potential in the 

dermatologic armamentarium
Parts of the plant are poisonous

Feels greasy

scientific data are sparse, tamanu oil are recommended through-
out the world for treating abrasions, acne, anal fissures, blisters, 
burns (chemical, sun, X-ray), chilblains, diabetic sores, eczema, 
hair loss, herpes lesions, psoriasis, scars, and xerosis as well as 
to diminish foot and body odor.4,8 The best published data sup-
port the anti-inflammatory properties of the oil.

Anti-inflammatory Activity
In 2012, Tsai et al. investigated the anti-inflammatory properties 
of an acetone extract of  C. inophyllum leaves using lipopolysac-
charide (LPS)-induced RAW 264.7 cells to assess the impact of the 
extract on nitric oxide (NO) expression and inducible nitric oxide 
synthase  (iNOS).  They  found  that  C.  inophyllum  significantly 
inhibited, in dose-dependent fashion, the LPS-induced synthesis 
of  NO  in  addition  to  the  expression  of  iNOS,  cyclooxygenase 
(COX)-2 and nuclear factor-κB (NF-κB). This suggested that the 
leaf  extracts  had  components  with  anti-inflammatory  activity, 
but this study did not evaluate tamanu oil.11 

The oil contains coumarin derivatives including calophyllolide 
and calophyllic acid. Coumarin derivatives have been shown to 

C H A P T E R  16  ■   TA M A N U   O I L 

45

function  as  nonsteroidal  anti-inflammatory  drugs  (NSAIDs) 
because of their ability to inhibit synthesis of prostaglandins and 
leukotrienes.16  Calophyllolide  has  been  shown  to  decrease 
capillary permeability, which decreases inflammation and edema.17 
Another study showed that this effect is likely due, in part, to a 
decrease in the release of histamine.8 The antioxidants in the oil 
likely play a role in decreasing inflammation as does the presence 
of linoleic acid (see Chapter 64, Anti-Inflammatory Agents).

Photoprotection
In 2007, Said et al. investigated the anti-UV activity of tamanu 
oil for eye protection. C. inophyllum oil, even at low concentration 
(1/10,000,  v/v),  exhibited  significant  UV  absorption  properties 
(maximum  at  300  nm)  and  was  associated  with  an  important 
sun  protection  factor.18–22  Tamanu  oil  appeared  to  act  as  a 
cytoprotective agent against oxidative stress and DNA damage 
(85 percent of the DNA damage induced by UV was inhibited 
with 1 percent tamanu oil).7 Given the apparent antioxidant and 
cytoprotective  effects  displayed  by  the  oil  in  the  study,  the 
researchers concluded that tamanu oil has potential as a natural 
UV filter in ophthalmic formulations.7

Wounds and Burns
Modern research supports the use of tamanu oil for corneal pro-
tection from burns. In 2009, Said et al. performed in vitro, in vivo, 
and ex vivo studies to evaluate the effects of different rinsing and 
healing protocols for alkali-induced ocular burn and inflamma-
tion in rabbits. NaOH was used to induce corneal reactions in 
rabbits, followed by rinses with NaCl 0.9 percent or controlled 
ionization  marine  formula  combined  with  N-acetylcysteine  or 
vegetable oils (from  C. inophyllum and  Aleurites moluccana). The 
investigators used confocal microscopy to assess corneal epithe-
lium regeneration and inflammatory cell infiltration in vivo and ex 
vivo histological cuts. They found that the combination of con-
trolled ionization marine solution with 10 percent C. inophyllum 
oil  and  90  percent  A.  moluccana  oil  spurred  corneal  epithelium 
regeneration while decreasing inflammatory cells, suggesting its 
suitability as ocular burn therapy.18

Scars
In  a  nine-week  open-label  noncontrolled  study  in  2002,  six 
subjects were given tamanu oil to apply to their scars twice a 
day. The scars were at least one year old. The appearance of the 
scars  was  found  to  significantly  improve,  and  a  decreased 
length  and  overall  size  was  noted.8  It  is  important  to  realize 
that this study did not utilize a placebo and the improvement 
in scars could be due to the natural healing process by which 
scars  improve  over  time;  however,  the  use  of  old  scars  gives 
some credibility to this trial.

Antimicrobial Activity
As  early  as  1954,  Bhat  et  al.  showed  that  C.  inophyllum  has 
activity  against  gram-positive  bacteria.12  Fifty  years  later, 
Yimdjo et al. investigated the chemical constituents of the root 
bark and nut of C. inophyllum, resulting in the isolation of the 
xanthone derivative inoxanthone, as well as several other com-
pounds  and  the  discovery...  of  antibacterial  activity  against 
several  microbes.19  Canophyllic  acid  has  also  been  demon-
strated to exhibit potent antimicrobial properties.20

C. inophyllum leaf extracts from the islands of French Polynesia 
have also been touted for several constituents that hold promise 
as anti-HIV-1 agents, including inophyllum B and P.5 In addition, 

 
46 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

quantitative  high-performance  liquid  chromatography  (HPLC) 
analysis of callus cultures of C. inophyllum has revealed the anti-
HIV activity of the dipyranocoumarins inophyllum B and P.3

Moisturizing Activity
Tamanu  oil  contains  oleic  acid,  linoleic  acid,  and  other  fatty 
acids, as do most oils. These fatty acids provide occlusive and 
emollient benefits (see Chapter 7, Moisturizing Agents). There 
are no published studies evaluating the effects of tamanu oil on 
dry skin; however, the data suggest that there would be a posi-
tive benefit in dry, inflamed skin.

 SAFETY ISSUES

One  case  of  allergic  contact  dermatitis  has  been  reported  in 
association with tamanu oil.4 The plant, including the mature 
fruit,  kernel  seed,  sap,  and  milky  juice,  are  virulent  poisons.8 
Samoans  use  the  sap  as  an  arrow  poison.8  The  milky  juice 
causes blindness when it comes into contact with the eye.20

 ENVIRONMENTAL IMPACT

C. inophyllum is abundant in tropical regions worldwide and its 
harvesting is not known to damage the local environment. It is 
rated as lower risk/least concern on the International Union for 
Conservation of Nature and Natural Resources (IUCN) Red List 
of Threatened Species because its timber is cut in fairly large 
amounts and sold as “beach calophyllum.”21

 FORMULATION CONSIDERATIONS

Tamanu oil is extracted from the seeds or raw fruits, filtered, and 
stabilized with vitamin E.4 Tamanu oil is thought to have a shelf 
life of approximately five years if stored in a cool, dry location.

 USAGE CONSIDERATIONS

Currently, tamanu oil is sometimes used in lomi lomi massage 
and can be formulated to make soap as well as various topical 
skin care formulations.

 SIGNIFICANT BACKGROUND

In 2011, Ayyanar et al. concluded a four-year study intended to 
identify the herbs used in traditional medicine practiced by the 
Kani tribes in the Tirunelveli hills of Western Ghats, India. The 
researchers identified 90 species of plants used traditionally as 
ethnomedicinal  treatments,  with  65  different  indications 
reported, particularly dermatologic conditions and gastrointes-
tinal illnesses. Based on their study, they identified 16 species, 
including  C.  inophyllum,  for  additional  ethnopharmacological 
investigation as potential sources of new drug agents.22

Anticancer  activity  has  been  exhibited  by  C.  inophyllum 
according to some recent studies. Just over a decade ago, Itogawa 
et al. examined the potential inhibitory effects of  C. inophyllum 
4-phenylcoumarin  isolates  on  Epstein-Barr  virus  early  antigen 
(EBV-EA)  activation  caused  by  12-O-tetradecanoylphorbol-13-
acetate  in  Raji  cells.  All  10  of  the  isolates  displayed  inhibitory 
activity  against  EBV  and  no  cytotoxicity.  The  strongest  com-
pound tested was calocoumarin-A 5, which also demonstrated a 
significant capacity to suppress murine skin tumor promotion in 
a two-stage cancer model. The investigators concluded that some 

4-phenylcoumarin constituents of C. inophyllum warrant further 
study as possible antitumor agents.23

C.  inophyllum  was  one  of  among  155  extracts  from  93  plant 
species found on peninsular Malaysia screened by Ong et al. in 
2009  for  in  vitro  photocytotoxic  activity  using  human  leukemia 
cells  (cell  line  HL-60).  Further,  C.  inophyllum  was  among  the  
29 plants to lower the in vitro cell viability by more than 50 percent 
after exposure to 9.6 J/cm2 of a broad-spectrum light tested at a 
concentration of 20 μg/mL.24 In addition, Li et al. isolated one new 
friedelane-type triterpene and seven previously discovered triter-
penoids from the stems and leaves of C. inophyllum and found that 
the compounds demonstrated growth-inhibitory activity against 
human leukemia HL-60 cells.25

In 2008, Xiao et al. isolated a new prenylated xanthone (calox-
anthone) as well as two previously known xanthones from the 
ethanolic extract of C. inophyllum twigs and reported that two of 
the  constituents  (including  the  new  xanthone)  demonstrated 
cytotoxicity against myelogenous leukemia (cell line K562).26

Tamanu oil has the potential to treat many topical inflamma-
tory diseases but data are lacking. The myriad uses for tamanu 
oil are quite amazing, though. It has even demonstrated poten-
tial use for humans and domestic animals as an insect repellent, 
specifically against Stomoxys calcitrans (stable fly).27,28

 CONCLUSION

The oil of C. inophyllum has been used in traditional societies in 
the  mainly  eastern  and  southern  hemispheres  for  medicinal 
and  culinary  purposes  for  centuries.  There  are  sparse  data  in 
the  form  of  randomized,  placebo-controlled  clinical  trials  to 
establish the effectiveness and appropriate role(s) of C. inophyl-
lum within the topical dermatologic arsenal. However, the fact 
that tamanu oil contains fatty acids, coumarin derivatives, and 
antioxidant  abilities  in  addition  to  antimicrobial  properties 
makes  it  quite  unique  and  worthy  of  further  study.  In  the 
author’s experience, this oil is a useful moisturizing ingredient 
in dry skin types that suffer from acne. 

REFERENCES

1.  Crane  S,  Aurore  G,  Joseph  H,  et  al.  Composition  of  fatty  acids 
triacylglycerols and unsaponifiable matter in Calophyllum calaba 
L. oil from Guadeloupe. Phytochemistry. 2005;66:1825.

2.  He L, Mo H, Hadisusilo S, et al. Isoprenoids suppress the growth 
of  murine  B16  melanomas  in  vitro  and  in  vivo.  J  Nutr. 
1997;127:668.

3.  Pawar KD, Joshi SP, Bhide SR, et al. Pattern of anti-HIV dipyrano-
coumarin expression in callus cultures of Calophyllum inophyl-
lum Linn. J Biotechnol. 2007;130:346.

4.  Le  Coz  CJ.  Allergic  contact  dermatitis  from  tamanu  oil 
(Calophyllum  inophyllum,  Calophyllum  tacamahaca).  Contact 
Dermatitis. 2004;51:216.

5.  Laure F, Raharivelomanana P, Butaud JF, et al. Screening of anti-
HIV-1 inophyllums by HPLC-DAD of Calophyllum inophyllum 
leaf  extracts  from  French  Polynesia  Islands.  Anal  Chim  Acta. 
2008;624:147.

6.  Shen  YC,  Hung  MC,  Wang  LT,  et  al.  Inocalophyllins  A,  B  and 
their methyl esters from the seeds of Calophyllum inophyllum. 
Chem Pharm Bull (Tokyo). 2003;51:802.

7.  Said  T,  Dutot  M,  Martin  C,  et  al.  Cytoprotective  effect  against 
UV-induced DNA damage and oxidative stress: Role of new bio-
logical UV filter. Eur J Pharm Sci. 2007;30:203.

8.  Dweck  AC,  Meadows  T.  Tamanu  (Calophyllum  inophyllum)  – 
The African, Asian, Polynesian and Pacific Panacea. Int J Cosmet 
Sci. 2002;24:341.

9.  Kilham C. Tamanu oil: A tropical topical remedy. Herbal Gram. 63. 
Austin,  TX:  American  Botanical  Council.  www.herbalgram.org; 
2004:10–15.

 
10.  Leu T, Raharivelomanana P, Soulet S, et al. New tricyclic and tet-
racyclic  pyranocoumarins  with  an  unprecedented  C-4  substitu-
ent.  Structure  elucidation  of  tamanolide,  tamanolide  D  and 
tamanolide P from Calophyllum inophyllum of French Polynesia. 
Magn Reson Chem. 2009;47:989.

11.  Tsai SC, Liang YH, Chiang JH, et al. Anti-inflammatory effects of 
Calophyllum  inophyllum  L.  in  RAW  264.7  cells.  Oncol  Rep. 
2012;28:1096.

12.  Bhat SG, Kane JG, Sreenivasan A. The in vitro evaluation of the 
antibacterial activity of undi oil (Calophyllum inophyllum Linn.). 
J Am Pharm Assoc Am Pharm Assoc (Baltim). 1954;43:543.

13.  Petard  P.  Tahiti-Polynesian  medicinal  plants  and  Tahitian  reme-
dies. Noum!a, New Caledonia: South Pacific Commission; 1972.

14.  Hemavathy  J,  Prabhakar  JV.  Lipid  composition  of  Calophyllum 

inophyllum kernel. J Am Oil Chem Soc. 1990;67:955.

15.  Lederer E, Dietrich P, Polonsky J. On the chemical constitution of 
calophylloide and calophyllic acid from the nuts of Calophyllum 
inophyllum. Bull Fr Chem Soc. 1953;5:546.

16.  Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, et al. Natural 
and  synthetic  coumarin  derivatives  with  anti-inflammatory/
antioxidant activities. Curr Pharm Des. 2004;10(30):3813.

17.  Saxena RC, Nath R, Palit G, et al. Effect of calophyllolide, a non-
steroidal  anti-inflammatory  agent,  on  capillary  permeability. 
Planta Med. 1982;44:246.

18.  Said T, Dutot M, Labbé A, et al. Ocular burn: rinsing and healing 
with ionic marine solutions and vegetable oils. Ophthalmologica. 
2009;223:52.

19.  Yimdjo  MC,  Azebaze  AG,  Nkengfack  AE,  et  al.  Antimicrobial 
inophyllum. 

from  Calophyllum 

and  cytotoxic  agents 
Phytochemistry. 2004;65:2789.

C H A P T E R  16  ■   TA M A N U   O I L 

47

20.  Lim  TK.  Calophyllum  inophyllum.  In:  Edible  Medicinal  and 
Non-Medicinal  Plants.  Vol  2.  Fruits.  New  York:  Spring;  2012: 
7–19.

21.  International  Union  for  Conservation  of  Nature  and  Natural 
Resources  (IUCN).  The  Red  List  of  Threatened  Species.  www.
iucnredlist.org. Accessed October 25, 2012.

22.  Ayyanar M, Ignacimuthu S. Ethnobotanical survey of medicinal 
plants  commonly  used  by  Kani  tribals  in  Tirunelveli  hills  of 
Western Ghats, India. J Ethnopharmacol. 2011;134:851.

23.  Itoigawa M, Ito C, Tan HT, et al. Cancer chemopreventive agents, 
4-phenylcoumarins  from  Calophyllum  inophyllum.  Cancer  Lett. 
2001;169:15.

24.  Ong  CY,  Ling  SK,  Ali  RM,  et  al.  Systematic  analysis  of  in  vitro 
photo-cytotoxic  activity  in  extracts  from  terrestrial  plants  in 
Peninsula  Malaysia  for  photodynamic  therapy.  J  Photochem 
Photobiol B. 2009;96:216.

25.  Li YZ, Li ZL, Yin SL, et al. Triterpenoids from Calophyllum ino-
phyllum and their growth inhibitory effects on human leukemia 
HL-60 cells. Fitoterapia. 2010;81:586.

26.  Xiao Q, Zeng YB, Mei WL, et al. Cytotoxic prenylated xantho-
nes  from  Calophyllum  inophyllum.  J  Asian  Nat  Prod  Res. 
2008;10:993.

27.  Hieu TT, Kim SI, Lee SG, et al. Repellency to Stomoxys calcitrans 
(Diptera: Muscidae) of plant essential oils or in combination with 
Calophyllum inophyllum nut oil. J Med Entolmol. 2010;47:575.
28.  Hieu TT, Kim SI, Kwon HW, et al. Enhanced repllency of binary 
mixtures of Zanthoxylum piperitum pericarp steam distillate or 
Zanthoxylum armamatum seed oil constituents and Calophyllum 
inophyllum  nut  oil  and  their  aerosols  to  Stomoxys  calcitrans.  
Pes Manag Sci. 2010;66:1191.

 
48 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   1 7

Petrolatum

Activities:

Hydrating, protecting

Important Chemical Components:

Aliphatic hydrocarbons

Origin Classification:

Petrolatum is derived from petroleum, and is considered 
synthetic because solvents and other chemicals are used 
during the refining process.

Personal Care Category:

Emollient, occlusive

Recommended for the following Baumann Skin 
Types:

All 16 skin types can use this ingredient but it is most 
useful for dry and S4 sensitive (allergic) skin types.

 SOURCE

Petrolatum  is  a  byproduct  of  the  process  of  converting 
petroleum  to  gasoline.  Petroleum  itself  is  composed  of  fossil 
plankton  and  algae-derived  substances  largely  made  up  of 
hydrocarbons.1 Mineral oil and petrolatum are similar but not 
identical  compounds.  Both  are  produced  from  petroleum  but 
through  different  complex  processes  resulting  in  substances 
made  with  hydrocarbons  but  with  very  different  characteris-
tics. Confusion occurs among many people regarding mineral 
oil and petrolatum because mineral oil is sometimes referred to 
as “liquid petrolatum” or “petrolatum liquid.” Mineral oil is a 
mixture of alkanes in the C18–C24 range while petrolatum is a 
mixture of C24–C30 alkanes.2

 HiSt ORy

Industrial  drilling  for  petroleum  started  in  1852.1  The  legend 
goes  that  Robert  A.  Chesebrough,  a  kerosene  dealer  in  the 
Brooklyn  borough  of  New  York  City  at  the  time,  went  to  
the  Titusville,  Pennsylvania  oil  strike  to  buy  cheap  kerosene. 
He heard the men talking about a fatty grease that would accu-
mulate on the drill rods that could cure all kinds of ailments.3 
He developed a way to produce petrolatum from raw crude oil, 
filed  US  Patent  number  127,568  and  Vaseline  Petroleum  Jelly 
was born in 1872 as a skin care product.4 Petrolatum has long 
been considered by many, including Kligman, to be one of the 
best moisturizers.5 It is recognized by the United States Food 
and Drug Administration (USFDA) as an over-the-counter skin 
protectant and there is a monograph on its use. Petrolatum is 
regarded as the most effective of the best occlusive ingredients, 
which include lanolin, silicones, and mineral oil (Table 17-1).6 
As  such,  it  is  a  popular  cosmetic  ingredient  in  moisturizers, 
creams, and baby lotions.

TABLE 17-1
Pros and Cons of Petrolatum

Pros
Considered the most effective occlusive 

Cons
Cosmetically inelegant (greasy feeling)

ingredient
Inexpensive
Extremely stable
Does not inactivate other ingredients

May increase susceptibility to UV damage
Effects reverse once ingredient is removed
May prevent penetration of other 

ingredients

 CHEMiStR y

Petrolatum  is  a  hydrophobic  mixture  of  long-chain  aliphatic 
hydrocarbons  with  a  melting  point  of  37°C  (99°F).  Aliphatic 
hydrocarbons  are  thought  to  protect  terrestrial  plants  and 
insects.7 Studies have shown that petrolatum confers a protec-
tive effect on human skin.8 It is used to prevent diaper rash and 
chapped lips as well as to protect wounds while they heal.

Petroleum  jelly  for  cosmetic  use  comes  in  the  following 
grades: United States Pharmacopeia (USP), British Pharmacopeia 
(BP), or European Pharmacopeia (Ph. Eur.) grade. These grades 
are  assigned  according  to  the  purity  of  the  raw  materials  and 
how the petroleum jelly is processed and intended for medical 
and  personal  care,  with  methods  and  ranges  for  physical  tests 
varying by regulatory body.

The  Environmental  Protection  Agency’s  Toxic  Substances 
Control Act (TSCA) Inventory Number for Petrolatum, 8009-03-8, 
officially  defines  petrolatum  as  “A  complex  combination  of 
hydrocarbons obtained as a semi-solid from dewaxing paraffinic 
residual  oil.  It  consists  predominantly  of  saturated  crystalline 
and liquid hydrocarbons having carbon numbers predominately 
greater than C25.”9 This definition gives no information about the 
processing or purity of the petrolatum.

Petrolatum is a superior occlusive, and is thought by many 
to have the best occlusive effects of any substance, because it 
has  the  proper  alkyl  chain  lengths  that  stack  up  and  align  to 
form  a  tight  palisade.  Its  high  viscosity,  which  prevents  the 
substance from spreading laterally, allows petrolatum to stay in 
a  thick  layer  at  the  spot  of  application.  The  high  viscosity 
accounts  in  part  for  its  superior  occlusive  abilities  but  causes 
low  spreadability,  which  makes  petrolatum  less  cosmetically 
elegant  than  other  ingredients.  Occlusive  membranes  applied 
to  the  surface  of  the  skin  inhibit  lipid  synthesis  and  barrier 
repair  by  blocking  the  many  steps  in  barrier  repair  linking 
increased  cholesterol  and  lipid  synthesis  and  lamellar  body 
formation and DNA synthesis. Although it displays occlusive 
properties, topical petrolatum does not impair barrier function 
or any of these processes.10

 ORAL USES

Petrolatum is not to be taken internally.

 
 t OPiCAL USES

Petrolatum, when applied topically, has been shown to pene-
trate  into  all  layers  of  the  stratum  corneum  (SC).  It  has  also 
been  demonstrated  to  impart  an  occlusive  effect  and  to 
improve  barrier  function.  Grubauer  has  shown  that  vapor-
impermeable  membranes  impede  barrier  recovery,  while 
vapor-permeable  ones  do  not  (although  they  do  slow  lipid 
biosynthetic  rates).11  Petrolatum  does  not  interfere  with  bar-
rier  recovery  and  may  actually  improve  barrier  repair.12  One 
study  by  Loden  compared  barrier  recovery  in  tape-stripped 
skin  in  subjects  treated  with  either  skin  lipids  or  petrolatum 
and  found  that  petrolatum  performed  as  well  as  lipids.13 
However, in this study, oleic acid was used as one of the lipids, 
even though it is not the ideal lipid choice for barrier repair.

The hydration effect of petrolatum is well established and has 
been  demonstrated  using  capacitance,  conductance,  optother-
mal  infrared  spectrometry,  and  transepidermal  water  loss.14–17 
Ghadially et al. showed that topically applied petrolatum accu-
mulates intercellularly in a nonlamellar manner.12

 SAFEty iSSUES

Because of its source, several concerns have emerged regarding 
petrolatum,  particularly  regarding  its  potential  for  toxicity  or 
provoking  unwanted  side  effects.  The  main  purity  test  for 
petrolatum is the analytical procedure for polynuclear aromatic 
hydrocarbons.  In  animals  as  well  as  humans,  particular 
condensed polynuclear aromatic (PNA) compounds have been 
demonstrated to cause cancer. The FDA and others developed 
a  method  in  the  1960s  that  minimized  the  PNA  content  of 
petrolatum  and  petroleum  wax.9  It  is  also  worth  noting  that 
several years of animal feeding studies have yielded no evidence 
that petrolatum plays a role in carcinogenesis.9 In some feeding 
studies, very small portions of petrolatum hydrocarbons have 
been shown to be absorbed by Fisher 344 rats. The liver and 
mesenteric lymph nodes were the sites of hydrocarbon accu-
mulation,  leading  to  the  typical  immune  response  that  any 
foreign  body  would  provoke.  All  of  the  animals  successfully 
eliminated  the  oil  from  their  systems  when  petrolatum  was 
removed from their diets.9

Notably,  petrolatum  is  well  known  for  being  noncomedo-
genic.18  Although  extremely  rare,  allergic  contact  dermatitis  to 
petrolatum has been reported in the literature.19,20 The possibility 
of an individual being allergic to petrolatum is so infrequent that 
most  dermatologists  believe  it  to  be  a  nonsensitizing  agent.21 
Formulations that contain petrolatum have demonstrated excel-
lent stability with minimal chemical degradation and minor alter-
ations in incorporated compound concentrations.22,23

 ENViRONMENt AL iMPAC t

See Chapter 13, Mineral Oil.

 FORMULAtiON CONSiDERA tiONS

Petrolatum  used  in  drug  products  is  either  an  active  or  non-
active (excipient) ingredient. It can also serve as the “carrier” or 
“vehicle” for the active ingredient. In addition, petrolatum can 
be  deemed  the  active  ingredient  in  over-the-counter  (OTC) 
products.9 Petrolatum has a markedly long shelf life because of 
its oxidation-resistant qualities and the fact that it undergoes 
minimal  chemical  degradation.24  It  can  be  used  as  a  delivery 

C H A P T E R  17  ■   P E T R O L AT U M  

49

system  for  lipophilic  agents  and  in  liposomal  formulations.25 
The  USP  sets  a  range  for  consistency,  melting  point,  and 
maximum color in the two monographs for petrolatum: White 
Petrolatum  USP  and  Petrolatum  USP.  The  basic  difference 
between  these  categories  is  the  maximum  color.  White 
Petrolatum USP can have some yellow coloring but Petrolatum 
USP has a definite yellow tint.

 USAGE CONSiDERA tiONS

Petrolatum displays a water vapor loss resistance 170 times 
that of olive oil.26 However, petrolatum is associated with a 
greasy feeling on the skin that may render agents containing 
it  cosmetically  unacceptable.  Other  commonly  used  occlu-
sive  ingredients  include  paraffin,  squalene,  dimethicone, 
soybean  oil,  grapeseed  oil,  propylene  glycol,  lanolin,  and 
beeswax.27

 SiGNiFiCANt  BACKGROUND

Petrolatum  is  a  purified  mixture  of  hydrocarbons  that  is 
derived  from  petroleum  (crude  oil).  The  hydrocarbon  mole-
cules present in petrolatum prevent oxidation, giving petrola-
tum a long shelf life. In a 1995 study comparing the capacity of 
physiologic  lipid  mixtures  to  petrolatum  in  providing  barrier 
repair  showed  that  petrolatum  remains  limited  to  the  SC 
whereas  physiologic  lipids  (cholesterol,  free  fatty  acids,  and 
ceramides)  penetrate  the  barrier  and  are  incorporated  into 
organelles.10 Importantly, though, exogenously applied petro-
latum improves the skin barrier within minutes, while exoge-
nously  applied  physiologic  lipids  take  around  two  hours  to 
improve  the  skin  barrier.  This  is  likely  due  to  the  fact  that 
considerable time is elapsed as keratinocytes absorb the lipids 
and  process  them  into  lamellar  bodies.  Petrolatum  provides 
immediate barrier recovery even in cold-exposed skin (which 
experiences slower lamellar body formation), whereas physi-
ologic lipids take longer to repair the barrier.10 Because petro-
latum  is  one  of  the  most  occlusive  moisturizing  ingredients 
known, it is often the gold standard to which other occlusive 
ingredients are compared.23 However, when used alone, many 
find the greasy, oily texture cosmetically inelegant. Therefore, 
petrolatum is often combined with other ingredients to mini-
mize the greasy feeling.

 CONCLUSiON

Petrolatum  is  the  most  effective  occlusive  ingredient,  but  is 
significantly undermined as a popular choice by its uncomfort-
able feeling on the skin.

REFERENCES

1.  Rawlings AV, Lombard KJ. A review on the extensive skin benefits 

of mineral oil. Int J Cosmet Sci. 2012;34:511.

2.  Stoker  S.  Chemical  properties  of  alkanes  and  cycloalkanes.  In: 
General,  Organic,  and  Biological  Chemistry.  6th  ed.  Stamford, 
Brooks/Cole: Cengage Learning; 2012:369.

3.  Goodrum  C,  Dalrymple  H.  Cosmetics  –  How  to  attract  the 
opposite sex. In: The First 200 Years: Adverting in America. New York: 
Harry Abrams Inc.; 1990:125.

4.  Lodén  M.  Role  of  topical  emollients  and  moisturizers  in  the 
treatment  of  dry  skin  barrier  disorders.  Am  J  Clin  Dermatol. 
2003;4771.

5.  Kligman  A.  Regression  method  for  assessing  the  efficacy  of 

moisturizers. Cosm Toiletr. 1978;93:27.

 
50 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

6.  Kraft JN, Lynde CW. Moisturizers: What they are and a practical 

approach to product selection. Skin Therapy Lett. 2005;10:1.

7.  Hadley NF. Lipid water barriers in biological systems. Prog Lipid 

Res. 1989;28:1.

8.  Wigger-Alberti  W,  Elsner  P.  Petrolatum  prevents  irritation  in  a 
human  cumulative  exposure  model  in  vivo.  Dermatology. 
1997;194:247.

9.  Faust HR, Casserly EW. Petrolatum and Regulation Requirements. 

Penreco, 2004.

10.  Mao-Qiang  M,  Brown  BE,  Wu-Pong  S,  et  al.  Exogenous 
nonphysiologic vs physiologic lipids. Divergent mechanisms for 
correction  of  permeability  barrier  dysfunction.  Arch  Dermatol. 
1995;131:809.

11.  Grubauer G, Feingold KR, Elias PM. Relationship of epidermal 
lipogenesis  to  cutaneous  barrier  function.  J  Lipid  Res. 
1987;28:746.

12.  Ghadially R, Halkier-Sorensin L, Elias P. Effects of petrolatum on 
stratum  corneum  structure  and  function.  J  Am  Acad  Dermatol. 
1992;26:387.

13.  Lodén M, Bárány E. Skin identical lipids versus petrolatum in the 
treatment of tape stripped and detergent perturbed human skin. 
Acta Derm Venereol. 2000;80:412.

14.  Skin  Moisturization.  In:  Leyden  JJ,  Rawlings  AV,  eds.  Zug, 

Switzerland: Informa Healthcare; 2002:229.

15.  Jemee GB, Wulf HC. Correlation between the greasiness and the 
plasticizing effect of moisturizers. Acta Derm Venereol. 1999;79:115.
16.  Petersen  EN.  The  hydrating  effect  of  a  cream  and  white 
petrolatum measured by optothermal infrared spectrophotometry 
in vivo. Acta Derma Venereol. 1991;71:373.

17.  Lodén  M,  Lindberg  M.  The  influence  of  a  single  application  of 
different moisturizers on the skin capacitance. Acta Derm Venereol. 
1991;71:79.

18.  American Academy of Dermatology Invitational Symposium on 

Comedogenicity. J Am Acad Dermatol. 1989;20:272.

19.  Tam CC, Elston DM. Allergic contact dermatitis caused by white 

petrolatum on damaged skin. Dermatitis. 2006;17:201.

20.  Ulrich G, Schmutz JL, Trechot P et al. Sensitization to petrolatum: 
an  unusual  cause  of  false-positive  drug  patch-tests.  Allergy. 
2004;59:1006.

21.  Schnuch A, Lessmann H, Geier J et al. White petrolatum (Ph. Eur.) 
is  virtually  non-sensitizing.  Analysis  of  IVDK  data  on  80  000 
patients  tested  between  1992  and  2004  and  short  discussion  of 
identification  and  designation  of  allergens.  Contact  Dermatitis. 
2006;54:338.

22.  Fluhr J, Holleran WM, Berardesca E. Clinical effects of emollients 
on  skin.  In:  Leyden  JJ,  Rawlings  AV,  eds.  Skin  Moisturization.  
New York: CRC Press; 2002:232.

23.  Morrison DS. Petrolatum. In: Lodén M, Maibach H, eds. Dry Skin 

and Moisturizers. Boca Raton: CRC;2000:251–257.

24.  Fluhr J, Holleran WM, Berardesca E. Clinical effects of emollients 
on  skin.  In:  Leyden  JJ,  Rawlings  AV,  eds.  Skin  Moisturization.  
New York: CRC Press; 2002:229.

25.  Foldvari M. Effect of vehicle on topical liposomal drug delivery: 

petrolatum bases. J Microencapsul. 1996;13:589.

26.  Spruitt  D.  The  interference  of  some  substances  with  the  water 

vapor loss of human skin. Dermatologica. 1971;142:89.

27.  Draelos  Z.  Moisturizers.  In:  Atlas  of  Cosmetic  Dermatology.  

New York: Churchill Livingstone; 2000:83.

 
C H A P T E R  18  ■   D I M E T H I CO N E   A N D   S I L I CO N E S  

51

C H A P T E R   1 8

Dimethicone and Silicones

Activities:

Occlusive, emollient, skin protectant, antifoaming agent

Important Chemical Components:

The  chemical  formula  for  dimethicone  (also  known  as 
polydimethylsiloxane  or  PDMS)  is  CH3[Si(CH3)2O]n 
Si(CH3)3 where n is the number of repeating monomer units 
[molecular formula = (C2H6OSi)n]. Silicon dioxide (silica) is 
the base material from which silicones are derived. Silicon is 
element number 14 on the atomic chart (see Figure 18-1).

Origin Classification:

Laboratory made from natural ingredients

Personal Care Category: 

Hair conditioner, moisturizer

Recommended for the following Baumann Skin 
Types: 

All 16 skin types can use these ingredients.

 SOURCE

Dimethicone  is  derived  from  silicon.  It  is  a  hypoallergenic, 
noncomedogenic,  and  nonacnegenic  silicone-based  polymer 
second only to petrolatum in terms of frequency of use as an 
ingredient  in  moisturizers.1  Silicones  are  derived  from  silica 
(silicon dioxide), found in sandstone, beach sand, granite, and 
quartz, and represent the source of all oil-free moisturizers.2

 HISTORY

Silicon  was  discovered  by  the  Swedish  chemist  Jöns  Jacob 
Berzelius in 1824. Today it is produced by heating sand (SiO2) 
with  carbon  to  temperatures  approaching  2200°C.  For  this 
reason  it  is  difficult  to  categorize  silicones  as  natural  or 
laboratory  made.  Dimethicone  was  suggested  as  a  protective 
ingredient for the skin barrier as early as the late 1950s, and is 
covered  in  the  United  States  Food  and  Drug  Administration 
(USFDA) monograph for skin protectants.3–5

 CHEMISTRY

According  to  Nair,  “Dimethicone  is  a  fluid  mixture  of  fully 
methylated  linear  siloxane  polymers  end-blocked  with 
trimethylsiloxy  units.”6  The  potent  siloxane  bonds  that  unite 

(CH3)3SiO

CH3

SiO

Si(CH3)3

CH3
Dimethicone

x

▶

FIGURE 18-1  Chemical structure of dimethicone.

silica  and  oxygen  in  these  compounds  account  for  the  noted 
thermal and oxidizing stability of silicones.7 The silicone used 
in  topical  skin  care  products  is  odorless,  colorless,  as  well  as 
nontoxic and is ideal for water-resistant formulations because 
it is also immiscible and insoluble in water.2

 ORAL USES

Dimethicone  and  silicone  products  are  found  in  some  foods 
and are not considered to be toxic when taken orally. However, 
they have no oral activity that would justify their use for skin 
conditions.6

 TOPICAL USES

Dimethicone and silicones exert a protective effect on the skin 
by forming a barrier that hinders the penetration of irritants and 
allergens. They also decrease transepidermal water loss (TEWL), 
but  not  as  effectively  as  petrolatum  (Table  18-1).  Whereas 
petrolatum lowers TEWL by 98 percent, dimethicone and other 
silicones typically reduce TEWL by 20 to 30 percent.8–10 

The permeability of dimethicone to water vapor makes it an 
attractive ingredient in facial products because it allows sweat to 
evaporate off of the skin, but it is insoluble in water and does not 
mix well with sebum, which gives it staying power on the skin.2 
Dimethicone  is  commonly  used  in  primers  and  makeup 
foundations because its emollient characteristics allow it to fill in 
surface imperfections, creating a “smoother canvas” for makeup 
application. It is often found in “long wearing,” “oil control,” and 
“waterproof” skin care formulations. Dimethicone coats the hair 
shaft, smoothing irregularities, so it is found in hair products that 
condition and add shine to the hair.

In  2000,  Fowler  enrolled  31  subjects  with  chronic  hand 
dermatitis lasting at least one year and strongly linked to their 
work  in  a  study  over  two  months  (including  a  two-week 
observation period prior to treatment) to determine if a protective 
foam  containing  dimethicone  and  glycerin  could  mitigate  the 
condition.  Twenty-eight  patients  completed  the  study,  with  
21  experiencing  significant  improvement.  The  tested  foam 

TABLE 18-1
Pros and Cons of Dimethicone and Silicones

Cons
Inert
Less effective than petrolatum
May hold sebum on the skin’s surface
May clog pores if used over uncleansed 

skin

Pros
Prevents some TEWL
Inexpensive
Less greasy than petrolatum 
Insoluble in water

Water permeable
Hypoallergenic
Does not mix with sebum
Has an FDA monograph

 
52 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

product was indeed found to be protective as subjects continued 
in their occupations while reporting favorable effects.11 

Earlier  that  year,  Zhai  et  al.  assessed  the  efficacy  of  a 
dimethicone skin protectant lotion against sodium lauryl sulfate 
(SLS)-induced irritant contact dermatitis in 12 healthy subjects. 
The  flexor  aspects  of  both  forearms  of  each  individual  were 
pretreated  with  the  test  formulation  or  vehicle  control  
30 minutes before exposure to SLS (0.2 mL of 0.5 percent SLS). A 
third  test  site,  serving  as  positive  control,  received  only  the 
irritant. Investigators evaluated the test sites for five days based 
on visual scoring, TEWL, skin color, and cutaneous blood flow 
volume.  Although  they  found  no  statistical  differences  in 
treatment sites in terms of cutaneous blood flow and skin color, 
the researchers noted a significant reduction on the site pretreated 
with  dimethicone  as  compared  to  the  SLS-only  and  control 
vehicle sites in terms of visual score. In addition, TEWL values 
were significantly lower in the dimethicone lotion-treated sites 
as compared to the SLS-only sites. The investigators concluded 
that  the  appropriate  use  of  dimethicone  products  can  prevent 
irritant contact dermatitis.12

 SAFETY ISSUES

Dimethicone  and  other  silicones  are  unlikely  to  be  absorbed 
systemically  when  used  topically  according  to  the  Cosmetic 
Ingredient Review (CIR) because of their large molecular weight.6 
Specific silicones found to be safe for use in cosmetic formulations 
by the CIR include stearoxy dimethicone, dimethicone, methicone 
(a linear monomethyl polysiloxane), amino bispropyl dimethicone, 
aminopropyl  dimethicone,  amodimethicone,  amodimethicone 
hydroxystearate,  behenoxy  dimethicone,  C24–C28  alkyl  methi-
cone,  C30–C45  alkyl  methicone,  C30–C45  alkyl  dimethicone, 
cetearyl  methicone,  cetyl  dimethicone,  dimethoxysilyl 
ethylenediaminopropyl  dimethicone,  hexyl  methicone, 
hydroxypropyldimethicone,  stearamidopropyl  dimethicone, 
stearyl dimethicone, stearyl methicone, and vinyldimethicone.6

Dimethicone and other silicones have not been found to be 
comedogenic or to cause contact dermatitis, but are mild ocular 
irritants.6 Dimethicone was negative in all genotoxicity assays.

 ENVIRONMENTAL IMPACT

Dimethicone and cyclotetrasiloxane degrade into the environ-
ment with dimethicone settling into the soil and cyclotetrasi-
loxane dissipating into the atmosphere. Both are degraded to 
inorganic  constituents,  carbon  dioxide,  silicic  acid,  and  water 
with no noted ill effects on the environment.13

 SIGNIFICANT BACKGROUND

Combination Treatments
In  2007,  Short  et  al.  evaluated  the  effects  of  a  moisturizer 
containing  dimethicone  and  glycerin  on  15  women  with 
moderately  photoaged  forearms  treated  twice  daily  for  four 
weeks. The investigators noted increases in epidermal thickness, 
barrier  function  improvement  as  evidenced  by  13  percent 
reduction in TEWL, a decline in melanin intensity, and increased 
keratinocyte  proliferation,  suggesting  structural  and  functional 
enhancement  via  daily  use  of  a  dimethicone-  and  glycerin-
containing moisturizer.15

Dimethicone, along with glycerin, has also been shown to be an 
important  added  ingredient  for  providing  moisturization  in  an 
acne formulation that combines clindamycin and benzoyl peroxide 
in a water-based gel. The same formulation that lacked dimethi-
cone and glycerin was less satisfying and tolerable for patients.16

A 2011 randomized, controlled clinical trial with 141 patients 
in 11 nursing home wards in 4 nursing homes in Belgium showed 
that a washcloth treated with a 3 percent dimethicone formula 
significantly  outperformed  standard  of  care  (water  and  pH-
neutral  soap)  for  incontinence-associated  dermatitis.  The 
dimethicone-treated  washcloth  also  significantly  lowered  the 
prevalence of incontinence-associated dermatitis, and was linked 
to a trend toward reduced severity.17

 CONCLUSION

As  the  second  most  used  ingredient  in  moisturizers, 
dimethicone  plays  an  important  role  in  the  topical  skin  care 
arsenal. It is an oil-free moisturizing alternative; therefore, it is 
often  used  in  oil  control  products  because  it  helps  hold  the 
sebum  to  the  surface  of  the  skin,  preventing  facial  shine. 
However,  dimethicone  gives  the  product  a  slippery  feel  that 
some individuals with oily skin types find objectionable. Many 
studies have shown that dimethicone is not comedogenic. In 
the author’s experience, though, when dimethicone-containing 
ingredients are not washed off at night, they may contribute to 
dirt and sebum clogging the pores by holding this debris close 
to the skin’s surface. It is recommended to thoroughly cleanse 
the  dirt  and  sebum  from  the  face  before  applying  products 
containing this ingredient and to cleanse the face again at night. 
It  is  acceptable  to  reapply  a  silicone-containing  product  to  a 
cleansed face at night. Dimethicone is a safe and useful ingredi-
ent  in  thousands  of  skin  care  products  when  combined  with 
proper cleansing techniques.

 FORMULATION CONSIDERATIONS

REFERENCES

Dimethicone comes in various viscosities and is known to add 
slip and glide to formulations. It is popular in hair conditioning 
products as well as many skin care products including moistur-
izers and sunscreens. Dimethicone is often found in “oil-free” 
personal care products. It is covered by an FDA monograph as 
a skin care protectant so it does not have to be declared as an 
active ingredient on product labels.

 USAGE CONSIDERATIONS

Dimethicone  has  not  been  found  to  alter  drug  penetration 
rates.14

1.  Nolan K, Marmur E. Moisturizers: Reality and the skin benefits. 

Dermatol Ther. 2012;25:229.

2.  Draelos ZD. Active agents in common skin care products.  Plast 

Reconstr Surg. 2010;125:719.

3.  Carter BN 2nd, Sherman RT. Dimethicone (silicone) skin protec-

tion in surgical patients. AMA Arch Surg. 1957;75:116.

4.  Banerjee BN, Chakrabarty J. Dimethicone 20 B.P.C. (SILOCERM) – 
A new multipurpose skin protective barrier ointment as prophy-
laxis  in  skin  disease,  a  preliminary  report.  Indian  J  Dermatol. 
1969;14:133.

5.  Johnson  AW.  The  skin  moisturizer  marketplace.  In:  Leyden  JJ, 
Rawlings  AV,  eds.  Skin  Moisturization.  New  York:  CRC  Press; 
2002:20.

6.  Nair  B.  Final  report  on  the  safety  assessment  of  dimethicone. 
Cosmetic  Ingredients  Review  Expert  panel.  Int  J  Toxicol. 
2003;22(Suppl 2):11.

 
C H A P T E R  18  ■   D I M E T H I CO N E   A N D   S I L I CO N E S  

53

7.  Draelos  ZD.  New  treatments  for  restoring  impaired  epidermal 
barrier  permeability:  Skin  barrier  repair  creams.  Clin  Dermatol. 
2012;30:345.

8.  Kraft JN, Lynde CW. Moisturizers: What they are and a practical 

approach to product selection. Skin Therapy Lett. 2005;10:1.

9.  Lynde CW. Moisturizers: What they are and how they work. Skin 

Therapy Lett. 2001;6:3.

10.  Ghadially R, Halkier-Sorensen L, Elias PM. Effects of petrolatum 
on stratum corneum structure and function. J Am Acad Dermatol. 
1992;26(3 Pt 2):387.

11.  Fowler JF Jr. Efficacy of a skin-protective foam in the treatment of 

chronic hand dermatitis. Am J Contact Dermat. 2000;11:165.

12.  Zhai H, Brachman F, Pelosi A, et al. A bioengineering study on the 
efficacy  of  a  skin  protectant  lotion  in  preventing  SLS-induced 
dermatitis. Skin Res Technol. 2000;6:77.

13.  Stevens  C.  Environmental  fate  and  effects  of  dimethicone  and 
cyclotetrasiloxane  from  personal  care  applications.  Int  J  Cosmet 
Sci. 1998;20:296.

14.  Leopold CS, Maibach HI. Effect of lipophilic vehicles on in vivo 
skin  penetration  of  methyl  nicotinate  in  different  races.  Int  J 
Pharm. 1996;139:161.

15.  Short RW, Chan JL, Choi JM, et al. Effects of moisturization on epider-

mal homeostasis and differentiation. Clin Exp Dermatol. 2007;32:88.
16.  Del  Rosso  JQ.  The  role  of  the  vehicle  in  combination  acne 

therapy. Cutis. 2005;76(Suppl 2):15.

17.  Beeckman D, Verhaeghe S, Defloor T, et al. A 3-in-1 perineal care 
washcloth impregnated with dimethicone 3% versus water and 
pH neutral soap to prevent and treat incontinence-associated der-
matitis:  a  randomized,  controlled  clinical  trial.  J  Wound  Ostomy 
Continence Nurs. 2011;38:627.

 
54 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

SECTION

C

Barrier Repair Ingredients

C H A P T E R   1 9

Barrier Repair Ingredients

The skin barrier is a watertight seal around the keratinocytes in 
the  upper  levels  of  the  epidermis.  It  prevents  evaporation  of 
water from the surface of the skin, which is known as trans- 
epidermal water loss (TEWL). It is important to note that TEWL 
is  not  the  same  as  sweating  or  perspiration.  Increased  TEWL 
occurs when a defect in the permeability barrier allows exces-
sive  water  to  be  lost  to  the  atmosphere.  The  skin  barrier 
decreases TEWL and helps keep unwanted compounds out of 
the  skin,  such  as  allergens  and  irritants.  Skin  with  an  injured 
barrier is more susceptible to contact and irritant dermatitis as 
well  as  infection.  Skin  barrier  perturbation  can  be  caused  by 
many  different  factors  such  as  detergents,  acetone,  friction, 
ultraviolet exposure, prolonged or frequent water immersion, 
cholesterol-lowering drugs, low-fat diets, and genetic predispo-
sition (e.g., to disorders of filaggrin).

The  extracellular  lipid  mixture  surrounding  keratinocytes  in 
the upper layer of the epidermis (stratum corneum or SC) is well 
known to be responsible for that layer’s water barrier function.1 
This lipid mixture, which is synthesized by lamellar bodies  in 
the  lower  levels  of  the  epidermis,  is  composed  of  50  percent 
ceramides,  about  25  percent  cholesterol,  and  about  15  percent 
fatty acids.2 Many studies have considered the effect of topically 
applying these important skin barrier lipids to improve skin bar-
rier function and, thus, skin hydration. These investigations have 
demonstrated that the exogenously applied lipids must be in the 
proper ratio to form the correct three-dimensional structure of 
the skin barrier. When the correct ratios of ceramides, fatty acids, 
and cholesterol were used, the barrier recovered.3 Application of 
a mixture of cholesterol, ceramides, and the essential/nonessen-
tial free fatty acids palmitate and linoleate in an equimolar ratio 
allows normal barrier recovery, whereas a 3:1:1:1 ratio of these 
four ingredients accelerates barrier recovery.4 Today, the goal of 
the best barrier repair moisturizers is to provide these vital com-
ponents in a 3:1:1:1 ratio. 

 AGE AND THE SKIN BARRIER

Older  skin  displays  increased  drug  penetration,  dryness,  and 
other signs that the skin barrier may be impaired. Ghadially et al. 
showed  that  although  the  composition,  dimensions,  and 
lamellar  structure  of  the  bilayer  lipids  were  normal  in  older 
individuals  (80+  years),  their  skin  had  30  percent  less  lipids 
than younger people (20–30 years old) and the number of focal 
SC  lamellar  bilayers  was  decreased.  In  addition,  the  barrier 
recovery  time  was  much  longer  in  older  individuals.5  Waller 

and  Maibach  reviewed  studies  on  lipids  in  aged  skin  and 
deemed  the  findings  to  be  conflicting,  with  no  consensus  on 
whether or not older skin displays a different lipid composition 
as compared to younger skin.6

 EXOGENOUSLY APPLIED LIPIDS

Topically applied lipids are transported to the nucleated layers 
of the SC (such as the spinous layer), internalized, and trans-
ported  to  the  distal  Golgi  apparatus  where  they  are  incorpo-
rated into lamellar bodies.7 These lamellar bodies are present in 
the granular layer of the epidermis and are secreted (containing 
the  newly  synthesized  lipids)  into  the  intercellular  space 
between  the  keratinocytes,  thus  contributing  to  the  lipid 
bilayer membrane. This de novo synthesis of lipids is a crucial 
mechanism involved in barrier recovery.8

The  lamellar  or  Odland  bodies  play  an  important  role  in 
barrier function, because they deliver enzymes that metabolize 
lipid hydrolases and lipids to the intercellular spaces of the SC. 
The lipid hydrolases metabolize lipid precursors such as choles-
terol  sulfate,  phospholipids,  sphingomyelin,  and  glycosylcera-
mides  into  nonpolar  products,  which  form  the  extracellular 
lamellar  membrane.1,9  This  lipid  processing  cascade  is  affected 
by changes in pH and other metabolic activity that remains to be 
elucidated.10,11 The presence of cholesterol seems to be important 
in  the  normal  function  of  lamellar  bodies  in  barrier  repair.12 
When  cholesterol  levels  are  low,  peroxisome  proliferator-
activated  receptors  (PPARs)  and  retinoid  X  receptors  increase 
expression  of  ATP-binding  cassette  transporter  A1  (ABCA1),  a 
membrane transporter that regulates cholesterol efflux,13 result-
ing in increased transport of cholesterol across keratinocyte cell 
membranes. It is important to note that replacement of only one 
of  the  three  primary  components  of  the  extracellular  matrix 
(cholesterol, ceramides, or fatty acids) impairs the barrier, while 
replacement  in  a  1:1:1  ratio  of  all  of  these  three  classes  of 
compounds repairs the barrier.3

 ENDOGENOUSLY SYNTHESIZED LIPIDS

Basal cells are capable of absorbing cholesterol from the circula-
tion; however, most lipids are synthesized in cells such as the 
keratinocytes. Exogenously applied lipids are incorporated into 
the keratinocytes and lamellar bodies in the granular layer of 
the SC.3,8

 
There  are  three  rate-limiting  enzymes  involved  in  the 
production  of  the  main  lipids  of  epidermal  skin.  They  include 
3-hydroxy-3-methylglutaryl  coenzyme  A  (HMG-CoA)  reduc-
tase  (the  rate-limiting  enzyme  in  cholesterol  synthesis),  acetyl 
Co-A carboxylase (ACC), and the fatty acid synthase involved in 
the synthesis of free fatty acids and serine palmitoyl transferase 
(SPT), which is the regulatory enzyme for the synthesis of cera-
mides.14,15 As expected, when skin barrier disruption occurs, the 
activity of these enzymes is enhanced in order to compensate for 
barrier dysfunction.16,17 In addition, a group of transcription fac-
tors  known  as  sterol  regulatory  element-binding  proteins 
(SREBPs)  regulate  cholesterol  and  fatty  acid  synthesis.  When 
epidermal  sterols  are  decreased,  the  SREBPs  are  activated  via 
proteolytic processes, enter the cell nucleus and activate genes, 
leading  to  increased  production  of  cholesterol  and  fatty  acid 
synthesis enzymes.18,19 There are three known types of SREBPs: 
SREBP-1a, -1c, and SREBP-2. In human keratinocytes, SREBP-2 
has been shown to be the predominant form and is involved in 
regulating  cholesterol  and  fatty  acid  synthesis.18  Interestingly, 
the ceramide pathway is not affected by SREBPs.

 FAT TY ACIDS

Fatty acids play a crucial role in conferring hydrophobic charac-
teristics to the epidermis. Their addition to cream formulations 
makes  them  slightly  alkaline  with  a  pH  of  7.5  to  9.5.20  The 
properties of the fatty acids, and the lipids derived from them, 
are markedly dependent on chain length and degree of satura-
tion.21 Fatty acids that have double bonds are known as unsatu-
rated  while  fatty  acids  without  double  bonds  are  known  as 
saturated. Fatty acids are divided into categories depending on 
the length of their aliphatic tail chain. Short-chain fatty acids 
are  fatty  acids  with  aliphatic  tails  of  fewer  than  six  carbons, 
medium-chain  fatty  acids  have  6  to  12  carbons,  long-chain 
fatty  acids  have  13  to  21  carbons,  and  very  long-chain  fatty 
acids have aliphatic tails longer than 22 carbons. Unsaturated 
fatty  acids  found  in  skin  include  oleic  acid,  linoleic  acid, 
α-linolenic  acid,  and  arachidonic  acid.  Saturated  fatty  acids 
found in skin include palmitic and stearic acids. Studies investi-
gating  the  use  of  fatty  acids  to  repair  the  skin  barrier  have 
shown  that  linoleic,  palmitic,  and  stearic  acids  can  repair  the 
barrier within two hours when applied exogenously.22

A few notable fatty acids play an important role in inflamma-
tion. Linoleic acid, found in corn oil, sunflower seed oil, sesame 
oil,  and  safflower  oil,  forms  a  prostaglandin  known  as  PGE1, 
which exhibits anti-inflammatory and immune-enhancing prop-
erties.  The  fatty  acid  arachidonic  acid  forms  PGE2  and  leukot-
rienes, which are highly inflammatory substances. Arachidonic 
acid  is  found  rarely  in  plant  oils  but  is  abundantly  present  in 
animal-derived products such as meat, eggs, and dairy.

C H A P T E R  19  ■   B A R R I E R   R E PA I R   I N G R E D I E N T S  

55

 CHOLESTEROL

Cholesterol is found in the diet and is included in some mois-
turizers; however, most of the cholesterol found in the skin is 
produced  by  keratinocytes.  Cholesterol  is  synthesized  in  the 
keratinocytes by the enzyme cholesterol sulfotransferase type 
2B  isoform  1b,  abbreviated  as  SULT2B1b.  The  rate-limiting 
enzyme in this process is HMG-CoA reductase (see Chapter 21, 
Cholesterol).  Cholesterol  esters  added  to  skin  moisturizers 
without the presence of the correct ratio of ceramides and fatty 
acids have been shown to disrupt barrier function.1

 BARRIER DISRUPTION

Barrier disruption is caused when alterations occur in the cera-
mides, cholesterol, and fatty acids that constitute the bilamellar 
membrane  that  renders  the  SC  watertight.  The  three-
dimensional  structure  of  this  bilayer  is  important  and  many 
factors can affect its shape and function. Cholesterol levels can 
be reduced by cholesterol-lowering drugs such as statins, lead-
ing  to  decreased  cholesterol  in  the  bilamellar  membrane.  All 
three  components  can  be  damaged  or  diminished  by  sur-
factants, friction, ultraviolet light, prolonged water immersion, 
immersion in chlorine, and application of moisturizers. Stress 
and increased cortisol levels have been shown to damage the 
skin barrier.23,24

Certain  ingredients  can  negatively  impact  the  skin’s  barrier. 
Solvents such as propylene glycol can cause lipid fluidization or 
extraction  that  can  alter  the  barrier.25  Ingredients  with  a  polar 
head  group  attached  to  alkyl  chain  lengths  of  around  C10–C12 
yield a potent penetration enhancer, for example, oleic acid,26,27 
which  disrupts  the  barrier  by  inserting  alkyl  chains  into  cera-
mides. This leads to pools of oleic acid in the membrane, which 
becomes more fluid and easier for molecules to diffuse through 
than  intact  ceramides.25  Other  ingredients  containing  unsatu-
rated alkyl chains can also enhance penetration but, in this case, 
C18  appears  near  optimum.  For  such  unsaturated  compounds, 
the  bent  cis  configuration  disturbs  intercellular  lipid  packing 
more so than the trans arrangement, which differs little from the 
saturated analogue.28 Fatty acid analogues have been developed 
to function as penetration enhancers.29

In summary, the epidermis and surrounding lipid barrier have 
been described as having a brick-and-mortar structure, with the 
keratinocytes as the bricks and the cholesterol, ceramides, and 
fatty acids representing the mortar. Many well-controlled intri-
cate  processes  govern  the  formation  of  this  brick-and-mortar 
structure and much can go awry that impairs its function. Skin 
care  products  can  significantly  influence  the  formation  and 
proper functioning of this structure as has been shown by a mul-
titude of studies. 

 CERAMIDES

REFERENCES

Ceramide 1 is the most important type of ceramide in skin. It is 
composed  partially  of  linoleic  acid.  Because  ceramides  are 
expensive  additions  to  skin  care  formulations,  a  less  costly 
alternative is to use ingredients that contain linoleic acid, which 
may  help  the  skin  increase  production  of  certain  ceramides. 
Linoleic acid is found in vegetable oils, rapeseed, walnuts, soy-
beans, and flaxseed. Applying ceramide alone to the skin (with-
out the proper ratio of fatty acids and cholesterol) disrupts the 
skin barrier and increases TEWL.22

1.  Elias PM, Menon GK. Structural and lipid biochemical correlates 
of the epidermal permeability barrier. Adv Lipid Res. 1991;24:1.
2.  Feingold  KR.  Thematic  review  series:  Skin  lipids.  The  role  of 
epidermal  lipids  in  cutaneous  permeability  barrier  homeostasis.  
J Lipid Res. 2007;48:2531.

3.  Man MQ, Feingold KR, Elias PM. Exogenous lipids influence per-
meability  barrier  recovery  in  acetone-treated  murine  skin.  Arch 
Dermatol. 1993;129:728.

4.  Zettersten EM, Ghadially R, Feingold KR, et al. Optimal ratios of 
topical stratum corneum lipids improve barrier recovery in chron-
ologically aged skin. J Am Acad Dermatol. 1997;37(3 Pt 1):403.

 
56 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

5.  Ghadially R, Brown BE, Sequeira-Martin SM, et al. The aged epi-
dermal permeability barrier. Structural, functional, and lipid bio-
chemical abnormalities in humans and a senescent murine model. 
J Clin Invest. 1995;95:2281.

6.  Waller J, Maibach H. Age and skin structure and function, a quan-
titative  approach  (II):  protein,  glycosaminoglycan,  water,  and 
lipid content and structure. Skin Res Technol. 2006;12:145.

7.  Madison KC, Howard EJ. Ceramides are transported through the 
Golgi apparatus in human keratinocytes in vitro. J Invest Dermatol. 
1996;106:1030.

8.  Mao-Qiang  M,  Brown  BE,  Wu-Pong  S,  et  al.  Exogenous  non-
physiologic vs physiologic lipids. Divergent mechanisms for cor-
rection  of  permeability  barrier  dysfunction.  Arch  Dermatol. 
1995;131:809.

9.  Elias PM. The epidermal permeability barrier: from the early days 
at Harvard to emerging concepts. J Invest Dermatol. 2004;122:xxxvi.
10.  Behne  MJ,  Meyer  JW,  Hanson  KM,  et  al.  NHE1  regulates  the 
stratum  corneum  permeability  barrier  homeostasis. 
Microenvironment  acidification  assessed  with  fluorescence  life-
time imaging. J Biol Chem. 2002;277:47399.

11.  Fluhr JW, Kao J, Jain M et al. Generation of free fatty acids from 
phospholipids regulates stratum corneum acidification and integ-
rity. J Invest Dermatol. 2001;117:44.

12.  Feingold KR, Man MQ, Menon GK, et al. Cholesterol synthesis is 
required  for  cutaneous  barrier  function  in  mice.  J  Clin  Invest. 
1990;86:1738.

13.  Proksch E, Jensen J-M. Skin as an organ of protection. In: Wolff K, 
Goldsmith  LA,  Katz  SI,  Gilchrest  BA,  Paller  AS,  Leffell  DJ,  eds. 
Fitzpatrick’s  Dermatology  in  General  Medicine.  7th  ed.  New  York: 
McGraw-Hill; 2007:386–387.

14.  Bigby  M,  Corona  R,  Szklo  M.  Evidence-based  dermatology.  In: 
Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell 
DJ, eds. Fitzpatrick’s Dermatology in General Medicine. 7th ed. New 
York: McGraw-Hill; 2007:13.

15.  Holleran WM, Feingold KR, Man MQ et al. Regulation of epider-
mal  sphingolipid  synthesis  by  permeability  barrier  function.  
J Lipid Res. 1991;32:1151.

16.  Brown MS, Goldstein JL. Sterol regulatory element binding pro-
teins (SREBPs): Controllers of lipid synthesis and cellular uptake. 
Nutr Rev. 1998;56:S1.

17.  Wertz  PW.  Biochemistry  of  human  stratum  corneum  lipids.  In: 
Elias  PM,  Feingold  KR,  eds.  Skin  Barrier.  New  York:  Taylor  & 
Francis; 2006:33–42.

18.  Elias  PM.  Stratum  corneum  defensive  functions:  An  integrated 

view. J Invest Dermatol. 2005;125:183.

19.  Harris  IR,  Farrell  AM,  Holleran  WM  et  al.  Parallel  regulation  of 
sterol regulatory element binding protein-2 and the enzymes of 
cholesterol and fatty acid synthesis but not ceramide synthesis in 
cultured human keratinocytes and murine epidermis. J Lipid Res. 
1998;39:412.

20.  Cosmetic  Ingredient  Review.  Final  Report  on  the  Safety 
Assessment  of  Oleic  Acid,  Lauric  Acid,  Palmitic  Acid,  Myristic 
Acid,  and  Stearic  Acid.  J  Am  Col  Toxicol.  1987;6:321.  http://
www.cir-safety.org/sites/default/files/115_draft_steary_suppl3 
.pdf. Accessed November 1, 2012.

21.  Berg JM, Tymoczko JL, Stryer L. Lipids and Cell Membranes. In: 

Biochemistry. 5th ed. New York: WH Freeman; 2002:321.

22.  Man MQ M, Feingold KR, Thornfeldt CR, et al. Optimization of 
physiological  lipid  mixtures  for  barrier  repair.  J  Invest  Dermatol. 
1996;106:1096.

23.  Altemus M, Rao B, Dhabhar FS, et al. Stress-induced changes in 
skin  barrier  function  in  healthy  women.  J  Invest  Dermatol. 
2001;117:309.

24.  Denda  M,  Tsuchiya  T,  Elias  PM,  et  al.  Stress  alters  cutaneous 
permeability barrier homeostasis. Am J Physiol Regul Integr Comp 
Physiol. 2000;278:R367.

25.  Hadgraft  J.  Modulation  of  the  barrier  function  of  the  skin.  Skin 

Pharmacol Appl Skin Physiol. 2001;14(Suppl 1):72.

26.  Naik  A,  Pechtold  LA,  Potts  RO  et  al.  Mechanism  of  oleic  acid-
induced  skin  penetration  enhancement  in  vivo  in  humans. 
J Control Release. 1995;37:299.

27.  Ongpipattanakul  B,  Burnette  RR,  Potts  RO,  et  al.  Evidence  that 
oleic  acid  exists  in  a  separate  phase  within  stratum  corneum 
lipids. Pharm Res. 1991;8:350.

28.  Williams  AC,  Barry  BW.  Penetration  enhancers.  Adv  Drug  Deliv 

Rev. 2004;56:603.

29.  Takahashi  K,  Sakano  H,  Numata  N,  et  al.  Effect  of  fatty  acid 
diesters  on  permeation  of  anti-inflammatory  drugs  through  rat 
skin. Drug Dev Ind Pharm. 2002;28:1285.

 
C H A P T E R   2 0

Ceramides

C H A P T E R  20  ■   C E R A M I D E S  

57

Activities:

Barrier integrity, cell signaling, anti-inflammatory, cellu-
lar differentiation and apoptosis,1 intermediate in sphin-
gomyelin synthesis (effects on cell membranes)2,3

Important Chemical Components:

Sphingolipids  (sphingosine,  phytosphingosine,  or 
6-hydroxysphingosine)
Linoleic acid

Origin Classification:

Ceramides  are  naturally  occurring  but  synthetic  forms 
and pseudoceramides are also available.

Personal Care Category: 

Barrier repair moisturizer

Recommended for the following Baumann Skin 
Types: 

DRNT,  DRNW,  DRPT,  DRPW,  DSNT,  DSNW,  DSPT, 
and DSPW. Important to use in all S4 (allergic) sensitive 
skin types.

 SOURCE

Ceramides  are  derived  from  the  precursor  glucosylceramides 
(GC), which is formed in large quantities by the epidermis and 
stored  in  lamellar  granules.  The  enzyme  responsible  for  GC 
synthesis has been localized to the golgi apparatus and is called 
ceramide  glucosyltransferase.4  Structured  in  lamellar  sheets, 
the  primary  lipids  of  the  epidermis  –  ceramides,  cholesterol, 
and free fatty acids – play a crucial role in the barrier function 
of  the  skin  (see  Chapter  19,  Barrier  Repair  Ingredients).  The 
intercellular  lipids  of  the  SC  are  composed  of  approximately 
equal proportions of ceramides (which may constitute up to 40 
percent),5 cholesterol, and fatty acids.6 Ceramides are found in 
the upper levels of the stratum corneum (SC) but are not found 
in significant supply in the lower levels of the epidermis such as 
the stratum granulosum or basal layer. This is simply because 
ceramides are produced in the lamellar bodies in the granular 
layer of the SC.

There are several ways to generate ceramides in mammalian 

cells7–9:

1.  Catabolism of sphingomyelin by the enzyme sphingomy-
elinase, which is coded by the gene SMPD1. (This is the 
most important pathway because sphingomyelin is abun-
dant in most cell membranes.)

2.  De novo synthesis from palmitate and serine by the enzyme 
serine  palmitoyltransferase  (SPT),  which  is  coded  in  part 
by the gene SPTLC1.10

3.  Hydrolysis of glucosylceramides by β-glucocerebrosidase.
4.  Hydrolysis of galactosylceramides by galactoceramidase.

5.  Synthesis from sphinogosine and fatty acid.

6.  Dephosphorylation of ceramide 1-phosphate.

Ceramide Synthesis
Production  of  ceramides  is  affected  by  many  processes. 
Exposure  to  ultraviolet  B  (UVB)  radiation  and  cytokines  has 
been associated with an increase in the regulatory enzyme for 
ceramide synthesis, SPT and increased sphingolipid synthesis 
at  the  mRNA  and  protein  levels.11  Stress  and  other  causes  of 
increased cortisol and exposure to glucocorticoids affect barrier 
function,  but  the  mechanism  has  not  yet  been  delineated.12 
Dexamethasone  stimulates  ceramide  biosynthesis by upregu-
lating gene expression of SPT.13 Ceramide production has been 
shown to be increased by 1,25-dihydroxyvitamin D3, retinoic 
acid, ursolic acid, and lactic acid.14–17 An alkaline pH suppresses 
β-glucocerebrosidase and acid sphingomyelinase activity (these 
enzymes need an acidic pH).18 This is one of the reasons that 
alkaline soaps can result in poor barrier formation. In addition, 
a low or neutral pH is associated with poor barrier recovery.19

Cytokines may also play a role in ceramide synthesis. TNF 
and  interleukin-1  alpha  (IL-1α)  stimulate  ceramide  synthesis 
and  SPT  levels.20  Imiquimod,  a  TLR-7  receptor  agonist,  is 
known to increase IL-1α levels and has been shown to improve 
the skin’s barrier. IL-4 inhibits the production of ceramides.21

UV radiation has been shown to increase the amount of intra-
cellular ceramides,22–24 and UV-damaged skin has been reported 
to exhibit increased barrier function that renders it less susceptible 
to damage from irritants.25 A study by Kim et al. showed that 
UV  radiation  induces  ceramide  production  by  activation  of 
sphingomyelinase.23

Enchanced Ceramide Synthesis Using Precursors
Topical  formulations  containing  linoleic  acid  such  as  saf-
flower  oil  have  been  shown  to  increase  the  formation  of 
Ceramide  1.26  Nicotinamide  applied  topically  has  been 
shown to increase ceramide synthesis and decrease transepi-
dermal  water  loss  (TEWL).27  N-acetyl-L-hydroxyproline 
topically  applied  to  a  synthetic  skin  model  resulted  in 
increased  ceramide  synthesis  through  its  actions  on  SPT.28 
Topical  lactic  acid,  especially  the  L-isomer,  can  increase 
ceramides.17

 HISTORY

Ceramide 1 was the first natural ceramide identified, in 1982. 
Synthetic ceramides, studied since the 1950s, are increasingly 
sophisticated because they are easier to formulate (Table 20-1). 
Ceramides  have  come  to  be  known  as  a  complex  family  of 
lipids  (sphingolipids  –  a  sphingoid  base  and  a  fatty  acid) 
involved  in  cell  signaling  in  addition  to  their  role  in  barrier 
homeostasis  and  water-holding  capacity.  In  fact,  they  are 
known to play a critical role in cell proliferation, apoptosis, cell 
growth, senescence, and cell cycle control differentiation.29,30

 
58  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

TABLE 20-1
Pros and Cons of Synthetic Ceramides

Pros
Improves skin barrier when formu-

lated properly

Cons
Must be used in combination with fatty acids and 
cholesterol or the barrier is impacted negatively

Hydrates and decreases sensitivity 

Expensive

to irritant agents

Some forms are derived from animal CNS tissue

 CHEMISTRY

Ceramides can be free lipids but in most cases are found as the 
hydrophobic backbone of a sphingolipid. Ceramides have been 
classified as Ceramides 1 to 9, along with two protein-bound 
ceramides labeled as Ceramides A and B, which are covalently 
bound  to  cornified  envelope  proteins  (e.g.,  involucrin).31  (See 
Figure  20-1.)  All  epidermal  ceramides  are  produced  from  a 
lamellar body-derived glucosylceramide (GC) precursor.

Ceramides  are  named  based  on  the  polarity  and  composi-
tion  of  the  molecule.  As  suggested  above,  the  foundational 
ceramide structure is an amide-linked free fatty acid covalently 
bound  to  a  long-chain  amino  alcohol  sphingoid  base.32  The 
various  classes  of  ceramides  are  grouped  according  to  the 
arrangements  of  sphingosine  (S),  phytosphingosine  (P),  or 
6-hydroxysphingosine (H) bases, to which an α-hydroxy (A) or 
nonhydroxy (N) fatty acid is attached, in addition to the pres-
ence or absence of a discrete ω-esterified linoleic acid residue.33
Ceramide 1 is unique insofar as it is nonpolar and contains the 
fatty  acid  linoleic  acid.  The  unique  structure  of  Ceramide  1 
allows it to act as a molecular rivet, binding the multiple bilayers 
of  the  SC  together,5  and  contributing  to  the  stacking  of  lipid 
bilayers in the intercellular lamellar sheets. Ceramides 1, 4, and 7 
exhibit critical functions in terms of epidermal integrity and by 
serving as the primary storage areas for linoleic acid, an essential 
fatty  acid  with  significant  roles  in  the  epidermal  lipid  barrier34 
(see  Chapter  15,  Safflower  Oil,  and  Chapter  19  Barrier  Repair 
Ingredients). The sphingomyelin-derived ceramides (Ceramides 2, 5) 
are essential for maintaining the integrity of the SC.35

Synthetic  ceramides,  or  pseudoceramides,  contain  hydroxyl 
groups,  two  alkyl  groups,  and  an  amide  bond  –  the  same  key 
structural components of natural ceramides. Consequently, vari-
ous  synthetic  ceramides 
including  N-(3-hexadecyloxy- 
2-hydroxypropyl)-N-2-hydroxyethylhexadecanamide  (PC-104) 
and  N-(2-hydroxyethyl)-2-pentadecanolylhexadecanamide 
(Bio391) have been reported to form the multilamellar structure 
observed in the intercellular spaces of the SC.36,37

 ORAL USES

Synthetic ceramides have no effect on skin condition when taken 
internally  because  they  are  broken  down  by  stomach  acids. 
However,  oral  ingestion  of  precursors  such  as  linoleic  acid  may, 
according to the sparse studies available, help facilitate ceramide 
production. One study looked at oral administration of glucosyl-
ceramides in mice and found that proinflammatory cytokines and 
scratching were suppressed in an irritant contact dermatitis model.38

O

Ceramide 1

Ceramide 2

Ceramide 3

O

O

Ceramide 4 [EOH]

Ceramide 5 [AS]

Ceramide 6 [AP]

Ceramide 7 [AH]

Ceramide 8 [NH]

O

O

Ceramide 9 [EOP]

HO

Ceramide A [OS]

HO

Ceramide B [OH]

O

HN

OH

OH

O

HN

OH

HN

OH

O

OH

OH

O

HN

OH

OH

OH

OH

O

HN

OH

OH

OH

O

HN

OH

OH

OH

HN

O

OH

OH

O

OH

OH

HN

OH

OH

O

HN

OH

OH

O

HN

OH

OH

O

OH

OH

HN

OH

 TOPICAL USES

▶

FIGURE 20-1  Chemical structures of ceramides.

Ceramides  are  popular  ingredients  in  skin  care  preparations. 
They  have  been  shown  to  be  able  to  penetrate  into  the  skin 
when exogenously applied.39,40 Several derivatives of ceramides 

are  currently  being  studied  in  the  dermatology  field.  Skin 
conditions  such  as  atopic  dermatitis  (AD),  psoriasis,  contact 
dermatitis,  and  some  genetic  disorders  have  been  associated 

 
with depleted ceramide levels,41 but can be ameliorated through 
the use of exogenous ceramides or their synthetic analogues. 

Atopic Dermatitis
AD is known to be a multifactorial disorder recently found to be 
related to a defect in the filaggrin gene. Prior to the discovery of the 
role of the filaggrin defect in AD, many studies evaluated the role of 
barrier lipids in the disease. In 1991, Imokawa reported that sub-
jects with AD had a significantly decreased amount of ceramides in 
the  skin,  with  Ceramide  1  being  the  most  significantly  reduced 
compared to normal subject skin ceramide content.42 In addition, 
the  activities  of  enzymes  that  break  down  ceramides  and  other 
important lipids in the SC, particularly ceramidase, sphingomyelin 
deacylase, and glucosylceramide deacylase, have been shown to be 
elevated in epidermal AD.41 In a 2004 study published in the Journal 
of Investigative Dermatology, AD skin was found to have less sphingo-
myelinase activity than normal skin.43

Kang  et  al.  conducted  studies  using  synthetic  ceramide 
derivatives of PC-9S (N-Ethanol-2-mirystyl-3-oxo-stearamide), 
which have been shown to be effective in atopic and psori-
atic  patients.  Both  mice  studies  demonstrated  that  the 
topical  application  of  the  derivatives  K6PC-9  and  K6PC-9p 
resulted  in  the  reduction  of  skin  inflammation  and  AD 
symptoms.44,45 Subsequently, Kang et al. studied the effects 
of  another  ceramide  derivative,  K112PC-5  (2-Acetyl-N-(1,3-
dihydroxyisopropyl)-tetradecanamide),  on  immune  cell 
function,  skin  inflammation,  and  AD  in  mice.  Among  several 
findings, the investigators noted that K112PC-5 suppressed AD 
induced by extracts of dust mites and exhibited in vitro and in vivo 
anti-inflammatory  activity.  They  concluded  that  K112PC-5  is 
another synthetic ceramide derivative with potential as a topical 
agent for the treatment of AD.46

Frankel  et  al.  compared  the  short-term  effectiveness  and 
desirability  of  a  ceramide-hyaluronic  acid  emollient  to  pime-
crolimus cream 1 percent in treating AD. Both agents displayed 
efficacy  in  mild-to-moderate  AD  across  a  broad  age  range  of 
patients over four weeks. Target lesions were deemed “clear” 
or “almost clear” in 82 percent of the cases using the ceramide 
foam and in 71 percent of lesions treated with pimecrolimus, 
with no reported adverse reactions.47

In  2011,  Kircik  et  al.  conducted  a  multicenter,  open-label, 
interventional  study  to  assess  the  clinical  efficacy  of  a  topical 
emulsion containing ceramides, cholesterol, and fatty acids in a 
3:1:1  ratio  in  207  patients  with  mild-to-moderate  AD  over  a 
three-week period. The formulation was used as single therapy 
or in combination with another AD medication. The investiga-
tors  reported  that  about  half  of  participants  received  clear  or 
almost  clear  investigator  global  assessment  scores  after  mono-
therapy  or  combination  therapy.  A  majority  (75  percent)  of 
patients reported satisfaction with the treatment as pruritus was 
diminished and quality of life improved. The authors concluded 
that the ceramide-containing lipid-based formulation was effec-
tive in treating mild-to-moderate AD.48

That  same  year,  Miller  et  al.  compared  the  efficacy  of  three 
formulations,  including  a  glycyrrhetinic  acid-containing  barrier 
repair cream (BRC-Gly, Atopiclair®), a ceramide-dominant, triple-
lipid barrier repair cream (BRC-Cer, EpiCeram™),49 and a petro-
leum-based  skin  protectant  moisturizer  (OTC-Pet,  Aquaphor 
Healing Ointment®). The study looked at mild-to-moderate AD 
in 39 children aged 2 to 17 years old randomized 1:1:1 to receive 
one  of  the  three  treatments  three  times  daily  for  three  weeks. 
Investigators  evaluated  disease  severity  and  improvement  at 
baseline and days 7 and 21, finding no statistically significant dif-
ference in efficacy between the three groups at each time point.50

C H A P T E R  20  ■   C E R A M I D E S  

59

In  2012,  Simpson  et  al.  conducted  a  randomized,  intra-
individual  study  to  examine  the  effects  of  a  new  moisturizer 
containing a ceramide precursor on barrier function in patients 
with controlled AD over a four-week period. In this investigator-
blinded  study,  the  cream  was  applied  to  one  lower  leg  for  
27  days  while  the  other  leg  served  as  the  untreated  control. 
Researchers took readings at baseline and day 28 on TEWL, skin 
hydration, and xerosis severity, reporting that after four weeks, 
significant reductions in TEWL and clinical dryness scores were 
observed along with increased skin hydration in the areas treated 
with  ceramide  cream.  In  addition,  no  adverse  events  were 
reported.51  In  another  study  of  pseudoceramide  formulations 
and patients with AD, the use of a ceramide complex that also 
included  eucalyptus  leaf  extract  dose-dependently  reduced 
erythema and improved TEWL in comparison to a control vehi-
cle and also increased endogenous SC ceramide levels.52

Diminution of Effects from Steroids
Corticosteroids  are  well  known  to  cause  atrophy  of  the  skin 
with  prolonged  use.  They  also  cause  a  defect  in  the  barrier 
function  of  the  skin  demonstrated  by  increased  TEWL.53 
Studies have shown that they disrupt epidermal differentiation 
resulting  in  deceased  keratohyaline  granule  formation  and  a 
disruption  of  the  lamellar  lipid  bilayers.54  A  study  by  Ahn 
showed that a pseudoceramide containing multilamellar emul-
sion (MLE) reduced the atrophy resulting from topical steroid 
use.55 In addition, the MLE cream when applied after the ster-
oid cream prevented the increase in TEWL normally associated 
with  steroid  use  and  preserved  the  normal  structure  of  the 
lamellar lipid bilayers.

Dry Non-Atopic Skin
Ceramide deficiency leads to increased TEWL. Subjects that do 
not have a history of AD or inflammation can still suffer dry 
skin due to a ceramide deficiency. In the Baumann Skin Typing 
system, these subjects would be classified as “Dry, Resistant” 
types,  because  they  exhibit  dry  skin  without  underlying 
inflammation.

Keratinocyte Differentiation

While extracellular ceramides play important roles in skin hydra-
tion, intracellular ceramides found in keratinocytes affect differ-
entiation  of  keratinocytes.6,56  In  2007,  Kwon  et  al.  generated 
multiple  ceramide  derivatives  and  assessed  their  impact  on 
keratinocyte  differentiation.  They  found  that  K6PC-4  [N-(2,3-
dihydroxypropyl)-2-hexyl-3-oxo-decanamide], K6PC-5, [N-(1,3-
dihydroxypropyl-2-hexyl-3-oxo-decanamide]  and  K6PC-9 
(N-ethanol-2-hexyl-3-oxo-decanamide)  spurred  a  fleeting 
increase in intracellular calcium levels, incited the phosphoryla-
tion  of  p42/44  extracellular  signal-regulated  kinase  and  c-Jun 
N-terminal kinase, and, in the suprabasal layer of a reconstituted 
epidermis  model,  significantly  enhanced  keratin  1  expression. 
The investigators concluded that synthetic ceramide derivatives 
exhibit  potential  for  treating  skin  diseases  involving  abnormal 
keratinocyte differentiation.57 Ceramides have also been shown 
to induce phosphorylation of the epidermal growth factor recep-
tor, possibly by activating a protein kinase.58

Inflammation

For years, the deficit of ceramides in AD was thought to be the 
cause  of  the  disorder,  leading  to  many  studies  examining  the 

 
60  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

effects of ceramides on inflammation. Some studies have shown 
ceramides  to  have  proinflammatory  properties  while  others 
emphasize its anti-inflammatory properties.59,60 For example, in 
1996 Di Nardo et al. demonstrated that skin with low ceramide 
levels  was  characterized  by  increased  cutaneous  inflammation 
while other studies have shown that ceramides lead to eicosa-
noid synthesis.61,62 Sallusto et al. showed that ceramides inhibit 
the  uptake  and  presentation  of  antigens  by  dendritic  cells  in  a 
murine  model.63  Ceramides  seem  to  modulate  inflammation 
through prostaglandins and by modulation of cytokines such as 
IL-1,  and  interferon-γ.64–66  However,  the  role  of  ceramides  in 
inflammation is not completely understood. It may be that the 
amount of ceramide present influences the inflammatory path-
ways.21 Ceramide 1-phosphate may be a more important form 
of ceramide with respect to its purported proinflammatory activ-
ity.67–69  Ceramide  1-phosphate  plays  a  role  in  activation  of 
degranulation  in  mast  cells  and  stimulation  of  macrophage 
migration.70,71

 SAFETY ISSUES

Early  forms  of  ceramides  were  obtained  from  animal  brains 
and spinal cords such as cows. The fear of mad cow disease led 
to  the  development  of  laboratory-made  ceramides;  however, 
these were initially very expensive. New forms derived from 
wheat germ and other sources provide a more natural option.

Excess amounts of intracellular ceramides can be toxic to cells, 
inhibiting  growth  and  causing  apoptosis.22,37,72  Synthetic 
pseudoceramides  differ  in  structure  from  naturally  occurring 
ceramides, which raises concerns about their safety.37

In  2009,  Morita  et  al.  conducted  a  study  evaluating  potential 
adverse effects of the synthetic pseudoceramide SLE66 and showed 
that  the  tested  product  failed  to  provoke  cutaneous  irritation  or 
sensitization in animal and human studies. In addition, no photo-
toxicity or photosensitization was observed and they established 
1,000  mg/kg/day  (the  highest  level  tested)  as  the  no-observed-
adverse-effect (NOAEL) for systemic toxicity after oral administration 
or  topical  application.73  In  a  related  rat  study  on  the  potential 
maternal  and  fetal  effects  of  SLE66,  Morita  et  al.  observed  no 
clinical or internal impact from the orally-administered pseudocer-
amide across multiple metrics, including fetal malformations.29

EpiCeram™ was used in a 2012 study by Lowe et al. to test 
safety and compliance in a six-week, open-label, phase one trial 
that found 80 percent of mothers daily applied the cream to their 
infants (0–4 weeks of age) on 80 percent or more of the days of 
the study.49 The investigators concluded that EpiCeram is suffi-
ciently safe and demonstrated satisfactory parental compliance 
to prevent eczema.74

In  light  of  the  uncertainty  regarding  the  metabolic  impact  of 
pseudoceramides, in 2008, Uchida et al. compared the effects of 
two  chemically  unrelated  commercially  available  products  to 
exogenous cell-permeant or natural ceramide on cell growth and 
apoptosis thresholds in cultured human keratinocytes and found 
that commercial ceramides did not suppress keratinocyte growth 
or increase cell toxicity, as did the cell-permeant. The investigators 
suggested that these findings buttress the preclinical studies indi-
cating that these pseudoceramides are safe for topical application.37

 ENVIRONMENTAL IMPACT

Now that ceramides can be made in the lab and derived from 
plants such as wheat germ the environmental impact as was seen 
when these were sourced from animals is considerably blunted.

 FORMULATION CONSIDERATIONS

Natural vs. Synthetic
Identical  synthetic  ceramides  are  very  expensive  ($2,000–
$10,000/kg).37  Less  expensive  naturally  occurring  ceramides 
are  derived  from  the  bovine  central  nervous  system,  which 
raises  the  concern  of  transmission  of  bovine  spongiform 
encephalopathy (also known as mad cow disease). For these 
reasons,  synthetic  pseudoceramides  are  often  used  in  skin 
care products.37

Ceramides  and  pseudoceramides  are  very  hydrophobic  and 
tend to crystallize, thus are difficult to formulate.75 Organic sol-
vents have been used but tend to dry the skin. Liposomes are 
often unstable. Oil-in-water emulsions are often used.

Linoleic acid, an important component of ceramides, is very 

susceptible to oxidation.76

 USAGE CONSIDERATIONS

Ceramides  alone  will  impair  the  skin  barrier.  They  must  be 
combined with the proper ratio of cholesterol and fatty acids to 
improve the skin barrier (see Chapter 19 Barrier Repair Ingredients).

 SIGNIFICANT BACKGROUND

Coderch  et  al.,  in  a  review  of  ceramides  and  skin  function, 
endorsed the potential of topical therapy for several skin condi-
tions  using  complete  lipid  mixtures  and  some  ceramide 
supplementation, as well as the topical delivery of lipid precursors.6 
And,  in  fact,  the  topical  application  of  synthetic  ceramides  has 
been  shown  to  speed  up  the  repair  of  impaired  SC.77,78  Recent 
reports by Tokudome et al. also indicate that the application of 
sphingomyelin-based  liposomes  effectively  augments  the  levels 
of  various  ceramides  in  cultured  human  skin  models.79,80  It  is 
important  to  note  that  ceramides  applied  topically  without  the 
proper equimolar ratio of cholesterol and fatty acids will actually 
delay  barrier  recovery  in  perturbed  skin  and  amplify  TEWL81  
(see Chapter 19 Barrier Repair Ingredients).

In 2005, de Jager et al. used small-angle and wide-angle X-ray 
diffraction  to  show  that  lipid  mixtures  prepared  with  well-
defined synthetic ceramides are very similar to the lamellar and 
lateral SC lipid organization and lipid phase behavior and can be 
used  to  further  elucidate  the  molecular  structure  and  roles  of 
individual  ceramides.82  Previously,  stress-induced  ceramide 
accumulation  had  been  shown  to  result  in  plasma  membrane 
reorganization  and  development  of  ceramide-laden  structures 
known as “rafts,” which attract and cluster receptors as well as 
signaling molecules at the cell membrane to promotesignal trans-
duction  cascades.9  Interestingly,  the  pathogenesis  of  various 
common  disorders  has  been  ascribed  to  raft-related  signaling 
processes, primarily through ceramide accumulation and activa-
tion of apoptotic signaling pathways.83

Effects of Ceramides on Collagen Production 
and Degradation
Type  I  collagen  levels  in  the  skin  have  been  shown  to  be 
important in the appearance of skin.84 Antiaging strategies are 
aimed at: 1) Increasing the amount of collagen produced in the 
skin and 2) Decreasing the amount of collagen breakdown by 
collagenase  and  other  matrix  metalloproteinases  (MMPs). 

 
Ceramides  have  been  shown  to  play  a  role  in  both  of  these 
processes and, therefore, likely play an important role in pho-
toaging.  Kim  demonstrated  that  UV  radiation  induces  cera-
mide  production  by  activation  of  sphingomyelinase.23  The 
increased  ceramide  levels  led  to  increased  production  of  
MMP-1,  which  is  known  to  degrade  collagen  and  facilitate 
photoaging  of  the  skin.85  Reunanen  showed  that  ceramide 
induces  collagenase  synthesis  and  that  Ceramide  2  inhibits 
collagen  synthesis  when  added  to  fibroblast  cultures.86  It  is 
unknown  at  this  time  if  including  ceramides  in  topical  skin 
formulations can lead to increased induction of MMP-1 mRNA 
expression because such studies have not been done. However, 
one study revealed that when linoleic acid was applied to skin 
and  then  irradiated  with  UV,  MMP-1  expression  was 
increased,87 which may have been caused by the oxidation of 
linoleic  oxide  to  linoleic  hyperoxide  by  the  UV.39  MMP-1 
expression  also  increased  when  the  synthetic  ceramide 
N-oleoyl-phytosphingosine was applied. However, when cho-
lesterol was applied alone, MMP-1 expression was decreased.39 
A small German study (10 human subjects) showed that when 
jojoba oil and jojoba oil with vitamins were placed on human 
skin  and  irradiated  with  UVA,  downregulation  of  collagen 
genes resulted.88 However, when the same oils were combined 
with  phytosterols  and  ceramides,  less  downregulation 
occurred. It is possible that the phytosterols had a protective 
effect.  Antioxidants  (such  as  phytosterols)  that  block  the 
ERK1/2 pathway may also help inhibit the downregulation of 
collagen genes. In the case of Ceramide 2 downregulation of 
collagen  synthesis,  the  downregulation  was  dependent  upon 
activation  of  the  ERK1/2  pathway,  p38  MAPK  pathway,  and 
PKC.86 In the author’s opinion, antioxidants may help mitigate 
the  deleterious  effects  of  ceramides  on  collagen  in  the  skin, 
especially in the presence of UV radiation.

 CONCLUSION

Ceramides are among the primary lipid constituents, along with 
cholesterol and fatty acids, of the lamellar sheets found in the 
intercellular spaces of the SC. Together, these lipids maintain the 
water permeability barrier role of the skin. Ceramides also play 
an  important  role  in  cell  signaling.  Research  over  the  last  
20 years, in particular, indicates that topically applied synthetic 
ceramide  agents,  so-called  topical  ceramide-dominant  creams, 
can effectively compensate for diminished ceramide levels asso-
ciated  with  various  skin  disorders.  These  products  appear  to 
restore barrier integrity and are considered safe and associated 
with minimal side effects. Ceramides are a crucial component in 
the  skin  care  regimen  of  all  dry  skin  types  and  sensitive  skin 
types (S4) susceptible to irritant and allergic dermatitis.

REFERENCES

1.  Kolesnick RN, Krönke M. Regulation of ceramide production and 

apoptosis. Annu Rev Physiol. 1998;60:643.

2.  Hannun YA. The sphingomyelin cycle and the second messenger 

function of ceramide. J Biol Chem. 1994;269:3125.

3.  Ruiz-Argüello MB, Basáñez G, Goñi FM, et al. Different effects of 
enzyme-generated ceramides and diacylglycerols in phospholipid 
membrane fusion and leakage. J Biol Chem. 1996;271:26616.

4.  Madison KC, Howard EJ. Ceramides are transported through the 
Golgi apparatus in human keratinocytes in vitro. J Invest Dermatol. 
1996;106:1030.

5.  Downing  DT,  Stewart  ME,  Wertz  PW,  et  al.  Skin  lipids:  An 

update. J Invest Dermatol. 1987;88:2s.

6.  Coderch  L,  López  O,  de  la  Maza  A,  et  al.  Ceramides  and  skin 

function. Am J Clin Dermatol. 2003;4:107.

C H A P T E R  20  ■   C E R A M I D E S  

61

7.  Holleran WM, Gao WN, Feingold KR, et al. Localization of epi-
dermal  sphingolipid  synthesis  and  serine  palmitoyl  transferase 
activity:  alterations  imposed  by  permeability  barrier  require-
ments. Arch Dermatol Res. 1995;287:254.

8.  Jensen JM, Schütze S, Förl M, et al. Roles for tumor necrosis factor 
receptor  p55  and  sphingomyelinase  in  repairing  the  cutaneous 
permeability barrier. J Clin Invest. 1999;104:1761.

9.  He X, Schuchman EH. Potential role of acid sphingomyelinase in 
environmental  health.  Zhong  Nan  Da  Xue  Xue  Bao  Yi  Xue  Ban. 
2012;37:109.

10.  Elias  PM.  Stratum  corneum  defensive  functions:  An  integrated 

view. J Invest Dermatol. 2005;125:183.

11.  Farrell  AM,  Uchida  Y,  Nagiec  MM,  et  al.  UVB  irradiation  up-
regulates serine palmitoyltransferase in cultured human keratino-
cytes. J Lipid Res. 1998;39:2031.

12.  Altemus M, Rao B, Dhabhar FS, et al. Stress-induced changes in 
skin  barrier  function  in  healthy  women.  J  Invest  Dermatol. 
2001;117:309.

13.  Holland WL, Brozinick JT, Wang LP, et al. Inhibition of ceramide 
synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-
induced insulin resistance. Cell Metab. 2007;5:167.

14.  Geilen CC, Bektas M, Wieder T, et al. The vitamin D3 analogue, 
calcipotriol,  induces  sphingomyelin  hydrolysis  in  human 
keratinocytes. FEBS Lett. 1996;378:88.

15.  Kalén A, Borchardt RA, Bell RM. Elevated ceramide levels in GH4C1 

cells treated with retinoic acid. Biochim Biophys Acta. 1992;1125:90.

16.  Both DM, Goodtzova K, Yarosh DB, et al. Liposome-encapsulated 
ursolic acid increasea ceramides and collagen in human skin cells. 
Arch Dermatol Res. 2002;293:569.

17.  Rawlings AV, Davies A, Carlomusto M, et al. Effect of lactic acid 
isomers  on  keratinocyte  ceramide  synthesis,  stratum  corneum 
lipid levels and stratum corneum barrier function. Arch Dermatol 
Res. 1996;288:383.

18.  Hachem  JP,  Man  MQ,  Crumrine  D,  et  al.  Sustained  serine  pro-
teases activity by prolonged increase in pH leads to degradation 
of  lipid  processing  enzymes  and  profound  alterations  of  barrier 
function  and  stratum  corneum  integrity.  J  Invest  Dermatol. 
2005;125:510.

19.  Hachem JP, Crumrine D, Fluhr J, et al. pH directly regulates epi-
dermal  permeability  barrier  homeostasis,  and  stratum  corneum 
integrity/cohesion. J Invest Dermatol. 2003;121:345.

20.  Barland  CO,  Zettersten  E,  Brown  BS,  et  al.  Imiquimod-induced 
interleukin-1  alpha  stimulation  improves  barrier  homeostasis  in 
aged murine epidermis. J Invest Dermatol. 2004;122:330.

21.  Hatano Y, Terashi H, Arakawa S, et al. Interleukin-4 suppresses 
the enhancement of ceramide synthesis and cutaneous permea-
bility  barrier  functions  induced  by  tumor  necrosis  factor-alpha 
and  interferon-gamma  in  human  epidermis.  J  Invest  Dermatol. 
2005;124:786.

22.  Geilen CC, Wieder T, Orfanos CE. Ceramide signaling: Regulatory 
role in cell proliferation, differentiation and apoptosis in human 
epidermis. Arch Dermatol Res. 1997;289:559.

23.  Kim  S,  Kim  Y,  Lee  Y,  et  al.  Ceramide  accelerates  ultraviolet-
induced  MMP-1  expression  through  JAK1/STAT-1  pathway  in 
cultured human dermal fibroblasts. J Lipid Res. 2008;49:2571.
24.  Grether-Beck S, Timmer A, Felsner I, et al. Ultraviolet A-induced 
signaling involves a ceramide-mediated autocrine loop leading to 
ceramide de novo synthesis. J Invest Dermatol. 2005;125:545.
25.  Lehmann P, Hölzle E, Melnik B, et al. Effects of ultraviolet A and B 
on  the  skin  barrier:  a  functional,  electron  microscopic  and  lipid 
biochemical  study.  Photodermatol  Photoimmunol  Photomed. 
1991;8:129.

26.  Prottey C, Hartop PJ, Press M. Correction of the cutaneous mani-
festations of essential fatty acid deficiency in man by application 
of sunflower-seed oil to the skin. J Invest Dermatol. 1975;64:228.

27.  Tanno O, Ota Y, Kitamura N, et al. Nicotinamide increases bio-
synthesis of ceramides as well as other stratum corneum lipids to 
improve  the  epidermal  permeability  barrier.  Br  J  Dermatol. 
2000;143:524.

28.  Hashizume  E,  Nakano  T,  Kamimura  A,  et  al.  Topical  effects  of 
N-acetyl-L-hydroxyproline  on  ceramides  synthesis  and  allevia-
tion of pruritus. Clin Cosmet Investig Dermatol. 2013;6:43.

29.  Morita  O,  Knapp  JF,  Tamaki  Y,  et  al.  Safety  studies  of  pseudo-
ceramide SLE66. Part 3: Effects on embryo/fetal development in 
rats. Food Chem Toxicol. 2009;47:681.

30.  Sawai H, Domae N, Okazaki T. Current status and perspectives 
in  ceramidetargeting  molecular  medicine.  Curr  Pharm  Des. 
2005;11:2479.

 
62 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

31.  Bouwstra JA, Pilgrim K, Ponec M. Structure of the skin barrier. In: 
Elias  PM,  Feingold  KR,  eds.  Skin  Barrier.  New  York:  Taylor  and 
Francis; 2006:65.

´

32.  Sajic D, Asiniwasis R, Skotnicki-Grant S. A look at epidermal bar-
rier  function  in  atopic  dermatitis:  physiologic  lipid  replacement 
and the role of ceramides. Skin Therapy Lett. 2012;17:6.

33.  de Jager MW, Gooris GS, Dolbnya IP, et al. Novel lipid mixtures 
based on synthetic ceramides reproduce the unique stratum cor-
neum lipid organization. J Lipid Res. 2004;45:923.

34.  Elias PM, Brown BE, Ziboh VA. The permeability barrier in essen-
tial fatty acid deficiency: Evidence for a direct role for linoleic acid 
in barrier function. J Invest Dermatol. 1980;74:230.

35.  Uchida Y, Hara M, Nishio H, et al. Epidermal sphingomyelins are 
precursors  for  selected  stratum  corneum  ceramides.  J  Lipid  Res. 
2000;41:2071.

36.  Mizushima H, Fukasawa J, Suzuki T. Phase behavior of artificial 
stratum corneum lipids containing a synthetic pseudo-ceramide: 
A study of the function of cholesterol. J Lipid Res. 1996;37:361.
37.  Uchida Y, Holleran WM, Elias PM. On the effects of topical syn-
thetic  pseudoceramides:  Comparison  of  possible  keratinocyte 
toxicities provoked by the pseudoceramides, PC104 and BIO391, 
and natural ceramides. J Dermatol Sci. 2008;51:37.

38.  Yeom M, Kim SH, Lee B, et al. Oral administration of glucosyl-
ceramide ameliorates inflammatory dry-skin condition in chronic 
oxazolone-induced  irritant  contact  dermatitis  in  the  mouse  ear.  
J Dermatol Sci. 2012;67:101.

39.  Byun HJ, Cho KH, Eun HC, et al. Lipid ingredients in moisturizers 
can  modulate  skin  responses  to  UV  in  barrier-disrupted  human 
skin in vivo. J Dermatol Sci. 2012;65:110.

40.  Mao-Qiang  M,  Brown  BE,  Wu-Pong  S,  et  al.  Exogenous  non-
physiologic vs physiologic lipids. Divergent mechanisms for cor-
rection  of  permeability  barrier  dysfunction.  Arch  Dermatol. 
1995;131:809.

41.  Choi  MJ,  Maibach  HI.  Role  of  ceramides  in  barrier  function  of 

healthy and diseased skin. Am J Clin Dermatol. 2005;6:215.

42.  Imokawa G, Abe A, Jin K, et al. Decreased level of ceramides in 
stratum  corneum  of  atopic  dermatitis:  An  etiologic  factor  in 
atopic dry skin? J Invest Dermatol. 1991;96:523.

43.  Jensen JM, Fölster-Holst R, Baranowsky A, et al. Impaired sphin-
gomyelinase activity and epidermal differentiation in atopic der-
matitis. J Invest Dermatol. 2004;122:1423.

44.  Kang JS, Youm JK, Jeong SK, et al. Topical application of a novel 
ceramide  derivative,  K6PC-9,  inhibits  dust  mite  extract-induced 
atopic  dermatitis-like  skin  lesions  in  NC/Nga  mice.  Int 
Immunopharmacol. 2007;7:1589.

45.  Kang JS, Yoon WK, Youm JK, et al. Inhibition of atopic dermatitis-
like skin lesions by topical application of a novel ceramide deriva-
tive, K6PC-9p, in NC/Nga mice. Exp Dermatol. 2008;17:958.
46.  Kang JS, Lee CW, Lee K, et al. Inhibition of skin inflammation and 
atopic dermatitis by topical application of a novel ceramide deriv-
ative, K112PC-5, in mice. Arch Pharm Res. 2008;31:1004.

47.  Frankel A, Sohn A, Patel RV, et al. Bilateral comparison study of 
pimecrolimus  cream  1%  and  a  ceramide-hyaluronic  acid  emol-
lient  foam  in  the  treatment  of  patients  with  atopic  dermatitis.  
J Drugs Dermatol. 2011;10:666.

48.  Kircik  LH,  Del  Rosso  JQ,  Aversa  D.  Evaluating  clinical  use  of  a 
ceramide-dominant, physiologic lipid-based topical emulsion for 
atopic dermatitis. J Clin Aesthet Dermatol. 2011;4:34.

49.  Draelos  ZD.  New  treatments  for  restoring  impaired  epidermal 
barrier  permeability:  Skin  barrier  repair  creams.  Clin  Dermatol. 
2012;30:345.

50.  Miller DW, Koch SB, Yentzer BA, et al. An over-the-counter mois-
turizer is as clinically effective as, and more cost-effective than, 
prescription  barrier  creams  in  the  treatment  of  children  with 
mild-to-moderate  atopic  dermatitis:  a  randomized,  controlled 
trial. J Drugs Dermatol. 2011;10:531.

51.  Simpson E, Böhling A, Bielfeldt S, et al. Improvement of skin bar-
rier function in atopic dermatitis patients with a new moisturizer 
containing a ceramide precursor. J Dermatolog Treat. 2013;24:122.

52.  Ishikawa J, Shimotoyodome Y, Chen S, et al. Eucalyptus increases 
ceramide levels in keratinocytes and improves stratum corneum 
function. Int J Cosmet Sci. 2012;34:17.

53.  Kolbe L, Kligman AM, Schreiner V, et al. Corticosteroid-induced 
atrophy and barrier impairment measured by non-invasive meth-
ods in human skin. Skin Res Technol. 2001;7:73.

54.  Radoja N, Komine M, Jho SH, et al. Novel mechanism of steroid 
action  in  skin  through  glucocorticoid  receptor  monomers.  Mol 
Cell Biol. 2000;20:4328.

55.  Ahn SK, Bak HN, Park BD, et al. Effects of a multilamellar emul-
sion  on  glucocorticoid-induced  epidermal  atrophy  and  barrier 
impairment. J Dermatol. 2006;33:80.

56.  Geilen CC, Barz S, Bektas M. Sphingolipid signaling in epidermal 
homeostasis. Current knowledge and new therapeutic approaches 
in dermatology. Skin Pharmacol Appl Skin Physiol. 2001;14:261.
57.  Kwon  YB,  Kim  CD,  Youm  JK,  et  al.  Novel  synthetic  ceramide 
derivatives increase intracellular calcium levels and promote epi-
dermal keratinocyte differentiation. J Lipid Res. 2007;48:1936.
58.  Raines  MA,  Kolesnick  RN,  Golde  DW.  Sphingomyelinase  and 
ceramide  activate  mitogen-activated  protein-kinase  in  myeloid 
HL-60 cells. J Biol Chem. 1993;268:14572.

59.  Hayakawa M, Jayadev S, Tsujimoto M, et al. Role of ceramide in 
stimulation  of  the  transcription  of  cytosolic  phospholipase  A2 
and cyclooxygenase 2. Biochem Biophys Res Commun. 1996;220:681.
60.  Masini  E,  Giannini  L,  Nistri  S,  et  al.  Ceramide:  A  key  signaling 
molecule  in  a  Guinea  pig  model  of  allergic  asthmatic  response 
and airway inflammation. J Pharmacol Exp Ther. 2008;324:548.
61.  di Nardo A, Sugino K, Wertz P, et al. Sodium lauryl sulfate (SLS) 
induced irritant contact dermatitis: A correlation study between 
ceramides and in vivo parameters of irritation. Contact Dermatitis. 
1996;35:86.

62.  Lamour  NF,  Stahelin  RV,  Wijesinghe  DS,  et  al.  Ceramide  kinase 
uses ceramide provided by ceramide transport protein: Localization 
to organelles of eicosanoid synthesis. J Lipid Res. 2007;48:1293.
63.  Sallusto F, Nicolò C, De Maria R, et al. Ceramide inhibits antigen 
uptake  and  presentation  by  dendritic  cells.  J  Exp  Med. 
1996;184:2411.

64.  Kirtikara K, Laulederkind SJ, Raghow R, et al. An accessory role 
for ceramide in interleukin-1beta induced prostaglandin synthe-
sis. Mol Cell Biochem. 1998;181:41.

65.  Ballou  LR,  Chao  CP,  Holness  MA,  et  al.  Interleukin-1-mediated 
PGE2  production  and  sphingomyelin  metabolism.  Evidence  for 
the regulation of cyclooxygenase gene expression by sphingosine 
and ceramide. J Biol Chem. 1992;267:20044.

66.  Wakita H, Nishimura K, Tokura Y, et al. Inhibitors of sphingolipid 
synthesis modulate interferon (IFN)-gamma-induced intercellular 
adhesion  molecule  (ICAM)-1  and  human  leukocyte  antigen 
(HLA)-DR  expression  on  cultured  normal  human  keratinocytes: 
Possible  involvement  of  ceramide  in  biologic  action  of  IFN-
gamma. J Invest Dermatol. 1996;107:336.

67.  Pettus BJ, Bielawska A, Spiegel S, et al. Ceramide kinase mediates 
cytokine-  and  calcium  ionophore-induced  arachidonic  acid 
release. J Biol Chem. 2003;278:38206.

68.  Wijesinghe  DS,  Lamour  NF,  Gomez-Munoz  A,  et  al.  Ceramide 
kinase and ceramide-1-phosphate. Methods Enzymol. 2007;434:265.
69.  Chalfant  CE,  Spiegel  S.  Sphingosine  1-phosphate  and  ceramide 
1-phosphate:  Expanding  roles  in  cell  signaling.  J  Cell  Sci. 
2005;118:4605.

70.  Mitsutake S, Kim TJ, Inagaki Y, et al. Ceramide kinase is a media-
tor of calcium-dependent degranulation in mast cells. J Biol Chem. 
2004;279:17570.

71.  Granado MH, Gangoiti P, Ouro A, et al. Ceramide 1-phosphate 
(C1P)  promotes  cell  migration  involvement  of  a  specific  C1P 
receptor. Cell Signal. 2009;21:405.

72.  Hannun YA, Obeid LM. The Ceramide-centric universe of lipid-
mediated cell regulation: Stress encounters of the lipid kind. J Biol 
Chem. 2002;277:25847.

73.  Morita O, Ogura R, Hayashi K, et al. Safety  studies of  pseudo-
ceramide SLE66: Acute and short-term toxicity. Food Chem Toxicol. 
2009;47:669.

74.  Lowe AJ, Tang ML, Dharmage SC, et al. A phase I study of daily 
treatment  with  a  ceramide-dominant  triple  lipid  mixture  com-
mencing in neonates. BMC Dermatol. 2012;12:3.

75.  Park BD, Kim Y, Lee M-J, et al. Properties of a pseudoceramide multi-
lammellar emulsion in vitro and in vivo. Cosm Toiletr. 2001;116:65.
76.  Spiteller  G.  The  relation  of  lipid  peroxidation  processes  with 
atherogenesis: A new theory on atherogenesis. Mol Nutr Food Res. 
2005;49:999.

77.  Imokawa G, Yada Y, Higuchi K, et al. Pseudo-acylceramide with 
linoleic acid produces selective recovery of diminished cutaneous 
barrier  function  in  essential  fatty  acid-deficient  rats  and  has  an 
inhibitory effect on epidermal hyperplasia. J Clin Invest. 1994;94:89.
78.  Takagi Y, Nakagawa H, Higuchi K, et al. Characterization of sur-
factant-induced skin damage through barrier recovery induced by 
pseudoacylceramides. Dermatology. 2005;211:128.

79.  Tokudome Y, Jinno M, Todo H, et al. Increase in ceramide level 
after application of various sizes of sphingomyelin liposomes to 

 
C H A P T E R  20  ■   C E R A M I D E S  

63

a  cultured  human  skin  model.  Skin  Pharmacol  Physiol. 
2011;24:218.

80.  Tokudome Y, Uchida R, Yokote T, et al. Effect of topically applied 
sphingomyelin-based liposomes on the ceramide level in a three-
dimensional cultured human skin model. J Liposome Res. 2010;20:49.
81.  Man MQ M, Feingold KR, Thornfeldt CR, et al. Optimization of 
physiological  lipid  mixtures  for  barrier  repair.  J  Invest  Dermatol. 
1996;106:1096.

82.  de Jager MW, Gooris GS, Ponec M, et al. Lipid mixtures prepared 
with well-defined synthetic ceramides closely mimic the unique 
stratum corneum lipid phase behavior. J Lipid Res. 2005;46:2649.

83.  Gulbins  E,  Kolesnick  R.  Raft  ceramide  in  molecular  medicine. 

Oncogene. 2003;22:7070.

84.  Baumann L, Saghari S. Basic science of the dermis. In: Baumann L, 
Saghari  S,  Weisberg  E,  eds.  Cosmetic  Dermatology:  Principles  and 
Practice. 2nd ed. New York: McGraw-Hill; 2009:8.

85.  Reunanen N, Westermarck J, Häkkinen L, et al. Enhancement of 
fibroblast  collagenase  (matrix  metalloproteinase-1)  gene  expres-
sion  by  ceramide  is  mediated  by  extracellular  signal-regulated 
and  stress-activated  protein  kinase  pathways.  J  Biol  Chem. 
1998;273:5137.

86.  Reunanen  N,  Foschi  M,  Han  J,  et  al.  Activation  of  extracellular 
signal-regulated kinase 1/2 inhibits type I collagen expression by 
human skin fibroblasts. J Biol Chem. 2000;275:34634.

87.  Ohuchida  M,  Sasaguri  Y,  Morimatsu  M,  et  al.  Effect  of  linoleic 
acid  hydroperoxide  on  production  of  matrix  metalloproteinases 
by human skin fibroblasts. Biochem Int. 1991;25:447.

88.  Grether-Beck S, Mühlberg K, Brenden H, et al. Topical application 
of  vitamins,  phytosterols  and  ceramides.  Protection  against 
increased  expression  of  interstital  collagenase  and  reduced 
collagen-I  expression  after  single  exposure  to  UVA  irradiation. 
Hautarzt. 2008;59:557.

 
64 

Co s m eCe u t iCa l s   a n d   Co s m e t iC  in g r e d i e n t s

C H A P T E R   2 1

Cholesterol

Activities:

Barrier  repair,  regulation  of  cell  membrane  fluidity, 
effects on keratinization

Important Chemical Components:

Sterols, phospholipids

Origin Classification:

Naturally  occurs  in  animal  fats  including  cheese,  egg 
yolks, beef, poultry, fish, and breast milk. Flaxseed and 
peanuts  contain  cholesterol-like  components  called 
phytosterols.1,2

Personal Care Category:

Emollient, occlusive, moisturizer

Recommended for the following Baumann Skin 
Types: 

DRNW,  DRNT,  DRPT,  DRPW,  DSNW,  DSNT,  DSPT, 
and DSPW

 SOURCE

Cholesterol  is  found  in  all  biologic  membranes  including 
keratinocytes,  where  it  is  organized  into  “lipid  rafts.”3,4 
Cholesterol sulfate is very abundant in the epidermis with the 
highest levels found in the granular layer. Amounts of choles-
terol sulfate decline progressively from the granular layer to the 
outer stratum corneum (SC).5

Diet
Cholesterol  is  readily  available  in  the  diet  and  basal 
keratinocytes  are  capable  of  absorbing  cholesterol  from  the 
circulation 
(Table  21-1).  Cholesterol  absorption  by 
keratinocytes is regulated in part by peroxisome proliferator-
activated  receptors  (PPARs)  and  retinoid  X  receptors.  These 
have  been  found  to  play  a  role  in  transporting  cholesterol 
across keratinocyte cell membranes by increasing expression 
of  ATP-binding  cassette  transporter  (ABCA1),  a  membrane 
transporter  that  regulates  cholesterol  efflux.6  Low-density 
lipoprotein (LDL) receptors may play a role in the absorption 

of  cholesterol  by  skin  cells.  Although  LDL  receptors  are  not 
expressed on basal keratinocytes when the barrier is normal, 
when  the  barrier  is  first  perturbed,  LDL  mRNA  and  protein 
levels  and  apolipoprotein  E  (ApoE)  expression  rise.7,8  In 
chronic  barrier  disruption,  the  keratinocytes  express  LDL 
receptors.9 Increased expression of LDL or ApoE can augment 
delivery  of  exogenously  applied  cholesterol  to  suprabasal 
keratinocytes. Most of the cholesterol in skin, however, is not 
derived from diet but, rather, is synthesized by skin cells.

Endogenous Synthesis
Most cholesterol in the skin is synthesized in keratinocytes by 
the  enzyme  cholesterol  sulfotransferase  type  2B  isoform  1b, 
abbreviated  as  SULT2B1b  (Table  21-2).  The  rate-limiting 
enzyme  in  this  process  is  3-hydroxy-3-methylglutaryl 
coenzyme  A  (HMG-CoA)  reductase  (see  Figure  21-1  for  the 
pathway  of  cholesterol  synthesis).  A  group  of  transcription 
factors  known  as  sterol  regulatory  element-binding  proteins 
(SREBPs)  also  regulate  cholesterol  and  fatty  acid  synthesis. 
When  epidermal  sterols  decline,  SREBPs  are  activated  via 
proteolytic  processes.  The  SREBPs  enter  the  cell  nucleus  and 
activate genes leading to increased synthesis of cholesterol.10,11 
There are three known types of SREBPs: SREBP-1a, SREBP-1c, 
and  SREBP-2.  In  human  keratinocytes,  SREBP-2  has  been 
shown to be the predominant type and is involved in regulating 
cholesterol production.11

Cholesterol  synthesis  does  not  seem  to  be  influenced  by 
dietary or circulating sterol levels, but it is controlled by alterations 
in the integrity of the skin’s permeability barrier, and increased in 
the presence of high amounts of calcium.12–15 Perturbation of the 
skin’s barrier results in increases in the quantity and activity of 
HMG-CoA reductase, resulting in greater cholesterol synthesis.16 
Blocking the activity of HMG-CoA reductase reduces cholesterol 
synthesis  and  impedes  barrier  repair,  while  the  addition  of 
mevalonate  increases  cholesterol  synthesis  and  restores  barrier 
repair in the absence of HMG-CoA reductase.12,17

 HISTORY

Nonpolar lipids in the SC, including ceramides, cholesterol, and 
fatty  acids,  have  been  known  to  play  a  role  in  regulating 
transepidermal  water  loss  (TEWL)  since  the  early  1970s.18 

TABLE 21-1
Influence on Cholesterol Synthesis

diet
Barrier disruption
High calcium levels
Hmg-Coa reductase activity
sreBP-2
mevalonate

DepenDent On

↑ prODuctiOn

nO influence
√

√

√
√

√
√ in the absence of Hmg-Coa reductase

 
TABLE 21-2
Pros and Cons of Cholesterol

Pros
Endogenous synthesis

Key regulator of membrane fluidity and 

keratinization

Con
Topical application alone (without ceramides 

or fatty acids) delays barrier repair

Leaders  of  the  research  in  this  field  include  Elias,  Feingold, 
Menon,  and  Ghadially.  Their  work  showed  that  cholesterol, 
fatty acids, and ceramides must all be replaced in the skin in an 
equivalent  ratio  (1:1:1)  in  order  for  barrier  repair  to  occur. 
Topically placing only cholesterol on the skin leads to delayed 
barrier repair.

Research in the ensuing years has examined the process by 
which  cholesterol  is  synthesized  and  released  into  the  space 
between skin cells providing a watertight  barrier.  Ceramides, 
cholesterol,  and  fatty  acids  are  synthesized  by  keratinocytes 
and packaged in lamellar bodies, which carry them until they 
are extruded into the intracellular space where they form the 
“skin  barrier”  that  helps  prevent  TEWL  from  the  epidermis  
(see Chapter 19, Barrier Repair Ingredients). When the skin bar-
rier  is  disturbed  by  detergents,  friction,  prolonged  water 
immersion, and other insults, keratinocytes repair it by synthe-
sizing more lipids. Cholesterol plays a crucial role in the early 
stages of barrier repair as shown in a 1990 study that demon-
strated  that  when  cholesterol  synthesis  is  inhibited,  lamellar 
secretion  is  impaired  and  lamellar  body  internal  structure  is 
altered, leading to delayed barrier repair.19 Studies have shown 
that delivery of circulating sterols does not increase after barrier 
disruption, implying that locally derived sterol from cholesterol 
is necessary for the synthesis of lipids in lamellar bodies.13,20,21 
It  is  now  known  that  in  the  early  stages  of  barrier  repair, 
cholesterol  is  essential  to  contribute  to  the  free  sterol  that  is 
packaged into lamellar bodies. In fact, the topical application of 
lovastatin, a competitive inhibitor of HMG-CoA reductase that 
is  known  to  block  cholesterol  synthesis,  delays  barrier 
recovery.12

 CHEMISTRY

Cholesterol is a lipid but it differs in structure from other lipids 
because of its steroid nucleus. A hydrocarbon tail is linked to the 
steroid nucleus at one end and a hydroxyl group is attached at the 

Acetyl-CoA

HMG-CoA
Reductase

HMG-CoA

Mevalonate

Statins

Mevalonate-PP

Isopentenyl-PP

Geranyl-PP

C H A P T E R  21  ■   C H O L E S T E R O L  

65

H3C

CH3

CH3

CH3

CH3

HO

Cholesterol

FIGURE 21-2  A hydrocarbon tail is linked to a steroid nucleus at one 

▶
end and a hydroxyl group is attached at the other end.

other  end  (Figure  21-2).  The  hydroxyl  group  (polar  head)  in 
position 3 causes cholesterol to be roughly perpendicular to the 
bilayer membrane surface. This structure allows cholesterol to be 
a key regulator of membrane fluidity, plasticity, and rigidity.22,23

In  the  biosynthetic  pathway  of  endogenous  cholesterol 
synthesis, the conversion of HMGCoA to mevalonic acid is an 
early  rate-limiting  step.  Cholesterol-lowering  drugs  such  as 
lovastatin  block  this  enzyme,  leading  to  a  decrease  in  serum 
cholesterol but also to a decrease in barrier recovery.19

 ORAL USES

Cholesterol in the diet has been associated with an increased risk 
of cardiovascular disease, but dietary cholesterol does not neces-
sarily correlate with serum cholesterol levels or increases in LDL, 
the so-called “bad” cholesterol. This is a complex topic a thorough 
discussion of which is beyond the scope of this book, however.

 TOPICAL USES

Barrier Repair
Topically  applied  cholesterol  can  penetrate  into  the  nucle-
ated layers of the SC and be taken up into the cytosol, where 
its components are broken down and packaged into lamellar 
bodies.12  Exogenously  applied  cholesterol  does  not  down-
regulate cholesterol synthesis in the skin.24 For these reasons, 
cholesterol  is  an  important  and  popular  additive  to  barrier 
repair  creams.  Cholesterol  is  required  for  the  permeability 
barrier  to  function  normally  (see  Chapter  19  Barrier  Repair 
Ingredients).  Aged  skin  shows  a  decreased  ability  for  lipid 
synthesis, particularly cholesterol synthesis, which leads to a 
delayed  barrier  recovery  response  in  older  individuals. 
Ghadially  reported  that  topical  application  of  cholesterol 
after  perturbation  of  the  skin  barrier  accelerated  barrier 
repair in aged mice skin and, in a different study a year later 
with Zettersten, was able to accelerate barrier repair using a 
mixture  containing  cholesterol/ceramide/palmitate  and 
linoleate at a ratio of 3:1:1:1.25,26 Topically applied lovastatin, 
a  drug  that  inhibits  HMG-CoA  reductase  and  prevents 
cholesterol synthesis, delayed barrier recovery in mice by 50 
percent.  Addition  of  cholesterol  to  the  skin  of  these  same 
mice  normalized  barrier  recovery,  showing  the  importance 
of cholesterol in barrier recovery and function.19

Cholesterol

Squalene

Famesyl-PP

▶
FIGURE  21-1  Cholesterol  Synthesis.  Cholesterol  is  synthesized  from 
Acetyl Co A. The rate-limiting enzyme is HMG-CoA reductase, which is the 
enzyme that statin cholesterol-lowering drugs block.

Keratinization
In order for keratinocytes to develop the permeability barrier, 
they must first undergo differentiation and maturation, which 
culminates  in  the  formation  of  the  outermost  layer  of  the  

 
66 

Co s m eCe u t iCa l s   a n d   Co s m e t iC  in g r e d i e n t s

skin  –  the  SC.  This  process  is  known  as  keratinization. 
Keratinization affects the skin barrier and skin moisturization 
for  two  main  reasons:  1)  Keratinocyte  maturation  allows 
formation  of  the  lamellar  bodies  in  which  cholesterol,  phos-
pholipids,  and  glucosylceramides  are  synthesized  and  stored 
prior  to  being  released  into  the  extracellular  space;  2) 
Keratinocyte maturation leads to the  production  of  structural 
proteins such as loricrin and involucrin that provide scaffolding 
needed for the development of lamellar bodies.5,27,28

Cholesterol plays a crucial role in regulating the keratinization 
process,  through  various  mechanisms.29,30  In  cell  membranes, 
cholesterol is organized into “lipid rafts,”4 which modulate the 
activation of epidermal stem cells into amplifying keratinocytes 
by regulating specific enzymes and influencing various signaling 
processes.4,29,31  Many  pathways  affect  the  keratinization 
process in the skin. A few that are known to alter keratiniza-
tion by affecting cholesterol synthesis include:

1.  SULT2B1b  is  the  key  enzyme  in  the  synthesis  of  choles-

terol sulfate.

2.  HMG-CoA  reductase  is  the  rate-limiting  step  in  the 

production of cholesterol.

3.  Activation  of  PPARα,  PPAR  β/∆,  and  PPAR-γ  increases 

cholesterol synthesis.32

4.  SREBPs also regulate cholesterol and fatty acid synthesis.

5.  Liver X receptors (LXR) and PPARs regulate the expression 

of SULT2B1b.33–36

Cholesterol  sulfate  is  important  for  cell-to-cell  cohesion. 
The  removal  of  sulfate  by  steroid  sulfatase  is  required  for 
desquamation  of  the  SC.23  Alterations  in  cholesterol  sulfate 
result  in  impaired  epidermal  differentiation  and  corneocyte 
desquamation.36 For example, X-linked ichthyosis (also known 
as  steroid  sulfatase  deficiency),  a  skin  disease  caused  by  a 
deficiency of cholesterol sulfate, is characterized by abnormal 
corneocyte retention, resulting in rough, dry, “fish-like” skin. 
Ichthyosis  has  also  been  reported  in  patients  on  cholesterol-
lowering drugs.37

 SAFETY ISSUES

There  are  no  studies  that  demonstrate  that  topically  applied 
cholesterol raises serum cholesterol levels.

 ENVIRONMENTAL IMPACT

None

 FORMULATION CONSIDERATIONS

Applying  topical  cholesterol  alone  is  known  to  impair  the  skin 
barrier.  It  must  be  combined  with  an  equimolar  amount  of 
ceramides and fatty acids as discussed above and in Chapter 19.38

 USAGE CONSIDERATIONS

One intriguing aspect about cholesterol is that it need not be 
applied to the skin. The skin cells can be prompted to synthesize 
cholesterol. For example, cytokines such as interleukin-1α and 
interferon-γ increase cholesterol synthesis.39

 SIGNIFICANT BACKGROUND

Cholesterol and Photoaging
Ultraviolet  A  has  been  shown  to  engender  peroxidation  of 
cholesterol  to  cholesterol  hydroperoxides  (Chol-OOHs),40 
which can cause damage to cell membranes and become even 
more  deleterious  when  further  reduced  to  oxylradicals.41 
Oxylradicals  are  free  radicals  that  lead  to  a  cascade  of  chain 
peroxidation reactions, thus elevating matrix metalloproteinase-9 
MMP-9  levels,41  collagenase  expression,  and  other  harmful 
effects (see Chapter 2, Basic Cosmetic Chemistry, and Chapter 
46,  Antioxidants).  Notably,  Chol-OOHs  have  been  used  as  a 
biomarker of physiological aging in the skin.42

 CONCLUSION

Cholesterol is a fascinating skin care ingredient because of its 
effects  on  the  skin  barrier  and  the  keratinization  process. 
Cholesterol  may  play  a  role  in  skin  care  even  when  it  is  not 
included  in  the  actual  skin  care  product,  because  other 
ingredients can influence or spur cholesterol production.

REFERENCES

1.  Herchi W, Harrabi S, Sebei K, et al. Phytosterols accumulation in 
the  seeds  of  Linum  usitatissimum  L.  Plant  Physiol  Biochem. 
2009;47:880.

2.  Ros E. Health benefits of nut consumption. Nutrients. 2010;2:652.
3.  Gniadecki R, Christoffersen N, Wulf HC. Cholesterol-rich plasma 
membrane  domains  (lipid  rafts)  in  keratinocytes:  Importance  in 
the  baseline  and  UVA-induced  generation  of  reactive  oxygen 
species. J Invest Dermatol. 2002;118:582.

4.  Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev 

Mol Cell Biol. 2000;1:31.

5.  Feingold  KR,  Jiang  YJ.  The  mechanisms  by  which  lipids 
coordinately  regulate  the  formation  of  the  protein  and  lipid 
domains of the stratum corneum: Role of fatty acids, oxysterols, 
cholesterol  sulfate  and  ceramides  as  signaling  molecules. 
Dermatoendocrinol. 2011;3:113.

6.  Proksch E, Jensen J-M. Skin as an organ of protection. In: Wolff K, 
Goldsmith  LA,  Katz  SI,  Gilchrest  BA,  Paller  AS,  Leffell  DJ,  eds. 
Fitzpatrick’s  Dermatology  in  General  Medicine.  7th  ed.  New  York: 
McGraw-Hill; 2007:386–387.

7.  Jackson SM, Wood LC, Lauer S, et al. Effect of cutaneous perme-
ability barrier disruption on HMG-CoA reductase, LDL receptor, 
and  apolipoprotein  E  mRNA  levels  in  the  epidermis  of  hairless 
mice. J Lipid Res. 1992;33:1307.

8.  Fenjves ES, Gordon DA, Pershing LK, et al. Systemic distribution 
of apolipoprotein E secreted by grafts of epidermal keratinocytes: 
implications  for  epidermal  function  and  gene  therapy.  Proc  Natl 
Acad Sci U S A. 1989;86:8803.

9.  Mommaas-Kienhuis  AM,  Grayson  S,  Wijsman  MC,  et  al.  Low 
density  lipoprotein  receptor  expression  on  keratinocytes  in 
normal and psoriatic epidermis. J Invest Dermatol. 1987;89:513.
10.  Elias  PM.  Stratum  corneum  defensive  functions:  an  integrated 

view. J Invest Dermatol. 2005;125:183.

11.  Harris IR, Farrell AM, Holleran WM, et al. Parallel regulation of 
sterol regulatory element binding protein-2 and the enzymes of 
cholesterol and fatty acid synthesis but not ceramide synthesis in 
cultured human keratinocytes and murine epidermis. J Lipid Res. 
1998;39:412.

12.  Menon GK, Feingold KR, Mao-Qiang M, et al. Structural basis for 
the barrier abnormality following inhibition of HMG CoA reduc-
tase in murine epidermis. J Invest Dermatol. 1992;98:209.

13.  Grubauer  G,  Feingold  KR,  Elias  PM.  Relationship  of  epidermal 
lipogenesis to cutaneous barrier function. J Lipid Res. 1987;28:746.
14.  Wertz  PW.  Biochemistry  of  human  stratum  corneum  lipids.  In 
Elias  PM,  Feingold  KR,  eds.  Skin  Barrier.  New  York:  Taylor  and 
Francis; 2006:33–42.

 
15.  Ponec M, Havekes L, Kempenaar J, et al. Calcium-mediated regu-
lation  of  the  low  density  lipoprotein  receptor  and  intracellular 
cholesterol  synthesis  in  human  epidermal  keratinocytes.  J  Cell 
Physiol. 1985;125:98.

16.  Proksch  E,  Elias  PM,  Feingold  KR.  Regulation  of  3-hydroxy-
3-methylglutaryl-coenzyme  A  reductase  activity  in  murine 
epidermis: Modulation of enzyme content and activation state by 
barrier requirements. J Clin Invest. 1990;85:874.

17.  Feingold  KR,  Man  MQ,  Proksch  E,  et  al.  The  lovastatin-treated 
rodent: A new model of barrier disruption and epidermal hyper-
plasia. J Invest Dermatol. 1991;96:201.

18.  Elias  PM.  The  epidermal  permeability  barrier:  From  the  early 
days  at  Harvard  to  emerging  concepts.  J  Invest  Dermatol. 
2004;122:xxxvi.

19.  Feingold KR, Man MQ, Menon GK, et al. Cholesterol synthesis is 
required  for  cutaneous  barrier  function  in  mice.  J  Clin  Invest. 
1990;86:1738.

20.  Feingold KR, Brown BE, Lear SR, et al. Effect of essential fatty acid 
deficiency  on  cutaneous  sterol  synthesis.  J  Invest  Dermatol. 
1986;87:588.

21.  Grubauer G, Elias PM, Feingold KR. Transepidermal water loss: 
the  signal  for  recovery  of  barrier  structure  and  function.  J  Lipid 
Res. 1989;30:323.

22.  Berg JM, Tymoczko JL, Stryer L. Lipids and cell membranes.  In 

Biochemistry. 5th ed. New York: WH Freeman and Co.; 2002:338.

23.  Choi  MJ,  Maibach  HI.  Role  of  ceramides  in  barrier  function  of 

healthy and diseased skin. Am J Clin Dermatol. 2005;6:215.

24.  Menon GK, Feingold KR, Moser AH, et al. De novo sterologenesis 
in  the  skin.  II.  Regulation  by  cutaneous  barrier  requirements.  
 J Lipid Res. 1985;26:418.

25.  Ghadially  R,  Brown  BE,  Hanley  K,  et  al.  Decreased  epidermal 
lipid synthesis accounts for altered barrier function in aged mice. 
 J Invest Dermatol. 1996;106:1064.

26.  Zettersten EM, Ghadially R, Feingold KR, et al. Optimal ratios of 
topical stratum corneum lipids improve barrier recovery in chron-
ologically aged skin. J Am Acad Dermatol. 1997;37:403.

27.  Elias PM, Schmuth M, Uchida Y, et al. Basis for the permeability 
barrier  abnormality  in  lamellar  ichthyosis.  Exp  Dermatol. 
2002;11:248.

28.  Schmuth  M,  Fluhr  JW,  Crumrine  DC,  et  al.  Structural  and 
functional consequences of loricrin mutations in human loricrin 
keratoderma  (Vohwinkel  syndrome  with  ichthyosis).  J  Invest 
Dermatol. 2004;122:909.

C HaPt e r  21  ■   C Ho l e s t e r o l  

67

29.  Jans R, Atanasova G, Jadot M, et al. Cholesterol depletion upregu-
lates  involucrin  expression  in  epidermal  keratinocytes  through 
activation of p38. J Invest Dermatol. 2004;123:564.

30.  Schmidt R, Parish EJ, Dionisius V, et al. Modulation of cellular cho-
lesterol and its effect on cornified envelope formation in cultured 
human epidermal keratinocytes. J Invest Dermatol. 1991;97:771.
31.  Gniadecki R, Bang B. Flotillas of lipid rafts in transit amplifying 

cell-like keratinocytes. J Invest Dermatol. 2003;121:522.

32.  Man MQ, Choi EH, Schmuth M, et al. Basis for improved perme-
ability barrier homeostasis induced by PPAR and LXR activators: 
liposensors stimulate lipid synthesis, lamellar body secretion and 
post-secretory lipid processing. J Invest Dermatol. 2006;126:386.
33.  Kömüves LG, Schmuth M, Fowler AJ, et al. Oxysterol stimulation 
of epidermal differentiation is mediated by liver X receptor-beta 
in murine epidermis. J Invest Dermatol. 2002;118:25.

34.  Jiang  YJ,  Lu  B,  Kim  P,  et  al.  PPAR  and  LXR  activators  regulate 
ABCA12  expression  in  human  keratinocytes.  J  Invest  Dermatol. 
2008;128:104.

35.  Rivier  M,  Castiel  I,  Safonova  I,  et  al.  Peroxisome  proliferator-
activated  receptor-alpha  enhances  lipid  metabolism  in  a  skin 
equivalent model. J Invest Dermatol. 2000;114:681.

36.  Jiang YJ, Kim P, Elias PM, et al. LXR and PPAR activators stimulate 
cholesterol sulfotransferase type 2 isoform 1b in human keratinocytes. 
J Lipid Res. 2005;46:2657.

37.  Williams  ML,  Feingold  KR,  Grubauer  G,  Elias  PM.  Ichthyosis 
induced by cholesterol-lowering drugs. Implications for epidermal 
cholesterol homeostasis. Arch Dermatol. 1987;123:1535.

38.  Madison KC. Barrier function of the skin: “la raison d’être” of the 

epidermis. J Invest Dermatol. 2003;121:231.

39.  Grunfeld  C,  Soued  M,  Adi  S,  et  al.  Evidence  for  two  classes  of 
cytokines that stimulate hepatic lipogenesis: Relationships among 
tumor  necrosis  factor,  interleukin-1  and  interferon-alpha. 
Endocrinology. 1990;127:46.

40.  Girotti AW. Photosensitized oxidation of cholesterol in biological 
systems: Reaction pathways, cytotoxic effects and defense mech-
anisms. J Photochem Photobiol B. 1992;13:105.

41.  Minami  Y,  Kawabata  K,  Kubo  Y,  et  al.  Peroxidized  cholesterol-
induced  matrix  metalloproteinase-9  activation  and  its  suppres-
sion by dietary β-carotene in photoaging of hairless mouse skin.  
J Nutr Biochem. 2009;20:389.

42.  Tahara S, Matsuo M, Kaneko T. Age-related changes in oxidative 
damage  to  lipids  and  DNA  in  rat  skin.  Mech  Ageing  Dev. 
2001;122:415.

 
68 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   2 2

Lanolin

Activities:

Occlusive, emollient

Important Chemical Components:

Lanolin contains long-chain waxy esters many of which 
have  not  yet  been  characterized.  It  is  thought  of  as  a 
highly  complex  combination  of  esters,  di-esters,  and 
hydroxyl esters of high molecular weight lanolin alcohols 
(i.e.,  aliphatic  alcohols,  sterols,  including  cholesterol, 
and trimethyl sterols) as well as high molecular weight 
lanolin  acids  (i.e.,  normal,  iso-,  anteiso-,  and  hydroxyl 
acids).1,2

Significantly,  the  method  used  to  refine  the  compound 
determines the quality and composition of the resulting formu-
lation; therefore, not all lanolin products exhibit the same activ-
ity.5 Unfortunately, a small percentage of individuals who use 
lanolin develop contact sensitization to the occlusive/emollient 
agent.  Consequently,  lanolin  has  developed  a  reputation  as  a 
sensitizer  that,  according  to  some,  may  not  be  deserved.3,6 
Nevertheless, manufacturers have responded to such claims and 
many moisturizing products are now touted as “lanolin free.” 
Another response to the notion that lanolin provokes allergic reac-
tions has spurred the development of an ultrapure hypoallergenic 
medical grade lanolin formulation such as Medilan™. 

Origin Classification: 

 ORAL USES

This ingredient is considered natural. It is animal derived.

Lanolin is not to be taken internally.

Personal Care Category: 

Lipophilic

 TOPICAL USES

Recommended for the following Baumann Skin 
Types: 

DRNW, DRNT, DRPT, and DRPW

Lanolin is one among several commonly used occlusive agents 
and  is  effective  as  an  ingredient  in  skin  care  products  for  its 
ability  to  treat  dry  skin,  delivering  an  emollient  effect  and 
reducing TEWL.

 SOURCE

 SAFETY ISSUES

Lanolin  is  a  greasy  yellow  substance  derived  from  the  seba-
ceous  secretions  of  sheep  and  other  wool-bearing  animals. 
Most  lanolin  used  in  skin  care  products  is  obtained  from 
domesticated sheep.

 HISTORY

Lanolin has been used for thousands of years by human beings 
for its emollient qualities, and for hundreds of years as an ingre-
dient in skin care ointments (Table 22-1).3

 CHEMISTRY

Lanolin  shares  two  important  features  with  stratum  corneum 
(SC) lipids: 1) lanolin contains cholesterol, an essential constituent 
of SC lipids, and 2) lanolin and SC lipids can coexist as solids 
and liquids at physiologic temperatures. Lanolin is characterized 
by a very different composition than human sebum, though.4 
This  is  also  the  case  for  commercial  lanolin  products. 

Lanolin had long been thought of as a sensitizer given reports 
beginning  several  decades  ago  of  links  to  contact  dermatitis. 
However, lanolin is no longer considered a common allergen so 
much as one affecting compromised or high-risk populations, 
such as elderly individuals with chronic xerosis, dermatitis, or 
venous stasis dermatitis.7–9 In a 2008 study of 276 moisturizers, 
lanolin,  found  in  10  percent  of  products,  was  the  ninth  most 
common  allergen,  far  behind  fragrance,  parabens,  vitamin  E, 
and essential oils and biologic additives.9

In  2008,  investigators  sought  to  identify  the  frequency  of 
positive patch test reactions to common allergens in leg ulcer 
or venous disease patients by using a case series of 100 con-
secutive  consenting  subjects  suffering  from  chronic  venous 
disease  and  other  leg  ulcer  etiologies.  At  least  one  positive 
patch test was observed in 46 percent of patients, with multiple 
reactions in the same subject frequently seen. Of the 38 common 
allergens  tested,  lanolin  was  identified  among  the  most  fre-
quent sensitizers, which also included fragrances, antibacterial 
agents,  and  rubber-related  compounds.10  Of  course,  these 
results suggest that lanolin may be contraindicated in patients 
with leg ulcers, but are not generalizable to a healthy population.

TABLE 22-1
Pros and Cons of Lanolin

Pro
Effective emollient

Cons
Is a chemical sensitizer
Is unsuitable for those who are opposed to 

using animal products

 ENVIRONMENTAL IMPACT

The  impact  on  the  environment  of  lanolin  cultivation  is 
directly related to the effects of sheep farming on land and air 
quality as well as water run-off. As an animal-derived product, 
lanolin is not an option for vegan or vegetarian patients.

 
 FORMULATION CONSIDERATIONS

Although  a  plant-derived  substitute  has  been  recently  pro-
duced, lanolin itself is a complex natural product that cannot be 
synthesized. It is also a commonly used occlusive ingredient, 
along with products or compounds such as paraffin, squalene, 
dimethicone, soybean oil, grapeseed oil, propylene glycol, and 
beeswax.11  Importantly,  though,  lanolin,  like  mineral  oil  and 
petrolatum, is known for its dual activity exerting both occlu-
sive and emollient effects. 

 USAGE CONSIDERATIONS

Lanolin is typically used to moisturize and smooth the skin and 
is generally considered safe in noncompromised skin. It is easily 
absorbed through the skin and is thus conducive to delivering 
medicinal chemicals in an ointment.9

 SIGNIFICANT BACKGROUND

In  2003,  Dodd  and  Chalmers  led  a  multicenter,  prospective, 
randomized  controlled  clinical  trial  to  compare  the  effects  of 
hydrogel dressings to lanolin ointment for the prevention and 
treatment of nipple soreness in 106 lactating mothers. A board-
certified lactation specialist provided breastfeeding guidance at 
the  beginning  of  the  study.  During  the  first  12  days  of  the 
study, participants, who were randomized to either of the two 
groups,  were  instructed  to  rate  pain  intensity  according  to  a 
numeric  pain  intensity  scale  as  well  as  a  verbal  description 
scale.  Patients  then  forwarded  self-reported  skin  assessments 
of the bilateral breasts, nipples, and areolae to investigators. A 
significantly  greater  reduction  in  pain  score  mean  values  was 
identified in the hydrogel group at baseline, day 10, and day 12, 
as compared to the lanolin group, and the hydrogel group dis-
continued treatment earlier than the participants using lanolin. 
Overall,  researchers  found  hydrogel  to  be  superior  to  lanolin 
ointment for the management of nipple soreness.12

Additional evidence that lanolin is not the optimal therapeutic 
option  for  sore  or  cracked  nipples  came  four  years  later  when 
investigators conducted a randomized double-blind clinical trial 
to compare a peppermint gel formulation, modified lanolin, and 
a  placebo  control  ointment  for  the  treatment  of  nipple  fissures 
related to breastfeeding. Two hundred and sixteen primiparous 
mothers were randomly assigned to the three groups, compara-
ble in mean age, and were instructed to apply their selected for-
mulation on both breasts for 14 days. Patients were seen for up to 
four follow-up visits as well as a final visit at week 6. Researchers 
found that nipple and areola cracks were less frequent in the pep-
permint gel group as compared to the lanolin or placebo groups.13
Nevertheless, such results do not detract from the appropriate-
ness of lanolin for other dry skin indications. In 2003, investigators 
conducted  a  four-week  double-blind,  randomized-comparison 
clinical  trial  to  assess  the  effectiveness  of  pure  lanolin  as  com-
pared to ammonium lactate 12 percent cream in the treatment 
of moderate to severe xerosis on the feet. Fifty-one patients, of 
the original 92 enrolled, completed the study. Both treatment 
groups  exhibited  significant  improvement  in  xerosis  scores 
after  two  and  four  weeks  of  treatment,  with  no  statistically 
significant  differences  identified  between  the  groups.  The 
researchers concluded that pure lanolin as well as ammonium 
lactate  cream  used  twice  daily  for  a  month  were  effective  in 
ameliorating moderate to severe dry skin.14

C H A P T E R  22  ■   L A N O L I N  

69

In 2008, authors reported on a comparison of two different 
topical ointments used in cutaneous therapy on 173 prospec-
tively enrolled infants between 25 and 36 weeks of gestation 
admitted to a neonatal intensive care unit from October 2004 
and  November  2006.  Each  infant  was  treated  for  up  to  four 
weeks after being randomly assigned to daily treatment with 
water-in-oil  emollient  cream  (Bepanthen),  olive  oil  cream  
(70  percent  lanolin,  30  percent  olive  oil),  or  a  topical  control. 
Skin  was  evaluated  weekly.  Investigators  found  that  while 
both treatment groups exhibited greater improvement than the 
control group, with enduring treatment effects, infants in the 
lanolin/olive oil group experienced statistically less dermatitis 
than the water-in-oil emollient group.15

 CONCLUSION

Through the last several decades, only a small proportion of the 
population has been found to be allergic to lanolin. Although 
allergic responses have not been reported in association with 
the use of more modern, medical grade, or other highly refined 
lanolin products, the author has seen several patients with lan-
olin allergy. To patients who demur to use lanolin due to the 
animal origin of the substance, it is important to at least address 
this argument by noting that while lanolin is secreted by the 
sebaceous glands of sheep and then obtained from their shorn 
wool  and  refined,  the  process  is  conducted  without  harming 
the animal. Lanolin, particularly in the newest formulations, is 
an effective first-line occlusive and emollient agent for various 
xerotic conditions.

REFERENCES

1.  Barnett G. Lanolin and derivatives. Cosm Toiletr. 1986;101:21.
2.  Clark EW. A brief history of lanolin. Pharm Hist. 1980;10:5.
3.  Stone L. Medlian: A hypoallergenic lanolin for emollient therapy. 

Br J Nurs. 2000;9:54.

4.  Proserpio G. Lanolides: Emollients or moisturizers? Cosm Toiletr. 

1978;93:45.

5.  Harris I, Hoppe U. Lanolins. In: Loden M, Maibach H, eds. Dry 

Skin and Moisturizers. Boca Raton: CRC Press; 2000:259.

6.  Kligman  AM.  The  myth  of  lanolin  allergy.  Contact  Dermatitis. 

1998;39:103.

7.  White-Chu EF, Reddy M. Dry skin in the elderly: complexities of 

a common problem. Clin Dermatol. 2011;29:37.

8.  Lee  B,  Warshaw  E.  Lanolin  allergy:  History,  epidemiology, 
responsible allergens, and management. Dermatitis. 2008;19:63.
9.  Zirwas MJ, Stechschulte SA. Moisturizer allergy: Diagnosis and 

management. J Clin Aesthet Dermatol. 2008;1:38.

10.  Smart V, Alavi A, Coutts P, et al. Contact allergens in persons with 
leg  ulcers:  A  Canadian  study  in  contact  sensitization.  Int  J  Low 
Extrem Wounds. 2008;7:120.

11.  Draelos  Z.  Moisturizers.  In:  Draelos  Z,  ed.  Atlas  of  Cosmetic 

Dermatology. New York: Churchill Livingstone; 2000:83.

12.  Dodd V, Chalmers C. Comparing the use of hydrogel dressings to 
lanolin ointment with lactating mothers. J Obstet Gynecol Neonatal 
Nurs. 2003;32:486.

13.  Melli MS, Rashidi MR, Nokhoodchi A, et al. A randomized trial 
of peppermint gel, lanolin ointment, and placebo gel to prevent 
nipple crack in primiparous breastfeeding women. Med Sci Monit. 
2007;13:CR406.

14.  Jennings MB, Alfieri DM, Parker ER, et al. A double-blind clinical 
trial  comparing  the  efficacy  and  safety  of  pure  lanolin  versus 
ammonium lactate 12% cream for the treatment of moderate to 
severe foot xerosis. Cutis. 2003;71:78.

15.  Kiechl-Kohlendorfer U, Berger C, Inzinger R. The effect of daily 
treatment with an olive oil/lanolin emollient on skin integrity in 
preterm  infants:  a  randomized  controlled  trial.  Pediatr  Dermatol. 
2008;25:174.

 
70 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   2 3

Stearic Acid

Activities:

Emulsifying, hydrating, barrier repair, surfactant

Important Chemical Components:

Saturated fatty acid containing long alkyl chains.
The International Union of Pure and Applied Chemistry 
(IUPAC) name is octadecanoic acid and its chemical for-
mula  is  CH3(CH2)16CO2H.  Its  molecular  formula  is 
C18H36O2.

Origin Classification:

Stearic acid plays an important role in the skin’s permeability 
barrier along with linoleic acid and palmitic acid (from palm oil). 
Palmitic and stearic acids are both saturated fatty acids. Linoleic 
acid is an unsaturated fatty acid and displays anti-inflammatory 
properties that stearic acid does not exhibit. Stearic acid has been 
incorporated  into  many  personal  care  products  because  of  its 
safety  profile,  ubiquity,  and  inexpensive  cost  in  addition  to  its 
surfactant and hydrating abilities. It is found in many “hydrating” 
body washes and bars that deposit stearic acid on the skin. Stearic 
acid  is  found  in  argan  oil,  the  world’s  most  expensive  oil,  at  a 
concentration of 4 to 7 percent.1

Stearic  acid  is  a  naturally  occurring  fatty  acid  found  in 
many natural and organic moisturizers and soaps.

 CHEMISTRY

Personal Care Category: 

Cleanser, moisturizer

Recommended for the following Baumann Skin 
Types: 

DRNT,  DRNW,  DRPT,  DRPW,  DSNT,  DSNW,  DSPT, 
and DSPW or any skin types with allergic type sensitive 
skin (S4)

 SOURCE

Stearic  acid,  a  waxlike  saturated  fatty  acid  also  known  as 
octadecanoic acid, is an important naturally occurring component 
of  stratum  corneum  (SC)  lipids.  Besides  being  synthesized  by 
human beings, stearic acid is also found in butter, cocoa butter, 
shea  butter,  vegetable  fats,  and  animal  tallow.  It  is  found  in 
many  oils  but  the  highest  concentrations  are  in  cocoa  butter 
(chocolate), butter, and shea butter. The nonanimal-derived oil 
with  one  of  the  highest  amounts  of  stearic  acid  is  argan  oil, 
which  has  a  concentration  of  4  to  7  percent.1  Stearic  acid  is 
found in all cosmetic product categories including soaps, syndet 
bars, body oils, moisturizers, color cosmetics, and perfumes.

 HISTORY

Stearic  acid  is  one  of  the  most  common  fatty  acids  found  in 
nature. It is one of the oldest cosmetic ingredients because it is 
a component of vegetable and animal oils that have been used 
on the skin for centuries. Historically it has not been used as a 
singular  ingredient,  but  is  found  as  a  component  of  many 
popular ingredients such as cocoa butter and various oils.

Stearic  acid  is  a  saturated  long-chain  fatty  acid  with  the 
chemical  formula  CH3(CH2)16CO2H  (see  Figure  23-1).  The 
International  Union  of  Pure  and  Applied  Chemistry  (IUPAC) 
name is octadecanoic acid. It is also known as cetylacetic acid 
and stearophanic acid.

Stearic acid is the saturated form of oleic acid, a monounsatu-
rated  ω-9  fatty  acid  (see  Figure 23-2).  While  stearic  acid  helps 
improve the skin’s barrier function, oleic acid impairs it.

 ORAL USES

Stearic  acid  can  be  safely  taken  as  an  ingredient  in  dietary 
supplements;  however,  it  is  the  most  poorly  absorbed  of  the 
fatty acids.2

Stearic acid gives food a desirable taste and texture. It makes up 
about 9 to 12 percent of total calories in beef, pork, lamb, and veal 
and about 6 percent of calories in poultry. Although it is a satu-
rated fatty acid, it may be associated with fewer health risks than 
other saturated fatty acids in the diet. Studies in humans and ani-
mals suggest that it has a neutral effect on plasma cholesterol lev-
els in contrast to lauric, myristic, and palmitic acids.3 Stearic acid 
makes up about 2 to 4 percent of calories in most cooking oils.4

 TOPICAL USES

As a Food and Drug Administration (FDA)-approved ingredient 
in several cosmetic products, it is used as a surfactant and emul-
sifying agent, for fragrance, and as the base for other fatty acid 
ingredients that are synthesized into emollients and lubricants 
(Table  23-1).  Specifically,  it  is  used  most  often  to  retain  the 
shape  of,  and  as  a  thickener  in,  soaps  (indirectly,  through 
saponification of triglycerides composed of stearic acid esters) 
as well as in shampoos, shaving creams, and detergents. 

H H H H H H H H H H H H H H H H H

O

H

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C O H

▶

FIGURE 23-1  Stearic acid is a saturated fatty acid with an 18-carbon chain.

H H H H H H H H H H H H H H H H H

 
C H A P T E R  23  ■   S T E A R I C   AC I D  

71

H H H H H H H H H H H H H H H H H

O

H

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C

C O H

▶

FIGURE 23-2  Oleic acid is an unsaturated fatty acid with an 18-carbon chain.

H H H H H H H H

H H H H H H H

Con
Oral use is controversial because saturated 
fatty acids increase risk of heart disease, 
although this has been shown not to be 
the case with stearic acid. Thus, this 
issue is a source of confusion.

TABLE 23-1
Pros and Cons of Stearic Acid

Pros
Effective as an emulsifier and surfactant

Use in cleansers allows deposition on the 

skin even after rinsing

Found in inexpensive products such as cocoa 

butter

Repairs skin barrier when used in combina-

tion with ceramide and cholesterol
More stable than unsaturated fatty acids

 SAFETY ISSUES

Stearic acid is approved by the FDA for use in topical skin care 
formulations  and  is  generally  considered  safe.  Evaluation  by 
the Cosmetic Ingredient Review (CIR) showed no phototoxic-
ity,  minimal  to  no  skin  irritation,  no  tumorigenicity,  and  no 
comedogenicity. Stearic acid was labeled as “safe” by the CIR.

 ENVIRONMENTAL IMPACT

Stearic acid is found abundantly in animals and plants, more so in 
the fat of animals. Individuals concerned about harming animals 
are advised to delve more deeply into the origins of the stearic acid 
used in products that they might consider. A significant environ-
mental impact is not exerted in culling and processing stearic acid.

ingredients,  docosanol  or  stearic  acid,  were  associated  with 
antiviral  and  anti-inflammatory  activity.  Burns  were  engen-
dered by painting murine abdomens with a chloroform solution 
of phenol. Researchers then topically applied the test formula-
tions  0.5,  3,  and  6  hours  after  injury.  They  found  that  the 
docosanol-  and  stearic  acid-containing  creams  significantly 
lessened the severity and progression of skin lesions compared 
to  untreated  sites,  yielding,  respectively,  76  and  57  percent 
declines in mean lesion scores.6 

In  2001,  Fluhr  et  al.,  in  a  study  of  the  effects  of  the  free 
fatty  acid  pool  on  SC  acidification  and  function,  topically 
applied two phospholipase inhibitors, bromphenacylbromide 
and 1-hexadecyl-3-trifluoroethylglycero-sn-2-phosphomethanol, 
for  three  days  to  murine  skin.  This  raised  skin  pH  and 
yielded  permeability  barrier  abnormality,  altered  SC  integ-
rity,  and  reduced  SC  cohesion.  All  malfunctions  were 
normalized,  including  SC  pH,  with  the  coapplication  of 
either  palmitic,  stearic,  or  linoleic  acids  along  with  the 
inhibiting agents.7 

In 2010, Mukherjee et al. evaluated a recently-marketed mild 
moisturizing  body  wash,  with  stearic  acid  and  emollient 
soybean  oil,  to  determine  the  location  and  amount  of  stearic 
acid deposited in the SC after in vivo usage of the product. They 
conducted clinical cleansing studies using the soybean product 
or  petroleum  jelly.  The  deuterated  variant  of  stearic  acid 
replaced the free stearic acid in the soybean formulation. The 
investigators  detected  deuterated  stearic  acid 
in  all  
10  consecutive  layers  of  SC,  with  a  total  stearic  acid  level 
measured at 0.33 μg/cm² after five washes with the soybean oil 
product.  They  concluded  that  the  estimated  total  fatty  acid 
delivered  to  the  skin  from  cleansing,  probably  incorporated 
into the SC lipid phase, is comparable to the fatty acid level in 
an SC layer.8

 FORMULATION CONSIDERATIONS

 CONCLUSION

Stearic  acid  is  used  to  thicken  and  stabilize  formulations.  Its 
high  amount  of  saturation  makes  it  more  solid  at  room  tem-
perature and gives it a waxy consistency. The acid can be neu-
tralized  with  triethanolamine  and  other  alkalis  to  form  soap 
(sodium stearate), which acts as an emulsifier.5

 USAGE CONSIDERATIONS

Saturated fats such as stearic acid are more stable than unsatu-
rated  fatty  acids.  This  is  important  because  oxygen  and  heat 
can  degrade  fatty  acids,  rendering  them  rancid.  Combination 
with antioxidants can slow the degradation process. Notably, 
stearic acid may decrease penetration of other ingredients by 
strengthening the skin barrier.

Stearic  acid  is  an  important  component  in  stratum  corneum 
lipids, but it is rarely used alone. Therefore, there is a paucity 
of research to consider its individual attributes. Most studies 
use  stearic  acid-containing  substances,  such  as  argan  oil  or 
shea  butter,  that  are  not  purely  stearic  acid  so  other  compo-
nents also play a role in the results seen. Although it is difficult 
to tease out the individual role of stearic acid, it seems certain 
that its presence affects skin penetration and barrier function 
and  is  a  superior  moisturizing  ingredient  when  combined  in 
the proper ratio with cholesterol and ceramides (see Chapter 19, 
Barrier  Repair  Ingredients).  Much  more  research  is  necessary, 
then, to determine just how significant stearic acid is as a thera-
peutic agent.

REFERENCES

 SIGNIFICANT BACKGROUND

In 2000, Khalil et al. studied the effects of cream formulations 
on chemically-induced burns in mice based on reports that the 

1.  Guillaume D, Charrouf Z. Argan oil. Monograph. Altern Med Rev. 

2011;16:275.

2.  Cosmetic Ingredient Review. Final Report on the Safety Assessment of 
Oleic Acid, Lauric Acid, Palmitic Acid, Myristic Acid, and Stearic Acid.  

 
72 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

 J  Am  Col  Toxicol.  1987;6:321.  http://www.cir-safety.org/sites/default 
/files/115_draft_steary_suppl3.pdf. Accessed November 14, 2012.
3.  Monsma CC, Ney DM. Interrelationship of stearic acid content 
and  triacylglycerol  composition  of  lard,  beef  tallow  and  cocoa 
butter in rats. Lipids. 1993;28:539.

4.  Beef  Facts:  Nutrition,  Stearic  Acid—A  Unique  Saturated  Fat. 
Website: www.beefnutrition.org. Accessed November 14, 2012.
5.  Website:  http://www.lotioncrafter.com/stearic-acid-nf.html. 

Accessed November 14, 2012.

6.  Khalil  MH,  Marcelletti  JF,  Katz  LR,  et  al.  Topical  application  of 
docosanol- or stearic acid-containing creams reduces severity of 
phenol burn wounds in mice. Contact Dermatitis. 2000;43:79.

7.  Fluhr JW, Kao J, Jain M, et al. Generation of free fatty acids from 
phospholipids regulates stratum corneum acidification and integ-
rity. J Invest Dermatol. 2001;117:44.

8.  Mukherjee  S,  Edmunds  M,  Lei  X,  et  al.  Stearic  acid  delivery  to 
corneum from a mild and moisturizing cleanser. J Cosmet Dermatol. 
2010;9:202.

 
C H A P T E R   2 4

Humectants

C H A P T E R  24  ■   H U M E C TA N T S  

73

Humectants  are  water-soluble  materials  with  high  water 
absorption  capabilities.  They  are  hygroscopic  and  therefore 
able  to  attract  water  from  the  atmosphere  (if  atmospheric 
humidity is greater than 80 percent) and from the underlying 
epidermis.  Although  humectants  may  draw  water  from  the 
environment to help hydrate the skin, in low-humidity condi-
tions  they  may  take  water  from  the  deeper  epidermis  and 
dermis,  resulting  in  increased  skin  dryness.1  For  this  reason, 
they work better when combined with occlusives. Humectants 
are also popular additives to cosmetic moisturizers for many 
reasons.  They  prevent  product  evaporation  and  thickening, 
which  increases  the  shelf  life  of  formulations,  and  some 
humectants  help  prevent  bacterial  growth  in  products.2 
Humectants can cause an almost immediate improvement in 
skin texture because they draw water into the skin, causing a 
slight  swelling  of  the  stratum  corneum  (SC)  that  gives  the 
perception of smoother skin with fewer wrinkles. Humectants, 
by  inducing  swelling,  can  temporarily  give  the  user  the  per-
ception  of  increased  skin  firmness.  Humectants  have  been 
shown  to  enhance  the  penetration  of  other  ingredients  by 

causing swelling of keratinocytes,3 and disruption of the skin 
barrier  by  loosening  the  closely  packed  SC  cells.4  Propylene 
glycol enhances penetration of minoxidil and steroids,5 while 
hyaluronic acid increases drug delivery in prescription medica-
tions  such  as  Diclofenac.4  Examples  of  commonly  used 
humectants  include  glycerin,  sorbitol,  sodium  hyaluronate 
(hyaluronic  acid),  urea,  propylene  glycol,  α-hydroxy  acids, 
and sugars.

REFERENCES

1.  Idson  B.  Dry  skin:  moisturizing  and  emolliency.  Cosmet  Toiletr. 

1992;107:69.

2.  Mitsui T, ed. New Cosmetic Science. New York: Elsevier; 1997:134.
3.  Warner  RR,  Stone  KJ,  Boissy  YL.  Hydration  disrupts  human 
stratum corneum ultrastructure. J Invest Dermatol. 2003;120:275.
4.  Brown MB, Jones SA. Hyaluronic acid: A unique topical vehicle 
for the localized delivery of drugs to the skin. J Eur Acad Dermatol 
Venereol. 2005;19:308.

5.  Hannuksela M. Glycols. In: Loden M, Maibach H. eds. Dry Skin 

and Moisturizers. Boca Raton: CRC Press; 2000:413–415.

 
74  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   2 5

Glycerin

Activities:

Anti-inflammatory, barrier recovery

Important Chemical Components:

Simple polyol with three hydroxyl groups derived from 
triglycerides

Origin Classification:

Glycerin  is  a  natural  ingredient  and  organic  forms  are 
available.  Synthetic,  laboratory-made  forms  are  also 
used.

Personal Care Category: 

Humectant, moisturizer

Recommended  for  the  following  Baumann  Skin 
Types:

Is a superior choice for dry skin types but is appropriate 
for all 16 types (DRNT, DRNW, DRPT, DRPW, DSNT, 
DSNW,  DSPT,  DSPW,  ORNT,  ORNW,  ORPT,  ORPW, 
OSPT, OSPW, OSNT, and OSNW).

 SOURCE

Glycerol  provides  the  molecular  skeleton  of  all  animal  and 
vegetable fats known as triglycerides. It is derived from the saponi-
fication of fats. Throughout this chapter, the terms “glycerol” and 
“glycerin” (also spelled as glycerine and referred to more often in 
the literature as glycerol) will be used interchangeably; glycerin is 
the designation most familiar to consumers (and the one used here 
more  often  in  relation  to  topical  products).  Glycerol  is  a  potent, 
nonvolatile trihydroxylated humectant. When the body consumes 
fat stores (triglycerides) to produce energy, glycerol and fatty acids 
are released into the bloodstream. The glycerol component is con-
verted  to  glucose  in  the  liver,  thus  providing  energy  for  cellular 
metabolism. Natural glycerol is obtained hydrolytically from fats 
and oils during soap and fatty acid manufacturing, and by transes-
terification (an interchange of fatty acid groups with another alco-
hol)  during  the  production  of  biodiesel  fuel.1  Synthetic  glycerol 
refers to material obtained from nontriglyceride sources.

Glycerin exhibits hygroscopic ability very similar to that 
associated with natural moisturizing factor (NMF).2 NMF is 
found within keratinocytes in the stratum corneum (SC) and 
is composed of amino acids, lactate, urea, citrate, and sugars. 
It  can  absorb  large  quantities  of  water  (i.e.,  hygroscopic) 
even  when  humidity  levels  are  low.  This  allows  the  SC  to 
maintain  a  sufficient  hydration  level  even  in  dry  environ-
ments. Numerous ingredients have been used in moisturiz-
ing  products  to  mimic  NMF  activity;  glycerin  is  one  of  the 
primary ones.

The  topical  application  of  glycerin  is  considered  a  useful 
component  in  treatment  regimens  for  various  cutaneous 

conditions,  including  bedsores,  bites,  burns,  calluses,  cuts, 
rashes and, occasionally, psoriasis. It is well known to protect 
against cutaneous irritation.

 HISTORY

The name glycerol is derived from the Greek word glyko, mean-
ing ‘‘sweet.’’ Carl Wilhelm Scheele discovered glycerol in 1779. 
Since then it has been included and used widely in topical skin 
cosmetics,  with  approximately  160,000  tons  of  glycerol  sold 
annually  in  the  United  States  alone.3,4  Glycerol  is  one  of  the 
most versatile and valuable chemical substances known and is 
considered the most effective humectant ingredient in the per-
sonal care industry ( Table 25-1).5,6 It has long been used as an 
active  as  well  as  excipient  ingredient  in  skin  care  products. 
Procter and Gamble (P&G) started producing glycerin around 
1858,  about  the  time  they  started  producing  consumer  prod-
ucts. Today, P&G Chemicals is one of the largest manufactur-
ers of glycerin in the world.

 CHEMISTRY

Glycerol contains three hydrophilic alcoholic hydroxyl groups, 
which are responsible for its solubility in water and its hygro-
scopic nature (Figure 25-1). It is a highly flexible molecule form-
ing both intra- and intermolecular hydrogen bonds. There are 
126 possible conformers of glycerol.7

TABLE 25-1
Pros and Cons of Glycerin

Pros
Contributes to barrier repair
One of the most effective humectant 

ingredients

Useful in prolonging product shelf life
Inexpensive
Nonallergenic
Transverses aquaporin-3 channels
Helps skin retain water for over 24 hours

Cons
May feel sticky
Individuals with oily skin may object to 

the feel of the product

More data needed

H

H 1

C

OH

H

OH

HO

H

C

2

C

3

H

▶

FIGURE 25-1  Glycerol has three hydroxyl groups.

 
 ORAL USES

Glycerin has been shown to display some antibacterial proper-
ties and is useful in treating halitosis. It is commonly used as an 
artificial sweetener. Its oral use has no known role in skin care.

 TOPICAL USES

Glycerin,  which  helps  condition  the  skin,  is  the  most  widely 
used hydrating agent and, consequently, a common ingredient 
in  skin  cleansers,  creams,  and  lotions.  In  addition  to  its  well-
established hygroscopic activity and solubility similar to water, 
glycerin is characterized by the ability to prevent freezing and 
prolong the shelf life of a product.3 Glycerin is one of the best 
moisturizing  ingredients  because  of  its  strong  humectant 
(hygroscopic)  properties.  It  is  often  combined  with  occlusive 
agents to impart a synergistic improvement in dry skin disor-
ders.6,8 Glycerin may also play a role in increasing desquama-
tion  because  it  facilitates  corneocyte  maturation  by  spurring 
the activity of residual transglutaminase in the SC.6,9

In addition to its humectant properties, glycerol is a unique 
ingredient because it is able to transverse between keratinocytes 
via aquaporin-3 (AQP-3) channels, which allows the movement 
from cell to cell10 (see Chapter 29, Aquaporin).

 SAFETY ISSUES

Glycerin has a long track record of safety with no risk of aller-
gic reactions. Some Internet sites state that glycerin will dry out 
the skin; however, this occurs when it is used in a dry environ-
ment  without  an  occlusive  ingredient,  a  setting  in  which  the 
glycerin pulls water fom the skin. When glycerin is formulated 
properly it gives the skin sustained moisturization.11

 ENVIRONMENTAL IMPACT

The  synthesis  of  glyercin  poses  no  environmental  risk.  It  is 
naturally occurring in plants and animals.

 FORMULATION CONSIDERATIONS

Glycerin  is  soluble  in  water.  Its  versatility  makes  it  easy  to 
formulate.

 USAGE CONSIDERATIONS

Glycerin can be used in conjunction with other ingredients. It is 
known to enhance the skin barrier but has also been shown to 
enhance skin penetration of some other ingredients.12

 SIGNIFICANT BACKGROUND

In Vitro Studies
Xerosis, or dry skin, is associated with incomplete desmosome 
degradation. In a 1995 in vitro study of moisturizers facilitating 
the process of desmosome digestion, investigators observed via 
electron  microscopy  that  desmosomes  treated  with  glycerol 
were  in  more  advanced  stages  of  degradation  than  control 
tissue. In two other in vitro models evaluated by the same team, 
glycerol  raised  the  corneocyte  loss  rate  from  the  superficial 

C H A P T E R  25  ■   G LYC E R I N  

75

surface of human skin biopsies and significantly lowered inter-
corneocyte forces.13 Since then, it has been established that by 
inducing activity of residual transglutaminase in the SC, glycerol 
accelerates  corneocyte  maturation.6,9  In  addition,  glycerol 
diminishes xerotic scaling by contributing to desmosome diges-
tion and then enhancing desquamation.6,13 These studies show 
that glycerol can function as an aid to skin exfoliation.

Animal Studies
In a 2003 study in which mice deficient in the epidermal water/
glycerol transporter AQP-3 exhibited diminished SC hydration and 
skin elasticity, as well as poor barrier recovery after SC removal, 
investigators showed that glycerol replacement ameliorated each 
defect in AQP-3-null mice. Notably, SC water content, which was 
measured as threefold lower in AQP-3-null mice than wild-type 
mice, was restored via topical or systemic glycerol administration, 
but administration of glycerol-like osmolytes (e.g., xylitol, erythri-
tol, and propanediol) was unsuccessful. In addition to concluding 
that glycerol is an important determinant of SC water retention, 
investigators suggested that their data provide a strong scientific 
foundation  for  the  centuries-old  practice  of  including  glycerol  in 
skin  formulations  for  medicinal  as  well  as  cosmetic  purposes.4 
Further, the authors noted that when added to SC lipids  in vitro, 
glycerol is thought to combine with lipid lamellae and foster water 
absorption and hinder the conversion of lipid lamellar structures 
from liquid to solid crystal, thereby inhibiting or preventing water 
loss.4,14 This hypothesis, the data from this study, and the fact that 
in three days pure glycerol absorbs its own weight in water,15 led 
the  authors  to  speculate  that  glycerol  likely  improves  SC  water 
absorption and retention.4

Also in 2003, a study of asebia mice with profound sebaceous 
gland hypoplasia revealed that the topical application of glycerol, 
which, endogenously, is believed to be the result of triglyceride 
hydrolysis  in  sebaceous  glands,  restored  normal  SC  hydration 
whereas  the  endogenous  humectant  urea  did  not.  Further,  the 
investigators showed that glycerol from triglycerides in sebaceous 
glands contributes significantly to SC hydration.16

Human Studies
In a five-year study in which two high-glycerin moisturizers were 
compared to 16 other popular moisturizers in 394 patients with 
severe xerosis, the high-glycerin products were found to perform 
better  than  all  other  products  tested  throughout  the  period  by 
more  rapidly  restoring  normal  hydration  and  preventing  the 
resumption of dryness for a longer period, longer even than petro-
latum.17 According to ultrastructural analysis of skin treated with 
high-glycerin formulations, glycerin expands the space between 
layers  of  corneocytes  and  the  thickness  of  corneocytes,  which 
results in the expansion of the SC.18 These findings indicate that 
glycerin gives the skin the capacity to hold a reservoir of moisture 
that renders it more resistant to drying. In addition, glycerin stabi-
lizes and fluidizes cell membranes as well as hydrates enzymes 
required for desmosome degradation.17

In 1999, Fluhr et al. conducted two studies to examine the 
capacity  of  glycerol  as  a  barrier  stabilizer  and  moisturizing 
compound.  In  the  first  study,  barrier  repair  was  found  to  be 
more rapid in glycerol-treated sites; significant differences were 
noted  three  days  after  treatment  between  glycerol  open  vs. 
untreated and glycerol occluded vs. untreated, and SC hydra-
tion  was  superior  in  the  glycerol  plus  occlusion  sites.  In  the 
second  study,  barrier  repair  was  again  more  rapid  in  areas 
treated  by  glycerol,  with  significant  differences  compared  to 
untreated and base-treated areas at day 7, and after three days 

 
76 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

of  treatment,  SC  hydration  was  superior  in  areas  treated  by 
glycerol. The authors concluded that glycerol promotes barrier 
repair, notably after acute exogenous disturbance, and enhances 
SC hydration.2

In  a  study  on  dermatologic  vehicles  and  their  effect  on  the 
horny  layer,  investigators  found  that  adding  glycerol  to  oil- 
in-water  (O/W)  emulsions  eliminated  the  barrier-damaging 
effect of such formulations. Glycerol added to O/W emulsions 
also  decreased  horny  layer  damage  in  stress  tests  with  wash 
solutions. O/W emulsions that contain glycerol are also appropriate 
in atopic dermatitis therapy.19

In  2005,  investigators  found  that  endogenous  glycerol  from 
circulation into the epidermis via AQP-3 and from triglyceride 
hydrolysis in sebaceous glands is associated with SC hydration 
in  humans.  Indeed,  they  observed  glycerol  from  both  sources 
forms a water reservoir that affects such hydration. The authors 
also noted that other findings in their study support the use of 
therapeutic moisturizers that contain glycerol.20

Also, in 2008, a small pilot study with nine healthy women 
supported the “proof of concept” that hydrolyzed jojoba esters 
combined with glycerol produces an additive effect, enhancing 
moisturization for at least 24 hours.21

In  a  2010  study  of  the  effects  of  glycerol  on  human  skin 
impaired  by  acute  irritation  induced  by  sodium  lauryl  sulfate 
(SLS),  Atrux-Tallau  et  al.  found  that  glycerol  seems  to  serve 
the same function as natural moisturizing factors eliminated by 
the detergent action of SLS. This leads to improving skin hydration. 
The investigators concluded that the inclusion of glycerol in topi-
cal formulations intended to treat irritated skin is warranted.22

 CONCLUSION

Glycerin is an important ingredient in skin care products, cos-
metics, and cosmeceuticals because of its efficacy, safety, low 
cost,  long  history  of  use,  and  pervasiveness  in  the  skin  care 
product  market.  Recent  research  has  indicated  that  glycerin 
displays several mechanisms of action and its efficacy depends 
on the choice of vehicle and emulsifying agent.

REFERENCES

1.  Pagliaro M, Ross M. The future of glycerol: New uses of a versatile raw 
material  (RSC  Green  Chemistry  Series).  London:  Royal  Society  of 
Chemistry; 2008:10.

2.  Fluhr  JW,  Gloor  M,  Lehmann  L,  et  al.  Glycerol  accelerates 
recovery  of  barrier  function  in  vivo.  Acta  Derm  Venereol. 
1999;79:418.

3.  Thau  P.  Glycerin  (glycerol):  Current  insights  into  the  functional 
properties  of  a  classic  cosmetic  raw  material.  J  Cosmet  Sci. 
2002;53:229.

4.  Hara  M,  Verkman  AS.  Glycerol  replacement  corrects  defective 
skin  hydration,  elasticity,  and  barrier  function  in  aquaporin-
3-deficient mice. Proc Natl Acad Sci U S A. 2003;100:7360.

5.  Bonnardeaux J. Glycerin Overview, report for the Western Australia 
Department  of  Agriculture  and  Food,  Novemeber  2006.  http://
www.agric.wa.gov.au/content/sust/biofuel/glycerinoverview.pdf. 
Accessed July 5, 2013.

6.  Kraft JN, Lynde CW. Moisturizers: What they are and a practical 

approach to product selection. Skin Therapy Lett. 2005;10:1.

7.  Callam CS, Singer Sj, Lowary TL, et al. Computational analysis of 
the  potential  energy  surfaces  of  glycerol  in  thegas  and  aqueous 
phases:  Effects  of  level  of  theory,  basis  set,  and  solvation  on 
strongly intramolecularly hydrogen-bonded systems. J Am Chem 
Soc. 2001;123:11743.

8.  Summers  RS,  Summers  B,  Chandar  P,  et  al.  The  effect  of  lipids 
with and without humectant on skin xerosis. J Soc Cosmet Chem. 
1996;47:39.

9.  Harding  CR,  Long  S,  Richardson  J,  et  al.  The  cornified  cell 
envelope: An important marker of stratum corneum maturation 
in healthy and dry skin. Int J Cosmet Sci. 2003;25:157.

10.  Hara M, Ma T, Verkman AS. Selectively reduced glycerol in skin 
of  aquaporin-3-deficient  mice  may  account  for  impaired  skin 
hydration,  elasticity,  and  barrier  recovery.  J  Biol  Chem. 
2002;277:46616.

11.  Lodén  M,  Wessman  W.  The  influence  of  a  cream  containing  
20% glycerin and its vehicle on skin barrier properties. Int J Cosmet 
Sci. 2001;23:115.

12.  Bettinger J, Gloor M, Peter C, et al. Opposing effects of glycerol 
on the protective function of the horny layer against irritants and 
on the penetration of hexyl nicotinate. Dermatology. 1998;197:18.
13.  Rawlings A, Harding C, Watkinson A, et al. The effect of glycerol 
and  humidity  on  desmosome  degradation  in  stratum  corneum. 
Arch Dermatol Res. 1995;287:457.

14.  Froebe CL, Simion FA, Ohlmeyer H, et al. Prevention of stratum 
corneum lipid phase transitions in vitro by glycerol: An alternative 
mechanism for skin moisturization. J Soc Cosmet Chem. 1990;41:51.
15.  Rieger  MM,  Deem  DE.  Skin  moisturizers  II.  The  effects  of 
cosmetic  ingredients  on  human  stratum  corneum.  J  Soc  Cosmet 
Chem. 1974;25:253.

16.  Fluhr  JW,  Mao-Qiang  M,  Brown  BE,  et  al.  Glycerol  regulates 
stratum corneum hydration in sebaceous gland deficient (asebia) 
mice. J Invest Dermatol. 2003;120:728.

17.  Orth D, Appa Y. Glycerine: A natural ingredient for moisturizing 
skin. In: Loden M, Maibach H, eds. Dry Skin and Moisturizers. Boca 
Raton, FL: CRC Press; 2000:217.

18.  Orth D, Appa Y, Contard E, et al. Effect of high glycerin therapeutic 
moisturizers on the ultrastructure of the stratum corneum. Poster 
presentation at the 53rd annual meeting of the American Academy 
of Dermatology, New Orleans, LA, February 1995.

19.  Gloor  M.  How  do  dermatological  vehicles  influence  the  horny 

layer? Skin Pharmacol Physiol. 2004;17:267.

20.  Choi  EH,  Man  MQ,  Wang  F,  et  al.  Is  endogenous  glycerol  a 
determinant  of  stratum  corneum  hydration  in  humans?  J  Invest 
Dermatol. 2005;125:288.

21.  Meyer  J,  Marshall  B,  Gacula  M  Jr,  et  al.  Evaluation  of  additive 
effects  of  hydrolyzed  jojoba  (Simmondsia  chinensis)  esters  and 
glycerol: A preliminary study. J Cosmet Dermatol. 2008;7:268.
22.  Atrux-Tallau N, Romagny C, Padois K, et al. Effects of glycerol on 
human skin damaged by acute sodium lauryl sulphate treatment. 
Arch Dermatol Res. 2010;302:435.

 
C H A P T E R   2 6

Hyaluronic Acid

C H A P T E R  26  ■   H Y A LU R O N I C   AC I D 

77

Activities: 

Humectant, antiaging

Important Chemical Components:

Hyaluronic acid (HA) is formed by repeating units of the 
disaccharides  D-glucuronic 
and  D-N-
acetylglucosamine,  which  are  linked  to  each  other  by 
alternating β-1,4 and β-1,3 glycosidic bonds. HA is com-
posed  of  carbon,  hydrogen,  nitrogen,  and  oxygen 
(molecular formula: C14H21NO11). See Figure 26-1.

acid 

Origin Classification:

HA  is  isolated  from  bacterial  or  yeast  cultures,  so  it  is 
considered natural but laboratory made. It is not consid-
ered organic.

Personal Care Category: 

Humectant, moisturizer

Recommended for the following Baumann Skin 
Types:

DRNT,  DRNW,  DRPT,  DRPW,  DSNT,  DSNW,  DSPT, 
and DSPW, but only if used in a humid environment or 
with  an  occlusive  ingredient.  ORNW,  ORPW,  OSNW, 
and OSPW in any environment.

–

CO2

H

CH2OH

H

O

HO

O

H

H

HO

O

O

H

H

O

H

H

OH

H

O

C

H

NH

CH3

FIGURE  26-1  Hyaluronic  acid  is  composed  of  repeating  dimers  of 

▶
glucuronic acid and N-acetyl glucosamine assembled into long chains.

 SOURCE

Hyaluronic  acid  (HA),  or  hyaluronan,  is  the  most  abundant 
glycosaminoglycan (GAG) found in the human dermis (Table 26-1). 
GAGs  are  polysaccharide  chains  made  up  of  repeating  disac-
charide  units  linked  to  a  core  protein.  Together  the  GAGs  

TABLE 26-1
Pros and Cons of Hyaluronic Acid

Pros
Strong humectant
Nonimmunogenic
Forms reservoirs in the epidermis
May effect cytokines
Enhances drug delivery
Various biological/medical applications

Cons
Penetration into skin depends on size
Does not penetrate into the dermis
High consumer recognition
Dehydrates skin in a dry environment

(HA, dermatan sulfate, heparin, heparin sulfate, keratin sulfate, 
chondroitin-4,  and  chondroitin-6-sulfate)  and  attached  core 
proteins form proteoglycans. The only nonsulfated GAG and 
the only one not synthesized on a core protein, HA is produced 
by an enzyme complex of the plasma membrane.1 In addition, 
HA  is  a  hygroscopic  sugar  that  can  bind  over  1,000  times  its 
weight in water. It is responsible for giving skin its plumpness 
and volume. HA is made by fibroblasts and broken down by 
the enzyme hyaluronidase. 

The HA used in skin care products and injectables was origi-
nally harvested from rooster combs but now most HA in skin 
care products is derived from a bacterial origin and produced in 
the laboratory setting. The molecular weight of the HA varies 
according to its source and chain length. The HA isolation pro-
cess can be adjusted to determine its corresponding molecular 
weight, altering its physiochemical properties. 

Uncrosslinked chains of HA in the skin are broken down by 
hyaluronidase and free radicals in approximately 24 to 36 hours. 
Chemical  modifications,  such  as  crosslinking  HA  chains  with 
1,4-butanediol diglycidyl ether (BDDE), can increase the amount 
of time that HA resides in the skin. Dermal fillers such as Restylane 
are crosslinked with BDDE so that the HA lasts in the skin for six 
or more months; however, these crosslinked HA chains are too 
large  to  penetrate  into  the  skin  and  must  be  injected.2  Topical 
forms of HA must have a small enough molecular weight to pass 
into the skin, thus obviating the use of crosslinked HA.

 HISTORY

HA  was  discovered  in  bovine  vitreous  humor  by  Meyer  and 
Palmer in 1934.3 It was named based on its glassy appearance 
(the Greek word for glass is hyalos) and the presence of a sugar 
known as uronic acid. HA, which appears freely in the dermis 
and is more concentrated in areas where cells are less densely 
packed,  is  an  important  dermal  component  responsible  for 
attracting water and giving the dermis its volume. The popular-
ity of HA fillers for injection into the dermis to correct wrinkles 
emerged in the 1990s and available products now include the 
Juvéderm line, Belotero, Restylane, Perlane, and Voluma. HA is 
also  a  popular  ingredient  in  cosmetic  products  because  of  its 
humectant  activity.  However,  traditionally,  the  HA  found  in 
many  moisturizers,  because  of  its  large  size,  could  not  pene-
trate the epidermis and enter the dermis when topically applied, 
despite the claims of manufacturers.4 Conflicting reports claim 
that  smaller  sizes  of  HA  may  penetrate  into  the  epidermis 
when used in the proper formulations. In the author’s knowl-
edge, there are no published studies demonstrating the pene-
tration of topical HA into the dermis.

 CHEMISTRY

HA is a linear, naturally occurring polyanionic polysaccharide that 
consists  of  repeating  disaccharide  units  of  N-acetyl- 
D-glucosamine  and  β-glucuronic  acid  (D-glucuronate).5,6 

 
78 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Present  in  most  biologic  fluids  and  tissues  (notably,  most 
vertebrate  connective  tissue),  it  is  most  abundant,  and  an 
important  component,  in  the  extracellular  matrix  of  soft 
connective tissues, particularly skin, where it plays a protec-
tive,  shock-absorbing  role.5,6  Although  it  can  be  derived 
from humans, animals, or bacterial cultures, the structure of 
HA is identical among all of these species. HA exhibits key 
functions  in  cell  growth  and  signaling,  membrane  receptor 
function,  and  adhesion,  as  well  as  wound  repair  and 
regeneration,  morphogenesis,  matrix  organization,  and 
pathobiology.6 In young skin, HA is present at the periphery 
of collagen and elastin fibers and where these fibers interface. 
Such  connections  with  HA  are  absent  in  aged  skin.7  
In  addition,  HA  appears  to  play  a  role  in  keratinocyte 
differentiation  and  lamellar  body  formation  through  its 
interaction with CD44,8 a cell surface glycoprotein receptor 
with  HA  binding  sites.9–11  It  is  also  thought  to  foster 
neutrophil migration, fibroblast proliferation, and neoangio-
genesis.12 In 2000, Sakai et al. used high performance liquid 
chromatography to show that HA is delivered by keratino-
cytes and is present in the normal stratum corneum (SC) of 
mice. Further, they speculated that HA contributes to mois-
turizing the SC and/or regulating its mechanical properties.13

 SAFETY ISSUES

Studies that considered HA for drug delivery have shown that 
it can facilitate drug penetration into the epidermis and prevent 
it from entering the dermis as well as the blood stream.5

 ENVIRONMENTAL IMPACT

No  significant  environmental  impact  is  likely  due  to  the 
production of topical HA products.

 FORMULATION CONSIDERATIONS

Although HA is a very important skin component, its topical 
utility is thwarted by its large size and inability to pass into the 
dermis. However, if the proper size of HA is used, it can pene-
trate into the epidermis causing a rapid, if short-lived, improve-
ment  of  fine  lines  through  its  effects  on  skin  hydration.  It  is 
important  to  realize  that  the  process  of  isolating  and  chemi-
cally  processing  HA  greatly  impacts  its  biological  activity  so 
that “not all HA is created equal.”

 ORAL USES

HA  is  available  in  oral  supplement  form,  but  the  stomach 
breaks it down rendering it worthless to the skin when taken in 
an  oral  form.  Glucosamine  supplements,  however,  may  help 
skin increase its production of HA.

 USAGE CONSIDERATIONS

HA can enhance drug penetration, an important consideration 
when designing a skin care regimen and designating the order 
in  which  products  will  be  applied.  For  example,  applying  a 
retinol  after  using  a  product  with  HA  could  theoretically 
increase absorption of retinol.17

 TOPICAL USES

HA is the main ingredient in the barrier repair products Bionect 
and  Hylatopic  to  impart  water  retention.  Bionect  contains  
0.2 percent HA sodium salt, which acts as a humectant, with 
other  humectant  ingredients  (e.g.,  glycerin)  and  a  70  percent 
sorbitol solution. Hylatopic combines HA sodium salt with the 
humectant glycerin in a foam preparation along with occlusive 
ingredients such as dimethicone and petrolatum.14 Notably, the 
Food and Drug Administration (FDA) has approved the barrier 
repair  products  Atopiclair  and  Hylatopic,  in  which  HA  is  the 
main  ingredient.14  Topical  medications  such  as  3  percent 
Diclofenac have HA as an additive in the formulation.5

The  humectant  properties  of  HA  allow  it  to  bind  
1,000 times its weight in water. Topical use of HA has been 
shown  to  improve  skin  hydration.15  It  functions  as  a  skin-
hydrating  agent  best  when  used  in  a  humid  environment.  
In a dry environment, it can draw water from the skin into 
the  HA,  thus  dehydrating  the  skin.  For  this  reason,  HA 
should be used in combination with an occlusive ingredient 
in a dry environment. Individuals with oily skin types have 
sufficient  sebum  to  impart  occlusive  properties.  Therefore, 
those with oily skin types can use HA in any environment 
but people with dry skin should not use it in a dry environ-
ment  unless  the  HA  is  combined  with  an  occlusive  agent. 
Applying  HA  to  the  skin  in  a  humid  environment  attracts 
water to the skin and can result in immediate improvement 
of wrinkles. The effect is lessened in a low-humidity envi-
ronment  because  there  is  less  water  in  the  atmosphere  to 
draw  to  the  skin.  In  one  study,  subjects  saw  improvement 
within minutes after using a face product with HA.16

 SIGNIFICANT BACKGROUND

HA, in large part due to its viscoelastic nature, biocompatibility, 
and nonimmunogenicity, is included in multiple clinical applica-
tions, including as an oral supplement and injectable to increase 
HA in synovial fluid in arthritic patients, an eye aid after cataract 
surgery, a wound-healing agent, a filling agent in cosmetic and 
soft tissue surgery, a device in various surgical procedures, and in 
tissue engineering.5,6 Topically it has become a popular additive 
in skin care products with claims ranging from decreasing eye 
puffiness to smoothing wrinkles and firming skin.

Wound Healing
In a small prospective study of 27 patients delivering by cesarean 
section  and  20  patients  delivering  vaginally  with  episiotomy, 
researchers assessed the effects of an HA sodium salt (Bionect) in  
15 subjects from the cesarean group and 10 from the episiotomy 
group (with standard wound care applied to the remaining patients) 
and  found  that  daily  application  of  the  HA  treatment  yielded  a 
lower incidence of edema, infiltration, and wound exudates com-
pared to standard treatment. One case of wound dehiscence in each 
standard treatment group occurred, but none in the HA groups.12

In  a  recent  60-day,  double-blind,  randomized,  controlled 
superiority trial intended to examine the efficacy and safety of 
a  gauze  pad  containing  HA  in  local  treatment  of  venous  leg 
ulcers  in  89  patients,  Humbert  et  al.  found  that  ulcer  surface 
was diminished significantly in the HA group compared to the 
neutral control group at day 45. In addition, at days 45 and 60, 
the number of healed ulcers was significantly higher in the HA 
treatment  group.  Notably,  pain  intensity  was  significantly 
lower in the HA group at day 30.18

 
Topical Antiaging Activity
In 2011, Pavicic et al. studied the efficacy of topically applied 
0.1 percent HA formulations of various molecular weights (50, 
130,  300,  800,  and  2,000  kDa)  in  the  periocular  area  to  treat 
wrinkles in 76 randomized females ranging in age from 30 to 60 
years.  Subjects  applied  one  of  the  preparations  twice  daily 
around one eye and a vehicle control cream around the other 
eye.  Investigators  measured  skin  hydration  and  elasticity  at 
baseline  as  well  as  30  and  60  days  posttreatment.  They 
observed significant improvement in skin hydration and elas-
ticity in association with all of the HA-based creams in com-
parison  to  placebo.  Wrinkle  depth  measurements  indicated 
significant  improvement  in  the  periocular  areas  treated  with  
50 and 130 kDA HA as compared to areas treated with placebo. 
The  researchers  concluded  that  lower  molecular  weight  HA 
formulations  were  linked  to  greater  wrinkle  depth  reduction 
due  likely  to  deeper  penetration  capacity.15  This  study  con-
trolled  room  humidity  at  50  percent  during  wrinkle  assess-
ment, which is an important aspect to consider when using HA 
for antiaging.

Anti-inflammatory Activity
In 2012, Schlesinger et al. conducted, in an outpatient setting, a 
small  prospective,  observational,  nonblinded  safety  and  effi-
cacy study of a topical anti-inflammatory formulation contain-
ing low-molecular weight HA (HA sodium salt gel 0.2 percent) 
to treat facial seborrheic dermatitis in 15 subjects ranging in age 
from 18 to 75 years. The hypothesis was that low-molecular 
weight HA would have an anti-inflammatory effect because of 
its  actions  on  the  immune  system  and  cytokine  formation.19 
Although  immune  system  effects  and  cytokines  were  not 
measured  in  this  study,  interim  data  for  seven  of  the  
15  patients  showed  that  HA  treatment  resulted  in  improve-
ment of all measured endpoints, including erythema, pruritus, 
and scaliness.20 This is the only published study looking at the 
use of HA in inflammatory skin disorders. Most of the litera-
ture on this topic is in the treatment of osteoarthritis.

Combination Therapy
HA  has  been  shown  to  be  effective  in  several  combination 
products.  In  2010,  Guevara  et  al.  evaluated  the  safety  and 
efficacy  of  a  new  cream  for  treating  melasma  that  contains 
hydroquinone,  glycolic  acid,  and  HA.  In  this  small,  open, 
uncontrolled  12-week  study,  15  Latin  American  women 
applied the formulation to both sides of their face twice daily. 
Fourteen  of  the  patients  improved,  with  a  significant  reduc-
tion  in  melasma  area  and  severity  index  (MASI)  scores  of  
64 percent. After eight weeks of treatment, 53 percent of the 
subjects needed to use a moisturizer. Most reported adverse 
events were mild.21

In 2011, Cordero et al. conducted a three-month, open, mul-
ticentered, international study of 1,462 subjects to evaluate a 
cream combining retinaldehyde and HA fragments for treating 
photoaging. Participants were instructed to daily apply either 
retinaldehyde 0.05 percent-HA fragments 0.5 percent (Eluage® 
cream),  retinaldehyde  0.05  percent-HA  fragments  1  percent 
(Eluage®  antiwrinkle  concentrate)  or  both  products. 
Dermatologists  evaluated  photoaging  severity  at  baseline  as 
well  as  days  30  and  90  using  Larnier’s  scale.  Significant 
improvement was observed by the investigators, with reduc-
tion in Larnier scores in all three groups. Wrinkles (i.e., on the 
forehead,  nasolabial  folds,  crow’s  feet,  and  perioral)  were 

C H A P T E R  26  ■   H YA LU R O N I C   AC I D  

79

significantly ameliorated in subjects using Eluage antiwrinkle 
concentrate as well as both formulations. Both products were 
well  tolerated  by  subjects  and  clinical  signs  of  photoaging 
diminished  significantly  in  the  Eluage  cream  and  the  group 
using both products in terms of elasticity, hyperpigmentation, 
and ptosis.22

In  2011,  Frankel  et  al.  conducted  a  bilateral  comparison 
investigation of pimecrolimus cream 1 percent and a ceramide-
HA  emollient  foam  for  the  treatment  of  mild-to-moderate 
atopic dermatitis, and reported that both products displayed 
efficacy.  After  four  weeks  of  treatment,  82  percent  of  target 
lesions  treated  with  the  ceramide-HA  foam  were  scored 
“clear”  or  “almost  clear”  compared  to  71  percent  of  lesions 
treated with pimecrolimus.23

Later that year, Gazzabin et al. evaluated a spray product com-
bining  colloidal  silver  and  HA  in  54  patients,  30  with  chronic 
wounds and 24 with superficial traumatic wounds. Patients were 
instructed to apply treatments at intervals of three to seven days 
based  on  lesion  traits.  Investigators  found  that  chronic  lesions 
healed by week 12 (70 percent closure rate at six weeks) and trau-
matic wounds healed at six weeks (80 percent substantial closure 
at three weeks). They also noted satisfactory microbial contamina-
tion control in treated ulcers and concluded that the HA and silver 
combination spray was effective in spurring re-epithelialization of 
superficial cutaneous wounds of various origins.24

In  2012,  Joksimovic  et  al.  conducted  a  small  double-blind, 
placebo-controlled clinical trial with 36 hemorrhoid patients to 
assess the efficacy and tolerability of a gel medical device con-
taining HA, tea tree oil, and methyl-sulfonyl-methane. Findings 
from the 14-day treatment regimen showed statistically signifi-
cant  reductions  in  all  symptoms  as  compared  to  placebo.  The 
HA-containing gel was also found to be safe and tolerable in this 
small sample.25 HA is also being used in combination with an 
iodine complex to achieve measurable clinical benefits in various 
wound types.26

 CONCLUSION

HA is a ubiquitous and versatile component of the extracel-
lular matrix and a key constituent of the dermis, contributing 
significantly  to  skin  hydration,  skin  volume,  and  a  youthful 
appearance. HA is known to diminish as one ages. Aside from 
its role in popular dermal filling agents, HA has also been used 
in exogenous topical products as a moisturizing agent. Its util-
ity  in  a  topical  formulation  is  determined  by  several  factors 
including the ambient humidity, the molecular weight of the 
HA, and what chemical alterations have been made to the HA 
molecule.  Topically  delivered  HA  may  not  be  able  to  pene-
trate into the skin at all due to its large size. If it does pene-
trate,  it  remains  localized  in  the  epidermis  forming  reser-
voirs,27 and does not penetrate into the dermis. This makes it 
a popular ingredient to enhance drug delivery to the epider-
mis but impairs its ability to add volume to a photoaged der-
mis like an injectable form of HA would do. For this reason, 
much of the marketing of HA in skin care products is mislead-
ing. Topically delivered HA should be considered as a humec-
tant skin moisturizer when used in a normal or humid envi-
ronment. Any antiaging properties it demonstrates would be 
based on skin hydration alone and the effects are temporary. 
Injectable  HA  is  a  different  topical  agent  altogether  and  is 
covered thoroughly in Chapter 2, Basic Science of the Dermis 
in  Cosmetic  Dermatology:  Principles  and  Practice,  2nd  ed. 
(McGraw-Hill, 2009).

 
80 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

REFERENCES

1.  Uitto J, Chu M, Gallo R, et al. Collagen, elastic fibers, and extra-
cellular matrix of the dermis. In: Wolff K, Goldsmith L, Katz S, 
Gilchrest  B,  Paller  A,  Leffell  D,  eds.  Fitzpatrick’s  Dermatology  in 
General Medicine. 7th ed. New York: McGraw-Hill; 2008:539.
2.  Baumann L, Saghari S. Basic science of the dermis. In: Baumann L, 
Saghari  S,  Weisberg  E,  eds.  Cosmetic  Dermatology:  Principles  and 
Practice. 2nd ed. New York: McGraw-Hill; 2009:11.

3.  Meyer K, Palmer JW. The polysaccharide of the vitreous humor.  

 J Biol Chem. 1934;107:629.

4.  Rieger M. Hyaluronic acid in cosmetics. Cosm Toiletr. 1998;113:35.
5.  Brown MB, Jones SA. Hyaluronic acid: A unique topical vehicle 
for the localized delivery of drugs to the skin. J Eur Acad Dermatol 
Venereol. 2005;19:308.

6.  Volpi N, Schiller J, Stern R, et al. Role, metabolism, chemical modifi-
cations and applications of hyaluronan. Curr Med Chem. 2009;16:1718.
7.  Ghersetich I, Lotti T, Campanile G, et al. Hyaluronic acid in cuta-

neous intrinsic aging. Int J Dermatol. 1994;33:119.

8.  Bourguignon  LY,  Ramez  M,  Gilad  E,  et  al.  Hyaluronan-CD44 
interaction stimulates keratinocyte differentiation, lamellar body 
formation/secretion,  and  permeability  barrier  homeostasis.  
 J Invest Dermatol. 2006;126:1356.

9.  Aruffo A, Stamenkovic I, Melnick M, et al. CD44 is the principal 

cell surface receptor for hyaluronate. Cell. 1990;61:1303.

10.  Culty M, Miyake K, Kincade PW, et al. Thy hyaluronate receptor 
is  a  member  of  the  CD44  (H-CAM)  family  of  cell  surface 
glycoproteins. J Cell Biol. 1990;111:2765.

11.  Underhill C. CD44: the hyaluronan receptor. J Cell Sci. 1992;103:293.
12.  Ivanov C, Mochova M, Russeva R, et al. Clinical application of 
Bionect (Hyaluronic Acid Sodium Salt) in wound care by cesarean 
section and episiotomy. Akush Ginekol (Sofia). 2007;46:20.

13.  Sakai S, Yasuda R, Sayo T, et al. Hyaluronan exists in the normal 

stratum corneum. J Invest Dermatol. 2000;114:1184.

14.  Draelos ZD. New treatments for restoring impaired epidermal barrier 

permeability: skin barrier repair creams. Clin Dermatol. 2012;30:345.

15.  Pavicic  T,  Gauglitz  GG,  Lersch  P,  et  al.  Efficacy  of  cream-based 
novel  formulations  of  hyaluronic  acid  of  different  molecular 
weights in anti-wrinkle treatment. J Drugs Dermatol. 2011;10:990.
16.  Trookman NS, Rizer RL, Ford R, et al. Immediate and long-term 
clinical  benefits  of  a  topical  treatment  for  facial  lines  and  wrin-
kles. J Clin Aesthet Dermatol. 2009;2:38.

17.  Jenning V, Gysler A, Schäfer-Korting M, et al. Vitamin A loaded 
solid  lipid  nanoparticles  for  topical  use:  Occlusive  properties 
and  drug  targeting  to  the  upper  skin.  Eur  J  Pharm  Biopharm. 
2000;49:211.

18.  Humbert P, Mikosinki J, Benchikhi H, et al. Efficacy and safety of 
a gauze pad containing hyaluronic acid in treatment of leg ulcers 
of venous or mixed origin: a double-blind, randomised, controlled 
trial. Int Wound J. 2013;10:159.

19.  Wang CT, Lin YT, Chiang BL, et al. High molecular weight hyalu-
ronic acid down-regulates the gene expression of osteoarthritis-
associated cytokines and enzymes in fibroblast-like synoviocytes 
from  patients  with  early  osteoarthritis.  Osteoarthritis  Cartilage. 
2006;14:1237.

20.  Schlesinger T, Rowland Powell C. Efficacy and safety of a low-
molecular weight hyaluronic acid topical gel in the treatment of 
facial seborrheic dermatitis. J Clin Aesthet Dermatol. 2012;5:20.
21.  Guevara IL, Werlinger KD, Pandya AG. Tolerability and efficacy 
of  a  novel  formulation  in  the  treatment  of  melasma.  J  Drugs 
Dermatol. 2010;9:215.

22.  Cordero  A,  Leon-Dorantes  G,  Pons-Guiraud  A,  et  al. 
Retinaldehyde/hyaluronic  acid  fragments:  a  synergistic  associa-
tion  for  the  management  of  skin  aging.  J  Cosmet  Dermatol. 
2011;10:110.

23.  Frankel A, Sohn A, Patel RV, et al. Bilateral comparison study of 
pimecrolimus  cream  1%  and  a  ceramide-hyaluronic  acid  emol-
lient  foam  in  the  treatment  of  patients  with  atopic  dermatitis.  
 J Drugs Dermatol. 2011;10:666.

24.  Gazzabin L, Bucalossi M, Mariani F, et al. Spray formulation of 
silver and hyaluronic acid in the treatment of superficial cutaneous 
ulcers of different etiopathogenesis: Analysis of fifty-four clinical 
cases. Panminerva Med. 2011;53:185.

25.  Joksimovic  N,  Spasovski  G,  Joksimovic  V,  et  al.  Efficacy  and 
tolerability  of  hyaluronic  acid,  tea  tree  oil  and  methyl-sulfonyl-
methane  in  a  new  gel  medical  device  for  treatment  of 
haemorrhoids in a double-blind, placebo-controlled clinical trial. 
Updates Surg. 2012;64:195.

26.  Cutting KF. Wound healing through synergy of hyaluronan and 

an iodine complex. J Wound Care. 2011;20:424.

27.  Brown MB, Ingham S, Moore A, et al. A preliminary study of the 
effect  of  hyaluronan  in  drug  delivery.  In:  Willoughby  DA,  ed. 
Hyaluronan in Drug Delivery. London: Royal Society of Medicine 
Press; 1995:48–52.

 
C H A P T E R  27  ■   V I TA M I N   B 5  ( PA N TOT H E N I C   AC I D / D E X PA N T H E N O L )  

81

C H A P T E R   2 7

Vitamin B5 (Pantothenic Acid/Dexpanthenol)

Activities:

Hydration, barrier protection, reduction of transepider-
mal  water  loss  (TEWL),  fibroblast  stimulation,  re-
epithelialization.

Important Chemical Components:

Pantothenic  acid  (C9H17O5N):  chemically  known  as 
3-[(2,4-Dihydroxy-3,3-dimethylbutanoyl)  amino]  pro-
panoic acid
Dexpanthenol  (D-panthenol):  chemically  known  as 
(+)-2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylb-
utyramide

Origin Classification:

Pantothenic  acid  is  natural  and  found  throughout  the 
plant and animal kingdoms. Dexpanthenol is synthetic 
and, therefore, not considered organic or natural.

Personal Care Category:

Humectant, emollient, anti-inflammatory

Recommended for the following Baumann Skin 
Types:

DRNT,  DRNW,  DRPT,  DRPW,  DSNT,  DSNW,  DSPT, 
and DSPW

 CHEMISTRY

Not found naturally, synthetic dexpanthenol is converted to PA 
in  the  skin,  stimulating  skin  regeneration  in  a  fashion 
comparable  to  vitamin  A.  This  process  of  cell  division  and 
formation  of  new  skin  tissue  restores  skin  elasticity  and 
promotes  wound  healing.  In  fact,  both  in  vitro  and  in  vivo, 
dexpanthenol  has  been  shown  to  promote  fibroblast 
proliferation.1 Therefore, water-soluble dexpanthenol has been 
used topically to foster wound healing. Formulations containing 
dexpanthenol  have  exhibited  a  capacity  to  stimulate 
epithelialization  and  granulation  while 
imparting  an 
antipruritic,  anti-inflammatory  effect  on  experimental 
ultraviolet-induced  erythema.1  In  an  early  study,  treatment 
with dexpanthenol over a three- to four-week period resulted 
in significant improvement in skin-irritation symptoms such as 
xerosis,  pruritus,  erythema,  roughness,  scaling,  and  fissures.1 
Several  other  benefits  to  the  skin  have  been  associated  with 
provitamin  B5.  In  a  randomized,  double-blind,  placebo-
controlled  study,  treatment  with  topical  dexpanthenol  over  a 
seven-day period resulted in enhanced stratum corneum (SC) 
hydration and decreased TEWL.3

Dexpanthenol is used in a wide range of cosmetic products, 
typically  to  moisturize  the  skin,  and  formulated  in  some 
intramuscular  and  intravenous  products.  Topically  applied 
provitamin  B5  also  acts  to  prevent  TEWL  while  moisturizing 
the skin. It is well tolerated and poses minimal risk of irritation 
or sensitivity.

 SOURCE

 ORAL USES

Present in all living cells, pantothenic acid is a precursor for 
the production of acetyl coenzyme A, an essential substrate 
for acetylcholine synthesis. Pantothenic acid, or vitamin B5, 
belongs to the water-soluble B vitamin family and is also an 
essential ingredient in the enzymes necessary for metaboliz-
ing carbohydrates and fats. Proper growth and development 
depends  partly  on  this  vitamin  as  does  the  maintenance  of 
normal epithelial function, including skin regrowth.1 Among 
the best sources of pantothenic acid (PA) are fish, beef, whole 
grains, dairy, eggs, mushrooms, peanuts and other legumes, 
cashews, broccoli, soybeans, and avocados, but most whole 
foods contain some PA. In fact, deficiency of PA is virtually 
unknown because of its broad availability in food sources.

 HISTORY

The  word  “pantothenic”  is  derived  from  the  Greed  word 
pantos  (“everywhere”),  suggesting  the  omnipresence  of  the 
vitamin  in  the  plant  and  animal  world.  Dexpanthenol  
(provitamin  B5)  is  the  stable  alcohol  form  of  pantothenic 
acid.  It  is  popular  and  well  regarded  in  the  treatment  of 
various skin conditions.2

Vitamin B5 is available in various foods. Dexpanthenol can also 
be taken orally, and is metabolized into pantothenic acid.

 TOPICAL USES

Topical  dexpanthenol  is  well  established  as  an  effective 
moisturizer, enhancing SC hydration and decreasing TEWL in 
healthy  skin,  protecting  against  irritation  as  a  pretreatment, 
and facilitating wound healing (Table 27-1).1

TABLE 27-1
Pros and Cons of Vitamin B5

Pros
Found in many products

Decent data demonstrate healing, anti-
inflammatory, and hydrating activity

Safe 

Cons
Should not be combined or layered with 
oil-containing vehicles because pene-
tration is decreased

No organic forms

 
82  

C o s m eC e u t i C a l s   a n d   Co s m e t i C   i n g r e d i e n t s

Human Studies
Proksch  and  Nissen,  in  2002,  conducted  a  study  with  
20  subjects  (12  women,  8  men)  to  identify  the  effects  of  a 
dexpanthenol-containing  cream,  applied  twice  daily,  on  skin 
barrier repair, SC hydration, skin roughness, and inflammation 
after  irritation  induced  by  sodium  lauryl  sulfate  (SLS).  The 
investigators  found  that  the  dexpanthenol-containing  cream 
significantly increased the pace of skin barrier repair compared 
with  placebo  or  untreated  skin.  SC  hydration  was  enhanced 
and skin roughness reduced by both the dexpanthenol cream 
and  placebo,  but  significantly  more  by  the  cream  containing 
dexpanthenol.  The  test  cream  also  significantly  diminished 
erythema, whereas the placebo had no impact on skin redness.4 
A different study in 2002, a prospective, randomized, double-
blind trial, demonstrated that the prophylactic and consistent 
use  of  an  emollient  containing  dexpanthenol  ameliorated  the 
effects of radiation dermatitis, though it was less effective than 
topical corticosteroid (0.1 percent methylprednisolone).5

In 2003, Biro et al. conducted a prospective, randomized, double-
blind,  placebo-controlled  study  of  25  healthy  volunteers  (21  of 
whom completed the trial) to study the efficacy of dexpanthenol in 
protecting against skin irritation. For 26 days, the patients (between 
18  and  45  years  old)  twice  daily  applied  either  Bepanthol 
Handbalsam containing 5 percent dexpanthenol or placebo to the 
inner part of both forearms. Twice daily from days 15 to 22, SLS  
2  percent  was  applied.  The  investigators  reported  that  intraindi-
vidual  comparisons  revealed  better  results  in  areas  treated  with 
dexpanthenol in 11 cases as compared to one placebo site. Irritant 
contact dermatitis was reported by six patients, with greater sever-
ity associated with the placebo site in five of the cases.2

In 2009, Radtke et al. conducted a prospective observational 
study  in  392  networked  pharmacies,  consecutively  recruiting 
1,886 patients with irritated skin to determine the patient-relevant 
benefit of dexpanthenol treatment. They found that 94.7 percent 
achieved  successful  results  and  all  symptoms  of  irritated  skin 
improved significantly independent of age, gender, and underly-
ing cutaneous disease.6

Dexpanthenol  is  firmly  established  enough  as  a  therapeutic 
option  for  irritant  dermatitis  and  cutaneous  inflammation  to 
have allowed Wolff and Kieser to use it as a comparison standard 
in an observational study to gauge the effectiveness of hamamelis 
(better  known  as  witch  hazel)  for  children  with  minor  skin 
disorders. They treated 309 children (231 with hamamelis and 
78  with  dexpanthenol)  and  found  statistically  significant 
improvements  in  both  groups,  with  both  products  equally 
effective and hamamelis slightly better tolerated.7

In 2011,Camargo et al. studied the skin moisturizing capacity 
of  formulations  including  0.5,  1.0,  or  5.0  percent  panthenol 
topically applied daily to the forearms of healthy subjects over 
15-  and  30-day  periods.  They  found  that  use  of  the  1.0  and  
5.0 percent formulations yielded significant reductions in TEWL 
after application for 30 days. To assess the immediate effects on 
TEWL  and  skin  moisture,  the  research  protocol  also  included 
using the formulations after skin washing with sodium laureth 
sulfate  (SLES).  The  investigators  noted  significant  TEWL 
decreases two hours after using the panthenol formulations in 
comparison to control and vehicle.8

Early  in  2012,  a  small  comparative  pilot  study,  completed  by  
26  children  (mean  age  7.19  years),  revealed  that  5  percent 
dexpanthenol  was  equally  effective  as  1  percent  hydrocortisone 
ointment in treating mild-to-moderate childhood atopic dermatitis.9
Also in 2012, Heise et al. set out to correlate in vitro findings of 
a  stimulatory  effect  rendered  by  pantothenate  on  migration, 

proliferation,  and  gene  regulation  in  cultured  human  dermal 
fibroblasts to the in vivo wound healing environment. Their clin-
ical  data  resulting  from  comparisons  of  dexpanthenol-treated 
skin  and  placebo-treated  skin  were  analyzed  at  the  molecular 
level and revealed that the provitamin B modulated gene expres-
sion  in  cutaneous  wound  healing  (upregulating  IL-6,  IL-1β, 
CYP1B1,  CXCL1,  CCL18  and  KAP  4-2  gene  expression  and 
downregulating psorasin mRNA and protein expression).10

Combination Therapy
Over  a  decade  ago,  dexpanthenol  was  used  effectively  in 
combination therapy with xylometazoline for the treatment of 
rhinitis.11 Dexpanthenol has also been shown, in combination 
with  zinc  oxide,  to  be  effective  in  treating  irritant  diaper 
dermatitis, as demonstrated in a prospective, block randomized, 
investigator-blinded study of 46 children.12

In 2008, Abdelatif et al. assessed the safety and effectiveness of 
an ointment combining royal jelly and panthenol (PEDYPHAR) in 
60 patients with limb-threatening diabetic foot infections. Patients 
were divided into three treatment groups, based on lesion sever-
ity. After irrigation and cleansing with normal saline, as well as 
surgical debridement if necessary, patients were treated with the 
combination ointment. Lesions were then covered with dressings 
and the patients were followed up for six months or until full heal-
ing, with clinical response checked at weeks 3, 9, and 24. By week 
9 and through the follow-up period, 96 percent of the patients in 
groups 1 and 2 [Group 1: full-thickness skin ulcer (Wagner grades 
1 and 2); group 2: deep tissue infection and suspected osteomyeli-
tis (Wagner grade 3)] were deemed to have been cured, with all 
ulcers  in  group  1  patients  healed  and  92  percent  among  group  
2 patients. Group 3 patients [gangrenous lesions (Wagner grades 4 
and 5)] healed after surgery, debridement, and conservative ther-
apy with PEDYPHAR. The investigators concluded that the oint-
ment appears promising but additional randomized, double-blind 
trials are necessary to bear this out.13

In a 2011 prospective open pilot trial conducted over 28 days, 
Castello  and  Milani  evaluated  the  effect  of  topically  applied  
10 percent Urea ISDIN® plus dexpanthenol lotion in the treatment 
of  xerosis  and  pruritus 
in  15  hemodialyzed  patients  
(12 women, 3 men, mean age 66 years). The results of twice-daily 
application  on  arms  and  legs  were  assessed  after  two  and  four 
weeks of treatment and measured against baseline scores for itch, 
scaling, roughness, redness, and cracks. Significant reductions were 
observed in all parameters through two, and especially four, weeks 
of treatment. One patient experienced a mild burning sensation, 
but the urea and dexpanthenol lotion was found to be effective in 
ameliorating xerosis and pruritus in hemodialysis patients.14

Further,  in  a  2011  study  using  Wistar  rats,  Guimarães  et  al. 
found  that  the  combination  of  ultrasound  and  dexpanthenol  
(10 percent) sped up the production and organization of collagen 
in the early phases of wound healing.15

 SAFETY ISSUES

Dexpanthenol  confers  soothing  effects  to  formulations  for  the 
treatment of sunburn and other types of burn. Topically applied 
dexpanthenol is considered safe, with minimal association with 
local skin reactions or sensitization. Products with a high concen-
tration of dexpanthenol may be contraindicated in people with 
hemophilia. Despite its frequency of use in topical products, con-
tact  allergy  is  rare.  There  is  one  report  of  one  case  of  allergic 
contact dermatitis to panthenol combined with cocamidopropyl 
PG dimonium chloride phosphate in a facial hydrating lotion.16

 
C H A P T E R  27  ■   V I TA M I N   B 5  ( PA N TOT H E N I C   AC I D / D E X PA N T H E N O L )  

83

 ENVIRONMENTAL IMPACT

There  is  no  measureable  environmental  impact  from  the 
vitamin  pantothenic  acid,  found  throughout  nature,  or  the 
synthetic dexpanthenol.

 FORMULATION CONSIDERATIONS

Water-in-oil  topical  emulsions  are  the  best  vehicle  to  deliver 
sufficient  skin  penetration  and  local  concentrations  of 
dexpanthenol.1

 USAGE CONSIDERATIONS

Pantothenic acid is not well absorbed into skin but dexpanthe-
nol is well absorbed through the skin and is rapidly converted 
to  pantothenic  acid.1  Absorption  into  skin  was  found  to  be 
reduced  when  dexpanthenol  is  combined  with  olive  oil, 
highlighting  the  relevance  of  the  vehicle.17  One  study  used  a 
perfused skin udder model and demonstrated that the rate and 
extent of penetration of dexpanthenol is much lower in an oil/
water formulation.18 Therefore, panthenol-containing formula-
tions should not be layered over oil-containing preparations if 
maximal dexpanthenol absorption is desired.

 SIGNIFICANT BACKGROUND

Dexpanthenol is included as an ingredient in various topical skin 
formulations and shampoos. In fact, this form of vitamin B5 has 
long  been  considered  an  effective  ingredient  in  cosmetic 
products.  The  foundation  for  the  use  of  dexpanthenol  in 
shampoo – and anecdotal reports that its use restores color to 
gray  hair  –  stems  from  a  study  several  years  ago  evaluating 
dexpanthenol deficiency in rats. Deficiency was correlated with 
hair  turning  gray  or  falling  out.  Pantothenic  acid  deficiency  in 
humans is exceedingly rare, though, and is not likely associated 
with hair changes in humans.19 Clearly, the etiologies of graying 
of hair and baldness are not related to this vitamin. Also, no oral 
or  topical  formulations  containing  pantothenic  acid  or 
dexpanthenol as the main active ingredient have been shown to 
prevent  gray  hair  or  balding  in  humans.  Nevertheless,  it  is 
believed that dexpanthenol penetrates well into the hair shaft, 
promotes luster and elasticity, and leaves the hair easier to comb.

 CONCLUSION

Dexpanthenol  is  a  versatile  compound  suitable  for  use  in 
treating  various  dermatoses  and  its  topical  application  is 
employed  broadly  in  clinical  practice  to  enhance  wound 
healing.  Few  controlled  clinical  trials  have  been  conducted 
evaluating  the  efficacy  of  topical  formulations  containing 
dexpanthenol  intended  for  skin  care.  Despite  a  dearth  of 
randomized, double-blind, case-controlled studies establishing 
the  efficacy  of  such  products,  current  data  warrant  further 
study  and  support  the  conclusion  that  dexpanthenol  as  an 
active ingredient at least confers some benefit as a humectant. 

There is an increasing body of anecdotal, empirical evidence also 
suggesting significant potential contributions by provitamin B5 
as an ingredient in topical formulations.

REFERENCES

1.  Ebner F, Heller A, Rippke F, et al. Topical use of dexpanthenol in 

skin disorders. Am J Clin Dermatol. 2002;3:427.

2.  Biro K, Thaçi D, Ochsendorf FR, et al. Efficacy of dexpanthenol in 
skin  protection  against  irritation:  A  double-blind,  placebo-
controlled study. Contact Dermatitis. 2003;49:80.

3.  Gehring W, Gloor M. Effect of topically applied dexpanthenol on 
epidermal  barrier  function  and  stratum  corneum  hydration. 
Results  of  a  human  in  vivo  study.  Arzneimittelforschung. 
2000;50:659.

4.  Proksch E, Nissen HP. Dexpanthenol enhances skin barrier repair 
and  reduces  inflammation  after  sodium  lauryl  sulphate-induced 
irritation. J Dermatolog Treat. 2002;13:173.

5.  Schmuth M, Wimmer MA, Hofer S, et al. Topical corticosteroid 
therapy  for  acute  radiation  dermatitis:  A  prospective,  rand-
omized, double-blind study. Br J Dermatol. 2002;146:983.

6.  Radtke  MA,  Lee-Seifert  C,  Rustenbach  SJ,  et  al.  Efficacy  and 
patient benefit of treatment of irritated skin with ointments con-
taining  dexpanthenol:  Health  services  research  (observational 
study) on self-medication in a pharmaceutical network. Hautarzt. 
2009;60:414.

7.  Wolff HH, Kieser M. Hamamelis in children with skin disorders 
and skin injuries: Results of an observational study. Eur J Pediatr. 
2007;166:943.

8.  Camargo FB Jr, Gaspar LR, Maia Campos PM. Skin moisturizing 
effects of panthenol-based formulations. J Cosmet Sci. 2011;62:361.
9.  Udompataikul M, Limpa-o-vart D. Comparative trial of 5% dex-
panthenol  in  water-in-oil  formulation  with  1%  hydrocortisone 
ointment in the treatment of childhood atopic dermatitis: a pilot 
study. J Drugs Dermatol. 2012;11:366.

10.  Heise R, Skazik C, Marquardt Y, et al. Dexpanthenol modulates 
gene  expression  in  skin  wound  healing  in  vivo.  Skin  Pharmacol 
Physiol. 2012;25:241.

11.  Kehrl  W,  Sonnemann  U.  Improving  wound  healing  after  nose 
surgery by combined administration of xylometazoline and dex-
panthenol. Laryngorhinootologie. 2000;79:151.

12.  Wananukul  S,  Limpongsanuruk  W,  Singalavanija  S,  et  al. 
Comparison of dexpanthenol and zinc oxide ointment with oint-
ment base in the treatment of irritant diaper dermatitis from diar-
rhea: a multicenter study. J Med Assoc Thai. 2006;89:1654.

13.  Abdelatif M, Yakoot M, Etmaan M. Safety and efficacy of a new 
honey ointment on diabetic foot ulcers: A prospective pilot study. 
J Wound Care. 2008;17:108.

14.  Castello M, Milani M. Efficacy of topical hydrating and emollient 
lotion containing 10% urea ISDIN® plus dexpanthenol (Ureadin 
Rx 10) in the treatment of skin xerosis and pruritus in hemodia-
lyzed  patients:  an  open  prospective  pilot  trial.  G  Ital  Dermatol 
Venerol. 2011;146:321.

15.  Guimarães GN, Pires-De-Campos MS, Leonardi GR, et al. Effect 
of ultrasound and dexpanthenol on collagen organization in tegu-
mentary lesions. Rev Bras Fisioter. 2011;15:227.

16.  Roberts H, Williams J, Tate B. Allergic contact dermatitis to pan-
thenol and cocomidopropyl PG dimonium chloride phosphate in 
a facial hydrating lotion. Contact Dermatitis. 2006;55:369.

17.  Stuettgen  G,  Krause  H.  Percutaneous  absorption  of  tritium-
labelled  panthenol  in  man  and  animal.  Arch  Klin  Exp  Dermatol. 
1960;209:578.

18.  Förster T, Pittermann W, Schmitt M, et al. Skin penetration prop-
erties  of  cosmetic  formulations  using  a  perfused  bovine  udder 
model. J Cosmet Sci. 1999;50:147.

19.  Plesofsky-Vig N. Pantothenic acid. In: Ziegler EE, Filer LJ Jr, eds. 
Present Knowledge in Nutrition. 7th ed. Washington, DC: ILSI Press; 
1996:210–211.

 
84 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   2 8

Urea

Activities:

Anti-inflammatory, hydrating, keratolytic

Important Chemical Components:

the  “urea  cycle”  was  identified  by  German  physician  Hans  
A. Krebs and his medical student Kurt Henseleit in 1932.2 Urea 
has  been  used  in  hand  creams  since  the  1940s.4  Thirty  years 
later, urea in 20 percent concentrations was found to be effec-
tive in treating pruritus.5

The chemical formula of urea (or carbamide) is CO(NH2)2. 
Its molecular formula is CH4N2O.

 CHEMISTRY

Origin Classification:

Urea is a natural organic compound.

Personal Care Category: 

Humectant, emollient

Recommended  for  the  following  Baumann  Skin 
Types: 

DRNT, DRNW, DRPT, and DRPW

 SOURCE

Urea,  the  primary  nitrogen-containing  substance  found  in 
mammalian  urine,  is  among  the  most  commonly  used 
humectant  ingredients,  along  with  glycerin,  sorbitol,  sodium 
hyaluronate,  propylene  glycol,  α-hydroxy  acids,  and  sugars 
(Table  28-1).  It  is  a  component  of  the  natural  moisturizing 
factor (NMF) and also exhibits a mild antipruritic effect.1 Urea 
in  high  concentrations  (e.g.,  40  percent)  is  effective  as  a 
hydrating and keratolytic agent in various cutaneous conditions 
including  xerosis,  psoriasis,  onychomycosis  and  other  nail 
disorders, ichthyosis, eczema, calluses, and corns.

 HISTORY

Urea was first discovered in the 1700s in Europe. Its discovery 
is  most  often  attributed  to  French  chemist  Hilaire  Rouelle’s 
work  in  1773,  though  Dutch  scientist  Herman  Boerhaave  is 
said to have first identified the compound as a major constitu-
ent  of  mammalian  urine  in  1727.2,3  German  physician  and 
chemist Friedrich Wöhler discovered, in 1828, that urea could 
be synthesized in vitro by combining the inorganic materials 
cyanic  acid  and  ammonium  without  using  any  organic  sub-
stances.2 This was the first credited laboratory synthesis of a 
naturally  occurring  organic  compound.2  Interestingly,  the 
chemical  synthesis  reported  by  Wöhler  is  not  the  chain  of 
events  that  occurs  in  the  mammalian  liver  to  produce  urea; 

TABLE 28-1
Pros and Cons of Urea

Pros
Strong humectant activity
Inexpensive
Easy to find brands that contain it

Cons
Occasional contact allergy
Mild odor

The urea molecule has two NH2 groups united with a carbonyl 
functional group. It acts as a physiological NMF.6

 ORAL USES

Oral urea is used for some medical indications and has a long 
history of traditional folk medicine use, but this mode of admin-
istration is not thought to have appreciable cutaneous benefits.

 TOPICAL USES

Twenty years ago, a double-blind, randomized comparison 
of  two  urea-containing  creams  revealed  that  3  and  10  per-
cent urea cream were equally effective in treating aspects of 
dry  skin,  particularly  increasing  hydration  and  decreasing 
scaling,  and  more  effective  than  the  vehicle  control. 
Transepidermal  water  loss  (TEWL)  was  unchanged  after 
treatment with the 3 percent urea cream, but the 10 percent 
urea  cream  reduced  TEWL.  Use  of  the  3  percent  cream 
resulted in a slightly golden tint to the skin color.7

In 1998, Jennings et al. conducted a double-blind, randomized 
paired comparison of the keratolytic effects of 5 percent salicylic 
acid  and  10  percent  urea  ointment  (Kerasal)  on  one  foot  and  
12  percent  ammonium  lactate  lotion  (Lac-Hydrin)  on  the  other 
foot  in  70  patients  with  mild-to-moderate  xerosis.  After  two 
weeks of treatment, 54 patients were evaluated, 39 of whom were 
evaluated after four weeks of treatment. There were no significant 
differences  in  the  treatment  arms,  but  after  four  weeks  of 
treatment, both yielded significant reductions in xerosis severity.8
Urea  in  high  concentrations  is  also  a  useful  adjuvant,  as  is 
salicylic acid, in the keratolytic phase of psoriasis treatment.9 In 
10  percent  creams,  urea  is  used  to  treat  ichthyosis  and 
hyperkeratotic  skin  conditions;10  in  lower  concentrations,  it  is 
employed to treat mild xerosis.6

In  2002,  Ademola  et  al.  conducted  a  randomized,  double-
blind, bilateral study with 25 women and men to compare the 
clinical effectiveness and tolerability of a 40 percent urea topical 
cream  (Carmol  40)  and  12  percent  ammonium  lactate  topical 
lotion (Lac-Hydrin 12 percent) used to treat moderate-to-severe 
xerosis.  Patients  were  assessed  at  baseline  as  well  as  two  and 
four  weeks  after  the  initiation  of  therapy.  Ratings  by  the  
18  patients  who  completed  the  study  as  well  as  investigators 
revealed that xerosis symptoms were reduced in less time in the 
urea  group.  Further,  instrumental  and  clinical  measurements 
showed that by day 14, 40 percent urea cream was associated 
with  less  skin  roughness,  fissures,  thickness,  and  dryness  than  
12 percent ammonium lactate lotion.11

 
In  2008,  Stebbins  et  al.  performed  a  single-blind  pilot  study 
with  12  trained  female  panelists  to  evaluate  the  acceptability 
(spreadability,  odor,  and  postapplication  residue)  of  six  40  to  
50  percent  urea  preparations.  They  compared  the  composite 
scores of the five older formulations with that of new emollient 
product,  and  found  that  the  novel  preparation  (U-Kera  E)  was 
the most cosmetically acceptable (most spreadable and left less 
residue). Odor scores were low overall and comparable among 
the six preparations. The investigators noted that while all urea-
based creams exhibited a detectable odor, it was usually fleeting 
and often such products are used in areas furthest from the nose 
(i.e., legs and feet).12

In 2010, Lodén et al. randomized 53 patients with successfully 
treated hand eczema to compare the time to relapse when using 
a barrier-strengthening urea (5 percent) preparation or receiving 
no  treatment.  They  observed  that  the  median  time  to  relapse 
was two days in the no treatment group and 20 days in the urea-
containing moisturizer group. At the time of relapse, there were 
no noted variations in severity. The investigators concluded that 
the  barrier-strengthening  moisturizer  containing  urea  success-
fully acted to extend the remission of controlled hand eczema.13

 SAFETY ISSUES

Cases of contact allergy from urea-containing products are rare. 
In  one  instance,  at  least,  the  reaction  may  have  been  due  to 
ingredients  other  than  urea.14  However,  urea  is  considered 
generally safe and nontoxic. Urea is contraindicated in neonates 
due to the risk of systemic absorption.15

 ENVIRONMENTAL IMPACT

Used widely in fertilizer as well as cosmetic products, urea is 
produced in copious amounts on an industrial scale from liquid 
ammonia and liquid carbon dioxide, with global production in 
2012 estimated at 184 million tons.16 The inclusion of urea in 
topical products, thus, certainly exerts some kind of impact on 
the environment, primarily in fuel transportation costs.

 FORMULATION CONSIDERATIONS

There are many different types of formulations using urea as 
discussed  in  this  chapter  that  are  beyond  the  scope  of  this 
book.  (Please  see  the  NWU  Institutional  Repository  website,  
http://dspace.nwu.ac.za/handle/10394/251, for more informa-
tion on urea product formulations.)

 USAGE CONSIDERATIONS

The combination of urea with hydrocortisone, retinoic acid, and 
other agents has been shown to enhance the penetration of these 
agents.17,18  Urea  has  also  been  combined  with  several  other 
compounds in recent years to achieve significant clinical effects.

 SIGNIFICANT BACKGROUND

In  2009,  Amichai  and  Gunwald  conducted  a  three-week 
randomized,  double-blind  study  with  36  males  and  females 
with mild-to-moderate atopic dermatitis, ranging in age from  
3 to 40 years, to ascertain the efficacy of liquid soap containing 
12 percent ammonium lactate and 20 percent urea. Investigator 
and patient assessment indicated that significant improvements 

C H A P T E R  28  ■   U R E A  

85

were  observed,  specifically  reductions  in  erythema,  scaling, 
and xerosis, in the active soap group (24 patients) compared to 
results in the 12-person control group.19

In 2010, Pardo Masferrer led a prospective observational study 
in 98 breast cancer patients to investigate the intensive use of a 
hydrating  lotion  containing  3  percent  urea,  polidocanol  and 
hyaluronic  acid  to  treat  and  mitigate  the  severity  of 
radiodermatitis.  The  investigators  monitored  patients  weekly 
for  skin  toxicity  and  compared  the  incidence  and  grade  of 
toxicity with a control sample from 174 breast cancer patients 
whose  skin  was  treated  at  radiotherapy  initiation  in  2006  or 
upon  the  emergence  of  radiodermatitis.  They  found  the 
incidence of radiodermatitis lower in the intensive use group. In 
addition,  intensive  use  of  the  combination  lotion  was  also 
associated with a lower grade of toxicity.20

The use of urea in combination with other ingredients in the 
Ureadin line of products has garnered recent attention. In 2011, 
Castello and Milani found, in a prospective open pilot trial with 
15 patients, that the twice-daily application of topical 10 percent 
urea  plus  dexpanthenol  (Ureadin  Rx  10)  significantly  reduced 
itching  scores  as  well  as  scores  along  the  SRRC  (scaling, 
roughness,  redness,  and  cracks)  Index,  indicating  that  the 
formulation was effective in treating xerosis and pruritus in such 
patients.21

Later that year, Tadini et al. studied the keratolytic and mois-
turizing  activity  of  Ureadin  Rx10  in  a  four-week  randomized, 
controlled,  single-blind,  two-center,  intra-patient  trial  with  30 
ichthyosis  vulgaris  patients  ranging 
in  age  between  
8  and  56  years.  In  a  right-vs.-left  study  design,  patients  were 
treated with 10 percent urea-based Ureadin Rx 10 lotion on one 
side  and  the  glycerol-based  emollient  cream  Dexeryl  on  the 
other side. Patients were assessed at baseline as well as two and 
four weeks after treatment initiation. Twenty-seven participants 
completed the study, in which the researchers found that both 
topical  formulations  were  clinically  effective  after  four  weeks 
and well tolerated. SRRC scores significantly fell from 9.5 to 3.3 
(65 percent decline) in association with Ureadin use and from 9.5 
to 5.7 (40 percent decline) in Dexeryl-treated areas. Mean global 
efficacy  scores  were  significantly  higher  in  areas  treated  with 
Ureadin  (8.9)  as  compared  to  Dexeryl  (7.3).  The  investigators 
concluded that Ureadin is a more effective option than Dexeryl 
for  reducing  the  hyperkeratosis  and  xerosis  associated  with 
ichthyosis, but larger sample sizes would be necessary in future 
research  to  establish  safety  and  tolerability  for  the  urea-based 
lotion in these patients.22

In  2012,  Federici  et  al.  conducted  a  28-day,  randomized, 
evaluator-blinded,  comparative  study  in  40  type  2  diabetics, 
aged 40 to 75 years, to assess the efficacy of a topical preparation 
containing urea 5 percent, arginine, and carnosine (Ureadin) as 
compared to the glycerol-based emollient Dexeryl. Twice-daily 
application  of  the  urea-based  product  resulted  in  significantly 
more  hydration  as  compared  to  the  glycerol-based  emollient. 
Visual Analogue Scores increased in both groups, but were sig-
nificantly  higher  in  the  Ureadin  group.  The  investigators  con-
cluded  that  the  urea/arginine/carnosine  cream  enhanced  skin 
hydration  while  lessening  xerosis  in  type  2  diabetic  patients 
more efficiently than the glycerol-based control formulation.23

Also  in  2012,  Emtestam  et  al.  led  a  24-week,  randomized, 
double-blind,  placebo-controlled  multicenter  study  of  
493 patients (n = 346; placebo = 147) to test the efficacy, safety, 
and tolerability of a novel topical preparation (K101) combining 
urea, propylene glycol, and lactic acid for treating distal subun-
gual  onychomycosis.  Patients  were  stratified  based  on  level  of 
nail involvement, with investigators finding that 27.2 percent of 

 
86 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

patients with ≤ 50 percent nail involvement treated with K101 
achieved the primary endpoint and 10.4 percent in the placebo 
group.  Among  the  patients  with  51  to  75  percent  nail 
involvement,  19.1  percent  achieved  the  primary  endpoint  as 
compared to 7.0 percent in the placebo group (not a significant 
difference).  The  investigators  noted  that  the  antifungal  topical 
preparation was safe and imparted clinically significant as well as 
visible nail improvements. Further, they noted that when applied 
in  concentrations  greater  than  20  percent,  urea  displays  nail-
dissolving  properties.24–26  Others  have  noted  a  concentration-
dependent keratolytic effect of softening and macerating the nail 
with 30 to 50 percent concentrations of urea.14

Ciammaichella et al. reported at the end of that year on a pilot 
registry study of the effects of twice-daily application of Ureadin 
for  four  weeks  in  diabetic  patients  with  microangiopathy  and 
mild-to-moderate xerosis of the foot. A reduction in skin breaks 
was associated with Ureadin treatment as compared to controls. 
Improvements  were  also  linked  to  Ureadin  use  along  various 
other  parameters  in  comparison  to  controls  (i.e.,  greater  skin 
thickness, favorable investigator global assessments and subject 
assessments, no new skin lesions vs. four lesions in the control 
group). The researchers concluded that given the good level of 
diabetes  control  prior  to  inclusion  in  the  study  and  no  such 
changes after four weeks, the improvements seen in the study 
could be attributed to the topical application of Ureadin and not 
to systemic diabetes management.27

 CONCLUSION

Urea has long been used in dermatology for its well-established 
activity  as  a  hydrating  and  moisturizing  agent.  It  remains  as 
one of the most effective humectant agents.

REFERENCES

1.  Kligman  AM.  Dermatologic  uses  of  urea.  Acta  Derm  Venereol. 

1957;37:155.

2.  Kinne-Saffran E, Kinne RK. Vitalism and synthesis of urea. From 
Friedrich Wöhler to Hans A. Krebs. Am J Nephrol. 1999;19:290.
3.  Kurzer F, Sanderson PM. Urea in the history of organic chemistry: 

Isolation from natural sources. J Chem Educ. 1956;33:452.

4.  Harding C, Bartolone J, Rawlings A. Effects of natural moisturiz-
ing factor and lactic acid isomers on skin function. In: Lodén M, 
Maibach H, eds. Dry Skin and Moisturizers. Boca Raton, FL: CRC 
Press; 2000:236.

5.  Swanbeck  G,  Rajka  G.  Antipruritic  effect  of  urea  solutions.  An 
experimental and clinical study. Acta Derm Venereol. 1970;50:225.
6.  Lodén M. The clinical benefit of moisturizers. J Eur Acad Dermatol 

Venereol. 2005;19:672.

7.  Serup  J.  A  double-blind  comparison  of  two  creams  containing 
urea  as  the  active  ingredient.  Assessment  of  efficacy  and  side-
effects by non-invasive techniques and a clinical scoring scheme. 
Acta Derm Venereol Suppl. 1992;177:34.

8.  Jennings MB, Alfieri D, Ward K, et al. Comparison of salicylic acid 
and urea versus ammonium lactate for the treatment of foot xerosis. 

A  randomized,  double-blind,  clinical  study.  J  Am  Podiatr  Med 
Assoc. 1998;88:332.

9.  Fluhr  JW,  Cavallotti  C,  Berardesca  E.  Emollients,  moisturizers, 
and keratolytic agents in psoriasis. Clin Dermatol. 2008;26:380.
10.  Rosten M. The treatment of ichthyosis and hyperkeratotic condi-

tions with urea. Australas J Dermatol. 1970;11:142.

11.  Ademola  J,  Frazier  C,  Kim  SJ,  et  al.  Clinical  evaluation  of  40% 
urea  and  12%  ammonium  lactate  in  the  treatment  of  xerosis.  
Am J Clin Dermatol. 2002;3(3):217.

12.  Stebbins  W,  Alexis  A,  Levitt  J.  Cosmetic  acceptability  of  six 
40–50% urea preparations: a single-blind, pilot study. Am J Clin 
Dermatol. 2008;9:319.

13.  Lodén  M,  Wirén  K,  Smerud  K,  et  al.  Treatment  with  a  barrier-
strengthening  moisturizer  prevents  relapse  of  hand-eczema.  An 
open,  randomized,  prospective,  parallel  group  study.  Acta  Derm 
Venereol. 2010;90:602.

14.  Piraccini  BM,  Alessandrini  A,  Bruni  F,  et  al.  Acute  periungueal 
dermatitis induced by application of urea-containing cream under 
occlusion. J Dermatol Case Rep. 2012;6:18.

15.  Oji V, Traupe H. Ichthyosis: Clinical manifestations and practical 

treatment options. Am J Clin Dermatol. 2009;10:351.

16.  Ceresana  Market  Intelligence  Consulting.  http://www.ceresana 
.com/en/market-studies/agriculture/urea/. Accessed June 9, 2013.
17.  Wohlrab W. The influence of urea on the penetration kinetics of 
topically applied corticosteroids. Acta Derm Venereol. 1984;64:233.
18.  Wohlrab W. Effect of urea on the penetration kinetics of vitamin 

A acid into human skin. Z Hautkr. 1990;65:803.

19.  Amichai B, Gunwald MH. A randomized, double-blind, placebo-
controlled  study  to  evaluate  the  efficacy  in  AD  of  liquid  soap 
containing 12% ammonium lactate + 20% urea. Clin Exp Dermatol. 
2009;34:e602.

20.  Pardo  Masferrer  J,  Murcia  Mejía  M,  Vidal  Fernández  M,  et  al. 
Prophylaxis with a cream containing urea reduces the incidence 
and  severity  of  radio-induced  dermatitis.  Clin  Transl  Oncol. 
2010;12:43.

21.  Castello M, Milani M. Efficacy of topical hydrating and emollient 
lotion containing 10% urea ISDIN® plus dexpanthenol (Ureadin 
Rx 10) in the treatment of skin xerosis and pruritus in hemodia-
lyzed  patients:  An  open  prospective  pilot  trial.  G  Ital  Dermatol 
Venereol. 2011;146:321.

22.  Tadini  G,  Giustini  S,  Milani  M.  Efficacy  of  topical  10%  urea-
based  lotion  in  patients  with  ichthyosis  vulgaris:  A  two-center, 
randomized, controlled, single-blind, right-vs.-left study in com-
parison with standard glycerol-based emollient cream. Curr Med 
Res Opin. 2011;27:2279.

23.  Federici A, Federici G, Milani M. An urea, arginine and carnosine 
based cream (Ureadin Rx Db ISDIN) shows greater efficacy in the 
treatment of severe xerosis of the feet in Type 2 diabetic patients 
in  comparison  with  glycerol-based  emollient  cream.  A  rand-
omized,  assessor-blinded,  controlled  trial.  BMC  Dermatol. 
2012;12:16.

24.  Emtestam L, Kaaman T, Rensfeldt K. Treatment of distal subun-
gual onychomycosis with a topical preparation of urea, propylene 
glycol  and  lactic  acid:  Results  of  a  24-week,  double-blind,  
placebo-controlled study. Mycoses. 2012;55:532.

25.  South DA, Farber EM. Urea ointment in the nonsurgical avulsion 

of nail dystrophies – A reappraisal. Cutis. 1980;25:609.

26.  Farber EM, South DA. Urea ointment in the nonsurgical avulsion 

of nail dystrophies. Cutis. 1978;22:689.

27.  Ciammaichella  G,  Belcaro  G,  Dugall  M,  et  al.  Product  evalua-
tion of Ureadin Rx Db (ISDIN) for prevention and treatment of 
mild-to-moderate  xerosis  of  the  foot  in  diabetic  patients. 
Prevention of skin lesions due to microangiopathy. Panminerva 
Med. 2012;54:35.

 
C H A P T E R   2 9

Aquaporin

C H A P T E R  29  ■   AQ U A P O R I N  

87

Aquaporins (AQPs) are integral membrane proteins that form a 
water  channel  and  facilitate  water  transport  in  various  organs 
such as the skin, renal tubules, eyes, the digestive tract, and the 
brain. In 2003, Peter Agre received the Nobel Prize in chemistry 
for discovering AQPs. There are 13 isoforms of AQPs found in 
mammals  classified  as  types  1  to  13.  Functionally,  they  can  be 
classified into two subtypes: AQPs 1, 2, 4, 5, and 8, which only 
transport  water,  and  AQPs  3,  7,  9,  and  10,  which  can  conduct 
other substances such as glycerol (also known as glycerin) or urea 
in addition to water.1 AQP-3 is the predominant water channel 
found in human epidermis, and is permeable to both water and 
glycerin.  For  years  scientists  have  known  that  glycerin  plays  a 
superior role in hydrating skin,2 but the reasons for this became 
more  clear  when  AQP-3  was  discovered.  Studies  have  shown 
that defects in AQP-3 in mice models result in epidermal dryness 
as  well  as  decreased  stratum  corneum  hydration  and  glycerin 
content  of  the  epidermis,  followed  by  reduced  elasticity  and 
impaired skin barrier recovery.3,4 Aquaporin facilitates the trans-
port of water, glycerin, and solutes between keratinocytes.

AQPs  are 

transmembrane  structures  arranged  as 
homotetramers  in  the  cell  membrane.  Each  subunit  of  the 
tetramer consists of six a -helical domains and contains a distinct 
aqueous  pore.  The  intricate  shape  and  the  transmembrane 
position  make  it  impossible  to  exogenously  add  aquaporin  to 
skin as the marketing claims of some cosmetic products imply. 
Ultraviolet light has been shown to diminish the expression of 
AQP-3, likely through MAP kinase pathways.5 Free radicals have 
also been demonstrated to decrease AQP-3 expression.5 This is 
one of the reasons that sun-exposed skin becomes dehydrated.5 

In  addition,  aquaporin  performance  can  be  affected  by  topical 
ingredients  that  can  increase  the  opening  and  closing  of  the 
aquaporin  pore  or  upregulate  AQP-3  expression.  Ajuga 
turkestanica has been shown to increase AQP-3 function.6 Retinol 
and the antioxidant n-acetyl cysteine both have been shown to 
inhibit the downregulation of AQP-3 upon UV exposure.5 AQPs 
are intriguing water channels that allow water and glycerin to 
flow from cell to cell. In the next few years, many more facets of 
their dynamic mechanisms of action will be elucidated.

REFERENCES

1.  Takata  K,  Matsuzaki  T,  Tajika  Y.  Aquaporins:  Water  channel 
proteins of the cell membrane. Prog Histochem Cytochem. 2004;39:1.
2.  Choi EH, Man MQ, Wang F, et al. Is endogenous glycerol a deter-
minant  of  stratum  corneum  hydration  in  humans?  J  Invest 
Dermatol. 2005;125:288.

3.  Hara M, Ma T, Verkman AS. Selectively reduced glycerol in skin 
of  aquaporin-3-deficient  mice  may  account  for  impaired  ski 
hydration,  elasticity,  and  barrier  recovery.  J  Biol  Chem. 
2002;277:46616.

4.  Hara  M,  Verkman  AS.  Glycerol  replacement  corrects  defective 
skin  hydration,  elasticity,  and  barrier  function  in  aquaporin-
3-deficient mice. Proc Natl Acad Sci USA. 2003;100:7360.

5.  Cao  C,  Wan  S,  Jiang  Q,  et  al.  All-trans  retinoic  acid  attenuates 
ultraviolet radiation-induced down-regulation of aquaporin-3 and 
water  permeability  in  human  keratinocytes  J  Cell  Physiol. 
2008;215:506.

6.  Dumas M, Gondran C, Barré P, et al. Effect of an Ajuga turkestanica 
extract on aquaporin 3 expression, water flux, differentiation and 
barrier  parameters  of  the  human  epidermis.  Eur  J  Dermatol. 
2002;12:XXV.

 
88 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   3 0

Ajuga Turkestanica

Activities:

Activation of aquaporin
Antimicrobial, antiviral, antitumor, antibiotic
Anabolic steroidal

Important Chemical Components:

Clerodane diterpenes
Phytoecdysteroids,  including  α-ecdysone,  2-desoxy-
ecdysterone, ecdysterone, sileneoside A, and turkesterone
Iridoid glycosides

Origin Classification: 

This ingredient is considered natural, but was not certi-
fied  by  the  Natural  Products  Association  (NPA)  when 
this book went to press.

 CHEMISTRY

There  are  three  classes  of  potentially  bioactive  compounds 
found in the Ajuga genus5:

1.  Clerodane  diterpenes  are  recognized  sources  of  antimi-
crobial,  antiviral,  antitumor,  antibiotic,  and  amoebicidal 
activities.6 

2.  Phytoecdysteroids  have  anabolic  steroid  activity.  A.  turke-
stanica  reportedly  contains  several  phytoecdysteroids 
(turkesterone, 20-hydroxyecdysone, cyasterone, cyasterone 
22-acetate,  ajugalactone,  ajugasterone  B,  α-ecdysone  and 
ecdysone  2,  3-monoacetonide)  as  well  as  the  iridoids  har-
pagide and harpagide 8-acetate.5,7–12

3.  Iridoid glycosides, especially abundant in Ajuga decumbens, 

have exhibited anticancer activity.13 

Personal Care Category: 

Skin hydration, skin conditioning

 ORAL USES

Recommended for the following Baumann Skin 
Types:

DRNT,  DRPT,  DRNW,  DRPW,  DSNT,  DSNW,  DSPT, 
and DSPW

 SOURCE

Ajuga turkestanica is a perennial herb and member of the mint 
family  Lamiaceae.  There  are  over  300  species  of  the  genus 
Ajuga found throughout Europe, Asia, Africa, Australia, and 
North America. A. turkestanica is indigenous to Uzbekistan. 
It derives its name from the fact that it contains a powerful 
ecdysteroid called turkesterone. Ecdysterones are a group of 
plant  sterols  that  have  a  steroid-like  effect  on  the  human 
body.

 HISTORY

This plant has been used in traditional medicine to treat fevers, 
toothaches, dysentery, malaria, high blood pressure, diabetes, 
and  gastrointestinal  disorders,  as  well  as  antifungal,  antihel-
minthic,  anti-inflammatory,  antimycobacterial,  and  diuretic 
agents.1 Athletes and body builders have used A. turkestanica 
as an anabolic steroid because it contains phytoecdysteroids.2 
Many bodybuilding supplements containing turkesterone can 
be found on the Internet. A. turkestanica is known to contain 
several bioactive compounds and has been used in traditional 
medical  approaches  to  heart  disease  as  well  as  stomach  and 
muscle aches.3,4 In addition, it is one of the many species of 
Ajuga  gaining  attention  for  demonstrating  medicinal  proper-
ties  with  the  potential  for  commercial  applications.5  In 
November 2000, US Patent Number 7060693 was filed for the 
cosmetic use of A. turkestanica (awarded in 2006) by scientists 
at Dior Research.

A.  turkestanica  extract  is  included  in  some  anabolic  muscle 
growth supplements.

 TOPICAL USES

Patented  extracts  of  A.  turkestanica  were  shown  in  2006  to 
have sufficient ecdysteroids and other active ingredients to 
improve the differentiation of keratinocytes, thus facilitating 
skin hydration and yielding antiaging effects (Table 30-1).14,15 
The  patent  inventors  observed  that  the  extracts  are  espe-
cially  effective  in  regulating  epidermal  water  and  glycerol 
transport,  achieving  improved  hydration  of  the  basal  layer 
by  working  in  concert  with  or  enhancing  aquaporin-3  
(AQP-3).14,16  AQP-3  is  a  water  transport  channel  known  to 
transport  water  and  glycerol  between  cells.17  The  function 
of  AQP-3  was  shown  to  be  increased  by  A.  turkestanica 
extract.18

 SAFETY ISSUES

A. turkestanica has not been reviewed for safety by the Cosmetic 
Ingredient Review (CIR) panel.

TABLE 30-1
Pros and Cons of Ajuga Turkestanica

Pros
The only agent known and commercially 

available to play a role in regulating AQP-325

Unique and proven mechanism of action
Proven efficacy
Can be combined with other ingredients
Good shelf stability

Cons
Limited number of brands contain this extract

Expensive

 
 ENVIRONMENTAL IMPACT

A.  turkestanica  hairy  root  cultures  have  been  developed  as  a 
sustainable alternative to wild-harvesting.19

 FORMULATION CONSIDERATIONS

C H A P T E R  30  ■   A J U G A  T U R K E S TA N I C A 

89

applied the formulation twice daily to their forearms for 21 days. 
Significant  reductions  in  TEWL  were  seen  in  the  treated  area 
compared  to  the  control  at  days  7  and  21.  The  researchers 
concluded  that  the  tested  A.  turkestanica  extract  formulation 
enhanced AQP-3 expression and human epidermal differentiation 
in  vitro  and  ameliorated  epidermal  barrier  structure  and  human 
skin recovery in vivo.15,18

The  only  considerations  that  have  been  made  public  are  dis-
closed in US Patent Number 7060693.

 CONCLUSION

 USAGE CONSIDERATIONS

There are no known restrictions. A. turkestanica can be used in 
the morning or at night and can be used in combination with 
other skin care products.

 SIGNIFICANT BACKGROUND

Aquaporins
Aquaporins (AQPs) are integral membrane proteins that facili-
tate water transport in several organs, including the skin, brain, 
renal  tubules,  eyes,  and  digestive  tract. Thirteen  isoforms  of 
aquaporins (AQP 0–12) are found in mammals. Of these, there 
are two functional subtype classifications: AQPs 1, 2, 4, 5, and 
8 conduct only water, and AQPs 3, 7, 9, and 10 transport water 
and  other  substances  including  glycerol  and  urea.20  AQP-3, 
permeable to water and glycerol, is the main water channel 
in human epidermis. Glycerol acts as an endogenous humec-
tant  thereby  facilitating  hydration  of  the  stratum  corneum 
(SC).21  Defects  in  AQP-3  in  mice  models  have  been  demon-
strated to lead to epidermal xerosis, reduced SC hydration and 
epidermal glycerol content, followed by diminished elasticity 
and  impaired  skin  barrier  recovery.22,23  Such  findings  under-
score  the  important  role  of  glycerol  in  cutaneous  hydration. 
AQP-3 contributes to the transport of water, glycerol and sol-
utes between keratinocytes.

Dumas et al. note that the role of AQPs in hydrating the living 
layers of the epidermis where keratinocyte differentiation occurs 
and in barrier development and recovery suggests that they are 
significant protein targets for improving the quality and resist-
ance  of  the  skin  surface  as  well  as  ameliorating  aging-  and 
UV-induced xerosis.18

Ajuga Turkestanica and Aquaporins
In 2007, Dumas et al. conducted in vitro and in vivo studies of active 
ingredients capable of raising AQP-3 levels to enhance hydration 
in  human  skin  keratinocytes,  with  the  understanding  that 
improving  hydration  in  human  keratinocytes  would  ultimately 
improve  epidermal  hydration.24  They  used  an  ethanolic/water 
(70/30 v/v) extract of A. turkestanica as the hydrating agent (2.5 µg/
mL) and found that after 17 days of in vitro treatment every 2 days 
in human reconstructed epidermis, AQP-3 expression measured 
at the protein level was significantly elevated. Increased epidermal 
proliferation  and  differentiation  was  also  noted.  Electron 
microscopy showed a significantly thicker, compact SC and more 
clearly differentiated desmosomes.18

The investigators prepared an oil-water emulsion infused with 
A.  turkestanica  extract  (0.3  percent  w/w)  for  an  in  vivo  study  in 
which 15 healthy female volunteers (between 22 and 56 years old) 

The Ajuga turkestanica story is a very interesting one because the 
cosmetic scientists Dumas, Bonté, and Gondran were the first to 
identify AQP-3 in skin cells. They published this information, 
sharing it with other scientists rather than keeping the informa-
tion  hidden  and  proprietary.  Several  compounds  were  tested 
with A. turkestanica found to affect water flux through the AQP 
channels. They filed patents to protect this technology. This is a 
great example of scientific discovery leading to new technolo-
gies. Unfortunately, many companies have started to claim that 
their products “contain aquaporin,” which is misleading. If AQP 
was included in a formulation, it would not be able to penetrate 
into the skin and span the lipid bilayer in the manner that is neces-
sary to affect water flux ( Figure 30-1). The only way that is proven 
to affect water flux between cells is for an ingredient to act upon 
AQP in the manner that Ajuga turkestanica does. The discovery 
of  AQP-3  as  well  as  the  understanding  of  its  significance  and 
how to harness its power to improve skin appearance occurred 
over a span of two decades. The scientists should be congratu-
lated for their perseverance.

A
6

1

2

C

5

3

4

D

E

C

P
N A
A
N

P

B

Hourglass

H2N

HOOC

▶
FIGURE 30-1  Hourglass model for aquaporin-1 membrane topology. 
Reprinted with permission from Borgnia M, Nielsen S, Engel A, et al. Cellular 
and molecular biology of the aquaporin water channels. Annu Rev Biochem 
1999;68:425. Copyright  1999, Annual Reviews.

REFERENCES

1.  Israili ZH, Lyoussi B. Ethnopharmacology of the plants of genus 

Ajuga. Pak J Pharm Sci. 2009;22:425.

2.  Cheng  DM,  Yousef  GG,  Grace  MH,  et  al.  In  vitro  production  of 
metabolism-enhancing phytoecdysteroids from Ajuga turkestanica. 
Plant Cell Tiss Organ Cult. 2008;93:73.

3.  Mamatkhanov AU, Yakubova MR, Syrov VN. Isolation of turkes-
terone from the epigeal part of Ajuga turkestanica and its anabolic 
activity. Chem Nat Compd. 1998;34:150.

4.  Abdukadirov  IT,  Khodzhaeva  MA,  Turakhozhaev  MT,  et  al. 
Carbohydrates from Ajuga turkestanica. Chem Nat Compd. 2004;40:85.
5.  Grace MH, Cheng DM, Raskin I, et al. Neo-Clerodane Diterpenes 

from Ajuga turkestanica. Phytochem Lett. 2008;1:81.

6.  Coll J, Tandron YA. Neo-Clerodane diterpenoids from Ajuga: struc-
tural elucidation and biological activity. Phytochem Rev. 2008;7:25.

 
90 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

7.  Ramazanov NS. Phytoecdysteroids and other biologically active 
compounds  from  plants  of  the  genus  Ajuga.  Chem  Nat  Compd. 
2005;41:361.

8.  Baltaev  UA.  Phytoecdysteroids:  Structure,  sources,  and  biosyn-

thesis in plants. Russ J Bioorg Chem. 2000;26:799.

9.  Usmanov VZ, Rashkes YV, Abubakirov NK. Phytoecdysones of 
Ajuga  turkestanica  VI.  22-acetylcyasterone.  Chem  Nat  Compd. 
1978;2:215.

10.  Usmanov VZ, Gorovits MB, Abubakirov NK. Phytoecdysones of 

Ajuga turkestanica III. Chem Nat Compd. 1975;4:466.

11.  Usmanov VZ, Gorovits MB, Abubakirov NK. Phytoecdysones of 

Ajuga turkestanica II. Chem Nat Compd. 1973;1:125.

12.  Usmanov VZ, Gorovits MB, Abubakirov NK. Phytoecdysones of 

Ajuga turkestanica. Chem Nat Compd. 1971;4:535.

13.  Konoshima  T,  Takasaki  M,  Tokuda  H,  et  al.  Cancer  chemopre-
ventive activity of an iridoid glycoside, 8-acetylharpagide, from 
Ajuga decumbens. Cancer Lett. 2000;157:87.

14.  Brewster  B.  Aquaporins:  stimulation  by  vitamins,  steroids  and 

sugar alcohols. Cosmet Toil. 2008;123:20.

15.  Dumas  M,  Bonté  F,  Gondran  C,  inventors.  LVMH  Recherche, 
assignee.  Ajuga  turkestanica  extract  and  its  cosmetic  uses.  US 
Patent 7,060,693 B1, June 13, 2006.

16.  WIPO Patent Application WO/1994/004132. Use of an ecdysteroid 

in cosmetics or dermatology.

17.  Bonté F. Skin moisturization mechanisms: New data. Ann Pharm Fr. 

2011;69:135.

18.  Dumas  M,  Sadick  NS,  Noblesse  E,  et  al.  Hydrating  skin  by 
stimulating  biosynthesis  of  aquaporins.  J  Drugs  Dermatol. 
2007;6:s20.

19.  Cheng DM, Yousef GG, Grace MH, et al. In vitro production of 
metabolism-enhancing phytoecdysteroids from Ajuga turkestanica. 
Plant Cell Tiss Organ Cult. 2008;93:73.

20.  Takata  K,  Matsuzaki  T,  Tajika  Y.  Aquaporins:  water  channel 
proteins  of  the  cell  membrane.  Prog  Histochem  Cytochem. 
2004;39:1.

21.  Choi EH, Man MQ, Wang F, et al. Is endogenous glycerol a deter-
minant  of  stratum  corneum  hydration  in  humans?  J  Invest 
Dermatol. 2005;125:288.

22.  Hara M, Ma T, Verkman AS. Selectively reduced glycerol in skin 
of  aquaporin-3-deficient  mice  may  account  for  impaired  skin 
hydration,  elasticity,  and  barrier  recovery.  J  Biol  Chem. 
2002;277:46616.

23.  Hara  M,  Verkman  AS.  Glycerol  replacement  corrects  defective 
skin  hydration,  elasticity,  and  barrier  function  in  aquaporin-3- 
deficient mice. Proc Natl Acad Sci U S A. 2003;100:7360.

24.  Dumas  M,  Gondran  C,  Barré  P,  et  al.  Effect  of  an  Ajuga  turke-
stanica extract on aquaporin 3 expression, water flux, differentia-
tion  and  barrier  parameters  of  the  human  epidermis.  Eur  
 J Dermatol. 2002;12:XXV.

25.  Baumann L. Cosmetics and skin care in dermatology. In: Goldsmith 
LA, Katz SI, Gilchrest BA, et al. Fitzpatrick’s Dermatology in General 
Medicine. 8th ed. Vol. 2. New York: McGraw-Hill; 2012:3010.

 
C H A P T E R  31  ■   N AT U R A L   M O I S T U R I Z I N G   FAC TO R  

91

C H A P T E R   3 1

Natural Moisturizing Factor

Natural moisturizing factor (NMF) is found inside keratinocytes 
and helps regulate stratum corneum (SC) hydration. NMF is a 
mixture  of  amino  acids  including  pyrrolidone  carboxylic  and 
urocanic  acids,1,2  which  are  water-soluble  byproducts  of 
filaggrin. 

Filaggrin, also known as filament aggregating protein, has two 
different cutaneous functions. In lower levels of the skin, filaggrin 
plays a structural role; however, higher up in the skin, it is broken 
down  into  amino  acids  that  are  hygroscopic  and  strongly  bind 
water.  Histidine,  glutamine,  and  arginine  are  metabolites  of 
filaggrin in the SC that are metabolized into trans-urocanic acid, 
pyrrolidone  carboxylic  acid,  and  citrulline,  respectively.  They 
create  the  osmotically  active  component  that  regulates  skin 
hydration known as NMF.1,3 Other constituents of NMF include 
lactic acid, urea, and inorganic ions such as sodium, potassium, 
calcium,  and  chloride,  all  of  which  contribute  to  epidermal 
hydration.  The  osmotically  active  and  humectant  properties  of 
NMF  allow  the  epidermis  to  retain  hydration  even  in  dry 
environments.  Extraction  of  NMF  components  results  in  a 
decrease  in  the  moisture  accumulation  rate  (MAT)  of  the 
epidermis,4  emphasizing  the  importance  of  NMF  in  skin 
hydration.  Interestingly,  NMF  constituents  undergo  seasonal 
changes:  the  breakdown  of  filaggrin  and  production  of  NMF 
increase in low humidity and decrease in high humidity. NMF is 
intracellular and at this time it is not known if exogenously applied 
NMF or its precursors would result in increased NMF levels.

Patients  with  atopic  dermatitis  exhibit  a  reduction  in  NMF 
and have been found to have mutations in the filaggrin gene.6,7 A 
defect in filaggrin also results in a structural impairment that is 

seen in atopic dermatitis because filaggrin plays a structural role 
in lower levels of the epidermis.8 NMF levels are decreased by 
ultraviolet  exposure,  surfactants,  and  prolonged  water 
immersion.

REFERENCES

1.  Scott  IR,  Harding  CR,  Barrett  JG.  Histidine-rich  protein  of  the 
keratohyalin  granules.  Source  of  the  free  amino  acid,  urocanic 
acid  and  pyrrolidone  carboxylic  acid  in  the  stratum  corneum. 
Biochim Biophys Acta. 1982;719:110.

2.  Horii I, Kawasaki K, Koyama J, et al. Histidine-rich protein as a 
possible origin of free amino acids of stratum corneum. Curr Probl 
Dermatol. 1983;11:301.

3.  Elias  PM.  Stratum  corneum  defensive  functions:  an  integrated 

view. J Invest Dermatol. 2005;125:183.

4.  Visscher MO, Tolia GT, Wickett RR, et al. Effect of soaking and 
natural  moisturizing  factor  on  stratum  corneum  water-handling 
properties. J Cosmet Sci. 2003;54:289.

5.  Nakagawa N, Sakai S, Matsumoto M, et al. Relationship between 
NMF (lactate and potassium) content and the physical properties 
of  the  stratum  corneum  in  healthy  subjects.  J  Invest  Dermatol. 
2004;122:755.

6.  Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations 
within  the  filaggrin  gene  predispose  for  atopic  dermatitis  with 
allergic sensitizations. J Allergy Clin Immunol. 2006;118:214.

7.  Irvine AD, McLean WH. Breaking the (un)sound barrier: Filaggrin 
is  a  major  gene  for  atopic  dermatitis.  J  Invest  Dermatol. 
2006;126:1200.

8.  Chu  DH.  Development  and  structure  of  skin.  In:  Goldsmith 
LA,  Katz  SI,  Gilchrest  BA,  et  al.  Fitzpatrick’s  Dermatology  In 
General  Medicine.  8th  ed.  New  York:  McGraw-Hill  Medical; 
2012:62.

 
92 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

SECTION

D

C H A P T E R   3 2

Skin Lightening Agents

Overview of the Pigmentation Process

Skin color results from the incorporation of melanin-containing 
melanosomes, produced by the melanocytes, into the keratino-
cytes in the epidermis and their ensuing degradation. Although 
other  factors  contribute  to  skin  color,  such  as  carotenoids  or 
hemoglobin,1 the amount, quality, and distribution of melanin 
present  in  the  epidermis  represent  the  primary  sources  of 
human skin color. The number of melanocytes in human skin 
is  equal  across  humanity,  thus,  their  activity  and  interaction 
with  the  keratinocytes  emerge  as  the  accountable  factors  for 
skin color.2

Melanin  pigment  is  produced  in  the  melanosome,  an  orga-
nelle  located  in  the  cytoplasm  of  melanocytes.  When  excess 
melanin is produced, disorders of pigmentation or dyschromia 
can result. Melanin production is stimulated by several factors 
including ultraviolet light, estrogen, melanocyte-stimulating hor-
mones  (MSH),  stress,  inflammation,  injury,  infrared  light,  and 
heat.  The  most  common  forms  of  dyschromia  are  melasma, 
solar  lentigos,  postinflammatory  hyperpigmentation,  and  dark 
circles under the eyes.

Melasma, also known as chloasma or “mask of pregnancy,” 
refers to a very common condition that is usually seen in women 
of childbearing age. It is a chronic disorder that can be frustrating 
to patients and physicians because it often recurs, especially due 
to exposure to the sun or estrogen. Melasma presents as irregu-
larly  shaped,  but  often  distinctly  defined,  blotches  of  light-  to 
dark-brown pigmentation. These patches are usually seen on the 
upper lip, nose, cheeks, chin, arms, forehead, and neck.

Solar lentigos are caused by both acute and chronic exposure 
and manifest as macular brown lesions usually 1 cm in diameter. 
The face, shoulders, chest, back, and hands are the areas typi-
cally affected because they receive the most sun exposure.

Postinflammatory  hyperpigmentation,  also  known  as  post-
inflammatory pigment alteration (PIPA), can present as a result of 
various  skin  disorders.  Occasionally,  therapies  for  skin  disease 
can cause or exacerbate dyschromia, such as resurfacing lasers or 

chemical  peels.  This  occurs  more  commonly  in  people  with 
darker skin types.

The cause of dark circles under the eyes is poorly understood. 
Many believe that the thin skin in this area allows the blood ves-
sels to become more visible. Any inflammation or vasodilation 
in this region may manifest as darkening.3 However, there also 
seems  to  be  a  pigmentary  component  that  may  be  caused  by 
excessive melanin production or deposition of the iron-storage 
complex  hemosiderin  from  sluggish  blood  flow  in  the  area. 
Unfortunately, there is no consensus about the best treatment of 
dark under-eye circles. 

Disorders of pigmentation are best treated using a combina-
tion of ingredients including tyrosinase inhibitors, PAR-2 block-
ers,  and  exfoliating  agents.  These  should  be  combined  with 
ingredients such as lignin peroxidase and laser or light devices, 
which attack or target melanin. Antioxidants can also be used to 
prevent  hyperpigmentation  by  hindering  inflammation. 
Polyphenol antioxidants have been found to be strong chelators 
of metal ions, such as Fe2+, Fe3+, Cu2+, Zn2+, and Mn2+, and can 
interfere  with  the  function  of  tyrosinase.4,5  Sun  protection  as 
well as heat and sun avoidance are also vital for the successful 
treatment of dyschromia.

REFERENCES

1.  Jimbow K, Quevedo WC Jr, Fitzpatrick TB, et al. Some aspects of 

melanin biology: 1950–1975. J Invest Dermatol. 1976;67:72.

2.  Bolognia  JL,  Pawelek  JM.  Biology  of  hypopigmentation.  J  Am 

Acad Dermatol. 1988;19(2 Pt 1):217.

3.  Matsumoto M, Kobayashi N, Hoshina O, et al. Study of causal 
factors of dark circles around the eyes. IFCC Magazine. 2001;4:281.
4.  Brown  JE,  Khodr  H,  Hider  RC,  et  al.  Structural  dependence  of 
flavonoid interactions with Cu2+ ions: Implications for their anti-
oxidant properties. Biochem J. 1998;330(Pt 3):1173.

5.  Afanas’ev IB, Dorozhko AI, Brodskii AV, et al. Chelating and free 
radical scavenging mechanisms of inhibitory action of rutin and 
quercetin in lipid peroxidation. Biochem Pharmacol. 1989;38:1763.

 
C H A P T E R  33  ■   O V E R V I E W   O F   M E L A N I N   P R O D U C T I O N  

93

C H A P T E R   3 3

Overview of Melanin Production

Melanin production occurs inside the melanosomes located in the 
melanocytes. The process of melanin synthesis begins with the 
hydroxylation of tyrosine to 3,4-dihydroxyphenylalanine (DOPA) 

using  the  enzyme  tyrosinase  (Figure  33-1).1  Two  types  of 
melanin  are  produced:  eumelanin  and  pheomelanin.  The 
relative amounts of these two forms of melanin determine hair 

▶

FIGURE 33-1  The conversion of tyrosine to melanin is controlled by the rate-limiting enzyme tyrosinase.

 
94 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

color  and  skin  tone.  Individuals  with  darker  skin  tones  have 
mostly eumelanin and a lower level of pheomelanin, while the 
opposite is true in people with a light skin color.

inhibitors  covered  in  this  section  include:  aloesin,  arbutin, 
hydroquinone,  kojic  acid,  mulberry  extract,  vitamin  C  
(ascorbic acid), and cucumber.

Tyrosinase  is  the  rate-limiting  enzyme  for  melanin 
production.  Tyrosinase  is  stimulated  by  ultraviolet  (UV) 
radiation,  DNA  fragments  such  as  thymidine  dinucleotides 
that emerge as a result of UV exposure,2 melanocyte-stimulating 
hormone  (MSH),  and  growth  factors  such  as  bFGF  and 
endothelin.  Protein  kinase  C  3,4  and  the  cyclic  adenosine 
monophosphate  (cAMP)±protein  kinase  A  pathway 2  play  a 
role in increasing melanin production as do prostaglandins (D2, 
E2,  and  F2),  tumor  necrosis  factor-α  (TNF-α),  and  interleukins 
(IL-α,  IL-1β,  and  IL-6).2–5  Vitamin  D3  may  play  a  role  in 
stimulating  melanogenesis  as  well.6  For  more  information, 
please  see  Chapter  13  of  Cosmetic  Dermatology:  Principles  and 
Practice, 2nd edition (McGraw-Hill 2009).

The most popular way to treat unwanted skin pigmentation is 
through the use of tyrosinase inhibitors. These do not eliminate 
melanin that is already present but help prevent future melanin 
production in the treated area. It is usually necessary to wait 8 to 
16  weeks  to  see  improvement  in  pigmentation.  Tyrosinase 

REFERENCES

1.  Park HY, Yaar M. Disorders of melanocytes. In: Goldsmith LA, Katz 
SI,  Gilchrest  BA,  et  al.  eds.  Fitzpatrick’s  Dermatology  in  General 
Medicine. 8th ed. New York: McGraw-Hill; 2012:773–774.

2.  Khlgatian  MK,  Hadshiew  IM,  Asawanonda  P,  et  al.  Tyrosinase 
gene  expression  is  regulated  by  p53.  J  Invest  Dermatol. 
2002;118:126.

3.  Chang  MW.  Disorders  of  hyperpigmentation.  In:  Bolognia  JL, 
Jorizzo JL, Schaffer JV, eds. Dermatology. 3rd ed. London: Saunders; 
2012:1051.

4.  Park  HY,  Russakovsky  V,  Ohno  S,  et  al.  The  beta  isoform  of 
protein kinase C stimulates human melanogenesis by activating 
tyrosinase in pigment cells. J Biol Chem. 1993;268:11742.

5.  Lee JH, Park JG, Lim SH, et al. Localized intradermal microinjection 
of tranexamic acid for treatment of melasma in Asian patients: A 
preliminary clinical trial. Dermatol Surg. 2006;32:626.

6.  Tomita  Y,  Torinuki  W,  Tagami  H.  Stimulation  of  human 
melanocytes by vitamin D3 possibly mediates skin pigmentation 
after sun exposure. J Invest Dermatol. 1988;90:882.

 
C H A P T E R   3 4

Aloesin

C H A P T E R  34  ■   A LO E S I N  

95

Activities:

Tyrosinase inhibition, antioxidant, anti-inflammatory

Important Chemical Components:

Aloesin  (2-acetyonyl-8-glucopyranosyl-7-hydroxy-
5-methylchromone)

Origin Classification:

This ingredient is natural, and a key constituent of Aloe. 
Organic forms exist.

Personal Care Category:

Depigmenting, sun protective (UVB)

Recommended for the following Baumann Skin 
Types:

DRPT, DRPW, DSPT, DSPW, ORPT, ORPW, OSPT, and 
OSPW

 SOURCE

A  moderately-high-molecular-weight  hydroxymethyl 
C-glycosylated  chromone  derivative  isolated  from  fresh  Aloe 
vera leaves (as well as those from other Aloe species), aloesin is 
a natural compound that has been found to exert appreciable 
depigmenting activity. It is among the top choices for cosmetic 
and  therapeutic  applications  to  lighten  skin.1–4  While  aloesin 
appears to be an important component in the armamentarium 
against  hyperpigmentation  disorders,  its  hydrophilic  nature 
renders it less able than hydroquinone to penetrate the skin.5 
Some  argue  that  its  slower  penetration  into  the  skin  endows 
aloesin  with  greater  potential  as  a  skin-lightening  agent  for 
cosmetic purposes as compared to hydroquinone, however.6

 HISTORY

In  traditional  folk  medicine,  topical  A.  vera  is  used  to  treat 
inflammation, cicatrization, and dyspigmentation. Its constituent 
aloesin  has  been  demonstrated  to  inhibit  tyrosinase  activity 
from human, murine, and mushroom sources.7

 CHEMISTRY

Aloesin  dose-dependently  inhibits  tyrosinase  by  blocking  the 
hydroxylation of tyrosine to 3,4-dihydroxyphenylalanine (DOPA) 
as well as the oxidation of DOPA to dopaquinone; it has also been 
found  to  suppress  melanin  production  in  cultured  normal 
melanocytes.7 Aloesin and a few chemically related chromones, 
particularly  the  5-methyl-7-methoxy-2(2’-benzyl-3’-oxobutyl)-
chromone, have been demonstrated to exhibit stronger inhibi-
tory activity on tyrosinase than arbutin and kojic acid.6,8,9 This 

is especially noteworthy because tyrosinase is the rate-limiting 
enzyme  in  melanin  production  and,  thus,  directly  influences 
the development of skin pigment.

 ORAL USES

Interestingly, aloesin has been suggested as having a potential 
role as a functional food. Lynch et al. have recently shown in 
experiments with Sprague-Dawley rats that aloesin appears to 
confer benefits pertaining to prediabetic states, including meta-
bolic syndrome.10 Aloesin is available in oral supplements and 
in aloe juice.

 TOPICAL USES

Although less effective than hydroquinone when used as single 
therapy  (Table  34-1),  aloesin  is  safer,  and  has  been  most 
successfully used in hypopigmenting regimens for its synergistic 
activity  in  combination  therapies  with  two  or  more  agents 
acting on various mechanisms.6

 SAFETY ISSUES

The Ames test has demonstrated no genotoxicity or mutagen-
icity linked to aloesin and cell-based assays have revealed no 
cytotoxicity.8 More recent in vitro and in vivo genotoxicity assays 
conducted  by  Lynch  et  al.,  including  the  Ames  test  (bacterial 
mutation  assay),  in  vitro  mammalian  cell  cytogenetics  assay, 
and mouse micronucleus test, have shown a lack of genotoxic 
potential in aloesin.4

 ENVIRONMENTAL IMPACT

The effects of aloesin culling and processing depend directly on 
the impact of Aloe plant cultivation (see Chapter 65, Aloe Vera).

 FORMULATION CONSIDERATIONS

Aloesin is difficult to synthesize.

TABLE 34-1
Pros and Cons of Aloesin

Pros
Effective as a depigmenting ingredient, 
particularly when used in combination

Good for type 2 (rosacea) sensitive skin

Natural

Organic forms exist

Cons
Less effective than hydroquinone

More research is necessary to determine 
what other ingredients are most 
effective in combination

 
96 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

 USAGE CONSIDERATIONS

Aloesin is a good choice for Baumann Skin Type sensitive skin 
type 2 (rosacea) and should be combined with niacinamide and 
antioxidants  for  these  types.  For  individuals  with  other  skin 
types,  aloesin  can  be  combined  with  retinoids  and  another 
tyrosinase inhibitor and α-hydroxy acids.

 SIGNIFICANT BACKGROUND

For  many  years,  hydroquinone  was  the  standard  skin-
whitening  agent  throughout  the  world,  but  its  reputed 
cytotoxicity  prompted  a  ban  in  2000  in  Europe  and  strict 
regulation  in  Asia.  Several  active  constituents  extracted  from 
plants,  including  aloesin,  arbutin,  flavonoids,  gentisic  acid, 
hesperidin,  licorice,  niacinamide,  yeast  derivatives,  and 
polyphenols,  which  inhibit  melanogenesis  through  varying 
mechanisms  without  inducing  melanocytotoxicity,  have 
emerged  as  alternatives  to  hydroquinone  used  alone  or  in 
combination.11 In 1999, aloesin and arbutin were shown to act 
synergistically  in  suppressing  tyrosinase  activity,  and  thus 
melanin  production,  in  a  combined  treatment,  but  through 
different mechanisms, with aloesin noncompetitively inhibiting 
tyrosinase activity while arbutin acted competitively.1

In  2002,  Jones  et  al.  demonstrated  that  aloesin  modulates 
melanogenesis  by  competitively  inhibiting  tyrosinase  at  the 
dihydroxyphenylalanine  oxidation  site,  suppressing  melanin 
synthesis  in  vitro,  and  that  it  is  a  tyrosinase  inhibitor  from 
mushroom, human, and murine sources. They also found that 
aloesin  dose-dependently  inhibited  tyrosine  hydroxylase  and 
DOPA  oxidase  activities  of  tyrosinase  from  normal  human 
melanocyte cell lysates. The researchers concluded that aloesin 
indeed  demonstrated  potential  as  a  cosmetic  or  therapeutic 
agent for altering skin pigmentation.7

Also in that year, Choi et al. studied the inhibitory effects of 
aloesin  and  arbutin  against  UV-induced  hyperpigmentation  in 
humans. Subjects were exposed to UV radiation on the inner fore-
arm and the treated areas were assigned to four daily treatments 
for 15 days with vehicle control, aloesin, arbutin, or a combination 
of the two botanical ingredients. Aloesin blocked pigmentation by 
34 percent, arbutin, by 43.5 percent, and the combination treat-
ment, 63.3 percent, as compared to the control. In addition, inves-
tigators noted that aloesin dose-dependently inhibited UV-induced 
pigmentation and concluded that the compound may be a suitable 
agent for blocking UV-induced melanin formation.2

In 2004, Yang et al. also investigated the synergistic effects of 
aloesin and arbutin. They treated normal cultured human melano-
cytes  in  vitro  with  an  aloesin  and  arbutin  mixture,  which  was 
found  to  have  suppressed  tyrosinase  activity  and  resulted  in  a 
significant decline in melanin content in the cultured melanocytes. 
The  mixture  had  little  effect  on  melanocyte  viability.12  In  2008, 
many of the same researchers, led this time by Wang, explored the 
effects of aloesin on melanogenesis in an in vitro pigmented skin 
equivalent, based on recent success in the study of skin metabo-
lism and depigmenting agents in such models, which have been 
shown  to  evince  similar  morphological  and  growth  qualities  to 
human skin. The investigators found that aloesin exhibited direct 
inhibitory  effects  on  melanogenesis  and  dose-dependently  initi-
ated  a  reduction  in  tyrosinase  activity  and  melanin  content. 
Arbutin  also  exhibited  dose-dependent  inhibitory  activity,  but 
was  less  effective  than  aloesin.  Tea  polyphenols  demonstrated 
greater  inhibitory  activity  than  aloesin  but  also  greater  toxicity. 
Consequently,  the  authors  concluded  that  aloesin  displayed  the 

most potential of the ingredients tested as an agent intended to 
affect pigmentation for cosmetic or therapeutic purposes.3

Antioxidant and Anti-inflammatory Activity
In a wide-ranging study of the anti-inflammatory and antioxi-
dant  properties  of  various  Aloe  isolates,  including  cinnamoyl, 
p-coumaroyl,  feruloyl,  caffeoyl  aloesin,  and  related  com-
pounds, Yagi et al. found that the involvement of the caffeoyl, 
feruloyl,  and  coumaroyl  groups  bound  to  aloesin  was  well 
established,  and  the  contact  hypersensitivity  response  sug-
gested that aloesin prevented UVB-induced immune suppres-
sion. In addition, they noted that aloesin inhibited the tyrosine 
hydroxylase and DOPA oxidase activities of tyrosinase in nor-
mal  human  melanocyte  cell  lysates.  The  investigators  con-
cluded  that  the  potent  antioxidant  and  anti-inflammatory 
effects  imparted  by  aloesin  derivatives  helped  explain,  in  
part,  the  anti-inflammatory  and  wound-healing  properties  of  
Aloe vera.13,14

 CONCLUSION

Aloesin is a less effective but safe alternative to using hydroqui-
none to treat unwanted hyperpigmentation. It is an ideal choice 
in  rosacea  patients  with  hyperpigmented  skin  areas  such  as 
those  seen  in  photoaging.  Used  with  other  skin-lightening 
agents,  aloesin  is  a  key  ingredient  in  depigmenting  regimens. 
Much more research is needed to ascertain whether aloesin can 
play  a  more  independent  role  as  a  cosmetic  and  therapeutic 
depigmenting  agent.  Currently,  aloesin  is  considered  a  useful 
adjuvant among skin-lightening options.

REFERENCES

1.  Jin  YH,  Lee  SJ,  Chung  MH,  et  al.  Aloesin  and  arbutin  inhibit 
tyrosinase activity in a synergistic manner via a different action 
mechanism. Arch Pharm Res. 1999;22:232.

2.  Choi S, Lee SK, Kim JE, et al. Aloesin inhibits hyperpigmentation 

induced by UV radiation. Clin Exp Dermatol. 2002;27:513.

3.  Wang Z, Li X, Yang Z, et al. Effects of aloesin on melanogenesis in 

pigmented skin equivalents. Int J Cosmet Sci. 2008;30:121.

4.  Lynch B, Simon R, Roberts A. In vitro and in vivo assessment of 
the  genotoxic  activity  of  aloesin.  Regul  Toxicol  Pharmacol. 
2011;61:215.

5.  Draelos ZD. Skin lightening preparations and the hydroquinone 

controversy. Dermatol Ther. 2007;20:308.

6.  Solano F, Briganti S, Picardo M, et al. Hypopigmenting agents: An 
updated  review  on  biological,  chemical  and  clinical  aspects. 
Pigment Cell Res. 2006;19:550.

7.  Jones K, Hughes J, Hong M, et al. Modulation of melanogenesis 
by aloesin: A competitive inhibitor of tyrosinase. Pigment Cell Res. 
2002;15:335.

8.  Picardo  M,  Carrera  M.  New  and  experimental  treatments  of 
cloasma and other hypermelanoses. Dermatol Clin. 2007;25:353.
9.  Piao LZ, Park HR, Park YK, et al. Mushroom tyrosinase inhibition 

activity of some chromones. Chem Pharm Bull. 2002;50:309.
10.  Lynch B, Simon R, Roberts A. Subchronic toxicity evaluation of 

aloesin. Regul Toxicol Pharmacol. 2011;61:161.

11.  Zhu  W,  Gao  J.  The  use  of  botanical  extracts  as  topical  skin-
lightening  agents  for  the  improvement  of  skin  pigmentation 
disorders. J Investig Dermatol Symp Proc. 2008;13:20.

12.  Yang ZQ, Wang ZH, Tu JB, et al. The effects of aloesin and arbutin 
on cultured melanocytes in a synergetic method. Zhonghua Zheng 
Xing Wai Ke Za Zhi. 2004;20:369.

13.  Yagi  A,  Takeo  S.  Anti-inflammatory  constituents,  aloesin  and 
aloemannan in Aloe species and effects of tanshinon VI in Salvia 
miltiorrhiza on heart. Yakugaku Zasshi. 2003;123:517.

14.  Yagi  A,  Kabash  A,  Okamura  N,  et  al.  Antioxidant,  free  radical 
scavenging and anti-inflammatory effects of aloesin derivatives in 
Aloe vera. Planta Med. 2002;68:957.

 
C H A P T E R   3 5

Arbutin

C H A P T E R  35  ■   A R B U T I N  

97

Activities:

Tyrosinase inhibition, antioxidant, anti-inflammatory

Important Chemical Components:

The molecular formula for arbutin is C12H16O7.

Origin Classification:
β-arbutins are natural; deoxyarbutin and α-arbutins are 
synthetic.

Personal Care Category:

Depigmenting, sun protective

Recommended  for  the  following  Baumann  Skin 
Types: 

DRPT, DRPW, DSPT, DSPW, ORPT, ORPW, OSPT, and 
OSPW

 CHEMISTRY

This  β-d-glucopyranoside  is  composed  of  a  molecule  of  HQ 
bound to glucose. Similar in structure to HQ, arbutin inhibits 
tyrosinase and 5,6-dihydroxyindole-2-carboxylic acid (DHICA) 
polymerase activities at noncytotoxic concentrations, with the 
hydrolyzation of the glycosidic bond resulting in a significant 
reduction  in  melanin  synthesis.5,6  In  particular,  arbutin  seems 
to act as a reversible competitive inhibitor of tyrosinase (post-
translational  level).5  That  is,  the  depigmenting  mechanism  of 
arbutin involves a reversible inhibition of melanosomal tyrosi-
nase  activity  rather  than  suppressing  the  expression  and  pro-
duction of tyrosinase.5 Tyrosinase is the rate-limiting enzyme 
that regulates melanin production and is a unique product of 
melanocytes. Therefore, agents that block tyrosinase activity, a 
crucial  step  in  melanogenesis,  prevent  the  production  of  the 
pigment  melanin  and  are  considered  key  cosmetic  skin-
whitening ingredients. In essence, arbutin is thought to inhibit 
tyrosinase activity and melanosome maturation.7

 SOURCE

 ORAL USES

Arbutin is a natural β-d-glucopyranoside derivative of hydro-
quinone (HQ) found in the dry leaves of bearberry, cranberry, 
blueberry,  wheat,  and  other  plants.1,2  Arbutin  is  the  primary 
active constituent in bearberry (Arctostaphylos uva-ursi).

Arbutin is available in oral supplements for bladder health. As 
the  main  active  constituent  of  bearberry,  which  has  been 
used in traditional medicine as a diuretic, arbutin is thought 
to  play  a  role  in  treating  urinary  tract  infections.  Arbutin 
taken in oral form has not been shown to impact pigment in 
any way.

 HISTORY

Bearberry  has  been  used  for  medicinal  purposes  at  least 
since  the  13th  century,  when  it  was  thought  to  have  been 
used  in  Wales.3  It  is  official  in  most  pharmacopoeias.3 
Arbutin,  specifically,  has  been  used  in  traditional  medicine 
in Japan as a skin-lightening agent and has become an alter-
native  to  HQ  for  such  purposes  in  the  West  (Table  35-1). 
Cosmetic products used for the purposes of skin whitening 
may  include  α-  or  β-arbutins.  Of  these  glycosylated  HQs, 
β-arbutin is naturally found in various plants, but α-arbutin 
and other arbutin derivatives, such as deoxyarbutin, are syn-
thesized  by  chemical  and  enzymatic  methods. 4 
Approximately  50  years  ago,  scientists  in  Japan  were  the 
first  to  synthesize  α-arbutin  from  the  chemical  reaction  of 
penta-O-acetyl-β-d-glucopyranose and HQ.4

 TOPICAL USES

Arbutin is included as an ingredient in several cosmetic prod-
ucts,  typically  for  depigmenting  purposes.  But  the  synthetic 
arbutin  derivative  deoxyarbutin  (4-[(tetrahydro-2H-pyran-
2-yl)oxy]phenol)  has  displayed  promising  in  vitro  and  in  vivo 
results  with  a  greater  inhibition  of  tyrosinase  than  its  plant-
derived  precursor,8  and,  similarly,  evidence  suggests  that 
α-arbutin  (4-hydroxyphenyl  α-glucopyranoside)  exhibits 
more potent inhibitory activity against human tyrosinase than 
arbutin.9 This was previously demonstrated in studies of the 
effects of α- and β-arbutin on the tyrosinases from mushroom 
and  murine  melanoma.10  The  synthetic  α-arbutin  has  also 
been found to be a safe and effective skin-lightening agent.11

TABLE 35-1
Pros and Cons of Arbutin

Pros
May be allowed in countries that do not 

Cons
Typically found to be less potent than 

allow hydroquinone

May confer antioxidant effects

hydroquinone

Must be formulated properly to enhance 

skin penetration

 SAFETY ISSUES

Although arbutin has been considered safe in a handful of stud-
ies,  the  European  Union  Scientists  Committee  on  Consumer 
Products deemed, due to the release of HQ from the molecule, 
that the use of arbutin in cosmetic formulations is unsafe.12,13 
No such rulings have been issued in the United States, where 
arbutin is thought to be a safe alternative to HQ.

 
98 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

 ENVIRONMENTAL IMPACT

It is not well established what impact the cultivation of arbutin 
sources has on the environment. Similarly, it is not yet known 
how the culling of plants containing arbutin for the processing 
of synthetic forms of the ingredient affects the environment.

 FORMULATION CONSIDERATIONS

Skin  penetration  is  an  issue  with  many  ingredients  including 
arbutin. Various methods have been used to enhance skin pen-
etration.14

 USAGE CONSIDERATIONS

No  interactions  with  other  ingredients  are  known  by  the 
author.

 SIGNIFICANT BACKGROUND

HQ,  the  gold  standard  cosmetic  skin-lightening  agent  for 
many years, is more potent than arbutin but due to reports of 
cytotoxicity, nephrotoxicity, and genotoxicity was banned in 
Europe in 2000 and is strictly regulated in Asia.15 Several skin-
whitening  formulations  containing  arbutin  are  available  on 
the market; however, there are only a few small clinical stud-
ies in peer-reviewed journals on the depigmenting activity of 
this  compound  and  its  clinical  efficacy  is  not  firmly  estab-
lished.  An  open-label  study  on  10  melasma  patients  found 
that  a  gel  formulation  containing  arbutin  significantly 
decreased pigmentation in all of the patients, as assessed by 
Mexameter.16

Although the use of arbutin has been reported to be successful 
for cosmetic and therapeutic purposes, its suitability as an alter-
native depigmenting agent to HQ continues to be debated and 
much  more  study  in  humans  is  necessary.  Fifteen  years  ago, 
tyrosinase activity was found to decrease in normal human mel-
anocytes treated with arbutin, but an increase of pigmentation 
was also reported.17 Indeed, Maeda and Fukuda had previously 
reported that while higher concentrations of arbutin displayed 
greater  efficacy  than  lower  concentrations,  a  paradoxical 
discoloration  emerged  as  a  result  of  postinflammatory 
hyperpigmentation.2,5,18

In  a  2002  study  examining  the  inhibitory  effects  of  arbutin 
and/or aloesin on pigmentation in human skin after UV radiation, 
the administration of either or both compounds four times daily 
for 15 days revealed pigmentation suppression of 43.5 percent by 
arbutin,  34  percent  by  aloesin,  and  63.3  percent  by  the  
co-treatment  of  the  skin-lightening  agents  compared  with  the 
control.19

In  January  2008,  Yang  et  al.  constructed  a  pigmented  skin 
equivalent model in vitro and then studied the effects on melano-
cyte  cell  shape,  tyrosinase  activity,  and  melanin  formation 
exerted by aloesin, tea polyphenols, and arbutin. A concentration-
dependent  inhibitory  effect  on  melanocyte  tyrosinase  activity 
and melanin content was achieved by tea polyphenols, aloesin, 
and arbutin, in descending order, but significantly lower toxicity 
was  associated  with  aloesin  and  arbutin.20  Arbutin  was  also 
found  to  be  less  toxic  than  HQ  in  an  in  vitro  study  using  a 
melanocyte-keratinocyte  co-culture  model  in  which  four 
melanogenic-inhibiting compounds (i.e., arbutin, HQ, kojic acid, 
and niacinamide) were compared.21

Early in 2009, Lim et al. determined that arbutin both inhib-
ited melanin production in B16 cells induced with α-melanocyte 
stimulating hormone (α-MSH) and reduced tyrosinase activity in 
a cell-free system. The addition of arbutin to brownish guinea 
pig  and  human  skin  tissues  also  resulted  in  neutralizing  the 
hyperpigmentary impact of α-MSH. The authors concluded that 
arbutin  is  a  useful  skin-whitening  agent.22  Direct  proof  of  its 
clinical  efficacy  as  a  depigmenting  agent  remains  lacking, 
however.23

Antioxidant Activity
Antioxidant activity has also been attributed to arbutin and is 
thought to play a role in its potential therapeutic effectiveness. 
In September 2008, Bang et al. measured the hydrolytic activity 
of  the  primary  skin  microflora,  Staphylococcus  epidermidis  and 
Staphylococcus  aureus,  in  order  to  determine  if  skin  microflora 
can  hydrolyze  arbutin  to  HQ.  They  found  that  arbutin  was 
hydrolyzed by all strains, with the hydrolyzed HQ exhibiting 
greater 1,1-diphenyl-2-picrylhydrazyl radical-scavenging activ-
ity  and  tyrosinase  inhibition  than  arbutin.  The  investigators 
concluded that the antioxidant activity of HQ allows the main 
skin  microflora  to  enhance  the  skin-lightening  properties  of 
arbutin.15

In 2010, Takebayashi et al. used five assay systems to evaluate 
the antioxidant activity of arbutin and noted, in particular, that in 
two  cell-based  antioxidant  assays  using  erythrocytes  and  skin 
fibroblasts, arbutin displayed potent antioxidant activity compa-
rable to or greater than HQ.24

Synthetic Arbutin
While naturally-occurring arbutin has garnered attention in the 
cosmetic  and  therapeutic  realm  as  an  alternative  to  HQ  use, 
recent evidence suggests that a synthetic version of the botani-
cal is even more effective. In 2006, Hamed et al. evaluated the 
effects  of  deoxyarbutin  in  cultured  human  melanocytes,  on 
xenographs, and in a clinical trial, finding it to be a safe, effec-
tive, and reversible tyrosinase inhibitor.25

In 2005, Boissy et al., using a hairless pigmented guinea pig 
model, observed that topically applied deoxyarbutin exhibited a 
more sustained effect than HQ, with the effect found to be com-
pletely  reversible.  Kojic  acid  and  arbutin  failed  to  induce  skin 
lightening.  The  investigators  also  evaluated  deoxyarbutin  in  a 
12-week human clinical trial. Topical treatment with 3 percent 
deoxyarbutin induced a significant or slight decrease in overall 
skin lightness and amelioration of solar lentigines in light skin or 
dark skin patients, respectively.8

Building  on  previous  work  in  which  they  showed  that 
deoxyarbutin  is  a  more  effective  and  less  toxic  skin  lightener 
than  HQ,  Chawla  et  al.  used  standard  assays  to  evaluate  the 
efficacy and reversibility of deoxyarbutin and its derivatives on 
inhibiting  tyrosine  hydroxylase  and  dihydroxyphenylalanine 
(DOPA)-oxidase. They found that the agents, when used in con-
centrations  keeping  95  percent  cell  viability  in  culture,  dose-
dependently inhibited tyrosine hydroxylase and DOPA-oxidase 
activities,  thus  suppressing  melanin  synthesis  by  healthy  mel-
anocytes. Removal of the agents resulted in complete reversal of 
the depigmenting effect. An in vitro test using human and puri-
fied  mushroom  tyrosinase  also  revealed  tyrosinase  inhibition, 
which the authors cited as additional support for the notion that 
these agents directly inhibit the tyrosinase enzyme. They con-
cluded that deoxyarbutin and its second-generation derivatives 
impede  melanogenesis  at  safe  concentrations  by  suppressing 

 
tyrosinase,  and  deserve  consideration  as  effective  agents  to 
lighten the skin.26

In 2009, Hu et al. studied the impact of HQ, arbutin, and 
deoxyarbutin on melanogenesis and antioxidation using cul-
tured melan-a melanocytes exposed or not exposed to UVA-
induced oxidative stress and also sought to ascertain whether 
deoxyarbutin has the potential to serve as an alternative skin-
whitening agent to HQ and arbutin. The notable differences 
among the treatments were seen when the melanocytes were 
exposed to a nontoxic dose of UVA; increases in the cytotox-
icity of HQ and arbutin emerged. In addition, the production 
of reactive oxygen species was inhibited in association with 
the treatment of deoxyarbutin in comparison to arbutin and 
HQ and the investigators identified decreased protein expres-
sion of tyrosinase only in deoxyarbutin-treated melanocytes. 
The three whitening agents exhibited similar dose-dependent 
tyrosinase-inhibiting  activity,  with  two-  to  threefold  reduc-
tions  in  comparison  to  the  untreated  control  cells.  The 
researchers concluded that deoxyarbutin indeed is a safe and 
effective  alternative  to  HQ,  as  it  displays  strong  tyrosinase 
suppression, clear antioxidant potential, and reduced cytotox-
icity in comparison to the long-time standard skin-whitening 
compound.27

Overall, the data appear to indicate that α-arbutin is somewhat 
more effective than β-arbutin, but as some have noted, both are 
HQ  prodrugs  and  their  antityrosinase  activity  is  influenced  by 
HQ release from the molecule.12,28 Notably, synthetic α-arbutin 
(7  percent  solution)  has  been  successfully  used  in  combination 
with the MedLite C6 Q-switched Nd:YAG laser to treat refractory 
melasma, as shown in a prospective 10-week study of 35 patients. 
Treatments  were  well  tolerated  and  at  six  months  after  initial 
therapy,  30  percent  of  the  participants  had  excellent  clearance 
(greater  than  81  percent  melasma  reduction)  and  36.7  percent 
experienced good clearance (51–80 percent reduction).29

It is also worth noting that recent in vitro and in vivo data sug-
gest that 4-n-butylresorcinol is a more potent tyrosinase inhibi-
tor than HQ, arbutin, and kojic acid.12

 CONCLUSION

Arbutin has been traditionally used in Japan and recently in the 
West as a skin-lightening agent in cosmetic products. It is less 
effective  but  safer  than  HQ.  Synthetic  versions  of  arbutin 
appear  to  rival  HQ  in  effectiveness  while  achieving  a  safety 
profile comparable to arbutin. The clinical efficacy of arbutin as 
a depigmenting agent has yet to be firmly established.

REFERENCES

1.  Sheth VM, Pandya AG. Melasma: A comprehensive update Part II. 

J Am Acad Dermatol. 2011;65:699.

2.  Draelos ZD. Skin lightening preparations and the hydroquinone 

controversy. Dermatol Ther. 2007;20:308.

3.  Grieve M. A Modern Herbal. Vol 1. New York: Dover Publications; 

1971:90.

4.  Seo  DH,  Jung  JH,  Lee  JE,  et  al.  Biotechnological  production  of 
arbutins  (α-  and  β-arbutins),  skin-lightening  agents,  and  their 
derivatives. Appl Microbiol Biotechnol. 2012;95:1417.

5.  Maeda  K,  Fukuda  M.  Arbutin:  mechanism  of  its  depigmenting 
action  in  human  melanocyte  culture.  J  Pharmacol  Exp  Ther. 
1996;276:765.

C H A P T E R  35  ■   A R B U T I N  

99

6.  Chakraborty AK, Funasaka Y, Komoto M, et al. Effect of arbutin 
on melanogenic proteins in human melanocytes. Pigment Cell Res. 
1998;11:206.

7.  Davis EC, Callender VD. Postinflammatory hyperpigmentation: 
A  review  of  the  epidemiology,  clinical  features,  and  treatment 
options in skin of color. J Clin Aesthet Dermatol. 2010;3:20.

8.  Boissy  RE,  Visscher  M,  DeLong  MA.  DeoxyArbutin:  A  novel 
reversible tyrosinase inhibitor with effective in vivo skin lighten-
ing potency. Exp Dermatol. 2005;14:601.

9.  Zhu  W,  Gao  J.  The  use  of  botanical  extracts  as  topical  skin-
lightening agents for the improvement of skin pigmentation dis-
orders. J Investig Dermatol Symp Proc. 2008;13:20.

10.  Funayama M, Arakawa H, Yamamoto R, et al. Effects of alpha- 
and beta-arbutin on activity of tyrosinases from mushroom and 
mouse melanoma. Biosci Biotechnol Biochem. 1995;59:143.

11.  Sugimoto K, Nishimura T, Nomura K, et al. Inhibitory effects of 
alpha-arbutin on melanin synthesis in cultured human melanoma 
cells and a three-dimensional human skin model. Biol Pharm Bull. 
2004;27:510.

12.  Kolbe L, Mann T, Gerwat W, et al. 4-n-butylresorcinol, a highly 
effective  tyrosinase  inhibitor  for  the  topical  treatment  of  hyper-
pigmentation. J Eur Acad Dermatol Venereol. 2013;27(Suppl 1):19.
13.  Scientific Committee on Consumer Products (SCCP). Opinion on 
β-arbutin.  April  15,  2008.  http://ec.europa.eu/health/ph_risk/
committees/04_sccp/docs/sccp_o_134.pdf.  Accessed  January  24, 
2013.

14.  Wiechers JW, Kelly CL, Blease TG, et al. Formulating for efficacy. 

Int J Cosmet Sci. 2004;26:173.

15.  Bang  SH,  Han  SJ,  Kim  DH.  Hydrolysis  of  arbutin  to  hydroqui-
none by human skin bacteria and its effect on antioxidant activ-
ity. J Cosmet Dermatol. 2008;7:189.

16.  Ertam I, Mutlu B, Unal I, et al. Efficiency of ellagic acid and arbu-
tin  in  melasma:  A  randomized,  prospective,  open-label  study.  
J Dermatol. 2008;35:570.

17.  Nakajima M, Shinoda I, Fukuwatari Y, et al. Arbutin increases the 
pigmentation of cultured human melanocytes through mechanisms 
other  than  the  induction  of  tyrosinase  activity.  Pigment  Cell  Res. 
1998;11:12.

18.  Halder  RM,  Richards  GM.  Topical  agents  used  in  the  manage-

ment of hyperpigmentation. Skin Therapy Lett. 2004;9:1.

19.  Choi S, Lee SK, Kim JE, et al. Aloesin inhibits hyperpigmentation 

induced by UV radiation. Clin Exp Dermatol. 2002;27:513.

20.  Yang  ZQ,  Wang  ZH,  Zhang  TL,  et  al.  The  effect  of  aloesin  on 
melanocytes in the pigmented skin equivalent model. Zhonghua 
Zheng Xing Wai Ke Za Zhi. 2008;24:50.

21.  Lei TC, Virador VM, Vieira WD, et al. A melanocyte-keratinocyte 
coculture  model  to  assess  regulators  of  pigmentation  in  vitro. 
Anal Biochem. 2002;305:260.

22.  Lim YJ, Lee EH, Kang TH, et al. Inhibitory effects of arbutin on 
melanin biosynthesis of alpha melanocyte stimulating hormone-
induced hyperpigmentation in cultured brownish guinea pig skin 
tissues. Arch Pharm Res. 2009;32:367.

23.  Leyden JJ, Shergill B, Micali G, et al. Natural options for the man-
agement  of  hyperpigmentation.  J  Eur  Acad  Dermatol  Venereol. 
2011;25:1140.

24.  Takebayashi J, Ishii R, Chen J, et al. Reassessment of antioxidant 
activity of arbutin: Multifaceted evaluation using five antioxidant 
assay systems. Free Radic Res. 2010;44:473.

25.  Hamed SH, Sriwiriyanont P, deLong MA, et al. Comparative effi-
cacy  and  safety  of  deoxyarbutin,  a  new  tyrosinase-inhibiting 
agent. J Cosmet Sci. 2006;57:291.

26.  Chawla S, deLong MA, Visscher MO, et al. Mechanism of tyrosi-
nase inhibition by deoxyArbutin and its second-generation deriv-
atives. Br J Dermatol. 2008;159:1267.

27.  Hu ZM, Zhou Q, Lei TC, et al. Effects of hydroquinone and its 
glucoside  derivatives  on  melanogenesis  and  antioxidation: 
Biosafety as skin whitening agents. J Dermatol Sci. 2009;55:179.
28.  Briganti  S,  Camera  E,  Picardo  M.  Chemical  and  instrumental 
approaches  to  treat  hyperpigmentation.  Pigment  Cell  Res. 
2003;16:101.

29.  Polnikorn N. Treatment of refractory melasma with the MedLite 
C6  Q-switched  Nd:YAG  laser  and  alpha  arbutin:  A  prospective 
study. J Cosmet Laser Ther. 2010;12:126.

 
100 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   3 6

Hydroquinone

Activities:

Tyrosinase inhibition

Important Chemical Components:

Chemical formula: 1,4 dihydroxybenzene

Origin Classification:

Derived from natural sources, but synthetic in topically 
applied form

Personal Care Category:

Depigmenting, brightening, lightening

Recommended  for  the  following  Baumann  Skin 
Types:

DRPT, DRPW, DSPT, DSPW, ORPT, ORPW, OSPT, and 
OSPW. Hydroquinone (HQ) should be used with caution 
in sensitive skin types 2 and 4 because it may cause skin 
redness and irritation.

 SOURCE

Hydroquinone  (HQ),  a  hydroxyphenolic  derivative  of  benzene, 
occurs naturally as an ingredient in various plant-derived foods and 
beverages,  such  as  vegetables  (e.g.,  onions),  fruits  (particularly 
cranberries, blueberries, and pears), grains (especially wheat, wheat 
germ, and rice), coffee, tea, beer, and red wine.1–3 It is known to 
cause reversible inhibition of cellular metabolism by affecting both 
DNA and RNA synthesis. For many years, HQ has been the first-
line  therapy  for  postinflammatory  hyperpigmentation  and 
melasma. It is known to act as one of the most effective inhibitors 
of melanogenesis in vitro and in vivo (Table 36-1).4

 HISTORY

In 1936, Oettel was the first to report that HQ exhibited a lightening 
effect on the coat of black-hair cats that was reversible after drug 
withdrawal.2,5 Martin and Ansbacher were able to duplicate these 
results in 1941 in mice.2,6 The use of HQ to lighten the skin finally 

TABLE 36-1
Pros and Cons of Hydroquinone

Pros
Most effective depigmenting agent
Suitable component in various combination 

Cons
Questions about safety that scare patients
Banned in Europe in OTC products

emerged  in  the  1950s  after  anecdotal  reports  from  the  southern 
United States of depigmentation resulting from the use of sunscreens 
containing  HQ.1,7  Dermatologists  first  started  using  HQ  as  a 
depigmenting agent in 1961, after Spencer’s report that 45 percent 
of 98 subjects treated with 1.5 and 2 percent HQ showed improve-
ment in hyperpigmentation without adverse side effects.2,7 HQ has 
been used safely and effectively since that time for hypermelanosis, 
senile lentigos, vitiligo, and melasma, and has long been considered 
the most effective skin-lightening product for hyperpigmented skin 
disorders and the gold standard of treatment.1,2,8–10

Concerns about its safety and potential to cause cancer, however, 
led  to  its  ban  for  general  cosmetic  purposes  in  Europe  at  the 
beginning  of  the  millennium.  In  Asia,  HQ  is  legal,  but  highly 
regulated. In the United States, the Food and Drug Administration 
(FDA)  has  long  been  considering  the  status  of  HQ  but  not  yet 
decided whether to ban it in over-the-counter (OTC) products. HQ 
has  never  been  etiologically  linked  with  human  cancer  and  has 
been safely used by dermatologists in the United States for decades. 
Consensus among dermatologists is that it is safe.2 Pigmentation of 
the  eye  and  permanent  corneal  damage  are  the  most  serious 
adverse health effects seen in workers exposed to HQ.1 Exogenous 
ochronosis (darkening of the skin) is also associated with topically 
applied  HQ,  although  only  30  cases  of  ochronosis  have  been 
ascribed  to  HQ  use  in  North  America.2,11,12  Skin  rashes  and  nail 
discoloration have also been linked to HQ use. The safety debate 
about HQ within the FDA has provided the impetus for manufac-
turers  to  research  and  develop  newer  skin-lightening  agents. 
However, many of them are chemical derivatives of HQ, can cause 
the same types of complications, and are not as effective as HQ.

 CHEMISTRY

HQ depletes glutathione and results in oxidative damage to mem-
brane lipids and proteins, including tyrosinase.13 It is a strong oxi-
dant and is quickly converted to p-benzoquinone and hydroxyben-
zoquinone.14  Its  primary  cutaneous  use  is  in  OTC  products  
(2 percent concentration or less), prescription drugs (4 percent), and 
custom pharmacy formulations (2 to ≥10 percent) as an ingredient 
to inhibit melanin synthesis to achieve skin lightening. Cosmetic 
products  containing  HQ  are  often  labeled  as  “skin  brighteners.” 
HQ  imparts  its  depigmenting  effect  by  efficiently  inhibiting 
tyrosinase, lowering its activity by 90 percent,15 and by virtue of its 
hampering of melanosome formation and cytotoxicity to melano-
cytes.16,17  Further,  HQ  suppresses  the  enzymatic  oxidation  of 
tyrosine  and  phenol  oxidases  as  well  as  melanin  production  by 
blocking sulfhydryl groups, in the latter case.17 Although it is useful 
as a sole agent, HQ is often combined with other agents such as 
tretinoin, glycolic acid, kojic acid, and azelaic acid.18

products

Preferred by dermatologists in the United States

Easily oxidized
Difficult to formulate
Reacts with other ingredients
Allergic contact dermatitis can occur

 ORAL USES

HQ is found in various foods and beverages as well as in the 
general environment and thus can be orally ingested or inhaled 
(it is also found in cigarette smoke).2 However, oral use of HQ 

 
does  not  confer  any  known  or  studied  effects  on  skin 
pigmentation.

 TOPICAL USES

For  over  half  a  century,  HQ  has  been  the  standard-bearing 
topical  treatment  for  disorders  of  pigmentation.  Safety 
concerns  about  this  benzene  derivative  have  led  to  the 
introduction  of  various  alternative  treatments  for  skin 
lightening. Nevertheless, HQ remains in wide use and is well 
regarded by dermatologists. Although there are reports in the 
media  about  safety  concerns  pertaining  to  HQ  and  many 
consumers  are  afraid  of  it,  most  dermatologists  consider  it 
very  safe  and  effective  as  it  remains  the  gold  standard  of 
depigmentation products used in dermatology.

 SAFETY ISSUES

Despite a lengthy record of medical usage, concerns have been 
raised about HQ because it is derived from benzene, which is 
known to engender aplastic anemia and leukemia in humans.2,19 
Therefore,  fears  that  HQ  may  exhibit  mutagenic  properties 
have  been  expressed.  In  addition,  there  have  been  some  side 
effects associated with the long-term use of cosmetic products 
with  high  HQ  concentrations.2  Consequently,  since  January 
2001, HQ has been banned as an OTC cosmetic skin-bleaching 
agent  in  Europe,  where  it  is  available  only  by  prescription,20 
and it is highly regulated in Asia.

Exogenous  ochronosis  is  the  most  prevalent  among  the 
actual  adverse  events  associated  with  HQ  usage.  By  far,  the 
highest number of cases have occurred among Bantu females in 
sub-Saharan  Africa,  particularly  in  South  Africa,  where  other 
ingredients besides HQ, including quinine injection, resorcinol, 
and antimalarials, may be implicated.17,21 It is also widely held 
that  unsupervised  and  protracted  use  of  adulterated  HQ  has 
played  an  important  role  in  the  incidence  of  HQ-induced 
exogenous ochronosis in Africa.17

Concerns  about  the  effects  of  intermediate  and  particu-
larly  long-term  use  of  HQ,  such  as  leukomelanoderma  en 
confetti  and  exogenous  ochronosis,  contributed  to  the 
European ban.20,22 Ironically, exogenous ochronosis presents 
as  yellow-brown  or  blue-black  hyperpigmentary  macules 
that can result from the treatment of other hyperpigmentary 
conditions  with  skin-bleaching  formulations  containing 
HQ.21  Exogenous  ochronosis  occurs  in  the  area  of  HQ 
application, usually after extended use of even low concen-
trations (2 percent) of HQ, and more often in patients with 
darker  skin  types.  This  adverse  response  is  thought  to  be 
caused  by  the  inhibition  of  the  enzyme  homogentisic  acid 
oxidase  in  the  skin,  resulting  in  the  local  accumulation  of 
homogentisic acid that then polymerizes to form ochronotic 
pigment.23 Despite widespread use of HQ in North America, 
the number of reported cases of exogenous ochronosis due to 
HQ use has been limited to 30.9 To reduce the likelihood of 
adverse  effects  seen  with  HQ,  it  is  best  to  use  it  in  four-
month cycles, alternating it with kojic acid, azelaic acid, and 
other alternative lightening agents.24

Some studies have shown that large doses of  HQ  delivered 
systemically  –  not  by  topical  application  –  resulted  in  some 
evidence  of  cancer  in  rats.  However,  rats  metabolize  HQ  very 
differently  than  humans,  who  detoxify  it  in  the  liver.2,25  In 
humans, HQ is probably metabolized to detoxified derivatives, 
such as glucuronide and sulfate conjugates of HQ.26

C H A P T E R  36  ■   H Y D R O Q U I N O N E  

101

Recently, investigators conducted a literature search focusing 
on  the  biochemistry  and  toxicology  of  HQ,  benzene,  and 
related molecules, with an eye toward the potential long-term 
side effects of HQ use in cosmetics. After surveying the large 
body of literature, particularly since 1996, on the carcinogenic-
ity  of  these  compounds,  the  researchers  concluded  that  the 
long-term use of topically applied HQ does pose an increased 
risk for cancer, and recommended that this benzene derivative 
no  longer  be  used  as  a  skin-lightening  agent.22  Nevertheless, 
there  are  no  reports  in  the  medical  literature  of  any  human 
cutaneous  or  internal  malignancies  linked  to  HQ.2  In  animal 
experiments,  HQ  use  has  been  demonstrated  to  induce  renal 
adenomas  and  leukemia.  As  absorption  of  HQ  is  more  rapid 
than its elimination through urine, daily use is now known to 
accumulate in the body.20 In workers exposed to HQ, the most 
serious health effects have been pigmentation of the eye and, 
in a very small number of cases, permanent corneal damage.1

At  the  time  that  this  chapter  was  written,  debate  was 
ongoing in the United States as to whether the FDA will ban 
HQ  in  OTC  formulations.  Several  companies  have  removed 
HQ from their products in anticipation of such a policy change. 
In  addition,  many  companies  with  pharmaceutical  products 
containing HQ that have not undergone the FDA approval pro-
cess fear that the product will soon be banned by the FDA. 

Irritant  and  allergic  contact  dermatitis  as  well  as  nail 
discoloration  have  also  been  associated  with  HQ  use,  with 
postinflammatory hyperpigmentation also resulting from con-
tact dermatitis. In addition, hypopigmentation has been known 
to arise around the sites treated with HQ. Discontinuing HQ 
therapy  resolves  these  side  effects.9,27  Despite  the  European 
ban  and  tight  regulation  in  Asia,  the  American  Academy  of 
Dermatology  and  others  have  not  found  justification  for 
restricting use of HQ and the FDA has not yet established new 
rules governing its use in the United States.24

Contact dermatitis to HQ can occur. The author had a patient 
that  experienced  an  immediate  hypersensitivity  to  HQ  that 
occurred three minutes after application and had to be managed 
with Benadryl and topical steroids (Figure 36-1).

 ENVIRONMENTAL IMPACT

In addition to the presence of HQ, or its β-d-glucopyranoside 
derivative  arbutin,  in  various  herbal  formulations  and  foods, 
HQ is manufactured annually for use as a skin-lightening agent 
as well as industrial purposes, including use as a photographic 
developer for black and white film and a stabilizing component 

▶

FIGURE 36-1  Contact dermatitis in response to hydroquinone use.

 
102 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

for paints, varnishes, motor fuels, and oils.2 It is not clear how 
the environment is impacted by these processes, but exposure 
of workers to HQ has been studied extensively and not found 
to have significant long-range health implications.

 FORMULATION CONSIDERATIONS

HQ is very difficult to formulate because it is a highly reactive 
oxidant  that  rapidly  combines  with  oxygen.  This  renders  it 
unstable, which, in turn, affects the stability of other ingredients 
combined in the same formulation or applied at the same time 
on  the  skin.  HQ  changes  color  when  oxidized  to  a  darker 
yellow or brown hue indicating that it has lost its effectiveness. 
For  this  reason,  many  preparations  are  kept  refrigerated. 
Microsponge delivery systems have been developed with the 
intention of stabilizing HQ.28

 USAGE CONSIDERATIONS

Although the 4 percent concentration is more effective than the 
more conventional 2 percent concentration, it is more irritating 
and  may  be  more  likely  to  lead  to  side  effects  such  as  skin 
redness.  Prolonged  application  of  HQ,  often  eight  weeks  or 
more, is necessary before any improvement becomes noticeable. 
A prescription is required in the United States for 4 percent HQ.
Most dermatologists recommend an HQ holiday after three 
months  of  use  because  patients  can  develop  tachyphylaxis 
(a  sudden  or  acute  decrease  in  response  or  tolerance)  to  it. 
Stopping HQ for four weeks after three months of use seems to 
increase the effectiveness when it is restarted at month 4. In the 
author’s practice, patients are advised to use a treatment regimen 
consisting of HQ. Once the spots clear, patients are switched to 
a maintenance regimen consisting of soy or niacinamide and a 
retinoid.  The  author  also  includes  an  antioxidant,  which  can 
chelate copper, hampering tyrosinase.29

 SIGNIFICANT BACKGROUND

In  a  study  of  16  women  with  idiopathic  melasma,  patients 
nightly applied 5 percent ascorbic acid cream on one side of the 
face and 4 percent HQ cream on the other side for 16 weeks, 
and  applied  sunscreen  daily.  The  best  subjective  results  were 
seen on the HQ side (93 percent vs. 62.5 percent), though no 
statistical  differences  were  identified  through  colorimetric 
analysis.  The  side  effect  profile  strongly  favored  the  ascorbic 
acid side, with adverse reactions seen in 11 of 16 HQ sides as 
opposed to only 1 of 16 ascorbic acid sides.30 The safety debate 
about HQ within the FDA has spurred companies to research 
newer, less controversial skin lighteners as well as combination 
therapies.

Tri-Luma
Because  of  escalating  concerns  regarding  HQ  monotherapy, 
numerous  studies  have  been  conducted  that  include  HQ  in 
combination  topical  therapy.  HQ,  along  with  tretinoin  and 
topical corticosteroids, are well established as effective single 
agents for treating melasma and hyperpigmentation. In 1975, 
Kligman  described  combining  HQ,  tretinoin,  and  a  topical 
steroid to treat skin pigmentation – a formula that to this day is 
referred to as the “Kligman formula.”31 Athough the Kligman 
formula is often compounded by independent pharmacists, the 
once-daily  triple  combination  cream  containing  0.05  percent 

tretinoin,  4.0  percent  HQ,  and  0.01  percent  fluocinolone 
acetonide  (Tri-Luma)  is  the  only  commercially  available 
combination of all three agents. In fact, this product is the only 
HQ-containing product that has been approved by the FDA to 
treat  facial  melasma.32  Extensive  studies  have  indicated  an 
efficacious and safe profile for this triple combination cream in 
treating melasma.32

In  a  multicenter,  open-label,  12-month  study  of  once-daily 
application  of  Tri-Luma  Cream  for  the  treatment  of  facial 
melasma,  which  173  out  of  228  patients  completed,  the 
formulation  was  deemed  to  be  safe  and  effective.  Patient  and 
physician  assessment  revealed  complete  or  nearly  complete 
clearing in over 90 percent of cases; 129 patients experienced at 
least  one  adverse  event  related  to  treatment,  with  most 
categorized  as  mild  and  transient.33  More  evidence  to  support 
the  triple  combination  approach  comes  from  an  eight-week, 
multicenter, open-label, community-based study evaluating the 
hydrophilic cream formulation Tri-Luma used on 1,290 patients 
of diverse races/ethnicities and the full gamut of Fitzpatrick skin 
types. Global evaluations at the end of the study period revealed 
that  75  percent  of  patients  exhibited  “moderate  or  marked 
improvement” or were judged to be “almost clear” or “clear.”34 A 
12-month extension of a randomized, investigator-blinded, mul-
ticenter,  eight-week  trial  evaluating  Tri-Luma  Cream  for  facial 
melasma  netted  389  patients  completing  six  months  of  treat-
ment  and  327  patients  completing  12  months,  with  
80  percent  of  patients  exhibiting  complete  or  nearly  complete 
clearance  of  lesions.  This  study  reinforced  a  previous  smaller 
study indicating that once-daily application is effective, safe, and 
tolerable over a lengthy period for the treatment of moderate-to-
severe melasma.35

If a ban on HQ is implemented, the one product that would 
remain unaffected is Tri-LumaTM. When the FDA solicited safety 
data  on  HQ  several  years  ago,  only  the  manufacturers  of  Tri-
Luma complied and it has now been approved for the short-term 
and  intermittent  long-term  treatment  of  moderate-to-severe 
melasma.

Other Combination Therapies
In  2004,  a  12-week  open-label  study  with  28  patients  (25  of 
whom completed the study) evaluated the safety and efficacy of 
a  then-novel  formulation  of  4  percent  HQ  with  0.15  percent 
retinol entrapped in microsponge reservoirs, which were used for 
the gradual release of HQ to extend treatment exposure and limit 
skin irritation. With patients applying the study cream twice daily 
to the full face in the morning and evening and a broad-spectrum 
sunscreen 15 minutes after the morning application of the study 
product,  patients  were  assessed  at  4,  8,  and  12  weeks. 
Improvement was seen in all study end points (including melasma 
or  postinflammatory  hyperpigmentation  disease  severity  and 
intensity,  as  well  as  lesion  area).  The  HQ/retinol  combination 
was found to be safe and effective, with only one patient drop-
ping out due to an adverse reaction not judged to be serious.8

Other studies of dual-combination formulations have yielded 
encouraging results. A 16-week comparison study revealed that 
an  emollient  cream  containing  4  percent  HQ  and  0.3  percent 
retinol  more  effectively  eliminated  the  signs  of  photodamage 
(i.e., dyspigmentation, fine wrinkles, and tactile roughness) than 
a  0.05  percent  tretinoin  emollient  cream  and,  according  to 
researchers, may represent a viable therapy for hyperpigmenta-
tion associated with photoaging.36 Further, in a 24-week study in 
2006, topical application of tazarotene plus HQ was found to be 
more  effective  in  ameliorating  the  dyspigmentation  associated 

 
with  photodamage  than  tazarotene  alone.37  In  addition  to  the 
various  combination  formulations  containing  HQ,  various 
additives, such as antioxidants (e.g., vitamin C in addition to the 
more  standard  retinoids)  and  α-hydroxy  acids,  can  be  used  to 
enhance efficacy and penetration.9

Alternatives
As  the  gold  standard  depigmenting  agent,  HQ  is  really  the 
focus  of  this  section  of  the  book.  The  other  chapters  are  a 
reaction to it, in a sense. Alternatives such as azelaic, thioctic 
(α-lipoic), kojic, and glycolic acids, as well as deoxyarbutin,38 
have  been  proposed  as  safer  alternatives  to  the  topical 
application  of  HQ.20  Small  proteins  found  in  soy  as  well  as 
niacinamide,  a  vitamin  B3  derivative,  also  appear  to  have 
potential  as  alternatives.  The  soy  proteins,  such  as  soybean 
trypsin inhibitor (STI) and Bowman-Birk Inhibitor (BBI), may 
inhibit skin pigmentation. These soy proteins have been found 
not only to exhibit depigmenting activity, but also to prevent 
UV-induced pigmentation both in vitro and in vivo.39 Niacinamide 
has also been demonstrated to inhibit melanosome movement 
from melanocytes to keratinocytes.40

 CONCLUSION

HQ has a long record of successful and safe use in medicine, 
particularly  as  a  skin-lightening  agent  for  dermatologic  use. 
Recently, this agent has come under greater scrutiny due to its 
putative  potential  for  inducing  adverse  effects.  In  2006,  the 
FDA  published  a  monograph  proposing  a  ban  of  all  HQ 
products  not  approved  through  the  New  Drug  Application 
process  and  asking  companies  that  market  HQ  products  to 
provide product safety data. Since then, we have been facing 
the  prolonged  possibility  of  a  loss  of  a  superlative  cosmetic 
ingredient  as  the  FDA  mulls  over  the  unpopular  prospect  of 
enacting its proposed ban (although the longer the FDA remains 
quiet on the issue, the less likely a ban appears to be, it might 
be argued). If a ban of HQ occurs, many dermatologists may 
choose to continue to have products containing HQ formulated 
for  their  patients  in  a  pharmacy,  which  is  becoming  a  very 
common practice in the United States. Unfortunately, it is dif-
ficult to stabilize a steroid, HQ, and tretinoin in a formulation, 
so this option may not be ideal for patients. The overwhelming 
opinion among dermatologists is that HQ warrants continued 
use  in  the  prescription  depigmenting  armamentarium.  The 
most challenging problem with HQ is that it is reactive with 
other  ingredients  and  oxidizes  rapidly.  For  that  reason,  the 
formulation  of  HQ,  the  order  in  which  it  is  applied,  and  the 
other products with which it is used is very important in order 
to  achieve  maximum  efficacy.  HQ  should  only  be  used  for 
three months and when the patient is experiencing pigmenta-
tion issues. Stopping HQ use for four weeks every three months 
may improve its efficacy. Combining HQ with skin lighteners 
that  block  protease-activated  receptor-2  and  exhibit  sun 
protection factor is critical for success.

REFERENCES

1.  DeCaprio  AP.  The  toxicology  of  hydroquinone  –  Relevance  to 
occupational  and  environmental  exposure.  Crit  Rev  Toxicol. 
1999;29:283.

2.  Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. 

J Eur Acad Dermatol Venereol. 2006;20:781.

3.  Deisinger  PJ,  Hill  TS,  English  JC.  Human  exposure  to  naturally 
occurring hydroquinone. J Toxicol Environ Health. 1996;47:31.

C H A P T E R  36  ■   H Y D R O Q U I N O N E  

103

4.  Parvez S, Kang M, Chung HS, et al. Survey and mechanism of skin 
depigmenting and lightening agents. Phytother Res. 2006;20:921.
5.  Oettel  H.  Hydroquinone  poisoning.  Arch  Exp  Pathol  Pharmacol. 

1956;183:319.

6.  Martin  GJ,  Ansbacher  S.  Confirmatory  evidence  of  the  chro-
motrichal  activity  of  p-aminobenzoic  acid.  J  Biol  Chem. 
1941;13:441.

7.  Fitzpatrick TB, Arndt KA, el-Mofty AM, et al. Hydroquinone and 
psoralens  in  the  therapy  of  hypermelansosis  and  vitiligo.  Arch 
Dermatol. 1966;93:589.

8.  Grimes PE. A microsponge formulation of hydroquinone 4% and 
retinol 0.15% in the treatment of melasma and postinflammatory 
hyperpigmentation. Cutis. 2004;74:362.

9.  Halder RM, Richards GM. Topical agents used in the management 

of hyperpigmentation. Skin Therapy Lett. 2004;9:1.

10.  Engasser PG, Maibach HI. Cosmetics and dermatology: Bleaching 

creams. J Am Acad Dermatol. 1981;5:143.

11.  Lawrence N, Bligard CA, Reed R, et al. Exogenous ochronosis in 

the United States. J Am Acad Dermatol. 1988;18:1207.

12.  Levin  CY,  Maibach  H.  Exogenous  ochronosis:  An  update  on 
clinical features, causative agents and treatment options. Am J Clin 
Dermatol. 2001;2:213.

13.  Kim H, Choi HR, Kim DS, et al. Topical hypopigmenting agents 
for  pigmentary  disorders  and  their  mechanisms  of  action.  Ann 
Dermatol. 2012;24:1.

14.  Dadzie  OE,  Petit  A.  Skin  bleaching:  Highlighting  the  misuse  of 
cutaneous  depigmenting  agents.  J  Eur  Acad  Dermatol  Venereol. 
2009;23:741050.

15.  Nordlund JJ. Postinflammatory hyperpigmentation. Dermatol Clin. 

1988;6:185.

16.  Penney  KB,  Smith  CJ,  Aleen  JC.  Depigmenting  action  of 
hydroquinone  depends  on  disruption  of  fundamental  cell 
processes. J Invest Dermatol. 1984;82:308.

17.  Tse  TW.  Hydroquinone  for  skin  lightening:  Safety  profile, 
duration  of  use  and  when  should  we  stop?  J  Dermatolog  Treat. 
2010;21:272.

18.  Guevara  IL,  Pandya  AG.  Melasma  treated  with  hydroquinone, 
tretinoin and a fluorinated steroid. Int J Dermatol. 2001;40:212.
19.  Rinsky RA, Smith AB, Hornung R, et al. Benzene and leukemia. 
An epidemiologic risk assessment. N Engl J Med. 1987;316:1044.
20.  Kooyers TJ, Westerhof W. Toxicological aspects and health risks 
associated  with  hydroquinone  in  skin  bleaching  formula.  Ned 
Tijdschr Geneeskd. 2004;148:768.

21.  Bongiorno  MR,  Aricò  M.  Exogenous  ochronosis  and  striae 
atrophicae following the use of bleaching creams. Int J Dermatol. 
2005;44:112.

22.  Kooyers TJ, Westerhof W. Toxicology and health risks of hydro-
quinone  in  skin  lightening  formulations.  J  Eur  Acad  Dermatol 
Venereol. 2006;20:777.

23.  Kramer KE, Lopez A, Stefanato CM, et al. Exogenous ochronosis. 

J Am Acad Dermatol. 2000;42:869.

24.  Burkhart CN, Katz KN. Chapter 222: Other topical medications. 
In:  Goldsmith  LA,  Katz  SI,  Gilchrest  BA,  Paller  AS,  Leffell  DJ, 
Wolff K, eds. Fitzpatrick’s Dermatology in General Medicine. 8th ed. 
Vol. 2. New York: McGraw-Hill; 2012:2704.

25.  Bates B. Derms react to possible FDA ban of hydroquinone: Cite 
poor  scientific  reasoning,  ethnic  bias.  Skin  and  Allergy  News. 
2007;38:1.

26.  Picardo  M,  Carrera  M.  New  and  experimental  treatments  of 
cloasma and other hypermelanoses. Dermatol Clin. 2007;25:353.
27.  Grimes  PE.  Melasma.  Etiologic  and  therapeutic  considerations. 

Arch Dermatol. 1995;131:1453.

28.  Mandava  SS,  Thavva  V.  Novel  approach:  Microsponge  drug 

delivery system. IJPSR. 2012;3:967.

29.  Kim  YJ,  Uyama  H.  Tyrosinase  inhibitors  from  natural  and 
synthetic  sources:  Structure,  inhibition  mechanism  and 
perspective for the future. Cell Mol Life Sci. 2005;62:1707.

30.  Espinal-Perez  LE,  Moncada  B,  Castanedo-Cazares  JP.  A  double-
blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone 
in melasma. Int J Dermatol. 2004;43:604.

31.  Kligman AM, Willis I. A new formula for depigmenting human 

skin. Arch Dermatol. 1975;111:40.

32.  Torok HM. A comprehensive review of the long-term and short-
term  treatment  of  melasma  with  a  triple  combination  cream.  
Am J Clin Dermatol. 2006;7:223.

33.  Torok  HM,  Jones  T,  Rich  P,  et  al.  Hydroquinone  4%,  tretinoin 
0.05%,  fluocinolone  acetonide  0.01%:  A  safe  and  efficacious 
12-month treatment for melasma. Cutis. 2005;75:57.

 
104 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

34.  Grimes P, Kelly AP, Torok H, et al. Community-based  trial  of a 
triple-combination  agent  for  the  treatment  of  facial  melasma. 
Cutis. 2006;77:177.

35.  Torok H, Taylor S, Baumann L, et al. A large 12-month extension 
study of an 8-week trial to evaluate the safety and efficacy of triple 
combination  (TC)  cream  in  melasma  patients  previously  treated 
with TC cream or one of its dyads. J Drugs Dermatol. 2005;4:592.
36.  Draelos ZD. Novel approach to the treatment of hyperpigmented 
photodamaged skin: 4% hydroquinone/0.3% retinol versus treti-
noin 0.05% emollient cream. Dermatol Surg. 2005;31:799.

37.  Lowe N, Horwitz S, Tanghetti E, et al. Tazarotene versus tazaro-
tene plus hydroquinone in the treatment of photodamaged facial 

skin:  A  multicenter,  double-blind,  randomized  study.  J  Cosmet 
Laser Ther. 2006;8:121.

38.  Hamed SH, Sriwiriyanont P, deLong MA, et al. Comparative effi-
cacy  and  safety  of  deoxyarbutin,  a  new  tyrosinase-inhibiting 
agent. J Cosmet Sci. 2006;57:291.

39.  Paine  C,  Sharlow  E,  Liebel  F,  et  al.  An  alternative  approach  to 
depigmentation by soybean extracts via inhibition of the PAR-2 
pathway. J Invest Dermatol. 2001;116:587.

40.  Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide 
on  reducing  cutaneous  pigmentation  and  suppression  of 
melanosome transfer. Br J Dermatol. 2002;147:20.

 
C H A P T E R   3 7

Kojic Acid

C H A P T E R  37  ■   KO J I C   AC I D  

105

Activities:
Anti-inflammatory, antibiotic, anodyne, skin lightening1

Important Chemical Components:

Molecular formula: C6H6O4

Origin Classification:

This  agent  is  a  natural  metabolite  of  various  bacterial 
species.

Personal Care Category:

Skin lightener

Recommended for the following Baumann Skin 
Types:

DRPT, DRPW, DSPT, DSPW, ORPT, ORPW, OSPT, and 
OSPW

 SOURCE

(5-hydroxy-2-hydroxymethyl-γ -pyrone  or 
Kojic  acid 
5-hydroxy-2-(hydroxymethyl)-4H-pyran-4-one)  is  a  fungal 
metabolite of several species of bacteria, including Acetobacter, 
Penicillium,  and  Aspergillus,  particularly  Aspergillus  oryzae,  a 
fungus used for centuries in Asia in the production of soy sauce, 
miso, and sake.2 Derivatives of kojic acid have been reported to 
display enhanced efficiency via greater skin penetration.3

 HISTORY

Kojic acid was discovered as a fungal natural product in 1907.4 It 
was used widely in cosmetic agents, particularly in Japan from 
1988  to  2003,  for  its  capacity  to  reduce  pigmentation.5–7  Kojic 
acid was deemed a “quasi-drug” and banned from the market in 
Japan by the Ministry of Health, Labor and Welfare in 2003 and 
subsequently in Korea and Switzerland due to safety concerns 
stemming  from  animal  test  results  suggesting  mutagenicity. 
Some countries have reportedly since reintroduced it as a skin-
lightening agent, but it remains excluded in others.8

 CHEMISTRY

Kojic  acid  inhibits  tyrosinase  activity,  mainly  by  chelating 
copper,  leading  to  a  cutaneous  whitening  effect.9  It  is  also 
believed to act by inhibiting the tautomerization of dopachrome 
to  5,6-dihydroxyindole-2-carboxylic  acid.5,10  In  addition,  the 
preservative and antibiotic activities of this agent contribute to 
extending  product  shelf  life.11  Such  stability  is  one  of  the 
advantages of kojic acid in comparison to hydroquinone (HQ) 
as well as other skin-lightening ingredients (Table 37-1).12 The 
efficacy  of  kojic  acid  in  achieving  such  an  effect  is  similar  to 
that of HQ, the gold standard but controversial depigmenting 

TABLE 37-1
Pros and Cons of Kojic Acid

Pros
More stable than hydroquinone
Found to be effective in combination 

therapy

Cons
High sensitizing potential
Lack of peer-reviewed data of 

monotherapy achieving depigmenting 
effect

agent.13,14  However,  while  kojic  acid  yields  greater  stability 
than  HQ,  the  fungal  derivative  does  have  labile  oxidative 
properties,  which  are  enhanced  by  light  and  heat  exposure. 
Therefore,  kojic  acid  is  included  in  cosmetic  formulations 
through its dipalmitic ester (as kojic dipalmitate).15

 ORAL USES

Kojic  acid  is  widely  used  as  a  food  additive  for  preventing 
enzymatic  browning,  and  to  promote  reddening  of  unripe 
strawberries.16 It is used in Asia as a dietary antioxidant.17,18

 TOPICAL USES

Kojic  acid  is  second  only  to  HQ  in  effectiveness  as  a  skin-
lightening agent in topical over-the-counter products, and is the 
most popular agent for treating melasma in East Asia.8,18 Given 
the regulatory status of HQ, which has been banned in Europe 
and is tightly regulated in Asia, while remaining under scrutiny 
in the United States, this makes sense. 

However,  kojic  acid  is  not  a  first-line  therapy  for  melasma 
because  it  may  cause  skin  irritation.1,19,20  However,  it  can  be 
effective in patients that do not tolerate the first-line products, 
particularly  HQ.20  Further,  combining  a  topical  corticosteroid 
with  kojic  acid  can  reduce  the  irritant  qualities  of  the  fungal 
derivative.17,21 In the experimental setting, kojic acid is regularly 
used as a reference or positive control to test the skin-whitening 
potential of new agents.

Kojic acid products are typically used twice daily for one to 

two months or until the patient achieves the desired results.

 SAFETY ISSUES

Despite  the  success  of  kojic  acid  at  1  percent  concentrations, 
particularly in Japan, some studies have indicated that longer-
term  use  of  the  agent  may  engender  contact  dermatitis  and 
erythema.14,22,23  In  addition,  an  association  between  hepatic 
tumors  in  heterozygous  p53-deficient  mice  and  the  topical 
application of kojic acid has been identified.24,25 In 2003, Japan’s 
health  ministry  ordered  the  removal  of  kojic  acid  from  the 
market  over  fears,  based  on  animal  studies,  that  the  fungal 
metabolite might cause cancer.7

In response to such findings and concerns, specifically the link 
between potential tumor promotion in mouse and rat livers due 
to  kojic  acid,  Higa  et  al.  examined  the  presence  of  initiation 

 
106 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

activity in rat liver and the potential of photogenotoxicity and 
carcinogenicity in mouse skin in relation to kojic acid. In one of 
the  team’s  multiple  experiments,  a  cream  containing  1.0  or  
3.0 percent kojic acid was applied twice to the backs of mice in a 
24-hour  period,  with  researchers  noting  that  kojic  acid  failed  
to  induce  epidermal  cell  micronuclei.  In  addition,  a  skin 
carcinogenesis  bioassay  for  initiation-promotion  potential 
revealed  the  emergence  of  no  skin  nodules  due  to  the  topical 
application of 3.0 percent kojic acid cream to the backs of mice daily 
for  seven  days  or  five  times  a  week  for  19  weeks  administered 
during either cancer stage. Overall, the investigators concluded that 
kojic acid poses a minimal risk of photocarcinogenesis in the skin 
and does not exhibit skin carcinogenesis initiation or promotion 
activity. They also supported the contention that kojic acid is a 
safe ingredient in cosmeceuticals.26 In addition, in 2006, Lee et al. 
reported on derivatives of kojic acid displaying greater efficiency 
through increased penetration into the skin.27

Given its extensive use in foods, it may not be surprising to 
learn  that  there  have  been  many  reports  on  its  oral  safety. 
Toxicity resulting from an oral dose has been reported in a recent 
Japanese  study,  recording  the  occurrence  of  hepatocellular 
tumors  in  p53-deficient  mice.24  Furthermore,  convulsions  may 
occur if kojic acid is injected.11,12

 ENVIRONMENTAL IMPACT

There is no known significant environmental impact associated 
with kojic acid preparation for medicinal purposes.

 FORMULATION CONSIDERATIONS

Kojic  acid  has  reportedly  provoked  contact  allergies  and  is 
considered to display a high sensitizing potential.23 Because prepa-
rations containing a 2.5 percent concentration of kojic acid have 
been  associated  with  facial  dermatitis,28  a  concentration  of  
1 percent has become more common. However, there have also 
been some reports of sensitization linked to 1 percent creams.23 
Mild  facial  erythema  is  the  primary  adverse  effect  reported  in 
association with the typically well-tolerated fungal metabolite.25

 USAGE CONSIDERATIONS

Kojic acid (1 percent) products are usually suggested for twice-
daily use for one to two months or until the desired cosmetic 
result is achieved, though sensitization to 1 percent creams has 
been  reported.23  Concentrations  of  2.5  percent  have  been 
associated with facial dermatitis, and it is considered to have a 
high sensitizing potential.23,28

 SIGNIFICANT BACKGROUND

production  to  43  percent  of  control  in  normal  human 
melanocytes.  Kojyl-APPA  was  also  eightfold  as  capable  of 
permeating  the  skin  as  kojic  acid.29  A  kojic  acid  derivative 
identified  as  eight  times  more  potent  than  kojic  acid  as  a 
tyrosinase inhibitor was also synthesized in 2006. In addition, 
the  compound  produced  by  Lee  et  al.  exhibited  strong 
inhibitory  activity  toward  melanin  production.27  This  work 
suggests  a  fruitful  area  of  research  for  the  development  of 
synthetic kojic acid agents for skin lightening.

Combination Therapy
In two separate studies in the mid-1990s, kojic acid combined 
with  glycolic  acid  was  found  to  be  more  effective  than  
10 percent glycolic acid and 4 percent HQ for the treatment of 
hyperpigmentation.30,31  In  one  case,  Garcia  and  Fulton 
evaluated  and  compared  the  effects  on  melasma  and  other 
pigmentary  conditions  of  a  glycolic  acid/HQ  formulation  as 
well as a glycolic acid/kojic acid formulation. Wood’s light and 
ultraviolet  (UV)  light  photography  were  used  to  evaluate  the 
effects  of  the  different  compounds,  one  on  each  side  of  the 
face, on 39 patients. No statistically significant differences were 
found between the reactions: 28 percent of the patients experi-
enced marked improvements on the kojic acid side, 21 percent 
on the HQ side. The responses to each formulation were equal 
in 51 percent of the participants. While the kojic acid formula-
tion was considered more irritating, the researchers found that 
both formulations effectively treated melasma.31

In 1999, Lim conducted a 12-week study of the effects on mel-
asma of 2 percent kojic acid in a gel containing 10 percent glycolic 
acid and 2 percent HQ in 40 Chinese women with epidermal mel-
asma. Subjects were randomized to receive the test formulation on 
one side of the face and the same formulation minus kojic acid on 
the other side. Self-assessment questionnaires every four weeks, 
photographs, and clinical evaluations were used to rate the efficacy 
of the treatment. Lim found that the addition of kojic acid to the 
glycolic  acid/HQ  gel  reduced  the  signs  of  melasma.  Specifically, 
more than half of the melasma cleared in 24 of 40 patients who 
received the kojic acid formulation as compared to 19 of 40 who 
received the kojic acid-free gel. Two patients experienced complete 
clearance, in both cases on the side of the face on which the kojic 
acid gel was used.18 Two years later, Ferioli et al. found that com-
bining  HQ  and  kojic  acid  imparted  a  synergistic  effect,  with  an 
equimolecular distribution leading to the optimal result.32

Further,  in  a  recent  three-month,  paired,  double-blind  study 
comparing  a  combination  of  kojic  acid,  emblica  extract,  and 
glycolic  acid  to  4  percent  HQ  in  80  multiethnic  patients  with 
mild-to-moderate facial dyschromia, the two formulations were 
found to yield similar skin-lightening effects, suggesting that the 
combination therapy is a worthy alternative to HQ.33 However, 
no  peer-reviewed  clinical  studies  have  yet  been  reported  that 
show a depigmenting effect from kojic acid monotherapy.34

In  2003,  Kim  et  al.  studied  the  effects  of  a  stable  kojic  acid 
d e r i v a t i v e ,   5 - [ ( 3 - a m i n o p r o p y l ) p h o s p h i n o o x y ] - 2 -
(hydroxymethyl)-4H-pyran-4-one  (Kojyl-APPA),  on 
tyrosinase activity and melanin production. They found that 
Kojyl-APPA  is  not  a  direct  inhibitor  of  tyrosinase,  but  is 
enzymatically converted to kojic acid in cells. The derivative 
suppressed  tyrosinase  activity  significantly  24  hours  after 
treatment in normal human melanocytes and demonstrated a 
30 percent inhibition of tyrosinase in situ (though not in vitro). 
The  kojic  acid  derivative  also  lowered  melanin  content  to  
75  percent  of  control  in  melanoma  cells  and  neomelanin 

Antiwrinkling Indication?
In  2001,  Mitani  et  al.  assessed  the  potential  of  kojic  acid  to 
deliver antiwrinkling effects given the iron-chelating properties 
of  the  acid  and  the  known  association  between  chronic 
photodamage  and  cutaneous  iron.  Over  20  weeks,  the 
investigators  topically  applied  kojic  acid  before  exposing 
hairless  mice  to  UV  radiation.  They  found  that  the  agent 
successfully  suppressed  wrinkle  formation,  epidermal 
hyperplasia, lower dermis fibrosis, as well as increases in upper 
dermis extracellular matrix components.35

 
 CONCLUSION

A mainstay among skin-lightening agents over the last quarter 
century, the fungal derivative kojic acid is best used in combi-
nation with other depigmenting ingredients. This enhances the 
overall  effect  of  the  formulation  and  mitigates  the  irritating 
effects of the acid. Recent evidence has allayed fears regarding 
long-term  carcinogenic  effects,  but,  as  always,  research  is 
ongoing to develop newer, safer derivatives.

REFERENCES

C H A P T E R  37  ■   KO J I C   AC I D  

107

17.  Parvez S, Kang M, Chung H-S, et al. Survey and mechanism of 
skin  depigmenting  and  lightening  agents.  Phytother  Res. 
2006;20:921.

18.  Lim JT. Treatment of melasma using kojic acid in a gel containing 
hydroquinone and glycolic acid. Dermatol Surg. 1999;25:282.
19.  Lynde CB, Kraft JN, Lynde CW. Topical treatments for melasma 
and  postinflammatory  hyperpigmentation.  Skin  Therapy  Lett. 
2006;11:1.

20.  Cayce  KA,  McMichael  AJ,  Feldman  SR.  Hyperpigmentation:  an 
overview of the common afflictions. Dermatol Nurs. 2004;16:401.
21.  Piamphongsant T. Treatment of melasma: a review with personal 

experience. Int J Dermatol. 1998;37:897.

22.  Serra-Baldrich E, Tribo MJ, Camarasa JG. Allergic contact derma-

titis from kojic acid. Contact Dermatitis. 1998;39:86.

23.  Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in 

1.  Prignano F, Ortonne JP, Buggiani G, et al. Therapeutical approaches 

skin care products. Contact Dermatitis. 1995;32:9.

in melasma. Dermatol Clin. 2007;25:337.

2.  Bhat R, Hadi SM. Photoinactivation of bacteriophage lambda by 
kojic acid and Fe(III): role of oxygen radical intermediates in the 
reaction. Biochem Mol Biol Int. 1994;32:731.

3.  Lee YS, Park JH, Kim MH, et al. Synthesis of tyrosinase inhibitory 

kojic acid derivative. Arch Pharm Chem Life Sci. 2006;339:11.

4.  Bentley R. From miso, saké and shoyu to cosmetics: A century of 

science for kojic acid. Nat Prod Rep. 2006;23:1046.

5.  Cabanes J, Chazarra S, Garcia-Carmona F. Kojic acid, a cosmetic 
skin whitening agent, is a slow-binding inhibitor of catecholase 
activity of tyrosinase. J Pharm Pharmacol. 1994;46:982.

6.  Grimes  PE.  Management  of  hyperpigmentation  in  darker  racial 

ethnic groups. Semin Cutan Med Surg. 2009;28:77.

7.  Fuyuno  I.  Spotlight  turns  on  cosmetics  for  Asian  skin.  Nature. 

2004;432:938.

8.  Draelos ZD. Skin lightening preparations and the hydroquinone 

controversy. Dermatol Ther. 2007;20:308.

9.  Hira Y, Hatae S, Inoue T, et al. Inhibitory effects of kojic acid on 
melanin formation. In vitro and in vivo studies in black goldfish.  
J Jpn Cosmet Sci Soc. 1982;6:193.

10.  Gillbro  JM,  Olsson  MJ.  The  melanogenesis  and  mechanisms  of 
skin-lightening agents – Existing and new approaches. Int J Cosmet 
Sci. 2011;33:210.

11.  Uher M, Brtko J, Rajniakova O, et al. Kojic acid and its derivatives 
in cosmetics and health protection. Parfuem Kosmet. 1993;74:554.
12.  Burdock GA, Soni MG, Carrabin IG. Evaluation of health aspects 

of kojic acid in food. Regul Toxicol Pharmacol. 2001;33:80.

13.  Halder RM, Richards GM. Management of dyschromias in ethnic 

skin. Dermatol Ther. 2004;17:151.

14.  Halder  RM,  Richards  GM.  Topical  agents  used  in  the  manage-

ment of hyperpigmentation. Skin Therapy Lett. 2004;9:1.

15.  Balaguer  A,  Salvador  A,  Chisvert  A.  A  rapid  and  reliable  size-
exclusion chromatographic method for determination of kojic dipal-
mitate in skin-whitening cosmetic products. Talanta. 2008;75:407.
16.  Curtis  PJ.  Chemical  induction  of  local  reddening  in  strawberry 

fruits. J Sci Food Agr. 1977;28:243.

24.  Takizawa T, Mitsumori K, Tamura T, et al. Hepatocellular tumor 
induction in heterozygous p53-deficient CBA mice by a 26-week 
dietary administration of kojic acid. Toxicol Sci. 2003;73:287.
25.  Picardo  M,  Carrera  M.  New  and  experimental  treatments  of 
cloasma  and  other  hypermelanoses.  Dermatol  Clin. 
2007;25:353.

26.  Higa Y, Kawabe M, Nabae K, et al. Kojic acid – Absence of tumor-
initiating  activity  in  rat  liver,  and  of  carcinogenic  and  photo-
genotoxic potential in mouse skin. J Toxicol Sci. 2007;32:143.
27.  Lee YS, Park JH, Kim MH, et al. Synthesis of tyrosinase inhibitory 

kojic acid derivative. Arch Pharm. 2006;339:111.

28.  Nakayama  G,  Watanabe  N,  Nishioka  K,  et  al.  Treatment  of 
chloasma  with  kojic  acid  cream.  Jpn  J  Clin  Dermatol. 
1982;36:715.

29.  Kim DH, Hwang JS, Baek HS, et al. Development of 5-[(3-amino-
propyl)phosphinooxy]-2-(hydroxymethyl)-4H-pyran-4-one  as  a 
novel whitening agent. Chem Pharm Bull. 2003;51:113.

30.  Ellis DA, Tan AK, Ellis CS. Superficial micropeels: Glycolic acid 
and  alpha-hydroxy  acid  with  kojic  acid.  Facial  Plast  Surg. 
1995;11:15.

31.  Garcia A, Fulton JE Fr. The combination of glycolic acid and hyd-
roquinone or kojic acid for the treatment of melasma and related 
conditions. Dermatol Surg. 1996;22:443.

32.  Ferioli V, Rustichelli C, Pavesi G, et al. New combined treatment 
of  hypermelanosis:  Analytical  studies  on  efficacy  and  stability 
improvement. Int J Cosmet Sci. 2001;23:333.

33.  Draelos  ZD,  Yatskayer  M,  Bhushan  P,  et  al.  Evaluation  of  a 
kojic acid, emblica extract, and glycolic acid formulation com-
pared  with  hydroquinone  4%  for  skin  lightening.  Cutis. 
2010;86:153.

34.  Leyden  JJ,  Shergill  B,  Micali  G,  et  al.  Natural  options  for  the 
management of hyperpigmentation. J Eur Acad Dermatol Venereol. 
2011;25:1140.

35.  Mitani H, Koshiishi I, Sumita T, et al. Prevention of the photoda-
mage  in  the  hairless  mouse  dorsal  skin  by  kojic  acid  as  an  iron 
chelator. Eur J Pharmacol. 2001;411:169.

 
108 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   3 8

Emblica Extract

Activities:

Antioxidant,  anti-inflammatory,  antipyretic,  antitumor, 
chemopreventive,  hepatoprotective,  analgesic,  antibac-
terial1,2

Important Chemical Components:

Tannins (emblicanin A and B, corilagin, puningluconin, 
pedunclagin),  ascorbic  acid,  amino  acids,  flavonoids, 
gallic acid, ellagic acid, rutin, curcuminoids, kaempferol, 
phyllembelic  acid,  linoleic  acid,  norsesquiterpenoids, 
pyrogallol1,3–6

Origin Classification:

Natural  components  isolated  from  various  parts  of 
Emblica officinalis. A standardized extract of E. officinalis 
(trade name Emblica) is 100 percent natural.

Personal Care Category:

Depigmenting, antiaging, sunscreen

Recommended for the following Baumann Skin 
Types:

DRPT, DRPW, DSPT, DSPW, ORPT, ORPW, OSPT, and 
OSPW

 SOURCE

Emblica officinalis (also referred to taxonomically as Phyllanthus 
emblica,  and  popularly  known  as  Indian  gooseberry,  amla  in 
Hindi,  amaliki  in  Sanskrit,  as  well  as  various  other  names  in 
multiple languages) is a deciduous tree of the Euphorbiaceae 
family  indigenous  to  India  (and  is  variably  classified  in  the 
Phyllanaceae family). Its fruit is a rich dietary source of ascor-
bic acid (vitamin C), various minerals, amino acids, as well as 
phenolic compounds and is the most important of the many 
parts of the plant used for food and medicinal purposes.7 Amla 
has  long  been  used  in  Ayurveda  and  Unani  medicine,  and  is 
highly  regarded  for  its  unique  array  of  tannins  (particularly 
emblicanin A and emblicanin B) and flavonoids, which display 
potent antioxidant properties.4,8,9 Indeed, it is actually one of 
the  most  important  plants  in  Ayurveda.10  The  amla  fruit  is 
known  to  confer  strong  antioxidant  activity  and  to  protect 
human  dermal  fibroblasts  against  oxidative  stress.  For  this 
reason, it is considered a useful and intriguing component in 
natural skin care.11 In fact, E. officinalis is the foremost agent in 
the  Ayurvedic  arsenal  for  combating  cutaneous  aging  and  is 
considered a rasayana or restorative and adaptogenic agent.9,12 
Besides India, the plant is also found extensively throughout 
Asia,  including  Sri  Lanka,  Uzbekistan,  Pakistan,  Bangladesh, 
China, Thailand, Malaysia, and Indonesia, and has been used 
in other longstanding medical practices such as Siddha, Unani 
Tibetan, and Sri Lankan as well as traditional Chinese medi-
cine and traditional Thai medicine.1,7

 SOME  TR adITIOnal MEdIC al SYSTEMS 
THa T USE  EMblIC a

Ayurveda:  derived  from  the  Sanskrit  ayu  (life)  and  veda  
(knowledge), it is a 5,000-year-old traditional medical system in 
India.
Unani: Graeco-Arabic traditional medicine based on Arab and 
Persian  adaptations  of  the  teachings  of  the  Greek  physician 
Hippocrates and Roman physician Galen that has been broadly 
practiced by Muslims in the Middle East and South Asia.
Siddha: one of the oldest known traditional medical systems, 
traced back 10,000 years in India.

 HISTORY

Emblica has been a staple in traditional medical practices through-
out Asia for hundreds of years and is considered one of the most 
important  plants  in  Ayurvedic  medical  practice  (Table  38-1).7 
Traditional  indications  in  Ayurveda  include  diarrhea,  jaundice, 
and inflammation.4 Amla has been used in folk medicine on the 
Indian subcontinent to treat inflammatory disease, liver disease, 
stomach and metabolic disorders, skin conditions, and geriatric 
issues as well as for beauty/cosmetic purposes including use as a 
hair  tonic.7,13  In  addition,  it  is  known  to  have  been  used  for 
medicinal purposes during the Indian famine of 1939 to 1940 and 
to treat scurvy in what is now Rajasthan in 1837.10 P. emblica has 
also been used in traditional medicine in Pakistan as a diuretic 
and  to  treat  anemia  and  excessive  bile.14  Of  note,  the  earlier 
taxonomic name Phyllanthus emblica, based on the Greek words 
phyllom (leaf) and anthòs (flower), was attributed to Carl Linnaeus 
based  on  observations  about  the  branches  of  the  tree,  which 
appeared to be flat like leaves. It is thought that “emblica” comes 
from the bastardization of the Sanskrit amlika or Arabic embelgi.10 

 CHEMISTRY

Emblicanin A (2,3-di-O-galloyl-4,6-(S)-hexahydroxydiphenoyl-2-
keto-glucono-δ-lactone)  and  emblicanin  B  (2,3,4,6-bis-(S)-
hexahydroxydiphenoyl-2-keto-glucono-δ-lactone) are considered 
to be among the most important of the various active constitu-
ents of Indian gooseberry. However, the presence of emblicanins 

TABLE 38-1
Pros and Cons of Emblica Extract

Pros
Can be used in countries that do not allow 
the use of hydroquinone or kojic acid

Cons
Not as effective as the standard-bearing 

depigmenting agents

Safer than hydroquinone or kojic acid

Limited clinical evidence of depigmenting 

efficacy

Long history of traditional medical use
Potential for broad-spectrum applications
Very affordable as part of the ayurvedic 

formula triphala

 
A  and  B  in  the  extract  has  been  questioned  by  Majeed  et  al.15 
Nevertheless, the wide array of beneficial effects imparted by the 
fruit of E. officinalis are attributed to the complex interactions of 
these  components  along  with  ascorbic  acid,  gallic  acid,  ellagic 
acid, and key flavonoids. Majeed et al. have also investigated the 
role  of  vitamin  C  in  amla,  which  is  reputed  to  display  greater 
antioxidant activity than vitamin C itself. Majeed et al. found that 
previous attempts to estimate ascorbic acid levels in amla failed to 
account  for  coeluting  mucic  acid  gallates.  They  concluded  that 
the potent antioxidant activity of amla should be ascribed to gallic 
acid esters.15 Scartezzini et al. earlier claimed that the fruit con-
tains vitamin C but in smaller amounts previously estimated, and 
that  the  constituent  emblicanins  recycle  vitamin  C,  thus 
amplifying the overall antioxidant capacity exhibited by amla.10

A  dynamic  botanical  source  of  several  traditional  medical 
practices,  antidiabetic,  hypolipidemic,  antibacterial,  antioxidant, 
antiulcerogenic,  hepatoprotective,  gastroprotective,  and  chemo-
preventive activity have all been associated with various parts of 
E. officinalis.4 Regardless of what emerges regarding the source of 
the  antioxidant  strength  of  emblica  or  its  relative  richness  as  a 
source for vitamin C and tannins, its activity in suppressing tyrosi-
nase activity has come to the fore in more recent research.16,17

 ORal USES

For centuries, the Indian gooseberry fruit has been consumed 
raw, cooked, or pickled alone and as a part of other food prod-
ucts, and is also used now in supplement form. It is considered 
an  important  dietary  source  of  vitamin  C  as  well  as  various 
minerals, amino acids, and tannins.6,18

It  is  worth  noting  the  results  of  Banu  et  al.  in  assessing  the 
capacity  of  orally  administered  P.  emblica  extract  to  protect 
against  7,12-dimethylbenz(a)anthracene  (DMBA)  in  Swiss 
albino  mice.  Emblica  was  found  to  dose-dependently  protect 
against  the  genotoxin,  with  the  fruit-treated  animals  demon-
strating  significant  elevation  in  liver  antioxidants  (e.g., 
glutathione, glutathione peroxidase, glutathione reductase, and 
detoxifying enzyme glutathione-S-transferase).19

 TOPICal USES

Among over-the-counter products, amla is contained in various 
hair care, skin care, color cosmetics, and soaps.12 In particular, 
it  is  included  in  products  intended  to  deliver  antiaging  and 
depigmenting activity.16

In a 2012 study of 17 Thai plants used traditionally to treat 
hair, particularly hair loss, Kumar et al. found P. emblica to be the 
second  strongest  inhibitor  of  5α-reductase,  behind  Carthamus 
tinctorius, with a close relationship noted between inhibition of 
5α-reductase and hair promotion.20

Skin Whitening
A standardized extract of P. emblica (trade name Emblica®) was 
found  to  exert  long-lasting  and  broad-spectrum  antioxidant 
activity. Due to its iron and chelating ability, the product does 
not  provide  pro-oxidation  activity  induced  by  iron  and/or 
copper. Emblica helps to protect the skin from the deleterious 
effects  of  free  radicals,  non-radicals,  and  transition  metal-
induced oxidative stress. It contains emblicanins A and B and is 
photochemically  and  hydrolytically  stable.  Therefore,  it  is 
considered  appropriate  for  incorporation  into  skin  care 
formulations. The product is intended for use in antiaging, sun-
screen,  and  general  purpose  skin  care  products.17  Because 

C H A P T E R  38  ■   E M B L I C A   E X T R AC T  

109

Emblica  also  acts  at  various  sites  in  the  melanogenesis  path-
way,  as  an  inhibitor  of  tyrosinase  and/or  tyrosinase-related 
proteins  (TRP-1  and  2)  and  peroxidase/H2O2,17  as  well  as  a 
broad-spectrum cascading antioxidant, it is conducive to use as 
a  skin-whitening  agent.  It  is  thought  to  be  as  effective  as 
hydroquinone  (HQ)  and  kojic  acid,  without  reports  of 
provoking adverse side effects.

In 2010, Costa et al. assessed the efficacy and safety of a cream 
combining emblica, belides, and licorice 7 percent in comparison 
to HQ 2 percent for melasma treatment. Fifty-six women between 
18  and  60  years  of  age  (phototypes  I  to  IV),  with  epidermal  or 
mixed  melasma,  were  instructed  to  use  SPF  35  sunscreen  for  
60 days. At that point, they were assigned in a mono-blind clinical 
study to twice daily application of the botanical formulation or 
nightly use of HQ for a 60-day period. Follow-up occurred every 
15 days, with the investigators observing no statistical differences 
between the groups in the successful improvement of melasma in 
most  patients.  Fewer  side  effects  were  noted  in  the  group  that 
received the botanical formulation, supporting the notion that it is 
a suitable alternative to HQ to treat melasma.16

Also that year, Draelos et al. conducted a double-blind skin-
lightening  activity  comparison  between  HQ  and  a  kojic  acid, 
emblica extract, and glycolic acid topical formulation in 80 mul-
tiethnic  subjects  with  mild-to-moderate  facial  dyschromia. 
Individuals were randomly assigned to use the study product or 
HQ  4  percent  twice  daily  for  12  weeks,  with  results  showing 
parity between the products. The researchers concluded that the 
new combination preparation including emblica is an effective 
alternative  to  HQ  4  percent  for  individuals  with  mild-to-
moderate facial dyschromia.21

 SaFETY ISSUES

The  use  of  emblica  is  considered  safe  and  effective  with  no 
adverse side effects reported.

 EnVIROnMEnT al IMPaCT

E.  officinalis  is  found  extensively  throughout  Asia.  No  signifi-
cant  environmental  risks  related  to  its  cultivation  have  been 
established.

 FORMUlaTIOn  COnSIdER aTIOnS

There  is  a  wide  variety  of  commercial  preparations  of  Indian 
gooseberry available, with varying levels of key ingredients. Thus, 
standardization is necessary across the broad range of products.22 
Scartezzini et al. have noted that processed emblica fruit contains 
more ascorbic acid and polyphenols than the dried fruit.10

 USa GE COnSIdER aTIOnS

No  interactions  with  other  ingredients  are  known  by  the 
author.

 SIGnIFIC anT ba CKGROUnd

Antioxidant and Antiaging Activity
In 2002, a standardized extract of P. emblica (trade name, Emblica) 
was noted for delivering long-lasting and broad-spectrum antioxi-
dant  activity,  appropriate  for  use  in  antiaging,  sunscreen,  and 

 
110 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

general purpose skin formulations, given its demonstrated capacity 
to protect the skin from damage engendered by free radicals, non-
radicals, and transition metal-induced oxidative stress.17

The  protective  effects  of  emblica  have  also  been  found  to 
extend  to  activity  against  arsenic.  Specifically,  Sharma  et  al. 
showed that adult Swiss albino mice treated with emblica fruits 
before  and  after  exposure  to  arsenic  evinced  significantly  less 
oxidative stress in the liver as compared to the rats treated only 
with arsenic.6

In 2009, Poltanov et al. studied the chemistry and antioxidant 
properties  of  four  commercial  E.  officinalis  fruit  extracts  and 
found different levels of antioxidative efficacy, with each none-
theless demonstrating free radical-scavenging capacity, primarily 
attributed to total phenolic and tannin content.22

In addition, Yokozawa et al., studying the effects of an ethyl 
acetate extract of amla on lipid metabolism and protein expres-
sion  pertaining  to  the  aging  process  in  young  and  aged  rats, 
determined that the administration of the botanical extract pre-
vented dyslipidemia and oxidative stress.18

Chemopreventive Activity
In 2005, Sancheti et al. performed a two-stage skin carcinogene-
sis study in Swiss albino mice to ascertain the chemopreventive 
action of E. officinalis fruit extract. A single application of DMBA 
was  used  to  induce  skin  cancer,  followed  two  weeks  later  by 
thrice weekly applications of croton oil (through the end of the 
16-week experiment) to promote tumors. A statistically signifi-
cant difference in tumor incidence, yield, and burden as well as 
cumulative number of papillomas favored the mice treated with 
E.  officinalis  as  opposed  to  the  control  group.  The  investigators 
concluded that E. officinalis fruit extract exhibited chemopreven-
tive potential against DMBA-induced skin cancer in Swiss albino 
mice.8

In  2010,  Ngamkitidechakul  et  al.  investigated  the  reputed 
anticancer  activity  of  an  aqueous  extract  of  P.  emblica  against 
cancer  cell  lines,  and  in  terms  of  mouse  skin  tumorigenesis,  in 
vitro  invasiveness,  and  in  vitro  apoptosis.  They  found  that  cell 
growth  was  suppressed  in  six  human  cancer  cell  lines  [A549 
(lung),  HepG2  (liver),  HeLa  (cervical),  MDA-MB-231  (breast), 
SK-OV3 (ovarian), and SW620 (colorectal)] with an extract of 50 
to 100 μg/mL. In addition, P. emblica extract treatment of mouse 
skin yielded a 50 percent decrease in tumor  numbers  and  vol-
umes  in  the  two-stage  skin  carcinogenesis  model  initiated  by 
DMBA and promoted by 12-O-tetradecanoylphorbol-13-acetate 
(TPA).  The  investigators  also  noted  apoptosis  in  HeLa  cells 
spurred  by  the  extract  and  inhibited  invasiveness  of 
MDA-MB-231 cells in the in vitro Matrigel invasion assay. They 
concluded that P. emblica displays anticancer activity and merits 
additional investigation as a potential chemopreventive agent.1

Photoprotection
In 2002, Morganti et al. assessed the in vitro and in vivo activity of 
various  topical  antioxidants  and  nutritional  supplements  in  a 
randomized,  double-blind,  placebo-controlled  study  conducted 
over  eight  weeks  on  30  female  volunteers  (aged  48–59  years) 
with  moderate  dry  skin  and  photodamage.  All  subjects  twice 
daily applied a nanocolloidal gel (α-lipoic acid 05. mg, melatonin/
emblica 15 mg) and/or daily took two capsules of an oral diet 
supplement  (ascorbic  acid  45  mg,  tocopherol  5  mg,  lutein  
3 mg, α-lipoic acid 2.5 mg). Oral and topical administration of 
the antioxidant-rich compounds resulted in significant reduction 
in oxidative stress and lipid peroxidation. Free radicals recovered 

in blood serum and on skin, in vivo, and reactive oxygen species 
(ROS)  induced  by  in  vitro  irradiation  of  leukocytes  with 
ultraviolet B (UVB) were also decreased in antioxidant-treated 
patients. The investigators concluded that all of the compounds 
showed  therapeutic  potential,  in  topical  or  systemic  form,  as 
photoprotectants  and  agents  intended  to  lower  the  oxidative 
stress of photoaging-affected individuals, with the α-lipoic and 
melatonin/emblica combination showing promise as a topical 
preparation.23

In 2010, Adil et al. investigated the efficacy of amla to suppress 
UVB-induced photoaging in human skin fibroblasts. They found 
that the botanical agent had broad effects, protecting procollagen 1 
against  UVB  damage  by  suppressing  UVB-induced  matrix 
metalloproteinase-1  (MMP-1)  proliferation  in  fibroblasts, 
inhibiting hyaluronidase activity, and preventing UVB from dis-
rupting  the  normal  cell  cycle.  They  observed  that  amla 
concentration-dependently promoted fibroblast proliferation and 
provided  a  potent  photoprotective  effect  against  UVB-induced 
cytotoxicity.13 In 2011, Majeed et al. showed that P. emblica fruit 
extract effec-tively protected against UVB-induced ROS and col-
lagen damage in normal human dermal fibroblasts and demon-
strates  potential  as  a  topical  component  of  the  dermatologic 
armamentarium against photoaging.24

Previously, Fujii et al. conducted an in vitro investigation of 
the  effects  of  amla  extract  on  human  skin  fibroblasts, 
particularly  in  relation  to  the  synthesis  of  procollagen  and 
MMPs.  They  noted  that  amla  concentration-dependently 
stimulated fibroblast production and concentration- and time-
dependently  spurred  procollagen  synthesis.  In  addition,  the 
extract markedly reduced MMP-1 production while significantly 
elevating tissue inhibitors of MMP-1 (TIMP-1). The researchers 
concluded that amla can play an important role in controlling 
collagen metabolism and thus shows therapeutic and cosmetic 
potential.11 Chanvorachote et al. also reported on their findings 
that  P.  emblica  extract  exhibited procollagen type I-promoting 
and collagenase-inhibiting effects in murine fibroblasts, which 
the investigators suggested was an indication of its potential as 
an antiaging agent.25

Combination Therapy: Triphala
Based on evidence that triphala (an antioxidant-rich herbal for-
mulation  that  combines  dried  fruits  of  Terminalia  chebula, 
Terminalia  bellirica,  and  E.  officinalis;  the  word  is  derived  from 
the Sanskrit tri, three, and phala, fruits), long used in Ayurveda, 
has demonstrated in vitro antimicrobial activity against wound 
pathogens, including Staphylococcus aureus, Pseudomonas aerugi-
nosa, and Streptococcus pyogenes, Kumar et al. recently prepared 
a triphala ointment and evaluated its effects for in vivo wound 
healing  on  infected  rats.  The  investigators  identified  signifi-
cantly improved wound closure and bacterial count decreases 
in the treated group, along with significant hexosamine, uronic 
acid,  and  superoxide  dismutase  levels  and  diminished  MMP 
expression.  They  concluded  that  triphala  ointment  exhibited 
antioxidant, antibacterial, and wound-healing activities suitable 
for treating infected wounds and that the active constituents of 
the  ointment  warrant  further  consideration  for  wound 
therapy.26  Subsequently,  the  same  team  successfully 
demonstrated the healing effects of triphala incorporated into a 
collagen sponge to treat the infected dermal wounds in albino 
rats.27  Triphala,  also  used  as  a  colon  cleanser,  digestive  aid, 
diuretic, and laxative, is useful in the prevention of cancer and 
exhibits  antineoplastic,  radioprotective,  and  chemoprotective 
effects, according to recent studies.5

 
In 2005, Naik et al. studied the aqueous extract of the fruits of 
E. officinalis, Terminalia chebula, and Terminalia belerica as well as 
their equiproportional mixture triphala to compare their in vitro 
antioxidant activity. The investigators found that the individual 
triphala  constituents  displayed  somewhat  different  activities 
under  various  conditions,  with  emblica  exhibiting  the  greatest 
efficiency  in  lipid  peroxidation  and  the  plasmid  DNA  assay, 
while  Terminalia  chebula  was  the  most  effective  at  scavenging 
free radicals. They concluded that the combination formulation 
triphala appears to show the greatest efficiency by virtue of com-
bining the strengths of each of its constituents.28

In  a  2009  study  by  Nariya  et  al.  comparing  an  equipropor-
tional formulation of triphala with an unequal one (1:2:4 propor-
tion of T. chebula, T. belerica, and E. officinalis, respectively), the 
one favoring a much larger percentage of emblica was found to 
confer much greater intestinal protection against methotrexate-
induced damage in rats. The investigators attributed their results 
to the greater proportion of antioxidants, particularly the ellagic 
and gallic acids and flavonoids found in E. officinalis.29

In 2010, Hazra et al. studied the 70 percent methanol extracts 
of Terminalia chebula, Terminalia belerica, and E. officinalis fruit to 
assess their  in  vitro antioxidant and ROS-scavenging properties 
against 2,2-diphenyl-1-picrylhydrazyl (DPPH), hydroxyl, super-
oxide,  nitric  oxide,  H2O2,  peroxynitrite,  singlet  oxygen,  and 
hypochlorous acid. The investigators identified varying orders of 
potency  of  the  extracts  in  the  manifestation  of  antioxidative 
properties,  scavenging  of  particular  ROS,  as  well  as  flavonoid 
and  phenolic  content  but  each  of  these  components  of  the 
Ayurvedic staple triphala demonstrated significant antioxidative 
capacity, and the researchers concluded that these compounds 
represent strong natural antioxidant sources.2

In  a  2012  review,  Baliga  et  al.  noted  that  scientific  studies 
over  the  previous  two  decades  have  confirmed  numerous 
ethnomedical claims and investigators have found that triphala 
exhibits  a  broad  array  of  beneficial  activities,  including  free 
radical  scavenging,  antioxidant,  anti-inflammatory,  analgesic, 
antibacterial,  antimutagenic,  wound  healing,  antistress, 
adaptogenic, hypoglycemic, anticancer, chemoprotective, radi-
oprotective, and chemopreventive among others.30 Baliga and 
Dsouza  had  previously  reported  that  preclinical  studies  have 
shown that antipyretic, analgesic, antitussive, antiatherogenic, 
adaptogenic,  cardioprotective,  gastroprotective,  antianemia, 
antihypercholesterolemia, wound-healing, antidiarrheal, antia-
therosclerotic, hepatoprotective, nephroprotective, and neuro-
protective  properties  have  been  ascribed  to  amla  alone.7 
In addition, they noted that amla reportedly exerts radiomodu-
latory,  chemomodulatory,  chemopreventive,  free  radical- 
scavenging,  antioxidant,  anti-inflammatory,  antimutagenic, 
immunomodulatory, and wound-healing activities.7

Extracts of E. officinalis have also been combined with those of 
Terminalia  chebula,  Terminalia  bellerica,  Albizia  lebbeck,  Piper 
nigrum,  Zingiber  officinale,  and  Piper  longum  in  a  polyherbal 
formulation  (Aller-7/NR-A2)  that  has  been  found  safe  for  the 
treatment of allergic rhinitis.31

In Vitro Studies with Dermatologic Implications
In  2008,  Fujii  et  al.  studied  the  effects  of  amla  extract  on 
human skin fibroblasts, with a focus on in vitro production of 
procollagen and MMPs. They employed the WST-8 assay to 
assess  human  skin  fibroblast  mitochondrial  activity  and  an 
immunoassay  to  measure  procollagen,  MMPs,  and  TIMP-1 
released  from  the  fibroblasts.  The  researchers  found  that 
amla extract controls collagen metabolism in therapeutic and 

C H A P T E R  38  ■   E M B L I C A   E X T R AC T  

111

cosmetic  applications.  Specifically,  they  found  that  in  a 
concentration-dependent  fashion,  amla  promoted  fibroblast 
proliferation  and  in  a  concentration-  and  time-dependent 
manner  stimulated  procollagen  synthesis.  They  also  noted 
that  amla  significantly  lowered  MMP-1  production,  with 
significant increases in TIMP-1, but had no effect on MMP-2. 
The  authors  concluded  that  their  findings  suggest  the 
potential of amla to confer mollifying and therapeutic as well 
as cosmetic benefits.11

 COnCl USIOn

The fruit and most other parts of E. officinalis have long been 
used in various traditional medical practices in Asia, especially 
India, for a wide range of indications. Recent evidence suggests 
broad  potential  for  the  extract  of  the  amla  fruit  in  modern 
Western medical treatment and, in particular, as an ingredient 
in general purpose dermatologic topical formulations as well as 
antiaging, hypopigmenting, and sunscreen agents. Much more 
research  is  necessary  to  establish  the  effectiveness  of  such 
products, but current findings are encouraging.

REFEREnCES

1.  Ngamkitidechakul C, Jaijoy K, Hansakul P, et al. Antitumor effects 
of Phyllanthus emblica L.: Induction of cancer cell apoptosis and 
inhibition of in vivo tumour promotion and in vitro invasion of 
human cancer cells. Phytother Res. 2010;24:1405.

2.  Hazra B, Sarkar R, Biswas S, et al. Comparative study of the anti-
oxidant and reactive oxygen species scavenging properties in the 
extracts  of  the  fruits  of  Terminalia  chebula,  Terminalia  belerica 
and Emblica officinalis. BMC Complement Altern Med. 2010;10:20.
3.  Pozharitskaya ON, Ivanova SA, Shikov AN, et al. Separation and 
evaluation  of  free  radical-scavenging  activity  of  phenol  compo-
nents  of  Emblica  officinalis  extract  by  using  an  HPTLC-DPPH* 
method. J Sep Sci. 2007;30:1250.

4.  Krishnaveni M, Mirunalini S. Therapeutic potential of Phyllanthus 
emblica  (amla):  The  ayurvedic  wonder.  J  Basic  Clin  Physiol 
Pharmacol. 2010;21:93.

5.  Baliga  MS.  Triphala,  Ayurvedic  formulation  for  treating  and 
preventing  cancer:  A  review.  J  Altern  Complement  Med. 
2010;16:1301.

6.  Sharma  A,  Sharma  MK,  Kumar  M.  Modulatory  role  of  Emblica 
officinalis fruit extract against arsenic induced oxidative stress in 
Swiss albino mice. Chem Biol Interact. 2009;180:20.

7.  Baliga MS, Dsouza JJ. Amla (Emblica officinalis Gaertn), a wonder 
berry in the treatment and prevention of cancer. Eur J Cancer Prev. 
2011;20:225.

8.  Sancheti G, Jindal A, Kumari R, et al. Chemopreventive action of 
emblica  officinalis  on  skin  carcinogenesis  in  mice.  Asian  Pac  J 
Cancer Prev. 2005;6:197.

9.  Datta  HS,  Mitra  SK,  Patwardhan  B.  Wound  healing  activity  of 
topical  application  forms  based  on  Ayurveda.  Evid  Based 
Complement Alternat Med. 2011;134378.

10.  Scartezzini  P,  Antognoni  F,  Raggi  MA,  et  al.  Vitamin  C  content 
and  antioxidant  activity  of  the  fruit  and  of  the  Ayurvedic 
preparation  of  Emblica  officinalis  Gaertn.  J  Ethnopharmacol. 
2006;104:113.

11.  Fujii  T,  Wakaizumi  M,  Ikami  T,  et  al.  Amla  (Emblica  officinalis 
Gaertn.)  extract  promotes  procollagen  production  and  inhibits 
matrix  metalloproteinase-1 
in  human  skin  fibroblasts.  
J Ethnopharmacol. 2008;119:53.

12.  Datta HS, Paramesh R. Trends in aging and skin care: Ayurvedic 

concepts. J Ayurveda Integr Med. 2010;1:110.

13.  Adil  MD,  Kaiser  P,  Satti  NK,  et  al.  Effect  of  Emblica  officinalis 
(fruit) against UVB-induced photo-aging in human skin fibroblasts. 
J Ethnopharmacol. 2010;132:109.

14.  Ishtiaq M, Hanif W, Khan MA, et al. An ethnomedicinal survey 
and  documentation  of  important  medicinal  folklore  food 
phytonims of flora of Samahni valley, (Azad Kashmir) Pakistan. 
Pak J Biol Sci. 2007;10:2241.

 
112 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

15.  Majeed  M,  Bhat  B,  Jadhav  AN,  et  al.  Ascorbic  acid  and  tannins 
from  Emblica  officinalis  Gaertn.  Fruits–A  revisit.  J  Agric  Food 
Chem. 2009;57:220.

16.  Costa  A,  Moisés  TA,  Cordero  T,  et  al.  Association  of  emblica, 
licorice  and  belides  as  an  alternative  to  hydroquinone  in  the 
clinical treatment of melasma. An Bras Dermatol. 2010;85:613.
17.  Chaudhuri  RK.  Emblica  cascading  antioxidant:  A  novel  natural 
skin care ingredient. Skin Pharmacol Appl Skin Physiol. 2002;15:374.
18.  Yokozawa  T,  Kim  HY,  Kim  HJ,  et  al.  Amla  (Emblica  officinalis 
Gaertn.) prevents dyslipidaemia and oxidative stress in the ageing 
process. Br J Nutr. 2007;97:1187.

19.  Banu  SM,  Selvendiran  K,  Singh  JP,  et  al.  Protective  effect  of 
Emblica officinalis ethanolic extract against 7,12-dimethylbenz(a)
anthracene (DMBA) induced genotoxicity in Swiss albino mice. 
Hum Exp Toxicol. 2004;23:527.

20.  Kumar N, Rungseevijitprapa W, Narkkhong NA, et al. 5α-reductase 
inhibition and hair growth promotion of some Thai plants tradition-
ally used for hair treatment. J Ethnopharmacol. 2012;139:765.

21.  Draelos ZD, Yatskayer M, Bhushan P, et al. Evaluation of a kojic 
acid,  emblica  extract,  and  glycolic  acid  formulation  compared 
with hydroquinone 4% for skin lightening. Cutis. 2010;86:153.
22.  Poltanov EA, Shikov AN, Dorman HJ, et al. Chemical and antioxi-
dant  evaluation  of  Indian  gooseberry  (Emblica  officinalis  Gaertn., 
syn. Phyllanthus emblica L.) supplements. Phytother Res. 2009;23:1309.
23.  Morganti P, Bruno C, Guarneri F, et al. Role of topical and nutri-
tional supplement to modify the oxidative stress. Int J Cosmet Sci. 
2002;24:331.

24.  Majeed M, Bhat B, Anand S, et al. Inhibition of UV-induced ROS 
and  collagen  damage  by  Phyllanthus  emblica  extract  in  normal 
human dermal fibroblasts. J Cosmet Sci. 2011;62:49.

25.  Chanvorachote P, Pongrakhananon V, Luanpitpong S, et al. Type 
I  pro-collagen  promoting  and  anti-collagenase  activities  of 
Phyllanthus  emblica  extract  in  mouse  fibroblasts.  J  Cosmet  Sci. 
2009;60:395.

26.  Kumar MS, Kirubanandan S, Sripriya R, et al. Triphala promotes 
healing  of  infected  full-thickness  dermal  wound.  J  Surg  Res. 
2008;144:94.

27.  Kumar MS, Kirubanandan S, Sripriya R, et al. Triphala incorpo-
rated  collagen  sponge–a  smart  biomaterial  for  infected  dermal 
wound healing. J Surg Res. 2010;158:162.

28.  Naik  GH,  Priyadarsini  KI,  Bhagirathi  RG,  et  al.  In  vitro 
antioxidant  studies  and  free  radical  reactions  of  triphala,  an 
ayurvedic  formulation  and  its  constituents.  Phytother  Res. 
2005;19:582.

29.  Nariya M, Shukla V, Jain S, et al. Comparison of enteroprotective 
efficacy  of  triphala  formulations  (Indian  Herbal  Drug)  on 
methotrexate-induced  small  intestinal  damage  in  rats.  Phytother 
Res. 2009;23:1092.

30.  Baliga MS, Meera S, Mathai B, et al. Scientific validation of the 
ethnomedicinal  properties  of  the  Ayurvedic  drug  Triphala:  
a review. Chin J Integr Med. 2012;18:946.

31.  Amit  A,  Joshua  AJ,  Bagchi  M,  et  al.  Safety  of  a  novel  botanical 
extract  formula  for  ameliorating  allergic  rhinitis.  Part  II.  
Toxicol Mech Methods. 2005;15:193.

 
C H A P T E R  39  ■   M U L B E R RY   E X T R AC T  

113

C H A P T E R   3 9

Mulberry Extract

Activities:
Antityrosinase,  antihyperglycemic,1,2  antitumorigenic,3 
anti-inflammatory,3  antiypyretic,3  antioxidant,3,4  antia-
therogenic,4  antimicrobial,5  chemopreventive,5  neuro-
protective5

Important Chemical Components:

Morus  alba:  Mulberroside  F  (the  phytoalexin  moracin 
M-6, 3’-di-O-beta-D-glucopyranoside), mulberroside A, 
various  polyphenols,  including  moracetin,  rutin,  iso-
quercitrin, gallic acid, quercetin 3-(6-malonylglucoside), 
and astragalin,1,4 oxyresveratrol (the aglycone of mulber-
roside A),6 and fatty acids (e.g., linoleic and palmitic)7
Morus australis: Oxyresveratrol, multiple chalcones, aus-
traone A, moracenin D, sanggenon T, and kuwanon O8
Morus  nigra:  Mulberroside  A,  5’-geranyl-5,7,2’,4’-
tetrahydroxyflavone, steppogenin-7-O-beta-D-glucoside, 
morachalcone A, 2,4,2’,4’-tetrahydroxychalcone, moracin 
N,  kuwanon  H,  mulberrofuran  G,  morachalcone  A, 
oxyresveratrol-3’-O-beta-D-glucopyranoside,  and 
oxyresveratrol-2-O-beta-D-glucopyranoside9
Morus notabilis: Moracin O, moracin P10
Morus  papyrifera  (or  Broussonetia  papyrifera):  Prenylated, 
polyhyrdroxylated  mono-  and  bis-phenyl  derivatives, 
flavonoids (quercetin, luteolin), linoleic acid, methyl pal-
mitate,  oleic  acid,  linoleic  acid  ester,  and  diterpenes 
(three different broussonetones)11,12

Origin Classification:

Natural  components  isolated  from  various  Moraceae 
species

Personal Care Category:

Depigmenting

Recommended  for  the  following  Baumann  Skin 
Types:

DRPT, DRPW, DSPT, DSPW, ORPT, ORPW, OSPT, and 
OSPW

 SOURCE

The  family  Moraceae,  which  is  native  to  eastern  Asia,  is  the 
source  of  multiple  species  of  deciduous  trees  associated  with 
skin-lightening  activity,  including  Morus  alba,  Morus  australis, 
Morus Nigra, Morus notabilis, and Morus papyrifera. Moraceae are 
fast-growing perennial trees that now are cultivated in tropical, 
subtropical, and temperate climates.5 The fruits of these trees are 
consumed throughout the world and various parts of the plants 
have been and continue to be used in traditional medicine.

The genus Broussonetia, a member of the Moraceae family 
and  closely  related  to  the  genus  Morus,  is  found  throughout 
Asia  and  the  Pacific  Islands.11  Broussonetia  papyrifera  (also 
known as Morus papyrifera and, commonly, as paper mulberry) 

is a deciduous tree native to eastern Asia. Its bark is used for 
making  high-quality  paper,  but  other  parts  of  the  tree  have 
been used in traditional medicine and such uses continue today. 

 HISTORY

The leaves of Morus alba are an important source of nutrition 
for  the  silkworm  (Bombyx  mori).1,3,5,13  Therapeutic  uses  of  the 
leaves,  bark,  and  branches  for  human  beings  have  long  been 
found in traditional Chinese medicine (TCM).4,11,14 M. alba has 
been  deployed  in  TCM  as  a  wind-heat-effusing  agent.15  In 
addition, various parts of several Moraceae species have been 
used  in  TCM  to  treat  tinea,  dysentery,  hernia,  and  edema.11 
Ayurvedic medicine has also employed this herb to treat diar-
rhea, intestinal ulcers, small pox, back pain, vocal cord inflam-
mation, and cutaneous cracks on the soles of the feet.3 From a 
global finance perspective, mulberry is one of the most impor-
tant  plants  in  the  economy  of  India.5  The  roots,  barks,  and 
stems of Morus australis have also been long used in traditional 
Japanese  medicine  (known  as  Kampo)  to  treat  diabetes  and 
arthritis.16  In  China,  the  leaves,  stem,  leaf  juice,  roots,  fruits, 
and bark of B. papyrifera have all been utilized for various health 
benefits, with the stem and leaf juice used to treat skin disor-
ders and insect bites.11

 CHEMISTRY

Tyrosinase  is  the  rate-limiting  enzyme  for  melanogenesis.  In 
the early stages of melanin production, it catalyzes the hydrox-
ylation  of  L-tyrosine  to  3,4-dihydroxyphenylalanine  (DOPA) 
and the oxidation of DOPA to dopaquinone.16 Several Moraceae 
species represent a new frontier of natural tyrosinase inhibitors, 
which  are  thought  to  be  less  expensive  to  process  than  syn-
thetic agents such as hydroquinone and, importantly, less likely 
to induce adverse side effects (Table 39-1).

Tyrosinase activity has been demonstrated to be suppressed 
by  dried  white  mulberry  (M.  alba)  leaves  (85  percent  ethanol 
extract).7  The  primary  active  component  of  white  mulberry, 
mulberroside  F  (moracin  M-6,  3’-di-O-β-d-glucopyranoside), 
which is extracted from the dried leaves of the tree, has also been 
shown to inhibit tyrosinase activity as well as melanin formation 
in melan-a cells.7,17 Other potent constituents found in M. alba 
leaves include phenolic flavonoids, such as gallic acid and querce-
tin, and fatty acids, such as linoleic and palmitic acids.

TABLE 39-1
Pros and Cons of Mulberry Extract

Pros
Potent inhibitors of tyrosinase
Indications that mulberry is more effective 

than kojic acid and arbutin

Safer than hydroquinone

Con
Dearth of clinical studies of each species

 
114  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Mulberroside  A  is  the  main  active  constituent  of  black  mul-
berry (M. nigra), but it has weak tyrosinase-inhibitory properties.9 
Nevertheless, it has been utilized in Korea as a raw material in 
cosmetic products intended for skin whitening.18 Black mulberry 
also contains morachalcone A, among several other compounds, 
with  reported  inhibitory  activity  against  mushroom  tyrosinase 
and melanin biosynthesis.9,19 M. nigra and M. alba are believed to 
have especially potent antioxidant potential, and mulberroside F 
has displayed superoxide-scavenging activity in particlar.1,20

The  methanol  extract  of  Morus  australis  (known  as  Chinese 
mulberry  or,  in  Japan,  as  shimaguwa),  found  in  China,  Japan, 
Korea,  and  parts  of  Southeast  Asia,  is  also  known  to  confer  a 
skin-whitening effect due to tyrosinase inhibition.16

Extracts of paper mulberry have been demonstrated to inhibit 
L-DOPA oxidation, more potently than arbutin, and to scavenge 
free radicals such as 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 
hydrogen peroxide among others.11

 ORAL USES

White  mulberry  is  consumed  regularly  in  Korea,  Japan,  India, 
and Chile. It is sometimes used in preserves or syrup.4 The fruits 
of black and red mulberry (Morus rubra, which is native to North 
America), in particular, are used in baked goods and alcoholic 
beverages. Mulberry is also available in oral supplement form.

It is also worth noting that the dietary consumption of mul-
berry leaf powder derived from M. alba or especially quercetin 
3-(6-malonylglucoside), its quantitatively primary active flavonol 
glycoside, has been shown to ameliorate hyperglycemia in obese 
mice and lowered oxidative stress in the liver.21

Animal Study: Antioxidant Effects
In a 2010 study of the effects of daily administration of mulberry 
leaves (M. alba) in rats fed a high-fat diet, Kobayashi et al. found 
that  the  botanical  lowered  plasma  triglyceride  reactive  oxygen 
species synthesis and limited oxidative stress by upregulating the 
expression of genes involved in responding to oxidative stress.14

 TOPICAL USES

Extracts of M. alba are currently in use as additives in cosmetic 
products for the purposes of skin lightening.15

In 2013, Singh et al. evaluated the effects of mulberry, kiwi, 
and Sophora extracts on melanogenesis and melanin transfer in 
human melanocytes and in co-cultures with phototype-matched 
normal  adult  epidermal  keratinocytes.  They  assessed  these 
botanicals  against  isobutylmethylxanthine,  hydroquinone, 
vitamin C, and niacinamide, finding that compared with unstim-
ulated control, the extracts significantly lowered melanogenesis 
in normal adult epidermal melanocytes as well as human mela-
noma cells. Melanin transfer was also decreased as was filopodia 
expression  on  melanocytes.  The  investigators  concluded  that 
their  results,  comparable  to  standard-bearing  depigmenting 
agents, suggest the effectiveness of the tested extracts as topical 
agents for reducing hyperpigmentation.22

Morus alba (White Mulberry)
Lee et al. studied the in vitro effects of an 85 percent methanol 
extract of dried M. alba leaves on melanin biosynthesis in 2002 
and  found  that  one  of  the  primary  bioactive  constituents, 
mulberroside  F  (moracin  M-6,  3’-di-O-β-d-glucopyranoside), 
suppressed  the  tyrosinase  activity  that  converts  dopa  to 

dopachrome in the melanin synthesis process and also inhib-
ited  the  melanin  formation  of  melan-a  cells.  This  study  was 
one  of  the  earlier  indications  that  mulberry,  specifically  the 
component  mulberroside  F,  which  also  displayed  some  
superoxide-scavenging  capacity,  may  be  a  viable  skin-
whitening agent. Further, the mulberry extracted more potently 
inhibited tyrosinase activity than kojic acid.1 In 2003, a different 
team of investigators observed that the young twigs of M. alba 
also displayed the ability to inhibit tyrosinase activity as well 
as  melanin  production  in  B16  melanoma  cells.  In  vivo,  the 
extracts  reduced  melanin  synthesis  in  a  guinea  pig  model 
without exhibiting toxicity.23

In  2006,  Wang  et  al.  investigated  25  traditional  Chinese 
herbal medicines potentially useful in dermatology, particularly 
for skin whitening. M. alba was one of four species of extracts 
that  displayed  strong  inhibitory  activity  against  tyrosinase, 
more potent, in fact, than arbutin.15 Extracts of M. alba were 
also  found  to  be  one  of  the  seven  species  among  52  crude 
Nepalese drugs tested by Adhikari et al. for mushroom tyrosi-
nase inhibitory activity in 2008 to concentration-dependently 
exhibit potent properties in this realm.6

A 2008 study by Nattapong and Omboon showed in vitro that 
the  extracts  from  Thai  mulberry,  a  hybrid  of  M.  alba  and  M. 
rotundiloba, were effective as a whitening agent, partly owing to 
the presence of the pentacyclic triterpenoid betulinic acid.24

In 2011, Park et al. found that topically applied mulberroside 
A  isolated  from  the  roots  of  M.  alba  as  well  as  its  derivatives 
oxyresveratrol and oxyresveratrol-3-O-glucoside inhibited mel-
anogenesis  in  UV-induced  hyperpigmented  guinea  pig  skin. 
Specifically, they showed that the mulberry ingredients caused 
depigmentation and lowered melanin content, with oxyresvera-
trol more strongly suppressing melanogenesis than mulberroside 
A.25 The investigators concluded that these ingredients warrant 
attention as potential cosmetic skin-whitening agents.26

Morus australis (Chinese Mulberry/Shimaguwa)
In 2012, Takahashi et al. isolated the components of a 95 percent 
methanol extract of the dried stems of shimaguwa to study the 
mechanism of the plant’s skin-whitening activity. They identified 
four  chalcones,  all  of  which  were  found  to  inhibit  mushroom 
tyrosinase  activity  more  effectively  than  arbutin.  Three  of  the 
four  chalcones  were  actually  measured  as  exhibiting  100-fold 
greater tyrosinase inhibitory activity than arbutin, with minimal 
or no cytoxicity, as assessed in assays to evaluate the effects of 
the  chalcones  on  melanin  production,  without  altering  cell 
growth,  in  melanin-producing  B16  murine  melanoma  cells.  
The  investigators  concluded  that  these  three  chalcones  may 
account  for  the  depigmenting  activity  of  shimaguwa.  Further, 
they noted that the skin-whitening activity of M. australis is not 
limited to the inhibition of tyrosinase.16

Also that year, Zheng et al. isolated constituents from the roots 
of M. australis and conducted tyrosinase inhibitory testing. They 
found  that  several  ingredients,  including  oxyresveratrol,  mora-
cenin D, sanggenon T, and kuwanon O, displayed more potent 
tyrosinase suppression than that of kojic acid. The investigators 
concluded that M. australis, widespread in Asia, is a good natural 
source of tyrosinase inhibitors potentially useful in cosmetic skin-
lightening products as well as in foods as antibrowning agents.8

Morus nigra (Black Mulberry)
In 2010, Zheng et al. compared the phytochemical profiles of M. 
nigra roots and twigs with old and young M. alba twigs. In the 
process,  the  researchers  discovered  one  previously  unknown 

 
compound  (5’-geranyl-5,7,2’,4’-tetrahydroxyflavone)  as  well  as 
eight others, among 28 known phenolic compounds in M. nigra, 
which exhibited better tyrosinase inhibition than kojic acid. The 
other  compounds  include  steppogenin-7-O-β-d-glucoside, 
2,4,2’,4’-tetrahydroxychalcone,  moracin  N,  kuwanon  H, 
mulberrofuran  G,  morachalcone  A,  oxyresveratrol-3’-O-β-d- 
glucopyranoside  and  oxyresveratrol-2-O-β-d-glucopyranoside, 
with  2,4,2’,4’-tetrahydroxychalcone  and  morachalcone  A 
associated with significantly lower IC(50) (half maximal inhibitory 
concentration) values than kojic acid, suggesting their viability as 
effective natural suppressors of tyrosinase.9

Morus notabilis
In 2012, Hu et al. conducted a phytochemical evaluation of the 
stem of M. notabilis, isolating and characterizing several com-
pounds  in  the  process,  including  moracins  O  and  P.  These 
Moraceae  family  constituents  demonstrated  stronger  mush-
room tyrosinase-inhibiting effects as compared to kojic acid.10

Morus papyrifera (Paper Mulberry)
In a 2007 study of 101 plant extracts screened for their inhibitory 
activities  against  tyrosinase,  L-DOPA  oxidation,  and  melanin 
biosynthesis  in  B16  mouse  melanoma  cells,  Hwang  and  Lee 
noted  that  extracts  of  Broussonetia  papyrifera  (also  known  as 
Morus papyrifera), one of the 31 extracts to exhibit greater than 
50 percent inhibition of mushroom tyrosinase, concentration-
dependently  suppressed  tyrosinase  activity  and  L-DOPA 
oxidation.  Further,  extracts  of  Morus  bombycis  (also  known  as 
Morus australis or Chinese mulberry), one of the 17 groups of 
tyrosinase-inhibiting  extracts  tested  on  melanogenesis, 
significantly inhibited melanin production. These two species 
of mulberry were deemed by the authors to be among a group 
of botanicals to represent potential sources of skin-whitening 
agents for skin particularly sensitive to ultraviolet radiation.27

In 2008, Ko et al. isolated three previously unknown constitu-
ents of B. papyrifera leaves along with seven known compounds. 
The newly discovered diterpenes (broussonetones) were found 
to  marginally  block  tyrosinase  but  to  significantly  inhibit  xan-
thine  oxidase.  In  their  preliminary  screening,  the  investigators 
found that the parent flavonoids of the isolated diterpenes from 
methanolic extracts of the ground leaves of the plant exhibited 
greater mushroom tyrosinase inhibition than kojic acid as well as 
significant  DPPH  free  radical-scavenging  activity.  The  authors 
concluded that their results suggest the utility of the active con-
stituents of paper mulberry as ingredients in skin-protecting cos-
metics.12 Also in 2008, Zheng et al. isolated one new compound 
and 10 known ones from B. papyrifera twigs and found greater 
tyrosinase-inhibitory activity as compared to arbutin.11,28

The bark of paper mulberry is composed of extremely strong 
fibers used to produce high-quality paper and cloth. The roots of 
the tree have been found to display potent tyrosinase-inhibiting 
properties.  In  one  study,  a  0.4  percent  concentration  of  paper 
mulberry extract was demonstrated to suppress tyrosinase activ-
ity  by  50  percent  compared  to  5.5  percent  hydroquinone  and  
10 percent kojic acid. Notably, paper mulberry is not considered 
a significant irritant even at 1 percent concentration.29,30

 SAFETY ISSUES

Pollen from the M. alba tree has been associated with respira-
tory  allergies  as  well  as  contact  urticaria.13,31  There  are  no 
known adverse side effects from topical use.

C H A P T E R  39  ■   M U L B E R RY   E X T R AC T  

115

 ENVIRONMENTAL IMPACT

The  availability  of  mulberry  leaves,  particularly  white  mul-
berry,  for  the  silkworm  and  the  silk  industry  are  important 
factors related to the environmental impact of mulberry culti-
vation.  Several  varieties  of  mulberry  species  are  cultivated  in 
China,  Japan,  Korea,  and  India  for  the  sericulture,  or  silk 
farming,  industry.32  For  economic  reasons,  efforts  to  develop 
higher  yield  mulberry  varieties  are  ongoing.32  High  water 
demands are associated with high-yielding mulberry cultivars.5

 FORMULATION CONSIDERATIONS

Optimal solvents have been found to extract the active ingredi-
ents from the plant.33

 USAGE CONSIDERATIONS

No  interactions  with  other  ingredients  are  known  by  the 
author.

 SIGNIFICANT BACKGROUND

Cancer
In 2004, Prasad et al. showed that Morus indica (very similar to 
or another designation for M. alba) exhibited in vitro and in vivo 
activity  against  tumorigenesis  in  mice.  Investigators  studied 
the inhibitory activity and level of aryl hydrocarbon hydroxy-
lase,  cytochrome  P450,  DNA  sugar  damage  in  calf  thymus 
DNA,  and  Fe(++)/ascorbate-induced  lipid  peroxidation  in 
microsomes of mice, finding significant elevation in the activity 
of antioxidant enzymes and reduction in cutaneous malondial-
dehyde  levels  at  three  doses  of  the  extract  in  vitro.  Using  the 
two-stage  12-O-tetradecanoyl-phorbol-13-acetate  (TPA)-
induced  oxidative  stress  initiation  and  7,12-dimethylbenz(a)
anthracene  (DMBA)-induced  and  croton  oil-promoted  skin 
tumorigenesis model in Swiss albino mice, the researchers also 
found that applying the mulberry extract one hour before cro-
ton oil application extended the tumor latency period and also 
led to the reduction in the number of tumors per mouse and 
percentage  of  mice  developing  tumors.  Pretreatment  with  
M.  indica  also  dose-dependently  suppressed  TPA-induced 
stimulation of mouse epidermal ornithine decarboxylase activity. 
The authors concluded that white mulberry extract appears to 
have potential as a therapeutic agent for cancer control.3

Melasma
In  2011,  Alvin  et  al.  conducted  a  randomized,  single-blind, 
placebo-controlled  trial  of  50  Filipino  patients  (49  women,  
1  man)  to  assess  the  safety  and  efficacy  of  75  percent  white 
mulberry extract oil in a comparison with placebo for melasma 
treatment.  Patients  were  followed  up  at  weeks  4  and  8.  The 
mulberry extract group performed significantly better than the 
placebo group in each measurement [i.e., the melasma area and 
severity  score  (MASI),  Mexameter  reading,  and  melasma 
quality of life score (MelasQOL)]. The 25 patients treated with 
mulberry  extract  improved  from  a  baseline  MASI  reading  of 
4.076 (± 0.24) to 2.884 (± 0.25) at week 8 with a mean difference 
of  1.19;  the  placebo  group  mean  difference  of  improvement 
was 0.06. The mean Mexameter reading showed a significant 

 
116 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

difference,  with  a  slight  increase  for  the  mulberry  group 
(indicating lighter pigmentation) and the placebo group scoring 
a  slightly  higher  value.  Further,  the  MelasQOL  score  for  the 
mulberry  group  markedly  increased  from  baseline  to  week  
8 [58.84 (SD: ± 3.18) to 44.16 (SD: ± 4.29)], whereas the placebo 
group improved slightly from 57.44 (SD: ± 4.66) at baseline to 
54.28 (SD: ± 4.79) at week 8. The only adverse events reported 
were  mild  itching  in  four  patients  from  the  mulberry  group;  
12  cases  of  either  itching  or  erythema  were  reported  by  the 
placebo  group.  The  researchers  concluded  that  75  percent 
mulberry extract oil objectively ameliorates melasma in Fitzpatrick 
skin types III to V, though they recommend further research with a 
larger sample size and longer treatment duration and follow-up.34

 CONCLUSION

The Moraceae family of deciduous trees includes several spe-
cies  that  have  been  used  as  food  and  in  traditional  medical 
practices throughout Asia. Such uses have expanded in recent 
years  as  evidence  has  emerged  that  multiple  constituents  of 
these trees exert potent antityrosinase activity, in some cases 
more than kojic acid and arbutin. As such, mulberry has joined 
the  ranks  of  naturally  sourced  dermatologic  skin-whitening 
agents.

REFERENCES

1.  Lee SH, Choi SY, Kim H, et al. Mulberroside F isolated from the 
leaves  of  Morus  alba  inhibits  melanin  biosynthesis.  Biol  Pharm 
Bull. 2002;25:1045.

2.  Hoffmann  D.  The  endocrine  system.  In:  Medical  Herbalism:  The 
Science and Practice of Herbal Medicine. Rochester, VT: Healing Arts 
Press; 2003:464.

3.  Prasad L, Khan TH, Sehrawat A, et al. Modulatory effect of Morus 
indica against two-stage skin carcinogenesis in Swiss albino mice: 
Possible mechanism by inhibiting aryl hydrocarbon hydroxylase. 
J Pharm Pharmacol. 2004;56:1291.

4.  Enkhmaa B, Shiwaku K, Katsube T, et al. Mulberry (Morus alba L.) 
leaves and their major flavonol quercetin 3-(6-malonylglucoside) 
attenuate  atherosclerotic  lesion  development  in  LDL  receptor-
deficient mice. J Nutr. 2005;135:729.

5.  Khurana P, Checker VG. The advent of genomics in Mulberry and 
perspectives  for  productivity  enhancement.  Plant  Cell  Rep. 
2011;30:825.

6.  Adhikari A, Devkota HP, Takano A, et al. Screening of Nepalese 
crude  drugs  traditionally  used  to  treat  hyperpigmentation:  In 
vitro tyrosinase inhibition. Int J Cosmet Sci. 2008;30:353.

7.  Zhu  W,  Gao  J.  The  use  of  botanical  extract  as  topical  skin-
lightening  agents  for  the  improvement  of  skin  pigmentation 
disorders. J Investig Dermatol Symp Proc. 2008;13:20.

8.  Zheng ZP, Tan HY, Wang M. Tyrosinase inhibition constituents 

from the roots of Morus australis. Fitoterapia. 2012;83:1008.

9.  Zheng  ZP,  Cheng  KW,  Zhu  Q,  et  al.  Tyrosinase  inhibitory  con-
stituents from the roots of Morus nigra: A structure-activity rela-
tionship study. J Agric Food Chem. 2010;58:5368.

10.  Hu X, Wang M, Yan GR, et al. 2-Arylbenzofuran and tyrosinase 
inhibitory constituents of Morus notabilis. J Asian Nat Prod Res. 
2012;14:1103.

11.  Wang GW, Huang BK, Qin LP. The genus Broussonetia: A review of 
its phytochemistry and pharmacology. Phytother Res. 2012;26:1.

12.  Ko  HH,  Chang  WL,  Lu  TM.  Antityrosinase  and  antioxidant 
effects of ent-kaurane diterpenes from leaves of Broussonetia papy-
rifera. J Nat Prod. 2008;71:1930.

13.  Navarro AM, Orta JC, Sánchez MC, et al. Primary sensitization to 

Morus alba. Allergy. 1997;52:1144.

14.  Kobayashi Y, Miyazawa M, Kamei A, et al. Ameliorative effects 
of mulberry (Morus alba L.) leaves on hyperlipidemia in rats fed a 
high-fat diet: Induction of fatty acid oxidation, inhibition of lipo-
genesis,  and  suppression  of  oxidative  stress.  Biosci  Biotechnol 
Biochem. 2010;74:2385.

15.  Wang KH, Lin RD, Hsu FL, et al. Cosmetic applications of selected 
traditional  Chinese  herbal  medicines.  J  Ethnopharmacol. 
2006;106:353.

16.  Takahashi M, Takara K, Toyozato T, et al. A novel bioactive chal-
cone  of  Morus  australis  inhibits  tyrosinase  activity  and  melanin 
biosynthesis in B16 melanoma cells. J Oleo Sci. 2012;61:585.
17.  Konda S, Geria AN, Halder RM. New horizons in treating disor-
ders of hyperpigmentation in skin of color. Semin Cutan Med Surg. 
2012;31:133.

18.  Kim JK, Kim M, Cho SG, et al. Biotransformation of mulberroside 
A from Morus alba results in enhancement of tyrosinase inhibi-
tion. J Ind Microbiol Biotechnol. 2010;37:631.

19.  Zhang X, Hu X, Hou A, et al. Inhibitory effect of 2,4,2’,4’-tetrahy-
droxy-3-(3-methyl-2-butenyl)-chalcone  on  tyrosinase  activity 
and melanin biosynthesis. Biol Pharm Bull. 2009;32:86.

20.  Arfan  M,  Khan  R,  Rybarczyk  A,  et  al.  Antioxidant  activity  of 

mulberry fruit extracts. Int J Mol Sci. 2012;13:2472.

21.  Katsube T, Yamasaki M, Shiwaku K, et al. Effect of flavonol gly-
coside in mulberry (Morus alba L.) leaf on glucose metabolism and 
oxidative  stress  in  liver  in  diet-induced  obese  mice.  J  Sci  Food 
Agric. 2010;90:2386.

22.  Singh SK, Baker R, Wibawa JI, et al. The effects of Sophora angus-
tifolia  and  other  natural  plant  extracts  on  melanogenesis  and 
melanin transfer in human skin cells. Exp Dermatol. 2013;22:67.
23.  Lee KT, Lee KS, Jeong JH, et al. Inhibitory effects of Ramulus mori 

extracts on melanogenesis. J Cosmet Sci. 2003;54:133.

24.  Nattapong S, Omboon L. A new source of whitening agent from 
a Thai Mulberry plant and its betulinic acid quantitation. Nat Prod 
Res. 2008;22:727.

25.  Kim  YM,  Yun  J,  Lee  CK,  et  al.  Oxyresveratrol  and  hydroxystil-
bene compounds. Inhibitory effect on tyrosinase and mechanism 
of action. J Biol Chem. 2002;277:16340.

26.  Park KT, Kim JK, Hwang D, et al. Inhibitory effect of mulberro-
side A and its derivatives on melanogenesis induced by ultraviolet 
B irradiation. Food Chem Toxicol. 2011;49:3038.

27.  Hwang JH, Lee BM. Inhibitory effects of plant extracts on tyrosi-
nase, L-DOPA oxidation, and melanin synthesis. J Toxicol Environ 
Health A. 2007;70:393.

28.  Zheng ZP, Cheng KW, Chao J, et al. Tyrosinase inhibitors from 
paper mulberry (Broussonetia papyrifera). Food Chem. 2008;106:529.
29.  Baumann L, Woolery-Lloyd H, Friedman A. “Natural” ingredients 

in cosmetic dermatology. J Drugs Dermatol. 2009;8:s5.

30.  Dong-Il  Jang.  Melanogenesis  inhibitor  from  paper  Mulberry. 

Cosm Toiletr. 1997;112:59.

31.  Muñoz FJ, Delgado J, Palma JL, et al. Airborne contact urticaria 
due  to  mulberry  (Morus  alba)  pollen.  Contact  Dermatitis. 
1995;32:61.

32.  Umate P. Mulberry improvements via plastid transformation and 

tissue culture engineering. Plant Signal Behav. 2010;5:785.

33.  Kim J-M, Chang S-M, Kim I-H, et al. Design of optimcal solvent 
for  extraction  of  bio-active  ingredients  from  mulberry  leaves. 
Biochem Eng J. 2007;37:271.

34.  Alvin G, Catambay N, Vergara A, et al. A comparative study of 
the safety and efficacy of 75% mulberry (Morus alba) extract oil 
versus placebo as a topical treatment for melasma: a randomized, 
single-blind,  placebo-controlled  trial.  J  Drugs  Dermatol. 
2011;10:1025.

 
C H A P T E R  40  ■   V I TA M I N   C   ( A S CO R B I C   AC I D )  

117

C H A P T E R   4 0

Vitamin C (Ascorbic Acid)

Activities:

Anti-inflammatory, antioxidant, photoprotectant, depig-
menting

Important Chemical Components:

Esterified  forms  of  l-ascorbic  acid,  such  as  ascorbyl-
6-palmitate  and  magnesium  ascorbyl  phosphate.  Its 
molecular formula is C6H8O6.

Origin Classification:

Ascorbic acid is natural and found throughout the plant 
kingdom.  Organic  forms  are  available.  Numerous 
synthetic topical formulations contain ascorbic acid.

Personal Care Category:

Depigmenting

Recommended  for  the  following  Baumann  Skin 
Types: 

DRNW, DRPT, DRPW, ORNW, ORPT, and ORPW

 SOURCE

Vitamin C (ascorbic acid) can be found in citrus fruits and green 
leafy  vegetables.  Although  this  essential  nutrient  cannot  be 
synthesized by the human body, dietary consumption renders 
it the most abundant antioxidant in human skin and vitamin C 
plays an important role in endogenous collagen production.1,2 
This chapter will discuss the use of vitamin C in skin pigmenta-
tion.  Its  antiaging  and  antioxidant  properties  are  discussed  in 
Chapter 55, Ascorbic Acid (Vitamin C).

 HISTORY

Ascorbic acid, also known as vitamin C, is an essential nutrient. 
It is necessary for the formation of bone and connective tissue. 
Scurvy,  a  disease  caused  by  the  lack  of  vitamin  C,  was  first 
described in the 13th century. In the 18th century, it was dis-
covered that citrus fruits cured scurvy. Vitamin C was first iso-
lated by Dr. Albert Szent-Györgyi, who won the Nobel Prize in 
Physiology or Medicine in 1937 for this work. Ascorbic is derived 
from  the  Latin  a-(without)  and  scorbuticus  (scurvy).  Nobel 
Laureate Linus Pauling championed the use of oral vitamin C in 
1971 in his book Vitamin C and the Common Cold. The capacity 
of vitamin C to inhibit melanin formation was known as early 
as  1950.3,4  In  the  late  1980s,  Dr.  Sheldon  Pinnell  from  Duke 
University began looking at vitamin C as a photoprotectant. In 
1987, he published a paper in the Archives of Dermatology dem-
onstrating that collagen synthesis could be induced by ascorbic 
acid.5 He filed a patent in 1989 on a way to stabilize vitamin C 
in a topical formulation that later became the basis for the com-
pany  Skinceuticals.  His  diligence  and  adherence  to  evidence-

based science made a great impact and now vitamin C is one of 
the ingredients most recognized by consumers in the antiaging 
skin care market. Vitamin C is less known as an ingredient to 
decrease skin pigmentation because the form of ascorbic acid 
(magnesium  ascorbyl  phosphate)  that  is  the  best  inhibitor  of 
tyrosinase does not easily penetrate into the skin.6

 CHEMISTRY

Ascorbic acid is necessary for the hydroxylation of lysine and 
proline in procollagen to form the structural protein known as 
collagen.  It  is  the  loss  of  this  process  that  leads  to  scurvy  in 
vitamin  C  deficiency  because  the  loss  of  collagen  results  in 
blood vessel fragility and other symptoms of scurvy.

Ascorbic acid is very unstable and upon exposure to light and air 
reversibly  oxidizes  to  dehydroascorbic  acid,  ascorbate-2-sulfate, 
and oxalic acid. These metabolites are excreted in the urine.7

Ascorbic  acid  suppresses  melanin  formation  and  diminishes 
oxidized melanin through its capacity to reduce o-quinones, spe-
cifically  o-dopaquinone,  back  to  dopa,  thus  preventing  melanin 
formation. Ascorbic acid also inhibits pigmentation by interacting 
with copper ions that are needed by tyrosinase to function.8–10

 ORAL USES

Of course, vitamin C is readily available in a wide range of fruits 
and vegetables. It is also widely available in oral supplement form. 
Notably, most data buttressing the beneficial effects of vitamin C 
have  arisen  from  investigations  of  oral  vitamin  C  or  vitamin  C 
applied  to  tissue  cultures.  Although  oral  vitamin  C  is  easily 
absorbed into the circulation because low stomach pH provides 
the optimal environment, studies suggest that oral ingestion alone 
is not sufficient for skin protection. No studies have examined the 
effects of oral vitamin C on skin pigmentation.

 TOPICAL USES

Among cosmetic indications, vitamin C has been shown to be 
effective in treating skin aging, melasma, postlaser erythema, 
and  stretch  marks.  This  chapter  will  focus  on  the  effects  of 
ascorbic acid on skin pigmentation. 

Melasma
In  1996,  Kameyama  et  al.  showed  in  vitro  that  magnesium- 
l-ascorbyl-2-phosphate  inhibited  melanin  formation  on  purified 
tyrosinase or cultured cells and suppressed such formation without 
hindering cell growth on cultured human melanoma cells.4 In addi-
tion, the twice-daily topical application of 10 percent magnesium-
l-ascorbyl-2-phosphate was effective or fairly effective in lighten-
ing ephelides, melasma, or senile lentigos in 19 of 34 subjects.4

In 2004, Espinal-Perez et al. conducted a double-blind rand-
omized trial of 5 percent ascorbic acid as compared to 4 percent 
hydroquinone  (HQ)  water–oil  emulsion  in  16  female  patients, 

 
118 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

aged  23  to  43  years  (mean,  36  years)  with  melasma.  Of  those 
treated with vitamin C, 62.5 percent exhibited good or excellent 
subjectively evaluated skin lightening. There was no statistically 
significant difference in depigmenting activity in the HQ group, 
but  68.7  percent  of  patients  experienced  irritation  whereas 
vitamin C was well tolerated.11

In  a  randomized,  double-blind,  placebo-controlled  study, 
investigators used iontophoresis to enhance the penetration of 
vitamin C into the skin and significantly decrease pigmentation 
compared to placebo.12

Ascorbic acid is largely viewed as ineffective as a depigment-
ing  agent  alone  but  effective,  particularly  in  5  to  10  percent 
concentrations, when used in combination with other ingredi-
ents, such as HQ.13 In the magnesium-l-ascorbyl-2-phosphate 
esterified form, however, vitamin C is among the most popular 
prescribed depigmenting agents around the world, especially in 
countries where HQ and its derivatives are banned.14

PIPA
Vitamin  C  can  be  used  to  prevent  postinflammatory  pigment 
alteration  (PIPA)  after  procedures  because  it  inhibits  tyrosinase, 
decreases inflammation and quenches free radicals. In one study, 
the application of topical vitamin C two or more weeks after sur-
gery reduced the duration and degree of erythema in a study of 
10 patients receiving skin resurfacing with a carbon dioxide laser.15

Stretch Marks
Stretch  marks  can  be  red,  white,  or  brown  in  color.  Ascorbic 
acid  can  improve  the  texture  of  stretch  marks  by  increasing 
collagen  synthesis.  The  depigmenting  effects  can  lighten  the 
pigmentation  associated  with  stretch  marks.  The  anti-
inflammatory  capabilities  of  ascorbic  acid  may  also  help 
diminish the redness associated with these lesions. This unique 
combination of properties renders ascorbic acid an ideal ingre-
dient  to  treat  all  types  of  stretch  marks.  In  a  comparison  of 
topical vitamin C and glycolic acid to tretinoin and glycolic acid 
for the treatment of striae alba, both preparations resulted in an 
objective improvement, though only the tretinoin/glycolic acid 
combination increased elastin content of the striae.16

 SAFETY ISSUES

Vitamin C is an essential nutrient and is safe for oral consump-
tion. After a thorough review by the Cosmetic Ingredient Review 
Expert  Panel,  l-ascorbic  acid  and  various  esters,  including  cal-
cium  ascorbate,  magnesium  ascorbate,  magnesium  ascorbyl 
phosphate, sodium, ascorbate, and sodium ascorbyl phosphate, 
were deemed safe in topical cosmetic formulations.17

 ENVIRONMENTAL IMPACT

Vitamin  C  is  not  the  specific  target  in  the  cultivation  of  the 
numerous fruits and vegetables that contain it but its collection 
is implicit and essential for human health. It is unlikely that its 
use  has  any  deleterious  effects  on  the  environment.  Organic 
forms of vitamin C are available.

 FORMULATION CONSIDERATIONS

Ascorbic acid is hydrophilic and very unstable due to its ability to 
rapidly oxidize. Multiple topical preparations contain vitamin C; 
however,  many  of  these  products  have  problems  with  stability 
and  their  utility  is  questionable  (Table  40-1).  The  companies  IS 

TABLE 40-1
 Pros and Cons of Vitamin C

Pros
Potent anti-inflammatory and antioxidant 

Cons
Difficult to formulate

activity 

Strong safety profile
Tyrosinase inhibitor 
Oral ingestion results in increased skin levels

Topical forms are expensive
Does not readily penetrate the skin
Not very effective when used as 

monotherapy

Oral forms are inexpensive
Readily found in diet

Clinical, Skinceuticals, and La Roche-Posay have developed stabi-
lized  vitamin  C  preparations  that  are  packaged  in  a  manner 
intended to minimize inactivation of this easily degraded product. 
Specifically, the packaging of these products limits ultraviolet (UV) 
and  air  exposure  from  rapidly  oxidizing  vitamin  C.  However, 
these  formulations  do  not  contain  magnesium-l-ascorbyl-
2-phosphate,  the  form  of  ascorbic  acid  that  is  the  strongest 
tyrosinase inhibitor.

Magnesium-l-ascorbyl-2-phosphate  is  a  stable  derivative  of 
ascorbic  acid,  an  ascorbate  ester  developed  specifically  to 
improve  stability,  absorption,  and  hypopigmenting  activity.18 
One study examining the effects of daily topical application of 
magnesium-l-ascorbyl-2-phosphate  on  patients  with  melasma 
or senile lentigos demonstrated a significant lightening effect in 
19 of 34 patients.4 However, percutaneous absorption of magne-
sium  ascorbyl  phosphate  is  marginal  because  it  is  a  charged 
molecule, making it difficult to traverse the stratum corneum.

 USAGE CONSIDERATIONS

Ascorbic acid penetrates best in a pH of 2-2.5; therefore, an acidic 
environment is necessary. For this reason, it is optimal to use ascor-
bic acid after a low-pH cleanser such as a glycolic acid or a salicylic 
acid product. Combining with other acidic agents such as azelaic 
acid may be useful. However, ascorbic acid is unstable and can be 
so easily oxidized that it is crucial to apply it in the correct order in 
a regimen to ensure its stability and maximize the chance of pen-
etration. Combining ascorbic acid with ferulic acid has been shown 
to enhance its stability (see Chapter 54, Ferulic Acid). Combinations 
with  phloretin  may  enhance  its  depigmentation  ability  as  well  
(see  Chapter  52,  Phloretin),  but  more  studies  are  needed  to 
determine  its  usefulness  in  the  treatment  and  prevention  of 
pigmentation disorders when combined with other ingredients.

 SIGNIFICANT BACKGROUND

In addition to its utility as a depigmenting agent, vitamin C has 
antioxidant  properties  and  has  been  shown  to  stimulate 
collagen synthesis [see Chapter 55, Ascorbic Acid (Vitamin C)].

 CONCLUSION

Vitamin C preparations are safe and  effective in ameliorating 
hyperpigmentation, striae, and postlaser erythema, as well as 
preventing  or  mitigating  the  harmful  effects  of  UV  radiation. 
While  a  versatile  agent  in  dermatology,  vitamin  C  is  more 
commonly  used  to  treat  pigmentation  disorders  in  countries 
that do not allow hydroquinone and its derivatives. It is most 
effective when used in combination with another agent.

 
REFERENCES

1.  Shindo Y, Witt E, Han D, et al. Enzymic and non-enzymic anti-
oxidants in epidermis and dermis of human skin. J Invest Dermatol. 
1994;102:122.

2.  Farris PK. Topical vitamin C: A useful agent for treating photoaging 
and other dermatologic conditions. Dermatol Surg. 2005;31:814.
3.  Lerner  AB,  Fitzpatrick  TB.  Biochemistry  of  melanin  formation. 

Physiol Rev. 1950;30:91.

4.  Kameyama  K,  Sakai  C,  Kondoh  S,  et  al.  Inhibitory  effect  of 
magnesium l-ascorbyl-2-phosphate (VC-PMG) on melanogenesis 
in vitro and in vivo. J Am Acad Dermatol. 1996;34:29.

5.  Pinnell SR, Murad S, Darr D. Induction of collagen synthesis by 
ascorbic  acid:  A  possible  mechanism.  Arch  Dermatol. 
1987;123:1684.

6.  Wang  PC,  Huang  YL,  Hou  SS,  et  al.  Lauroyl/palmitoyl  glycol 
chitosan gels enhance skin delivery of magnesium ascorbyl phos-
phate. J Cosmet Sci. 2013;64:273.

7.  National  Library  of  Medicine  Hazardous  Substances  Database. 
Ascorbic  Acid  –  Compound  Summary:  Biomedical  Effects  and 
Toxicity – Absorption, Distribution and Excretion. http://pubchem 
.ncbi.nlm.nih.gov/summary/summary.cgi?cid=54670067.  
Accessed October 22, 2013.

8.  Ros  JR,  Rodríguez-López  JN,  García-Cánovas  F.  Effect  of 
l-ascorbic  acid  on  the  monophenolase  activity  of  tyrosinase. 
Biochem J. 1993;295:309.

9.  Gukasyan GS. Study of the kinetics of oxidation of monophenols 
by  tyrosinase:  The  effect  of  reducers.  Biochemistry  (Mosc). 
2002;67:277.

C H A P T E R  40  ■   V I TA M I N   C   ( A S CO R B I C   AC I D )  

119

10.  Kim H, Choi HR, Kim DS, et al. Topical hypopigmenting agents 
for  pigmentary  disorders  and  their  mechanisms  of  action.  Ann 
Dermatol. 2012;24:1.

11.  Espinal-Perez  LE,  Moncada  B,  Castanedo-Cazares  JP.  A  double-
blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone 
in melasma. Int J Dermatol. 2004;43:604.

12.  Huh  CH,  Seo  KI,  Park  JY,  et  al.  A  randomized,  double-blind, 
placebo-controlled trial of vitamin C iontophoresis in melasma. 
Dermatology. 2003;206:316.

13.  Callender VD, St Surin-Lord S, Davis EC, et al. Postinflammatory 
hyperpigmentation: Etiologic and therapeutic considerations. Am 
J Clin Dermatol. 2011;12:87.

14.  Parvez  S,  Kang  M,  Chung  HS,  et  al.  Survey  and  mechanism  of 
skin  depigmenting  and  lightening  agents.  Phytother  Res. 
2006;20:921.

15.  Alster TS, West TB. Effect of topical vitamin C on postoperative 
carbon  dioxide  laser  resurfacing  erythema.  Dermatol  Surg. 
1998;24:331.

16.  Ash K, Lord J, Zukowski M, et al. Comparison of topical ther-
apy  for  striae  alba  (20%  glycolic  acid/0.05%  tretinoin  versus 
20%  glycolic  acid/10%  l-ascorbic  acid).  Dermatol  Surg. 
1998;24:849.

17.  Elmore  AR.  Final  report  of  the  safety  assessment  of  l-ascorbic 
acid,  calcium  ascorbate,  magnesium  ascorbate,  magnesium 
ascorbyl  phosphate,  sodium  ascorbate,  and  sodium  ascorbyl 
phosphate as used in cosmetics. Int J Toxicol. 2005;24(Suppl 2):51.
18.  Solano  F,  Briganti  S,  Picardo  M,  et  al.  Hypopigmenting  agents:  
An  updated  review  on  biological,  chemical  and  clinical  aspects. 
Pigment Cell Res. 2006;19:550.

 
120  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   4 1

Cucumber

Activities:

Antityrosinase,  antioxidant,  anti-inflammatory,  anti-
hyaluronidase, anti-elastase

Important Chemical Components:

steroids, 

glycosides, 

Extracts: 
flavonoids, 
lutein,  carbohydrates,  tannins,  and  terpenoids.1,2  A 
group of triterpenoids known as cucurbitacins (particu-
larly cucurbitacin D and 23, 24-dihydrocucurbitacin D),3 
cucumegastigmanes I and II, cucumerin A and B, vitexin, 
isoscoparin  2”-O-(6”-(E)-p-coumaroyl) 
orientin, 
glucoside, apigenin 7-O-(6”-O-p-coumaroylglucoside)4

Pulp: Water, ascorbic acid (vitamin C), caffeic acid, lactic 
acid4
Seeds: α- and β-amyrin, sitosterols, cucurbitasides2

Origin Classification:

This ingredient is considered natural. Organic forms are 
available.

Personal Care Category:

Depigmenting, anti-inflammatory, occlusive,  emollient, 
sun protective, antioxidant, antiwrinkle, scar treatment, 
and first aid for burns

Recommended  for  the  following  Baumann  Skin 
Types:

DRPT, DRPW, DSPT, DSPW, ORPT, ORPW, OSPT, and 
OSPW

TABLE 41-1
Pros and Cons of Cucumber

Pros
Uses for skin care date back to antiquity

Cons
Paucity of research and clinical data to 

Broad spectrum of reported activity
Anti-inflammatory activity makes cucumber 
a good choice for treating sensitive skin 

buttress traditional claims
No studies on use in rosacea

conditions, including sunburn and under-eye swelling, and it has 
been noted for its soothing, antipruritic, emollient effects.5 Other 
medical indications for cucumber arose during its early use, and 
included headaches and acne (for which the fruit juice was used 
as a demulcent in lotions); the seeds were also used as a diuretic.2 
In traditional Chinese medicine, the leaves, roots, and stems of 
the plant have been used to detoxify as well as to treat diarrhea 
and gonorrhea.6 In addition, the application of cucumber slices to 
ameliorate swelling or dark circles under the eyes has long been 
accepted throughout the world as an effective treatment.

 CHEMISTRY

The  activity  that  cucumber  exhibits  in  suppressing  tyrosinase 
and  melanin  production  is  attributed  to  its  primary  bioactive 
components cucurbitacin D and 23, 24-dihydrocucurbitacin D.3,8 
These bitter compounds are also thought to be characteristic of 
the  species  and  have  displayed  anti-inflammatory,  purgative, 
and  antifertility  activity  in  vitro  and  in  vivo.4  Other  important 
constituents of cucumber include lutein and ascorbic acid.

 SOURCE

 ORAL USES

Cucumis  sativus,  an  annual  creeping  vine,  is  a  member  of  the 
Cucurbitaceae family, which also includes pumpkin, zucchini, 
watermelon,  and  squash.  Found  wildly  in  the  Himalayan 
region and commonly referred to as cucumber in English, khira 
in Hindi, sakusa as well as trapusah in Sanskrit, sasa in Bengali, 
and vellarikkay in Tamil, the plant is cultivated throughout India 
and  China,  in  particular,  as  well  as  Europe  and  the  United 
States.2,5 It is grown as a food crop, with its fruit, the cucumber, 
found in many cuisines as well as a component in traditional 
medicine and folk cosmetics.6

 HISTORY

C. sativus has been cultivated in Asia for 3,000 years as a food 
source  (Table  41-1).7  It  has  also  long  been  used  for  cosmetic 
purposes as the cucumber is known to impart a healing, sooth-
ing,  and  cooling  effect  to  irritated  skin.7  Its  use  for  treating 
hyperpigmentation  dates  back  centuries.5  The  leaves,  fruits, 
and  seeds  of  C.  sativus  have  been  used  in  traditional  Indian 
medicine,  especially  Ayurveda,  to  treat  numerous  skin 

By far, its primary use is in the culinary realm. Cucumber, con-
sidered  a  fruit  botanically  but  a  vegetable  gastronomically,  is 
cultivated throughout the world as a seasonal vegetable and is 
particularly popular in India and the Middle East.

 TOPICAL USES

Cucumber extracts can be found in a wide range of over-the-
counter  skin  care  creams,  lotions,  and  eye  gels  for  various 
indications,  primarily  to  soothe  and  soften  skin  and  to  treat 
wrinkles and sunburn. Skin whitening, though, is also one of 
the indications increasingly seen for this botanical.

Early in 2011, Akhtar et al. reported on their efforts to formu-
late a topical water in oil (w/o) emulsion of 3 percent cucumber 
extracts and evaluate it according to multiple parameters versus 
its base as a control (lacking cucumber ingredients) in 21 healthy 
volunteers over four weeks. The use of the cucumber formula-
tion  yielded  statistically  significant  reductions  in  sebum  and  a 
decline in melanin content that was not statistically significant. 
Transepidermal water loss and erythema were elevated by the 

 
test  formulation,  but  these  changes  were  also  not  statistically 
significant. There were also statistically nonsignificant differences 
found between the base and formulation in altering melanin con-
tent  through  four  weeks,  gradually  reducing  melanin  content 
over the final three weeks after an initial mild increase in the case 
of  the  formulation.  The  authors  concluded  that  their  findings 
point to the potential for cucumber extracts to be effective ingre-
dients  in  skin  care  agents  for  medical  and  cosmetic  purposes, 
particularly skin whitening, though more research is necessary.3

 SAFETY ISSUES

Though rare, there have been a few reports of contact dermatitis 
and urticaria in reaction to cucumber.9,10 Of course, this edible plant 
is considered safe and its fruit is consumed throughout the world.

 ENVIRONMENTAL IMPACT

Despite a long history of traditional use and anecdotal evidence, 
there is no scientific basis for the use of C. sativus in folk cosmetics.6 
Not surprisingly, then, the harvesting of cucumber fruits typically 
results in the remaining plant parts being left as waste. No signifi-
cant environmental damage from the industry has been reported.

 FORMULATION CONSIDERATIONS

None known by author.

 USAGE CONSIDERATIONS

No interactions with other ingredients are known by the author.

 SIGNIFICANT BACKGROUND

Analgesic, Antioxidant, Anticancer, Antiwrinkle 
Activity
In 2002, Villaseñor et al. assessed the comparative effectiveness 
of  sugar  beet  roots,  cucumber  fruits,  New  Zealand  spinach 
leaves, and turmeric rhizomes against dimethylbenz[a]anthra-
cene (DMBA)-initiated and croton oil-promoted skin tumors in 
a Swiss Webster albino mouse model using three different pro-
tocols. The four species were selected based on prior findings 
of  antioxidant  activity  and  effectiveness  in  preventing  skin 
tumors induced in laboratory settings. All four displayed anti-
oxidant activity and all were found to be effective in lowering 
skin tumor incidence and the number of skin tumors as well as 
delaying the onset of skin tumor formation in comparison to 
the control, with turmeric exhibiting the greatest potency.11

In  2010,  Kumar  et  al.  evaluated  the  aqueous  fruit  extract  of  
C.  sativus  for  free  radical-scavenging  and  analgesic  activities 
using  in  vitro  and  in  vivo  models.  Preliminary  phytochemical 
screening  indicated  that  cucumber  contains  various  classes  of 
compounds  known  to  exert  antioxidant  as  well  as  analgesic 
activity,  including  flavonoids  and  tannins.  The  investigators 
found that the fruit extract showed maximum antioxidant and 
analgesic  effect  at  500  μ g/mL  and  500  mg/kg,  respectively, 
though the exact constituents of C. sativus fruits responsible for 
the promising effects were not elucidated by the study.2

In  2011,  Nema  et  al.  subjected  the  lyophilized  juice  of  
C.  sativus  fruit  to  1,1-diphenyl-2-picrylhydrazyl  (DPPH)  and 

C H A P T E R  41  ■   C U C U M B E R  

121

superoxide radical-scavenging assays, in reference to butylated 
hydroxytoluene, as well as hyaluronidase and elastase inhibitory 
assays, in reference to oleanolic acid. The cucumber juice, rich in 
ascorbic  acid,  was  found  to  display  significant  free  radical 
scavenging  activity  as  well  as  potent  anti-hyaluronidase  and 
anti-elastase activity. The researchers concluded that C. sativus 
warrants  consideration  for  its  potential  use  as  an  antiwrinkle 
ingredient in cosmetic formulations.5

Skin Whitening
In 2008, Kai et al. assessed six plant parts of C. sativus to com-
pare  inhibitory  effects  on  melanogenesis.  They  found  that 
methanol extracts of the leaves and stems suppressed melanin 
production  in  cultured  B16  mouse  melanoma  cells.  Although 
they  did  not  alter  mushroom  tyrosinase  activity  or  crude 
enzyme lysate activity in these cells, the methanol extracts did 
reduce tyrosinase expression at the protein level. The research-
ers suggested that these findings indicate that the depigmenting 
activity of C. sativus extracts is associated with the downregu-
lation rather than inhibition of tyrosinase. They also found that 
lutein, of eight compounds isolated from the leaves, inhibited 
melanogenesis,  significantly  lowering  tyrosinase  expression. 
The  investigators  concluded  that  C.  sativus  leaves  and,  espe-
cially,  lutein  effectively  suppress  tyrosinase  expression  and 
deserve consideration for skin-whitening indications.6

The  roots  of  Chinese  cucumber  (Trichosanthes  kirilowii),  a 
member of the Cucurbitaceae family, have been used in tradi-
tional Chinese medicine as an anti-inflammatory agent and also 
as an abortifacient. Significantly, T. kirilowii and C. sativus share 
some of the same primary active constituents. In 2002, Oh et al. 
isolated  cucurbitacin  D  and  23,24-dihydrocucurbitacin  D  from 
the  root  of  T.  kirilowii  via  tyrosinase  inhibitory  activity-guided 
fractionation. The investigators found that the compounds effec-
tively inhibited tyrosinase activity as well as melanin synthesis 
in B16/F10 melanoma cells.12

 CONCLUSION

The use of cucumber as an effective agent for the temporary 
relief of swollen eyes, or dark circles under the eyes, has been 
established.  Also,  cucumber  has  an  anecdotal  reputation  as  a 
diuretic systemically and topically acting against water reten-
tion,  thus  ameliorating  burns,  dermatitis,  and  swollen  eyes. 
This folk medicine success or popularity has, perhaps, spurred 
the inclusion of C. sativa in various skin care products. There is 
a dearth of research on the dermatologic benefits of the plant, 
however. Its anti-inflammatory activity nevertheless makes it a 
good choice as a lightening ingredient for individuals with sen-
sitive  skin  types.  In  the  author’s  experience,  the  anti-
inflammatory activities are mild and have not proven to be of 
much benefit in the treatment of rosacea. Much more research 
is necessary to determine the appropriate role of cucumber in 
dermatology but its potential is intriguing.

REFERENCES

1.  Gandía-Herrero  F,  Jiménez  M,  Cabanes  J,  et  al.  Tyrosinase 
inhibitory activity of cucumber compounds: Enzymes responsible 
for browning in cucumber. J Agric Food Chem. 2003;51:7764.

2.  Kumar  D,  Kumar  S,  Singh  J,  et  al.  Free  radical  scavenging  and 
analgesic  activities  of  Cucumis  sativus  L.  fruit  extract.  J  Young 
Pharm. 2010;2:365.

3.  Akhtar  N,  Mehmood  A,  Khan  BA,  et  al.  Exploring  cucumber 
extract for skin rejuvenation. African J Biotechnol. 2011;10:1206.

 
122 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

4.  Mukherjee  PK,  Nema  NK,  Maity  N,  et  al.  Phytochemical  and 

9.  Zachariae  CO.  Cucumber  contact  dermatitis.  Contact  Dermatitis. 

therapeutic potential of cucumber. Fitoterapia. 2013;84:227.

2000;43:240.

5.  Nema NK, Maity N, Sarkar B, et al. Cucumis sativus fruit-potential 
antioxidant,  anti-hyaluronidase,  and  anti-elastase  agent.  Arch 
Dermatol Res. 2011;303:247.

6.  Kai H, Baba M, Okuyama T. Inhibitory effect of Cucumis sativus 
on melanin production in melanoma B16 cells by downregulation 
of tyrosinase expression. Planta Med. 2008;74:1785.

7.  Grieve M. A Modern Herbal. Vol. 1. New York: Dover Publications; 

1971:239–240.

8.  Chen JC, Chiu MH, Nie RL, et al. Cucurbitacins and cucurbitane 
glycosides:  structures  and  biological  activities.  Nat  Prod  Rep. 
2005;22:386.

10.  Weltfriend  S,  Kwangsukstith  C,  Maibach  HI.  Contact  urticaria 
from  cucumber  pickle  and  strawberry.  Contact  Dermatitis. 
1995;32:173.

11.  Villaseñor IM, Simon MK, Villanueva AM. Comparative potencies 
of  nutraceuticals  in  chemically  induced  skin  tumor  prevention. 
Nutr Cancer. 2002;44:66.

12.  Oh  H,  Mun  YJ,  IM  SJ,  et  al.  Cucurbitacins  from  Trichosanthes 
kirilowii as the inhibitory components on tyrosinase activity and 
melanin  synthesis  of  B16/F10  melanoma  cells.  Planta  Med. 
2002;68:832.

 
C H A P T E R  42  ■   L I G N I N   P E R OX I DA S E  

123

C H A P T E R   4 2

Lignin Peroxidase

Activities:

Skin lightening

Important Chemical Components:

Also  known  as  diarylpropane  oxygenase,  diarylpropane 
peroxidase, ligninase I, and LiP, lignin peroxidase catalyzes 
the  following  reaction:  1,2-bis(3,4-dimethoxyphenyl) 
propane-1,3-diol + H2O2 ⇋ 3,4-dimethoxybenzaldehyde + 
1-(3,4-dimethoxyphenyl)ethane-1,2-diol  +  H2O.  The 
molecular  formulae  for  lignin  are  C9H10O2,  C10H12O3, 
C11H14O4.

Origin Classification:

This a naturally occurring enzyme derived from one of 
the  most  abundant  organic  polymers  that  is  highly 
processed for commercial use.

Personal Care Category:

Depigmenting, toning

Recommended  for  the  following  Baumann  Skin 
Types:

DRPT, DRPW, DSPT, DSPW, ORPT, ORPW, OSPT, and 
OSPW

 SOURCE

Derived from the white-rot tree fungus Phanerochaete chrysosporium, 
lignin peroxidase is a naturally occurring enzyme identified as the 
enzyme  responsible  for  breaking  down  lignin  in  decaying  trees, 
resulting in rapid decolorization.1 Lignin peroxidase emerges extra-
cellularly  during  submerged  fermentation  of  the  P.  chrysosporium 
fungus and is then purified from the fermented liquid medium.2,3

 HISTORY

The enzyme lignin peroxidase was first identified  in  1984,  and 
has been studied for many years as a potential agent to break down 
lignin in order to whiten wood pulp in paper production.4 It was 
subsequently  found  to  break  down  eumelanin,  which  has  a 
similar  chemical  structure  to  lignin.  The  development  of  lignin 
peroxidase  as  a  skin-lightening  agent  resulted  from  these 
discoveries.3,5  In  2004,  Woo  et  al.  published  the  first  report 
indicating that lignin peroxidase/hydrogen peroxide (H2O2) had 
the capacity to eliminate the pigment in synthetic melanin.1,3

 CHEMISTRY

Lignin, an organic polymer found in the cell walls of plants, is 
similar  in  molecular  structure  to  melanin  as  well  as  coal.  In 
1994,  P.  chrysosporium  was  found  to  cause  decolorization  and 

depolymerization  of  low-grade  coal  in  culture  conditions 
conducive  to  mineralization  of  lignin.3,6  Recent  research  has 
verified that lignin peroxidase has the potential to break down 
or depolymerize melanin.3

 ORAL USES

This agent is for topical use only.

 TOPICAL USES

A trademarked (by Syneron of Israel) lignin peroxidase formula-
tion, Melanozyme is a glycoprotein active at pH 2 to 4.5, above 
which  it  is  inactive  (5.5  is  the  normal  pH  of  skin,  with  some 
variation between 5.0 and 6.5), that identifies epidermal eumelanin 
and  breaks  it  down  without  suppressing  tyrosinase  or  affecting 
melanin  biosynthesis.  Melanozyme,  produced  in  liquid  form  by 
Lonza  of  Switzerland  in  a  proprietary,  high-yield  production 
process that produces a commercially concentrated formulation, is 
available only in the new skin-lightening product known as Elure.

The two-sided product includes Melanozyme on one side and 
an activator containing H2O2 0.12 percent that oxidizes, thereby 
activating the lignin peroxidase to lighten the skin and even skin 
tone.7  Melanozyme  could  not  lighten  the  skin  without  the 
activating role of H2O2, which is applied to the skin surface after 
Melanozyme. After the enzyme is oxidized, it is reduced by a 
substrate molecule, such as veratryl alcohol, before the melanin 
is  oxidized.  After  application  of  the  formulation  (lotion  or 
cream), the individual’s cutaneous pH temporarily declines to 3.5 
before  rebounding  to  the  normal  level,  as  the  enzyme  is 
inactivated.  At  that  stage,  it  becomes  a  simple  glycoprotein 
hydrolyzed in the skin into amino acids by naturally occurring 
proteases  and  other  glycosidases.  At  the  time  this  book  was 
published,  Melanozyme  was  the  only  lignin  peroxidase 
established as an effective skin-lightening agent.

 SAFETY ISSUES

The  safety  of  lignin  peroxidase  as  a  skin-lightening  active 
ingredient  has  been  demonstrated  in  preclinical  studies  with 
doses  that  are  17,000  times  the  recommended  dose  without 
prompting  any  side  effects.8  Lignin  peroxidase  is  nonmuta-
genic and nonirritating to eyes. The potential for skin irritation 
is  very  low  and  in  studies  of  50  subjects  each,  there  were  no 
reports  of  skin  irritation  during  acute  sensitivity,  cumulative 
sensitivity, or when used in sensitized skin (Table 42-1).

 ENVIRONMENTAL IMPACT

Global production of lignin is approximately 1.1 million metric 
tons  annually.9  Lignin  peroxidase  represents  a  very  small 
fraction of this output. The culling and processing of lignin is a 
highly  industrialized  process  and  likely  exacts  some  toll,  but 
this is a renewable resource.

 
124 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

TABLE 42-1
Pros and Cons of Lignin Peroxidase

Pro
Strong safety profile

Cons
Paucity of research to establish effectiveness
H2O2 is required to potentiate its activity in 

current formulations
No activity on pheomelanin

 FORMULATION CONSIDERATIONS

New formulations that do not contain H2O2 are currently being 
researched.7

 USAGE CONSIDERATIONS

The Melanozyme ingredient is active at pH 2 to 4.5 so it needs 
to be in an acidic environment. It can be used in combination 
with acidic agents such as hydroxy acids.

 SIGNIFICANT BACKGROUND

In  2004,  Woo  et  al.  isolated  and  identified  the  melanin 
decolorization  fungus  and  depigmented  the  melanin 
biopolymer  with  lignin  peroxidase  and  H2O2,  and  further 
showed  that  crude  lignin  peroxidase  prepared  from  culture 
broth could also decolorize human skin pigment.3

In  2011,  Mauricio  et  al.  conducted  a  randomized,  double-
blind,  placebo-controlled,  split-face,  single-center  study  of  
51 women of East Asian (Chinese and Korean) and Southeast 
Asian (Filipino, Thai, and Vietnamese) ethnicity (ranging in age 
from 20 to 60 years and Fitzpatrick skin types 3 to 5) to assess 
the  skin-lightening  safety  and  efficacy  of  lignin  peroxidase 
creams  compared  with  2  percent  hydroquinone  (HQ)  cream 
and  placebo.  Participants  were  randomized  to  receive  lignin 
peroxidase day and night creams for one side of the face and 
HQ  cream  or  placebo  for  the  other.  Whereas  no  statistically 
significant  lightening  effect  was  seen  with  either  HQ  or 
placebo,  the  researchers  noted  a  statistically  significant  mean 
reduction  in  the  melanin  index  of  7.6  percent  from  baseline 
associated with the lignin peroxidase side. In addition, patients 

preferred the lignin peroxidase products. Overall, a more rapid 
and  observable  skin-lightening  effect  was  observed  with  the 
lignin peroxidase creams.7

 CONCLUSION

Lignin peroxidase shows potential to enter the ever-expanding 
list  of  viable  skin-lightening  agents.  While  the  few  extant 
results suggest such efficacy, much more research is necessary 
to  establish  this  ingredient  as  a  suitable  alternative  in  the 
depigmenting armamentarium. In the author’s experience, this 
ingredient works well in skin types with an Asian ancestry and 
less well in other demographic groups, likely due to the ratio of 
eumelanin to pheomelanin in various ethnicities. Those with a 
preponderance of eumelanin will have better efficacy with this 
ingredient.

REFERENCES

1.  Nagasaki K, Kumazawa M, Murakami S, et al. Purification, char-
acterization, and gene cloning of Ceriporiopsis sp. Strain MD-1 
peroxidases  that  decolorize  human  hair  melanin.  Appl  Environ 
Microbiol. 2008;74:5106.

2.  Spruit  D.  The  interference  of  some  substances  with  the  water 
vapour loss of human skin. Dermatologica. 1971;142(2):89–92.
3.  Woo S, Cho J, Lee B, et al. Decolorization of melanin by lignin 
peroxidase  from  Phanerochaete  chrysosporium.  Biotechnol 
Bioprocess Eng. 2004;9:256.

4.  Gold  MH,  Kuwahara  M,  Chiu  AA,  et  al.  Purification  and 
characterization of an extracellular H2O2-requiring diarylpropane 
oxygenase  from  the  white  rot  basidiomycete,  Phanerochaete 
chrysosporium. Arch Biochem Biohphys. 1984;234:353.

5.  USPTO Patent Applicatioin 20060051305. Methods of producing 

lignin peroxidase and its use in skin and hair lightening.

6.  Ralph  JP,  Catchesidex  DEA.  Decolourisation  and  depolymerisa-
tion of solubilised low lank coal by the white rot basidiomycete 
Phanerochaete  chrysosporium.  Appl  Microbiol  Biotechnol. 
1994;42:536.

7.  Mauricio  T,  Karmon  Y,  Khaiat  A.  A  randomized  and  placebo-
controlled  study  to  compare  the  skin-lightening  efficacy  and 
safety  of  lignin  peroxidase  cream  vs.  2%  hydroquinone  cream.  
J Cosmet Dermatol. 2011;10:253.

8.  Data on file. Rakuto Bio Technologies, 5 Carmel Street, P.O. Box 

528, New Industrial Park, Yokneam, 20692.

9.  Higson  A,  Smith  C.  The  National  Non-Food  Crops  Centre 
(NNFCC)  Renewable  Chemicals  Factsheet:  Lignin.  http://www 
.nnfcc.co.uk/publications/nnfcc-renewable-chemicals-factsheet-
lignin. Accessed June 17, 2013.

 
C H A P T E R  43  ■   O vE Rv iE w  Of   T H E   PA R - 2  RE C E P TO R  

125

C H A P T E R   4 3

Overview of the PAR-2 Receptor

Protease-activated  receptor-2  (PAR-2)  is  a  G-protein-coupled 
receptor that is able to enhance the capacity of keratinocytes to 
ingest  melanosomes  from  the  neighboring  melanocyte.  Each 
melanocyte  is  in  contact  with  an  average  of  36  keratinocytes 
forming an “epidermal melanin unit” (Figure 43-1).1,2 Once mel-
anin is created within melanosomes, it migrates into the den-
drite tips of the melanocyte and is then incorporated into other 
keratinocytes  of  the  epidermal  melanin  unit.  Although  the 
exact process of melanin transfer is not completely understood, 
PAR-2 has been shown to play an important role.3 The PAR-2 
can be up- or downregulated, and is upregulated by ultraviolet 
radiation.4 It is thought to be important in hyperpigmentation 
disorders because it has been found that serine protease inhibi-
tors  that  interfere  with  PAR-2  activation  induce  depigmenta-
tion  by  reducing  melanosome  transfer  and  distribution.5 
Soybeans, which contain the serine protease inhibitors soybean 
trypsin inhibitor (STI) and Bowman–Birk protease inhibitor (BBI), 

have been demonstrated to inhibit melanosome transfer, result-
ing in an improvement of mottled facial pigmentation.6 In addi-
tion, activation of PAR-2 with trypsin and other synthetic pep-
tides has been shown to result in visible skin darkening.5

Other systems play a role in melanosome transfer as well. For 
example, b -amyloid precursor protein (APP) is a newly detected 
epidermal growth factor that has been demonstrated to increase 
the release of melanin as well as enhance the movements of the 
melanocyte dendritic tips.7 Keratinocyte growth factor also pro-
motes melanosome transfer by stimulating the phagocytic pro-
cess.8  Many  different  factors  affect  melanosome  transfer  and 
play a role in the complex pigmentation process. At this time, 
only PAR-2 blockers have been added in cosmeceutical skin care 
products to block the transfer of melanosomes, so this section 
will focus on these agents. PAR-2 blockers do not break down 
melanin  that  is  already  in  keratinocytes;  therefore,  results  will 
not be seen for 8 to 16 weeks of using such skin care products.

REFERENCES

1.  Jimbow K, Quevedo WC Jr, Fitzpatrick TB, et al. Some aspects of 

melanin biology: 1950–1975. J Invest Dermatol. 1976;67:72.

2.  Nordlund JJ. The melanocyte and the epidermal melanin unit: An 

expanded concept. Dermatol Clin. 2007;25:271.

3.  Seiberg M, Paine C, Sharlow E, et al. Inhibition of melanosome 
transfer results in skin lightening. J Invest Dermatol. 2000;115:162.
4.  Seiberg M. Keratinocyte-melanocyte interactions during melano-

some transfer. Pigment Cell Res. 2001;14:236.

5.  Seiberg  M,  Paine  C,  Sharlow  E,  et  al.  The  protease-activated 
receptor  2  regulates  pigmentation  via  keratinocyte-melanocyte 
interactions. Exp Cell Res. 2000;254:25.

6.  Wallo W, Nebus J, Leyden JJ. Efficacy of a soy moisturizer in pho-
toaging:  a  double-blind,  vehicle-controlled,  12-week  study.  
J Drugs Dermatol. 2007;6:917.

7.  Quast T, Wehner S, Kirfel G, et al. sAPP as a regulator of dendrite 
motility and melanin release in epidermal melanocytes and mela-
noma cells. FASEB J. 2003;17:1739.

8.  Cardinali  G,  Bolasco  G,  Aspite  N,  et  al.  Melanosome  transfer 
promoted by keratinocyte growth factor in light and dark skin-
derived keratinocytes. J Invest Dermatol. 2008;128:558.

FIGURE 43-1  Epidermal melanin unit. One melanocyte can interca-

▶
late with many keratinocytes.

 
126 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   4 4

Niacinamide

Activities:

PAR-2  inhibition,  anti-inflammatory,  antioxidant, 
antiaging, photoprotective

Important Chemical Components:

Also known as nicotinamide (and 3-pyridinecarboxamide), 
molecular formula is C6H6N2O

Origin Classification:

Natural  vitamin  constituent  of  various  foods  but  the 
cosmetic ingredient is laboratory made

Personal Care Category:

Depigmenting, exfoliant

Recommended  for  the  following  Baumann  Skin 
Types:

Is a superior choice for dry, sensitive and wrinkle-prone 
skin  types.  Best  for  DRNT,  DRNW,  DRPT,  DRPW, 
DSNT,  DSNW,  DSPT,  DSPW,  ORPT,  ORPW,  OSPT, 
OSPW, OSNT, and OSNW.

 SOURCE

Niacinamide,  also  known  as  nicotinamide,  is  the  biologically 
active amide of niacin (vitamin B3). This form of the vitamin is 
found  naturally  in  a  wide  variety  of  foods,  particularly  root 
vegetables,  mushrooms,  yeasts,  some  fruits,  peanuts,  and 
seeds.1,2 Significantly, the effects of niacinamide on pigmenta-
tion have been shown to be reversible (Table 44-1).3

 HISTORY

Research  on  and  the  use  of  oral  niacinamide  dates  back  to  the 
1930s, but the data on the use of topical niacinamide are relatively 
new. The first use of topical niacinamide to ameliorate skin barrier 
function  in  individuals  with  pellagra,  which  is  characterized  by 
pronounced  cutaneous  sensitivity  to  sunlight,  was  reported  in 
1976.4–6 For over 40 years, niacinamide has been used in dermatol-
ogy for a broad array of disorders including acne, atopic dermatitis, 
autoimmune bullous dermatoses, excess sebum, as well as rosacea, 

TABLE 44-1
Pros and Cons of Niacinamide

Pros
PAR-2 blocking agent
Water soluble
Easily tolerated

Anti-inflammatory
Can be formulated in SPF
No interactions with other ingredients

Cons
Not well known by consumers
Not as potent as hydroquinone
No organic or natural forms are available 

on the market

and more recently to treat hyperpigmentation and to prevent pho-
toaging and photoimmunosuppression.7,8

 CHEMISTRY

Niacinamide  is  an  important  part  of  the  niacin  coenzymes 
nicotinamide  adenine  dinucleotide  (NAD+)  and  nicotinamide 
adenine dinucleotide phosphate (NADP+), and their respective 
reduced  forms  the  antioxidants  NADH  and  NADPH.  
These compounds contribute to cellular oxidation and reduc-
tion reactions as well as DNA synthesis and repair, are involved 
in  over  200  enzymatic  reactions,  and  may  play  a  role  in 
providing cosmetic benefits.2,9–11 Surjana and Damian suggest 
that niacinamide is able to confer clinical effects because of its 
role as a cellular energy precursor, a modulator of inflammatory 
cytokines,  and  a  suppressor  of  the  nuclear  enzyme 
poly(adenosine diphosphate-ribose) polymerase-1.7 It has also 
been shown to increase intercellular lipid production.3,12

Niacinamide has been demonstrated to suppress melanosome 
transfer  to  epidermal  keratinocytes,  by  up  to  68  percent  in  an  
in  vitro  model,  and  to  render  improvement  in  undesired  facial 
pigmentation.9  This  inhibition  of  melanosome  transfer  from 
melanocytes to keratinocytes is considered the primary method 
by which niacinamide lessens skin pigmentation.

 ORAL USES

The  nutritional  value  of  niacin  or  niacinamide  has  been  long 
understood.  Niacinamide  is  found  in  various  vegetables  (par-
ticularly  asparagus  and  root  vegetables),  mushrooms,  yeasts, 
some  fruits,  peanuts,  and  seeds.  Oral  niacinamide  is  best 
known for curing pellagra, but it has also been linked to playing 
a  role  in  preventing  insulin-dependent  diabetes  mellitus 
development.9,13 Evidence amassed during the last 15 years has 
also  shown 
that  oral  niacinamide  has  prevented 
photocarcinogenesis  in  mice,  as  well  as  protected  against 
photoimmunosuppression in humans and mice.14–16 In addition, 
recent results of phase II double-blinded randomized controlled 
trials led by Surjana et al. indicate that oral niacinamide (500 mg) 
effectively diminishes actinic keratoses and shows potential for 
chemopreventive activity against skin cancer.17

 TOPICAL USES

Niacinamide has been used for various indications in dermatology, 
including  acne  and  rosacea.18–20  This  water-soluble  vitamin  is 
known  to  be  a  significant  active  ingredient  in  moisturizers 
intended to improve xerosis and stratum corneum (SC) barrier 
function.4  In  addition,  it  has  recently  been  shown  in  topical 
form to protect against UVA and UVB radiation and is thought 
to be a promising agent to prevent against skin cancer.21

In a 2005 study, twice daily application of a 5 percent niacina-
mide preparation for 8 weeks yielded significant improvement in 

 
hyperpigmentation  as  did  the  use  of  3.5  percent  niacinamide 
combined with retinyl palmitate.22

In  2013,  Mohammed  et  al.  studied  the  effects  of  twice-daily 
application of a niacinamide-containing formulation for 28 days on 
the left and right mid-volar forearms of 20 healthy volunteers in 
terms  of  transepidermal  water  loss  (TEWL),  corneocyte  surface 
area and maturity, SC thickness, and selected protease activities. 
Overall,  areas  treated  with  niacinamide-containing  formulations 
exhibited larger and more mature corneocytes, less inflammatory 
activity and TEWL, and greater SC thickness as compared to pre-
treatment baseline and areas left untreated or treated with vehicle 
control. The investigators concluded that niacinamide displays 
unique SC barrier-bolstering qualities and merits consideration 
as  a  topical  formulation  adjunct.4  During  the  last  decade, 
though,  its  greatest  application  in  dermatology  has  been 
thought to be in relation to its activity as a depigmenting agent.

Combination Therapy
In 2006, Hakozaki et al. studied the effects of combining high-
frequency  ultrasound  with  topical  skin-lightening  agents 
(ascorbyl glucoside and niacinamide) on facial hyperpigmenta-
tion  in  60  Japanese  women.  They  found  in  their  four-week 
clinical trial that the use of ultrasound radiation along with skin-
lightening gel significantly diminished facial hyperpigmentation 
spots  as  compared  with  no  treatment  and  skin-lightening  gel 
alone,  which  they  attributed  to  the  facilitating  effect  of  ultra-
sound on the transepidermal transport of the topical agents.23

In 2009, Bissett et al. performed two double-blind, 10-week, 
left-right randomized, split-face clinical studies to ascertain if the 
combination of N-undecyl-10-enoyl-L-phenylalanine, which has 
reportedly lowered melanin production in cultured melanocytes, 
and  niacinamide  is  more  effective  than  niacinamide  alone  in 
diminishing facial hyperpigmentation. In one study, 80 Japanese 
women (76 of whom completed the study) randomized into two 
groups  each  applied  one  of  two  formulation  pairs  to  the  ran-
domly assigned side of the face, a vehicle control and a 5 percent 
niacinamide  formulation,  or  a  5  percent  niacinamide  and  a  
5 percent niacinamide plus 1 percent N-undecylenoyl phenylala-
nine formulation. In the other study, 152 Caucasian women (of 
whom 147 completed the study) applied either vehicle control, a 
5 percent niacinamide formulation, or a 5 percent niacinamide 
and  1  percent  N-undecylenoyl-phenylalanine  combination 
formulation  to  the  randomly  assigned  side  of  the  face.  The 
investigators found that the combination formulation was more 
effective than the vehicle or niacinamide alone in improving the 
appearance  of  hyperpigmentation  in  both  studies.  They 
concluded  that  this  combination  formulation  is  an  effective 
antiaging agent for facial skin.24

Early in the next year, Jerajani et al. measured the effects in 
246 Indian women (aged 30–60 years) with epidermal hyperpig-
mentation  of  the  daily  use  of  a  lotion  containing  niacinamide, 
panthenol,  and  tocopherol  acetate  for  10  weeks.  In  this  rand-
omized, double-blind trial, which 207 women completed, those 
who  used  the  well-tolerated  test  formulation  experienced  sig-
nificant improvements in the appearance of hyperpigmentation, 
skin tone, and texture as compared to controls.25

Also  in  2010,  Kimball  et  al.  conducted  a  10-week,  double-
blind, vehicle-controlled, full-face, parallel-group clinical study in 
202 women (aged 40–60 years) to evaluate the effects of a com-
bination  of  niacinamide  and  N-acetyl  glucosamine  in  a  topical 
moisturizing  formulation  on  irregular  facial  pigmentation.  The 
evenly  divided  groups  daily  applied  either  a  morning  sun 
protection  factor  (SPF)  15  sunscreen  moisturizing  lotion  and 

C H A P T E R  44  ■   N I AC I N A M I D E  

127

evening  moisturizing  cream  each  containing  4  percent 
niacinamide and 2 percent N-acetyl glucosamine or the SPF 15 
lotion and cream vehicles. All measurement parameters revealed 
that  the  test  formulation  was  significantly  more  effective  in 
alleviating detectable hyperpigmentation than the control product 
and yielded results superior to using an SPF sunscreen alone.26

Niacinamide  was  also  a  key  active  ingredient  in  an  SPF  30 
moisturizing  lotion  used  in  a  recent  randomized,  controlled 
comparative  study  on  wrinkle  reduction.  In  this  eight-week 
parallel-group study of 196 women with moderate to moderately 
severe periorbital wrinkles, 99 women used the SPF moisturizer 
containing 5 percent niacinamide, peptides, and antioxidants; a 
moisturizing cream containing niacinamide and peptides; and a 
targeted wrinkle product containing niacinamide, peptides, and 
0.3  percent  retinyl  propionate.  The  remaining  cohort  of  
97  women  used  0.02  percent  tretinoin  plus  moisturizing  SPF  
30 sunscreen. The niacinamide regimen was significantly better 
tolerated  and  provided  significantly  improved  wrinkle  appear-
ance compared to the tretinoin group.27

 SAFETY ISSUES

Niacinamide is very well tolerated by the skin and has an excel-
lent safety profile.

 ENVIRONMENTAL IMPACT

Given  the  widespread  availability  of  plants  containing 
niacinamide,  no  discrete  environmental  toll  is  exacted  in  the 
culling of niacinamide specifically.

 FORMULATION CONSIDERATIONS

Niacinamide is chemically stable, easily formulated, and compati-
ble with various other potential cosmetic formulation ingredients.28

 USAGE CONSIDERATIONS

Niacinamide  can  be  used  in  conjunction  with  retinoids, 
sunscreens,  hydroxy  acids,  and  other  ingredients  without 
concern for cross-reactivity.

 SIGNIFICANT BACKGROUND

In 2002, Hakozaki et al. examined the in vitro effects of niacina-
mide  on  melanogenesis  and  in  vivo  effects  on  18  Japanese 
women  with  hyperpigmentation.  In  cultured  melanocytes, 
niacinamide  exerted  no  effect  on  mushroom  tyrosinase  cata-
lytic activity or melanogenesis but significantly inhibited mela-
nosome transfer in a keratinocyte/melanocyte coculture model 
and decreased cutaneous pigmentation in a pigmented recon-
structed epidermis model. In the clinical trial over four weeks, 
the  18  participants  with  hyperpigmentation  used  5  percent 
niacinamide moisturizer and a vehicle moisturizer in a paired 
design, and 120 subjects with facial tanning were assigned to 
two  of  three  treatments  (vehicle,  sunscreen,  and  2  percent 
niacinamide  plus  sunscreen).  The  investigators  found  that 
niacinamide  significantly  reduced  hyperpigmentation  and 
enhanced skin lightness in comparison to vehicle alone. They 
concluded that niacinamide effectively lightens skin by suppressing 
melanosome transfer from melanocytes to keratinocytes.9

 
128 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

In  2004,  Bissett  et  al.  conducted  a  12-week,  double-blind, 
placebo-controlled,  split-face,  left-right  randomized  clinical 
study  with  50  Causcasian  women  (aged  40–60  years)  to  com-
pare a moisturizer containing 5 percent niacinamide and a con-
trol moisturizer. The investigators found that the well-tolerated 
niacinamide formulation imparted significant improvements in 
fine lines/wrinkles, hyperpigmentation, skin texture, red blotchi-
ness, and sallowness compared to the control product.28

The next year, Bissett et al. sought to clinically determine the 
antiaging effects of topical niacinamide in addition to the well-
established  improvement  on  hyperpigmentation.  In  this 
12-week,  double-blind,  left-right  randomized  study,  50  white 
females  with  clinical  signs  of  facial  photoaging  twice  daily 
applied 5 percent niacinamide to half of the face and its vehicle 
control  to  the  other  half.  The  researchers  observed  that  the 
niacinamide-treated  areas  demonstrated  marked  improvement 
in  elasticity  as  well  as  in  reducing  fine  lines  and  wrinkles, 
hyperpigmented spots, red blotchiness, and skin sallowness.29

Also  in  2005,  Greatens  et  al.  used  an  in  vitro  melanocyte-
keratinocyte  coculture  to  find  that  both  agents  are  reversible 
inhibitors of melanosome transfer at concentrations not affect-
ing  cell  viability.  In  a  related  study,  the  investigators  observed 
that  topically  applied  niacinamide  dose-dependently  and 
reversibly diminished hyperpigmented lesions.3

 CONCLUSION

Niacinamide, the biologically active amide of niacin (vitamin B3), 
the dearth of which leads to pellagra, has long been known to 
play  an  important  role  in  cutaneous  health.  This  versatile 
vitamin  exhibits  its  most  dynamic  dermatologic  activity  as  a 
depigmenting  agent.  It  is  a  safe  and  effective  alternative  to 
hydroquinone,  though  not  as  potent  or  effective  as  the 
standard-bearing  depigmenting  agent.  However,  niacinamide 
has  a  well-established  role  in  dermatology  and  its  range  of 
indications  appears  to  be  broadening.  Niacinamide  is  one  of 
the author’s favorite ingredients because of its utility in treating 
inflammation and pigmentation, and preventing of skin aging 
and skin cancer, as well as its tolerability.

REFERENCES

1.  Leydenx JJ, Shergillx B, Micalix G, et al. Natural options for the 
management of hyperpigmentation. J Eur Acad Dermatol Venereol. 
2011;25:1140.

2.  Zhu  W,  Gao  J.  The  use  of  botanical  extracts  as  topical  skin-
lightening  agents  for  the  improvement  of  skin  pigmentation 
disorders. J Investig Dermatol Symp Proc. 2008;13:20.

3.  Greatens A, Hakozaki T, Koshoffer A, et al. Effective inhibition of 
melanosome transfer to keratinocytes by lectins and niacinamide 
is reversible. Exp Dermatol. 2005;14:498.

4.  Mohammed D, Crowther JM, Matts PJ, et al. Influence of niacina-
mide containing formulations on the molecular and biophysical 
properties of the stratum corneum. Int J Pharm. 2013;441:192.
5.  Comaish JS, Felix RH, McGrath H. Topically applied niacinamide 

in isoniazid-induced pellagra. Arch Dermatol. 1976;112:70.

6.  Benavente CA, Schnell SA, Jacobson EL. Effects of niacin restric-
tion  on  sirtuin  and  PARP  responses  to  photodamage  in  human 
skin. PLoS One. 2012;7:e42276.

7.  Surjana D, Damian DL. Nicotinamide in dermatology and photo-

protection. Skinmed. 2011;9:360.

8.  Namazi MR. Nicotinamide in dermatology: A capsule summary. 

Int J Dermatol. 2007;46:1229.

9.  Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacina-
mide  on  reducing  cutaneous  pigmentation  and  suppression  of 
melanosome transfer. Br J Dermatol. 2002;147:20.

10.  Konda S, Geria AN, Halder RM. New horizons in treating disor-
ders of hyperpigmentation in skin color. Semin Cutan Med Surg. 
2012;31:133.

11.  Gillbro  JM,  Olsson  MJ.  The  melanogenesis  and  mechanisms  of 
skin-lightening agents – Existing and new approaches. Int J Cosmet 
Sci. 2011;33:210.

12.  Sharlow  ER,  Paine  CS,  Babiarz  L,  et  al.  The  protease-activated 
receptor-2  upregulates  keratinocyte  phagocytosis.  J  Cell  Sci. 
2000;113:3093.

13.  Elliott RB, Pilcher CC, Fergusson DM, et al. A population based 
strategy  to  prevent  insulin-dependent  diabetes  using  nicotina-
mide. J Pediatr Endocrinol Metab. 1996;9:501.

14.  Gensler  HL,  Williams  T,  Huang  AC,  et  al.  Oral  niacin  prevents 
photocarcinogenesis  and  photoimmunosuppression  in  mice.  
Nutr Cancer. 1999;34:36.

15.  Damian  DL.  Photoprotective  effects  of  nicotinamide.  Photochem 

Photobiol Sci. 2010;9:578.

16.  Yiasemides  E,  Sivapirabu  G,  Halliday  GM,  et  al.  Oral  nicotina-
mide protects against ultraviolet radiation-induced immunosup-
pression in humans. Carcinogenesis. 2009;30:101.

17.  Surjana  D,  Halliday  GM,  Martin  AJ,  et  al.  Oral  nicotinamide 
reduces actinic keratoses in phase II double-blinded randomized 
controlled trials. J Invest Dermatol. 2012;132:1497.

18.  Callender VD, St Surin-Lord S, Davis EC, et al. Postinflammatory 
hyperpigmentation:  Etiologic  and  therapeutic  considerations.  
Am J Clin Dermatol. 2011;12:87.

19.  Niren  NM,  Torok  HM.  The  Nicomide  Improvement  in  Clinical 
Outcomes  Study  (NICOS):  results  of  an  8-week  trial.  Cutis. 
2006;77(1 Suppl):17.

20.  Fowler JF Jr, Woolery-Lloyd H, Waldorf H, et al. Innovations in 
natural  ingredients  and  their  use  in  skin  care.  J  Drugs  Dermatol. 
2010;9(6 Suppl):S72.

21.  Sivapirabu  G,  Yiasemides  E,  Halliday  GM,  et  al.  Topical 
nicotinamide modulates cellular energy metabolism and provides 
broad-spectrum  protection  against  ultraviolet  radiation-induced 
immunosuppression in humans. Br J Dermatol. 2009;161:1357.
22.  Otte N, Borelli C, Korting HC. Nicotinamide – Biologic actions of 
an emerging cosmetic ingredient. Int J Cosmet Sci. 2005;27:255.
23.  Hakozaki T, Takiwaki H, Miyamoto K, et al. Ultrasound enhanced 
skin-lightening  effect  of  vitamin  C  and  niacinamide.  Skin  Res 
Technol. 2006;12:105.

24.  Bissett  DL,  Robinson  LR,  Raleigh  PS,  et  al.  Reduction  in  the 
appearance of facial hyperpigmentation by topical N-undecyl-10-
enoyl-L-phenylalanine  and  its  combination  with  niacinamide.  
J Cosmet Dermatol. 2009;8:260.

25.  Jerajani HR, Mizoguchi H, Li J, et al. The effects of a daily facial 
lotion  containing  vitamins  B3  and  E  and  provitamin  B5  on  the 
facial  skin  of  Indian  women:  a  randomized,  double-blind  trial. 
Indian J Dermatol Venereol Leprol. 2010;76:20.

26.  Kimball AB, Kaczvinsky JR, Li J, et al. Reduction in the appear-
ance of facial hyperpigmentation after use of moisturizers with a 
combination  of  topical  niacinamide  and  N-acetyl  glucosamine: 
Results  of  a  randomized,  double-blind,  vehicle-controlled  trial.  
Br J Dermatol. 2010;162:435.

27.  Fu JJ, Hillebrand GG, Raleigh P, et al. A randomized, controlled 
comparative study of the wrinkle reduction benefits of a cosmetic 
niacinamide/peptide/retinyl  propionate  product  regimen  vs.  a 
prescription  0.02%  tretinoin  product  regimen.  Br  J  Dermatol. 
2010;162:647.

28.  Bissett DL, Miyamoto K, Sun P, et al. Topical niacinamide reduces 
yellowing, wrinkling, red blotchiness, and hyperpigmented spots 
in aging facial skin. Int J Cosmet Sci. 2004;26:231.

29.  Bissett DL, Oblong JE, Berge CA. Niacinamide: A B vitamin that 
improves aging facial skin appearance. Dermatol Surg. 2005;31:860.

 
C H A P T E R   4 5

Soy

C H A P T E R  45  ■   S OY  

129

Activities:

PAR-2  inhibition,  anti-inflammatory,  antioxidant, 
photoprotectant, moisturizing

Important Chemical Components:

Isoflavones  (e.g.,  genistein  and  daidzein),  phytoestro-
gens, vitamin E, and serine protease inhibitors, including 
the  proteins  soybean  trypsin  inhibitor  (STI)  and  the 
Bowman-Birk inhibitor (BBI)

Origin Classification:

Soybean  is  a  natural  ingredient.  Organic  forms  are 
available.  Forms  that  have  been  altered  in  the  lab  to 
remove  the  estrogenic  components  are  referred  to  as 
“active naturals.”

Personal Care Category:

Depigmenting,  brightening,  lightening,  moisturizing, 
antiaging

BST Treatable with this Ingredient:

DRPT, DRPW, DSPT, DSPW, ORPT, ORPW, OSPT, and 
OSPW

 SOURCE

The  soybean  plant  belongs  to  the  pea  family,  Leguminosae.  It 
contains a higher amount of oil than other legumes. Soy is usually 
divided  into  two  categories:  nonfermented  and  fermented. 
Nonfermented soy foods include whole dry soy beans, soy nuts, 
fresh green soybeans (edamame), soymilk, tofu, okara and yuba. 
Soymilk,  also  known  as  soy  juice,  soy  drink  or  soya  milk,  is 
produced by soaking dry soybeans and grinding them with water. 
Soy  ice  cream,  soy  yogurt,  and  soy-based  cheeses  are  derived 
from soymilk. Soybean cake is a by-product obtained during the 
processing of soybean oil. Tofu is made by coagulating soymilk 
with a curdling agent and then pressing the curds into blocks. 

Fermented  soy  products  include  tempeh,  miso,  soy  sauce, 
natto,  and  fermented  tofu  and  soymilk  products.  Miso  is 
produced  from  fermented  soybeans  and  used  as  a  soup  base 
and flavoring ingredient. Soy sauce is made in a process similar 
to that of miso except that the paste is pressed to yield a liquid.1 
The  fermentation  process  breaks  down  many  of  the  soy 
components, including the proteins soybean trypsin inhibitor 
(STI) and the Bowman-Birk inhibitor (BBI) as well as saponins, 
but  some  studies  suggest  that  the  isoflavones  are  spared  and 
one found that lactic fermentation increased levels of aglycone, 
an  important  bioactive  form  of  isoflavone.2  The  important 
point is that there are various forms of soy and fractions of soy 
used in cosmeceuticals. Therefore, “soy” on the label does not 
provide  enough  information.  It  is  necessary  to  look  at  the 
clinical trials using the final formulation of a soy product before 
making any assumptions about efficacy.

 HISTORY

Soy  is  considered  one  of  the  earliest  crops  cultivated  by 
humans,  dating  back  to  the  11th  century  BCE  in  Northern 
China. In North America, the first soybean plants emerged in 
the  1700s.3  In  the  United  States,  the  earliest  terminology  for 
soy  oil  was  “Chinese  bean  oil”  by  Roelofsen  in  1894.4  The 
expression “soy oil” was first used by Jordan in 1918, but it was 
not  widely  adopted  until  the  1940s.4  In  the  early  1940s,  the 
protein  proteinase  inhibitors  STI  and  BBI  were  isolated  from 
soybeans.5  Today,  soy  is  one  of  the  most  commonly  used 
ingredients in cosmeceutical moisturizers as well as extremely 
popular  worldwide  in  foods,  beverages,  food  additives,  and 
livestock feed.6

 CHEMISTRY

Soy  contains  many  components  that  render  it  useful  as  a 
cosmeceutical  ingredient.  Important  soy  constituents  include 
linoleic  acid,  phospholipids,  polysaccharides,  B  vitamins, 
tocopherol, phytosterols, isoflavones, and saponins.7 Flavonoids 
are polyphenolic components of plants with active properties. 
Isoflavones  are  a  subtype  of  flavonoids  (see  Chapter  46, 
Antioxidants) found in soy (Table 45-1). The most potent iso-
flavones  in  soy  are  genistein  and  daidzein.8  Isoflavones  are 
present in leguminous plants but are particularly abundant in 
soy.  Isoflavones  have  2-phenylnaphthalene-type  chemical 
structures similar to those of estrogens and have been found to 
bind to estrogen receptors and engender estrogen-like activity.9 
For this reason they are classified as phytoestrogens (Figure 45-1). 
There are 12 different isoforms among soy isoflavones that can 

TABLE 45-1
Pros and Cons of Soy

Pros
Good source of isoflavone antioxidants

Strong safety profile
Crops are good for the environment

Organic forms are available

Cons
Serine protease inhibitors are inactivated 
by heat in the processing of soybeans 
and soymilk
Confusing labeling
Many companies add “soy” to their prod-

ucts without using the right formulation 
of soy and without testing efficacy
Insufficient trials looking at efficacy of the 

various formulations

“Total soy” imparts proven benefits
Dietary soy may have antiaging and anti-

Estrogenic activity
Safety concerns about unfermented soy

inflammatory properties

Moisturizing

Good option for sensitive skin, including 

rosacea types

Dietary soy does not affect  
pigmentation disorders

 
130 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

O

O

HO

1a. Formononetin

Isoflavones

O

O

HO

OCH3

1b. Daidzein

OH

OH

HO

O

1d. Equol

OH

O

OH

HO

O

1c. Genistein

OH

HO

3. 17 β-Estradiol

Estrogen

▶

FIGURE 45-1  The family of isoflavones have a chemical structure similar to that of estradiol (estrogen).

be divided into four chemical forms: aglycone (daidzein, gen-
istein,  and  glycitein),  glucoside  (daidzin,  genistin,  and 
glycitin),acetylglucoside  (acetyldaidzin,  acetylgenistin,  and 
acetylglycitin),  and  malonylglucoside  (malonyldaidzin,  malo-
nylgenistin,  and  malonylglycitin).10  The  aglycone  and  acetyl-
glucoside groups possess stronger antioxidant properties than 
the other isoforms.11

 ORAL USES

Soybean has been a staple of the Asian diet for thousands 
of  years  and  some  credit  this  botanical  for  the  greater 
longevity seen in subsets of the Japanese population. Soy is 
thought  to  yield  the  following  unproven  health  benefits: 
lowering  cholesterol,  decreasing  cardiovascular  disease, 
decreasing breast and other cancers,12 preventing osteopo-
rosis,  slowing  skin  aging,13  and  improving  menopausal 
symptoms.9  These  benefits  are  partially  explained  by  the 
estrogenic effects of soy.

The  health  impact  of  plant-derived  estrogens  depends  on 
several  factors,  including  concentration,  the  concentrations  of 
endogenous  estrogens,  and  individual  characteristics,  such  as 
gender and menopausal status.9,14 The beneficial effects of these 
compounds may be due to their influence on estrogen receptors 
but they are also known to affect enzymes, protein synthesis, cell 
proliferation, angiogenesis, calcium transport, Na+/K+ adenosine 
triphosphatase,  growth  factor  action,  vascular  smooth  muscle 
cells, lipid oxidation, and cell differentiation.9

Oral  soy  may  help  protect  skin  through  its  antioxidant 
activities,  especially  the  genistein  component.15  After  oral 
administration,  soy  isoflavones  have  been  shown  to  protect 

against  ultraviolet  B  (UVB)-induced  oxidative  stress  and 
keratinocyte death.10,11,13,16,17

Dietary soy does not play a role in treating skin pigmentation 
because  fermentation  of  the  soy  seeds  is  required  for  dietary 
consumption.  This  fermentation  process  eliminates  the  STI 
and  BBI  proteins.  Stomach  acids  would  also  break  down  the 
STI  and  BBI  proteins,  preventing  them  from  being  absorbed 
when  taken  orally.5  However,  dietary  soy  may  play  a  role  in 
skin  moisturization  and  antiaging.  Phosphatidylserine 
synthesized  from  soy  lecithin  was  shown  to  increase  skin 
moisturization and decrease wrinkles in human subjects when 
taken orally.18 Another double-blind study demonstrated that a 
supplemental  drink  containing  soy  isoflavones,  lycopene, 
vitamins C and E, and fish oil resulted in increased deposition 
of collagen fibers in the dermis; however, these effects could be 
due to the presence of vitamin C in the supplement, which is 
well known to increase collagen synthesis19 [(see Chapter 55, 
Ascorbic Acid (Vitamin C)].

 TOPICAL USES

In  addition  to  systemic  activity,  many  key  soy  constituents 
(i.e.,  isoflavones,  vitamin  E,  and  serine  protease  inhibitors) 
have  demonstrated  cutaneous  benefits.  The  soy  isoflavones 
genistein  and  daidzein  are  classified  as  phytoestrogens  with 
weak estrogenic activity and have reportedly displayed anticar-
cinogenic,  antiphotocarcinogenic,  photoprotective,  and 
antiphotodamage activity.10,13,20–22 In addition, they have been 
shown, in vitro, to increase collagen content and to act as anti-
oxidants by scavenging free radicals.10,11,13,16,17

 
Depigmenting Activity
Soy  is  an  interesting  treatment  for  skin  pigmentation  when 
used properly and when the proper forms of it are used. Soy 
can exacerbate melasma because natural soy contains estrogenic 
phytoestrogens  and  melasma  is  known  to  be  an  estrogen-
responsive disorder. Soybean seeds, but not other parts of the 
plant,  contain  the  soymilk-derived  proteins  STI  and  BBI  that 
inhibit the activation of protease-activated receptor 2 (PAR-2). 
PAR-2 allows phagocytosis of melanosomes by keratinocytes 
during keratinocyte–melanocyte interaction and is upregulated 
by  UV  exposure,  leading  to  increased  skin  pigmentation.23,24 
PAR-2  is  a  seven  transmembrane  G-protein-coupled  receptor 
on  the  surface  of  keratinocytes  that  is  necessary  for  the 
keratinocyte to engulf and phagocytize melanosomes. The soy 
small protein components known as STI and BBI block PAR-2,5 
thereby  preventing  skin  pigmentation  by  diminishing  the 
transfer  of  melanin-containing  melanosomes  to  keratino-
cytes5,25–27  (see Chapter 43, Overview of the PAR-2 Receptor). 
STI and BBI have been shown to reversibly reduce pigmentation 
or  prevent  UVB-induced  photodamage  in  preclinical  studies, 
suggesting that UVB-induced skin pigmentation may be regu-
lated by PAR-2 activation.5,25,28,29

The depigmenting activity of soy-derived STI and BBI and 
their capacity to prevent UV-induced pigmentation has been 
shown  both  in  vitro  and  in  vivo.  Unfortunately,  BBI  and  STI 
become denatured during heat processing, fermentation, and 
when exposed to stomach acids. A patented technology was 
created to preserve the proteins in their active nondenatured 
state so that they can be applied topically in skin care formu-
lations. In this process the estrogenic components of soy are 
removed  but  the  BBI  and  STI  proteins  are  retained.  This 
ingredient is found on cosmetic labels as “active soy” or “total 
soy.”  The  topical  application  of  total  soy  formulations  has 
been  convincingly  shown  in  human  trials  to  lighten  various 
dyschromias including melasma.30,31 For that reason, total soy 
(which  contains  STI  and  BBI)  has  been  incorporated  into 
several  cosmetic  formulations  to  impart  skin-lightening 
activity and many studies show improvement of skin hyper-
pigmentation.27,32  In  addition,  whole  soy  extract  has 
demonstrated  some  efficacy  when  combined  with  salicylic 
acid and retinol in treating postinflammatory hyperpigmenta-
tion resulting from acne.27,33

Anti-inflammatory Activity
There are several mechanisms by which soy can reduce inflam-
mation. Flavonoids are known to inhibit eicosanoid-generating 
enzymes  (see  Chapter  64,  Anti-Inflammatory  Agents)  and 
modulate  proinflammatory  gene  expression.34  The  flavonoids 
genistein and daidzein have been shown to inhibit the activa-
tion of nuclear factor-κB (NF-κB).35 Soy isoflavones are known 
to  decrease  the  secretions  of  interleukin-1  (IL-1),  IL-6,  nitric 
oxide (NO) and prostaglandin E2 (PGE2) in the cell supernatant 
and fluid of mouse peritoneal exudate.36,37 Soy contains large 
amounts of isoflavones that are known to affect the inflamma-
tory process at multiple levels.38

Anticarcinogenic Activity
Nondenatured  soymilk  has  been  demonstrated  to  prevent  or 
decrease  the  formation  of  UVB-induced  thymine  dimers  and 
apoptotic  cells  in  the  epidermis,  to  enhance  UVB-induced 
checkpoint  kinase-1  activation  (yielding  more  time  for  DNA 
repair),  and  to  lower  the  incidence  or  progression  of  

C H A P T E R  45  ■   S OY  

131

UVB-induced skin tumors.39,40 Soy also appears to hinder UVB-
induced  inflammation,  as  suggested  by  a  decrease  in  UVB-
induced  cyclooxygenase-2  (COX-2)  expression  and  PGE2 
secretion.40

Antiaging Activity
Skin aging manifests from the loss of collagen, elastin, and 
hyaluronic  acid  (see  Chapter  5,  Epidermis  and  Dermis). 
Nondenatured  “total  soy”  soybean  extracts  have  also  been 
shown to promote collagen synthesis and bolster the elastic 
fiber framework.41,42 Because total soy has had the estrogenic 
components  removed,  an  increase  in  collagen  production 
cannot  be  attributed  to  estrogenic  effects.  Liu  et  al.  found 
that  the  elastic  tissue  in  total  soy-treated  skin  displayed 
augmented  fine  and  highly  branched  elastin  fibers  in  the 
upper dermis similar to the “repair zone” seen after retinoid 
treatment.41 These changes are thought to be due to elevated 
elastin  promoter  activity,  suppression  of  elastase  activity, 
and protection of elastic fibers from exogenous elastases.42

Chiu  et  al.  demonstrated  that  an  isoflavone  extracted  from 
soy decreased expression of c-Jun N-terminal kinases (JNK) and 
extracellular  signal-regulated  kinase  (ERK)  genes  and  p38 
signaling pathways known to play a role in the destruction of 
collagen  that  occurs  after  sun  exposure.8,43  Soy  fractions 
containing  daidzein,  genistein,  and  glycitein  were  shown  to 
inhibit  UVB-induced  apoptosis  of  human  keratinocytes  and 
reduce  the  level  of  desquamation,  transepidermal  water  loss, 
erythema, and epidermal thickness in mouse skin.10 The UVB-
protective  effects  of  soy  isoflavones  might  be  related  to  their 
antioxidant activities.11,44

A recent study examined the activity of a soy fraction on the 
retinoic acid receptor (RAR), which is known to be responsible 
for many of the antiaging properties demonstrated by retinoids 
such as tretinoin [see Chapter 83, Retinoids (Retinol)]. This study 
showed  that  the  daidzein  fraction  of  soy  directly  binds  to  the 
RAR and increases expression of RAR mRNA.45

The  effects  of  Bifidobacterium-fermented  and  nonfermented 
soymilk extracts were compared in cultures of human keratino-
cytes, human fibroblasts, and in hairless mouse skin following 
topical application for two weeks. The fermented soymilk, but 
not the nonfermented one, enhanced the production of hyalu-
ronic  acid  (HA)  in  all  of  these  models.  Genistein  and  daidzein 
were  detected  in  the  fermented  soymilk  at  a  concentration  of 
0.18  and  0.07  mM,  respectively,  but  not  in  the  nonfermented 
product. The researchers concluded that genistein released from 
its  glycoside  during  fermentation  with  Bifidobacterium  has  the 
potential  to  enhance  HA  production  in  the  epidermis  and 
dermis.46

Moisturizing Activity
Soybeans are composed of 19 percent oil (high for a legume), 
characterized by triglycerides and polyunsaturated fatty acids 
such as linoleic and α-linoleic acids. Linoleic acid helps the skin 
produce ceramides. Recall that ceramides and fatty acids help 
form the skin barrier that prevents water from evaporating off 
of  the  skin 
(see  Chapter  7,  Moisturizing  Agents). 
Oligosaccharides in soy can function as humectants, attracting 
water to the skin’s surface while the oil component functions 
as  an  occlusive,  preventing  water  from  evaporating  from  the 
skin’s  surface.  The  fact  that  soy  has  been  shown  to  increase 
levels of HA in skin might help explain why skin appears more 
hydrated when exposed to soy.

 
132 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

 SAFETY ISSUES

The safety of fermented versus unfermented soy in the diet has 
been debated for several years.47 A 2003 review of the literature 
concluded that soy in the diet is generally safe even though it has 
estrogenic activity; however, long-term studies are needed.47

 ENVIRONMENTAL IMPACT

Soy is one of the primary commodity crops in the United States. 
It is often used as a cover crop to improve soil for future crops 
because  it  increases  levels  of  organic  matter,  improves  the  
water-holding capacity of soil, enhances drainage in clay soils, 
and provides a range of macro- and micronutrients that optimize 
plant health.48 Soybeans form a symbiotic relationship between 
various strains of Rhizobium bacteria found in the soil. The bacte-
ria  infect  the  soy  plant  roots  and  extract  nitrogen  from  the 
atmosphere and metabolize it into a form that the soy plants can 
use to make protein. In return, these “nitrogen-fixing bacteria” 
receive  sugars  from  the  plant  for  their  own  nutrition.  That  is 
why  farmers  rotate  soybeans  with  corn,  to  take  advantage  of 
this legume’s nitrogen-fixing ability to improve the soil.

 FORMULATION CONSIDERATIONS

Formulation of soy depends on the type of soy or soy fractions 
used. The final formula must be studied in order to make state-
ments about efficacy. For this reason, products labeled “clinically 
proven” to reduce skin pigmentation are preferred to products 
that  do  not  say  clinically  proven.  Generic  “copied”  products 
with soy are unreliable because of the many issues relating to 
formulating soy, including whether the estrogenic components 
have been removed, if the STI and BBI proteins are present, and 
whether the soy is fermented or nonfermented. A manufacturing 
process was developed in 2001 to incorporate a wide array of 
nondenatured  soy  proteins,  essential  fatty  acids,  carbohy-
drates,  and  vitamins  in  topical  formulations,  enhancing  the 
capacity of products to harness soy potency.3

 USAGE CONSIDERATIONS

The polyunsaturated fatty acids in soy leave products suscepti-
ble to going rancid, so they should be kept in a cold, dark place 
and  discarded  on  their  expiration  date.  Soy  products  can  be 
used in conjunction with retinoids and glycolic acids and other 
ingredients without increasing the risk of irritation. In fact, the 
anti-inflammatory  and  hydrating  properties  of  soy  may  help 
mitigate irritation due to retinoids.

 SIGNIFICANT BACKGROUND

Animal Studies
In 2000, Seiberg et al. conducted in vitro and in vivo studies to 
demonstrate the interference with PAR-2 activation displayed 
by serine protease inhibitors that results in the suppression of 
melanosome  transfer  and  distribution.  They  showed  that  in 
vitro  treatment  with  a  serine  protease  inhibitor  resulted  in 
reduced  pigmentation  in  swine  skin  samples.  They  also 
reported  from  their  in  vivo  experiments  that  twice-daily 

application  of  a  serine  protease  inhibitor  for  eight  or  nine 
weeks  visibly  and  dose-dependently  lightened  the  skin  of 
Yucatan swine.25

In 2001, Paine et al. performed in vitro and in vivo studies in 
which  dark-skinned  Yucatan  microswine  were  treated  with 
soybean  extract  serine  protease  inhibitor.  Diminished  skin 
color was observed visually and confirmed by F&M staining 
of  histologic  sections  that  displayed  decreased  melanin 
deposition in the skin biopsies of treated skin. The effect was 
associated  only  with  fresh  soymilk  and  not  pasteurized 
soymilk  preparations.  This  suggests  that  a  heat-labile 
component  of  the  soymilk,  STI,  is  the  active  depigmenting 
agent.  Soymilk  treatment  also  prevented  UVB-induced 
hyperpigmentation of the animals’ skin.5

Clinical Studies
In  2000,  Hermanns  et  al.  conducted  a  clinical  study  of  
44  Caucasian  men  with  solar  lentigines  (ages  52–61  years)  in 
which subjects applied either stabilized soy extract, 15 percent 
azelaic acid, or 12 percent glycolic acid formulation once daily 
to  the  face  for  three  weeks.  Analysis  of  videomicroscopic 
images showed that the soy formulation produced a significant 
decrease  in  pigmentation  at  the  end  of  three  weeks  and 
performed better than the other two products.30

In a 12-week study in 2001, 16 Hispanic women with melasma 
applied stabilized soy extract once daily to one lesion, leaving a 
second lesion untreated. Fourteen of the subjects showed some 
depigmentation from using the soy formulation, with an average 
12 percent reduction in clinical score at the end of the study.49

In  2002,  Hermanns  et  al.  conducted  a  two-month  open 
randomized trial in Belgium in 30 women of Southeast Asian 
ancestry (between the ages of 42 and 57 years) who presented 
with hyperpigmentation on the dorsal forearms and backs of 
the hands. Twice daily, the volunteers applied a stabilized soy 
extract to the lesions and surrounding area, with the other arm/
hand  serving  as  a  control.  The  investigators  reported  that  a 
modest lightening effect was revealed using corneomelametry. 
In addition, they noted that the faintly mottled skin as indicated 
by  UV  light  examination  responded  better  to  the  soy 
formulation.50

In  2007,  Wallo  et  al.  examined  the  effects  of  a  novel  soy 
moisturizer containing nondenatured STI and BBI on pigmenta-
tion, skin tone amelioration, and other signs of photoaging in a 
double-blind,  parallel,  vehicle-controlled  study.  Sixty-three 
women, aged 30 to 61 with Fitzpatrick phototypes I to III, with 
moderately  severe  mottled  hyperpigmentation,  lentigines, 
blotchiness, tactile roughness, and dullness completed the study. 
The moisturizer and the vehicle respectively were administered 
twice daily for a period of 12 weeks. By clinical observation, self-
assessment, colorimetry, and digital photography, the research-
ers  noted  a  significant  improvement  of  mottled  pigmentation, 
blotchiness,  dullness,  fine  lines,  as  well  as  overall  texture,  skin 
tone, and appearance in the soy moisturizer group as compared 
to the vehicle subjects. Improvement in the soy group was seen 
as early as the second week of treatment.51

 CONCLUSION

There are many different forms of soy and soy extracts on the 
market; therefore, looking for “soy” on the label is not sufficient 
information  on  which  to  base  a  purchasing  decision.  Soy 
delivers  antioxidant,  anti-inflammatory,  moisturizing,  and 

 
depigmenting benefits to the skin. However, the nondenatured 
soy  extracts,  as  opposed  to  the  more  processed  ingredients, 
appear to be more effective as topical agents for pigmentation 
disorders. Dietary soy can play an important role in skin care, 
but  does  not  influence  skin  pigmentation  because  stomach 
acids destroy the STI and BBI proteins.

REFERENCES

1.  Golbitz P. Traditional soyfoods: Processing and products. J Nutr. 

1995;125:570S.

2.  Lai LR, Hsieh SC, Huang HY, et al. Effect of lactic fermentation on 
the  total  phenolic,  saponin  and  phytic  acid  contents  as  well  as 
anti-colon  cancer  cell  proliferation  activity  of  soymilk.  J  Biosci 
Bioeng. 2013;115:552.

3.  Leyden JJ, Shergill B, Micali G, et al. Natural options for the man-
agement  of  hyperpigmentation.  J  Eur  Acad  Dermatol  Venereol. 
2011;25:1140.

4.  Shurtleff W, Aoyagi A. A special report on the history of soy oil, 
soybean meal, and modern soy products. Soy Info Center. http://
www.soyinfocenter.com/HSS/soybean_crushing1.php. Accessed 
September 7, 2013.

5.  Paine  C,  Sharlow  E,  Liebel  F,  et  al.  An  alternative  approach  to 
depigmentation by soybean extracts via inhibition of the PAR-2 
pathway. J Invest Dermatol. 2001;116:587.

6.  Draelos ZD. Skin lightening preparations and the hydroquinone 

controversy. Dermatol Ther. 2007;20:308.

7.  Dixit  AK,  Antony  JIX,  Sharma  NK,  et  al.  Soybean  constituents 
and  their  functional  benefits.  In:  Tiwari  VK,  ed.  Opportunity, 
Challenge  and  Scope  of  Natural  Products  in  Medicinal  Chemistry. 
Kerala, India: Research Signpost; 2011:367–383.

8.  Chiu TM, Huang CC, Lin TJ, et al. In vitro and in vivo anti-pho-
toaging  effects  of  an  isoflavone  extract  from  soybean  cake.  
J Ethnopharmacol. 2009;126:108.

9.  Tham DM, Gardner CD, Haskell WL. Clinical review 97: Potential 
health benefits of dietary phytoestrogens: A review of the clinical, 
epidemiological,  and  mechanistic  evidence.  J  Clin  Endocrinol 
Metab. 1998;83:2223.

10.  Huang CC, Hsu BY, Wu NL, et al. Anti-photoaging effects of soy 
isoflavone  extract  (aglycone  and  acetylglucoside  form)  from 
soybean cake. Int J Mol Sci. 2010;11:4782.

11.  Kao TH, Chen BH. Functional components in soybean cake and 
their  effects  on  antioxidant  activity.  J  Agric  Food  Chem. 
2006;54:7544.

12.  Ingram  D,  Sanders  K,  Kolybaba  M,  et  al.  Case-control  study  of 

phyto-oestrogens and breast cancer. Lancet. 1997;350:990.

13.  Kim SY, Kim SJ, Lee JY, et al. Protective effects of dietary soy iso-
flavones against UV-induced skin-aging in hairless mouse model. 
J Am Coll Nutr. 2004;23:157.

14.  Knight DC, Eden JA. A review of the clinical effects of phytoes-

trogens. Obstet Gynecol. 1996;87:897.

15.  Wei H, Bowen R, Cai Q, et al. Antioxidant and antipromotional 
effects of the soybean isoflavone genistein. Proc Soc Exp Biol Med. 
1995;208:124.

16.  Südel KM, Venzke K, Mielke H, et al. Novel aspects of intrinsic 
and  extrinsic  aging  of  human  skin:  Beneficial  effects  of  soy 
extract. Photochem Photobiol. 2005;81:581.

17.  Accorsi-Neto A, Haidar M, Simões R, et al. Effects of isoflavones 
on  the  skin  of  postmenopausal  women:  A  pilot  study.  Clinics  
(Sau Paulo). 2009;64:505.

18.  Choi HD, Han JJ, Yang JH, et al. Effect of soy phosphatidylserine 
supplemented  diet  on  skin  wrinkle  and  moisture  in  vivo  and 
clinical trial. J Kor Soc Appl Biol Chem. 2013;56:227.

19.  Jenkins G, Wainwright LJ, Holland R, et al. Wrinkle reduction in 
post-menopausal women consuming a novel oral supplement: a 
double-blind  placebo-controlled  randomised  study.  Int  J  Cosmet 
Sci. 2013 August 8. [Epub ahead of print]

20.  Barnes  S.  Effect  of  genistein  on  in  vitro  and  in  vivo  models  of 

cancer. J Nutr. 1995;125:777S.

21.  Moore JO, Wang Y, Stebbins WG, et al. Photoprotective effect of 
isoflavone  genistein  on  ultraviolet  B-induced  pyrimidine  dimer 
formation and PCNA expression in human reconstituted skin and 
its implications in dermatology and prevention of cutaneous car-
cinogenesis. Carcinogenesis. 2006;27:1627.

C H A P T E R  45  ■   S OY  

133

22.  Cassidy  A,  Albertazzi  P,  Lise  Nielsen  I,  et  al.  Critical  review  of 
health effects of soyabean phyto-oestrogens in post-menopausal 
women. Proc Nutr Soc. 2006;65:76.

23.  Seiberg M. Keratinocyte-melanocyte interactions during melano-

some transfer. Pigment Cell Res. 2001;14:236.

24.  Scott G, Deng A, Rodriguez-Burford C, et al. Protease-activated 
receptor 2, a receptor involved in melanosome transfer, is upregu-
lated  in  human  skin  by  ultraviolet  irradiation.  J  Invest  Dermatol. 
2001;117:1412.

25.  Seiberg M, Paine C, Sharlow E, et al. Inhibition of melanosome 
transfer results in skin lightening. J Invest Dermatol. 2000;115:162.
26.  Parvez  S,  Kang  M,  Chung  HS,  et  al.  Survey  and  mechanism  of 
skin  depigmenting  and  lightening  agents.  Phytother  Res. 
2006;20:921.

27.  Callender VD, St Surin-Lord S, Davis EC, et al. Postinflammatory 
hyperpigmentation: Etiologic and therapeutic considerations. Am 
J Clin Dermatol. 2011;12:87.

28.  Seiberg  M,  Paine  C,  Sharlow  E,  et  al.  The  protease-activated 
receptor  2  regulates  pigmentation  via  keratinocyte-melanocyte 
interactions. Exp Cell Res. 2000;254:25.

29.  Konda S, Geria AN, Halder RM. New horizons in treating disor-
ders of hyperpigmentation in skin of color. Semin Cutan Med Surg. 
2012;31:133.

30.  Hermanns JF, Petit L, Martalo O, et al. Unraveling the patterns of 
subclinical  pheomelanin-enriched  facial  hyperpigmentation: 
Effect of depigmenting agents. Dermatology. 2000;201:118.

31.  Leyden J, Wallo W. The mechanism of action and clinical benefits 
of  soy  for  the  treatment  of  hyperpigmentation.  Int  J  Dermatol. 
2011;50:470.

32.  Finkey MB, Herndon J, Stephens T, et al. Soy moisturizer SPF 15 
J  Am  Acad  Dermatol. 

[poster]. 

improves  dyschromia 
2005;52(Suppl):P170.

33.  Sah A, Stephens TJ, Kurtz ES. Topical acne treatment improves 
postacne  postinflammatory  hyperpigmentation  (PIH)  in  skin  of 
color [poster]. J Am Acad Dermatol. 2005;52(Suppl):P25.

34.  Kim HP, Son KH, Chang HW, et al. Anti-inflammatory plant flavo-
noids and cellular action mechanisms. J Pharmacol Sci. 2004;96:229.

35.  Hämäläinen  M,  Nieminen  R,  Vuorela  P,  Heinonen  M, 
Moilanen  E.  Anti-inflammatory  effects  of  flavonoids: 
Genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 
and  NF-kappaB  activations,  whereas  flavones,  isorhamnetin, 
naringenin,  and  pelargonidin  inhibit  only  NF-kappaB  activa-
tion  along  with  their  inhibitory  effect  on  iNOS  expression 
and  NO  production  in  activated  macrophages.  Mediators 
Inflamm. 2007:45673.

36.  Kao TH, Wu WM, Hung CF, et al. Anti-inflammatory effects of 
isoflavone  powder  produced  from  soybean  cake.  J  Agric  Food 
Chem. 2007;55:11068.

37.  Kao TH, Huang RF, Chen BH. Antiproliferation of hepatoma cell 
and  progression  of  cell  cycle  as  affected  by  isoflavone  extracts 
from soybean cake. Int J Mol Sci. 2007;8:1095.

38.  Stoner G, Wang LS. Natural products as anti-inflammatory agents. 
In: AJ Dannenberg, NA Berger, eds. Energy Balance and Cancer Vol. 7: 
Obesity, Inflammation and Cancer. New York: Springer; 2013:341–361.
39.  Huang MT, Xie JG, Lin CB, et al. Inhibitory effect of topical appli-
cations of nondenatured soymilk on the formation and growth of 
UVB-induced skin tumors. Oncol Res. 2004;14:387.

40.  Chen  N,  Scarpa  R,  Zhang  L,  et  al.  Nondenatured  soy  extracts 
reduce  UVB-induced  skin  damage  via  multiple  mechanisms. 
Photochem Photobiol. 2008;84:1551.

41.  Liu JC, Seiberg M, Chen T, et al. Pre-clinical and clinical evalua-
tion  of  total  soy  preparations  in  improving  skin  physical  tone 
parameters. Poster presented at the 60th American Academy of 
Dermatology meeting, New Orleans, LA, 2002.

42.  Zhao R, Bruning E, Rossetti D, et al. Extracts from Glycine max 
(soybean)  induce  elastin  synthesis  and  inhibit  elastase  activity. 
Exp Dermatol. 2009;18:883.

43.  Peus D, Vasa RA, Beyerle A, et al. UVB activates ERK1/2 and p38 
signaling  pathways  via  reactive  oxygen  species  in  cultured 
keratinocytes. J Invest Dermatol. 1999;112:751.

44.  Chiang  HS,  Wu  WB,  Fang  JY,  et  al.  UVB-protective  effects  of 
isoflavone  extracts  from  soybean  cake  in  human  keratinocytes. 
Int J Mol Sci. 2007;8:651.

45.  Oh  HJ,  Kang  YG,  Na  TY,  et  al.  Identification  of  daidzein  as  a 
ligand  of  retinoic  acid  receptor  that  suppresses  expression  of 
matrix  metalloproteinase-9  in  HaCaT  cells.  Mol  Cell  Endocrinol. 
2013;376:107.

 
134 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

46.  Miyazaki  K,  Hanamizu  T,  Iizuka  R,  et  al.  Bifidobacterium-
fermented soy milk extract stimulates hyaluronic acid production 
in human skin cells and hairless mouse skin. Skin Pharmacol Appl 
Skin Physiol. 2003;16:108.

47.  Munro  IC,  Harwood  M,  Hlywka  JJ,  et  al.  Soy  isoflavones:  A 

safety review. Nutr Rev. 2003;61:1.

48.  Reed  BH.  The  Texas  Gardener.  http://www.texasgardener.com 
/pastissues/mayjun05/Soybean.html. Accessed September 7, 2013.
49.  Piérard G, Graf J, Gonzalez R, et al. Effects of soy on hyperpig-
mentation  in  Caucasian  and  Hispanic  populations.  Poster 

presented at the 59th American Academy of Dermatology meet-
ing. Washington, DC, 2001.

50.  Hermanns JF, Petit L, Piérard-Franchimont C, et al. Assessment of 
topical  hypopigmenting  agents  on  solar  lentigines  of  Asian 
women. Dermatology. 2002;204:281.

51.  Wallo W, Nebus J, Leyden JJ. Efficacy of a soy moisturizer in pho-
toaging:  A  double-blind,  vehicle-controlled,  12-week  study.  
J Drugs Dermatol. 2007;6:917.

 
C H A P T E R  46  ■   A N T I OX I DA N T S  

135

Antioxidants

SECTION

E

C H A P T E R   4 6

Antioxidants

The skin has naturally occurring antioxidants that protect against 
the  ravages  of  free  radicals  by  reducing  and  neutralizing  them 
(see Chapter 2, Basic Cosmetic Chemistry, for an explanation of 
free radicals). Antioxidative enzymes that naturally occur in the 
skin include superoxide dismutase, catalase, and glutathione per-
oxidase; nonenzymatic endogenous antioxidative molecules are 
a -tocopherol (vitamin E), ascorbic acid (vitamin C), glutathione, 
and  ubiquinone  (better  known  as  coenzyme  Q10  or  CoQ10).1 
However, as part of the natural aging process our defense mecha-
nisms decrease. This leads to an imbalance and increased number 
of  unchecked  free  radicals,  which  engender  damage  to  DNA, 
cytoskeletal elements, cellular proteins, and cellular membranes. 
Moreover,  many  of  these  antioxidant  defense  mechanisms  are 
inhibited  by  ultraviolet  (UV)  and  visible  light.2,3  Topical 
antioxidants are currently marketed for the prevention of aging 
and UV-mediated skin damage. The free radical theory of aging 
explains why antioxidants are thought to prevent wrinkles, but 
this theory does not justify the use of antioxidants to treat wrin-
kles that are already present. Several companies claim that their 
antioxidant-containing products “treat” wrinkles; however, this is 
an exaggeration. The only antioxidant that can improve wrinkles 
that have already been formed is ascorbic acid, through its effects 
on collagen synthesis.4

In addition to the effects associated with their antioxidative 
activity, many antioxidants exhibit anti-inflammatory properties 
or depigmenting activities, which are described in more detail in 
other  sections.  There  are  several  important  factors  to  consider 
when evaluating the efficacy of antioxidants. In order to be con-
sidered biologically active, orally administered products must be 
absorbed  and  shown  to  raise  antioxidant  levels  in  the  skin. 
Topically administered products must be absorbed into the skin 
and delivered to the target tissue in the active form and remain 
there long enough to exert the desired effects. Antioxidants can 

be  activated  or  inactivated  by  enzymes  in  the  skin.  Some 
antioxidants are very unstable; therefore, some ingredients such 
as  vitamin  C  become  oxidized  and  rendered  inactive  before 
reaching  the  target.  Stabilizing  them  in  formulation  and 
packaging them to minimize air and light exposure are challeng-
ing tasks. Absorption is also important and depends on several 
factors  such  as  the  molecular  form  of  the  compound,  its  pH, 
whether it is water soluble or fat soluble, and the vehicle that 
contains the product. This section will discuss the most popular 
types of antioxidants found in topical cosmetic products. 

Fat-soluble antioxidants function in the lipophilic portion of 
the cell membrane and include vitamin E, idebenone, lycopene, 
curcumin,  and  CoQ10.5  Other  antioxidants  are  water  soluble 
and found in hydrophilic areas of the cell. These include ascor-
bic acid, green tea, silymarin, coffeeberry, and resveratrol.

 POLYPHENOLS AND THE CLASSIFICATION 
OF ANTIOXIDANTS

Polyphenols are widely distributed in nature and in the plant 
kingdom  in  particular.  They  are  synthesized  by  plants  in 
response to environmental hazards that induce enhanced free-
radical  production.6  Polyphenol  biosynthesis  begins  when 
phenylalanine  ammonia-lyase  is  induced  by  exposure  to  UV 
light,  g -irradiation,  ozone,  low  temperatures,  organic  toxins, 
and/or heavy metals. Phenylalanine is catalytically deaminated 
to cinnamic acid and then cinnamic acid is converted to various 
polyphenols, which share a definitive structural component: a 
phenol or an aromatic ring with at least one hydroxyl group. 
Polyphenols are an exceedingly important source of antioxidants 
and  are  found  in  a  vast  spectrum  of  vegetables,  fruits,  herbs, 
grains,  tea,  coffee  beans,  honey,  and  red  wine  (Table  46-1). 

TABLE 46-1
Subclasses of the Most Abundant Polyphenols, Flavonoids, and Food Sources of Each Class7–9

Flavones
Celery
Fresh parsley
Sweet red pepper

Flavonols
Apples
Broccoli
Olives
Onions
Tea (black and green)

Flavanones
Oranges
Grapefruit

IsoFlavones
Soy

Flavanols (catechIns)
Apples
Cocoa
Dark chocolate
Tea (black and green)

anthocyanIns
Blackberries
Cherries
Currants (black and red)
Grapes
Plums
Raspberries
Strawberries

ProanthocyanIdIns
Apples
Dark chocolate
Grapes
Pears
Red wine
Tea (black and green)

 
136 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

TABLE 46-2
Categories of Polyphenols Currently Pertinent to Skin Care

A. Flavonoids

Flavones
Apigenin
Luteolin

B. Nonflavonoids

tannIns
Ellagic acid

Flavonols
Quercetin

Flavanones

IsoFlavones
Genistein

Flavanals (catechIns)
Green tea

anthocyanIns

ProanthocyanIdIns
Pycnogenol

dIhydrochalcone10
Phloretin11

stIlbenes or 
PhytoalexIns
Resveratrol

lIgnans
Flaxseed
Sesame seed

hydroxycInnamIc 
acIds
Caffeic acid
Ferulic acid

Note: Some categories have been excluded.

When  the  “parent  polyphenol”  known  as  cinnamic  acid  is 
further  catalytically  transformed,  myriad  polyphenolic  com-
pounds  result  that  are  divided  into  classes:  glycosylated 
phenylpropanoids,  flavonoids,  isoflavonoids,  stilbenoids, 
coumarins, curcuminoids, phenolic polymers such as tannins, 
proanthocyanidins, suberin, lignins, and lignans. Flavonoids are 
the most abundant polyphenols in the human diet as well as 
the most studied polyphenols, and can be further divided into 
several categories (Table 46-2). An ingredient does not have to 
be  a  polyphenol  to  have  antioxidant  abilities.  Vitamins, 
minerals, substances that confer pigments to plants, and other 
ingredients  may  exhibit  antioxidant  activity  as  well.  
This section will discuss various antioxidants used in skin care. 
The particular characteristics that these ingredients display are 
derived  from  the  subcategories  they  fall  into  based  on  their 
chemical structure.

REFERENCES

1.  Shindo Y, Witt E, Han D, et al. Enzymic and non-enzymic anti-
oxidants in epidermis and dermis of human skin. J Invest Dermatol. 
1994;102:122.

2.  Fuchs  J,  Huflejt  ME,  Rothfuss  LM,  et  al.  Acute  effects  of  near 
ultraviolet and visible light on the cutaneous antioxidant defense 
system. Photochem Photobiol. 1989;50:739.

3.  Fuchs J, Huflejt ME, Rothfuss LM, et al. Impairment of enzymic 
and nonenzymic antioxidants in skin by UVB irradiation. J Invest 
Dermatol. 1989;93:769.

4.  Pinnell SR, Murad S, Darr D. Induction of collagen synthesis by 
ascorbic acid: A possible mechanism. Arch Dermatol. 1987;123:1684.
5.  Baumann S, Bogdan Allemann I. Antioxidants. In: Baumann L, 
Saghari S, Weisberg E, eds. Cosmetic Dermatology: Principles and 
Practice. 2nd ed. New York: McGraw-Hill Medical; 2009:294–
296.

6.  Korkina L, De Luca C, Pastore S. Plant polyphenols and human 

skin: Friends or foes. Ann N Y Acad Sci. 2012;1259:77.

7.  Scalbert  A,  Williamson  G.  Dietary  intake  and  bioavailability  of 

polyphenols. J Nutr. 2000;130:2073S.

8.  Ross  JA,  Kasum  CM.  Dietary  flavonoids:  Bioavailability,  meta-

bolic effects, and safety. Annu Rev Nutr. 2002;22:19.

9.  Grove  K.  Catechins  are  the  major  source  of  flavonoids  in  a 
J  Clin  Nutr. 

group  of  Australian  women.  Asia  Pac 
2004;13(Suppl):S72.

10.  Nakamura  Y,  Watanabe  S,  Miyake  N,  et  al.  Dihydrochalcones: 
Evaluation as novel radical scavenging antioxidants. J Agric Food 
Chem. 2003;51:3309.

11.  Rezk BM, Haenen GR, van der Vijgh WJ, et al. The antioxidant 
activity of phloretin: The disclosure of a new antioxidant pharma-
cophore in flavonoids. Biochem Biophys Res Commun. 2002;295:9.

 
C H A P T E R   4 7

Green Tea

Activities:
Antioxidant,  antiaging,1  antiacne,  antiangiogenic, 
anticarcinogenic,  anticariogenic,  anti-inflammatory, 
antimicrobial,  chemopreventive,  immunomodulatory,2 
photoprotective

Important Chemical Components:

ECG [(-)EpiCatechin-3-O-Gallate]
GCG [(-)GalloCatechin-3-O-Gallate]
EGC [(-)EpiGalloCatechin]
EGCG [(-)EpiGalloCatechin-3-O-Gallate]

Origin Classification:

This ingredient is considered natural. Organic forms are 
available.

Personal Care Category:

Antiaging,  moisturizing,  antiacne,  anogenital  wart  
treatment

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW,  DRPW,  DSNT,  DSPT,  DSNW,  DSPW,  ORNW, 
ORPW, OSNT, OSPT, OSNW, and OSPW

 SOURCE

Derived from Camellia sinensis, an evergreen tree belonging to 
the  Theaceae  family  (Figure  47-1),  green  tea  has  long  been  a 
popular  beverage  worldwide,  particularly  in  Asian  countries. 
Its use by human beings is thought to date back 4,000 years.3 
During  the  last  15  years,  it  has  also  gained  notable  attention 
because  of  its  purported  antioxidant  and  anticarcinogenic 
properties.  In  fact,  green  tea  is  one  of  the  most  heavily 
researched  of  the  antioxidants  and  myriad  studies  on  the 

▶
    FIGURE 47-1  Leaves of Camellia sinensis. Reprinted with permission 
from Meltzer SM, Mon BJ, Tewari KS. Green tea catechins for treatment of 
external genital warts. Am J Obstet Gynecol 2009;200:233.e2 with permission 
from Elsevier.

C H A P T E R  47  ■   G R E E N  T E A 

137

TABLE 47-1
Pros and Cons of Green Tea

Pros
More evidence than other antioxidants

Cons
Clinical efficacy has not yet been clearly 

Wide range of health benefits conferred
Found in many topical products

Insufficient number of clinical studies9,73
Products often contain an insufficient 

established73,86

Tolerated by sensitive skin types

Does not treat wrinkles that are already 

amount

Minimal reaction with other ingredients

May turn the cream brown when included 

in large concentrations

present

cutaneous effects of green tea appear in the literature.4 Green 
tea, rife with plant polyphenols, displays significant antioxidant, 
chemopreventive, immunomodulatory, and anti-inflammatory 
activity and affects the biochemical pathways important in cell 
proliferation, when administered either topically or orally.2,5,6 
For this reason, and because of its widespread popularity as a 
beverage, green tea polyphenols are among the most frequently 
studied herbal agents used in medicine.

Polyphenols,  many  of  which  are  potent  antioxidants,  are  a 
large, diverse family of thousands of chemical substances found 
in  plants  (Table  47-1).  The  four  major  polyphenolic  catechins 
found  in  green  tea  include:  ECG  [(-)EpiCatechin-3-O-Gallate], 
GCG [(-)GalloCatechin-3-O-Gallate], EGC [(-)EpiGalloCatechin], 
and  EGCG  [(-)EpiGalloCatechin-3-O-Gallate],  the  most  abun-
dant and biologically active green tea constituent. Like green tea, 
white  tea  is  derived  from  C.  sinensis,  but  it  is  more  expensive 
because it is harder to obtain. White tea actually comes from the 
tips of the green tea leaves or leaves not yet fully opened, with 
buds still covered by fine white hair. Of the four primary “true 
teas,” green and white are unfermented; black tea is fermented; 
and oolong tea is semi-fermented.2,7

In a wide-ranging evidence-based review of the use of botani-
cals in dermatology, Reuter et al. concluded in 2010 that the oral 
administration  and  topical  application  of  antioxidant  plant 
extracts  of  green  and  black  tea,  among  other  botanicals, 
can protect skin against the deleterious effects of ultraviolet (UV) 
exposure, including erythema, premature aging, and cancer.8

 HISTORY

Tea has been consumed as a beverage for thousands of years, 
becoming  popular  on  a  wide  scale  about  700  years  ago; 
currently, it is second in global popularity only to water.3,9–11 
Chinese records trace the use of tea as a beverage to the time 
of Emperor Shen Nung circa 2700 BCE,3 though it is thought 
that  its  use  for  medicinal  purposes  may  date  back  300  years 
earlier.10  Traditional  Chinese  medicine  (TCM)  began 
emphasizing the consumption of tea circa 1100 BCE.10 It was 
introduced  in  Japan  in  the  500s  CE,  and  its  pharmacological 
properties, among others, were described in text by a Japanese 
Zen priest, Yeisai, in 1211.12 It was also cultivated in India and 

 
138  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Indonesia,  through  which  the  respective  imperial  powers  of 
the English and Dutch imported and, in the case of the English, 
popularized the beverage on a large scale.3

Research into the health benefits of tea, particularly green tea, 
is  a  relatively  recent  phenomenon,  as  is  the  research  into  and 
topical application of green tea. In the late 1980s and early 1990s, 
several early studies with mice demonstrated, using a two-stage 
skin  tumorigenesis  model,  that  green  tea  polyphenols  (GTPs), 
administered  orally  or  applied  topically,  exhibit  broad  activity 
against skin tumor initiation and promotion involving multiple 
tumor-inducing agents.13–25

 CHEMISTRY

In particular, studies in mouse skin tumor bioassay systems in 
the 1990s showed that topically applied GTPs protected skin 
against  skin  cancer  induced,  initiated,  or  promoted  by  
3-methylcholanthrene,  initiated  by  7,12-dimethylbenz(a)
anthracene (DMBA), promoted by 12-O-tetradecanoylphorbol-
13-acetate  (TPA),  or  enhanced  by  benzoyl  peroxide-  and 
4-nitroquinoline  N-oxide,  and  other  agents.15  GTPs  are  also 
known  to  have  the  capacity  to  scavenge  a  vast  range  of  free 
radicals,  including  1,1-diphenyl-2-picryl-hydrazyl  (DPPH), 
hydroxyl radicals, and lipid-derived radicals.26

Ras and activator protein (AP)-1, both of which are involved 
in  the  mitogen-activated  protein  kinase  (MAPK)  pathway,  are 
among the molecular targets of GTPs.27 The antiapoptotic effects 
exhibited by EGCG on UVB-irradiated keratinocytes appear to 
be brought about by increased expression of the antiapoptotic 
molecule Bcl-2 and a decline in the proapoptotic protein Bax.28 
EGCG  reduces  UV-induced  immunosuppression  by  limiting 
interleukin  (IL)-10  synthesis  and  increasing  IL-12  production; 
both are major cytokines that mediate UV-induced immunosup-
pression.29 Further, the EGCG-induced IL-12 increase enhances 
the  production  of  enzymes  that  repair  UV-induced  DNA 
damage.30 EGCG also appears to lower UVB-induced immuno-
suppression  by  decreasing  CD11b,  a  cell  surface  marker  for 
activated  macrophages  and  neutrophils  in  animals  treated 
with UVB.31

In  mice,  EGCG  has  been  demonstrated  to  downregulate 
UV-induced  expression  of  AP-1  and  NF-κB  while  inhibiting 
matrix metalloproteinases (MMPs), which are known to degrade 
collagen, thus leading to photodamage. In one study, GTPs were 
administered  in  drinking  water  to  SKH-1  hairless  mice,  which 
were  then  exposed  to  multiple  doses  of  UVB.  The  result  was 
suppression of UVB-induced protein oxidation in vivo in mouse 
skin;  these  findings  were  also  observed  in  vitro  in  human  skin 
fibroblast  HS68  cells.  Oral  administration  of  GTPs  was  also 
demonstrated  to  inhibit  UVB-induced  expression  of  matrix-
degrading  MMPs  in  the  hairless  mouse  skin,  suggesting  the 
antiphotoaging activity of GTPs.32

 ORAL USES

Green  tea  is  one  of  the  most  popular  beverages  worldwide. 
Many  of  the  salutary  effects  associated  with  green  tea  are 
based  on  oral  administration.  Recent  evidence  also  suggests 
that green tea exerts an anticariogenic effect when used as an 
oral rinse, as it has been shown to reduce the acidity of saliva 
and plaque.33 In addition to its popularity in liquid form, green 
tea extracts are also available as dietary pill supplements.

A 2007 review article by Katiyar et al. on the photoprotective 
efficacy  of  GTPs  against  UV-induced  carcinogenesis  concluded 

that  the  oral  administration  of  GTPs  or  topical  application  of 
EGCG prevents the development of UVB-induced skin tumors in 
mice.  The  investigators  suggested  that  this  chemopreventive 
activity is mediated via several mechanisms involving IL-12, angio-
genesis suppression, and the stimulation of cytotoxic T cells in a 
tumor microenvironment.34

 TOPICAL USES

Green tea is found in several over-the-counter (OTC) skin care 
products. The formulations vary by the type of green tea poly-
phenol component (e.g., EGCG), and the amount of polyphenol, 
both of which are important to know when evaluating product 
efficacy.  Green  tea  seems  to  decrease  skin  inflammation  and 
neutralize free radicals, which explains its popularity as an addi-
tive in rosacea and antiaging skin care products. The antiaging 
effects of green tea are difficult to measure because it functions 
as  an  antioxidant  that  prevents  aging  and  does  not  have  the 
capacity  to  increase  collagen  synthesis  or  ameliorate  extant 
wrinkles. However, there is relatively good evidence (compared 
to  other  antioxidants)  to  suggest  that  topically  applied  green 
tea can help protect skin from UV radiation.

In 2012, Pazyar performed a thorough literature search of all in 
vitro, in vivo, and controlled clinical trials involving green tea formu-
lations  and  their  dermatologic  applications.  They  evaluated  
20 studies, with evidence suggesting that orally administered green 
tea displays a broad range of healthy activity, including quenching 
free radicals, cancer prevention, treating hair loss, slowing cutane-
ous aging, and protecting against the side effects of psoralen-UVA 
therapy. Further, they found supportive data for the use of topically 
applied  green  tea  extract  to  treat  several  cutaneous  conditions, 
including  acne, rosacea,  atopic dermatitis,  androgenetic  alopecia, 
hirsutism, candidiasis, keloids, leishmaniasis, and genital warts.35

Also,  a  green  tea  topical  formulation,  green  tea  sinecatechin 
polyphenon E (Veregen®) ointment, has recently been shown to 
exert antioxidant, antiviral, and antitumor activity, and has dem-
onstrated  efficacy  in  treating  condylomata  acuminata  (external 
anogenital  warts).36  In  addition,  topically  applying  GTPs  in  the 
morning in combination with traditional sunscreens is believed to 
have the potential to protect the skin from UV-induced damage. 
Topical green tea may improve rosacea, prevent retinoid dermati-
tis, and play a role in managing pigmentation disorders. Few of the 
many  OTC  products  that  contain  GTPs  have  been  tested  in 
controlled clinical trials and the concentration of polyphenols in 
these products is too low to demonstrate efficacy. It is necessary to 
know the amount of GTPs in a formulation to judge its efficacy.

Green tea extracts have also been shown, through data from 
60  patients  analyzed  retrospectively,  to  mitigate  the  effects  of 
acute radiation-induced skin toxicity, through complex mecha-
nisms that do not rely only on the effects of EGCG.37

Acne
In 2009, Elsaie et al. enrolled 20 patients in a six-week study to 
investigate  the  efficacy  of  2  percent  green  tea  lotion  for  the 
treatment  of  mild-to-moderate  acne  vulgaris.  Participants 
applied lotion twice daily and were evaluated every two weeks. 
The researchers reported a statistically significant reduction in 
mean total lesion count from 24 to 10 after the treatment period 
(a decrease of 58.33 percent). A statistically significant decline in 
mean severity index (devised by the authors to correlate with 
total  lesion  count  in  increasing  intensity,  scaled  from  1  to  3) 
from 2.05 to 1.25 (39.02 percent decrease) was also noted. The 
investigators concluded that 2 percent green tea lotion is both 

 
an effective and cost-effective approach for ameliorating mild-
to-moderate acne lesions.38

A  2012  study  revealed  that  ethanol  extracts  of  several  herbs, 
including  green  tea,  exhibited  the  potential  for  inhibiting  acne 
when  incorporated  into  a  topical  moisturizer,  specifically  acting 
against acne-causing bacteria without provoking irritation.39 Earlier 
that year, Jung et al. conducted in vitro and in vivo experiments to 
evaluate the effects against acne of polyphenon-60, which contains 
various green tea catechins (now referred to as sinecatechins in the 
United States).40 In their clinical study, patients exhibited improve-
ment in acne symptoms, including a reduction in the number of 
pustules and comedones. In vitro work revealed that Propionibacterium 
acnes-enhanced toll-like receptor 2 (TLR2) and IL-8 levels in THP-1 
cells were diminished by polyphenon-60. Human monocyte cell 
lines  and  human  primary  monocytes  were  also  decreased.  The 
investigators concluded that polyphenon-60 inhibits inflammation 
through  the  downregulation  of  the  extracellular  signal-regulated 
kinases 1/2 (ERK1/2) pathway and AP-1 pathway, thus suppressing 
TLR2 expression and IL-8 secretion.41

In  2013,  Mahmood  et  al.  conducted  a  single-blind,  placebo-
controlled, split-face comparative study in 22 individuals to evaluate 
the efficacy of green tea as well as green tea plus lotus as compared 
to placebo for controlling casual sebum secretions in healthy adults. 
Over  a  60-day  period,  volunteers  in  Group  1  applied  a  multiple 
emulsion formulation containing green tea extract; Group 2 applied 
a multiple emulsion with green tea and lotus extract. Compared to 
placebo, consistent and statistically significant decreases in sebum 
secretions were observed in both treatment groups. The combina-
tion of green tea and lotus extracts also achieved statistically sounder 
results  than  green  tea  alone.  The  investigators  concluded  that  a 
synergistic  interaction  between  green  tea  and  lotus  extract 
constituents  appears  to  hold  promise  for  the  treatment  of  skin 
conditions in which elevated sebum levels are involved.42

Anogenital Warts
Gross  et  al.  reported  in  2007  on  a  randomized,  double-blind, 
placebo-controlled  Phase  II/III  12-week  clinical  efficacy  and 
safety  study  of  polyphenon  E,  consisting  of  more  than  
85  percent  catechins,43  in  242  outpatients  with  external  genital 
warts  at  28  hospitals  in  Germany  and  Russia.  Polyphenon  E  
15 percent ointment was found efficacious and safe for men and 
women  in  clearing  external  genital  warts,  with  statistically 
significant differences seen compared to placebo and higher clear-
ance and lower recurrence compared to the 10 percent ointment.44
In  2006,  the  United  States  Food  and  Drug  Administration 
(USFDA) approved of the use of a green tea extract formulation 
(Veregen)  for  the  topical  treatment  of  genital  and  perianal 
warts, typically caused by the human papillomavirus (HPV)-6 
or HPV-11.40,45,46 In 2008, Tatti et al. conducted a randomized, 
double-blind, vehicle-controlled trial to evaluate the efficacy of 
topical sinecatechins, a defined green tea extract, in 502 male 
and female patients (aged 18 years and older) for the treatment 
of anogenital warts. For 16 weeks or until complete clearance, 
subjects  applied  sinecatechins  ointment  15  or  10  percent  or 
vehicle  (placebo)  three  times  daily.  A  12-week  follow-up  to 
gauge recurrence ensued. Complete clearance was achieved in 
57.2  percent  of  patients  treated  with  15  percent  ointment,  
56.3 percent using 10 percent ointment, and 33.7 percent who 
used  only  the  vehicle.  Respective  recurrence  rates  were  
6.5  percent,  8.3  percent,  and  8.8  percent.  The  investigators 
concluded  that  topical  sinecatechins  in  15  and  10  percent 
concentrations  represent  effective  and  well-tolerated  options 
for  anogenital  wart  treatment.47  Similarly  favorable  results 

C H A P T E R  47  ■   G R E E N  T E A  

139

regarding  polyphenon  E  15  percent  were  reported  by  Gross 
that year in reference to three placebo-controlled clinical stud-
ies in 1,400 patients with genital warts from Europe, North and 
South America, and South Africa.48

In 2010, Tatti et al. conducted randomized, double-blind, 
vehicle-controlled  safety  and  efficacy  trials  in  nearly  
1,000 patients with external genital warts who were treated with 
polyphenon  E  ointment  10  percent,  polyphenon  E  ointment 
15 percent, or vehicle. They concluded that the sinecatechin 
formulation was effective and well tolerated, with complete 
clearance  observed  in  54.9  percent  of  subjects  taking  the  
15 percent ointment, 53.6 percent of those taking the 10 percent 
ointment, and 35.4 percent using only the vehicle.40

Hoy et al. reported in 2012 on the evaluation of polyphenon E 
10 percent ointment in two double-blind, multinational studies in 
adults  with  external  genital  and  perianal  warts.  Polyphenon  E  
10  percent  was  found  to  be  significantly  more  effective  than 
vehicle in completely or partially clearing all warts (baseline and 
those emerging during treatment) in both studies. During 12-week 
follow-up  periods  in  both  studies,  rates  of  recurrence  or  new 
warts appearing were less than 9 percent in both treatment arms. 
Polyphenon E 10 percent was well tolerated, with most adverse 
effects involving minor skin irritation at the treatment site.49

Earlier that year, Stockfleth and Meyer reviewed the use of 
sinecatechins  (polyphenon  E)  ointment  for  the  treatment  of 
external  anogenital  warts.  They  noted  that  while  clearance 
rates are similar among sinecatechins and other indicated topi-
cal  medications  such  as  imiquimod  and  podophyllotoxin, 
recurrence  rates  are  lower  for  patients  treated  with  sinecate-
chins. The authors concluded that the use of sinecatechins for 
condylomata  acuminata  is  safe  and  effective  and  its  various 
molecular activities suggest broader applications to other viral 
and tumor lesions.50 Previously, Stockfleth et al., in 2008, had 
found,  in  a  randomized  controlled  trial  of  503  patients,  that 
polyphenon E (15 and 10 percent) was safe and efficacious for 
the treatment of external genital and perianal warts.51 Ahn et al. 
showed earlier, in a study with 51 patients, that polyphenon E 
and  EGCG  delivered  topically  or  in  capsule  form  were  also 
effective in treating HPV-infected cervical lesions.52

Sinecatechins, derived from green tea catechins and other con-
stituents of C. sinensis, in a topical 15 percent ointment (Veregen®), 
is the first botanical drug formulation to be approved by the FDA 
for  the  treatment  of  external  genital  and  perianal  warts.40,53,54 
Sinecatechins have been shown  in vitro to suppress HPV-infected 
tumor  cell  lines,  and  to  manifest  antiproliferative  activity  that 
Tyring  speculates  may  be  involved  in  the  overall  anticancer  and 
antiviral properties associated with these GTPs that also lead to 
the clearance of external genital and perianal warts.55 Interestingly, 
sinecatechins  have  been  recently  shown  to  hinder,  often  dose-
dependently,  several  kinases  and  enzymes,  including  MMPs 
(MMP-1, MMP-2, MMP-7, and MMP-9), lipoxygenases, cyclooxy-
genases,  and  proteases,  which  are  involved  in  inflammatory 
mediator generation.53,54

Other Antimicrobial Uses
In  2013,  De  Oliveira  et  al.  showed  that  modified  EGCG 
(palmitoyl-EGCG) has potential as a topical antiviral agent for 
herpes simplex virus (HSV-1) infection.56

Indeed,  EGCG  has  been demonstrated to exhibit significant 
activity  against  HSV,  inactivating  several  clinical  isolates  of 
HSV-1  as  well  as  HSV-2,  and,  given  its  stability  in  pH  ranges 
characteristic in the vagina, is emerging as a viable microbicidal 
agent for lowering HSV transmission, according to Isaacs et al.57

 
140 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

In addition, EGCG has been found in one study to suppress the 
human  immunodeficiency  virus-1  (HIV-1)  infectivity-enhancing 
activity  of  human  semen,  though  with  significant  variability.  
The  investigators  speculate  that  topically  applied  EGCG  may 
emerge as an additional tactic to reduce the likelihood of sexual 
transmission of HIV, but note that more information regarding the 
differences in efficacy is necessary before therapeutic human trials 
can commence.58 EGCG has also been demonstrated to lower the 
number of plaques in HIV-infected cultured cells.56

Further, Shin et al. recently developed and used an experimental 
skin  contact  model  for  influenza  virus  to  assess  a  green  tea 
handwash disinfectant, finding that viral infectivity was eliminated 
on skin cell layers washed with the green tea solution.59

Other Indications
Hsu  et  al.  showed  in  2007  that  the  topical  application  of  
0.5 percent GTPs attenuated the symptoms of psoriasis in a flaky 
skin mouse model, suggesting that GTP-induced caspase 14 may 
serve as a potential target of novel formulations aimed at alleviating 
psoriasis.60  Green  tea  extracts  have  also  protected  against  the 
phototoxic effects engendered by the psoriasis treatment psoralen 
plus  UVA,  by  inhibiting  DNA  damage  and  attenuating  the 
inflammatory effects of the treatment.11,61

Kwon et al. observed in vitro the growth stimulation of dermal 
papilla  cells  by  EGCG  as  well  as  on  human  scalps  in  vivo  in  a 
2007 study. The investigators suggested that EGCG exerts dual 
proliferative and antiapoptotic effects on dermal papilla cells and 
has potential to thwart androgenetic alopecia.62

In a small randomized, double-blind, six-week split-face trial 
in 2010, Domingo et al. found that the topical application of a 
cream containing 2.5 percent EGCG may have potential in pre-
venting telangiectasias.63

A  small  pilot  study  of  four  atopic  dermatitis  patients 
conducted by Kim et al. in 2012 revealed that all four patients 
using  bath  therapy  with  green  tea  extracts  three  times  each 
week  over  four  weeks  improved  markedly.  The  investigators 
concluded that the green tea-infused bath therapy is a safe and 
effective  alternative  to  corticosteroid  treatment  for  patients 
with atopic dermatitis associated with Malassezia sympodialis.64
In addition, the use of green tea catechins in a local delivery 
system was shown in a clinical pilot study in 2002 to be effective 
in  ameliorating  periodontal  status.65  Green  tea  had  previously 
been shown in human and laboratory studies to impart protec-
tion against dental caries.10,66,67

Combination Therapy
Green tea has been shown to work in combination with red light 
to  exert  a  rejuvenating  effect  on  the  skin,  as  Sommer  and  Zhu 
reported in 2009 that green tea-filled cotton pads applied once daily 
for 20 minutes prior to treatment with light-emitting diodes (cen-
tral wavelength 670 nm, dermal dose 4 J/cm2) diminished wrinkles 
in one month comparably to 10 months of light treatment alone.68
In a small 2013 study with 16 subjects with facial redness, a 
topical  formulation  combining  GTPs,  resveratrol,  and  caffeine 
was found to reduce erythema after six weeks of treatment, with 
no adverse effects seen.69

 SAFETY ISSUES

Green tea and green tea extracts are generally recognized as safe 
(GRAS).  After  extensive  safety  testing  of  oral  and  topical 
preparations  of  EGCG  in  rats,  guinea  pigs,  rabbits,  and  dogs, 

Isbrucker et al. established a no-observed adverse effect level 
of 500 mg EGCG preparation/kg/day.70 Previously, Stratton et 
al. found no toxicity associated with daily topical EGCG use 
in studies with female SKH-1 hairless mice, but noted that use 
of  topical  depilatories  could  activate  dermal  toxicity  from 
EGCG use.61

 ENVIRONMENTAL IMPACT

It  is  improbable  that  the  cultivation  of  C.  sinensis  adversely 
effects the environment. Rather, it is more likely that the sus-
tainability of tea plantations may be challenged or threatened 
by global climate change. In a recent study by Wijeratne et al., 
the investigators concluded that tea yields are likely to decrease 
in  lower  and  moderate  elevations  and  increase  in  higher 
elevations.71

 FORMULATION CONSIDERATIONS

Green tea is thought to be challenging to formulate because of 
the inherent hydrophilicity of EGCG, which limits penetration 
into human skin.72,73

Dvorakova et al. ascertained, in a 1999 study of the pharma-
cokinetics of EGCG applied topically in mouse and human skin, 
that the stability of the green tea constituent in hydrophilic oint-
ment  depends  on  time,  temperature,  and  degree  of  oxidation. 
Stability  was  enhanced  by  the  supplementation  of  butylated 
hydroxytoluene.74

A 2011 study by Bianchi et al. showed that use of the water-
soluble  UVB  filter  benzophenone-4  rendered  EGCG  more  
photostable in topical formulations designed to protect the skin 
from photodamage.75

In 2013, Silva et al. evaluated the efficacy of five commer-
cial green tea extracts in cosmetic formulations in protecting 
against UV-induced damage to human and mouse fibroblasts 
and compared the results to the effects of a fluid preparation 
meeting Brazilian Pharmacopoeia standards. As comparative 
parameters, they used individual EGCG content, catalase and 
superoxide  dismutase  status,  and  MMP-1,  MMP-9,  and  
MMP-13 levels. The researchers found substantial variability 
in  EGCG  content,  unlike  the  fluid  product,  which  was  also 
the  only  formulation  capable  of  markedly  lowering  MMP 
degradation  while  increasing  superoxide  dismutase  and 
catalase  levels.  The  investigators  stated  that  their  findings 
represent the first report indicating that the methods of pre-
paring  herbal  mixtures  can  substantially  interfere  with  con-
stituents  with  inherent  photoprotective  properties,  and, 
specifically, the efficacy of C. sinensis extracts can be compro-
mised in such products.76

 USAGE CONSIDERATIONS

EGCG is the component in green and white tea responsible for 
antioxidant  activity.26,77  Therefore,  one  must  know  which 
polyphenols  are  present  in  a  skin  care  formulation  to  assess 
product usefulness. Learning the percentage of polyphenols in 
the product is also important. Some products turn brown due 
to  the  inclusion  of  a  large  amount  of  green  tea  components. 
Green  tea  does  not  easily  react  with  other  ingredients  and 
seems  to  facilitate  or  support  their  stability;  therefore,  it  is 
relatively easy to combine with other ingredients.

 
 SIGNIFICANT BACKGROUND

In  a  2010  systematic  database  review  (MEDLINE,  Embase, 
CINAHL®,  CENTRAL,  and  AMED  databases)  of  randomized 
clinical trials or controlled clinical trials showing evidence for 
the effectiveness or efficacy of botanical treatments in reducing 
skin  aging  and  wrinkling,  Hunt  et  al.  reported  that  of  the  
11 trials of botanical extracts that met all the inclusion criteria, 
no significant reduction in skin wrinkling was associated with 
green  tea  or  Vitaphenol®  (a  combination  of  green  and  white 
teas,  mangosteen,  and  pomegranate  extract).  They  noted, 
though, that all trials were of poor methodological quality and 
more rigorous studies are necessary to explain or validate their 
finding.78 Elbling et al. also cautioned against the excessive con-
sumption  of  green  tea  or  topical  use  of  green  tea  products 
before the performance of extensive in vivo investigations given 
their in vitro findings that EGCG increased hydrogen peroxide-
induced oxidative stress and DNA damage.79

Nonetheless, GTPs are believed to impart broad photopro-
tective effects against UV-induced carcinogenic activity as well 
as  sunburn  response,  immunosuppression,  and  photoaging. 
Therefore, green tea is thought to be a  potentially  significant 
agent  to  be  combined  with  traditional  sunscreens  to  buttress 
photoprotection.80

Photoprotection
Early studies of GTPs demonstrated inhibition of chemical- and 
UV-induced  carcinogenesis  in  hairless  or  Sencar  mice  receiving 
orally  administered  or  topically  applied  test  drug.81–83  Such 
evidence  has  been  confirmed  in  subsequent  work,  with  EGCG 
emerging  as  a  potent  suppressor  of  photocarcinogenesis.84  The 
photoprotective effects of topically applied GTPs have also been 
noted in human skin, with a dose-dependent decline of UV-induced 
erythema,  diminished  sunburn  cell  formation,  protection  of 
epidermal Langerhans cells, and limitation of DNA damage.85

As Mnich et al. noted in 2009, the limited studies conducted in 
humans of the effects of topical green tea extracts have typically 
included high concentrations of extracts over short test periods. 
In their five-week study with 21 volunteers, however, stabilized 
low-dose green tea extracts incorporated into a cosmetic product 
(OM24)  were  found  to  be  effective,  at  cosmetically  usable 
concentrations, in conferring photochemopreventive activity, low-
ering UVB-mediated epithelial damage without tachyphylaxis.86

Also  that  year,  Camouse  et  al.  analyzed  skin  samples  from 
volunteers  or  skin  explants  and  showed  that  topically  applied 
green or white tea extracts provided protection to human skin 
from solar-simulated UV light, concluding that both agents are 
potential photoprotective agents.87

In 2011, a study by Katiyar elucidated aspects of the mecha-
nisms of action of GTPs, topically applied or orally administered 
in the drinking water of mice, which have been shown to pre-
vent  UVB-induced  nonmelanoma  skin  cancer  development.  
The process appears to be at least partly mediated through DNA 
repair.88 Another recent study with Katiyar at the helm showed 
that  GTPs  prevent  UV-induced  immunosuppression  through  a 
similar mechanism, rapid DNA damage repair and amelioration 
of nucleotide excision repair genes. The authors suggest that this 
process  may  explain  the  chemopreventive  effects  of  GTPs  in 
warding off photocarcinogenesis.89

In Vitro Studies
A study comparing the effects of EGCG and retinoic acid on 
alterations in the extracellular matrix induced by UVA exposure 

C H A P T E R  47  ■   G R E E N  T E A  

141

revealed,  using  artificial  skin  and  cultured  keratinocytes  and 
fibroblasts, that topically applied EGCG can reverse UV-induced 
changes. EGCG was also found by Lee et al., in this 2005 study, 
to be slightly more effective than retinoic acid.90

In 2009, Osterburg et al. demonstrated in vitro that EGCG acts 
as  an  effective  bactericidal  against  antibiotic-resistant 
Acinetobacter baumannii, an increasingly common source of infec-
tions in intensive care units worldwide.91

Additional  antibacterial  activity  exhibited  by  green  tea  has 
been  recently  supported.  In  2012,  Sharma  et  al.  found  that 
selected  bacterial  strains,  including  Staphylococcus  epidermidis, 
Micrococcus  luteus,  Brevibacterium  linens,  Pseudomonas  fluorescens, 
and Bacillus subtilis, were sensitive to green tea extract via disc 
diffusion assay.1

Using  A375  (BRAF-mutated)  and  Hs294t  (Non-BRAF-
mutated) melanoma cell lines in 2011, Singh and Katiyar ascer-
tained the effect of green tea catechins on the invasive potential 
of human melanoma cells in an in vitro model. They determined 
that  EGCG  exhibited  the  capacity  to  suppress  melanoma  cell 
invasion/migration  by  targeting  the  endogenous  expression  of 
cyclooxygenase-2, and prostaglandin E2 receptors, as well as the 
cellular epithelial-to-mesenchymal transition or transformation.92
Recent in vitro evidence also suggests that green tea extracts 

have the potential for efficacy against leishmaniasis.93

Additional Animal Studies
The  preponderance  of  studies  supporting  anticarcinogenic,  
anti-inflammatory,  antioxidant,  and  photoprotective  activity 
associated with green tea has been performed in animals.9,15,34,94,95
In 2003, Vayalil et al. demonstrated in an in vivo mouse model 
that  the  topical  application  of  GTPs  or  EGCG  in  hydrophilic 
ointment prior to single or multiple UVB exposures led to a sig-
nificant prevention of UVB-induced antioxidant enzyme deple-
tion, particularly glutathione peroxidase and catalase. Treatment 
with  EGCG  also  substantially  inhibited,  in  a  time-dependent 
manner, the phosphorylation of the ERK1/2, JNK, and p38 pro-
teins of the MAPK family after one or multiple UVB exposures.96
In 2006, Meeran et al. demonstrated that EGCG can prevent 
photocarcinogenesis  in  mice  by  inducing  an  IL-12  DNA  repair 
mechanism.30

The next year, Sevin et al. determined that 2 percent EGCG 
topically  applied  to  the  skin  of  Wistar  albino  rats  rendered  a 
photoprotective effect against UVA when applied before but not 
after UV exposure.97

EGCG, through injection or topical application, has also been 
shown  to  enhance  neovascularization  and  regional  perfusion 
leading to the amelioration of skin flap survival in a rat dorsal 
skin flap model.98

Human Studies
The broad effects of GTPs in human beings have been exam-
ined in a spate of studies during the last 15 years.

Katiyar et al., in 1999, demonstrated that the topical applica-
tion of EGCG to human skin displays the potential to hinder the 
UVB-generated infiltration of inflammatory leukocytes and the 
ensuing  development  of  reactive  oxygen  species.99  The  next 
year,  Katiyar  et  al.  extended  a  mouse  model  to  an  in  vivo 
demonstration  in  humans  that  topically  applied  GTPs  prevent 
the formation of UVB-induced DNA damage as manifested by 
the  inhibition  of  cutaneous  cyclobutane  pyrimidine  dimers,  at 
least  partially  accounting  for  the  suppression  of  photocarcino-
genesis  associated  with  green  tea.100  In  2001,  Katiyar  et  al. 

 
142 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

showed that pretreatment of human skin with EGCG prior to 
UV irradiation prevents the cascade of oxidative stress, including 
the protection of the antioxidant enzyme glutathione peroxidase. 
It  also  suppresses  UV-induced  infiltration  of  inflammatory 
leukocytes and significantly reduces the UV-induced synthesis of 
hydrogen peroxide and nitric oxide.101

Chiu  et  al.  conducted,  in  2005,  a  double-blind,  placebo-
controlled,  eight-week  trial  with  40  women  with  moderate 
photoaging who were randomized for treatment with either a  
10 percent green tea cream and 300 mg twice-daily green tea oral 
supplement or a placebo regimen. The investigators found sig-
nificant histologic (elastic content of treated specimens) but no 
clinical signs of improvement in photoaged skin. They concluded 
that  a  longer  treatment  period  might  be  necessary  to  achieve 
clinical improvement.102

In  2013,  Hong  et  al.  conducted  an  eight-week  study  in  
42  healthy  Korean  females  (aged  30–59  years)  to  examine  the 
antiwrinkle effects of topically applied green tea extract display-
ing  high  antioxidant  activity  after  tannase  treatment,  with 
increased levels of gallic acid, EGC, and EC. Subjects were ran-
domly divided into two groups, one of which applied tannase-
converted green tea extract on their crow’s feet and the other, 
normal green tea extract. Reductions in the average roughness of 
skin values were much greater in the tannase group as were the 
scavenging abilities against free radicals. In addition, marked or 
moderate improvements in wrinkles were reported in the tan-
nase  group  (63.6  percent)  compared  to  the  normal  green  tea 
group (36.3 percent). The researchers concluded that tannase treat-
ment enhanced the antioxidant activity of green tea extract, ren-
dering it better able to combat wrinkles, adding that the tannase 
green tea formulation warrants attention as an antiwrinkle agent.103
At around the same time, Gianeti conducted clinical studies in 
24  volunteers  to  assess  the  effects  of  a  cosmetic  formulation 
containing 6 percent C. sinensis glycolic leaf extracts. The experi-
mental  formulation  was  compared  to  vehicle  alone  in  the 
treatment of forearm skin, which was evaluated before and after 
two hours of application as well as after 15 and 30 days of use. 
Skin moisture was enhanced after 30 days of topical application 
as was the viscoelastic-to-elastic ratio as compared with vehicle 
and control (a forearm area left untreated). Skin roughness was 
significantly  diminished  after  30  days.  The  investigators 
concluded that the use of green tea in a topical cosmetic formulation 
yielded salient moisturizing and cutaneous microrelief benefits.104

Also in 2013, Rhodes et al. found that the oral intake of green 
tea catechins in 16 healthy human subjects (with 14 completing 
the  study)  appeared  to  result  in  the  integration  of  catechin 
metabolites into human skin linked to the negation of UV-induced 
12-hydroxyeicosatetraenoic  acid  (12-HETE).  They  speculated 
that this incorporation of catechins may render protection against 
sunburn inflammation and even cumulative UV-induced harm.105
In  addition,  in  a  small  study  of  10  healthy  male  volunteers 
conducted over a 60-day period, Mahmood et al. found that a 
green tea extract cream had a significant impact on the viscoelas-
tic properties of the skin.106

After  earlier  showing  the  efficacy  of  green  tea  and  lotus 
extracts  in  skin  disorders  involving  excess  sebum,  Mahmood 
and  Akhtar  conducted  a  60-day,  placebo-controlled,  and 
comparative, split-face study in 33 healthy Asian men to evaluate 
the efficacy of two cosmetic formulations (green tea and lotus 
extract) in treating facial wrinkles. The participants were divided 
into  three  groups,  with  one  applying  multiple  emulsions  with 
green  tea,  one  applying  multiple  emulsions  with  lotus  extract, 
and one applying a combination of both botanicals. Applications 
were once daily, with each of the active formulations applied to 

one  side  of  the  face  and  placebo  on  the  other  side.  All  of  the 
formulations yielded improvements in skin roughness, scaliness, 
smoothness, and wrinkling, with the greatest reduction in wrin-
kling conferred by the combination formulation. The investiga-
tors concluded that the synergistic activity of green tea and lotus 
extracts  exerted  significant  improvement  along  several  skin 
parameters,  suggesting  the  potential  for  these  ingredients  in 
antiaging products.105

 CONCLUSION

Investigations into the health benefits of green tea and its con-
stituent polyphenols represents one of the most fertile areas of 
antioxidant research. While broad-spectrum clinical efficacy of 
topically  applied  green  tea  polyphenols  (particularly  EGCG) 
has  not  been  established,  evidence  is  amassing  that  these 
constituents due indeed deliver cutaneous benefits. Green tea 
polyphenols  are  in  use  for  a  growing  number  of  indications, 
especially  acne  and  genital  warts,  and  there  is  reason  for 
optimism that topically applied green tea will gain favor as an 
adjuvant therapy option in several cases. More clinical studies 
are necessary to further elucidate the versatile role of green tea 
in the dermatologic armamentarium. This popular herbal agent 
holds particular promise in relation to photoprotection against 
UV-induced skin cancer and aging.

REFERENCES

1.  Sharma A, Gupta S, Sarethy IP, et al. Green tea extract: Possible 
mechanism  and  antibacterial  activity  on  skin  pathogens.  Food 
Chem. 2012;135:672.

2.  Oyetakin White P, Tribout H, Baron E. Protective mechanisms of 
green  tea  polyphenols  in  skin.  Oxid  Med  Cell  Longev. 
2012;2012:560682.

3.  Weisburger  JH.  Tea  and  health:  A  historical  perspective.  Cancer 

Lett. 1997;114:315.

4.  Hsu S. Green tea and the skin. J Am Acad Dermatol. 2005;52:1049.
5.  Katiyar  SK,  Ahmad  N,  Mukhtar  H.  Green  tea  and  skin.  Arch 

Dermatol. 2000;136:989.

6.  Katiyar SK, Elmets CA, Agarwal R, et al. Protection against UVB 
radiation-induced  local  and  systemic  suppression  of  contact 
hypersensitivity  and  edema  responses  in  C3H/HeN  mice  by 
green tea polyphenols. Photochem Photobiol. 1995;62:855.

7.  Thornfeldt C. Cosmeceuticals containing herbs: fact, fiction, and 

future. Dermatol Surg. 2005;31:873.

8.  Reuter J, Merfort I, Schempp CM. Botanicals in dermatology: An 

evidence-based review. Am J Clin Dermatol. 2010;11:247.

9.  Wright  TI,  Spencer  JM,  Flowers  FP.  Chemoprevention  of 

nonmelanoma skin cancer. J Am Acad Dermatol. 2006;54:933.
10.  Cooper R, Morré DJ, Morré DM. Medicinal benefits of green tea: 
Part I – Review of noncancer health benefits. J Altern Complement 
Med. 2005;11:521.

11.  Bickers DR, Athar M. Novel approaches to chemoprevention of 

skin cancer. J Dermatol. 2000;27:691.

12.  Suzuki  Y,  Miyoshi  N,  Isemura  M.  Health-promoting  effects  of 

green tea. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88:88.

13.  Katiyar  SK,  Mohan  RR,  Agarwal  R,  et  al.  Protection  against 
induction  of  mouse  skin  papillomas  with  low  and  high  risk  of 
conversion to malignancy by green tea polyphenols. Carcinogenesis. 
1997;18:497.

14.  Katiyar  SK,  Rupp  CO,  Korman  NJ,  et  al.  Inhibition  of 
skin 
12-O-tetradecanoylphorbol-13-acetate  and  other 
tumor-promoter-caused  induction  of  epidermal  interleukin-1 
alpha mRNA and protein expression in SENCAR mice by green 
tea polyphenols. J Invest Dermatol. 1995;105:394.

15.  Mukhtar  H,  Katiyar  SK,  Agarwal  R.  Green  tea  and  skin  – 

Anticarcinogenic effects. J Invest Dermatol. 1994;102:3.

16.  Katiyar SK, Agarwal R, Mukhtar H. Inhibition of both stage I and 
stage II skin tumor promotion in SENCAR mice by a polyphenolic 
fraction  isolated  from  green  tea:  Inhibition  depends  on  the 
duration of polyphenol treatment. Carcinogenesis. 1993;14:2641.

 
17.  Katiyar SK, Agarwal R, Mukhtar H. Protection against malignant 
conversion of chemically induced benign skin papillomas to squa-
mous cell carcinomas in SENCAR mice by a polyphenolic fraction 
isolated from green tea. Cancer Res. 1993;53:5409.

18.  Katiyar  SK,  Agarwal  R,  Ekker  S,  et  al.  Protection  against 
12-O-tetradecanoylphorbol-13-acetate-caused  inflammation  in 
SENCAR mouse ear skin by polyphenolic fraction isolated from 
green tea. Carcinogenesis. 1993;14:361.

19.  Katiyar  SK,  Agarwal  R,  Wood  GS,  et  al.  Inhibition  of 
12-O-tetradecanoylphorbol-13-acetate-caused  tumor  promotion 
in  7,12-dimethylbenz[a]anthracene-initiated  SENCAR  mouse 
skin  by  a  polyphenolic  fraction  isolated  from  green  tea.  Cancer 
Res. 1992;52:6890.

20.  Agarwal R, Katiyar SK, Zaidi SI, et al. Inhibition of skin tumor pro-
moter-caused  induction  of  epidermal  ornithine  decarboxylase  in 
SENCAR mice by polyphenolic fraction isolated from green tea and 
its individual epicatechin derivatives. Cancer Res. 1992;52:3582.
21.  Wang ZY, Khan WA, Bickers DR, et al. Protection against polycy-
clic aromatic hydrocarbon-induced skin tumor initiation in mice 
by green tea polyphenols. Carcinogenesis. 1989;10:411.

22.  Conney  AH,  Wang  ZY,  Huang  MT,  et  al.  Inhibitory  effect  of 
green tea on tumorigenesis by chemicals and ultraviolet light. Prev 
Med. 1992;21:361.

23.  Katiyar  SK,  Agarwal  R,  Wang  ZY,  et  al.  (-)-Epigallocatechin-3-
gallate  in  Camellia  sinensis  leaves  from  Himalayan  region  of 
Sikkim: Inhibitory effects against biochemical events and tumor 
initiation in Sencar mouse skin. Nutr Cancer. 1992;18:73.

24.  Huang  MT,  Ho  CT,  Wang  ZY,  et  al.  Inhibitory  effect  of  topical 
application of a green tea polyphenol fraction on tumor initiation 
and promotion in mouse skin. Carcinogenesis. 1992;13:947.

25.  Wang ZY, Huang MT, Ferraro T, et al. Inhibitory effect of green 
tea in the drinking water on tumorigenesis by ultraviolet light and 
12-O-tetradecanoylphorbol-13-acetate in the skin of SKH-1 mice. 
Cancer Res. 1992;52:1162.

26.  Shi X, Ye J, Leonard SS, et al. Antioxidant properties of (-)-epicatechin-
3-gallate  and  its  inhibition  of  Cr(VI)-induced  DNA  damage  and 
Cr(IV)-  or  TPA-stimulated  NF-kappaB  activation.  Mol  Cell 
Biochem. 2000;206:125.

27.  Stratton  SP,  Dorr  RT,  Alberts  DS.  The  state-of-the-art  in 
chemoprevention of skin cancer. Eur J Cancer. 2000;36:1292.
28.  Chung JH, Han JH, Hwang EJ, et al. Dual mechanisms of green 
tea  extract  (EGCG)-induced  cell  survival  in  human  epidermal 
keratinocytes. FASEB J. 2003;17:1913.

29.  Katiyar SK, Challa A, McCormick TS, et al. Prevention of UVB-
induced immunosuppression in mice by the green tea polyphenol 
(-)-epigallocatechin-3-gallate  may  be  associated  with  alterations 
in IL-10 and IL-12 production. Carcinogenesis. 1999;20:2117.
30.  Meeran SM, Mantena SK, Elmets CA, et al. (-)- Epigallocatechin-
3-gallate  prevents  photocarcinogenesis  in  mice  through 
interleukin-12-dependent DNA repair. Cancer Res. 2006;66:5512.
31.  Katiyar  SK,  Bergamo  BM,  Vayalil  PK,  et  al.  Green  tea  polyphe-
nols:  DNA  photodamage  and  photoimmunology.  J  Photochem 
Photobiol B. 2001;65:109.

32.  Vayalil PK, Mittal A, Hara Y, et al. Green tea polyphenols prevent 
ultraviolet  light-induced  oxidative  damage  and  matrix  metallo-
proteinases  expression  in  mouse  skin.  J  Invest  Dermatol. 
2004;122:1480.

33.  Awadalla HI, Ragab MH, Bassuoni MW, et al. A pilot study of the 
role of green tea use on oral health. Int J Dent Hyg. 2011;9:110.
34.  Katiyar  S,  Elmets  CA,  Katiyar  SK.  Green  tea  and  skin  cancer: 
photoimmunology, angiogenesis and DNA repair. J Nutr Biochem. 
2007;18:287.

35.  Pazyar  N,  Feily  A,  Kazerouni  A.  Green  tea  in  dermatology. 

Skinmed. 2012;10:352.

36.  Tzellos TG, Sardeli C, Lallas A, et al. Efficacy, safety and tolerabil-
ity of green tea catechins in the treatment of external anogenital 
warts: A systematic review and meta-analysis. J Eur Acad Dermatol 
Venereol. 2011;25:345.

37.  Pajonk F, Riedisser A, Henke M, et al. The effects of tea extracts 

on proinflammatory signaling. BMC Med. 2006;4:28.

38.  Elsaie  ML,  Abdelhamid  MF,  Elsaaiee  LT,  et  al.  The  efficacy  of 
lotion  in  mild-to-moderate  acne 

topical  2%  green  tea 
vulgaris. J Drugs Dermatol. 2009;8:358.

39.  Rasheed A, Shama SN, Joy JM, et al. Formulation and evaluation 
of herbal anti-acne moisturizer. Pak J Pharm Sci. 2012;25:867.
40.  Tatti  S,  Stockfleth  E,  Beutner  KR,  et  al.  Polyphenon  E:  A  new 
treatment  for  external  anogenital  warts.  Br  J  Dermatol. 
2010;162:176.

C H A P T E R  47  ■   G R E E N  T E A  

143

41.  Jung MK, Ha S, Son JA, et al. Polyphenon-60 displays a therapeu-
tic effect on acne by suppression of TLR2 and IL-8 expression via 
down-regulating  the  ERK1/2  pathway.  Arch  Dermatol  Res. 
2012;304:655.

42.  Mahmood T, Akhtar N, Moldovan C. A comparison of the effects 
of topical green tea and lotus on facial sebum control in healthy 
humans. Hippokratia. 2013;17:64.

43.  Meltzer  SM,  Monk  BJ,  Tewari  KS.  Green  tea  catechins  for 
treatment  of  external  genital  warts.  Am  J  Obstet  Gynecol. 
2009;200:233.e1.

44.  Gross G, Meyer KG, Pres H, et al. A randomized, double-blind, 
four-arm  parallel-group,  placebo-controlled  Phase  II/III  study  to 
investigate  the  clinical  efficacy  of  two  galenic  formulations  of 
Polyphenon  E  in  the  treatment  of  external  genital  warts.  J  Eur 
Acad Dermatol Venereol. 2007;21:1404.

45.  Wu  KM,  Ghantous  H,  Birnkrant  DB.  Current  regulatory 
toxicology perspectives on the development of herbal medicines 
to  prescription  drug  products  in  the  United  States.  Food  Chem 
Toxicol. 2008;46:2606.

46.  Chen  ST,  Dou  J,  Temple  R,  et  al.  New  therapies  from  old 

medicines. Nat Biotechnol. 2008;26:1077.

47.  Tatti S, Swinehart JM, Thielert C, et al. Sinecatechins, a defined 
green tea extract, in the treatment of external anogenital warts: a 
randomized controlled trial. Obstet Gynecol. 2008;111:1371.
48.  Gross G. Polyphenon E. A new topical therapy for condylomata 

acuminate. Hautarzt. 2008;59:31.

49.  Hoy  SM.  Polyphenon  E  10%  ointment:  In  immunocompetent 
adults with external genital and perianal warts. Am J Clin Dermatol. 
2012;13:275.

50.  Stockfleth E, Meyer T. The use of sinecatechins (polyphenon E) 
ointment for treatment of external genital warts. Expert Opin Biol 
Ther. 2012;12:783.

51.  Stockfleth E, Beti H, Orasan R, et al. Topical Polyphenon E in the 
treatment  of  external  genital  and  perianal  warts:  a  randomized 
controlled trial. Br J Dermatol. 2008;158:1329.

52.  Ahn  WS,  Yoo  J,  Huh  SW,  et  al.  Protective  effects  of  green  tea 
extracts  (polyphenon  E  and  EGCG)  on  human  cervical  lesions. 
Eur J Cancer Prev. 2003;12:383.

53.  Berman  B,  Wolf  J.  The  role  of  imiquimod  3.75%  cream  in  the 

treatment of external genital warts. Skin Therapy Lett. 2012;17:5.

54.  Tyring  SK.  Sinecatechins:  Effects  on  HPV-induced  enzymes 
involved  in  inflammatory  mediator  generation.  J  Clin  Aesthet 
Dermatol. 2012;5:19.

55.  Tyring SK. Effect of sinecatechins on HPV-activated cell growth 
and induction of apoptosis. J Clin Aesthet Dermatol. 2012;5:34.
56.  De  Oliveira  A,  Adams  SD,  Lee  LH,  et  al.  Inhibition  of  herpes 
simplex  virus  type  1  with  the  modified  green  tea  polyphenol 
palmitoyl-epigallocatechin  gallate.  Food  Chem  Toxicol. 
2013;52:207.

57.  Isaacs  CE,  Wen  GY,  Xu  W,  et  al.  Epigallocatechin  gallate 
inactivates  clinical  isolates  of  herpes  simplex  virus.  Antimicrob 
Agents Chemother. 2008;52:962.

58.  Hartjen P, Frerk S, Hauber I, et al. Assessment of the range of the 
HIV-1  infectivity  enhancing  effect  of  individual  human  semen 
specimen  and  the  range  of  inhibition  of  EGCG.  AIDS  Res  Ther. 
2012;9:2.

59.  Shin WJ, Kim YK, Lee KH, et al. Evaluation of the antiviral activ-
ity  of  a  green  tea  solution  as  a  hand-wash  disinfectant.  Biosci 
Biotechnol Biochem. 2012;76:581.

60.  Hsu S, Dickinson D, Borke J, et al. Green tea polyphenol induces 
caspase 14 in epidermal keratinocytes via MAPK pathways and 
reduces psoriasiform lesions in the flaky skin mouse model. Exp 
Dermatol. 2007;16:678.

61.  Zhao  JF,  Zhang  YJ,  Jin  XH,  et  al.  Green  tea  protects  against 
psoralen  plus  ultraviolet  A-induced  photochemical  damage  to 
skin. J Invest Dermatol. 1999;113:1070.

62.  Kwon  OS,  Han  JH,  Yoo  HG,  et  al.  Human  hair  growth 
enhancement  in  vitro  by  green  tea  epigallocatechin-3-gallate 
(EGCG). Phytomedicine. 2007;14:551.

63.  Domingo  DS,  Camouse  MM,  Hsia  AH,  et  al.  Anti-angiogenic 
effects of epigallocatechin-3-gallate in human skin. Int J Clin Exp 
Pathol. 2010;3:705.

64.  Kim HK, Chang HK, Baek SY, et al. Treatment of atopic dermatitis 
associated  with  Malassezia  sympodialis  by  green  tea  extracts 
bath therapy: A pilot study. Mycobiology. 2012;40:124.

65.  Hirasawa  M,  Takada  K,  Makumura  M,  et  al.  Improvement  of 
periodontal  status  by  green  tea  catechin  using  a  local  delivery 
system: A clinical pilot study. J Periodontal Res. 2002;37:433.

 
144 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

66.  Otake  S,  Makimura  M,  Kuroki  T,  et  al.  Anticaries  effects  of 
polyphenolic  compounds  from  Japanese  green  tea.  Caries  Res. 
1991;25:438.

67.  Horiba  N,  Maekawa  Y,  Ito  M,  et  al.  A  pilot  study  of  Japanese 
green tea as a medicament: antibacterial and bactericidal effects.  
J Endod. 1991;17:122.

68.  Sommer AP, Zhu D. Green tea and red light – A powerful duo in 

skin rejuvenation. Photomed Laser Surg. 2009;27:969.

69.  Ferzil G, Patel M, Phrsai N, et al. Reduction of facial redness with 
resveratrol  added  to  topical  product  containing  green 
tea polyphenols and caffeine. J Drugs Dermatol. 2013;12:770.
70.  Isbrucker RA, Edwards JA, Wolz E, et al. Safety studies on epigal-
locatechin  gallate  (EGCG)  preparations  –  Part  2:  dermal,  acute 
and short-term toxicity studies. Food Chem Toxicol. 2006;44:636.
71.  Wijeratne MA, Anandacoomaraswamy A, Amarathunga MSKLD, 
et al. Assessment of impact of climate change on productivity of 
tea  (Camellia  sinensis  L.)  plantations  in  Sri  Lanka.  J  Natn  Sci 
Foundation Sri Lanka. 2007;35:119.

72.  Farris P. Idebenone, green tea, and Coffeeberry extract: New and 

innovative antioxidants. Dermatol Ther. 2007;20:322.

73.  Levin  J,  Momin  SB.  How  much  do  we  really  know  about  our 
favorite  cosmeceutical  ingredients?  J  Clin  Aesthet  Dermatol. 
2010;3:22.

74.  Dvorakova  K,  Dorr  RT,  Valcic  S,  et  al.  Pharmacokinetics  of  the 
green tea derivative, EGCG, by the topical route of administration 
in  mouse  and  human  skin.  Cancer  Chemother  Pharmacol. 
1999;43:331.

75.  Bianchi  A,  Marchetti  N,  Scalia  S.  Photodegradation  of 
(-)-epigallocatechin-3-gallate in topical cream formulations and its 
photostabilization. J Pharm Biomed Anal. 2011;56:692.

76.  Silva  AR,  Seidl  C,  Furusho  AS,  et  al.  In  vitro  evaluation  of  the 
efficacy of commercial green tea extracts in UV protection. Int J 
Cosmet Sci. 2013;35:69.

77.  Wei H, Zhang X, Zhao JF, et al. Scavenging of hydrogen peroxide 
and inhibition of ultraviolet light-induced oxidative DNA damage 
by  aqueous  extracts  from  green  and  black  teas.  Free  Radic  Biol 
Med. 1999;26:1427.

78.  Hunt  KJ,  Hung  SK,  Ernst  E.  Botanical  extracts  as  anti-aging 
preparations  for  the  skin:  A  systematic  review.  Drugs  Aging. 
2010;27:973.

79.  Elbling L, Weiss RM, Teufelhofer O, et al. Green tea extract and 
(-)-epigallocatechin-3-gallate,  the  major  tea  catechin,  exert 
oxidant but lack antioxidant activities. FASEB J. 2005;19:807.
80.  Yusuf N, Irby C, Katiyar SK, et al. Photoprotective effects of green 
tea polyphenols. Photodermatol Photoimmunol Photomed. 2007;23:48.
81.  Wang  ZY,  Agarwal  R,  Bickers  DR,  et  al.  Protection  against 
ultraviolet  B  radiation-induced  photocarcinogenesis  in  hairless 
mice by green tea polyphenols. Carcinogenesis. 1991;12:1527.
82.  Gensler  HL,  Timmermann  BN,  Valcic  S,  et  al.  Prevention  of 
photocarcinognesis by topical administration of pure epigallocat-
echin gallate isolated from green tea. Nutr Cancer. 1996;26:325.
83.  Khan  WA,  Wang  ZY,  Athar  M,  et  al.  Inhibition  of  the  skin 
tumorigenicity  of  (+/-)-7  beta,8  alpha-dihydroxy-9  alpha,10  alpha-
epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene by tannic acid, green tea 
polyphenols and quercetin in Sencar mice. Cancer Lett. 1988;42:7.
84.  Mittal  A,  Piyathilake  C,  Hara  Y,  et  al.  Exceptionally  high 
protection  of  photocarcinogenesis  by  topical  application  of  
(-)-  epigallocatechin-3-gallate  in  hydrophilic  cream  in  SKH-1 
hairless mouse model: relationship to inhibition of UVB-induced 
global DNA hypomethylation. Neoplasia. 2003;5:555.

85.  Elmets CA, Singh D, Tubesing K, et al. Cutaneous photoprotec-
tion from ultraviolet injury by green tea polyphenols. J Am Acad 
Dermatol. 2001;44:425.

86.  Mnich CD, Hoek KS, Virkki LV, et al. Green tea extract reduces 
induction  of  p53  and  apoptosis  in  UVB-irradiated  human  skin 
independent of transcriptional controls. Exp Dermatol. 2009;18:69.

87.  Camouse MM, Domingo DS, Swain FR, et al. Topical application 
of  green  and  white  tea  extracts  provides  protection  from  solar-
simulated  ultraviolet  light  in  human  skin.  Exp  Dermatol. 
2009;18:522.

88.  Katiyar  SK.  Green  tea  prevents  non-melanoma  skin  cancer  by 
enhancing DNA repair. Arch Biochem Biophys. 2011;508:152.
89.  Katiyar  SK,  Vaid  M,  van  Steeg  H,  et  al.  Green  tea  polyphenols 
prevent UV-induced immunosuppression by rapid repair of DNA 
damage  and  enhancement  of  nucleotide  excision  repair  genes. 
Cancer Prev Res (Phila). 2010;3:179.

90.  Lee  JH,  Chung  JH,  Cho  KH.  The  effects  of  epigallocatechin-
3-gallate  on  extracellular  matrix  metabolism.  J  Dermatol  Sci. 
2005;40:195.

91.  Osterburg A, Gardner J, Hyon SH, et al. Highly antibiotic-resistant 
Acinetobacter baumannii clinical isolates are killed by the green 
tea  polyphenol  (-)-epigallocatechin-3-gallate  (EGCG).  Clin 
Microbiol Infect. 2009;15:341.

92.  Singh T, Katiyar SK. Green tea catechins reduce invasive potential 
of  human  melanoma  cells  by  targeting  COX-2,  PGE2  receptors 
transition.  PLoS  One. 
and  epithelial-to-mesenchymal 
2011;6:e25224.

93.  Feily  A,  Saki  J,  Maraghi  S,  et  al.  In  vitro  activity  of  green  tea 
extract Leishmania major promastigotes. Int J Clin Pharmacol Ther. 
2012;50:233.

94.  Katiyar SK. Skin photoprotection by green tea: Antioxidant and 
immunomodulatory  effects.  Curr  Drug  Targets  Immune  Endocr 
Metabol Disord. 2003;3:234.

95.  Katiyar SK, Elmets CA. Green tea polyphenolic antioxidants and 

skin photoprotection (Review). Int J Oncol. 2001;18:1307.

96.  Vayalil PK, Elmets CA, Katiyar SK. Treatment of green tea poly-
phenols in hydrophilic cream prevents UVB-induced oxidation of 
lipids and proteins, depletion of antioxidant enzymes and phos-
phorylation  of  MAPK  proteins  in  SKH-1  hairless  mouse  skin. 
Carcinogenesis. 2003;24:927.

97.  Sevin A, Ozta s¸   P, Senen D, et al. Effects of polyphenols on skin 
damage due to ultraviolet A rays: An experimental study on rats. 
J Eur Acad Dermatol Venereol. 2007;21:650.

98.  Cheon YW, Tark KC, Kim YW. Better survival of random pattern 
skin  flaps  through  the  use  of  epigallocatechin  gallate.  Dermatol 
Surg. 2012;38:1835.

99.  Katiyar SK, Matsui MS, Elmets CA, et al. Polyphenolic antioxidant 
(-)-epigallocatechin-3-gallate from green tea reduces UVB-induced 
inflammatory responses and infiltration of leukocytes in human 
skin. Photochem Photobiol. 1999;69:148.

100.  Katiyar SK, Perez A, Mukhtar H. Green tea polyphenol treatment 
to human skin prevents formation of ultraviolet light B-induced 
pyrimidine dimers in DNA. Clin Cancer Res. 2000;6:3864.

101.  Katiyar  SK,  Afaq  F,  Perez  A,  et  al.  Green  tea  polyphenol  
(-)-epigallocatechin-3-gallate  treatment  of  human  skin  inhibits 
ultraviolet  radiation-induced  oxidative  stress.  Carcinogenesis. 
2001;22:287.

102.  Chiu  AE,  Chan  JL,  Kern  DG,  et  al.  Double-blinded,  placebo- 
controlled trial of green tea extracts in the clinical and histologic 
appearance of photoaging skin. Dermatol Surg. 2005;31:855.
103.  Hong  YH,  Jung  EY,  Shin  KS,  et  al.  Tannase-converted  green  tea 
catechins  and  their  anti-wrinkle  activity  in  humans.  J  Cosmet 
Dermatol. 2013;12:137.

104.  Gianeti  MD,  Mercurio  DG,  Campos  PM.  The  use  of  green  tea 
extract in cosmetic formulations: Not only an antioxidant active 
ingredient. Dermatol Ther. 2013;26:267.

105.  Mahmood  T,  Akhtar  N.  Combined  topical  application  of  lotus 
and green tea improves facial skin surface parameters. Rejuvenation 
Res. 2013;16:91.

106.  Mahmood  T,  Akhtar  N,  Khan  BA,  et  al.  Changes  in  skin 
mechanical properties after long-term application of cream con-
taining green tea extract. Aging Clin Exp Res. 2011;23:333.

 
C H A P T E R   4 8

Rosa Damascena

C H A P T E R  48  ■   R O S A   DA M A S C E N A  

145

Activities:

Antioxidant, antibacterial, antimicrobial, anti-inflammatory, 
antiseptic, and anxiolytic

Important Chemical Components:

Geraniol,  which  exhibits  potent  antiseptic  activity 
(seven times that of phenol), and citronellol are the main 
constituents1,2.
Phenyl ethyl alcohol, nerol, linalool, eugenol, quercetin, 
tocopherol, 
kaempferol,  myricetin, 
g -tocopherol,  ascorbic  acid,  farnesol,  stearpoten,  and 
phenolic acids are also key active ingredients.

b -carotene, 

Origin Classification:

This  ingredient  is  considered  natural.  As  an  ingredient 
used for dermatologic purposes, it is laboratory made.

Personal Care Category:

Antioxidant

Recommended for the following Baumann Skin 
Types:

DRNW, DRPW, DSNW, DSPW, ORNW, ORPW, OSNW, 
and OSPW

 SOURCE

Known  as  the  Damask  Rose  and  Rose  of  Castile  (and  Gole 
Mohammadi  in  Iran),  Rosa  damascena,  a  member  of  the 
Rosaceae  family,  is  a  rose  hybrid  the  flowers  of  which  have 
been used for rose oil in perfume and for rosewater.3 The petals 
are rich sources of vitamin C and flavonoids and water extracts 
of the flower are important components of the ancient herbal 
remedy  “Safi”  (cleansing  agent),  used  safely  for  centuries  in 
Unani medicine (practiced in South Asia and founded on tradi-
tional  Graeco-Arabic  medicine)  in  Pakistan.4  Indeed,  various 
medicinal  properties  have  been  associated  with  this  species.  
R. damascena is an important ingredient in the food and cosmet-
ics industries in addition to traditional medicine.

 HISTORY

Originally found in the Middle East (the name “Damask Rose” 
is based on Damascus, Syria), R. damascena was introduced to 
Europe during the Crusades.5 It is no longer found in the wild, 
but  is  cultivated  for  rose  oil  in  several  countries,  primarily 
Bulgaria, Turkey, France, Morocco, Iran, and India.6 Rosewater 
has been used for centuries in religious rites and for physical, 
emotional, and spiritual purposes or healing. Thriving rosewa-
ter industries are found in Bulgaria, France, and Iran.3,7 The first 
use  of  rosewater  has  been  attributed  to  the  Persian  doctor 
Avicenna  (an  anglicized  version  of  Ibn  Sina)  in  the  early  
11th  century.8  The  use  of  R.  damascena  in  Unani  medicine, 

particularly as an anti-inflammatory agent, has a long history 
and includes gastrointestinal and cardiovascular indications.3,9  
R. damascena is also used for culinary purposes in several global 
cuisines. The climatic conditions of the northern Indian state of 
Uttarakhand have been found to be especially conducive to the 
production of rose oil meeting international standards.10

Recent History
Some  of  the  earliest  work  to  indicate  the  potential  health  and 
dermatologic  benefits  of  R.  damascena  dates  to  the  late  1970s. 
Murphy and Hamilton isolated a strain of cultured cells of the 
plant that displayed strong resistance to ultraviolet (UV) radia-
tion  (254  nm)  and  generated  a  greater  amount  of  polyphenols 
(primarily flavonoids) during the latter stages of culture growth. 
They found that this UV resistance was associated with increased 
polyphenolic  production.11  Flavonoids  are  the  most  prevalent 
and frequently studied polyphenols, which are the most abun-
dant source of antioxidants in the human diet, often linked to a 
preventive role in cancer and heart disease as well as cutaneous 
signs  of  aging.12–17  These  phenolics,  found  throughout  the  
R.  damascena  plant  (i.e.,  fruits,  seeds,  leaves,  roots,  bark)  are 
thought  to  be  the  main  constituents  responsible  for  the  strong 
antioxidant activity exhibited by extracts of the plant (Table 48-1).3

 CHEMISTRY

The rosewater and rose oil produced in mountainous northern 
India  contains  phenyl  ethyl  alcohol  as  a  major  constituent, 
with geraniol and citronellol appearing in many cultivars, as 
well as nerol nonadecane, heneicosane, and linalool.10 Other 
chemical components include farnesol and stearpoten.

Ulusoy  et  al.  examined  the  phenolic  content  as  well  as  the 
antioxidant  and  antibacterial  activities  of  R.  damascena  flower 
extracts absolute, essential oil, and hydrosol. The major constituents 
of rose essential oil and hydrosol (>55 percent) were found to be 
citronellol and geraniol, with phenylethyl alcohol (78.83 percent) 
identified as the primary component of rose absolute. The levels 
of key antioxidants (i.e., b -carotene, tocopherol, and g -tocopherol)  
were found to be higher in rose absolute as compared to hydrosol 
and rose oil. High levels of phenolics were noted in rose absolute 
and the essential oil, which exhibited potent antibacterial activity 
against  Escherichia  coli,  Pseudomonas  aeruginosa,  Bacillus  subtilis, 
Staphylococcus  aureus,  Chromobacterium  violaceum,  and  Erwinia 
carotovora.2  Hydrosols,  also  referred  to  as  floral  waters,  flower 
waters, hydroflorates, or distillates, are derived from steam dis-
tilling plant materials.

TABLE 48-1
Pros and Cons of Rosa Damascena

Pros
Promising data to support antibacterial, 

antioxidant reputation

Wide range of medical benefits reported

Con
Insufficient research to establish potential 
in the dermatologic armamentarium

 
146 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

 ORAL USES

R. damascena is edible and is found as a spice in the cuisine of 
Morocco, Turkey, and Iran.

 TOPICAL USES

In 2003, Tabrizi et al. assessed various extracts of R. damascena 
for its capacity as an antisolar agent in absorbing UV. The pres-
ence of flavonoids as the primary constituents of the extracts 
was verified before investigators identified the UV absorption 
spectra, with all three extracts found to be effective in absorb-
ing UV in the 200 to 400 nm range. The team then incorporated 
the extracts into oil-in-water creams at 5 and 8 percent concen-
trations. The hydroalcoholic extract provided the highest SPF, 
but  the  cream  containing  5  percent  ether  extract  yielded  the 
most  satisfactory  appearance  and  stability.  The  investigators 
ascribed the UV absorption ability of the extracts to the flavo-
noid constituents and suggested that other synthetic antisolar 
compounds might be added to R. damascena extracts to enhance 
overall  product  efficacy.  In  addition,  they  concluded  that  the 
presence  of  R.  damascena  in  the  tested  formulation  would 
confer  cooling,  soothing,  and  anti-inflammatory  properties 
suitable for a general skin care product as well as a photopro-
tective agent.7

 SAFETY ISSUES

R. damascena has a long history of safe use in traditional medi-
cine and cuisine. Although the sample size is small, there are no 
significant  reports  of  adverse  effects  from  products  with  
R. damascena as a main active ingredient. 

 ENVIRONMENTAL IMPACT

Like any botanical crop cultivated for industrial uses, the indus-
try itself exacts an environmental toll, but R. damascena is con-
sidered a friendly-to-the environment rural crop.6

 FORMULATION CONSIDERATIONS

R. damascena has been formulated into various food products, 
including teas, in Korea.18 Rosewater, rose oil, and rose hips are 
the main products extracted and processed from this plant. Due 
to the low oil content in R. damascena and the dearth of natural 
and synthetic alternatives, the essential oil is one of the most 
expensive in the world, earning the epithet “fluid gold.”3,6

 USAGE CONSIDERATIONS

The author knows of no interactions with other ingredients.

 SIGNIFICANT BACKGROUND

Antioxidant Activity
In 2005, Schiber et al. extracted and characterized flavonol gly-
cosides  from  R.  damascena  petals  following  industrial  distilla-
tion for essential oil recovery. After analyzing 22 constituents, 
kaempferol and quercetin were the only flavonoids (specifically, 

flavonols)  detected,  with  kaempferol  compounds  accounting 
for 80 percent of the compounds measured. In noting the high 
flavonol  content  (approximately  16  g/kg  in  dry  weight),  the 
researchers concluded that R. damascena represents a promising 
source of natural antioxidants.19

In a late 2010 study using a reversed-phase high-performance 
liquid  chromatographic  (RP-HPLC)  method  to  simultaneously 
measure the flavonols, flavones, and phenolic acids as important 
compounds  in  various  fruits,  vegetables,  and  medicinal  plants,  
R.  damascena  was  identified  as  one  of  the  species,  along  with 
Solidago virgaurea, Ginkgo biloba, and Camellia sinensis (the source 
of green tea), as having the highest flavonoid content.17

Also in late 2010, Kalim et al. assessed the antioxidant activity 
of plants typically used in Unani medicine, of which the 10 dis-
playing  the  most  promising  effects,  including  R.  damascena,  an 
astringent used for cardiac health and as an anti-inflammatory and 
astringent  in  Unani,  were  identified  for  additional  analysis.  The 
total phenolic, flavonoid, and ascorbic acid contents were ascer-
tained  from  methanol  (50  percent)  extract  preparations  of  all  
10 species and researchers also evaluated the in vitro scavenging of 
reactive oxygen and nitrogen species and the ability of the plant 
extracts to prevent oxidative DNA harm. R. damascena was among 
seven of the extracts to display moderate antioxidant activity and 
one of three species found to potentially have significant preven-
tive activity against oxidative DNA damage as well as antioxidant 
activity.  The  investigators  concluded  that  R.  damascena,  Cleome 
icosandra, and Cyperus scariosus, all of which are commonly used 
in  Unani  medicine  and  reportedly  deliver  substantial  benefits  in 
the treatment of various human disorders, are potentially useful as 
natural antioxidants in pharmaceutical products.20 In 2012, Moein 
et al. investigated plants growing in Iran that are used for medicinal 
purposes and confirmed the antioxidant potency of R. damascena.21

Antibacterial Activity
In 2002, R. damascena was among eight essential oils studied for 
composition  and  antimicrobial  characteristics.  The  antibacte-
rial activities of the aromatic extracts were ascertained by disk 
diffusion  testing.  Among  the  standard  test  bacterial  strains 
Escherichia coli, Staphylococcus aureus, and Pseudomonas aeruginosa, 
R.  damascena  demonstrated  antimicrobial  activity  against  
S. aureus.22 Recent work has provided additional evidence of its 
antibacterial activity. In 2010, Zu et al. tested 10 essential oils 
for antibacterial activity against Propionibacterium acnes as well 
as  in  vitro  toxicology  against  three  human  cancer  cell  lines. 
Among the essential oils tested, which included mint, ginger, 
lemon, grapefruit, jasmine, lavender, chamomile, thyme, rose 
(R.  damascena),  and  cinnamon,  thyme,  cinnamon,  and  rose 
exhibited the greatest antibacterial potency against P. acnes.23

The  antimicrobial  activity  of  R.  damascena  extract  has  been 
further  established  in  recent  tests.  In  a  study  published  in  the 
dental literature, the antimicrobial effects of     2 percent  R. damascena 
extract  were  compared  to  those  of  a  5.25  percent  sodium 
hypochlorite  (NaOCl)  and  2  percent  chlorhexidine  (CHX)  on 
endodontic pathogens, including Enterococcus faecalis, Actinomyces 
naeslundii, Porphyromonas gingivalis, Fusobacerium nucleatum, and 
Candida albicans. The minimum inhibitory concentrations (MIC) 
for R. damascena were lower than those for CHX except in the 
case of F. nucelatum; the MIC for R. damascena was lower than 
that for NaOCl for C. albicans and otherwise equal. In each case, 
test  microorganisms  were  destroyed  within  one  minute.  The 
researchers concluded that the botanical exhibited strong activity 
against gram-positive (E. faecalis, A. naeslundii, and C. albicans) as 
well as gram-negative (P. gingivalis and F. nucleatum) strains.24

 
Also, in a 2010 investigation of the antimicrobial activity and 
cytotoxicity  of  51  ethanol,  methanol,  aqueous,  butanol,  and 
n-hexane extracts of different parts of 14 plants all used in tradi-
tional medicine in Jordan, the highest activity (100 percent inhi-
bition)  reported  was  for  the  butanol  extract  of  R.  damascena 
against Salmonella typhimurium and Bacillus cereus. The aqueous 
extract  of  R.  damascena  was  also  active  against  C.  albicans.  In 
addition, the butanol and aqueous extracts of R. damascena sup-
pressed methicillin-resistant Staphylococcus aureus.25

Anxiolytic Activity
In a recent study on the relaxing effects of rose oil administered 
by transdermal absorption, 40 healthy volunteers were assessed 
based on autonomic parameters (i.e., blood pressure, breathing 
rate, blood oxygen saturation, pulse rate, and skin temperature) 
as  well  as  self-report  after  receiving  rose  oil  or  placebo. 
Olfactory stimulation was prevented through the use of breath-
ing  masks.  Significant  reductions  in  systolic  blood  pressure, 
breathing  rate,  and  blood  saturation  were  observed  as  com-
pared  to  placebo.  The  rose  oil  group  also  self-reported  as 
calmer, more relaxed, and less alert. The author suggested that 
this small study lends support for the use of rose oil in aroma-
therapy for the relief of stress and depression.26

In 2011, Hoseinpour et al. conducted a randomized, double-
blind,  placebo-controlled  two-week  study  in  50  patients  of  a  
R. damascena mouthwash to treat aphthous stomatitis (canker sores) 
based  on  the  reputed  anti-inflammatory  and  antinociceptive 
activity of the plant. The investigators found that by days 4 and 7, 
there  were  statistically  significant  differences  between  the  pla-
cebo and test groups according to all parameters (i.e., pain, size, 
and number of ulcers), with the R. damascena mouthwash show-
ing  greater  effectiveness  than  the  placebo.27  Rose  oil  is  one  of 
several popular anxiolytic essential oils used in aromatherapy.28

Other Activities
In  1996,  water  and  methanol  extracts  of  R.  damascena  were 
found to display moderate anti-HIV activity, with the pure com-
pounds quercetin and kaempferol playing an important role.29

More recently, in 2010, flavonoids isolated from R. damascena 
buds were demonstrated to hinder the activity of 3-hydroxy-
3-methylglutaryl-coenzyme  A  (HMG-CoA)  reductase  as  well 
as  angiotensin  I-converting  enzyme  (ACE),  suggesting  the 
potential for the herb to impart beneficial effects on the cardio-
vascular system.18

 CONCLUSION

The data that exist on R. damascena are interesting and suggest a 
wide range of medical benefits but do not yet establish its use in 
the  dermatologic  realm.  Much  more  research  is  necessary  to 
determine the potential efficacy of this botanical, particularly for 
its antioxidant and antimicrobial activities, in topical products.

REFERENCES

1.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

Medicine. Rochester, VT: Healing Arts Press; 2003:64.

2.  Ulusoy S, Bosgelmez-Tinaz G, Seçilmis¸-Canbay H. Tocopherol, 
carotene,  phenolic  contents  and  antibacterial  properties  of  rose 
essential oil, hydrosol and absolute. Curr Microbiol. 2009;59:554.
3.  Boskabady  MH,  Shafei  MN,  Saberi  Z,  et  al.  Pharmacological 

effects of rosa damascena. Iran J Basic Med Sci. 2011;14:295.

C H A P T E R  48  ■   R O S A   DA M A S C E N A  

147

4.  Mahmood N, Piacente S, Pizza C, et al. The anti-HIV activity and 
mechanisms  of  action  of  pure  compounds  isolated  from  Rosa 
damascena. Biochem Biophys Res Commun. 1996;229:73.

5.  Grieve M. A Modern Herbal. Vol 2. New York: Dover Publications; 

1971:684.

6.  Tsanaktsidis CG, Tamoutsidis E, Kasapidis G, et al. Preliminary 
results on attributes of distillation products of the rose rosa dama-
scena as a dynamic and friendly to the environment rural crop. 
ICESD. 2012;1:66.

7.  Tabrizi H, Mortazavi SA, Kamalinejad M. An in vitro evaluation 
of various Rosa damascene flower extracts as a natural antisolar 
agent. Int J Cosmet Sci. 2003;25:259.

8.  Ericksen M. Healing with Aromatherapy. New York: McGraw-Hill 

Professional; 2000:9.

9.  Zaidi SF, Muhammad JS, Shahryar S, et al. Anti-inflammatory and 
cytoprotective  effects  of  selected  Pakistani  medicinal  plants  in 
Helicobacter  pylori-infected  gastric  epithelial 
cells.  
 J Ethnopharmacol. 2012;141:403.

10.  Verma RS, Padalia RC, Chauhan A, et al. Volatile constituents of 
essential  oil  and  rose  water  of  damask  rose  (Rosa  damascena 
Mill.)  cultivars  from  North  Indian  hills.  Nat  Prod  Res. 
2011;25:1577.

11.  Murphy TM, Hamilton CM. A strain of Rosa damascene cultured 
cells resistant to ultraviolet light. Plant Physiol. 1979;64:936.
12.  Svobodvá  A,  Psotová  J,  Walterová  D.  Natural  phenolics  in  the 
prevention  of  UV-induced  skin  damage:  A  review.  Biomed  Pap 
Med Fac Univ Palacky Olomouc Czech Repub. 2003;147:137.

13.  Scalbert  A,  Williamson  G.  Dietary  intake  and  bioavailability  of 

polyphenols. J Nutr. 2000;130:2073S.

14.  Ross  JA,  Kasum  CM.  Dietary  flavonoids:  Bioavailability,  meta-

bolic effects, and safety. Annu Rev Nutr. 2002;22:19.

15.  Birt  DF,  Hendrich  S,  Wang  W.  Dietary  agents  in  cancer  preven-

tion: Flavonoids and isoflavonoids. Pharmacol Ther. 2001;90:157.

16.  Rechner AR, Spencer JP, Kuhnle G, et al. Novel biomarkers of the 
metabolism of caffeic acid derivatives in vivo. Free Radic Biol Med. 
2001;30:1213.

17.  Haghi  G,  Hatami  A.  Simultaneous  quantification  of  flavonoids 
and phenolic acids in plant materials by a newly developed iso-
cratic high-performance liquid chromatography approach. J Agric 
Food Chem. 2010;58:10812.

18.  Kwon EK, Lee DY, Lee H, et al. Flavonoids from the buds of Rosa 
damascena  inhibit  the  activity  of  3-hydroxy-3-methylglutaryl-
coenzyme  a  reductase  and  angiotensin  I-converting  enzyme.  
 J Agric Food Chem. 2010;58:882.

19.  Schiber A, Mihalev K, Berradini N, et al. Flavonol glycosides from 
distilled  petals  of  Rosa  damascene  Mill.  Z  Naturforsch  C. 
2005;60:379.

20.  Kalim MD, Bhattacharyya D, Banerjee A, et al. Oxidative DNA 
damage  preventive  activity  and  antioxidant  potential  of  plants 
used in Unani system of medicine. BMC Complement Altern Med. 
2010;10:77.

21.  Moein  S,  Moein  M,  Khoshnoud  MJ,  et  al.  In  vitro  antioxidant 
properties evaluation of 10 Iranian medicinal plants by different 
methods. Iran Red Crescent Med J. 2012;14:771.

22.  Aridogˇan BC, Baydar H, Kaya S, et al. Antimicrobial activity and 
chemical  composition  of  some  essential  oils.  Arch  Pharm  Res. 
2002;25:860.

23.  Zu Y, Yu H, Liang L, et al. Activities of ten essential oils towards 
Propionibacterium  acnes  and  PC-3,  A-549  and  MCF-7  cancer 
cells. Molecules. 2010;15:3200.

24.  Shokouhinejad N, Emaneini M, Aligholi M, et al. Antimicrobial 
effect of Rosa damascena extract on selected endodontic patho-
gens. J Calif Dent Assoc. 2010;38:123.

25.  Talib WH, Mahasneh AM. Antimicrobial, cytotoxicity and phy-
tochemical screening of Jordanian plants used in traditional medi-
cine. Molecules. 2010;15:1811.

26.  Hongratanaworakit T. Relaxing effect of rose oil on humans. Nat 

Prod Commun. 2009;4:291.

27.  Hoseinpour H, Peel SA, Rakhshandeh H, et al. Evaluation of Rosa 
damascena  mouthwash  in  the  treatment  of  recurrent  aphthous 
stomatitis:  a  randomized,  double-blinded,  placebo-controlled 
clinical trial. Quintessence Int. 2011;42:483.

28.  Setzer WN. Essential oils and anxiolytic aromatherapy. Nat Prod 

Commun. 2009;4:1305.

29.  Mahmood N, Piacente S, Pizza C, et al. The anti-HIV activity and 
mechanisms  of  action  of  pure  compounds  isolated  from  Rosa 
damascena. Biochem Biophys Res Commun. 1996;229:73.

 
148 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   4 9

Pycnogenol

Activities:

Antioxidant,  anti-inflammatory,  anticarcinogenic, 
photoprotective, antimicrobial

Important Chemical Components:

Flavonoids, primarily procyanidins (which are biopolymers 
of  catechin  and  epicatechin  subunits),1  taxifolin,2  and 
phenolic  acids  (i.e.,  ferulic,  caffeic,  p-hydroxybenzoic, 
vanillic, gallic, and protocatechuic acids)1,3–5

Origin Classification:

Pycnogenol  is  a  legal  trademark  for  a  process  of 
extracting flavonoids and other compounds from French 
maritime pine bark.6 Thus, its origin is  natural  but  the 
marketed  standardized  pine  bark  extract  product  is 
synthesized and processed in the laboratory.

Personal Care Category:

Anti-inflammatory, hydrating

Recommended  for  the  following  Baumann  Skin 
Types:

DRNT, DRNW, DRPW, DSNT, DSNW, DSPW, ORNT, 
ORNW, ORPW, OSNT, OSNW, and OSPW

 SOURCE

Growing  in  the  coastal  areas  of  southwest  France,  Pinus 
pinaster (previously known as Pinus maritima) is the source of 
the  procyanidin  (also  known  as  proanthocyanidin)-rich 
standardized extract Pycnogenol.7,8 Twenty years ago, it was 
found that procyanidol oligomers (PCOs) bind to elastic skin 
fibers  when  intradermally  injected  into  young  rabbits. 
Research showed that PCOs and (+) catechin (catechins are 
the fundamental antioxidant elements in green tea) bound to 
insoluble  elastin  significantly  decelerating  the  rate  of 
degradation engendered by elastases, which is characteristic 
of  inflammatory  processes.9  Since  this  time,  a  small  but 
cogent  body  of  research  has  evolved  regarding  PCOs  
(now referred to as oligomeric proanthocyanidins, or OPCs), 
particularly  in  grape  seed  extract  and  French  maritime  pine 
bark  extract.  OPCs,  usually  referred  to  simply  as  proantho-
cyanidins,  are  the  most  potent  antioxidant  free-radical 
scavengers yet identified. Great varieties of fruits, vegetables, 
nuts, seeds, flowers, and bark, particularly, grape seed, grape 
skin,  bilberry,  cranberry,  black  currant,  green  tea,  black  tea, 
blueberry, blackberry, strawberry, black cherry, red wine, red 
cabbage,  and  red  apple  skins  are  the  sources  of  widely 
available  OPCs.10  Grape  seed  and  pine  bark  are  the  most 
commercially  viable  sources.  P.  pinaster,  like  the  extract  of 
grape  seed,  is  emerging  as  a  versatile  component  in  the 
medical armamentarium against several diseases, and appears 
to offer potential dermatologic applications.

 HISTORY

“Pycnogenols,” based on the ancient Greek puknos (“condensed”) 
and genos (“class, family”), is a term originally coined to describe 
a class of polyphenols (flavan-3-ol derivatives), but “Pycnogenol” 
has come to refer to the patented name for a proprietary mix of 
procyanidins extracted from French maritime pine bark, Pinus 
pinaster,  standardized,  and  sold  primarily  as  a  nutritional 
supplement.3,11 The use of pine bark itself dates back to the 4th 
century  BCE  and  records  showing  that  Hippocrates 
recommended it to treat inflammation.3

Native Americans are said to have been well aware of pine 
bark’s medicinal benefits for centuries, as far back as the 1500s, 
and reportedly used pine bark (thought to be white pine) to treat 
scurvy during the winter in Canada in 1535.12–14 It has been used 
as  a  health  supplement  since  1853.15  Today,  Pycnogenol 
continues to be used worldwide as a nutritional supplement and 
to  treat  various  conditions  including  chronic  inflammation, 
circulatory  dysfunction,  and  several  psychophysiological 
impairments.7  It  has  also  been  shown  to  be  effective  treating 
mild-to-moderate asthma and inflammatory bowel disorders,2,16 
and is thought to be useful in various other conditions, including 
diabetes, attention deficit hyperactivity disorder, systemic lupus 
erythematosus (as a second-tier therapy for inflammation), and 
some cancers.1,17 In addition, the extract has been shown to be 
effective in inhibiting the growth of several different prokaryotic 
(gram-positive  and  gram-negative)  and  eukaryotic  (yeast  and 
fungi) microorganisms.18

 CHEMISTRY

Proanthocyanidins are polyphenolic bioflavonoids believed to 
confer a vast array of biological, pharmacological, chemopro-
tective, and antioxidant activity.19 Between 65 and 75 percent 
of  Pycnogenol  is  made  up  of  procyanidins  composed  of 
catechin and epicatechin subunits with varying chain lengths.7 
Polyphenolic monomers, phenolic or cinnamic acids, and their 
glycosides  are  additional  constituents.7  These  compounds 
acting  synergistically  are  thought  to  have  the  capacity  to 
stabilize collagen and elastin, by neutralizing collagenase and 
elastase,9,15 which would improve the elasticity, flexibility, and 
appearance of skin, and protect the skin from ultraviolet (UV) B 
damage. The constituents of Pycnogenol are considered to be 
highly bioavailable.3,7

 ORAL USES

In  2004,  Segger  et  al.  conducted  a  double-blind,  placebo-
controlled trial in 62 women between the ages of 45 and 73 years 
to evaluate the efficacy of a proprietary oral supplement (Evelle) 
in  treating  skin  roughness  and  elasticity.  Pycnogenol  is  a  key 
active  ingredient  of  the  formulation  along  with  amino  acids, 
blueberry extract, carotenoids, glycosaminoglycans, selenium, 
vitamins C and E, and zinc. The investigators used an optical 

 
cutometer  to  measure  skin  elasticity,  which  was  found  to  be 
statistically significantly greater (by 9 percent) as compared to 
placebo  after  six  weeks  of  treatment.  After  12  weeks  of 
treatment,  skin  roughness,  assessed  using  three-dimensional 
microtopography  imaging,  was  statistically  significantly 
reduced  by  6  percent  compared  with  the  control  group.  The 
authors concluded that the oral supplement Evelle displays the 
potential to reduce the signs of skin aging.20

Pycnogenol  has  also  been  proposed  as  one  among  several 
nutritional supplements as part of a new therapeutic approach to 
a  collagen  tissue  disorder  known  as  Ehlers–Danlos  syndrome 
classic  type,  including  cutaneous  and  vascular  manifestations 
such as easy bruising, bleeding, varicose veins, and inadequate 
tissue healing.21

A daily supplement dosage of 100 mg of Pycnogenol® has also 
recently been found to ease early symptoms of menopause, as 
shown in an eight-week study of 38 women. Hot flashes, night 
sweats,  mood  swings,  irregular  periods,  loss  of  libido,  and 
vaginal  dryness  subsided  in  the  treatment  group,  with  no 
changes  experienced  by  the  control  group.  The  investigators 
concluded  that  Pycnogenol  significantly  diminished  major  and 
minor symptoms of early menopause in the women studied due, 
in  part,  to  the  reduced  oxidative  stress  imparted  by  the 
antioxidant.22

The  efficacy  of  oral  Pycnogenol  for  the  treatment  and 
management of chronic venous insufficiency (CVI) and venous 
microangiopathy  has  also  been  suggested  by  a  series  of 
prospective controlled trials by Cesarone et al., with the extract 
rapidly limiting edema, cramps, and the feeling of heavy legs.2,23,24

 TOPICAL USES

Pycnogenol  is  known  to  have  potent  antioxidant,  anti-
inflammatory,  and  anticarcinogenic  properties.25–27  In  fact,  in  a 
2007  study  comparing  the  total  oxygen  radical  scavenging 
capacity of 11 different phytochemicals using the oxygen radical 
absorbance  capacity  (ORAC)  assay  and  the  total  oxyradical 
scavenging capacity (TOSC) assay, quercetin, Pycnogenol, grape 
skin  extract,  and  green  tea  polyphenols  were  found  to  exhibit 
the greatest antioxidant activity.28 Significantly, Pycnogenol also 
reportedly  confers  cardiovascular  benefits,  exhibits  strong  free 
radical-scavenging against reactive oxygen and nitrogen species, 
and plays a role in the cellular antioxidant network, as supported 
by its demonstrated capacity to regenerate the ascorbyl radical 
and  to  protect  endogenous  vitamin  E  and  glutathione  from 
oxidative stress (Table 49-1).3

TABLE 49-1
Pros and Cons of Pycnogenol

Pros
Potent antioxidant

Protects vitamin E from oxidation

Recycles oxidized vitamin C
Highly bioavailable
Reportedly 50 times more potent than 

vitamin E and 30 times more potent than 
vitamin C15

No reported cases of contact dermatitis

Cons
Brief history of investigation and use of 

topical formulations

“Pycnogenol” is a trademarked name for a 
particular formulation of French pine bark
More data on French pine bark are needed

C H A P T E R  49  ■   P y C N O G E N O L  

149

Most research on Pycnogenol has been conducted in vitro using 
cell cultures or in animal models. Some small studies on the topical 
application  of  this  potent  antioxidant  have  been  performed  on 
humans, however. In a study evaluating the capacity of pine bark 
extract to protect human skin against erythema induced by solar 
radiation, 21 fair-skinned volunteers were given oral supplementa-
tion  of  Pycnogenol.  During  supplementation,  the  UV  radiation 
(UVR) level necessary to reach one minimal erythema dose (MED) 
was significantly elevated, suggesting that oral pine bark extract 
supplementation  mitigates  the  effects  of  UVR  on  the  skin, 
lowering  erythema.  The  investigators  noted  that  the  extract 
inhibited nuclear factor-κB-dependent gene expression, a marker 
of the UV-induced proinflammatory response in HaCaT cells.4

The  efficacy  of  Pycnogenol  in  protecting  against  UVR 
prompted a 30-day clinical trial of 30 women with melasma in 
which  patients  were  given  one  25  mg  tablet  of  Pycnogenol  at 
each meal, three times daily. Investigators found that the average 
surface  area  of  melasma  significantly  decreased,  showing 
Pycnogenol  to  be  an  effective  and  safe  treatment  for  this 
condition.26 This dynamic OPC is also said to exhibit potential or 
actual  efficacy  in  treating  other  dermatologic  conditions.  Pine 
bark extract has been found to downregulate calgranulin A and B 
genes,  both  of  which  are  characteristically  upregulated  in 
psoriasis and various dermatoses.13

In  a  study  of  another  application  of  pine  bark  extract,  
40 patients with diagnosed CVI were treated daily in an open, 
controlled  comparative  study  with  either  600  mg  Venostasin 
(horse chestnut seed extract) or 360 mg Pycnogenol over a four-
week  period  (see  Chapter  74,  Horse  Chestnut).  Pycnogenol 
significantly  reduced  lower  limb  circumference,  as  well  as 
cholesterol and low-density lipoprotein values though not high-
density  lipoproteins,  and  significantly  improved  subjective 
symptoms.  Both  treatments  were  tolerated  equally  well,  but 
Venostasin  had  only  marginal  effects  on  the  lower  limbs  and 
overall symptoms and no effect on lipid values. Investigators found 
that for the treatment of CVI, Pycnogenol showed greater efficacy 
than Venostasin, a well-regarded therapy for this indication.29

In 2012, Marini et al. conducted a 12-week investigation to 
ascertain  whether  nutritional  supplementation  with 
Pycnogenol®  could  improve  the  cosmetic  appearance  of  
20 healthy postmenopausal women. The skin condition of the 
volunteers was evaluated before, during, and after supplemen-
tation using corneometry, cutometry, visioscan and ultrasound 
analyses as well as biopsies and subsequent polymerase chain 
reaction (PCR) analyses. The investigators found that the well-
tolerated supplementation led to improved skin hydration and 
elasticity, a manifestation that was marked in the subjects who 
initially presented with dry skin. They also noted a significant 
increase in the mRNA expression of hyaluronic acid synthase-1 
(HAS-1), a key enzyme involved in hyaluronic acid production, 
as  well  as  salient  increases  in  gene  expression  involved  in 
collagen  synthesis,  to  which  the  researchers  attributed  the 
clinical improvements. The investigators concluded that their 
results, including the first molecular evidence of the cutaneous 
benefits  of  improved  hydration  and  elasticity,  suggest  the 
potential  for  Pycnogenol  supplementation  to  mitigate  the 
clinical signs of aging skin.30

 SAFETY ISSUES

Oral  Pycnogenol  is  generally  recognized  as  safe  (GRAS)  for 
consumption  at  prescribed  doses  and  is  not  associated  with 
any  adverse  side  effects.24,26  It  is  included  in  many  dietary 
supplements and multivitamins.31

 
150 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

 ENVIRONMENTAL IMPACT

The  wood  industry  considered  pine  bark  an  inconvenient 
residue with limited practical use until recent years; now it is 
used as a vegetal substrate and combustible.7 P. pinaster is a fast-
growing evergreen tree widely planted for timber (and cut after 
30–50 years of cultivation) in its native Mediterranean climates 
and for use as a nutritional source.1 It is an invasive species in 
South  Africa,  where  it  was  introduced  in  the  late  1600s.  
P. pinaster is cultivated in large monocultures, which environ-
mentalists criticize for limiting biodiversity.

 FORMULATION CONSIDERATIONS

The  quality  of  aqueous  pine  bark  extract  is  specified  in  the 
United States Pharmacopeia (USP 28).7,31

 USAGE CONSIDERATIONS

Pycnogenol is thought to be unique in that it displays greater 
biologic  effects  as  a  whole  compound  or  mixture  than  its 
purified constituents do individually, which suggests synergistic 
interaction among its components.3,7

 SIGNIFICANT BACKGROUND

In Vitro Studies
In  vitro  studies  of  Pycnogenol  have  indicated  a  wide  range  of 
benefits  imparted  by  this  botanical  extract.  Research  has 
demonstrated  that  Pycnogenol  is  significantly  more  potent 
than  vitamins  C  and  E  and  exhibits  the  capacity  to  recycle 
vitamin  C,  regenerate  vitamin  E  (as  does  vitamin  C),  and 
facilitate  the  activity  of  endogenous  antioxidant  enzymes.26 
Protective effects against UV radiation have also been associated 
with Pycnogenol.26

The known antioxidant and anti-inflammatory characteristics 
of Pycnogenol spurred the study of the interaction, and related 
molecular  mechanisms,  of  T  cells  with  human  keratinocytes 
after  activation  with  interferon  (IFN)-γ.  Various  pretreatment 
regimens of HaCaT cells with Pycnogenol significantly inhibited 
IFN-γ-induced adherence of T cells to HaCaT cells as well as IFN- 
γ-induced  expression  of  ICAM-1  expression  in  such  cells, 
suggesting Pycnogenol’s potential as a treatment component for 
inflammatory skin disorders.27

In  an  in  vitro  study  aimed  at  identifying  natural  compounds 
capable of stimulating human growth hormone (HGH) as a via-
ble replacement for the successful but problematic recombinant 
human growth hormone (rHGH), equal amounts of L-arginine, 
L-lysine, aged garlic extract, S-allyl cysteine and Pycnogenol sig-
nificantly raised the secretion of HGH.32 This potential applica-
tion has antiaging implications given the association of decreased 
levels of HGH and increased signs of aging, including the thin-
ning of the skin.

Animal Studies
In 1997, Blazsó et al. showed that topically applied Pycnogenol 
on  the  shaved  backs  of  rats  delivered  protection  from  UVB-
induced erythema.33 In 2004, Sime and Reeve exposed Skh:hr 
hairless  mice  to  solar-simulated  ultraviolet  radiation  (SSUVR) 
and  after  irradiation  topically  applied  lotions  containing 

Pycnogenol.  Dose-dependent  reductions  in  the  inflammatory 
sunburn  reaction  and  immunosuppression  (as  manifested  by 
suppression  of  contact  hypersensitivity  reactions)  were 
observed  as  a  result  of  Pycnogenol  treatment.  Tumor  forma-
tion,  induced  by  chronic  exposure  to  SSUVR  five  days/week 
for 10 weeks, was delayed in mice treated with Pycnogenol and 
tumor prevalence was significantly reduced (from 100 percent 
of control mice to 85 percent of 0.2 percent Pycnogenol-treated 
mice)  as  was  tumor  multiplicity.  The  investigators  concluded 
that topical Pycnogenol exhibits potential as a photoprotective 
complement  to  sunscreens,  clearly  showing  biologic  activity 
when applied after exposure to UV radiation.25

In 2009, Ince et al. demonstrated the strong anti-inflammatory 
properties of Pycnogenol as well as Pinus brutia (Turkish pine) in 
a rat model of carageenan-induced inflammation, with intraperi-
toneal  administration  of  each  dose-dependently  suppressing 
paw swelling.14

Earlier that year, in a study on the effects of tobacco smoke and 
UV light radiation on murine skin, Pavlou et al. also considered the 
potential  protective  effects  conferred  by  Pycnogenol  and  found 
that the potent antioxidant appeared to protect male and female 
hairless SKH-2 mouse skin from squamous cell carcinoma induced 
by exposure to cigarette smoke and UV radiation.34

Pycnogenol was also a key constituent in an oral antioxidant 
mixture that has shown promising dermatologic results. In 2007, 
Cho  et  al.  investigated  the  effects  on  UVB-induced  wrinkle 
formation in female SKH-1 hairless mice of an orally adminis-
tered  antioxidant  compound  composed  of  vitamins  C  and  E, 
Pycnogenol, and evening primrose oil. In addition, the researchers 
also  examined  the  potential  molecular  mechanisms  of 
photoprotection  against  UVB  damage.  After  10  weeks  of  oral 
administration  of  the  antioxidant  solution  or  a  vehicle  control 
and thrice weekly UVB irradiation, wrinkle formation was found 
to  be  significantly  decreased  in  mice  given  the  antioxidant 
cocktail.  Further,  significant  declines  in  epidermal  thickness, 
UVB-induced hyperplasia, acanthosis, and hyperkeratosis were 
observed. The investigators concluded that the significant inhibi-
tion  of  UVB-induced  wrinkle  formation  rendered  by  the  oral 
antioxidant  mixture  occurred  by  virtue  of  the  antioxidants 
suppressing  matrix  metalloproteinase  activity  spurred  by  UVB 
exposure while bolstering collagen production.35

In addition, in 2012, Lee et al. showed that topical application 
of  pine  bark  extract  imparted  protection  against  hexavalent 
chromium-induced  dermatotoxicity  in  rats,  significantly  and 
dose-dependently  reducing  the  incidence  and  severity  of 
cutaneous irritation and histopathological lesions caused by the 
heavy  metal  found  commonly  in  the  environment.  Treatment 
with the extract also lowered malondialdehyde concentrations 
and augmented catalase and glutathione-S-transferase activity in 
skin tissues. The investigators concluded that pine bark extract is 
a  viable  agent  for  the  protection  against  the  formation  of 
oxidative stress-induced dermal lesions.31

In a 2013 in vivo comparison of Pycnogenol and P. brutia bark 
extract  in  an  incision  wound  model  in  rats,  both  topical 
formulations were found to inhibit lipid peroxidation, increase 
vascularization, and reduce necrotic areas, though the wound-
healing  activity  of  the  P.  brutia  extract  was  found  to  be  more 
substantial, as it significantly accelerated wound healing.36

 CONCLUSION

Though the body of research is not exhaustive, extant evidence 
suggests  that  pine  bark  extract  confers  significant  beneficial 
biological effects. In particular, research indicates that pine bark 

 
extract  possesses  notable  antioxidant,  anti-inflammatory, 
photoprotective,  and  anticarcinogenic  capacity.  In  addition, 
several authors suggest that OPCs inhibit enzymes involved in 
cutaneous  breakdown,  that  is,  collagenase,  elastase,  and 
hyaluronidase.  Pine  bark  extract  might  not  have  the  same 
media buzz as its fellow proanthocyanidin grape seed extract, 
but current research provides just as much reason for optimism. 
That said, the efficacy of oral pine bark extract is much more 
firmly  established  than  that  of  topical  formulations.  Much 
more research is necessary to evaluate the current limited range 
of topical products and to determine the viability of translating 
promising  laboratory  findings  into  effective  and  safe  topical 
clinical and over-the-counter products.

REFERENCES

1.  Rohdewald P. A review of the French maritime pine bark extract 
(Pycnogenol), a herbal medication with a diverse clinical pharma-
cology. Int J Clin Pharmacol Ther. 2002;40:158.

2.  Cesarone  MR,  Belcaro  G,  Rohdewald  P,  et  al.  Comparison  of 
Pycnogenol and Daflon in treating chronic venous insufficiency: 
A  prospective,  controlled  study.  Clin  Appl  Thromb  Hemost. 
2006;12:205.

3.  Packer L, Rimbach G, Virgili F. Antioxidant activity and biologic 
properties  of  a  procyanidin-rich  extract  from  pine  (Pinus 
maritime) bark, pycnogenol. Free Radic Biol Med. 1999;27:704.
4.  Saliou  C,  Rimbach  G,  Moini  H,  et  al.  Solar  ultraviolet-induced 
erythema  in  human  skin  and  nuclear  factor-kappa-B-dependent 
gene  expression  in  keratinocytes  are  modulated  by  a  French 
maritime pine bark extract. Free Radic Biol Med. 2001;30:154.
5.  Svobodová A, Psotová J, Walterová D. Natural phenolics in the 
prevention  of  UV-induced  skin  damage:  A  review.  Biomed  Pap 
Med Fac Univ Palacky Olomouc Czech Repub. 2003;147:137.

6.  Hoffmann  D.  The  endocrine  system.  In:  Medical  Herbalism:  The 
Science and Practice of Herbal Medicine. Rochester, VT: Healing Arts 
Press; 2003:13.

7.  D’Andrea G. Pycnogenol: A blend of procyanidins with multifac-

eted therapeutic applications? Fitoterapia. 2010;81:724.

8.  Baumann  L.  How  to  prevent  photoaging?  J  Invest  Dermatol. 

2005;125:xii.

9.  Tixier JM, Godeau G, Robert AM, et al. Evidence by in vivo and 
in  vitro  studies  that  binding  of  pycnogenols  to  elastin  affect  its 
rate of degradation by elastases. Biochem Pharmacol. 1984;33:3933.
10.  Bagchi D, Bagchi M, Stohs SJ, et al. Free radicals and grape seed 
proanthocyanidin  extract:  Importance  in  human  health  and 
disease prevention. Toxicology. 2000;148:187.

11.  Masquelier J, Michaud J, Laparra J, et al. Flavonoids and pycnog-

enols. Int J Vitam Nutr Res. 1979;49:307.

12.  Chandler  RF,  Freeman  L,  Hooper  SN.  Herbal  remedies  for  the 

Maritime Indians. J Ethnopharmacol. 1979;1:49.

13.  Rihn  B,  Saliou  C,  Bottin  MC,  et  al.  From  ancient  remedies  to 
modern  therapeutics:  Pine  bark  uses  in  skin  disorders  revisited. 
Phytother Res. 2001;15:76.

14.  Ince I, Yesil-Celiktas O, Karabay-Yavasoglu NU, et al. Effects of 
Pinus  brutia  bark  extract  and  Pycnogenol  in  a  rat  model  of 
carrageenan induced inflammation. Phytomedicine. 2009;16:1101.

15.  Rona  C,  Vailati  F,  Berardesca  E.  The  cosmetic  treatment  of 

wrinkles. J Cosmet Dermatol. 2004;3:26.

16.  Lau BH, Riesen SK, Truong KP, et al. Pycnogenol as an adjunct in 
the management of childhood asthma. J Asthma. 2004;41:825.

C H A P T E R  49  ■   P y C N O G E N O L  

151

17.  Stefanescu M, Matache C, Onu A, et al. Pycnogenol efficacy in 
the treatment of systemic lupus erythematosus patients. Phytother 
Res. 2001;15:698.

18.  Torras MA, Faura CA, Schönlau F, et al. Antimicrobial activity of 

pycnogenol. Phytother Res. 2005;19:647.

19.  Bagchi D, Garg A, Krohn RL, et al. Oxygen free radical scaveng-
ing abilities of vitamins C and E, and a grape seed proanthocya-
nidin  extract  in  vitro.  Res  Commun  Mol  Pathol  Pharmacol. 
1997;95:179.

20.  Segger D, Schönlau F. Supplementation with Evelle improves skin 
smoothness  and  elasticity  in  a  double-blind,  placebo-controlled 
study with 62 women. J Dermatolog Treat. 2004;15:222.

21.  Mantle D, Wilkins RM, Preedy V. A novel therapeutic strategy for 
Ehlers–Danlos  syndrome  based  on  nutritional  supplements.  
Med Hypotheses. 2005;64:279.

22.  Errichi  S,  Bottari  A,  Belcaro  G,  et  al.  Supplementation  with 
Pycnogenol®  improves  signs  and  symptoms  of  menopausal 
transition. Panminerva Med. 2011;53:65.

23.  Cesarone  MR,  Belcaro  G,  Rohdewald  P,  et  al.  Rapid  relief  of 
signs/symptoms  in  chronic  venous  microangiopathy  with 
pycnogenol:  A  prospective,  controlled  study.  Angiology. 
2006;57:569.

24.  Cesarone  MR,  Belcaro  G,  Rohdewald  P,  et  al.  Improvement  of 
diabetic  microangiopathy  with  pycnogenol:  A  prospective, 
controlled study. Angiology. 2006;57:431.

25.  Sime  S,  Reeve  VE.  Protection  from  inflammation,  immunosup-
pression and carcinogenesis induced by UV radiation in mice by 
topical Pycnogenol. Photochem Photobiol. 2004;79:193.

26.  Ni Z, Mu Y, Gulati O. Treatment of melasma with pycnogenol. 

Phytother Res. 2002;16:567.

27.  Bito T, Roy S, Sen CK, et al. Pine bark extract pycnogenol down-
regulates  IFN-gamma-induced  adhesion  of  T  cells  to  human 
keratinocytes  by  inhibiting  inducible  ICAM-1  expression.  Free 
Radic Biol Med. 2000;28:219.

28.  Tomer  DP,  McLeman  LD,  Ohmine  S,  et  al.  Comparison  of  the 
total oxyradical scavenging capacity and oxygen radical absorb-
ance capacity antioxidant assays. J Med Food. 2007;10:337.

29.  Koch  R.  Comparative  study  of  Venostasin  and  Pycnogenol  in 
chronic venous insufficiency. Phytother Res. 2002;16(Suppl 1):S1.
30.  Marini A, Grether-Beck S, Jaenicke T, et al. Pycnogenol® effects 
on  skin  elasticity  and  hydration  coincide  with  increased  gene 
expressions  of  collagen  type  I  and  hyaluronic  acid  synthase  in 
women. Skin Pharmacol Physiol. 2012;25:86.

31.  Lee  IC,  Kim  SH,  Shin  IS,  et  al.  Protective  effects  of  pine  bark 
extract on hexavalent chromium-induced dermatotoxicity in rats. 
Phytother Res. 2012;26:1534.

32.  Buz’Zard AR, Peng Q, Lau BH. Kyolic and Pycnogenol increase 
human  growth  hormone  secretion  in  genetically-engineered 
keratinocytes. Growth Horm IGF Res. 2002;12:34.

33.  Blazsó G, Gábor M, Rohdewald P. Antiinflammatory activities of 
procyanidin-containing extracts from Pinus pinaster Ait. after oral 
and cutaneous application. Pharmazie. 1997;52:380.

34.  Pavlou P, Rallis M, Deliconstantinos G, et al. In-vivo data on the 
influence of tobacco smoke and UV light on murine skin. Toxicol 
Ind Health. 2009;25:231.

35.  Cho HS, Lee MH, Lee JW, et al. Anti-wrinkling effects of the mix-
ture of vitamin C, vitamin E, pycnogenol and evening primrose 
oil, and molecular mechanisms on hairless mouse skin caused by 
chronic  ultraviolet  B  irradiation.  Photodermatol  Photoimmunol 
Photomed. 2007;23:155.

36.  Cetin  EO,  Yesil-Celiktas  O,  Cavusoglu  T,  et  al.  Incision  wound 
healing activity of pine bark extract containing topical formula-
tions: A study with histopathological and biochemical analyses in 
albino rats. Pharmazie. 2013;68:75.

 
152 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   5 0

Resveratrol

Activities:

Antioxidant, antibacterial, anticancer, anti-inflammatory, 
antitumorigenic, antityrosinase, cardioprotective

Important Chemical Components:
Also  known  as  trans-3,5,4′ ,-trihydroxystilbene,  or  
3, 4′, 5-stilbenetriol

Origin Classification:

Resveratrol  is  natural  and  found  in  approximately  
70  plants,  including  many  plant  foods.  It  can  also  be 
synthesized chemically.

Personal Care Category:

Antiaging, anticancer

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW, DRPW, DSNW, DSPW, ORNW, ORPW, OSNW, 
and OSPW

 SOURCE

Resveratrol  (trans-3,5,4′-trihydroxystilbene),  a  polyphenolic 
phytoalexin synthesized in nearly 70 species and found notably 
in  the  skin  and  seeds  of  grapes,  berries  (e.g.,  blueberries, 
cranberries,  mulberries,  bilberries,  lingberries,  partridgeberries, 
sparkleberries, and deerberries), peanuts (in the nonedible as well 
as edible parts of the plant), red wine, purple grape juice, jackfruit, 
pomegranate,  eucalyptus,  the  roots  of  Polygonum  cuspidatum 
(Japanese  knotweed,  known  as  Ko-jo-kon  in  Japanese),  scots  
pine, spruce, corn lily, gnetum, and butterfly orchid tree, displays 
a wide range of biological and pharmacological properties.1–13 It is 
particularly abundant in the skin and seeds of Vitis vinifera, known 
as the grapevine, which is native to southern Europe and western 
Asia.14 P. cuspidatum is used in traditional Chinese and Japanese 
medicine to treat dermatitis, among other conditions.15

Studies  have  shown  that  resveratrol  possesses  potent  anti-
oxidant,  antiproliferative,  and  anti-inflammatory  characteris-
tics (Table 50-1).15–18 Specifically, in vitro and in vivo studies have 
shown that resveratrol exerts chemopreventive and antiprolif-
erative activity against various cancers,  including  skin  cancer, 
by suppressing cellular events associated with tumor initiation, 

TABLE 50-1
Pros and Cons of Resveratrol

Pros
Wide-ranging biological and pharmacological 

Cons
Poor bioavailability28

properties

Potent anticancer properties demonstrated 

More clinical evidence of topical efficacy is 

in preclinical studies

needed

promotion,  and  progression  and  triggering  apoptosis  in  such 
tumor cells.10,19,20

 HISTORY

Vitis vinifera, the primary source of resveratrol (particularly in 
the form of red wine), has been used since antiquity. The use 
of  grapevine  or  grapeseed  as  food  is  believed  to  predate 
recorded  history  and  its  use  for  wine  has  been  traced  back 
4,500  years  to  ancient  Egypt.17  Resveratrol  itself  was  first 
identified  from  the  roots  of  Veratrum  grandiflorum  (white 
hellebore),  though,  in  1940.21–24  The  so-called  “French 
paradox,”  the  phenomenon  identified  in  the  early  1990s 
indicating  that  the  low  rate  of  heart  disease  seen  in  France 
despite a rich diet including regular consumption of red wine, 
has been partially attributed to the antioxidant properties of 
the resveratrol found in red wine and prompted great interest 
in the compound.5,13,25–28 Indeed, resveratrol has been shown 
in  several  in  vitro  and  in  vivo  models  to  have  the  capacity  to 
mitigate  damage  in  heart  ischemia  reperfusion  as  well  as 
brain ischemia/reperfusion in rodent models.29

Research  on  resveratrol  really  exploded  after  a  seminal 
report in the journal Science in 1997 suggesting chemopreven-
tive properties. In that study, purified resveratrol was found to 
exhibit  major  inhibitory  activity  against  cancer  initiation, 
promotion,  and  progression.  Specifically,  its  antioxidant  and 
antimutagenic  potency  and  induction  of  phase  II  drug-
metabolizing  enzymes  were  seen  as  counter  to  carcinogenic 
initiation.  Resveratrol  hindered  cyclooxygenase  (COX)  and 
hydroperoxidase  and  initiated  anti-inflammatory  effects 
thereby  demonstrating  antipromotion  activity.  The  induction 
of  human  promyelocytic  leukemia  cell  differentiation  by  this 
newly-discovered  botanical  ingredient  also  thwarted  the 
progress  of  carcinogenic  activity.  In  addition,  significant 
inhibitory  effects  were  demonstrated  by  resveratrol  in  vitro, 
with  carcinogen-induced  preneoplastic  lesions  in  mouse 
mammary glands, and in vivo, with tumorigenesis in the two-
stage mouse skin cancer model.1

Since then, copious research has been performed on this botan-
ical compound that has developed a strong reputation as a potent 
antioxidant, anti-inflammatory, and antiproliferative agent.15,30,31 
Most  importantly,  it  is  considered  to  act  as  a  chemopreventive 
agent against skin cancer and to exert antiproliferative influence 
on oral squamous, breast, colon, and prostate cancer cells,19 trig-
gering  apoptosis  in  such  tumor  cells.20  Generally,  it  has  been 
shown to inhibit tumor initiation, promotion, and progression in 
chemically- and ultraviolet B (UVB)-induced skin carcinogenesis 
in mice and multiple murine models of human cancers.10,31,32

The most recent data indicate that resveratrol protects against 
UVB-mediated skin damage in SKH-1 hairless mice, particularly 
by suppressing survivin, the overexpression of which is associated 
with various forms of cancer.33,34 Significantly, this antioxidant has 
come to develop a reputation for having the capacity to prevent 
cardiovascular disease and cancer.35 Not surprisingly then, resvera-
trol is one of the most often studied polyphenolic compounds.

 
 CHEMISTRY

There are two isoforms of resveratrol: trans-resveratrol, the more 
stable form and the one to which most of its salutary effects are 
attributed, and cis-resveratrol.36,37 Among its numerous antioxidant 
activities,  resveratrol  has  been  demonstrated  to  potently  inhibit 
nitric oxide generation and inducible nitric oxide synthase protein 
expression.38 Its chemopreventive activity was further supported 
in 2008 by a study in which resveratrol induced apoptosis through 
mitochondrial pathway modulation by stimulating p53 activity in 
mouse skin tumors.39 In human skin, resveratrol has been found to 
sensitize  keratinocytes  to  UVA-induced  apoptosis.3  In  addition, 
resveratrol has also been shown to act as a sensitizer to enhance 
the therapeutic effects of ionizing radiation against cancer cells.12

Boyer  et  al.  showed  that  oxidative  stress  to  mitochondria 
engendered by UVA and resveratrol reduces the mitochondrial 
membrane  potential  resulting  in  the  opening  of  mitochondrial 
pores  and  then  apoptosis  in  human  keratinocytes.  They  sug-
gested  that  this  understanding  may  lead  to  developing  future 
chemotherapeutic approaches to cutaneous tumors.3

In 2013, Choi et al. analyzed whether resveratrol influences 
autophagy  in  human  dermal  fibroblasts  grown  in  complete 
medium  and  found  that  resveratrol-induced  autophagy  can  be 
mediated by death-associated protein kinase 1 (DAPK1). They 
concluded that some of the health benefits derived from resvera-
trol may be ascribed to its capacity to regulate DAPK1.40

In 2010, Bastianetto et al. found that resveratrol appears to act 
on specific polyphenol binding sites in the epidermis, knowledge 
that  they  suggest  might  be  applied  to  the  prevention  of  skin 
conditions linked to aging.11

Also, five new stilbenoids, vatalbinosides A-E, and 13 known 
compounds were isolated from the stem of Vatica albiramis by 
Abe et al. They examined the effects of these new compounds 
on interleukin (IL)-1β-induced production of matrix metallopro-
teinase  (MMP)-1  in  human  dermal  fibroblasts  and  identified 
three  resveratrol  tetramers  [(-)-hopeaphenol,  vaticanol  C,  and 
stenophyllol C] as potent inhibitors of MMP-1 production.41

 ORAL USES

Resveratrol is consumed regularly as a key active ingredient in 
several foods, beverages, and dietary supplements. Its bioavail-
ability is extremely limited, however.

In  2012,  Buonocore  et  al.  conducted  a  placebo-controlled, 
double-blind  study  for  60  days  with  50  participants  (25  taking 
supplements  and  25  taking  placebo)  to  assess  the  topical  and 
systemic  effects  of  a  resveratrol-  and  procyanidin-containing 
dietary  supplement  on  age-related  changes  in  the  skin.  The 
investigators  found  that  after  60  days  of  treatment,  significant 
increases  in  systemic  oxidative  stress,  plasmatic  antioxidant 
capacity,  and  skin  antioxidant  power  emerged.  Further,  skin 
moisturization and elasticity were enhanced and decreases were 
noted  in  skin  roughness  and  wrinkle  depth.  Age  spots  also 
subsided.  The  researchers  concluded  that  the  use  of  a  dietary 
supplement containing resveratrol and procyanidin exhibits poten-
tial for contributing to an antiaging regimen in support of wrinkle 
reduction and lowering systemic and cutaneous oxidative stress.42

 TOPICAL USES

In 2013, Ikeda et al., studying the effect of resveratrol on the 
regulation of extracellular matrix expression, proliferation, and 
apoptosis  of  keloid  fibroblasts,  found  that  type  I  collagen, 

C H A P T E R  50  ■   R E S V E R AT R O L  

153

α-smooth muscle actin, and heat shock protein 47 expression 
dose-dependently  diminished  in  resveratrol-treated  keloid 
fibroblasts but not in normal skin fibroblasts. Resveratrol also 
reduced  transforming  growth  factor  (TGF)-β1  synthesis  by 
keloid  fibroblasts,  inhibited  their  proliferation,  and  induced 
apoptosis  of  the  fibroblasts.  The  investigators  concluded  that 
resveratrol appears to confer an antifibrogenic effect on keloid 
fibroblasts without harming normal skin fibroblasts, indicating 
its potential use for treating keloids.43

Skin Lightening
Resveratrol  was  previously  shown  to  work  synergistically 
with 4-n-butylresorcinol (a derivative of resorcinol, one of the 
primary phenols found in argan oil; see Chapter 10, Argan Oil) 
to  lower  tyrosinase  levels  and  significantly  reduce  melanin 
synthesis more effectively than either compound alone.44 As 
Franco et al. also noted that year, resveratrol can inhibit tyrosi-
nase but it does not sufficiently suppress melanin production 
to justify its use as a lone skin-whitening agent in pharmaceu-
tical formulations, but warrants attention as a coadjuvant for 
treating hyperpigmentation.45 The potential role of resveratrol 
in skin lightening was reinforced by a recent study in which 
52  medicinal  plants  grown  in  Korea  were  tested  for  human 
tyrosinase  activity  and  the  dried  stems  of  the  grape  tree  
V.  vinifera  were  found  to  potently  inhibit  human  tyrosinase, 
and  more  effectively  than  arbutin.46  In  addition,  it  is  worth 
noting  that  resveratrol,  through  its  antioxidant  activity  and 
potentially  inhibitory  impact  on  cytochrome  P450  2E1 
expression,  has  been  shown  to  protect  mouse  primary 
hepatocytes from hydroquinone-induced cytotoxicity.47 Also, 
Galgut and Ali, studying the effects of topical ethanolic extract of 
Arachis hypogaea (peanuts, which contain half the resveratrol of 
red wine) on the tail melanophores of tadpole Bufo melanostictus, 
observed discrete gathering of pigment cells and resultant skin 
lightening.  They  concluded  that  resveratrol,  the  main  active 
ingredient in A. hypogaea, warrants attention for potential clinical 
use as a nontoxic melanolytic agent to treat hyperpigmentation.7,48

Acne
In a single-blind pilot study in 2011, Fabbrocini et al. investigated 
the  potential  therapeutic  impact  of  resveratrol  on  20  patients 
with  acne.  A  resveratrol-containing hydrogel was applied daily 
on the right side of the face for 60 days, with the left side receiving 
the hydrogel vehicle as control. No adverse effects were reported 
and all patients were satisfied with the treatment. Investigators 
reported  a  53.75  percent  mean  decrease  in  the  Global  Acne 
Grading  System  score  on  the  resveratrol-treated  sides  and  a  
6.10 percent decline on the control sides. In addition, histologic 
analysis revealed a statistically significant reduction of lesions in 
areas treated with resveratrol (66.7 percent mean reduction in the 
average area of microcomedones on the resveratrol-treated sides 
vs. 9.7 percent reduction on the control sides).37

Erythema
In a small 2013 study by Ferzli et al., 16 subjects with erythema 
applied a formulation containing resveratrol, green tea polyphe-
nols, and caffeine twice daily to the whole face. Clinical photo-
graphs and spectrally enhanced images taken before treatment 
and  every  two  weeks  through  three  months  were  evaluated. 
The  researchers  reported  that  improvement  was  seen  in  16  of  
16  clinical  images  and  13  of  16  spectrally  enhanced  images. 
Erythema reduction was observable by six weeks of treatment.49

 
154 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

 SAFETY ISSUES

Resveratrol  is  associated  with  low  toxicity  and  minimal  side 
effects.28  In  higher  doses,  it  has  been  shown  to  exhibit  pro-
apoptotic activity toward healthy cells as well as tumor cells.13

Ndiaye et al. point out that the many commercially available 
skin care products that contain resveratrol have not been rigor-
ously tested. In addition, several deliver the polyphenol through 
microparticles, which ostensibly extend resveratrol release into 
the skin but actually lower the amount of the compound availa-
ble to penetrate the skin.28

 ENVIRONMENTAL IMPACT

Resveratrol  is  present  in  roughly  70  species  of  plants.  Few  if 
any of the plants are cultivated to harness resveratrol specifi-
cally, though. As such, the environmental impact of cultivating 
plants such as V. vinifera, in particular, might be extrapolated to 
understand the effects from the industrial harvesting of plants 
containing resveratrol. Interestingly, resveratrol itself is gener-
ated in plants as a reaction to infection with the fungus Botrytis 
cinera as well as other environmental conditions, such as injury, 
exposure to ozone, sunlight, and heavy metals, as well as water 
deprivation.10,13,50

 FORMULATION CONSIDERATIONS

In 2009, Kobierski et al. identified two nonionic stabilizers to 
achieve  a  nanosuspension  of  resveratrol  stable  at  room  tem-
perature and for 30 days. The nanosuspensions are thought to 
be capable of improving skin penetration and solubility.28,51 The 
previous  year,  Gelo-Pujic  et  al.  synthesized  new  resveratrol 
precursors, combining resveratrol and lipoic acid as well as res-
veratrol and vitamin E, to improve on photostability and lipo-
philicity of the antioxidants; both new molecules demonstrated 
good chemical stability under heat and photoaging conditions.9
In 2013, Pando et al. showed that novel niosomes formulated 
with Plurol oleique or Peceol were more effective than liposomes 
in cutaneous delivery of resveratrol.52 Investigations of various 
nanoformulations  of  resveratrol  in  phospholipid  vesicles  by 
Caddeo  et  al.  revealed  that  conventional  phosphatidylcholine 
liposomes prepared with penetration enhancer-containing vesi-
cles  were  able  to  include  resveratrol  in  satisfactory  yields  
(>74 percent). Researchers noted that the lamellarity of the vesicles 
relied on formulation composition and the antioxidant activity 
of  resveratrol  was  not  influenced  by  vesicular  formulation. 
Estimated  shelf  life  for  the  preparations  ranged  from  three  to  
six months.53

Significantly, Detoni et al. caution that preventing the photoi-
somerization  of  resveratrol  from  its  E-isomeric  form  to  its 
Z-configuration  is  integral  in  maintaining  the  biological  and 
pharmacological activities of the polyphenol in topical skin for-
mulations.  In  their  study  of  various  supramolecular  structures 
infused with E-resveratrol, they found that E-resveratrol concen-
tration  was  maintained  for  the  longest  time  by  liposomes  but 
their  size  decreased  after  UVA  exposure.  Nanocarriers  were 
most successful in achieving higher levels of E-resveratrol in the 
epidermis under UVA exposure. Skin penetration profiles of the 
different tested vehicles were similar in the dark.54

Interestingly, resveratrol has been incorporated into cosmeto-
textile products (i.e., cotton and polyamide fabrics) and shown in 
vitro to be delivered into the stratum corneum (SC), epidermis, 
and  dermis.  The  skin  penetration  efficacy  of  these  resveratrol-
containing products was also tested in volunteers, with an in vitro 
percutaneous absorption method detecting resveratrol in the SC, 
epidermis,  and  dermis  and  an  in  vivo  method  (i.e.,  stripping) 
detecting resveratrol in the SC. Less resveratrol penetrated the 
skin  when  incorporated  in  the  cosmeto-textile  preparations  as 
compared to direct topical application.55

 USAGE CONSIDERATIONS

Resveratrol is associated with poor bioavailability and the fact 
that it is rapidly metabolized limits its viability as a systemic 
therapy.28  However,  some  topical  delivery  systems  have 
recently been cited as effective in the laboratory and worthy of 
consideration for development, including a hydrogel patch suc-
cessful in preventing resveratrol from escaping into the body as 
well  as  nonionic  nanosuspensions.51,56  That  said,  there  are 
already a few topical products available that feature resveratrol 
as a key ingredient. Like many such preparations, their marketing 
claims  have  not  been  confirmed  by  stringent  testing,  such  as 
randomized, double-blind clinical studies.

In a 2013 study by Pastore et al. of the molecular mechanisms 
of resveratrol activity in normal human epidermal keratinocytes, 
the  phytoalexin  was  found  to  synergize  with  tumor  necrosis 
factor (TNF)-α to engender delayed, enduring IL-8 expression via 
consistent  activation  of  the  epidermal  growth  factor  receptor 
(EGFR)-extracellular  signal  regulated  kinase  (ERK)  axis.  They 
cautioned  that  patients  with  psoriasis  who  overexpress  TNF-α, 
IL-8,  and  EGFR-ERK  in  the  skin  should  be  wary  of  topically 
applying  resveratrol.  In  addition,  the  authors  suggested  that 
habitual topical  application of  resveratrol  might pose  risk given 
that high nuclear levels of EGFR correlate to elevated tumorigenesis 
risk. Finally, they expressed skepticism regarding the potential of 
resveratrol  to  accelerate  wound  healing  because  of  its 
antiproliferative  impact  on  normal  keratinocytes.57  Further, 
Mukherjee et al. note that at lower doses, resveratrol is effective in 
contributing to health maintenance, but at higher doses it displays 
proapoptotic activity toward healthy cells as well as tumor cells.13

 SIGNIFICANT BACKGROUND

Resveratrol is known to exert a wide range of biologic activities 
as demonstrated in multiple preclinical studies.

In Vitro Studies
In 2001, human epidermoid carcinoma A432 cells treated with 
resveratrol  were  demonstrated  to  suppress  cell  growth,  G1 
phase  arrest  of  the  cell  cycle,  apoptosis,  and  dose-  and  time-
dependent  induction  of  WAF1/p21  and  multiple  decreases  in 
various  protein  expressions.58,59  Also  that  year,  Khanna  et  al. 
reported  that  grape  seed  proanthocyanidin  extract  (GSPE) 
containing  5,000  parts  per  million  resveratrol  was  found  to 
facilitate  oxidant-induced  vascular  endothelial  growth  factor 
(VEGF)  expression  in  cultured  keratinocytes,  with  GSPE 
pretreatment of human keratinocyte (HaCaT) cells upregulating 
hydrogen peroxide (H2O2) and TNF-α-induced VEGF expression 
and release. The authors concluded that resveratrol-containing 
GSPE  has  potential  to  ameliorate  dermal  wounds  and  similar 
skin conditions.60 The ensuing year, Khanna et al. reported on 
the in vivo success of topically applied GSPE on dermal wounds. 
Specifically,  the  compound  increased  the  rate  of  wound 
contractions  and  closure  as  well  as  the  expression  of  VEGF  
and  tenascin  in  wound  edge  tissue.  Greater  cell  density  and 

 
definition in the hyperproliferative epithelial region along with 
augmented deposition of connective tissue were also observed 
as a result of grape seed extract topical application.61 Many of 
the  same  investigators,  reporting  that  year  that  grape  seed 
extract and resveratrol were shown in combination to promote 
VEGF  expression,  suggested  that  such  activity  is  an  important 
step  in  wound-angiogenesis.62  It  is  worth  noting  that  the  anti-
inflammatory and wound-healing activity of polyphenols such 
as  resveratrol  have  been  found  to  be  dependent  on  their 
interaction  with  EGFR-regulated  cytoplasmic  and  nuclear 
pathways, not their redox characteristics.63

In 2008, Park et al. examined the effect of resveratrol pretreat-
ment on UVB-treated HaCaT cells. They found that resveratrol 
increased cell survival and diminished caspase-3 and caspase-8 
activation, suggesting the potential of the botanical ingredient as 
a photoprotective agent in sunscreen formulations.64

In a 2009 in vitro study of the potential cancer-preventive prop-
erties  exhibited  by  several  phytochemicals  (i.e.,  ellagic  acid, 
grape seed extract, lycopene, N-acetylcysteine, resveratrol, and 
ursolic acid) against murine skin carcinogenesis, Kowalczyk et al. 
observed  that  resveratrol,  ellagic  acid,  and  grape  seed  extract 
strongly  scavenged  peroxyl  and  superoxide  radicals.  All  of  the 
tested  phytochemicals  also  protected  cells  from  H2O2-induced 
DNA damage.65

Also that year, Roy et al. determined that resveratrol and UVB 
can work synergistically against skin cancer cells, with the poly-
phenol sensitizing A431 human epidermoid carcinoma cells to 
UVB-induced apoptosis.66

In  2010,  Jagdeo  et  al.  demonstrated  that  resveratrol  dose-
dependently  imparted  a  significant  reduction  of  intracellular 
H2O2-induced upregulation of reactive oxygen species in normal 
human skin fibroblasts in vitro.67

Liu  et  al.  conducted  an  in  vitro  study  the  following  year  to 
examine the protective role of resveratrol in HaCaT cells against 
UVA-induced  oxidative  damage  and  found  that  resveratrol 
degrades  Kelch-like-ECH-associated  protein  1  (Keap  1)  and 
expedites Nrf2 accretion in cell nuclei, thus shielding the HaCaT 
cells from oxidative harm.68

In 2012, Osmond et al. conducted in vitro and in vivo experi-
ments to assess the potential of resveratrol as a chemotherapy 
adjunct  for  melanoma  treatment.  Resveratrol  significantly 
reduced  melanoma  cell  viability  in  both  melanoma  cell  lines 
tested. The polyphenol was also found to selectively spare cells 
in the nonmalignant fibroblast lines as compared to its cytotoxic 
impact on melanoma cells. In addition, cytotoxicity to malignant 
cells was greatly amplified by 72 hours  of  treatment  with  res-
veratrol and temozolomide as compared to temozolomide treat-
ment  alone.  No  significant  differences  were  seen  in  vivo.  The 
authors concluded that the in vitro antitumor activity of resvera-
trol  positions  the  botanical  as  a  potential  therapeutic  agent  in 
melanoma management.69

Animal Studies
In  one  of  the  early  studies  with  resveratrol,  pretreatment  of 
mouse skin with this potent antioxidant significantly lowered 
the oxidative stress induced by 12-O-tetradecanoylphorbol-13-
acetate  (TPA)  and  restored  glutathione  levels  and  superoxide 
dismutase  activity.70  Resveratrol  pretreatment  also  dose-
dependently  reversed  or  reduced  several  of  the  carcinogenic 
effects induced by TPA by disrupting the pathways of reactive 
oxidants.71 TPA-mediated increases in the expression of COX-1, 
COX-2, c-myc, c-fos, c-jun, TGF-β1, and TNF-α were all inhib-
ited by resveratrol pretreatment.58,71

C H A P T E R  50  ■   R E S V E R AT R O L  

155

In  an  investigation  involving  the  two-stage  mouse  skin 
carcinogenesis model [7,12 dimethylbenz(a)anthracene (DMBA)-
initiated,  TPA-promoted],  resveratrol  was  shown  to  exhibit 
significant  inhibitory  activity  against  Epstein-Barr  virus  early 
antigen  induction.  Resveratrol  also  conferred  a  60  percent 
reduction  in  papillomas  at  20  weeks  in  an  in  vivo  assay  at  a 
50-fold molar ratio to TPA.72

The molecular mechanisms of its antitumorigenic properties 
were suggested by the results of an investigation by Kundu et al. 
of the effects of resveratrol on TPA-induced COX-2 expression 
in mouse skin. Researchers observed dose-dependent inhibition 
of  COX-2  expression  following  pretreatment  of  dorsal  skin  of 
female ICR mice with resveratrol. Decreases in the phosphoryla-
tion of ERK and the catalytic activity of ERK and p38 mitogen-
activated  protein  kinases  (MAPK)  were  also  noted  as  was  the 
DNA binding of activator protein-1 (AP-1) induced by TPA.73

In a 2005 study of the effects of resveratrol on UVB-mediated 
skin tumorigenesis in SKH-1 hairless mice, controls were chroni-
cally exposed to UVB, twice weekly for 28 weeks, while resvera-
trol was topically applied pretreatment (30 minutes before each 
UVB exposure) or posttreatment (5 minutes after). Pre- and post-
treatment  were  found  to  confer  equal  benefit,  both  equally 
inhibiting tumor incidence and postponing tumorigenesis onset. 
Resveratrol treatment was also found to mitigate the deleterious 
effects  of  UVB  on  survivin  as  well  as  on  apoptosis  in  UVB-
mediated skin tumors. The authors concluded that their findings 
are  the  first  results  with  direct  implications  regarding  human 
skin cancers. Further, they speculated that resveratrol is suitable 
for  inclusion  in  various  product  types  (e.g.,  emollient,  patch, 
sunscreens,  and  other  skin  care  products)  intended  to  prevent 
skin  cancer  and  other  conditions  thought  to  be  generated  by  
the sun.34

Researchers  assessing  the  effects  of  pretreatment  with  res-
veratrol on H2O2-induced oxidative stress and apoptosis in cul-
tured rat pheochromocytoma (PC12) cells found several effects 
of the oxidizer, including cytotoxicity, DNA fragmentation, tran-
sient activation of nuclear factor (NF)-κB, and intracellular accu-
mulation of reactive oxygen species, to be diminished.26 Another 
potential application of resveratrol was suggested by a study in 
which resveratrol pretreatment suppressed the NF-κB activation 
in  cultured  rat  PC12  cells  transiently  induced  by  β-amyloid. 
Resveratrol also thwarted other effects of the β-amyloid peptide, 
which is believed to account for the senile plaques characteristic 
of the brains of Alzheimer’s patients. Specifically, the polyphenol 
was  found  to  have  attenuated  the  cytotoxicity,  apoptosis,  and 
intracellular reactive oxygen intermediate formation.74 In 2005, 
resveratrol  was  found  to  increase  cellular  antioxidant  defense 
capacity,  specifically  protecting  the  tested  cultured  PC12  cells 
from oxidative damage.4

In 2009, Roy et al. evaluated the chemopreventive potential of 
resveratrol  in  DMBA-induced  mouse  skin  tumorigenesis  over  
28 weeks. Resveratrol was topically applied to the animals one hour 
before DMBA exposure. The results showed definite chemopre-
ventive  activity,  specifically  a  delay  in  tumorigenesis  onset  as 
well as decreases in tumor volume and total number of tumors. 
Notably,  resveratrol  increased  apoptotic  protease-activating 
factor-1 as well as DMBA-inhibited p53 and Bax and suppressed 
skin  tumorigenesis  by  regulating  phosphatidylinositol-3-kinase 
(PI3K) and AKT proteins, which are thought to foster cancer by 
facilitating proliferation and inhibiting apoptosis. The investiga-
tors  concluded  that  resveratrol  warrants  consideration  as  a 
chemopreventive agent.75

Later that year, Yusuf et al. examined whether Toll-like recep-
tor 4 (TLR4), which like other Toll-like receptors plays an important 

 
156 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

role in immune responses, was necessary for the chemopreven-
tive  activity  imparted  by  resveratrol  against  DMBA-induced 
cutaneous  carcinogenesis.  Investigators  compared  mice  with 
normal  and  deficient  TLR4  function  when  pretreated  with 
resveratrol and then exposed to a DMBA-induced skin carcino-
genesis  protocol.  Fewer  tumors/group  were  observed  in 
resveratrol-treated TLR4-competent mice as opposed to TLR4-
deficient mice. Tumor size was also diminished in vivo and their 
survival suppressed in vitro by resveratrol much more so in the 
TLR4-competent  mice.  In  addition,  angiogenesis  was  more 
significantly inhibited in TLR4-competent mice. The researchers 
concluded that TLR4 plays a key mediating role in the chemo-
prevention  of  DMBA-induced  skin  carcinogenesis  exerted  by 
resveratrol.76

In  2011,  Kim  et  al.  demonstrated  that  orally  administered 
resveratrol  inhibits  UV-induced  skin  tumorigenesis  in  highly 
tumor-susceptible p53(±)/SKH-1 mice and suppresses the inva-
siveness of human A432 squamous cell carcinoma partly by tar-
geting and downregulating TGF-β2.77

Recently, resveratrol was also found by Hao et al. to suppress 
the  growth  of  a  human  skin  squamous  cell  carcinoma  A431 
xenograft  in  nude  mice.78  Several  of  the  same  investigators 
showed  that  the  inhibition  mechanism  of  resveratrol  is  the 
upregulation of the protein and mRNA expression of p53 and the 
downregulation of the protein and mRNA expression of survivin, 
leading to tumor cell apoptosis.21

Photoprotection
Resveratrol  has  been  demonstrated  to  protect  against  UVB-
mediated  cutaneous  damage  in  SKH-1  hairless  mice. 
Specifically,  a  significant  decline  in  UVB-mediated  generation 
of H2O2 as well as infiltration of leukocytes and inhibition of 
skin edema has been associated with the topical application of 
resveratrol  to  SKH-1  hairless  mice  before  UVB  exposure. 
Topically  applied  resveratrol  also  significantly  hinders  UVB-
mediated  induction  of  COX-2  and  ornithine  decarboxylase 
(ODC)  enzyme  activities  and  protein  expression  of  ODC, 
which are markers for tumor promotion. In addition, it inhibits 
the UVB-mediated rise in lipid peroxidation, a marker of oxida-
tive  stress.33,34  Pretreatment  of  normal  human  epidermal 
keratinocytes  with  resveratrol  was  shown  in  one  study  to 
inhibit UVB-induced activation of the NF-κB pathway.79 This 
protective  effect  delivered  by  resveratrol  against  the  damage 
from multiple UVB exposures has been ascribed to the inhibi-
tion of the MAPK pathway and mediated via modulation in the 
expression  and  function  of  the  cell  cycle  regulatory  protein 
cki–cyclin–cdk  network.80  In  short-term  experiments, 
resveratrol  topically  applied  to  SKH-1  hairless  mouse  skin 
before  UVB  irradiation  led  to  marked  suppression  of  cell 
proliferation  and  phosphorylation  of  survivin.81  Inhibition  of 
UVB-induced  tumor  incidence  and  delay  in  the  onset  of  skin 
tumorigenesis  has  been  demonstrated  in  long-term  studies 
entailing  the  topical  application  of  resveratrol  both  pre-  and 
postexposure.82  The  postexposure  application  of  resveratrol 
yielded  equal  protection  to  the  pre-exposure  application, 
suggesting  that  resveratrol-mediated  responses  may  not  be 
sunscreen  effects.  Evidence  pointing  to  the  photoprotective 
effects of resveratrol continues to be collected.12,83

Other deleterious effects of UV exposure have been mitigated 
by resveratrol. Afaq et al. showed that UVB-induced skin edema 
was  significantly  inhibited  by  the  topical  application  of 
resveratrol to SKH-1 hairless mice.84 In another experiment by 
Afaq  et  al.,  topically  applied  resveratrol  significantly  inhibited  

UVB-mediated increases in bifold skin thickness and edema and 
greatly  diminished  UVB-induced  lipid  peroxidation,  COX  and 
ODC  activities,  as  well  as  protein  expression  of  the  ODC 
enzyme  in  SKH-1  hairless  mice.15  The  authors  concluded  that 
topically applied resveratrol appears to impart significant photo-
protective capacity against the damage wrought by UVB radia-
tion. Additional research by this team buttresses their position, 
as they demonstrated that resveratrol dose- and time-dependently 
blocked  UVB-mediated  activation  of  NF-κB  in  normal  human 
epidermal keratinocytes and that this pathway plays an impor-
tant role in the photoprotective activity expressed by stilbene.16 
In an experiment by some of the same investigators, resveratrol 
was topically applied to SKH-1 hairless mice 30 minutes before 
exposure  to  UVB;  24  hours  later,  significant  reductions  were 
observed in bifold skin thickness, hyperplasia, and infiltration 
of leukocytes. Critical cell cycle regulatory proteins, the target 
of  the  investigation,  were  substantially  downregulated  as  a 
result of the resveratrol treatment. The researchers concluded 
that  this  potent  antioxidant  may  have  the  potential  to  play  a 
significant role in preventing UVB-mediated photodamage and 
carcinogenesis.80

Antiaging Activity
In 2008, Baxter reported that in an oxygen radical absorbance 
capacity  (ORAC)  comparison,  a  new  skin  formulation  with  
1 percent resveratrol exhibited 17 times the antioxidant activity 
of  a  1  percent  idebenone  formulation.2  Idebenone  has  been 
reported to be the most potent topical antioxidant (see Chapter 61, 
Idebenone).85

In 2010, Giardina et al. conducted an in vitro study to assess 
the tonic-trophic characteristics of resveratrol as well as resvera-
trol  plus  N-acetylcysteine  on  cultured  skin  fibroblasts.  They 
found  that  both  formulations  dose-dependently  yielded  
an  increase  in  cell  proliferation  and  inhibition  of  collagenase 
activity.86

In 2012, Wu et al. studied the protective effects of resveratrate, 
a stable derivative of resveratrol, against damage to human skin 
caused  by  repetitive  solar  simulator  UV  radiation  (SSUVR)  in  
15  healthy  human  volunteers.  Six  sites  on  nonexposed  dorsal 
skin of each participant were studied, with four sites exposed to 
SSUVR  and  the  remaining  sites  serving  as  positive  control 
(SSUVR only) and baseline control (no treatment or exposure). 
The investigators observed minimal erythema on areas treated 
with  resveratrate  and  the  resveratrol  derivative  significantly 
suppressed sunburn cell formation. They concluded that resvera-
trate protects the skin against sunburn and suntan provoked by 
repetitive SSUVR.6

In a 2013 in vitro study of the skin permeation kinetics of poly-
phenols using diffusion cells via ex vivo pig skin and a cellulose 
membrane, Zillich et al. demonstrated that several polyphenols, 
including  resveratrol,  (-)epigallocatechin-3-O-gallate  (EGCG), 
quercetin,  rutin,  and  protocatechuic  acid  formulated  in  oil-in-
water  (o/w)  emulsions  could  pass  through  the  SC  and  were 
identified  in  the  epidermis  and  dermis.  The  investigators  con-
cluded  that  their  findings  validate  the  use  of  polyphenols  as 
active ingredients in antiaging products.87

Antimicrobial and Antiviral Activity
Resveratrol has also been evaluated as an antifungal or antimi-
crobial  because  this  potent  compound  is  synthesized  in 
response to injury or fungal attack.88,89 In one study, researchers 
assessed the antimicrobial activity of resveratrol against bacteria 

 
and dermatophytes known to be important causes of human 
skin  infections,  including  the  bacteria  Staphylococcus  aureus, 
Enterococcus  faecalis,  and  Pseudomonas  aeruginosa.  Resveratrol 
was found to inhibit the growth of the tested bacteria as well 
as the growth of the fungal species Trichophyton mentagrophytes, 
Trichophyton  tonsurans,  Trichophyton  rubrum,  Epidermophyton  
floccosum,  and  Microsporum  gypseum.  Investigators  concluded 
that the potential dermatologic applications of resveratrol, and 
its analogs, appear to be even wider than previously believed 
and may even come to include clinical applications for diabetic 
wounds.30

In another study with direct implications regarding new der-
matologic applications, investigators evaluated the in vivo effects 
of resveratrol on herpes simplex virus (HSV) given prior success 
in vitro. Topical application of two concentrations of resveratrol 
(12.5 and 25 percent) cream to the abraded epidermis of SKH-1 
mice infected with HSV-1 effectively suppressed lesion develop-
ment when applied multiple times a day within one or six hours 
after infection, but not at after 12 hours of infection. In compari-
sons  between  resveratrol  cream,  10  percent  docosanol  cream 
(Abreva) and 5 percent acyclovir ointment (Zovirax), resveratrol 
cream  and  acyclovir  were  comparably  effective  whereas  mice 
treated  with  docosanol  developed  lesions  at  the  same  rate  as 
cream-only control mice. In addition, the resveratrol creams suc-
cessfully  inhibited  lesion  formation  when  the  experiment  was 
repeated with an HSV-1 acyclovir-resistant virus.90

 CONCLUSION

Grape skin and seeds, berries, peanuts, and some other foods 
that  contain  the  potent  antioxidant  resveratrol  are  the  main 
sources of what is emerging as a compound with the potential 
to deliver significant health benefits, particularly in the realm of 
cardioprotective, cancer-preventive, and photoprotective activity. 
While there has been intense research over the last two decades, 
more is necessary to establish resveratrol for consideration as a 
standard first-line therapy and to further elucidate its range of 
cutaneous  applications.  Data  and  preclinical  evidence  do 
appear  to  support  the  use  of  resveratrol  in  various  product 
types (e.g., emollients, patches, sunscreens, and additional skin 
care products) intended to prevent skin cancer and other condi-
tions caused or exacerbated by solar exposure, such as photoaging. 
More clinical evidence is needed, though, to establish the full 
potential of topically applied resveratrol.

REFERENCES

1.  Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity 
of  resveratrol,  a  natural  product  derived  from  grapes.  Science. 
1997;275:218.

2.  Baxter  RA.  Anti-aging  properties  of  resveratrol:  Review  and 
report of a potent new antioxidant skin care formulation. J Cosmet 
Dermatol. 2008;7:2.

3.  Boyer  JZ,  Jandova  J,  Janda  J,  et  al.  Resveratrol-sensitized  UVA 
induced  apoptosis  in  human  keratinocytes  through  mitochon-
drial  oxidative  stress  and  pore  opening.  J  Photochem  Photobiol  B. 
2012;113:42.

4.  Chen  CY,  Jang  JH,  Li  MH,  et  al.  Resveratrol  upregulates  heme 
oxygenase-1 expression via activation of NF-E2-related factor 2 in 
PC12 cells. Biochem Biophys Res Commun. 2005;331:993.

5.  She QB, Bode AM, Ma WY, et al. Resveratrol-induced activation 
of p53 and apoptosis is mediated by extracellular-signal-regulated 
protein kinases and p38 kinase. Cancer Res. 2001;61:1604.

6.  Wu Y, Jia LL, Zheng YN, et al. Resveratrate protects human skin 
from damage due to repetitive ultraviolet irradiation. J Eur Acad 
Dermatol Venereol. 2012 Jan 5. Venereol. 2013;27:345.

C H A P T E R  50  ■   R E S V E R AT R O L  

157

7.  Konda S, Geria AN, Halder RM. New horizons in treating disor-
ders of hyperpigmentation in skin of color. Semin Cutan Med Surg. 
2012;31:133.

8.  Saraf  S,  Kaur  CD.  Phytoconstituents  as  photoprotective  novel 

cosmetic formulations. Pharmacogn Rev. 2010;4:1.

9.  Gelo-Pujic  M,  Desmurs  JR,  Kassem  T,  et  al.  Synthesis  of  new 
antioxidant conjugates and their in vitro hydrolysis with stratum 
corneum enzymes. Int J Cosmet Sci. 2008;30:195.

10.  Athar  M,  Back  JH,  Tang  X,  et  al.  Resveratrol:  A  review  of  pre-
clinical  studies  for  human  cancer  prevention.  Toxicol  Appl 
Pharmacol. 2007;224:274.

11.  Bastianetto S, Dumont Y, Duranton A, et al. Protective action of 
resveratrol in human skin: Possible involvement of specific recep-
tor binding sites. PLoS One. 2010;5:e12935.

12.  Reagan-Shaw S, Mukhtar H, Ahmad N. Resveratrol imparts pho-
toprotection of normal cells and enhances the efficacy of radia-
tion therapy in cancer cells. Photochem Photobiol. 2008;84:415.
13.  Mukherjee S, Dudley JI, Das DK. Dose-dependency of resveratrol 

in providing health benefits. Dose Response. 2010;8:478.

14.  Nassiri-Asl M, Hosseinzadeh H. Review of the pharmacological 
effects  of  Vitis  vinifera  (Grape)  and  its  bioactive  compounds. 
Phytother Res. 2009;23:1197.

15.  Afaq F, Adhami VM, Admad N. Prevention of short-term ultravio-
let B radiation-mediated damages by resveratrol in SKH-1 hairless 
mice. Toxicol Appl Pharmacol. 2003;186:28.

16.  Adhami  VM,  Afaq  F,  Ahmad  N.  Suppression  of  ultraviolet  B  
exposure-mediated  activation  of  NF-kappaB  in  normal  human 
keratinocytes by resveratrol. Neoplasia. 2003;5:74.

17.  Foster S. 101 Medicinal Herbs: An Illustrated Guide. Loveland, CO: 

Interweave Press; 1998:108-9.

18.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

Medicine. Rochester, VT: Healing Arts Press; 2003:99-100.

19.  Ding XZ, Adrian TE. Resveratrol inhibits proliferation and induces 
apoptosis in human pancreatic cancer cells. Pancreas. 2002;25:e71.
20.  Delmas D, Rébé C, Lacour S, et al. Resveratrol-induced apoptosis 
is associated with Fas redistribution in the rafts and the formation 
of a death-inducing signaling complex in colon cancer cells. J Biol 
Chem. 2003;278:41482.

21.  Hao Y, Huang W, Liao M, et al. The inhibition of resveratrol to 
human  skin  squamous  cell  carcinoma  A431  xenografts  in  nude 
mice. Fitoterapia. 2013;86:84.

22.  Namasivayam  N.  Chemoprevention  in  experimental  animals. 

Ann N Y Acad Sci. 2011;1215:60.

23.  Das S, Das DK. Resveratrol: A therapeutic promise for cardiovas-
cular diseases. Recent Pat Cardiovasc Drug Discov. 2007;2:133.
24.  Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol 
in  prevention  and  therapy  of  cancer:  Preclinical  and  clinical 
studies. Anticancer Res. 2004;24:2783.

25.  Simini B. Serge Renaud: From French paradox to Cretan miracle. 

Lancet. 2000;355:48.

26.  Jang  JH,  Surh  YJ.  Protective  effects  of  resveratrol  on  hydrogen 
peroxide-induced  apoptosis  in  rat  pheochromocytoma  (PC12) 
cells. Mutat Res. 2001;496:181.

27.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

Medicine. Rochester, VT: Healing Arts Press; 2003:110.

28.  Ndiaye M, Philippe C, Mukhtar H, et al. The grape antioxidant 
resveratrol for skin disorders: Promise, prospects, and challenges. 
Arch Biochem Biophys. 2011;508:164.

29.  Zhuang  H,  Kim  YS,  Koehler  RC,  et  al.  Potential  mechanism  by 
which resveratrol, a red wine constituent, protects neurons. Ann 
N Y Acad Sci. 2003;993:276.

30.  Chan MM. Antimicrobial effect of resveratrol on dermatophytes 
and bacterial pathogens of the skin. Biochem Pharmacol. 2002;63:99.
31.  Svobodová A, Psotová J, Walterová D. Natural phenolics in the 
prevention  of  UV-induced  skin  damage.  A  review.  Biomed  Pap 
Med Fac univ Palacky Olomouc Czech Repub. 2003;147:137.

32.  Afaq F, Mukhtar H. Photochemoprevention by botanical antioxi-

dants. Skin Pharmacol Appl Skin Physiol. 2002;15:297.

33.  Aziz MH, Afaq F, Ahmad N. Prevention of ultraviolet-B radiation 
damage by resveratrol in mouse skin is mediated via modulation 
in surviving. Photochem Photobiol. 2005;81:25.

34.  Aziz MH, Reagan-Shaw S, Wu J, et al. Chemoprevention of skin 
cancer by grape constituent resveratrol: Relevance to human dis-
0ease? FASEB J. 2005;19:1193.

35.  Hebbar V, Shen G, Hu R, et al. Toxicogenomics of resveratrol in 

rat liver. Life Sci. 2005;76:2299.

36.  Puizina-Ivi ´c  N, Miri ´c   L, Carija A, et al. Modern approach to topical 

treatment of aging skin. Coll Antropol. 2010;34:1145.

 
158 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

37.  Fabbrocini G, Staibano S, De Rosa G, et al. Resveratrol-containing 
gel  for  the  treatment  of  acne  vulgaris:  A  single-blind,  vehicle-
controlled, pilot study. Am J Clin Dermatol. 2011;12:133.

38.  Bhat KP, Pezzuto JM. Cancer chemopreventive activity of resver-

atrol. Ann N Y Acad Sci. 2002;957:210.

39.  Kalra  N,  Roy  P,  Prasad  S,  et  al.  Resveratrol  induces  apoptosis 
involving mitochondrial pathways in mouse skin tumorigenesis. 
Life Sci. 2008;82:348.

40.  Choi  MS,  Kim  Y,  Jung  JY,  et  al.  Resveratrol  induces  autophagy 
through  death-associated  protein  kinase  1  (DAPK1)  in  human 
dermal fibroblasts under normal culture conditions. Exp Dermatol. 
2013;22:491.

41.  Abe N, Ito T, Ohguchi K, et al. Resveratrol oligomers from Vatica 

albiramis. J Nat Prod. 2010;73:1499.

42.  Buonocore  D,  Lazzeretti  A,  Tocabens  P,  et  al.  Resveratrol-
procyanidin blend: Nutraceutical and antiaging efficacy evaluated 
in  a  placebocontrolled,  double-blind  study.  Clin  Cosmet  Investig 
Dermatol. 2012;5:159.

43.  Ikeda K, Torigoe T, Matsumoto Y, et al. Resveratrol inhibits fibro-
genesis and induces apoptosis in keloid fibroblasts. Wound Repair 
Regen. 2013;21:616.

44.  Kim  SY,  Park  KC,  Kwon  SB,  et  al.  Hypopigmentary  effects  of 
4-n-butylresorcinol  and  resveratrol  in  combination.  Pharmazie. 
2012;67:542.

45.  Franco DC, de Carvalho GS, Rocha PR, et al. Inhibitory effects of 
resveratrol  analogs  on  mushroom  tyrosinase  activity.  Molecules. 
2012;17:11816.

46.  Park J, Booy YC. Isolation of resveratrol from vitis viniferae caulis 
and  its  potent  inhibition  of  human  tyrosinase.  Evid  Based 
Complement Alternat Med. 2013;2013:645257.

47.  Wang DH, Ootsuki Y, Fujita H, et al. Resveratrol inhibited hydro-
quinone-induced cytotoxicity in mouse primary hepatocytes. Int 
J Environ Res Public Health. 2012;9:3354.

48.  Galgut JM, Ali SA. Effect and mechanism of action of resveratrol: 
A novel melanolytic compound from the peanut skin of Arachis 
hypogaea. J Recept Signal Transduct Res. 2011;31:374.

49.  Ferzli G, Patel M, Phrsai N, et al. Reduction of facial redness with 
resveratrol  added  to  topical  product  containing  green  tea  poly-
phenols and caffeine. J Drugs Dermatol. 2013;12:770.

50.  De Nisco M, Manfra M, Bolognese A, et al. Nutraceutical proper-
ties and polyphenolic profile of berry skin and wine of Vitis vinif-
era L. (cv. Aglianico). Food Chem. 2013;140:623.

51.  Kobierski S, Ofori-Kwakye K, Müller RH, et al. Resveratrol nano-
suspensions  for  dermal  application—production,  characteriza-
tion, and physical stability. Pharmazie. 2009;64:741.

52.  Pando D, Caddeo C, Manconi M, et al. Nanodesign of olein vesi-
cles for the topical delivery of the antioxidant resveratrol. J Pharm 
Pharmacol. 2013;65:1158.

53.  Caddeo C, Manconi M, Fadda AM, et al. Nanocarriers for anti-
oxidant resveratrol: Formulation approach, vesicle self-assembly 
and stability evaluation. Colloids Surf B Biointerfaces. 2013;111C:327.
54.  Detoni CB, Souto GD, da Silva AL, et al. Photostability and skin 
penetration  of  different  E-resveratrol-loaded  supramolecular 
structures. Photochem Photobiol. 2012;88:913.

55.  Alonso  C,  Martí  M,  Martínez  V,  et  al.  Antioxidant  cosmeto-
textiles: Skin assessment. Eur J Pharm Biopharm. 2013;84:192.
56.  Hung CF, Lin YK, Huang ZR, et al. Delivery of resveratrol, a red 
wine polyphenol, from solutions and hydrogels via the skin. Biol 
Pharm Bull. 2008;31:955.

57.  Pastore  S,  Lulli  D,  Maurelli  R,  et  al.  Resveratrol  induces  long-
lasting IL-8 expression and peculiar EGFR activation/distribution 
in  human  keratinocytes:  Mechanisms  and  implications  for  skin 
administration. PLoS One. 2013;8:e59632.

58.  Gupta  S,  Mukhtar  H.  Chemoprevention  of  skin  cancer  through 
natural agents. Skin Pharmacol Appl Skin Physiol. 2001;14:373.
59.  Ahmad N, Adhami VM, Afaq F, et al. Resveratrol causes WAF-1/
p21-mediated  G(1)-phase  arrest  of  cell  cycle  and  induction  of 
apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer 
Res. 2001;7:1466.

60.  Khanna S, Roy S, Bagchi D, et al. Upregulation of oxidant-induced 
VEGF expression in cultured keratinocytes by a grape seed proan-
thocyanidin extract. Free Radic Biol Med. 2001;31:38.

61.  Khanna S, Venojarvi M, Roy S, et al. Dermal wound healing prop-
erties  of  redox-active  grape  seed  proanthocyanidins.  Free  Radic 
Biol Med. 2002;33:1089.

62.  Sen CK, Khanna S, Gordillo G, et al. Oxygen, oxidants, and anti-
oxidants in wound healing: An emerging paradigm. Ann N Y Acad 
Sci. 2002;957:239.

63.  Pastore  S,  Lulli  D,  Fidanza  P,  et  al.  Plant  polyphenols  regulate 
chemokine expression and tissue repair in human keratinocytes 
through interaction with cytoplasmic and nuclear components of 
epidermal  growth  factor  receptor  system.  Antioxid  Redox  Signal. 
2012;16:314.

64.  Park K, Lee JH. Protective effects of resveratrol on UVB-irradiated 
HaCaT cells through attenuation of the caspase pathway. Oncol 
Rep. 2008;19:413.

65.  Kowalczyk  MC,  Walaszek  Z,  Kowalczyk  P,  et  al.  Differential 
effects of several phytochemicals and their derivatives on murine 
keratinocytes  in  vitro  and  in  vivo:  Implications  for  skin  cancer 
prevention. Carcinogenesis. 2009;30:1008.

66.  Roy P, Madan E, Kalra N, et al. Resveratrol enhances ultraviolet 
B-induced  cell  death  through  nuclear  factor-kappaB  pathway  in 
human  epidermoid  carcinoma  A431  cells.  Biochem  Biophys  Res 
Commun. 2009;384:215.

67.  Jagdeo J, Adams L, Lev-Tov H, et al. Dose-dependent antioxidant 
function of resveratrol demonstrated via modulation of reactive 
oxygen species in normal human skin fibroblasts in vitro. J Drugs 
Dermatol. 2010;9:1523.

68.  Liu Y, Chan F, Sun H, et al. Resveratrol protects human keratino-
cytes HaCaT cells from UVA-induced oxidative stress damage by 
downregulating Keap1 expression. Eur J Pharmacol. 2011;650:130.
69.  Osmond  GW,  Augustine  CK,  Zipfel  PA,  et  al.  Enhancing  mela-
noma treatment with resveratrol. J Surg Res. 2012;172:109.
70.  Jang M, Pezzuto JM. Cancer chemopreventive activity of resvera-

trol. Drugs Exp Clin Res. 1999;25:65.

JM.  Effects  of 

71.  Jang  M,  Pezzuto 

resveratrol  on 
12-O-tetradecanoylphorbol-13-acetate-induced  oxidative  events 
and gene expression in mouse skin. Cancer Lett. 1998;134:81.
72.  Kapadia  GJ,  Azuine  MA,  Tokuda  H,  et  al.  Chemopreventive 
effect of resveratrol, sesamol, sesame oil and sunflower oil in the 
Epstein-Barr virus early antigen activation assay and the mouse 
skin two-stage carcinogenesis. Pharmacol Res. 2002;45:499.

73.  Kundu JK, Chun KS, Kim SO, et al. Resveratrol inhibits phorbol 
ester-induced  cyclooxygenase-2  expression  in  mouse  skin: 
MAPKs  and  AP-1  as  potential  molecular  targets.  Biofactors. 
2004;21:33.

74.  Jang JH, Surh YJ. Protective effect of resveratrol on beta-amyloid-
induced  oxidative  PC12  cell  death.  Free  Radic  Biol  Med. 
2003;34:1100.

75.  Roy  P,  Kalra  N,  Prasad  S,  et  al.  Chemopreventive  potential  of 
resveratrol in mouse skin tumors through regulation of mitochon-
drial and PI3K/AKT signaling pathways. Pharm Res. 2009;26:211.
76.  Yusuf  N,  Nasti  TH,  Meleth  S,  et  al.  Resveratrol  enhances  cell-
mediated  immune  response  to  DMBA  through  TLR4  and  pre-
vents  DMBA  induced  cutaneous  carcinogenesis.  Mol  Carcinog. 
2009;48:713.

77.  Kim KH, Back JH, Zhu Y, et al. Resveratrol targets transforming 
growth  factor-β2  signaling  to  block  UV-induced  tumor  progres-
sion. J Invest Dermatol 2011;131:195.

78.  Hao YQ, Huang WX, Feng HX, et al. Study of apoptosis related 
factors regulatory mechanism of resveratrol to human skin squa-
mous cell carcinoma A431 xenograft in nude mice. Zhonghua Yi 
Xue Za Zhi. 2013;93:464.

79.  Ash K, Lord J, Zukowski M, et al. Comparison of topical therapy 
for  striae  alba  (20%  glycolic  acid/0.05%  tretinoin  versus  20% 
glycolic acid/10% L-ascorbic acid). Dermatol Surg. 1998;24:849.
80.  Reagan-Shaw S, Afaq F, Aziz MH, et al. Modulations of critical 
cell cycle regulatory events during chemoprevention of ultraviolet 
B-mediated  responses  by  resveratrol  in  SKH-1  hairless  mouse 
skin. Oncogene. 2004;23:5151.

81.  Shi X, Ye J, Leonard S, et al. Antioxidant properties of (-)-epicatechin 
-3-gallate and its inhibition of Cr(VI)-induced DNA damage and 
Cr(IV)-  or  TPA-stimulated  NF-kappaB  activation.  Mol  Cell 
Biochem. 2000;206:125.

82.  Wei H, Zhang X, Zhao JF, et al. Scavenging of hydrogen peroxide 
and inhibition of ultraviolet light-induced oxidative DNA damage 
by  aqueous  extracts  from  green  and  black  teas.  Free  Radic  Biol 
Med. 1999;26:1427.

83.  Nichols JA, Katiyar SK. Skin photoprotection by natural polyphe-
nols:  Anti-inflammatory,  antioxidant  and  DNA  repair  mecha-
nisms. Arch Dermatol Res. 2010;302:71.

84.  Afaq F, Adhami VM, Ahmad N, et al. Botanical antioxidants for 
chemoprevention  of  photocarcinogenesis.  Front  Biosci. 
2002;7:d784.

85.  McDaniel DH, Neudecker BA, DiNardo  JC, et al. Idebenone: A 
new antioxidant – Part I. Relative assessment of oxidative stress 

 
C H A P T E R  50  ■   R E S V E R AT R O L  

159

protection capacity compared to commonly known antioxidants. 
J Cosmet Dermatol. 2005;4:10.

86.  Giardina S, Michelotti A, Zavattini G, et al. Efficacy study in vitro: 
Assessment  of  the  properties  of  resveratrol  and  resveratrol  + 
N-acetyl-cysteine  on  proliferation  and  inhibition  of  collagen 
activity. Minerva Ginecol. 2010;62:195.

87.  Zillich OV, Schweiggert-Weisz U, Hasenkopf K, et al. Release and 
in  vitro  skin  permeation  of  polyphenols  from  cosmetic  emul-
sions. Int J Cosmet Sci. 2013;35:491.

88.  Brito  P,  Almeida  LM,  Dinis  TC.  The  interaction  of  resveratrol 
with ferrylmyoglobin and peroxynitrite; protection against LDL 
oxidation. Free Radic Res. 2002;36:621.

89.  Becker  JV,  Armstrong  GO,  van  der  Merwe  MJ,  et  al.  Metabolic 
engineering of Saccharomyces cerevisiae for the synthesis of the 
wine-related antioxidant resveratrol. FEMS Yeast Res. 2003;4:79.

90.  Docherty  JJ,  Smith  JS,  Fu  MM,  et  al.  Effect  of  topically  applied 
resveratrol on cutaneous herpes simplex virus infections in hair-
less mice. Antiviral Res. 2004;61:19.

 
160 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   5 1

Flaxseed Oil

Activities:

Antioxidant,  antiaging,  anti-inflammatory,  and  anti-
apoptotic

Important Chemical Components:
Linoleic  acid,  α-linolenic  acid,  oleic  acid,  palmitic  acid, 
stearic acid, arachidic acid1,2

Origin Classification:

This  ingredient  is  considered  natural.  As  an  ingredient 
used for dermatologic purposes, it is laboratory made.

Personal Care Category:

Antioxidant, antiaging

Recommended  for  the  following  Baumann  Skin 
Types:

DSNT, DSNW, DSPT, and DSPW

 Source

Linum  usitatissimum,  an  annual  plant  in  the  Linaceae  family 
native to the eastern Mediterranean to India and better known 
as  flax  (or  linseed,  though  the  popularity  of  this  name  has 
waned),  is  grown  commercially  for  its  meal,  oil,  and  seeds. 
Flaxseed oil, derived from the seeds of the plant, is thought to 
possess significant health properties. Indeed, flaxseed oil is one 
of the richest sources of ω-3 fatty acids, in particular α-linolenic 
acid (ALA), which represents more than 50 percent of its total 
fatty acid content (Table 51-1).1,3 In addition to an abundance of 
ω-3 fatty acids, flaxseeds possess copious dietary fiber and lig-
nans, which are polyphenolic phytoestrogens with antioxidant 
properties, linoleic acid (an ω-6 polyunsaturated fatty acid), and 
oleic acid (an ω-9 monounsaturated fatty acid). The only foods 
that contain appreciable lignan levels are flaxseed and flaxseed 
oil.4,5  Most  commercial  supplies  are  produced  in  Argentina, 
Canada, North Africa, and Turkey, but it is grown widely.6

 HISTorY

Linum usitatissimum was cultivated in ancient Egypt and Ethiopia 
and used for multiple purposes, including medicine, soap, hair 
products,  and  textiles  (linen).7  Its  use  dates  back  to  the  
23rd century BCE in Egypt and, for culinary purposes, to the  

TABLE 51-1
Pros and Cons of Flaxseed Oil

Pros
Rich source of α-linolenic acid
Compelling dietary benefits

Cons
Minimal research to establish its cutaneous efficacy
May increase penetration of other ingredients

7th  century  BCE  in  Greece.6  Flaxseed  oil  is  one  of  the  oldest 
commercial oils and was used for centuries as a drying oil in 
painting and varnishing.8 In traditional medical practice it was 
used  as  a  laxative  and  to  treat  urinary  tract  infections,  colds, 
and  lung  disorders.6,7  Currently,  it  is  used  to  treat  irritable 
bowel as well as constipation.6

 cHeMISTr Y

Antioxidant,  anti-inflammatory,  and  antiapoptotic  activities 
have  been  associated  with  flaxseed  oil  and  warrant  medical 
consideration.  The  substantial  anti-inflammatory  activity  of  
L. usitatissimum has been ascribed to its primary active constituent 
ALA (57.38 percent), which suppresses arachidonic acid metab-
olism  thus  inhibiting  the  synthesis  of  proinflammatory  n-6 
eicosanoids and reducing vascular permeability.9

In  2011  experiments,  Kaithwas  et  al.  identified  significant 
anti-inflammatory,  analgesic,  and  antipyretic  activities 
exhibited  by  the  fixed  oil  of  L.  usitatissimum.  The  oil  variably 
suppressed  prostaglandin  E2,  leukotriene-,  histamine-,  brady-
kinin-, and arachidonic acid-induced inflammation. In a mouse 
tail  immersion  model,  the  oil  showed  analgesic  properties 
similar to aspirin against acetic acid-induced writhing. The oil 
was  also  comparable  to  aspirin  in  antipyretic  activity  in 
response to typhoid paratyphoid A/B vaccine-induced pyrexia. 
The  investigators  attributed  this  broad  range  of  biological 
activity to the ALA rife in the herbal extract.8

 orAL uSeS

Flaxseed meal and oil have long been used for dietary purposes 
and as oral medications. In modern times, the anti-inflammatory 
activity  of  dietary  flaxseed  oil,  rich  in  ALA,  was  found  by 
Takemura et al. in 2002 to be effective in inhibiting ultraviolet 
(UV) B-induced skin damage to hairless mice; no such effects 
were observed from topical application.10

In  2011,  Neukam  et  al.  conducted  a  randomized,  double-
blind,  12-week  intervention  with  two  healthy  13-member 
groups  of  females  with  sensitive  skin  to  assess  the  effect  of 
daily supplementation with flaxseed oil and safflower seed oil. 
On day 0 and at weeks 6 and 12, investigators evaluated fatty 
acid profiles, transepidermal water loss (TEWL), as well as skin 
sensitivity, hydration, and surface. The flaxseed group experi-
enced significant reductions in skin roughness, scaling, and sen-
sitivity  (after  irritation  provoked  by  nicotinate),  as  well  as 
TEWL.  Smoothness  and  hydration  were  augmented  in  this 
group  while  the  ratio  of  ω-6  to  ω-3  fatty  acids  in  plasma 
declined.  This  ratio  increased  in  the  safflower  group,  which 
experienced  a  significant  decrease  in  skin  roughness  and 
increase in hydration, but less so and at a later point than the 
flaxseed  group  and  no  other  improvements  were  noted.  The 
investigators concluded that daily consumption of flaxseed oil 
imparts cutaneous benefits.11

 
 ToPIc AL uSeS

In a randomized, double-blind, placebo-controlled application test 
in 2009, De Spirt et al. studied the cutaneous effects of supplemen-
tation with flaxseed or borage oil for 12 weeks in two groups of 
women (n = 45) between the ages of 18 and 65 with sensitive and 
dry  skin.  Fifteen  women  were  in  each  treatment  group,  with  
15 randomly assigned to a control group given a placebo composed 
of  medium-chain  fatty  acids.  ALA  and  linoleic  acids  were  the 
primary constituents in the flaxseed oil and linoleic and γ-linolenic 
acids were the main constituents in the borage oil used. ALA was 
found to have contributed to the significant rise in total fatty acids 
in plasma seen in the flaxseed oil group at weeks 6 and 12. An 
increase  in  γ-linolenic  acid  was  noted  in  the  borage  oil  group. 
Erythema,  roughness,  and  scaling  were  decreased  in  both 
treatment groups compared to baseline while skin hydration was 
markedly  elevated  after  12  weeks.  In  addition,  TEWL  was 
diminished  by  10  percent  after  six  weeks  in  both  oil  treatment 
groups,  with  further  reductions  after  12  weeks  identified  in  the 
flaxseed oil group. The investigators concluded that intervention 
with dietary lipids can manifest in skin improvements.1

In 2012, Felippi et al. conducted a pilot study to ascertain the 
safety  and  efficacy  of  nanoparticle  formulation  for  cosmetic 
application, with various antioxidants including flaxseed oil and 
coenzyme Q10 among the encapsulated active ingredients in the 
nanoparticles. Various  in vitro and clinical tests revealed that the 
nanoparticles were not comedogenic, sensitizing, or irritating and 
showed no potential for cytotoxicity or producing oxidative stress. 
Further, exposure to UVA did not result in phototoxicity. Efficacy 
was  tested  and  established  in  healthy  volunteers  with  varying 
levels of periorbital wrinkles. The nanoparticles yielded significant 
decreases in wrinkling after 21 days of application as compared to 
a  control  product.  The  investigators  concluded  that  the  antioxi-
dant-laden  nanoparticles  were  safe  for  topical  application  in 
antiaging cosmetic products.12

Notably,  flaxseed  oil  is  also  among  several  natural  agents 
developed for the diverse armamentarium used to treat psoriasis.13 
The raw oil is used as an astringent in fungicidal lotions, and for 
insect repellent and insecticidal activity.8

 SAFe TY ISSueS

Although too volatile to cook with, flaxseed oil is considered safe 
and  healthy  to  consume.6  There  are  no  reports  of  significant 
adverse events associated with topically applied flaxseed products.

 eNVIroNMeNTAL IMPA cT

Pesticides  and  fungicides  are  used  in  the  conventional 
cultivation  of  flax.  Organic  farming  of  flaxseed  mitigates  the 
environmental toll. The use of flax as a fiber plant for clothing 
was  largely  supplanted  by  the  cotton  industry  in  the  late 
19th century, but it is still cultivated for this purpose. Oil flax is 
cultivated for dietary, cosmetic, and pharmaceutical purposes.14

 ForMuLATIoN coNSIDer ATIoNS

Flaxseed oil, as a calcareous liniment oil, is included in Brazil’s 
national  pharmacopeia  as  a  treatment  for  burns  and  pruritic 
dermatoses.15 It is indicated for wounds and as a moisturizer and 
dermal antioxidant in traditional Chinese and Ayurvedic medi-
cine.15,16  A  test  water-in-oil  emulsion  containing  flaxseed  oil, 
Shorea robusta, and Yashada bhasma (zinc complex) was recently 

C H A P T E R  51  ■   F L A X S E E D   O I L  

161

shown by Datta et al. to be more effective at wound contraction, 
enhancing  cutaneous  tensile  strength,  and  increasing  collagen 
levels in Wistar rats as compared to a control group.16

 uSAGe  coNSIDer ATIoNS

Oils  may  affect  absorption  of  other  ingredients,  especially 
those that contain oleic acid. This should be kept in mind when 
choosing other ingredients to use with flaxseed oil.17

 SIGNIFIc ANT BAcKGrouND

Animal Studies
In 2010, Kaithwas and Majumdar evaluated the anti-inflamma-
tory  potential  of  flaxseed  fixed  oil  against  castor  oil-induced 
diarrhea, turpentine oil-induced joint edema, as well as formal-
dehyde  and  Complete  Freund’s  Adjuvant  (CFA)-induced 
arthritis  in  Wistar  albino  rats.  They  found  that  flaxseed  oil 
dose-dependently inhibited the adverse effects of castor oil and 
turpentine oil as well as CFA, and a significant inhibitory effect 
was also exerted by flaxseed oil against formaldehyde-induced 
proliferation  of  global  edematous  arthritis.  Flaxseed  oil  also 
significantly diminished the secondary lesions engendered by 
CFA by dint of a delayed hypersensitivity reaction. The authors 
concluded  that  the  significant  anti-inflammatory  activity 
imparted  by  L.  usitatissimum  fixed  oil  suggests  its  therapeutic 
viability  for  inflammatory  conditions,  such  as  rheumatoid 
arthritis.9

Recently, de Souza Franco et al. studied the effects on skin 
wounds in Wistar rats of a semisolid formulation of flaxseed oil 
(1, 5, or 10 percent). The investigators assessed the contraction/
re-epithelialization of the wound and resistance to mechanical 
traction in incisional and excisional models, respectively. They 
found that the groups treated with flaxseed oil 1 or 5 percent 
largely  started  re-epithelialization  earlier  than  the  petroleum 
jelly control group and achieved complete re-epithelialization 
on the 14th day after injury, as compared to 33.33 percent of 
animals  in  the  petroleum  jelly  group.  The  investigators  con-
cluded that flaxseed oil, at low concentrations, exhibits poten-
tial  in  a  solid  pharmaceutical  preparation,  for  use  in  dermal 
repair.15

Early in 2012, Tülüce et al. set out to ascertain the antioxi-
dant  and  antiapoptotic  effects  of  flaxseed  oil  exerted  against 
UVC-induced  damage  in  Sprague-Dawley  albino  male  rats. 
They  divided  animals  into  three  groups:  control,  UVC  alone, 
and UVC and flaxseed oil. UVC light exposure lasted for one 
hour twice daily for four weeks in the two exposure groups. In 
the flaxseed oil group, the oil was administered by gavage prior 
to each irradiation (4 mL/kg bw). The investigators noted that 
malondialdehyde  and  protein  carbonyl  levels  were  higher  in 
the UVC group compared to the controls, but such levels were 
reduced in the flaxseed oil group compared to the UVC only 
group, in skin, lens, and sera. Also, the activities of glutathione 
peroxidase and superoxide dismutase were found to be higher 
in the skin, lens, and sera of the flaxseed oil group as compared 
to  the  UVC  only  group.  In  addition,  retinal  apoptosis  was 
lower in the flaxseed group than the UVC group. The research-
ers  concluded  that  flaxseed  oil  may  be  useful  in  conferring  a 
photoprotective effect against UVC-induced damage, as mani-
fested  in  protein  carbonylation  and  reactive  oxygen  species 
generation, in rats.2

 
162 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

 coNcL uSIoN

Flaxseed oil has gained recent attention for its salutary effects as 
part  of  the  diet.  Rich  in  ω-3  essential  fatty  acids  and  lignans, 
flaxseed  oil  has  been  found  to  improve  fatty  acid  profiles. 
Significantly, emerging evidence points to beneficial cutaneous 
effects  being  derived  from  dietary  use  of  flaxseed  oil.  Much 
more research is necessary to determine whether the beneficial 
constituents of flaxseed oil can be harnessed in topical products.

reFereNceS

1.  De Spirt S, Stahl W, Tronnier H, et al. Intervention with flaxseed 
and borage oil supplements modulates skin condition in women. 
Br J Nutr. 2009;101:440.

2.  Tülüce Y, Ozkol H, Koyuncu I. Photoprotective effect of flax seed 
oil (Linum usitatissimum L.) against ultraviolet C-induced apop-
tosis and oxidative stress in rats. Toxicol Ind Health. 2012;28:99.
3.  Hoffmann D. Medical Herbalism: The science and  practice of herbal 

medicine. Rochester, VT: Healing Arts Press; 2003:57.

4.  Axelson  M,  Sjövall  J,  Gustafsson  BE,  et  al.  Origin  of  lignans  in 
mammals  and  identification  of  a  precursor  from  plants.  Nature. 
1982;298:659.

5.  Scalbert  A,  Williamson  G.  Dietary  intake  and  bioavailability  of 

polyphenols. J Nutr. 2000;130:2073S.

6.  Foster S. 101 Medicinal Herbs: An Illustrated Guide. Loveland, CO: 

Interweave Press; 1998:88-89.

7.  Grieve M. A Modern Herbal (Vol 1). New York: Dover Publications; 

1971:317-9.

8.  Kaithwas G, Mukherjee A, Chaurasia AK, et al. Anti-inflammatory, 
analgesic  and  antipyretic  activities  of  Linum  usitatissimum  L. 
(flaxseed/linseed) fixed oil. Indian J Exp Biol. 2011;49:932.

9.  Kaithwas  G,  Majumdar  DK.  Therapeutic  effect  of  Linum 
usitatissimum  (flaxseed/linseed)  fixed  oil  on  acute  and  chronic 
arthritic  models  in  albino  rats.  Inflammopharmacology.  2010; 
18:127.

10.  Takemura  N,  Takahashi  K,  Tanaka  H,  et  al.  Dietary,  but  not 
topical, alpha-linolenic acid suppresses UVB-induced skin injury 
in  hairless  mice  when  compared  with  linoleic  acids.  Photochem 
Photobiol. 2002;76:657.

11.  Neukam K, De Spirt S, Stahl W, et al. Supplementation of flaxseed 
oil diminishes skin sensitivity and improves skin barrier function 
and condition. Skin Pharmacol Physiol. 2011;24:67.

12.  Felippi  CC,  Oliveira  D,  Ströher  A,  et  al.  Safety  and  efficacy  of 
antioxidants-loaded  nanoparticles  for  an  anti-aging  application. 
J Biomed Nanotechnol. 2012;8:316.

13.  Rahman  M,  Alam  K,  Ahmad  MZ,  et  al.  Classical  to  current 
approach  for  treatment  of  psoriasis:  A  review.  Endocr  Metab 
Immune Disord Drug Targets. 2012;12:287.

14.  GMO  Compass.  http://www.gmo-compass.org/eng/database/

plants/11.flaxseed.html. Accessed June 25, 2013.

15.  de Souza Franco E, de Aquino CM, de Medeiros PL, et al. Effect of 
a semisolid formulation of Linum usitatissimum L. (Linseed) oil 
on the repair of skin wounds. Evid Based Complement Alternat Med. 
2012;2012:270752.

16.  Datta  HS,  Mitra  SK,  Patwardhan  B.  Wound  healing  activity  of 
topical  application  forms  based  on  ayurveda.  Evid  Based 
Complement Alternat Med. 2011;2011:134378.

17.  Naik  A,  Pechtold  L,  Potts  RO,  et  al.  Mechanism  of  oleic  acid-
induced  skin  penetration  enhancement  in  vivo  in  humans. 
J Control Release. 1995;37:299.

 
C H A P T E R   5 2

Phloretin

C H A P T E R  52  ■   P H LO R E T I N  

163

Activities:
Antioxidant, anti-inflammatory,1 antibacterial,1 antican-
cer,2  penetration  enhancement,  photoprotection,  skin 
lightening

Important Chemical Components:

The International Union of Pure and Applied Chemistry 
(IUPAC)  designation  is  3-(4-hydroxyphenyl)-1-(2,4,6-
trihydroxyphenyl)-1-propanone.3  It  is  also  known  as 
2′,4′,6′-trihydroxy-3-(4-hydroxyphenyl)-propiophe-
none. Its molecular formula is C15H14O5.

Origin Classification:

Phloretin is natural and found in various foods.

Personal Care Category: 

Photoprotection

Recommended for the following Baumann Skin 
Types: 

DRNW,  DRPT,  DRPW,  DSNW,  DSPW,  ORPT,  ORPW, 
OSPT, OSPW, and OSNW

 SOURCE

Reportedly  capable  of  demonstrating  antioxidant  activity, 
phloretin  (also  known  as  dihydronaringenin,  phloretol,  and 
naringenin chalcone) is a plant-derived dihydrochalcone poly-
phenol primarily found in various species of apple (in copious 
supply),  pear,  and  other  plants  in  the  Rosaceae  family,  and 
recently  found  in  much  smaller  quantities  in  various  tomato 
species and strawberries.2,4 Phloretin and its glucoside phlorid-
zin have also been identified in tomatoes and are considered an 
important source of dietary flavonoids.5

 HISTORY

Phloridzin  was  first  isolated  from  apple  tree  bark  in  1835  by 
DeKonnick.6 Of course, the health benefits of apples and other 
sources  of  phloretin  have  been  passed  down  anecdotally  for 
centuries. In the late 1980s, botanically-derived flavonoid com-
pounds, specifically phloretin and the structurally related com-
pound  nordihydroguaiaretic  acid  (NDGA),  were  found  to 
strongly inhibit keratinocyte growth and were therefore thought 
to exhibit antipsoriatic activity.7 The preponderance of research 
on phloretin and phloridzin has taken place in an in vitro setting.

scavenging and the suppression of lipid peroxidation.8 Along 
with  its  glucoside  phloridzin,  phloretin  is  believed  to  be  an 
important  contributor  to  the  health  benefits  of  apples.9  In 
addition, it was once used as a substitute for quinine. Notably, 
dihydrochalcones  are  among  five  polyphenolic  groups  that 
have  been  identified  in  apples,  also  including  hydroxycin-
namic acids, flavan-3-ols/procyanidins, anthocyanins, and fla-
vonols.9–11 One of the main biological actions of phloretin is 
the inhibition of glucose cotransporter 1.4 It is also thought to 
exert antithrombotic activity.4

 ORAL USES

Phloretin is consumed regularly as a key active ingredient in sev-
eral  fruits.  In  a  study  of  eight  different  apple  cultivars  (Red 
Delicious, Golden Delicious, Cortland, Empire, Ida Red, McIntosh, 
Mutsu, and Northern Spy), a much greater concentration of poly-
phenols was found in the peel as compared to the flesh.9

 TOPICAL USES

Phloretin has been studied as a key ingredient in a combination 
topical solution. In 2008, Oresajo et al. assessed the effects of a 
topical antioxidant formulation including 10 percent L-ascorbic 
acid,  2  percent  phloretin,  and  0.5  percent  ferulic  acid  in 
mitigating ultraviolet (UV)-induced harm in 10 normal, healthy 
volunteers  (aged  18–69  years).  Biomarkers  of  cutaneous 
damage,  including  formation  of  sunburn  cells  and  thymine 
dimers,  and  the  expression  of  matrix  metalloproteinase 
(MMP)-9  and  p53  protein,  were  evaluated  in  the  Fitzpatrick 
skin type II or III subjects who were randomized and treated 
daily for four days with the antioxidant combination or vehicle 
control on the lower back. Pretreatment with the antioxidant 
mixture  effectively  suppressed  UV-induced  damage  and  also 
prevented  UV  exposure  from  provoking  immunosuppressive 
effects. The investigators concluded that the dual role of phlo-
retin,  as  strong  antioxidant  and  penetration  enhancer,  acts  in 
this topical formulation to augment the skin availability of the 
other  antioxidants.  They  also  suggested  that  the  antioxidant 
formulation could enhance photoprotection of human skin by 
serving a complementary role to sunscreens.12

 SAFETY ISSUES

There  are  no  specific  reports  of  adverse  effects  associated  with 
phloretin or phloridzin in the literature to the author’s knowledge.

 CHEMISTRY

Phloretin occurs as a glycoside, particularly in the Rosaceae and 
Ericaceae  families.1  Phloridzin,  the  glucoside  form  of  phloretin, 
has been found to display potent antioxidant activity in peroxyni-
trite, hydroxyl, and 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical 

 ENVIRONMENTAL IMPACT

The effects on the environment traceable to phloretin pertain 
to the cultivation and transport of the fruits in which the poly-
phenol is found.

 
164 

COs mE C EuT I C A Ls  A Nd   C

Os mE T I C   INgR EdI E N T

s

TABLE 52-1
Pros and Cons of Phloretin

Pros
Potent antioxidant
Cancer prevention potential
Can penetrate the skin and interact with 

other antioxidants

Cons
Expensive
difficult to formulate

 FORMULATION CONSIDERATIONS

Phloridzin typically displays a brown color, rendering it diffi-
cult  to  formulate  (Table  52-1).  In  2012,  Baldisserotto  et  al. 
reported on the production, stability, and antimicrobial activity 
of  a  novel  semi-synthetic  phloridzin  derivative.  The  product, 
F2,  was  found  to  exhibit  antioxidant  potency  comparable  to 
phloridzin but was more stable in topical formulations.6

 USAGE CONSIDERATIONS

No interactions with other ingredients are known by the author.

 SIGNIFICANT BACKGROUND

In Vitro Studies
In  2001,  phloretin  was  evaluated  for  its  potential  to  enhance 
the  cutaneous  penetration  of  lignocaine  hydrochloride  deliv-
ered  transdermally.  Investigators  first  treated  excised  human 
skin  samples  with  phloretin  applied  as  a  methanolic  solution  
12 hours before lignocaine application, at pH 4 and 7. At a pH 
of 4, a 3.2-fold increase in total permeation was seen as com-
pared with the control after 24 hours. Unilamellar phosphati-
dylcholine liposomes were used as a vehicle for phloretin in a 
subsequent  test,  with  a  5.4-fold  greater  permeation  of  ligno-
caine observed in pretreated skin compared with control after 
24 hours. Investigators concluded that phloretin  indeed  dem-
onstrated potential as a transdermal penetration enhancer for 
lignocaine.13

In 2003, Auner et al. showed that permeation of porcine skin 
with  phloretin  and  6-ketocholestanol  prior  to  treatment  with 
5-aminolevulinic acid increased acid diffusion (the permeation of 
which was enhanced by cetylpyridinium chloride and benzalko-
nium  chloride)  at  pH  7  approximately  1.7-fold.14  In  an  experi-
ment  also  published  in  April  2003,  the  same  team  studied  the 
same  compounds,  phloretin  and  6-ketocholestanol  included  in 
unilamellar liposomes, for the viability of enhancing the trans-
port of sodium-fluorescein across rat, porcine, and human skin. 
Both compounds were used to pretreat the skin. Phloretin was 
found to have a significant positive effect on sodium-fluorescein 
diffusion in rat and porcine skin after 30 hours but no influence 
on human skin as compared to control; 6-ketocholestanol exhib-
ited a positive effect on all skin types.3

Using various methods to evaluate membrane interactions, 
some of the same investigators, led by Valenta, subsequently 
determined that phloretin and 6-ketocholestanol interact with 
the lipid layer and alter the structure, rendering a greater fluidity 
in the membrane.15 In addition, Auner and Valenta published a 
study on the effects of phloretin on the topical permeation of 
lidocaine  using  one  hydrophilic  and  three  lipophilic  delivery 

systems.  The  researchers  conducted  standard  diffusion 
experiments  with  Franz  type  diffusion  cells  through  porcine 
skin  and  found  that  phloretin  enhanced  lidocaine  diffusion, 
with permeation enhanced 1.39-fold in the hydrophilic formu-
lation  and  from  1.25-  to  1.76-fold  in  the  lipophilic  formula-
tions.16  More  recently,  Auner  et  al.  have  shed  light  on  the 
mechanisms of action of phloretin, as well as 6-ketocholestanol. 
Their  increase  in  stratum  corneum  (SC)  intercellular  lipid 
bilayer fluidity is thought to impart the observed penetration-
enhancing effects associated with these compounds. Evaluation 
of  the  effects  of  these  compounds  on  phase  transition  and 
enthalpy  revealed  that  both  compounds  decrease  the  diffu-
sional resistance of the SC to drugs with a hydrophilic-lipophilic 
equilibrium.17

In a 2008 examination of the phytochemicals in apples and 
apple juices for the purposes of ascertaining the relative contri-
butions to potential chemopreventive properties, investigators 
fractionated  a  polyphenol-enriched  apple  juice  extract  and 
measured  antioxidant  effects,  modulation  of  carcinogen  
metabolism,  anti-inflammatory  and  antihormonal  activities, 
and  antiproliferative  potential.  They  identified  phloretin  and 
epicatechin  as  the  strongest  inhibitors  of  cyclooxygenase  1, 
which  could  contribute  to  an  anti-inflammatory  effect 
potentially  conferred  by  apples.18  The  researchers  concluded 
that  the  combination  of  various  constituents  exhibiting 
complementary properties may lead to increased total chemo-
preventive benefits.

Earlier in 2003, investigators assessing the contribution of the 
major phenolic phytochemicals in apples to the total antioxidant 
capacity of the fruit using a 2, 2’-azinobis (3-ethylbenzothiazoline-
6-sulfonic  acid)  radical-scavenging  assay,  and  expressed  as 
vitamin  C  equivalent  antioxidant  capacity,  found  a  linear  rela-
tionship  between  phenolic  concentration  and  total  antioxidant 
activity. Therefore, they estimated the greatest phenolic contri-
bution to the total antioxidant capacity of apples to be derived 
from quercetin, followed in order by epicatechin, procyanidin B2, 
phloretin,  and  chlorogenic  acid,  with  the  contribution  from 
vitamin C falling just ahead of phloretin.19

In 2007, Lin et al. isolated and identified 13 compounds from 
the Formosan apple (Malus doumeri), a native Taiwanese botani-
cal,  including  3-hydroxyphloretin,  which  demonstrated  potent 
antioxidant and cellular tyrosinase-reducing activities in human 
epidermal  melanocytes.  In  addition,  3-hydroxyphloretin  was 
found to be one of the two most active constituents, along with 
catechol, also exhibiting activity as a competitive inhibitor in a 
kinetic analysis of mushroom tyrosinase. The investigators con-
cluded  that  both  compounds  display  potential  as  cosmetic 
agents.20  The  tyrosinase-reducing  activities  associated  with 
phloretin suggest intriguing potential as a skin-lightening agent.

Several  of  the  same  investigators  earlier  reported  on  the 
seven phenolic compounds isolated from the Taiwanese apple 
that were assessed for their potential application in skin care. 
Specifically,  the  researchers  found  that  the  compounds 
3-hydroxyphloridzin, 3-hydroxyphloretin, and quercetin dem-
onstrated  the  most  potent  free  radical-scavenging  properties 
against  DPPH  and  superoxide  radicals.  The  phloretin  com-
pounds  (the  glucoside  phloridzin)  also  exhibited  inhibitory 
activity  against  xanthine  oxidase  and  elastase.  These  sub-
stances  were  also  found  to  suppress  MMP-1  synthesis  in 
human  fibroblast  cells.  This  is  significant  because  these 
enzymes break down key dermal constituents, contributing to 
cutaneous  aging.  The  team  concluded  that  the  phloretin 
extracts as well as quercetin show potential for use in antiaging 
or other cosmetic formulations.21

 
skin 

carcinogenesis 

Anticancer Activity
In 2012, Shin et al. studied the effects of phloretin in a mouse tumor 
model  and  found  that  topically  applied  phloretin  significantly 
blocked  mouse 
initiated  with 
7,12-dimethylbenz[a]anthracene  (DMBA)  and  promoted  with 
12-O-tetradecanoylphorbol  13-acetate  (TPA).  Further,  phloretin 
pretreatment  of  dorsal  skin  dose-dependently  suppressed  TPA-
induced cyclooxygenase-2 (COX-2) expression. The investigators 
also noted that topically applied phloretin reduced the TPA-induced 
DNA binding of nuclear factor-κB (NF-κB), the transcription factor 
that accounts for TPA-induced COX-2 expression in mouse skin. 
The investigators suggested that these and other inhibitory effects 
may partially explain the antitumor-promoting effects of phloretin 
on skin carcinogenesis in mice.2 Notably, phloretin had previously 
been  shown  to  selectively  suppress  TPA-induced  calcium-  and 
phospholipid-dependent protein kinase activity in mouse epider-
mis.22  Also,  phloretin  derivatives  have  been  demonstrated  to 
inhibit croton oil-induced mouse ear edema.23

Interestingly,  phloretin  has  also  been  found  to  hinder  the 
growth  of  several  cancer  cells  and  to  induce  apoptosis  of  B16 
melanoma,  HL60  human  leukemia  cells,  and  HT-29  human 
colon cancer cells, which Park et al., in an investigation of the 
effects  of  the  flavonoid  on  the  human  colon  cancer  cell  line, 
speculate may be mediated via mitochondrial membrane perme-
ability alterations and activation of caspase pathways.24

Other Applications
Gitzinger et al. have engineered a hybrid  Pseudomonas putida-
mammalian genetic unit responsive to phloretin – the phloretin-
adjustable control element (PEACE) – which, when formulated 
in  a  skin  lotion,  was  found  to  have  the  capacity  to  calibrate 
target genes and adjust heterologous serum protein levels when 
topically  applied  to  mice.  The  investigators  believe  that  this 
new technology has potential in gene- and cell-based biophar-
maceutical treatments.25

 CONCLUSION

The evidence thus far compiled on the potential salutary effects 
of  topical  phloretin,  a  phenolic  compound  found  most  abun-
dantly in various species of apples, and also in pears, is relatively 
modest.  Nevertheless,  data  appear  to  suggest  that  phloretin 
exhibits antioxidant activity in oral form and a potentially signifi-
cant influence on the skin, particularly in enhancing the permea-
tion of other ingredients. While much more research is necessary, 
particularly randomized controlled trials, this botanical ingredient 
is an intriguing addition to the ever-expanding roster of naturally-
derived ingredients with the potential to impart significant health 
benefits to the skin. Of course, it also may provide some support 
to the old adage “an apple a day keeps the doctor away.”

REFERENCES

1.  Hoffmann  D.  The  endocrine  system.  In:  Medical  Herbalism:  The 
Science and Practice of Herbal Medicine. Rochester, VT: Healing Arts 
Press; 2003:108.

2.  Shin  JW,  Kundu  JK,  Surh  YJ.  Phloretin  inhibits  phorbol  ester-
induced tumor promotion and expression of cyclooxygenase-2 in 
mouse  skin:  Extracellular  signal-regulated  kinase  and  nuclear 
factor-κB as potential targets. J Med Food. 2012;15:253.

C H A P T E R  52  ■   P H LO R E T I N  

165

3.  Auner  BG,  Valenta  C,  Hadgraft  J.  Influence  of  phloretin  and 
6-ketocholestanol on the skin permeation of sodium-fluorescein. 
J Control Release. 2003;89:321.

4.  Stangl V, Lorenz M, Ludwig A, et al. The flavonoid phloretin sup-
presses stimulated expression of endothelial adhesion molecules 
and reduces activation of human platelets. J Nutr. 2005;135:172.
5.  Slimestad R, Fossen T, Verheul MJ. The flavonoids of tomatoes.  

 J Agric Food Chem. 2008;56:2436.

6.  Baldisserotto A, Malisardi G, Scalambra E, et al. Synthesis, anti-
oxidant and antimicrobial activity of a new phloridzin derivative 
for dermo-cosmetic applications. Molecules. 2012;17:13275.

7.  Wilkinson DI, Orenberg EK. Effects of nordihydroguaiaretic acid, 
phloretin,  and  phloridzin  on  the  activity  of  adenylate  cyclase, 
lipoxygenase  and  hexose  transport,  and  growth  of  cultured 
keratinocytes. Int J Dermatol. 1987;26:660.

8.  Rezk BM, Haenen GR, van der Vijgh WJ, et al. The antioxidant 
activity of phloretin: The disclosure of a new antioxidant phar-
macophore  in  flavonoids.  Biochem  Biophys  Res  Commun. 
2002;295:9.

9.  Tsao  R,  Yang  R,  Young  JC,  et  al.  Polyphenolic  profiles  in  eight 
apple  cultivars  using  high-performance  liquid  chromatography 
(HPLC). J Agric Food Chem. 2003;51:6347.

10.  Hyson DA. A comprehensive review of apples and apple compo-
nents  and  their  relationship  to  human  health.  Adv  Nutr. 
2011;2:408.

11.  Gerhauser C. Cancer chemopreventive potential of apples, apple 

juice, and apple components. Planta Med. 2008;74:1608.

12.  Oresajo  C,  Stephens  T,  Hino  PD,  et  al.  Protective  effects  of  a 
topical  antioxidant  mixture  containing  vitamin  C,  ferulic  acid, 
and phloretin against ultraviolet-induced photodamage in human 
skin. J Cosmet Dermatol. 2008;7:290.

13.  Valenta  C,  Cladera  J,  O’Shea  P,  et  al.  Effect  of  phloretin  on  the 
percutaneous  absorption  of  lignocaine  across  human  skin.  
 J Pharm Sci. 2001;90:485.

14.  Auner BG, Valenta C, Hadgraft J. Influence of lipophilic counter-
ions in combination with phloretin and 6-ketocholestanol on the 
skin  permeation  of  5-aminolevulinic  acid.  Int  J  Pharm. 
2003;255:109.

15.  Valenta C, Steininger A, Auner BG. Phloretin and 6-ketocholestanol: 
Membrane interactions studied by a phospholipids/polydiacety-
lene  colorimetric  assay  and  differential  scanning  calorimetry.  
Eur J Pharm Biopharm. 2004;57:329.

16.  Auner BG, Valenta C. Influence of phloretin on the skin permea-
tion  of  lidocaine  from  semisolid  preparations.  Eur  J  Pharm 
Biopharm. 2004;57:307.

17.  Auner BG, O’Neill MA, Valenta C, et al. Interaction of phloretin 
and  6-ketocholestanol  with  DPPC-liposomes  as  phospholipid 
model membranes. Int J Pharm. 2005;294:149.

18.  Zessner  H,  Pan  L,  Will  F,  et  al.  Fractionation  of  polyphenol-
enriched apple juice extracts to identify constituents with cancer 
chemopreventive  potential.  Mol  Nutr  Food  Res.  2008; 
52(Suppl 1):S28.

19.  Lee  KW,  Kim  YJ,  Kim  DO,  et  al.  Major  phenolics  in  apple  and 
their  contribution  to  the  total  antioxidant  capacity.  J  Agric  Food 
Chem. 2003;51:6516.

20.  Lin YP, Hsu FL, Chen CS, et al. Constituents from the Formosan 
apple  reduce  tyrosinase  activity  in  human  epidermal  melano-
cytes. Phytochemistry. 2007;68:1189.

21.  Leu  SJ,  Lin  YP,  Lin  RD,  et  al.  Phenolic  constituents  of  Malus 
doumeri var. formosana in the field of skin care. Biol Pharm Bull. 
2006;29:740.

22.  Gschwendt M, Horn F, Kittstein W, et al. Calcium and phospholipid-
dependent  protein  kinase  activity  in  mouse  epidermis  cytosol. 
Stimulation  by  complete  and  incomplete  tumor  promoters  and 
inhibition  by  various  compounds.  Biochem  Biophys  Res  Commun. 
1984;124:63.

23.  Blazsó G, Gábor M. Effects of prostaglandin antagonist phloretin 
derivatives on mouse ear edema induced with different skin irri-
tants. Prostaglandins. 1995;50:161.

24.  Park SY, Kim EJ, Shin HK, et al. Induction of apoptosis in HT-29 

colon cancer cells by phloretin. J Med Food. 2007;10:581.

25.  Gitzinger M, Kemmer C, El-Baba MD, et al. Controlling transgene 
expression in subcutaneous implants using a skin lotion contain-
ing  the  apple  metabolite  phloretin.  Proc  Natl  Acad  Sci  U S A. 
2009;106:10638.

 
166 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   5 3

Caffeic Acid

Activities:
Antioxidant, anticarcinogenic,1 anti-inflammatory, anti-
microbial,2,3  immunostimulatory,  neuroprotective,4 
photoprotective

Important Chemical Components:

Also known as 3,4-dihydroxycinnamic acid, its molecu-
lar formula is C9H8O4.

Origin Classification:

Naturally  found  in  a  wide  array  of  fruits,  grains,  and 
vegetables. Organic forms are available.

Personal Care Category: 

Antioxidant, antiaging

Recommended for the following Baumann Skin 
Types: 

DRNT, DRNW, DRPW, DSNT, DSNW, DSPW, ORNT, 
ORNW, ORPW, OSNT, OSNW, and OSPW

 SOURCE

Caffeic  acid  (3,4-dihydroxycinnamic  acid)  is  found  in  several 
grains,  fruits,  and  vegetables.5  It  also  occurs  in  Coffea  arabica 
(coffee  beans),  particularly  in  its  esterified  form,  chlorogenic 
acid  (5-caffeoylquinic  acid).6,7  Some  of  the  best  sources  of 
caffeic  acid,  besides  coffee,  include  grapes,  wine,  tea,  apples 
and apple juice, cider, blueberries, sunflower seeds, olives, olive 
oil,  argan  oil,  spinach,  cabbage,  asparagus,  and  globe  arti-
choke.4,8–12  Caffeic  acid  is  one  of  the  main  hydroxycinnamic 
acids (along with ferulic and coumaric), a major class of phe-
nolic  compounds  that  represent  the  most  widely  dispersed 
phenylpropanoids in plants.6,8 Further, it is one of the primary 
constituents  of  Rosmarinus  officinalis  (rosemary)  and  Capparis 
spinosa (caper bush), which have been shown to confer cutane-
ous benefits.13,14 Rosemary, in fact, is used often as a spice and 
is included in beverages, cosmetics, and as a therapeutic herb in 
traditional medicine.13

Caffeic acid has also been isolated in various other plants, 
including Melissa officinalis (lemon balm), and several species of 
Echinacea, which are known to exhibit various clinical proper-
ties.15–20 In addition, derivatives of caffeic acid are important 
components  in  Plantago  major,  a  plant  used  broadly  in  tradi-
tional  folk  medicines.21  Caffeic  acid  phenethyl  ester  (CAPE), 
an active constituent of propolis extract, a product of honey-
bee  hives  (see  Chapter  60,  Honey/Propolis/Royal  Jelly),  spe-
cifically inhibits nuclear factor (NF)-κB and is known to display 
a wide array of biological activity, including antioxidant, anti-
inflammatory, antiproliferative, cytostatic, and antineoplastic.22 
It  has  greater  lipid  solubility  and  is  thought  to  exert  greater 
anti-inflammatory  and  antibacterial  activity  as  compared  to 
caffeic acid.23,24

 HISTORY

Cognizance of health benefits derived from caffeic acid dates back 
at least to 400 BCE, when herbal formulations including caffeic 
acid were administered to facilitate sleep. It is not known who 
first discovered caffeic acid. Notably, even though caffeic acid and 
caffeine are present in coffee, they are unrelated compounds. 

 CHEMISTRY

Along with other polyphenolic acids such as ferulic, ellagic, and 
tannic, caffeic acid is thought to have considerable anticarcinogenic 
potential,25  and  is  known  to  confer  antioxidant  activity  
(Table 53-1).12 Like ferulic acid, caffeic acid is also synthesized in 
the  wide  variety  of  plants  in  which  it  is  found  through  the 
shikimate  pathway  from  l-phenylalanine  or  l-tyrosine  (see 
Chapter 54, Ferulic Acid).8,26 Caffeic acid is conjugated with sac-
charides,5,26 reacts with nitrogen oxides, and has been shown to 
protect phopholipidic membranes from ultraviolet (UV)-induced 
peroxidation by inhibiting the lipid peroxidative chain reaction.27 
More  significantly,  caffeic  acid  has  also  been  demonstrated  to 
protect human skin from UVB-induced erythema.5 Caffeic acid is 
thought to be a stronger antioxidant than ferulic acid but not as 
effective at permeating the skin.4,27

 ORAL USES

Consumed  regularly  through  myriad  foods  and  beverages 
throughout the world as the primary dietary hydroxycinnamic 
acid,  caffeic  acid  is  a  key  constituent  of  several  vegetables, 
fruits, and grains and, especially, coffee. It is difficult to quan-
tify the direct contributions of caffeic acid to skin health.

 TOPICAL USES

Caffeic acid is a key constituent in kigelia fruit extract, which 
has shown significant anticarcinogenic activity and is used in 
various  parts  of  the  world,  other  than  the  United  States,  in 
products  to  help  defend  against  skin  cancer.  Standardized 
water, ethanol, and dichloromethane extracts of Kigelia pinnata 
have been found to dose-dependently inhibit several melanoma 
cell lines.28 In addition, caffeic acid is found as an ingredient in 
several multibotanical formulations.

The esterified form of caffeic acid known as CAPE has been 
used  topically  as  an  ingredient  in  sunless  tanning  products  to 
provide a more natural-looking tan than previous products.29

TABLE 53-1
Pros and Cons of Caffeic Acid

Pros
Potent antioxidant
Abundant in a range of dietary sources
Good in vitro evidence of photoprotective activity
Can penetrate the stratum corneum27

Cons
Limited clinical evidence for topical use
Usually not listed on cosmetic label

 
 SAFETY ISSUES

The author is unaware of any reports of adverse side effects or 
toxicity associated with caffeic acid.

 ENVIRONMENTAL IMPACT

Caffeic acid appears throughout the plant kingdom. Few if any 
of the plants are cultivated to harness caffeic acid specifically, 
however. Therefore, there is no known detrimental impact on 
the environment from cultivating plants such as C. arabica.

 FORMULATION CONSIDERATIONS

Noting that caffeic acid has displayed synergistically enhanced 
antioxidant activity when conjugated with amino acids, Kwak 
et  al.  used  hydroxamic  acid  and  prepared  caffeoyl-amino 
acidyl-hydroxamic  acid.  They  found  that  caffeoyl-prolyl-
hydroxamic  acid  then  exhibited  strong  antioxidant  and 
tyrosinase-inhibitory activity in several bioassays.30

In  2012,  Centini  et  al.  synthesized  several  new  multifunc-
tional surfactants in which ferulic or caffeic acid, coupled with 
an amino acid, played significant roles. The surfactants meet the 
most recent requirements for cosmetic ingredients by displaying 
emulsifying,  UV-protective,  and  radical-scavenging  activity. 
Notably, the investigators report that these versatile surfactants 
have the potential to be useful in treating various skin conditions, 
including those related to the deleterious effects of UV exposure, 
free radical damage, and loss of cellular antioxidants.4

In a 2013 in vitro study of the capacity of propolis phenolic 
acids  (including  caffeic  acid)  from  semisolid  formulations  to 
penetrate  into  human  skin,  Žilius  et  al.  indeed  showed  that 
these  acids  (caffeic,  ferulic,  vanillic,  and  coumaric)  demon-
strated  this  property.  Caffeic  acid  was  found  to  penetrate 
slowly into the epidermis with dermal penetration not clearly 
ascertained. Deeper penetration was observed in relation to the 
other  phenolic  compounds.  The  investigators  suggested  that 
more research is necessary in order to devise semisolid topical 
application systems that can more reliably deliver antioxidants 
from propolis into the skin.31

 USAGE CONSIDERATIONS

Caffeic acid is not typically seen on the cosmeceutical product 
label because it is usually a constituent of another ingredient in 
the product such as coffee or rosemary extract.

 SIGNIFICANT BACKGROUND

In Vitro Studies
In 2007, Marti-Mestres et al. studied the permeation of caffeic 
acid,  chlorogenic  acid,  and  the  natural  glycoside  oraposide 
through pig ear skin in vitro in order to evaluate the viability of 
these compounds for use in photoprotective skin formulations. 
After  at  least  48  hours  of  drug  contact,  investigators  found 
caffeic  and  chlorogenic  acids  in  all  skin  sections,  which  they 
thought  might  be  attributed  to  systemic  activity.  Oraposide 
was  found  in  the  upper  superficial  skin  layer,  suggesting  a 
greater facility of use for topical skin care formulation.32

In an in vitro study in five melanoma cell lines (B16-F0, B16-
F10,  SK-MEL-28,  SK-MEL-5,  and  MeWo),  Kudugunti  et  al. 

C H A P T E R  53  ■   C A F F E I C   AC I D  

167

demonstrated  that  CAPE  displays  significant  antimelanoma 
efficacy and low toxicity at 10 mg/kg/day.24

Caffeic acid was among the ingredients tested when Chiang 
et al. extracted C. arabica leaves with methanol and hydrolyzed 
various  concentrations  of  hydrochloric  acid  to  ascertain 
antiphotoaging  activity  in  2011.  Concentrations  of  caffeic  acid 
and  chlorogenic  acid  were  tested  for  matrix  metalloproteinase 
(MMP)  and  elastase  inhibition  and  in  vitro  results  showed  that 
caffeic acid mitigated UVB irritation by suppressing MMP-1 and 
MMP-9 expression and both caffeic and chlorogenic acids down-
regulated  the  mitogen-activated  protein  kinase  (MAPK)  path-
way.  None  of  the  extracts  affected  elastase.  The  investigators 
concluded that C. arabica and its polyphenolic constituents have 
potential as photodamage-preventing agents.33

In 2012, Pluemsamran et al. pretreated immortalized human 
keratinocyte (HaCaT) cells with caffeic acid or ferulic acid and 
found that the antioxidants suppressed UVA-induced cytotoxicity 
as  well  as  the  induction  of  MMP-1  activity  and  mRNA  and 
oxidant formation. The investigators speculated that caffeic and 
ferulic acids delivered protection against UVA-mediated MMP-1 
induction  in  HaCaT  cells  by  restoring  the  antioxidant  defense 
system at the cellular and molecular levels.34

Animal Studies
In 1988, Huang et al. assessed the effects of the topical applica-
tion  of  curcumin  as  well  as  caffeic,  chlorlogenic,  and  ferulic 
acids on 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced 
epidermal  ornithine  decarboxylase  activity,  epidermal  DNA 
synthesis,  and  skin  tumor  promotion  in  female  CD-1  mice. 
Although  curcumin  was  the  most  successful  in  suppressing 
TPA-induced tumors, all of the hydroxycinnamic acids showed 
some antitumorigenic activity (see Chapter 69, Turmeric).35

In  2006,  Staniforth  et  al.  reported  that  caffeic  acid  inhibited 
UVB  radiation-induced  interleukin-10  (IL-10)  expression  and 
phosphorylation of MAPK as well as MAPK signal transduction 
pathways  in  mouse  skin,  also  finding  that  the  polyphenol 
significantly  suppressed  UVB-induced  IL-10  mRNA  expression 
and protein synthesis. In addition, the investigators noted that a 
contact hypersensitivity assay demonstrated attenuation of local 
immune suppression imparted by caffeic acid. The investigators 
concluded  that  their  in  vivo  findings  indicate  that  caffeic  acid 
appears to offer significant protection against photocarcinogenesis 
and  immune  suppression  engendered  by  UVB  radiation.  They 
also  suggested  that  caffeic  acid  warrants  consideration  for  its 
potential as a topical protective agent against UVB damage.1

Also  in  the  same  year,  Yamada  et  al.  showed  that  orally 
administered caffeic acid lessened the skin damage induced by 
UVA-induced  reactive  oxygen  species  (ROS)  generation  in  the 
abdominal skin of live hairless mice. The researchers noted that 
caffeic  acid  was  efficiently  distributed  in  the  skin  after  oral 
administration. Topically applied caffeic acid also inhibited ROS 
generation from exposure to UVA.36

Using skin-incised mice to analyze the wound-healing effect 
of caffeic acid, Song et al. found that the polyphenol exhibited 
significant  anti-inflammatory  and  wound-healing  properties, 
including  collagen-like  polymer  production,  lipid  peroxidation, 
myeloperoxidase  activity,  and  phospholipase  A2  activity  while 
suppressing  the  silica-induced  generation  of  ROS,  melittin-
induced arachidonic acid release, and PGE2 production in Raw 
264.7  cells,  and  melittin-  or  arachidonic  acid-promoted  hista-
mine release in RBL 2H3 cells. The investigators concluded that 
their findings suggest strong antioxidant and anti-inflammatory 
effects imparted by caffeic acid contributing to wound healing in 
skin-incised mice.37

 
168 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

In  2012,  Khan  et  al.  studied  the  protective  effects  of  caffeic 
acid  against  TPA-induced  oxidative  stress,  inflammatory  dam-
age, as well as expression of NF-κB and cyclooxygenase (COX-2) 
in  mouse  skin.  Pretreatment  with  caffeic  acid  at  two  different 
doses before TPA application demonstrated that the polyphenol 
significantly suppressed TPA-induced lipid peroxidation, inflam-
matory  responses,  and  tumor  necrosis  factor-α  release  while 
upregulating glutathione content and various antioxidant enzy-
matic  activity.  Caffeic  acid  also  hindered  TPA-induced  NF-κB 
and COX-2 expression.38

Caffeic Acid Phenethyl Ester (CAPE)
In 1993, Frenkel et al. isolated CAPE from propolis to examine 
the effects of the compound on TPA-induced tumor promotion 
in SENCAR mice. Topical treatment with low doses of CAPE 
(0.1–6.5  nmol/topical  treatment)  were  found  to  inhibit 
polymorphonuclear leukocyte infiltration into mouse skin and 
ears,  hydrogen  peroxide  (H2O2)  synthesis,  and  formation  of 
oxidized bases in epidermal DNA. The investigators also found 
that CAPE suppressed TPA-induced H2O2 synthesis in bovine 
lenses. Overall, the investigators concluded that CAPE appears 
to  be  a  potent  chemopreventive  agent  with  broad  potential 
against diseases characterized by marked inflammatory and/or 
oxidative stress features, including cancers and cataracts.23

Indeed,  CAPE  has  been  found  to  possess  anticarcinogenic 
potential. In a mouse model, TPA was applied twice weekly to 
the  backs  of  CD-1  mice  previously 
initiated  with 
7,12-dimethylbenz[a]anthracene  (DMBA),  resulting  in  skin 
papillomas. Topical application of CAPE along with the tumor-
promoter TPA significantly inhibited the number of skin papillo-
mas  per  mouse  in  a  dose-dependent  manner  and  resulted  in 
reduced tumor size, also dose dependently. Further, CAPE appli-
cation  decreased  the  level  of  5-hydroxymethyl-2’-deoxyuridine 
(HMdU)  residue  in  epidermal  DNA  that  resulted  from  DMBA 
initiation.39  CAPE  was  previously  found  to  have  inhibited 
keratinocyte proliferation in a time- and concentration-dependent 
fashion. Investigators making this observation 10 years ago also 
noted that CAPE significantly inhibited full induction of ornithine 
decarboxylase (ODC) by epidermal growth factor (EGF) also in a 
time- and concentration-dependent fashion and suppressed ODC 
gene expression. The researchers concluded that CAPE exhibits 
potential as an agent to treat hyperproliferative skin conditions.40
In 2007, Serarslan et al. investigated the effects of CAPE, an 
antioxidant and anti-inflammatory agent, on wound healing in 
rats by treating 20 male rats with CAPE and comparing them to 
an  untreated  control  group  of  20  male  rats.  The  investigators 
performed linear full-thickness incisions on the backs of each rat 
and administered either treatment or saline. Biochemical analy-
sis of wound tissues revealed a significant rise in glutathione and 
nitric oxide levels and significant reductions in malondialdehyde 
and superoxide dismutase levels in the group treated with CAPE 
as compared to controls. In the histopathological analysis, inves-
tigators  reported  rapid  epithelium  development  in  the  wound 
tissues of the CAPE group compared with controls. They con-
cluded that their findings suggest CAPE contributes to accelerat-
ing  full-thickness  wound  healing  through  its  antioxidant  and 
ROS-scavenging activities.41

Photoprotective Activity
In 1995, Facino et al. examined the protective effects of several 
caffeoyl  derivatives,  including  caffeic  acid,  from  Echinacea 
family extracts on the free radical-induced degradation of type III 

collagen. Macromolecules were exposed to superoxide anions 
and  hydroxyl  radicals  produced  by  the  xanthine/xanthine  
+/EDTA  system.  The  investigators  found  that 
oxidase/Fe2
collagen  breakdown  was  dose-dependently  suppressed  by  all 
of  the  Echinacea  species  constituents  (order  of  potency: 
echinacoside  ≈  chicoric  acid  >  cynarine  ≈  caffeic  acid  > 
chlorogenic acid). They concluded that Echinacea polyphenols 
protect  collagen  from  free  radical  damage  and  warrant 
consideration for topical use to protect skin against UV-induced 
oxidative  stress.42  Although  phenolic  concentrations  vary 
among commercial herbal Echinacea medicines, a 2004 study 
designed to quantify the caffeic acid concentrations in Echinacea 
angustifolia, E. pallida, and E. purpurea showed that the roots and 
derivatives  of  E.  angustifolia,  E.  pallida,  and  E.  purpurea  are  a 
good  source  of  natural  antioxidants  with  the  concomitant 
potential to impart protective benefits.43

Caffeic, ferulic, and tannic acids were topically applied to mice 
along  with  either  phorbol-12-myristate-13-acetate  (PMA)  or  
mezerein,  resulting  in  significant  protection  against  DMBA-
induced skin tumors in a 1998 study of dietary polyphenolic acids 
on the tumor-promotion stage of carcinogenesis. Caffeic acid was 
found to be more effective than the other compounds as a tumor-
promotion inhibitor. Also in this study, superoxide anion radicals, 
which resulted from the in vivo and in vitro treatment of murine 
peritoneal macrophages with the tumor promoters were potently 
suppressed by all three acids.25

In a study by Saija et al. evaluating the capacity of caffeic and 
ferulic acids to permeate the stratum corneum, both acids were 
dissolved in saturated aqueous solutions at pH 3 or 7.2, and were 
found  to  be  able  to  permeate  through  excised  human  skin 
mounted in Franz cells, with ferulic acid, which is more lipophilic, 
performing  slightly  better.  Investigators  then  based  an  in  vivo 
experiment on their in vitro model to assess the capacity of the 
two  polyphenolic  acids  to  alleviate  UVB-induced  erythema  in 
healthy human volunteers. In this experiment, both caffeic and 
ferulic  acids,  dissolved  in  saturated  aqueous  solution  pH  7.2, 
were  found  to  significantly  protect  human  skin  against  UVB-
induced erythema. Investigators concluded that both caffeic and 
ferulic  acids  are  viable  as  agents  for  the  topical  protection  of 
human  skin  against  UV-induced  insult  and  that  the  pH  of  the 
formulation does not influence their skin absorption.44

In a 2003 study by Neradil et al., caffeic acid was demonstrated 
to  impart  protection  to  the  skin  against  UVC  radiation. 
Specifically, human KF1 diploid fibroblast and A431 epidermoid 
carcinoma cell lines, untreated and treated with the antioxidants 
caffeic  acid  or  α-tocopherol,  were  exposed  to  UVC.  A  potent 
protective effect delivered by caffeic acid was observed at both 
tested  concentrations;  the  significant  increase  in  proliferation 
activity after UVC irradiation was observed in both cell cultures 
grown in the presence of caffeic acid. In addition, the caffeic acid 
was more effective than α-tocopherol in countering the cytotoxic 
effects of UVC. Investigators ascribed the protective effect, which 
was more marked in transformed cells than normal diploid ones, 
to the antioxidant free radical-scavenging activity of caffeic acid.12
In 2009, Prasad et al. investigated the photoprotective effect of 
caffeic  acid  in  human  blood  lymphocytes  exposed  to  UVB 
radiation.  Pretreatment  of  lymphocytes  with  the  polyphenol 
significantly lowered the levels of lipid peroxidation markers and 
UVB-induced cytotoxicity while maintaining antioxidant status. 
The  investigators  also  found  that  the  largest  of  three  doses  of 
caffeic acid normalized UVB-induced cellular changes.11

Also that year, Kang et al. conducted in vitro and in vivo experi-
ments  showing  that  caffeic  acid  blocked  UVB-induced  skin 
carcinogenesis in JB6 P+ mouse skin epidermal cells by directly 

 
suppressing Fyn (a member of the non-receptor protein tyrosine 
kinase family) kinase activity. Caffeic acid was also more effec-
tive  than  chlorogenic  acid  in  hindering  UVB-induced  COX-2 
expression. The researchers noted that in vivo results from mouse 
skin buttressed the notion that caffeic acid inhibited UVB-induced 
COX-2 expression by thwarting Fyn kinase activity. They con-
cluded that caffeic acid appears to exhibit significant potential as 
a strong chemopreventive agent against cutaneous cancers.7

Another  related  compound,  dihydrocaffeic  acid,  has  also 
been  shown  to  exhibit  photoprotective  effects  such  as 
decreasing  cytotoxicity  and  proinflammatory  cytokine  pro-
duction (interleukin-6 and interleukin-8) in HaCaT cells after 
UV exposure.45

Anticarcinogenic Activity
An early indication of the anticarcinogenic potential of caffeic 
acid was seen more than a decade ago when dietary adminis-
tration of several plant phenolic antioxidants including caffeic 
acid  was  performed  on  F344  rats  to  determine  the  effects 
during  the  initiation  phase  on  4-nitroquinoline-1-oxide 
(4-NQO)-induced tongue carcinogenesis. Consumption of the 
four phenolic compounds (besides caffeic, ellagic, chlorogenic, 
and  ferulic  acids  were  included)  over  the  seven-week  study 
resulted in significant decreases by 32 weeks in the incidence of 
tongue  neoplasms  (squamous  cell  papilloma  and  carcinoma) 
and  preneoplastic  lesions  (hyperplasia  and  dysplasia).  No 
tongue neoplasms appeared in rats fed caffeic or ellagic acids. 
The  researchers  concluded  that  these  phenolic  compounds 
might  be  suitable  for  use  as  chemopreventive  agents  against 
cancer of the tongue as well as the skin and other tissues.46

In a 2013 study of malignant HaCaT cells treated with caffeic 
acid, Yang et al. found that the polyphenol diminished the migra-
tory  ability  and  cancer  stem  cells-like  phenotype,  facilitating  the 
p38-mediated downregulation of the NF-κB/snail signal pathway.47

 CONCLUSION

While data are less voluminous on caffeic acid than ferulic acid, 
the available research is promising regarding the potential posi-
tive  effects  imparted  to  the  skin  by  the  most  prolific  of  the 
dietary hyroxycinnamic acids. That said, much more research 
is  necessary  to  determine  the  relative  potency  of  caffeic  acid 
within the vast family of polyphenolic acids as well as its most 
effective role(s) in the dermatologic armamentarium.

REFERENCES

1.  Staniforth  V,  Chiu  LT,  Yang  NS.  Caffeic  acid  suppresses  UVB 
radiation-induced expression of interleukin-10 and activation of 
mitogen-activated  protein  kinases  in  mouse.  Carcinogenesis. 
2006;27:1803.

2.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

Medicine. Rochester, VT: Healing Arts Press; 2003:94.

3.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy:  Modern 

Herbal Medicine. London: Churchill Livingstone; 2000:25.

4.  Centini M, Rossato MS, Sega A, et al. New multifunctional sur-
factants from natural phenolic acids. J Agric Food Chem. 2012;60:74.
5.  Svobodová A, Psotová J, Walterová D. Natural phenolics in the 
prevention  of  UV-induced  skin  damage.  A  review.  Biomed  Pap 
Med Fac Univ Palacky Olomouc Czech Repub. 2003;147:137.

6.  Olthof MR, Hollman PC, Katan MB. Chlorogenic acid and caffeic 

acid are absorbed in humans. J Nutr. 2001;131:66.

7.  Kang NJ, Lee KW, Shin BJ, et al. Caffeic acid, a phenolic phyto-
chemical in coffee, directly inhibits Fyn kinase activity and UVB-
induced COX-2 expression. Carcinogenesis. 2009;30:321.

C H A P T E R  53  ■   C A F F E I C   AC I D  

169

8.  Rice-Evans CA, Miller NJ, Paganga G. Structure-antioxidant activ-
ity relationships of flavonoids and phenolic acids. Free Radic Biol 
Med. 1996;20:933.

9.  Lutz M, Jorquera K, Cancino B, et al. Phenolics and antioxidant 
capacity of table grape (Vitis vinifera L.) cultivars grown in Chile. 
J Food Sci. 2011;76:C1088.

10.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy:  Modern 

Herbal Medicine. London: Churchill Livingstone; 2000:434.

11.  Prasad NR, Jeyanthimala K, Ramachandran S. Caffeic acid modu-
lates ultraviolet radiation-B induced oxidative damage in human 
blood lymphocytes. J Photochem Photobiol B. 2009;95:196.

12.  Neradil J, Veselská R, Slanina J. UVC-protective effect of caffeic 
acid on normal and transformed human skin cells in vitro. Folia 
Biol (Praha). 2003;49:197.

13.  al-Sereiti MR, Abu-Amer KM, Sen P. Pharmacology of rosemary 
(Rosmarinus officinalis Linn.) and its therapeutic potentials. Indian 
J Exp Biol. 1999;37:124.

14.  Bonina F, Puglia C, Ventura D, et al. In vitro antioxidant and in 
vivo photoprotective effects of a lyophilized extract of Capparis 
spinosa L buds. J Cosmet Sci. 2002;53:321.

15.  Cases J, Ibarra A, Feuillère N, et al. Pilot trial of Melissa officinalis 
L. leaf extract in the treatment of volunteers suffering from mild-
to-moderate  anxiety  disorders  and  sleep  disturbances.  Med  J 
Nutrition Metab. 2011;4:211.

16.  Ibarra A, Feuillère N, Roller M, et al. Effects of chronic administra-
tion of Melissa officinalis L. extract on anxiety-like reactivity and 
on  circadian  and  exploratory  activities  in  mice.  Phytomedicine. 
2010;17:397.

17.  Kennedy  DO,  Little  W,  Scholey  AB.  Attenuation  of  laboratory-
induced  stress  in  humans  after  acute  administration  of  Melissa 
officinalis (Lemon Balm). Psychosom Med. 2004;66:607.

18.  Cohen  RA,  Kucera  LS,  Herrmann  EC  Jr.  Antiviral  activity  of 
Melissa  officinalis  (lemon  balm)  extract.  Proc  Soc  Exp  Biol  Med. 
1964;117:431.

19.  Oh C, Price J, Brindley MA, et al. Inhibition of HIV-1 infection by 

aqueous extracts of Prunella vulgaris L. Virol J. 2011;8:188.

20.  Barnes J, Anderson LA, Gibbons S, et al. Echinacea species (Echinacea 
angustifolia  (DC.)  Hell.,  Echinacea  pallid  (Nutt.)  Nutt.,  Echinacea 
purpurea (L. Monench): A review of their chemistry, pharmacology 
and clinical properties. J Pharm Pharmacol. 2005;57:929.

21.  Samuelsen  AB.  The  traditional  uses,  chemical  constituents  and 
biological activities of Plantago major L. A review. J Ethnopharmacol. 
2000;71:1.

22.  Ozturk G, Ginis Z, Akyol S, et al. The anticancer mechanism of 
caffeic acid phenethyl ester (CAPE): Review of melanomas, lung 
and prostate cancers. Eur Rev Med Pharmacol Sci. 2012;16:2064.
23.  Frenkel K, Wei H, Bhimani R, et al. Inhibition of tumor promoter-
mediated processes in mouse skin and bovine lens by caffeic acid 
phenethyl ester. Cancer Res. 1993;53:1255.

24.  Kudugunti SK, Vad NM, Ekogbo E, et al. Efficacy of caffeic acid 
phenethyl ester (CAPE) in skin B16-F0 melanoma tumor bearing 
C57BL/6 mice. Invest New Drugs. 2011;29:52.

25.  Kaul A, Khanduja KL. Polyphenols inhibit promotional phase of 
tumorigenesis:  Relevance  of  superoxide  radicals.  Nutr  Cancer. 
1998;32:81.

26.  Bourne LC, Rice-Evans C. Bioavailability of ferulic acid. Biochem 

Biophys Res Commun. 1998;253:222.

27.  Saija A, Tomaino A, Lo Cascio R, et al. Ferulic and caffeic acids as 
potential protective agents against photooxidative skin damage.  
 J Sci Food Agric. 1999;79:476.

28.  Houghton  PJ,  Photiou  A,  Uddin  S,  et  al.  Activity  of  extracts  of 
Kigelia pinnata against melanoma and renal carcinoma cell lines. 
Planta Med. 1994;60:430.

29.  Muizzuddin N, Maremus KD, Maes DH. Tonality of suntan vs sun-

less tanning with dihydroxyacetone. Skin Res Technol. 2000;6:199.

30.  Kwak SY, Lee S, Choi HR, et al. Dual effects of caffeoyl-amino 
acidyl-hydroxamic  acid  as  an  antioxidant  and  depigmenting 
agent. Bioorg Med Chem Lett. 2011;21:5155.

31.  Žilius M, Ramanauskienè K, Briedis V. Release of propolis phe-
nolic acids from semisolid formulations and their penetration into 
the  human  skin  in  vitro.  Evid  Based  Complement  Alternat  Med. 
2013;2013:958717.

32.  Marti-Mestres G, Mestres JP, Bres J, et al. The “in vitro” percuta-
neous  penetration of  three  antioxidant  compounds.  Int  J  Pharm. 
2007;331:139.

33.  Chiang HM, Lin TJ, Chiu CY, et al. Coffea Arabica extract and its 
constituents  prevent  photoaging  by  suppressing  MMPs  expres-
sion and MAP kinase pathway. Food Chem Toxicol. 2011;49:309.

 
170 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

34.  Pluemsamran T, Onkoksoong T, Panich U. Caffeic acid and feru-
lic acid inhibit UVA-induced matrix metalloproteinase-1 through 
regulation of antioxidant defense system in keratinocyte HaCaT 
cells. Photochem Photobiol. 2012;88:961.

35.  Huang MT, Smart RC, Wong CQ, et al. Inhibitory effect of cur-
cumin,  chlorogenic  acid,  caffeic  acid,  and  ferulic  acid  on  tumor 
promotion  in  mouse  skin  by  12-O-tetradecanoylphorbol-13-
acetate. Cancer Res. 1988;48:5941.

36.  Yamada Y, Yasui H, Sakurai H. Suppressive effect of caffeic acid 
and  its  derivatives  on  the  generation  of  UVA-induced  reactive 
oxygen species in the skin of hairless mice and pharmacokinetic 
analysis  on  organ  distribution  of  caffeic  acid  in  ddY  mice. 
Photochem Photobiol. 2006;82:1668.

37.  Song HS, Park TW, Sohn UD, et al. The effect of caffeic acid on wound 
healing in skin-incised mice. Korean J Physiol Pharmacol. 2008;12:343.
38.  Khan  AQ,  Khan  R,  Qamar  W,  et  al.  Caffeic  acid  attenuates 
12-O-tetradecanoyl-phorbol-13-acetate  (TPA)-induced  NF-κB 
and  COX-2  expression  in  mouse  skin:  Abrogation  of  oxidative 
stress,  inflammatory  responses  and  proinflammatory  cytokine 
production. Food Chem Toxicol. 2012;50:175.

39.  Huang  MT,  Ma  W,  Yen  P,  et  al.  Inhibitory  effects  of  caffeic  acid 
phenethyl ester (CAPE) on 12-O-tetradecanoylphorbol-13-acetate-
induced  tumor  promotion  in  mouse  skin  and  the  synthesis  of 
DNA, RNA and protein in HeLa cells. Carcinogenesis. 1996;17:761.
40.  Zheng ZS, Xue GZ, Grunberger D, et al. Caffeic acid phenethyl 
ester inhibits proliferation of human keratinocytes and interferes 

with  the  EGF  regulation  of  ornithine  decarboxylase.  Oncol  Res. 
1995;7:445.

41.  Serarslan G, Altug E, Kontas T, et al. Caffeic acid phenethyl ester 
accelerates cutaneous wound healing in a rat model and decreases 
oxidative stress. Clin Exp Dermatol. 2007;32:709.

˘

42.  Facino RM, Carini M, Aldini G, et al. Echinacoside and caffeoyl 
conjugates  protect  collagen  from  free  radical-induced  degrada-
tion:  A  potential  use  of  Echinacea  extracts  in  the  prevention  of 
skin photodamage. Planta Med. 1995;61:510.

43.  Pellati F, Benvenuti S, Magro L, et al. Analysis of phenolic com-
pounds and radical scavenging activity of Echinacea spp. J Pharm 
Biomed Anal. 2004;35:289.

44.  Saija A, Tomaino A, Trombetta D, et al. In vitro and in vivo evalu-
ation of caffeic and ferulic acids as topical photoprotective agents. 
Int J Pharm. 2000;199:39.

45.  Poquet  L,  Clifford  MN,  Williamson  G.  Effect  of  dihydrocaffeic 
acid on UV irradiation of human keratinocyte HaCaT cells. Arch 
Biochem Biophys. 2008;476:196.

46.  Tanaka T, Kojima T, Kawamori T, et al. Inhibition of 4-nitroquinoline-
1-oxide-induced  rat  tongue  carcinogenesis  by  the  naturally 
occurring plant phenolics caffeic, ellagic, chlorogenic and ferulic 
acids. Carcinogenesis. 1993;14:1321.

47.  Yang Y, Li Y, Wang K, et al. P38/NF-κB/snail pathway is involved 
in caffeic acid-induced inhibition of cancer stem cells-like proper-
ties  and  migratory  capacity  in  malignant  human  keratinocyte. 
PLoS One. 2013;8:e58915.

 
C H A P T E R   5 4

Ferulic Acid

C H A P T E R  54  ■   F E R U L I C   AC I D 

171

Activities:
Antioxidant, anticancer, anti-inflammatory,1 antimicrobial,2 
cardioprotective,  neuroprotective,  hepatoprotective, 
photoprotective, skin lightening3

Important Chemical Components:

Also  known  as  4-hydroxy-3-methoxycinnamic  acid  as 
well  as  3-(4-hydroxy-3-methoxyphenyl)-2-propenoic 
acid, its molecular formula is C10H10O4.

Origin Classification:

Natural ingredient; organic forms are possible. It can also 
be chemically synthesized in the laboratory

Personal Care Category:

Antioxidant, antiaging, photoprotection

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW,  DRPT,  DRPW,  DSNW,  DSPT,  DSPW,  ORNW, 
ORPT, ORPW, OSNW, OSPT, and OSPW

 SOURCE

Ferulic acid (4-hydroxy-3-methoxycinnamic acid) is pervasive 
in the plant world, present as it is in the cell walls of numerous 
plants,  including  grains,  fruit,  and  vegetables  where  it  is 
conjugated  with  mono-,  di-,  and  polysaccharides  and  other 
compounds  (Table  54-1).4–7  Derived  from  the  metabolism  of 
phenylalanine and tyrosine,5,8 ferulic acid is known to be prevalent 
in whole grains (e.g., rice, wheat, barley, oats, and sorghum), spin-
ach, parsley, grapes, olives, rhubarb, tomatoes, asparagus, peas, 
artichokes, eggplant, pineapples, berries, and maize bran.1,5,8,9 
Ferulic acid is also a key component in propolis, a product of 
honeybee hives (see Chapter 60, Honey/Propolis/Royal Jelly).10 
In addition, it is found along with several other polyphenols in 
hops used in beer.11,12 Ferulic acid is also one of the main active 
components  in  several  herbs  used  in  traditional  Chinese 
medicine  (TCM),  including  Angelica  sinensis,  which  is  used  to 
treat various skin traumas in TCM.1,6,13

TABLE 54-1
Pros and Cons of Ferulic Acid

Pros
Natural ingredient
Penetrates the stratum corneum
Abundance of in vitro data
Potent antioxidant
No reports of contact dermatitis
Safe
Enhances stability of vitamins C and E

Cons
Breaks down with heat and light exposure22
Difficult to formulate
May interact with other products in a regimen

 HISTORY

Ferulic acid was first isolated and identified by Hlasiwetz and 
Barth in Innsbruck, Austria in 1866.8 Other than an 1891 report 
on  the  isolation  of  the  compound  from  Pinus  laricio  (Corsican 
pine),  little  research  on  ferulic  acid  was  published  until  1925, 
when it was chemically synthesized from vanillin with malonic 
acid.8,14 The stereochemistry of ferulic acid was determined in 
1976  by  nuclear  magnetic  resonance  spectroscopy  and 
confirmed  in  1988  by  X-ray  crystallographic  analysis.8 
Investigations,  particularly  in  vitro,  regarding  the  potential 
health benefits of ferulic acid have since become commonplace.
In  a  1983  study  on  the  inhibitory  effects  of  three  phenolic 
compounds on neoplasia in mice, ferulic acid was active against 
lung  carcinogenesis  but  completely  ineffective  against  skin 
tumor formation.15 Since that time, however, much evidence has 
emerged  regarding  the  oral  and  topical  benefits  of  ferulic  acid 
against skin cancer. The inhibitory effects of the topical applica-
tion and oral administration of Ixora javanica flower extract on 
the growth and onset of tumors in mice was attributed, in a 1991 
study,  to  the  active  compounds  in  the  extract,  namely  ferulic 
acid.16 In addition to its reported cutaneous benefits, ferulic acid 
has drawn interest for potential salutary effects in treating car-
diovascular disease, diabetes, neurodegenerative conditions, and 
various cancers.1,17

 CHEMISTRY

Ferulic  acid,  a  precursor  to  vanillin,  belongs  to  the  family  of 
polyphenolic  compounds  known  as  hydroxycinnamic  acids, 
which are known to confer cutaneous benefits (Figure 54-1).6,11,18 
Other hydroxycinnamic acids include caffeic and sinapic acids, 
as well as the ferulic acid precursors p-coumaric and p-hydroxy-
cinnamic acids. Hydroxycinnamic acids are produced in plants 
from  phenylalanine  or  l-tyrosine  through  the  shikimate 
pathway (Figure 54-2).5

Ferulic  acid  is  a  potent  antioxidant  and  a  strong  ultraviolet 
(UV) absorber,4,19 effectively protecting human skin from UVB-
induced  erythema  in  particular.4  Phospholipid  membranes  are 
also protected by ferulic acid from UV-induced peroxidation as 
the  lipid  peroxidative  chain  reaction  is  interrupted.4,20  The 
phenolic nucleus and extended side chain conjugation of ferulic 
acid  accounts  for  its  facility  in  forming  a  resonance-stabilized 
phenoxy radical, to which its antioxidant activity is attributed.8

 ORAL USES

Ferulic  acid  is  consumed  regularly  through  the  diet  as  a  key 
constituent of numerous vegetables, fruits, and grains. While it 
is difficult to quantify the direct contributions of ferulic acid, it 
is likely that the frequent intake of such foods imparts multiple 
cutaneous benefits. Indeed, dietary ferulic acid is now consid-
ered a significant antioxidant substance.21

 
172 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

CO2H

Mg2+, ATP,
CoASH

Hydroxycinnamate-CoA
ligase-synthetase
(HCLS)

O

S-CoA

HO

OMe

Feruloyl-CoA, 2

HO

OMe

Ferulic acid
4-hydroxy-3-methoxy-
cinnamic acid
1

O

CH3COSCoA

Hydroxycinnamoyl-CoA
hydratase lyase
(HCHL)

OH

O

S-CoA

HO

OMe

Vanillin
4-hydroxy-3-methoxy-
benzaldehyde
4

HCHL

HO

OMe

4-Hydroxy-3-methoxyphenyl-
β-hydroxypropionyl-SCoA
(HMPHP-CoA), 3

▶

FIGURE 54-1  Ferulic acid is converted to vanillin.42

 TOPICAL USES

Ferulic acid is known to provide photoprotection to skin when it 
is incorporated into cosmetic lotions,8 and has been approved as 
a sunscreen agent in Japan.22 Multiple studies have shown the 
utility in combining ferulic acid with vitamins C and E to enhance 
the antioxidant capacity and stability of the formulation.

Shikimic acid

Shikimate 5-phosphate

3-Enolpyruvoylshikimate 5-phosphate

Chorismate

Arogenic acid

Tyrosine

Phenylalanine

p-Coumaric acid

Cinnamic acid

Caffeic acid

Ferulic acid

Sinapic acid

▶FIGURE 54-2  Ferulic acid is formed from tyrosine or phenylalanine.

In a 2005 study by Lin et al., the addition of 0.5 percent ferulic 
acid to a solution of 15 percent l-ascorbic acid (vitamin C) and  
1  percent  α-tocopherol  (vitamin  E)  stabilized  the  formulation  
(C E Ferulic®) and, more significantly, enhanced the skin-protective 
capacity  of  the  topically-applied  formulation,  doubling  photo-
protection to skin from fourfold to eightfold.23 The researchers 
found  that  the  addition  of  ferulic  acid  imparted  a  synergistic 
effect, greatly amplifying the already synergistic effects seen in 
the combination of vitamins C and E, further supporting previ-
ous  evidence  of  cooperative  relationships  between  ferulic  acid 
and vitamins C and E, and β-carotene.24 Lin et al. speculated that 
a topical antioxidant formulation combining vitamins C and E 
with  ferulic  acid  in  a  broad-spectrum  sunscreen  would  be  an 
optimal way to protect the skin from sun damage via a topically- 
applied product.23

In a subsequent study by several of the same authors, com-
parison of the same formulation with vitamins C and E as well 
as ferulic acid with a 1 percent ubiquinone, 1 percent idebenone, 
and 0.5 percent kinetin preparation and three different commer-
cial  creams  (0.1  percent  kinetin,  1  percent  idebenone,  and 
0.5  percent  idebenone)  revealed  that  the  ferulic  acid-containing 
topical  antioxidant  combination  was  more  effective  at 
photoprotection. Results also supported the finding of eightfold 
photoprotection from UV conferred to the skin.25

Ferulic  acid  has  also  been  included  in  a  topical  antioxidant 
formulation  with  vitamin  C  and  phloretin  (see  Chapter  52, 
Phloretin). In this small study with 10 subjects, the antioxidant 
combination protected against all of the various harmful effects 
measured due to UV exposure.26

 SAFETY ISSUES

Ferulic acid is readily absorbed and metabolized in the body.6 It 
has a low toxicity with a median lethal dose (LD50) of 2,445 mg/kg 
body weight in male and 2,113 mg/kg body weight in female 
rats. Because of this low toxicity it is considered safe. Ferulic 
acid is frequently used as a food additive and found in natural  

 
extracts of herbs, coffee, vanilla beans, and spices. It is added to 
foods as a Food and Drug Administration-approved antioxidant 
concoction.6 There are no reports of contact dermatitis to ferulic 
acid in the literature.

 ENVIRONMENTAL IMPACT

Ferulic acid is found throughout the plant kingdom. Few if any 
of the plants are cultivated to harness ferulic acid alone; there-
fore,  there  is  no  known  impact  on  the  environment  of  using 
this ingredient.

 FORMULATION CONSIDERATIONS

Ferulic  acid  appears  most  effective  for  topical  administration 
when  combined  with  other  active  ingredients,  particularly 
vitamin C because ferulic acid works synergistically with other 
antioxidants,  stabilizing  and,  in  turn,  being  stabilized  in  the 
interaction. In 2008, Anselmi et al. demonstrated that encapsu-
lating ferulic acid with α-cyclodextrin enhanced the chemical 
stability  of  the  antioxidant  when  exposed  to  UVB  while 
increasing the bioavailability of ferulic acid on the skin.22 The 
efficacy  of  ferulic  acid  is  diminished  by  its  tendency  toward 
thermal-, air-, and photo-induced decomposition through what 
is thought to be a decarboxylation mechanism.2

In a 2011 study of the chemical stability of ferulic acid, Wang 
et al. evaluated the antioxidant in eight prototypical formulations, 
finding  that  the  stability  of  the  acid  is  related  to  pH  and 
temperature. In addition, they noted that the solvent dipropylene 
glycol  exhibited  a  stabilizing  effect  on  ferulic  acid.3  The  pH 
effects differed from the report by Saija et al., who had previously 
found that the efficacy of ferulic acid appears to be unaffected by 
the pH of the formulation in which it may be included.19 In an 
attempt  to  improve  absorption  of  ferulic  acid,  new  delivery 
systems, such as liposomes, nanoparticles, and niosomes, have 
been developed.1

A ferulic acid-containing biodegradable polymer was prepared 
in 2013 through solution polymerization to chemically integrate 
the  antioxidant  into  a  poly(anhydride-ester).  Ouimet  et  al. 
reported  that  in  vitro  analysis  revealed  that  the  polymer  was 
hydrolytically degradable, allowing for the potential of controlled 
release  of  the  bioactive  constituents  in  skin  care  formulations. 
Also, polymer degradation products displayed  antioxidant and 
antibacterial activity similar to free ferulic acid, and in vitro cell 
viability analysis showed no cytotoxicity to fibroblasts.2

 USAGE CONSIDERATIONS

Because  of  the  conflicting  reports  of  the  effects  of  pH  on  the 
stability of ferulic acid, it is possible that application at the same 
time  or  immediately  after  a  low  pH  product  such  as  glycolic 
acid could decrease the efficacy of the product. Studies looking 
at the combination of ferulic acid-containing formulations with 
other products in a regimen that alter pH should be conducted.

 SIGNIFICANT BACKGROUND

In a 2010 study with in vitro and in vivo components, Zhang et 
al. assessed the efficacy and safety of the cutaneous delivery of 
ferulic acid and its derivatives (five total compounds) into por-
cine skin. The in vitro efficacy study revealed that ferulic acid 
ethyl ether (FAEE) with a pH 6 buffer achieved the greatest skin 

C H A P T E R  54  ■   F E R U L I C   AC I D  

173

delivery. FAEE, which occurs naturally and is more hydrophobic 
than ferulic acid,27 divided readily into and penetrated across the 
skin via intercellular pathways. The investigators used a nude 
mouse model to determine the level of permeants remaining in 
the skin, with FAEE deposition comparable with that of coniferyl 
aldehyde.  The  safety  assessment,  based  on  transepidermal 
water loss, erythema, and cutaneous pH, showed no irritation 
after  24  hours.  The  investigators  concluded  that  the  topical 
administration of ferulic acid and its derivatives is a potentially 
safe and effective approach to thwart photodamage.17

In Vitro Studies
The vitamin E/ferulic acid compound α-tocopheryl ferulate is 
known  to  have  the  capacity  to  absorb  UV  radiation,  thereby 
maintaining tocopherol in a stable state. As such, researchers 
investigated whether α-tocopheryl ferulate can act as a depig-
menting  agent  and  antioxidant  to  improve  and  prevent 
UV-induced facial hyperpigmentation. Studying the effects of 
α-tocopheryl  ferulate  using  cultured  human  melanoma  cells 
and normal human melanocytes in vitro, α-tocopheryl ferulate 
was  found  to  inhibit  melanization  significantly  better  than 
arbutin,  kojic  acid,  ascorbic  acid,  and  tranexamic  acid, 
suggesting potential as a whitening agent by, as investigators 
hypothesized,  indirectly  inhibiting  tyrosine  hydroxylase 
activity.28  In  related  studies,  most  of  the  same  researchers 
determined  that  α-tocopheryl  ferulate  inhibits  the  biological 
responses  prompted  by  reactive  oxygen  species,29  and  may 
mitigate  the  damage  induced  by  active  oxygen  species,  thus 
helping to suppress or decelerate skin carcinogenesis.28

In a 2002 in vitro study by Ogiwara et al. of the free radical- 
scavenging abilities of ferulic acid and eugenol, ferulic acid more 
efficiently scavenged nitric oxide and the hydroxyl radical and 
was comparable to eugenol in scavenging the superoxide radical. 
The  investigators  concluded  that  ferulic  acid  exhibited  the 
potential  to  be  an  effective  antioxidant  in  living  systems  in 
preventing cell damage caused by free radicals such as superoxide, 
and especially the hydroxyl radical and nitric oxide.30

In 2008, Calabrese et al. showed that 25 µmol/L ferulic acid 
ethyl  ester  abrogated  protein  and  lipid  oxidation  induced  in 
human  dermal  fibroblasts  by  exposure  to  up  1,000  µmol/L  of 
H2O2,  and  mitigated  the  loss  in  cell  viability  spurred  by  
500 µmol/L of H2O2. In addition, the nutritional antioxidant led 
to an increase in heme oxygenase-1 and heat shock protein-70 in 
the  fibroblasts  compared  with  fibroblasts  treated  only  with 
H2O2.  The  investigators  concluded  that  their  findings  support 
the protective roles of ferulic acid, and its derivatives, as well as 
vitagenes such as heme oxygenase-1 and heat shock protein-70 
against free radical-induced skin damage.27 In addition, the ethyl 
ester  derivative  of  ferulic  acid  has  been  shown  to  protect  skin 
melanocytes from UV-induced oxidative stress, lowering reactive 
oxygen species generation and significantly inhibiting apoptosis 
and other biomarkers of oxidation.31

In 2012, Pluemsamran et al. pretreated immortalized human 
keratinocyte  (HaCaT)  cells  with  caffeic  acid  or  ferulic  acid  to 
assess the inhibitory effects of the antioxidants on UVA-induced 
cytotoxicity, MMP-1 activity, and mRNA level. They found that 
both  antioxidants  suppressed  cytotoxicity,  MMP-1  activity 
induction, and mRNA and oxidant formation. In addition, both 
hydroxycinnamic  acids  upregulated  glutathione  content, 
γ-glutamate cysteine ligase mRNA, and the activities as well as 
mRNA  expression  of  catalase  and  glutathione  peroxidase  in 
UVA-exposed cells.32

 
174 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Animal Studies
More than 20 years ago, the topical application of ferulic acid 
was found to inhibit by 46 percent the induction of ornithine 
decarboxylase  activity  by  12-O-tetradecanoylphorbol-13-
acetate (TPA) in female CD-1 mice. Similar treatment of mice 
with  ferulic  acid  together  with  TPA  also  dose-dependently 
inhibited the number of TPA-induced tumors per mouse.33 In a 
1994 study, the topical application of a dehydrogenation poly-
mer of ferulic acid suppressed TPA-induced tumor promotion, 
though  a  monomeric  ferulic  acid  failed  to  exhibit  the  same 
inhibitory effect in female ICR mice.34

Phenolic  antioxidants  including  ferulic  acid  fed  to  male  
F344  rats  were  found  to  significantly  lower  the  incidence  of 
tongue neoplasms (squamous cell papilloma and carcinoma) and 
preneoplastic  lesions  (hyperplasia  and  dysplasia)  and  show 
promise  as  chemopreventive  agents  in  tongue,  skin,  and  other 
organs, researchers concluded.35 In a study evaluating the poten-
tial of dietary polyphenols as anticarcinogenic agents, ellagic acid, 
tannic acid, caffeic acid, and ferulic acid were each combined with 
phorbol-12-myristate-13-acetate (PMA) or mezerein and topically 
applied to mice and showed significant protection against benzo[a]
pyrene-  and  7,12-dimethylbenz[a]anthracene  (DMBA)-induced 
skin tumors in both in vivo and in vitro conditions.36

In 2009, Alias et al. assessed the effects of topically applied as 
well  as  orally  administered  ferulic  acid  on  squamous  cell 
carinoma  induced  by  painting  DMBA  on  the  shaved  backs  of 
Swiss albino mice. DMBA was administered twice weekly for 
eight  weeks  to  engender  tumor  formation.  Whereas  the  oral 
administration of ferulic acid resulted in complete prevention of 
skin tumor formation, the topical application of the antioxidant 
exerted no significant chemopreventive effects. The investigators 
speculated  that  orally  administered  ferulic  acid  yielded  such 
results through its modulatory impact in reversing lipid peroxi-
dation  byproducts  and  antioxidants  to  approximately  the  nor-
mal range in DMBA-treated mice.37

In 2012, Staniforth et al. investigated the inhibitory effects of 
ferulic acid on UVB-induced matrix metalloproteinase (MMP)-2 
and  MMP-9  activities  in  mouse  skin,  finding  through 
histological  analysis  that  the  antioxidant  diminished  collagen 
degradation,  abnormal  elastic  fiber  accumulation,  and 
epidermal  hyperplasia.  The  researchers  concluded  that  their 
findings  pointed  to  a  potential  clinical  application  for  ferulic 
acid  for  treating  cutaneous  conditions  resulting  from  MMP-2 
and MMP-9 overexpression.38

In an interesting 2013 comparison study using mice, Burns et al. 
exposed  mice  to  UVB  for  10  weeks  to  create  skin  damage. 
Before  the  appearance  of  cutaneous  lesions,  the  investigators 
treated the animals for 15 weeks with a stable topical formula 
containing  vitamins  C  and  E  and  ferulic  acid  (C  E  Ferulic®) 
without additional UVB exposure. Tumor number and burden 
were  reduced  and  the  antioxidant  combination  prevented  the 
formation of malignant skin tumors in female mice with UVB-
induced damage. Female mice also chronically exposed to UVB 
but  treated  only  with  topical  vitamin  E,  however,  displayed 
increased tumor growth, cutaneous proliferation, angiogenesis, 
and overall DNA damage.39

Human Studies
Based on in vitro results testing the capacity of ferulic and caffeic 
acids  to  permeate  through  excised  human  skin,  researchers 
evaluated  the  capacity  of  the  same  organic  acids  to  reduce 
UVB-induced  erythema  in  healthy  human  volunteers. 

Dissolved  in  saturated  aqueous  solution  (pH  7.2),  both 
compounds  conferred  significant  cutaneous  protection.  Both 
ferulic  acid,  which  is  more  lipophilic  and  thus  better  able  to 
penetrate the stratum corneum, and caffeic acid were assessed 
as worthy photoprotective agents in topical formulations and 
judged to be unaffected by the pH of the product into which 
they might be incorporated.19

In 2008, Murray et al. showed in a small study that a stable 
topical  formulation  of  15  percent  l-ascorbic  acid,  1  percent 
α-tocopherol,  and  0.5  percent  ferulic  acid  (CEFer)  protected 
human skin in vivo from substantial solar-simulated UV radiation 
(SSUVR), especially lowering thymine dimer mutations, which 
are known to be linked to skin cancer.40

In 2013, Wu et al. conducted a small study with 12 healthy 
Chinese  females  to  ascertain  the  potential  photoprotective 
effects of a formulation containing vitamins C and E and ferulic 
acid  against  SSUVR-induced  acute  photodamage  in  human 
skin.41 For four consecutive days, dorsal skin areas were treated 
with  the  topical  antioxidant  preparation  or  vehicle.  On  day  4, 
these areas along with an untreated site (positive control) were 
exposed  to  SSUVR  five  times  the  minimal  erythema  dose.  
A negative control site received neither treatment nor exposure. 
Using  digital  photographs,  pre-  and  postexposure  skin  color 
measurements,  and  skin  biopsies,  the  researchers  determined 
that the antioxidant formulation imparted significant protection 
against  SSUVR-induced  photodamage  and  concluded  that  the 
topical complex has potential in the dermatologic armamentar-
ium as a photoprotective agent.

 CONCLUSION

Significant  antioxidant,  photoprotective,  and  anticarcinogenic 
properties have been associated with ferulic acid, with a sub-
stantial body of in vitro evidence. The cutaneous benefits long 
associated  with  this  phenolic  compound  also  continue  to  be 
borne out by emerging research. Ferulic acid has already been 
introduced  into  several  photoprotective  dermatologic  prod-
ucts. Although good data exist to support the use of ferulic acid 
as  a  topical  antioxidant,  it  is  unstable  when  exposed  to  heat 
and light. Studies looking at the effects on stability of pH and 
combination with other ingredients in the regimen would be 
helpful. 

REFERENCES

1.  Barone E, Calabrese V, Mancuso C. Ferulic acid and its therapeutic 
potential  as  a  hormetin  for  age-related  diseases.  Biogerontology. 
2009;10:97.

2.  Ouimet MA, Griffin J, Carbone-Howell AL, et al. Biodegradable 
ferulic  acid-containing  poly(anhydride-ester):  degradation 
products  with  controlled  release  and  sustained  antioxidant 
activity. Biomacromolecules. 2013;14:854.

3.  Wang QJ, Gao X, Gong H, et al. Chemical stability and degrada-
tion  mechanisms  of  ferulic  acid  (F.A)  within  various  cosmetic 
formulations. J Cosmet Sci. 2011;62:483.

4.  Svobodová A, Psotová J, Walterová D. Natural phenolics in the 
prevention  of  UV-induced  skin  damage.  A  review.  Biomed  Pap 
Med Fac Univ Palacky Olomouc Czech Repub. 2003;147:137.

5.  Bourne LC, Rice-Evans C. Bioavailability of ferulic acid. Biochem 

Biophys Res Commun. 1998;253:222.

6.  Ou S, Kwok KC. Ferulic acid: pharmaceutical functions, prepara-
tions and applications in foods. J Sci Food Agric. 2004;84:1261.
7.  Rice-Evans  CA,  Miller  NJ,  Paganga  G.  Structure-antioxidant 
activity relationships of flavonoids and phenolic acids. Free Radic 
Biol Med. 1996;20:933.

8.  Graf E. Antioxidant potential of ferulic acid. Free Radic Biol Med. 

1992;13:435.

 
9.  Centini M, Rossato MS, Sega A, et al. New multifunctional sur-
factants from natural phenolic acids. J Agric Food Chem. 2012;60:74.
10.  Žiliusx  M,  Ramanauskienex  K,  Briedisx  V.  Release  of  propolis 
phenolic acids from semisolid formulations and their penetration 
into the human skin in vitro. Evid Based Complement Alternat Med. 
2013;2013:958717.

11.  Chen W, Becker T, Qian F, et al. Beer and beer compounds: phys-
iological effects on skin health. J Eur Acad Dermatol Venereol. 2013 
Jun 27. [Epub ahead of print]

12.  Arranz S, Chiva-Blanch G, Valderas-Martinez P, et al. Wine, beer, 
alcohol  and  polyphenols  on  cardiovascular  disease  and  cancer. 
Nutrients. 2012;4:759.

13.  Hsiao CY, Hung CY, Tsai TH, et al. A study of the wound healing 
mechanism of a traditional Chinese medicine, Angelica sinensis, 
using a proteomic approach. Evid Based Complement Alternat Med. 
2012;2012:467531.

14.  Dutt  S.  General  synthesis  of  α-unsaturated  acids  from  malonic 

acid. Quart J Chem Soc. 1925;1:297.

15.  Lesca P. Protective effects of ellagic acid and other plant phenols 
on  benzo[a]pyrene-induced  neoplasia  in  mice.  Carcinogenesis. 
1983;4:1651.

16.  Nair SC, Panikkar B, Akamanchi KG, et al. Inhibitory effects of 
Ixora javanica extract on skin chemical carcinogenesis in mice and 
its antitumor activity. Cancer Lett. 1991;60:253.

17.  Zhang  LW,  Al-Suwayeh  SA,  Hsieh  PW,  et  al.  A  comparison  of 
skin delivery of ferulic acid and its derivatives: evaluation of their 
efficacy and safety. Int J Pharm. 2010;399:44.

18.  Bonina F, Puglia C, Ventura D, et al. In vitro antioxidant and in 
vivo photoprotective effects of a lyophilized extract of Capparis 
spinosa L buds. J Cosmet Sci. 2002;53:321.

19.  Saija A, Tomaino A, Trombetta D, et al. In vitro and in vivo evalu-
ation of caffeic and ferulic acids as topical photoprotective agents. 
Int J Pharm. 2000;199:39.

20.  Saija A, Tomaino A, Lo Cascio R, et al. Ferulic and caffeic acids as 
potential protective agents against photooxidative skin damage. 
J Sci Food Agric. 1999;79:476.

21.  Wang X, Geng X, Egashira Y, et al. Purification and characteriza-
tion  of  a  feruloyl  esterase  from  the  intestinal  bacterium 
Lactobacillus acidophilus. Appl Environ Microbiol. 2004;70:2367.
22.  Anselmi C, Centini M, Maggiore M, et al. Non-covalent inclusion 
of  ferulic  acid  with  alpha-cyclodextrin  improves  photo-stability 
and  delivery:  NMR  and  modeling  studies.  J  Pharm  Biomed  Anal. 
2008;46:645.

23.  Lin FH, Lin JY, Gupta RD, et al. Ferulic acid stabilizes a solution of 
vitamins C and E and doubles its photoprotection of skin. J Invest 
Dermatol. 2005;125:826.

24.  Trombino  S,  Serini  S,  Di  Nicuolo  F,  et  al.  Antioxidant  effect  of 
ferulic  acid  in  isolated  membranes  and  intact  cells:  synergistic 
interactions  with  alpha-tocopherol,  beta-carotene,  and  ascorbic 
acid. J Agric Food Chem. 2004;52:2411.

25.  Tournas JA, Lin FH, Burch JA, et al. Ubiquinone, idebenone, and 
kinetin  provide  ineffective  photoprotection  to  skin  when  com-
pared to a topical antioxidant combination of vitamins C and E 
with ferulic acid. J Invest Dermatol. 2006;126:1185.

26.  Oresajo  C,  Stephens  T,  Hino  PD,  et  al.  Protective  effects  of  a 
topical  antioxidant  mixture  containing  vitamin  C,  ferulic  acid, 
and phloretin against ultraviolet-induced photodamage in human 
skin. J Cosmet Dermatol. 2008;7:290.

C H A P T E R  54  ■   F E R U L I C   AC I D  

175

27.  Calabrese V, Calafato S, Puleo E, et al. Redox regulation of cellular 
stress response by ferulic acid ethyl ester in human dermal fibro-
blasts: role of vitagenes. Clin Dermatol. 2008;26:358.

28.  Ichihashi M, Funasaka Y, Ohashi A, et al. The inhibitory effect of 
DL-alpha-tocopheryl  ferulate  in  lecithin  on  melanogenesis. 
Anticancer Res. 1999;19:3769.

29.  Funasaka Y, Chakraborty AK, Komoto M, et al. The depigmenting 
effect  of  alpha-tocopheryl  ferulate  on  human  melanoma  cells. 
Br J Dermatol. 1999;141:20.

30.  Ogiwara T, Satoh K, Kadoma Y, et al. Radical scavenging activity 
and cytotoxicity of ferulic acid. Anticancer Res. 2002;22:2711.
31.  Di Domenico F, Perluigi M, Foppoli C, et al. Protective effect of 
ferulic acid ethyl ester against oxidative stress mediated by UVB 
irradiation  in  human  epidermal  melanocytes.  Free  Radic  Res. 
2009;43:365.

32.  Pluemsamran T, Onkoksoong T, Panich U. Caffeic acid and feru-
lic acid inhibit UVA-induced matrix metalloproteinase-1 through 
regulation of antioxidant defense system in keratinocyte HaCaT 
cells. Photochem Photobiol. 2012;88:961.

33.  Huang  MT,  Smart  RC,  Wong  CQ,  et  al.  Inhibitory  effect  of 
curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor 
promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. 
Cancer Res. 1988;48:5941.

34.  Asanoma M, Takahashi K, Miyabe M, et al. Inhibitory effect of 
topical application of polymerized ferulic acid, a synthetic lignin, 
on  tumor  promotion  in  mouse  skin  two-stage  tumorigenesis. 
Carcinogenesis. 1994;15:2069.

35.  Tanaka T, Kojima T, Kawamori T, et al. Inhibition of 4-nitroquin-
oline-1-oxide-induced rat tongue carcinogenesis by the naturally 
occurring plant phenolics caffeic, ellagic, chlorogenic and ferulic 
acids. Carcinogenesis. 1993;14:1321.

36.  Kaul A, Khanduja KL. Polyphenols inhibit promotional phase of 
tumorigenesis:  relevance  of  superoxide  radicals.  Nutr  Cancer. 
1998;32:81.

37.  Alias LM, Manoharan S, Vellaichamy L, et al. Protective effect of 
ferulic  acid  on  7,12-dimethylbenz[a]anthracene-induced  skin 
carcinogenesis  in  Swiss  albino  mice.  Exp  Toxicol  Pathol. 
2009;61:205.

38.  Staniforth  V,  Huang  WC,  Aravindaram  K,  et  al.  Ferulic  acid,  a 
phenolic  phytochemical,  inhibits  UVB-induced  matrix  metallo-
proteinases  in  mouse  skin  via  posttranslational  mechanisms. 
J Nutr Biochem. 2012;23:443.

39.  Burns EM, Tober KL, Riggenbach JA, et al. Differential effects of 
topical vitamin E and C E Ferulic® treatments on ultraviolet light 
B-induced  cutaneous  tumor  development  in  Skh-1  mice.  PLoS 
One. 2013;8:e63809.

40.  Murray  JC,  Burch  JA,  Streilein  RD,  et  al.  A  topical  antioxidant 
solution  containing  vitamins  C  and  E  stabilized  by  ferulic  acid 
provides  protection  for  human  skin  against  damage  caused  by 
ultraviolet irradiation. J Am Acad Dermatol. 2008;59:418.

41.  Wu Y, Zheng X, Xu XG, et al. Protective effects of a topical anti-
oxidant  complex  containing  vitamins  C  and  E  and  ferulic  acid 
against  ultraviolet  irradiation-induced  photodamage  in  Chinese 
women. J Drugs Dermatol. 2013;12:464.

42.  Bennett  JP,  Bertin  L,  Moulton  B,  et  al.  A  ternary  complex  of 
hydroxycinnamoyl-Co-A  hydratase-lyase  (HCHL)  with  acetyl-
CoA  and  vanillin  gives  insights  into  substrate  specificity  and 
mechanism. Biochem J. 2008;414:281.

 
176 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

SECTION

F

Vitamins

C H A P T E R   5 5

Ascorbic Acid (Vitamin C)

Activities:

Antioxidant, anti-inflammatory, photoprotectant, depig-
menting, collagen synthesis promotion, wound healing

Important Chemical Components:

Esterified forms of l-ascorbic acid, such as ascorbyl pal-
mitate  (ascorbic-6-palmitate)  and  magnesium  ascorbyl 
phosphate. Its molecular formula is C6H8O6.

Origin Classification:

Most topical formulations contain synthetic laboratory-
made ascorbic acid because of the inherent obstacles in 
properly  formulating  this  ingredient.  Ascorbic  acid  is 
naturally occurring and organic forms are available, but 
their efficacy is doubtful due to instability and difficulty 
penetrating into the skin.

Personal Care Category:

Antioxidant, antiaging

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW, DRPT, DRPW, ORNW, ORPT, and ORPW

 SOURCE

Ascorbic acid (vitamin C) is found in citrus fruits and green leafy 
vegetables.  It  is  produced  in  most  plants  and  animals,  but  a 
mutated gene in humans has resulted in a deficiency of l-gulono-
γ-lactone  oxidase,  the  enzyme  required  for  its  production.1,2 
Although  ascorbic  acid  cannot  be  synthesized  by  the  human 
body, dietary consumption renders it the most abundant anti-
oxidant  in  human  skin  and  blood,  and  vitamin  C  plays  an 
important  role  in  endogenous  collagen  production  and  the 
inhibition of collagen degradation (Table 55-1).2–6 This essential 
nutrient  is  also  a  cofactor  necessary  for  the  function  of 
numerous hydroxylases and mono-oxygenases,7 and plays an 
important  role  in  the  glycosaminoglycan  synthesis  of 
proteoglycan.5,8,9  In  addition,  ascorbic  acid  is  known  to 
regenerate  α-tocopherol  (vitamin  E)  levels  and  is  therefore 
thought to protect against diseases related to oxidative stress.10 
Epidermal vitamin C can be depleted by sunlight and environ-
mental  pollution,  such  as  ozone  in  urban  pollution.11,12  This 

TABLE 55-1
Pros and Cons of Ascorbic Acid

Pros
Potent anti-inflammatory and antioxidant activity
Used in a wide variety of cosmetic formulations
Strong safety profile
Readily found in diet
Most abundant antioxidant in human skin
Increases collagen production
Aids wound healing
Exerts a depigmenting effect

Cons
Difficult to formulate
Topical forms are expensive
Does not readily penetrate the skin
Can increase redness in S2 rosacea types
Can cause stinging in S3 stinging types

chapter  will  discuss  the  antiaging  and  antioxidant  activity  of 
vitamin  C  [see  Chapter  40,  Vitamin  C  (Ascorbic  Acid),  for 
information on the depigmenting activities of ascorbic acid].

 HISTORY

The discovery of ascorbic acid is inextricably linked to scurvy, a 
disease  known  for  several  hundred  years  now  to  result  from 
protracted vitamin C deficiency. In fact, “ascorbic” literally means 
“against scurvy.”13 Scurvy (derived from the Latin scorbutus, French 
scorbut,  and  German  skorbut)  was  rampant  among  the  world’s 
navies and is believed to have afflicted as many as two million 
sailors by the mid-1700s.14 The condition was actually described 
in  writings  by  the  ancient  Egyptians,  Greeks,  and  Romans.5,15 
Eating onions and vegetables was recommended as treatment in 
Egypt three millennia ago, but the first formal description of the 
condition  is  attributed  to  the  Greek  physician  Hippocrates.5,15 
Several hundred years later, scurvy emerged in great numbers on 
the  high  seas  as  noted  by  the  voyages  of  Portuguese  explorer 
Vasco da Gama in 1498.5,15 By 1747, as shown by James Lind,14 
sailors knew that consuming citrus fruits, oranges and lemons in 
particular,  prevented  this  condition  characterized  by  dental 
abnormalities,  bleeding,  distinctive  purpuric  skin  lesions,  and 
mental  deterioration.  Several  cases  of  scurvy  also  reportedly 
occurred during Ireland’s “great potato famine” in 1845.14

In  1928,  Albert  Szent-Györgyi  isolated  an  organic  acid  from 
oranges, lemons, cabbage, and adrenal gland tissue from guinea 
pigs  (which,  like  humans,  require  dietary  vitamin  C),14  later 
dubbing  it  “hexuronic  acid.”13,14  Researchers  confirmed  during 
the  1930s  that  the  key  constituent  in  citrus  fruit  that  prevents 
scurvy was indeed hexuronic acid, with Walter Norman Haworth 

 
identifying its chemical structure in 1933.14 Haworth and Szent-
Györgyi ultimately decided on the name “ascorbic acid” for the 
compound, though it is now better known as vitamin C.13

In the late 1980s, Dr. Sheldon Pinnell from Duke University 
began  looking  at  vitamin  C  as  a  photoprotectant.  In  1987,  he 
published a paper in the Archives of Dermatology demonstrating 
that collagen synthesis could be induced by ascorbic acid.16 He 
filed a patent in 1989 on a way to stabilize vitamin C in a topical 
formulation  that  later  became  the  basis  for  the  company 
Skinceuticals.  His  diligence  and  adherence  to  evidence-based 
science made a great impact and now vitamin C is one of the 
ingredients most recognized by consumers in the antiaging skin 
care market.

Today,  the  role  of  vitamin  C  as  a  potent  antioxidant  is  the 
subject  of  intense  research.  Oral  vitamin  C  has  been  linked  to 
reports  of  risk  reduction  of  developing  certain  cancers,  cardio-
vascular  disease,  and  cataracts,  as  well  as  improvements  in 
wound healing and immune modulation.17,18 As a topical agent, 
vitamin  C  has  been  used  to  harness  its  antioxidant  activity  to 
prevent  photodamage,  and  to  treat  melasma,  striae  albae,  and 
postoperative erythema in laser patients.19–21

 CHEMISTRY

Ascorbic acid, or ascorbate, is an α-ketolactone that functions 
as a hydrophilic monovalent hydroxyl anion. The active por-
tion of ascorbic acid includes a carbon double bond with two 
hydroxyl  groups  attached.  This  structure,  called  an  enediol, 
donates two electrons, which can bond with the unpaired elec-
trons of a free radical.22 Ascorbate and glutathione are among 
the antioxidants found in hydrophobic areas of the cell and the 
serum. The addition of one electron to ascorbate results in the 
ascorbate free radical, a transient compound more stable than 
other  free  radicals  and  capable  of  accepting  other  electrons. 
This renders it an effective free radical scavenger, and therefore 
a significant antioxidant. If the transient form cannot accept an 
electron, it will surrender its unpaired electron to an enzymatic 
reaction,  thereby  becoming  an  electron  donor.  Vitamin  C  is 
known  as  an  effective  scavenger  of  superoxide  and  hydroxyl 
radicals, in particular, as well as singlet oxygen, and has been 
shown  in  vitro  to  protect  plasma  lipids  and  low-density 
lipoproteins against peroxidative damage.5

The addition of two electrons to ascorbic acid results in the 
formation of dehydro-l-ascorbic acid (DHAA). Under physiolog-
ical conditions, vitamin C exists primarily in its reduced form, 
ascorbic acid; in trace quantities, it is also present in the oxidized 
form  of  DHAA.  This  substance  can  be  converted  back  into 
ascorbate,  but  if  the  lactone  ring  irreversibly  opens,  yielding 
diketogulonic  acid,  the  compound  is  rendered  inactive.  When 
vitamin C formulations are oxidized, diketogulonic acid is often 
one of the results. Such solutions are ineffective and useless in 
terms of delivering any vitamin C benefits.23,24

Essentially, when vitamin C preparations are exposed to ultra-
violet (UV) radiation or air, the molecule rapidly adds two elec-
trons and transforms into DHAA, which  contains  an  aromatic 
ring. With additional oxidation, the ring irreversibly opens and 
the vitamin C solution is left permanently inactive. For this rea-
son, vitamin C formulations are best preserved in opaque airless 
containers with no exposure to light or air during storage, use, 
and application.

Ascorbyl  palmitate  is  a  fat-soluble  ester  of  vitamin  C  with 
increased stability. It is effective at a neutral pH and its lipid solu-
bility greatly enhances penetration versus polar l-ascorbic acid. 

C H A P T E R  55  ■   A S CO R B I C   AC I D   ( V I TA M I N   C )  

177

Hydrolysis of ascorbyl palmitate yields l-ascorbic acid and pal-
mitic acid in the skin; however, ascorbyl palmitate is also effec-
tive  as  an  intact  molecule,22  and  has  been  shown  to  decrease 
inflammation and deliver beneficial effects to patients with der-
matologic conditions including psoriasis and eczema.25

 ORAL USES

A  small  study  in  2002  compared  the  skin  of  eight  untreated 
volunteers to the skin of 12 volunteers who were treated with 
oral  vitamin  C  supplements  (500  mg/day)  for  eight  weeks. 
Those given oral vitamin C showed significant rises in plasma 
and cutaneous vitamin C content.26 This study demonstrated 
that ingested vitamin C will increase ascorbic acid levels in the 
skin.  However,  when  the  ascorbic  acid-treated  subjects  were 
given a broadband UVB (peak 310 nm, range 270–400 nm) chal-
lenge of 120 mJ/cm2, there was no difference in UVB-induced 
erythemal  response  between  the  two  groups.  Surprisingly, 
reduction in the skin content of total glutathione was seen in 
the vitamin C-treated group versus the untreated group.

A  much  more  recent  study  measured  skin  radical-scavenging 
activity  with  electron  paramagnetic  resonance  spectroscopy  and 
showed that after four weeks of orally ingested vitamin C, 100 mg 
vitamin  C/day  and  180  mg  vitamin  C/day  resulted  in  a 
significant  increase  in  the  radical-scavenging  activity  by  
22 percent and 37 percent, respectively.27 Oral doses of ascorbyl 
palmitate  have  been  shown  to  exhibit  nearly  10-fold  the 
absorption  of  oral  l-ascorbic  acid.28  Similarly,  oral 
supplementation  with  a  5  percent  pelleted  form  of  ascorbyl 
palmitate  was  shown  to  have  an  80  percent  inhibition  on 
12-O-tetradecanoylphorbol-13-acetate  (TPA)-induced  tumors 
in a mouse model versus no improvement following a 27 g/L  
ad libitum concentration of  l-ascorbic acid in drinking water.29 
At this time the belief is that oral supplements of vitamin C do 
help increase the skin’s antioxidant capacity but food sources of 
vitamin C are preferred when possible.

Vitamin  C  has  also  been  shown  in  combination  to  exert  a 
significant antioxidant effect from oral administration. In 2007, 
Cho et al. investigated the effects on UVB-induced wrinkle for-
mation in female SKH-1 hairless mice of an orally administered 
antioxidant compound containing vitamins C and E, Pycnogenol, 
and  evening  primrose  oil  (see  Chapter  49,  Pycnogenol).  Mice 
were  exposed  to  three  weekly  doses  of  UVB  over  10  weeks, 
during which they were administered the antioxidant mixture or 
vehicle  control.  Wrinkle  formation  and  epidermal  thickness 
were significantly lower in the antioxidant group. The investiga-
tors  concluded  that  the  significant  inhibition  of  UVB-induced 
wrinkle  formation  delivered  by  the  oral  antioxidant  cocktail 
resulted from the active constituents hindering matrix metallo-
proteinase activity engendered by UVB exposure, thus allowing 
collagen production to proceed.30

 TOPICAL USES

The preponderance of data supporting beneficial effects of vitamin C 
stem  from  investigations  of  oral  vitamin  C  or  vitamin  C 
applied  to  tissue  cultures.  There  are  no  studies  that  indicate 
that  the  ingestion  of  oral  vitamin  C  increases  cutaneous 
vitamin C levels, however. Manufacturers have seized on this 
gap  in  knowledge  by  developing  topical  vitamin  C  prepara-
tions, which have become quite popular. Ascorbic acid can be 
formulated into water- or lipid-soluble products.31 Unfortunately, 
few of the currently available topical vitamin C preparations 

 
178 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

can  penetrate  the  stratum  corneum  because  they  are  not 
formulated  properly.  Absorption  of  vitamin  C  is  critically 
dependent on formulation characteristics such as a pH of 2 to 
2.5  and  the  percentage  of  ascorbic  acid  in  the  formulation.2 
Some  manufacturers  claim  that  their  products  are  nonionic 
and less lipophobic, which improves the chances for percuta-
neous absorption.32

Another  challenge  in  creating  effective  topical  ascorbic  acid 
products is achieving stability with this volatile ingredient at a 
pH that is optimal for vitamin C absorption. The low pH that is 
required for absorption is easily obtained in the acidic stomach 
but  on  the  skin  can  lead  to  stinging,  which  makes  this  a  poor 
ingredient choice for individuals with S3 type sensitive skin (also 
known as “stingers”). Exposure to air or UV light will cause the 
lactone ring to irreversibly open, yielding diketogulonic acid, and 
then  the  compound  is  rendered  inactive.  Because  few  topical 
vitamin C preparations are packaged in airtight containers that 
are protected from UV radiation, most preparations are rendered 
inactive  within  hours  of  opening  the  bottle.  Nevertheless, 
vitamin C has been found to be effective in combination with 
other antioxidants, such as vitamin E and ferulic acid in one case 
and ferulic acid and phloretin in another, in topical formulations 
that  exert  photoprotective  activity  (see  Chapter  52,  Phloretin, 
and Chapter 54, Ferulic Acid).33–35

A  lipid  form  of  vitamin  C,  topical  ascorbyl  palmitate,  is 
nonirritating  as  well  as  reportedly  photoprotective  and  anti-
inflammatory.25 Its stability at nonacidic pH decreases potential 
irritation and its ester form increases penetration and stability. 
In patch testing on human skin, areas pretreated with 3 percent 
ascorbyl  palmitate  (vs.  non-pretreated  patches)  have  been 
shown  to  decrease  erythema  following  exposure  to  one  to 
three times the minimal erythema dose (MED). Further, appli-
cation of a 5 percent solution of ascorbyl palmitate following 
exposure to one to two times MED decreased the duration of 
erythema  in  some  patients.25  In  1991,  two  topical  forms  of 
vitamin C (l-ascorbic acid and ascorbyl palmitate, an ascorbic 
acid ester) were compared using a TPA-induced tumor model 
in  mice  to  determine  their  ability  to  reduce  reactive  oxygen 
species  (ROS).  TPA-induced  tumor  progression  is  largely 
enhanced  by  reactive  oxygen  superoxide  ions  and  protein 
kinase C. In this study, topical ascorbyl palmitate was found to 
be over 30-fold more effective than l-ascorbic acid at inhibiting 
tumor progression with efficacy at substantially lower concen-
trations.  Much  of  this  benefit  is  attributed  to  the  fact  that 
ascorbyl  palmitate  is  an  amphipathic  molecule  with  a  polar 
ascorbic head and a long hydrophobic side chain. This means 
that it is both lipid- and water-soluble, leading to superior pen-
etration into the skin. In addition, palmitic acid, a product of 
hydrolysis of ascorbyl palmitate in the skin, was also found to 
reduce tumor production in the mouse model indicating that its 
efficacy was not only due to its antioxidant characteristics.29

 SAFETY ISSUES

Type  3  sensitive  skin  (“stingers”)  patients  often  experience 
stinging  and  mild  irritation  from  topically  applied  vitamin  C 
formulations,  especially  those  that  contain  l-ascorbic  acid. 
Ascorbyl palmitate may be associated with a lower incidence 
of  skin  irritation  than  l-ascorbic  acid,  which  must  be  formu-
lated at a low pH to be effective. Some type 2 (rosacea) sensi-
tive  skin  types  experience  increased  redness  from  low-pH 
preparations.  The  major  disadvantages  of  these  products 
include  high  cost  when  formulated  properly,  questionable 

efficacy when not formulated properly, and a plethora of use-
less  products  on  the  market  that  confuse  consumers.  The 
Cosmetic Ingredient Review Expert Panel identified l-ascorbic 
acid  and  various  esters,  including  ascorbyl  palmitate,  calcium 
ascorbate,  magnesium  ascorbate,  magnesium  ascorbyl  phos-
phate,  sodium,  ascorbate,  and  sodium  ascorbyl  phosphate  as 
safe  as  incorporated  in  topical  cosmetic  formulations.36  For 
individuals that cannot tolerate topical vitamin C, oral vitamin 
C at 500 mg twice daily is recommended. Of course, the best 
source  of  oral  vitamin  C  is  through  vitamin  C-rich  foods, 
including  citrus  fruits,  berries,  chili  peppers,  Brussels  sprouts, 
broccoli, and many other fruits and vegetables.37

 ENVIRONMENTAL IMPACT

Organic forms of vitamin C are widely available. It is unlikely 
that  the  synthesis  of  topical  products  featuring  ascorbic  acid 
exacts an environmental toll. More likely, of course, is the poten-
tial of ambient toxins, particularly pesticides, affecting ascorbic 
acid-containing plants. As of the time this text was printed, there 
were no properly formulated organic forms of topical vitamin C.

 FORMULATION CONSIDERATIONS

To be effective, topical vitamin C products and l-ascorbic acid, 
in  particular,  must  be  formulated  properly  and  stored  in  air-
tight, light-resistant containers. Pinnell et al. found that l-ascorbic 
acid must be formulated at a pH less than 3.5 to permeate the 
skin.2 Because few topical vitamin C preparations are packaged 
in  airtight  containers  that  are  protected  from  UV  radiation, 
most preparations are rendered inactive within hours of open-
ing  the  container,  and  appear  yellowish  due  to  the  oxidation 
byproduct  dehydroascorbic  acid.4  Nevertheless,  as  noted 
above,  vitamin  C  has  been  found  to  have  increased  stability 
and  efficacy  in  combination  with  other  antioxidants,  such  as 
vitamin E, ferulic acid, phloretin, and Pycnogenol. Topical for-
mulations containing these combinations have been shown to 
exert photoprotective activity.33,34

Ascorbic  acid  derivatives  such  as  ascorbyl-6-palmitate  and 
magnesium ascorbyl phosphate are used in topical formulations 
as  more  stable  forms  of  the  vitamin.33  Of  these,  magnesium 
ascorbyl phosphate has been found to be the most stable in solu-
tion as well as emulsion and l-ascorbic acid, the least stable.4,38 
However,  little  of  the  antioxidant  potency  of  magnesium 
ascorbyl phosphate is maintained on the skin and absorption is 
difficult. It is more popularly used as a depigmenting ingredient 
[see Chapter 40, Vitamin C (Ascorbic Acid)].2,33

 USAGE CONSIDERATIONS

Oral ingestion of vitamin C does not increase vitamin C levels 
in the skin to the same extent that can be achieved with the 
appropriate use of topical formulations. Use of vitamin C both 
orally (preferably in the diet) and topically twice daily is recom-
mended to prevent photoaging and collagen loss, although this 
has not been proven in human trials.

 SIGNIFICANT BACKGROUND

Ascorbic  acid  is  known  to  exhibit  a  wide  range  of  biologic 
activity.  Antibacterial,  antimycotic,  and  antiviral  properties 
were  reported  by  Wahlqvist  in  1958.39  In  1995,  Hovi  et  al. 

 
conducted a randomized, double-blind, placebo-controlled trial 
in 43 women and 3 men with recurrent mucocutaneous herpes 
to evaluate the effects of Ascoxal, an ascorbic acid-containing 
formulation. They found that the brief topical treatment atten-
uated symptom intensity and persistence.39

Antioxidant and Antiaging Activity
Vitamin C is unique among antioxidants because of its ability 
to increase collagen production in addition to its free radical- 
scavenging  “antioxidant”  activity.  It  is  also  one  of  the  most 
recognized antioxidants by consumers. Due to its capacity to 
interfere with the UV-induced generation of ROS by reacting 
with the superoxide anion or the hydroxyl radical, vitamin C 
has become a popular addition to “after-sun” products.40,41 The 
nutrient  is  also  known  to  delay  the  incidence  of  UV-induced 
neoplasms in mice.42 In a study of the photoprotective proper-
ties  of  vitamin  C,  histologic  examination  revealed  that  pigs 
treated with topical ascorbic acid exhibited fewer sunburn cells 
than  those  treated  with  vehicle  alone  when  exposed  to  both 
UVA and UVB irradiation.43 Investigators also noted a signifi-
cant reduction in erythema in areas treated with vitamin C and 
decreases  in  the  amount  of  vitamin  C  remaining  on  the  skin 
after UV exposure. In a subsequent study, the same researchers 
found that topical vitamin C combined with either a UVA or 
UVB  sunscreen  improved  sun  protection  as  compared  to  the 
sunscreen alone.44 Also, the combination of vitamins C and E 
delivered  protection  from  UVB  insult,  though  the  bulk  of 
protection was attributable to vitamin E. But vitamin C alone 
has been demonstrated in other studies to mitigate the effects 
of UVB, such as erythema and signs of photoaging, on porcine 
and human skin.2,45,46

In 1999, Traikovich reported on improvements in fine wrin-
kles,  roughness,  coarse  rhytides,  skin  tone,  and  sallowness 
delivered  by  topical  vitamin  C  (Cellex-C)  in  a  small  three-
month, double-blind, randomized, vehicle-controlled trial with 
19 subjects.4,47  In 2003, Humbert et al. conducted a six-month, 
double-blind,  vehicle-controlled  trial  with  20  healthy  female 
volunteers  showing  that  patients  treated  with  5  percent  vita-
min  C  cream  experienced  significant  improvements  in  deep 
furrows on the neck and forearms.4,48

In a 2001 study in 10 postmenopausal women, Nusgens et al. 
found  that  daily  topical  application  of  5  percent  l-ascorbic  acid 
enhanced the levels of procollagen types I and III, their posttrans-
lational maturation enzymes, and tissue inhibitor of matrix metal-
loproteinase (TIMP)-1.7 This led to increased levels of collagen in 
the skin.

Several  studies  indicate  that  mice  treated  with  topical 
vitamin  C  have  less  erythema,  fewer  sunburn  cells,  and 
diminished tumor formation in treated skin after UV exposure.49 
As  noted  above,  vitamin  C  reduces  (and  therefore  recycles) 
oxidized vitamin E back into its active form so the antioxidant 
potency of vitamin E is regenerated.50 Potent anti-inflammatory 
activities have also been associated with vitamin C.4

In  2003,  Lin  et  al.  developed  a  stable  aqueous  solution  of  
15  percent  l-ascorbic  acid  and  1  percent  α-tocopherol  and 
applied it daily to pig skin, finding that while each antioxidant 
alone conferred a protective effect against erythema and sun-
burn  cell  formation,  the  combination  yielded  an  antioxidant 
protection  factor  of  fourfold.51  Subsequently,  they  combined 
the antioxidant ferulic acid with 15 percent l-ascorbic acid and 
1 percent α-tocopherol to improve the chemical stability of the 
vitamins and found that this solution also acted synergistically, 
doubling  photoprotection  from  fourfold  to  eightfold  as 

C H A P T E R  55  ■   A S CO R B I C   AC I D   ( V I TA M I N   C )  

179

measured by erythema and sunburn cell formation in porcine 
skin  (see  Chapter  54,  Ferulic  Acid).  Further,  the  antioxidant 
preparation  efficiently  diminished  thymine  dimer  formation 
and inhibited apoptosis. The investigators concluded that this 
combination of potent antioxidants should provide protection 
against skin cancer and photoaging.35

In 2008, Murray et al. investigated whether a stable topical 
preparation of 15 percent l-ascorbic acid, 1 percent α-tocopherol, 
and  0.5  percent  ferulic  acid  could  protect  human  skin  in  vivo 
from UV-induced damage. In this small study with nine adults 
with Fitzpatrick skin types II or III, they found that the anti-
oxidant  formulation,  with  a  mechanism  of  action  differing 
from  sunscreens,  supplemented  the  antioxidant  pool  of  the 
skin  and  imparted  significant  photoprotection,  guarding  the 
skin  against  erythema  and  apoptosis  as  well  as  effectively 
inhibiting p53 activation and diminishing thymine dimer muta-
tions known to be linked to skin cancer.33

In 2012, Xu et al. assessed the efficacy and safety of topical 
23.8  percent  l-ascorbic  acid  on  photoaged  skin  in  a  split-face 
study  in  20  Chinese  women.  Significant  improvements  in  fine 
lines, dyspigmentation, and surface roughness were noted, with-
out adverse side effects.52

Also that year, Taniguchi et al. assessed a stable ascorbic acid 
derivative,  2-O-α-glucopyranosyl-l-ascorbic  acid  (AA-2G), 
and compared it with ascorbic acid for its protective effect on 
human  dermal  fibroblasts  against  cellular  damage  and 
senescence spurred by hydrogen peroxide (H2O2). They found 
that  pretreatment  with  AA-2G  for  72  hours  fostered  the 
proliferation  of  normal  human  dermal  fibroblasts  and 
protected against H2O2-induced cell damage. The same results 
were  achieved  with  ascorbic  acid  only  when  the  culture 
medium was replenished every 24 hours. The derivative prod-
uct was also found to be stronger than ascorbic acid in down-
regulating  senescence-associated-β-galactosidase  (SA-β-gal) 
activity, a cellular aging biomarker. In addition, the expression 
of the antiaging factor sirtuin 1 (SIRT1) was markedly reduced 
in  H2O2-exposed  normal  fibroblasts  compared  to  untreated 
cells.  Pretreatment  with  AA-2G  prior  to  H2O2  exposure 
significantly blunted the decrease in SIRT1 expression while 
ascorbic  acid  exerted  no  effect,  however  (see  Chapter  81, 
Overview of Aging). Pretreatment with AA-2G also prevented 
the  increase  of  p53  and  p21  expression  levels  due  to  H2O2 
exposure. The investigators concluded that the stable ascorbic 
acid derivative 2-O-α-glucopyranosyl-l-ascorbic acid protects 
against oxidative stress and cellular senescence, suggesting a 
potential role as an antiaging agent.53

In  a  blinded,  35-subject,  split-face  study  conducted  by  the 
Baumann Cosmetic and Research Institute, subjects applied a  
7 percent ascorbyl palmitate solution with dimethylaminoetha 
nol,  hyaluronic  acid,  and  vitamin  E  (C-ESTA  Face  Serum,  Jan 
Marini Skin Research) on one side of their face and a 15 percent 
l-ascorbic acid, 1 percent vitamin E, 0.5 percent ferulic acid (C 
E Ferulic, Skinceuticals) on the opposite side of the face for two 
weeks. A notably higher rate of irritation was observed on the 
l-ascorbic  acid  side  of  the  face  versus  the  ascorbyl  palmitate 
side of the face (29 percent noted greater irritation vs. 11 per-
cent). A significant number of subjects also perceived superior 
improvement in texture on the ascorbyl palmitate side of the 
face versus the l-ascorbic acid side of the face (43 percent noted 
greater improvement vs. 14 percent). Results trended higher on 
the  ascorbyl  palmitate  side  for  additional  antiaging  concerns, 
but differences were not significant given the sample size and 
study duration. Overall, subjects indicated a statistically signifi-
cant preference for the ascorbyl palmitate product.54

 
180 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

 CONCLUSION

As  a  result  of  dietary  consumption,  ascorbic  acid  is  the  most 
abundant  antioxidant  found  in  human  skin.  It  plays  a  critical 
role  in  multiple  biologic  functions,  including  wound  healing, 
collagen  production,  and  replenishing  other  antioxidants 
thereby  acting  against  diseases  and  other  processes,  such  as 
aging,  that  are  mediated  through  oxidative  stress.  Though 
orally administered ascorbic acid is readily bioavailable, ascor-
bic acid in the skin is rapidly depleted and oral supplementa-
tion  alone  does  not  result  in  optimal  skin  levels;  therefore, 
topical use is desirable. In order for ascorbic acid to be effective, 
it must be produced and packaged away from UV light and air 
to prevent the irreversible opening of the lactone ring, which 
generates diketogulonic acid that renders the compound inac-
tive  and  useless.  Numerous  formulation  considerations  are 
involved in the stabilization and effective penetration of ascor-
bic acid into the skin. Issues such as packaging, exposure to air 
or light during use, skin sensitivity, and user preference factor 
into selection of a vitamin C product. The process of develop-
ing, manufacturing, and packaging effective, stable vitamin C 
formulations is expensive. In combination with other antioxi-
dants, vitamin C has been demonstrated to be an integral con-
stituent in topical antioxidant and antiaging formulations that 
show  promise  in  the  dermatologic  armamentarium,  particu-
larly against photoaging.

REFERENCES

1.  Nishikimi  M,  Fukuyama  R,  Minoshima  S,  et  al.  Cloning  and 
chromosomal  mapping  of  the  human  nonfunctional  gene  for 
L-gulono-gamma-lactone oxidase, the enzyme for L-ascorbic acid 
biosynthesis missing in man. J Biol Chem. 1994;269:13685.

2.  Pinnell  SR,  Yang  H,  Omar  M,  et  al.  Topical  L-ascorbic  acid: 
Percutaneous absorption studies. Dermatol Surg. 2001;27:137.
3.  Shindo Y, Witt E, Han D, et al. Enzymic and non-enzymic anti-
oxidants in epidermis and dermis of human skin. J Invest Dermatol. 
1994;102:122.

4.  Farris PK. Topical vitamin C: A useful agent for treating photoaging 
and other dermatologic conditions. Dermatol Surg. 2005;31:814.
5.  Sauberlich  HE.  Pharmacology  of  vitamin  C.  Annu  Rev  Nutr. 

1994;14:371.

6.  Burgess C. Topical vitamins. J Drugs Dermatol. 2008;7:s2.
7.  Nusgens BV, Humbert P, Rougier A, et al. Topically applied vitamin C 
enhances  the  mRNA  level  of  collagens  I  and  III,  their  processing 
enzymes and tissue inhibitor of matrix metalloproteinase 1 in the 
human dermis. J Invest Dermatol. 2001;116:853.

8.  Bird  TA,  Schwartz  NB,  Peterkofsky  B.  Mechanism  for  the 
decreased biosynthesis of cartilage proteoglycan in the scorbutic 
guinea pig. J Biol Chem. 1986;261:11166.

9.  Peterkofsky  B.  Ascorbate  requirement  for  hydroxylation  and 
secretion  of  procollagen:  Relationship  to  inhibition  of  collagen 
synthesis in scurvy. Am J Clin Nutr. 1991;54:1135S.

10.  Lin JY, Selim MA, Shea CR, et al. UV photoprotection by combi-
nation topical antioxidants vitamin C and vitamin E. J Am Acad 
Dermatol. 2003;48:866.

11.  Shindo  Y,  Witt  E,  Han  D,  et  al.  Dose-response  effects  of  acute 
ultraviolet irradiation on antioxidants and molecular markers of 
oxidation  in  murine  epidermis  and  dermis.  J  Invest  Dermatol. 
1994;102:470.

12.  Thiele JJ, Traber MG, Tsange KG, et al. In vivo exposure to ozone 
depletes vitamins C and E and induces lipid peroxidation in epi-
dermal layers of murine skin. Free Radic Biol Med. 1997;23:85.
13.  De Tullio MC. Beyond the antioxidant: The double life of vitamin 

C. Subcell Biochem. 2012;56:49.

14.  Carpenter  KJ.  The  discovery  of  vitamin  C.  Ann  Nutr  Metab. 

2012;61:259.

15.  Magiorkinis  E,  Beloukas  A,  Diamantis  A.  Scurvy:  Past,  present 

and future. Eur J Intern Med. 2011;22:147.

16.  Pinnell SR, Murad S, Darr D. Induction of collagen synthesis by 
ascorbic acid. A possible mechanism. Arch Dermatol. 1987;123:1684.

17.  Gey KF. Vitamins E plus C and interacting conutrients required for 
optimal health. A critical and constructive review of epidemiol-
ogy  and  supplementation  data  regarding  cardiovascular  disease 
and cancer. Biofactors. 1998;7:113.

18.  McLauren S. Nutrition and wound healing. Wound Care. 1992;1:45.
19.  Kameyama K, Sakai C, Kondoh S, et al. Inhibitory effect of mag-
nesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in 
vitro and in vivo. J Am Acad Dermatol. 1996;34:29.

20.  Ash K, Lord J, Zukowski M, et al. Comparison of topical therapy 
for  striae  alba  (20%  glycolic  acid/0.05%  tretinoin  versus  20% 
glycolic acid/10% L-ascorbic acid). Dermatol Surg. 1998;24:849.
21.  Alster TS, West TB. Effect of topical vitamin C on postoperative car-
bon dioxide laser resurfacing erythema. Dermatol Surg. 1998;24:331.

22.  Perricone  NV.  Topical  vitamin  C  ester  (ascorbyl  palmitate).  

J Geriatr Dermatol. 1997;5:162.

23.  Bush  JA,  Cheung  KJ  Jr.,  Li  G.  Curcumin  induces  apoptosis  in 
human  melanoma  cells  through  a  Fas  receptor/caspase-8  path-
way independent of p53. Exp Cell Res. 2001;271:305.

24.  Jee SH, Shen SC, Tseng CR, et al. Curcumin induces a p53-dependent 
apoptosis  in  human  basal  cell  carcinoma  cells.  J  Invest  Dermatol. 
1998;111:656.

25.  Perricone NV. The photoprotective and anti-inflammatory effects 

of topical ascorbyl palmitate. J Geriatric Derm. 1993;1:5.

26.  McArdle F, Rhodes LE, Parslew R, et al. UVR-induced oxidative 
stress in human skin in vivo: Effects of oral vitamin C supplemen-
tation. Free Radic Biol Med. 2002;33:1355.

27.  Lauer  AC,  Groth  N,  Haag  SF,  et  al.  Dose-dependent  vitamin  C 
uptake and radical scavenging activity in human skin measured 
with in vivo electron paramagnetic resonance spectroscopy. Skin 
Pharmacol Physiol. 2013;26:147.

28.  Pokorski M, Marczak M, Dymecka A, et al. Ascorbyl palmitate as 
a carrier of ascorbate into neural tissues. J Biomed Sci. 2003;10:193.
29.  Smart RC, Crawford CL. Effect of ascorbic acid and its synthetic 
lipophilic  derivative  ascorbyl  palmitate  on  phorbol  ester-
induced  skin-tumor  promotion  in  mice.  Am  J  Clin  Nutr. 
1991;54:1266S.

30.  Cho HS, Lee MH, Lee JW, et al. Anti-wrinkling effects of the mix-
ture of vitamin C, vitamin E, pycnogenol and evening primrose 
oil, and molecular mechanisms on hairless mouse skin caused by 
chronic  ultraviolet  B  irradiation.  Photodermatol  Photoimmunol 
Photomed. 2007;23:155.

31.  Colven RM, Pinnell SR. Topical vitamin C in aging. Clin Dermatol. 

1996;14:227.

32.  Darr D, Pinnell S. U. S. Patent no. 5,140,043, 1992.
33.  Murray  JC,  Burch  JA,  Streilein  RD,  et  al.  A  topical  antioxidant 
solution  containing  vitamins  C  and  E  stabilized  by  ferulic  acid 
provides  protection  for  human  skin  against  damage  caused  by 
ultraviolet irradiation. J Am Acad Dermatol. 2008;59:418.

34.  Oresajo  C,  Stephens  T,  Hino  PD,  et  al.  Protective  effects  of  a 
topical  antioxidant  mixture  containing  vitamin  C,  ferulic  acid, 
and phloretin against ultraviolet-induced photodamage in human 
skin. J Cosmet Dermatol. 2008;7;290.

35.  Lin FH, Lin JY, Gupta RD, et al. Ferulic acid stabilizes a solution of 
vitamins C and E and doubles its photoprotection of skin. J Invest 
Dermatol. 2005;125:826.

36.  Elmore  AR.  Final  report  of  the  safety  assessment  of  L-Ascorbic 
Acid,  Calcium  Ascorbate,  Magnesium  Ascorbate,  Magnesium 
Ascorbyl  Phosphate,  Sodium  Ascorbate,  and  Sodium  Ascorbyl 
Phosphate as used in cosmetics. Int J Toxicol. 2005;24(Suppl 2):51.
37.  Baumann  L.  Nutrition  and  the  skin.  In:  Baumann  L,  Saghari  S, 
Weisberg E, eds. Cosmetic Dermatology: Principles and Practice. 2nd ed. 
New York: McGraw-Hill; 2009:53–59.

38.  Austria R, Semenzato A, Bettero A. Stability of vitamin C deriva-
tives  in  solution  and  topical  formulations.  J  Pharm  Biomed  Anal. 
1997;15:795.

39.  Hovi T, Hirvimies A, Stenvik M, et al. Topical treatment of recur-
rent mucocutaneous herpes with ascorbic acid-containing solution. 
Antiviral Res. 1995;27:263.

40.  Scarpa M, Stevanato R, Viglino P, et al. Superoxide ion as active 
intermediate  in  the  autoxidation  of  ascorbate  by  molecular 
oxygen.  Effect  of  superoxide  dismutase.  J  Biol  Chem. 
1983;258:6695.

41.  Cabelli DE, Bielski BH. Kinetics and mechanism for the oxidation 
of ascorbic acid/ascorbate by HO2/O2 radicals: A pulse radiolysis 
and stopped flow photolysis study. J Phys Chem. 1983;87:1805.
42.  Dunham WB, Zuckerkandl E, Reynolds R, et al. Effects of intake 
of L-ascorbic acid on the incidence of dermal neoplasms induced 
in mice by ultraviolet light. Proc Natl Acad Sci U S A. 1982;79:7532.

 
43.  Knekt P, Aromaa A, Maatela J, et al. Vitamin E and cancer preven-

tion. Am J Clin Nutr. 1991;53:283S.

44.  Darr D, Dunston S, Faust H, et al. Effectiveness of antioxidants 
(vitamin C and E) with and without sunscreens as topical photo-
protectants. Acta Derm Venereol. 1996;76:264.

45.  Darr  D,  Combs  S,  Dunston  S,  et  al.  Topical  vitamin  C  protects 
porcine  skin  from  ultraviolet  radiation-induced  damage.  Br  J 
Dermatol. 1992;127:247.

46.  Murray  J,  Darr  D,  Reich  J,  et  al.  Topical  vitamin  C  treatment 
reduces ultraviolet B radiation-induced erythema in human skin. 
J Invest Dermatol. 1991;96:587.

47.  Traikovich SS. Use of topical ascorbic acid and its effects on pho-
todamaged  skin  topography.  Arch  Otolaryngol  Head  Neck  Surg. 
1999;125:1091.

48.  Humbert PG, Haftek M, Creidi P, et al. Topical ascorbic acid on 
photoaged skin. Clinical, topographical and ultrastructural evalu-
ation: Double-blind study vs. placebo. Exp Dermatol. 2003;12:237.

C H A P T E R  55  ■   A S CO R B I C   AC I D   ( V I TA M I N   C )  

181

49.  Werninghaus K. The role of antioxidants in reducing photodam-
age. In: Gilchrest B, ed. Photodamage. London: Blackwell Science; 
1995:249.

50.  Chan  AC.  Partners  in  defense,  vitamin  E  and  vitamin  C.  Can  J 

Physiol Pharmacol. 1993;71:725.

51.  Lin JY, Selim MA, Shea CR, et al. UV photoprotection by combi-
nation topical antioxidants vitamin C and vitamin E. J Am Acad 
Dermatol. 2003;48:866.

52.  Xu TH, Chen JZ, Li YH, et al. Split-face study of topical 23.8% 
L-ascorbic  acid  serum  in  treating  photo-aged  skin.  J  Drugs 
Dermatol. 2012;11:51.

53.  Taniguchi  M,  Arai  N,  Kohno  K,  et  al.  Anti-oxidative  and  anti-
aging  activities  of  2-O-α-glucopyranosyl-L-ascorbic  acid  on 
human dermal fibroblasts. Eur J Pharmacol. 2012;674:126.

54.  Baumann  L,  Schirripa  MJ,  Duque  D.  C-ESTA  serum  and  CE 
Ferulic  split-face  vitamin  C  comparison  study.  J  Drugs  Dermatol, 
submitted for publication.

 
182 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   5 6

Tocopherol (Vitamin E)

Activities:

Antioxidant, photoprotection, wound healing

Important Chemical Components:

Vitamin  E  is  actually  a  family  of  eight  fat-soluble  iso-
mers that include four tocopherols and four tocotrienols. 
The molecular formula of α-tocopherol, the most active 
form of vitamin E, is C29H50O2. By contrast, the molecu-
lar formula of α-tocotrienol is C29H44O2. The molecular 
formula for γ-tocopherol, the most frequently consumed 
form of vitamin E in the U.S. is C28H48O2.1

Origin Classification:

Vitamin  E  is  found  naturally  in  many  vegetables,  oils, 
seeds, nuts, and other foods. Most topical formulations 
contain synthetic laboratory-made α-tocopherol or one 
of its many esters or ethers.

Personal Care Category:

Antioxidant, moisturizing, antiaging

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW, DRPW, DSNW, DSPW, ORNW, ORPW, OSNW, 
and OSPW

 SOURCE

Obtained in the diet through fresh vegetables (especially green 
leafy vegetables), vegetable oils, seeds, nuts, grains, corn, soy, 
whole  wheat  flour,  margarine,  and  in  some  meat  and  dairy 
products,  vitamin  E,  or  tocopherol,  is  the  main  lipid-soluble 
antioxidant  found  in  human  skin  (via  sebum),  membranes, 
plasma,  and  tissues  that  protects  cells  from  oxidative  stress 
(Table  56-1).2–5  Meeting  the  definition  of  a  vitamin,  it  is  not 
synthesized by humans. Vitamin E is frequently used to treat 
minor burns, surgical scars, and other wounds, although its use 
for  dermatoses  has  not  been  approved  by  the  United  States 
Food and Drug Administration (USFDA). The use of vitamin E 

TABLE 56-1
Pros and Cons of Tocopherol

Pros
Potent antioxidant activity and primary 

lipophilic antioxidant

Synergistically interacts with other antioxidants
Exhibits emollient activity
Easy to formulate
Can be regenerated back into its reduced 

form by hydrophilic antioxidants vitamin C 
and glutathione

Cons
Dearth of evidence in controlled trials to 

support use for dermatologic conditions

Risk of contact dermatitis

is  thought  to  mitigate  lipid  peroxidation  and  protect  against 
cardiovascular  disease.6  Similarly,  it  protects  cutaneous  cell 
membranes  from  peroxidation.  In  addition  to  its  antioxidant 
activity, it is now understood to regulate cell signaling and gene 
expression.7 The main biologically active form of vitamin E is 
α-tocopherol.8

Tocopherols,  unlike  tocotrienols,  are  found  in  olive,  peanut, 
sunflower, and walnut oils.9 One of the most abundant sources of 
tocotrienols is palm oil, which is free of trans-fatty acids, account-
ing  for its increasingly widespread popularity, particularly in the 
United States.9,10 Tocotrienols are also found in edible sources such 
as rice bran, coconut oil, cocoa butter, soy bean, barley, and wheat 
germ, as well as inedible ones such as latex (Hevea brailiensis).9–11

 HISTORY

Herbert Evans and Katherine Bishop are credited with discovering 
vitamin E in 1922.12–14 After inducing sterility in rats, they found 
that feeding the animals lettuce or wheat germ oil, but not cod 
liver oil or wheat flour or chaff, restored fertility. Initially, they 
labeled  an  essential  dietary  ingredient  as  “factor  X.”13 
They adopted the expression “vitamin E,” as suggested by Sure, 
in 1924.7,13 The first description of the antioxidant activity of 
vitamin E is attributed to Olcott and Mattill in 1931, with the 
first  recorded  isolation  of  α-tocopherol  occurring  in  1936.13,14 
Also  in  1936,  George  Calhoun,  professor  of  Greek  at  the 
University  of  California,  Berkeley,  suggested  the  name 
“tocopherol”  based  on  the  Greek  words  tokos  (offspring  or 
childbirth)  and  phero  or  phérein  (to  bear  or  to  bring  forth),  to 
Evans and colleagues, who also worked at Berkeley; the “-ol” 
indicates  the  alcohol  characteristics  of  the  compound.7,13  In 
1938, Karrer, Fritzche, Ringier, and Salomon became the first to 
synthesize  α-tocopherol.9,13  In  the  1940s,  vitamin  E  became 
known  as  a  “chain-breaking”  antioxidant  for  its  role  in 
suppressing the chain reaction induced by free radicals.14

 CHEMISTRY

Vitamin  E  is  a  family  of  compounds  called  tocopherols, 
including, α-, β-, γ-, and δ-tocopherol, of which α-tocopherol is 
the  most  active  form,  and  four  tocotrienols  (α-,  β-,  γ-,  and 
δ-tocotrienol).  Tocotrienols,  with  three  unsaturated  bonds  in 
the  carbon  side  chain  with  one  chiral  center,  have  an  isopre-
noid instead of a phytyl side chain (long saturated carbon side 
chain with a chiral center).3,9 The four forms differ by the num-
ber of methyl groups found on the chromanol nucleus (α- has 
three; β- and γ- each have two; and δ- has one).3 The side chain 
is  linked  to  position  2  of  the  chroman  ring  in  all  cases.7  The 
chemical names for all vitamin E types begin with either “d” for 
the  natural  form  or  “dl”  (or  “all-rac”)  for  the  synthetic  form. 
Natural vitamin E is more active and better absorbed. Synthetic 
vitamin E supplements contain only α-tocopherol, while food 
sources  contain  various  tocopherols,  including  α-,  δ-,  and 
γ-tocopherol.  Forms  of  vitamin  E  are  labeled  as  either 

 
“tocopherol”  or  the  esterified  “tocopheryl”  followed  by  the 
name of the substance to which it is attached, as in “tocopheryl 
acetate.”

Although  less  studied  than  tocopherols  (approximately  one 
percent of the literature on vitamin E addresses tocotrienols),10 
tocotrienols have been reported to act as stronger antioxidants 
but  exhibit  lower  biovailability;9,15–17  the  δ-tocotrienol  form  is 
thought to be especially effective in combating actinic damage.18 
Of  note,  some  believe  that  α-tocotrienol  is  a  more  potent 
antioxidant  than  α-tocopherol.9  Tocotrienols  are  not  only 
members of the vitamin E family based on structure, but func-
tion  as  well.  For  instance,  tocotrienols  can  alleviate  symptoms 
engendered  by  α-tocopherol  deficiency.10  In  addition, 
tocotrienols reportedly display hypocholesterolemic, anticancer, 
and  neuroprotective  activity  seldom  associated  with 
tocopherols.10 Tocopherols are much more widely dispersed in 
the plant kingdom than are tocotrienols.10,19

Vitamin  E,  CoQ10,  curcumin,  and  feverfew  are  among  the 
antioxidants found in the lipophilic portion of the cell membrane 
(see  Chapter  57,  Coenzyme  Q10;  Chapter  66,  Feverfew;  and 
Chapter  69,  Turmeric).  Other  fat-soluble  antioxidants  include 
carotenoids, particularly lycopene, and idebenone, the synthetic 
analog  of  CoQ10  (see  Chapter  61,  Idebenone).  But  several 
investigations  have  shown  that  vitamin  E  is  the  predominant 
antioxidant in the skin barrier.20 One of the primary functions of 
α-tocopherol  is  the  scavenging  of  lipid  peroxyl  radicals  (one 
molecule  of  tocopherol  has  the  capacity  to  scavenge  two 
molecules of peroxyl radicals); γ-tocopherol is better at scaveng-
ing  reactive  nitrogen  oxide  species  (up  to  six  times  the 
reactivity).7,14,21–23  In  addition,  α-tocopherol  has  twice  the 
capacity  of  γ-tocopherol  in  scavenging  oxygen  radicals; 
γ-tocopherol  has  10  percent  of  the  biological  activity  of 
α-tocopherol.7 Concentrations of vitamin E are found to be high-
est in the lowest layers of the stratum corneum (SC).24 Exogenous 
factors such as ultraviolet (UV) exposure are known to deplete 
the stores of vitamin E in the skin.

 ORAL USES

Oral  vitamin  E  has  been  used  in  a  wide  range  of  cutaneous 
conditions as a treatment or prophylaxis, including skin cancer, 
dystrophic  epidermolysis  bullosa,  discoid  lupus  erythemato-
sus,  atopic  dermatitis,  yellow  nail  syndrome,  granuloma 
annulare,  pemphigus,  and  lichen  sclerosus  et  atrophicus.25 
Results have varied significantly. Vitamin E has also been used 
in oral form to treat cutaneous ulcers, vibration disease, as well 
as claudication, and to stimulate collagen synthesis and wound 
healing.3,26

In 2002, Tsoureli-Nikita et al. conducted a single-blind clinical 
study in 96 patients with atopic dermatitis randomly divided into 
a  group  given  400  international  units  (IU)  of  natural  vitamin  E 
or  a  placebo,  once  daily  for  eight  months.  The  subjects  in  the 
vitamin  E  group  experienced  significantly  better  results  than 
those on placebo, with nearly complete remission in seven of the 
50 vitamin E subjects and none on placebo. Great improvement 
was observed in 23 of the 50 using vitamin E and only one in the 
placebo group. Slight improvement was seen in 10 using vitamin E 
and four in the placebo group, with no changes recorded in six of 
the  vitamin  E  group  and  five  in  the  placebo  cohort.  Thirty-six 
patients using the placebo experienced an exacerbation of their 
symptoms, compared to four patients using vitamin E. A reduc-
tion of 62 percent in serum immunoglobulin E levels was noted 
in the vitamin E patients who exhibited great improvement and 
near remission. The difference was approximately 34.4 percent 

C H A P T E R  56  ■   TO CO P H E R O L   ( V I TA M I N   E )  

183

in  those  taking  placebo.  The  investigators  reported  significant 
improvements in facial erythema, lichenification, and the appear-
ance  of  normal-looking  skin,  concluding  that  vitamin  E  is 
promising as a therapeutic agent for atopic dermatitis.27

Some authors have reported that the use of oral vitamin E will 
reduce  the  side  effects  of  retinoids;28  however,  other  studies 
have not shown this benefit.29

Thiele and Ekanayake-Mudiyanselage note that oral vitamin E 
doses  ranging  from  50  to  1000  IU  have  been  well  tolerated  in 
human  beings  with  minimal  or  no  side  effects.30  Oral  supple-
mentation with tocotrienols has been shown to protect against 
stroke.31,32 When incorporated into oral supplements tocotrienols 
are typically processed into softgel capsules.9

Several studies have demonstrated a protective effect against 
prostate cancer purportedly delivered by α-tocopherol supple-
mentation.33,34 However, in a 2007 prospective study analyzing 
the relationship of vitamin E supplementation and dietary con-
sumption of α-, δ-, γ- and δ-tocopherol to prostate cancer risk 
in 295,344 men (between 50 and 71 years old) free of cancer at 
enrollment in 1995–1996, investigators found that α-tocopherol 
did not impart protection but higher intake of γ-tocopherol was 
associated with a lowered risk of clinically relevant disease.21

A  2013  study  suggests  a  role  for  argan  oil  improving  the 
vitamin  E  profile  and  attenuating  the  symptoms  of  disorders 
seen  more  often  in  postmenopausal  women.  In  a  study  of  
151 menopausal women in Morocco, serum level of vitamin E 
was increased in women consuming edible argan oil but not in 
women  in  an  olive  oil  group.  Investigators  suggested  that  an 
argan-rich diet increases antioxidant status and may contribute 
to  the  prevention  of  some  postmenopausal  disorders  (see 
Chapter 10, Argan Oil).35

 TOPICAL USES

Vitamin E is generally used in 1 to 5 percent concentrations as 
α-tocopherol  or  tocopherol  acetate  in  over-the-counter 
products.24 When topically applied, vitamin E has been shown 
to hydrate the SC and improve water-binding capacity.24

In a 2005 study with 13 volunteers, Ekanayake-Mudiyanselage 
et  al.  examined  whether  a  one-time  use  of  an  α-tocopherol-
enriched  rinse-off  product  could  yield  effective  deposition  of 
α-tocopherol on the SC. The α-tocopherol-enriched product or 
an  α-tocopherol-free  vehicle  control  was  applied.  Skin  surface 
lipids  were  analyzed  after  extraction  from  all  volunteers, 
including a group subjected to irradiation of their forearms with 
low-dose  UVA  (8  J/cm2).  The  investigators  found  that  the 
α-tocopherol  product  increased  α-tocopherol  levels  in  surface 
lipids whereas such levels were decreased in the control group. 
Deposition levels remained consistent for at least 24 hours. The 
α-tocopherol  rinse-off  product  also  significantly  suppressed 
photooxidation  of  squalene.  The  researchers  concluded  that 
α-tocopherol-enriched  rinse-off  products  can  contribute  skin 
barrier integrity maintenance by protecting it at the surface lipid 
level against photooxidative insult.8

In a small study of nine patients in 2008, Murray et al. found 
that  a  stable  topical  preparation  of  15  percent  l-ascorbic  acid, 
1  percent  α-tocopherol,  and  0.5  percent  ferulic  acid  protected 
human  skin  in  vivo  from  UV-induced  damage,  specifically 
erythema  and  apoptosis  [see  Chapter  54,  Ferulic  Acid,  and 
Chapter  55,  Ascorbic  Acid  (Vitamin  C)].  The  formulation  also 
suppressed p53 activation and limited thymine dimer mutations, 
which are associated with skin cancer.36

Topically applied vitamin E is considered an effective ingredi-
ent for conferring skin protection and to treat atopic dermatitis.3,37

 
184 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Wound Healing
Oxygen radicals form in response to injury and further inhibit 
recovery by attacking DNA, cellular membranes, proteins, and 
lipids. It is believed that antioxidants act to ameliorate wounds 
by reducing the damage induced by free oxygen radicals, which 
are  released  by  neutrophils  in  the  inflammatory  phase  of  the 
healing process.38 In the late 1960s, Kamimura et al. performed 
quantitative  research  demonstrating  that  topically  applied 
vitamin  E  penetrates  into  the  deep  dermis  and  subcutaneous 
tissue.39 Numerous scientists, as well as many laypersons, have 
interpreted this to mean that topically applied vitamin E may 
improve  wound  healing.  Contradictory  results  have  emerged 
from  animal  studies  undertaken  to  evaluate  the  effects  of 
vitamin E on wound healing, however. This may be explained 
by  the  fact  that  unlike  other  vitamins,  tocopherols  exhibit 
species-specific mechanisms of action.26

In a prospective, double-blind, randomized study on humans, 
Jenkins et al. tried to diminish scarring in burn patients following 
reconstructive  surgery  by  applying  topical  vitamin  E.  The 
researchers  observed  no  difference  between  the  control  and 
treatment groups, however, and nearly 20 percent of the patients 
reported  local  reactions  to  the  vitamin  E  cream.40  In  another 
study,  Baumann  et  al.  assessed  the  cosmetic  benefit  resulting 
from the use of topically applied vitamin E to surgical scars.37 In 
a  double-blind  fashion,  patients  applied  320  IU  of  d-α-
tocopheryl/g of Aquaphor to one side of the scar and Aquaphor 
alone to the other side of the scar. The patients were followed 
for  six  months.  At  the  conclusion  of  the  study,  the  vitamin  E 
preparation failed to improve the cosmetic appearance of surgical 
scars, and resulted in contact dermatitis in a few subjects.

Skin Lightening
In 1999, Funasaka et al. showed in a pigmented human mela-
noma cell line that α-tocopherol and ferulic acid, connected by 
an ester bond in the compound α-tocopheryl ferulate, appears 
to  be  a  viable  facial  skin-whitening  agent,  inhibiting 
melanogenesis  as  well  as  biological  responses  to  reactive 
oxygen species (see Chapter 54, Ferulic Acid).41 In addition, the 
compound  more  efficiently  hindered  melanin  formation  than 
the  well-known  skin-lightening  agents  arbutin,  kojic  acid, 
magnesium-l-ascorbyl 2-phosphate (esterified vitamin C), and 
tranexamic  acid  [see  Chapter  35,  Arbutin;  Chapter  37,  Kojic 
Acid; and Chapter 40, Vitamin C (Ascorbic Acid)].41

Skin Cancer Protection
In  2013,  Burns  et  al.  demonstrated  in  female  SKH-1  hairless 
mice that topical treatment with a combination of vitamins C 
(15  percent  l-ascorbic)  and  E  (1  percent  α-tocopherol)  and  
0.5  percent  ferulic  acid  (C  E  Ferulic®)  for  15  weeks  reduced 
squamous  cell  cancer  (SCC)  tumor  burden  and  inhibited  the 
development  of  new  tumors  after  10  weeks  of  exposure  to 
UVB.  They  also  found  that  treatment  with  topical  5  percent 
α-tocopherol alone may actually augment SCC formation.42

application of vitamin E.45 In 1994, Swiss researchers evaluated 
1,000 cases of an atypical papular and follicular contact derma-
titis  provoked  by  vitamin  E  linoleate  used  as  an  additive  to 
cosmetics. They concluded that oxidized vitamin E derivatives 
can operate synergistically in vivo as haptens or as irritants and 
were  responsible  for  the  allergic  reaction,  not  the  vitamin  E 
ester.3,46  Reports  of  allergic  contact  dermatitis  or  irritation  in 
response to topical vitamin E are rare overall, though, and it is 
considered safe for use in topical skin care products.

Bendich  and  Machlin  conducted  a  comprehensive  literature 
review in 1988, finding extended use of oral vitamin E up to 3,000 
mg/d to be safe.47 Kappus and Diplock later established as abso-
lutely safe vitamin E doses up to 400 mg/d, with doses between 
400 mg and 2,000 mg deemed as unlikely to cause adverse reac-
tions, and doses greater than 3,000 mg/d over a prolonged period 
as a potential source of side effects.48 Patients on anticoagulant 
therapy  are  advised  to  avoid  high  doses  of  vitamin  E 
(>4,000  IU)  because  the  nutrient  can  contribute  to  blood  thin-
ning.49  In  addition,  patients  are  often  counseled  to  suspend 
vitamin  E  supplementation,  although  a  clinically  significant 
reduction in platelet aggregation in those with normal platelets is 
unlikely. Such a suspension is necessary for patients who have 
abnormal  platelets  or  vitamin  K  deficiency,  or  who  are  taking 
antiplatelet agents.50

Tocopherol is used in concentrations up to 5 percent in cosmetic 
formulations,  with  tocopheryl  acetate  and  tocopheryl  linoleate 
used in concentrations up to 36 and 2 percent, respectively.51 The 
Cosmetic  Ingredient  Review  (CIR)  Expert  Panel  has  found  that 
tocopherol and its ester and ether derivatives, tocopheryl acetate, 
tocopheryl linoleate, tocopheryl linoleate/oleate, tocopheryl nico-
tinate,  tocopheryl  succinate,  dioleyl  tocopheryl  methylsilanol, 
potassium ascorbyl tocopheryl phosphate, and tocophersolan are 
safe as used in skin care formulations.51

 ENVIRONMENTAL IMPACT

Organic forms of vitamin E are widely available. It is unlikely 
that  the  synthesis  of  topical  products  featuring  tocopherols 
exacts  an  environmental  toll.  More  likely,  as  in  the  case  of 
vitamin  C,  is  the  potential  of  ambient  toxins,  particularly 
pesticides,  affecting  plants  that  contain  forms  of  vitamin  E. 
However,  the  cultivation  and  extraction  of  the  oil  palm  fruit 
(Elaies guineensis) for palm oil (a semi-solid fat rich in palmitic 
and  oleic  acids)  should  not  be  ignored  insofar  as  vitamin  E 
(30 percent tocopherols, 70 percent tocotrienols) is a significant 
minor  component  in  palm  oil  and  the  oil  palm  is  the  highest 
yielding oil crop in the world.9,52,53 The desire to cultivate and 
capitalize  on  the  economic  potential  of  the  two  oils  derived 
from E. guineensis (native to West Africa but grown for commer-
cial purposes mainly in Southeast Asia, particularly Malaysia), 
palm oil (primarily used for edible qualities in food preparation 
and processing) and palm kernel oil (used for commercial food 
preparation as well as oil and chemistry industries), has contrib-
uted to widespread and continuing deforestation and threats to 
biodiversity in Southeast Asia.52,54–56

 SAFETY ISSUES

The incidence of contact dermatitis elicited by topical vitamin E 
application  may  be  relatively  high  for  certain  forms  of 
tocopherol,37,40  particularly  tocopherol  acetate,43  with  allergy 
to dl-α-tocopheryl nicotinate also reported.44 Contact urticaria, 
eczematous dermatitis, and erythema multiforme-like reactions 
have  also  been  reported  in  association  with  the  topical 

 FORMULATION CONSIDERATIONS

The  lipophilic  nature  of  vitamin  E  renders  it  conducive  to 
topical  application  and  percutaneous  absorption  through  the 
skin.57,58  The  form  of  vitamin  E  used  in  formulation  is  a  key 
factor  in  its  potential  efficacy  in  a  skin  care  product.  Because 
vitamin C can restore oxidized vitamin E, the combination of 

 
the  antioxidants  is  a  stabilizing  factor  in  topical  formulations 
[see Chapter 55, Ascorbic Acid (Vitamin C)].42,59 Further, ferulic 
acid has been shown to stabilize both vitamins, with the topical 
combination  exerting  photoprotective  effects  against  UVB 
exposure, including the significant reduction in thymine dimer 
formation  (see  Chapter  54,  Ferulic  Acid).42,58,60  Vitamin  E  is 
often incorporated in its esterified forms, typically as acetates 
and succinates, as these compounds are more stable.61

 USAGE CONSIDERATIONS

Oral  ingestion  of  tocotrienols  sufficient  to  achieve  biologic 
activity is exceedingly difficult. Dietary supplements are there-
fore  recommended.  The  highest  bioavailability  among  the 
natural vitamin E isomers is exhibited by α-tocopherol and is 
the standard by which other forms of vitamin E are compared.10
Tocopherol  displays  better  absorption,  while  tocopheryl 
exhibits slightly better shelf life. The most common oral sup-
plementation  forms  of  vitamin  E  are  d-α  tocopherol,  d-α-
tocopheryl  acetate,  and  α-tocopheryl  succinate.  In  cosmetic 
products, the most common vitamin E forms are α-tocopheryl 
acetate and α-tocopheryl linoleate, which are less likely to pro-
voke contact dermatitis than d-α-tocopheryl and more stable at 
room temperature. Notably, the tocopherol esters are less well 
absorbed by the skin than tocopherols,62 and may not render as 
much  photoprotection.  In  one  study,  α-tocopheryl  acetate  or 
α-tocopheryl  succinate  may  have  actually  enhanced 
photocarcinogenesis,  rather  than  protected  against  it.63  Such 
α-tocopherol  esters  are  included  in  many  skin  lotions, 
cosmetics,  and  sunscreens;  therefore,  more  research  is  neces-
sary  to  determine  if  esterified  vitamin  E  forms  indeed  foster 
photocarcinogenesis.

 SIGNIFICANT BACKGROUND

Dietary  deficiency  of  vitamin  E  has  been  correlated  with  an 
increase in oxidative stress and cell injury.2 In 1993, Tanaka et al. 
observed that reactive oxygen species induce alterations in the 
biosynthesis  of  collagen  and  glycosaminoglycans  (GAGs)  in 
cultured  human  dermal  fibroblasts.64  The  addition  of 
α-tocopherol  to  the  fibroblasts  prevented  such  changes. 
Vitamin  E  has  also  been  demonstrated  to  decrease 
prostaglandin  E2  production,65  and  increase  interleukin  (IL)-2 
production,  yielding  anti-inflammatory  and  immunostimula-
tory  activity.  This  stabilizing  effect  is  thought  to  potentially 
play a role in collagen biosynthesis.66 However, in vivo attempts 
to measure and correlate changes in collagen production with 
vitamin  E  concentration  changes  have  not  yet  yielded 
conclusive results.

Animal Studies
In  1992,  Trevithick  et  al.  noted  that  topical  d-α-tocopherol 
acetate diminished erythema due to sunburn, edema, and skin 
sensitivity in mice when application occurred following expo-
sure  to  UVB  radiation.67  In  a  study  in  which  tocopherol  
5 percent was applied to mice prior to UVB exposure, Bissett et 
al. observed a 75 percent decrease in skin wrinkling, a rise in 
tumor latency, and a reduction of cutaneous tumors; however, 
vitamin E failed to affect UVA-induced skin sagging.68 Indeed, 
the topical application of α-tocopherol to animal skin has been 
repeatedly shown to be effective in reducing sunburn cell pro-
duction,69,70 attenuating chronic UVB-induced damage,71,72 and 

C H A P T E R  56  ■   TO CO P H E R O L   ( V I TA M I N   E )  

185

inhibiting  photocarcinogenesis.73  Specifically,  oral  and  topical 
vitamin  E  supplementation  in  certain  animals  diminishes  the 
effects  of  photoaging,  inhibits  skin  cancer  formation,  and 
reverses  UV-induced  immunosuppression.74–76  In  mice,  the 
topical application of d-α-tocopherol has been demonstrated to 
be  much  more  effective  than  d-α-tocopheryl  succinate  in 
protecting against acute and chronic UV-induced damage.4

As mentioned in the previous chapter, Cho et al. found that 
female SKH-1 hairless mice orally administered an antioxidant 
formulation containing vitamins C and E, Pycnogenol, and even-
ing  primrose  oil  (see  Chapter  49,  Pycnogenol),  given  during  a 
10-week  period  that  included  three  weekly  doses  of  UVB, 
exhibited significantly reduced wrinkle formation and epidermal 
thickness compared to controls.77

Antioxidant Activity and Photoprotection
Depletion of cutaneous vitamin E is considered an early indication 
of extrinsically caused oxidative damage.20,37 Studies on elderly 
subjects that exhibit high plasma tocopherol levels reveal a lower 
incidence  of  infectious  disease  and  cancer  than  in  the  age-
matched  population.78–80  Therefore,  vitamin  E  is  thought  by 
many to be a potent and essential antioxidant. As an ingredient 
in skin care agents, significant evidence has been amassed to sug-
gest its effectiveness as a photoprotective agent. It also appears to 
deliver photoprotection when taken orally or applied topically.

In a study in which subjects facially applied tocopherol 5 to  
8 percent cream for four weeks, observations included diminished 
skin roughness, shorter length of facial lines, and reduced wrinkle 
depth as compared to placebo.81 In addition, in a study in which 
vitamin  E  (5  percent)  was  applied  to  human  skin  under  light-
tight  occlusion  24  hours  before  UV  treatment,  UV-induced 
expression of human macrophage metalloelastase, a member of 
the matrix metalloproteinase family involved in degradation of 
elastin, appeared to be inhibited.82

There are studies that cast doubt on the efficacy of vitamin E 
alone  in  imparting  photoprotective  effects,  however.  A  double-
blind, placebo-controlled six-month study of the protective effects 
of orally administered vitamin E (400 IU/day) against UV-induced 
epidermal damage in humans considered minimal erythema dose 
(MED)  and  histologic  response  at  baseline,  one  month,  and  
six  months.  There  was  no  significant  difference  between  the 
placebo group and those treated with vitamin E and the researchers 
concluded that daily ingestion of 400 IU of oral α-tocopherol daily 
yielded  no  meaningful  photoprotection.83  Other  authors  have 
suggested that if vitamin E provides any photoprotection at all, it 
may do so only in cooperation with other antioxidants, such as 
vitamin  C.59  In  fact,  Lin  et  al.,  in  a  study  with  Yorkshire  pigs, 
demonstrated  that  the  combined  application  of  1  percent 
α-tocopherol  with  15  percent  l-ascorbic  acid  rendered  superior 
protection  against  erythema  and  sunburn  cell  development 
compared to either 1 percent α-tocopherol or 15 percent l-ascorbic 
acid  alone.58  Of  note,  some  data  suggest  a  cumulative  benefit 
derived  from  using  oral  and  topical  antioxidant  products  in 
combination, including vitamins C and E in particular.84–86

Sorg et al., who noted that vitamins A and E absorb UV radia-
tion  in  the  solar  spectrum  range  most  responsible  for 
photodamage,  suggested  that  these  vitamins  perform  comple-
mentary functions in the skin, with topical vitamin E shown in 
mice to prevent UV-induced oxidative stress as well as cutaneous 
and  systemic  immunosuppression.  Topical  vitamin  A  has  been 
demonstrated  in  mice  to  prevent  epidermal  hypovitaminosis 
engendered by UV exposure. The authors contend that combining 
these topical agents can reinforce the activities of each.87

 
186 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Nevertheless,  a  2009  six-month  study  in  healthy  human 
volunteers  with  actinic  keratoses  revealed  that  while  topically 
applied dl-α-tocopherol, of which cutaneous levels were signifi-
cantly increased at the conclusion of the study, did not markedly 
change already present lesions, changes in polyamine metabolism 
indicated  that  squamous  cell  carcinogenesis  potential  was 
significantly reduced.88

Overall, several studies using topical E have yielded evidence 
of  photoprotective  activity  against  erythema,  edema,  sunburn 
cell  formation,  and  additional  indicators  of  acute  UV-induced 
damage as well as responses to chronic UVA and UVB exposure, 
including skin wrinkling and skin cancer.3,58,68,74,89–91

 CONCLUSION

Antioxidant activity emerges as the primary but not exclusive 
reason  for  research  into  the  dermatologic  use  of  vitamin  E. 
Combination with other antioxidants appears to enhance the 
potency of vitamin E and, likely, the other interacting antioxi-
dants.  The  potential  therapeutic  benefits  of  vitamin  E  in  the 
prevention and treatment of skin cancer and photoaging remain 
an  important  focus  of  research.  As  an  ingredient  in  topical 
antiaging skin care preparations, vitamin E exhibits emollient 
properties and is stable, easy to formulate, and relatively inex-
pensive, rendering it a popular additive. Much more research, 
in  the  form  of  randomized  controlled  trials,  is  necessary, 
though,  to  establish  the  role  of  vitamin  E  in  treating  various 
dermatoses.  Tocotrienols  have  gained  increasing  attention  in 
the last two decades and warrant much more investigation to 
elucidate a fuller role of the vitamin E family in dermatology.

REFERENCES

1.  Jiang Q, Christen S, Shigenaga MK, et al. Gamma-tocopherol, the 
major form of vitamin E in the US diet, deserves more attention. 
Am J Clin Nutr. 2001;74:714.

2.  Nachbar F, Korting HC. The role of vitamin E in normal and dam-

aged skin. J Mol Med (Berl). 1995;73:7.

3.  Thiele  JJ,  Hsieh  SN,  Ekanayake-Mudiyanselage  S.  Vitamin  E: 
Critical review of its current use in cosmetic and clinical derma-
tology. Dermatol Surg. 2005;31:805.

4.  Burke KE. Photodamage of the skin: Protection and reversal with 

topical antioxidants. J Cosmet Dermatol. 2004;3:149.

5.  Thiele JJ. Oxidative targets in the stratum corneum. A new basis 
for  antioxidative  strategies.  Skin  Pharmacol  Appl  Skin  Physiol. 
2001;14(Suppl 1):87.

6.  Halliwell B. The antioxidant paradox. Lancet. 2000;355:1179.
7.  Pfluger P, Kluth D, Landes N, et al. Vitamin E: Underestimated as 

an antioxidant. Redox Rep. 2004;9:249.

8.  Ekanayake-Mudiyanselage  S,  Tavakkol  A,  Polefka  TG,  et  al. 
Vitamin  E  delivery  to  human  skin  by  a  rinse-off  product: 
Penetration  of  alpha-tocopherol  versus  wash-out  effects  of  skin 
surface lipids. Skin Pharmacol Physiol. 2005;18:20.

9.  Wong  RS,  Radhakrishnan  AK.  Tocotrienol  research:  Past  into 

present. Nutr Rev. 2012;70:483.

10.  Sen CK, Khanna S, Roy S. Tocotrienols in health and disease: The 
other  half  of  the  natural  vitamin  E  family.  Mol  Aspects  Med. 
2007;28:692.

11.  Theriault A, Chao JT, Wang Q, et al. Tocotrienol: A review of its 

therapeutic potential. Clin Biochem. 1999;32:309.

12.  Evans  HM,  Bishop  KS.  On  the  existence  of  a  hitherto  unrecog-
nized  dietary  factor  essential  for  reproduction.  Science. 
1922;56:650.

13.  Bell EF. History of vitamin E in infant nutrition. Am J Clin Nutr. 

1987;46:183.

14.  Niki  E,  Traber  MG.  A  history  of  vitamin  E.  Ann  Nutr  Metabl. 

2012;61:207.

15.  Packer L, Weber SU, Rimbach G. Molecular aspects of alpha-tocotrie-
nol  antioxidant  action  and  cell  signaling.  J  Nutr.  2001; 
131:369S.

16.  Serbinova EA, Packer L. Antioxidant properties of alpha-tocopherol 

and alpha-tocotrienol. Methods Enzymol. 1994;234:354.

17.  Serbinova  E,  Kagan  V,  Han  D,  et  al.  Free  radical  recycling  and 
intramembrane  mobility  in  the  antioxidant  properties  of  alpha-
tocopherol and alpha-tocotrienol. Free Radic Biol Med. 1991;10:263.
18.  Rona C, Vailati F, Berardesca E. The cosmetic treatment of wrin-

kles. J Cosmet Dermatol. 2004;3:26.

19.  Horvath G, Wessjohann L, Bigirimana J, et al. Differential distri-
bution  of  tocopherols  and  tocotrienols  in  photosynthetic  and 
non-photosynthetic tissues. Phytochemistry. 2006;67:1185.

20.  Thiele JJ, Schroeter C, Hsieh SN, et al. The antioxidant network 

of the stratum corneum. Curr Probl Dermatol. 2001;29:26.

21.  Wright  ME,  Weinstein  SJ,  Lawson  KA,  et  al.  Supplemental  and 
dietary  vitamin  E  intakes  and  risk  of  prostate  cancer  in  a  large 
prospective study. Cancer Epidemiol Biomarkers Prev. 2007;16:1128.
22.  Christen S, Woodall AA, Shigenaga MK, et al. Gamma-tocopherol 
traps  mutagenic  electrophiles  such  as  NO(X)  and  complements 
alpha-tocopherol:  Physiological  implications.  Proc  Natl  Acad  Sci  
U S A. 1997;94:3217.

23.  Cooney  RV,  Franke  AA,  Harwood  PJ,  et  al.  Gamma-tocopherol 
detoxification of nitrogen dioxide: Superiority to alpha-tocopherol. 
Proc Natl Acad Sci U S A. 1993;90:1771.

24.  Manela-Azulay  M,  Bagatin  E.  Cosmeceuticals  vitamins.  Clin 

Dermatol. 2009;27:469.

25.  Keller KL, Fenske NA. Uses of vitamins A, C, and E and related 
compounds  in  dermatology:  A  review.  J  Am  Acad  Dermatol. 
1998;39:611.

26.  Pehr K, Forsey RR. Why don’t we use vitamin E in dermatology? 

CMAJ. 1993;149:1247.

27.  Tsoureli-Nikita E, Hercogova J, Lotti T, et al. Evaluation of dietary 
intake of vitamin E in the treatment of atopic dermatitis: A study 
of  the  clinical  course  and  evaluation  of  the  immunoglobulin  E 
serum levels. Int J Dermatol. 2002;41:146.

28.  Dimery IW, Hong WK, Lee JJ, et al. Phase I trial of alpha-tocopherol 
effects on 13-cis-retinoic acid toxicity. Ann Oncol. 1997;8:85.
29.  Strauss JS, Gottlieb AB, Jones T, et al. Concomitant administra-
tion of vitamin E does not change the side effects of isotretinoin 
as used in acne vulgaris: A randomized trial. J Am Acad Dermatol. 
2000;43:777.

30.  Thiele JJ, Ekanayake-Mudiyanselage S. Vitamin E in human skin: 
Organ-specific  physiology  and  considerations  for  its  use  in  der-
matology. Mol Aspects Med. 2007;28:646.

31.  Khanna S, Roy S, Slivka A, et al. Neuroprotective properties of the 

natural vitamin E alpha-tocotrienol. Stroke. 2005;36:2258.

32.  Khanna  S,  Roy  S,  Parinandi  NL,  et  al.  Characterization  of  the 
potent neuroprotective properties of the natural vitamin E alpha-
tocotrienol. J Neurochem. 2006;98:1474.

33.  Rodriguez  C,  Jacobs  EJ,  Mondul  AM,  et  al.  Vitamin  E  supple-
ments and risk of prostate cancer in U.S. men. Cancer Epidemiol 
Biomarkers Prev. 2004;13:378.

34.  Chan JM, Stampfer MJ, Ma J, et al. Supplemental vitamin E intake 
and prostate cancer risk in a large cohort of men in the United States. 
Cancer Epidemiol Biomarkers Prev. 1999;8:893.

35.  El  Monfalouti  H,  Charrouf  Z,  El  Hamdouchi  A,  et  al.  Argan  oil 
and postmenopausal Moroccan women: Impact on the vitamin E 
profile. Nat Prod Commun. 2013;8:55.

36.  Murray  JC,  Burch  JA,  Streilein  RD,  et  al.  A  topical  antioxidant 
solution  containing  vitamins  C  and  E  stabilized  by  ferulic  acid 
provides  protection  for  human  skin  against  damage  caused  by 
ultraviolet irradiation. J Am Acad Dermatol. 2008;59:418.

37.  Baumann LS, Spencer J. The effects of topical vitamin E on the 

cosmetic appearance of scars. Dermatol Surg. 1999;25:311.

38.  Martin  A.  The  use  of  antioxidants  in  healing.  Dermatol  Surg. 

1996;22:156.

39.  Kamimura M, Matsuzawa T. Percutaneous absorption of alpha-

tocopheryl acetate. J Vitaminol (Kyoto). 1968;14:150.

40.  Jenkins M, Alexander JW, MacMillan BG, et al. Failure of topical 
steroids  and  vitamin  E  to  reduce  postoperative  scar  formation 
following reconstructive surgery. J Burn Care Rehabil. 1986;7:309.
41.  Funasaka Y, Chakraborty AK, Komoto M, et al. The depigment-
ing effect of alpha-tocopheryl ferulate on human melanoma cells. 
Br J Dermatol. 1999;141:20.

42.  Burns EM, Tober KL, Riggenbach JA, et al. Differential effects of 
topical vitamin E and C E Ferulic® treatments on ultraviolet light 
B-induced  cutaneous  tumor  development  in  Skh-1  mice.  PLoS 
One. 2013;8:e63809.

43.  Matsumura T, Nakada T, Iijima M. Widespread contact dermati-
tis from tocopherol acetate. Contact Dermatitis. 2004;51:211.

 
44.  Oshima H, Tsuji K, Oh-I T, et al. Allergic contact dermatitis due 
to DL-alpha-tocopheryl nicotinate. Contact Dermatitis. 2003;48:167.
45.  Hunter D, Frumkin A. Adverse reactions to vitamin E and aloe vera 
preparations after dermabrasion and chemical peel. Cutis. 1991;47:193.
46.  Perrenoud  D,  Homberger  HP,  Auderset  PC,  et  al.  An  epidemic 
outbreak  of  papular  and  follicular  contact  dermatitis  to  tocoph-
eryl  linoleate  in  cosmetics.  Swiss  Contact  Dermatitis  Research 
Group. Dermatology. 1994;189:225.

47.  Bendich A, Machlin LJ. Safety of oral intake of vitamin E. Am J 

Clin Nutr. 1988;48:612.

48.  Kappus H, Diplock AT. Tolerance and safety of vitamin E: A toxi-

cological position report. Free Radic Biol Med. 1992;13:55.

49.  Bendich  A.  Safety  issues  regarding  the  use  of  vitamin  supple-

ments. Ann N Y Acad Sci. 1992;669:300.

50.  Petry  JJ.  Surgically  significant  nutritional  supplements.  Plast 

Reconstr Surg. 1996;97:233.

51.  Zondlo  Fiume  M.  Final  report  on  the  safety  assessment  of 
Tocopherol,  Tocopheryl  Acetate,  Tocopheryl  Linoleate, 
Tocopheryl Linoleate/Oleate, Tocopheryl Nicotinate, Tocopheryl 
Succinate, Dioleyl Tocopheryl Methylsilanol, Potassium Ascorbyl 
Tocopheryl  Phosphate,  and  Tocophersolan.  Int  J  Toxicol. 
2002;21(Suppl 3):51.

52.  Sundram  K,  Sambanthamurthi  R,  Tan  YA.  Palm  fruit  chemistry 

and nutrition. Asia Pac J Clin Nutr. 2003;12:355.

53.  Persson  UM,  Azar  C.  Preserving  the  world’s  topical  forest—a 
price on carbon may not do. Environ Sci Technol. 2010;44:210.
54.  Wilcove DS, Koh LP. Addressing the threats to biodiversity from 

oil-palm agriculture. Biodivers Conserv. 2010;19:999.

55.  Koh LP, Wilcove DS. Is oil palm agriculture really destroying trop-

ical biodiversity? Conserv Lett. 2008;1:60.

56.  Rudel TK, Defries R, Asner GP, et al. Changing drivers of defor-
estation  and  new  opportunities  for  conservation.  Conserv  Biol. 
2009;23:1396.

57.  Krol  ES,  Kramer-Strickland  KA,  Liebler  DC.  Photoprotective 
actions of topically applied vitamin E. Drug Metab Rev. 2000;32:413.
58.  Lin JY, Selim MA, Shea CR, et al. UV photoprotection by combi-
nation topical antioxidants vitamin C and vitamin E. J Am Acad 
Dermatol. 2003;48:866.

59.  Chan  AC.  Partners  in  defense,  vitamin  E  and  vitamin  C.  Can  J 

Physiol Pharmacol. 1993;71:725.

60.  Lin FH, Lin JY, Gupta RD, et al. Ferulic acid stabilizes a solution of 
vitamins C and E and doubles its photoprotection of skin. J Invest 
Dermatol. 2005;125:826.

61.  Burke KE. Interaction of vitamins C and E as better cosmeceuti-

cals. Dermatol Ther. 2007;20:314.

62.  Alberts DS, Goldman R, Xu MJ, et al. Disposition and metabolism 
of  topically  administered  alpha-tocopherol  acetate:  A  common 
ingredient  of  commercially  available  sunscreens  and  cosmetics. 
Nutr Cancer. 1996;26:193.

63.  Gensler HL, Aickin M, Peng YM, et al. Importance of the form of 
topical  vitamin  E  for  prevention  of  photocarcinogenesis.  Nutr 
Cancer. 1996;26:183.

64.  Tanaka H, Okada T, Konishi H, et al. The effect of reactive oxygen 
species on the biosynthesis of collagen and glycosaminoglycans in 
cultured human dermal fibroblasts. Arch Dermatol Res. 1993;285:352.
65.  Diplock  AT,  Xu  G,  Yeow  C,  et  al.  Relationship  of  tocopherol 
structure  to  biological  activity,  tissue  uptake,  and  prostaglandin 
synthesis. In: Diplock AT, Machlin LJ, Packer L, et al. eds. Vitamin 
E:  Biochemistry  and  Health  Implications.  New  York:  New  York 
Academy of Sciences; 1989:72-84.

66.  Palmieri  B,  Gozzi  G,  Palmieri  G.  Vitamin  E  added  silicone  gel 
sheets  for  treatment  of  hypertrophic  scars  and  keloids.  Int  J 
Dermatol. 1995;34:506.

67.  Trevithick  JR,  Xiong  H,  Lee  S,  et  al.  Topical  tocopherol  acetate 
reduces post-UVB, sunburn-associated erythema, edema, and skin 
sensitivity in hairless mice. Arch Biochem Biophys. 1992;296:575.
68.  Bissett  DL,  Chatterjee  R,  Hannon  DP.  Photoprotective  effect  of 
superoxide-scavenging antioxidants against ultraviolet radiation-
induced chronic skin damage in the hairless mouse. Photodermatol 
Photoimmunol Photomed. 1990;7:56.

C H A P T E R  56  ■   TO CO P H E R O L   ( V I TA M I N   E )  

187

69.  Darr  D,  Combs  S,  Dunston  S,  et  al.  Topical  vitamin  C  protects 
porcine  skin  from  ultraviolet  radiation-induced  damage.  Br  J 
Dermatol. 1992;127:247.

70.  Pathak MA, Carbonare MD. Photoaging and the role of mamma-
lian  skin  superoxide  dismutase  and  antioxidants.  Photochem 
Photobiol. 1988;47:7S.

71.  Pinnell  SR,  Murad  S.  Vitamin  C  and  collagen  metabolism.  In: 
Kligman AM, Takase Y, eds. Cutaneous Aging. Tokyo: University 
of Tokyo Press; 1988:275-292.

72.  Bissett  DL,  Majeti  S,  Fu  JJ,  et  al.  Protective  effect  of  topically 
applied  conjugated  hexadienes  against  ultraviolet  radiation-
induced chronic skin damage in the hairless mouse. Photodermatol 
Photoimmunol Photomed. 1990;7:63.

73.  Gensler HL, Magdaleno M. Topical vitamin E inhibition of immu-
nosuppression and tumorigenesis induced by ultraviolet irradia-
tion. Nutr Cancer. 1991;15:97.

74.  Jurkiewicz BA, Bissett DL, Buettner GR. Effect of topically applied 
tocopherol on ultraviolet radiation-mediated free radical damage 
in skin. J Invest Dermatol. 1995;104:484.

75.  Slaga TJ, Bracken WM. The effects of antioxidants on skin tumor 
initiation  and  aryl  hydrocarbon  hydroxylase.  Cancer  Res. 
1977;37:1631.

76.  Meydani SN, Barklund MP, Liu S, et al. Vitamin E supplementa-
tion enhances cell-mediated immunity in healthy elderly subjects. 
Am J Clin Nutr. 1990;52:557.

77.  Cho HS, Lee MH, Lee JW, et al. Anti-wrinkling effects of the mix-
ture of vitamin C, vitamin E, pycnogenol and evening primrose 
oil, and molecular mechanisms on hairless mouse skin caused by 
chronic  ultraviolet  B  irradiation.  Photodermatol  Photoimmunol 
Photomed. 2007;23:155.

78.  Knekt P, Aromaa A, Maatela J, et al. Vitamin E and cancer preven-

tion. Am J Clin Nutr. 1991;53:283S.

79.  Menkes  MS,  Comstock  GW,  Vuilleumier  JP,  et  al.  Serum  beta-
carotene, vitamins A and E, selenium, and the risk of lung cancer. 
N Engl J Med. 1986;315:1250.

80.  Chevance M, Brubacher G, Herbeth B, et al. Immunological and 
nutritional  status  among  the  elderly.  In:  Chandra  RK,  eds. 
Nutrition, Immunity, and Illness in the Elderly. New York: Pergamon 
Press; 1985:137-142.

81.  Mayer  P.  The  effects  of  vitamin  E  on  the  skin.  Cosmet  Toiletries. 

1993;108:99.

82.  Chung JH, Seo JY, Lee MK, et al. Ultraviolet modulation of human 
macrophage  metalloelastase  in  human  skin  in  vivo.  J  Invest 
Dermatol. 2002;119:507.

83.  Werninghaus K, Meydani M, Bhawan J, et al. Evaluation of the 
photoprotective  effect  of  oral  vitamin  E  supplementation.  Arch 
Dermatol. 1994;130:1257.

84.  Greul  AK,  Grundmann  JU,  Heinrich  F,  et  al.  Photoprotection  of 
UV-irradiated human skin: An antioxidative combination of vita-
mins E and C, carotenoids, selenium and proanthocyanidins. Skin 
Pharmacol Appl Skin Physiol. 2002;15:307.

85.  Passi S, De Pita O, Grandinetti M, et al. The combined use of oral 
and  topical  lipophilic  antioxidants  increases  their  levels  both  in 
sebum and stratum corneum. Biofactors. 2003;18:289.
86.  Burgess C. Topical vitamins. J Drugs Dermatol. 2008;7:s2.
87.  Sorg  O,  Tran  C,  Saurat  JH.  Cutaneous  vitamins  A  and  E  in  the 
context  of  ultraviolet-  or  chemically-induced  oxidative  stress. 
Skin Pharmacol Appl Skin Physiol. 2001;14:363.

88.  Foote JA, Ranger-Moore JR, Einspahr JG, et al. Chemoprevention 
of  human  actinic  keratoses  by  topical  DL-alpha-tocopherol. 
Cancer Prev Res (Phila). 2009;2:394.

89.  Ritter EF, Axelrod M, Minn KW, et al. Modulation of ultraviolet 
light-induced epidermal damage: Beneficial effects of tocopherol. 
Plast Reconstr Surg. 1997;100:973.

90.  Darr D, Dunston S, Faust H, et al. Effectiveness of antioxidants 
(vitamin C and E) with and without sunscreens as topical photo-
protectants. Acta Derm Venereol. 1996;76:264.

91.  Bissett DL, Hillebrand GG, Hannon DP. The hairless mouse as a 
model  of  skin  photoaging:  Its  use  to  evaluate  photoprotective 
materials. Photodermatol. 1989;6:228.

 
188 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Other Ingredients

SECTION

G

C H A P T E R   5 7

Coenzyme Q10

Activities:

Antioxidant,  anti-inflammatory,  antiaging,  ATP  energy 
producing

Important Chemical Components:

Also known as ubiquinone or 2,3-dimethoxy-5-methyl-
6-decaprenyl-1,4-benzoquinone.  Its  molecular  formula 
is C59H90O4.

Origin Classification:

This nutrient or vitamin-like compound is found in most 
eukaryotic  cells  in  the  human  body.1  It  is  also  synthe-
sized for oral supplementation and topical application.

Personal Care Category:

Antiaging, moisturizing

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW, DRPW, DSNW, DSPW, ORNW, ORPW, OSNW, 
and OSPW

 SOURCE

Coenzyme Q10 (CoQ10) is a fat-soluble compound found in all 
cells  in  the  lipophilic  portion  of  the  cell  membrane.  It  is  the 
only lipid-soluble antioxidant synthesized endogenously and, 
as such, is not a vitamin.2 CoQ10 acts as a cofactor in numerous 
biological  processes  and  contributes  to  the  electron  transfer 
chain responsible for energy production, playing an essential 
role  for  electron  transport  in  the  mitochondrial  respiratory 
chain (Table 57-1).3 CoQ10 is thought to contribute 95 percent 
of the body’s adenosine triphosphate (ATP) or energy needs.4 
It also plays a critical role in endogenous free radical scaveng-
ing.1 In addition to its natural presence in human cells, CoQ10 
can  be  obtained  through  the  diet,  with  fish  and  shellfish 
known to be good sources. As a supplement, the recommended 
oral dose is 90 to 150 mg daily, though some doctors recom-
mend 200 to 400 mg daily. CoQ10 has a caffeine-like effect and 
therefore  supplements  should  be  taken  in  the  morning  
to prevent insomnia.

TABLE 57-1
Pros and Cons of Coenzyme Q10

Pros
Plays integral role in electron transport in 
the mitochondrial respiratory chain

Potent antioxidant
Acts as a network antioxidant, as it recy-

cles vitamins C and E12

Does not negatively affect other ingredients
Well tolerated with a low risk of sensitivity

Cons
More clinical studies are needed to substantiate 
reported capacity to prevent DNA damage

Formulation is often yellow
Expensive

 HISTORY

CoQ10 and related compounds have, as Hoppe et al. suggested, 
developed with biological evolution through millions of years.5 
It is now known to be widely distributed among humans and 
animals.6  But  CoQ10  was  first  discovered  by  Crane  et  al.  in 
1957,  when  they  identified  and  isolated  the  compound  from 
beef  heart  mitochondria.7  The  chemical  structure  was  subse-
quently  determined  and  Peter  Mitchell  elucidated  the  role  of 
CoQ10 in oxidative phosphorylation and the electron transport 
chain in 1961, work for which he was awarded the Nobel Prize 
in Chemistry in 1978.8 A great deal of the literature since that 
period,  and  stemming  from  seminal  work  by  Folkers  and 
Littarru in 1972 on the role of CoQ10 deficiency in human heart 
disease, has focused on its oral administration for atherosclero-
sis,  muscle  contractility,  congestive  heart  failure,  and  other 
cardiovascular issues.2,9,10 A year earlier, Littarru, Folkers, and 
colleagues reported on CoQ10 deficiency in the gingival tissue 
of adults with periodontal disease.11 In recent years, the poten-
tial  application  of  CoQ10  in  the  treatment  of  various  health 
conditions,  including  neurodegenerative  disorders  such  as 
Parkinson’s  disease  and  Huntington’s  disease,  migraine 
headaches,  memory  loss,  inflammation,  and  skin  aging  has 
garnered considerable research attention.9,12

 CHEMISTRY

CoQ10  is  a  1,4-benzoquinone  compound.  It  is  also  known  as 
ubidecarenone as well as ubiquinone, because it is known to be 
ubiquitous  in  all  biological  systems.12,13  The  “Q”  in  CoQ10 
refers to its inclusion in the quinone family; the “10” identifies 
the number of isoprenoid units on its side chain, a number that 

 
renders  the  compound  highly  lipophilic.14  Its  chemical  struc-
ture consists of a p-benzoquinone ring with a polyisoprenoid 
side  chain.14  The  biosynthesis  of  CoQ10,  which  primarily 
involves  4-hydroxybenzoate  and  the  polyprenyl  chain,6  is  a 
complex  process  that  depends  on  an  abundance  of  essential 
amino  acids,  such  as  tyrosine,  and  numerous  vitamins  and 
trace elements. Several studies on the use of CoQ10 in cardiol-
ogy appear in the literature,15 and CoQ10 has also been found to 
exhibit antioxidant properties, with the reduced form of CoQ10 
(ubiquinol,  Q10H2)  known  to  be  particularly  effective  as  an 
antioxidant in biological membranes.3 In its oxidized state, as 
ubiquinone, CoQ10 can accept electrons from free radicals but 
not donate them.9 Multiple in vitro and in vivo studies suggest 
that  CoQ10  imparts  protective  effects  on  various  markers  of 
oxidative DNA damage and genomic stability.3 CoQ10 has also 
exhibited a direct antiatherogenic effect in a mouse model.2

In  addition,  CoQ10  has  been  demonstrated  to  influence  the 
production  of  some  key  cutaneous  proteins  and  to  reduce  the 
expression of some matrix metalloproteinases (MMPs) such as 
collagenase.8 Further, it has been shown  to  regenerate  another 
potent lipophilic antioxidant, α-tocopherol.6 The ability to syn-
thesize CoQ10 endogenously declines after the age of 35 to 40, as 
does the quantity of CoQ10 in human sebum, deficiencies which 
can be exacerbated by poor eating habits, stress, and infection; 
therefore,  supplementation  is  thought  to  contribute  to  various 
health metrics to compensate for the reduced CoQ10 levels that 
emerge with age.1,16

 ORAL USES

Commercial CoQ10 has the reputation of poor intestinal absorp-
tion.17 Bhagavan and Chopra showed that total plasma CoQ10 
and net increase over baseline CoQ10 concentrations gradually 
rise  with  increasing  doses  of  orally  ingested  CoQ10,  with  the 
absorption efficiency declining with increasing dose.12 Extended 
supplementation  of  CoQ10  in  humans  has  been  shown  by 
Ashida  et  al.  to  diminish  periocular  wrinkle  formation.  Daily 
oral supplementation with CoQ10 (0, 1, 100 mg/kg p.o.) for two 
weeks in adult hairless mice has also been associated with sig-
nificantly higher levels of CoQ10 in the epidermis, but not in the 
dermis. The researchers speculated that this might be a precon-
dition  for  wrinkle  reduction  and  other  benefits  related  to  the 
potent  antioxidant  and  energizing  effects  of  CoQ10  in  skin.18 
Notably, CoQ10 is known to be present in humans at 10-fold 
higher levels in the epidermis than the dermis.19

In  2010,  López  et  al.  studied  the  in  vitro  effects  of  CoQ10, 
CoQ2, the synthetic CoQ10 analog idebenone (see Chapter 61, 
Idebenone), and vitamin C, finding that primary CoQ10 deficien-
cies can be treated sufficiently with CoQ10 supplementation but 
not  with  short-tail  analogs  (e.g.,  idebenone  and  CoQ2).20  Oral 
supplementation with CoQ10 has gained in popularity in recent 
years and such dietary supplements are readily available.12

 TOPICAL USES

In an early study of the topical application of CoQ10, Giovannini 
et al. suspended CoQ10 in olive oil and administered it to rats at 
two  different  concentrations.  Subsequent  CoQ10  levels  were 
directly proportional to the concentrations and contact times. 
They concluded that the topical use of CoQ10 might warrant 
consideration for use in the dermatologic realm.21

In 1999, Hoppe et al. showed that CoQ10 penetrated into the 
viable  layers  of  the  epidermis,  and  lowered  oxidation  levels  as 

C H A P T E R  57  ■   CO E N Z Y M E   Q 10 

189

measured  by  weak  photon  emission.  They  also  measured 
decreases in wrinkle depth after CoQ10 application. Further, the 
researchers observed that the antioxidant inhibited the expression 
of collagenase in human dermal fibroblasts after ultraviolet (UV)  
A  exposure  and  prevented  oxidative  DNA  damage  as  well  as 
UVA-mediated oxidative stress in keratinocytes. The investigators 
considered their findings good evidence that CoQ10 displays the 
capacity to prevent several sequelae of photoaging.5

In 2003, Passi et al. set out to ascertain the combined effect 
of  topical  and  oral  lipophilic  antioxidants  on  the  antioxidant 
content  of  sebum  and  the  stratum  corneum  (SC).  For  two 
months,  50  female  volunteers,  aged  21  to  40,  were  treated 
daily on the face and back with a base cream containing CoQ10, 
vitamin  E,  and  squalene.  To  half  of  the  volunteers,  an  oral 
preparation including the same ingredients was administered. 
While  the  daily  topical  application  resulted  in  a  significant 
boost in the levels of the lipophilic antioxidants and squalene 
in the sebum without affecting SC or plasma concentrations, 
the  concomitant  oral  administration  in  the  one  group  led  to 
significantly higher lipophilic antioxidant measurements in the 
SC and plasma but no such increase in sebum levels. The inves-
tigators  concluded  that  topically  applying  the  antioxidants 
raised their levels in sebum and concomitant oral administra-
tion increased CoQ10 and vitamin E levels in the SC as well.16,22
In  2010,  Liu  and  Artmann  conducted  a  double-blind,  parallel-
design,  controlled,  single-dose  (120  mg)  bioavailability  study  in  
20 healthy male and female volunteers to compare a novel colloidal-
Q10 delivery system based on new and patented technology with 
three  commercially  available  CoQ10  products.  The  colloidal-Q10 
formulation was associated with the highest plasma concentrations 
throughout  the  24-hour  period  along  with  the  greatest  relative 
bioavailability,  with  statistically  significant  differences  seen  in  
both  metrics.  The  researchers  concluded  that  their  novel  CoQ10 
delivery system enhanced enteral absorption and bioavailability.17

Also  that  year,  Lee  and  Tsai  demonstrated  the  efficacy  of  a 
liposomal  formulation  of  soybean  phosphatidylcholine  and 
α-tocopherol to encapsulate CoQ10 for topical delivery. They found 
that it augmented CoQ10 accumulation in rat skin over twofold in 
comparison  with  an  unencapsulated  suspension.  In  addition, 
lengthening the treatment time and elevating CoQ10 content in the 
formulation  increased  CoQ10  levels  in  rat  skin,  with  inadequate 
treatment time limiting accumulation. The investigators concluded 
that their liposomal CoQ10 formulation shows promise as a topical 
delivery agent for CoQ10 given sufficient treatment duration.14 It is 
important  to  note  that  topical  products  containing  CoQ10  as  the 
main ingredient should appear to have a yellow tint.

In 2010, Yue et al. developed a novel CoQ10 topical delivery 
system using a nano-structured lipid carrier to enhance photopro-
tection. The in vitro protection of fibroblasts against UVA radia-
tion  afforded  by  a  CoQ10-loaded  nano-structured  lipid  carrier 
(CoQ10-NLC) was greater than that provided by a CoQ10 emul-
sion. In cells treated with CoQ10-NLC, malondialdehyde concen-
tration was reduced by 61.5 percent as compared to the CoQ10 
emulsion cells. The presence of CoQ10-NLC also yielded signifi-
cant increases in the antioxidant enzymes superoxide dismutase 
and  glutathione  peroxidase.  CoQ10-NLC  also  exhibited  better 
penetration  into  the  SC  and  dermis  after  topical  application  in 
Sprague-Dawley rats as compared to the CoQ10 emulsion.23

In  2012,  Gokce  et  al.  investigated  CoQ10-loaded  liposomes 
and  solid  lipid  nanoparticles  as  delivery  systems  of  the  com-
pound  for  antioxidant  purposes  into  the  skin,  finding  that  the 
liposome  system  exhibited  the  capacity  to  promote  cell 
proliferation  and  the  solid  lipid  nanoparticle  system  failed  to 
protect against the accumulation of reactive oxygen species.24

 
190 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Felippi et al. conducted a pilot study in 2012 on the safety 
and efficacy of a nanoparticle formulation encapsulating vari-
ous  active  ingredients,  including  CoQ10,  retinyl  palmitate, 
tocopheryl  acetate,  grape  seed  oil,  and  linseed  oil.  The 
nanoparticles  demonstrated  no  irritating,  sensitizing,  or 
comedogenic  properties  and  phototoxicity  was  not  evident 
after  exposure  to  UVA  light.  In  the  efficacy  assessment  with 
volunteers, significant decreases in wrinkles were observed as 
compared to controls after 21 days of treatment. The investiga-
tors  concluded  that  the  antioxidant-loaded  nanoparticle 
formulation  is  safe  for  topical  administration  and,  having 
displayed in vivo antiaging activity, warrants consideration as a 
cosmetic agent for such purposes.25

In 2013, Chen et al. formulated a CoQ10-NLC  using  high-
pressure  microfluidics  and  assessed  it  in  vitro  for  epidermal 
targeting  effects.  The  CoQ10-NLC  displayed  fast  release 
through the first three hours and extended release subsequently. 
The accumulation of CoQ10 in rat epidermis was over 10-fold 
higher with the CoQ10-NLC as compared to a CoQ10 emulsion 
in an in vitro skin permeation study. Further, the CoQ10 level in 
CoQ10-NLC  fell  5.59  percent  as  compared  to  reductions  of 
24.61  percent  in  the  CoQ10  emulsion  and  49.74  percent  in  a 
CoQ10  ethanol  solution  after  24  hours  of  UV  exposure.  The 
investigators  concluded  that  their  CoQ10-NLC  formulation 
demonstrated  a  significant  epidermal  targeting  effect, 
establishing  itself  as  a  potential  carrier  for  the  topical 
application of CoQ10.26

Recent  in  vivo  studies  have  shown  reductions  in  the 
symptoms  of  photoaging  through  the  use  of  topically 
applied  CoQ10,  though  bioavailability  of  CoQ10  has 
remained poor.14 In 1999, Blatt et al. showed through in vivo 
studies  that  the  long-term  application  of  CoQ10  could 
reduce crow’s feet.27

CoQ10 in Combination Therapy
In  2009,  Kharaeva  et  al.  assessed  the  clinical  effects  of 
supplementation of a combination of CoQ10, vitamin E, and 
selenium  in  the  treatment  of  58  patients  with  severe 
erythrodermic  and  arthropathic  psoriasis.  Patients  were 
randomized into four groups with two groups receiving the 
antioxidant combination dissolved in soy lecithin for 30 to 
35  days.  The  placebo  groups  received  soy  lecithin.  The 
investigators  reported  that  supplementation  yielded 
significant improvements in clinical conditions, correlating 
with a quicker normalization of oxidative stress markers as 
compared  to  the  placebo  groups.  They  concluded  that  the 
use of these antioxidants merits consideration for managing 
severe psoriasis.28

Several of the same investigators conducted two controlled 
clinical  trials  in  2012  to  compare  a  nutraceutical  approach  to 
standard  therapy  for  two  mucocutaneous  chronic  DNA-virus 
infections.  The  nutraceutical,  containing  CoQ10,  vitamin  E, 
selenium, and methionine, or a placebo was administered for 
180 days to 68 patients with relapsing human papillomavirus 
skin  warts  treated  with  cryotherapy  in  the  first  trial.  In  the 
second trial, the combination of acyclovir followed by 90 days 
of  nutraceutical  administration  was  compared  to  acyclovir 
alone in 60 patients with recurrent herpes or 29 patients with 
herpes zoster. The nutraceutical was found to provoke signifi-
cantly more rapid healing with lower relapse incidence in com-
parison  to  control  groups.  In  addition,  plasma  antioxidant 
capacity was found to be higher in the nutraceutical group as 
compared to controls.29

 SAFETY ISSUES

Oral  CoQ10  supplementation  can  elicit  nervousness  or  a 
jittery feeling not unlike one of the side effects of caffeine. 
CoQ10 should be taken during the day to reduce the risk of 
causing  insomnia.  Other  reported  side  effects  include 
appetite loss, diarrhea, and mild nausea.30 Overall, the safety 
of  orally  administered  CoQ10,  even  at  high  doses  (up  to  
900 mg/day), has been established.17,31 No contact dermatitis 
or  any  other  side  effects  have  been  associated  with  the 
topical application of CoQ10, which is photostable and well 
tolerated.5 However, the synthetic analog of CoQ10, known 
as idebenone, has been reported to cause contact dermatitis 
(see Chapter 61, Idebenone).

 ENVIRONMENTAL IMPACT

There  is  no  environmental  impact  of  commercial CoQ10 pro-
duction known by the author.

 FORMULATION CONSIDERATIONS

Low aqueous solubility and the high molecular weight of this 
compound limit the topical delivery of CoQ10 to deeper skin 
layers.24,32 It is a lipophilic compound and to increase penetra-
tion must be formulated in liposomes and other formulations 
designed  to  increase  penetration.  Orally  ingested  solubilized 
formulations  of  CoQ10  (both  ubiquinone  and  ubiquinol,  the 
predominant form – 95 percent – of circulating CoQ10) exhibit 
superior bioavailability to nonsolubilized powder-based products 
as indicated by their enhanced plasma CoQ10 responses.12

 USAGE CONSIDERATIONS

CoQ10  is  stable  in  topical  formulations.  It  does  not,  to  the 
author’s  knowledge,  interact  with  other  ingredients  in  a  skin 
care  regimen.  Products  that  contain  a  significant  amount  of 
CoQ10 appear yellow.

 SIGNIFICANT BACKGROUND

Reduced levels of CoQ10 in humans have been associated with 
aging  as  well  as  with  various  pathologies  (e.g.,  cardiac  disor-
ders, neurodegenerative diseases, AIDS, and cancer).6,16

Network Antioxidants
Vitamin C and CoQ10 exhibit the ability to recycle vitamin E, 
donating electrons to return vitamin E to its antioxidant state. 
The  antioxidants  identified  as  acting  cooperatively  in  this 
fashion have been called network antioxidants.33 The five com-
pounds  designated  as  network  antioxidants  are  vitamins  C 
and  E,  glutathione,  lipoic  acid,  and  CoQ10.  Network  antioxi-
dants are a staple in cosmetic preparations, but it is likely that 
many  antioxidants  work  synergistically,  and  that  the  expres-
sion  “network  antioxidant”  is  actually  applicable  to  many 
more  antioxidants  than  the  five  identified  as  the  “network.” 
For example, in 2013, Wölfle et al. demonstrated that the addi-
tion of low concentrations of antioxidants such as CoQ10 and 
vitamin E synergistically amplified the potent antioxidant and 
photoprotective activity of the flavonoid luteolin in solar sim-
ulator-irradiated  human  skin  fibroblasts.34  One  of  the  same 

 
researchers  previously  demonstrated  that  a  topically  applied 
cream containing luteolin, CoQ10, and vitamin E, in the same 
ratio as in the in vitro study (4:4:1, luteolin, vitamin E, CoQ10, 
respectively), was effective in protecting the skin from chemi-
cal-induced irritation.35

Antiaging Activity
An age-related decline of CoQ10 levels has been reported in ani-
mals  and  humans.36  Consequently,  the  antioxidant  activities  of 
CoQ10  have  been  targeted  for  potential  applications  in  treating 
aged skin. Hoppe et al. showed that CoQ10 penetrated into the 
viable  layers  of  the  skin  and  significantly  inhibited  collagenase 
expression in human dermal fibroblasts following UVA exposure.5
In  2006,  Fuller  et  al.  found  that  CoQ10  has  the  capacity  to 
inhibit the inflammatory response in dermal fibroblasts induced 
by  UV  radiation  (UVR)  or  interleukin  (IL)-1.  In  addition,  they 
observed that CoQ10 suppressed UVR-induced MMP-1 synthesis. 
In  combination  with  the  colorless  carotenoids  phytoene  and 
phytofluene,  CoQ10  enhanced  inflammation  suppression.  
The  investigators  concluded  that  combining  CoQ10  and 
carotenoids in a topical skin care formulation may render dual 
protection against photoaging and inflammation.9

In 2008, Prahl et al. took skin biopsies of young and old donors 
and  observed  marked  age-dependent  differences  in  the  mito-
chondrial function of the sampled keratinocytes. This led them 
to conclude that aging skin is functionally anaerobic, conducted 
mainly  through  a  nonmitochondrial  pathway.  They  suggested 
that  the  topical  application  of  CoQ10  quickly  enhances  mito-
chondrial function in skin in vivo, thus conferring antiaging activ-
ity.37 Insofar as CoQ10 preserves mitochondrial functioning, thus 
contributing to energy level maintenance, it acts to prevent aging 
skin from employing anaerobic energy production mechanisms.8
Inui et al. demonstrated in vitro that UVB-induced IL-6 produc-
tion of normal human keratinocytes was reduced in the presence 
of CoQ10. MMP-1 synthesis of cultured fibroblasts was also sig-
nificantly  diminished.  In  the  investigators’  clinical  study  of  31 
female subjects aged 27 to 61 years, 1 percent CoQ10 cream used 
for five months resulted in wrinkle score decreases as noted by a 
dermatologist. They concluded that CoQ10 appears to rejuvenate 
wrinkled skin by virtue of suppressing IL-6 production, which 
spurs  fibroblasts  in  the  dermis  to  upregulate  MMP  production 
thus contributing to dermal fiber degradation.38,39

In an in vitro study in 2012, Zhang et al. considered the effects of 
CoQ10 on primary human dermal fibroblasts. They showed that 
CoQ10  exerted  a  broad  array  of  effects  in  embryonic  and  adult 
cells, including the spurring of fibroblast proliferation, augmenting 
type  IV  collagen  expression,  and  lowering  the  levels  of  MMPs 
induced by UV radiation. CoQ10 also dose-dependently fostered 
elastin  gene  expression  in  cultured  fibroblasts  and  markedly 
reduced IL-1α synthesis in keratinocytes induced by UVR. In addi-
tion, they found that the antioxidant inhibited tyrosinase activity 
similarly to ascorbic acid, suggesting the potential for imparting 
depigmenting effects. Overall, they concluded that CoQ10 demon-
strated activity against intrinsic aging as well as photoaging.40

Coenzyme Q10 and Skin Cancer
Patients with breast, lung, or pancreatic cancer have been found 
to have abnormally low plasma levels of CoQ10.41 A study by 
Rusciani et al. examined the usefulness of CoQ10 plasma levels 
in predicting the risk of metastasis and the length of the metas-
tasis-free interval in melanoma patients. They found that CoQ10 
levels  were  significantly  lower  in  melanoma  patients  than  in 

C H A P T E R  57  ■   CO E N Z Y M E   Q 10 

191

control subjects and in patients who experienced metastases as 
compared  to  the  metastasis-free  subgroup.  The  investigators 
concluded that baseline plasma CoQ10 levels can serve as a prog-
nostic factor to estimate the risk for melanoma progression.42

Large quantities of ATP are essential for an immune response 
initiated by interferon (IFN) to be effective in the adjuvant therapy 
of melanoma. Accordingly, some have theorized that the failure 
of some patients to respond to IFN therapy may be the result of 
an inability to meet the excess demand for ATP engendered by 
this medication. However, CoQ10 is known to play a significant 
role in the mitochondrial respiratory cycle and ATP synthesis.43,44 
In 2007, Rusciani et al. conducted a clinical trial in stages I and II 
melanoma patients investigating a postsurgical adjuvant therapy 
with recombinant IFN α-2b combined with CoQ10 vs. IFN α-2b 
alone  for  the  control  group.  In  the  three-year  trial,  reported  in 
2007, patients were given twice-daily administrations of low-dose 
recombinant  IFN  α-2b  and  CoQ10  (400  mg/day).  The  control 
group received only low-dose recombinant IFN α-2b in the same 
dosage  and  administration.  Treatment  efficacy  was  assessed  as 
incidence  of  recurrences  at  five  years.  The  risk  of  developing 
metastases was found to be about 10 times lower in the IFN + 
CoQ10 patients compared with the IFN-alone group.45 A 10-year 
follow-up will be needed to yield more significant results.

Gingivitis and Retinopathy
CoQ10 has garnered attention for an increasingly broad array of 
health conditions. In 2012, Chatterjee et al. conducted a rand-
omized,  controlled  split-mouth  trial  with  30  subjects  with 
plaque-induced  gingivitis  to  identify  the  effects  of  a  solitary 
application  of  CoQ10  after  28  days.  Significant  reductions  in 
gingivitis, bleeding, and plaque scores were observed in areas 
where the antioxidant was topically applied.46

That same year, Hans et al. performed a split-mouth clinical 
evaluation of topically applied CoQ10, in the form of Perio-Q gel, 
in  12  patients  with  chronic  gingivitis  and  periodontitis.  The 
CoQ10  gel  was  associated  with  similar  clinical  results  to  sub-
gingival  mechanical  debridement.  The  researchers  concluded 
that there was insufficient clinical support to indicate the superi-
ority of the gel to basic mechanical approaches, but suggested 
the potential additive effect of CoQ10 while calling for long-term 
clinical studies to assess the antioxidant.47 Previously, Hanioka et 
al.,  in  a  study  with  10  male  patients  in  whom  30  periodontal 
pockets were selected for examination, observed that the topical 
application  of  CoQ10  ameliorated  adult  periodontitis  alone  as 
well as in combination with traditional nonsurgical treatment.48
Topical applications of CoQ10 have also been emerging in the 
ophthalmologic  armamentarium.  For  example,  Lulli  et  al. 
showed that CoQ10 eye drops protected retinal cells from apop-
tosis  in  a  mouse  model  of  kainite-induced  retinal  damage, 
prompting them to conclude that topical CoQ10 be further con-
sidered for apoptosis-driven retinopathy therapies.49

In a 2011 investigation of the potential of N-trimethyl chitosan 
(TMC)-coated  liposomes  containing  CoQ10  as  an  ophthalmic 
drug delivery system, Wang et al. found that CoQ10 concentra-
tion-dependently  raised  the  viability  of  human  lens  epithelial 
cells  and  lowered  oxidative  damage.  They  concluded  that  the 
CoQ10-containing liposomes were effective in protecting human 
lens epithelial cells against hydrogen peroxide-induced oxidative 
harm and appear to have potential as a suitable ophthalmic drug 
delivery agent.50

In 2013, Fogagnolo et al. assessed the postoperative effects of 
topical CoQ10 (and vitamin E d-α-tocopheryl polyethylene glycol 
1,000) in 40 consecutive patients who were randomized to receive 

 
192 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

CoQ10 or saline solution twice daily for nine months after une-
ventful cataract surgery with a temporal port. They found that the 
antioxidant contributed to restoring the anatomy of the subbasal 
nerve plexus of the cornea as well as ocular surface stability.51

 CONCLUSION

CoQ10, like melatonin (see Chapter 62, Melatonin), is intrigu-
ing  insofar  as  it  is  found  naturally  in  humans,  plays  multiple 
biological  roles,  and  is  associated  with  age-related  decline. 
Indeed, the increased cellular oxidation seen with age may be 
due, in part, to a decrease in the endogenous synthesis of such 
antioxidants.  Both  antioxidants  also  appear  to  engage  other 
antioxidants  synergistically  and  are  associated  with  multiple 
benefits when supplied exogenously through oral supplemen-
tation or topical administration. There is a wealth of research 
on the role of endogenous CoQ10 in the human body and the 
broad effects of oral administration of this essential substance. 
While  the  body  of  research  on  the  topical  administration  of 
CoQ10 is not scant by any means, there remains the need for 
more randomized, double-blind, placebo-controlled trials, pref-
erably on a larger scale than has been seen thus far, to clearly 
delineate  its  potential  in  the  dermatologic  armamentarium. 
The potential for CoQ10 does appear to be vast, though.

REFERENCES

1.  Hojerová J. Coenzyme Q10 – Its importance, properties and use 

in nutrition and cosmetics. Ceska Slov Farm. 2000;49:119.

2.  Littarru  GP,  Tiano  L.  Bioenergetic  and  antioxidant  properties  of 
coenzyme Q10: Recent developments. Mol Biotechnol. 2007;37:31.
3.  Schmelzer  C,  Döring  F.  Micronutrient  special  issue:  Coenzyme 
Q(10)  requirements  for  DNA  damage  prevention.  Mutat  Res. 
2012;733:61.

4.  Ernster  L,  Dallner  G.  Biochemical,  physiological  and  medical 
aspects  of  ubiquinone  function.  Biochim  Biophys  Acta. 
1995;1271:195.

5.  Hoppe  U,  Bergemann  J,  Diembeck  W,  et  al.  Coenzyme  Q10,  a 

cutaneous antioxidant and energizer. Biofactors. 1999;9:371.

6.  Siemieniuk E, Skrzydlewska E. Coenzyme Q10: Its biosynthesis 
and  biological  significance  in  animal  organisms  and  in  humans. 
Postepy Hig Med Dosw (Online). 2005;59:150.

7.  Crane FL, Hatefi Y, Lester RL, et al. Isolation of a quinone from 

beef heart mitochondria. Biochim Biophys Acta. 1957;25:220.

8.  Blatt T, Littarru GP. Biochemical rationale and experimental data 
on  the  antiaging  properties  of  CoQ(10)  at  skin  level.  Biofactors. 
2011;37:381.

9.  Fuller B, Smith D, Howerton A, et al. Anti-inflammatory effects 
of CoQ10 and colorless carotenoids. J Cosmet Dermatol. 2006;5:30.
10.  Folkers  K,  Littarru  GP,  Ho  L,  et  al.  Evidence  for  a  deficiency  of 
coenzyme  Q10  in  human  heart  disease.  Int  Z  Vitaminforsch. 
1970;40:380.

11.  Littarru  GP,  Nakamura  R,  Ho  L,  et  al.  Deficiency  of  coenzyme 
Q10 in gingival tissue from patients with periodontal disease. Proc 
Natl Acad Sci U S A. 1971;68:2332.

12.  Bhagavan  HN,  Chopra  RK.  Plasma  coenzyme  Q10  response  to 
oral  ingestion  of  coenzyme  Q10  formulations.  Mitochondrion. 
2007;7(Suppl):S78.

13.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

Medicine. Rochester, VT: Healing Arts Press; 2003:167.

14.  Lee WC, Tsai TH. Preparation and characterization of liposomal 
coenzyme  Q10  for  in  vivo  topical  application.  Int  J  Pharm. 
2010;395:78.

15.  Greenberg  S,  Frishman  WH.  Co-enzyme  Q10:  A  new  drug  for 

cardiovascular disease. J Clin Pharmacol. 1990;30:596.

16.  Passi S, De Pità O, Puddu P, et al. Lipophilic antioxidants in human 

sebum and aging. Free Radic Res. 2002;36:471.

17.  Liu ZX, Artmann C. Relative bioavailability comparison of differ-
ent  coenzyme  Q10  formulations  with  a  novel  delivery  system. 
Altern Ther Health Med. 2009;15:42.

18.  Ashida Y, Yamanishi H, Terada T, et al CoQ10 supplementation 
elevates  the  epidermal  CoQ10  level  in  adult  hairless  mice. 
Biofactors. 2005;25:175.

19.  Shindo Y, Witt E, Han D, et al. Enzymic and non-enzymic anti-
oxidants in epidermis and dermis of human skin. J Invest Dermatol. 
1994;102:122.

20.  López LC, Quinzii CM, Area E, et al. Treatment of CoQ(10) defi-
cient fibroblasts with ubiquinone, CoQ analogs, and vitamin C: 
Time-  and  compound-dependent  effects.  PLoS  One. 
2010;5(7):e11897.

21.  Giovannini  L,  Bertelli  AA,  Scalori  V,  et  al.  Skin  penetration  of 

CoQ10 in the rat. Int J Tissue React. 1988;10:103.

22.  Passi S, De Pità O, Grandinetti M, et al. The combined use of oral 
and  topical  lipophilic  antioxidants  increases  their  levels  both  in 
sebum and stratum corneum. Biofactors. 2003;18:289.

23.  Yue Y, Zhou H, Liu G, et al. The advantages of a novel CoQ10 
delivery system in skin photo-protection. Int J Pharm. 2010;392:57.
24.  Gokce EH, Korkmaz E, Tuncay-Tanriverdi S, et al. A comparative 
evaluation  of  coenzyme  Q10-loaded  liposomes  and  solid  lipid 
nanoparticles  as  dermal  antioxidant  carriers.  Int  J  Nanomedicine. 
2012;7:5109.

25.  Felippi  CC,  Oliveira  D,  Ströher  A,  et  al.  Safety  and  efficacy  of 
antioxidants-loaded  nanoparticles  for  an  anti-aging  application.  
J Biomed Nanotechnol. 2012;8:316.

26.  Chen S, Liu W, Wan J, et al. Preparation of Coenzyme Q10 nano-
structured lipid carriers for epidermal targeting with high-pressure 
microfluidics technique. Drug Dev Ind Pharm. 2013;39:20.

27.  Blatt  T,  Mundt  C,  Mummert  C,  et  al.  Modulation  of  oxidative 
stresses in human aging skin. Z Gerontol Geriatr. 1999;32:83.
28.  Kharaeva Z, Gostova E, De Luca C, et al. Clinical and biochemical 
effects of coenzyme Q(10), vitamin E, and selenium supplemen-
tation to psoriasis patients. Nutrition. 2009;25:295.

29.  De  Luca  C,  Kharaeva  Z,  Raskovic  D,  et  al.  Coenzyme  Q(10), 
vitamin  E,  selenium,  and  methionine  in  the  treatment  of 
chronic  recurrent  viral  mucocutaneous  infections.  Nutrition. 
2012;28:509.

30.  Feigin A, Kieburtz K, Como P, et al. Assessment of coenzyme Q10 
tolerability in Huntington’s disease. Mov Disord. 1996;11:321.
31.  Ikematsu H, Nakamura K, Harashima Sh, et al. Safety assessment 
of  coenzyme  Q10  (Kaneka  Q10)  in  healthy  subjects:  A  double-
blind,  randomized,  placebo-controlled  trial.  Regul  Toxicol 
Pharmacol. 2006;44:212.

32.  Teeranachaideekul V, Souto EB, Junyaprasert VB, et al. Cetyl pal-
mitate-based  NLC  for  topical  delivery  of  Coenzyme  Q(10)  – 
Development,  physicochemical  characterization  and  in  vitro 
release studies. Eur J Pharm Biopharm. 2007;67:141.

33.  Packer  L,  Colman  C.  The  Antioxidant  Miracle.  New  York:  John 

Wiley & Sons, Inc.; 1999:9.

34.  Wölfle  U,  Haarhaus  B,  Schempp  CM.  The  photoprotective  and 
antioxidative properties of luteolin are synergistically augmented 
by tocopherol and ubiquinone. Planta Med. 2013;79:963.

35.  Schempp  CM,  Meinke  MC,  Lademann  J,  et  al.  Topical  antioxi-
dants  protect  the  skin  from  chemical-induced  irritation  in  the 
repetitive washing test: A placebo-controlled, double-blind study. 
Contact Dermatitis. 2012;67:234.

36.  Beyer R, Ernster L. The antioxidant role of Coenzyme Q10. In: 
Lenaz  G,  Barnabei  O,  Rabbi  A,  eds.  Highlights  in  Ubiquinone 
Research. London: Taylor & Francis; 1990:191–213.

37.  Prahl  S,  Kueper  T,  Biernoth  T,  et  al.  Aging  skin  is  functionally 
anaerobic: Importance of coenzyme Q10 for anti aging skin care. 
Biofactors. 2008;32:245.

38.  Inui M, Ooe M, Fujii K, et al. Mechanisms of inhibitory effects of 
CoQ10 on UVB-induced wrinkle formation in vitro and in vivo. 
Biofactors. 2008;32:237.

39.  Littarru  GP,  Tiano  L.  Clinical  aspects  of  coenzyme  Q10:  An 

update. Nutrition. 2010;26:250.

40.  Zhang M, Dang L, Guo F, et al. Coenzyme Q(10) enhances dermal 
elastin expression, inhibits IL-1α production and melanin synthe-
sis in vitro. Int J Cosmet Sci. 2012;34:273.

41.  Folkers K, Ostemborg A, Nylander M, et al. Activities of vitamin 
Q10  in  animal  models  and  serious  deficiency  in  patients  with 
cancer. Biochem Biophys Res Commun. 1997;234:296.

42.  Rusciani  L,  Proietti  I,  Rusciani  A,  et  al.  Low  plasma  coenzyme 
Q10  levels  as  an  independent  prognostic  factor  for  melanoma 
progression. J Am Acad Dermatol. 2006;54:234.

43.  Crane  FL.  Biochemical  functions  of  coenzyme  Q10.  J  Am  Coll 

Nutr. 2001;20:591.

 
44.  Beyer RE, Nordenbrand K, Ernster L. The role of coenzyme Q as 
a  mitochondrial  antioxidant:  A  short  review.  In:  Folkers  K, 
Yamamura Y, eds. Biomedical and Clinical Aspects of Coenzyme Q. 
Amsterdam:  The  Netherlands,  Elsevier  Science  Publishers  B  V 
(Biomedical Division); 1986:17–24.

45.  Rusciani  L,  Proietti  I,  Paradisi  A,  et  al.  Recombinant  interferon 
alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy 
for melanoma: A 3-year trial with recombinant interferon-alpha 
and 5-year follow-up. Melanoma Res. 2007;17:177.

46.  Chatterjee A, Kandwal A, Singh N, et al. Evaluation of Co-Q10 
anti-gingivitis effect on plaque induced gingivitis: A randomized 
controlled trial. J Indian Soc Periodontol. 2012;16:539.

47.  Hans M, Prakash S, Gupta S. Clinical evaluation of topical appli-
cation of perio-Q gel (Coenzyme Q(10)) in chronic periodontitis 
patients. J Indian Soc Periodontol. 2012;16:193.

C H A P T E R  57  ■   CO E N Z Y M E   Q 10 

193

48.  Hanioka T, Tanaka M, Ojima M, et al. Effect of topical application 
of  coenzyme  Q10  on  adult  periodontitis.  Mol  Aspects  Med. 
1994;15(Suppl):s241.

49.  Lulli M, Witort E, Papucci L, et al. Coenzyme Q10 instilled as eye 
drops on the cornea reaches the retina and protects retinal layers 
from apoptosis in a mouse model of kainite-induced retinal dam-
age. Invest Ophthalmol Vis Sci. 2012;53:8295.

50.  Wang  S,  Zhang  J,  Jiang  T,  et  al.  Protective  effect  of  Coenzyme 
Q(10) against oxidative damage in human lens epithelial cells by 
novel ocular drug carriers. Int J Pharm. 2011;403:219.

51.  Fogagnolo  P,  Sacchi  M,  Ceresara  G,  et  al.  The  effects  of  topical 
coenzyme Q10 and vitamin E D-α-tocopheryl polyethylene gly-
col  1000  succinate  after  cataract  surgery:  A  clinical  and  in  vivo 
confocal study. Ophthalmologica. 2013;229:26.

 
194 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   5 8

Coffeeberry

Activities:

Antioxidant, anti-inflammatory, photoprotective

Important Chemical Components:

Chlorogenic acid, caffeic acid, condensed proanthocyan- 
idins, quinic acid, ferulic acid, p-coumaric acid, phenolic 
diterpenes (kahweol, cafestol), α-tocopherol

Origin Classification:

Coffeeberry  is  a  legal  trademark  for  a  process  of 
harvesting  subripe  fruit  from  the  plant  Coffea  arabica 
and processing it to accentuate its antioxidant ingredients 
while  eliminating  microbial  contaminants.1–3  Thus,  its 
origin is natural but marketed standardized Coffeeberry® 
extract  products  are  synthesized  and  processed  in  the 
laboratory.

Personal Care Category:

Antiaging, moisturizing

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW, DRPW, DSNW, DSPW, ORNW, ORPW, OSNW, 
and OSPW

 SOURCE

The coffee plant Coffea arabica, a member of the Rubiaceae family, 
is cultivated throughout the world and is, of course, a source of the 
globally popular beverage. Extracts of the coffee plant have been 
demonstrated to display antioxidant activity (Table 58-1).4

While  much  attention  has  been  focused  on  coffee  beans, 
particularly once roasted, the fruit of the coffee plant has been 
long ignored, and usually discarded, because it decays rapidly.1 
The  fruit  that  grows  on  C.  arabica,  however,  is  suffused  with 
polyphenols,  especially  chlorogenic  acid  (the  primary  phenolic 
substance in coffee), condensed proanthocyanidins, quinic acid, 
caffeic acid, and ferulic acid (see Chapter 53, Caffeic Acid, and 
Chapter 54, Ferulic Acid).1,5,6 It is also believed to exhibit higher 
antioxidant  activity  than  green  tea,  white  tea,  pomegranate, 
blueberries,  strawberries,  and  raspberries  (see  Chapter  47,  
Green Tea). Polyphenols, which are secondary metabolites in 
plants, play an integral role in a healthy human diet, as these 

TABLE 58-1
Pros and Cons of Coffeeberry

Pros
Strong antioxidant activity
Superlative ORAC assay data suggest greater 
antioxidant potency than many standard 
antioxidants

Con
Dearth of clinical evidence

compounds are active constituents in various fruits, vegetables, 
grains,  green  and  black  tea,  and  coffee  beans.7–11  In  addition, 
copious research during the last several years has shown that 
polyphenols  represent  a  wealth  of  potential  health  benefits, 
typically related to anti-inflammatory and antioxidant proper-
ties. Consequently, manufacturers have targeted the activity of 
polyphenols  for  medical  and  cosmetic  applications  in  several 
pharmaceutical and cosmeceutical products.

The  Coffeeberry  fruit,  which  is  harvested  subripe  from  the  
C.  arabica  plant,  has  been  traditionally  ignored,  as  mentioned 
above, but a method to translate its claimed prodigious proper-
ties  has  been  developed  and  given  the  proprietary  name 
Coffeeberry®.  Analogous  to  the  patented  trade  name  for  the 
antioxidant Pycnogenol® (see Chapter 49, Pycnogenol), derived 
from  French  maritime  pine  bark,  Coffeeberry  is  a  proprietary 
blend of antioxidants harvested from a natural botanical source.

 HISTORY

C. arabica actually comes from Ethiopia and is thought to have 
been introduced into Arabia before or early in the 1400s, into 
Java before 1700, and into the West Indies as well as Central 
and South America in the 1700s.12,13

 CHEMISTRY

Extracts of the beans of C. arabica have demonstrated antioxi-
dant  activity  after  roasting.4  In  addition  to  the  beans  of  the 
coffee plant, the fruit, especially when harvested in a subrip-
ened state, also displays peak antioxidant activity.14 This is due 
to  its  constituent  polyphenols,  particularly  chlorogenic  acid, 
condensed  proanthocyanidins,  quinic  acid,  caffeic  acid,  and 
ferulic  acid.  Indeed,  polyphenols,  which  are  also  found  in 
green, white, and black tea, various fruits, vegetables, as well as 
grains,  are  known  to  confer  multiple  health  benefits,  mainly 
due to their anti-inflammatory and antioxidant properties.15,16

Chlorogenic acid, an ester formed between caffeic and quinic 
acids (see Chapter 53, Caffeic Acid), is one of the most broadly 
consumed polyphenols as it is ubiquitous in food and coffee.17 
Both  chlorogenic  and  caffeic  acids  have  been  found  to  inhibit 
ultraviolet (UV) B-induced skin tumor promotion in mouse skin.17

 ORAL USES

The coffee plant C. arabica is cultivated throughout the world 
as the source of the widely popular coffee beverage. Only the 
seeds of the fruit are used to produce the popular beverage. The 
Coffeeberry fruit is available as an oral supplement as well as in 
topical cosmetic formulations.

In 2008, Ostojic et al. examined the changes in total antioxidant 
capacity  and  aerobic  and  anaerobic  performance  in  20  college 
athletes  (14  males,  6  females)  engendered  by  supplementation 
with  an  oral  Coffeeberry  formulation  for  four  weeks.  After  the 
trial,  total  antioxidant  capacity  was  significantly  higher  in  the 

 
C H A P T E R  58  ■   CO F F E E B E R RY  

195

group  supplementing  with  Coffeeberry  as  compared  to  the 
placebo group. No adverse effects were observed in either group 
and  there  were  no  other  significant  differences  between  the 
groups.  The 
investigators  concluded  that  Coffeeberry 
supplementation yielded a slight increase in antioxidant capacity, 
and minimal effects in terms of recovery after exercise.18

improvements in the appearance of photodamaged skin in the 
subjects using the test regimen.25

Coffeeberry  extract  has  also  been  shown,  in  preclinical  and 
small clinical trials, to confer protection from oxidative damage, 
UVB-induced  pyrimidine  dimer  formation  and  inflammation, 
and to facilitate accelerated recovery from UVB exposure.26

 TOPICAL USES

 SAFETY ISSUES

The  C.  arabica  plant  is  used  in  some  botanical  formulations 
intended to treat cellulite. The caffeine used in this context as 
an active ingredient is extracted from the leaves, however, not 
the  berries.19  Green  C.  arabica  seed  oil  is  also  being  broadly 
used  as  an  ingredient  in  cosmetic  formulations.20  Therefore, 
multiple parts of the plant are now under investigation and in 
active use in the dermatologic realm. Preliminary data on the 
use of the proprietary fruit suggest that Coffeeberry extract has 
the potential to ameliorate overall appearance, hyperpigmenta-
tion, as well as fine lines and wrinkles.21

In 2008, Draelos conducted a double-blind, randomized clinical 
trial in 50 subjects over age 30 with mild symptoms of photoaging 
to assess the cutaneous benefits of Coffeeberry extract. Over the 
12-week period, both groups used a Coffeeberry facial cleanser 
twice  daily.  Afterwards,  one  group  would  apply  a  Coffeeberry 
day cream in the morning and a Coffeeberry night cream in the 
evening  to  the  whole  face.  The  other  group  applied  control 
creams. Compared to the control group, significant improvements 
were  observed  in  the  Coffeeberry  extract  group  along  all 
parameters  considered  (i.e.,  erythema,  roughness,  scaling, 
wrinkling,  and  global  assessment).  Transepidermal  water  loss 
decreased from baseline in the Coffeeberry group and increased in 
the control group. Draelos concluded that the Coffeeberry extract 
system of facial cleanser and morning and evening creams was 
well tolerated and led to significant improvements in diminishing 
multiple symptoms of photoaged skin.22,23

In a six-week pilot study conducted by McDaniel and sponsored 
by Stiefel Laboratories, 30 female patients (31–71 years old) with 
moderate actinic damage used an antioxidant system composed of 
0.1 percent Coffeeberry extract facial cleanser as well as 1 percent 
Coffeeberry  extract  night  and  day  creams  (the  latter  of  which 
contained  octinate  and  oxybenzone  with  an  SPF  of  15).14,24  
Twenty subjects applied all three products to the whole face and 10 
subjects applied each to half the face and vehicle on the other half. 
Compared  to  vehicle,  split-face  patients  experienced  significant 
improvements in fine lines and wrinkles, pigmentation, and overall 
appearance. Patients treated on the whole face displayed improve-
ments in all parameters (including fine lines and wrinkles, roughness 
and dryness, pigmentation, and overall appearance) compared to 
baseline, with marked changes in pigmentation as the most salient 
improvement. McDaniel also reported that skin biopsies revealed 
that  the  use  of  Coffeeberry  extract  led  to  an  increase  in  key 
structural dermal proteins (i.e., collagen types I and IV) as well as a 
decrease in collagenase and inflammatory mediators.24

In late 2010, Palmer and Kitchin reported on their 12-week, 
double-blind,  randomized,  controlled  clinical  usage  study  of 
the efficacy and tolerance of a new C. arabica-containing topical 
high-antioxidant  skin  care  system  (facial  wash,  day  lotion, 
night  cream  and  eye  serum)  to  ameliorate  photoaging  in  
40 Caucasian females. One group of participants used the test 
system,  including  twice-daily  facial  wash,  application  of  the 
antioxidant day lotion each morning, and nightly application of 
the  antioxidant  night  cream  and  eye  serum,  with  the  second 
group  using  the  control  products  according  to  the  same 
protocol.  The  authors  observed  statistically  significant 

Topical products that contain C. arabica, or Coffeeberry extract 
in particular, are generally regarded as safe, though extensive 
data are not available.

Some  safety  studies  have  been  performed  on  the  oral  use  of 
Coffeeberry. In 2010, Heimbach et al. conducted a series of geno-
toxicity studies, three short-term oral toxicity studies, and a 90-day 
dietary toxicity study of Coffeeberry products, including a ground 
whole powder, a water extract, and a water-ethanol extract. None 
of  the  products  exhibited  genotoxic  or  mutagenic  potential  in 
murine peripheral cells. Although palatability issues emerged, rats 
displayed a tolerance for the whole powder and ethanol extracts, 
with  females  showing  a  higher  tolerance  for  both.  Finally,  no 
adverse effects were seen in Sprague-Dawley rats fed the ethanol 
extract for 90 days at concentrations up to 5 percent.1

In the few preclinical or small clinical trials thus far performed, 
no serious adverse events have been reported as treatments have 
been well tolerated.27

 ENVIRONMENTAL IMPACT

A  significant  environmental  impact  is  exacted  by  C.  arabica 
cultivation, including deforestation, water pollution and other 
effects  of  agrochemical  use,  soil  quality  degradation,  loss  
of biodiversity, and changes in forest cover and structure.28–32 
The details and depth of the full range of actual and potential 
effects  of  industrial  coffee  growth  as  well  as  sustainable 
management approaches are beyond the scope of this text.

 FORMULATION CONSIDERATIONS

Harvesting C. arabica fruit in a subripened state is essential to 
both  optimize  antioxidant  potency  and  attenuate  the  risk  of 
contamination  with  mycotoxins,  which  is  typical  later  in  the 
ripening process. The whole berry fruit is crushed and processed 
for its antioxidant components.27

 USAGE CONSIDERATIONS

Coffeeberry®,  a  proprietary  ingredient  for  the  antioxidant 
derived  from  the  fruit  of  C.  arabica,  is  the  fundamental 
component  in  the  RevaléSkin™  line  of  cosmetic  products 
intended  to  reverse  various  signs  of  photodamage  and 
photoaging and to impart photoprotection.33 The hydroxycin-
namic acid ferulic acid, another potent antioxidant, is also an 
important active ingredient in these products (see Chapter 54, 
Ferulic Acid). In the oxygen radical absorbance capacity assay 
(ORAC),  Coffeeberry®  exhibited  greater  antioxidant  activity 
than  green  tea,  pomegranate  extract,  and  vitamins  C  and  E  
[see  Chapter  55,  Ascorbic  Acid  (Vitamin  C),  and  Chapter  56, 
Tocopherol (Vitamin E)].14 Of note, the proprietary Coffeeberry® 
technology  associated  with  the  cultivation,  harvesting,  and 
processing  of  the  whole  coffee  fruit  eliminates  the  risk  of 
contamination  by  bacteria  or  fungi  and  the  potential  for 
generating mycotoxins.1–3

 
196 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

 SIGNIFICANT BACKGROUND

Antioxidant Activity
Two recent studies point to the antioxidant properties of roasted 
C. arabica. In one, in which coffee model systems were prepared 
from  combinations  of  compounds,  including  chlorogenic  acid, 
sucrose,  and  cellulose,  various  tests  revealed  that  antioxidant 
activity  exhibited  a  positive,  nonlinear  relationship  with  the 
level of chlorogenic acid, a known antioxidant, after roasting.4

In  the  other  study,  both  C.  arabica  and  C.  robusta  (Coffea 
canephora)  demonstrated  potent  antiradical  activity  against  the 
hydroxyl radical in an in vitro assay and ex vivo in IMR32 cells. 
The investigators concluded that both green and roasted coffee 
exhibit  antiradical  activity,  with  5-O-caffeoyl-quinic  acid,  a 
chlorogenic acid isomer, as the most active constituent, and that 
the  roasting  process  stimulates  high  molecular  weight 
components to display antiradical activity in coffee. The authors 
speculated  that  these  findings  could  account  for  the 
neuroprotective  effects  associated  with  coffee  consumption  in 
several epidemiologic studies.34 In fact, a number of such studies 
have  provided  evidence  linking  regular  coffee  and  caffeine 
consumption  with  a  lower  incidence  or  reduced  risk  of 
developing Parkinson’s disease.35,36

Coffea Arabica in Skin Care Research
In 2009, green coffee oil was shown through in vitro studies and 
in ex vivo human skin models to dose-dependently promote the 
production of the key dermal constituents collagen, elastin, and 
glycosaminoglycans, as well as stimulate a greater release of the 
growth factors transforming growth factor-β1 and granulocyte 
-macrophage  colony-stimulating  factor.  In  addition,  green 
coffee  oil  spurred  the  expression  of  aquaporin-3  (AQP-3) 
mRNA, up to 6.5-fold higher than levels seen in control cultures. 
The investigators concluded that green coffee oil has potential 
to  contribute  to  the  formation  of  new  connective  tissue  and 
improving  cutaneous  function  by  mitigating  wrinkles  and 
preventing xerosis by raising levels of AQP-3 (see Chapter 29, 
Aquaporin). Consequently, they suggested that including green 
coffee oil in cosmetic formulations merits consideration.20

In early 2011, Chiang et al. reported on their investigation of the 
antiphotoaging effects of C. arabica leaf extract, its hydrolysates, 
chlorogenic  acid,  and  caffeic  acid.  The  various  polyphenol- 
containing test compounds were subjected to matrix metallopro-
teinase  (MMP)  and  elastase  inhibition  tests.  They  found  that  
C.  arabica  leaf  extracts  stimulated  type  I  procollagen  expression, 
suppressed MMP-1, MMP-3, and MMP-9 expression, and hindered 
the phosphorylation of JNK, ERK and p38. They concluded that 
the  extracts  of  C.  arabica  leaves  can  prevent  photodamage  by 
inhibiting MMP expression and the MAP kinase pathway.37

 CONCLUSION

Given the widespread cultivation of the Coffea arabica plant, and 
the growing scientific interest in exploring the ramifications of its 
use, it would certainly be cost-effective if companies that harvest 
the plant also made use of its fruit in some capacity. Accordingly, 
the manufacturers of Coffeeberry® and their researchers deserve 
credit for resourcefulness and innovative thinking at the very least. 
In  addition,  preliminary  evidence  suggests  that  Coffeeberry 
warrants  consideration  for  its  strong  antioxidant  potential. 
However,  claims  that  Coffeeberry  improves  wrinkles  are  likely 

due to a moisturizing effect as it is well established that antioxi-
dants  can  prevent  wrinkles  from  developing  but  do  not  eliminate 
wrinkles  that  are  already  present.  The  effects  seen  on  improved 
hyperpigmentation are not unexpected as antioxidants play a role 
in the pigmentation process. In the author’s opinion, the “superior 
antioxidant protection” that any product claims cannot be proven, 
because there is no consensus on the ideal test to evaluate antioxi-
dant  activity.  Much  more  research,  preferably  in  the  form  of 
randomized, double-blind, placebo-controlled clinical trials, is nec-
essary to determine the true potential impact of Coffeeberry in the 
dermatologic arsenal.

REFERENCES

1.  Heimbach  JT,  Marone  PA,  Hunter  JM,  et  al.  Safety  studies  on 
products from whole coffee fruit. Food Chem Toxicol. 2010;48:2517.
2.  Miljkovic D, Duell B, Miljkovic V. Low-mycotoxin coffee cherry 

products. Int Patent App Publ. WO 2004/098303.

3.  Miljkovic  D,  Duell  B,  Miljkovic  V.  Methods  for  coffee  cherry 

products. Int Patent App Publ. WO 2004/098320.

4.  Charurin  P,  Ames  JM,  del  Castillo  MD.  Antioxidant  activity  of 

coffee model systems. J Agric Food Chem. 2002;50:3751.

5.  Del  Rio  D,  Stalmach  A,  Calani  L,  et  al.  Biovailability  of  coffee 
chlorogenic acids and green tea flavan-3-ols. Nutrients. 2010;2:820.
6.  Olthof MR, Hollman PC, Katan MB. Chlorogenic acid and caffeic 

acid are absorbed in humans. J Nutr. 2001;131:66.

7.  Ross JA, Kasum CM. Dietary flavonoids: Bioavailability, metabolic 

effects, and safety. Annu Rev Nutr. 2002;22:19.

8.  Hertog MG, Hollman PC, Katan MB, et al. Intake of potentially 
anticarcinogenic  flavonoids  and  their  determinants  in  adults  in 
The Netherlands. Nutr Cancer. 1993;20:21.

9.  Birt  DF,  Hendrich  S,  Wang  W.  Dietary  agents  in  cancer  preven-
tion: Flavonoids and isoflavonoids. Pharmacol Ther. 2001;90:157.

10.  Rechner AR, Spencer JP, Kuhnle G, et al. Novel biomarkers of the 
metabolism of caffeic acid derivatives in vivo. Free Radic Biol Med. 
2001;30:1213.

11.  Svobodová A, Psotová J, Walterová D. Natural phenolics in the 
prevention  of  UV-induced  skin  damage.  A  review.  Biomed  Pap 
Med Fac univ Palacky Olomouc Czech Repub. 2003;147:137.

12.  Morton  JF.  Major  Medicinal  Plants.  Springfield,  IL:  C.C.  Thomas; 

1977.

13.  Grieve M. A Modern Herbal (Vol 1). New York: Dover Publications; 

1971:210.

14.  Farris P. Idebenone, green tea, and Coffeeberry extract: New and 

innovative antioxidants. Dermatol Ther. 2007;20:322.

15.  Chen  D,  Milacic  V,  Chen  MS,  et  al.  Tea  polyphenols,  their 
biological effects and potential molecular targets. Histol Histopathol. 
2008;23:487.

16.  Halder  B,  Bhattacharya  U,  Mukhopadhyay  S,  et  al.  Molecular 
mechanism of black tea polyphenols induced apoptosis in human 
skin cancer cells: Involvement of Bax translocation and mitochon-
dria mediated death cascade. Carcinogenesis. 2008;29:129.

17.  Kang NJ, Lee KW, Shin BJ, et al. Caffeic acid, a phenolic phyto-
chemical in coffee, directly inhibits Fyn kinase activity and UVB-
induced COX-2 expression. Carcinogenesis. 2009;30:321.

18.  Ostojic SM, Stojanovic MD, Djordjevic B, et al. The effects of a 
4-week  coffeeberry  supplementation  on  antioxidant  status, 
endurance,  and  anaerobic  performance  in  college  athletes.  Res 
Sports Med. 2008;16:281.

19.  Hexsel D, Orlandi C, Zechmeister do Prado D. Botanical extracts 
used in the treatment of cellulite. Dermatol Surg. 2005;31:866.
20.  Velazquez  Pereda  Mdel  C,  Dieamant  Gde  C,  Eberlin  S,  et  al. 
Effect of green Coffea arabica L. seed oil on extracellular matrix 
components and water-channel expression in in vitro and ex vivo 
human skin models. J Cosmet Dermatol. 2009;8:56.

21.  Berson DS. Natural antioxidants. J Drugs Dermatol. 2008;7:s7.
22.  Draelos  Z.  A  double-blind,  randomized  clinical  trial  evaluating 
the  dermatologic  benefits  of  coffee  berry  extract.  J  Am  Acad 
Dermatol. 2008;58(Suppl 2):AB64.

23.  Draelos  ZD.  Optimal  skin  care  for  aesthetic  patients:  Topical 
products to restore and maintain healthy skin. Cosmet Dermatol. 
2009;22:S1.

24.  McDaniel DH. Clinical safety and efficacy in photoaged skin with 
coffeeberry  extract,  a  natural  antioxidant.  Cosmet  Dermatol. 
2009;22:610.

 
C H A P T E R  58  ■   CO F F E E B E R RY  

197

25.  Palmer DM, Kitchin JS. A double-blind, randomized, controlled 
clinical  trial  evaluating  the  efficacy  and  tolerance  of  a  novel 
phenolic antioxidant skin care system containing Coffea arabica 
and  concentrated  fruit  and  vegetable  extracts.  J  Drugs  Dermatol. 
2010;9:1480.

26.  Leyden JJ, Shergill B, Micali G, et al. Natural options for the man-
agement  of  hyperpigmentation.  J  Eur  Acad  Dermatol  Venereol. 
2011;25:1140.

27.  Lupo  MP,  Draelos  ZD,  Farris  PK,  et  al.  CoffeeBerry:  A  new, 
natural  antioxidant  in  professional  antiaging  skin  care.  Cosmet 
Dermatol. 2007;20:2.

28.  Natural  Resources  Defense  Council.  Environmental  Issues: 
Health.  Coffee,  Conservation,  and  Commerce  in  the  Western 
Hemisphere:  How  Individuals  and  Institutions  Can  Promote 
Ecologically Sound Farming and Forest Management in Northern 
Latin  America.  http://www.nrdc.org/health/farming/ccc/chap4 
.asp#note54. Accessed October 3, 2013.

29.  Hylander  K,  Nemomissa  S,  Delrue  J,  et  al.  Effects  of  coffee 
management on deforestation rates and forest integrity. Conserv 
Biol. 2013;27:1031.

30.  Hundera K, Aerts R, Fontaine A, et al. Effects of coffee manage-
ment intensity on composition, structure, and regeneration status 

of  Ethiopian  moist  evergreen  afromontane  forests.  Environ 
Manage. 2013;51:801.

31.  Takahashi R, Todo Y. The impact of a shade coffee certification 
program on forest conservation: A case study from a wild coffee 
forest in Ethiopia. J Environ Manage. 2013;130C:48.

32.  Philpott SM, Arendt WJ, Armbrecht I, et al. Biodiversity loss in 
Latin  American  coffee  landscapes:  Review  of  the  evidence  on 
ants, birds, and trees. Conserv Biol. 2008;22:1093.

33.  Beer K, Kellner E, Beer J. Cosmeceuticals for rejuvenation. Facial 

Plast Surg. 2009;25:285.

34.  Daglia M, Racchi M, Papetti A, et al. In vitro and ex vivo antihy-
droxyl  radical  activity  of  green  and  roasted  coffee.  J  Agric  Food 
Chem. 2004;52:1700.

35.  Ascherio A, Zhang SM, Hernán MA, et al. Prospective study of 
caffeine consumption and risk of Parkinson’s disease in men and 
women. Ann Neurol. 2001;50:56.

36.  Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee 
and  caffeine  intake  with  the  risk  of  Parkinson’s  disease.  JAMA. 
2000;283:2674.

37.  Chiang HM, Lin TJ, Chiu CY, et al. Coffea arabica extract and its 
constituents  prevent  photoaging  by  suppressing  MMPs  expres-
sion and MAP kinase pathway. Food Chem Toxicol. 2011;49:309.

 
198 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   5 9

Ginger

Activities:

Antioxidant,  anticarcinogenic,  anti-inflammatory,  anti- 
nausea, wound healing

Important Chemical Components:

Terpenes, phenolic vanilloids ([6]-gingerol and other gin-
gerols;  the  structurally  related  [6]-paradol,  and  other 
paradols),  shogaols,  [10]-shogaol  and  other  shogaols, 
zingerone, β-carotene, ascorbic acid, rutin

Origin Classification:

This  ingredient  is  considered  natural.  As  an  ingredient 
used for dermatologic purposes, it is laboratory made.

Personal Care Category:

Antioxidant, analgesic, photoprotectant

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW, DRPW, ORNW, and ORPW

 SOURCE

Ginger, the tuberous root or rhizome of Zingiber officinalis, is one of 
the  most  widely  used  species  of  the  tropical  and  subtropical 
Zingiberaceae  family,  particularly  as  a  condiment  and  spice  for 
many foods and beverages.1 Indeed, the use of ginger rhizomes, 
commonly referred to as ginger, in culinary spices and as medicine 
to  treat  various  conditions  has  a  long-standing  and  widespread 
tradition throughout Asia  (Table 59-1). The designation  ginger is 
thought to be derived from the Sanskrit word singabera, meaning 
“horn-shaped,”  which  alludes  to  the  knobby  protuberances  of 
ginger’s rhizomes. It is now cultivated in China, India, Southeast 
Asia, Mexico, Africa, Fiji, and Australia.2 Traditional uses of the 
herb,  to  treat  nausea,  indigestion,  joint  inflammation,  fever  and 
infection, continue today, but the list of indications is expanding as 
research reveals a wider variety of potential applications.

In fact, ginger is known as one of the most effective herbal 
remedies for nausea and has a longstanding reputation as a gas-
troprotective,  carminative  agent.  Its  antiemetic  properties  are 
attributed  to  an  effect  on  gastric  activity  rather  than  a  central 
nervous  system  mechanism.  Ginger  is  also  touted  for  its 

TABLE 59-1
Pros and Cons of Ginger

Pros
Long and varied history of traditional uses

Vast spectrum of biologic activity
One of the top botanical ingredients in terms 
of the number of medical indications
Compelling evidence related to skin cancer

Con
More clinical evidence is needed to substan-
tiate topical antioxidant and other benefits

antioxidant, antiviral, antifungal, and antibacterial activity.3,4 It is 
thought to be effective against the growth of both Gram-positive 
and Gram-negative microbes.

Ginger has also been cited as an effective element in treating 
stomach  ulcers,  arthritis,  rheumatism,  and  migraines.5  Its 
purported  ability  to  improve  circulation  and  to  act  as  an 
antioxidant has led to research into its viability as an ingredient 
in  skin  care  products  aimed  at  enhancing  facial  complexion. 
Evidence  is  gathering,  also,  of  the  chemopreventive, 
antineoplastic activity of ginger.6

 HISTORY

Native to much of Asia, ginger, dubbed Zingiber officinale in 1807 
by  English  botanist  William  Roscoe,  appears  in  records  of  its 
use in ancient Sanskrit and Chinese writings as well as Greek, 
Roman, and Arabic medical texts.2 Ginger has been used as a 
traditional herb for over 2,500 years and long considered a uni-
versal remedy.1,7 Generally, it has been employed in traditional 
Chinese  medicine  (TCM),  Ayurveda,  and  Tibb-Unani  herbal 
medicine to treat various illnesses involving inflammation and 
oxidative stress.8 In these ancient medical systems as well as Sri 
Lankan,  Arabic,  and  African  traditional  medicine,  ginger  has 
been used to treat a wide range of ailments, including common 
colds,  fever,  sore  throats,  vomiting,  motion  sickness,  indiges-
tion,  constipation,  arthritis,  rheumatism,  sprains,  muscular 
aches,  cramps,  hypertension,  dementia,  helminthiasis,  and 
infectious  diseases,  and  continues  to  be  used  for  such  indica-
tions as well as asthma, allergy, headaches, diabetes, gingivitis, 
and stroke in TCM and other Eastern medical practices.5,6,9-12

In a 2010 study to ascertain the ethnopharmacological appli-
cation of medicinal plants used to treat skin diseases and in folk 
cosmetics  in  northwestern  Pakistan,  Abbasi  et  al.  identified 
Zingiber officinale as one of 15 mostly wild and rare plant species 
used for various skin and hair conditions.13

 CHEMISTRY

Ginger is widely used as an herbal medicine, particularly due to 
the  presence  of  homologous  phenolic  ketones,  of  which 
[6]-gingerol  (1-[4′-hydroxy-3′-methoxyphenyl]-5-hydroxy- 
3-decanone)  is  the  primary  and  most  abundant.14,15  The 
chemistry  of  ginger  is  complicated,  though.  In  fact,  the  chief 
components found in ginger oil vary according to the region in 
which it was grown. An oleoresin, known as “ginger oil,” and 
terpenes are the major active components of ginger; however, 
pungent phenolic substances, such as [6]-gingerol and [6]-para-
dol, are considered the source of the discrete antioxidative and 
anti-inflammatory action of ginger.16,17 In addition, ginger has 
been found to exert anticancer activity, which is also ascribed 
to  [6]-gingerol  and  [6]-paradol,  as  well  as  shogaols  (the  main 
dehydration products of gingerols) and zingerone.1,16,18

Several  animal  studies  have  demonstrated  the  antioxidant 
capacity of ginger. More than a decade ago, ginger was found to 
inhibit lipid peroxidation in rat liver microsomes.19 Researchers 

 
also  showed  that  ginger  effectively  scavenges  superoxide  ani-
ons.20 A study on SENCAR mice demonstrated the antioxidant, 
anti-inflammatory  and  anticarcinogenic  properties  of  ginger 
extracts. Ginger oil placed directly on the skin of mice prevented 
the  development  or  growth  of  skin  cancer  after  the  mice  were 
exposed to chemicals that promote cancer.21 The anti-inflammatory 
effect  is  thought  to  be  due  to  inhibition  of  cyclooxygenase 
(COX) and 5-lipoxygenase.22 Further, ginger has been shown to 
inhibit fibroblast-derived elastase, suggesting a significant role in 
the prevention of wrinkle formation.23

 ORAL USES

Ginger is commonly used as a condiment for foods and in bev-
erages, particularly tea, throughout the world; it is one of the 
most frequently and heavily consumed of all the spices.17 The 
distinctive, spicy taste of fresh ginger is attributed to the lipid-
soluble [6]-gingerol, one of its main phenolic constituents; the 
pungency of dry ginger is linked to the shogaols.11,24 In addition 
to its wide use in foods and beverages, ginger is available as a 
dietary supplement.

 TOPICAL USES

Knee Osteoarthritis
Ginger is one among several adjuvant or secondary options in 
the treatment of knee osteoarthritis, which affects more than 
one-third of individuals over the age of 65.25 In a 2011 double-
blind, randomized controlled trial with 92 patients, an herbal 
ointment containing ginger, cinnamon, mastic, and sesame oil 
was clinically effective and comparable to a salicylate ointment 
in  reducing  pain,  morning  stiffness,  and  motion  limitations.26 
Previously, among 247 patients who could be evaluated from 
an  original  261  in  a  randomized,  double-blind,  placebo- 
controlled, multicenter, parallel-group, six-week study, 63 percent 
of  responders  in  the  ginger  extract  group  experienced  dimin-
ished  knee  pain  as  compared  to  50  percent  in  the  control 
group.27  However,  a  systematic  review  of  the  literature  to 
assess  the  safety  and  effectiveness  of  ginger  to  treat  osteoar-
thritis in adults yielded weak evidence of its effectiveness as a 
lone therapy.28

Hair Care
Although ginger is used in East Asia in various products touted 
to stem hair loss and promote growth, Miao et al. pointed out 
that supportive evidence is lacking. In 2013, they investigated 
the effects of [6]-gingerol on hair shaft growth and human der-
mal papilla cells in vitro and in vivo. The researchers found that 
the ginger constituent inhibited hair growth as well as the pro-
liferation of dermal papilla cells in culture as well as in mice. 
They  concluded  that  contrary  to  popular  usage  in  East  Asia, 
[6]-gingerol appears better suited for hair removal than stimu-
lating hair growth.29

 SAFETY ISSUES

Ginger is listed by the Food and Drug Administration as gener-
ally recognized as safe (GRAS).30 It can be irritating to the skin 
and  should  not  be  used  in  sensitive  skin  types,  particularly  S2 
rosacea types. Contact dermatitis to ginger has been reported.31

C H A P T E R  59  ■   G I N G E R  

199

 ENVIRONMENTAL IMPACT

Z.  officinale  is  abundant  in  tropical  regions  throughout  the 
world and its harvesting is not known to damage the local envi-
ronment as it is easily cultivated.32 In fact, ethanol extracts of 
ginger  have  shown  sufficient  antifungal  activity  to  suggest 
potential for use in agriculture as one of several natural alterna-
tives to conventional synthetic pesticides, which would protect 
the  environment  and  human  health.33  Nevertheless,  in  an 
industry in which there is much money to be made by growers 
from  a  cash  crop  such  as  ginger,  environmental  concerns  are 
often supplanted by bottom-line financial interests.

 FORMULATION CONSIDERATIONS

The  constituents  of  ginger  vary  by  region  and  whether  the 
rhizomes  are  fresh  or  dry.11  The  CO2  extracts  of  ginger  have 
the  most  abundant  polyphenolic  content  and  most  closely 
resemble the composition of the Z. officinale rhizome.32

 USAGE CONSIDERATIONS

Ginger  is one  of the several  commonly used herbs, including 
feverfew, garlic, ginkgo, and ginseng, which may contribute to 
bleeding during surgical procedures.34

 SIGNIFICANT BACKGROUND

Ginger is one of the most widely used herbs on the planet as a 
flavoring agent in food and for numerous medical indications. 
It exerts potent antioxidant activity, attenuating or preventing 
the formation of reactive oxygen species (ROS) and is known 
to  impart  anti-inflammatory,  antiapoptotic,  antitumorigenic, 
antihyperglycemic,  antilipidemic,  antiemetic,  and  immu-
nomodulatory activity.11

Antioxidant and Anti-inflammatory Activity
The phenol [6]-gingerol displayed strong antioxidant activity in 
1994 as ascertained by Aeschbach et al., who showed that the 
compound inhibited phospholipid peroxidation brought on by 
the FeCl3-ascorbate system.17,35

In a 2010 study by Dugasani et al. of the in vitro activities of 
[6]-gingerol, [8]-gingerol, [10]-gingerol, and [6]-shogaol in scav-
enging  1,1-diphenyl-2-picyrlhydrazyl  (DPPH),  superoxide,  and 
hydroxyl  radicals,  suppression  of  N-formyl-methionyl-leucyl-
phenylalanine  (f-MLP)-induced  ROS  synthesis  in  human 
polymorphonuclear  neutrophils  (PMN),  and  the  hindering  of 
lipopolysaccharide-induced nitrite and prostaglandin E2 production 
in RAW 264.7 cells, [6]-shogaol displayed the strongest antioxi-
dant  and  anti-inflammatory  characteristics,  with  [10]-gingerol 
exhibiting  the  greatest  potency  among  the  gingerols.  The 
researchers concluded that their findings buttress the use of dry 
ginger in traditional medical systems.8

Also that year, Ghasemzadeh et al. investigated the antioxi-
dant activities of methanol extracts from the leaves, stems, and 
rhizomes of two Z. officinale varieties. Using various assays, they 
determined that Halia Bara possessed higher phenolic and flavo-
noid  concentrations  and  exhibited  higher  antioxidant  activity 
than Halia Bentong. Their findings supported the potential med-
ical  applications  of  Z.  officinale  (Halia  Bara)  leaves  and  young 
rhizomes.32

 
200 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Previously, Minghetti et al. investigated the ex vivo skin per-
meation and in vivo topical anti-inflammatory activity of a com-
mercial ginger dry extract and a gingerols-enriched dry extract in 
mice.  Both  extracts  dose-dependently  reduced  ear  edema 
induced by Croton oil, though the enriched extract was slightly 
less potent. Medicated plasters, with 1 mg/cm2 of either extract, 
displayed anti-inflammatory properties and the enriched extract 
permeated through mouse skin (22.1 μg/cm2) as well as human 
epidermis  (6.9  μg/cm2).  The  investigators  concluded  that  the 
anti-inflammatory  effects  of  the  extracts  noted  in  mice  could 
also be delivered in human skin.18

In addition, crude extracts of Z. officinale have been shown to 
diminish  rat  paw  and  skin  edema  provoked  by  carrageenan, 
48/80  compound,  and  serotonin.36  The  substantial  antioxidant 
potency and anti-inflammatory properties ascribed to ginger are 
thought to play important roles in exerting photoprotective and 
chemopreventive activity.

Photoprotection
In  2006,  Tsukahara  et  al.  studied  the  role  of  elastase  in 
UV-induced wrinkle formation by evaluating the effects of gin-
ger extract. They found that topically applying the extract to 
rat hind limb skin or hairless mouse dorsal skin strongly sup-
pressed wrinkle development engendered by chronic ultravio-
let B (UVB) exposure at a suberythemal dose. The concomitant 
reduction  in  skin  elasticity  that  accompanies  such  exposure 
was  also  significantly  prevented,  as  the  elasticity  of  rat  hind 
limb skin was maintained. The authors concluded that herbal 
extracts  with  the  demonstrated  capacity  to  hinder  fibroblast-
derived elastase, which is key in UVB-induced wrinkle forma-
tion, represent potentially effective antiwrinkling agents.23

In vitro and in vivo experiments were conducted by Kim et al. 
in 2007 to characterize the antioxidant, anti-inflammatory, and 
antiapoptotic  activities  of  the  ginger  extract  [6]-gingerol. 
Pretreatment with the phenolic lowered,  in  vitro, UVB-induced 
intracellular  ROS  levels,  as  well  as  the  activation  of  caspase-3, 
caspase-8, and caspase-9, Fas expression, and the expression and 
transactivation  of  COX-2.  In  vivo,  the  topical  application  of 
[6]-gingerol to hairless mice before UVB exposure led to the sup-
pression of COX-2 mRNA induction and nuclear factor-κB (NF-κB) 
translocation.  The  researchers  concluded  that  [6]-gingerol 
shows  potential  as  a  photoprotective  agent  against  cutaneous 
disorders caused by UVB exposure.15 In a separate study, by Pan 
et  al.,  [6]-shogaol  was  shown  to  downregulate  inflammatory 
inducible nitric oxide synthase (iNOS) and COX-2 gene expres-
sion  in  murine  macrophages  by  suppressing  the  activation  of 
NF-κB.37

The  next  year,  Imokawa  reported  that  a  one-year  clinical 
study on human facial skin revealed that a water-soluble ginger 
extract blocked the UV-induced reduction in skin elasticity, by 
inhibiting  fibroblast-derived  elastase,  and  prevented  or  dimin-
ished wrinkle formation in periorbital skin without altering stra-
tum corneum water content.38

In 2010, Guahk et al. reported that Z. officinale exerts protec-
tion  of  the  human  keratinocyte  cell  line  HaCaT  in  vitro  and 
C57BL/6 mice in vivo from inflammation induced by UVB expo-
sure and, therefore, warrants consideration as a photoprotective 
anti-inflammatory agent.39

In  a  2013  study  of  the  protection  conferred  against  UVB-
induced DNA damage and cytotoxicity by 15 Thai herb species, 
Thongrakard et al. found that the greatest UV absorption was 
associated with the dichloromethane extract of ginger and etha-
nol extract of turmeric (see Chapter 69, Turmeric). Both extracts 

promoted the production of the antioxidant protein thioredoxin 1 
and the investigators concluded that the herbs exhibit potential 
to  protect  human  keratinocytes  from  UV-induced  harm  thus 
warranting use in photoprotective cosmetic agents.40

Anticarcinogenic Activity
The  anticarcinogenic  activity  of  ginger  has  emerged  as  the 
most  compelling  area  of  investigation.  The  pungent  phenolic 
substance  [6]-paradol  (1-[4′-hydroxy-3′-methoxyphenyl]-3-
decanone) has been identified as the component most respon-
sible for inhibiting tumor activity in skin cancer of mice. Other 
structurally-related derivatives, in addition to [6]-paradol, have 
been shown to induce apoptosis through a mechanism depend-
ent  on  caspase-3.17,41  Both  [6]-paradol  and  the  structurally- 
related [6]-gingerol, acting through different mechanisms, have 
been shown to inhibit epidermal growth factor (EGF)-induced 
cell transformation.42

In one of the earlier investigations into the effects of ginger 
extract  on  skin  tumorigenesis  in  mice,  Katiyar  et  al.  topically 
applied an ethanol extract of ginger to the skin of SENCAR mice, 
which  significantly  and  dose-dependently  suppressed  12- 
O-tetradecanoylphorbol-13-acetate  (TPA)-induced  epidermal 
ornithine decarboxylase (ODC), COX, and lipoxygenase activities 
as well as ODC mRNA expression. Ginger extract pretreatment 
also led to substantial suppression of TPA-generated epidermal 
edema  and  hyperplasia.  Ginger-treated  mice  also  displayed 
significantly  lower  tumor  incidence  than  controls  after 
7,12-dimethylbenz[a]anthracene  (DMBA)  tumor  initiation  and 
TPA  tumor  promotion.  These  findings,  the  investigators 
concluded, represented the first clear evidence that ginger extract 
protects against skin tumor promotion.21

In a two-stage mouse model, Park et al. showed in 1998 that 
the topical application of [6]-gingerol onto the shaved backs of 
female  ICR  mice  before  topical  doses  of  the  tumor  promoter 
TPA significantly suppressed skin papillomagenesis induced by 
DMBA. TPA-induced epidermal ODC activity and inflammation 
were  also  inhibited  by  the  ginger  constituent.17  Many  of  the 
same  investigators  reported  on  similar  findings  the  following 
year, also including [6]-paradol along with [6]-gingerol as exhibiting 
potential chemopreventive properties. In this study, both ginger 
substances were topically applied to female ICR mice in the two-
stage  carcinogenesis  model  using  TPA  and  DMBA  and  were 
found to suppress TPA-stimulated inflammation, tumor necrosis 
factor (TNF)-α synthesis, as well as epidermal ODC activity. In a 
separate investigation by the same team, both compounds also 
inhibited  superoxide  production  spurred  by  TPA  in  differenti-
ated HL-60 cells.41

In 2001, Bode et al. offered the first evidence that [6]-gingerol 
and  [6]-paradol  hinder  EGF-induced  cell  transformation,  thus 
blocking  a  critical  pathway  in  tumor  formation.42  Two  years 
later, Bode et al. reported a chemopreventive effect after admin-
istering 500 mg of [6]-gingerol or a placebo to athymic nude mice 
three  times  weekly  for  two  weeks  before  injecting  them  with 
human  colon  cancer  cells.  Administering  the  ginger  extract  or 
placebo was resumed then, with the investigators finding that it 
took  longer  for  tumors  to  emerge  and  grow  in  the  gingerol-
treated animals.43

In 2004, Kim et al. demonstrated that the topical application 
of  [6]-gingerol  blocks  phorbol  12-myristate  13-acetate  (also 
known  as  12-O-tetradecanoylphorbol-13-acetate)-induced 
COX-2 expression, which is targeted by several anti-inflammatory 
and chemopreventive agents. In addition, [6]-gingerol inhibited 
NF-κB  DNA  binding  activity  in  mouse  skin  as  well  as  the 

 
phosphorylation of p38 mitogen-activated protein (MAP) kinase, 
which the authors cited as a possible explanation for the impact 
of [6]-gingerol on NF-κB and its inhibition of COX-2 expression.24 
In 2005, many of the same investigators showed that [6]-gingerol 
suppressed  TPA-induced  COX-2  expression  in  TPA-treated 
mouse skin in vivo by hindering the p38 MAP kinase-NF-κB sign-
aling pathway.7

In 2009, Nigam et al. found that [6]-gingerol evinced signifi-
cant  cytotoxicity  in  human  epidermoid  carcinoma  A431  cells, 
engendering  ROS  increases  that  provoked  reductions  in  mito-
chondrial  membrane  potential  and  apoptosis.  Treatment  with 
[6]-gingerol  also  yielded  an  upregulation  of  cytochrome-c  and 
apoptotic  protease-activating  factor  (Apaf)-1,  spurring  the  cas-
pase  cascade,  which  plays  an  essential  role  in  apoptosis.  The 
investigators  concluded  that  [6]-gingerol  warrants  attention  as  
a potentially effective agent in treating skin cancer.14 In a study 
the  following  year,  Nigam  et  al.  topically  treated  mice  with 
[6]-gingerol before inducing skin tumorigenesis through 32 weeks 
of  exposure  to  benzo[a]pyrene  (B[a]P).  Pretreatment  with  the 
ginger component yielded delays in the onset of tumorigenesis, 
decreased cumulative tumors, and lower tumor volume. B[a]P- 
suppressed  p53  levels  were  augmented  by  [6]-gingerol,  which 
also aided in the release of cytochrome-c, activation of caspases, 
and  the  increase  in  Apaf-1,  thus  inducing  apoptosis.  These 
results  further  support  the  investigators’  claims  regarding  the 
chemopreventive activity of [6]-gingerol.44

Other components of ginger have also been investigated. In 
2004, Murakami et al. showed that zerumbone, a sesquiterpene 
present in the tropical ginger species Zingiber zerumbet, inhibits 
skin tumor initiation with DMBA and promotion by TPA in ICR 
mice by inducing antioxidative and phase II drug metabolizing 
enzymes  and  interrupting  proinflammatory  signaling  path-
ways.45 In 2011, Shin et al. investigated the effects on mice of 
topically applied zerumbone, previously found to block chemi-
cally-induced  papilloma  formation  in  mouse  skin.  They  found 
that  the  ginger  component  upregulated  the  expression  of  the 
protein heme oxygenase-1 (HO-1) through activation of NF-E2-
related factor 2 (Nrf2) signaling, which the researchers suggested 
provided an explanation for the inhibitory effect on skin carcino-
genesis exhibited by zerumbone in mice.46

In addition, the tropical ginger-derived compound 1’-acetoxy-
chavicol acetate has exhibited the capacity to inhibit skin tumori- 
genesis in K5.Stat3C mice.47

The anticarcinogenic effects of ginger have also been seen in 
Chinese herbal medicine. The methanolic extract of Alpinia oxy-
phylla, a member of the Zingiberaceae family, has been found to 
suppress mouse skin tumor promotion and noted for inducing 
apoptosis in cultured human promyelocytic leukemia cells.48 It is 
speculated that the antitumor activity of the phenolic diarylhep-
tanoids derived from A. oxyphylla are linked to its anti-inflamma-
tory characteristics.48

Wound Healing
In 2009, Bhagavathula et al. topically treated hairless rats for a 
21-day period with a combination of 10 percent curcumin and 
3 percent ginger extract or with each agent alone. For another 
15 days, investigators treated the animals with the corticoster-
oid  Temovate.  Superficial  abrasions  were  then  induced  in 
treated skin, with healing occurring sooner in skin pretreated 
with either curcumin or ginger extract alone or in combination 
as  compared  to  skin  treated  only  with  the  corticosteroid  and 
vehicle alone. The investigators analyzed skin samples taken at 
wound closure, finding an increase in collagen production and 

C H A P T E R  59  ■   G I N G E R  

201

decrease in matrix metalloproteinase-9 in the skin treated with 
the herbal ingredients compared to the skin treated with corti-
costeroid and vehicle. The investigators concluded that a com-
bination of curcumin and ginger extract may have an adjuvant 
role to play in wound healing.30

In 2012, Chen et al. demonstrated that 10-shogaol, an active 
ingredient in ginger, exhibited potent radical scavenging activity 
when tested with the DPPH radical. It was also shown to foster 
human  normal  epidermal  keratinocyte  and  dermal  fibroblast 
production as well as the synthesis of multiple growth factors 
and the migration of keratinocytes and fibroblasts in an in vitro 
wound-healing assay.9

Skin Lightening
Ginger may have yet another indication. Huang et al. showed 
in  2011  that  [6]-gingerol  dose-dependently  inhibited  murine 
tyrosinase activity and lowered melanin as well as ROS levels. 
They concluded that [6]-gingerol is an effective suppressor of 
melanogenesis of B16-F10 melanoma cells and merits attention 
as a skin-lightening agent.49

 CONCLUSION

The long history of traditional use and well-established safety 
profile of ginger make the herb a strong candidate for extensive 
research  regarding  its  inclusion  in  drugs  and  cosmeceuticals. 
New data on the anticarcinogenic potential of ginger appears 
especially promising, but the overall antitoxic properties of the 
perennial herb may very well position ginger to be a key new 
ingredient in a wider array of skin care products. As is often the 
case, more randomized, placebo-controlled studies are needed 
to  substantiate  the  dermatologic  uses  of  popular  botanical 
ingredients  such  as  ginger.  Nevertheless,  its  broad  biologic 
activity  has  been  clearly  demonstrated  and  the  antioxidant, 
anti-inflammatory,  and  chemopreventive  properties  mani-
fested by ginger extracts indicate potential for topical dermato-
logic uses.

REFERENCES

1.  Shukla Y, Singh M. Cancer preventive properties of ginger: A brief 

review. Food Chem Toxicol. 2007;45:683.

2.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy:  Modern 

Herbal Medicine. London: Churchill Livingstone; 2000:394.

3.  Ficker CE, Arnason JT, Vindas PS, et al. Inhibition of human path-
ogenic fungi by ethnobotanically selected plant extracts. Mycoses. 
2003;46:29.

4.  Akoachere JF, Ndip RN, Chenwi EB, et al. Antibacterial effect of 
Zingiber officinale and Garcinia kola on respiratory tract patho-
gens. East Afr Med J. 2002;79:588.

5.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 
Medicine. Rochester, VT: Healing Arts Press; 2003:493, 501, 502, 
520, 597.

6.  Baliga MS, Haniadka R, Pereira MM, et al. Update on the chemo-
preventive effects of ginger and its phytochemicals. Crit Rev Food 
Sci Nutr. 2011;51:499.

7.  Kim SO, Kundu JK, Shin YK, et al. [6]-Gingerol inhibits COX-2 
expression  by  blocking  the  activation  of  p38  MAP  kinase  and 
NF-kappaB  in  phorbol  ester-stimulated  mouse  skin.  Oncogene. 
2005;24:2558.

8.  Dugasani S, Pichika MR, Nadarajah VD, et al. Comparative anti-
oxidant and anti-inflammatory effects of [6]-gingerol, [8]-gingerol, 
[10]-gingerol  and  [6]-shogaol.  J  Ethnopharmacol.  2010;127: 
515.

9.  Chen CY, Cheng KC, Chang AY, et al. 10-Shogaol, an antioxidant 
from Zingiber officinale for skin cell proliferation and migration 
enhancer. Int J Mol Sci. 2012;13:1762.

 
202 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

10.  Afzal M, Al-Hadidi D, Menon M, et al. Ginger: An ethnomedical, 
chemical and pharmacological review. Drug Metabol Drug Interact. 
2001;18:159.

11.  Ali BH, Blunden G, Tanira MO, et al. Some phytochemical, phar-
macological and toxicological properties of ginger (Zingiber offic-
inale  Roscoe):  A  review  of  recent  research.  Food  Chem  Toxicol. 
2008;46:409.

12.  Haghighi M, Khalvat A, Toliat T, et al. Comparing the effects of 
ginger (Zingiber officinale) extract and ibuprofen on patients with 
osteoarthritis. Arch Iran Med. 2005;8:267.

13.  Abbasi  AM,  Khan  MA,  Ahmad  M,  et  al.  Ethnopharmacological 
application of medicinal plants to cure skin diseases and in folk 
cosmetics among the tribal communities of North-West Frontier 
Province, Pakistan. J Ethnopharmacol. 2010;128:322.

14.  Nigam N, Bhui K, Prasad S, et al. [6]-Gingerol induces reactive oxy-
gen species regulated mitochondrial cell death pathway in human 
epidermoid carcinoma A431 cells. Chem Biol Interact. 2009;181:77.

15.  Kim JK, Kim Y, Na KM, et al. [6]-Gingerol prevents UVB-induced 
ROS production and COX-2 expression in vitro and in vivo. Free 
Radic Res. 2007;41:603.

16.  Surh  Y.  Molecular  mechanisms  of  chemopreventive  effects  of 
selected  dietary  and  medicinal  phenolic  substances.  Mutat  Res. 
1999;428:305.

17.  Park KK, Chun KS, Lee JM, et al. Inhibitory effects of [6]-gingerol, 
a  major  pungent  principle  of  ginger,  on  phorbol  ester-induced 
inflammation,  epidermal  ornithine  decarboxylase  activity  and 
skin tumor promotion in ICR mice. Cancer Lett. 1998;129:139.
18.  Minghetti P, Sosa S, Cilurzo F, et al. Evaluation of the topical anti-
inflammatory  activity  of  ginger  dry  extracts  from  solutions  and 
plasters. Planta Med. 2007;73:1525.

19.  Reddy AC, Lokesh BR. Studies on spice principles as antioxidants 
in the inhibition of lipid peroxidation of rat liver microsomes. Mol 
Cell Biochem. 1992;111:117.

20.  Krishnakantha TP, Lokesh BR. Scavenging of superoxide anions 

by spice principles. Indian J Biochem Biophys. 1993;30:133.

21.  Katiyar SK, Agarwal R, Mukhtar H. Inhibition of tumor promo-
tion in SENCAR mouse skin by ethanol extract of Zingiber offici-
nale rhizome. Cancer Res. 1996;56:1023.

22.  Kiuchi F, Iwakami S, Shibuya M, et al. Inhibition of prostaglandin 
and leukotriene biosynthesis by gingerols and diarylheptanoids. 
Chem Pharm Bull (Tokyo). 1992;40:387.

23.  Tsukahara K, Nakagawa H, Moriwaki S, et al. Inhibition of ultra-
violet-B-induced  wrinkle  formation  by  an  elastase-inhibiting 
herbal  extract:  Implication  for  the  mechanism  underlying 
elastase-associated wrinkles. Int J Dermatol. 2006;45:460.

24.  Kim  SO,  Chun  KS,  Kundu  JK,  et  al.  Inhibitory  effects  of  [6]- 
gingerol  on  PMA-induced  COX-2  expression  and  activation  of 
NF-kappaB and p38 MAPK in mouse skin. Biofactors. 2004;21:27.

25.  Ringdahl  E,  Pandit  S.  Treatment  of  knee  osteoarthritis.  Am  Fam 

Physician. 2011;83:1287.

26.  Zahmatkash M, Vafaeenasab MR. Comparing analgesic effects of 
a topical herbal mixed medicine with salicylate in patients with 
knee osteoarthritis. Pak J Biol Sci. 2011;14:715.

27.  Altman  RD,  Marcussen  KC.  Effects  of  a  ginger  extract  on  knee 
pain in patients with osteoarthritis. Arthritis Rheum. 2001;44:2531.
28.  Leach MJ, Kumar S. The clinical effectiveness of ginger (Zingiber 
officinale)  in  adults  with  osteoarthritis.  Int  J  Evid  Based  Healthc. 
2008;6:311.

29.  Miao  Y,  Sun  Y,  Wang  W,  et  al.  6-Gingerol  inhibits  hair  shaft 
growth  in  cultured  human  hair  follicles  and  modulates  hair 
growth in mice. PLoS One. 2013;8:e57226.

30.  Bhagavathula N, Warner RL, DaSilva M, et al. A combination of 
curcumin and ginger extract improves abrasion wound healing in 
corticosteroid-impaired  hairless  rat  skin.  Wound  Repair  Regen. 
2009;17:360.

31.  Kanerva  L,  Estlander  T,  Jolanki  R.  Occupational  allergic  contact 

dermatitis from spices. Contact Dermatitis. 1996;35:157.

32.  Ghasemzadeh  A,  Jaafar  HZ,  Rahmat  A.  Antioxidant  activities, 
total phenolics and flavonoids content in two varieties of Malaysia 
young ginger (Zingiber officinale Roscoe). Molecules. 2010;15:4324.
33.  Al-Samarrai  G,  Singh  H,  Syarhabil  M.  Evaluating  eco-friendly 
botanicals (natural plant extracts) as alternatives to synthetic fun-
gicides. Ann Agric Environ Med. 2012;19:673.

34.  Pribitkin ED, Boger G. Herbal therapy: What every facial plastic 

surgeon must know. Arch Facial Plast Surg. 2001;3:127.

35.  Aeschbach  R,  Löliger  J,  Scott  BC,  et  al.  Antioxidant  actions  of 
thymol,  carvacrol,  6-gingerol,  zingerone  and  hydroxytyrosol. 
Food Chem Toxicol. 1994;32:31.

36.  Penna  SC,  Medeiros  MV,  Aimbire  FS,  et  al.  Anti-inflammatory 
effect of the hydralcoholic extract of Zingiber officinale rhizomes 
on rat paw and skin edema. Phytomedicine. 2003;10:381.

37.  Pan MH, Hsieh MC, Hsu PC, et al. 6-Shogaol suppressed lipopol-
ysaccharide-induced  up-expression  of  iNOS  and  COX-2  in 
murine macrophages. Mol Nutr Food Res. 2008;52:1467.

38.  Imokawa G. Recent advances in characterizing biological mecha-
nisms  underlying  UV-induced  wrinkles:  A  pivotal  role  of  fibro-
blast-derived elastase. Arch Dermatol Res. 2008;300(Suppl 1):7.
39.  Guahk  GH,  Ha  SK,  Jung  HS,  et  al.  Zingiber  officinale  protects 
HaCaT cells and C57BL/6 mice from ultraviolet B-induced inflam-
mation. J Med Food. 2010;13:673.

40.  Thongrakard V, Ruangrungsi N, Ekkapongpisit M, et al. Protection 
from  UVB  toxicity  in  human  keratinocytes  by  Thailand  native 
herbs extracts. Photochem Photobiol. 2013 Aug 12. [Epub ahead of 
print].

41.  Surh YJ, Park KK, Chun KS, et al. Anti-tumor-promoting activities 
of  selected  pungent  phenolic  substances  present  in  ginger.  
 J Environ Pathol Toxicol Oncol. 1999;18:131.

42.  Bode AM, Ma WY, Surh YJ, et al. Inhibition of epidermal growth 
factor-induced cell transformation and activator protein 1 activa-
tion by [6]-gingerol. Cancer Res. 2001;61:850.

43.  Burton  A.  Chemoprevention:  Eat  ginger,  rub  on  pomegranate. 

Lancet Oncol. 2003;4:715.

44.  Nigam N, George J, Srivastava S, et al. Induction of apoptosis by 
[6]-gingerol associated with the modulation of p53 and involve-
ment of mitochondrial signaling pathway in B[a]P-induced mouse 
skin tumorigenesis. Cancer Chemother Pharmacol. 2010;65:687.
45.  Murakami A, Tanaka T, Lee JY, et al. Zerumbone, a sesquiterpene 
in subtropical ginger, suppresses skin tumor initiation and promo-
tion stages in ICR mice. Int J Cancer. 2004;110:481.

46.  Shin JW, Ohnishi K, Murakami A, et al. Zerumbone induces heme 
oxygenase-1 expression in mouse skin and cultured murine epi-
dermal  cells  through  activation  of  Nrf2.  Cancer  Prev  Res  (Phila). 
2011;4:860.

47.  Batra V, Syed Z, Gill JN, et al. Effects of the tropical ginger com-
pound,  1’-acetoxychavicol  acetate,  against  tumor  promotion  in 
K5.Stat3C transgenic mice. J Exp Clin Cancer Res. 2012;31:57.
48.  Chun KS, Park KK, Lee J, et al. Inhibition of mouse skin tumor 
promotion  by  anti-inflammatory  diarylheptanoids  derived  from 
Alpinia oxyphylla Miquel (Zingiberaceae). Oncol Res. 2002;13:37.
49.  Huang HC, Chiu SH, Chang TM. Inhibitory effect of [6]-gingerol 
on melanogenesis in B16F10 melanoma cells and a possible mech-
anism of action. Biosci Biotechnol Biochem. 2011;75:1067.

 
C H A P T E R  60  ■   H O N E Y / P R O P O L I S / R OYA L   J E L LY  

203

C H A P T E R   6 0

Honey/Propolis/Royal Jelly

Activities:

Analgesic, antioxidant, anti-inflammatory, 
antimicrobial, antitumor, antiseptic, antipyretic, 
antiulcer,1 hepatoprotective, immunomodulatory2

Important Chemical Components:

Honey: Hydrogen peroxide, lysozyme, polyphenols, 
phenolic acids, flavonoids, methylglyoxal, ascorbic 
acid, α-tocopherol, carotenoids, glucose oxidase, 
catalase, and bee peptides3
Propolis: Flavonoids (e.g., galangin, chrysin, pinocembrin, 
quercetin),4 phenolic acids and their esters (particularly 
caffeic acid phenethyl ester),5 cinnamic acid derivatives 
(i.e., drupanin, baccharin, and artepillin C), sesquiterpene 
quinones, coumarins, amino acids, and steroids1
Royal Jelly: 10-hydroxy-2-decenoic acid (10-HDA), 
water, proteins, free amino acids, carbohydrates, lipids, 
minerals, and vitamins

Origin Classification:

All  of  these  ingredients  used  in  skin  care  are  natural 
products of bees.

Personal Care Category:

Antioxidant,  antiaging,  photoprotection,  antiseptic, 
wound healing

Recommended  for  the  following  Baumann  Skin 
Types:

DRNT,  DRNW,  DRPT,  DRPW,  DSNW,  DSPW,  ORNT, 
ORNW, ORPT, ORPW, OSNW, and OSPW

 SOURCE

Honeybees, Apis mellifera, play an important but often underap-
preciated role in our lives (Figure 60-1). Human beings rely on 
bees  for  pollinating  approximately  one-third  of  our  crops, 
including  numerous  fruits,  vegetables,  nuts,  and  seeds.6,7  Of 
course, they also play a pivotal role in the propagation of other 
plants,  flower  nectar,  and  flower  pollen.  A.  mellifera,  the 
European  honeybee,  is  the  primary  pollinator  in  Europe  and 
North America but other species, including A. cerana, A. dorsata, 
A. floria, A. andreniformis, A. koschevnikov, and A. laborisa produce 
honey.8 Further, the honeybee is the only insect that produces 
food consumed by human beings.3

Honey is a sweet food product produced by honeybees from 
flower nectar. It contains over 180 substances and is supersatu-
rated in sugar, though it also contains phenolic acids, flavonoids, 
ascorbic  acid,  α-tocopherol,  carotenoids,  the  enzymes  glucose 
oxidase and catalase, organic and amino acids, and proteins.9 In 
Ayurvedic medicine, honey has been used to treat diabetes since 
ancient times.8 It has also been used for millennia to treat infected 

wounds.10 For dermatologic purposes, honey has and continues 
to be used in Ayurvedic medicine to treat acne, and is also used 
in  cosmetic  formulations  such  as  facial  washes,  skin 
moisturizers, and hair conditioners.8

Propolis is a yellowish-green to dark brown resinous material 
that  originates  in  the  buds  and  barks  of  various  plant  sources, 
mostly poplar trees,1,11,12 and is gathered by honeybees and used 
in  the  construction  and  maintenance  of  their  hives.13,14  The 
sources of propolis can vary widely by region and even season, 
however. In all cases, propolis, used to seal holes and trap preda-
tors,  stabilizes  bee  hives  and  honeycombs  and  protects  bees 
against cold weather and potential intruders.11 Also known as bee 
glue, this extract from bee hives has been used for hundreds of 
years in naturopathic medicine and is known to display biologic 
and pharmacologic properties. In traditional medicine, it has been 
used for its purported antioxidant, anticancer, anti-inflammatory, 
and  immunomodulatory  effects.15  Currently,  some  radiation 
therapists use propolis to treat actinic stomatitis and mucositis,11 
but this bee product is used more often for wound care and minor 
cutaneous  indications  as  well  as  a  dietary  supplement.  It  is 
believed to contain as many as 300 constituents, including resin, 
wax, essential oils, pollen, and organic substances such as phe-
nolic  acids  and  their  esters,  particularly  caffeic  acid  phenethyl 
ester (CAPE), flavonoids, terpenes, β-steroids, aromatic aldehydes 
and alcohols, sesquiterpenes, and stilbene terpenes.1,9

Royal  jelly,  a  yellowish,  viscous  secretion  from  the 
hypopharyngeal  and  mandibular  glands  of  worker  bees  that 
nourishes bee larvae of all kinds (i.e., drones, workers, queens) 
after  which  it  becomes  the  exclusive  nourishment  for  queens 
throughout  their  development,  has  been  used  by  humans  for 
centuries for its health-promoting characteristics.16–18 Antitumor, 
antihypercholesterolemic, antibacterial, anti-inflammatory, anti-
oxidant, antiangiogenetic, collagen production-promoting, estro-
genic,  hypotensive,  immunomodulatory,  vasodilative,  and 
wound-healing activity have been linked to royal jelly.9,18–22

 HISTORY

Honey, propolis, and royal jelly have all been used for medici-
nal purposes since ancient times, with honey, the earliest bee 
product  discovered,  particularly  known  for  its  use  in  wound 
healing.3,9,11,12,14,23,24 In fact, the topical application of honey for 
various  conditions  has  been  a  common  traditional  medical 
practice for at least 2,700 years, which many researchers have 
retrospectively  attributed  to  its  antibacterial  properties.3,25  Of 
course, the antiseptic and antimicrobial properties of honey are 
recent discoveries,3 with the antibacterial properties of honey 
reported in 1892 (as cited by Dustmann in 1919).26

In folk remedies, honey has served as a potent anti-inflamma-
tory  and  antibacterial  agent  and  its  use  dates  back  to  ancient 
Egypt  [it  was  even  found  in  the  tomb  of  King  Tutankhamun 
(better  known  as  King  Tut)],  Greece,  and  Rome,  with  the  bee 
products mentioned in writings in Egypt, India, and China dating 
back to 5500 BCE.3,11,12,27,28 Honey has been used in Ayurvedic 

 
204  

C o s m eC e u t i C a l s   a N D   Co s m e t i C   i N g r e D i e N t s

FIGURE 60-1  Glandular secretions of the honeybee. Reprinted with permission from Israili Z. Antimicrobial properties of Honey. Am J Ther 2013. doi: 

▶
10.1097/MJT.0b013e318293b09b, accessed May 2014.

medicine  for  at  least  4,000  years.3  The  use  of  honey  to  treat 
wounds  was  practiced  in  China  during  the  Xin  dynasty  (circa 
2000 BCE), and ancient physicians (the Greeks Hippocrates and 
Dioscorides,  Romans  Celsus  and  Galen,  and  Arabs  El  Mad 
Joussy and El Basry) are said to have cited the healing qualities of 
honey.3  Abu  Ali  bin  Sina  (Latinized  as  Avicenna),  a  leading 
Persian doctor and scholar circa 11th century CE, wrote of using 
cooked  honey  and  myrrh  to  decrease  exudates  from  wounds 
contributing to partial tissue loss.1,29 More recent uses of honey 
in  medicine  hewed  to  wound  treatment,  including  gunshot 
wounds in the 17th and 18th centuries (it was an official drug in 
London  pharmacopoeias  in  the  17th  century)5,30  and  through 
World War I usage by the Russians and Germans.29,31,32 Not until 
the discovery of antibiotics in the 1940s did the traditional med-
ical use of honey begin to wane.29,33

The  word  “propolis”  is  derived  from  the  Greek  words  pro 
(before)  and  polis  (city),  which  reflects  the  ancient  observation 
that bees built walls of the substance near the entrance of their 
hives.5,12,14,34,35  It  was  considered  the  third  natural  product  of 
bees (in addition to honey and wax). Ancient Egyptians, making 
use of the antiputrefactive activity of bee glue, used propolis to 
embalm their dead.34,35 The Greek philosopher Aristotle wrote 
about  the  basic  characteristics  of  propolis  in  his  work  Historia 
Animalium over 2,000 years ago, with recordings of its use dating 
back  to  at  least  300  BCE;  its  use  in  medical  applications  was 
covered by Alexander of Tralles in the 6th century CE.11,14,34

Propolis  has  been  used  for  centuries  in  folk  medicine  in 
Europe,  the  Americas,  China,  and  Japan.1  In  traditional  medi-
cine,  propolis  was  most  successful  in  treating  a  wide  range  of 
wounds  because  of  its  antiedematous  and  anti-infectious 
properties.  Propolis  was  also  used  in  the  ancient  world  for 
muscle, tendon, and joint pain. In addition, bee glue was used to 
treat cutaneous conditions such as lichens and condylomata.11 In 
more recent times, propolis was used to treat wounds during the 
Anglo-Boer war between 1899 and 1902 as well as World War II, 
and  was  an  accepted  medical  ingredient  in  the  former  Soviet 
Union  as  recently  as  1969.1  Other  indications  have  included 
burns,  sore  throat,  and  stomach  ulcers.36  In  fact,  propolis  has 
continued  to  be  a  popular  therapeutic  choice  in  the  Balkan 

countries  of  Southeast  Europe  for  these  indications  and  it  is 
marketed  in  some  European  countries  for  the  treatment  of 
prostate hyperplasia.37

Modern  studies  of  the  medicinal  benefits  of  propolis  are 
traced to Stan Scheller in 1960s Poland, where the study of its 
biological characteristics by way of a novel approach to delivering 
hydrophobic ethanol extracts of propolis into aqueous solutions 
led  to  the  identification  of  antioxidant,  antibacterial,  immu-
nostimulating, and radioprotective qualities.38

The  “queen  substance”  9-oxo-2-decenoic  acid  (9-ODA),  a 
queen honeybee pheromone, was isolated from queen honey-
bee mandibular glands by Butler et al. in 1961.39,40 Johnston et al. 
found in 1965 that this minor component of royal jelly rapidly 
metabolizes into 9-hydroxy-2-decenoic acid (9-HDA), a precur-
sor to royal jelly that stabilizes swarm activity.39,41,42 Royal jelly 
is now used in cosmetics, dietary supplements, and beverages. 
Particularly  in  Asia,  it  is  deployed  as  a  health  tonic.17,43  Royal 
jelly  has  also  exhibited  effectiveness  in  alleviating  chilliness  in 
young women.44.

 CHEMISTRY

The  myriad  biological  functions  associated  with  honey  (e.g., 
antibacterial,  antioxidant,  antitumor,  anti-inflammatory,  anti-
browning, and antiviral), propolis (e.g., antitumor, antioxidant, 
antimicrobial,  anti-inflammatory,  and  immunomodulatory), 
and royal jelly (e.g., antibacterial, anti-inflammatory, vasodila-
tive,  hypotensive,  disinfectant,  antioxidant,  antihypercholes-
terolemic, and antitumor) are chiefly ascribed to the plethora of 
phenolic  compounds,  such  as  flavonoids,  found  in  these  bee 
products  (Table  60-1).9  The  flavonoid  chrysin  is  present  in 
honey and propolis and is thought to play a key role in confer-
ring anti-inflammatory activity.9

Honey itself contains carbohydrates, proteins, 18 free amino 
acids  (of  which  proline  is  the  most  abundant),  vitamins  (trace 
amounts of B2, B4, B5, B6, B11, and C), minerals (e.g., calcium, chro-
mium,  iron,  magnesium,  manganese,  phosphorus,  potassium, 
selenium, and zinc), antioxidants (primarily flavonoids, including 
pinocembrin,  which  is  found  only  in  honey  and  propolis), 

 
TABLE 60-1
Pros and Cons of Honey/Propolis/Royal Jelly

Pros
Broad biological activities

Cons
Scant data on the pharmacologic efficacy 

of topical royal jelly

Long history of traditional use

Both honey and propolis are challenging 

to standardize and formulate

Viable antibiotic alternative in cases of 
antibiotic-resistant bacterial infection 
(honey and, perhaps, propolis)

enzymes  (e.g.,  invertase,  amylase,  glucose  oxidase,  catalase, 
and acid phosphorylase), as well as acetic, butanoic, citric, for-
mic,  gluconic,  lactic,  malic,  pyroglutamic,  and  succinic 
acids.8,45,46  Medical-grade  honeys  such  as  manuka  honey  (a 
monofloral  honey  derived  from  Leptospermum  scoparium,  a 
member of the Myrtaceae family, native to New Zealand) and 
Medihoney®  (a  standardized  mix  of  Australian  and  
New Zealand honeys mainly originating from Leptospermum 
species)  are  rich  in  flavonoids.45,47–49  Honey  exhibits  a  pH 
ranging between 3.2 and 4.5, an acidity level that hinders the 
growth of many microorganisms.29,50–52

Propolis is a complex mixture of partially digested resins from 
trees  and  bees  wax,  containing  approximately  anywhere  from  
50 to 300 constituents including balsams, resins, waxes, essential 
oils, pollen, cinnamyl alcohol, flavonoids, minerals (e.g., calcium, 
copper, iodine, iron, magnesium, manganese, potassium, sodium, 
and  zinc),  as  well  as  vitamins  A,  B  (B1,  B2,  B6),  C,  and  E.1,53 
Interestingly, Tsai et al. have shown that while propolis acts as 
an  antioxidant,  it  can  also  induce  oxidative  DNA  damage  by 
producing hydrogen peroxide (H2O2). But they note that propo-
lis-treated cells display a lower level of DNA damage when chal-
lenged  with  another  oxidative  compound  (e.g.,  amoxicillin). 
They concluded that this adaptive response may play a role in 
the beneficial results associated with propolis.4 Overall, propolis 
is  thought  to  confer  significant  antioxidant  activity.  Phenolic 
compounds  (particularly  vanillic,  coumaric,  rosmarinic,  chloro-
genic, caffeic, and ferulic acids) and flavonoids such as quercetin 
are thought to account for these propolis properties, which has 
been found, according to  in  vitro and  in  vivo studies, to protect 
skin against ultraviolet (UV)-induced damage.1,35,54–58

Royal jelly, which bees produce from pollen, contains water, 
proteins (82–90 percent of which are known as the major royal 
jelly  proteins,  with  five  primary  members),  lipids,  sugars, 
carbohydrates,  free  amino  acids,  vitamins,  and  minerals.8,9,19  
Its primary unsaturated fatty acid is 10-hydroxy-2-decenoic acid 
(10-HDA), which is uniquely found in royal jelly.59 The benefits 
to  human  health  associated  with  royal  jelly  can  be  partly 
attributed to the activity of constituent lipids, primarily aliphatic 
free  fatty  acids  and  few  esters,  which  render  the  royal  jelly 
emulsion highly acidic and therefore able to impart antimicro-
bial properties.8 These royal jelly components are considered to 
function in ways that protect against skin aging, modulate the 
immune system, potentially thwart cancer development, induce 
neurogenesis, and alleviate symptoms of menopause.16

 ORAL USES

Honey is the oldest sweetener and one of the oldest foods con-
sumed  by  humans,  having  been  in  popular  usage  in  the  diet 
throughout  the  world  for  thousands  of  years.  It  never  spoils 
and was even found in edible condition in King Tut’s tomb.45 

C H A P T E R  60  ■   H O N E Y / P R O P O L I S / R OYA L   J E L LY  

205

The preservative qualities of honey have been attributed to its 
antioxidant  properties.58  Darker  honeys  (such  as  buckwheat) 
are associated with greater antioxidant activity.58

Propolis is extensively used in food and beverage products to 
boost human health.1,60 In 1995, the National Food Institute of 
Argentina  recognized  propolis  as  a  dietary  supplement.1  It  is 
typically available in capsule form.

In 1990, Fujii et al. found that orally administered royal jelly 
exhibited anti-inflammatory activity and wound-healing capac-
ity in streptozotocin-diabetic rats,61 a result supported by more 
recent  findings.62  For  instance,  in  2003,  Taniguchi  et  al.  found 
that  the  oral  administration  of  royal  jelly  hinders  the  develop-
ment of atopic dermatitis-like skin lesions in mice.63

 TOPICAL USES

In over-the-counter cosmetic formulations, honey is used pri-
marily as a moisturizing agent and in hair conditioning prod-
ucts because it has strong humectant properties. It is also used 
in home remedies for burns, wounds, eczema, and dermatitis, 
particularly in Asia.8

Propolis has been shown to have several potential topical den-
tal applications worthy of investigation. In a study of the histo-
logical effects of propolis topically applied to dental sockets and 
skin  wounds  in  rats,  a  10  percent  hydroalcoholic  solution  of 
propolis or a 10 percent hydroalcoholic solution alone were com-
pared. Examination of cutaneous wound healing and the socket 
wound after tooth extraction revealed that topical application of 
the propolis hydroalcoholic solution accelerated epithelial repair 
but had no effect on socket wound healing.64 Propolis has also 
been found to be effective in treating aphthous ulceration.65–67

There  are  several  commercially  available  products  such  as 
lotions,  creams,  shampoos,  lipsticks,  toothpastes,  and  mouth-
washes,  as  well  as  cough  syrups,  lozenges,  and  vitamins  that 
contain propolis as an active ingredient.

Wound Healing
In 2010, Majtan et al. showed that incubation with honey acti-
vated human keratinocytes to increase production of mediators 
including  cytokines  [tumor  necrosis  factor-α,  interleukin 
(IL)-1β, and transforming growth factor (TGF)-β1] and matrix 
metalloproteinase  (MMP)-9.  In  addition,  they  demonstrated 
that this increased amount of epidermal MMP-9 facilitated the 
degradation  of  collagen  type  IV  in  the  basement  membrane, 
buttressing the notion that honey has the capacity to accelerate 
wound healing.24

A 2013 systematic literature review of honey in contemporary 
wound care included 55 studies revealing that honey does appear 
to  stimulate  healing  of  burns,  ulcers,  and  other  wounds.  The 
authors were hesitant to draw many broad conclusions due to 
methodological  concerns,  but  found  that  honey  displays  anti-
bacterial activity in burn treatment and also exerts deodorizing, 
debridement,  anti-inflammatory,  and  analgesic  activity.29 
However, a search of the Cochrane Wounds Group Specialized 
Register,  the  Cochrane  Central  Register,  Ovid  Medline,  Ovid 
Embase,  and  EBSCO  CINAHL  completed  earlier  that  year  of  
25 randomized and quasi-randomized trials assessing honey in 
the  treatment  of  acute  or  chronic  wounds  found  that  honey 
might delay healing in partial- and full-thickness burns compared 
to  early  excision  and  grafting,  and  it  does  not  significantly 
enhance  healing  of  chronic  venous  leg  ulcers.68  The  authors 
suggested  that  while  honey  may,  indeed,  prove  to  be  more 
effective than some conventional dressings, there is insufficient 
evidence to support this claim.

 
206 

CO SmE C EuT I C A L S   A N D   CO SmE T I C   INgR E D I E N T S

Propolis has also been found to exert a wound-healing effect. 
In 2002, Pachalski et al. assessed the use of propolis in treating the 
skin of the stumps of 156 patients rehabilitating after lower limb 
amputation (55 upper leg and 101 lower leg). Patients were treated 
twice  daily  with  4  percent  propolis  ointment  for  seven  days. 
Treatment  was  extended  to  14  days  in  cases  of  unsatisfactory 
improvement within one week. Patients with upper leg amputa-
tions  experienced  slightly  better  results,  though  both  groups 
exhibited the best outcomes with  Staphylococcus infections. The 
investigators noted that topically applied propolis improves circu-
lation, stimulates intracellular metabolism, and alters skin reactiv-
ity. They also concluded that propolis ointment is indicated for 
skin disorders on stumps and local trophic conditions.69

Like  its  associated  bee  products,  royal  jelly  has  reportedly 
contributed  to  wound  healing.  In  2008,  Abdelatif  et  al.  con-
ducted a pilot study to ascertain the safety and effectiveness of a 
new ointment combining royal jelly and panthenol (Pedyphar) in 
60 patients with limb-threatening diabetic foot infections. By the 
end of week 9 and through six months of follow-up, 96 percent 
of the patients with full-thickness skin ulcers (Wagner grades 1 
and  2)  or  deep  tissue  infection  and  suspected  osteomyelitis 
(grade 3) responded well, with all grade 1 and 2 ulcers healing 
and 92 percent of grade 3 ulcers healing. All patients with gan-
grenous  lesions  (grades  4  and  5)  healed  after  surgical  excision, 
debridement,  and  conservative  treatment  with  the  royal  jelly/
panthenol formulation [see Chapter 27, Vitamin B5 (Pantothenic 
Acid/Dexpanthenol)].  The  investigators  suggested  that  more 
double-blind, randomized controlled studies are required to con-
firm their promising findings that the royal jelly/panthenol com-
bination is safe and effective.70

Suemaru et al. compared the effects of topically applied honey, 
propolis, and royal jelly on 5-fluorouracil (5-FU)-induced experi-
mental oral mucositis in hamsters. The size of the lesions was not 
diminished by the use of honey (1, 10, and 100 percent) or propo-
lis (0.3, 1, and 3 percent) in comparison to the Vaseline-treated 
control  group.  Royal  jelly  ointments  (3,  10,  and  30  percent) 
dose-dependently led to significant improvements and healing, 
suggesting  its  possible  use  in  treating  chemotherapy-induced 
moral mucositis in humans.71 More recently, several of the same 
investigators furthered their study of royal jelly and its effects on 
5-FU-induced  oral  mucositis  in  hamsters.  Chitosan-sodium 
alginate film containing royal jelly was used to achieve healing. 
These  films  (10  and  30  percent)  significantly  ameliorated  the 
damage  caused  by  5-FU,  decreasing  myeloperoxidase  activity 
and proinflammatory cytokine production. In addition to such 
anti-inflammatory effects, the investigators noted that royal jelly 
displayed antioxidant activity. They attributed the healing effect 
from  severe  oral  mucositis  to  the  anti-inflammatory  and 
antioxidant properties of royal jelly.72

In  2010,  Kim  et  al.  treated  freshly  scratched  normal  human 
dermal  fibroblasts  with  different  concentrations  of  royal  jelly 
(0.1, 1, or 5 mg/mL) for up to 48 hours. They found that fibro-
blast migration peaked at 24 hours after wounding and that royal 
jelly  significantly  and  dose-dependently  accelerated  the  migra-
tion at the eight-hour mark. In addition, various lipids in fibro-
blasts involved in the wound-healing process were influenced by 
royal  jelly  treatment,  with  the  cholesterol  level  lowered  and 
sphinganines increased.62

The following year, Siavash et al. conducted a small study of 
eight patients to assess the efficacy of topically applied royal jelly 
in  the  treatment  of  diabetic  foot  ulcers.  Of  the  eight  ulcers 
treated, seven healed, with a mean healing duration of 41 days. 
The eighth ulcer improved, with significant reductions in size. 
The investigators concluded that a royal jelly dressing appears to 

be  an  effective  alternative  treatment  option  for  diabetic  foot 
ulcers.73 However, in 2013, Siavash et al. assessed the efficacy of 
topical  royal  jelly  on  diabetic  foot  ulcers  in  a  double-blind  
placebo-controlled clinical trial of 25 patients (6 females, 19 males). 
The 60 ulcers considered in the final analysis were treated with 
either 5 percent sterile topical royal jelly or placebo. They found 
no significant differences in the regimens.21

CoLLAGEn  PRodUCTIon  Koya-Miyata  et  al.  have  demon-
strated that royal jelly fosters collagen production by skin fibro-
blasts in the presence of ascorbic acid-2-O-α-glucoside (AA-2G) 
and that its primary fatty acid constituent 10-HDA promotes 
the synthesis of collagen by AA-2G-treated fibroblasts by initi-
ating the production of TGF-β1 production.20

Seborrheic Dermatitis/Dandruff
In 2001, Al-Waili completed a study in 30 patients (20 males, 
10 females aged 15 to 60 years) with chronic seborrheic der-
matitis of the scalp, face, and chest to evaluate the potential of 
topically  applied  crude  honey  (90  percent  honey  diluted  in 
warm water). Treatment over a four-week period consisted of 
gentle rubbing of the ointment for two to three minutes onto 
lesions  every  other  day,  leaving  honey  on  for  three  hours 
before  gentle  warm  water  rinsing.  A  six-month  prophylactic 
phase  split  the  group  evenly  into  a  once-weekly  treatment 
group and a control group. Honey application yielded further 
marked  improvements,  with  itching  and  scaling  resolved 
within the first week. Within two weeks, skin lesions healed 
completely. Patients also reported subjective improvement in 
hair loss. Whereas no patients treated with honey experienced 
relapse, 12 of the 15 patients in the control group experienced 
relapse within two to four months of initial treatment cessa-
tion.  The  author  concluded  that  weekly  use  of  crude  honey 
delivers significant improvement in seborrheic dermatitis and 
related hair loss.74

Subsequently, Al-Waili et al. conducted a review of the anti-
microbial activity of honey, finding topical effectiveness in the 
treatment  of  adult  and  neonatal  postoperative  infection,  boils, 
burns, infected and nonhealing wounds and ulcers, necrotizing 
fasciitis, pilonidal sinus, diabetic foot ulcers, as well as venous 
ulcers.76 Internally, honey lowers prostaglandin levels while rais-
ing nitric oxide levels, and displays anti-inflammatory and prebi-
otic activity.75

 SAFETY ISSUES

Allergic reactions to honey, propolis, and royal jelly have been 
reported.76,77 Propolis is relatively innocuous, though.34 A no-
effect level (NOEL) of 1,400 mg/kg body weight/day was found 
in a 90-mouse study on propolis.14 Some cases of allergic con-
tact dermatitis as well as allergic contact cheilitis to propolis in 
humans have been reported.53,78–81

Royal  jelly  has  been  known  to  provoke  an  anaphylactic 
response  in  some  people.17,82  Asthmatic  and  anaphylactic  reac-
tions  to  the  ingestion  of  royal  jelly  have  been  found  to  be  true 
IgE-mediated hypersensitivity reactions.83 Contact dermatitis has 
also  been  reported  in  reaction  to  topical  royal  jelly.84  Indeed, 
although royal jelly has been linked to broad health benefits, such 
as promoting growth in children, improving general health, and 
enhancing longevity, adverse reactions ranging from contact der-
matitis,  acute  asthma,  anaphylaxis  and  even  death  have  been 
linked to its use.85

 
A 1997 cross-sectional survey of 1,472 hospital employees in 
Hong Kong conducted by Leung et al. revealed that 461 subjects 
(31.3 percent) had taken royal jelly in the past. Adverse reactions 
to  royal  jelly,  including  urticaria,  eczema,  rhinitis,  and  acute 
asthma,  were  reported  by  nine  subjects.  Skin  tests  were  con-
ducted  on  176  questionnaire  respondents  (13  of  whom  had  a 
positive skin test to pure royal jelly) and 300 consecutive asthma 
clinic patients (23 of whom had positive skin tests). Thirty-five 
of  the  36  participants  with  positive  royal  jelly  skin  tests  were 
atopic to other common allergens.86 In a retrospective evaluation 
of common environmental allergens in adult asthmatic patients 
completed  later  that  year  in  Hong  Kong,  many  of  the  same 
investigators found that royal jelly was the fifth most common 
allergen associated with positive skin tests (after Dermatophagoides 
pteronyssinus, D. farinae, cockroaches, and cat dander).87

In a 2008 study aimed at characterizing the major allergens of 
royal jelly, Rosmilah et al. identified major royal jelly protein 1 
and major royal jelly protein 2 as the main allergens in royal jelly 
that affected the 53 human subjects with royal jelly allergy who 
were evaluated.85

In  2013,  Moriyama  et  al.  assessed  the  hypoallergenicity  of 
alkaline protease-treated royal jelly in vitro and in vivo. They dem-
onstrated  that  the  immunoglobulin  E-binding  capacity  of  the 
treated royal jelly was substantially diminished via in vitro assays 
of the blood from patients sensitive to royal jelly. In 75 percent of 
royal jelly-sensitive patients given a skin-prick test, royal jelly did 
not elicit an allergic reaction.17

 ENVIRONMENTAL IMPACT

As  stated  above,  human  beings  depend  on  bees  to  pollinate 
approximately  one-third  of  our  crops,  including  a  large 
proportion  of  the  produce  that  we  consume.  Among  global 
agricultural  crops,  the  European  honeybee  is  the  most 
economically  valuable  pollinator.88  A.  mellifera  also  plays  a 
significant  role  in  maintaining  biodiversity  via  pollinating 
several species of plants that need an obligatory pollinator to 
be  fertilized.88  Notably,  the  antibacterial  activities  of  bee 
products, especially honey and propolis, place bees at an even 
more  potentially  crucial  position  related  to  human  health 
given  the  alarming  global  increase  in  antibiotic  resistance 
among  several  bacterial  strains.  Indeed,  Dr.  Margaret  Chan, 
director-general  of  the  World  Health  Organization,  has 
warned  of  the  dangers  of  increasingly  pervasive  antibiotic 
resistance,  referring  to  this  insidious  threat  as  the  possible 
“end of modern medicine as we know it.”89

Given  that  honey,  in  particular,  has  been  exploited  since 
ancient times for its antibacterial properties in treating infected 
wounds and is currently known to exhibit broad-spectrum effec-
tiveness against antibiotic-resistant strains, this iconic bee prod-
uct  would  appear  to  merit  careful  consideration  and  study,  as 
would propolis, along with a concerted effort to stem the over-
use,  abuse,  and  misuse  of  antibiotics.  However,  the  effects  of 
“colony collapse disorder” – the decimation of bee populations – 
certainly  loom  as  a  substantial  threat  to  further  exploring  a 
natural alternative to antibiotic resistance within our midst. The 
etiology  of  this  bee  colony  disaster  has  recently  become  less 
mysterious, as the use of neonicotinoid pesticides in industrial 
agriculture  appears  to  account  for  much  of  the  devastating 
impact on honeybees, though calls for more larger studies per-
sist.90,91 The European Commission has banned the use of three 
neonicotinoids based on such concerns.92 Colony collapse disor-
der is a global phenomenon,93 and poses significant worldwide 

C H A P T E R  60  ■   H O N E Y / P R O P O L I S / R OYA L   J E L LY  

207

risk  to  the  produce  on  which  human  beings  significantly  rely. 
Regardless of the cause or causes, whether it is pesticide use or 
the parasitic Varroa mite,94 colony collapse disorder presents a 
significant existential impact on honeybees and, possibly, numer-
ous other species including humans.

The  greater  environmental  impact  related  to  bee  products, 
then, is not in the harvesting and processing of these products 
themselves  but,  rather,  from  the  marked  strains  that  human 
industry places on the very existence of the honeybee. We quite 
possibly  continue  the  use  of  neonicotinoid  pesticides,  now 
believed  to  have  a  pernicious  effect  on  bees,95  and  overuse  of 
antibiotics for livestock96 at our own peril.

 FORMULATION CONSIDERATIONS

Geographical  location,  pollen  source,  climate,  environmen-
tal conditions, season during collection, genetic factors, and 
the  processing  methods  it  undergoes  influence  honey 
composition  and  quality.9,33  Because  honey  is  readily 
contaminated  through  processing,  medical  grade  honey  is 
sterilized  through  g -radiation,  which  destroys  various 
microorganisms  without  compromising  the  compound’s 
antibacterial activity.29,46,97–100

Like honey, the collection location, time, and plant source 
affect  propolis  quality,  chemical  composition,  and  biologic 
activity, thus there is great variability in these products.1,35,101,102 
However,  because  of  the  unique  ecosystems  in  which 
different honeybees live and the variety of plant sources from 
which  bees  collect  ingredients,  propolis  does  not  have  a 
specific  chemical  connotation  or  formula.35  Given  the 
potential for its use as a topical agent because of its antioxidant 
capacity, Marquele-Oliveira et al. found in 2007 that propolis 
formulations prepared with Polawax exhibited functional and 
physical stability in percutaneous studies in pig ear skin and 
hairless mouse skin as well as an in vivo study that indicated 
the viability of the formulation in protecting human skin from 
UVB photodamage.103

Dosage and safety are among the greatest challenges of using 
bee  products  for  medical  purposes.23  Honey  and  royal  jelly 
processed  into  formulations  for  wound  care  first  pass  through 
fine filters that remove the majority of pollen and other impuri-
ties. Some viable spores, such as clostridia, may be included in 
honey.23 Bacterial sensitivity to bee products is influenced by the 
botanical origin of the product and there is significant variability 
in bacterial sensitivity to bee products.23

 USAGE CONSIDERATIONS

Honey that is not medical grade is liable to contain viable bac-
terial  spores  (including  clostridia),  and  may  also  exhibit  less 
predictable  antibacterial  properties.10  Several  countries  have 
approved  of  the  use  of  medical-grade  honey  (e.g.,  manuka, 
Medihoney)  and  numerous  brands  of  sterile,  irradiated,  anti-
bacterial topical honey preparations are available.10,33,104,105

Royal  jelly  is  used  in  cosmetics,  dietary  supplements,  and 
beverages. Particularly in Asia, it is deployed as a health tonic.43

 SIGNIFICANT  BACk GROUND

Manuka honey and Medihoney are the primary forms of honey 
used  in  clinical  practice.  Propolis  is  one  of  the  most  copious 
sources  of  polyphenols,  particularly  flavonoids  and  phenolic 
acids, some of the most potent antioxidants yet discovered.106,107

 
208 

CO SmE C EuT I C A L S   A N D   CO SmE T I C   INgR E D I E N T S

Antioxidant Activity
In 2005, a study by Marquele et al. of Brazilian propolis extracts 
alone and in topical pharmaceutical formulations revealed that 
the antioxidant activity of the extracts was maintained in the 
topical products. The bee glue was particularly active against 
the superoxide radical.108

A 2006 study using New Zealand white rabbits revealed that 
topical  propolis  exhibited  antioxidant,  anti-inflammatory,  and 
antibacterial activity against Staphylococcus aureus keratitis.109

In 2009, Nakajima et al. compared the antioxidant effects of 
various bee products, specifically Brazilian green propolis, water-
soluble royal jelly, and a bee pollen ethanol extract against H2O2, 
superoxide  anion,  and  hydroxyl  radicals.  They  found  water 
extracts  of  propolis  to  have  the  greatest  potency,  followed  by 
ethanol  extracts  of  propolis,  and  pollen.  Royal  jelly  had  no 
effects. Of the primary constituents of propolis, caffeic acid dis-
played the greatest antioxidant activity, followed by artepillin C, 
and drupanin.110 Also that year, Izuta et al. found that Brazilian 
green propolis and Chinese red propolis and their components 
(CAPE and caffeoylquinic acid derivatives) acted as potent scav-
engers of the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical.111

Recent chemical analyses of Algerian propolis indicated a high 
content of polyphenols and diterpenes from samples in various 
north  Algerian  regions.  Using  the  DPPH  assay,  Piccinelli  et  al. 
found  that  the  polyphenol-rich  samples  of  propolis  exhibited 
potent antioxidant activity.112

In  addition,  propolis  has  been  shown  to  lower  oxidative 
stress, altering catalase, malondialdehyde, and nitric oxide levels, 
in Nω-nitro-l-arginine methyl ester (1-NAME)-induced hyperten-
sion in rats, suggesting a modulatory impact on the antioxidant 
system.113

A 2010 study by Cole et al. showed that Sydney propolis sig-
nificantly  and  dose-dependently  protected  mouse  skin  against 
edema, immunosuppression, and lipid peroxidation. The inves-
tigators  concluded  that  Sydney  propolis  has  the  potential  to 
protect  human  skin  against  UV-induced  skin  cancer  and  other 
photodamage.114

In 2011, Fonseca et al. showed that green and brown propolis 
extracts,  with  varying  composition  and  properties,  both  effec-
tively prevented UV-induced glutathione depletion in vivo. Oral 
administration  of  extracts  in  hairless  mice  yielded  a  higher 
recovery of glutathione, after reductions caused by UV exposure, 
in the green propolis group (30 percent vs. 22.8 percent). Topical 
propolis pretreatment before UV exposure netted a 14 percent 
recovery in both groups. The investigators concluded that both 
green and brown propolis extracts are promising agents for com-
bating oxidative stress in skin.55

In  2013,  Bolfa  et  al.  studied  the  wide-ranging  effects  of  a 
Romanian propolis topically applied in two concentrations (3 mg 
and 1.5 mg polyphenols/cm2) before or after UVB exposure in a 
Swiss mouse model. Both concentrations significantly decreased 
malondialdehyde formation and IL-6 levels while restoring the 
activity  of  glutathione  peroxidase.  Epidermal  hyperplasia  and 
dermal inflammation were diminished with the smaller concen-
tration, with only dermal inflammation reduced by pretreatment 
with the larger concentration. Romanian propolis also decreased 
sunburn cell formation and exhibited an antigenotoxic effect by 
significantly  attenuating  cyclobutane  pyrimidine  dimer  forma-
tion.  In  light  of  the  antioxidant,  anti-inflammatory,  antiapop-
totic, and antigenotoxic properties manifested in their study, the 
investigators concluded that Romanian propolis provides signifi-
cant photoprotection in the mouse model and warrants consid-
eration  as  a  chemopreventive  agent  for  mitigating  several  

UVB-induced  cutaneous  signaling  pathways.108  Also  that  year, 
Moniruzzaman et al. found that two Malaysian honeys, longan 
and sourwood, are good sources of antioxidants as compared to 
other rubber tree and manuka honeys.115

Antimicrobial and Anti-inflammatory Activity
Potent  antibacterial  activity  is  exhibited  by  honey,  propolis, 
royal jelly, as well as bee venom, with even epidemic strains of 
methicillin-resistant  Staphylococcus  aureus  (MRSA)  and 
Vancomycin-resistant Enterococcus (VRE) showing sensitivity.23 
Among the bee products, propolis has shown the greatest anti-
bacterial  activity,23  though  clinical  trials  and  laboratory  data 
suggest that honey acts as an effective broad-spectrum antimi-
crobial agent.3,76 These wide-ranging functions are thought to 
be  derived  from  its  acidity;  bacteriostatic,  bactericidal,  and 
antioxidant  constituents  (i.e.,  H2O2,  antioxidants,  lysozyme, 
polyphenols,  phenolic  acids,  flavonoids,  methylglyoxal,  and 
bee peptides); osmotic effect; high sugar concentration; induc-
tion  of  cytokine  release;  as  well  as  immunomodulatory  and 
anti-inflammatory activity.3,76

In  a  2008  evaluation  of  medical  grade  honey  (Revamil), 
Kwakman et al. found that within 24 hours 10 to 40 percent (vol/
vol)  honey  eradicated  antibiotic-susceptible  and  -resistant  iso-
lates  of  Staphylococcus  aureus,  Staphylococcus  epidermidis, 
Enterococcus  faecium,  Escherichia  coli,  Pseudomonas  aeruginosa, 
Enterobacter  cloacae,  and  Klebsiella  oxytoca.  They  also  noted  a  
100-fold decline in forearm skin colonization in healthy volun-
teers after two days of honey application, with the number of 
positive  skin  cultures  falling  by  76  percent.  The  investigators 
concluded  that  the  topical  antimicrobial  honey  agent  Revamil 
displays  significant  potential  to  prevent  or  treat  infections, 
including those engendered by multidrug-resistant bacteria.25 It 
is  worth  noting  that  honey  is  known  to suppress 150 bacteria 
species,  including  clinical  strains  of  MRSA  and  VRE,  with  no 
reports of microbial resistance.10 In fact, honey has been shown to 
be clinically effective in treating various kinds of wound infections, 
reducing skin colonization of several bacteria (including MRSA),25 
and  accelerating  wound  healing,  without  provoking  adverse 
effects.10 A 2009 report by Blair et al. supports the notion that 
medical-grade honey has the potential to lessen the strain caused 
by the emergence of antibiotic-resistant bacteria.116

In 2000, Vynograd et al. evaluated propolis for efficacy in the 
treatment  of  recurrent  genital  herpes  simplex  virus  type  2. 
Ninety adults, all with local symptoms, participated in a rand-
omized,  single-blind,  masked  investigator,  controlled  study  at 
seven medical centers in which Canadian propolis ointment con-
taining  natural  flavonoids  was  compared  with  ointments  of  
acyclovir  and  placebo,  with  30  people  randomized  to  each 
group.  Study  ointments  were  applied  four  times  daily. 
Participants  were  examined  on  the  3rd,  7th,  and  10th  days  of 
treatment for clinical symptoms, including the number and size 
of herpetic lesions, with lesions classified into four stages: vesic-
ular, ulcerated, crusted, and healed. On Day 3, 15 members of 
the propolis group had crusted lesions as opposed to eight in the 
acyclovir  group  and  none  on  placebo.  Local  symptoms  were 
noted  in  three  propolis  group  members,  eight  acyclovir 
individuals,  and  nine  on  placebo.  On  Day  7,  healing  was 
observed  in  10  propolis  patients,  four  acyclovir  patients,  and 
three in the placebo group. Investigators reported that 24 propolis 
patients and 14 acyclovir patients had healed by Day 10. Overall, 
the propolis ointment was considered more effective in healing 
lesions  and  reducing  local  symptoms.117  In  an  earlier  study  of  
65 patients, a topical ointment containing propolis, Nivcrisol-D, 

 
showed a significant therapeutic effect against recurrent herpes 
and zona zoster, with patients using the study drug healing from 
outbreaks in an average of four days while patients using placebo 
took an average of eight days to heal from outbreaks.118

In 2002, Gregory et al. assessed the purported antimicrobial, 
anti-inflammatory,  and  scar-healing  capacity  of  a  high-grade 
Brazilian  propolis  cream.  Patients  presenting  with  bilateral 
superficial  second-degree  burns  over  less  than  20  percent  of 
their body surface, with wounds of similar depth and quality, 
were admitted into the study within 48 hours of their injuries 
and then treated with propolis cream on one wound and silver 
sulfadiazene applied to a similar one on the other side. Wounds 
were  debrided  and  dressings  changed  on  the  following 
morning. Patients returned to the clinic at three-day intervals to 
have  their  wounds  checked  and  dressings  changed,  with 
reapplication of the ointment taking place only at these visits. 
In  addition,  investigators  cultured  the  wounds  for  microbial 
growth and took photographs to record inflammation and scar 
formation. No significant differences were noted in microbial 
colonization,  but  wounds  treated  with  the  propolis  cream 
showed  less  inflammation  and  quicker  scar  formation  as 
compared  to  the  silver  sulfadiazene-treated  burns.  While 
noting the beneficial effects of propolis on burns, the researchers 
speculated  that  more  frequent  changing  of  wound  dressings 
would have evinced antimicrobial results also.119

Omani propolis has been found to differ from many known 
propolis types, as it is derived from the resin of Azadiracta indica 
(neem tree), Acacia spp. (most probably A. nilotica) and Mangifera 
indica. However, like many other forms of propolis, the Omani 
variety  contains  biologically  active  phenolic  compounds  (e.g., 
prenylflavanones, cardols, and anacardic acids) and has exhibited 
antimicrobial activity.36

Activity Against Pruritus and Xerosis
In 2011, Duplan et al. assessed the activity of a synthetic coun-
terpart to 10-HDA in several experiments (in vitro, ex vivo, and  
in  vivo)  aimed  at  characterizing  its  potential  use  in  treating 
UV-induced xerosis. Hydroxydecine® induced involucrin, trans-
glutaminase-1,  and  filaggrin  protein  production  in  normal 
human keratinoctyes and yielded increases in these compounds 
in topical treatment of skin equivalents. In healthy volunteers 
with UV-induced xerosis, Hydroxydecine cream use led to an 
increase of 28.8 percent in the hydration index after seven days 
and  60.4  percent  after  21  days  of  treatment.  In  the  ex  vivo 
findings  in  a  model  of  inflammation  and  barrier  impairment 
involving human skin explants maintained alive, the formulation 
restored skin barrier function and lessened inflammation. The 
investigators  concluded  that  the  synthetic  version  of  10-HDA 
also displayed efficacy in activating keratinocyte differentiation in 
vitro as well as in vivo in hydrating dry human skin.60

In  2013,  Yamaura  et  al.  examined  an  experimental  allergic 
contact dermatitis model in hairless mice to ascertain the anti-
pruritic activity of topical royal jelly on chronic pruritus. They 
found that five weeks of treatment with topical royal jelly (0.01 
or 1 percent) and 0.01 percent β-methasone significantly allevi-
ated chronic pruritus induced by five weeks of repeated applica-
tion of 2,4,6-trinitro-1-chlorobenzene. The level of nerve growth 
factor  mRNA  in  back  skin  was  elevated  in  mice  with  contact 
dermatitis,  lower  in  those  treated  with  β-methasone,  and 
unchanged  in  mice  treated  with  royal  jelly.  The  investigators 
acknowledged the likely different mechanisms of action between 
royal jelly and β-methasone in suggesting that royal jelly may be 
a useful ingredient in cosmetics for easing chronic pruritus.43

C H A P T E R  60  ■   H O N E Y / P R O P O L I S / R OYA L   J E L LY  

209

Anticarcinogenic Activity
Various  components  of  propolis  have  also  been  isolated  and 
found  to  possess  anticarcinogenic  properties.  Flavonoid  agly-
cones are some of the significant constituents of propolis that 
are believed to contribute to antitumorigenic activity.13 A study 
with  a  fractionated  methanol  extract  of  a  Brazilian  propolis 
resulted in the isolation of a tumoricidal substance character-
ized as a new clerodane diterpenoid, which reduced the growth 
and number of skin tumors induced by 7,12-dimethylbenz(a)
anthracene (DMBA) application on mouse back skin by inhibi-
tion of DNA synthesis.13

In a study to determine whether CAPE, a propolis constituent, 
inhibits  the  tumor  promoter  12-O-tetradecanoylphorbol- 
13-acetate (TPA)-induced processes associated with carcinogen-
esis,  low  doses  of  CAPE  were  topically  applied  to  SENCAR 
mice. CAPE was found to strongly inhibit several TPA-mediated 
oxidative  processes  considered  sine  qua  non  for  tumor  promo-
tion,  including:  polymorphonuclear  leukocyte  infiltration  into 
mouse  skin  and  ears;  H2O2  production;  and  formation  of  oxi-
dized  bases  in  epidermal  DNA.  In  addition,  researchers  noted 
inhibition  of  edema  and  ornithine  decarboxylase  induction  in 
CD-1 and SENCAR mice after CAPE application, as well as the 
inhibition  of  TPA-induced  H2O2  production  in  bovine  lenses. 
Researchers  concluded  that  CAPE  appears  to  have  potent  
chemopreventive  capacity,  particularly  in  treating  disorders 
associated  with  strong  inflammatory  and/or  oxidative  stress 
processes, such as cancer and cataracts.27

In a different study on skin tumors, CD-1 mice were initiated 
with  DMBA  and  then  treated  twice  weekly  with  topically 
applied  TPA,  resulting  in  18.8  skin  papillomas  per  mouse. 
Subsequent topical application of CAPE to the backs of the mice 
together  with  TPA  twice  a  week  for  20  weeks  inhibited  the 
number  of  skin  papillomas  and  reduced  tumor  size  in  a  dose-
dependent  manner.  The  same  combination  also  decreased  the 
level of 5-hydroxymethyl-2′-deoxyuridine (HMdU) in epidermal 
DNA produced through the previous initiation with DMBA. In 
addition, in vitro CAPE introduction to cultured HeLa cells inhib-
ited DNA, RNA, and protein synthesis. All of these inhibitory 
effects conferred by CAPE were deemed by investigators to be 
potent.120

In a 2004 study on polyphenolic compounds and antitumori-
genic  properties,  a  water-soluble  derivative  of  propolis,  caffeic 
acid,  CAPE,  and  quercetin  administered  to  mice  resulted  in  a 
reduction  in  the  number  of  lung  tumor  nodules.  Researchers 
related the antitumor properties of the tested substances to their 
immunomodulatory  capacity,  cytotoxicity  to  tumor  cells,  and 
ability to induce apoptosis and necrosis, suggesting that propolis, 
caffeic acid, CAPE, and quercetin show promising potential for 
combating tumor growth.121

In 2011, Watanabe et al. found that propolis appears, in vitro 
and in vivo, to act against various tumor cells, suggesting its pos-
sible role in future anticancer drugs.15

Photoprotection
In 2011, Park et al. measured the 10-HDA content of royal jelly 
and investigated its effects on UVB-induced skin photoaging in 
normal  human  dermal  fibroblasts.  The  tested  royal  jelly  
(0.211 percent 10-HDA) led to increased synthesis of procollagen 
type  I  and  TGF-β1,  without  altering  MMP-1  levels.  The 
researchers concluded that due to its potential to spur collagen 
production, royal jelly could be used to protect the skin against 
UVB-induced photoaging.122 Park et al. followed this work up 

 
210 

CO SmE C EuT I C A L S   A N D   CO SmE T I C   INgR E D I E N T S

the following year, finding that the synthesis of type I collagen 
in the dorsal skin of ovariectomized Sprague-Dawley rats was 
augmented by the dietary supplementation of 1 percent royal 
jelly extract. Although MMP-1 levels were again unchanged, the 
investigators suggest that royal jelly may provide an antiaging 
benefit by virtue of enhanced collagen production alone.19

In 2013, Zheng et al. studied the protective effects of the royal 
jelly fatty acid component 10-HDA against UVA-induced dam-
age  in  human  dermal  fibroblasts  and  its  inhibitory  effects  on 
UVA-induced MMP expression. They found that 10-HDA signifi-
cantly  protected  the  fibroblasts  from  UVA-induced  cytotoxicity, 
reactive  oxygen  species,  and  cellular  senescence.  In  addition, 
10-HDA hindered the UVA-generated expression of MMP-1 as 
well  as  MMP-3,  and  stimulated  the  production  of  collagen. 
Activation of the c-Jun N-terminal kinase (JNK) and p38 mitogen-
activated protein kinase (MAPK) pathways was also diminished 
due to 10-HDA treatment. The investigators concluded that this 
royal jelly fatty acid exhibits potential for use in the prevention 
and treatment of cutaneous photoaging.22

In 2013, Angelo et al. demonstrated that the addition of prop-
olis  protected  L.  angustifolia  (lavender)  essential  oil  from 
UV-induced degradation and preserved its antioxidant capacity 
in cell oxidative damage assessments on B16–F10 melanoma cells 
as well as in vitro antioxidant assays. The investigators concluded 
that propolis may act as an efficient UV-protective and antiradi-
cal  adjuvant  to  sunscreens,  cosmetics,  and  other  products  that 
contain plant extracts (see Chapter 73, Lavandula).123

Skin Whitening
Skin-lightening indications may also be a viable use for royal 
jelly.  Han  et  al.  found  that  royal  jelly  dose-dependently  sup-
pressed melanin biosynthesis in the B16 -F1 mouse melanocyte 
cell  line  by  lowering  tyrosinase  activity.  Further,  royal  jelly 
decreased  mRNA  levels  of  tyrosinase.  The  researchers  con-
cluded  that  royal  jelly  merits  consideration  for  inclusion  as  a 
therapeutic agent in new skin-whitening products.18

 CONCLUSION

Honey,  propolis,  and  royal  jelly,  all  bee  products  with  a  long 
history of traditional medicinal use, have been found to exhibit 
sufficient biologic activity to warrant consideration in modern 
medicine. The antibacterial activity of these products is legend-
ary, and the wide array of additional biologic activities, particu-
larly  their  antioxidant  capacity,  suggest  broad  potential  for 
these agents, meriting greater attention and study for dermato-
logic application. Indeed, more research, in the form of rand-
omized, controlled trials, is needed prior to incorporating bee 
products into the armamentarium as first-line therapies, but the 
potential seems vast. 

REFERENCES

1.  Khalil  ML.  Biological  activity  of  bee  propolis  in  health  and  dis-

ease. Asian Pac J Cancer Prev. 2006;7:22.

2.  Oka H, Emori Y, Kobayashi N, et al. Suppression of allergic reac-
tions  by  royal  jelly  in  association  with  the  restoration  of  mac-
rophage function and the improvement of Th1/Th2 cell responses. 
Int Immunopharmacol. 2001;1:521.

3.  Israili ZH. Antimicrobial properties of honey. Am J Ther. 2013 Jun 18. 

[Epub ahead of print]

4.  Tsai YC, Wang YH, Liou CC, et al. Induction of oxidative DNA 
damage by flavonoids of propolis: Its mechanism and implication 
about antioxidant capacity. Chem Res Toxicol. 2012;25:191.

5.  Castaldo S, Capasso F. Propolis, an old remedy used in modern 

medicine. Fitoterapia. 2002;(73 Suppl 1):S1.

6.  Walsh B. The plight of the honeybee: Mass deaths in bee colonies 
may mean disaster for farmers – And your favorite Foods. Time 
Magazine,  August  19,  2013.  http://content.time.com/time 
/magazine/article/0,9171,2149141,00.html#ixzz2nhSJwyqZ 
.Accessed December 16, 2013.

7.  Klein AM, Vaissière BE, Cane JH, et al. Importance of pollinators 
in changing landscapes for world crops. Proc Biol Sci. 2007;274:303.
8.  Ediriweera ER, Premarathna NY. Medicinal and cosmetic uses of 

bee’s honey – A review. Ayu. 2012;33:178.

9.  Viuda-Martos  M,  Ruiz-Navajas  Y,  Fernández-López  J,  et  al. 
Functional properties of honey, propolis, and royal jelly. J Food Sci. 
2008;73:R117.

10.  Lipsky  BA,  Hoey  C.  Topical  antimicrobial  therapy  for  treating 

chronic wounds. Clin Infect Dis. 2009;49:1541.

11.  Golder  W.  Propolis.  The  bee  glue  as  presented  by  the  Graeco-

Roman literature. Wurzbg Medizinhist Mitt. 2004;23:133.

12.  Ghisalberti EL. Propolis: A review. Bee World. 1979;60:59.
13.  Mitamura T, Matsuno T, Sakamoto S, et al. Effects of a new clero-
dane  diterpenoid  isolated  from  propolis  on  chemically  induced 
skin tumors in mice. Anticancer Res. 1996;16:2669.

14.  Burdock GA. Review of the biological properties and toxicity of 

bee propolis (propolis). Food Chem Toxicol. 1998;36:347.

15.  Watanabe MA, Amarante MK, Conti BJ, et al. Cytotoxic constitu-
ents  of  propolis  inducing  anticancer  effects:  A  review.  J  Pharm 
Pharmacol. 2011;63:1378.

16.  Li  X,  Huang  C,  Xue  Y.  Contribution  of  lipids  in  honeybee  
(Apis mellifera) royal jelly to health. J Med Food. 2013;16:96.
17.  Moriyama T, Yanagihara M, Yano E, et al. Hypoallergenicity and 
immunological  characterization  of  enzyme-treated  royal  jelly 
from Apis mellifera. Biosci Biotechnol Biochem. 2013;77:789.

18.  Han  SM,  Yeo  JH,  Cho  YH,  et  al.  Royal  jelly  reduces  melanin 
synthesis  through  down-regulation  of  tyrosinase  expression.  
Am J Chin Med. 2011;39:1253.

19.  Park  HM,  Cho  MH,  Cho  Y,  et  al.  Royal  jelly  increases  collagen 
production in rat skin after ovariectomy. J Med Food. 2012;15:568.
20.  Koya-Miyata S, Okamoto I, Ushio S, et al. Identification of a col-
lagen production-promoting factor from an extract of royal jelly 
and its possible mechanism. Biosci Biotechnol Biochem. 2004;68:767.
21.  Siavash  M,  Shokri  S,  Haghighi  S,  et  al.  The  efficacy  of  topical 
royal  jelly  on  healing  of  diabetic  foot  ulcers:  A  double-blind 
placebo-controlled  clinical  trial.  Int  Wound  J.  2013  Apr  8.  
[Epub ahead of print]

22.  Zheng J, Lai W, Zhu G, et al. 10-Hydroxy-2-decenoic acid prevents 
ultraviolet  A-induced  damage  and  matrix  metalloproteinases 
expression  in  human  dermal  fibroblasts.  J  Eur  Acad  Dermatol. 
Venereol. 2013;27:1269.

23.  Boukraâ  L,  Sulaiman  SA.  Rediscovering  the  antibiotics  of  the 

hive. Recent Pat Antiinfect Drug Discov. 2009;4:206.

24.  Majtan J, Kumar P, Majtan T, et al. Effect of honey and its major 
royal jelly protein 1 on cytokine and MMP-9 mRNA transcripts in 
human keratinocytes. Exp Dermatol. 2010;19:e73.

25.  Kwakman  PH,  Van  den  Akker  JP,  Güçlü  A,  et  al.  Medical-grade 
honey  kills  antibiotic-resistant  bacteria  in  vitro  and  eradicates 
skin colonization. Clin Infect Dis. 2008;46:1677.

26.  Kwakman  PH,  Zaat  SA.  Antibacterial  components  of  honey. 

IUBMB Life. 2012;64:48.

27.  Frenkel K, Wei H, Bhimani R, et al. Inhibition of tumor promoter-
mediated processes in mouse skin and bovine lens by caffeic acid 
phenthyl ester. Cancer Res. 1993;53:1255.

28.  Toreti  VC,  Sato  HH,  Pastore  GM,  et  al.  Recent  progress  of 
propolis  for  its  biological  and  chemical  compositions  and  its 
botanical  origin.  Evid  Based  Complement  Alternat  Med. 
2013;2013:697390.

29.  Vandamme L, Heyneman A, Hoeksema H, et al. Honey in modern 
wound  care:  A  systematic  review.  Burns.  2013;pii:S0305-
4179(13)00197.

30.  Salatino A, Fernandes-Silva CC, Righi AA, et al. Propolis research 
and the chemistry of plant products. Nat Prod Rep. 2011;28:925.
31.  Bansal V, Medhi B, Pandhi P. Honey – A remedy rediscovered and 
its therapeutic utility. Kathmandu Univ Med J (KUMJ). 2005;3:305.
32.  Sare JL. Leg ulcer management with topical medical honey. Br J 

Community Nurs. 2008;13:S22.

33.  Khan FR, Ul Abadin Z, Rauf N. Honey: Nutritional and medicinal 

value. Int J Clin Pract. 2007;61:1705.

34.  Sforcin  JM.  Propolis  and  the  immune  system:  A  review.  

J Ethnopharmacol. 2007;113:1.

 
35.  Sforcin JM, Bankova V. Propolis: Is there a potential for the devel-

opment of new drugs? J Ethnopharmacol. 2011;133:253.

36.  Popova  M,  Dimitrova  R,  Al-Lawati  HT,  et  al.  Omani  propolis: 
Chemical profiling, antibacterial activity and new propolis plant 
sources. Chem Cent J. 2013;7:158.

37.  Popova M, Silici S, Kaftanoglu O, et al. Antibacterial activity of 
Turkish  propolis  and  its  qualitative  and  quantitative  chemical 
composition. Phytomedicine. 2005;12:221.

38.  Kuropatnicki AK, Szliszka E, Klósek M, et al. The beginnings of 
modern  research  on  propolis  in  Poland.  Evid  Based  Complement 
Alternat Med. 2013;2013:983974.

39.  Kodai  T,  Nakatani  T,  Noda  N.  The  absolute  configurations  of 
hydroxyl fatty acids from the royal jelly of honeybees (Apis mel-
lifera). Lipids. 2011;46:263.

40.  Butler CG, Callow RK, Johnston NC. The isolation and synthesis 
of  queen  substance,  9-oxodec-trans-2-enoic  acid,  a  honeybee 
pheromone. Proc R Soc Lond B Biol Sci. 1962;155:417.

41.  Johnston  NC,  Law  JH,  Weaver  N.  Metabolism  of  9-ketodec-
2-enoic acid by worker honeybees (Apis mellifera L.). Biochemistry. 
1965;4:1615.

42.  Kodai T, Umebayashi K, Nakatani T, et al. Compositions of royal 
jelly  II.  Organic  acid  glycosides  and  sterols  of  the  royal  jelly  of 
honeybees  (Apis  mellifera).  Chem.  Pharm  Bull  (Tokyo). 
2007;55:1528.

43.  Yamaura K, Tomono A, Suwa E, et al. Topical royal jelly alleviates 
symptoms of pruritus in a murine model of allergic contact der-
matitis. Pharmacogn Mag. 2013;9:9.

44.  Yamada  N,  Yoshimura  H.  Determinants  of  chilliness  among 
young  women  and  their  application  to  psychopharmacological 
trials. Nihon Shinkei Seishin Yakurigaku Zasshi. 2009;29:171.

45.  Khan FR, Ul Abadin Z, Rauf N. Honey: Nutritional and medicinal 

value. Int J Clin Pract. 2007;61:1705.

46.  Olaitan PB, Adeleke OE, Ola IO. Honey: A reservoir for microor-
ganisms  and  an  inhibitory  agent  for  microbes.  Afr  Health  Sci. 
2007;7:159.

47.  English HK, Pack AR, Molan PC. The effects of manuka honey on 
plaque  and  gingivitis:  A  pilot  study.  J  Int  Acad  Periodontol. 
2004;6:63.

48.  Simon A, Traynor K, Santos K, et al. Medical honey for wound 
care – Still the ‘latest resort’? Evid Based Complement Alternat Med. 
2009;6:165.

49.  Oelschlaegel  S,  Gruner  M,  Wang  PN,  et  al.  Classification  and 
characterization  of  manuka  honeys  based  on  phenolic  com-
pounds and methylglyoxal. J Agric Food Chem. 2012;60:7229.
50.  Bardy J, Slevin NJ, Mais KL, et al. A systematic review of honey 
uses  and  its  potential  value  within  oncology  care.  J  Clin  Nurs. 
2008;17:2604.

51.  Anderson  I.  Honey  dressings  in  wound  care.  Nurs  Times. 

2006;102:40.

C H A P T E R  60  ■   H O N E Y / P R O P O L I S / R OYA L   J E L LY  

211

61.  Fujii A, Kobayashi S, Kuboyama N, et al. Augmentation of wound 
healing  by  royal  jelly  (RJ)  in  streptozotocin-diabetic  rats.  Jpn  J 
Pharmacol. 1990;53:331.

62.  Kim J, Kim Y, Yun H, et al. Royal jelly enhances migration of human 
fibroblasts and alters the levels of cholesterol and sphinganine in an 
in vitro wound healing model. Nutr Res Pract. 2010;4:362.

63.  Taniguchi Y, Kohno K, Inoue S, et al. Oral administration of royal 
jelly  inhibits  the  development  of  atopic  dermatitis-like  skin 
lesions in NC/Nga mice. Int Immunopharmacol. 2003;3:1313.
64.  Magro Filho O, de Carvalho AC. Application of propolis to dental 
sockets and skin wounds. J Nihon Univ Sch Dent. 1990;32:4.
65.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy:  Modern 

Herbal Medicine. London: Churchill Livingstone; 2000:174.

66.  Morelli  V,  Calmet  E,  Jhingade  V.  Alternative  therapies  for  com-
mon dermatologic disorders, part 2. Prim Care. 2010;37:285.
67.  Samet N, Laurent C, Susarla SM, et al. The effect of bee propolis 
on recurrent aphthous stomatitis: A pilot study. Clin Oral Investig. 
2007;11:143.

68.  Jull AB, Walker N, Deshpande S. Honey as a topical treatment for 

wounds. Cochrane Database Syst Rev. 2013;2:CD005083.

69.  Pachalski  A,  Franczuk  B,  Wilk  M.  An  evaluation  of  the  use  of 
propolis  in  the  treatment  of  skin  disorders  on  the  stumps  of 
patients in rehabilitation following lower limb limb amputation. 
Ortop Traumatol Rehabil. 2002;4:60.

70.  Abdelatif M, Yakoot M, Etmaan M. Safety and efficacy of a new 
honey ointment on diabetic foot ulcers: A prospective pilot study. 
J Wound Care. 2008;17:108.

71.  Suemaru K, Cui R, Li B, et al. Topical application of royal jelly has 
a  healing  effect  for  5-fluorouracil-induced  experimental  oral 
mucositis  in  hamsters.  Methods  Find  Exp  Clin  Pharmacol. 
2008;30:103.

72.  Watanabe S, Suemaru K, Takechi K, et al. Oral mucosal adhesive 
films containing royal jelly accelerate recovery from 5-Fluorouracil-
induced oral mucositis. J Pharmacol Sci. 2013;121:110.

73.  Siavash  M,  Shokri  S,  Haghighi  S,  et  al.  The  efficacy  of  topical 
Royal Jelly on diabetic foot ulcers healing: A case series. J Res Med 
Sci. 2011;16:904.

74.  Al-Waili NS. Therapeutic and prophylactic effects of crude honey on 
chronic seborrheic dermatitis and dandruff. Eur J Med Res. 2001;6:306.
75.  Al-Waili NS, Salom K, Butler G, et al. Honey and microbial infec-
tions: A review supporting the use of honey for microbial control. 
J Med Food. 2011;14:1079.

76.  Shaw  D,  Leon  C,  Kolev  S,  et  al.  Traditional  remedies  and  food 
supplements. A 5-year toxicological study (1991–1995). Drug Saf. 
1997;17:342.

77.  Lombardi C, Senna GE, Gatti B, et al. Allergic reactions to honey 
and royal jelly and their relationship with sensitization to com-
positae. Allergol Immunopathol (Madr). 1998;26:288.

78.  Ting PT, Silver S. Allergic contact dermatitis to propolis. J Drugs 

52.  Stephen-Haynes J. Evaluation of a honey-impregnated tulle dress-

Dermatol. 2004;3:685.

ing in primary care. Br J Community Nurs. 2004(Suppl):S21.

79.  Walgrave SE, Warshaw EM, Glesne LA. Allergic contact dermati-

53.  Jacob  SE,  Chimento  S,  Castanedo-Tardan  MP.  Allergic  contact 
dermatitis  to  propolis  and  carnauba  wax  from  lip  balm  and 
chewable vitamins in a child. Contact Dermatitis. 2008;58:242.
54.  Zilius M, Ramanauskiene˙ K, Briedis V. Release of propolis phe-
nolic acids from semisolid formulations and their penetration into 
the  human  skin  in  vitro.  Evid  Based  Complement  Alternat  Med. 
2013;2013:958717.

55.  Fonseca YM, Marquele-Oliveira F, Vicentini FT, et al. Evaluation 
of the potential of Brazilian propolis against UV-induced oxida-
stress.  Evid  Based  Complement  Alternat  Med . 
tive 
2011;2011:pii:863917.

56.  Ramanauskiene K, Inkeniene AM, Savickas A, et al. Analysis of 
the antimicrobial activity of propolis and lysozyme in semisolid 
emulsion systems. Acta Pol Pharm. 2009;66:681.

57.  Banskota AH, Tezuka Y, Kadota S. Recent progress in pharmaco-

logical research of propolis. Phytother Res. 2001;15:561.

58.  Nagai T, Sakai M, Inoue R, et al. Antioxidative activities of some 
commercial  honeys,  royal  jelly,  and  propolis.  Food  Chem. 
2001;75:237.

59.  Duplan  H,  Questel  E,  Hernandez-Pigeon  H,  et  al.  Effects  of 
Hydroxydecine (®) (10-hydroxy-2-decenoic acid) on skin barrier 
structure  and  function  in  vitro  and  clinical  efficacy  in  the  treat-
ment of UV-induced xerosis. Eur J Dermatol. 2011;21:906.

60.  Búfalo MC, Ferreira I, Costa G, et al. Propolis and its constituent 
caffeic acid suppress LPS-stimulated pro-inflammatory response 
by  blocking  NF-κB  and  MAPK  activation  in  macrophages.  
J Ethnopharmacol. 2013;149:84.

tis from propolis. Dermatitis. 2005;16:209.

80.  Pasolini G, Semenza D, Capezzera R, et al. Allergic contact cheili-
tis  induced  by  repeated  contact  with  propolis-enriched  honey. 
Contact Dermatitis. 2004;50:322.

81.  Jensen  CD,  Andersen  KE.  Allergic  contact  dermatitis  from  cera 
alba (purified propolis) in a lip balm and candy. Contact Dermatitis. 
2006;55:312.

82.  Mizutani Y, Shibuya Y, Takahashi T, et al. Major royal jelly pro-
tein  3  as  a  possible  allergen  in  royal  jelly-induced  anaphylaxis.  
J Dermatol. 2011;38:1079.

83.  Thien  FC,  Leung  R,  Baldo  BA,  et  al.  Asthma  and  anaphylaxis 

induced by royal jelly. Clin Exp Allergy. 1996;26:216.

84.  Takahashi  M,  Matsuo  I,  Ohkido  M.  Contact  dermatitis  due  to 

honeybee royal jelly. Contact Dermatitis. 1983;9:452.

85.  Rosmilah M, Shahnaz M, Patel G, et al. Characterization of major 
allergens of royal jelly Apis mellifera. Trop Biomed. 2008;25:243.

86.  Leung R, Ho A, Chan J, et al. Royal jelly consumption and hyper-
sensitivity in the community. Clin Exp Allergy. 1997;27:333.
87.  Leung R, Lam CW, Ho A, et al. Allergic sensitisation to common 
environmental allergens in adult asthmatics in Hong Kong. Hong 
Kong Med J. 1997;3:211.

88.  Le  Conte  Y,  Navajas  M.  Climate  change:  Impact  on  honey  bee 

populations and diseases. Rev Sci Tech. 2008;27:485.

89.  Moisse K. Antibiotic resistance could bring “end of modern med-
icine.” ABC News, March 16, 2012. http://abcnews.go.com/blogs 
/health/2012/03/16/antibiotic-resistance-could-bring-end-of-
modern-medicine/. Accessed December 22, 2013.

 
212 

CO SmE C EuT I C A L S   A N D   CO SmE T I C   INgR E D I E N T S

90.  Ballingall  A.  Neonicotinoid  pesticides  blamed  for  bee  deaths 
could affect humans, EU agency says. Toronto Star, December 20, 
2013.  http://www.thestar.com/news/canada/2013/12/20 
/neonicotinoid_pesticides_blamed_for_bee_deaths_could 
_affect_humans_eu_agency_says.html.  Accessed  December  22, 
2013.

91.  Blacquière T, Smagghe G, van Gestel CA, et al. Neonicotinoids in 
bees:  A  review  on  concentrations,  side-effects  and  risk  assess-
ment. Ecotoxicology. 2012;21:973.

92.  European Food Safety Authority. Press release. January 16, 2013. 
http://www.efsa.europa.eu/en/press/news/130116.htm. 
Accessed December 22, 2013.

93.  Marghitas LA, Dezmirean DS, Bobis O. Important developments 
in  Romanian  propolis  research.  Evid  Based  Complement  Alternat 
Med. 2013;2013:159392.

94.  Martin SJ, Highfield AC, Brettell L, et al. Global honey bee viral 
landscape altered by a parasitic mite. Science. 2012;336:1304.
95.  Henry M, Béguin M, Requier F, et al. A common pesticide decreases 

foraging success and survival in honey bees. Science. 2012;336:348.

96.  Schmidt  CW.  Antibiotic  resistance  in  livestock:  More  at  stake 

than steak. Environ Health Perspect. 2002;110:A396.

97.  Snowdon  JA,  Cliver  DO.  Microorganisms  in  honey.  Int  J  Food 

Microbiol. 1996;31:1.

98.  Lusby PE, Coombes A, Wilkinson JM. Honey: A potent agent for 
wound healing? J Wound Ostomy Continence Nurs. 2002;29:295.
99.  Molan  PC.  Potential  of  honey  in  the  treatment  of  wounds  and 

burns. Am J Clin Dermatol. 2001;2:13.

100.  Alcaraz A, Kelly J. Treatment of an infected venous leg ulcer with 

honey dressings. Br J Nurs. 2002;11:859.

101.  Sforcin JM, Orsi RO, Bankova V. Effect of propolis, some isolated 
compounds  and  its  source  plant  on  antibody  production.  
J Ethnopharmacol. 2005;98:301.

102.  Bankova V. Recent trends and important developments in propo-
lis research. Evid Based Complement Alternat Med. 2005;2:29.
103.  Marquele-Oliveira F, Fonseca YM, de Freitas O, et al. Development 
of  topical  functionalized  formulations  added  with  propolis 
extract: Stability, cutaneous absorption and in vivo studies. Int J 
Pharm. 2007;342:40.

104.  Molan PC, Cooper RA. Honey and sugar as a dressing for wounds 

and ulcers. Trop Doct. 2000;30:249.

105.  Cooper RA, Molan PC, Harding KG. The sensitivity to honey of 
Gram-positive cocci of clinical significance isolated from wounds. 
J Appl Microbiol. 2002;93:857.

106.  Medic´ -Saric´  M, Rastija V, Bojic´  M, et al. From functional food to 
medicinal product: Systematic approach in analysis of polyphe-
nolics from propolis and wine. Nutr J. 2009;8:33.

107.  Bolfa P, Vidrighinescu R, Petruta A, et al. Photoprotective effects 
of  Romanian  propolis  on  skin  of  mice  exposed  to  UVB  irradia-
tion. Food Chem Toxicol. 2013;62C:329.

108.  Marquele FD, Di Mambro VM, Georgetti SR, et al. Assessment of the 
antioxidant  activities  of  Brazilian  extracts  of  propolis  alone  and  in 
topical pharmaceutical formulations. J Pharm Biomed Anal. 2005;39:455.

109.  Duran  N,  Koc  A,  Oksuz  H,  et  al.  The  protective  role  of  topical 
propolis on experimental keratitis via nitric oxide levels in rabbits. 
Mol Cell Biochem. 2006;281:153.

110.  Nakajima Y, Tsuruma K, Shimazawa M, et al. Comparison of bee 
products  based  on  assays  of  antioxidant  capacities.  BMC 
Complement Altern Med. 2009;9:4.

111.  Izuta  H,  Narahara  Y,  Shimazawa  M,  et  al.  1,1-diphenyl-
2-picrylhydrazyl  radical  scavenging  activity  of  bee  products 
and  their  constituents  determined  by  ESR.  Biol  Pharm  Bull. 
2009;32:1947.

112.  Piccinelli AL, Mencherini T, Celano R, et al. Chemical composi-
tion  and  antioxidant  activity  of  Algerian  propolis.  J  Agric  Food 
Chem. 2013;61:5080.

113.  Selamoglu Talas Z. Propolis reduces oxidative stress in l-NAME-
induced hypertension rats. Cell Biochem Funct. 2013 Jun 21. [Epub 
ahead of print]

114.  Cole N, Sou PW, Ngo A, et al. Topical ‘Sydney’ propolis protects 
against  UV-radiation-induced  inflammation,  lipid  peroxidation 
and immune suppression in mouse skin. Int Arch Allergy Immunol. 
2010;152:87.

115.  Moniruzzaman M, Sulaiman SA, Khalil MI, Gan SH. Evaluation 
of physicochemical and antioxidant properties of sourwood and 
other  Malaysian  honeys:  A  comparison  with  manuka  honey. 
Chem Cent J. 2013;7:138.

116.  Blair SE, Cokcetin NN, Harry EJ, et al. The unusual antibacterial 
activity  of  medical-greade  Leptospermum  honey:  Antibacterial 
spectrum,  resistance  and  transcriptome  analysis.  Eur  J  Clin 
Microbiol Infect Dis. 2009;28:1199.

117.  Vynograd  N,  Vynograd  I,  Sosnowski  Z.  A  comparative  multi-
centre study of the efficacy of propolis, acyclovir and placebo in 
the treatment of genital herpes (HSV). Phytomedicine. 2000;7:1.
118.  Giurcaˇneanu F, Crisan I, Esanu V, et al. Treatment of cutaneous 

herpes and herpes zoster with Nivcrisol-D. Virologie. 1988;39:21.

119.  Gregory SR, Piccolo N, Piccolo MT, et al. Comparison of propolis 
skin  cream  to  silver  sulfadiazine:  A  naturopathic  alternative  to 
antibiotics in treatment of minor burns. J Altern Complement Med. 
2002;8:77.

120.  120. Huang MT, Ma W, Yen P, et al. Inhibitory effects of caffeic 
acid  phenethyl  ester  (CAPE)  on  12-O-tetradecanoylphorbol-13-
acetate-induced tumor promotion in mouse skin and the synthe-
sis  of  DNA,  RNA  and  protein  in  HeLa  cells.  Carcinogenesis. 
1996;17:761.

121.  Orsolic´  N, Knezevic´  AH, Sver L, et al. Immunomodulatory and 
antimetastatic action of propolis and related polyphenolic com-
pounds. J Ethnopharmacol. 2004;94:307.

122.  Park  HM,  Hwang  E,  Lee  KG,  et  al.  Royal  jelly  protects  against 
ultraviolet  B-induced  photoaging  in  human  skin  fibroblasts  via 
enhancing collagen production. J Med Food. 2011;14:899.

123.  Angelo G, Lorena C, Marta G, et al. Biochemical composition and 
antioxidant properties of Lavandula angustifolia Miller essential 
oil  are  shielded  by  propolis  against  UV  radiations.  Photochem 
Photobiol. 2013 Dec 23. [Epub ahead of print]

 
C H A P T E R   6 1

Idebenone

C H A P T E R  61  ■   I D E B E N O N E  

213

Activities:

Antioxidant, photoprotective

Important Chemical Components:
Also  known  as  2,3-dimethoxy-5-methyl-6-(10′-
hydroxydecyl)-1,4-benzoquinone, CV-2619, QSA-10, or 
hydroxydecyl  ubiquinone.  Its  molecular  formula  is 
C19H30O5.

Origin Classification:

Idebenone is a synthetic analog of ubiquinone (coenzyme 
Q10).

Personal Care Category:

Antioxidant, antiaging, moisturizing

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW, DRPW, ORNW, and ORPW

 SOURCE

Idebenone,  also  known  as  2,3-dimethoxy-5-methyl-6-(10′-
hydroxydecyl)-1,4-benzoquinone,  CV-2619,  or  QSA-10,  is  a 
synthetic analog of, and similar in structure to, the potent anti-
oxidant ubiquinone, or coenzyme Q10 (CoQ10) (see Chapter 57, 
Coenzyme Q10). CoQ10 is an integral cell membrane nutrient 
and contributor to the adenosine triphosphate (ATP)-producing 
mitochondrial electron transport chain, activity in which ide-
benone has also been shown to engage.1 Idebenone has a sig-
nificantly  lower  molecular  weight  and  shorter  carbon  side 
chain as compared to CoQ10 and, therefore, greater solubility 
or  ability  to  penetrate  the  skin  than  its  natural  counterpart 
(Table 61-1).2–4

 HISTORY

Idebenone was first synthesized in 1984, and introduced as an 
active agent to treat age-related brain impairment in 1986.5,6 In 
nearly three decades of extensive research, the preponderance of 
data that have emerged pertain primarily to the relative success 
of this benzoquinone compound in comparison to other drugs 
for treating patients with Alzheimer’s disease; its use in organ 

TABLE 61-1
Pros and Cons of Idebenone

Pros
Can penetrate the skin more readily than CoQ10

Cons
Can cause contact dermatitis in 

sensitive skin types

Reportedly one of the most potent antioxidants

transplant  solutions;  and  its  success  in  ameliorating  various 
symptoms of Friedreich’s ataxia. More recently, idebenone has 
been included in cosmeceutical products, such as Prevage™, as 
an antiaging agent.6

 CHEMISTRY

As a potent free radical scavenger believed to be much stronger 
and efficient than other well-known antioxidants (e.g., vitamins C 
and  E,  CoQ10,  kinetin,  and  α-lipoic  acid),  idebenone  also 
functions  as  an  electron  carrier  and  is  not  characterized  by 
occasional activity as a strong pro-oxidant as is the case with 
CoQ10 under hypoxic conditions. In fact, under such conditions, 
idebenone  is  known  to  preserve  ATP  formation,  protecting 
against  free  radical  formation  and  cell  damage.1,7  In  addition, 
idebenone  is  considered  to  have  potential  as  a  therapy  to 
enhance energy and cognition, to protect organs against excita-
tory amino acid neurotoxicity, and to retard aging. As a CoQ10 
analog, it is thought that idebenone works at least as well as its 
natural  counterpart  within  the  electron  transport  chain  to 
maintain  a  high  energy  level.  Idebenone  was  shown  in  a  rat 
liver  microsomal  model  to  be  more  effective  than  CoQ10, 
though, in protecting against lipid peroxidation.8

 ORAL USES

Oral  administration  of  idebenone  has  been  demonstrated  to 
improve  mitochondrial  oxidative  metabolism  in  the  brain, 
suggesting a therapeutic potential in the treatment of myopathy, 
encephalopathy,  lactic  acidosis,  and  stroke-like  episodes 
(MELAS).9,10 The protection imparted by idebenone to the brain’s 
myelin  sheath  and  energy-producing  mitochondria  may  also 
position  this  antioxidant  to  play  a  therapeutic  role  in  multiple 
sclerosis.  Idebenone  has  been  used  orally  in  the  treatment  of 
several  conditions,  including  Alzheimer’s  disease,  liver  disease, 
cerebrovascular  disease,  and  Friedreich’s  ataxia.1,11  Cutaneous 
benefits of idebenone are gleaned through topical administration.

 TOPICAL USES

Idebenone has been used outside the United States for years as an 
antiaging  agent  and  for  improving  cognition  in  patients  with 
Alzheimer’s disease and other neurologic disorders. As a topical 
agent,  idebenone  is  believed  to  possess  a  much  greater  skin 
penetration  potential  and  higher  oxidative  stress  protection 
capacity than CoQ10.12 Idebenone has also reportedly displayed 
higher antioxidant activity than vitamins C and E, CoQ10, kinetin, 
and  α-lipoic  acid  [see  Chapter  55,  Ascorbic  Acid  (Vitamin  C), 
and Chapter 56, Tocopherol (Vitamin E)].12 Idebenone is thought 
by some, though, to be ineffective in conferring photoprotection 
to skin when compared to a topical antioxidant combination of 
vitamins  C  and  E  with  ferulic  acid  (see  Chapter  54,  Ferulic 
Acid).13  There  are  also  reports  that  suggest  greater  antioxidant 
activity has been exhibited by resveratrol as well as l-ergothioneine 
(see Chapter 50, Resveratrol).14,15

 
214 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

In 2005, McDaniel et al. conducted a nonvehicle-controlled 
clinical trial to assess the topical safety and efficacy of 0.5 and  
1 percent idebenone commercial formulations in 41 female sub-
jects (from ages 30 to 65 years) with moderate photodamaged 
skin.  Subjects  were  randomized  to  use  a  blind  labeled  (either  
0.5 or 1 percent idebenone in otherwise identical lotion bases) 
skincare  preparation  twice  daily  for  six  weeks.  Significant 
declines  in  skin  roughness/dryness  (by  26  percent)  as  well  as 
fine lines and wrinkles (by 29 percent) were associated with the 
use of 1.0 percent idebenone, as were a 37 percent increase in 
skin  hydration,  and  a  33  percent  improvement  in  global  skin 
assessment.  Similar  improvements  were  seen  with  the  use  of  
0.5 percent idebenone. In addition, immunofluorescence staining 
indicated  reductions  in  interleukin  (IL)-1β,  IL-6,  and  matrix 
metalloproteinase  (MMP)-1  as  well  as  an  increase  in  collagen 
type  I  corresponding  to  both  concentrations  of  idebenone.7  As 
Bruce  noted,  though,  the  actual  implications  of  the  reported 
enhancements  might  have  been  better  illustrated  with  the 
addition of a placebo arm in this study.16 Nevertheless, the stated 
purpose of the study by McDaniel and colleagues was to ascertain 
baseline and after effects of the two concentrations of idebenone 
and not to evaluate the benefits of the antioxidant per se.

Idebenone has also been used along with hyaluronic acid as 
one of two formulations successfully incorporated into a new 
minimally invasive mesotherapy technique shown in a study 
with 50 subjects (ranging in age from 30 to 65 years) who dem-
onstrated  significant  clinical  improvement  in  terms  of  the 
brightness, texture, and firmness of their facial skin. Biopsies at 
baseline and after three months showed increases in collagen 
type I as well as decreases in MMP-1, IL-6, and IL-1β.17

 SAFETY ISSUES

Idebenone is found in various over-the-counter topical antiaging 
products in concentrations ranging from 0.5 to 1 percent.11 It is 
generally  considered  safe  but  there  have  been  a  few  isolated 
reports of allergic contact dermatitis associated with idebenone-
based  Prevage  since  2008.  Specific  symptoms  have  included 
erythema, scaling, severe edema, and vesicular dermatitis of the 
face,  ears,  and  neck.2,11,18,19  Some  suggest  that  allergies  to 
idebenone may be undetected or more widespread because this 
substance is not routinely included in standard patch testing.19 
This ingredient is not recommended for sensitive skin types.

 ENVIRONMENTAL IMPACT

dioxide and tripolyphosphate. The nanoparticles evinced a ten-
fold increase of drug stability as compared to the free drug and 
preserved  the  in  vitro  antioxidant  activity  of  idebenone;  the 
nanoparticle formulation resulted in less mucous membrane irri-
tation as compared to the free form of idebenone. The investiga-
tors  concluded  that  chitosan  and  N-carboxymethylchitosan 
nanoparticles  warrant  consideration  as  carriers  for  the  topical 
and  nasal  use  of  hydrophobic  and  irritation-producing  drugs 
such as idebenone.20

In 2012, Li and Ge investigated the percutaneous permeation 
of idebenone in ex vivo guinea pig skin after the application of 
various  formulations,  including  nanostructured  lipid  carriers, 
nanoemulsions, and oil solutions. They found that nanostruc-
tured  lipid  carriers  exhibited  greater  chemical  stability  and 
more effectively enhanced skin permeation as compared to the 
other vehicles (delivering nearly threefold the amount of ide-
benone to the epidermis and dermis) and thus have potential in 
topical skin care formulations.22 Also that year, Montenegro et al. 
observed, after an in vitro evaluation, that loading idebenone in 
solid  lipid  nanoparticles  appears  to  be  an  effective  mode  of 
drug delivery to the outer skin layers.21

In  a  review  published  in  2012  that  covered  the  previous 
two decades, Carbone et al. found a wide range of delivery 
systems  for  idebenone,  including  cyclodextrin  inclusion 
complexes,  liposomes,  microemulsions,  prodrugs,  and 
polymeric and lipid nanoparticles. While direct comparison 
was  difficult,  they  maintained  that  these  various  carriers 
have successfully increased solubility and facilitated stability 
and  bioavailability.  They  noted,  also,  that  the  controlled 
release and targeting of idebenone remains a goal in product 
development.23

In a particularly interesting meta-analysis regarding the pre-
diction  of  responses  to  the  use  of  antiaging  cosmeceuticals, 
Sachs  et  al.  enrolled  100  subjects  with  16  to  20  participants 
applying  one  cosmeceutical  (l-ascorbic  acid,  pentapeptide, 
α-lipoic  acid,  yeast  extract,  or  1  percent  idebenone)  to  their 
photodamaged  forearms  for  several  weeks.  Results  varied 
widely, independent of age or gender, with some experiencing 
no  improvement  and  others  achieving  sevenfold  increases  in 
collagenesis. Statistical analysis revealed that age, gender, and 
cosmeceutical  type  exerted  no  influence,  with  preexisting 
hypocollagenesis as the only factor affecting outcome (volun-
teers  with  hypocollagenesis  responded  6.4  times  more  often 
than  those  with  normal  collagenesis).  The  authors  suggested 
that  this  parameter  might  guide  the  future  development  of 
antiaging skin care product formulations.24

There is no environmental impact of commercial  CoQ10  pro-
duction known by the author.

 USAGE CONSIDERATIONS

 FORMULATION CONSIDERATIONS

Although idebenone is considered more capable of permeating 
the skin barrier than CoQ10, it is known to be irritating in free 
form.20  In  addition,  it  has  been  known  to  degrade  and  lose 
antioxidant potency when exposed for a protracted period in 
conditions  with  a  relative  humidity  of  75  percent  and  a 
temperature  of  40°C  (104°F).20,21  Several  delivery  methods 
have been investigated to account for such deficiencies and to 
facilitate its penetration and bioavailability.

In  2010,  researchers  developed  nanoparticles  based  on 
chitosan  and  N-carboxymethylchitosan  crosslinked  with 
tripolyphosphate  by  co-drying  with  idebenone  in  different 
polymer-to-drug ratios with 20 percent (wt/wt) colloidal silicon 

In 2009, Wempe et al. investigated the inherent in vitro perme-
ability,  metabolism,  and  cytotoxicity  of  idebenone  and  com-
pared  it  to  the  idebenone  ester  idebenone  linoleate  using  pig 
ear skin and melanoma mouse cells. The researchers observed 
that idebenone permeated across the porcine tissue, but found 
no evidence that idebenone linoleate had after four hours. In 
the  porcine  tissue  as  well  as  mouse  melanocytes,  idebenone 
was metabolized to idebenone acid, with minimal idebenone 
linoleate metabolism noted. Further, no toxicity was associated 
with idebenone linoleate whereas idebenone exhibited delayed 
toxicity in melanocytes. The investigators concluded that the 
metabolic activation of idebenone likely accounts for the skin 
irritation  associated  with  in  vivo  use  of  idebenone,  which 
appears to have an inferior safety profile compared to its ester 
idebenone linoleate.6

 
 SIGNIFICANT BACKGROUND

In studies on rats that paved the way to hypotheses regarding 
applications  to  neurologic,  cardiologic,  and  antiaging  indica-
tions,  researchers  ascertained  that  idebenone  inhibited  lipid 
peroxidation,  protecting  cell  membranes  and  mitochondria 
from  oxidative  damage  and,  especially,  brain  mitochondria 
from swelling.1,25,26 In addition, idebenone has been shown to 
improve  cardiac  function  in  patients  with  Friedreich’s  ataxia, 
and  has  been  demonstrated  to  be  effective  in  treating  mito-
chondrial cardiomyopathy.27

Antioxidant Activity
The ability of idebenone to act as a potent free radical scaven-
ger was demonstrated by Mordente et al. over 15 years ago. In 
particular, they showed that it could scavenge the organic radi-
cals  2,2′-azinobis(3-ethylbenzothiazoline-6-sulfonic  acid)  and 
diphenylpicrylhydrazyl,  the  radicals  peroxyl  and  tyrosyl,  as 
well  as  peroxynitrite.  They  also  found  that  idebenone 
suppresses  microsomal  lipid  peroxidation  engendered  by 
adenosine  diphosphate  (ADP)-iron  complexes  or  organic 
hydroperoxides, thus preventing cytochrome P450 elimination. 
In  addition,  the  investigators  observed  in  comparative 
experiments that idebenone manifested antioxidant efficiency 
ranging from 50 to just short of 100 percent of vitamin E or its 
water-soluble analog trolox.28

In 2005, McDaniel et al. conducted in vitro and in vivo studies 
to compare the oxidative stress protective properties of several 
frequently  used  antioxidants,  including  vitamins  C  and  E, 
kinetin, α-lipoic acid, CoQ10, and idebenone. After establishing a 
standardized  method  to  summarize  all  results,  including  the 
human  sunburn  cell  assay  as  well  as  experiments  comparing 
antioxidant performance by photochemiluminescence, inhibition 
of  ultraviolet  B  irradiation  of  human  keratinocytes,  and 
measurement of primary and secondary oxidation products, the 
researchers compiled overall oxidative protection scores of 95, 80, 
68,  55,  52,  and  41  for  idebenone,  vitamin  E,  kinetin,  CoQ10,  
vitamin C, and α-lipoic acid, respectively, as idebenone acted as 
a  potent  antioxidant  most  consistently  across  various  experi-
ments.29 Further, they concluded that idebenone exhibits great 
potential for inclusion in topical skin protection products.

Neuroprotective Activity
In vitro and in vivo studies suggest that idebenone may reduce 
nerve cell damage induced by ischemia, repair neurotransmit-
ter defects and/or cerebral metabolism, and enhance memory 
and learning.1 Patients with mild dementia have been shown in 
clinical  trials  to  be  more  likely  to  respond  than  those  with 
greater  functional  decline.30  In  a  multicenter,  randomized, 
double-blind, placebo-controlled, parallel trial with Alzheimer’s 
patients,  idebenone  was  shown  to  be  effective  in  enhancing 
memory, attention, and orientation as well as slowing disease 
progression.31

In a different study, repeated oral administration of idebenone, 
which stimulates nerve growth factor (NGF) synthesis, partially 
restored the age-related reduction of NGF in the frontal and pari-
etal cortices. This is noteworthy because NGF is instrumental in 
maintaining  cholinergic  neurons  the  degeneration  of  which  is 
linked  to  the  cognitive  impairment  displayed  by  Alzheimer’s 
patients. Authors of this study determined then that oral admin-
istration  of  idebenone  has  potential  as  a  therapeutic  agent  in 
preventing cholinergic dysfunction.32 A prospective, randomized, 
double-blind, placebo-controlled multicenter study of two doses 

C H A P T E R  61  ■   I D E B E N O N E  

215

of idebenone in the treatment of patients with Alzheimer’s dis-
ease further established the efficacy and safety of the drug for 
this indication.33

In  a  subsequent  two-year  prospective,  randomized,  double-
blind multicenter study of the safety and efficacy of idebenone in 
the  treatment  of  Alzheimer’s  patients,  the  synthetic  CoQ10 
analog exerted beneficial therapeutic effects on the course of the 
disease by slowing down its progression. Also, the antioxidant 
was found to be safe and tolerable.34

 CONCLUSION

The synthetic coenzyme Q10 analog idebenone has been inves-
tigated  for  nearly  30  years,  yielding  an  extensive  body  of 
research.  Its  antioxidant  and  other  health  benefits  are  well 
established,  as  is  its  use  for  various  indications  outside  the 
United  States.  Recent  research  appears  to  validate  the  use  of 
idebenone as a topical antiaging agent and its use in Prevage, 
introduced in 2005, represents the first skin product to contain 
a clinically tested and proven topical antioxidant. Responses to 
its  use  have  been  mostly  favorable,  with  a  few  reports  of 
allergic contact dermatitis. Nevertheless, it would be helpful to 
see  studies  comparing  the  results  of  idebenone-containing 
topical products and the antiaging retinoid products known to 
be effective for symptoms of cutaneous aging.

REFERENCES

1.  Anonymous. Idebenone – Monograph. Altern Med Rev. 2001;6:83.
2.  Fleming  JD,  White  JM,  White  IR.  Allergic  contact  dermatitis  to 
hydroxydecyl ubiquinone: A newly described contact allergen in 
cosmetics. Contact Dermatitis. 2008;58:245.

3.  Reszko AE, Berson D, Lupo MP. Cosmeceuticals: Practical appli-

cations. Obstet Gynecol Clin North Am. 2010;37:547.

4.  Farris P. Idebenone, green tea, and Coffeeberry extract: New and 

innovative antioxidants. Dermatol Ther. 2007;20:322.

5.  Suno M, Nagaoka A. Inhibition of lipid peroxidation by a novel 
compound, idebenone (CV-2619). Jpn J Pharmacol. 1984;35:196.
6.  Wempe  MF,  Lightner  JW,  Zoeller  EL,  et  al.  Investigating  ide-
benone and idebenone linoleate metabolism: In vitro pig ear and 
mouse melanocyte studies. J Cosmet Dermatol. 2009;8:63.

7.  McDaniel DH, Neudecker BA, DiNardo JC, et al. Clinical efficacy 
assessment in photodamaged skin of 0.5% and 1.0% idebenone. 
J Cosmet Dermatol. 2005;4:167.

8.  Wieland  E,  Schütz  E,  Armstrong  VW,  et  al.  Idebenone  protects 
hepatic microsomes against oxygen radical-mediated damage in 
organ preservation solutions. Transplantation. 1995;60:444.

9.  Napolitano A, Salvetti S, Vista M, et al. Long-term treatment with 
idebenone  and  riboflavin  in  a  patient  with  MELAS.  Neurol  Sci. 
2000;21:S981.

10.  Ikejiri Y, Mori E, Ishii K, et al. Idebenone improves cerebral mito-
chondrial  oxidative  metabolism  in  a  patient  with  MELAS. 
Neurology. 1996;47:583.

11.  Sasseville D, Moreau L, Al-Sowaidi M. Allergic contact dermatitis 
to  idebenone  used  as  an  antioxidant  in  an  anti-wrinkle  cream. 
Contact Dermatitis. 2007;56:117.

12.  DiNardo  JC  et  al.  Antioxidants  compared  in  a  new  protocol  to 
measure  protective  capacity  against  oxidative  stress  –  Part  II. 
Paper presented at Annual Meeting of the American Academy of 
Dermatology; February 6–11, 2004; Washington, DC.

13.  Tournas JA, Lin FH, Burch JA, et al. Ubiquinone, idebenone, and 
kinetin  provide  ineffective  photoprotection  to  skin  when  com-
pared to a topical antioxidant combination of vitamins C and E 
with ferulic acid. J Invest Dermatol. 2006;126:1185.

14.  Baxter  RA.  Anti-aging  properties  of  resveratrol:  Review  and 
report of a potent new antioxidant skin care formulation. J Cosmet 
Dermatol. 2008;7:2.

15.  Dong KK, Damaghi N, Kibitel J, et al. A comparison of the relative 
antioxidant potency of L-ergothioneine and idebenone. J Cosmet 
Dermatol. 2007;6:183.

16.  Bruce  S.  Cosmeceuticals  for  the  attenuation  of  extrinsic  and 

intrinsic dermal aging. J Drugs Dermatol. 2008;7:s17.

 
216 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

17.  Savoia A, Landi S, Baldi A. A new minimally invasive mesother-
apy  technique  for  facial  rejuvenation.  Dermatol  Ther  (Heidelb). 
2013;3:83.

18.  Natkunarajah  J,  Ostlere  L.  Allergic  contact  dermatitis  to  ide-
benone  in  an  over-the-counter  anti-ageing  cream.  Contact 
Dermatitis. 2008;58:239.

19.  Mc Aleer MA, Collins P. Allergic contact dermatitis to hydroxydecyl 
ubiquinone  (idebenone)  following  application  of  anti-ageing 
cosmetic cream. Contact Dermatitis. 2008;59:178.

20.  Amorim  Cde  M,  Couto  AG,  Netz  DJ,  et  al.  Antioxidant  
idebenone-loaded  nanoparticles  based  on  chitosan  and 
N-carboxymethylchitosan. Nanomedicine. 2010;6:745.

21.  Montenegro  L,  Sinico  C,  Castangia  I,  et  al.  Idebenone-loaded 
solid  lipid  nanoparticles  for  drug  delivery  to  the  skin:  In  vitro 
evaluation. Int J Pharm. 2012;434:169.

22.  Li B, Ge ZQ. Nanostructured lipid carriers improve skin permea-
tion  and  chemical  stability  of  idebenone.  AAPS  PharmSciTech. 
2012;13:276.

23.  Carbone C, Pignatello R, Musumeci T, et al. Chemical and tech-
nological delivery systems for idebenone: A review of literature 
production. Expert Opin Drug Deliv. 2012;9:1377.

24.  Sachs DL, Rittié L, Chubb HA, et al. Hypo-collagenesis in photo-
aged skin predicts response to anti-aging cosmeceuticals. J Cosmet 
Dermatol. 2013;12:108.

25.  Nitta A, Hasegawa T, Nabeshima T. Oral administration of ide-
benone,  a  stimulator  of  NGF  synthesis,  recovers  reduced  NGF 
content in aged rat brain. Neurosci Lett. 1993;163:219.

26.  Suno M, Nagaoka A. Inhibition of brain mitochondrial swelling 

by idebenone. Arch Gerontol Geriatr. 1989;8:299.

27.  Lerman-Sagie T, Rustin P, Lev D, et al. Dramatic improvement in 
mitochondrial  cardiomyopathy  following  treatment  with  ide-
benone. J Inherit Metab Dis. 2001;24:28.

28.  Mordente A, Martorana GE, Minotti G, et al. Antioxidant proper-
ties  of  2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4- 
benzoquinone (idebenone). Chem Res Toxicol. 1998;11:54.

29.  McDaniel DH, Neudecker BA, DiNardo JC, et  al.  Idebenone:  A 
new antioxidant – Part I. Relative assessment of oxidative stress 
protection capacity compared to commonly known antioxidants. 
J Cosmet Dermatol. 2005;4:10.

30.  Gillis  JC,  Benefield  P,  McTavish  D.  Idebenone:  A  review  of  its 
pharmacodynamic and pharmacokinetic properties, and therapeu-
tic use in age-related cognitive disorders. Drugs Aging. 1994;5:133.

31.  Bergamasco B, Scarzella L, La Commare P. Idebenone, a new drug 
in  the  treatment  of  cognitive  impairment  in  patients  with 
dementia of the Alzheimer type. Funct Neurol. 1994;9:161.

32.  Yamada K, Nitta A, Hasegawa T, et al. Orally active NGF synthe-
sis  stimulators:  Potential  therapeutic  agents  in  Alzheimer’s  dis-
ease. Behav Brain Res. 1997;83:117.

33.  Weyer G, Babej-Dölle RM, Hadler D, et al. A controlled study of 
2  doses  of  idebenone  in  the  treatment  of  Alzheimer’s  disease. 
Neuropsychobiology. 1997;36:73.

34.  Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone 
in the treatment of Alzheimer’s disease: Update on a 2-year double-
blind multicentre study. J Neural Transm Suppl. 1998;54:301.

 
C H A P T E R   6 2

Melatonin

C H A P T E R  62  ■   M E L ATO N I N  

217

Activities:

Antioxidant, anticarcinogenic, antiaging, anti-inflamma-
tory,1 anxiolytic, immunomodulatory2

Significantly,  a  melatoninergic  antioxidative  system  that 
regulates cutaneous homeostasis and exhibits the potential to 
prevent ultraviolet (UV)-induced skin aging and skin cancer has 
been recently discovered.7,8,20,21

Important Chemical Components:

Also known as N-acetyl-5-methoxytryptamine

 CHEMISTRY

Origin Classification:

This  ingredient  is  a  natural  hormone  found  in  most 
living  organisms.  It  is  also  synthesized  for  oral 
supplementation and topical application.

Personal Care Category:

Antioxidant, antiaging

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW, DSNW, ORNW, and OSNW

 SOURCE

Melatonin  (N-acetyl-5-methoxytryptamine),  a  tryptophan 
derivative, is a hormone produced naturally by the pineal gland in 
humans, and stimulated by β-adrenergic receptors. In addition, it is 
synthesized  in  mammals  by  the  eyes,  ovaries,  bone  marrow, 
gastrointestinal  tract,  lymphocytes,  and  skin,  where  it  is  also 
metabolized.3–6  Additionally,  melatonin  has  been  recorded  at 
significant  levels  in  bile  fluid,  cerebrospinal  fluid,  and  gastral 
mucosa.7 Also found in most animal and plant species as well as 
fungi and even unicellular organisms, it follows a circadian light-
dependent rhythm of secretion, and is derived from tryptophan, 
which is present in all organisms.8,9 That is, melatonin is secreted 
during  the  dark  phase  of  the  light/dark  cycle,  and  also  regulates 
seasonal  biorhythms  (and  is  often  accordingly  referred  to  as  the 
“hormone of darkness” and the body’s chronological pacemaker).5,9 
In  fact,  melatonin  is  best  known  for  regulating  and  facilitating 
sleep,  with  its  “chronobiotic”  characteristics  justifying  its  use  to 
treat sleep disorders including jet lag, shift-work sleep disruption, 
and insomnia in elderly and depressive patients.5

 HISTORY

Although melatonin is a phylogenetically ancient methoxyin-
dole,  it  was  initially  isolated  from  bovine  pineal  glands  in 
1958.5,7–12  Subsequently,  researchers  learned  that  melatonin 
was produced nocturnally and secreted by the pineal gland and 
other organs in mammals including humans.8 Melatonin and its 
relations  to  skin  function  have  been  studied  since  its  skin-
lightening effects on frogs were observed in the late 1950s.10,13,14 
The status of melatonin as a potent free radical scavenger was 
uncovered  in  1993.8,15,16  That  same  year,  the  first  evidence 
emerged  of  the  production  of  melatonin  in  the  skin.17–19 

Melatonin is a methoxyindole produced primarily by the pineal 
gland.  In  the  skin,  the  essential  amino  acid  tryptophan  is  the 
precursor;  it  is  converted  by  tryptophan  hydroxylase  to 
5-OH-Trp and then to serotonin. The acetylation of serotonin 
leads to the formation of N-acetylserotonin, which is transformed 
after the hydroxyindole-O-methyltransferase into melatonin.9

 ORAL USES

Several plants are good sources of dietary melatonin, as it appears 
ubiquitously  in  nature  and  is  found  in  almost  60  herbs  used  in 
traditional  Chinese  medicine.5 Melatonin  is  also  used  as  an  oral 
supplement, primarily to restore regular sleep patterns. Prescriptions 
are required in some countries for melatonin supplements.

In  2008,  Otálora  et  al.,  noting  that  melanoma  is  known  to 
respond to melatonin in vitro, examined the effects of exogenous 
melatonin on hindering tumor growth and correcting impaired 
circadian rhythmicity. They found that melatonin administration 
(2 mg/kg/ BW/day) restored rhythmicity and improved survival 
in light-dark (12:12 cycle) conditions, but not under continuous 
light  and  circadian  disruption,  suggesting  the  need  to  restrict 
melatonin  administration  to  the  subjective  night  to  hamper 
melanoma progression.22

 TOPICAL USES

In recent years, melatonin has been gaining increased attention 
in  antiaging  medicine  and  dermatology  because  it  has  been 
found  to  exert  potent  antioxidant  activity  (Table  62-1), 
particularly  against  hydroxyl  radicals,5,23  and  melatonin 
levels  are  known  to  decrease  with  age.  In  addition  to  its 
antioxidative  and  regulatory  roles,  including  in  seasonal 
reproduction  control,  melatonin  is  known  to  play  a  role  in 
wound  healing,  to  modulate  the  immune  system,  and  to 
inhibit  inflammation.9,24  In  addition,  there  is  mounting 
evidence  to  suggest  its  viability  as  an  agent  to  prevent 
cutaneous  aging.8  Topical  application  is  preferable  to  oral 
administration  for  deriving  cutaneous  benefits  because 
orally ingested melatonin is metabolized in the liver, yielding 
low levels in the blood and available to the skin.8,25 Further, 
due  to  its  potent  lipophilicity,  topical  melatonin  can 
penetrate  the  stratum  corneum  (SC)  and  form  a  reservoir, 
from where it is continuously released to the rest of the skin 
and  dermal  vasculature,  potentially  complementing  and 
augmenting the activity of endogenous melatonin.3,8,26

Indeed, it is an important hormone in the dermatologic realm 
insofar as it is known to inhibit UV-induced erythema; implicated 
in skin functions such as hair growth, fur pigmentation/molting in 

 
218 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

TABLE 62-1
Pros and Cons of Melatonin

Pros
Potent antioxidant
One of the most potent scavengers of the 
hydroxyl radical(the strongest of free 
radicals)27

Activates other endogenous antioxidants 

Cons
Small population sizes in clinical studies
Much more research is needed on topical uses

Effect on cortisol levels in postmenopausal 
women not on estrogen replacement 
therapy

Exhibits immunomodulatory and oncostatic 

Anecdotal reports of melasma exacerbation

properties5

Extensive support for protective activity against 
UV-induced damage from in vitro studies

Strongly lipophilic
May strengthen the skin barrier

various  species,  and  melanoma  control;  and  thought  to  have 
potential  in  treating  various  human  dermatoses  (e.g.,  atopic 
eczema, psoriasis, and malignant melanoma) as well as conditions 
such as androgenetic alopecia.6,9,23 Of note, among the numerous 
plant  species  from  which  cutaneous  applications  are  derived, 
feverfew is known to contain an appreciable level of melatonin 
(see Chapter 66, Feverfew).28

Androgenetic Alopecia
In  2004,  Fisher  et  al.  also  investigated  whether  topically 
applied melatonin affects the anagen and telogen hair growth 
phases in women with androgenetic alopecia or diffuse hair 
loss.  In  their  double-blind,  randomized,  placebo-controlled 
pilot  study  with  40  women,  they  instructed  participants  to 
apply 0.1 percent melatonin or a placebo preparation to the 
scalp once daily for six months. In the 12 women with andro-
genetic  hair  loss,  melatonin  contributed  to  a  significantly 
greater  anagen  hair  rate  in  occipital  hair  as  compared  to 
placebo.  In  the  28  participants  with  diffuse  alopecia, 
melatonin  application  led  to  significant  growth  in  frontal 
hair.  Anagen  hair  growth  in  the  occipital  regions  was 
increased in both groups, with insignificant differences. The 
investigators  noted  that  while  melatonin  levels  rose  with 
treatment, the physiological night peak of serum melatonin 
was not exceeded. They concluded that their pilot study was 
the  first  to  their  knowledge  to  demonstrate  in  vivo  that 
topically applied melatonin has the potential to impact hair 
growth in humans.29

In  2012,  Fischer  et  al.  reported  on  one  pharmacodynamic 
study  and  four  clinical  pre–post  studies  of  topically  applied 
melatonin  as  a  treatment  for  androgenetic  alopecia.  All  five 
studies  demonstrated  positive  results,  with  significant 
reductions in hair loss seen in multiple tests all of which were 
associated  with  good  safety  and  tolerability.  In  the  largest  of 
the  studies,  a  three-month,  multicenter  (200  centers)  study 
with over 1,800 participants, the percentage of patients with a 
two-  to  threefold  positive  hair-pull  test  declined  from  
61.6 percent to 7.8 percent and those with a negative hair-
pull test rose from 12.2 percent to 61.5 percent. Seborrheic 
dermatitis  of  the  scalp  was  also  found  to  have  markedly 
diminished  in  these  patients.  The  researchers  concluded 
that the topical application of a cosmetic melatonin solution 
is a viable therapeutic option for patients with androgenetic 
alopecia.30

Antioxidant and Anticancer Activity
Melatonin  receptors  are  expressed  in  several  skin  cell  types, 
notably normal and malignant keratinocytes, melanocytes, and 
fibroblasts.8,14

Endogenous melatonin influences skin functions and structures 
through  cell-surface-  and  putative-nuclear  receptor-mediated 
expressions in skin cells and the broad expression and pleiotropic 
activity  of  the  cutaneous  melatoninergic  system  yields  a  high 
level of cell-specific selectivity, several investigators have found.3,7
The  dynamic  antioxidant  activity  of  melatonin  is  thought  to 
result from its capacity to scavenge free radicals, reduce free radical 
generation, and upregulate antioxidant enzymes.31 Further, mela-
tonin has been shown to counteract the effects of UV-induced solar 
damage, specifically thwarting mitochondrial and DNA harm.8

The decrease in endogenous melatonin synthesis with age is 
thought to significantly contribute to the gradual decline of the 
immune system and thus increased susceptibility to neoplastic 
disease development.4

In 2005, Slominski et al. identified the cutaneous expression 
of  the  mechanism  of  action  in  the  transformation  of 
l-tryptophan to serotonin and melatonin through detection of 
the  corresponding  genes  and  proteins  with  demonstrated 
enzymatic  activities  for  tryptophan  hydroxylase,  serotonin 
N-acetyl-transferase,  and  hydroxyindole-O-methyltransferase 
in extracts from skin and skin cells. The investigators concluded 
that  locally  synthesized  or  topically  administered  melatonin 
has  the  potential  to  attenuate  environmental  or  endogenous 
stresses and contribute to homeostasis as well as play a role in 
treating cutaneous disorders and acting as a photoprotectant.14
Melatonin  has  been  demonstrated  to  augment  T-helper  cell 
response against malignancy by releasing interleukin (IL)-2, IL-10 
and interferon (IFN)-γ. In addition, melatonin has been found to be 
effective in hindering neoplastic growth in melanoma, as well as 
breast, prostate, ovarian, and colorectal cancer.4 Indeed, multiple 
studies have shown that melatonin possesses oncostatic activity.5
In 2013, Fischer et al. reported that melatonin dose- and time-
dependently  protected  against  UV-induced  8-hydroxy-
2′-deoxyguanosine (8-OHdG) formation and antioxidant enzyme 
depletion  (i.e.,  catalase,  glutathione  peroxidase,  and  superoxide 
dismutase) using ex vivo human full-thickness skin. They concluded 
that melatonin acted as a strong antioxidant and protector of DNA 
against  oxidative  skin  damage.32  Previously,  Fischer  et  al.  had 
shown that melatonin more strongly scavenged UV-induced reac-
tive  oxygen  species  in  leukocytes  than  either  vitamin  C  or  the 
vitamin E analog trolox [see Chapter 55, Ascorbic Acid (Vitamin C), 
and Chapter 56, Tocopherol (Vitamin E)].9,33

Also in 2013, Sierra et al. investigated the in vivo and in vitro 
protective  effects  of  a  new  melatonin-containing  emulsion 
combined with UV filters against skin irradiation, finding good 
physical stability and melatonin permeation in an emulsion with 
a mixture of three UV filters. The formulation displayed signifi-
cant  radical-scavenging  activity  and  a  photoprotective  assay 
revealed that skin treated with melatonin/UV filter formulation 
was  statistically  equivalent  to  nonirradiated  control  skin.  The 
investigators concluded that melatonin acted in this formulation 
as a strong antioxidant and also activated endogenous enzymatic 
protection against oxidative stress.34

In Vitro Studies
In 2001, Ryoo et al. set out to elucidate the antioxidant role of 
melatonin  in  reaction  to  UVB  exposure  in  cultured  skin 
fibroblasts. Pretreatment with melatonin was found to mitigate 

 
cell  membrane  lipid  peroxidation,  yielding  an  increase  in  the 
absolute number of surviving cells and reducing malondialde-
hyde levels. Melatonin pretreatment also prevented the pre-G1 
arrest  leading  to  apoptosis.  The  researchers  concluded  that 
melatonin was shown to be an effective inhibitor of membrane 
peroxidation.  This  is  thought  to  be  the  first  report  on  the 
protection of dermal fibroblasts from UVB by melatonin.35

Melatonin was one of the several substances found to act as a 
viable antioxidant agent by Trommer and Neubert in 2005. They 
screened 47 substances (drugs, plant extracts, plant ingredients, 
and  polysaccharides)  for  new  antioxidative  compounds  for 
topical administration using skin lipid in vitro models.36

In 2006, Fischer et al. examined the in vitro protective effects of 
melatonin  against  UV-induced  cell  damage  in  human 
keratinocytes. They found that pre-incubation  is  necessary  for 
melatonin to display protective activity, which includes apoptosis 
inhibition.37

In a 2009 issue of  In Vivo, Izykowska  et  al. reported on the 
effects of melatonin on melanoma cells in culture medium and 
after its addition to culture medium for 30 minutes prior to UVA 
or UVB exposure, finding that melatonin clearly protected cells 
from UVA and UVB activity in vitro.38 In the same issue of In Vivo, 
noting  previous  studies  showing  a  protective  effect  on  cells 
exerted by melatonin mainly in relation to UVB, Izykowska et al. 
also reported on the effects of melatonin on keratinocytes and 
fibroblasts added to culture medium 30 minutes before exposure 
to UVA and UVB, again finding that melatonin affords protection 
to skin cells from the activity of UVA as well as UVB in vitro.39

In 2013, Rezzani et al. assessed the effects of pretreating murine 
fibroblast cells with melatonin before exposure to UVA radiation. 
They  found  that  melatonin  increased  heme-degrading  enzyme 
expression and inhibited UVA-induced photodamage, suggesting 
potential applications for limiting skin aging.31

Animal Studies
In 2006, Sener et al. studied the effects of melatonin in treating 
pressure ulcers in rats. Animals were treated twice daily during 
reperfusion  periods  with  a  locally  applied  ointment  or  given 
intraperitoneal  administration  of  the  antioxidant.  Topical 
melatonin treatment was associated with suppressed malondi-
aldehyde levels and attenuated decreases in glutathione in the 
skin induced by the pressure ulcers. Melatonin treatment also 
prevented  significant  increases  in  alanine  aminotransferase, 
aspartate  aminotransferase,  blood  urea  nitrogen,  creatinine, 
lactate  dehydrogenase,  and  collagen  levels.  In  addition,  the 
researchers  noted  degenerative  changes  in  the  dermis  and 
epidermis of the rats, with marked decreases in tissue injury in 
the  animals  that  received  topical  melatonin.  They  concluded 
that  melatonin,  delivered  topically  or  systemically,  warrants 
consideration as a pressure ulcer treatment.40

Two  years  later,  Pugazhenthi  et  al.  used  a  full-thickness 
incisional  rat  model  to  evaluate  the  dermal  wound  and  scar 
healing  effects  of  melatonin  (1.2  mg/kg  intradermal).  The 
investigators observed that melatonin significantly ameliorated 
scar quality. Treatment with melatonin also markedly reduced 
inducible  nitric  oxide  synthase  (iNOS)  activity  in  the  acute 
inflammatory  phase  but  substantially  elevated  iNOS  in  the 
resolving  phase.  Further,  melatonin  raised  cyclooxygenase-2, 
which  has  known  anti-inflammatory  properties,  following 
wound induction and facilitated angiogenesis. Arginase activity, 
instrumental in collagen production by synthesizing the building 
block proline, was increased by melatonin treatment, which also 
upregulated  the  protein  profiles  of  heme  oxygenase-1  and 

C H A P T E R  62  ■   M E L ATO N I N  

219

heme oxygenase-2 isoforms, which are essential in wound repair. 
The  investigators  suggested  that  their  findings  represented  the 
first  report  showing  that  melatonin  can  significantly  enhance 
wound healing and scar formation.2

In  a  2009  study  using  NC/Nga  mice,  researchers  investigated 
whether  melatonin  inhibits  the  development  of  2,4-dinitrofluor-
obenzene  (DNFB)-induced  atopic  dermatitis-like  skin  lesions. 
Topically administered melatonin hindered ear thickness increases 
and skin lesions engendered by DNFB treatment. Melatonin was 
also  found  to  significantly  inhibit  IL-4  and  IFN-γ  secretion  by 
activated CD4+ T cells from the draining lymph nodes of DNFB-
treated mice, and diminish serum total IgE levels. The investigators 
concluded that topically administered melatonin, by lowering total 
IgE  in  serum,  and  IL-4  and  IFN-γ  synthesis  by  activated  CD4+  
T  cells,  inhibits  atopic  dermatitis-like  skin  lesion  development 
provoked by DNFB treatment in NC/Nga mice.24

In a 2010 study comparing systemic and topical administra-
tion  of  melatonin  in  a  chronic  wound  model  in  rats  whose 
release  of  basal  melatonin  was  hindered  due  to  pinealectomy, 
Ozler et al. found that hydroxyproline levels were significantly 
lower  in  rats  that  underwent  pinealectomy  and  wound  
formation  compared  to  the  controls  (with  wound  formation 
only), with increased wound surface areas. Also compared to the 
control  group,  these  animals  exhibited  increased  malondialde-
hyde  levels  and  decreases  in  superoxide  dismutase  and 
glutathione peroxidase compared to control animals. However, 
superoxide  dismutase  and  glutathione  peroxidase  enzymes 
increased in the groups treated with melatonin and malondialde-
hyde  decreased.  The  researchers  concluded  that  melatonin 
exerts  a  positive  effect  on  wound  healing,  as  the  absence  of 
melatonin prolonged the healing process. Topical and systemic 
administration methods were equally effective.41

Recent  studies  have  also  shown  that  melatonin  and  the 
antidiabetes drug metformin have the capacity to suppress skin 
carcinogenesis as well as lipid peroxidation induced by benz(a)-
pyrene in female SHR mice.42,43

Human Studies
In 1996, in one of the earliest studies of the effects of topically 
applied  melatonin  on  UV-induced  erythema,  Bangha  et  al. 
conducted a double-blind, randomized study with 20 healthy 
volunteers. Each subject was exposed to UVB (0.099 J/cm2) on 
the lower back and then treated with various concentrations of 
melatonin.  The  investigators  observed  a  dose–response 
relationship between melatonin concentration and the degree 
of erythema, with significantly less redness found in the areas 
treated with 0.5 percent melatonin as compared to melatonin 
0.05 percent or just the vehicle gel.44

The next year, Bangha et al. performed another double-blind, 
randomized study in 20 volunteers to examine the antierythema 
effects of topical melatonin and the role of the application time in 
exerting the effect. Investigators treated small areas of the lower 
back with 0.6 mg/cm2 melatonin 15 minutes before or 1, 30, or 
240 minutes after simulated UVA and UVB irradiation at twice 
the  individual  minimal  erythema  dose.  They  found  that 
posttreatment  with  melatonin  exerted  no  protective  effect  
but pretreatment 15 minutes prior to irradiation yielded signifi-
cant protective effects against erythema.45 In a subsequent similar 
double-blind, randomized clinical trial with 20 healthy volunteers, 
this time led by Fischer, the visual score indicated that melatonin 
application  15  minutes  before  irradiation  significantly  hindered 
erythema  as  compared  to  vehicle  control.  Postirradiation 
treatment with melatonin did not yield UV inhibition.46

 
220 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

In a small study of the penetration kinetics of topical melatonin 
in six healthy volunteers between the ages of 26 and 34 years 
old,  Bangha  et  al.  found  that  melatonin  has  the  potential  to 
accumulate  in  the  SC  with  extended  release  into  the  blood 
system through cutaneous delivery.47

In 1998, Dreher et al. conducted a randomized, double-blind 
study in 12 healthy adults (6 women and 6 men, all Caucasian, 
ranging  in  age  from  29  to  49  years  old)  of  the  short-term 
photoprotective effects of topically applied melatonin as well as 
vitamins  C  and  E,  alone  or  in  combination.  All  formulations 
were applied 30 minutes after UV exposure. A dose-dependent 
photoprotective  effect  was  associated  with  melatonin,  with 
modest  effects  seen  with  the  vitamins  alone.  Photoprotective 
activity  was  clearly  enhanced  when  using  melatonin  in 
combination with vitamins C and E. This is thought to be the first 
in  vivo  demonstration  of  a  protective  effect  imparted  by  topical 
melatonin in combination with other antioxidants.48 The following 
year, Dreher et al. performed a similar experiment to assess the 
short-term photoprotective effects of the same compounds. This 
randomized,  double-blind,  placebo-controlled  human  study 
entailed the topical use of each antioxidant alone or in combina-
tion  after  UV  exposure  in  a  single  application  (immediately  or  
30  minutes  after  UV  exposure)  or  in  multiple  applications  
30  minutes,  one  hour,  and  two  hours  after  UV  exposure  
(totaling  three  applications).  Interestingly,  no  photoprotective 
effects were observed regardless of the number of applications of 
antioxidants. The investigators concluded that given the speed of 
damage to skin from UV radiation, antioxidants likely must be 
delivered at the appropriate site in sufficient concentrations at the 
outset of and during active oxidative insult.49

Similarly,  in  2006,  Howes  et  al.  studied  the  effects  of  topical 
melatonin applied after solar-simulated UV exposure in 16 healthy 
Mantoux-positive volunteers and found that melatonin conferred 
no protection against sunburn or immune suppression.50

However, four years prior, Morganti et al. conducted an eight-
week  randomized,  double-blind,  placebo-controlled  study  on  
30  xerotic  female  volunteers  (between  48  and  59  years  old)  to 
determine the effects of topical and systemic antioxidant-enriched 
formulation  administration  on  the  skin.  Subjects  applied  twice 
daily a nanocolloidal gel and/or took two capsules per day of an 
oral  diet  supplement.  The  antioxidant-enriched  formulations 
included vitamins C and E, α-lipoic acid, emblica, and melatonin 
(see Chapter 38, Emblica Extract). Investigators found that oxida-
tive stress and lipid peroxidation declined 30 to 40 percent in the 
blood serum of all participants who used the topical or systemic 
antioxidant formulation. Those treated with the antioxidants also 
experienced declines in free radicals recovered in blood serum and 
on skin and decreases in reactive oxygen species engendered by 
UVB irradiation of leukocytes (in vitro). The researchers concluded 
that the tested compounds indeed delivered topical and systemic 
photoprotection and represent promising ingredients for combat-
ing oxidative stress and photoaging.51

In 2004, Fischer et al. conducted a clinical study in 15 healthy 
volunteers to consider the skin penetration activity of melatonin 
0.01 percent in a cream and 0.01 and 0.03 percent in a solution. In 
a  24-hour  time  window,  investigators  took  blood  samples  for 
melatonin measurement prior to application at 9 am as well as 1, 
4,  8,  and  24  hours  after  application.  Preapplication  serum 
melatonin levels ranged from 0.6 to 15.9 pg/mL. The mean serum 
value 24 hours later after application of the 0.01 percent mela-
tonin cream was 9.0 pg/mL. For the 0.01 percent solution group, 
the mean melatonin level was 12.7 pg/mL 24 hours after applica-
tion. Melatonin levels also markedly increased just 1 and 8 hours 
later in the 0.03 percent solution group, with cumulative mela-

tonin  noted  as  7.1  pg/mL  in  the  0.01  percent  cream  subjects,  
8.6 pg/mL in the 0.01 percent solution participants, and 15.7 pg/mL 
in  the  0.03  percent  group.  The  investigators  concluded  that 
markedly  lipophilic  melatonin  penetrates  the  skin  with  serum 
blood levels increasing in a dose- and galenic-dependent manner 
without causing increases above the physiological range.26

In 2008, a single-blind, randomized study with 145 patients 
was  conducted  to  ascertain  the  effectiveness  of  a  formulation 
containing  2.5  mg  melatonin  and  100  mg  SB-73  (a  mixture  of 
magnesium, phosphate, and fatty acids extracted from Aspergillus 
species, which exhibit activity against the herpes virus) and to 
compare it to treatment with Acyclovir. Seventy subjects were 
treated  with  the  melatonin/SB-73  preparation  and  75  received  
200 mg of Acyclovir (group B). A statistically significant difference 
between the groups was noted by the authors. After seven days 
of  treatment,  67  participants  in  the  melatonin/SB-73  group  
(95.7  percent)  reported  complete  symptom  resolution;  
64 participants (85.3 percent) of the Acyclovir reported such a 
result.52

In  2012,  Morganti  et  al.  conducted  a  randomized,  placebo-
controlled, 12-week multicenter study with 70 healthy partici-
pants to again examine melatonin in combination. In this case, 
they considered the combined activity of melatonin, vitamin E, 
and β-glucan complexed with chitin nanocrystals administered 
topically and orally. All skin parameters reviewed were signifi-
cantly  better  after  treatment  with  the  melatonin,  vitamin  E, 
β-glucan  combination  as  compared  to  placebo,  with  greater 
improvements observed when these ingredients were complexed 
with  chitin  nanocrystals.  Specifically,  the  treatment  yielded 
decreased wrinkling and enhanced skin appearance.53

 SAFETY ISSUES

Exogenous  melatonin  is  reported  to  be  safe  for  short-term  
(<3  months)  use  for  sleep-related  disorders.54,55  A  fixed  drug 
eruption has been reported with the use of oral melatonin.56

 ENVIRONMENTAL IMPACT

Given  the  widespread  availability  of  plants  containing 
melatonin,  no  discrete  environmental  toll  is  exacted  in  the 
preparation of oral or topical melatonin products.

 FORMULATION CONSIDERATIONS

The  author  has  no  insight  on  the  challenges  of  formulating 
melatonin.

 USAGE CONSIDERATIONS

The  author  has  noticed  that  patients  with  melasma  seem  to 
worsen after taking melatonin supplements. For this reason, it 
is advised that individuals with pigmented skin (designated as 
“P” types in the Baumann Skin Type System) not use melatonin-
containing  preparations.  This  is  due  to  activation  of  melanin 
production by melatonin.

 SIGNIFICANT BACKGROUND

Melatonin should be used with care in postmenopausal women 
not  on  hormone  replacement  therapy.  Menopause  and  aging 
are  believed  to  impair  the  regulation  of  the  hypothalamic-

 
pituitary-adrenal (HPA) axis. The administration of melatonin 
increases cortisol levels in postmenopausal women, leading to 
increased serum glucose levels,57 and glycation. Administration 
of estrogen improves the regulation of the HPA axis and blocks 
the increase of cortisol levels with melatonin administration.58
Kim  et  al.  have  shown  that  melatonin  and  its  metabolite 
methoxykynuramine  appear  to  stimulate  differentiation  in 
human epidermis, suggesting their important role in building the 
skin  barrier.59  Further,  melatonin  receptors  are  expressed  in 
several  skin  cell  types,  notably  normal  and  malignant 
keratinocytes, melanocytes, and fibroblasts.8,14

 CONCLUSION

There  is  ample  research  on  the  biological  functions  of 
melatonin.  There  is  also  an  interesting,  emerging  body  of 
evidence  on  the  dermatologic  effectiveness  of  the  topical 
application of this hormone. In fact, there seems to be a wide 
variety  of  potential  cutaneous  uses  for  melatonin.  However, 
most of the clinical studies have been extremely small, including 
a  couple  of  investigations  that  indicated  no  photoprotective 
effect associated with melatonin. The effects of melatonin on 
melanogenesis  (skin  pigmentation),  the  skin  barrier,  and 
cortisol levels all play a significant but poorly understood role. 
Clearly,  much  more  research,  preferably  in  the  form  of 
randomized, double-blind studies is necessary before adequate 
recommendations  to  patients  about  melatonin  use  for  skin 
health can be issued.

REFERENCES

1.  Puizina-Ivic´ N, Miric´ L, Carija A, et al. Modern approach to topi-

cal treatment of aging skin. Coll Antropol. 2010;34:1145.

2.  Pugazhenthi K, Kapoor M, Clarkson AN, et al. Melatonin acceler-
ates  the  process  of  wound  repair  in  full-thickness  incisional 
wounds. J Pineal Res. 2008;44:387.

3.  Slominski  A,  Tobin  DJ,  Zmijewski  MA,  et  al.  Melatonin  in  the 
skin:  Synthesis,  metabolism  and  functions.  Trends  Endocrinol 
Metabl. 2008;19:17.

4.  Srinivasan  V,  Pandi-Perumal  SR,  Brzezinski  A,  et  al.  Melatonin, 
immune function and cancer. Recent Pat Endocr Metab Immune Drug 
Discov. 2011;5:109.

5.  Pandi-Perumal SR, Srinivasan V, Maestroni GJ, et al. Melatonin: 
Nature’s most versatile biological signal? FEBS J. 2006;273:2813.
6.  Fischer TW, Slominski A, Tobin DJ, et al. Melatonin and the hair 

follicle. J Pineal Res. 2008;44:1.

7.  Fischer  TW,  Slominski  A,  Zmijewski  MA,  et  al.  Melatonin  as  a 
major skin protectant: From free radical scavenging to DNA dam-
age repair. Exp Dermatol. 2008;17:713.

8.  Kleszczynski  K,  Fischer  TW.  Melatonin  and  human  skin  aging. 

Dermatoendorinol. 2012;4:245.

9.  Kleszczyn´ ski K, Hardkop LH, Fischer TW. Differential effects of 
melatonin  as  a  broad  range  UV-damage  preventive  dermato-
endocrine regulator. Dermatoendocrinol. 2011;3:27.

10.  Lerner  AB,  Case  JD,  Takahashi  Y,  et  al.  Isolation  of  melatonin,  a 
pineal  factor  that  lightens  melanocytes.  J  Am  Chem  Soc.  1958;80: 
2587.

11.  Lerner  AB,  Case  JD,  Takahasi  Y.  Isolation  of  melatonin  and  5- 
methoxyindole-3-acetic acid from bovine pineal glands. J Biol Chem. 
1960;235:1992.

12.  Wetterberg L. Melatonin and clinical application. Reprod Nutr Dev. 

1999;39:367.

13.  Lerner  AB,  Case  JD.  Pigment  cell  regulatory  factors.  J  Invest 

Dermatol. 1959;32(2, Part 2):211.

14.  Slominski  A,  Fischer  TW,  Zmijewski  MA,  et  al.  On  the  role  of 
melatonin  in  skin  physiology  and  pathology.  Endocrine.  2005; 
27:137.

15.  Poeggeler B, Reiter RJ, Tan DX, et al. Melatonin, hydroxyl radical-
mediated oxidative damage, and aging: A hypothesis. J Pineal Res. 
1993;14:151.

C H A P T E R  62  ■   M E L ATO N I N  

221

16.  Tan DX, Chen LD, Poeggeler B, et al. Melatonin: A potent, endog-

enous hydroxyl radical scavenger. Endocr J. 1993;1:57.

17.  Gaudet SJ, Slominski A, Etminan M, et al. Identification and char-
acterization  of 
forms  of  arylamine 
isozymic 
N-acetyltransferase  in  Syrian  hamster  skin.  J  Invest  Dermatol. 
1993;101:660.

two 

18.  Slominski A, Pisarchik A, Semak I, et al. Serotoninergic system in 

hamster skin. J Invest Dermatol. 2002;119:934.

19.  Desotelle JA, Wilking MJ, Ahmad N. The circadian control of skin 

and cutaneous photodamage. Photochem Photobiol. 2012;88:1037.

20.  Fischer  TW,  Sweatman  TW,  Semak  I,  et  al.  Constitutive  and 
UV-induced  metabolism  of  melatonin  in  keratinocytes  and  cell-
free systems. FASEB J. 2006;20:1564.

21.  Slominski A, Wortsman J, Tobin DJ. The cutaneous serotoninergic/
melatoninergic  system:  Securing  a  place  under  the  sun.  FASEB  
J. 2005;19:176.

22.  Otálora  BB,  Madrid  JA,  Alvarez  N,  et  al.  Effects  of  exogenous 
melatonin and circadian synchronization on tumor progression in 
melanoma-bearing C57BL6 mice. J Pineal Res. 2008;44:307.

23.  Fischer T, Wigger-Alberti W, Elsner P. Melatonin in dermatology. 

Experimental and clinical aspects. Hautarzt. 1999;50:5.

24.  Kim TH, Jung JA, Kim GD, et al. Melatonin inhibits the develop-
ment  of  2,4-dinitrofluorobenzene-induced  atopic  dermatitis-like 
skin lesions in NC/Nga mice. J Pineal Res. 2009;47:324.
25.  Arendt J. Melatonin. Clin Endocrinol (Oxf). 1988;29:205.
26.  Fischer TW, Greif C, Fluhr JW, et al. Percutaneous penetration of 
topically applied melatonin in a cream and an alcoholic solution. 
Skin Pharmacol Physiol. 2004;17:190.

27.  Reiter RJ. The pineal gland and melatonin in relation to aging: A 
summary of the theories and of the data. Exp Gerontol. 1995;30:199.
28.  Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and 

other medicinal plants. Lancet. 1997;350:1598.

29.  Fischer TW, Burmeister G, Schmidt HW, et al. Melatonin increases 
anagen hair rate in women with androgenetic alopecia or diffuse 
alopecia:  Results  of  a  pilot  randomized  controlled  trial.  
Br J Dermatol. 2004;150:341.

30.  Fischer  TW,  Trüeb  RM,  Hänggi  G,  et  al.  Topical  melatonin  for 
treatment of androgenetic alopecia. Int J Trichology. 2012;4:236.
31.  Rezzani  R,  Rodella  LF,  Favero  G,  et  al.  Attenuation  of  UVA-
induced alterations in NIH3T3 dermal fibroblasts by melatonin. 
Br J Dermatol. 2013 Sep 11. [Epub ahead of print]

32.  Fischer  TW,  Kleszczyn´ ski  K,  Hardkop  LH,  et  al.  Melatonin 
enhances  antioxidative  enzyme  gene  expression  (CAT,  GPx, 
SOD),  prevents  their  UVR-induced  depletion,  and  protects 
against  the  formation  of  DNA  damage  (8-hydroxy-2′-
deoxyguanosine) in ex vivo human skin. J Pineal Res. 2013;54:303.
33.  Fischer  TW,  Scholz  G,  Knöll  B,  et  al.  Melatonin  suppresses 
reactive  oxygen  species  in  UV-irradiated  leukocytes  more 
than  vitamin  C  and  trolox.  Skin  Pharmacol  Appl  Skin  Physiol. 
2002;15:367.

34.  Sierra AF, Ramírez ML, Campmany AC, et al. In vivo and in vitro 
evaluation  of  the  use  of  a  newly  developed  melatonin  loaded 
emulsion combined with UV filters as a protective agent against 
skin irradiation. J Dermatol Sci. 2013;69:202.

35.  Ryoo YW, Suh SI, Mun KC, et al. The effects of the melatonin on 
ultraviolet-B irradiated cultured dermal fibroblasts. J Dermatol Sci. 
2001;27:162.

36.  Trommer H, Neubert RH. Screening for new antioxidative com-
pounds for topical administration using skin lipid model systems. 
J Pharm Pharm Sci. 2005;8:494.

37.  Fischer TW, Zbytek B, Sayre RM, et al. Melatonin increases sur-
vival of HaCaT keratinocytes by suppressing UV-induced apop-
tosis. J Pineal Res. 2006;40:18.

38.  Izykowska I, Gebarowska E, Cegielski M, et al. Effect of mela-
tonin on melanoma cells subjected to UVA and UVB radiation in 
In vitro studies. In Vivo. 2009;23:733.

39.  Izykowska I, Cegielski M, Gebarowska E, et al. Effect of mela-
tonin on human keratinocytes and fibroblasts subjected to UVA 
and UVB radiation In vitro. In Vivo. 2009;23:739.

40.  Sener G, Sert G, Ozer Sehirli A, et al. Melatonin protects against 
pressure  ulcer-induced  oxidative  injury  of  the  skin  and  remote 
organs in rats. J Pineal Res. 2006;40:280.

41.  Ozler M, Simsek K, Ozkan C, et al. Comparison of the effect of 
topical and systemic melatonin administration on delayed wound 
healing  in  rats  that  underwent  pinealectomy.  Scand  J  Clin  Lab 
Invest. 2010;70:447.

42.  Man’cheva  TA,  Demidov  DV,  Plotnikova  NA,  et  al.  Melatonin 
and metformin inhibit skin carcinogenesis and lipid peroxidation 

 
222 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

induced  by  benz(a)pyrene  in  female  mice.  Bull  Exp  Biol  Med. 
2011;151:363.

43.  Deriabina  ON,  Plotnikova  NA,  Anisimov  VN.  Melatonin  and 
metformin inhibit skin carcinogenesis induced by benz(a)pyrene 
in mice. Vopr Onkol. 2010;56:583.

44.  Bangha  E,  Elsner  P,  Kistler  GS.  Suppression  of  UV-induced  ery-
thema  by  topical  treatment  with  melatonin  (N-acetyl-5-
methoxytryptamine).  A  dose  response  study.  Arch  Dermatol  Res. 
1996;288:522.

45.  Bangha  E,  Elsner  P,  Kistler  GS.  Suppression  of  UV-induced  ery-
thema  by  topical  treatment  with  melatonin  (N-acetyl-5-
methoxytryptamine).  Influence  of  the  application  time  point. 
Dermatology. 1997;195:248.

46.  Fischer  T,  Bangha  E,  Elsner  P,  et  al.  Suppression  of  UV-induced 
erythema by topical treatment with melatonin. Influence of the 
application time point. Biol Signals Recept. 1999;8:132.

47.  Bangha  E,  Lauth  D,  Kistler  GS,  et  al.  Daytime  serum  levels  of 
melatonin  after  topical  application  onto  the  human  skin.  Skin 
Pharmacol. 1997;10:298.

48.  Dreher  F,  Gabard  B,  Schwindt  DA,  et  al.  Topical  melatonin  in 
combination with vitamins E and C protects skin from ultraviolet-
induced  erythema:  A  human  study  in  vivo.  Br  J  Dermatol. 
1998;139:332.

49.  Dreher F, Denig N, Gabard B, et al. Effect of topical antioxidants 
on  UV-induced  erythema  formation  when  administered  after 
exposure. Dermatology. 1999;198:52.

50.  Howes RA, Halliday GM, Damian DL. Effect of topical melatonin 
on  ultraviolet  radiation-induced  suppression  of  Mantoux 

reactions  in  humans.  Photodermatol  Photoimmunol  Photomed. 
2006;22:267.

51.  Morganti P, Bruno C, Guarneri F, et al. Role of topical and nutri-
tional supplement to modify the oxidative stress. Int J Cosmet Sci. 
2002;24:331.

52.  Nunes Oda S, Pereira Rde S. Regression of herpes viral infection 
symptoms  using  melatonin  and  SB-73:  Comparison  with 
Acyclovir. J Pineal Res. 2008;44:373.

53.  Morganti P, Fabrizi G, Palombo P, et al. New chitin complexes and 
their  anti-aging  activity  from  inside  out.  J  Nutr  Health  Aging. 
2012;16:242.

54.  Buscemi N, Vandermeer B, Hooton N, et al. Efficacy and safety of 
exogenous  melatonin  for  secondary  sleep  disorders  and  sleep 
disorders  accompanying  sleep  restriction:  Meta-analysis.  BMJ. 
2006;332:385.

55.  Buscemi  N,  Vandermeer  B,  Hooton  N,  et  al.  The  efficacy  and 
safety  of  exogenous  melatonin  for  primary  sleep  disorders.  A 
meta-analysis. J Gen Intern Med. 2005;20:1151.

56.  Bardazzi  F,  Placucci  F,  Neri  I,  et  al.  Fixed  drug  eruption  due  to 

melatonin. Acta Derm Venereol. 1998;78:69.

57.  Cagnacci  A,  Arangino  S,  Renzi  A,  et  al.  Influence  of  melatonin 
administration  on  glucose  tolerance  and  insulin  sensitivity  of 
postmenopausal women. Clin Endocrinol (Oxf). 2001;54:339.
58.  Cagnacci A, Soldani R, Yen SS. Melatonin enhances cortisol levels 
in aged women: Reversible by estrogens. J Pineal Res. 1997;22:81.
59.  Kim TK, Kleszczynski K, Janjetovic Z, et al. Metabolism of mela-
tonin  and  biological  activity  of  intermediates  of  melatoninergic 
pathway in human skin cells. FASEB J. 2013;27:2742.

 
C H A P T E R   6 3

Peppermint

C H A P T E R  63  ■   P E P P E R M I N T  

223

Activities:

Antioxidant,  analgesic,  anesthetic,  anticarcinogenic,  
anti-inflammatory, antimicrobial, antipruritic, antiseptic, 
cooling, radioprotective1

Important Chemical Components:

Leaves, phenolic constituents: Rosmarinic acid, caffeic acid, 
eriocitrin, luteolin, rutin, and hesperidin
Other  leaf  components:  Palmitic  acid,  linoelic  acid,  lino-
lenic acid, and α-tocopherol
Essential oil constituents: Menthol, menthone, menthyl ace-
tate, isomenthone, menthofuran, eucalyptol (1,8-cineole), 
eugenol,  limonene,  pulegone,  carvone,  β-myrcene,  and 
β-caryophyllene2–4

Origin Classification:

Peppermint is natural. Menthol is an organic compound 
obtained  from  peppermint  or  other  mint  oils  or  pro-
duced synthetically.5

Personal Care Category:

Antioxidant, cooling

Recommended  for  the  following  Baumann  Skin 
Types:

ORNW and DRNW

 SOURCE

Mentha piperita, better known as peppermint, is a member of the 
Labiatae family and a popular herb used worldwide. A hybrid of 
Mentha  spicata  (spearmint)  and  Mentha  aquatica  (water  mint),  
peppermint is used in numerous forms (i.e., oil, leaf, leaf extract, and 
leaf  water),  with  the  oil  as  the  most  versatile  and  most  used.2,3  
In fact, peppermint oil is used in food, cosmetic, personal hygiene, 
and pharmaceutical products. Peppermint has long been known for 
its  beneficial  gastrointestinal  effects  and  has  a  well-established 
record of antimicrobial, antifungal, and analgesic activity.6,7 Topical 
preparations  of  peppermint  oil  are  used  to  confer  antipruritic, 
cooling, and calming effects to treat inflammation and cutaneous 
irritation.2 Menthol (C10H20O) is a naturally occurring monocyclic 
terpene alcohol derived from M. piperita as well as other mint oils,8 
and  has  been  associated  with  several  health  benefits.  Recently, 
anticancer properties have been attributed to menthol.9

 HISTORY

The use of peppermint for culinary and medical purposes dates 
back  to  ancient  Greece  and  Rome,10  though  there  is  also 
evidence  to  suggest  that  peppermint  has  been  cultivated  for 
medicinal  purposes 
Japan  for  over  2,000  years  
(Table 63-1).11,12 Most sources appear to point to Mediterranean 

in 

TABLE 63-1
Pros and Cons of Peppermint

Pros
Long history of traditional use
Broad range of biological activity

Cons
Dearth of clinical studies
Can act as a skin sensitizer

origins.  The  term  Mentha  is  thought  to  be  rooted  in  Greek 
mythology,  referring  to  the  nymph  pursued  by  Pluto  and 
subsequently trampled into the ground, transforming her into 
mint,  by  Pluto’s  jealous  wife  Persephone.2  M.  piperita  was 
cultivated  by  the  ancient  Egyptians  and  was  cited  in  the 
pharmacopoeias of Iceland in the 1200s.6,10

A  perennial  herb  native  to  Mediterranean  Europe  but 
disseminated  through  travel,  trade,  and  conquest  and  now 
cultivated  globally,  peppermint  has  been  used  in  various 
traditional  and  folk  medicines  through  Europe  and  Asia. 
Peppermint entered general medical usage in Western Europe in 
the 1700s, and the first commercial crops were grown in England 
around  1750.6,10,13  Known  for  many  years  through  traditional 
medicine as a stimulant as well as carminative agent effective for 
various  gastrointestinal  conditions  (e.g.,  dyspepsia,  dysentery, 
flatulence, nausea, vomiting, and gastritis), modern clinical trials 
have  borne  out  such  indications.3,6,13,14  It  has  been  used  as  a 
sedative and analgesic, and menthol, a key constituent, has been 
used as an inhalant for upper respiratory disorders. 

In  the  West,  menthol  was  first  isolated  by  the  German 
physician and chemist Gaubius in 1771.12 In 1886, Goldscheider 
attributed  the  cooling  sensation  conferred  by  menthol  to  the 
stimulation of thermoreceptors.12 It was not until 2002, though, 
that a common site of action for cold and menthol was identified 
in two unrelated studies.12,15,16

 CHEMISTRY

Peppermint has been shown to exhibit significant antimicrobial 
and  antiviral  activities,  strong  antioxidant  and  antitumor 
actions, and some antiallergenic potential in vitro.3 Its antioxi-
dant  activities  are  ascribed  primarily  to  important  active 
components such as the phenolic acids caffeic and rosmarinic 
acids as well as eugenol and α-tocopherol.1,17

 ORAL USES

Peppermint  or  menthol  is  a  popular  flavoring  agent  for  some 
foods,  including  confections  and  chewing  gums,  and  is  also  a 
widely  consumed  single  ingredient  herbal  tea,  or  tisane.3 
Peppermint leaf is used as a standard medicinal tea for dyspepsia in 
Germany and has been approved by the German Commission E 
for  internal  use  to  treat  various  gastrointestinal  issues.3  In 
addition,  it  is  also  used  to  add  flavor  to  a  wide  range  of  oral 
hygiene products, including toothpastes, mouthwashes, dental 
floss,  breath  fresheners,  and  dissolving  oral  thin  strips.2  The 

 
224 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

distinctive  and  refreshing  flavor  and  aroma  of  peppermint  is 
attributed to its constituents menthol and menthyl acetate.4,12 
For  this  reason,  it  is  also  used  as  a  fragrance,  as  well  as 
therapeutic agent.2

 TOPICAL USES

Due to its flavor, aroma, and cooling qualities, peppermint oil is 
used  in  a  wide  range  of  products,  including  cosmeceuticals, 
personal hygiene products (e.g., bath preparations, mouthwashes, 
toothpastes, and topical formulations), foods, pharmaceuticals, and 
aromatherapy  products.  Topical  indications  include  pruritus, 
irritation, and inflammation.

In 2003, Schuhmacher et al. investigated the virucidal effect of 
peppermint oil and found that it imparted a direct effect against 
herpes  simplex  virus  type  1  (HSV-1)  and  herpes  simplex  virus 
type 2 (HSV-2) as well as an acyclovir-resistant HSV-1 strain. The 
investigators concluded, noting the lipophilic nature of pepper-
mint  oil,  that  it  might  be  an  appropriate  topical  treatment  for 
recurrent herpes outbreaks.18

In  a  recent  examination  of  the  antibacterial  and  antifungal 
properties  as  well  as  speculated  anti-inflammatory  activity  of 
menthol as a topical treatment for diaper dermatitis, investiga-
tors  conducted  a  pilot  clinical  trial  in  a  hospital  setting  with  
84  neonates  with  diagnosed  candidal  diaper  dermatitis  who 
required  no  critical  care  or  systemic  antifungal  and  anti-
inflammatory medications. The menthol group (n = 42) received 
topical clotrimazole and topically applied menthol drops and the 
control group (n = 42) received topical clotrimazole and a placebo. 
Thirty-five  infants  in  each  group  completed  the  study.  The 
researchers  found  that  complete  healing  was  shorter  in  the 
menthol group, with significant relief of erythema and pustules 
observed  in  this  group.  They  concluded  that  topically  applied 
menthol may be an effective agent in the treatment of candidal 
diaper dermatitis.19

In  2011,  Qiu  et  al.  showed,  through  various  assays,  that 
menthol, in low concentrations, could significantly suppress the 
expression  of  α-hemolysin,  enterotoxins  A  and  B,  and  toxic 
shock syndrome toxin 1 in Staphylococcus aureus. The investiga-
tors  concluded  that  menthol  may  warrant  inclusion  in  the 
armamentarium against S. aureus when combined with β-lactam 
antibiotics, which, at subinhibitory concentrations, can actually 
augment  S.  aureus  toxin  secretion.  They  added  that  menthol 
may  also  have  possible  uses  in  novel  antiviral  drugs.20  
Currently, menthol is included in several over-the-counter (OTC) 
topical  pain  relief  medications  for  its  analgesic  and  anesthetic 
properties.

 SAFETY ISSUES

Peppermint  oil  can  act  as  a  skin  sensitizer,  particularly  in 
impaired and sensitive skin.2 Some recent reports indicate that 
acute allergic contact dermatitis has been seen in reaction to the 
use of lip balm containing peppermint oil.21 Peppermint oil and 
menthol have also been associated with sensitivity reactions in 
patients  with  burning  mouth  syndrome,  oral  lichenoid 
reactions,  recurrent  oral  ulcers,  perioral  dermatitis,  and 
stomatitis.2,22,23 For this reason peppermint should not be used 
in dry or sensitive skin types. Peppermint is a frequent cause of 
perioral dermatitis, a recurring irritation around the mouth that 
is often due to flavorings in toothpaste and mints.

Although peppermint oil has been reported to be a sensitizer 
in isolated cases, peppermint oil 8 percent was not found to be a 

sensitizer in a recent test using a maximization protocol and the 
various forms of peppermint (i.e., oil, extract, leaves, and water) 
used in skin care products, in fact, have been deemed safe for use 
in  cosmetic  formulations.24  The  United  States  Food  and  Drug 
Administration has also approved concentrations of menthol up 
to 16 percent in OTC topical products.8 It can provoke cold pain 
in concentrations of 30 percent and higher.8

 ENVIRONMENTAL IMPACT

Menthol  consumption  is  now  believed  to  surpass  7,000  tons 
annually, with a raw product value approximated at $300 million 
as of 2005, and with demand outpacing natural resource supply.12 
Production of menthol from natural sources has reportedly led to 
the consumption of more fossil fuel, production of more carbon 
dioxide effluent, and exerted more of an environmental impact 
than the primary synthetic production routes.25

 FORMULATION CONSIDERATIONS

In rinse-off products, peppermint oil is used in concentrations 
up to 3 percent and in leave-on formulations up to 0.2 percent.24 
The  concentration  of  pulegone  in  any  peppermint  products 
should be limited to 1 percent.3,24

 USAGE CONSIDERATIONS

Peppermint can cause stinging and irritation in individuals with 
sensitive skin. Those with dry skin may have an impaired skin 
barrier,  which  allows  increased  absorption.  Consequently, 
individuals with dry skin should also avoid peppermint.

 SIGNIFICANT BACKGROUND

Antioxidant Activity
Various Mentha species, including M. piperita, have exhibited 
significant  antioxidant  activity.17,26,27  In  a  2010  study  of  the 
antioxidant  activity  of  the  essential  oils  of  six  popular  herbs, 
including  lavender  (Lavendular  angustifolia),  peppermint  
(M.  piperita),  rosemary  (Rosmarius  officinalis),  lemon  (Citrus 
limon),  grapefruit  (Citrus  paradise),  and  frankincense  (Boswellia 
carteri),  investigators  found,  in  testing  free  radical-scavenging 
capacity and lipid peroxidation in the linoleic acid system, that 
peppermint essential oil exhibited the greatest radical-scavenging 
activity  against  the  2,2′-azinobis-(3-ethylbenzothiazoline-
6-sulfonic acid) ABTS radical.28

In  2010,  Baliga  and  Rao  showed  that  M.  piperita  and  
M. arvensis (wild mint) protected mice against γ-radiation-induced 
morbidity  and  mortality.  Specifically,  M.  piperita  protected 
murine  testes  as  well  as  gastrointestinal  and  hemopoietic 
systems.4 In a 2012 study of nine Mentha species, M. piperita was 
found  to  have  the  third  greatest  antioxidant  capacity,  with  all 
species  displaying  antioxidant  activity  in  scavenging  the 
1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical.17

Anticancer Activity
In 2002, Ohara and Matsuhisa found that of 120 screened edible 
plants,  peppermint  was  one  of  only  eight  to  exhibit  potent 
inhibitory effects against the tumor promoter okadaic acid.3,29

 
Kumar  et  al.  showed,  in  a  2004  two-stage  carcinogenesis 
model  in  mice,  that  orally  administered  M.  piperita  exerted 
inhibitory  effects.  Specifically,  the  botanical  suppressed  skin 
papilloma development induced by 7,12 dimethyl(a)anthracene 
and  promoted  by  croton  oil  application.  Significant  reductions 
were observed in total tumor number and incidence. There was 
also  a  significant  increase  in  the  latency  period  of  tumor 
formation in treated vs. control mice.1

Investigations  by  Jain  et  al.  into  the  molecular  mechanisms 
supporting  the  anticarcinogenic  potential  of  M.  piperita  leaf 
extracts  on  six  human  cancer  cell  lines  (HeLa,  MCF-7,  Jurkat, 
T24, HT-29, and MIAPaCa-2) in 2011 revealed that chloroform 
and ethyl acetate extracts dose- and time-dependently displayed 
anticarcinogenic  activity  leading  to  G1  cell  cycle  arrest  and 
mitochondrial-mediated apoptosis among the cascade of effects. 
The investigators identified their findings as the first evidence of 
direct  anticarcinogenic  activity  of  Mentha  leaf  extracts  and 
suggested  that  future  work  might  focus  on  isolating  active 
constituents  as  a  foundation  for  mechanistic  and  translational 
studies leading to new anticancer drugs, alone or in combination, 
to  prevent  and  treat  human  cancers.30  Previously,  peppermint 
was  reported  to  exhibit  antimutagenic  properties  in  a  hamster 
cheek pouch model, suppressing the carcinogenicity of benzo[a]-
pyrene, aflatoxin B1, methylmethane sulfonate, and an extract of 
shamma (a mixture of powdered tobacco, slaked lime, ash, oils, 
spices, and other additives, which has been correlated with oral 
cancer in Saudi Arabia).4,31

Pruritus, TRPM8, and Melanoma
Topically applied menthol, in concentrations of 1 to 3 percent, 
is  often  used  to  treat  pruritus,  particularly  in  the  elderly.8  In 
addition, recent evidence suggests that the presence of menthol 
can facilitate penetration of other agents in topical products.12,24 
Patel and Yosipovitch suggest that elderly patients who report 
diminished  pruritus  with  cooling  may  stand  to  benefit  from 
menthol-containing topical therapies.8,12 In 2002, two different 
teams discovered that menthol acts as an agonist of a thermally 
sensitive receptor, formerly known as the cold- and menthol-
sensitive  receptor  1  (CMR1),  and  now  known  as  transient 
receptor potential melastatin subfamily 8 (TRPM8) receptor, a 
member of a family of excitatory ion  channels.8,15,16  Notably, 
menthol  engenders  the  same  cooling  sensation  as  low 
temperature,  though  menthol  is  not  linked  to  a  reduction  in 
skin temperature.8,12

Although the exact mechanisms by which menthol exerts its 
antipruritic  and  analgesic  effects  remain  to  be  elucidated,  the 
discovery  that  the  TRPM8  is  its  underlying  receptor  appears 
pivotal  in  understanding  the  cooling  effect  of  the  botanical.12 
There are also indications that menthol may exhibit therapeutic 
potential  for  melanoma.  Specifically,  melanoma  expresses 
TRPM8  receptors,  the  activation  of  which  inhibits  melanoma 
viability. Menthol appears to mediate this response through an 
influx of extracellular calcium ions.5,32

Antibacterial Activity
In  2003,  Mimica-Dukic´  et  al.  investigated  the  antimicrobial 
activity  and  free  radical-scavenging  capacity  of  essential  oils 
from M. aquatica, M. longifolia, and M. piperita, finding that M. 
piperita  displayed  the  greatest  antibacterial  potency.  All  three 
species exhibited such properties, especially against Esherichia 
coli  strains,  though  Shigella  sonei  and  Micrococcus  flavus  ATTC 
10,240 were also susceptible. The investigators were especially 

C H A P T E R  63  ■   P E P P E R M I N T  

225

intrigued  by  the  finding  that  the  essential  oils  were  effective 
against  bacteria  known  to  be  resistant  to  synthetic  drugs  
(i.e., all tested E. coli species, and Salmonella typhi IPH-MR). All 
tested Mentha species also demonstrated significant fungistatic 
and  fungicidal  activity,  with  M.  piperita  again  particularly 
effective  against  Trichophyton  tonsurans  and  Candida  albicans. 
Further,  all  Mentha  species  dose-dependently  reduced  the 
DPPH  and  OH  radicals,  with  M.  piperita  again  most  effective 
against  both  radicals.  Monoterpene  ketones  (i.e.,  menthone 
and isomenthone) were found to be the strongest scavenging 
ingredients in M. piperita. The investigators concluded that all 
tested  species,  particularly  M.  piperita,  exhibited  significant 
antibacterial, antifungal, and antioxidant activity.33

Three years later, in a study of the biochemical activities of  
M. piperita and Myrtus communis, Yadegarinia et al. reported that 
the oils of both species, particularly M. piperita, exhibited strong 
antimicrobial activities against E. coli, S. aureus, and C. albicans. 
The  investigators  also  noted,  after  screening  both  species  for 
antioxidant activity, that M. piperita showed greater antioxidant 
capacity in DPPH free radical scavenging as well as β-carotene/
linoleic acid systems.34

 CONCLUSION

Peppermint  and  menthol,  its  naturally  occurring  monocyclic 
terpene alcohol derivative, have long been used for medical and 
culinary  purposes.  Contemporary  practice  and  continuing 
research continue to support various uses of Mentha piperita in 
the  medical  armamentarium,  with  its  use  in  dermatology 
ubiquitous  though  hardly  prominent.  Its  application  for 
antipruritic, analgesic, antiseptic, and cooling activity may be 
the  most  compelling  uses  for  cutaneous  purposes,  but  its 
potential  for  wider  use  remains  intriguing  as  much  more 
research is conducted.

REFERENCES

1.  Kumar A, Samarth RM, Yasmeen S, et al. Anticancer and radio-
protective potentials of Mentha piperita. Biofactors. 2004;22:87.
2.  Herro  E,  Jacob  SE.  Mentha  piperita  (peppermint).  Dermatitis. 

2010;21:327.

3.  McKay DL, Blumberg JB. A review of the bioactivity and poten-
tial  health  benefits  of  peppermint  tea  (Mentha  piperita  L.). 
Phytother Res. 2006;20:619.

4.  Baliga  MS,  Rao  S.  Radioprotective  potential  of  mint:  A  brief 

review. J Cancer Res Ther. 2010;6:255.

5.  Slominski  A.  Cooling  skin  cancer:  Menthol  inhibits  melanoma 
growth. Focus on “TRPM8 activation suppresses cellular viability 
in human melanoma.” Am J Physiol Cell Physiol. 2008;295:C293.
6.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy:  Modern 
Herbal Medicine. London: Churchill Livingstone; 2000:507–513.
7.  Toroglu  S.  In-vitro  antimicrobial  activity  and  synergistic/ 
antagonistic effect of interactions between antibiotics and some 
spice essential oils. J Environ Biol. 2011;32:23.

8.  Patel  T,  Yosipovitch  G.  The  management  of  chronic  pruritus  in 

the elderly. Skin Therapy Lett. 2010;15:5.

9.  Kim  SH,  Nam  JH,  Park  EJ,  et  al.  Menthol  regulates  TRPM8-
independent  processes  in  PC-3  prostate  cancer  cells.  Biochim 
Biophys Acta. 2009;1792:33.

10.  Grieve M. A Modern Herbal (Vol 2). New York: Dover Publications; 

1971:537.

11.  Simonsen  JL.  The  Terpenes:  The  Simpler  Acyclic  and  Monocyclic 
Terpenes  and  Their  Derivatives.  Volume  I  (2nd  ed.).  Cambridge: 
Cambridge University Press; 1947:230–249.

12.  Patel  T,  Ishiuji  Y,  Yosipovitch  G.  Menthol:  A  refreshing  look  at 

this ancient compound. J Am Acad Dermatol. 2007;57:873.

13.  Foster S. 101 Medicinal Herbs: An Illustrated Guide. Loveland, CO: 

Interweave Press; 1998:156.

 
226 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

14.  Naghibi F, Mosaddegh M, Motamed SM, et al. Labiatae family in 
folk medicine in Iran: From ethnobotany to pharmacology. Iran J 
Pharm Res. 2005;2:63.

15.  McKemy  DD,  Neuhausser  WM,  Julius  D.  Identification  of  a  cold 
receptor reveals a general role for TRP channels in thermosensation. 
Nature. 2002;416:52.

16.  Peier AM, Moqrich A, Hergarden AC, et al. A TRP channel that 

senses cold stimuli and menthol. Cell. 2002;108:705.

17.  Ahmad N, Fazal H, Ahmad I, et al. Free radical scavenging (DPPH) 
potential in nine Mentha species. Toxicol Ind Health. 2012;28:83.

18.  Schuhmacher A, Reichling J, Schnitzler P. Virucidal effect of pep-
permint oil on the enveloped viruses herpes simplex virus type 1 
and type 2 in vitro. Phytomedicine. 2003;10:504.

19.  Sabzghabaee  AM,  Nili  F,  Ghannadi  A,  et  al.  Role  of  menthol  in 
treatment of candidial napkin dermatitis. World J Pediatr. 2011;7:167.
20.  Qiu J, Luo M, Dong J, et al. Menthol diminishes Staphylococcus 
aureus  virulence-associated  extracellular  proteins  expression. 
Appl Microbiol Biotechnol. 2011;90:705.

21.  Tran A, Pratt M, DeKoven J. Acute allergic contact dermatitis of 
the lips from peppermint oil in a lip balm. Dermatitis. 2010;21:111.
22.  Morton CA, Garioch J, Todd P, et al. Contact sensitivity to men-
thol  and  peppermint  in  patients  with  intra-oral  symptoms. 
Contact Dermatitis. 1995;32:281.

23.  Wilkinson SM, Beck MH. Allergic contact dermatitis from men-

thol in peppermint. Contact Dermatitis. 1994;30:42.

24.  Nair B. Final report on the safety assessment of Mentha Piperita 
(Peppermint)  Oil,  Mentha  Piperita  (Peppermint)  Leaf  Extract, 
Mentha  Piperita  (Pepperming)  Leaf,  and  Mentha  Piperita 
(Peppermint) Leaf Water. Int J Toxicol. 2001;20(Suppl 3):61.

25.  Sell  CS,  ed.  The  Chemistry  of  Fragrances:  From  Perfumer  to 
Consumer.  2nd  ed.  London:  Royal  Society  of  Chemistry; 
2006:294–301.

26.  Schmidt  E,  Bail  S,  Buchbauer  G,  et  al.  Chemical  composition, 
olfactory evaluation and antioxidant effects of essential oil from 
Mentha x piperita. Nat Prod Commun. 2009;4:1107.

27.  Dorman HJ, Kosar M, Baser KH, et al. Phenolic profile and anti-
oxidant evaluation of Mentha x piperita L. (peppermint) extracts. 
Nat Prod Commun. 2009;4:535.

28.  Yang SA, Jeon SK, Lee EJ, et al. Comparative study of the chemical 
composition and antioxidant activity of six essential oils and their 
components. Nat Prod Res. 2010;24:140.

29.  Ohara A, Matsuhisa T. Anti-tumor promoting activities of edible 
plants against okadaic acid. Food Sci Technol Res. 2002;8:158.
30.  Jain  D,  Pathak  N,  Khan  S,  et  al.  Evaluation  of  cytotoxicity  and 
anticarcinogenic  potential  of  Mentha  leaf  extracts.  Int  J  Toxicol. 
2011;30:225.

31.  Samman MA, Bowen ID, Taiba K, et al. Mint prevents shamma-
induced  carcinogenesis  in  hamster  cheek  pouch.  Carcinogenesis. 
1998;19:1795.

32.  Yamamura  H,  Ugawa  S,  Ueda  T,  et  al.  TRPM8  activation  sup-
presses  cellular  viability  in  human  melanoma.  Am  J  Physiol  Cell 
Physiol. 2008;295:C296.

33.  Mimica-Dukic´  N,  Bozin  B,  Sokovic´  M,  et  al.  Antimicrobial  and 
antioxidant activities of three Mentha species essential oils. Planta 
Med. 2003;69:413.

34.  Yadegarinia D, Gachkar L, Rezaei MB, et al. Biochemical activities 
of Iranian Mentha piperita L. and Myrtus communis L. essential 
oils. Phytochemistry. 2006;67:1249.

 
C H A P T E R  64  ■   A N T I - I N F L A M M ATO RY   AG E N T S  

227

SECTION

H

Anti-Inflammatory Agents

C H A P T E R   6 4

Anti-Inflammatory Agents

In the 1st century CE, Cornelius Celsus described the signs of 
acute inflammation as: calor (heat), dolor (pain), rubor (redness) 
and tumor (swelling).1 This accurate depiction of the sequence 
of  events  that  occurs  in  inflammation  is  characteristic  of  all 
types  of  inflammation  regardless  of  the  provocative  stimuli, 
which  can  include  injury,  friction,  emotion,  exposure  to  irri-
tants or allergens, or infectious agents.2 The initial insult to the 
skin causes vasodilation that is seen as redness. The endothelial 
lining of the blood vessels becomes more permeable and leads 
to  extravasation.  In  other  words,  substances  leak  out  of  the 
vessel  causing  increased  fluid  in  the  tissues,  which  results  in 
swelling. Inflammatory mediators such as cytokines and inter-
leukins  are  released  and  activate  multiple  pathways  that  can 
lead to pain, redness, and swelling as well as serve to beckon 
immune cells to the area.

The process of inflammation is orchestrated by a large array of 
inflammatory mediators including histamines, cytokines, eicosa-
noids  (e.g.,  prostaglandins,  thromboxanes,  and  leukotrienes), 
complement  cascade  components,  kinins,  fibrinopeptide 
enzymes,  and  free  radicals.  For  a  more  extensive  review,  see 
Cosmetic  Dermatology:  Principles  and  Practice,  2nd  edition, 
Chapter 35 (McGraw-Hill, 2009).

Although the many causes of inflammation are very compli-
cated and beyond the scope of this book, arachidonic acid (AA) 
and its pathways are important to understand when considering 
the anti-inflammatory claims of skin care products. AA produc-
tion  is  a  major  cause  of  inflammation  because  AA  is  broken 
down into inflammation-causing substances such as prostaglan-
dins and leukotrienes. Production of AA is blocked by corticos-
teroids, which is one of the ways that topical steroids decrease 
inflammation (they also cause vasoconstriction). Two important 
pathways  involved  in  the  breakdown  of  AA  are  worth  noting 
(Figure 64-1).

1.  Cyclooxygenase  pathway:  Results  in  the  production  of 
prostaglandins.  This  is  the  pathway  in  which  salicylates 
(aspirin) and nonsteroidal anti-inflammatory drugs (NSAIDs) 
such as ibuprofen work.

2.  Lipoxygenase  pathway:  Results  in  the  production  of  the 

inflammatory mediator group leukotrienes.

Several  categories  of  anti-inflammatory  ingredients  are 
considered in this section: salicylates, prostaglandin antagonists, 
leukotriene  antagonists,  polyphenols,  and  vasoconstrictors. 
Examples  of  salicylates  include  salicylic  acid  and  Aloe  vera. 

Provocative stimuli

Membrane lipids

Glucocorticoids

Phospholipase C

Phospholipase A2

NSAIDs

Arachidonic acid

Lipoxygenase
inhibitors

Cyclooxygenase

Lipoxygenase

Prostaglandins

Leukotrienes

▶
FIGURE  64-1  This  simplified  chart  shows  how  arachidonic  acid  is 
broken  down  into  prostaglandins  and  leukotrienes,  key  groups  of 
inflammatory  mediators.  Many  contributors  to  the  arachidonic  acid  
cascade have been omitted here for ease of explanation.

Prostaglandin antagonists include feverfew, licorice extract, and 
oatmeal, while turmeric and chamomile are leukotriene antago-
nists.  Coumarin  and  its  derivatives,  found  in  tamanu  oil,  for 
example, suppress prostaglandin biosynthesis through inhibition 
of the lipoxygenase and cycloxygenase systems.3 Horse chestnut 
is  a  vasoconstrictor,  as  are  corticosteroids  such  as  hydrocorti-
sone. Polyphenols are also discussed in the Antioxidants section 
introduction  as  well  as  several  chapters  in  that  section.  Anti-
inflammatory  polyphenols  considered  here  include  calendula, 
edelweiss, and lavandula. Polyphenols decrease inflammation by 
neutralizing free radicals.

Inflammation is typically the common denominator for indi-
viduals with sensitive skin. The etiology varies depending on the 
condition.  For  example,  in  acne,  the  cause  of  inflammation  is 
thought to result from byproducts generated by bacteria as they 
digest fatty acids. In rosacea, part of the observed inflammation 
is due to vasodilation of unknown etiology. Those with allergic 
skin reactions develop inflammation when the immune system 
cells in the skin are exposed to an allergen.

 INFLAMMATION AND AGING

Inflammation  is  believed  to  play  a  role  in  aging  because  its 
activation can lead to the breakdown of skin collagen and elas-
tin and other important cutaneous components in addition to 

 
228 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

increased  glycation,  lipofuscin,  and  free  radical  production. 
This is discussed in Chapter 81, Overview of Aging.

Botanical,  natural,  and  organic  products  often  exhibit  potent 
anti-inflammatory activity. The most commonly seen ingredients 
in anti-inflammatory skin care include feverfew, green tea, cucum-
ber,  chamomile,  and  licorice  extract.  It  is  anticipated  that  many 
new ingredients will enter the market as our understanding of the 
causes of rosacea and other inflammatory skin conditions increases.

REFERENCES

1.  Williams RH, Stedman TL. Stedman’s Medical Dictionary. 25th ed. 

Philadelphia, PA: Williams & Wilkins; 1990.

2.  Kimball  ES.  Cytokines  and  Inflammation.  Boca  Raton,  FL:  CRC 

Press; 1991.

3.  Fylaktakidou KC, Hadjipavlou-Litina DJ, Litinas KE, et al. Natural 
and  synthetic  coumarin  derivatives  with  anti-inflammatory/
antioxidant activities. Curr Pharm Des. 2004;10:3813.

 
C H A P T E R   6 5

Aloe Vera

C H A P T E R  65  ■   A LO E  V E R A  

229

Activities:
Anti-inflammatory,  antioxidant,  antimicrobial,1  immu-
nomodulatory, laxative,2 wound healing3

Important Chemical Components:

Aloe  resin,  aloesin  (2-acetyonyl-8-glucopyranosyl-
7-hydroxy-5-methylchromone), 
glucomannans, 
particularly  acemannan  (also  known  as  acetylated 
mannose  or  mannose-6-phosphate),4  and  other 
polysaccharides  (galactose,  xylose,  arabinose);  aloe 
emodin and other anthraquinones, including aloin A and B 
(anthrone-C-glucosyls or C-glucosides of emodin and 
also known collectively as barbaloin);3,5 lectin, phenols 
(gentisic  acid,  epicatechin,  and  quercitrin),  amino 
acids,  enzymes,  lignin,  minerals  (selenium,  zinc), 
salicylic  acid,  magnesium  lactate,  saponins,  sterols, 
and vitamins A, C, and E1,6–11

Origin Classification:

This ingredient is natural. Organic forms exist. 

Personal Care Category:

Moisturizing, soothing, cooling, burn and wound healing

Recommended  for  the  following  Baumann  Skin 
Types:

DSNT, DSPT, DSNW, DSPW, OSNT, OSNW, OSPT, and 
OSPW

 SOURCE

A  cactus-like  perennial  succulent  and  member  of  the 
Xanthorrhoeaceae  family  and  the  subfamily  Liliaceae  (lily) 
native  to  North  Africa  and  the  Arabian  peninsula,  Aloe  vera 
(also  known  as  Aloe  barbadensis)  is  the  most  potent  of  the 
several  aloe  species  and  one  of  the  most  widely  used  herbal 
products throughout the world (Table 65-1).12 The plant is now 
widely  distributed  throughout  Africa,  Asia,  southern  Europe, 
the  Americas,  and  other  areas  with  tropical  climates.13  
Aloe (from the Arabic alloeh for a “shining bitter substance”) vera 
(Latin for “truth”) thrives in warm, dry climates, but can survive 

TABLE 65-1
Pros and Cons of Aloe Vera

Pros
One of the main herbal agents in widespread use for 

Con
Dearth of clinical trials

dermatologic purposes

Impressive anecdotal evidence of efficacy
Broad range of reputed medicinal, and dermato-

logic, applications

high  temperatures  and  even  humid  conditions  as  long  as  its 
roots  are  not  submerged  in  water.11,14  Various  cultures  have 
used  aloe  to  treat  burns  (including  sunburns),  wounds, 
abrasions, insect bites, cuts, blisters, and frostbite. A. vera has 
been used for several decades, both topically and systemically, 
to  enhance  wound  repair  based  more  on  traditional  and 
anecdotal  evidence  than  rigorously  established  scientific 
study.15  Its  effectiveness  in  healing  wounds  and  treating 
infections has been established in laboratory animals, though.9
Reputed to have potent anti-inflammatory and antimicrobial 
effects, the fresh or dehydrated whole aloe leaf is used for treat-
ment of radiation injuries, ulcers, burns, eczema, and psoriasis.13 
Other  anecdotal  cutaneous  indications  may  include  seborrhea, 
acne, androgenetic alopecia, and herpes zoster (shingles). Aloe is 
believed to balance the pH of the skin and is used in hundreds of 
medicines and over-the-counter (OTC) products such as sham-
poos, soaps, shaving creams, deodorants, tissue paper products, 
sunscreens, moisturizers, and other skin creams to soothe, heal, 
and  protect  the  skin.  It  is  also  believed  to  exhibit  antioxidant 
properties.16

In fact, the medical establishment recognizes the use of A. vera 
in treating radiation and stasis ulcers and has acknowledged the 
antibacterial and antifungal effects of A. vera components.17 Aloe 
is also indicated for the treatment of frostbite.1 The vasoconstric-
tive effects of thromboxane have been shown to be improved 
with  the  application  of  A.  vera  cream  such  as  Dermaide.18,19 
Further, A. vera is recognized as one of the many herbal products 
to contain pharmacologically active ingredients with the poten-
tial to enhance wound healing.20 Such ingredients include salicy-
lates  and  a  carboxypeptidase  that  inactivates  bradykinin  
in vitro.17 A. vera is considered the most commercially important 
of the more than 500 species in the genus Aloe.3,11,21

The manufacturing of  A.  vera extracts represents one of the 
largest  global  botanical  industries,  and  aloe  is  one  of  the  few 
herbal agents used broadly in Western cultures.22

 HISTORY

In  traditional  folk  medicine,  topical  A.  vera  is  used  to  treat 
inflammation, cicatrization, and dyspigmentation. Its constitu-
ent aloesin has been demonstrated to inhibit tyrosinase activity 
from human, murine, and mushroom sources.23 The traditional 
use of A. vera gel dates back nearly 2,500 years to ancient Egypt 
(where  it  was  known  as  the  “the  plant  of  immortality”)11,24, 
Greece,  India,  China  (where  it  was  dubbed  an  “elixir  of 
youth”)11, Japan, and Mexico.11,14,25 It is believed to have been 
included in the skin care regimens of Egyptian queens Nefertiti 
and Cleopatra, as well as for embalming and as an offering at 
funerals  for  pharoahs.14,24  Egyptians,  Assyrians,  and  others  in 
the Mediterranean region are said to have used the gel as well as 
the  latex  (found  inside  the  leaves).24  Aloe  was  also  reportedly 
used to treat battlefield wounds in ancient times under Alexander 
the  Great  and  more  than  1,500  years  later  under  Christopher 
Columbus.14  The  first  documentation  of  healing  properties 
associated  with  A.  vera  is  attributed  to  Mesopotamian  clay 

 
230 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

tablets circa 2100 BCE, with medicinal properties characterized 
with greater detail in Egyptian writings circa 1550 BCE.22

Through  human  trade  and  migration,  this  dynamic  plant 
became  known  and  widely  used  to  cure  burns  and  wounds 
throughout ancient civilizations in Persia, Egypt and elsewhere 
in  Africa,  Greece,  Rome,  India,  and  China  and  appears  in  the 
folklore of Japan, the Philippines, and Hawaii. The Spanish used 
it and brought it to South America and to such Caribbean locales 
as Aruba, Curaçao, and Barbados (from which the alternate INCI 
name Aloe barbadensis nomenclature is derived).26

Aloe  is  believed  to  have  been  first  cited  in  English  in  John 
Goodyew’s 1655 translation of De Materia Medica by the Greek 
physician  Dioscorides,  who  used  the  plant  to  treat  sores  and 
wounds in the first century CE.14,22,24 It was used as a laxative 
in  the  United  States  (US)  beginning  in  the  early  1800s,  and 
listed in the US pharmacopoeia in 1820 as a purgative and skin 
protectant.14,22  Modern  clinical  use  of  A.  vera  began  in  the 
1930s, when it was shown to be effective in treating chronic 
and severe radiation dermatitis.14,25 Aloe products have main-
tained their popularity through the course of time.27 In 1983, 
the US Food and Drug Administration (FDA) approved topical 
aloe to treat inflammation.10 It continues to be used today pri-
marily  for  anti-inflammatory  applications,  but  several  other 
uses are under investigation. A. vera is also approved as a food 
flavoring and oral cathartic (Aloe latex).10 In traditional Chinese 
medicine,  A.  vera  is  used  for  fungal  conditions;  in  Ayurvedic 
medicine, it is used to treat cutaneous and other conditions.22

 CHEMISTRY

Rich in glucomannans and other polysaccharides, the gel and sap 
from the inner core of the full leaf confer healing qualities and pose 
no  risk.  Aloe  is  known  to  lessen  the  itching  and  inflammation 
associated  with  minor  wounds.  The  gel  is  also  thought  to  be 
effective in eliminating the yeasts, fungi, and bacteria that infiltrate 
and inhabit wounds and, is believed by some to accelerate collagen 
production.  Research  in  recent  years  has  determined  that  aloe 
contains three agents with significant antitumor potential: emodin, 
mannose,  and  lectin.  While  the  use  of  A.  vera  has  not  achieved 
unqualified  acceptance  from  the  medical  establishment,  compo-
nents of the plant are under serious scientific investigation.

There  is  a  large  body  of  anecdotal  evidence  attesting  to  the 
efficacy  of  aloe  for  the  treatment  of  myriad  diseases;  unfortu-
nately, exaggerated claims are not uncommon and therefore cau-
tion is warranted in the interpretation of some of the available 
information.28  Explanations  of  aloe  gel  efficacy  are  still  varied 
because  it  has,  in  fact,  several  active  constituents  operating 
through different mechanisms.29 Indeed, aloe has been compared 
to honey as an exceedingly convoluted amalgam of natural com-
ponents (see Chapter 60, Honey/Propolis/Royal Jelly).30 Its action 
as a moisturizer is a popular use that may account for many of its 
effects.31  Furthermore,  aloe  is  reputed  to  exhibit  potent  
anti-inflammatory  effects,  and  the  substances  that  have  been 
proposed  as  its  active  anti-inflammatory  constituents  include 
salicylates  (providing  “aspirin-like  effects”);  magnesium  lactate, 
which is believed to inhibit the production of histamine; brady-
kinin and thromboxane inhibitors, which provide pain reduction; 
and polysaccharides, particularly acemannan, which has reported 
immunomodulatory properties.16,32,33 Another substance isolated 
from  aloe,  C-glucosyl  chromone,  has  exhibited  topical  anti-
inflammatory  activity  equivalent  to  that  of  hydrocortisone  
(200 µg/mouse ear).34 A glycoprotein fraction of A. vera is thought 
to  account,  through  cell  proliferation  and  migration,  for  the 
wound healing effect associated with extracts of the plant.35

 ORAL USES

Aloe  is  used  as  a  functional  food  and  an  ingredient  in  other 
food  products  as  well  as  health-boosting  beverages.3,11 
Traditionally, for health purposes, aloe has been used orally as 
a purgative and antihelminthic agent.10 In addition, it has been 
used systemically for ulcers and diverticulitis.36 The oral admin-
istration  of  A.  vera  has  recently  been  found  to  be effective in 
ameliorating  the  effects  of  acute  radiation-delayed  wound 
healing  in  rats  by  increasing  transforming  growth  factor 
(TGF)-β1  and  basic  fibroblast  growth  factor.37  Overall,  how-
ever,  oral  use  of  aloe  is  thought  to  exacerbate  some  chronic 
conditions  and  to  be  susceptible  to  multiple  drug 
interactions.36Therefore,  despite  some  evidence  of  systemic 
efficacy, oral use of aloe is not recommended.36

Acemannan,  a  polysaccharide  extracted  from  A.  vera,  has 
been shown to be an effective and safe alternative for treating 
oral  aphthous  ulcers  for  patients  who  prefer  to  avoid  steroid 
therapy,  though  it  is  less  effective  than  0.1  percent 
triamcinolone acetonide.38

In  2009,  Cho  et  al.  investigated  the  cutaneous  antiaging 
effects of dietary A. vera gel in 30 healthy females over 45 years 
old who received either a low-dose (1,200 mg/d) or high-dose 
(3,600  mg/d)  supplement  for  90  days,  with  baseline  status 
serving  as  control.  The  researchers  noted  significant 
improvement  in  facial  wrinkles  in  both  groups,  and  facial 
elasticity  was  enhanced  in  the  group  using  the  low-dose 
supplement.  Based  on  skin  samples  taken  before  and  after 
supplementation,  matrix  metalloproteinase  (MMP)-1  mRNA 
levels  were  found  to  be  significantly  diminished  in  the  high-
dose group. In both groups, type I procollagen immunostaining 
was  significantly  elevated.  The  investigators  concluded  that 
although  no  dose-response  relationship  was  found,  oral 
administration  of  aloe  gel  appeared  to  significantly  improve 
signs  of  photoaged  human  skin,  with  increases  noted  in 
collagen synthesis and decreases in collagen-degrading MMP-1 
gene expression.39

A. vera is also a featured ingredient in a multi-phytonutrient 
liquid dietary supplement that contains a proprietary blend of 
fruits, vegetables, and catechin complex from green tea (VIBE 
Cardiac  &  Life)  found  in  vitro  to  have  exerted  antimutagenic, 
and DNA-protective effects on human epidermal cells exposed 
to ultraviolet (UV)-induced DNA damage.

There  are  indications  that  the  oral  use  of  gel  may  lower 
blood glucose levels in type 2 diabetes mellitus, alleviate mild-
to-moderate  ulcerative  colitis,  and  even  stabilize  metastatic 
cancer.  Much  more  research  is  necessary  to  corroborate  such 
findings, according to Foster et al.22

 TOPICAL USES

In  2008,  Reuter  et  al.  conducted  a  randomized,  double-blind, 
placebo-controlled, Phase III study in 40 volunteers to evaluate 
the  anti-inflammatory  activity  of  a  highly  concentrated  
A.  vera  gel  (97.5  percent).  After  test  sites  on  the  back  were 
exposed  to  1.5-fold  minimal  erythema  dose  (MED)  of  UVB, 
these areas were treated for the next two days with A. vera gel, 
positive  controls  (0.25  percent  prednicarbate,  1  percent 
hydrocortisone  in  placebo  gel,  and  1  percent  hydrocortisone 
cream), or a placebo gel. After 48 hours, the A. vera gel was found 
to  have  significantly  lowered  UV-induced  erythema  more 
effectively than 1 percent hydrocortisone in placebo gel, but less 
efficiently  than  1  percent  hydrocortisone  cream.  Nevertheless, 

 
C H A P T E R  65  ■   A LO E  V E R A  

231

the researchers suggested the potential use of highly concentrated 
A. vera gel for topically treating inflammatory skin conditions.40

that  both  treatments  displayed  similar  efficacy  in  improving 
quality of life for psoriasis patients.46

Oyelami  et  al.  reported  in  2009,  based  initially  on  an  open, 
non-comparative study, that the crude gel of  A.  vera was used 
successfully  in  Nigeria  to  treat  five  patients  with  scabies. 
Subsequently,  the  investigators  compared  the  efficacy  of  the 
botanical  agent  (16  subjects)  with  that  achieved  with  benzyl 
benzoate lotion (14 subjects) in 30 patients. After two courses of 
treatment, three of the patients using benzyl benzoate lotion and 
two of those using A. vera still complained of pruritus. Lesions 
were found to have essentially disappeared in all patients, with 
no detectable side effects. The researchers concluded that A. vera 
gel is as effective as benzyl benzoate for treating scabies.41

Earlier  that  year,  Feily  and  Namazi  performed  a  literature 
search for in vitro, in vivo, and clinical trial data on dermatologic 
uses of A. vera, finding 40 pertinent studies. Oral administration 
in mice was seen as effective in wound healing, reducing the 
number and size of papillomas, and lowering the incidence of 
tumors  and  leishmaniasis.  The  researchers  found  that  while 
topically applied aloe offered no photoprotective or radiopro-
tective activity, it was noted for efficacy in treating aphthous 
stomatitis, burns and other wounds, frostbite,  genital  herpes, 
human papilloma virus, inflammation, lichen planus, psoriasis, 
seborrheic dermatitis, and xerosis. They added that data sup-
port the use of aloe as a biological vehicle, an antimicrobial and 
antifungal agent, and a potential option for photodynamic ther-
apy  for  some  forms  of  cancer.  Finally,  the  authors  cautioned 
that while encouraging results have been obtained for A. vera 
for a broad range of dermatologic applications, the clinical data 
establishing  effectiveness  of  oral  and  topical  A.  vera  remain 
insufficient.13

Psoriasis
Aloe is rarely, if ever, mentioned among the wide array of prod-
ucts comprising the dermatologic armamentarium for psoriasis. 
There  is  some  evidence  suggesting  its  usefulness,  however. 
Syed et al. performed a double-blind, placebo-controlled exam-
ination of A. vera extract 0.5 percent in a hydrophilic cream for 
the treatment of psoriasis vulgaris.42 Psoriatic plaques cleared 
in  only  two  of  30  subjects  on  placebo  while  the  aloe  group 
showed clearance in 25 of 30 patients, and significant improve-
ment in desquamation, erythema, and Psoriasis Area Severity 
Index (PASI) score.42,43 Inflammation remains a major indication 
for aloe products. Research has established the anti-inflammatory 
effects of A. vera gel extracts, which may also impart inhibitory 
activity, via cyclooxygenase, on the arachidonic acid pathway.44 
Immunomodulatory  properties  of  the  gel  polysaccharides, 
particularly  the  acetylated  mannans  (now  a  proprietary  com-
pound under several patents), have been reported.29

In  2005,  Paulsen  et  al.  led  a  randomized,  double-blind, 
placebo-controlled,  right/left  comparison  study  in  41  patients 
with  stable  plaque  psoriasis  to  determine  the  efficacy  of  a 
commercial A. vera gel. Results were modest, with the gel not 
shown  to  be  superior  to  placebo.  However,  the  researchers 
suggested  that  the  high  response  rate  to  placebo  might  have 
left the aloe gel looking less effective than it actually was.45

A  2010  randomized,  comparative,  double-blind,  eight-week 
study of 80 patients conducted by Choonhakarn et al. suggested 
that A. vera may be more effective than 0.1 percent triamcinolone 
acetonide in the treatment of mild-to-moderate plaque psoriasis. 
The  mean  PASI  score  decreased  from  11.6  to  3.9  over  eight 
weeks  in  the  A.  vera  group  and  from  10.9  to  4.3  in  the 
triamcinolone acetonide group. The researchers noted, though, 

In  2012,  Dhanabal  used  a  mouse  tail  model  to  assess  the 
antipsoriatic activity of A. vera, showing that an ethanolic extract 
of the gel generated a significant differentiation in the epidermis 
as well as a significant increase in relative epidermal thickness 
compared  to  negative  control  and  the  lack  of  change  in  
the  standard  positive  control  (tazarotene).  The  investigators 
concluded  that  A.  vera  exerted  an  overall  antipsoriatic  activity  of 
81.95 percent in the mouse tail model, as compared to 87.94 percent 
for tazarotene.47

Wound Healing
A.  vera  has  been  used  for  several  decades,  both  topically  and 
systemically,  to  enhance  wound  repair  based  more  on  tradi-
tional and anecdotal evidence than rigorously established sci-
entific study.15

A few recent studies buttress the long-standing anecdotal evi-
dence in support of aloe in the treatment of wounds. An investi-
gation  using  rats  showed  that  full-thickness  wounds  treated 
with A. vera displayed elevated biosynthesis of collagen and its 
degradation,  suggesting  that  aloe  affected  the  wound-healing 
process by enhancing collagen turnover in the wounded tissue.48 
In  another  study  using  rats,  A.  vera  exhibited  both  anti-
inflammatory  and  wound-healing  activity  when  applied  to 
second-degree burns.49 Similar effects have been seen in studies 
with  humans.  Researchers  observed  that  the  partial  thickness 
burn wounds of 27 patients treated with A. vera gel evinced early 
epithelialization  and  faster  healing  time  than  the  area  treated 
with Vaseline gauze. Some patients reported mild discomfort.50

After  an  exhaustive  literature  search  in  1999  of  controlled 
clinical trials on aloe, Vogler and Ernst sounded skeptical notes, 
however. They concluded that the topical application of A. vera 
may be effective for genital herpes and psoriasis, but its effec-
tiveness in promoting wound healing was, as yet, unproven, and 
its use does not prevent radiation-induced injuries.51

Ten years later, topically applied A. vera gel was shown in a 
study  in  63  male  rats  to  reduce  wound  diameter  significantly 
when administered twice daily as compared to once-daily treat-
ment or control groups.52

A 2012 report by Inpanya et al. demonstrated that a blended 
fibroin/aloe  gel  film  could  accelerate  wound  healing  in  
streptozotocin-induced  diabetic  rats,  with  wounds  treated 
with the blended film enhancing the attachment and prolifera-
tion of skin fibroblasts compared to aloe-free fibroin film and 
yielding smaller wounds after day 7 compared to untreated dia-
betic wounds. The investigators concluded that their fibroin/aloe 
gel film may have potential for treating diabetic non-healing skin 
ulcers in humans.53

Also  that  year,  in  a  randomized,  controlled,  comparative 
study by Tarameshloo et al., topically applied A. vera gel more 
rapidly  accelerated  the  healing  process  than  silver  sulfadiazine  
1 percent, thyroid hormone, or vehicle in skin wounds surgically 
induced in Wistar rats (see Chapter 80, Silver).54 Hosseinimehr et 
al.  previously  found  that  aloe  cream  was  significantly  more 
effective than silver sulfadiazine in augmenting reepithelializa-
tion in burn wounds in rats.55

Human  trials  have  been  lacking,  however.  Indeed,  Dat  el. 
conducted  a  2012  search  of  several  databases  (the  Cochrane 
Wounds  Group  Specialized  Register,  the  Cochrane  Central 
Register of Controlled Trials, Ovid MEDLINE, Ovid AMED, and 
EBSCO  CINAHL)  for  all  randomized  controlled  trials  assessing 
the effectiveness of A. vera, aloe-derived products, and dressings 

 
232 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

combining  A.  vera  and  other  components  in  treating  acute  or 
chronic wounds. Seven trials, with a total of 347 subjects treated, 
met inclusion criteria, but were deemed to be of such poor quality 
that trial results should be viewed cautiously. The authors cited 
the  paucity  of  high  quality  clinical  trials  on  the  use  of  A.  vera 
topical products or dressings for treating acute and chronic wounds 
as a justification for withholding support for such treatments.2

Lichen Planus
In  2010,  Cheng  et  al.  conducted  a  comprehensive  database 
search  [the  Cochrane  Skin  Group  Specialized  Register,  the 
Cochrane Central Register of Controlled Trials (CENTRAL) in 
The Cochrane Library, MEDLINE (from 2005), EMBASE (from 
2007), and LILACS (from 1982)] to evaluate the results of treat-
ment  for  erosive  lichen  planus  involving  the  anogenital,  oral, 
and/or esophageal regions. They identified 15 randomized con-
trolled trials (473 total subjects) pertaining to oral lichen planus 
only. Notably, in a study with 45 patients, A. vera gel was found 
to  be  six  times  more  likely  than  placebo  to  yield  at  least  a  
50 percent decline in pain symptoms.56

A. vera juice and gel were shown to be effective in a case study 
of  a  38-year-old  man  who  was  successfully  treated  for  lichen 
planus of the skin and oral mucosa with a two-month course of 
the botanical agent.57

Atopic Dermatitis and Xerosis
In 2006, Dal’Belo et al. assessed the effects of cosmetic prepara-
tions containing various concentrations of freeze-dried A. vera 
extract on the skin hydration of the volar forearm of 20 female 
volunteers. Stratum corneum (SC) water content and transepi-
dermal water loss (TEWL) were evaluated after a single applica-
tion as well as after one and two weeks of daily use of stable 
formulations  containing  5  percent  (w/w)  of  a  trilaureth-4  
phosphate-based blend with 0.10, 0.25, or 0.50 percent (w/w) 
of freeze-dried A. vera extract. SC water content increased after 
one  application  of  the  formulations  supplemented  with  0.25 
and  0.50  percent  (w/w)  A.  vera  extract.  After  two  weeks,  SC 
water content was higher as a result of using any of the formu-
lations. When compared with vehicle, TEWL was unaltered by 
any of the products. The investigators concluded that freeze-
dried  A.  vera  extract  is  effective  at  enhancing  skin  hydration 
and would be useful in cosmetic moisturizers.58

In 2010, Kim et al. demonstrated in a study of the effects of 
Scutellariae radix and A. vera gel, alone or in combination, on NC/
Nga mice that both plants modulate immunological responses in 
atopic dermatitis primarily by suppressing interleukin (IL)-5 and 
IL-10 levels.59

A. vera was cited as one of nine botanical extracts by Casetti et al. 
in a 2011 PubMed database search for botanical extracts noted 
for  enhancing  the  skin  barrier  and/or  facilitating  keratinocyte 
differentiation  in  vivo  after  topical  application.  The  researchers 
suggested  that  while  further  investigation  is  necessary,  A.  vera 
and the other herbs appear to have potential as dermocosmetic 
agents for treating dry skin.60,61

Aloe-coated Examination Gloves
A. vera-infused gloves were first shown to be effective in a 2003 
open, contralateral comparison study by  West  and  Zhu.  This 
investigation involved 30 adult females with bilateral dry skin 
due to occupational exposure on a factory assembly line who 
were directed to use the dry-coated A. vera glove on one hand 
for eight hours/day and no glove on the other hand for 30 days. 

The investigators reported that the gradual delivery of aloe to 
the skin yielded uniformly enhanced skin integrity, diminished 
fine wrinkling, and reduced erythema.62 In a letter responding 
to West and Zhu’s study, Mitchell emphasized that their study 
involved factory not health care workers, who must be vigilant 
about hand hygiene. Further, she noted that hands not decon-
taminated after patient contact risk serving as disease vectors, 
but speculated that decontaminating hands after using A. vera 
gloves  would  also  negate  any  benefits  of  the  herbal  agent. 
Finally, she wondered whether the soothing feeling conferred 
to hands by the A. vera-infused gloves might discourage some 
users from decontaminating their hands after use.63

In  a  2007  quasi-experimental  pilot  study  of  272  health  care 
workers as controls and 203 health care workers as test subjects, 
investigators  working  in  three  US  hospitals  and  one  Canadian 
hospital found that the use of A. vera-impregnated medical exam 
gloves  improved  perceived  skin  condition  and  attitudes  about 
hand hygiene.64 Although such gloves are available on the mar-
ket in the UK, a report by Ford and Phillips earlier in 2007 sug-
gested that it has not been established that the coating contains 
active aloe, whether the physical or chemical properties of the 
gloves  are  altered  by  aloe,  and  what,  if  any,  long-term  effects 
there are for users of the gloves. They did acknowledge that no 
adverse reactions had been published.65

Healing from Radiotherapy
In 2005, Richardson et al. systematically reviewed biomedical 
and alternative medicine databases for randomized controlled 
trials on the effectiveness of A. vera gel for treating radiation-
induced  skin  reactions.  In  the  five  published  trials  as  well  as 
two  unpublished  randomized  controlled  trials  that  they 
identified, they found no evidence that topically applied A. vera 
is  effective  in  preventing  or  attenuating  radiation-induced 
cutaneous reactions in cancer patients.66 Nevertheless, Wang et al. 
demonstrated during the previous year that aloe polysaccharides 
exerted  radioprotective  effects  in  vitro  and  in  vivo  in  mice 
through suppressing apoptosis.67

In a literature review published after the database investigation 
by Richardson and colleagues, Maddocks-Jennings et al. found 
data  to  suggest  that  A.  vera  gel  is  as  effective  as  mild  steroid 
creams (e.g., 1 percent hydrocortisone) in mitigating reactions to 
radiotherapy, with the added benefit of not provoking adverse 
side effects.68

In  a  2009  study  with  Swiss  albino  mice,  Goyal  and  Gehlot 
showed that A. vera leaf extract displays radioprotective effects 
against the biochemical alterations engendered by whole-body 
γ-irradiation.69

Combination Therapies: In Use  
or Under Investigation
A. vera extract is considered a key ingredient in a formulation 
also containing wheat germ oil and turmeric extract found to 
be an effective moisturizer in a small study with human volun-
teers (see Chapter 69, Turmeric).70

In 2008, Gupta et al. found that a poly-herbal topical formula-
tion combining the aqueous lyophilized leaf extracts of Hippophae 
rhamnoides  and  A.  vera  and  the  ethanol  rhizome  extract  of 
Curcuma longa (in an optimized ratio of 1:7:1) accelerated wound 
healing in normal and diabetic rats (see Chapter 69, Turmeric).71

Mendonça et al. performed a study with Wistar rats in 2009 
that  compared  the  wound-healing  effects  of  topically  applied  
A. vera gel alone or not with microcurrent application. The group 

 
treated only with aloe gel experienced accelerated wound healing 
compared to the control group. Animals treated only with micro-
current and those treated with aloe and microcurrent exhibited 
earlier proliferative phase activity compared to the control and 
aloe-only  groups.  The  investigators  concluded  that  A.  vera  gel 
and microcurrent acted synergistically in treating open wounds 
and has potential as a therapeutic option.72

A. vera extract is also an active ingredient in a cream containing 
Dead Sea minerals that was shown in 2009 to display antioxidant, 
anti-inflammatory,  and  photoprotective  activity  against  UVB 
irradiation when topically applied to human skin organ cultures.73
Aloe  is  included  in  a  4  percent  hydroquinone/10  percent 
l-ascorbic acid treatment system shown in 2011 to be effective 
in attenuating the early signs of photodamage in the normal to 
oily skin of 30 female subjects enrolled in a study by Bruce and 
Watson  [see  Chapter  36,  Hydroquinone,  and  Chapter  55, 
Ascorbic Acid (Vitamin C)].74

In  a  2012  randomized,  double-blind,  clinical  trial  with  
67 patients, an A. vera/olive oil cream was demonstrated to be as 
effective as β-methasone 0.1 percent in treating sulfur mustard-
induced chronic skin lesions, characterized by pruritus, xerosis, a 
burning sensation, and scaling.75

Aloe is also included in Menpentol Leche, an emulsion based 
on hyperoxygenated fatty acids,  A.  vera, and  Mimosa  tenuiflora 
that was found in a nonrandomized open clinical evaluation to 
be beneficial in alleviating the cutaneous symptoms prior to the 
appearance of ulcers in patients susceptible to vascular ulcers and 
diabetic foot ulcers.76

 SAFETY ISSUES

The  Cosmetic  Ingredient  Review  Expert  Panel  has  found  that 
anthraquinone levels have been well characterized and understood 
in  A.  vera  products  and  should  not  exceed  50  parts  per  million 
(ppm)  in  cosmetic  products.9  Further,  the  panel  reports  that 
the  phototoxicity  associated  with  some  anthraquinone 
constituents  of  A.  vera  has  been  undermined  by  multiple 
clinical  studies  using  amounts  of  the  ingredient  typical  of 
commercial preparations that have revealed no phototoxicity, 
suggesting that the concentrations of anthraquinones are too 
low  in  A.  vera  preparations  to  cause  phototoxicity. 9 
Anthraquinones are found in the sap of aloe, but not the leaf 
gel, which is the source of most aloe ingredients used in com-
mercial preparations.30

The yellow juice from the outer margins of the leaf is the tra-
ditional  source  for  a  laxative  and  while  used  by  many,  the  
FDA issued a statement in 2001 identifying the stimulant laxa-
tive  aloe  ingredients  (aloe  extract  and  aloe  flower  extract)  in 
OTC  drug  products  as  misbranded  and  not  generally  safe  and 
effective.77

Although the use of topical A. vera products is recognized as 
safe, with reports of truly adverse reactions extremely rare, der-
matologic side effects, including acute eczema, contact urticaria, 
and dermatitis have been documented.9,25,78 Mild discomfort has 
been linked to aloe use in some patients. Specifically, products 
containing A. vera (as well as vitamin E) as the major active ingre-
dient are contraindicated in the immediate weeks after surgery 
for  patients  undergoing  dermabrasion  or  chemical  peels.79 
Application of aloe gel is not contraindicated in women who are 
pregnant  or  lactating,  but  no  standards  regarding  a  maximum 
treatment period have been established.

A. vera is considered a sensitizing ingredient in emollients, and 

may exacerbate xerosis, particularly in the elderly.80

C H A P T E R  65  ■   A LO E  V E R A  

233

In 2007, Xia reported on findings that suggest humans exposed 
to  formulations  that  contain  A.  vera  whole  leaf  extract  may 
experience  amplified  sensitivity  to  UV  light,  likely  due  to  the 
anthraquinones  present  in  the  leaf  extract,  which  have  been 
demonstrated  to  produce  reactive  oxygen  species  due  to  UVA 
exposure.81

 ENVIRONMENTAL IMPACT

There  are  no  significant  challenges  or  effects  on  the  environ-
ment imposed by A. vera plant cultivation known by the author, 
though it is one of the largest botanical industries in the world.22 
As a succulent, it actually acts against desertification.

 FORMULATION CONSIDERATIONS

Cole  and  Heard  showed  in  2007  that  A.  vera  juice  displayed 
skin permeation-enhancing activity.82

In a 2007 study of vehicles for topically applied A. vera as well 
as Arnica  montana, Bergamante et al. found that a gel formula-
tion,  containing  Sepigel  305,  had  the  capacity  to  decrease  the 
release  and  permeation  of  aloin,  a  key  constituent  of  A.  vera 
extract known to exhibit antibacterial activity. Limiting aloin to 
surface activity was considered important because human skin 
fibroblasts  can  metabolize  absorbed  aloin  and  render  the  skin 
more sensitive to UV light.83

Two  years  later,  Takahashi  et  al.  showed  that  liposome 
encapsulation of A. vera leaf gel extracts significantly enhanced 
bioavailability and spurred proliferation and synthesis of type I 
collagen in normal human neonatal skin fibroblasts.84

Based  on  in  vitro  findings  in  2012,  Popadic  et  al.  suggested 
caution regarding the use and proper labeling of aloe emodin in 
topical products given the capacity of this hydroxyanthraqui-
none  constituent  of  A.  vera  to  suppress  the  proliferation  of 
adult  human  keratinocytes.85  Topically  applied  aloe  emodin 
has also been demonstrated to intensify cutaneous sensitivity 
to the effects of UV exposure.86,87 In addition, aloe emodin has 
been shown to induce apoptosis in nonmelanoma skin cancer 
cells, with such effects accelerated by the incorporation of aloe 
emodin  in  a  liposomal  formulation,  which  enhances 
transdermal delivery.88

In 2013, Vandana et al. formulated A. vera gel into a base to 
prepare  nimesulide  emulgel  with  a  higher  drug-load  capacity 
than commercial nimesulide gel (86.4 vs. 70.5 percent) and char-
acterized by significant anti-inflammatory potential.89

 USAGE CONSIDERATIONS

Known  traditionally  for  its  soothing  and  multifaceted 
capacity to treat a wide variety of skin lesions, A. vera use as 
an  active  ingredient  has  exploded  in  the  lucrative  field  of 
cosmetics and cosmeceuticals. Aloe and α-hydroxy acids are 
the natural products and extracts used most often in skin care 
formulations (see Chapter 82, Hydroxy Acids). Hundreds of 
such products have flooded the market since the mid-1990s. 
Aloe is even included in a new protective garment. Quantum 
Labs  received  FDA  approval  in  April  2002  for  its  SoftSkin  
A. vera gel-coated glove with vitamin E. The broad array of 
processed  and  commercially  available  aloe  products  are 
known  to  contain  several  ingredients,  but  little  is  known 
regarding  the  stability  of  the  active  ingredients.  Some  such 
products  have  so  little  aloe  or  active  ingredients  that  the 

 
234 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

agent is rendered diluted or unstable to the point of providing 
no  therapeutic  effects.  Products  that  list  “aloe  vera  extract” 
tend to be more dilute, while those listing “aloe gel” are more 
likely effective, but the lack of meaningful regulation of these 
products  makes  proper  selection  a  significant  challenge  for 
consumers. Indeed, aloe is known to be ineffective in concen-
trations below 50 percent; for optimal benefits, 100 percent is 
recommended.6

 SIGNIFICANT BACKGROUND

A.  vera  is  widely  used  in  various  products,  including  cosmetics, 
pharmaceuticals, food supplements, and beverages. An increasing 
array of biological activity has been associated with this plant 
long associated with the healing of minor wounds.

Antioxidant and Anti-inflammatory Activity
Aloe  constituents  such  as  salicylic  acid,  magnesium  lactate,  and 
several  polysaccharides  are  instrumental  in  reducing  levels  of 
thromboxane A2, thromboxane B2, and prostaglandin E2, thus ren-
dering anti-inflammatory effects (see Chapter 78, Salicylic Acid).24
In  a  wide-ranging  2003  study  of  the  anti-inflammatory  and 
antioxidant  properties  of  various  aloe  isolates,  including  cin-
namoyl, p-coumaroyl, feruloyl, caffeoyl aloesin, and related com-
pounds, Yagi et al. found that the involvement of the caffeoyl, 
feruloyl, and coumaroyl groups bound to aloesin was well estab-
lished, and the contact hypersensitivity response suggested that 
aloesin  prevented  UVB-induced  immune  suppression.  In  addi-
tion, they noted that aloesin inhibited the tyrosine hydroxylase 
and DOPA oxidase activities of tyrosinase in normal human mel-
anocyte cell lysates. The investigators concluded that the potent 
antioxidant  and  anti-inflammatory  effects  imparted  by  aloesin 
derivatives helped to explain, in part, the anti-inflammatory and 
wound-healing properties of A. vera.90,91 Further, in 2013, López et 
al. observed in vitro antioxidant activities displayed by methanol 
extracts of  A. vera leaf skin and flowers, using the 1,1-diphenyl-
2-picrylhydrazyl (DPPH) and ferric antioxidant reducing power 
(FRAP)  assays.  The  leaf  skin  fraction  was  more  active,  also 
exhibiting activity against tested microbial strains.92

Anticancer Activity
Aloe emodin has emerged as the focus of much of the research into 
the  capacity  of  A.  vera  for  cancer  inhibition.  A  hydroxyanthra-  
quinone naturally present in A. vera leaves, aloe emodin has been 
noted  for  its  strong  inhibition  of  Merkel  cell  carcinoma  (MCC) 
proliferation, but has been found to be nontoxic to normal cells.1,93 
The antineuroectodermal tumor activity of aloe emodin has been 
noted  in  vitro  and  in  vivo  and  may  represent  a  significant  new 
direction for antitumor drugs, according to some researchers.94

Key  factors  in  the  anticarcinogenic  potential  of  aloe  are  its 
active  constituents  found  to  have  immunomodulating  activity. 
The  small  molecular  weight  compounds  prevent  UVB-induced 
immune suppression in the skin by repairing UVB-induced dam-
ages  on  epidermal  Langerhans  cells  (LC).95,96  These  substances 
may also play a role in natural cancer therapy. Investigators have 
identified some therapeutic benefits, such as disease stabilization 
and  survival,  from  natural  cancer  therapy  with  melatonin  plus  
A. vera extracts for patients with advanced solid tumors and for 
whom no other standard therapies are judged appropriate.97 Also, 
a combination of vitamin C and A. vera gel extract supplementa-
tion was found to be effective in reducing the severity of chemical 
hepatocarcinogenesis in a study using Sprague-Dawley rats.98

In 2007, Chaudhary et al. used a two-stage skin carcinogen-
esis model in mice to ascertain the chemopreventive potential 
of  A.  vera.  Tumorigenesis  was  induced  in  Swiss  albino  mice 
with  a  single  topical  application  of  7,12-dimethylbenz(a)
anthracene  (DMBA)  and  promoted  with  croton  oil  for  
16 weeks. A. vera leaf extract was orally administered (1,000 mg/kg 
body  weight/d)  and/or  aloe  gel  topically  applied  (1  mL/ 
9 cm2/mice/d). Combined aloe treatment was found to reduce 
the number and size of papillomas, with a significantly lower 
tumor  incidence  seen  in  animals  treated  with  aloe  compared 
with 100 percent tumor incidence in the DMBA-treated control 
group. In addition, significantly fewer papillomas were seen in 
aloe-treated  mice  as  compared  to  controls  during  a  16-week 
observation  period;  a  significantly  longer  average  latency 
period and reduced tumor burden and tumor yield were associ-
ated with the aloe-treated animals.99

In a 2010 one-year study of the potential of A. vera in skin care 
formulations  enhancing  UV-induced  skin  cancer,  the  National 
Toxicology  Program  evaluated  topical  creams  containing  aloe 
plant extracts (aloe gel, whole leaf, decolorized whole leaf) or aloe 
emodin on SKH-1 hairless mice exposed to simulated solar light. 
A weak enhancing effect exerted by aloe gel or aloe emodin was 
identified in female but no male mice based on histologic analysis. 
There was also a weak enhancing effect rendered by whole or 
decolorized whole leaf in male and female SKH-1 mice as indi-
cated by histologically-ascertained squamous cell neoplasms. No 
effect from the creams was seen during the in-life phase.100

Also that year, Saini et al. investigated the antitumor activity 
of aloe in a two-stage skin carcinogenesis model in Swiss albino 
mice, using DMBA to induce and croton oil to promote tumors. 
The mice were randomly divided into four groups, with the first 
group exposed only to DMBA and croton oil and serving as con-
trols;  the  second  group  received  topical  A.  vera  gel;  the  third 
group was treated with oral A. vera extract; and the fourth group 
received both topical A. vera gel and oral A. vera extract. Tumor 
incidence was 100 percent in the first group, and dipped to 50, 
60,  and  40  percent,  in  the  second,  third,  and  fourth  groups, 
respectively. The number of papillomas, tumor yield, and tumor 
burden  in  the  treatment  groups  were  also  significantly  dimin-
ished  compared  to  controls,  while  the  average  latency  period 
increased  significantly  as  compared  to  controls.  The  investiga-
tors  concluded  that  A.  vera  exerts  a  protective  effect  against 
DMBA-croton oil-induced skin papillomagenesis in mice due to 
its high concentration of beneficial constituents, including vita-
mins A, C, and E, glutathione peroxidase, superoxide dismutase 
isozymes, selenium, zinc, and polysaccharides.8

Antimicrobial Activity
Antibacterial,  antifungal,  and  antiviral  activities  have  been 
associated  with  A.  vera.1,17  A  2007  study  by  Habeeb  et  al. 
explored  reports  of  antimicrobial  effects  associated  with  the 
plant.17,101  Using  a  simple  in  vitro  assay,  they  determined  the 
effect  of  the  inner  gel  of  aloe  on  bacterial-induced  pro-
inflammatory cytokine production (namely, TNF-α and IL-1β) 
from  human  leukocytes  stimulated  with  Shigella  flexneri. 
Results demonstrated the suppression of both bacterial-induced 
cytokines with the use of aloe inner gel.101 Further studies are 
still  needed  for  a  deeper  and  more  precise  understanding  of 
aloe constituents and their varied biological activities.

A 2009 in vitro comparison of a copper biocide/A. vera-based 
hand  rub  (Xgel)  revealed  that  the  agent  was  less  cytotoxic  to 
human  skin  cells  than  seven  commercially  available  products 
and  more  effective  than  Purell  against  all  tested  bacteria  

 
(i.e.,  methicillin-resistant  Staphylococcus  aureus  (MRSA), 
Acinetobacter baumanii, and Clostridium difficile).102

Photoprotection
In a recent in vitro study, Hwang et al. demonstrated that imma-
ture  aloe  shoot  extracts  (one-month  old)  were  more  effective 
than  adult  aloe  extracts  in  protecting  normal  human  dermal 
fibroblasts from UVB-induced damage, better inhibiting MMP-1, 
MMP-3, and IL-6 levels. The younger shoots also contributed 
to increasing type I procollagen and TGF-β1 levels.103

 CONCLUSION

For  decades,  the  use  of  A.  vera  has  been  promoted  for  a 
seemingly limitless variety of conditions. It remains one of the 
most  popular  botanical  products  in  mainstream  usage,  if  not 
the most popular, in the US. Often patients know more than 
doctors  about  the  purported  benefits.  Topical  products  that 
contain A. vera appear to be safe, but there is a scarcity of clini-
cal  evidence  establishing  efficacy.  Aloe  appears  to  have  great 
potential for a wide range of medical applications. Its use in a 
plethora of OTC topical products, though, is likely yet another 
attempt by manufacturers to capitalize on deeply entrenched 
cultural  knowledge  and  more  casual  popular  awareness 
regarding the benefits of the aloe plant. The risks of using such 
products are low, but much more clinical evidence is necessary 
from  randomized,  double-blind,  case-controlled  studies  to 
quantify  any  benefits  of  aloe  as  a  primary  active  ingredient. 
Such work is clearly warranted by current findings, especially 
when noting the cogent evidence on natural or less dilute forms 
of the plant. While clinical effectiveness has not yet been suffi-
ciently defined, promising outcomes have been seen.

REFERENCES

1.  Thornfeldt C. Cosmeceuticals containing herbs: Fact, fiction, and 

future. Dermatol Surg. 2005;31:873.

2.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

Medicine. Rochester, VT: Healing Arts Press; 2003:394.

3.  Hamman JH. Composition and applications of Aloe vera leaf gel. 

Molecules. 2008;13:1599.

4.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy:  Modern 

Herbal Medicine. London: Churchill Livingstone; 2000:70.

5.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

Medicine. Rochester, VT: Healing Arts Press; 2003:98.

C H A P T E R  65  ■   A LO E  V E R A  

235

14.  Surjushe  A,  Vasani  R,  Saple  DG.  Aloe  vera:  A  short  review.  

Indian J. Dermatol. 2008;53:163.

15.  MacKay  D,  Miller  AL.  Nutritional  support  for  wound  healing. 

Altern Med Rev. 2003;8:359.

16.  Wu J. Anti-inflammatory ingredients. J Drugs Dermatol. 2008;7:s13.
17.  Klein AD, Penneys NS. Aloe vera. J Am Acad Dermatol. 1988;18:714.
18.  McCauley  RL,  Heggers  JP,  Robson  MC.  Frostbite.  Methods  to 

minimize tissue loss. Postgrad Med. 1990;88:67.

19.  Miller  MB,  Koltai  PJ.  Treatment  of  experimental  frostbite  with 
pentoxifylline  and  aloe  vera  cream.  Arch  Otolaryngol  Head  Neck 
Surg. 1995;121:678.

20.  Pribitkin ED, Boger G. Herbal therapy: What every facial plastic 

surgeon must know. Arch Facial Plast Surg. 2001;3:127.

21.  Coopoosamy RM, Naidoo KK. A comparative study of three Aloe 
species used to treat skin diseases in South African rural commu-
nities. J Altern Complement Med. 2013;19:425.

22.  Foster M, Hunter D, Samman S. Evaluation of the nutritional and 
metabolic  effects  of  Aloe  vera.  In:  Benzie  IFF,  Wachtel-Galor  S, 
eds.  Biomolecular  and  Clinical  Aspects.  2nd  ed.  Boca  Raton  (FL): 
CRC Press; 2011:36-54.

23.  Jones K, Hughes J, Hong M, et al. Modulation of melanogenesis 
by aloesin: A competitive inhibitor of tyrosinase. Pigment Cell Res. 
2002;15:335.

24.  Fowler JF Jr, Woolery-Lloyd H, Waldorf H, et al. Innovations in 
natural  ingredients  and  their  use  in  skin  care.  J  Drugs  Dermatol. 
2010;9:S72.

25.  Foster S. An Illustrated Guide to 101 Medicinal Herbs: Their History, 
Use,  Recommended  Dosages,  and  Cautions.  Loveland,  CO: 
Interweave Press, 1998:18–19.

26.  Baumann LS. Aloe vera. Skin & Allergy News. 2003;34:32.
27.  Capasso R, Laudato M, Borrelli F. Meeting report: First National 
Meeting on Aloe, April 20-21, 2013, Isernia, Italy. New perspec-
tives in Aloe research: From basic science to clinical application. 
Nat Prod Commun. 2013;8:1333.

28.  Marshall  JM.  Aloe  vera  gel:  What  is  the  evidence?  Pharm  J. 

1990;244:360.

29.  Reynolds  T,  Dweck  AC.  Aloe  vera  leaf  gel:  A  review  update.  

J Ethnopharmacol. 1999;68:3.

30.  Davis SC, Perez R. Cosmeceuticals and natural products: Wound 

healing. Clin Dermatol. 2009;27:502.

31.  Briggs C. Herbal medicine: Aloe. Can Pharm J. 1995;128:48.
32.  Talmadge J, Chavez J, Jacobs L, et al. Fractionation of aloe vera L. 
inner  gel,  purification  and  molecular  profiling  of  activity.  
Int Immunopharmacol. 2004;4:1757.

33.  Lee  JK,  Lee  MK,  Yun  YP.  Acemannan  purified  from  Aloe  vera 
induces phenotypic and functional maturation of immature den-
dritic cells. Int Immunopharmacol. 2001;1:1275.

34.  Hutter  JA,  Salman  M,  Stavinoha  WB,  et  al.  Antiinflammatory 
C-glucosyl  chromone  from  Aloe  barbadensis.  J  Nat  Prod. 
1996;59:541.

35.  Choi SW, Son BW, Son YS, et al. The wound-healing effect of a 
glycoprotein  fraction  isolated  from  aloe  vera.  Br  J  Dermatol. 
2001;145:535.

36.  Goodyear-Smith F. Aloe vera – Aloe vera, Aloe barbadensis, Aloe 

6.  Korac RR, Khambholja KM. Potential of herbs in skin protection 

´

capensis. J Prim Health Care. 2011;3:322.

from ultraviolet radiation. Pharmacogn Rev. 2011;5:164.

7.  Dweck AC. Herbal medicine for the skin – their chemistry and 
effects on skin and mucous membranes. Pers Care Mag. 2002;3:19.
8.  Saini  M,  Goyal  PK,  Chaudhary  G.  Anti-tumor  activity  of  Aloe 
vera against DMBA/croton oil-induced skin papillomagenesis in 
Swiss albino mice. J Environ Pathol Toxicol Oncol. 2010;29:127.
9.  Cosmetic  Ingredient  Review  Expert  Panel.  Final  report  on  the 
safety  assessment  of  Aloe  Andongensis  Extract,  Aloe 
Andongensis  Leaf  Juice,  aloe  Arborescens  Leaf  Extract,  Aloe 
Arborescens  Leaf  Juice,  Aloe  Arborescens  Leaf  Protoplasts, 
Aloe  Barbadensis  Flower  Extract,  Aloe  Barbadensis  Leaf,  Aloe 
Barbadensis  Leaf  Extract,  Aloe  Barbadensis  Leaf  Juice,  aloe 
Barbadensis Leaf Polysaccharides, Aloe Barbadensis Leaf Water, 
Aloe Ferox Leaf Extract, Aloe Ferox Leaf Juice, and Aloe Ferox 
Leaf Juice Extract. Int J Toxicol. 2007;26(Suppl 2):1.

10.  Gallagher  J,  Gray  M.  Is  aloe  vera  effective  for  healing  chronic 

wounds? J Wound Ostomy Continence Nurs. 2003;30:68.

11.  Ahlawat KS, Khatkar BS. Processing, food applications and safety 
of aloe vera products: A review. J Food Sci Technol. 2011;48:525.
12.  Dat AD, Poon F, Pham KB, et al. Aloe vera for treating acute and 

chronic wounds. Cochrane Database Syst Rev. 2012;2:CD008762.

13.  Feily A, Namazi MR. Aloe vera in dermatology: A brief review.  

G Ital Dermatol Venereol. 2009;144:85.

37.  Atiba A, Nishimura M, Kakinuma S, et al. Aloe vera oral adminis-
tration  accelerates  acute  radiation-delayed  wound  healing  by 
stimulating  transforming  growth  factor-β  and  fibroblast  growth 
factor production. Am J Surg. 2011;201:809.

38.  Bhalang  K,  Thunyakitpisal  P,  Rungsirisatean  N.  Acemannan,  a 
polysaccharide extracted from Aloe vera, is effective in the treat-
ment  of  oral  aphthous  ulceration.  J  Altern  Complement  Med. 
2013;19:429.

39.  Cho S, Lee S, Lee MJ, et al. Dietary Aloe vera supplementation 
improves facial wrinkles and elasticity and it increases the type I 
procollagen gene expression in human skin in vivo. Ann Dermatol. 
2009;21:6.

40.  Reuter  J,  Jocher  A,  Stump  J,  et  al.  Investigation  of  the  anti-
inflammatory potential of Aloe vera gel (97.5%) in the ultraviolet 
erythema test. Skin Pharmacol Physiol. 2008;21:106.

41.  Oyelami OA, Onayemi A, Oyedeji OA, et al. Preliminary study 
of  effectiveness  of  aloe  vera  in  scabies  treatment.  Phytother  Res. 
2009;23:1482.

42.  Syed  TA,  Ahmad  SA,  Holt  AH,  et  al.  Management  of  psoriasis 
with  Aloe  vera  extract  in  a  hydrophilic  cream:  A  placebo- 
controlled, double-blind study. Trop Med Int Health. 1996;1:505.

43.  Morelli  V,  Calmet  E,  Jhingade  V.  Alternative  therapies  for  com-
mon dermatologic disorders, part 2. Prim Care. 2010;37:285.

 
236 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

44.  Vázquez B, Avila G, Segura D, et al. Antiinflammatory activity of 

extracts from Aloe vera gel. J Ethnopharmacol. 1996;55:69.

45.  Paulsen  E,  Korsholm  L,  Brandrup  F.  A  double-blind,  placebo- 
controlled study of a commercial Aloe vera gel in the treatment of 
slight to moderate psoriasis vulgaris. J Eur Acad Dermatol Venereol. 
2005;19:326.

46.  Choonhakarn  C,  Busaracome  P,  Sripanidkulchai  B,  et  al.  A  pro-
spective,  randomized  clinical  trial  comparing  topical  aloe  vera 
with 0.1% triamcinolone acetonide in mild to moderate plaque 
psoriasis. J Eur Acad Dermatol Venereol. 2010;24:168.

47.  Dhanabal SP, Priyanka Dwarampudi L, Muruganantham N, et al. 
Evaluation  of  the  antipsoriatic  activity  of  Aloe  vera  leaf  extract 
using a mouse tail model of psoriasis. Phytother Res. 2012;26:617.

48.  Chithra P, Sajithlal GB, Chandrakasan G. Influence of Aloe vera 
on collagen turnover in healing of dermal wounds in rats. Indian J 
Exp Biol. 1998;36:896.

49.  Somboonwong  J,  Thanamittramanee  S,  Jariyapongskul  A,  et  al. 
Therapeutic  effects  of  Aloe  vera  on  cutaneous  microcirculation 
and wound healing in second degree burn model in rats. J Med 
Assoc Thai. 2000;83:417.

50.  Visuthikosol V, Chowchuen B, Sukwanarat Y, et al. Effect of aloe 
vera gel to healing of burn wound: A clinical and histologic study. 
J Med Assoc Thai. 1995;78:403.

51.  Vogler BK, Ernst E. Aloe vera: A systematic review of its clinical 

effectiveness. Br J Gen Pract. 1999;49:823.

52.  Takzare N, Hosseini MJ, Hasanzadeh G, et al. Influence of Aloe 
vera  gel  on  dermal  wound  healing  process  in  rat.  Toxicol  Mech 
Methods. 2009;19:73.

53.  Inpanya P, Faikrua A, Ounaroon A, et al. Effects of the blended 
fibroin/aloe gel film on wound healing in streptozotocin-induced 
diabetic rats. Biomed Mater. 2012;7:035008.

54.  Tarameshloo M, Norouzian M, Zarein-Dolab S, et al. A compara-
tive study of the effects of topical application of Aloe vera, thy-
roid hormone and silver sulfadiazine on skin wounds in Wistar 
rats. Lab Animal Res. 2012;28:17.

55.  Hosseinimehr SJ, Khorasani G, Azadbakht M, et al. Effect of aloe 
cream versus silver sulfadiazine for healing burn wounds in rats. 
Acta Dermatovenerol Croat. 2010;18:2.

56.  Cheng  S,  Kirtschig  G,  Cooper  S,  et  al.  Interventions  for  erosive 
lichen planus affecting mucosal sites. Cochrane Database Syst Rev. 
2012;2:CD008092.

57.  Patil  BA,  Bhaskar  HP,  Pol  JS,  et  al.  Aloe  vera  as  cure  for  lichen 

planus. N Y State Dent J. 2013;79:65.

58.  Dal’Belo SE, Gaspar LR, Maia Campos PM. Moisturizing effect of 
cosmetic  formulations  containing  Aloe  vera  extract  in  different 
concentrations assessed by skin bioengineering techniques. Skin 
Res Technol. 2006;12:241.

59.  Kim J, Lee Is, Park S, et al. Effects of Scutellariae radix and Aloe 
vera  gel  extracts  on  immunoglobulin  E  and  cytokine  levels  in 
atopic dermatitis NC/Nga mice. J Ethnopharmacol. 2010;132:529.

60.  Casetti F, Wölfle U, Gehring W, et al. Dermocosmetics for dry skin: 
A  new  role  for  botanical  extracts.  Skin  Pharmacol  Physiol. 
2011;24:289.

70.  Saraf  S,  Sahu  S,  Kaur  CD,  et  al.  Comparative  measurement  of 
hydration  effects  of  herbal  moisturizers.  Pharmacognosy  Res. 
2010;2:146.

71.  Gupta A, Upadhyay NK, Sawhney RC, et al. A poly-herbal formu-
lation  accelerates  normal  and  impaired  diabetic  wound  healing. 
Wound Repair Regen. 2008;16:784.

72.  Mendonça FA, Passarini Junior JR, Esquisatto MA, et al. Effects of 
the application of Aloe vera (L.) and microcurrent on the healing 
of  wounds  surgically  induced  in  Wistar  rats.  Acta  Cir  Bras. 
2009;24:150.

73.  Portugal-Cohen M, Soroka Y, Ma’or Z, et al. Protective effects of 
a  cream  containing  Dead  Sea  minerals  against  UVB-induced 
stress in human skin. Exp Dermatol. 2009;18:781.

74.  Bruce S, Watson J. Evaluation of a prescription strength 4% hyd-
roquinone/10%  L-ascorbic  acid  treatment  system  for  normal  to 
oily skin. J Drugs Dermatol. 2011;10:1455.

75.  Panahi Y, Davoudi SM, Sahebkar A, et al. Efficacy of Aloe vera/
olive  oil  cream  versus  betamethasone  cream  for  chronic  skin 
lesions following sulfur mustard exposure: A randomized double-
blind clinical trial. Cutan Ocul Toxicol. 2012;31:95.

76.  Puentes Sánchez J, Pardo González CM, Pardo González MB, et al. 
Prevention of vascular ulcers and diabetic foot. Non-randomized 
open clinical evaluation on the effectiveness of “Mepentol Leche.” 
Rev Enferm. 2006;29:25.

77.  Food and Drug Administration, HHS. Status of certain additional 
over-the-counter drug category II and III active ingredients. Final 
rule. Fed Regist. 2002;67:31125.

78.  Ernst  E.  Adverse  effects  of  herbal  drugs  in  dermatology.  Br  J 

Dermatol. 2000;143:923.

79.  Hunter  D,  Frumkin  A.  Adverse  reactions  to  vitamin  E  and  aloe 
vera  preparations  after  dermabrasion  and  chemical  peel.  Cutis. 
1991;47:193.

80.  White-Chu EF, Reddy M. Dry skin in the elderly: Complexities of 

a common problem. Clin Dermatol. 2011;29:37.

81.  Xia  Q,  Yin  JJ,  Fu  PP,  et  al.  Photo-irradiation  of  Aloe  vera  by  
UVA – formation of free radicals, singlet oxygen, superoxide, and 
induction of lipid peroxidation. Toxicol Lett. 2007;168:165.

82.  Cole L, Heard C. Skin permeation enhancement potential of Aloe 
vera and a proposed mechanism of action based upon size exclu-
sion and pull effect. Int J Pharm. 2007;333:10.

83.  Bergamante V, Ceschel GC, Marazzita S, et al. Effect of vehicles 
on  topical  application  of  aloe  vera  and  arnica  Montana  compo-
nents. Drug Deliv. 2007;14:427.

84.  Takahashi M, Kitamoto D, Asikin Y, et al. Liposomes encapsulat-
ing Aloe vera leaf gel extract significantly enhance proliferation 
and  collagen  synthesis  in  human  skin  cell  lines.  J  Oleo  Sci. 
2009;58:643.

85.  Popadic D, Savic, E, Ramic Z, et al. Aloe-emodin inhibits prolifera-
tion  of  adult  human  keratinocytes  in  vitro.  J  Cosmet  Sci. 
2012;63:297.

86.  Wamer WG, Vath P, Falvey DE. In vitro studies on the photobio-
logical properties of aloe emodin and aloin A. Free Radic Biol Med. 
2003;34:233.

61.  Dohil  MA.  Natural  ingredients  in  atopic  dermatitis  and  other 

87.  Vath P, Wamer WG, Falvey DE. Photochemistry and phototoxicity 

inflammatory skin disease. J Drugs Dermatol. 2013;12:s128.
62.  West DP, Zhu YF. Evaluation of aloe vera gel gloves in the treat-
ment  of  dry  skin  associated  with  occupational  exposure.  Am  J 
Infect Control. 2003;31:40.

63.  Mitchell H. Evaluation of aloe vera gel gloves in the treatment of 
dry  skin  associated  with  occupational  exposure.  Am  J  Infect 
Control. 2003;31:516.

64.  Korniewicz  DM,  El  Masri  M.  Effect  of  aloe-vera  impregnated 
gloves on hand hygiene attitudes of health care workers. Medsurg 
Nurs. 2007;16:247.

65.  Ford JL, Phillips P. Are aloe-coated gloves effective in healthcare? 

Nurs Times. 2007;103:40.

66.  Richardson J, Smith JE, McIntyre M, et al. Aloe vera for preventing 
radiation-induced skin reactions: A systematic literature review. 
Clin Oncol (R Coll Radiol). 2005;17:478.

67.  Wang ZW, Zhou JM, Huang ZS, et al. Aloe polysaccharides medi-
ated  radioprotective  effect  through  the  inhibition  of  apoptosis.  
J Radiat Res. 2004;45:447.

68.  Maddocks-Jennings  W,  Wilkinson  JM,  Shillington  D.  Novel 
approaches  to  radiotherapy-induced  skin  reactions:  A  literature 
review. Complement Ther Clin Pract. 2005;11:224.

69.  Goyal  PK,  Gehlot  P.  Radioprotective  effects  of  Aloe  vera  leaf 
extract on Swiss albino mice against whole-body gamma irradia-
tion. J Environ Pathol Toxicol Oncol. 2009;28:53.

of aloe emodin. Photochem Photobiol. 2002;75:346.

88.  Chou TH, Liang CH. The molecular effects of aloe-emodin (AE)/
liposome-AE on human nonmelanoma skin cancer cells and skin 
permeation. Chem Res Toxicol. 2009;22:2017.

89.  Vandana K, Prasanna Raju Y, Sundaresan C, et al. In-vitro assessment 
and pharmacodynamics of nimesulide incorporated aloe vera transe-
mulgel. Curr Drug Discov Technol. 2013 Dec 2. [Epub ahead of print]
90.  Yagi  A,  Takeo  S.  Anti-inflammatory  constituents,  aloesin  and 
aloemannan in Aloe species and effects of tanshinon VI in Salvia 
miltiorrhiza on heart. Yakugaku Zasshi. 2003;123:517.

91.  Yagi  A,  Kabash  A,  Okamura  N,  et  al.  Antioxidant,  free  radical 
scavenging and anti-inflammatory effects of aloesin derivatives in 
Aloe vera. Planta Med. 2002;68:957.

92.  López  A,  de  Tangil  MS,  Vega-Orellana  O,  et  al.  Phenolic 
constituents,  antioxidant  and  preliminary  antimycoplasmic 
activities  of  leaf  skin  and  flowers  of  Aloe  vera  (L.)  Burm.  F.  
(syn.  A.  barbadensis  Mill.)  from  the  Canary  Islands  (Spain). 
Molecules. 2013;18:4942.

93.  Wasserman L, Avigad S, Beery E, et al. The effect of aloe emodin 
on  the  proliferation  of  a  new  merkel  carcinoma  cell  line.  Am  J 
Dermatopathol. 2002;24:17.

94.  Pecere T, Gazzola MV, Mucignat C, et al. Aloe-emodin is a new 
type of anticancer agent with selective activity against neuroecto-
dermal tumors. Cancer Res. 2000;60:2800.

 
C H A P T E R  65  ■   A LO E  V E R A  

237

95.  Lee CK, Han SS, Mo YK, et al. Prevention of ultraviolet radiation-
induced suppression of accessory cell function of Langerhans cells 
by Aloe vera gel components. Immunopharmacology. 1997;37:153.

96.  Lee  CK,  Han  SS,  Shin  YK,  et  al.  Prevention  of  ultraviolet  
radiation-induced  suppression  of  contact  hypersensitivity  by 
Aloe vera gel components. Int J Immunopharmacol. 1999;21:303.
97.  Lissoni P, Giani L, Zerbini S, et al. Biotherapy with the pineal immu-
nomodulating hormone melatonin versus melatonin plus aloe vera 
in untreatable advanced solid neoplasms. Nat Immun. 1998;16:27.
98.  Shamaan NA, Kadir KA, Rahmat A, et al. Vitamin C and aloe vera 
supplementation protects from chemical hepatocarcinogenesis in 
the rat. Nutrition. 1998;14:846.

99.  Chaudhary  G,  Saini  MR,  Goyal  PK.  Chemopreventive  poten-
tial  of  Aloe  vera  against  7,12-dimethylbenz(a)anthracene 
induced  skin  papillomagenesis  in  mice.  Integr  Cancer  Ther. 
2007;6:405.

100.  National Toxicology Program. Photocarcinogenesis study of aloe 
vera  [CAS  NO.  481-72-1(Aloe-emodin)]  in  SKH-1  mice  (simu-
lated solar light and topical application study). Natl Toxicol Program 
Tech Rep Ser. 2010;553:7.

101.  Habeeb  F,  Stables  G,  Bradbury  F,  et  al.  The  inner  gel  compo-
nent of Aloe vera suppresses bacterial-induced pro-inflamma-
immune  cells.  Methods . 
tory  cytokines  from  human 
2007;42:388.

102.  Hall TJ, Wren MW, Jeanes A, et al. A comparison of the antibacte-
rial  efficacy  and  cytotoxicity  to  cultured  human  skin  cells  of  
7 commercial hand rubs and Xgel, a new copper-based biocidal 
hand rub. Am J Infect Control. 2009;37:322.

103.  Hwang  E,  Kim  SH,  Lee  S,  et  al.  A  comparative  study  of  baby 
immature  and  adult  shoots  of  Aloe  vera  on  UVB-induced  skin 
photoaging in vitro. Phytother Res. 2013 Mar 15. [Epub ahead of 
print]

 
238 

Co s m eCe u t iCa l s  aN D   Co s m e t iC

 i Ng r eDi eNt s

C H A P T E R   6 6

Feverfew

Activities:

Anti-inflammatory, anticarcinogenic, analgesic, antipro-
liferative, antipyretic, antimicrobial

Important Chemical Components:

Sesquiterpene  lactones  (especially  parthenolide),  ses-
quiterpenes,  monoterpenes  (e.g.,  pinenes),  polyacety-
lene  compounds,  essential  oil  (including  the  terpenoid 
camphor  and  chrysanthenyl  acetate  in  both  the  aerial 
and  root  essential  oils;  bornyl  acetate),  flavonoids 
(including  tanetin,  quercetin,  apigenin,  and  luteolin), 
coumarins (e.g., isofraxidin), and melatonin1–4

Origin Classification:

This ingredient is natural. Organic forms exist. There are 
processed  formulations  available  using  feverfew  with 
parthenolide  removed.  This  puts  the  parthenolide-
removed  feverfew  in  a  category  known  as  “Active 
Naturals.”5

Personal Care Category:

Anti-inflammatory,  appearance  enhancing,  soothing, 
moisturizing

Recommended  for  the  following  Baumann  Skin 
Types:

DSNT, DSPT, DSNW, DSPW, OSNT, OSNW, OSPT, and 
OSPW

 SOURCE

Tanacetum parthenium, an aromatic perennial herb native to the 
Balkan peninsula and better known as feverfew, belongs to the 
Asteraceae  or  Compositae  family  and  has  long  been  used  in 
traditional  medicine  (Table  66-1).6  The  plant  (also  known  by 
previous botanical names, including Chrysanthemum parthenium, 
Pyrethrum parthenium, Matricaria pyrethrum, and Matricaria parth- 
enium)1,4,7  is  now  broadly  dispersed  throughout  the  world, 
primarily the northern hemisphere, and is particularly prolific 
in Iran and Turkey.2,3,8 The expression “feverfew” is believed to 
be a corruption of the word “febrifuge,” derived from the Latin 

TABLE 66-1
Pros and Cons of Feverfew

Pros
long history of traditional use

Potency and potential of its chief  

constituent, parthenolide, is compelling

Cons
may cause contact dermatitis especially in 

ragweed-allergic individuals

unknown how it reacts when exposed to 
other ingredients such as retinoids and 
skin lighteners

febris (fever) and fugure (to drive away) to describe the antipy-
retic actions of the plant.1,2 Feverfew has long been cultivated 
for ornamental and medicinal purposes.9 The term “parthenium” 
is derived from the ancient Greek name for the plant bestowed, 
according to legend, because the plant was used to save the life 
of  a  worker  who  had  fallen  from  the  Parthenon  during  its  
5th century BCE construction.6,10 Modern evidence of the anti-
inflammatory properties of feverfew has been accruing over the 
last several decades and is now considered well established.11

 HISTORY

For over 2,000 years, folk medicine has incorporated feverfew 
for internal use to regulate menstruation, assist in labor during 
childbirth,  and  treat  fevers,  headaches,  and  infertility; 
externally, it has been used as an analgesic.4,6 The first century 
CE Greek physician Dioscorides recommended feverfew for all 
inflammatory  conditions.6,10  Known  as  aqhovan  in  Iran,  the 
roots  and  rhizomes  of  feverfew  have  been  used  in  Iranian 
traditional  medicine  to  treat  gastrointestinal  disorders.2  Early 
European herbalists also used feverfew.9 The Kallaway people 
of the Andes mountains of South America have used feverfew 
to  treat  colic,  stomach  and  kidney  pain,  as  well  as  morning 
sickness.4  Native  Mexican  peoples  have,  for  centuries,  used 
feverfew to treat fever, arthritis, and migraines.12,13 The broad 
range  of  traditional  medical  uses  of  feverfew  also  includes 
therapeutic applications for allergies, arthritis, asthma, coughs 
and colds, constipation, depression, dermatitis, earache, edema, 
infant  colic,  inflammatory  conditions,  insect  bites,  kidney 
stones,  labor,  potential  miscarriage,  nausea  and  vomiting, 
psoriasis,  skin  wounds,  spasms,  tinnitus,  toothache,  vertigo, 
and  worms.4,5,9,14  Nonmedical  applications  have  included 
cosmetics,  balsams,  dyes,  preservatives,  and  insecticides.3 
Feverfew gained more modern, nontraditional adherents in the 
late 1970s and 1980s, with several reports suggesting its effec-
tiveness as an oral agent in preventing migraine headaches.4,15,16

 CHEMISTRY

Feverfew, vitamin E, coenzyme Q10, and turmeric are among the 
antioxidants found in the lipophilic portion of the cell membrane 
[see Chapter 56, Tocopherol (Vitamin E), Chapter 57, Coenzyme 
Q10,  and  Chapter  69,  Turmeric].  Other  fat-soluble  antioxidants 
include carotenoids (e.g., lycopene) and idebenone, the synthetic 
analog of coenzyme Q10 (see Chapter 61, Idebenone).

T. parthenium is known to suppress the release of proinflam-
matory  mediators  from  macrophages  and  lymphocytes.17  In  a 
Medline literature review of herbal agents that many people take 
but  that  might  warrant  discontinuing  before  dermatologic 
surgery,  authors  cited  feverfew  for  its  known  success  as  a 
treatment  for  migraines,15  and  arthritis  as  well  as  its  anti- 
inflammatory activity in blocking phospholipase breakdown of 
arachidonic acid into prostaglandins and leukotrienes.18,19 They 
noted that platelet aggregation is also induced by the feverfew 

 
extract  parthenolide  and  a  byproduct  of  the  arachidonic  acid 
cascade, thromboxane A2.18,20,21

Many of the anti-inflammatory, antioxidant, and antiprolifer-
ative  characteristics  of  feverfew  are  ascribed  to  its  primary 
constituent  parthenolide,  a  hydroalcoholic  extract  of  the  aerial 
parts  of  the  plant  known  to  inhibit  nuclear  factor-κB  (NF-κB), 
which contributes to anti-inflammatory activity, and to exhibit 
exceptional anticancer and antiproliferative properties.11,12,14,22 In 
fact, the sesquiterpene lactone parthenolide (within the subclass 
germacranolides)23 is the first small molecule discovered to act 
selectively  against  cancer  stem  cells.5  Notably,  parthenolide, 
which  is  not  present  in  all  varieties  of  feverfew,  is  thought  to 
account for the antimigraine activity of the herb.6 In 2011, Majdi 
et al. discovered that glandular trichomes of T. parthenium are the 
secretory  tissues  where  the  production  and  accumulation  of 
parthenolide  occur.24  Parthenolide  can  be  very  irritating  when 
applied  topically;  therefore,  manufacturers  have  marketed 
topical preparations with the parthenolide component removed 
from the molecule. Feverfew imparts numerous benefits that are 
not derived from parthenolide. The strong antioxidant melatonin 
is also found in feverfew.7,25 In addition, the lipophilic flavonoid 
tanetin, present in feverfew leaves, flowers, and seeds, has been 
found to inhibit prostaglandin production.4,26,27

Investigations  of  parthenolide  do  represent  a  significant 
portion  of  research  into  feverfew,  though.  In  2008,  Parada-
Turska  et  al.  conducted  an  in  vitro  study  of  the  effects  of 
parthenolide on the proliferation of the rabbit synoviocytes 
cell  line  HIG-82,  rheumatoid  arthritis  fibroblast-like 
synoviocytes,  and  human  skin  fibroblasts.  They  found  that 
parthenolide suppressed the proliferation of HIG-82 as well 
as the rheumatoid arthritis fibroblast-like synoviocytes, with 
human  skin  fibroblasts  inhibited  but  less  effectively.  The 
researchers  concluded  that  their  findings  highlighted  the 
antiproliferative  potential  of  parthenolide,  particularly  in 
relation to rheumatoid arthritis.28

 ORAL USES

Oral uses of feverfew have included infusions to treat arthritis, 
fever, migraine headaches, and stomach aches.29 The fresh leaves 
can  be  chewed  fresh,  freeze-dried-  or  dried,  and  supplements 
containing  the  dried  leaves  are  available  in  capsule,  tablet,  or 
liquid extract form in Europe and the United States.4,10

In  1999,  Jain  and  Kulkarni  demonstrated  that  orally  adminis-
tered feverfew extract dose-dependently exerted significant antino-
ciceptive and anti-inflammatory activity against acetic acid-induced 
writhing in mice and carageenan-induced paw edema in rats.9

An orally bioavailable analog of parthenolide, dimethylamino-
parthenolide (DMAPT), has been developed as a result of structure–
activity relationship studies of the feverfew constituent, and may 
have implications pertaining to the antiproliferative properties of 
the compound, particularly for patients with leukemia.5

Headache Treatment
Cady  et  al.  conducted  a  one-month,  multicenter,  double-blind, 
placebo-controlled  pilot  study  with  60  subjects  in  2011,  finding 
that a sublingual feverfew and ginger preparation (LipiGesic™ M) 
was safe and effective as a first-line therapy for patients who typi-
cally experience a mild headache before the onset of a moderate-
to-severe  migraine  (see  Chapter  59,  Ginger).30  De  Weerdt  et  al. 
performed a randomized, double-blind, placebo-controlled cross-
over trial in 1996 based on the encouraging results of two studies 
in the 1980s, but their results indicated that feverfew did not exert 
a significant prophylactic effect against migraines.31

C HaPt e r  66  ■   Fe Ve rFe W  

239

In  2012,  a  randomized  study  of  69  female  volunteers  was 
conducted by Ferro et al. to examine the efficacy and tolerability 
of acupuncture, T. parthenium, or a combination for the treatment 
of chronic migraines. Twenty-two patients received acupuncture 
in 20 sessions over 10 weeks; 23 patients received 150 mg/day of 
feverfew; and 23 patients received combination therapy. Using 
the  Short-Form  36  quality  of  life  assessment  score,  Migraine 
Disability Assessment, and a visual analog scale, the investigators 
determined  that  acupuncture  along  with  T.  parthenium  was 
substantially  more  effective  than  either  therapy  alone,  with 
statistically significant differences in yielding a greater analgesic 
effect and improved quality of life.32

However,  Loder  et  al.  reviewed  the  American  Headache 
Society and the American Academy of Neurology 2012 updated 
treatment guideline recommendations along with a systematic 
Medline search, including recent guidelines for migraine preven-
tion  from  the  Canadian  Headache  Society  and  the  European 
Federation of Neurological Societies, and found significant differ-
ences of opinion regarding the use of feverfew for migraines.33 
Goodyear-Smith  contends  that,  at  present,  there  is  insufficient 
data from five randomized, double-blind trials on migraine head-
aches  and  one  on  rheumatoid  arthritis  to  support  the  use  of 
feverfew  to  prevent  migraines  or  treat  rheumatoid  arthritis.34 
Triptans remain the “gold standard” for first-line migraine therapy, 
according to Cady et al.30

 TOPICAL USES

Topically applied feverfew is thought to improve the appearance 
of  the  skin.35  It  is  included  in  moisturizing  agents  to  impart  a 
calming,  soothing  effect.  A  parthenolide-free  formulation  has 
recently  been  studied  for  treatment  of  acne  and  rosacea,  with 
some indications of efficacy.36,37 In fact, parthenolide-free Feverfew 
PFE™ is a nonsteroidal anti-inflammatory topical product found 
to suppress multiple pathways related to skin irritation.38

 SAFETY ISSUES

The Compositae family (ragweed is an example) is known to 
cause  contact  dermatitis  in  susceptible  individuals,  and 
Compositae allergy is among the top ten contact sensitivities in 
Europe.  Sesquiterpene  lactones  are  considered  to  be  the 
primary sensitizing constituents in these plants.39 Nevertheless, 
feverfew  is  considered  safe,  with  reactions  typically  mild  to 
moderate  and  manifested  by  those  with  Compositae  allergy. 
Indeed,  feverfew  has  long  been  acknowledged  as  a  key 
sensitizer  in  European  Compositae-allergic  patients  due  to 
parthenolide,  which  is  known  as  a  potent  skin  sensitizer.16,40  
In 2007, there was a report of two patients experiencing contact 
dermatitis  from  using  a  topical  moisturizer  containing 
feverfew.41  Such  reactions  prompted  the  development  of 
parthenolide-depleted  formulations  even  though  adverse 
reactions to feverfew are considered to be minimal and rare.

Sensitivity  to  parthenolide-depleted  agents  remains  possible, 
nevertheless. In a small study with seven patients conducted in 
2010, Paulsen et al. used patch tests to examine the tolerance of 
individuals with known contact allergy to topical parthenolide-
depleted feverfew formulations. Subjects were patch tested with 
two  parthenolide-depleted  creams.  The  researchers  noted  that 
four patients tested positive to one of the agents and reactivity 
was  linked  to  simultaneous  positive  response  to  parthenolide. 
Two  years  later,  Paulsen  and  colleagues  analyzed  the  cream, 
finding no parthenolide, which they ascribed to degradation of 
the compound.40

 
240 

Co s m eCe u t iCa l s  aN D   Co s m e t iC

 i Ng r eDi eNt s

When feverfew is ingested orally for migraines, oral ulcers have 
been reported.34 Use of feverfew may increase the risk of bleeding 
during surgical procedures.42 Similarly, feverfew may elevate such 
risk  for  patients  using  warfarin  or  aspirin.34  Feverfew  is 
contraindicated in pregnant women as it acts as an emmenagogue.

 ENVIRONMENTAL IMPACT

Feverfew is one of several wild medicinal plants in the Concord 
area of New England that have undergone accelerated flowering 
times due to climate change.43

Fonseca  et  al.  have  shown  that  changing  environmental 
conditions  immediately  before  harvest  affects  secondary 
metabolites  in  feverfew,  with  parthenolide  yields  higher  with 
light and reduced water and phenolic yields higher with water 
and little light. They suggest that the controlled environment of 
a  greenhouse  might  be  the  ideal  setting  for  harnessing  the 
optimal phytochemicals from T. parthenium.27,44

Parthenolide content in feverfew plants is recognized as high in 
France and Germany, but the plants in Serbia, the US, and Mexico 
almost  completely  lack  parthenolide.45  Beyond  regional  and 
geographical differences, the parthenolide content of feverfew can 
also be influenced by processing and extraction methods (including 
drying temperature and extraction solvent used).45–47

 FORMULATION CONSIDERATIONS

Researchers  have  developed  a  form  of  feverfew  with  the 
parthenolide  portion  removed,  rendering  it  safer  as  a  topical 
ingredient.

In  vitro  and  in  vivo  antioxidant  efficacy  of  a  parthenolide-
depleted feverfew extract (PD-Feverfew) was reported by Martin 
et  al.  in  2008.  The  extract  restored  cigarette  smoke-mediated 
depletion  of  cellular  thiols,  diminished  the  formation  of 
ultraviolet  (UV)-induced  hydrogen  peroxide,  and  hindered 
proinflammatory  cytokine  release  in  vitro,  manifesting  greater 
radical  scavenging-potency  than  vitamin  C.  In  addition,  the 
topical formulation reduced UV-induced epidermal hyperplasia, 
DNA damage, and apoptosis in vivo. Phototoxicity and photoal-
lergy tests for the formulation were consistently negative, and 
clinical tolerance testing in over 1,200 individuals showed that 
formulations  containing  PD-Feverfew  did  not  elicit  allergic 
reactions.  The  researchers  also  reported  that  a  clinical  study  
(randomized,  placebo-controlled,  double-blinded  with  
12 females and males, Fitzpatrick types II and III) revealed that 
treatment  significantly  mitigated  UVB-induced  erythema  as 
compared to placebo 24 hours after exposure. They concluded 
that  their  parthenolide-depleted  feverfew  formulation  protects 
the skin from exogenous oxidizing factors.48

In  2009,  some  of  the  same  investigators  assessed  the  anti-
inflammatory  capacity  of  the  parthenolide-depleted  feverfew 
extract that they developed. In vitro, the extract hindered the activ-
ity  of  several  proinflammatory  enzymes  (i.e.,  5-lipoxygenase, 
phosphodiesterase-3,  and  phosphodiesterase-4)  as  well  as  the 
release  of  proinflammatory  mediators.  In  vivo,  the  extract 
thwarted oxazolone-induced dermatitis and was more effective 
than regular feverfew in treating 12-O-tetradecanoylphorbol-13-
acetate-induced dermatitis. In a clinical assessment, the investi-
gators found that their extract diminished erythema in a methyl 
nicotinate-induced  vasodilation  model.  They  concluded  that 
PD-Feverfew  exhibits  strong  anti-inflammatory  activity  but 
without the accompanying sensitizing activity characteristic of 
whole feverfew.16

In a three-week screening study in 2007, Jin et al. found that 
parthenolide  is  comparatively  stable  when  the  environmental 
pH is in the range of 5 to 7, and is unstable when the pH is less 
than  3  or  above  7.  They  also  found  that  it  is  compatible  with 
frequently  used  excipients  under  stressed  conditions.  Further, 
they  noted  that  parthenolide  degradation  in  feverfew  solution 
seems to be a typical first-order reaction but its degradation in the 
solid state fits no obvious reaction model. The degradation rate 
was  found  to  be  highly  influenced  by  moisture  content  and 
temperature,  with  an  increase  from  18  percent  to  32  percent 
degradation  of  parthenolide  after  six  months  of  storage  under 
40°C at a relative humidity of 75 percent.45

The  following  year,  the  same  researchers  evaluated  the 
flowability,  hygroscopicity,  compressibility,  and  compactibility 
of  multiple  commercial  feverfew  extracts,  and  ascertained  the 
parthenolide  content  of  the  formulations.  They  found  poor  to 
very  poor  flowability,  and  highly  variable  hygroscopicity  and 
compactibility  among  the  products,  with  no  tested  products 
actually containing the parthenolide quantity as claimed by the 
labels.  Parthenolide  content  varied  even  in  different  batches 
from the same manufacturers. The investigators suggested that 
proper  quality  controls  are  necessary  for  manufacturers,  who 
should  also  be  cognizant  of  inconsistent  physicochemical 
characteristics in the feverfew provided by myriad suppliers.49

 USAGE CONSIDERATIONS

Stability studies of feverfew products have not yet appeared in 
the  literature.45  It  is  unknown  how  feverfew  is  affected  by 
interaction  with  other  ingredients.  Feverfew  should  not  be 
used in patients with a known ragweed allergy.

 SIGNIFICANT BACKGROUND

Feverfew is known to provide a broad range of biologic activity 
with or without its primary constituent parthenolide. The anti-
inflammatory  activity  of  feverfew  is  thought  by  some  to  be 
more  potent  than  that  of  Aloe  vera,  Camellia  sinensis,  licorice 
extract, and other Asteraceae family members such as chamo-
mile  and  echinacea  (see  Chapter  47,  Green  Tea,  Chapter  65, 
Aloe  Vera,  Chapter  67,  Licorice  Extract,  and  Chapter  70, 
Chamomile).50,51

In 2013, Rodriguez et al. assessed the influence of a purified 
parthenolide-depleted  feverfew  extract  on  the  nuclear  factor 
erythroid 2-related factor-2 (Nrf2)/antioxidant response element 
(ARE) pathway and DNA repair in primary human keratinocytes 
or KB cells (subline of the keratin-forming tumor cell line HeLa). 
The  investigators  observed  that  the  feverfew  extract  induced 
Nrf2  nuclear  translocation  and  dose-dependently  augmented 
ARE  activity.  Activation  of  this  pathway  is  known  to  restore 
cutaneous oxidative homeostasis. The findings of this experiment 
led  the  authors  to  conclude  that  the  parthenolide-depleted 
feverfew extract promoted skin cell DNA repair through a phos-
phoinositide  (PI)3-kinase-dependent  Nrf2/ARE  pathway  and 
may contribute to protection against environmental insult.52

Antibacterial Activity
Polatoglu  et  al.  examined  the  water-distilled  essential  oils  of  
T.  parthenium  from  two  different  regions  in  Turkey  in  2010. 
Camphor was a key ingredient in samples collected from the 
Davutpasa-Istanbul  area  as  well  as  the  remote  eastern  part 
(Savs¸ at-Ardahan  region)  of  the  country.  Camphene  and  

 
trans-chrysanthenyl  acetate  were  also  found  in  the  Istanbul 
samples; camphene was identified in the eastern sample. The oil 
of the Istanbul sample evinced mild antibacterial activity against 
Bacillus  subtilis  and  methicillin-resistant  Staphylococcus  aureus. 
Similarly, the eastern sample demonstrated mild activity against 
S. aureus. Both oils demonstrated toxicity against Vibrio fischeri.8

In 2011, Mohsenzadeh et al. examined the components of the 
hydrodistilled  essential  oils  of  preflowering,  flowering,  and 
postflowering  T.  parthenium  from  western  Iran,  identifying 
camphor and bornyl acetate as prevalent among 29 components. 
They  also  found  that  the  essential  oils  displayed  appreciable 
activity  against  four  Gram-positive  and  four  Gram-negative 
bacteria without significant toxicity, with the antibacterial prop-
erties strongest during the flowering stage. They concluded that 
their findings suggest the viability of T. parthenium essential oil as 
a natural health product.3

Parthenolide, Skin Cancer, and Photoaging
Parthenolide  has  been  consistently  shown  to  exhibit  in  vitro 
antitumor activity.53 In 2004, Won et al. conducted in vitro and in 
vivo investigations of the cancer chemopreventive potential of 
parthenolide using a UVB-induced skin cancer model, revealing 
that  SKH-1  hairless  mice  given  parthenolide  exhibited  later 
onset of papilloma, significantly fewer papillomas/mouse, and 
smaller lesions in comparison to mice exposed only to UVB but 
not fed the primary component of feverfew. The in vitro phase 
of the study, using cultured JB6 murine epidermal cells, showed 
that noncytotoxic concentrations of parthenolide pretreatment 
significantly suppressed UVB-induced activator protein-1 DNA 
binding and transcriptional activity as well as c-Jun-N-terminal 
kinase (JNK) and p38 kinase signaling activation, all of which 
might  be  crucial  in  the  anticancer  mechanism  of  action  of 
parthenolide,  according  to  the  authors.11  Three  of  the  same 
investigators have also noted that parthenolide sensitizes UVB-
induced  apoptosis  through  pathways  that  depend  on  protein 
kinase C.54 Further, parthenolide has been found to reduce the 
number of viable adherent cells in melanoma cultures.55

The primary constituent of feverfew has become known as 
an  NF-κB  inhibitor.  In  a  2005  study,  parthenolide  effectively 
blocked  the  gene  expression  mediated  by  NF-κB  and  the 
synthesis  of  basic  fibroblast  growth  factor  (bFGF)  and  matrix 
metalloproteinase-1  as  well  as  the  UVB-induced  proliferation 
of  keratinocytes  and  melanocytes  in  mouse  skin,  leading  the 
authors to conclude that NF-κB inhibitors, especially partheno- 
lide,  may  have  a  role  in  preventing  photoaging.56  This 
conclusion has since been reinforced.57

In  2010,  Tanaka  et  al.  found  that  the  NF-κB  inhibitors  par- 
thenolide  and  magnolol  can  effectively  block  NF-κB-mediated 
gene  expression  as  well  as  UVB-induced  proliferation  of 
keratinocytes and melanocytes in murine skin, suggesting that 
both compounds may play a role in preventing photoaging.57

Also that year, Lesiak et al. studied the anticancer effects of 
parthenolide  in  melanoma  cells  in  vitro,  in  melanoma  cell  lines 
and  melanocytes,  as  well  as  melanoma  cells  obtained  from  a 
surgical  excision,  finding  that  the  herbal  compound  decreased 
the number of viable adherent cells in melanoma cultures. The 
researchers also noted that preincubation of parthenolide with 
the thiol nucleophile N-acetyl-cysteine shielded melanoma cells 
from  parthenolide-induced  cell  death,  implying,  as  they  inter-
preted, that the mechanism attributable to parthenolide activity 
is the reaction with intracellular thiols. They concluded that the 
apparent  anticancer  activity  of  parthenolide  warrants  further 
evaluation  for  melanoma  therapy.55  Parthenolide  has 

C HaPt e r  66  ■   Fe Ve rFe W  

241

demonstrated potential activity in vitro against several other cancer 
types,  including  acute  myelogenous  leukemia,  breast  cancer, 
cholangiocarcinoma, and pancreatic adenocarcinoma, as well as 
in vivo in an adjuvant breast cancer metastasis model.53,58–60

Mathema  et  al.  reported  in  2012  that  parthenolide  exhibits 
potent NF-κB and signal transduction and activation of transcription 
(STAT)-mediated transcriptional inhibition of proapoptotic genes. 
They also suggested that the unique capacity of parthenolide to 
spare normal cells while provoking sensitization to extrinsic and 
intrinsic apoptosis signaling in cancer cells renders the compound 
primed for use in treating cancer and disorders involving inflamma-
tion.22  Koprowska  and  Czyz  have  added  that  parthenolide  also 
protects normal cells from UVB and oxidative stress and appears to 
have  the  potential  to  target  some  cancer  stem  cells.  In  addition, 
they asserted that the low toxicity and diverse biological activity of 
parthenolide  position  the  sesquiterpene  lactone  as  a  promising 
agent with potentially vast pharmacologic applications.29

Other Potential Applications of Parthenolide
In  addition  to  its  potential  activity  against  skin  cancer  and 
photoaging,  the  feverfew  constituent  parthenolide  confers 
other benefits pertinent to dermatology. In 2005, investigators 
identified potent intracellular antioxidant activity displayed by 
parthenolide  in  hippocampal  HT22  cells,  properties  that  are 
mediated  by  an  increase  of  glutathione  but  not  found  to 
mediate the sesquiterpene lactone’s antiproliferative activities 
or  its  inhibition  of  NF-κB.12  Parthenolide  has  also  shown 
marked leishmanicidal activities suitable enough, according to 
researchers, to be considered for inclusion in the development 
of new drugs to treat this disease.14 While several in vitro studies 
have  indicated  that  parthenolide  delivers  anti-inflammatory 
effects,  a  recent  in  vivo  study  with  mice  demonstrated  that  the 
sesquiterpene  lactone  component  of  feverfew  modestly 
suppressed only one gene, interleukin-6 after lipopolysaccharide-
induced increases.61 The authors concluded that more study of 
the  effects  of  parthenolide  and  other  herbal  constituents  
on  inflammatory  gene  expression  using  animal  models  is 
needed to assess the efficacy of various supplements.61

Parthenolide was found, in 2006, to display significant activity 
in suppressing hepatitis C virus (HCV), which is often a precur-
sor  to  cirrhosis  and  hepatocellular  carcinoma.62  In  addition, 
parthenolide has also been found to enhance in hepatoma cells 
the apoptosis induced by fenretinide (N-4-hydroxyphenyl retin- 
amide,  4HPR),  a  synthetic  anticancer  retinoid  and  established 
apoptosis-inducing agent. In a study focusing on the relationship 
of  these  two  compounds,  parthenolide  was  found  to  up-  or 
downregulate 35 apoptosis-related genes and its role as an adju-
vant anticancer agent against hepatoma was elucidated.63

It is worth noting that while parthenolide has been cited as 
the  main  active  ingredient  in  feverfew,  a  double-blind  study 
revealed that it could not be the only active ingredient, and that 
melatonin is an antioxidant component of the plant, though its 
role in feverfew potency is not clearly understood.7,31

 CONCLUSION

Feverfew  is  best  known  as  an  effective  herbal  alternative  for 
treating  migraine  headaches.  New  evidence  is  emerging  that 
numerous  other  health  benefits  might  be  derived  from  this 
plant,  and  particularly  its  chief  component  parthenolide.  The 
findings  regarding  anticarcinogenic  and  anti-inflammatory 
capacity are promising and may soon have dermatologic impli-
cations. Cancer clinical trials using parthenolide are ongoing.

 
242 

Co s m eCe u t iCa l s  aN D   Co s m e t iC

 i Ng r eDi eNt s

Feverfew contains parthenolide and melatonin, both of which 
exhibit antioxidant activity. T. parthenium formulations must be 
developed to account for the allergenic potential of parthenolide 
while still harnessing its strong ameliorative properties. Notably, 
recent  success  has  been  observed  with  parthenolide-depleted 
feverfew. It remains unclear what role melatonin plays in such 
formulations. The ability to take a naturally occurring ingredient 
and improve it by removing an undesirable part of the chemical 
structure appears to be an integral part of the future of “natural” 
skin  care.  While  more  research  is  needed,  particularly 
randomized, controlled trials, cutaneous applications of feverfew 
are likely to proliferate. 

REFERENCES

1.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy.  London: 

Churchill Livingstone; 2000:385–393.

2.  Mojab F, Tabatabai SA, Naghdi-Badi H, et al. Essential oil of the 
root of Tanacetum parthenium (L.) Schulz. Bip. (Asteraceae) from 
Iran. Iran J Pharm Res. 2007;6:291.

3.  Mohsenzadeh F, Chehregani A, Amiri H. Chemical composition, 
antibacterial  activity  and  cytotoxicity  of  essential  oils  of 
Tanacetum parthenium in different developmental stages. Pharm 
Biol. 2011;49:920.

4.  Pareek A, Suthar M, Rathore GS, et al. Feverfew (Tanacetum par-
thenium L.): A systematic review. Pharmacogn Rev. 2011;5:103.
5.  Ghantous A, Sinjab A, Herceg Z, et al. Parthenolide: From plant 

shoots to cancer roots. Drug Discov Today. 2013;18:894.

6.  Foster S. An Illustrated Guide to 101 Medicinal Herbs: Their History, 
Use,  Recommended  Dosages,  and  Cautions.  Loveland,  CO: 
Interweave Press; 1998:86–87.

7.  Murch SJ, Simmons CB, Saxena PK. Melatonin in feverfew and 

other medicinal plants. Lancet. 1997;350:1598.

8.  Polatoglu K, Demirci F, Demirci B, et al. Antibacterial activity and 
the variation of Tanacetum parthenium (L.) Schultz Bip. Essential 
oils from Turkey. J Oleo Sci. 2010;59:177.

9.  Jain  NK,  Kulkarni  SK.  Antinociceptive  and  anti-inflammatory 
effects  of  Tanacetum  parthenium  L.  extract  in  mice  and  rats.  
J Ethnopharmacol. 1999;68:251.

10.  Setty  AR,  Sigal  LH.  Herbal  medications  commonly  used  in  the 
practice  of  rheumatology:  Mechanisms  of  action,  efficacy,  and 
side effects. Semin Arthritis Rheum. 2005;34:773.

11.  Won YK, Ong CN, Shi X, et al. Chemopreventive activity of par-
thenolide against UVB-induced skin cancer and its mechanisms. 
Carcinogenesis. 2004;25:1449.

12.  Herrera F, Martin V, Rodriguez-Blanco J, et al. Intracellular redox 
state  regulation  by  parthenolide.  Biochem  Biophys  Res  Commun. 
2005;332:321.

13.  Heinrich  M,  Robles  M,  West  JE,  et  al.  Ethnopharmacology  of 
Mexican  asteraceae  (Compositae).  Annu  Rev  Pharmacol  Toxicol. 
1998;38:539.

14.  Tiuman  TS,  Ueda-Nakamura  T,  Garcia  Cortez  DA,  et  al. 
Antileishmanial activity of parthenolide, a sesquiterpene lactone 
isolated from Tanacetum parthenium. Antimicrob Agents Chemother. 
2005;49:176.

15.  Johnson ES, Kadam NP, Hylands DM, et al. Efficacy of feverfew 
as  prophylactic  treatment  of  migraine.  Br  Med  J  (Clin  Res  Ed). 
1985;291:569.

16.  Sur  R,  Martin  K,  Liebel  F,  et  al.  Anti-inflammatory  activity  of 
parthenolide-depleted  Feverfew  (Tanacetum  parthenium). 
Inflammopharmacology. 2009;17:42.

17.  Amirghofran Z. Herbal medicines for immunosuppression. Iran J 

Allergy Asthma Immunol. 2012;11:111.

18.  Chang  LK,  Whitaker  DC.  The  impact  of  herbal  medicines  on 

dermatologic surgery. Dermatol Surg. 2001;27:759.

19.  Makheja AN, Bailey JM. A platelet phospholipase inhibitor from 
(Tanacetum  parthenium). 

the  medicinal  herb  feverfew 
Prostaglandins Leukot Med. 1982;8:653.

20.  Groenewegen WA, Heptinstall S. A comparison of the effects of an 
extract of feverfew and parthenolide, a component of feverfew, on 
human platelet activity in-vitro. J Pharm Pharmacol. 1990;42:553.
21.  Heptinstall S, Groenewegen WA, Spangenberg P, et al. Extracts of 
feverfew may inhibit platelet behaviour via neutralization of sul-
phydryl groups. J Pharm Pharmacol. 1987;39:459.

22.  Mathema VB, Koh YS, Thakuri BC, et al. Parthenolide, a sesquiter-
pene lactone, expresses multiple anti-cancer and anti-inflammatory 
activities. Inflammation. 2012;35:560.

23.  Kreuger MR, Grootjans S, Biavatti MW, et al. Sesquiterpene lac-
tones as drugs with multiple targets in cancer treatment: Focus on 
parthenolide. Anticancer Drugs. 2012;23:883.

24.  Majdi M, Liu Q, Karimzadeh G, et al. Biosynthesis and localiza-
tion  of  parthenolide  in  glandular  trichomes  of  feverfew 
(Tanacetum  parthenium  L.  Schulz  Bip.).  Phytochemistry. 
2011;72:1739.

25.  Taylor  FR.  Nutraceuticals  and  headache:  The  biological  basis. 

Headache. 2011;51:484.

26.  Williams CA, Hoult JR, Harborne JB, et al. A biologically active 
lipophilic  flavonol  from  Tanacetum  parthenium.  Phytochemistry. 
1995;38:267.

27.  Fonseca JM, Rushing JW, Rajapakse NC, et al. Phenolics and par-
thenolide levels in feverfew (Tanacetum parthenium) are inversely 
affected by environmental factors. J Appl Hort. 2008;10:36.

28.  Parada-Turska J, Mitura A, Brzana W, et al. Parthenolide inhibits 
proliferation of fibroblast-like synoviocytes in vitro. Inflammation. 
2008;31:281.

29.  Koprowska K, Czyz M. Molecular mechanisms of parthenolide’s 
action: Old drug with a new face. Postepy Hig Med Dosw (Online). 
2010;64:100.

30.  Cady  RK,  Goldstein  J,  Nett  R,  et  al.  A  double-blind  placebo-
controlled  pilot  study  of  sublingual  feverfew  and  ginger 
(LipiGesic™  M)  in  the  treatment  of  migraine.  Headache. 
2011;51:1078.

31.  De Weerdt CJ, Bootsma HPR, Hendricks H. Herbal medicines in 

migraine prevention. Phytomedicine. 1996;3:225.

32.  Ferro  EC,  Biagini  AP,  da  Silva  ÍE,  et  al.  The  combined  effect  of 
acupuncture  and  Tanacetum  parthenium  on  quality  of  life  in 
women  with  headache:  Randomised  study.  Acupunct  Med. 
2012;30:252.

33.  Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for 
prevention  of  episodic  migraine:  A  summary  and  comparison 
with  other  recent  clinical  practice  guidelines.  Headache. 
2012;52:930.

34.  Goodyear-Smith  F.  Feverfew.  Bachelor’s  buttons,  Featherfew 
(Tanacetum  parthenium  L,  aka  Chrysanthemum  parthenium 
L.  aka  Pyrethrum  parthenium  L.).  J  Prim  Health  Care. 
2010;2:337.

35.  Bowe WP. Cosmetic benefits of natural ingredients: Mushrooms, 
feverfew, tea, and wheat complex. J Drugs Dermatol. 2013;12:s133.
36.  Fowler JF Jr, Woolery-Lloyd H, Waldorf H, et al. Innovations in 
natural  ingredients  and  their  use  in  skin  care.  J  Drugs  Dermatol. 
2010;9:S72.

37.  Wu  J.  Treatment  of  rosacea  with  herbal  ingredients.  J  Drugs 

Dermatol. 2006;5:29.

38.  Baumann L, Woolery-Lloyd H, Friedman A. “Natural” ingredients 

in cosmetic dermatology. J Drugs Dermatol. 2009;8:s5.

39.  Jovanovic´  M,  Poljacki  M.  Compositae  dermatitis.  Med  Pregl. 

2003;56:43.

40.  Paulsen E, Christensen LP, Fretté XC, et al. Patch test reactivity to 
feverfew-containing creams in feverfew-allergic patients. Contact 
Dermatitis. 2010;63:146.

41.  Killoran CE, Crawford GH, Pedvis-Leftick A. Two cases of com-
positae  dermatitis  exacerbated  by  moisturizer  containing  fever-
few. Dermatitis. 2007;18:225.

42.  Pribitkin ED, Boger G. Herbal therapy: What every facial plastic 

surgeon must know. Arch Facial Plast Surg. 2001;3:127.

43.  Cavaliere C. The effects of climate change on medicinal and aro-
matic plants. HerbalGram. 2008;81:44–57. http://cms.herbalgram 
.org/herbalgram/issue81/article3379.html?Issue=81&ts=1392558
958&signature=9f349be3405f938bf4d897301c9e6934.  Accessed 
February 16, 2014.

44.  Fonseca JM, Rushing JW, Rajapakse NC, et al. Potential implications 
of medicinal plant production in controlled environments: The case 
of feverfew (Tanacetum parthenium). HortScience. 2006;41:531.
45.  Jin P, Madieh S, Augsburger LL. The solution and solid state sta-
bility  and  excipient  compatibility  of  parthenolide  in  feverfew. 
AAPS PharmSciTech. 2007;8:E105.

46.  Rushing  JW,  Hassell  RL,  Dufault  RJ.  Drying  temperature  and 
developmental  stage  at  harvest  influence  the  parthenolide  con-
tent of feverfew leaves and stems. Acta Hort. 2004;629:167.

47.  Kaplan M, Simmonds MR, Davidson G. Comparison of supercritical 
fluid  and  solvent  extraction  of  feverfew  (Tanacetum  parthenium). 
Turk J Chem. 2002;26:473.

 
C HaPt e r  66  ■   Fe Ve rFe W  

243

48.  Martin  K,  Sur  R,  Liebel  F,  et  al.  Parthenolide-depleted  Feverfew 
(Tanacetum  parthenium)  protects  skin  from  UV  irradiation  and 
external aggression. Arch Dermatol Res. 2008;300:69.

49.  Jin  P,  Madieh  S,  Augsburger  LL.  Selected  physical  and  chemical 
properties  of  feverfew  (Tanacetum  parthenium)  extracts  impor-
tant  for  formulated  product  quality  and  performance.  AAPS 
PharmSciTech. 2008;9:22.

50.  Reszko AE, Berson D, Lupo MP. Cosmeceuticals: Practical appli-

cations. Dermatol Clin. 2009;27:401.

51.  Wu J. Anti-inflammatory ingredients. J Drugs Dermatol. 2008;7:s13.
52.  Rodriguez  KJ,  Wong  HK,  Oddos  T,  et  al.  A  purified  feverfew 
extract protects from oxidative damage by inducing DNA repair 
in  skin  cells  via  a  PI3-kinase-dependent  Nrf2/ARE  pathway.  
J Dermatol Sci. 2013;72:304.

53.  Sweeney  CJ,  Mehrotra  S,  Sadaria  MR,  et  al.  The  sesquiterpene 
lactone  parthenolide  in  combination  with  docetaxel  reduces 
metastasis and improves survival in a xenograft model of breast 
cancer. Mol Cancer Ther. 2005;4:1004.

54.  Won YK, Ong CN, Shen HM. Parthenolide sensitizes ultraviolet 
(UV)-B-induced apoptosis via protein kinase C-dependent path-
ways. Carcinogenesis. 2005;26:2149.

55.  Lesiak K, Koprowska K, Zalesna I, et al. Parthenolide, a sesquiterpene 
lactone from the medical herb feverfew, shows anticancer activity 
against human melanoma cells in vitro. Melanoma Res. 2010;20:21.

56.  Tanaka K, Hasegawa J, Asamitsu K, et al. Prevention of the ultra-
violet  B-mediated  skin  photoaging  by  a  nuclear  factor  kappaB 
inhibitor, parthenolide. J Pharmacol Exp Ther. 2005;315:624.
57.  Tanaka K, Asamitsu K, Uranishi H, et al. Protecting skin photoag-
ing by NF-kappaB inhibitor. Curr Drug Metab. 2010;11:431.

58.  Guzman  ML,  Jordan  CT.  Feverfew:  Weeding  out  the  root  of  

leukaemia. Expert Opin Biol Ther. 2005;5:1147.

59.  Kim  JH,  Liu  L,  Lee  SO,  et  al.  Susceptibility  of  cholangiocarci-
noma  cells  to  parthenolide-induced  apoptosis.  Cancer  Res. 
2005;65:6312.

60.  Yip-Schneider  MT,  Nakshatri  H,  Sweeney  CJ,  et  al.  Parthenolide 
and sulindac cooperate to mediate growth suppression and inhibit 
the  nuclear  factor-kappa  B  pathway  in  pancreatic  carcinoma 
cells. Mol Cancer Ther. 2005;4:587.

61.  Smolinski  AT,  Pestka  JJ.  Comparative  effects  of  the  herbal  con-
stituent  parthenolide  (Feverfew)  on  lipopolysaccharide-induced 
inflammatory  gene  expression  in  murine  spleen  and  liver.  
J Inflamm (Lond). 2005;2:6.

62.  Hwang  DR,  Wu  YS,  Chang  CW,  et  al.  Synthesis  and  anti-viral 
activity  of  a  series  of  sesquiterpene  lactones  and  analogs  in  the 
subgenomic HCV replicon system. Bioorg Med Chem. 2006;14:83.
63.  Park JH, Liu L, Kim IH, et al. Identification of the genes involved 
in  enhanced  fenretinide-induced  apoptosis  by  parthenolide  in 
human hepatoma cells. Cancer Res. 2005;65:2804.

 
244 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   6 7

Licorice Extract

Activities:

Anti-inflammatory, antioxidant, antimicrobial, antitumor, 
antispasmodic, antiviral, immunomodulatory1–3

Important Chemical Components:

Glycyrrhiza glabra: glycyrrhizin, also known as glycyrrhi-
zic  acid  or  glycyrrhizinic  acid  (a  triterpenoid  saponin 
glycoside),  18β-glycyrrhetinic  acid,  polysaccharides,  and 
various polyphenols (such as the isoflavone formononetin 
and  the  prenylated  isoflavonoid  glabridin  as  well  as 
liquiritin, isoliquiritin, isoliquiritigenin, and liquiritigenin)4,5
Glycyrrhiza  inflata:  phenols,  namely  licochalcone  A,  lico- 
chalcone B, licochalcone C, licochalcone D, licochalcone E, 
echinatin, and isoliquiritigenin5,6
Glycyrrhiza uralensis: phenylflavonoids, such as dehydro-
glyasperin  C,  dehydroglyasperin  D,  isoangustone  A;  
glycyrrhetinic acid; and the benzofuran courmarin glycyrol7

Origin Classification:

This ingredient is natural. Many organic choices exist.

Personal Care Category:

Anti-inflammatory, antiaging, skin lightening

Recommended  for  the  following  Baumann  Skin 
Types:

DSNT, DSPT, DSNT, DSNW, OSNT, OSNW, OSPT, and 
OSPW. This ingredient is an optimal choice for sensitive 
pigmented types.

 SOURCE

Licorice (also spelled as “liquorice”) is best known in its popular 
confectionery  form  of  black  or  red  candy.  Although  it  is  not 
often  thought  of  as  a  plant,  it  is  derived  from  the  roots  and 
rhizomes of multiple Glycyrrhiza species and has been used in 
systemic  and  topical  herbal  medications  for  approximately 
4,000 years (Table 67-1). In fact, licorice is one of the oldest and 
most  popular  herbs  used  in  traditional  Chinese  medicine 
(TCM), second only to ginseng.8-10 Members of the Fabaceae or 
Leguminosae family (better known as the legume, pea, or bean 
family),  Glycyrrhiza  glabra  (also  known  as  Liquiritiae  officinalis) 

TABLE 67-1
Pros and Cons of Licorice Extract

Pros
Long history of traditional medical  

applications

Multiple bioactive ingredients in several 

species

Favorable safety record

Cons
Several contraindications for oral use,  

particularly chronic oral use
More data needed regarding use in 

patients with rosacea

and  G.  inflata  are  the  species  that  have  displayed  the  most 
therapeutic actions among the 18 known Glycyrrhiza species, 
with  G.  glabra  the  most  used  since  antiquity.  G.  inflata  is 
actually the Chinese licorice root, while G. glabra grows around 
the  Mediterranean  Sea,  the  Middle  East,  and  central  and 
southern  Russia.11  The  Roman  physician  of  Greek  extraction 
Pedanius Dioscorides, who practiced in the 1st century CE, is 
credited with bestowing the botanical name of the plant based 
on the Greek glukos (sweet) and riza (root).7,12,13 The Latin name 
“Liquiritiae” is a corruption of the Greek “Glycyrrhiza.”12

G. glabra is a perennial herb that originated on the land sur-
rounding the Mediterranean Sea as well as central and southern 
Russia and the Middle East.11 Licorice is now cultivated through-
out much of Asia, Europe, and the Middle East, though, and is 
also used globally as a pharmacologic agent,14 particularly as an 
effective  anti-inflammatory  product.15  In  addition  to  anti- 
inflammatory  potency,  licorice  root  is  believed  to  possess 
antiviral,  antiulcer,  and  anticarcinogenic  properties.10  In  China, 
licorice  root  has  served  as  a  folk  elixir  and  antidote,  and  long 
been used as a demulcent (an agent that provides a soothing film 
over  a  mucous  membrane).11  One  of  its  active  components, 
glycyrrhetinic  acid,  has  traditionally  been  used  in  Asian  and 
European herbal medicine to treat skin and pulmonary diseases, 
hepatitis, and peptic ulcers.2,16,17 A panel from the University of 
Würzburg, the World Wildlife Fund, and TRAFFIC chose licorice 
(G. glabra) as “medicinal plant of the year” for 2012 in recognition 
of its important roles in human health.18

 HISTORY

Licorice has been used for medicinal and dietary purposes for 
thousands of years, with such use dating back to ancient Egypt, 
Greece,  and  Rome  in  the  West  and  to  the  times  of  the  Han 
Dynasty (300–200 BCE) in ancient China.3 Asthma, dry cough, 
and  lung  disorders  were  described  by  the  Roman  naturalist 
Theophrastus  (circa  372–287  BCE)  as  indications  for  licorice 
root.12,19 Gastric ulcer and various forms of inflammation have 
also been targets of licorice root in traditional medicine.6

The radices of G. uralensis and herbal preparations containing 
Glycyrrhiza  spp.  have  been  used  for  thousands  of  years  as  an 
herbal medicine for the treatment of viral-induced cough, viral 
hepatitis, and viral skin diseases like ulcers in China.20 At least 
six  Glycyrrhiza  species,  mainly  G.  uralensis  and  G.  inflata,  are 
used in Chinese licorice gan-cao, or “sweet herb” (and known as 
kanzo in Japan).19,21 G. inflata has a wide range of pharmaceutical 
and dietary applications and is related to G. glabra.22

In contemporary times, licorice remains one of the most fre-
quently  used  herbs  in  TCM.3,7  Licorice  was  introduced  into 
Japan from China in the 8th century,3 and is also an important 
herb in Kampo (the Japanese adaptation of TCM) and Ayurvedic 
medicine.23,24 During the past 75 years, a glycyrrhizin formulation 
called Stronger Neo-Minophagen C (SNMC) has been used in 
the  clinical  setting  in  Japan  as  an  antiallergic  and  antihepatitis 
treatment.3 In 1946, the Dutch physician Revers recommended 

 
licorice extracts to treat gastric ulcer, but side effects led to its 
swift  removal  from  the  market.3  In  the  United  Kingdom,  
a  licorice  preparation  was  used  to  treat  peptic  ulcers.3  
The  modern  scientific  investigation  into  the  pharmacologic 
properties  of  licorice  species  began  in  earnest  in  the  1950s 
and quickly revealed a broad range of biologic activity.24 The 
long history of traditional uses of licorice root and its extensive 
study  over  the  last  several  decades  make  licorice  one  of  the 
most widely researched plants for medicinal purposes.

 CHEMISTRY

More than 400 compounds have been isolated from Glycyrrhiza 
species.25  Of  the  six  major  Glycyrrhiza  species,  G.  glabra,  
G.  uralensis,  and  G.  inflata  produce  glycyrrhizin  as  a  major 
saponin; G. echinata, G. macedonica, and G. pallidiflora produce 
macedonoside C as a major saponin. G. uralensis and G. inflata 
are closely related,26 but G. inflata is more often used medically 
and  in  the  diet.  G.  glabra,  G.  inflata,  and  G.  uralensis  are  the 
three species of licorice most often used medically, and are the 
focus of this discussion.

Glycyrrhiza Glabra
Extracts  from  this  more  Western  species  of  licorice,  sometimes 
referred  to  as  European  licorice,  are  increasingly  found  in  anti-
inflammatory products.5,14 Glycyrrhizin, the primary water-soluble 
constituent  of  licorice,  has  been  shown  to  confer  numerous 
pharmacological benefits, though various derivatives also possess 
such  properties.11  A  sweet-tasting  triterpene  saponin  exhibiting 
poor blood solubility as compared with other saponins, glycyrrhizin 
is typically present in the root in 5 to 10 percent concentrations,14,27 
and  is  the  source  of  the  plant’s  sweetness.28  In  addition  to  the 
triterpenoid glycyrrhizin, and its aglycone form glycyrrhizic acid, 
licorice  root  contains  polysaccharides  and  various  polyphenols, 
such  as  the  isoflavone  formononetin,  to  which  antioxidant 
characteristics have been ascribed.10

Glabridin, which is the main component in the hydrophobic 
fraction of licorice extract, was also found to exhibit inhibitory 
effects  on  melanogenesis  and  inflammation  when  evaluated 
using cultured murine melanoma cells and guinea pig skin.29 A 
prenylated  isoflavonoid  of  G.  glabra  roots,  glabridin  was  first 
described in 1976 and has since been characterized as exhibiting 
broad biologic activity, including antioxidant, anti-inflammatory, 
antiatherogenic, energy metabolism regulating, estrogenic, neu-
roprotective,  antiosteoporotic,  and  skin  whitening.  Its  anti-
inflammatory, antiatherogenic, estrogenic, and energy-regulating 
capacities are currently thought to be most prominent.5

Glycyrrhiza Inflata
The  primary  active  ingredient  isolated  and  extracted  from 
Chinese  licorice  roots  is  licochalcone  A,  also  known  as  3-a, 
a-dimethylallyl-4,4’-dihydroxy-6-methoxychalcone, an oxygenated 
or  reversely-constructed  chalcone  or  “retrochalcone.”22,30,31 
Licochalcone  A  has  been  shown  to  exhibit  antiparasitic  and 
antibacterial properties as well as antitumorigenic activity.31–33 
This extract has also demonstrated anti-inflammatory activity 
against  arachidonic  acid-  and  12-O-tetradecanoylphorbol 
13-acetate (TPA)-induced mouse ear edema and been reported 
to  manifest  in  vivo  antitumor  properties  in  mouse  skin  
papilloma initiated by 7,12-dimethylbenz(a)anthracene (DMBA) 
and  promoted  by  TPA.31  Chalcones  exhibit  activity  against 
oxidative  stress.  A  study  assessing  their  radical-scavenging 

C H A P T E R  67  ■   L I CO R I C E   E X T R AC T  

245

activity  revealed  that  licochalcones  B  and  D  potently  delay 
superoxide anion production.34

Noting that the herbal formulation PC-SPES, which contains 
licorice root, has been shown to possess potent estrogenic activity 
in  vitro,  in  animals,  and  in  patients  with  prostate  cancer, 
researchers  investigated  whether  the  flavonoid  licochalcone  A 
shared  these  characteristics.  Through  a  range  of  assays,  they 
determined that licochalcone A is a phytoestrogen, demonstrates 
antitumor  activity,  enhancing  the  effects  of  paclitaxel  and  vin-
blastine, and can affect the apoptotic protein bcl-2 in human cell 
lines derived from several cancers.33

In 2010, Cho et al. studied the capacity of the recently isolated 
licochalcone  E  to  influence  the  synthesis  of  interleukin  (IL)-
12p40, a subunit of IL-12 and IL-23, and found that the G. inflata 
extract inhibited IL-12p40 expression and attenuated symptoms 
induced  by  oxazolone  in  a  chronic  allergic  contact  dermatitis 
model. They concluded that licochalcone E displays potential for 
use in treating cutaneous inflammation.35

Glycyrrhiza Uralensis
Li  et  al.  used  a  calcineurin  inhibitory  test  in  2010  to  identify 
glycyrol, a benzofuran coumarin isolate, as an effective immu-
nosuppressant  in  G.  uralensis.  Various  assays  revealed  that 
glycyrol  exerted  immunosuppressive  activity  by  blocking 
calcineurin  activity,  thus  inhibiting  the  synthesis  of  IL-2  and 
regulating  T  lymphocytes.  The  investigators  concluded  that 
glycyrol  shows  promise  as  an  immunomodulatory  agent.36 
Previously,  glycyrol  had  been  shown  to  exert  in  vitro  anti-
inflammatory effects.37

 ORAL USES

Licorice is used broadly as a natural sweetening agent in food 
as well as tobacco products.7,25 Notably, glycyrrhizin is 50-fold 
sweeter  than  sugar.19  Indeed,  in  the  United  States,  it  is  used 
more often as a flavoring and sweetening agent in food prod-
ucts than for salutary purposes,10 though licorice candy is typi-
cally flavored with anise oil, not licorice. Glycyrrhizin can be 
found  in  the  confection,  though,  in  concentrations  ranging 
from 1 to 25 percent, with a minimum of 4 percent found in 
good quality licorice.19 Licorice is also widely available in sup-
plement form.24

Various  herbal  product  companies  provide  licorice  oral  sup-
plements  as  well  as  some  topical  preparations  that  contain 
licorice  extract  amid  a  cocktail  of  other  botanical  ingredients. 
Licorice extract is widely used as an anti-inflammatory in Europe 
and has been reported to be effective as an antiviral medication 
for chronic hepatitis.27 The use of oral licorice is approved by the 
German Commission E for bronchitis and chronic gastritis.

G. glabra has also been shown to effectively protect against or 
treat oral mucositis engendered by radiation and chemotherapy 
for head and neck malignancies.38

 TOPICAL USES

Modern research has shown that licorice extracts are comparably 
effective  to  corticosteroids  in  treating  dermatitis,  eczema,  and  
psoriasis.39 Licorice extracts are also among the compounds known 
to be effective in topical creams intended to repair the skin barrier.40
G.  glabra  has  been  used  for  a  wide  range  of  medical  indica-
tions.  Among  the  cutaneous  indications,  the  extract  has  been 
used to treat dermatitis, eczema, pruritus, cysts,41 and skin irrita-

 
246 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

tion.42 In the modern pharmacopoeia, licorice is incorporated into 
cosmetics for acne patients as well as the treatment of sunburn.42

Anti-inflammatory Uses
The topical anti-inflammatory properties and antiulcer capacity 
of licorice root have been attributed mainly to glycyrrhetic acid, 
the  biologically  active  metabolite  of  glycyrrhizic  acid,27,43,44 
which has been used successfully to treat inflammation with-
out  secondary  infection.45  It  has  been  reported  to  have  anti-
inflammatory activity in subacute and chronic dermatoses, and 
therefore has been used to treat eczema, pruritus, contact der-
matitis,  seborrheic  dermatitis,  and  psoriasis.41  In  a  series  of 
animal studies in 1988, glyderinine, a derivative of glycyrrhizic 
acid  isolated  from  G.  glabra,  was  shown  by  Azimov  et  al.  to 
exhibit anti-inflammatory effects as well as analgesic and anti-
pyretic properties. The researchers concluded that glyderinine 
is an appropriate ointment for treating skin diseases.46

Studies  have  shown  that  glycyrrhetic  acid  is  able  to  exert  a 
cortisone-like  effect,  thus  inhibiting  proinflammatory  prosta-
glandins and leukotrienes.47 Licorice (glycyrrhetic acid) has not 
been  demonstrated  to  be  superior  to  topical  corticosteroids  in 
treating  acute  inflammation,  such  as  atopic  dermatitis.41  The 
combination of corticosteroids with glycyrrhetic acid has been 
proven to be effective, however. One study displayed effective 
potentiation of hydrocortisone activity in skin by the addition of 
2 percent glycyrrhetic acid.48

A 2002 study assessing the effects of five different chalcones, 
including  licochalcone  A,  revealed  that  four  of  the  five  tested 
chalcones, including licochalcone A, inhibited the production of 
proinflammatory  cytokines  from  monocytes  and  T  cells.  The 
investigators  concluded  that  licochalcone  A  and  some  of  its 
synthetic  analogs  may  have  immunomodulatory  effects, 
potentially rendering them suitable agents for the treatment of 
infectious and other inflammatory diseases.32

Furuhashi et al., in 2005, studied the in vitro anti-inflammatory 
effects of licochalcone A on the formation of chemical mediators 
[e.g., prostaglandin E2 (PGE2) and cytokines) by IL-1β in human 
skin  fibroblasts  and  compared  it  to  the  effects  of  other  com-
pounds. The steroid dexamethasone was found to inhibit PGE2, 
prostaglandin  F(2α)  [PGF(2α)],  IL-6,  and  IL-8  production,  and 
potently  blocked  cyclooxygenase  (COX)-2  mRNA  and  protein 
expression,  whereas  licochalcone  A,  in  response  to  IL-1β,  hin-
dered PGF(2α) generation and PGE2 synthesis, but had no effect 
on increased levels of COX-2 mRNA and protein in cells or IL-6, 
and IL-8 production. The investigators concluded that the licorice 
isolate  engenders  anti-inflammatory  activity  by  suppressing 
COX-2-dependent PGE2 synthesis with a response to IL-1β that 
is markedly divergent from that of dexamethasone.49

In 2008, Kwon et al. reported on the dynamic anti-inflammatory 
properties  of  licochalcone  A  as  demonstrated  in  vitro  and  in  
animal models. The G. inflata extract inhibited the generation of 
nitric  oxide  (NO),  PGE2,  inflammatory  cytokines  such  as  IL-1 
and  IL-6,  as  well  as  the  expression  of  inducible  NO  synthase 
(iNOS)  and  COX-2  induced  by  lipopolysaccharide  (LPS)  in 
RAW264.7 cells in vitro. In addition, the investigators speculated 
that licochalcone A may have suppressed inflammatory cytokine 
and NO synthesis in the process of protecting BALB/c mice from 
LPS-induced  endotoxin  shock  in  an  animal  model.  They  con-
cluded that licochalcone A might be considered for use in treating 
various inflammatory conditions.50

Studies  by  Furusawa  et  al.  in  2009  revealed  that  the  anti- 
inflammatory  activity  of  G.  inflata  could  be  attributed  to  potent 
suppression of nuclear factor (NF)-κB exerted by licochalcones A, B, 
and D.6

Funakoshi-Tago et al. have shown in mice that licochalcone A 
potently  suppresses  tumor  necrosis  factor-α-induced  NF-κB 
activation and that the fixed structure of licochalcone A is pivotal 
in imparting its anti-inflammatory properties. They also noted, 
in 2010, that licochalcone A demonstrates great promise in vivo 
as an anti-inflammatory agent.51

In  2013,  Lee  et  al.  demonstrated  that  topically  applied  lico- 
chalcone  E  displayed  strong  anti-inflammatory  properties  in  a 
TPA-induced mouse ear edema model and similar effects when 
the  G.  inflata  extract  was  administered  in  vitro  in  an  LPS-
stimulated RAW 264.7 murine macrophage model. They found 
that  licochalcone  E  inhibited  AKT  and  p38  mitogen  activated 
protein  kinase  (MAPK),  thus  suppressing  NF-κB  and  activator 
protein  (AP)-1  transcriptional  activity,  which  in  turn  facilitates 
the decline of proinflammatory cytokines.52

Also that year, Fu et al. isolated six flavonoids from G. inflata and 
G.  uralensis,  with  all  six  compounds  [5-(1,1-dimethylallyl)-3, 
4,4’-trihydroxy-2-methoxychalcone,  licochalcones  A  and  B, 
echinatin,  glycycoumarin,  and  glyurallin  B]  found  to  possess 
varying  degrees  of  antioxidant  and  anti-inflammatory 
characteristics.25

Acne
In a 2003 study of antiacne activity displayed by Asian herbal 
extracts,  Name  et  al.  found  that  G.  glabra  showed  significant 
antibacterial  activity  against  Propionibacterium  acnes  without 
inducing  noteworthy  resistance.  The  investigators  suggested 
that  a  formulation  combining  three  herbal  extracts,  including 
G. glabra, Angelica dahurica, and Coptis chinensis, may be suitable 
for preventing and treating acne.53

Ten  years  later,  Angelova-Fischer  et  al.  conducted  a  nine-
week,  randomized,  double-blind,  vehicle-controlled  study 
with  60  volunteers  with  mild-to-moderately  severe  acne  to 
evaluate and provide proof-of-concept for a formulation con-
taining  licochalcone  A,  l-carnitine  and  1,2-decanediol.  After 
one week for standardization of the cleansing procedure, the 
participants  (40  females  and  20  males  between  the  ages  of  
14 and 40 years old) were randomized to apply either the test 
formulation or vehicle to the face twice daily for eight weeks. 
At the end of the study, the mean total lesion count and papular 
lesions  were  decreased  in  the  active  formulation  group  com-
pared  to  baseline.  Significant  reductions  in  pustules,  sebum 
levels,  and  P.  acnes  were  recorded  in  the  active  formulation 
subjects along with improvements in Dermatology Life Quality 
Index  (DLQI),  whereas  no  significant  improvements  were 
observed in the vehicle group. Evidence of acne improvement 
associated with the licochalcone A-containing formulation was 
noted in both physician and patient assessments.54

Atopic Dermatitis
G. glabra is one among various plant constituents demonstrated 
to be effective in treating atopic dermatitis.55,56 In a 2003 double-
blind study over two weeks, investigators evaluated the effect 
of 1 and 2 percent topical licorice extract preparations on atopic 
dermatitis in two 30-patient groups. Results indicated that the 
2  percent  licorice  topical  gel  was  more  effective  in  reducing 
erythema, edema, and pruritus. Significantly, the authors also 
concluded that licorice extract was effective in treating atopic 
dermatitis.41

In 2011, Udompataikul and Srisatwaja conducted a six-week, 
randomized,  controlled,  investigator-blinded  comparative  pilot 
study of the effects of moisturizers containing licochalcone A or 
hydrocortisone  on  children  with  atopic  dermatitis  (mean  

 
age, 5.8 years). Twenty-six patients completed the protocol, which 
included twice-daily application of licochalcone A on one side of 
the body and hydrocortisone on the other side. The response rate 
to both treatments was found to be 73.33 percent, with no signifi-
cant  differences  in  scoring  atopic  dermatitis  (SCORAD)  score 
reductions  from  treatment.  Edema  and  erythema  resolved  more 
rapidly with hydrocortisone, but the relapse rate associated with 
hydrocortisone was higher; in both cases, the differences were not 
significant. The investigators concluded that licochalcone A lotion, 
which was found to be equally effective as hydrocortisone lotion, 
is an option to treat mild-to-moderate childhood atopic dermatitis 
in the maintenance as well as acute phases.57

In  2013,  Wananukul  et  al.  led  a  four-week,  prospective, 
multicenter,  randomized,  double-blind,  split-side  study  in  
55  children  (three  months  to  14  years  of  age)  with  mild-to-
moderate atopic dermatitis to compare the efficacy of a licoch-
alcone A-containing moisturizer and 1 percent hydrocortisone. 
Simultaneous  treatment  with  either  the  licochalcone  A 
preparation  or  1  percent  hydrocortisone  on  opposite  sides  of 
the  lesion  were  administered  twice  daily.  The  SCORAD 
declined significantly for both treatments from baseline, with 
no statistically significant differences between the treatments. 
Transepidermal  water  loss  was  found  to  be  significantly 
decreased from baseline on the side that received licochalcone 
A  treatment.  The  investigators  also  reported  that  continuing 
treatment  with  licochalcone  A  for  four  weeks  maintained 
clinical and skin barrier benefits.58

Hyperpigmentation
Licorice extracts are included among the array of topical tyrosi-
nase  inhibitors  used  to  lighten  hyperpigmented  areas  of  the 
skin.59–61  Glabridin,  found  in  concentrations  between  10  and  
40 percent in commercial depigmenting agents, is thought to be 
the chief ingredient in licorice to provide skin-lightening activity.61 
Draelos has noted that the status of licorice extracts as the safest 
of  options  among  skin-lightening  agents  while  eliciting  the 
fewest side effects accounts for its popularity for this purpose.62,63
In a study of 20 women between the ages of 18 and 40 with a 
clinical diagnosis of bilateral and symmetrical idiopathic epider-
mal  melasma,  liquiritin  cream  was  applied  on  one  side  of  the 
face and a vehicle cream on the other twice daily for four weeks. 
Liquiritin is a flavonoid component of licorice that, along with 
other  ingredients,  contributes  to  the  natural  yellow  pigment. 
Individuals with dermal melasma, melasma with pregnancy, and 
those  receiving  hormone  replacement  therapy  were  excluded 
from  the  study.  Topical  sunscreen  use  was  encouraged  during 
the  treatment  period  while  sun  exposure  was  discouraged. 
Sixteen  patients  (80  percent)  were  characterized  as  exhibiting 
excellent  responses  from  liquiritin,  with  no  discernible  differ-
ences between the normal skin and previously pigmented areas. 
Two  patients  (10  percent)  showed  a  good  response  on  the  li- 
quiritin  side,  and  two  patients  (10  percent)  had  fair  responses 
from  liquiritin,  with  moderate  pigmentation,  while  moderate 
improvement was seen in only 20 percent on the vehicle side.64

Nerya  et  al.  found  in  2003  that  in  addition  to  glabridin, 
glabrene,  and  isoliquiritigenin  (2’,4’,4-trihydroxychalcone), 
constituents of licorice root extract contributed significantly and 
dose-dependently  in  the  observed  potent  tyrosinase-inhibiting 
activity displayed by the plant.65

In a 2010 single-blind, 60-day study with 56 women between 
18 to 60 years old, Costa et al. found that a formulation combining 
belides, emblica, and licorice was as effective as hydroquinone  
2 percent in ameliorating the effects of melasma (see Chapter 38, 

C H A P T E R  67  ■   L I CO R I C E   E X T R AC T  

247

Emblica  Extract).  There  were  no  statistically  significant 
differences between the groups and the herbal combination was 
associated with fewer adverse effects.66

In 2008, Adhikari et al. screened 52 crude drugs traditionally 
used in Nepal to treat hyperpigmentation for inhibitory activity 
against  mushroom  tyrosinase,  finding  that  methanolic  extracts 
of G. glabra manifested the greatest inhibitory activity, with kojic 
acid  used  as  a  positive  control.67  Licorice  extract  is  frequently 
combined with other skin-lightening ingredients (see Chapter 32, 
Overview  of  the  Pigmentation  Process).  Vitamin  C  is  often 
combined with licorice extracts or soy when deployed for skin-
lightening purposes [see Chapter 40, Vitamin C (Ascorbic Acid), 
and Chapter 45, Soy].68

Psoriasis
Cassano  et  al.  conducted  a  pilot,  randomized,  open-label,  
parallel-group trial in 40 patients in 2010 to assess the effects of 
an  emollient  cream  containing  milk  proteins  and  G.  glabra 
extracts  in  the  treatment  of  palmar  and/or  plantar  psoriasis 
treated  with  topical  corticotherapy.  Twenty  patients  were 
treated only with mometasone furoate ointment for four weeks 
and 20 patients received the same corticosteroid in combination 
with  the  licorice-containing  emollient,  which  was  applied 
twice  daily  during  the  four-week  study  period.  Statistically 
significant  decreases  in  the  severity  of  all  clinical  signs  of 
psoriasis were seen in all patients, all of whom completed the 
study. In the group treated with the test emollient, significantly 
greater reductions in desquamation, affected surface area, and 
subjective  symptoms  were  reported  as  compared  with  the 
corticosteroid-only  treatment  group.  The  investigators 
concluded that their findings support the adjuvant use of this 
new emollient combining G. glabra extracts and milk proteins 
for psoriasis management.69

The topical application of Tuhuai, a Chinese herbal medicine 
that includes licorice, has also been found by Man et al. to exhibit 
antiproliferative and anti-inflammatory activity in murine models 
of inflammatory dermatoses. The investigators suggest the herbal 
formulation may offer an effective, relatively safe, and inexpen-
sive option to treat inflammatory disorders such as psoriasis.70

Sensitive Skin/Rosacea
In 2006, Weber et al. assessed the cutaneous compatibility and 
efficacy  of  a  skin  care  regimen  containing  licochalcone  A  in  
62 patients with mild-to-moderate rosacea over eight weeks. The 
regimen was well tolerated and effective in reducing erythema, as 
indicated  by  clinical  evaluations,  subject  response,  and  photo-
graphic  review.  Responses  to  quality-of-life  questionnaires 
revealed subjective improvements, and average erythema scores 
at four and eight weeks indicated significant improvements. The 
investigators  concluded  that  licochalcone  A  use  is  suitable  for 
patients  with  sensitive  facial  skin,  as  characterized  by  rosacea, 
and  that  the  tested  licochalcone  A-containing  regimen  was 
compatible with daily metronidazole application.71

That  same  year,  Kolbe  et  al.  showed  in  prospective,  rand-
omized, vehicle-controlled clinical trials that licochalcone A dis-
plays significant anti-irritative efficacy in cosmetic formulations 
and is thus well suited for sensitive or irritated skin. They also 
showed in vitro that licochalcone A-rich extracts of G. inflata as 
well as synthetic licochalcone A potently inhibit proinflamma-
tory responses.72 Licorice extract is a popular ingredient in over-
the-counter  skin  care  products  designed  to  treat  rosacea, 
although few studies supporting its use in rosacea are published.

 
248 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

 SAFETY ISSUES

Most,  if  not  all,  pharmacopoeias  around  the  world  recognize 
and include licorice extract.12 The United States Food and Drug 
Administration  (FDA)  bestowed  generally  recognized  as  safe 
(GRAS)  status  upon  licorice  in  1983.28  The  dietary  ingredient 
licorice flavonoid oil, in which glabridin is a primary bioactive 
flavonoid, has been found to be safe when used once daily up 
to 1,200 mg/day.73

The rare side effects from the oral administration of licorice 
are dose-dependent and occur more frequently in women and 
with the use of oral contraceptives.74 At doses of less than 10 mg 
of glycycrrhizin daily, side effects are thought to be nominal.75 
Chronic use of high doses of glycyrrhizin or glycyrrhetinic acid 
can result in adverse effects such as edema, hypertension, and 
hypokalemia.  Chemical  modifications  to  licorice  formulations 
have been made to enhance therapeutic benefits while reducing 
the  risk  of  side  effects.3  Oral licorice is contraindicated in preg-
nancy according to the German Commission E, though doses up to 
3  g  daily  are  thought  to  be  safe;  hypertension,  cardiac  or  renal 
histories, various liver conditions, hypokalemia, and edema are 
also contraindications.24,27,75

The  Cosmetic  Ingredient  Review  (CIR)  Expert  Panel  sug-
gested that acute, short-term, subchronic, or chronic toxicity is 
minimal and deemed the use of all licorice constituents safe for 
skin care in the current usage and concentration practices.17

 ENVIRONMENTAL IMPACT

The CIR Expert Panel noted that the chemicals isolated from 
the licorice plant may have pesticide and toxic metal residues, 
and advised that polychlorobiphenyl (PCB)/pesticide contami-
nation  should  be  no  higher  than  40  parts  per  million.  They 
further cautioned that toxic metal levels should be limited to 3 mg/
kg of arsenic, 1 mg/kg of lead, and 0.002 percent heavy metals.17

In  2003,  Yamamoto  et  al.  acknowledged  that  cultivation  of  
G. uralensis had emerged to compensate for the waning supply of 
wild Glycyrrhiza plants in China incurred by collection restric-
tions spurred by over-collection of wild plants.21,76 Six years later, 
Gao  et  al.  reported  on  the  ramifications  of  using  G.  uralensis 
seeds  flown  on  a  recoverable  satellite  for  18  days.  After  their 
return to earth, the seeds were planted and grown to maturity. 
Analysis of the content of the roots of the seeds flown in space 
revealed  glycyrrhizic  acid  as  2.19  times  higher  than  a  control 
group and liquiritin content as 1.18 times that of the control. The 
investigators  suggested  that  extraterrestrial  breeding  warrants 
attention as an approach to future breeding of what is consid-
ered an endangered medicinal plant.76

 FORMULATION CONSIDERATIONS

The  licorice  derivatives  glycyrrhizin  and  glycyrrhetinic  acid 
occasionally  cause  edema,  hypertension,  and  hypokalemia 
when  used  orally  in  patients  treated  over  a  long  period  and 
with  higher  doses.  Topical  use  has  not  been  associated  with 
these side effects. Chemical modifications to the myriad com-
pounds have enhanced the anti-inflammatory activities of the 
various  forms  of  licorice  extract,3  and  several  products  have 
been formulated with the intent to increase penetration of the 
active compounds.

Hao  et  al.  demonstrated  in  2010  that  glycyrrhetinic  acid,  a 
metabolite of glycyrrhizic acid, could better penetrate the skin 
when combined with organic bases (triethanolamine or triethyl-
amine)  in  nonaqueous  solvent  comprising  isopropyl  myristate 

and  alcohols  (ethanol,  butanol,  octanol,  and  dodecanol). 
Specifically, they found that an ion pair between glycyrrhizic acid 
and an organic base enhanced the solubility of the extract in the 
stratum corneum as well as its partition into the viable skin, thus 
fostering the penetration of the licorice component into the skin.77
Marianecci et al. found in 2012 that using niosomes composed 
of surfactants (Tween 85 and Span 20) loaded with ammonium 
glycyrrhizinate is potentially effective for treating various inflam-
matory disorders, as the delivery system was shown to exhibit 
good skin tolerability and no toxicity while enhancing the drug 
anti-inflammatory  activity  in  mice.  Skin  erythema  chemically 
induced in a human model was also found to be improved by the 
ammonium glycyrrhizinate-infused vesicles.39

Early in 2014, Mostafa et al. reported on the formulation of a 
stable,  cost-effective,  easy-to-use  transdermal  microemulsion 
system (ME3) for G. glabra delivery that delivers 13-fold higher 
ex  vivo  antioxidant  capacity  than  the  licorice  extract  solution 
itself.78

 USAGE CONSIDERATIONS

No topical products with licorice extract as the primary active 
ingredient  are  FDA  approved  for  the  treatment  of  melasma, 
rosacea,  acne,  or  other  inflammatory  skin  disorders.27 
Glycyrrhetinic acid is used in many cosmeceuticals at concen-
trations  of  up  to  2  percent  and  glycyrrhizic  acid,  up  to  
0.1 percent.17 Studies have not been performed to investigate 
how other agents affect efficacy and penetration when used in 
combination with various forms of licorice extract.

 SIGNIFICANT BACKGROUND

In  some  of  the  earlier  research  on  licorice  extract,  the  use  of 
topical ointments containing active isomers of glycyrrhetic acid 
reportedly showed anti-inflammatory activity in subacute and 
chronic dermatoses, such as contact dermatitis, seborrheic der-
matitis, and psoriasis. Topical corticosteroids were more effec-
tive  than  the  glycyrrhetic  acid  formulation  in  treating  acute 
atopic  dermatitis.79  But  glycyrrhetic  acid  has  been  character-
ized as exerting a cortisone-like effect, rendering it viable as an 
anti-inflammatory  agent,  and  has  inhibited  proinflammatory 
prostaglandins  and  leukotrienes.47,80  Combining  glycyrrhetic 
acid with corticosteroids has also been shown to be effective. 
Results  from  topical  corticosteroid  application  were  signifi-
cantly  improved  with  the  addition  of  2  percent  glycyrrhetic 
acid in one study.48

Antioxidant Activity
Assays of physical stability and antioxidant activity of topical 
preparations containing various plant extracts performed by Di 
Mambro  and  Fonseca  in  2005  revealed  that  G.  glabra  and 
Ginkgo biloba are suitable for incorporation into topical formu-
lations intended to protect skin from the deleterious effects of 
free radical and reactive oxygen species.81

In 2011, Veratti et al. investigated the potential protective prop-
erties of glycyrrhizin, 18β-glycyrrhetinic acid, and glabridin against 
UVB-induced damage in human keratinocyte cultures. They found 
that 18β-glycyrrhetinic acid and glabridin exhibit strong antioxi-
dant activity by blocking oxidative DNA fragmentation as well as 
the induction of apoptosis in human keratinocytes.82

Also during that year, Li et al. employed novel techniques 
to screen and characterize 35 radical scavengers in G. inflata, 

 
G. glabra, G. pallidflora, and G. uralensis, with 21 identified as 
flavonoids.9

The  phenolic  compounds  licochalcone  A-D  and  echinatin, 
retrochalcones  isolated  from  G.  inflata  roots,  have  exhibited 
activity against an array of oxidative stresses. A study assessing 
their  inhibitory  capacity  on  lipid  peroxidation  and  radical- 
scavenging  activity,  specifically,  revealed  that  licochalcones  
B and D potently hindered superoxide anion production in the 
xanthine/xanthine  oxidase  system,  protected  red  cells  from  
oxidative hemolysis, and displayed potent scavenging activity.34 
These  retrochalcones  have  also  demonstrated  antimicrobial 
activity. Specifically, licochalcones A and C have been shown to 
exert  potent  activity  against  some  Gram-positive  bacteria  and 
hamper oxygen consumption in vulnerable bacterial cells.83

Antibacterial Activity
In a study evaluating the in vitro activities of licochalcone A against 
some food contaminant microorganisms, the licorice derivative 
exhibited  activity  against  all  Gram-positive  bacteria  tested, 
particularly  all  Bacillus  spp.  tested,  but  was  ineffective  against 
tested  Gram-negative  bacteria  and  eukaryotes  at  50  µg/mL. 
This study demonstrated the potential viability of licochalcone 
A as an integral constituent in antibacterial products designed 
to preserve food high in salts and proteases.22

Flavonoid  extracts  of  several  species  of  licorice  plant  have 
been  shown  to  exhibit  antiulcer  activity  for  peptic  ulcers. 
Inhibitory activity against Helicobacter pylori growth has also been 
observed in vitro among glabridin and glabrene (components of 
G. glabra), licochalcone A (G. inflata), as well as licoricidin and 
licoisoflavone B (G. uralensis). Among these licorice constituents, 
anti-H. pylori activity was also identified against a clarithromycin- 
and amoxicillin-resistant strain.23

In  2013,  Long  et  al.  showed  that  high  concentrations  of 
18β-glycyrrhetinic  acid,  a  constituent  of  the  root  of  several 
Glycyrrhiza  species,  were  bactericidal  to  methicillin-resistant 
Staphylococcus aureus (MRSA). In addition, both in vitro and in vivo, 
the  licorice  component,  at  sublethal  doses,  decreased  virulent 
gene expression in S. aureus.84

Chemopreventive/Photoprotective Activity
Oral  feeding  of  licorice  extract  to  Sencar  mice  was  shown  in 
1991  to  protect  against  skin  tumorigenesis  caused  by  DMBA 
initiation and TPA promotion. Tumors developed in much less 
time in mice not fed the licorice preparation; treated mice also 
had  significantly  fewer  tumors  during  and  at  the  end  of  the 
study. Researchers concluded that the considerable antitumori-
genic  activity  of  licorice  extract  might  ultimately  be  proved 
useful  in  protecting  against  some  forms  of  human  cancer.11 
Since the time that this study was published, the polyphenols 
in licorice have been shown to induce apoptosis in cancer cells, 
as  licorice  constituents  have  exhibited  significant  antimuta-
genic,  anticarcinogenic,  and  tumor-suppressive  capacity  in 
animal  models.10  In  fact,  the  National  Cancer  Institute  has 
formally  recognized  the  chemopreventive  worth  of  licorice 
root and its primary constituent glycyrrhizin.82,85

In 2005, Rossi et al. assessed the effect of glycyrrhizin and its 
aglycone  metabolite  18β-glycyrrhetinic  acid  on  UVB-irradiated 
human melanoma cells, finding that glycyrrhizin has the poten-
tial to confer photoprotection, though it is ineffective on meta-
static cells.86

Also that year, Agarwal et al. reported that 18β-glycyrrhetinic 
acid inhibits TPA-mediated oxidative stress and tumor promotion 

C H A P T E R  67  ■   L I CO R I C E   E X T R AC T  

249

in murine skin, attenuating the activity of ornithine decarboxy-
lase, incorporation of [3H]-thymidine in DNA, and induction of 
oxidative stress. The licorice component also suppressed DMBA/
TPA-induced  skin  tumor  formation  in  mice.  The  researchers 
concluded that the antioxidant glycyrrhetinic acid may be a via-
ble chemopreventive agent.87

In  2007,  Rahman  et  al.  investigated  the  chemopreventive 
effects  of  glycyrrhizin  on  TPA-induced  cutaneous  oxidative 
stress and tumor protection in Swiss albino mice. Pretreatment 
of animals with the licorice compound prior to TPA yielded sig-
nificant reductions in cutaneous microsomal lipid peroxidation 
and  restoration  of  cutaneous  glutathione  and  its  dependent 
enzymes. The investigators suggested that glycyrrhizin provided 
substantial  protection  to  mice  from  pernicious  TPA-induced 
effects.88

Cherng et al. showed in 2011 that oral administration of gly-
cyrrhizic  acid  to  SKH-1  hairless  mice  prior  to  UVB  exposure  
(180 mJ/cm2 per exposure) mitigates UVB-induced tumorigene-
sis  through  downregulation  of  cell  proliferation  controls  
(i.e.,  thymine  dimer-positive  cells,  proliferative  cell  nuclear 
antigen  expression,  apoptosis,  and  transcription  factor  NF-κB) 
and  inflammatory  responses  (i.e.,  COX-2,  PGE2,  and  NO)  and 
upregulation  of  p53  and  p21/Cip1  to  preclude  damage  while 
mediating repair to DNA.1

Afnan et al. conducted an in vitro study in 2012 of the effects of 
glycyrrhizic acid against UVB-induced photoaging in human der-
mal  fibroblasts,  finding  that  treatment  with  the  licorice  extract 
diminished  reactive  oxygen  species,  NF-κB,  cytochrome  c, 
and  caspase  3  levels  and  hindered  hyaluronidase.  The  investi- 
gators  speculated,  though,  that  the  botanical  ingredient  signifi-
cantly suppressed photoaging primarily through inhibiting matrix 
metalloproteinase-1  activation  and  altering  NF-κB  signaling. 
They concluded that glycyrrhizic acid appears to have potential 
as  a  key  ingredient  in  natural  and  safe  products  intended  to 
protect against UVB-induced damage.4

Dry, Itchy Scalp
A G. inflata extract containing licochalcone A was included in a 
formulation with urea, lactate, and polidocanol that was tested 
by Schweiger et al. in 2013 in 30 volunteers with dry and itchy 
scalp conditions. Participants applied the leave-on tonic three 
times  each  week  for  four  weeks  on  one  side  of  the  scalp. 
Investigators  found  that  scalp  moisture  was  significantly 
enhanced  after  treatment  with  the  tonic,  while  pruritus  was 
significantly  diminished.  A  substantial  decrease  in  key  proin-
flammatory markers was also confirmed through scalp wash-
up analyses. The investigators concluded that the formulation 
containing anti-inflammatory licochalcone A, urea, lactate, and 
polidocanol displayed great efficacy in normalizing scalp lipid 
disturbances  and,  more  importantly,  relieving  scalp  dryness, 
itching, and microinflammation.89

Infantile Seborrheic Dermatitis
In 2012, Wananukul et al. conducted a two-week, prospective, 
randomized,  double-blind,  split-side  comparison  study  of  a 
0.025 percent licochalcone-containing moisturizer and 1 percent 
hydrocortisone in 75 infants (72 of whom completed the study) 
with  infantile  seborrheic  dermatitis.  Patients  were  treated 
twice  daily  on  opposite  sides  of  the  lesion.  A  significantly 
higher clearance rate (42 percent vs. 32 percent) was recorded 
in  the  licochalcone  group  at  days  3  to  4,  with  the  products 
appearing equally effective at days 6 to 7 and 14.90

 
250 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Other Biologic Activity
Shin  et  al.  conducted  in  vitro  and  in  vivo  investigations  of  the 
antiallergic  effects  of  G.  glabra  and  its  constituents  in  2007, 
reporting that glycyrrhizin, 18β-glycyrrhetinic acid, and liquir-
itigenin  are  primarily  responsible  for  imparting  antiallergic 
activity  that  can  alleviate  the  symptoms  of  immunoglobulin 
E-mediated allergic conditions such as dermatitis and asthma.91
Pellati et al. showed in vitro in 2009 that 18β-glycyrrhetinic acid 
substantially stemmed, in a pH-dependent manner, the growth 
of clinical isolates of Candida albicans strains from patients with 
recurrent  vulvovaginal  candidiasis.  The  researchers  suggested 
that  the  constituent  of  Glycyrrhiza  species  has  potential  as  a 
topical therapeutic option for patients with the condition.92

Peng et al. showed in 2011 that glycyrrhetinic acid extracted 
from G. uralensis induced the dose-dependent expression of Toll-
like receptor 4 in Ana-1 murine macrophages and activated its 
downstream signaling pathway, which is involved in the regula-
tion of the innate immune reaction to encroaching pathogens.16
Kato  et  al.  studied  the  extracts  of  25  plants  used  in  Kampo 
medicine in 2012 to identify anti-UV and anti-HIV activity. Of 
the plants tested, licorice displayed the second highest anti-UV 
activity (gardenia fruit was first) and was one of only six plants 
to display some anti-HIV activity.93

In 2013, Wang et al. extracted the radices of G. uralensis with 
hot water and reported antiviral activity against enterovirus 71 
and coxackievirus A16, validating the use of the botanical extract 
against the etiological sources of hand, foot, and mouth disease, 
with glycyrrhizic acid identified as the primary antiviral compo-
nent of G. uralensis.20

 CONCLUSION

Licorice root has been used in traditional medicine in the East 
and West for well over two millennia. In addition, it has been 
evaluated  in  a  vast  range  of  modern  scientific  studies,  and 
licorice  extracts  have  been  included  in  the  cosmeceutical  as 
well  as  medical  realm.  The  reputed  anti-inflammatory  and 
depigmenting  properties  of  licorice  root  are  particularly 
intriguing.  The  great  challenge  in  producing  cosmeceutical 
products – harnessing the identified strengths of a given ingre-
dient  and  bottling  it,  delivering  health  benefits  in  a  topical 
formulation  –  applies  here  as  in  most  cases  discussed  in  this 
text. The wealth of evidence points to the benefits of several 
species  of  licorice  plant,  indicating  that  such  benefits  have 
been  reaped  in  oral  and  topical  preparations  of  the  extract. 
Given the relative wealth of history and research supporting its 
use, licorice root is likely to be incorporated into an increasing 
number  of  products.  Several  medical  applications  have  been 
derived from various species of licorice, particularly G. glabra, 
G. inflata, and G. uralensis. Overall, there appears to be ample 
reason  for  optimism  regarding  the  role  of  licorice  extracts  in 
dermatology.

REFERENCES

1.  Cherng JM, Tsai KD, Yu YW, et al. Molecular mechanisms under-
lying  chemopreventive  activities  of  glycyrrhizic  acid  against 
UVB-radiation-induced  carcinogenesis  in  SKH-1  hairless  mouse 
epidermis. Radiat Res. 2011;176:177.

2.  Asl MN, Hosseinzadeh H. Review of pharmacological effects of 
Glycyrrhiza  sp.  and  its  bioactive  compounds.  Phytother  Res. 
2008;22:709.

3.  Shibata S. A drug over the millennia: pharmacognosy, chemistry, 
and pharmacology of licorice. Yakugaku Zasshi. 2000;120:849.

4.  Afnan Q, Adil MD, Nissar-Ul A, et al. Glycyrrhizic acid (GA), a 
triterpenoid saponin glycoside alleviates ultraviolet-B irradiation-
induced  photoaging  in  human  dermal  fibroblasts.  Phytomedicine. 
2012;19:658.

5.  Simmler  C,  Pauli  GF,  Chen  SN.  Phytochemistry  and  biological 

properties of glabridin. Fitoterapia. 2013;90:160.

6.  Furusawa  J,  Funakoshi-Tago  M,  Mashino  T,  et  al.  Glycyrrhiza 
inflata-derived  chalcones,  Licochalcone  A,  Licochalcone  B  and 
Licochalcone  D,  inhibit  phosphorylation  of  NF-kappaB  p65  in 
LPS signaling pathway. Int Immunopharmacol. 2009;9:499.

7.  Kao TC, Wu CH, Yen GC. Bioactivity and potential health bene-
fits of licorice. J Agric Food Chem. 2014 Jan. 8. [Epub ahead of print]
8.  Gibson  MR.  Glycyrrhiza  in  old  and  new  perspectives.  Lloydia. 

1978;41:348.

9.  Li YJ, Chen J, Li Y, et al. Screening and characterization of natural 
antioxidants in four Glycyrrhiza species by liquid chromatogra-
phy  coupled  with  electrospray  ionization  quadrupole  time-of-
flight tandem mass spectrometry. J Chromatogr A. 2011;1218:8181.
10.  Wang ZY, Nixon DW. Licorice and cancer. Nutr Cancer. 2001;39:1.
11.  Agarwal  R,  Wang  ZY,  Mukhtar  H.  Inhibition  of  mouse  skin 
tumor-initiating activity of DMBA by chronic oral feeding of gly-
cyrrhizin in drinking water. Nutr Cancer. 1991;15:187.

12.  Grieve M. A Modern Herbal (Vol. II). New York: Dover Publications; 

1971:487-492.

13.  Fiore C, Eisenhut M, Ragazzi E, et al. A history of the therapeutic 

use of liquorice in Europe. J Ethnopharmacol. 2005;99:317.

14.  Aburjai  T,  Natsheh  FM.  Plants  used  in  cosmetics.  Phytother  Res. 

2003;17:987.

15.  Lee  O,  Kang  H,  Han  S.  Oriental  herbs  in  cosmetics.  Cosmet 

Toiletries. 1997;112:57.

16.  Peng LN, Li L, Qiu YF, et al. Glycyrrhetinic acid extracted from 
Glycyrrhiza  uralensis  Fisch.  induces  the  expression  of  Toll-like 
receptor  4  in  Ana-1  murine  macrophages.  J  Asian  Nat  Prod  Res. 
2011;13:942.

17.  Cosmetic Ingredient Review Expert Panel. Final report on the safety 
assessment  of  Glycyrrhetinic  Acid,  Potassium  Glycyrrhetinate, 
Disodium  Succinoyl  Glycyrrhetinate,  Glyceryl  Glycyrrhetinate, 
Glycyrrhetinyl Stearate, Stearyl Glycyrrhetinate, Glycyrrhizic Acid, 
Ammonium Glycyrrhizate, Dipotassium Glycyrrhizate, Disodium 
Glycyrrhizate, Trisodium Glycyrrhizate, Methyl Glycyrrhizate, and 
Potassium Glycyrrhizinate. Int J Toxicol. 2007;26(Suppl 2):79.

18.  Liquorice  named  “medicinal  plant  of  the  year  in  2012.”  
http://www.traffic.org/home/2011/11/21/liquorice-named-medic-
inal-plant-of-the-year-2012.html. Accessed March 15, 2014.

19.  Foster S. An Illustrated Guide to 101 Medicinal Herbs: Their History, 
Use,  Recommended  Dosages,  and  Cautions.  Loveland,  CO: 
Interweave Press; 1998:132–133.

20.  Wang J, Chen X, Wang W, et al. Glycyrrhizic acid as the antiviral 
component of Glycyrrhiza uralensis Fisch. against coxsackievirus 
A16  and  enterovirus  71  of  hand  foot  and  mouth  disease.  
J Ethnopharmacol. 2013;147:114.

21.  Yamamoto Y, Majima T, Saiki I, et al. Pharmaceutical evaluation 
of Glycyrrhiza uralensis roots cultivated in eastern Nei-Meng-Gu 
of China. Biol Pharm Bull. 2003;26:1144.

22.  Tsukiyama R, Katsura H, Tokuriki N, et al. Antibacterial activity 
of  licochalcone  A  against  spore-forming  bacteria.  Antimicrob 
Agents Chemother. 2002;46:1226.

23.  Fukai T, Marumo A, Kaitou K, et al. Anti-Helicobacter pylori fla-

vonoids from licorice extract. Life Sci. 2002;71:1449.

24.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy.  London: 

Churchill Livingstone; 2000:465–475.

25.  Fu  Y,  Chen  J,  Li  YJ,  et  al.  Antioxidant  and  anti-inflammatory 
activities  of  six  flavonoids  separated  from  licorice.  Food  Chem. 
2013;141:1063.

26.  Hayashi H, Hosono N, Kondo M, et al. Phylogenetic relationship 
of six Glycyrrhiza species based on rbcL sequences and chemical 
constituents. Biol Pharm Bull. 2000;23:602.

27.  Rico  MJ.  Rising  drug  costs:  the  impact  on  dermatology.  Skin 

Therapy Lett. 2000;5:1.

28.  Piersen  CE.  Phytoestrogens  in  botanical  dietary  supplements: 

implications for cancer. Integr Cancer Ther. 2003;2:120.

29.  Yokota  T,  Nishio  H,  Kubota  Y,  et  al.  The  inhibitory  effect  of 
glabridin from licorice extracts on melanogenesis and inflamma-
tion. Pigment Cell Res. 1998;11:355.

30.  Friis-Møller A, Chen M, Fuursted K, et al. In vitro antimycobacte-
rial  and  antilegionella  activity  of  licochalcone  A  from  Chinese 
licorice roots. Planta Med. 2002;68:416.

 
31.  Shibata S, Inoue H, Iwata S, et al. Inhibitory effects of licochal-
cone A isolated from Glycyrrhiza inflate root on inflammatory ear 
edema and tumour promotion in mice. Planta Med. 1991;57:221.
32.  Barfod L, Kemp K, Hansen M, et al. Chalcones from Chinese liq-
uorice inhibit proliferation of T cells and production of cytokines. 
Int Immunopharmacol. 2002;2:545.

33.  Rafi MM, Rosen RT, Vassil A, et al. Modulation of bcl-2 and cyto-
toxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer 
Res. 2000;20:2653.

34.  Haraguchi  H,  Ishikawa  H,  Mizutani  K,  et  al.  Antioxidative  and 
superoxide scavenging activities of retrochalcones in Glycyrrhiza 
inflata. Bioorg Med Chem. 1998;6:339.

35.  Cho YC, Lee SH, Yoon G, et al. Licochalcone E reduces chronic 
allergic  contact  dermatitis  and  inhibits  IL-12p40  production 
through  down-regulation  of  NF-kappa  B.  Int  Immunopharmacol. 
2010;10:1119.

36.  Li  J,  Tu  Y,  Tong  L,  et  al.  Immunosuppressive  activity  on  the 
murine immune responses of glycyrol from Glycyrrhiza uralensis 
via inhibition of calcineurin activity. Pharm Biol. 2010;48:1177.
37.  Shin EM, Zhou HY, Guo LY, et al. Anti-inflammatory effects of 
glycyrol  isolated  from  Glycyrrhiza  uralensis  in  LPS-stimulated 
RAW264.7 macrophages. Int Immunopharmacol. 2008;8:1524.
38.  Das  D,  Agarwal  SK,  Chandola  HM.  Protective  effect  of 
Yashtimadhu (Glycyrrhiza glabra) against side effects of radiation/
chemotherapy in head and neck malignancies. Ayu. 2011;32:196.

39.  Marianecci  C,  Rinaldi  F,  Mastriota  M,  et  al.  Anti-inflammatory 
activity  of  novel  ammonium  glycyrrhizinate/niosomes  delivery 
system: human and murine models. J Control Release. 2012;164:17.
40.  Draelos  ZD.  New  treatments  for  restoring  impaired  epidermal 
barrier  permeability:  skin  barrier  repair  creams.  Clin  Dermatol. 
2012;30:345.

41.  Saeedi M, Morteza-Semnani K, Ghoreishi MR. The treatment of 
atopic dermatitis with licorice gel. J Dermatolog Treat. 2003;14:153.
42.  Marks A. Herbal extracts in cosmetics. Agro-Food-Industry Hi-Tech. 

1997;8:28.

43.  Ploeger  B,  Mensinga  T,  Sips  A,  et  al.  The  pharmacokinetics  of 
glycyrrhizic acid evaluated by physiologically based pharmacoki-
netic modeling. Drug Metab Rev. 2001;33:125.

44.  Baker  ME,  Fanestil  DD.  Liquorice  as  a  regulator  of  steroid  and 

prostaglandin metabolism. Lancet. 1991;337:428.

45.  Olukoga A, Donaldson D. Historical perspectives on health. The 
history  of  liquorice:  the  plant,  its  extract,  cultivation,  commer-
cialization and etymology. J R Soc Promot Health. 1998;118:300.
46.  Azimov  MM,  Zakirov  UB,  Radzhapova  ShD.  Pharmacological 
study  of  the  anti-inflammatory  agent  dlyderinine.  Farmakol 
Toksikol. 1988;51:90.

47.  Ohuchi K, Kamada Y, Levine L, et al. Glycyrrhizin inhibits prosta-
glandin E2 production by activated peritoneal macrophages from 
rats. Prostaglandins Med. 1981;7:457.

48.  Teelucksingh S, Mackie AD, Burt D, et al. Potentiation of hydrocor-
tisone activity in skin by glycyrrhetinic acid. Lancet. 1990;335:1060.
49.  Furuhashi I, Iwata S, Shibata S, et al. Inhibition by licochalcone A, 
a novel flavonoid isolated from liquorice root, of IL-1beta-induced 
PGE2  production  in  human  skin  fibroblasts.  J  Pharm  Pharmacol. 
2005;57:1661.

50.  Kwon HS, Park JH, Kim DH, et al. Licochalcone A isolated from 
licorice  suppresses  lipopolysaccharide-stimulated  inflammatory 
reactions in RAW264.7 cells and endotoxin shock in mice. J Mol 
Med (Berl). 2008;86:1287.

51.  Funakoshi-Tago  M,  Nakamura  K,  Tsuruya  R,  et  al.  The  fixed 
structure of Licochalcone A by alpha, beta-unsaturated ketone is 
necessary for anti-inflammatory activity through the inhibition of 
NF-kappaB activation. Int Immunopharmacol. 2010;10:562.

52.  Lee HN, Cho HJ, Lim do Y, et al. Mechanisms by which licochalcone 
e exhibits potent anti-inflammatory properties: studies with phorbol 
ester-treated mouse skin and lipopolysaccharide-stimulated murine 
macrophages. Int J Mol Sci. 2013;14:10926.

53.  Nam  C,  Kim  S,  Sim  Y,  et  al.  Anti-acne  effects  of  Oriental  herb 
extracts: a novel screening method to select anti-acne agents. Skin 
Pharmacol Appl Skin Physiol. 2003;16:84.

54.  Angelova-Fischer  I,  Rippke  F,  Fischer  TW,  et  al.  A  double-
blind,  randomized,  vehicle-controlled  efficacy  assessment 
study of a skin care formulation for improvement of mild to 
moderately  severe  acne.  J  Eur  Acad  Dermatol  Venereol. 
2013;27(Suppl 2):6.

55.  Reuter J, Wölfle U, Weckesser S, et al. Which plant for which skin 
disease? Part 1: Atopic dermatitis, psoriasis, acne, condyloma and 
herpes simplex. J Dtsch Dermatol Ges. 2010;8:788.

C H A P T E R  67  ■   L I CO R I C E   E X T R AC T  

251

56.  Reuter J, Merfort I, Schempp CM. Botanicals in dermatology: an 

evidence-based review. Am J Clin Dermatol. 2010;11:247.

57.  Udompataikul M, Srisatwaja W. Comparative trial of moisturizer 
containing licochalcone A vs. hydrocortisone lotion in the treat-
ment  of  childhood  atopic  dermatitis:  a  pilot  study.  J  Eur  Acad 
Dermatol Venereol. 2011;25:660.

58.  Wananukul S, Chatproedprai S, Chunharas A, et al. Randomized, 
double-blind,  split-side,  comparison  study  of  moisturizer 
containing licochalcone A and 1% hydrocortisone in the treat-
ment  of  childhood  atopic  dermatitis.  J  Med  Assoc  Thai. 
2013;96:1135.

59.  Davis  EC,  Callender  VD.  Postinflammatory  hyperpigmenta-
tion:  a  review  of  the  epidemiology,  clinical  features,  and 
treatment  options  in  skin  of  color.  J  Clin  Aesthet  Dermatol. 
2010;3:20.

60.  Zhu W, Gao J. The use of botanical extracts as topical skin-lightening 
agents  for  the  improvement  of  skin  pigmentation  disorders.  
J Investig Dermatol Symp Proc. 2008;13:20.

61.  Leyden JJ, Shergill B, Micali G, et al. Natural options for the man-
agement  of  hyperpigmentation.  J  Eur  Acad  Dermatol  Venereol. 
2011;25:1140.

62.  Draelos ZD. Skin lightening preparations and the hydroquinone 

controversy. Dermatol Ther. 2007;20:308.

63.  Cronin H, Draelos ZD. Top 10 botanical ingredients in 2010 anti-

aging creams. J Cosmet Dermatol. 2010;9:218.

64.  Amer M, Metwalli M. Topical liquiritin improves melasma. Int J 

Dermatol. 2000;39:299.

65.  Nerya O, Vaya J, Musa R, et al. Glabrene and isoliquiritigenin as 
tyrosinase  inhibitors  from  licorice  roots.  J  Agric  Food  Chem. 
2003;51:1201.

66.  Costa  A,  Moisés  TA,  Cordero  T,  et  al.  Association  of  emblica, 
licorice and belides as an alternative to hydroquinone in the clini-
cal treatment of melasma. An Bras Dermatol. 2010;85:613.

67.  Adhikari A, Devkota HP, Takano A, et al. Screening of Nepalese 
crude drugs traditionally used to treat hyperpigmentation: in vitro 
tyrosinase inhibition. Int J Cosmet Sci. 2008;30:353.

68.  Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. 

J Am Acad Dermatol. 2011;65:699.

69.  Cassano N, Mantegazza R, Battaglini S, et al. Adjuvant role of a 
new emollient cream in patients with palmar and/or plantar pso-
riasis:  a  pilot  randomized  open-label  study.  G  Ital  Dermatol 
Venereol. 2010;145:789.

70.  Man  MQ,  Shi  Y,  Man  M,  et  al.  Chinese  herbal  medicine 
(Tuhuai  extract)  exhibits  topical  anti-proliferative  and  anti-
inflammatory activity in murine disease models. Exp Dermatol. 
2008;17:681.

71.  Weber TM, Ceilley RI, Buerger A, et al. Skin tolerance, efficacy, 
and quality of life of patients with red facial skin using a skin care 
regimen  containing  Licochalcone  A.  J  Cosmet  Dermatol. 
2006;5:227.

72.  Kolbe L, Immeyer J, Batzer J, et al. Anti-inflammatory efficacy of 
Licochalcone A: correlation of clinical potency and in vitro effects. 
Arch Dermatol Res. 2006;298:23.

73.  Aoki  F,  Nakagawa  K,  Kitano  M,  et  al.  Clinical  safety  of  licorice 
flavonoid oil (LFO) and pharmacokinetics of glabridin in healthy 
humans. J Am Coll Nutr. 2007;26:209.

74.  Bernardi  M,  D’Intino  PE,  Trevisan  F,  et  al.  Effects  of  prolonged 
ingestion  of  graded  doses  of  licorice  by  healthy  volunteers.  
Life Sci. 1994;55:863.

75.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

Medicine. Rochester, VT: Healing Arts Press; 2003:555.

76.  Gao W, Li K, Yan S, et al. Effects of space flight on DNA mutation 
and  secondary  metabolites  of  licorice  (Glycyrrhiza  uralensis 
Fisch.). Sci China C Life Sci. 2009;52:977.

77.  Hao J, Sun Y, Wang Q, et al. Effect and mechanism of penetration 
enhancement of organic base and alcohol on glycyrrhetinic acid 
in vitro. Int J Pharm. 2010;399:102.

78.  Mostafa  DM,  Ammar  NM,  Abd  El-Alim  SH,  et  al.  Transdermal 
microemulsions of Glycyrrhiza glabra L.: characterization, stability 
and evaluation of antioxidant potential. Drug Deliv. 2014;21:130.

79.  Evans FQ. The rational use of glycyrrhetinic acid in dermatology. 

Br J Clin Pract. 1958;12:269.

80.  Okimasu E, Moromizato Y, Watanabe S, et al. Inhibition of phos-
pholipase A2 and platelet aggregation by glycyrrhizin, an antiin-
flammation drug. Acta Med Okayama. 1983;37:385.

81.  Di  Mambro  VM,  Fonseca  MJ.  Assays  of  physical  stability  and 
antioxidant activity of a topical formulation added with different 
plant extracts. J Pharm Biomed Anal. 2005;37:287.

 
252 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

82.  Veratti E, Rossi T, Giudice S, et al. 18beta-glycyrrhetinic acid and 
glabridin prevent oxidative DNA fragmentation in UVB-irradiated 
human keratinocyte cultures. Anticancer Res. 2011;31:2209.

83.  Haraguchi H, Tanimoto K, Tamura Y, et al. Mode of antibacterial 
action of retrochalcones from Glycyrrhiza inflata. Phytochemistry. 
1998;48:125.

84.  Long  DR.  Mead  J,  Hendricks  JM,  et  al.  18β-Glycyrrhetinic  acid 
inhibits methicillin-resistant Staphylococcus aureus survival and 
attenuates virulence gene expression. Antimicrob Agents Chemother. 
2013;57:241.

85.  Craig  WJ.  Health-promoting  properties  of  common  herbs.  Am  J 

Clin Nutr. 1999;70:491S.

86.  Rossi  T,  Benassi  L,  Magnoni  C,  et  al.  Effects  of  glycyrrhizin  on 

UVB-irradiated melanoma cells. In Vivo. 2005;19:319.

87.  Agarwal  MK,  Iqbal  M,  Athar  M.  Inhibitory  effect  of  18beta- 
glycyrrhetinic  acid  on  12-O-tetradecanoyl  phorbol-13-acetate-
induced cutaneous oxidative stress and tumor promotion in mice. 
Redox Rep. 2005;10:151.

88.  Rahman S, Sultana S. Glycyrrhizin exhibits potential chemopre-
ventive  activity  on  12-O-tetradecanoyl  phorbol-13-acetate-

induced  cutaneous  oxidative  stress  and  tumor  promotion  in 
Swiss albino mice. J Enzyme Inhib Med Chem. 2007;22:363.

89.  Schweiger D, Baufeld C, Drescher P, et al. Efficacy of a new tonic 
containing urea, lactate, polidocanol, and glycyrrhiza inflata root 
extract in the treatment of a dry, itchy, and subclinically inflamed 
scalp. Skin Pharmacol Physiol. 2013;26:108.

90.  Wananukul S, Chatproedprai S, Charutragulchai W. Randomized, 
double-blind, split-side comparison study of moisturizer containing 
licochalcone vs. 1% hydrocortisone in the treatment of infantile 
seborrhoeic  dermatitis.  J  Eur  Acad  Dermatol  Venereol. 
2012;26:894.

91.  Shin  YW,  Bae  EA,  Lee  B,  et  al.  In  vitro  and  in  vivo  antiallergic 
effects  of  Glycyrrhiza  glabra  and  its  components.  Planta  Med. 
2007;73:257.

92.  Pellati D, Fiore C, Armanini D, et al. In vitro effects of glycyrrhe-
tinic acid on the growth of clinical isolates of Candida albicans. 
Phytother Res. 2009;23:572.

93.  Kato  T,  Horie  N,  Matsuta  T,  et  al.  Anti-UV/HIV  activity  of 
Kampo  medicines  and  constituent  plant  extracts.  In  Vivo. 
2012;26:1007.

 
C H A P T E R  68  ■   CO L LO I DA L   OAT M E A L  

253

C H A P T E R   6 8

Colloidal Oatmeal

Activities:

Anti-inflammatory,  antipruritic,  antioxidant,  antimicro-
bial, anticholesterolemic, antidiabetic, immunomodula-
tory, neurotonic, wound healing1

Important Chemical Components:
Polysaccharides (particularly β-glucan), lipids, polyphe-
nols (i.e., hydroxycinnamic acids such as caffeic, ferulic, 
p-coumaric,  and  sinapic  acids;  and  avenanthramides), 
proteins, vitamin E, vitamin B complex, phytic acid2–4

Origin Classification:

This  ingredient  is  natural.  Organic  forms  exist. 
Derivatives of avenanthramides have been synthesized 
in the laboratory.

Personal Care Category:

Anti-inflammatory, moisturizer, cleanser, buffer, barrier 
protection, soothing agent

Recommended  for  the  following  Baumann  Skin 
Types:

DSNW, DSPW, DSNT, and DSPT

 SOURCE

Avena sativa (also known as oatstraw or wild oats, and Jai or Javi 
on  the  Indian  subcontinent)5  has  a  long  history  of  traditional 
folk use, particularly as a poultice or soak, to alleviate pruritus 
and irritation related to dry skin conditions (Table 68-1).6,7 As a 
cultivated  plant,  this  annual  cereal  grain  and  member  of  the 
Poaceae  (also  known  as  Gramineae  or  true  grasses)  family,  is 
grown for its seeds for multiple uses. In recent decades, colloidal 
oatmeal  (CO),  dehulled  oats  ground  into  a  fine  powder,  has 
been  used,  typically  in  a  bath,  for  purposes  similar  to  the 
traditional  ones,  namely  lessening  the  irritation  and  mild 
pruritus  characteristic  of  eczema,  insect  bites,  rashes,  poison 
ivy,  and  other  contact  allergens.8  CO  has  also  been  used  for 
decades  as  an  adjunct  in  the  treatment  of  atopic  dermatitis.9 

TABLE 68-1
Pros and Cons of Colloidal Oatmeal

Pros
Long history of traditional medical use

One of the few natural products approved by 

the FDA for skin indications

Published clinical trials support therapeutic use

Con
More research and clinical studies are 
necessary to ascertain full range of  
skin-protective properties (particularly 
against UV radiation)

Generally, better benefits are seen with the use of oat fractions 
than whole oatmeal.10

Evidence suggests that CO, the modern version of the tradi-
tional elixir, is effective in protecting and repairing skin and hair 
damaged  from  environmental  insults  such  as  ultraviolet  (UV) 
radiation, smoke, bacteria, and free radicals as well as alleviating 
cutaneous  inflammation  and  discomfort.10  In  addition,  CO 
appears  to  have  the  capacity  to  repair  damage  from  other 
chemicals such as α-hydroxy acids, surfactants, and bleaches.11

A. sativa is also believed to promote the release of luteinizing 
hormone, which is integral in the production and release of sex 
hormones  such  as  testosterone.  This  might  account  for  its 
traditional use as an aphrodisiac and the origin of the expression 
“sowing wild oats.”

 HISTORY

The  skin  care  application  of  A.  sativa  dates  back  earlier  than  
2000 BCE to its native Mediterranean region, particularly Egypt and 
the  Arabian  Peninsula,  and  oatstraw  was  widely  cultivated  in 
Europe by 2000 BCE.6 Early references to the medical application of 
oats were made by Hippocrates (circa 460–370 BCE) and, later, by 
Dioscorides, Galen, and Pliny the Elder in the 1st century CE.12–14 
The use of oats as a food source has been traced to the 1st century 
CE.10 As teas, food, and in baths, oats were used for centuries to 
treat  anxiety,  insomnia,  and  various  cutaneous  conditions,  
including burns and eczema.15 Consumption of whole grain oats is 
now associated with a lower risk for coronary heart disease.5,16

In  the  19th  and  early  20th  centuries,  oatmeal  baths  were 
frequently  used  for  the  treatment  of  pruritic  inflammatory  skin 
conditions,  such  as  eczema  and  burns.  A  ready-to-use  CO 
preparation, created by finely grinding and then boiling the oat to 
extract the colloidal substance, became available in 1945.2,14 In the 
late 1950s, Dick and Sompayrac reported separately that CO baths 
were demonstrably effective in the management of pediatric atopic 
dermatitis.17,18  As  a  component  of  the  modern  dermatologic 
armamentarium, CO has replaced rolled oats and plain oatmeal, 
and  has  been  used  for  decades  to  ameliorate  inflammatory  and 
pruritic conditions. CO is composed of dehulled oats ground to a 
fine powder that retains the moisturizing effects of the whole oat 
grain and disperses more easily in bath water. It can also be added 
to creams and lotions for use in topical products. 

 CHEMISTRY

CO consists primarily of polysaccharides (60–85 percent), proteins 
and  enzymes,  such  as  superoxide  dismutase  (10–20  percent), 
lipids  (3–11  percent),  β-glucan  (5  percent),  fiber  (5  percent), 
and avenanthramides (0.03 percent).2,13 The remaining constituents 
include  saponins,  vitamins,  flavonoids,  and  inhibitors  of 
prostaglandin  synthesis.  Oat  lipids  contribute  to  the  viscosity  
of CO and help decrease transepidermal water loss, a key factor in 
skin dryness.19,20 Phenols in oatmeal contribute to the antioxidant 
and  anti-inflammatory  activity  of  the  extract,  and  some  oat 

 
254 

COsM E C E U T I C A Ls   A N D   C OsM E T I C   INgR E D I E N T s

phenols  exhibit  potent  UV-absorbing  properties.14  Constituent 
saponins are responsible for most of the cleansing activity of oat.14 
In  addition,  oatmeal  proteins  exhibit  emulsification,  hydration, 
and  antioxidant  activity  along  with  low  foaming  potential.  CO 
proteins and polysaccharides bind to skin and provide a protective 
barrier  to  external  insults.  The  proteins  further  act  as  a  buffer 
against strong acids and bases.21 The protective and water-retaining 
properties of CO are thought to result from its high concentration 
of starches (polysaccharides), particularly β-glucan.14 Oat β-glucan 
is believed to be immunomodulatory.CO lotion application is also 
known to affect arachidonic acid, cytosolic phospholipase A2, and 
tumor necrosis factor (TNF)-α pathways in exerting potent anti-
inflammatory activity.22 The biologic activity of oat compounds 
appears to be quite dynamic. The activity of whole oat flour is 
characterized  as  antioxidant,  prostaglandin  synthesis-inhibiting, 
cleansing, and protective in nature.

Avenanthramides
The  therapeutic  and  cosmetic  uses  of  oatmeal  have  been 
enhanced  by  the  isolation  and  identification  of  specific  oat 
components.  Oatmeal  has  been  found  to  contain  20  unique 
polypenolic  alkaloids,  avenanthramides,  which  act  as 
phytoalexins, exhibiting antimicrobial properties that serve to 
protect the plant.13 Found exclusively in oats, avenanthramides, 
which  are  substituted  N-cinnamoylanthranilic  acids  with 
hydroxycinnamic  acid  and  anthranilic  acid  moieties,  have 
exhibited potent antioxidant activity in vitro and in vivo as well 
as  anti-inflammatory,  antiproliferative,  and  antipruritic 
activity.4,16  This  is  not  surprising  insofar  as  phenolics,  as  a 
group,  display  a  broad  range  of  biologic  activities  including 
prevention of inflammation and oxidation.23 In fact, phenolics 
are  the  strongest  antioxidants  found  in  nature,24  although 
within  this  class  of  compounds,  individual  substances  exert 
varying levels of antioxidant activity. Oat phenolic compounds 
including  avenanthramides  have  been  identified  as  potent 
antioxidants  that  scavenge  reactive  oxygen  and  nitrogen 
species.23 Of the oat phenolics, avenanthramides are thought to 
manifest  10  to  30  times  the  antioxidant  activity  of  other  oat 
phenolics  such  as  caffeic  acid  or  vanillin.25  Furthermore,  they 
have been reported to inhibit prostaglandin biosynthesis nearly 
as well as the synthetic anti-inflammatory agent indomethacin.26 
Indeed,  avenanthramides  are  now  being  credited  with 
imparting many of the beneficial effects of CO.27

A  2007  study  by  Wallo  et  al.  provided  more  evidence  that 
avenanthramides  evince  potent  anti-inflammatory  activity.  The 
investigators incubated keratinocytes with an inducer of proin-
flammatory  interleukin  (IL)-8  in  the  presence  of  vehicle  or 
avenanthramides.  The  phenolic  compounds  diminished  the 
release of the proinflammatory cytokine IL-8 by 10 to 25 percent.28 
Avenanthramides in topical formulations have also been shown 
in multiple preclinical and preliminary clinical studies to suppress 
the  activity  of  nuclear  factor-κB  (NF-κB)  and  the  release  of 
proinflammatory  cytokines  and  histamine,  thus  blocking  the 
activation of inflammatory pathways in the skin.20,27 In addition, 
avenanthramides have been demonstrated to mitigate skin irrita-
tion and erythema induced by exposure to UVB irradiation.20

After previously showing that avenanthramides significantly 
inhibited  IL-1β-stimulated  secretion  of  proinflammatory 
cytokines, such as IL-6, IL-8, and monocyte chemotactic protein 
(MCP)-1, by human aortic endothelial cells, Guo et al. showed in 
2008 that oat polyphenols reduce the expression of endothelial 
proinflammatory cytokines, in part, via blocking NF-κB activa-
tion  by  suppressing  the  phosphorylation  of  the  inhibitor  of 

nuclear  factor  κB  (IκB)  complex  (IKK)  and  IκB,  and  hindering 
proteasome activity.3

In  2008,  Sur  et  al.  found  that  avenanthramides,  typically 
present  in  oats  at  approximately  300  parts  per  million  (ppm), 
suppressed the degradation of IκB-α in keratinocytes in concen-
trations as low as 1 part per billion. In this in vitro study, they also 
found  that  avenanthramide-treated  cells  significantly  inhibited 
TNF-α-induced NF-κB luciferase activity as well as IL-8 release. 
In  murine  models,  the  investigators  showed  that  topically 
applied avenanthramides (in concentrations of 1–3 ppm) attenu-
ated inflammation and diminished scratching. They concluded 
that avenanthramides are strong anti-inflammatory compounds 
that account for the anti-irritant activity manifested by oats.13

A  year  later,  Lee-Manion  et  al.  used  assays  to  assess  the 
antioxidant and antigenotoxic activity of synthetic avenanthra-
mides,  hydroxycinnamic  acids,  Tranilast,  and  ascorbic  acid. 
They  observed  that  N-(3’,4’-dihydroxy-(E)-cinnamoyl)-5-
hydroxyanthranilic  acid,  an  avenanthramide  compound  found 
in  copious  amounts  in  oats,  displayed  the  highest  activity, 
indicating  that  avenanthramides  possess  antioxidant  and 
antigenotoxic  characteristics  similar  to  those  of  ascorbic  acid 
with the potential to deliver beneficial physiological effects.4

 ORAL USES

A.  sativa  and  oat  products  have  been  consumed  since  the  
1st century CE.10 Oatmeal is known for its calming effects when 
taken internally, and remains a staple typically among breakfast 
options particularly among health-conscious consumers.

 TOPICAL USES

The combination of components and properties of CO renders 
it  suitable  for  various  uses  in  the  care  of  inflammatory  skin 
conditions,  such  as  cleaning,  moisturizing,  protecting  (i.e., 
barrier preservation), and relieving pruritus in inflamed skin. In 
fact, oatmeal is one of the few natural products recognized by 
the United States Food and Drug Administration (FDA) as an 
effective skin protectant.29 As a consequence, CO is one of the 
few  botanicals  subject  to  FDA  regulation.29  The  range  of 
dermatologic  applications  for  CO  is  extensive  and  includes 
adjunctive therapy in inflammatory and pruritic skin conditions 
such as atopic dermatitis; allergic and irritant contact dermatitis 
including contact to poison ivy, oak, and sumac; chicken pox; 
cercarial  dermatitis;  diaper  dermatitis;  epidermolysis  bullosa; 
ichthyosis; insect bites; pediatric and senile dermatoses; prickly 
heat;  pruritic  conditions;  psoriasis;  rashes;  sunburn;  urticaria; 
and  xerosis.15,17,21,30,31  CO  also  prevents  and  repairs  damage 
caused by environmental insults such as UV radiation, smoke, 
bacteria,  and  free  radicals.10  In  addition,  oatmeal  baths  are 
included  in  the  accepted  treatment  arsenal  for  erythroderma, 
also known as exfoliative dermatitis, which affects the majority 
of the cutaneous surface.32 Oatmeal extracts also confer modu-
lating effects in the sodium lauryl sulfate skin irritancy model.

In  a  small  study  with  20  patients  in  2007,  the  application  of 
topical CO lotion (derived from A. rhealba®, which is a white oat 
cultivar of A. sativa) was shown to be effective in treating acneiform 
eruptions  associated  with  the  use  of  small-molecule  tyrosine-
kinase  inhibitors  in  treating  epidermal  growth  factor  (EGFR)-
positive cancers, thus facilitating continued neoplastic therapy.22

Further, Wu contends that CO is well suited as a treatment 
option for rosacea due to its barrier and skin-protective, antipru-
ritic, anti-inflammatory, and antioxidant properties.33

 
Atopic Dermatitis
Several studies have shown that the daily use of CO-containing 
moisturizers  and/or  cleansers  has  significantly  improved  the 
symptoms of patients, from infants to those in their 60s, with 
mild-to-moderate atopic dermatitis and proven to be safe and 
well tolerated.34

In  2007,  Grimalt  et  al.  conducted  a  six-week  randomized 
controlled study in 173 infants treated for inflammatory lesions 
with moderate- or high-potency topical corticosteroids to assess 
the effects of an oat extract-containing emollient on the amount 
of steroid needed for treatment. While the 7.5 percent lower use 
of  moderate-strength  corticosteroids  in  the  emollient  group 
compared to the control group was not significant, the oatmeal 
emollient  treatment  significantly  decreased  the  use  of  high-
potency topical corticosteroid use in infants with atopic derma-
titis by 42 percent compared to controls.35

Also  that  year,  Boussault  et  al.  reported  findings  from  a 
study  of  302  prospectively  recruited  children  with  atopic 
dermatitis  who  were  referred  for  allergy  testing  between  
June  2001  and  December  2004.  Various  sensitivity  tests 
revealed that oat sensitization in atopic children under the age 
of two who were seen for allergy testing was higher than the 
investigators  expected.  They  speculated  that  repeated 
applications  of  oat-containing  cosmetics  on  an  already 
susceptible epidermal barrier may account for this phenomenon, 
concluding  that  such  oat  products  should  be  avoided  in 
infants with atopic dermatitis.36

 SAFETY ISSUES

In  1997,  the  FDA,  based  on  evidence  that  consumption  of 
oatmeal  or  oat  bran  decreased  low-density  lipoproteins  and 
total  plasma  cholesterol  (largely  attributed  to  its  constituent 
β-glucan), approved the heart-health benefit claim on labels of 
food containing oat-soluble fiber.5,16 Oatmeal is also one of the 
few natural products or ingredients acknowledged by the FDA 
as an effective skin protectant. Indeed, CO has been found to 
be safe, cosmetically stable, and nonirritating. With the issuance 
of its Over-The-Counter Final Monograph for Skin Protectant 
Drug Products issued in June 2003, the FDA began regulating 
CO as a skin protectant and its preparation is standardized in 
the United States Pharmacopeia.14,37 It is also approved for use 
in Germany for inflammatory skin conditions.6

While  rare,  cases  of  allergic  contact  dermatitis  and  urticaria 
have been reported in reaction to the use of CO preparations.38 
No adverse drug interactions have been reported in association 
with CO.39 Overall, oatmeal has an excellent safety profile in the 
treatment of dermatologic disorders.

In 2012, Criquet et al. performed a series of studies to examine 
the  safety  and  efficacy  of  personal  care  products  (i.e.,  creams, 
cleansers,  and  lotions)  containing  CO.  They  found  a  very  low 
potential in these agents for engendering irritation and allergenic 
sensitization.  Of  2,291  participants,  one  subject  developed  a 
persistent  but  dubious  (because  it  was  confirmed  with  the 
product but not with A. sativa) mild edema during the challenge 
phase in a test of 12 personal care products containing CO. In the 
induction  phase  of  insult  patch  testing,  1  percent  of  subjects 
experienced similarly low-level reactions. The investigators also 
reported that skin moisturization was sustained in subjects with 
dry skin, extending to two weeks beyond discontinuation of the 
product.  They  noted  that  no  allergies  were  documented  in  the  
80 subjects observed following patch testing after in-use applica-
tion or by consumers of 445,820 products sold during a three-year 

C H A P T E R  68  ■   CO L LO I DA L   OAT M E A L  

255

period.  Criquet  and  colleagues  concluded  that  personal  care 
products containing CO are safe and effective.40

 ENVIRONMENTAL IMPACT

The environmental impact from the cultivation and commercial 
use  of  A.  sativa  is  not  well  documented  to  the  author’s 
knowledge.

 FORMULATION CONSIDERATIONS

Most oatmeal products come in the form of colloidal baths, but 
shampoos, soaps, body washes, shaving gels, and moisturizing 
lotions and creams are also prepared with oatmeal.14

 USAGE CONSIDERATIONS

As  part  of  a  daily  skin  care  regimen,  CO  is  appropriate  for 
cleansing (especially dry, sensitive, or atopic skin), moisturizing, 
and providing protection to the skin.

 SIGNIFICANT BACKGROUND

In  a  literature  review  of  in  vitro,  in  vivo,  and  clinical  studies  of 
oatmeal preparations in 2012, Pazyar et al. found that oatmeal 
exhibits  antioxidant  and  anti-inflammatory  activity  in  its 
effective  medical  use  for  conditions  including  acneiform 
eruptions, atopic dermatitis, pruritus, and viral infections as well 
as in cosmetic formulations in providing photoprotection to the 
skin.2  Cerio  et  al.  have  noted  that  CO  has  also  demonstrated 
effectiveness in treating psoriasis and drug-induced rashes.2,27

Human Studies
In  a  1997  double-blind,  randomized  patch  study  of  two 
concentrations  of  colloidal  oat  and  rice  grains  (0.007  and 
0.7 percent), the products were applied topically to the backs of 
65 Italian children between 6 months and 2 years old (of whom 
43  were  atopic  and  22  were  normal).  Both  topical  colloidal 
grains  showed  efficacy  as  adjuncts  in  the  treatment  of  mild 
atopic dermatitis, with no evidence of inducing sensitization.9

In a 2001 10-month assessor-blind clinical study to identify an 
adequate treatment to alleviate pruritus experienced by 35 acute 
burn patients, the comparative effectiveness of two shower and 
bath oils, one containing liquid paraffin with 5 percent CO and 
the other containing liquid paraffin, was evaluated. Analysis of 
patient assessments of pain (recorded twice daily) and the daily 
number  of  their  antihistamine  requests  showed  that  the  CO 
group  reported  significantly  less  pruritus  and  requested 
significantly less antihistamine.41

In an influential study on 12 healthy individuals, researchers 
evaluated the anti-inflammatory activity of two topically applied 
oatmeal  extracts,  A.  sativa  and  A.  rhealba®,  using  the  sodium 
lauryl sulfate irritation model, finding that both extracts displayed 
preventive effects on skin irritation.42

Further, Boisnic et al. developed a clinical model of cutaneous 
inflammation involving the effects of an oatmeal extract oligomer 
on skin tissue fragments exposed to vasoactive intestinal peptide, 
a  proinflammatory  neuromediator.  The  application  of  the 
peptide  augmented  inflammation,  which  was  significantly 
reduced by treatment with the oatmeal extract.43

 
256 

COsM E C E U T I C A Ls   A N D   C OsM E T I C   INgR E D I E N T s

Antioxidant Activity
In 2013, Feng et al. investigated the protective effect of oat bran 
extract  by  enzymatic  hydrolysates  on  hydrogen  peroxide 
(H2O2)-induced  human  dermal  fibroblast  injury.  They  found, 
using  a  1,1-diphenyl-2-picrylhydrazyl  (DPPH)  radical-
scavenging  assay  that  peptide-rich  oat  bran  extracts 
concentration-dependently  exhibited  direct  antioxidant 
activity.  Further,  they  showed  that  incubating  human  dermal 
fibroblasts with oat bran extracts for 24 hours prior to exposure 
led to the significant suppression of H2O2-induced damage, but 
simultaneously applying oat peptides with H2O2 did not yield 
a  similar  result.  However,  the  oat  pretreatment  also  markedly 
reversed the H2O2-induced reduction of superoxide dismutase as 
well as malondialdehyde inhibition. The investigators concluded 
that oat peptides have potent antioxidant properties and that oat 
peptide-rich extract warrants further study and consideration as 
an  antioxidant  functional  food  with  the  capacity  to  prevent  or 
mitigate  cutaneous  aging  when  incorporated  into  skin  care 
products.44

 CONCLUSION

Oatmeal has a surprisingly long tradition in skin care and rare 
recognition  by  the  FDA  as  a  skin  protectant.  Over  the  last 
several  decades,  the  amassed  research  and  clinical  evidence 
appear to bear out the anti-inflammatory and other protective 
activities ascribed to oats in folk medicine.

REFERENCES

1.  Singh R, De S, Belkheir A. Avena sativa (Oat), a potential neutra-
ceutical  and  therapeutic  agent:  An  overview.  Crit  Rev  Food  Sci 
Nutr. 2013;53:126.

2.  Pazyar N, Yaghoobi R, Kazerouni A, et al. Oatmeal in dermatol-
ogy: A brief review. Indian J Dermatol Venereol Leprol. 2012;78:142.
3.  Guo W, Wise ML, Collins FW, et al. Avenanthramides, polyphe-
nols from oats, inhibit IL-1beta-induced NF-kappaB activation in 
endothelial cells. Free Radic Biol Med. 2008;44:415.

4.  Lee-Manion  AM,  Price  RK,  Strain  JJ,  et  al.  In  vitro  antioxidant 
activity and antigenotoxic effects of avenanthramides and related 
compounds. J Agric Food Chem. 2009;57:10619.

5.  Sadiq  Butt  M,  Tahir-Nadeem  M,  Khan  MK,  et  al.  Oat:  Unique 

among the cereals. Eur J Nutr. 2008;47:68.

6.  Foster S. An Illustrated Guide to 101 Medicinal Herbs: Their History, 
Use,  Recommended  Dosages,  and  Cautions.  Loveland,  CO: 
Interweave Press; 1998:146–147.

7.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy.  London: 

Churchill Livingstone; 2000:154.

8.  Reszko AE, Berson D, Lupo MP. Cosmeceuticals: Practical appli-

cations. Dermatol Clin. 2009;27:401.

9.  Pigatto P, Bigardi A, Caputo R, et al. An evaluation of the allergic 
contact dermatitis potential of colloidal grain suspensions. Am J 
Contact Dermat. 1997;8:207.

18.  Sompayrac LM, Ross C. Colloidal oatmeal in atopic dermatitis of 

the young. J Fla Med Assoc. 1959;45:1411.

19.  Baumann L, Woolery-Lloyd H, Friedman A. “Natural” ingredients 

in cosmetic dermatology. J Drugs Dermatol. 2009;8:s5.

20.  Castanedo-Tardan MP, Baumann L. Anti-inflammatory Agents. In 
Baumann  L.,  Saghari  S.,  Weisberg  E.  eds.  Cosmetic  Dermatology: 
Principles  and  Practice.  2nd  ed.  New  York:  McGraw-Hill;  
2009:320–1.

21.  Grais ML. Role of colloidal oatmeal in dermatologic treatment of 

the aged. AMA Arch Derm Syphilol. 1953;68:402.

22.  Alexandrescu  DT,  Vaillant  JG,  Dasanu  CA.  Effect  of  treatment 
with a colloidal oatmeal lotion on the acneform eruption induced 
by epidermal growth factor receptor and multiple tyrosine-kinase 
inhibitors. Clin Exp Dermatol. 2007;32:71.

23.  Chen  CY,  Milbury  PE,  Kwak  HK,  et  al.  Avenanthramides  and 
phenolic acids from oats are bioavailable and act synergistically 
with vitamin C to enhance hamster and human LDL resistance to 
oxidation. J Nutr. 2004;134:1459.

24.  Tsao  R,  Akhtar  MH.  Neutraceuticals  and  functional  foods:  I. 
Current trend in phytochemical antioxidant research. J Food Agric 
Environ. 2005;3:10.

25.  Dimberg  LH,  Theander  O,  Lingnert  H.  Avenanthramides  –  A 
group of phenolic antioxidants in oats. Cereal Chem. 1993;70:637.
26.  Saeed  SA,  Butt  NM,  McDonald-Gibson  WJ,  et  al.  Inhibitors  of 
prostaglandin biosynthesis in extracts of oat (Avena sativa) seeds. 
Biochem Soc Trans. 1981;9:444.

27.  Cerio  R,  Dohil  M,  Jeanine  D,  et  al.  Mechanism  of  action  and 
clinical  benefits  of  colloidal  oatmeal  for  dermatologic  practice.  
J Drugs Dermatol. 2010;9:1116.

28.  Wallo W, Nebus J, Nystrand G. Agents with adjunctive potential 
in atopic dermatitis. J Am Acad Dermatol. 2007;56(Suppl 2):AB70.
tract P712.

29.  U.S.  Food  and  Drug  Administration.  Title  21:  Food  and  Drugs, 
Chapter 1: Food and Drug Administration Department of Health 
and Humans Services, Subchapter D: Drugs for human use, Part 
347:  Skin  protectant  drug  products  for  over-the-counter  human 
use. U.S. Dept of Health and Human Services, FDA;21 CFR347. 
April 1, 2007.

30.  Smith GC. The treatment of various dermatoses associated with 

dry skin. JSC Med Assoc. 1958;54:282.

31.  Dick LA. Colloidal emollient baths in geriatric dermatoses. Skin 

(Los Angeles). 1962;1:89.

32.  Rothe MJ, Bernstein ML, Grant-Kels JM. Life-threatening erythro-
derma:  Diagnosing  and  treating  the  “red  man.”  Clin  Dermatol. 
2005;23:206.

33.  Wu  J.  Treatment  of  rosacea  with  herbal  ingredients.  J  Drugs 

Dermatol. 2006;5:29.

34.  Fowler JF, Nebus J, Wallo W, et al. Colloidal oatmeal formulations 
as  adjunct  treatments  in  atopic  dermatitis.  J  Drugs  Dermatol. 
2012;11:804.

35.  Grimalt R, Mengeaud V, Cambazard F, et al. The steroid-sparing 
effect of an emollient therapy in infants with atopic dermatitis: A 
randomized controlled study. Dermatology. 2007;214:61.

36.  Boussault P, Léauté-Labrèze C, Saubusse E, et al. Oat sensitization 
in  children  with  atopic  dermatitis:  Prevalence,  risks  and  associ-
ated factors. Allergy. 2007;62:1251.

37.  Food and Drug Administration HHS. Skin protectant drug prod-
ucts for over-the-counter human use; final monograph. Final rule. 
Fed Regist. 2003 Jun 4;68(107):33362–81.

38.  De  Paz  Arranz  S,  Pérez  Montero  A,  Remón  LZ,  et  al.  Allergic 

contact urticaria to oatmeal. Allergy. 2002;57:1215.

39.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

10.  Aburjai  T,  Natsheh  FM.  Plants  used  in  cosmetics.  Phytother  Res. 

Medicine. Rochester, VT: Healing Arts Press; 2003:532.

2003;17:987.

11.  Hart J, Polla C, Hull JC. Oat fractions. Cosmet Toiletries. 1998;113:45.
12.  Wickens GE. Economic Botany: Principles and Practice. Norwell, MA: 

Kluwer Academic Publishers; 2001:168.

13.  Sur  R, Nigam A, Grote D, et al. Avenanthramides, polyphenols 
from  oats,  exhibit  anti-inflammatory  and  anti-itch  activity.  Arch 
Dermatol Res. 2008;300:569.

14.  Kurtz  ES,  Wallo  W.  Colloidal  oatmeal:  History,  chemistry  and 

clinical properties. J Drug Dermatol. 2007;6:167.

15.  Baumann  LS.  Less-known  botanical  cosmeceuticals.  Dermatol 

Ther. 2007;20:330.

16.  Meydani M. Potential health benefits of avenanthramides of oats. 

Nutr Rev. 2009;67:731.

17.  Dick LA. Colloidal emollient baths in pediatric dermatoses. Arch 

Pediatr. 1958;75:506.

40.  Criquet  M,  Roure  R,  Dayan  L,  et  al.  Safety  and  efficacy  of  per-
sonal  care  products  containing  colloidal  oatmeal.  Clin  Cosmet 
Investig Dermatol. 2012;5:183.

41.  Matheson JD, Clayton J, Muller MJ. The reduction of itch during 

burn wound healing. J Burn Care Rehabil. 2001;22:76.

42.  Vié  K,  Cours-Darne  S,  Vienne  MP,  et  al.  Modulating  effects  of 
oatmeal extracts in the sodium lauryl sulfate skin irritancy model. 
Skin Pharmacol Appl Skin Physiol. 2002;15:120.

43.  Boisnic S, Branchet-Gumila MC, Coutanceau C. Inhibitory effect 
of  oatmeal  extract  oligomer  on  vasoactive  intestinal  peptide-
induced inflammation in surviving human skin. Int J Tissue React. 
2003;25:41.

44.  Feng B, Ma LJ, Yao JJ, et al. Protective effect of oat bran extracts on 
human  dermal  fibroblast  injury  induced  by  hydrogen  peroxide. 
J Zhejiang Univ Sci B. 2013;14:97.

 
C H A P T E R   6 9

Turmeric

C H A P T E R  69  ■   T U R M E R I C  

257

Activities:

Antioxidant, anti-inflammatory, anticarcinogenic, antiviral, 
antibacterial,  antifungal  immunomodulatory,  wound 
healing1,2

Important Chemical Components:

Curcuminoids (curcumin, the key constituent of which 
is  diferuloylmethane,  demethoxycurcumin,  bisdemeth-
oxycurcumin,  cyclocurcumin);  volatile  oils  (tumerone, 
atlantone,  and  zingiberone);  heptanoids;  turmerin, 
sugars, proteins, and resins3–8

Origin Classification:

This ingredient is natural. Organic forms exist. Curcumin 
can be isolated from Curcuma longa or synthesized in the 
laboratory.9

Personal Care Category:

Anti-inflammatory, anticancer

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW, DRPW, DSNW, DSPW, ORNW, ORPW, OSNW, 
and OSPW

 SOURCE

Native to the Indian subcontinent and Southeast Asia, turmeric 
(Curcuma longa), a member of the Zingiberaceae (ginger) family, 
is best known as a spice and coloring agent used primarily in 
Asian  cuisine,  particularly  curry,  and  in  prepared  mustard, 
margarine,  as  well  as  carbonated  and  other  beverages.10 
Turmeric is one of the best researched spices for pharmacologic 
application.11  It  is  used  as  a  preservative,  aromatic,  cosmetic 
ingredient,  and  in  some  traditional  Indian  communities  as  a 
topical burn treatment.12 In fact, turmeric has long been used as 
an  anti-inflammatory  agent  in  various  traditional  medical 
systems (Table 69-1). Specifically, turmeric has been deployed 
in  Ayurvedic  medicine  to  treat  sprains  and  edema  due  to 
injury.11,13-15  It  has  also  been  used  topically,  orally,  and  by 
inhalation for anti-inflammatory action.16 The rhizome of the 
curcuma plant is the portion used for medicinal purposes.14

In Samoa, the powdered rhizome of C. longa is sprinkled on 
newborn  infants  to  mend  the  belly  button  after  severing  the 
umbilical cord; to prevent diaper rash; to maintain skin softness 
and resilience; and to treat, as a paste or poultice, skin ulcers and 
eruptions.14  The  wide  array  of  modern  dermatologic  uses  of 
turmeric  and  its  principal  active  ingredient  curcumin  also 
includes  prevention  or  treatment  of  psoriasis,  acne,  wounds, 
burns,  eczema,  photodamage,  and  photoaging.17  The  turmeric 
rhizome  is  used  topically  in  Thailand  to  treat  wounds,  insect 
bites, ringworm, and bleeding.11,18 It is also a popular medicinal 
plant in Nepal, and one of the top two medicinal plants for use in 

TABLE 69-1
Pros and Cons of Turmeric

Pros
Long history of traditional medical use

One of the most thoroughly researched of 

the spices

Potent anti-inflammatory and antioxidant 
(at neutral or low – acidic – pH) activity
Compelling anticancer evidence from in vitro 

and in vivo animal studies

Cons
Not easy to formulate in topical products 
without transferring yellowish pigment 
and strong smell
Poor oral bioavailability

Poor solubility

Poor stability at alkaline, or high, pH

Controlled clinical trials are needed to 

establish the topical efficacy of turmeric 
or curcumin in rosacea and photoaging

skin ailments and cosmetics in the northeastern Indian state of 
Assam.19,20  Notably,  curcumin  is  incorporated  into  cosmetics, 
particularly for those used in Hindu rituals and ceremonies.10,21

 HISTORY

The turmeric rhizome has been used for medicinal purposes for 
thousands of years, with documented uses dating to 600 BCE 
in Assyria, where it was used in herbal therapy, and to ancient 
Rome,  where  the  Greece-born  physician  Dioscorides  
(circa 40–90 CE) was said to have cited it.22 Turmeric is believed 
to  have  been  used  for  therapeutic  purposes  in  Ayurvedic 
medicine as early as 1900 BCE and its use in traditional Chinese 
medicine dates back to ancient times.2 The traditional uses in 
these  medical  systems,  as  well  as  Unani  medicine,  included 
treatment  for  inflammation,  skin  wounds,  acne,  skin  rashes, 
warts,  and  liver  disorders.23,24  Turmeric  was  introduced  into 
Europe during the 14th century.25

In  1815,  Vogel  and  Pelletier  were  the  first  in  modern 
history  to  report  extracting  a  “yellow  coloring-agent”  from  
C. longa, which they named “curcumin.”10,26,27 In 1842, Vogel 
became the first to isolate curcumin, but he did not document 
its  formula.3,26  Although  several  scientists,  including  Daube 
and  Ivanov,  reported  on  possible  structures  in  the  ensuing 
decades, Lampe and Milobedzka, in 1910, became the first to 
identify  the  structure  of  curcumin  (C21H20O6)  as  diferuloyl-
methane.3,26,28  Three  years  later,  they  became  the  first  to 
synthesize  the  compound.26  The  first  article  to  address  the 
medical use of curcumin, specifically considering the effects 
on patients with biliary diseases, was published in The Lancet 
in  1937.10,27  In  a  Nature  article  in  1949,  Schraufstatter  and 
Bernt  identified  antibacterial  activity  against  Mycobacterium 
tuberculosis,  Salmonella  paratyphi,  Staphylococcus  aureus,  and 
Tricophyton  gypseum  displayed  by  curcumin.26,29  Over  the 
ensuing 20 years, only five papers were published, but during 
the  1970s,  antidiabetic,  antioxidant,  and  anti-inflammatory 
properties  of  the  polyphenolic  compound  were  observed, 

 
258 

COsM E C E U T I C A Ls   A N D   C OsM E T I C   INgR E D I E N T s

and  anticancer  activity  was  displayed  by  curcumin  and 
documented based on in vitro and in vivo models in the 1980s 
by  Kuttan  and  colleagues.26,30  In  1995,  Singh  and  Aggarwal 
were the first to report that curcumin evinced anti-inflammatory 
activity  by  inhibiting  nuclear  factor  (NF)-κB.26,31  Over  
6,400  research  articles  had  been  published  on  curcumin  and 
included in the National Institutes of Health PubMed database 
as  of  early  2014,  dating  back  to  Schraufstatter  and  Bernt’s 
1949 article, with more than 6,000 published since 1980.

 CHEMISTRY

Turmeric  tubers  contain  curcuminoids:  the  most  abundant  
(~77 percent) curcumin I [diferuloylmethane or bis(4-hydroxy-
3-methoxyphenyl)-1,6-heptadiene-3,5-dione],  curcumin  II,  or 
demethoxycurcumin  (6–17  percent),  curcumin  III,  or  bisde- 
methoxycurcumin  (0.3–3  percent),  and  curcumin  IV,  or 
cyclocurcumin (typically less abundant than curcumin III).5,6,32 
The key biologically active constituent of turmeric, curcumin I, 
or  simply  curcumin,  is  a  small-molecular-weight  naturally- 
occurring polyphenol found in the root of C. longa that confers 
a distinctive flavor and yellow color to food.14,33–36 Curcumin  
is  the  lipid-soluble  component  of  turmeric;  turmerin  is  its 
water-soluble  component.8,37  Curcumin  displays  more  acute 
anti-inflammatory  effects  when  compared  to  the  volatile  oil 
fraction  of  turmeric.38  Indeed,  it  has  displayed  great  potency 
against  acute  inflammation,13  and  is  associated  with  few 
adverse effects.39 It is an exceedingly pleiotropic molecule with 
multiple disease targets related to the skin.40

Evidence  compiled  over  the  last  several  decades  reveals 
that  curcumin  exhibits  a  broad  array  of  biologic  activities, 
such  as  anti-inflammatory,  anticarcinogenic,  antioxidant, 
antimicrobial,  and  wound  healing.15,41–44  These  effects  are 
mediated  through  the  regulation  of  numerous  signaling 
pathways, transcription factors, growth factors, inflammatory 
cytokines,  protein  kinases,  adhesion  molecules,  apoptotic 
genes,  angiogenesis  regulators,  and  enzymes,  such  as 
cyclooxygenase (COX) and glutathione S-transferases.45–47 But 
inhibition of NF-κB is thought to be the linchpin of the anti-
inflammatory  and  antioxidant  activity  of  the  curcuminoid.24 
Curcumin is also known, at various levels, to suppress other 
signaling  pathways  such  as  transforming  growth  factor 
(TGF)-β and the mitogen-activated protein kinase pathway, 
in particular.24,47 Further, it affects angiogenesis and cell–cell 
adhesion,  and  exerts  immunomodulatory  activity.47  This 
broad range of biologic activity forms the basis for additional 
study of the potential applications of curcumin to prevent or 
treat photoaging and photocarcinogenesis.48

The  anticarcinogenic  characteristics  of  curcumin  are 
particularly  well  documented  as  are  its  demonstrated  antioxi-
dant  and  lipid  peroxidation  properties.8,21,44,49–52  Antibacterial, 
antiparasitic,  and  anti-HIV  activities  have  also  reportedly  been 
manifested by turmeric or curcumin.53 In 1987, an ethanol extract 
of  turmeric  and  an  ointment  with  curcumin  as  its  active 
ingredient demonstrated efficacy in relieving patients of pruritus 
associated  with  external  cancerous  lesions.54  In  addition, 
curcumin  reportedly  has  greater  anti-inflammatory  capacity 
than  ibuprofen.13,55  More  importantly,  it  has  been  shown  to 
protect  against  ultraviolet  (UV)-induced  photodamage  by 
inhibiting  inflammation  and  attenuating  oxidative  stress.48 
Curcumin is also a selective inhibitor of phosphorylase kinase, 
which  fosters  photocarcinogenesis  in  photodamaged  skin  by 
activating NF-κB signaling pathways and suppressing apoptosis 
of photodamaged cells.56,57

 ORAL USES

Turmeric is consumed regularly in the diet, particularly in the 
Indian subcontinent. It is approved in Germany for the treatment 
of  dyspepsia.11  The  systemic  and  topical  use  of  turmeric  for 
medicinal purposes is also officially sanctioned in Thailand.11,18
Curcumin is available in oral supplement form throughout the 
world.10  When  used  orally,  curcumin  inhibits  leukotriene 
formation  as  well  as  platelet  aggregation  and  stabilizes 
neutrophilic  lysosomal  membranes,  thus  inhibiting  inflamma-
tion  at  the  cellular  level.58  Notably,  it  produces  varying  dose-
dependent effects: at low dose curcumin can be a prostaglandin 
inhibitor, while at higher levels it stimulates the adrenal glands 
to  secrete  cortisone.59  Overall,  though,  it  is  known  to  exhibit 
poor systemic bioavailability after oral administration, except in 
the  gastrointestinal  tract,  where  biologically  active  levels  have 
been recorded in animal and human studies.60,61 Low curcumin 
bioavailability to organs such as the skin partially accounts for 
the impetus for investigations into transdermal and other modes 
of delivery (see the Formulation Considerations section below).

In  2013,  Ryan  et  al.  conducted  a  randomized,  double-blind, 
placebo-controlled  clinical  trial  to  evaluate  the  effects  of  oral 
curcumin on radiation dermatitis in 30 adult female breast cancer 
patients. They found that 6 g of daily intake of curcumin during 
radiotherapy mitigated radiation dermatitis.61

 TOPICAL USES

A limited number of cosmetic products contain curcumin at the 
present time as its distinct and pungent aroma and color render it 
especially  challenging  to  formulate  into  a  cosmetically  elegant 
product. More clinical trials are required to assess the influence of 
topical curcumin on human skin. Bioavailability in topical products 
has also been problematic. A recent examination of the inhibitory 
activity of encapsulated curcumin on UV-induced photoaging in 
mice represents the first clinical support for the topical delivery of 
curcumin to minimize the effects of photoaging.62

In 2013, Heng showed that the topical application of curcumin 
gel in the clinical setting yielded rapid healing of burns, nominal 
or no scarring, and also ameliorated various signs of photodamage, 
such  as  hyperpigmentation,  solar  elastosis,  advanced  solar 
lentigines,  actinic  poikiloderma,  and  actinic  keratoses.57 
Curcumin is also thought to have a therapeutic role in eczema 
and scleroderma.63

 SAFETY ISSUES

No adverse effects, drug interactions, or general contraindica-
tions  have  been  reported  in  association  with  the  oral  use  of 
turmeric.11 Allergic reactions are thought to be rare. It has also 
been found to be safe in human trials.16 The United States Food 
and  Drug  Administration,  the  Natural  Health  Products 
Directorate of Canada, and the Expert Joint Committee of the 
Food and Agriculture Organization/World Health Organization 
on  food  additives  have  deemed  turmeric  and  curcumin  food 
products  safe  for  consumption.10,64  Even  at  high  doses, 
curcumin is characterized by a favorable safety profile for oral 
and  cutaneous  use.65  The  German  Commission  E  does  claim 
that  the  use  of  turmeric  is  contraindicated  in  patients  whose 
biliary tract is obstructed.22 Oral curcumin has been shown in 
animal  models  to  inhibit  the  activity  of  some  chemotherapy 
drugs and enhance the activity of others.3 The National Cancer 
Institute in the United States has listed curcumin as one among 

 
approximately 35 plant-based foods [including genistein from 
soybeans,  epigallocatechin  gallate  (ECGC)  from  green  tea, 
resveratrol from grapes, and gingerol from ginger] to have cancer-
preventive  characteristics  (see  Chapter  45,  Soy,  Chapter  47, 
Green Tea, Chapter 50, Resveratrol, and Chapter 59, Ginger).64

 ENVIRONMENTAL IMPACT

As  a  perennial  spice  plant,  C.  longa  is  cultivated  extensively 
throughout  India  and  Southeast  Asia.3  In  fact,  much  of  the 
world’s  turmeric  is  grown  by  India,  which  consumes 
approximately 90 to 95 percent of what is produced, with the 
remainder  exported.10  For  investigations  into  its  potential 
medical applications or incorporation into topical formulations, 
it  is  likely  that  a  significant  majority  of  the  turmeric,  and 
curcumin  in  particular,  can  be  attributed  to  synthesis  in  the 
laboratory. Therefore, the environmental impact of turmeric in 
skin care products is likely not substantial.

 FORMULATION CONSIDERATIONS

Topical  curcumin  is  inexpensive,  nontoxic,  and  safe.12,28,66 
However, given the undesirability of the yellow pigment and 
the  strong  smell  being  transferred  to  the  skin  via  topical 
application,  turmeric  and  curcumin  have  posed  formulation 
challenges,  though  some  authors  believe  new  technologies 
may soon remedy this problem.13 In fact, there are cosmetics 
containing  curcumin  available  throughout  the  world,  particu-
larly  India  and  Japan.67  In  addition,  extensive  research  into 
more  cosmetically  elegant  and  biologically  active  delivery 
systems to achieve skin permeability is well underway. These 
options also address the instability of curcumin when exposed 
to light or heat, and loss of activity in storage.68

The  myriad  technologies,  which  merit  continuing  attention, 
include  various  forms  of  nanoencapsulation:  β-cyclodextrin-
curcumin  nanoparticle  complex  in  a  hydrophilic  matrix  gel  
to  foster  skin  permeability  and  enhanced  bioavailability60; 
curcumin-loaded  monoolein  aqueous  dispersions  (for  extended 
curcumin activity) and lecithin organogels for conditions requiring 
rapid  curcumin  activity,  as  percutaneous  delivery  systems69,70; 
curcumin-loaded  micelles  and  thermosensitive  hydrogels71; 
curcumin/xanthan:galactomannan hydrogels72; curcumin-loaded 
oleic  acid-based  polymeric  bandages73;  curcumin-loaded 
proniosomal  gel  bases74;  C.  longa-loaded  vesicular  systems 
(niosomes,  liposomes,  ethosomes,  and  transferomes)  incorpo-
rated in cream formulations or carbopol gel or other curcuminoid 
niosomes75–78;  turmeric  oil  in  chitosan-alginate  nanocapsules79; 
and curcumin in eucalyptol microemulsions.80

In 2012, Basnet et al. also showed that liposomal delivery of 
curcumin appears to have potential as an appropriate formula-
tion for treating vaginal inflammation.81 During the same year, 
Liu et al. found that curcumin-loaded myristic acid microemul-
sions  were  capable  of  inhibiting  the  growth  of  Staphylococcus 
epidermidis on neonate pig skin. They suggested that this combi-
nation of curcumin and myristic acid in a microemulsion carrier 
has potential as an option for treating conditions associated with 
S. epidermidis as well as acne.82

 USAGE CONSIDERATIONS

Curcumin, in the form of a mouthwash used twice daily, was 
found in a small 2013 study of seven pediatric and young adult 
oncology  patients  to  be  safe,  well  tolerated,  and  effective  in 

C H A P T E R  69  ■   T U R M E R I C  

259

lowering  pain  scale  scores  associated  with  oral  mucositis.83 
Over-the-counter products such as Johnson & Johnson’s Band-
Aids™ include turmeric for the Indian market.25

 SIGNIFICANT BACKGROUND

In vitro studies have demonstrated that curcumin dose-dependently 
increases tumor cell apoptosis, slows cell growth, and lowers 
the  number  of  clonogenic  cells.12  Topical  curcumin  has  also 
been identified as one of the only safe therapies for radiation 
exposure and appears to be one of the only chemicals known 
to  protect  skin  after  exposure  to  radiation  or  during 
radiotherapy.12  Also,  curcumin  is  known,  along  with  other 
curcuminoids, to inhibit fibrosis and has recently been shown 
to  have  potential  as  a  chemopreventive  agent  to  prevent  or 
treat keloids.84

Antifungal  activity  was  displayed  by  curcumin  in  a  2013 
murine  model  study  of  oral  candidiasis.  Dovigo  et  al.  showed 
that the phenolic substance worked as a photosensitizer in the 
photoinactivation  of  Candida  albicans.  They  found  that 
curcumin-mediated  photodynamic  therapy  exerted  antifungal 
effects without damaging the murine host tissue.85

In  2012,  Takahashi  et  al.  set  out  to  identify  plants  with 
bioactive  potential  for  dermatologic  purposes  by  screening 
methanol extracts of 47 medical and edible plants cultivated in 
Okinawa,  Japan.  In  testing  for  proliferative  effects  on  skin 
fibroblast cells in vitro, the investigators reported that C. longa led 
to higher fibroblast proliferation than the control and augmented 
collagen  production.  They  noted  that,  as  compared  to  the 
positive  control  (ascorbic  acid),  expression  of  the  collagen 
synthesis marker TGF-β1 was higher after C. longa treatment.86 
The  ability  of  C.  longa  to  increase  fibroblast  proliferation  and 
increase collagen production could have implications for the use 
of curcumin in wound healing and photoprotection.

Curcumin has also been reported to hinder melanogenesis in 
B16 melanoma cells and been shown in vitro to inhibit melano-
genesis  in  human  melanocytes  by  activating  the  Akt/glycogen 
synthase kinase 3 (GSK 3β), extracellular signal-regulated kinase 
(ERK) or p38 MAPK signaling pathways. While more research is 
needed according to the authors Tu et al., their findings suggest 
the potential application of curcumin as a whitening agent for 
hyperpigmentation.87

Curcumin and Wound Healing
Wound closure was shown by Sidhu et al. to occur significantly 
faster  in  curcumin-treated  normal  and  genetically  diabetic 
animals as compared to controls. The improvement of neovas-
cularization and reepithelialization, the increase of TGF-β1 and 
fibronectin  expression  and  synthesis,  and  the  reduction  of 
apoptosis  were  cited  as  the  mechanisms  by  which  curcumin 
contributed  to  this  enhanced  healing  effect.88,89  Collagen 
deposition and fibroblast and vascular density have also been 
bolstered by curcumin treatment, enhancing normal as well as 
impaired wound healing. The observed proangiogenic effect of 
curcumin in wound healing has been attributed to the induction 
of  TGF-β,  which  in  turn  spurs  angiogenesis  and  the 
accumulation of extracellular matrix.90

In a study using Swiss albino mice, researchers assessed the 
effects on wound contraction of pretreatment with doses of 25, 
50,  100,  150,  or  200  mg/kg  body  weight  of  curcumin  before 
exposure  to  6  Gy  whole-body  γ-radiation.  While  irradiation 
resulted in delayed wound healing, curcumin pretreatment was 
associated with a dose-dependent increase in wound contraction 

 
260 

COsM E C E U T I C A Ls   A N D   C OsM E T I C   INgR E D I E N T s

in comparison to control, with optimal contraction noted with 
the  100  mg/kg  dose.  The  authors  concluded  that  curcumin 
shows great potential as a therapeutic agent for wound repair, 
particularly in reducing healing delays caused by radiation and 
involving combined injuries.36

A  2005  study  by  Kundu  et  al.  compared  the  wound-
healing capacity of fresh turmeric paste to that of honey and 
a  control  in  full-thickness  circular  wounds  in  18  rabbits  
(see Chapter 60, Honey/Propolis/Royal Jelly). The investiga-
tors  found  that  compared  to  the  control  group,  wound 
healing  in  animals  in  the  turmeric  and  honey  treatment 
groups  was  considerably  more  rapid,  with  statistically 
significant differences in healing time.91

C. longa was included in another polyherbal formulation that 
Gupta et al. investigated in 2008 for its effects in treating diabetic 
wound healing in rats. The preparation combined the aqueous 
lyophilized leaf extracts of Hippophae rhamnoides and Aloe vera 
along with the ethanol rhizome extract of C. longa (optimized 
ratio  of  1:7:1)  (see  Chapter  65,  Aloe  Vera).  The  investigators 
found  that  the  topically  applied  polyherbal  formulation 
augmented  cellular  proliferation  and  collagen  production  at  the 
wound  site  in  normal  rats  as  compared  to  positive  controls. 
Wound contraction was accelerated in normal and streptozotocin-
induced  diabetic  rats,  and  the  formulation  was  found  to  have 
fostered angiogenesis.92

In 2009, Bhagavathula et al. examined the effects of a combi-
nation of topical curcumin and ginger extracts on wound healing 
in corticosteroid-impaired hairless rats (see Chapter 59, Ginger). 
For 21 days, the researchers treated animals with a combination 
of  10  percent  curcumin  and  3  percent  ginger  extract  or  each 
herbal  agent  alone,  followed  by  a  15-day  period  of  topical 
application of the corticosteroid Temovate. Superficial abrasions 
were  induced  in  the  treated  skin  after  the  treatment  period. 
Healing was more rapid in the skin of control animals compared 
to animals treated only with Temovate, and in all of the groups 
pretreated  with  botanicals  compared  to  animals  treated  with 
Temovate  and  vehicle  alone.  Skin  samples  obtained  at  wound 
closure revealed that collagen synthesis was higher and matrix 
metalloproteinase (MMP)-9 synthesis lower in rats treated with 
the  herbal  combination  as  opposed  to  those  treated  with 
Temovate and vehicle.93

In  2011,  López-Jornet  et  al.  conducted  a  prospective, 
randomized  study  with  mice  to  evaluate  the  effects  of  topical 
curcumin on skin wounds induced by CO2 laser. Three groups of 
30 mice, each given three wounds, were divided into a control 
group  that  received  no  treatment,  a  vehicle  group  (which 
received  5  mg/day  per  wound  of  vehicle),  and  the  treatment 
group  that  received  5  mg/day  per  wound  of  topical  curcumin. 
After seven days, 73.33 percent of the curcumin-treated wounds 
displayed complete reepithelialization whereas 41.67 percent in 
the vehicle group and 37.50 percent in the control group showed 
such  improvement.  All  wounds  in  the  curcumin  group  were 
healed after 14 days.94

The  topical  application  of  curcumin  was  shown  by  Kulac  
et  al.  to  be  effective  in  accelerating  wound  healing  of  burns  in 
Wistar  albino  rats,  with  enhanced  collagen  deposition, 
angiogenesis, granulation tissue formation, and epithelialization.95
C.  longa  is  one  of  four  herbs  combined  in  a  Thai  herbal 
phytopharmaceutical agent that Chusri et al. found in 2013 to 
exert  strong  antibacterial  activities  in  vitro  against  methicillin-
resistant  Staphylococcus  aureus  (MRSA)  isolates  as  well  as  anti-
inflammatory and antioxidant activities and low toxicity on Vero 
cells.  They  concluded  that  given  such  potent  properties,  this 
formulation is suitable for use in treating wounds.96

Also that year, Chereddy et al. demonstrated using a mouse 
excisional  wound  model  that  a  combination  of  poly(lactic- 
co-glycolic)  acid  (PLGA)  and  curcumin  nanoparticles  exhibited 
twofold  greater  wound-healing  activity  compared  to  PLGA  or 
curcumin alone.97

Psoriasis
The  anti-inflammatory  potency  of  curcumin  is  considered  a 
potential  source  for  psoriasis  therapy.  A  small  study  with  
12 patients taking curcumin orally showed a low response rate.98,99 
Nevertheless, curcumin has displayed effectiveness in treating 
psoriasis.28,66,100

An in vitro study in 2011 by Saelee et al., who had previously 
shown that three Thai medicinal herbs, including C. longa, had 
antipsoriatic  activity,  considered  the  psoriasis-inhibiting 
potential of these herbs through the regulation of NF-κB signaling 
biomarkers. Specifically, they analyzed the influence of C. longa, 
Alpinia galangal, and Annona squamosa on 10 genes of the NF-κB 
signaling network in HaCaT cells. The investigators found that 
all of the herbs tested appear to have the capacity to suppress 
psoriasis  by  controlling  the  expression  of  NF-κB  signaling 
biomarkers, with C. longa found to significantly reduce CSF-1, 
interleukin (IL)-8, NF-κB1, NF-κB2, and RelA expression.101

In 2012, Sun et al. found in  vitro that curcumin reversed the 
antiapoptotic  action  of  tumor  necrosis  factor  (TNF)-α,  thus 
allowing for the induction of apoptosis in HaCaT cells treated 
with TNF-α. Their findings, they suggested, provide encourage-
ment  for  the  use  of  curcumin  in  psoriasis  treatment.56  The 
following year, Sun et al. used a mouse model to determine that 
the  topical  application  of  curcumin  suppressed  imiquimod-
induced  psoriasis-like  inflammation.  They  deduced  that  the 
polyphenol  was  able  to  alter  the  IL-23/IL-17A  cytokine  axis, 
which serves a crucial function in psoriasis etiology, by suppress-
ing IL-1β/IL-6 and then obliquely downregulating the synthesis 
of IL-17A/IL-22. These effects, which were similar to those of 
clobetasol, reinforced the authors’ belief that curcumin will have 
a role to play in the psoriasis armamentarium.102

Antioxidant and Anti-inflammatory  
Activities of Curcumin
Curcumin is a potent scavenger of various reactive oxygen species 
(ROS),  including  superoxide  anion  radicals,  hydroxyl  radicals, 
and nitrogen dioxide radicals at neutral and acidic pH levels.47,54 It 
is  thought  to  exhibit  10-fold  the  potency  of  vitamin  E 
as  an  antioxidant  [see  Chapter  56,  Tocopherol  (Vitamin  E)].28 
The  turmeric  constituent  has  manifested  particularly  high 
reactivity toward peroxyl radicals.103 In mouse models, curcumin 
has  been  shown  to  impart  antioxidant  and  anti-inflammatory 
activity, indicating that curcumin has a beneficial effect against 
chemo-  and  photocarcinogenesis.  More  research  is  needed  to 
ascertain whether topical applications or oral intake of curcumin 
can prevent or inhibit skin carcinogenesis in humans.51,104,105

Several  studies  have  shown  that  curcumin  displays  broad 
inhibitory action against phospholipase, lipoxygenase, COX-2, 
leukotrienes,  thromboxane,  prostaglandins,  nitric  oxide, 
collagenase, elastase, hyaluronidase, monocyte chemoattractant 
protein (MCP)-1, interferon-inducible protein, TNF-α, and IL-12.16

A 2001 study on wound healing revealed that the antioxidant 
effects of curcumin potently inhibited hydrogen peroxide-induced 
damage in cultured human keratinocytes and fibroblasts.44

The  anti-inflammatory  potency  of  curcumin  was  apparent  in 
the results of a 2012 randomized, double-blind trial among 96 male 

 
Iranian  veterans  with  chronic  sulphur  mustard-induced  pruritic 
skin  lesions.  Panahi  et  al.  found  that  curcumin  supplementation 
attenuated  inflammation  and  pruritus  in  these  patients,  with 
significant increases in serum IL-8 and high-sensitivity C-reactive 
protein, and decreases in calcitonin gene-related peptide; substan-
tial improvements in quality of life were also reported.106

In 2013, Thongrakard et al. examined the protective effects on 
human keratinocytes of extracts of 15 Thai herb species against 
UVB-induced DNA damage and cytotoxicity. Analysis revealed 
that the highest antioxidant activity was exhibited by the dichlo-
romethane  extract  of  turmeric.  Further,  the  ethanol  extract  of 
turmeric  and  the  dichloromethane  extract  of  ginger  demon-
strated  the  maximum  UV  absorptions  and  stimulated  the 
production of the antioxidant protein thioredoxin 1, as well as 
the capacity to protect human keratinocytes from the deleterious 
effects of UV exposure. The investigators concluded that their 
findings  suggest  the  viability  of  incorporating  turmeric  and 
ginger extracts into anti-UV cosmetic formulations.107

Curcumin, Skin Cancer, and Photoaging
While  the  anti-inflammatory  activity  of  turmeric  and,  more 
recently,  curcumin  has  been  the  focus  of  most  of  its  medical 
applications  through  the  millennia,  the  preponderance  of 
modern research on curcumin seems to pertain to its anticarci-
nogenic capacity. In 1988, Huang et al. evaluated the effects of 
topically applied curcumin as well as caffeic, chlorogenic, and 
ferulic  acids  on  12-O-tetradecanoylphorbol-13-acetate  (TPA)-
induced  epidermal  ornithine  decarboxylase  (ODC)  activity, 
epidermal DNA synthesis, and skin tumor promotion in female 
CD-1 mice. Results showed that ODC activity was inhibited by 
42 percent in the case of caffeic acid (91 percent by curcumin,  
46 percent by ferulic acid, and 25 percent by chlorogenic acid). 
Curcumin was more successful than the hydroxycinnamic acids in 
suppressing TPA-promoted DNA synthesis, and more effectively 
inhibited  the  number  of  TPA-induced  tumors  per  mouse  after 
twice weekly topical application with TPA after previous initia-
tion  with  7,12-dimethylbenz[a]anthracene  (DMBA)  (98  percent 
inhibition by curcumin, 60 percent by chlorogenic acid, 35 percent 
by ferulic acid, and 28 percent by caffeic acid).51

In various animal models, topical application of curcumin has 
been shown to inhibit initiation and promotion of tumorigene-
sis. Specifically, curcumin has been shown to block the growth in 
a broad range of tumors initiated by benzo[a]pyrene (B[a]P) and 
in  TPA-induced  or  TPA-promoted  skin  tumors  in  mice.34,35 
Topical application of curcumin was shown in the early 1990s to 
exhibit  antimutagenic  and  anticarcinogenic  properties,  specifi-
cally displaying potent inhibitory effects on TPA-induced tumor 
promotion  and  DNA  synthesis  as  well  as  TPA-induced  ODC 
activity  and  inflammation  in  mouse  skin,51,104,108  reversing  the 
UVA-enhancing effects of ODC induction.67 The phytochemical 
isolate  from  turmeric  has  also  exhibited  significant  inhibitory 
activity against arachidonic acid-induced inflammation in vivo in 
mouse skin and edema of mouse ears, and epidermal lipoxyge-
nase and COX in vitro.34,50,104

In addition, very low doses of topically applied curcumin have 
been found to mediate TPA-induced oxidation of DNA bases in 
the epidermis and tumor promotion in the skin.109 Pretreatment 
with curcumin has exhibited the same inhibitory effects on TPA-
mediated dermatitis.67

An  evaluation  of  four  nutraceuticals  for  their  comparative 
effectiveness  against  DMBA-initiated  and  croton  oil-promoted 
skin  tumors  showed  that  the  topical  application  of  turmeric 
rhizomes  one  hour  before  croton  oil  exposure  resulted  in 

C H A P T E R  69  ■   T U R M E R I C  

261

decreases in skin tumor incidence and number of skin tumors, 
and later onset of skin tumors (30 percent skin tumor incidence, 
87.2 percent decrease in skin tumors, and a five-week delay in 
skin  tumor  formation)  compared  with  the  positive  control.110 
Previously,  a  dose-  and  time-dependent  anticarcinogenic  effect 
of  dietary  turmeric  had  been  demonstrated  on  B[a]P-induced 
forestomach  neoplasia  and  DMBA-induced  skin  tumorigenesis 
in female Swiss mice.111

Curcumin  and  its  derivatives  have  been  shown  in  animal 
models  to  inhibit  the  progression  of  chemically-induced  colon 
and skin cancers. A study of the capacity of curcumin to inhibit 
the proliferation of primary endothelial cells in the presence and 
absence  of  basic  fibroblast  growth  factor  (bFGF),  and  the 
proliferation  of  an  immortalized  endothelial  cell  line  revealed 
that curcumin imparts direct antiangiogenic activity in vitro and 
in vivo, which the researchers believe may account for its cancer-
retarding effects in diverse organs.33

Other  promising  findings  related  to  skin  cancer  include  the 
demonstrated  potency  of  curcumin  to  potently  inhibit  the 
glutathione  S-transferase  activity  towards  1-chloro-2, 
4-dinitrobenzene in intact human IGR-39 melanoma cells and its 
capacity to induce apoptosis in human basal cell carcinoma cells 
in  a  dose-  and  time-dependent  manner.112,113  The  molecular 
mechanisms  of  action  underlying  its  chemopreventive  effects 
remain undetermined,114 but in recent research using female ICR 
mice, investigators found that the topical application of curcumin 
was  associated  with  the  suppression  of  COX-2  expression  by 
inhibiting  ERK  activity  and  NF-κB  activation.  The  researchers 
believe this may account for the molecular mechanisms that would 
explain the antitumorigenic effects of curcumin in mouse skin.114

In numerous tumor model systems, including skin neoplastic 
models,  curcumin  has  demonstrated  the  capacity  to  inhibit 
carcinogenesis.50,111,115 Although its mechanism of action has not 
been  clearly  elucidated,  curcumin  is  believed  to  inhibit  cancer 
initiation, promotion, and progression.116 In addition, curcumin 
is  known  to  suppress  UVA-induced  metallothionein  (MT) 
expression  and  ODC  activity,  and  to  initiate  p53-mediated 
apoptosis, as well as cell membrane-mediated apoptosis through 
Fas receptor induction and caspase-8 activation.113,117 Curcumin 
is  also  known  to  be  a  selective  noncompetitive  inhibitor  of 
phosphorylase  kinase,  which  fosters  photocarcinogenesis  in 
photodamaged skin by activating NF-κB signaling pathways and 
suppressing apoptosis of photodamaged cells.56,57

Recent  data  suggest  a  paradoxical  aspect  to  curcumin 
properties, though. The anticancer activity of the antioxidant has 
actually  promoted  the  generation  of  ROS.  Chen  et  al.  investi-
gated  the  antioxidant  and  anticancer  activity  of  curcumin  in 
human myeloid leukemia (HL-60) cells, finding that the anticancer 
activity  of  curcumin  was  effective  in  a  concentration-  and  
time-dependent  manner  in  lowering  the  proliferation  and 
viability  of  leukemia  cells,  but  its  effect  on  ROS  depended  on 
concentration.  Low  concentrations  of  curcumin  reduced  ROS 
generation, but high concentrations yielded the opposite effect. 
The  researchers  also  found  that  adding  water-soluble  antioxi-
dants  amplified  the  antioxidant  and  anticancer  activity  of  low 
curcumin concentrations.118

In  2009,  Sumiyoshi  and  Kimura  examined  the  effects  of  a 
turmeric  extract  on  a  cascade  of  long-term,  low-dose  UVB 
exposure  in  melanin-possessing  hairless  mice.  The  researchers 
found that the polyphenol administered twice daily prevented 
chronic  UVB  exposure  from  enhancing  skin  thickness  and 
diminishing  skin  elasticity.  Further,  the  extract  thwarted  the 
development  of  wrinkles  and  melanin  and  inhibited  the 
expression of MMP-2.23

 
262 

COsM E C E U T I C A Ls   A N D   C OsM E T I C   INgR E D I E N T s

In a 2010 review article, Heng found that curcumin has shown 
the capacity to inhibit multiple targets on signaling pathways thus 
blunting the effects of UV-induced skin aging and carcinogenesis.48
Chatterjee and Pandey reported in 2011 that the combination 
of  tamoxifen  and  curcumin  shows  potential  as  chemotherapy. 
Specifically,  they  found  in  vitro  that  chemoresistant  melanoma 
sensitized by tamoxifen to low-dose curcumin resulted in apop-
tosis and autophagy of melanoma cells while noncancerous cells 
were unaffected.1

Based  on  experiments  in  2011  indicating  that  curcumin 
suppressed cutaneous squamous cell carcinoma xenograft growth 
in  SCID  mice,  Phillips  et  al.,  in  2013,  performed  a  randomized 
experimental study using SKH-1 mice to test the anticancer effects 
of curcumin.119 For 14 days, animals were pretreated with oral or 
topical  curcumin  or  oral  or  topical  control.  For  24  weeks,  mice 
were exposed to UVB three times weekly or not at all. No signifi-
cant differences were observed between groups receiving oral or 
topical  curcumin.  Control  mice  exhibited  significantly  shorter 
time  to  tumor  onset  and  significantly  greater  tumor  formation 
than  the  curcumin  groups.  The  researchers  concluded  that  cur-
cumin  manifests  appreciable  chemopreventive  potential  against 
skin cancer that warrants investigation in human subjects.120

In the previous year, some of the same researchers found that 
a topical curcumin-based cream was equally effective as dietary 
curcumin in exerting antiproliferative effects in an aggressive skin 
cancer cell line tested in a mouse skin cancer model. The investi-
gators,  noting  that  their  study  was  the  first  to  compare  topical 
and oral curcumin, concluded that the turmeric constituent merits 
use  as  a  chemopreventive  agent  for  cutaneous  squamous  cell 
carcinoma particularly when condemned skin is an issue.121

Tsai et al. also demonstrated in 2012 that topical application of 
curcumin to SKH-1 hairless mice delivered significant protective 
effects  against  UVB-induced  skin  tumor  formation.  Delays  in 
tumor  emergence  and  growth  and  limited  tumor  size  resulted 
from the topical application of curcumin before UVB exposure. 
A  significant  decline  in  UVB-induced  thymine  dimer-positive 
cells  and  apoptotic  sunburn  cells  and  an  increase  in  p53  and 
p21/Cip1-positive epidermal cells, among other  changes, were 
generated  when  curcumin  was  applied  topically  before  and 
immediately after a single dose of UVB radiation (180 mJ/cm2). 
Curcumin was also found to have significantly suppressed levels 
of NF-κB, COX-2, prostaglandin E2, and nitric oxide.122

In 2013, Hwang et al. found in an in vitro investigation using 
human dermal fibroblast cells that curcumin blocked the UVB-
induced  expression  of  MMP-1  and  MMP-3  as  well  as  ROS 
generation,  the  activation  of  NF-κB  and  activator  protein-1,  
and  the  phosphorylation  of  p38  and  c-Jun  N-terminal  kinase. 
The  researchers  concluded  that  the  potent  inhibitory  anti-
inflammatory activity of curcumin suggests its potential utility in 
the prevention and treatment of photoaging.123

 CONCLUSION

The body of research on turmeric and curcumin is increasingly 
impressive,  revealing  great  potential  especially  related  to  its 
anticarcinogenic  and  anti-inflammatory  activity.  Of  course, 
more  clinical  research  is  necessary  to  determine  how  these 
promising findings may be applied effectively in the dermato-
logic armamentarium. The traditional dietary and medical uses 
of  the  C.  longa  rhizome  provide  additional  evidence  that 
researchers are moving in the right direction here. Indeed, there 
appears  to  be  sufficient  data  to  suggest  that  the  potential 
medical  applications  of  turmeric  may  certainly  prompt  some 
people to pay much more attention to their spice racks.

REFERENCES

1.  Chatterjee  SJ,  Pandey  S.  Chemo-resistant  melanoma  sensitized 
by tamoxifen to low dose curcumin treatment through induction 
of apoptosis and autophagy. Cancer Biol Ther. 2011;11:216.

2.  Aggarwal BB, Sundaram C, Malani N, et al. Curcumin: The Indian 

solid gold. Adv Exp Med Biol. 2007;595:1.

3.  Jurenka  JS.  Anti-inflammatory  properties  of  curcumin,  a  major 
constituent of Curcuma longa: A review of preclinical and clinical 
research. Altern Med Rev. 2009;14:141.

4.  Cohly HH, Taylor A, Angel MF, et al. Effect of turmeric, turmerin 
and  curcumin  on  H2O2-induced  renal  epithelial  (LLC-PK1)  cell 
injury. Free Radic Biol Med. 1998;24:49.

5.  Goel  A,  Kunnumakkara  AB,  Aggarwal  BB.  Curcumin  as 
“Curecumin”:  From  kitchen  to  clinic.  Biochem  Pharmacol. 
2008;75:787.

6.  Kiuchi  F,  Goto  Y,  Sugimoto  N,  et  al.  Nematocidal  activity  of 
turmeric:  Synergistic  action  of  curcuminoids.  Chem  Pharm  Bull 
(Tokyo). 1993;41:1640.

7.  Thornfeldt C. Cosmeceuticals containing herbs: Fact, fiction, and 

future. Dermatol Surg. 2005;31:873.

8.  Reddy AC, Lokesh BR. Effect of dietary turmeric (Curcuma longa) 
on  iron-induced  lipid  peroxidation  in  the  rat  liver.  Food  Chem 
Toxicol. 1994;32:279.

9.  Haukvik T, Bruzell E, Kristensen S, et al. Photokilling of bacteria 
by curcumin in selected polyethylene glycol 400 (PEG 400) prepa-
rations. Studies on curcumin and curcuminoids, XLI. Pharmazie. 
2010;65:600.

10.  Strimpakos AS, Sharma RA. Curcumin: Preventive and therapeutic 
properties in laboratory studies and clinical trials. Antioxid Redox 
Signal. 2008;10:511.

11.  Foster S. An Illustrated Guide to 101 Medicinal Herbs: Their History, 
Use,  Recommended  Dosages,  and  Cautions.  Loveland,  CO: 
Interweave Press; 1998:200–1.

12.  Kerr  C.  Curry  ingredient  protects  skin  against  radiation.  Lancet 

Oncol. 2002;3:713.

13.  Rico  MJ.  Rising  drug  costs:  The  impact  on  dermatology.  

Skin Therapy Lett. 2000;5:1.

14.  Aburjai  T,  Natsheh  FM.  Plants  used  in  cosmetics.  Phytother  Res. 

2003;17:987.

15.  Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta 

Med. 1991;57:1.

16.  Chainani-Wu  N.  Safety  and  anti-inflammatory  activity  of 
curcumin:  A  component  of  tumeric  (Curcuma  longa).  J  Altern 
Complement Med. 2003;9:161.

17.  PCT Intl Appl. 1999;WO9942094:76.
18.  Jankasem  M,  Wuthi-Udomlert  M,  Gritsanapan  W. 
Antidermatophytic properties of Ar-turmerone, turmeric oil, and 
Curcuma long preparations. ISRN Dermatol. 2013;2013:250597.
19.  Singh  AG,  Kumar  A,  Tewari  DD.  An  ethnobotanical  survey  of 
medicinal plants used in Terai forest of western Nepal. J Ethnobiol 
Ethnomed. 2012;8:19.

20.  Saikia AP, Ryakala VK, Sharma P, et al. Ethnobotany of medicinal 
plants  used  by  Assamese  people  for  various  skin  ailments  and 
cosmetics. J Ethnopharmacol. 2006;106:149.

21.  Scartezzini P, Speroni E. Review on some plants of Indian traditional 
medicine with antioxidant activity. J Ethnopharmacol. 2000;71:23.
22.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy.  London: 

Churchill Livingstone; 2000:569–78.

23.  Sumiyoshi M, Kimura Y. Effects of a turmeric extract (Curcuma 
longa) on chronic ultraviolet B irradiation-induced skin damage in 
melanin-possessing hairless mice. Phytomedicine. 2009;16:1137.
24.  Thangapazham RL, Sharad S, Maheshwari RK. Skin regenerative 

potentials of curcumin. Biofactors. 2013;39:141.

25.  Hatcher  H,  Planalp  R,  Cho  J,  et  al.  Curcumin:  From  ancient 

medicine to current clinical trials. Cell Mol Life Sci. 2008;65:1631.

26.  Gupta  SC,  Patchva  S,  Koh  W,  et  al.  Discovery  of  curcumin,  a 
component  of  golden  spice,  and  its  miraculous  biological 
activities. Clin Exp Pharmacol Physiol. 2012;39:283.

27.  Aggarwal  BB,  Sung  B.  Pharmacological  basis  for  the  role  of 
curcumin  in  chronic  diseases:  An  age-old  spice  with  modern 
targets. Trends Pharmacol Sci. 2009;30:85.

28.  Shishodia  S,  Sethi  G,  Aggarwal  BB.  Curcumin:  Getting  back  to 

the roots. Ann N Y Acad Sci. 2005;1056:206.

29.  Schraufstatter  E,  Bernt  H.  Antibacterial  action  of  curcumin  and 

related compounds. Nature. 1949;164:456.

30.  Kuttan  R,  Bhanumathy  P,  Nirmala  K,  et  al.  Potential  anticancer 
activity of turmeric (Curcuma longa). Cancer Lett. 1985;29:197.

 
31.  Singh  S,  Aggarwal  BB.  Activation  of  transcription  factor 
NF-kappaB is suppressed by curcumin (diferuloylmethane). J Biol 
Chem. 1995;270:24995.

32.  Ruby  J,  Kuttan  G,  Babu  KD,  et  al.  Anti-tumor  and  antioxidant 

activity of natural curcuminoids. Cancer Lett. 1995;94:79.

33.  Arbiser  JL,  Klauber  N,  Rohan  R,  et  al.  Curcumin  is  an  in  vivo 

inhibitor of angiogenesis. Mol Med. 1998;4;376.

34.  Huang MT, Newmark HL, Frenkel K. Inhibitory effects of curcumin 

on tumorigenesis in mice. J Cell Biochem Suppl. 1997;27:26.

35.  Chendil  D,  Ranga  RS,  Meigooni  D,  et  al.  Curcumin  confers 
radiosensitizing effect in prostate cancer cell line PC-3. Oncogene. 
2004;23:1599.

36.  Jagetia  GC,  Rajanikant  GK.  Effect  of  curcumin  on  radiation-
impaired  healing  of  excisional  wounds  in  mice.  J  Wound  Care. 
2004;13:107.

37.  Cohly HH, Taylor A, Angel MF, et al. Effect of turmeric, turmerin 
and  curcumin  on  H2O2-induced  renal  epithelial  (LLC-PK1)  cell 
injury. Free Radic Biol Med. 1998;24:49.

38.  Arora RB, Kapoor V, Basu N, et al. Anti-inflammatory studies on 

Curcuma longa (turmeric). Indian J Med Res. 1971;59:1289.

39.  Rao  TS,  Basu  N,  Siddiqui  HH.  Anti-inflammatory  activity  of 

curcumin analogues. Indian J Med Res. 1982;75:574.

40.  Basnet  P,  Skalko-Basnet  N.  Curcumin:  An  anti-inflammatory 
molecule  from  a  curry  spice  on  the  path  to  cancer  treatment. 
Molecules. 2011;16:4567.

41.  Maheshwari RK, Singh AK, Gaddipati J, et al. Multiple biological 
activities of curcumin: A short review. Life Sci. 2006;78:2081.
42.  Sharma  OP.  Antioxidant  activity  of  curcumin  and  related 

compounds. Biochem Pharmacol. 1975;25:1811.

43.  Surh  Y.  Molecular  mechanisms  of  chemopreventive  effects  of 
selected  dietary  and  medicinal  phenolic  substances.  Mutat  Res. 
1999;428:305.

44.  Phan TT, See P, Lee ST, et al. Protective effects of curcumin against 
oxidative damage on skin cells in vitro: Its implication for wound 
healing. J Trauma. 2001;51:927.

45.  Aggarwal  BB,  Kumar  A,  Bharti  AC.  Anticancer  potential  of 
curcumin: Preclinical and clinical studies. Anticancer Res. 2003;23:363.
46.  Surh YJ, Han SS, Keum YS, et al. Inhibitory effects of curcumin 
and capsaicin on phorbol ester-induced activation of eukaryotic 
transcription factors, NF-kappaB and AP-1. Biofactors. 2000;12:107.
47.  Sharma RA, Gescher AJ, Steward WP. Curcumin: The story so far. 

Eur J Cancer. 2005;41:1955.

48.  Heng MC. Curcumin targeted signaling pathways: Basis for anti-
photoaging  and  anti-carcinogenic  therapy.  Int  J  Dermatol. 
2010;49:608.

49.  Ozaki  K,  Kawata  Y,  Amano  S,  et  al.  Stimulatory  effect  of 
curcumin  on  osteoclast  apoptosis.  Biochem  Pharmacol. 
2000;59:1577.

50.  Huang MT, Lysz T, Ferraro T, et al. Inhibitory effects of curcumin 
on in vitro lipoxygenase and cylcooxygenase activities in mouse 
epidermis. Cancer Res. 1991;51:813.

51.  Huang MT, Smart RC, Wong CQ, et al. Inhibitory effect of cur-
cumin,  chlorogenic  acid,  caffeic  acid,  and  ferulic  acid  on  tumor 
promotion  in  mouse  skin  by  12-O-tetradecanoylphorbol-13-
acetate. Cancer Res. 1988;48:5941.

52.  Unnikrishnan MK, Rao MN. Inhibition of nitrite induced oxida-
tion of hemoglobin by curcuminoids. Pharmazie. 1995;50:490.
53.  Mazumder A, Raghavan K, Weinstein J, et al. Inhibition of human 
immunodeficiency  virus  type-1  integrase  by  curcumin.  Biochem 
Pharmacol. 1995;49:1165.

54.  Kuttan  R,  Sudheeran  PC,  Josph  CD.  Turmeric  and  curcumin  as 

topical agents in cancer therapy. Tumori. 1987;73:29.

55.  Srimal  RC,  Dhawan  BN.  Pharmacology  of  diferuloyl  methane 
(curcumin),  a  non-steroidal  anti-inflammatory  agent.  J  Pharm 
Pharmacol. 1973;25:447.

56.  Sun J, Han J, Zhao Y, et al. Curcumin induces apoptosis in tumor 
necrosis  factor-alpha-treated  HaCaT  cells.  Int  Immunopharmacol. 
2012;13:170.

57.  Heng MC. Signaling pathways targeted by curcumin in acute and 
chronic  injury:  Burns  and  photo-damaged  skin.  Int  J  Dermatol. 
2013;52:531.

58.  Srivastava  R.  Inhibition  of  neutrophil  response  by  curcumin. 

Agents Actions. 1989;28:298.

59.  Srivastava  R,  Srimal  RC.  Modification  of  certain  inflammation-
induced  biochemical  changes  by  curcumin.  Indian  J  Med  Res. 
1985;81:215.

60.  Rachmawati H, Edityaningrum CA, Mauludin R. Molecular inclu-
sion complex of curcumin-β-cyclodextrin nanoparticle to enhance 

C H A P T E R  69  ■   T U R M E R I C  

263

curcumin  skin  permeability  from  hydrophilic  matrix  gel.  AAPS 
PharmSciTech. 2013;14:1303.

61.  Ryan JL, Heckler CE, Ling M, et al. Curcumin for radiation derma-
titis: A randomized, double-blind, placebo-controlled clinical trial 
of thirty breast cancer patients. Radiat Res. 2013;180:34.

62.  Agrawal R, Kaur IP. Inhibitory effect of encapsulated curcumin on 
ultraviolet-induced  photoaging  in  mice.  Rejuvenation  Res. 
2010;13:397.

63.  Aggarwal  BB,  Harikumar  KB.  Potential  therapeutic  effects  of 
curcumin,  the  anti-inflammatory  agent,  against  neurodegenera-
tive,  cardiovascular,  pulmonary,  metabolic,  autoimmune  and 
neoplastic diseases. Int J Biochem Cell Biol. 2009;41:40.

64.  Saha  S,  Adhikary  A,  Bhattacharyya  P,  et  al.  Death  by  design: 
Where curcumin sensitizes drug-resistant tumours. Anticancer Res. 
2012;32:2567.

65.  Nguyen TA, Friedman AJ. Curcumin: A novel treatment for skin-

related disorders. J Drugs Dermatol. 2013;12:1131.

66.  Shehzad  A,  Rehman  G,  Lee  YS.  Curcumin  in  inflammatory 

diseases. Biofactors. 2013;39:69.

67.  Gupta  S,  Mukhtar  H.  Chemoprevention  of  skin  cancer  through 
natural agents. Skin Pharmacol Appl Skin Physiol. 2001;14:373.
68.  Suwannateep  N,  Wanichwecharungruang  S,  Haag  SF,  et  al. 
Encapsulated curcumin results in prolonged curcumin activity in 
vitro and radical scavenging activity ex vivo on skin after UVB-
irradiation. Eur J Pharm Biopharm. 2012;82:485.

69.  Esposito  E,  Ravani  L,  Mariani  P,  et  al.  Effect  of  nanostructured 
lipid  vehicles  on  percutaneous  absorption  of  curcumin.  Eur  J 
Pharm Biopharm. 2013 Dec 20. [Epub ahead of print]

70.  Puglia C, Cardile V, Panico AM, et al. Evaluation of monooleine 
aqueous  dispersions  as  tools  for  topical  administration  of  cur-
cumin: Characterization, in vitro and ex-vivo studies. J Pharm Sci. 
2013;102:2349.

71.  Gong C, Wu Q, Wang Y, et al. A biodegradable hydrogel system 
containing  curcumin  encapsulated  in  micelles  for  cutaneous 
wound healing. Biomaterials. 2013;34:6377.

72.  Da-Lozzo  EJ,  Moledo  RC,  Faraco  CD,  et  al.  Curcumin/ 
xanthan-galactomannan  hydrogels:  Rheological  analysis  and 
biocompatibility. Carbohydr Polym. 2013;93:279.

73.  Mohanty C, Das M, Sahoo SK. Sustained wound healing activity 
of curcumin loaded oleic acid based polymeric bandage in a rat 
model. Mol Pharm. 2012;9:2801.

74.  Kumar K, Rai AK. Proniosomal formulation of curcumin having 
anti-inflammatory  and  anti-arthritic  activity  in  different  experi-
mental animal models. Pharmazie. 2012;67:852.

75.  Kaur  CD,  Saraf  S.  Topical  vesicular  formulations  of  Curcuma 
longa  extract  on  recuperating  the  ultraviolet  radiation-damaged 
skin. J Cosmet Dermatol. 2011;10:260.

76.  Gupta  NK,  Dixit  VK.  Development  and  evaluation  of  vesicular 
system for curcumin delivery. Arch Dermatol Res. 2011;303:89.
77.  Patel  NA,  Patel  NJ,  Patel  RP.  Formulation  and  evaluation  of 
curcumin  gel  for  topical  application.  Pharm  Dev  Technol. 
2009;14:80.

78.  Rungphanichkul N, Nimmannit U, Muangsiri W, et al. Preparation 
of  curcuminoid  niosomes  for  enhancement  of  skin  permeation. 
Pharmazie. 2011;66:570.

79.  Lertsutthiwong P, Rojsitthisak P. Chitosan-alginate nanocapsules 

for encapsulation of turmeric oil. Pharmazie. 2011;66:911.

80.  Liu CH, Chang FY. Development and characterization of eucalyp-
tol  microemulsions  for  topic  delivery  of  curcumin.  Chem  Pharm 
Bull (Tokyo). 2011;59:172.

81.  Basnet  P,  Hussain  H,  Tho  I,  et  al.  Liposomal  delivery  system 
enhances anti-inflammatory properties of curcumin. J Pharm Sci. 
2012;101:598.

82.  Liu  CH,  Huang  HY.  Antimicrobial  activity  of  curcumin-loaded 
myristic acid microemulsions against Staphylococcus epidermidis. 
Chem Pharm Bull (Tokyo). 2012;60:1118.

83.  Elad  S,  Meidan  I,  Sellam  G,  et  al.  Topical  curcumin  for  the 
prevention  of  oral  mucositis  in  pediatric  patients:  Case  series. 
Altern Ther Health Med. 2013;19:21.

84.  Hsu YC, Chen MJ, Yu YM, et al. Suppression of TGF-β1/SMAD 
pathway  and  extracellular  matrix  production  in  primary  keloid 
fibroblasts  by  curcuminoids:  Its  potential  therapeutic  use  in  the 
chemoprevention of keloid. Arch Dermatol Res. 2010;302:717.
85.  Dovigo LN, Carmello JC, de Souza Costa CA, et al. Curcumin-
mediated  photodynamic  inactivation  of  Candida  albicans  in  a 
murine model of oral candidiasis. Med Mycol. 2013;51:243.

86.  Takahashi  M,  Asikin  Y,  Takara  K,  et  al.  Screening  of  medicinal 
and edible plants in Okinawa, Japan, for enhanced proliferative 

 
264 

COsM E C E U T I C A Ls   A N D   C OsM E T I C   INgR E D I E N T s

and collagen synthesis activities in NB1RGB human skin fibroblast 
cells. Biosci Biotechnol Biochem. 2012;76:2317.

87.  Tu CX, Lin M, Lu SS, et al. Curcumin inhibits melanogenesis in 

human melanocytes. Phytother Res. 2012;26:174.

88.  Sidhu GS, Singh AK, Thaloor D, et al. Enhancement of wound 
healing  by  curcumin  in  animals.  Wound  Repair  Regen . 
1998;6:167.

89.  Sidhu GS, Mani H, Gaddipati JP, et al. Curcumin enhances wound 
healing  in  streptozotocin  induced  diabetic  rats  and  genetically 
diabetic mice. Wound Rep Regen. 1999;7:362.

90.  Thangapazham RL, Sharma A, Maheshwari RK. Beneficial role of 

curcumin in skin diseases. Adv Exp Med Biol. 2007;595:343.

91.  Kundu  S,  Biswas  TK,  Das  P,  et  al.  Turmeric  (Curcuma  longa) 
rhizome paste and honey show similar wound healing potential: 
A preclinical study in rabbits. Int J Low Extrem Wounds. 2005;4:205.
92.  Gupta  A,  Upadhyay  NK,  Sawhney  RC,  et  al.  A  poly-herbal 
formulation  accelerates  normal  and  impaired  diabetic  wound 
healing. Wound Repair Regen. 2008;16:784.

93.  Bhagavathula N, Warner RL, DaSilva M, et al. A combination of 
curcumin and ginger extract improves abrasion wound healing in 
corticosteroid-impaired  hairless  rat  skin.  Wound  Repair  Regen. 
2009;17:360.

94.  López-Jornet  P,  Camacho-Alonso  F,  Jiménez-Torres  MJ,  et  al. 
Topical  curcumin  for  the  healing  of  carbon  dioxide  laser  skin 
wounds in mice. Photomed Laser Surg. 2011;29:809.

95.  Kulac M, Aktas C, Tulubas F, et al. The effects of topical treatment 
with  curcumin  on  burn  wound  healing  in  rats.  J  Mol  Histol. 
2013;44:83.

96.  Chusri S, Settharaksa S, Chokpaisarn J, et al. Thai herbal formulas 
used for wound treatment: A study of their antibacterial potency, 
anti-inflammatory,  antioxidant,  and  cytotoxicity  effects.  J  Altern 
Complement Med. 2013;19:671.

97.  Chereddy KK, Coco R, Memvanga PB, et al. Combined effect of 
PLGA and curcumin on wound healing activity. J Control Release. 
2013;171:208.

98.  Kurd  SK,  Smith  N,  VanVoorhees  A,  et  al.  Oral  curcumin  in  the 
treatment of moderate to severe psoriasis vulgaris: A prospective 
clinical trial. J Am Acad Dermatol. 2008;58:625.

99.  Morelli V, Calmet E, Jhingade V. Alternative therapies for common 

dermatologic disorders, part 2. Prim Care. 2010;37:285.

100.  Heng MC, Song MK, Harker J, et al. Drug-induced suppression of 
phosphorylase  kinase  activity  correlates  with  the  resolution  of 
psoriasis  as  assessed  by  clinical,  histological  and  immunohisto-
chemical parameters. Br J Dermatol. 2000;143:937.

101.  Saelee C, Thongrakard V, Tencomnao T. Effects of Thai medicinal 
herb  extracts  with  anti-psoriatic  activity  on  the  expression  on 
NF-κB  signaling  biomarkers  in  HaCaT  keratinocytes.  Molecules. 
2011;16:3908.

102.  Sun  J,  Zhao  Y,  Hu  J.  Curcumin  inhibits  imiquimod-induced  
psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production 
in mice. PLoS One. 2013;8:e67078.

103.  Marchiani A, Rozzo C, Fadda A, et al. Curcumin and curcumin-
like molecules: From spice to drugs. Curr Med Chem. 2014;21:204.
104.  Conney AH, Lysz T, Ferraro T, et al. Inhibitory effect of curcumin 
and  some  related  dietary  compounds  on  tumor  promotion  and 
arachidonic  acid  metabolism  in  mouse  skin.  Adv  Enzyme  Regul. 
1991;31:385.

105.  Nakamura  Y,  Ohto  Y,  Murakami  A,  et  al.  Inhibitory  effects  of 
curcumin  and  tetrahydrocurcuminoids  on  the  tumor  promoter-
induced reactive oxygen species generation in leukocytes in vitro 
and in vivo. Jpn J Cancer Res. 1998;89:361.

106.  Panahi  Y,  Sahebkar  A,  Parvin  S,  et  al.  A  randomized  controlled 
trial on the anti-inflammatory effects of curcumin in patients with 
chronic  sulphur  mustard-induced  cutaneous  complications.  Ann 
Clin Biochem. 2012;49:580.

107.  Thongrakard V, Ruangrungsi N, Ekkapongpisit M, et al. Protection 
from UVB Toxicity in Human Keratinocytes by Thailand Native 
Herbs Extracts. Photochem Photobiol. 2013 Aug 12. [Epub ahead of 
print]

108.  Oguro  T,  Yoshida  T.  Effect  of  ultraviolet  A  on  ornithine  decar-
boxylase  and  metallothionein  gene  expression  in  mouse  skin. 
Photodermatol Photoimmunol Photomed. 2001;17:71.

109.  Huang  MT,  Ma  W,  Yen  P,  et  al.  Inhibitory  effects  of  topical 
application of low doses of curcumin on 12-O-tetradecanoylphorbol-
13-acetate-induced tumor promotion and oxidized DNA bases in 
mouse epidermis. Carcinogenesis. 1997;18:83.

110.  Villaseñor IM, Simon MK, Villanueva AM. Comparative potencies 
of  nutraceuticals  in  chemically  induced  skin  tumor  prevention. 
Nutr Cancer. 2002;44:66.

111.  Azuine  MA,  Bhide  SV.  Chemopreventive  effect  of  turmeric 
against  stomach  and  skin  tumors  induced  by  chemical  carcino-
gens in Swiss mice. Nutr Cancer. 1992;17:77.

112.  Iersel  ML,  Ploemen  JP,  Struik  I,  et  al.  Inhibition  of  glutathione 
S-transferase  activity  in  human  melanoma  cells  by  alpha,beta-
unsaturated carbonyl derivatives. Effects of acrolein, cinnamalde-
hyde,  citral,  crotonaldehyde,  curcumin,  ethacrynic  acid,  and 
trans-2-hexenal. Chem Biol Interact. 1996;102:117.

113.  Jee SH, Shen SC, Tseng CR, et al. Curcumin induces a p53-dependent 
apoptosis  in  human  basal  cell  carcinoma  cells.  J  Invest  Dermatol. 
1998;111:656.

114.  Chun  KS,  Keum  YS,  Han  SS,  et  al.  Curcumin  inhibits  phorbol 
ester-induced  expression  of  cyclooxygenase-2  in  mouse  skin 
through  suppression  of  extracellular  signal-regulated  kinase 
activity and NF-kappB activation. Carcinogenesis. 2003;24:1515.

115.  Limtrakul P, Lipigorngoson S, Namwong O, et al. Inhibitory effect 
of dietary curcumin on skin carcinogenesis in mice. Cancer Lett. 
1997; 116:197.

116.  Nagabhushan M, Bhide SV. Curcumin as an inhibitor of cancer.  

J Am Coll Nutr. 1992;11:192.

117.  Bush  JA,  Cheung  KJ  Jr.,  Li  G.  Curcumin  induces  apoptosis  in 
human  melanoma  cells  through  a  Fas  receptor/caspase-8  path-
way independent of p53. Exp Cell Res. 2001;271:305.

118.  Chen J, Wanming D, Zhang D, et al. Water-soluble antioxidants 
improve the antioxidant and anticancer activity of low concentra-
tions of curcumin in human leukemia cells. Pharmazie. 2005;60:57.
119.  Phillips  JM,  Clark  C,  Herman-Ferdinandez  L,  et  al.  Curcumin 
inhibits  skin  squamous  cell  carcinoma  tumor  growth  in  vivo. 
Otolaryngol Head Neck Surg. 2011;145:58.

120.  Phillips J, Moore-Medlin T, Sonavane K, et al. Curcumin inhibits 
UV  radiation-induced  skin  cancer  in  SKH-1  mice.  Otolaryngol 
Head Neck Surg. 2013;148:797.

121.  Sonavane K, Phillips J, Ekshyyan O, et al. Topical curcumin-based 
cream is equivalent to dietary curcumin in a skin cancer model.  
J Skin Cancer. 2012;2012:147863.

122.  Tsai KD, Lin JC, Yang SM, et al. Curcumin protects against UVB-
induced skin cancers in SKH-1 hairless mouse: Analysis of early 
molecular  markers  in  carcinogenesis.  Evid  Based  Complement 
Alternat Med. 2012;2012:593952.

123.  Hwang  BM,  Noh  EM,  Kim  JS,  et  al.  Curcumin  inhibits  UVB-
induced matrix metalloproteinase-1/3 expression by suppressing 
the  MAPK-p38/JNK  pathways  in  human  dermal  fibroblasts.  
Exp Dermatol. 2013;22:371.

 
C H A P T E R   7 0

Chamomile

C H A P T E R  70  ■   C H A M O M I L E  

265

Activities:

Anti-inflammatory, antioxidant, analgesic, antimicrobial, 
antiseptic, antispasmodic, antiulcer, sedative

Important Chemical Components:

Flowers:  flavonoids  (i.e.,  apigenin,  quercetin,  patuletin, 
luteolin,  and  their  glucosides;  isohamnetin),  coumarins 
(herniarin  and  umbelliferone),  mucilages,  mono-  and 
oligosaccharides
Essential  oil  of  the  flower:  the  terpenoids  (-)-α-bisabolol 
and its oxides (α-bisabolol A and B), sesquiterpene lac-
tones  (anthocotulide),  cadinene,  farnesene,  furfural, 
spathulenol, spiroethers, the proazulenes matricarin and 
matricine  (also  spelled  “matricin”),  and  chamazulene 
(a transformation product of matricine)1–4

Origin Classification:

This ingredient is natural. Organic forms exist.

Personal Care Category: 

Anti-inflammatory

Recommended  for  the  following  Baumann  Skin 
Types: 

DSNT, DSNW, DSPT, DSPW, OSNT, OSNW, OSPT, and 
OSPW

 SOURCE

Topical herbal drugs, including chamomile, have been used for 
centuries to treat skin conditions.5 Native to western and southern 
Europe, western Asia, and India, chamomile (also spelled “camo-
mile”) is a sweet-scented flower belonging to the Asteraceae (or 
Compositae) family, also commonly known as the aster, daisy, or 
sunflower  family.  The  Compositae  family  refers  to  plants  in 
which  the  flower  heads  are  a  composite  of  individual  flowers. 
They  are  also  given  the  name  Asteraceae  because  the  flower 
heads  are  star-shaped  (aster  is  Greek  for  star).  Chamomile  has 
been  used  as  a  medicinal  herb  worldwide  for  thousands  of 
years.6,7 It remains one of the most widely used medicinal herbs 
as well as one of the most frequently studied plants.8

The generic designation “chamomile” is rooted in the Greek 
expressions  khamai  or  chamos  (on  the  ground,  or  ground)  and 
melon  (apple).9,10  There  are  two  primary  types  of  chamomile: 
Chamaemelum nobile (Roman chamomile, sometimes referred to 
as  English  chamomile)  and  Matricaria  recutita,  also  known  as 
Chamomilla recutita or Matricaria chamomilla (German chamomile, 
sometimes  referred  to  as  Hungarian  chamomile,  mayweed, 
sweet  false  chamomile,  true  chamomile,  or  wild  chamo-
mile).1,3,11–13 Roman chamomile is a low-growing perennial that 
emits an apple-like aroma when trod upon. German chamomile 
is a robust, self-seeding annual plant.

TABLE 70-1 
Pros and Cons of Chamomile

Pros
Long history of traditional use
Strong evidence of anti-inflammatory 

activity seen in vitro and in animal studies

Fair empirical evidence of efficacy in humans

One of the most frequently studied plants
Inexpensive and readily available

Cons
Paucity of clinical trials
Individuals with allergies to members of 
the Asteraceae (Compositae) family are 
susceptible to allergic reactions
Source of the plant determines the 

amount of beneficial components in the 
extracts used

No studies evaluating use in rosacea

Both  plants  have  been  used  for  medicinal  purposes,  with 
Roman  chamomile  considered  therapeutic  for  burns,  bruises, 
boils,  as  well  as  small  cuts  and  reputed  to  foster  the  natural 
healing  of  acne,  dermatitis,  and  athlete’s  foot.  Compared  to 
Roman  chamomile,  German  chamomile  contains  a  higher 
concentration  of  key  active  ingredients  that  have  shown  anti-
inflammatory activity in vivo, namely the terpenoids chamazulene 
and  α-bisabolol  (also  known  as  levomenol)4,14;  therefore, 
German  chamomile  is  the  focus  of  this  chapter.  In  Germany, 
chamomile is referred to as alles zutraut (“capable of anything”).15 
Its  traditional  medical  uses  include  inflammatory  conditions 
such as eczema, gout, neuralgia, and rheumatic discomfort.1,12,16 
Despite a long history of traditional use (Table 70-1), chamomile 
has  only  been  subjected  to  the  rigors  of  the  scientific  method 
during the past 40 years.

 HISTORY

Chamomile  has  long  been  used  in  folk  medicine  and  aroma-
therapy,  systemically  and  topically,  to  treat  inflammation 
disorders, primarily gastrointestinal and cutaneous.17 Through 
human  migration,  this  sweet-scented  plant  has  also  become 
abundant  throughout  North  America,  growing  freely 
throughout much of the continent. The earliest recorded uses 
of chamomile date back 2,500 years to the time of Hippocrates  
(circa 500 BCE), who is believed to have recognized therapeutic 
properties in the herb.18 Later recorded writings on chamomile 
were  also  attributed  to  the  Greek-speaking  Roman  physician 
Galen  as  well  as  Dioscorides.3,10  Ancient  Egyptians,  Greeks, 
and  Romans  used  crushed  chamomile  flowers  for  medicinal 
purposes, such as treating erythema and dry skin brought on 
by harsh, dry weather.10,19 Chamomile tea has also been used 
as  a  folk  remedy  in  eye  washing  to  treat  conjunctivitis  and 
other superficial ocular conditions.20 Decoctions of chamomile 
in cold wet packs have been used traditionally to treat acute, 
exudative  eczema.21  In  1951,  α-bisabolol,  one  of  the  primary 
active  ingredients  of  chamomile,  was  isolated  and  is  now 
included in many cosmetic skin care products to prevent and 
treat inflammation.22

 
266 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

A recent ethnobotanical survey in southwestern Serbia revealed 
that  chamomile  was  one  of  the  most  highly  valued  medicinal 
plants used in local folk medicine, primarily for curing minor gas-
trointestinal, respiratory, and cutaneous conditions.23 Chamomile 
is also widely used for wound care in Europe.21 Currently, chamo-
mile  is  one  of  the  seven  most  common  herbs  used  for  medical 
purposes.19  A  large  body  of  research  conducted  over  the  last  
40 years has buttressed the traditional uses of the herb,10 and it is 
now listed as a drug in the official pharmacopoeias of 26 nations 
(including Belgium, France, Germany, and the United Kingdom).10,15

 CHEMISTRY

Chamazulene, flavonoids (which are known to have antioxi-
dant properties), coumarins, mucilages, and mono- and oligo-
saccharides are the primary active components of M. recutita 
deemed medically important among the 120 identified com-
pounds in chamomile flowers.1,24 Chamazulene is a transfor-
mation product of matricine and both of these constituents of 
chamomile extracts have shown anti-inflammatory and anti-
pyretic activity in vivo.4,25 Chamazulene, but not matricine, is 
thought to be involved in exerting anti-inflammatory activity 
in chamomile by suppressing leukotriene production.24

Levomenol,  or  α-bisabolol,  is  another  key  anti-inflammatory 
component found in great abundance in German chamomile, and 
comprises nearly half of its essential oil.22 It is believed to confer 
significant  effects  on  skin,  such  as  soothing  inflammation  and 
diminishing pruritus (itching). The combined effects of levomenol, 
a  natural  moisturizer,  and  chamazulene  are  said  to  soothe  skin 
exhibiting inflammation due to eczema, allergy, and sunburn.

In  addition  to  reports  of  anti-inflammatory  effects, 
chamomile  is  believed,  based  on  chemical  assays,  to  possess 
some antioxidant properties.26 These characteristics are mainly 
associated  with  the  terpenoid  matricine  as  well  as  the  flavo-
noids  apigenin,  luteolin,  and  quercetin,  with  the  flavonoids 
recognized  for  strongly  inhibiting  histamine  release  and  the 
infiltration of leukocytes, and for possessing antioxidant prop-
erties.24,27 As a result of its various beneficial properties, chamo-
mile is now included in many cosmetic products intended to 
improve  skin  appearance.  Of  note,  chamomile  has  been 
reported  to  cause  allergic  contact  dermatitis  in  susceptible 
types,28 such as those with known allergies to the Compositae 
family (e.g., ragweed and feverfew) (see Chapter 66, Feverfew).
Chamomile is notably versatile in the medicinal realm, with 
the dried flowers of M. recutita exhibiting sedative and antispas-
modic properties.29 Chamomile also acts as an antiallergenic and 
antibacterial.  The  traditional  indications  for  chamomile  and  its 
various  teas  and  topical  formulations  range  from  stomach 
cramping and pains, menstrual cramping, and diarrhea, to inflam-
matory skin and eye problems, mood disorders, and even the flu. 
In a 2006 review by McKay and Blumberg, chamomile was 
found to deliver moderate in vitro antioxidant and antimicrobial 
as  well  as  significant  antiplatelet  activities.  Strong  anti-
inflammatory  as  well  as  mild  antimutagenic  and  cholesterol-
reducing  activities  have  been  displayed  by  the  herb  in  animal 
experiments, they noted, in addition to some antispasmodic and 
anxiolytic effects, but data from human studies are limited.1

A key active ingredient in German chamomile that is believed 
to deliver anti-inflammatory and soothing activity is α-bisabolol 
(matricine),  as  well  as  α-bisabolol  oxide  A  and  B.  These  are 
known to exhibit anti-inflammatory activity due to inhibition of 
cyclooxygenase  (COX)  and  lipoxygenase  (see  Chapter  64, 
Anti-inflammatory  Agents).30  For  this  reason,  α-bisabolol  is 

commonly included in various personal care products, including 
moisturizing  creams  and  ointments,  lotions,  cleansers,  sun-
screens, antiperspirants, and makeup.22

 ORAL USES

Globally,  chamomile  is  one  of  the  most  popular  medicinal 
plants  and  is  extensively  consumed  as  a  beverage  in  herbal 
teas (or tisanes) brewed from dried flower heads.1,31 In fact, 
as of 2006, it was estimated that chamomile is consumed in 
more than a million cups per day around the world.32,33 As an 
infusion, chamomile has also been traditionally used to ease 
colic and teething in babies, and to calm restless children. In 
addition, this bittersweet herb has been shown to be effec-
tive in relieving acid indigestion, intestinal gas, constipation, 
and  peptic  ulcers.  Importantly,  chamomile  herbal  tea  is  not 
just for drinking. The use of chamomile tea as an eye wash 
for  conjunctivitis  and  other  external  ocular  symptoms  is  a 
traditional  remedy.20  Oral  uses  of  chamomile  are  extensive 
and a detailed description is beyond the scope of this chapter.

 TOPICAL USES

Topically  applied  chamomile  oil  is  used  to  soothe  cutaneous 
inflammation and is well tolerated. Chamomile is thought to 
diminish photodamage and pruritus,18 and it is believed to act 
as a natural moisturizer.18,34,35 It is a common home remedy to 
treat inflammation of various causes including sunburn, insect 
bites, and rashes.

Atopic Dermatitis
In a 1985 study of 161 patients with eczema on their hands, 
forearms,  and  lower  legs,  Aertgeerts  et  al.  compared  the 
effects of a chamomile-containing cream (Kamillosan®) with 
0.25  percent  hydrocortisone,  0.75  percent  fluocortin  butyl 
ester, and 5 percent bufexamac as maintenance therapy over 
three to four weeks. In this bilateral comparative study, they 
found that the herbal cream was equally effective as hydro-
cortisone  and  achieved  better  results  than  the  nonsteroidal 
anti-inflammatory  drug  (NSAID)  bufexamac  and  the  gluco-
corticoid aging fluocortin butyl ester.36

In  2000,  Patzelt-Wenczler  and  Ponce-Pöschl  performed  a 
two-week,  partially  double-blind,  randomized  half-side  com-
parison  of  Kamillosan®  cream  (which  contains  chamomile 
extract) and 0.5 percent hydrocortisone cream and placebo in 
patients with moderate atopic eczema. This proof of efficacy 
revealed that the chamomile formulation was marginally better 
than hydrocortisone and placebo in diminishing symptoms of 
atopic eczema.37 Previously, clinical studies demonstrated that 
the  chamomile-containing  patented  Camocare®  cream  was 
efficacious and safe as a maintenance therapy after corticoster-
oid treatment for severe inflammatory conditions and as single 
therapy for milder cutaneous inflammatory issues.10

In 2010, Lee et al. induced atopic dermatitis in mice using  
1 percent 2,4-dinitrochlorobenzene (DNCB) to sensitize and 
then  challenge  the  animals.  Subsequently,  the  researchers 
daily applied 3 percent German chamomile oil on the dorsal 
skin  for  four  weeks  or  a  saline  or  jojoba  oil  in  controls  (see 
Chapter  12,  Jojoba  Oil).  Significantly  lower  histamine  levels 
were recorded in the chamomile group compared to controls 
after  two  weeks,  and  scratching  was  displayed  much  less 
frequently  by  the  mice  treated  with  chamomile.  The 

 
investigators  reported  that  this  was  the  first  study  to  show 
the immunoregulatory potential of chamomile to ease atopic 
dermatitis by affecting the activation of Th2 cells.38

Anti-inflammatory Activity
In  1984,  Tubaro  et  al.  induced  ear  edema  in  male  albino  Swiss 
mice using croton oil to assess the anti-inflammatory activity of 
topically applied chamomile. They found that the herbal extract 
was as effective as a reference NSAID in reducing inflammation.39
In  an  animal  study  in  which  inflammation  was  induced  via 
the  injection  of  carrageenan  and  prostaglandin  E1,  German 
chamomile was found to inhibit the inflammatory effect as well 
as  leukocyte  infiltration.40  Specifically,  chamazulene  decreases 
the inflammatory process by inhibiting leukotriene synthesis.4

In  an  in  vitro  model,  Srivastava  et  al.  showed  in  2009  that 
aqueous  extracts  of  chamomile  inhibited  COX-2  enzyme 
activity,  hindering  the  release  of  lipopolysaccharide  (LPS)-
induced  prostaglandin  E2  and  limiting  LPS-induced  COX-2 
mRNA and protein expression, without altering COX-1 expres-
sion. The investigators found that chamomile acted similarly to 
NSAIDs  in  this  context  and  suggested  that  their  findings  may 
have implications regarding the prevention and management of 
inflammatory and neoplastic disorders.33

In 2010, Bhaskaran et al. showed that chamomile suppresses 
LPS-induced nitric oxide production and inducible nitric oxide 
synthase  gene  expression,  thus  implying  its  viability  as  an 
anti-inflammatory agent.12

In  2013,  Drummond  et  al.  investigated  the  potential  use  as 
anti-inflammatory  agents  of  chamomile,  meadowsweet 
(Filipendula ulmaria), and willow bark (Salix alba), based on their 
traditional uses. The researchers isolated polyphenols from each 
herb  (apigenin,  quercetin,  and  salicylic  acid,  respectively)  and, 
along  with  aqueous  herbal  extracts,  incubated  the  compounds 
with  THP1  macrophages.  Both  apigenin  and  quercetin  signifi-
cantly  lowered  interleukin  (IL)-6  and  tumor  necrosis  factor 
(TNF)-α.  Overall,  willow  bark  exerted  the  greatest  anti-
inflammatory  activity  and  chamomile,  the  least.  The  authors 
noted  that  this  was  the  first  study  to  reveal  that  these  herbal 
extracts  display  positive  anti-inflammatory  activity  in  human 
macrophages, suggesting that in vivo study is warranted.41

In  a  small  skin  penetration  study  with  nine  healthy  female 
volunteers,  Merfort  et  al.  showed  in  1994  that  the  chamomile 
flavones apigenin, luteolin, and apigenin 7-O-β-glucoside were 
adsorbed at the skin surface and also penetrated into deeper skin 
layers, suggesting suitability as anti-inflammatory agents.42

Wound Healing
In 2009, Martins et al. conducted in vitro as well as in vivo studies 
in  male  rats  that  indicated  that  chamomile  facilitated  signifi-
cantly faster wound healing as compared to corticosteroids.13

Using 30 male albino Wistar rats with linear incisional wounds 
on the back in a 2010 study, Jarrahi et al. randomized the animals 
into  control,  olive  oil,  and  chamomile  treatment  groups  (see 
Chapter 14, Olive Oil). No drug or cold cream was administered 
to the control group. Topical olive oil was administered to the 
olive oil group once daily until wounds were completely healed. 
M. chamomilla extract dissolved in olive oil was used topically on 
the  chamomile  group.  Statistically  significant  differences  were 
observed  on  most  days  between  the  olive  oil  and  treatment 
groups. The investigators concluded that topically applied cham-
omile  exhibits  potential  as  a  wound-healing  agent,  supporting 
findings by Jarrahi in a similar experiment two years earlier.43,44

C H A P T E R  70  ■   C H A M O M I L E  

267

Cutaneous benefits of chamomile have been demonstrated 
in various ways. A 2011 controlled clinical study of 72 colos-
tomy patients revealed that a German chamomile solution was 
effective  in  alleviating  pruritus  and  inflammation  associated 
with  peristomal  skin  lesions.  Twice  daily  application  of  the 
chamomile solution promoted healing and was more effective 
than hydrocortisone 1 percent ointment.45

In a literature review intended to identify the potential uses of 
complementary and alternative therapies in relation to dermato-
logic surgery, Reddy et al. found citations for numerous natural 
ingredients  that  can  be  used  perioperatively,  including 
chamomile,  as  well  as  other  ingredients  discussed  in  this  text 
such  as  honey,  propolis,  vitamin  C,  aloe  vera  gel,  turmeric,  
calendula,  and  lavender  oil  [see  Chapter  55,  Ascorbic  Acid 
(Vitamin C), Chapter 60, Honey/Propolis/Royal Jelly, Chapter 65, 
Aloe  Vera,  Chapter  69,  Turmeric,  Chapter  71,  Calendula,  and 
Chapter 73, Lavandula]. Specifically, they found that chamomile 
was  conducive  to  wound  healing,  decreasing  edema  and  pur-
pura, and delivering anti-inflammatory effects in animals.46

 SAFETY ISSUES

The use of chamomile in any form is considered by the United 
States Food and Drug Administration as generally recognized 
as  safe  (GRAS)  with  few  side  effects.  There  have  been  some 
reports  of  contact  dermatitis  as  well  as  contact  urticaria  and 
angioedema  following  the  topical  application  of  chamomile 
products.  Allergic  conjunctivitis  has  also  been  reported  in 
patients who manifested positive skin prick reactions to cham-
omile  tea  extract,  M.  chamomilla  pollen,  and  Artemisia  vulgaris 
(mugwort) pollen extracts.20,47 Overall, reactions to chamomile 
tend  to  be  mild-to-moderate,  and  occur  in  individuals  with 
sensitivities to members of the Compositae family (see Table 
70-2).48  M.  recutita  is  known  as  a  weak  sensitizer.7,49,50  De  la 
Torre  et  al.  have  identified  significant  in  vivo  cross-reactivity 
between  A.  vulgaris  and  chamomile.51  In  addition,  there  have 
been reports of adverse reactions to topically applied chamo-
mile  or  chamomile  orally  consumed  in  individuals  allergic  to 
other plants in the daisy family.1 Specifically, sensitization has 
been linked to the use of various chamomile creams, ointments, 
and  lotions,  and,  to  a  lesser  degree,  chamomile  oil  and  tea. 
Chamomile, comfrey, and tea tree oil are considered the ingredi-
ents  in  cosmeceutical  formulations  at  highest  risk  of  eliciting  a 
reaction (see Chapter 77, Tea Tree Oil).52

In  2004,  Jovanovic´   et  al.  found  an  overall  prevalence  of  
30 percent Compositae-sensitivity among patients with extrin-
sic  or  allergic  atopic  dermatitis  who  were  patch  tested  with 

TABLE 70-2 
Some Members of the Compositae (Asteraceae) Family of Plants

Burdock
Chamomile
Chrysanthemum
Daisy
Dandelion
Echinacea
Edelweiss
Feverfew
Marigold
Ragweed
Sunflower
Yarrow

 
268 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Compositae mix, including its individual ingredients, extracts 
of  arnica  (Arnica  montana),  chamomile  (C.  recutita),  tansy 
(Tanacetum  vulgare),  feverfew  (Tanacetum  parthenium),  and  yar-
row  (Achillea  millefolium);  sesquiterpene  lactone  mix;  and  spe-
cific  series  for  atopic  dermatitis  patients  (see  Chapter  66, 
Feverfew). Five patients were specifically sensitive to chamo-
mile. The researchers concluded that atopic dermatitis is a risk 
factor for Compositae allergy.53

Type-IV allergic reactions to chamomile manifesting as aller-
gic contact dermatitis are not uncommon. Andres et al. suggested, 
based on a case study of an anaphylactic response to chamomile 
tea, that the incidence and risk of type-I allergic responses may 
be underestimated.54 In addition, Paulsen et al. advised caution 
to  Compositae-sensitive  patients  regarding  the  topical  use  of 
cosmetics or remedies containing Compositae ingredients.28

Certainly the risk of allergy depends upon the compounds in 
the herb and these can vary by geographic origin. For instance, 
chamomile from Argentina has been found to contain higher 
levels of the potent allergen anthocotulide, perhaps due to con-
tamination  with  the  morphologically  comparable  Anthemis 
cotula (dog fennel).7,35 Up to 7.3 percent anthocotulide is found 
in dog fennel; the sesquiterpene lactone is found in only trace 
amounts in chamomile of European origin.7 In the commercial 
production  of  the  chamomile  product  Kamillosan®,  the  final 
product is filtered to eliminate allergens.7

Chamomile is one among the several herbs that can interact 
with  warfarin,  elevating  the  risk  of  bleeding  or  other  adverse 
effects  for  a  patient  on  warfarin  therapy.55  Herniarin 
(7-methoxycoumarin), the main coumarin found in the plant, is 
responsible for the antiplatelet activity and has been identified as 
one  of  the  non-sesquiterpene  lactone  sensitizers  in  German 
chamomile.2 NSAIDs, particularly aspirin, have the potential to 
interact with herbal supplements that contain coumarin, such as 
chamomile, augmenting the risk of bleeding and bruising.56

The  German  Commission  E  approved  of  chamomile  for 
internal use to treat gastrointestinal spasms and inflammatory 
disorders, and as an inhalant for respiratory inflammation; for 
external use, for the treatment of mucocutaneous disorders as 
well as wounds and burns, genital inflammation, and bacterial 
skin  disorders,  including  the  oral  cavity  and  gums.10,52 
Chamomile  is  one  of  the  most  commonly  used  herbs  for 
treating morning sickness, but there is contradictory evidence 
amid an overall dearth of data on whether use of chamomile 
is safe during pregnancy.57

Bisabolol
Ogata  et  al.  showed  in  a  study  using  rats,  that  α-bisabolol 
oxide A is essentially safe in the conventional use of German 
chamomile.58 However, α-bisabolol has been linked to cases 
of periorbital swelling and contact cheilitis from lipstick.22,59,60 
In 2010, Russell and Jacob recommended, based on reports in 
Europe  of  contact  dermatitis  from  bisabolol,  that  patch 
testing  with  α-bisabolol  or  α-bisabolol-containing  products 
be  included  in  the  work-up  of  patients  with  presumptive 
allergic contact dermatitis or aggravated atopic dermatitis.22

 ENVIRONMENTAL IMPACT

The environmental impact from the cultivation and commer-
cial use of German chamomile is not well reported; however, it 
is a naturally occurring plant and organically grown crops are 
available. 

 FORMULATION CONSIDERATIONS

Chamomile is included in a wide array of cosmetic products to 
provide  anti-inflammatory  and  soothing  activity  for  sensitive 
skin. Various processes are used to isolate the active compounds 
from  the  plants,  and  the  formulation  considerations  depend 
upon which processes are used.

 USAGE CONSIDERATIONS

Chamomile  is  available  in  several  forms  including  alcohol 
extracts,  tea  infusions,  and  oil.50,52  It  is  often  formulated  in 
cleansers, lotions, creams, and serums.50

 SIGNIFICANT BACKGROUND

In a 2005 survey of English-language medical journals and sym-
posia, Thornfeldt identified German chamomile as one of the 
top  dozen  important  botanicals  used  in  cosmeceutical 
products.52 A 2007 ethnobotanical survey on the highest mountain 
in  Central  Serbia  identified  83  wild  species,  with  M.  chamomilla 
found  to  be  one  of  the  most  frequently  used  for  health  
purposes; skin injuries and issues were second only to gastroin-
testinal illnesses as the main indication.61 Recent studies appear 
to suggest a wider range of biologic activity than first thought, 
such  as  antioxidant,  antiparasitic,  hypocholesterolemic, 
antiaging,  and  anticancer  properties.12  Nevertheless,  despite 
increasing popular use of herbal products, and those including 
chamomile  in  particular,  clinical  evidence  substantiating  the 
cutaneous  effects  of  chamomile  remains  sparse,  according  to 
the 2010 findings of a systematic review by Rügge et al.62

In  1996,  Ramos  et  al.  performed  preliminary  experiments 
toward  incorporating  plant  extracts  as  sun-protective  agents, 
finding  that  liquid  and  dry  extracts  of  M.  recutita,  Hamamelis 
virginiana (witch hazel), Aesculus hippocastanum (horse chestnut), 
Rhamnus  purshiana,  and  Cinnamomum  zeylanicum  amplified  the 
solar protection factors (SPF) of a 2 percent solution of the syn-
thetic sunscreen octylmethoxycinnamate (see Chapter 74, Horse 
Chestnut). They concluded that such herbal extracts could inten-
sify SPF values when included in commercial sunscreens, while 
also enhancing the emollient activity of the product.63

Anticancer Activity
Chamomile is incorporated along with six other standardized 
botanical  extracts  (Panax  ginseng,  cranberry,  green  tea,  grape 
skin,  grape  seed,  and  Ganoderma  lucidum)  in  a  proprietary 
botanical  agent,  Traditional  Botanical  Supplement-101 
(TBS-101), demonstrated by Evans et al. in 2009 to have a good 
safety  profile  and  significant  anticancer  activities  
(see  Chapter  47,  Green  Tea).  The  botanical  agent  dose- 
dependently  inhibited  cell  growth  and  induced  apoptosis  
of  PC-3  cells  in  a  xenograft  mouse  model  and,  according  to  
the  investigators,  merits  consideration  as  a  treatment  for 
aggressive prostate cancer. They ascribed the contributions of 
chamomile to its constituent apigenin, which has been found 
to suppress cell proliferation and induce apoptosis.64,65

In 2013, Mamalis et al. investigated the antioxidant activity of 
key constituents of chamomile, silymarin, and halophilic bacteria 
(α-bisabolol, silymarin, and ectoin, respectively) finding that each 
substance hindered the in vitro upregulation of H2O2-induced free 
radicals in human skin fibroblasts. The researchers concluded that 

 
the antioxidant capacities of these herbs deserve additional study in 
clinical trials to ascertain their antiaging and anticancer potential.66
Later that year, Kogiannou et al. analyzed the phenolic profile of 
six  herbal  infusions  and  investigated  potential  anticarcinogenic 
properties,  identifying  chamomile  as  rich  in  genistein,  a  potent 
isoflavone (see Chapter 45, Soy). They found that the molecular 
target  for  chamomile  in  epithelial  colon  cancer  appears  to  be 
nuclear  factor-κB,  and  it,  along  with  the  other  herbal  infusions, 
displayed antiradical activity in relation to total phenolic content.67

Antiviral Activity
Koch et al. screened the essential oils of several plants, including 
chamomile, in 2008, to ascertain inhibitory activity against herpes 
simplex virus type 2 (HSV-2). All of the essential oils (which also 
included anise, hyssop, thyme, ginger, and sandalwood), displayed 
a dose-dependent virucidal capacity against HSV-2 (see Chapter 59, 
Ginger).  The  researchers  noted  a  high  selectivity  index  for  
chamomile, suggesting that it was especially promising among the 
herbs tested for topical therapeutic use for genital herpes.68

Oral Mucositis
In 2013, Curra et al. examined the effects of topical chamomile 
and  corticosteroid  treatment  on  IL-1β  and  TNF-α  levels  in 
5-fluorouracil-induced oral mucositis in hamsters, with 36 ani-
mals randomized into control, chamomile, and corticosteroid 
groups.  They  found  that  topically  applied  chamomile  was 
associated  with  lower  scores  for  both  proinflammatory 
cytokines, indicating the anti-inflammatory activity of the herb 
in treating oral mucositis.8

In  an  earlier  experiment  with  105  hamsters  with  oral 
mucositis  induced  by  5-fluorouracil,  Pavesi  et  al.  randomized 
animals  into  control,  topical  chamomile,  and  corticosteroid 
groups.  The  group  treated  with  chamomile  exhibited  milder 
clinical  symptoms  throughout  the  study  and  had  a  12-fold 
greater  chance  of  being  clear  of  mucositis  than  the  control 
group.  Histopathological  results  showed  that  chamomile-
treated hamsters displayed milder symptoms of mucositis than 
the other groups throughout the evaluation period.35

Notably, a mouthwash containing German chamomile was 
found to be effective in resolving oral mucositis arising from 
methotrexate therapy in a patient with rheumatoid arthritis.69

 CONCLUSION

Although  the  health  benefits  of  chamomile  might  be  most 
often  associated  with  its  tea  preparation  in  the  popular 
consciousness, there is a long history of effective, therapeutic 
application of various types of chamomile extracts to the skin. 
The body of clinical research on chamomile is relatively slim, 
but  does  support  its  use  as  a  natural  anti-inflammatory 
ingredient.  Caution  must  be  taken  when  used  in  individuals 
with  a  history  of  allergy  to  plants  in  the  Compositae  family. 
Double-blind,  placebo-controlled  trials  are  necessary  to 
establish the range of therapeutic potential of this herb and to 
compare  its  efficacy  with  other  natural  anti-inflammatory 
ingredients such as willow bark, argan oil, and feverfew.

REFERENCES

1.  McKay DL, Blumberg JB. A review of the bioactivity and poten-
tial  health  benefits  of  chamomile  tea  (Matricaria  recutita  L.). 
Phytother Res. 2006;20:519.

C H A P T E R  70  ■   C H A M O M I L E  

269

2.  Paulsen E, Otkjaer A, Andersen KE. The coumarin herniarin as a 
sensitizer  in  German  chamomile  [Chamomilla  recutita  (L.) 
Rauschert, Compositate]. Contact Dermatitis. 2010;62:338.

3.  No authors listed. Matricaria chamomilla (German chamomile). 

Monograph. Altern Med Rev. 2008;13:58.

4.  Safayhi  H,  Sabieraj  J,  Sailer  ER,  et  al.  Chamazulene:  An 
antioxidant-type  inhibitor  of  leukotriene  B4  formation.  Planta 
Med. 1994;60:410.

5.  Hörmann HP, Korting HC. Evidence for the efficacy and safety of 
topical  herbal  drugs  in  dermatology:  Part  I:  Anti-inflammatory 
agents. Phytomedicine. 1994;1:161.

6.  O’Hara M, Kiefer D, Farrell K, et al. A review of 12 commonly 

used medicinal herbs. Arch Fam Med. 1998;7:523.

7.  Paulsen  E.  Contact  sensitization  from  Compositae-containing 
herbal remedies and cosmetics. Contact Dermatitis. 2002;47:189.
8.  Curra M, Martins MA, Lauxen IS, et al. Effect of topical chamo-
mile  on  immunohistochemical  levels  of  IL-1β  and  TNF-α  in 
5-fluoouracil-induced  oral  mucositis  in  hamsters.  Cancer 
Chemother Pharmacol. 2013;71:293.

9.  Grieve M. A Modern Herbal (Vol. I). New York: Dover Publications; 

1971:185.

10.  Ross SM. An integrative approach to eczema (atopic dermatitis). 

Holist Nurs Pract. 2003;17:56.

11.  Wu J. Anti-inflammatory ingredients. J Drugs Dermatol. 2008;7:s13.
12.  Bhaskaran N, Shukla S, Srivastava JK, et al. Chamomile: An anti-
inflammatory  agent  inhibits  inducible  nitric  oxide  synthase 
expression  by  blocking  RelA/p65  activity.  Int  J  Mol  Med. 
2010;26:935.

13.  Martins  MD,  Marques  MM,  Bussadori  SK,  et  al.  Comparative 
analysis  between  Chamomilla  recutita  and  corticosteroids  on 
wound  healing.  An  in  vitro  and  in  vivo  study.  Phytother  
Res. 2009;23:274.

14.  Barene I, Daberte I, Zvirgzdina L, et al. The complex technology 
on  products  of  German  chamomile.  Medicina  (Kaunas). 
2003;39(Suppl 2):127.

15.  Foster S. An Illustrated Guide to 101 Medicinal Herbs: Their History, 
Use,  Recommended  Dosages,  and  Cautions.  Loveland,  CO: 
Interweave Press; 1998:54-55.

16.  Srivastava JK, Gupta S. Antiproliferative and apoptotic effects of 
chamomile  extract  in  various  human  cancer  cells.  J  Agric  Food 
Chem. 2007;55:9470.

17.  Dohil  MA.  Natural  ingredients  in  atopic  dermatitis  and  other 

inflammatory skin disease. J Drugs Dermatol. 2013;12:s128.

18.  Baumann  LS.  Less-known  botanical  cosmeceuticals.  Dermatol 

Ther. 2007;20:330.

19.  Dockrell TR, Leever JS. An overview of herbal medications with 

implications for the school nurse. J Sch Nurs. 2000;16:53.

20.  Subiza  J,  Subiza  JL,  Alonso  M,  et  al.  Allergic  conjunctivitis  to 

chamomile tea. Ann Allergy. 1990;65:127.

21.  Reuter J, Merfort I, Schempp CM. Botanicals in dermatology: An 

evidence-based review. Am J Clin Dermatol. 2010;11:247.

22.  Russell K, Jacob SE. Bisabolol. Dermatitis. 2010;21:57.
23.  Savikin K, Zdunic´ G, Menkovic´ N, et al. Ethnobotanical study on 
traditional  use  of  medicinal  plants  in  South-Western  Serbia, 
Zlatibor district. J Ethnopharmacol. 2013;146:803.

24.  Máday E, Szöke E, Muskáth Z, et al. A study of the production of 
essential oils in chamomile hairy root cultures. Eur J Drug Metab 
Pharmacokinet. 1999;24:303.

25.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

Medicine. Rochester, VT: Healing Arts Press; 2003:68.

26.  Lee KG, Shibamoto T. Determination of antioxidant potential of 
volatile  extracts  isolated  from  various  herbs  and  spices.  J  Agric 
Food Chem. 2002;50:4947.

27.  Reszko AE, Berson D, Lupo MP. Cosmeceuticals: Practical appli-

cations. Dermatol Clin. 2009;27:401.

28.  Paulsen  E,  Christensen  LP,  Andersen  KE.  Cosmetics  and  herbal 
remedies with Compositae plant extracts - are they tolerated by 
Compositae-allergic patients? Contact Dermatitis. 2008;58:15.
29.  Avallone  R,  Zanoli  P,  Puia  G,  et  al.  Pharmacological  profile  of 
apigenin,  a  flavonoid  isolated  from  Matricaria  chamomilla. 
Biochem Pharmacol. 2000;59:1387.

30.  Wu  J.  Skin  care  update:  The  role  of  natural  products  in  clinical 

practice. Introduction. J Drugs Dermatol. 2008;7:s1.

31.  Chandrashekhar  VM,  Halagali  KS,  Nidavani  RB,  et  al.  Anti-
allergic activity of German chamomile (Matricaria recutita L.) in 
mast cell mediated allergy model. J Ethnopharmacol. 2011;137:336.
32.  Speisky H, Rocco C, Carrasco C, et al. Antioxidant screening of 

medicinal herbal teas. Phytother Res. 2006;20:462.

 
270  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

33.  Srivastava JK, Pandey M, Gupta S. Chamomile, a novel and selec-
tive  COX-2  inhibitor  with  anti-inflammatory  activity.  Life  Sci. 
2009;85:663.

34.  Gardiner  P.  Complementary,  holistic,  and  integrative  medicine: 

Chamomile. Pediatr Rev. 2007;28:e16.

35.  Pavesi VC, Lopez TC, Martins MA, et al. Healing action of topical 
chamomile  on  5-fluoracil  induced  oral  mucositis  in  hamster. 
Support Care Cancer. 2011;19:639.

36.  Aertgeerts P, Albring M, Klaschka F, et al. Comparative testing of 
Kamillosan  cream  and  steroidal  (0.25%  hydrocortisone,  0.75% 
fluocortin butyl ester) and non-steroidal (5% bufexamac) derma-
tologic  agents  in  maintenance  therapy  of  eczematous  diseases. 
Z Hautkr. 1985;60:270.

37.  Patzelt-Wenczler  R,  Ponce-Pöschl  E.  Proof  of  efficacy  of 

Kamillosan® cream in atopic eczema. Eur J Med Res. 2000;5:171.

38.  Lee SH, Heo Y, Kim YC. Effect of German chamomile oil applica-
tion  on  alleviating  atopic  dermatitis-like  immune  alterations  in 
mice. J Vet Sci. 2010;11:35.

39.  Tubaro A, Zilli C, Redaelli C, et al. Evaluation of anti-inflammatory 
activity  of  a  chamomile  extract  after  topical  application.  Planta 
Med. 1984;50:359.

40.  Shipochliev  T,  Dimitrov  A,  Aleksandrova  E.  Anti-inflammatory 
action of a group of plant extracts. Vet Med Nauki. 1981;18:87.
41.  Drummond EM, Harbourne N, Marete E, et al. Inhibition of pro-
inflammatory biomarkers in THP1 macrophages by polyphenols 
derived  from  chamomile,  meadowsweet  and  willow  bark. 
Phytother Res. 2013;27:588.

42.  Merfort  I,  Heilmann  J,  Hagedorn-Leweke  U,  et  al.  In  vivo  skin 
penetration  studies  of  chamomile  flavones.  Pharmazie. 
1994;49:509.

43.  Jarrahi  M,  Vafaei  AA,  Taherian  AA,  et  al.  Evaluation  of  topical 
Matricaria chamomilla extract activity on linear incisional wound 
healing in albino rats. Nat Prod Res. 2010;24:697.

44.  Jarrahi  M.  An  experimental  study  of  the  effects  of  Matricaria 
chamomilla extract on cutaneous burn wound healing in albino 
rats. Nat Prod Res. 2008;22:422.

45.  Charousaei F, Dabirian A, Mojab F. Using chamomile solution or 
a  1%  topical  hydrocortisone  ointment  in  the  management  of 
peristomal  skin  lesions  in  colostomy  patients:  Results  of  a  con-
trolled clinical study. Ostomy Wound Manage. 2011;57:28.

46.  Reddy  KK,  Grossman  L,  Rogers  GS.  Common  complementary 
and alternative therapies with potential use in dermatologic sur-
gery: Risks and benefits. J Am Acad Dermatol. 2013;68:e127.

47.  Foti  C,  Nettis  E,  Panebianco  R,  et  al.  Contact  urticaris  from 

Matricaria chamomile. Contact Dermatitis. 2000;42:360.

48.  Compositae  Allergy.  http://www.dermnetnz.org/dermatitis 

/compositae-allergy.html. Accessed March 16, 2014.

49.  Paulsen  E,  Andersen  KE.  Patch  testing  with  constituents  of 

Compositae mixes. Contact Dermatitis. 2012;66:241.

50.  Aburjai  T,  Natsheh  FM.  Plants  used  in  cosmetics.  Phytother  Res. 

2003;17:987.

51.  de la Torre Morín F, Sánchez Machín I, García Robaina JC, et al. 
Clinical  cross-reactivity  between  Artemisia  vulgaris  and 
Matricaria  chamomilla  (chamomile).  J  Investig  Allergol  Clin 
Immunol. 2001;11:118.

52.  Thornfeldt C. Cosmeceuticals containing herbs: Fact, fiction, and 

future. Dermatol Surg. 2005;31:873.

53.  Jovanovic´  M,  Poljacki  M,  Duran  V,  et  al.  Contact  allergy  to 
Compositae plants in patients with atopic dermatitis. Med Pregl. 
2004;57:209.

54.  Andres  C,  Chen  WC,  Ollert  M,  et  al.  Anaphylactic  reaction  to 

chamomile tea. Allergol Int. 2009;58:135.

55.  Heck AM, De Witt BA, Lukes AL. Potential interactions between 
alternative  therapies  and  warfarin.  Am  J  Health  Syst  Pharm. 
2000;57:1221.

56.  Abebe  W.  Herbal  medication:  Potential  for  adverse  interactions 

with analgesic drugs. J Clin Pharm Ther. 2002;27:391.

57.  Wilkinson JM. What do we know about herbal morning sickness 

treatments? A literature survey. Midwifery. 2000;16:224.

58.  Ogata I, Kawanai T, Hashimoto E, et al. Bisabololoxide A, one of 
the  main  constituents  in  German  chamomile  extract,  induces 
apoptosis in rat thymocytes. Arch Toxicol. 2010;84:45.

59.  Wilkinson SM, Hausen BM, Beck MH. Allergic contact dermatitis 

from plant extracts in a cosmetic. Contact Dermatitis. 1995;33:58.

60.  Pastor  N,  Silvestre  JF,  Mataix  J,  et  al.  Contact  cheilitis  from 
bisabolol and polyvinylpyrrolidone/hexadecane copolymer in lip-
stick. Contact Dermatitis. 2008;58:178.

61.  Jaric´  S, Popovic´ Z, Macukanovic´  -Jocic´   M, et al. An ethnobotanical 
study  on  the  usage  of  wild  medicinal  herbs  from  Kopaonik 
Mountain (Central Serbia). J Ethnopharmacol. 2007;111:160.
62.  Rügge SD, Nielsen M, Jacobsen AS, et al. Evidence of dermato-
logical effects of chamomile. Ugeskr Laeger. 2010;172:3492.
63.  Ramos  MF,  Santos  EP,  Bizarri  CH,  et  al.  Preliminary  studies 
towards utilization of various plant extracts as antisolar agents. 
Int J Cosmet Sci. 1996;18:87.

64.  Evans S, Dizeyi N, Abrahamsson PA, et al. The effect of a novel 
botanical  agent  TBS-101  on  invasive  prostate  cancer  in  animal 
models. Anticancer Res. 2009;29:3917.

65.  Shukla S, Gupta S. Apigenin suppresses insulin-like growth factor 
I receptor signaling in human prostate cancer: An in vitro and in 
vivo study. Mol Carcinog. 2009;48:243.

66.  Mamalis  A,  Nguyen  DH,  Brody  N,  et  al.  The  active  natural  anti-
oxidant properties of chamomile, milk thistle, and halophilic bacte-
rial components in human skin in vitro. J Drugs Dermatol. 2013;12:780.
67.  Kogiannou DA, Kalogeropoulos N, Kefalas P, et al. Herbal infusions; 
their phenolic profile, antioxidant and anti-inflammatory effects in 
HT29 and PC3 cells. Food Chem Toxicol. 2013;61:152.

68.  Koch C, Reichling J, Schneele J, et al. Inhibitory effect of essential 
oils against herpes simplex virus type 2. Phytomedicine. 2008;15:71.
69.  Mazokopakis  EE,  Vrentzos  GE,  Papadakis  JA,  et  al.  Wild 
chamomile (Matricaria recutita L.) mouthwashes in methotrexate-
induced oral mucositis. Phytomedicine. 2005;12:25.

 
C H A P T E R   7 1

Calendula

C H A P T E R  71  ■   C A L E N D U L A  

271

Activities:

Anti-inflammatory, antioxidant, antimicrobial, antiseptic, 
immunomodulatory, photoprotective

Important Chemical Components:

Triterpenoids  (i.e.,  sesquiterpene  lactones,  faradiol, 
taraxasterol), flavonoids (i.e., quercetin, rutin, isorham-
netin, kaempferol, narcissin), phenolic acids, ubiquinone 
(CoQ10)  and  other  quinines  (including  polyprenylqui-
nones), mucilages, saponins, carotenoids (i.e., β-carotene, 
lutein, lycopene, xanthophylls), essential oils (1,8-cineole, 
α-pinene,  α-thujene,  dihydrotagetone,  T-muurolol),  
resins, sterins, sugars, sterins, sterols, tocopherols 1–7

Origin Classification:

This ingredient is natural. Organic forms exist.

Personal Care Category:

Analgesic, anti-inflammatory

Recommended  for  the  following  Baumann  Skin 
Types:

DSNT, DSNW, DSPT, DSPW, OSNT, OSNW, OSPT, and 
OSPW

 SOURCE

Popularly known as pot marigold, garden marigold, holligold/
holigold,  marigold,  marybud,  common  marigold,  maravilla, 
ruddles,  and  goldbloom,  Calendula  officinalis  is  a  bright, 
flowering  annual  herb  native  to  Asia,  central  and  southern 
Europe,  northern  Africa,  and  the  Mediterranean  region.2,8 
Despite one of its appellations, it is not related to the garden 
marigolds  of  the  Tagetes  genus,  also  within  the  Asteraceae  
(or  Compositae)  family.9  Like  many  other  members  of  the 
Asteraceae  family,  which  includes  daisies,  arnica,  feverfew, 
chamomile, edelweiss, and yarrow, calendula is now cultivated 
throughout  the  world  (see  Chapter  70,  Chamomile,  and 
Chapter  72,  Edelweiss).  Like  many  other  popular  herbs, 
calendula  is  valued  for  its  culinary  and  medicinal  uses  and  is 
cultivated  for  ornamental  purposes.  Through  traditional  use, 
calendula has long been considered a soothing herb that, more 

TABLE 71-1
Pros and Cons of Calendula

Pros
Considered to have potent anti-
inflammatory properties

Broad naturopathic uses

Cons
Limited clinical data

Risk of allergy
Efficacy greatly depends upon the source of the 

herb and the formulation

recently,  has  been  found  to  possess  anti-inflammatory, 
antibacterial, and antioxidant properties.6,7,10 Today, its primary 
indications are cutaneous and inflammatory conditions, scalds, 
bruises,  boils,  rashes,  and  first-degree  burns,  including 
sunburns8,11 (Table 71-1).

 HISTORY

In ancient Rome, calendula was regarded for its properties in 
breaking  fevers.  It  was  used  as  a  topical  anti-inflammatory 
agent prior to the 12th century in medieval Europe,12 where 
its  use  further  spread  in  the  13th  century,13  when  it  was 
grown  in  monastery  gardens  and  used  for  wound  healing. 
Calendula  has  continued  to  serve  as  a  staple  among  topical 
and systemic homeopathic remedies through the succeeding 
centuries.1,11 In the 1860s, it was used to treat battle wounds 
during the United States Civil War. Essentially, the antiseptic 
properties  were  seen  to  prevent  gangrene  and  clean  and 
repair wounds. Further, calendula has been used traditionally 
for treating an array of burns, bruises, skin tumors, cutaneous 
lesions, gastric ulcers and other stomach ailments, dysmenor-
rhea, edema, jaundice, and nervous disorders.3,9 In Bulgarian 
folk  medicine,  it  has  been  used  as  an  anti-inflammatory, 
antipyretic,  and  antitumorigenic  agent.14  In  Ayurvedic  and 
Unani  medicine,  C.  officinalis  has  been  noted  for  conferring 
anti-inflammatory,  antipyretic,  antiepileptic,  and  antimicro-
bial  activity.3  Currently,  calendula  is  broadly  accepted  in 
Europe for mild burns, sunburn, and slow-healing wounds; it 
is  approved  in  Germany  and  other  European  countries 
specifically for leg ulcers and slow-healing wounds.9

 CHEMISTRY

The mechanism of action is not fully understood, but the con-
stituents  in  calendula  that  likely  play  a  role  in  the  chemical 
activity of the herb include saponins, carotenoids, essential oil, 
sterols, flavonoids, and mucilage. Triterpenoids, though, appear 
to be the most significant anti-inflammatory components of the 
flower.15 The anti-inflammatory activity of calendula seems to 
be  supported  by  emerging  scientific  evidence.  A  study  with 
mice showed significant anti-inflammatory evidence by several 
members of the Compositae family, including calendula.16 As is 
the case with all members of the Compositae family, calendula 
can cause contact dermatitis and it seems to be the sesquiterpene 
lactones most responsible for eliciting these allergic reactions.17
Research has shown that the butanolic fraction of C. officinalis 
displays  antioxidant,  free  radical-scavenging  activity.18  The 
concentrations of flavonoids and carotenoids in calendula are suf-
ficiently  high  that  calendula  flowers  have  been  used  as  natural 
orange-yellow  dyes.  More  importantly,  such  components  are 
quite  possibly  responsible  for  yielding  the  reputed  antioxidant 
effect. In fact, calendula flowers contain the potent antioxidant 
carotenoids β-carotene, lutein, and lycopene. This may at least 
partially  account  for  the  anti-inflammatory,  antiseptic, 

 
272 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

antihemorrhagic,  antiulcerogenic,  and  immunostimulating 
characteristics  that  have  been  attributed  to  calendula.  Recent 
research indeed continues to bear out the viability of producing 
formulations  with  biological  activity  using  the  extracts  of  
C. officinalis, given the prevalence of saponins, triterpenes, and 
flavonols.5

 ORAL USES

Naturopathic  healers  ascribe  antispasmodic,  antimicrobial,  and 
antiviral activity to calendula. As such, these practitioners consider 
calendula indicated systemically for digestive problems and as a 
gargle for oral/dental problems such as sores and toothaches.

Notably,  orally  administered  C.  officinalis  extract  has  been 
shown to accelerate wound healing in rats with burn injury, with 
collagen-hydroxyproline  and  hexosamine  levels  significantly 
elevated  in  treated  animals  and  lipid  peroxidation  significantly 
reduced compared to untreated controls.19

 TOPICAL USES

Calendula is a popular antiseptic component in the armamen-
tarium for the treatment of scrapes, cuts, burns, and wounds. 
Naturopathic  healers  also  recommend  its  use  for  treating 
eczema,  and  note  that  the  nontoxic  herb  acts  topically  as  an 
anti-inflammatory and systemically to promote blood clotting. 
Topically  applied  calendula  formulations  have  been  found  to 
be effective in treating diaper rash and for nipples tender from 
breastfeeding.  Nearly  200  cosmetic  creams,  lotions,  and 
shampoos  are  thought  to  contain  C.  officinalis  extract.2,3  The 
myriad topical uses by naturopathic practitioners include as an 
external  wash, for  ocular  inflammations,  abscesses,  acne, bee 
stings, boils, eczema, and varicose veins.

Among  homeopathic  practitioners,  calendula  is  considered  a 
suitable home remedy for treating scrapes and burns.20 Western 
medicine has also incorporated calendula as an antiseptic and anti-
inflammatory agent, treating some skin disorders and pain.18 Like 
the expansive range of calendula products, the number of poten-
tial indications is wide and growing. In vitro anti-HIV activity has 
been discerned in organic C. officinalis extract, which has prompted 
research  into  possible  therapeutic  applications,  especially  given 
the  known  antiviral  properties  of  the  flavonoid  components  of 
the plant.14 In addition, several calendula cream formulations have 
also been demonstrated, in healthy volunteers, to protect against 
irritant contact dermatitis provoked by sodium lauryl sulfate.21 In 
cosmetic or personal care products, it is used for skin conditioning 
in concentrations ranging from 0.1 to 1 percent.8

Diaper Dermatitis
A postmarketing surveillance study performed in Italy in 2007 
comparing  the  efficacy  and  safety  of  two  baby  creams  in  
82 infants with diaper dermatitis revealed that the calendula-
based cream was rated slightly safer and equally efficacious as 
a zinc oxide-based cream. Both creams were well tolerated and 
rated, with approximately 80 percent of physicians labeling the 
creams  as  “very  good”  or  “good”;  in  78  percent  of  cases,  the 
doctor would prescribe the calendula cream and in 65.9 percent, 
the zinc oxide cream.22

Panahi  et  al.  conducted  a  randomized,  double-blind  trial  to 
compare the effects of calendula ointment and aloe vera cream 
on the frequency and severity of diaper dermatitis in 66 infants 
treated three times daily for 10 days (see Chapter 65, Aloe Vera). 
No adverse reactions were reported for either group. Symptoms 

were  mitigated  in  both  groups,  but  the  calendula  group 
experienced  significantly  fewer  rash  sites.  The  researchers 
concluded that both botanicals, but especially topical calendula, 
offer safe and effective treatment options for diaper dermatitis.23

Radiation Dermatitis
In 2004, Pommier et al. performed a Phase III randomized trial 
to compare the effects of calendula and trolamine in 254 patients 
treated in a regional cancer center in France for the prevention 
of acute radiation dermatitis after breast cancer surgery. They 
found that acute dermatitis of grade 2 or higher occurred sig-
nificantly  less  often  in  the  calendula  group  (41  percent  vs.  
63 percent), with fewer interruptions in radiotherapy and less 
radiation-induced  pain  in  patients  treated  with  calendula. 
Although  calendula  was  deemed  more  difficult  to  apply  than 
trolamine,  patient  self-assessment  revealed  that  calendula 
treatment was more satisfying. The investigators concluded that 
calendula  is  extremely  effective  in  preventing  acute  dermatitis 
of  grade  2  or  higher  and  is  a  worthy  option  for  patients 
undergoing postoperative radiotherapy for breast cancer.24

Five years later, Kassab et al. conducted a database review of 
randomized controlled trials (RCTs) of homeopathic medicines 
used  to  treat  the  adverse  effects  associated  with  cancer 
treatments. Eight controlled trials met inclusion criteria, with the 
Pommier and colleagues study cited above indicating that topical 
calendula was more effective than topical trolamine in preventing 
radiation dermatitis, and a small study with 32 subjects showing 
the  superiority  of  Traumeel  S®  (a  proprietary  homeopathic 
formulation that includes calendula along with 11 other natural 
ingredients)  over  placebo  as  a  mouthwash  in  treating 
chemotherapy-induced stomatitis.25

A  2010  systematic  literature  review  of  skin  toxicity 
management  during  radiation  therapy  in  Australia  and  
New Zealand by Kumar et al. identified only seven articles, of  
29  meeting  search  criteria,  citing  statistically  significant  side-
effect management outcomes. Calendula was one of the topical 
therapies associated with such results.26

In  a  2011  clinical  update  covering  the  previous  four  years  of 
publications on evidence-based skin care management in radiation 
therapy,  McQuestion  highlighted  the  Pommier  report  on  calen-
dula cream as having the potential to lower the incidence of grade 
2 or 3 cutaneous reactions in women with breast cancer, with the 
Radiodermatitis  Putting  Evidence  into  Practice  (PEP)  Resource 
consequently categorizing the herb as “likely to be effective.”27,28

However,  in  2013,  an  international  interdisciplinary  study 
group of experts convened to develop RCT-based guidelines on 
radiation dermatitis prevention and treatment was less impressed. 
Following  an  extensive  literature  review,  they  determined  that 
while  some  evidence  supported  the  use  of  silver  sulfadiazine 
cream  to  lower  dermatitis  score,  insufficient  evidence  had  been 
compiled  to  support  the  use  of  numerous  topical  treatments, 
including calendula (see Chapter 80, Silver). For that reason, the 
panel recommended against the use of such interventions.29

 SAFETY ISSUES

In  terms  of  oral  safety,  the  United  States  Food  and  Drug 
Administration  (FDA),  in  1997,  labeled  the  dried  flower  of 
calendula  used  in  spices  and  other  natural  seasonings  and 
flavorings as generally recognized as safe (GRAS).2,8

Calendula has been associated with cases of contact dermatitis 
and  can  cause  allergy  in  those  allergic  to  ragweed  and  other 
members of the Compositae family (see Table 70-2). Reider et al. 

 
tested  443  consecutive  patients  with  Compositae  mix, 
sesquiterpene lactone mix, arnica, calendula, and propolis, along 
with the European standard and other series, in a 2001 contact 
sensitization study. Nine patients (approximately 2.03 percent) 
reacted to calendula, of whom four were among the total of 18 
subjects  who  reacted  to  Compositae  mix.  The  researchers 
observed  that  calendula  and  arnica  sensitization  was  often 
correlated  with  colophonium,  fragrance  mix,  Myroxylon 
Pereirae  resin,  and  propolis  reactions  (see  Chapter  60,  Honey/
Propolis/Royal Jelly). They concluded that testing calendula and 
arnica  sensitivity  only  with  Compositae  or  sesquiterpene  mix 
alone is insufficient and that Compositae allergy is a significant 
contributor to the prevalence of contact dermatitis. Further, they 
suggested that given the pervasive use of extracts of such plants 
in cosmetic and occupational products, patch testing should be 
adapted accordingly, with additional plant extracts or additions 
to the commercial Compositae mix.30

Some  authors  believe  that  the  increasing  use  of  herbal 
medicine and herb-based cosmetics may lead to an increase in 
contact  dermatitis  as  some  of  the  more  popular  herbs  (e.g., 
arnica, chamomile, marigold, and echinacea) are members of the 
Compositae family. It is not yet known what the relative risks of 
provoking  contact  dermatitis  are  from  the  use  of  products 
containing herbs of the Compositae family.17 In addition, despite 
a growing body of research on the use of calendula, current data 
are not sufficient to establish a scientific standard of safety for  
C. officinalis extract in cosmetic formulations.2

The results of a prospective, multicenter, observational study of 
adverse drug reactions to Asteraceae extracts in German primary 
care between September 2004 to September 2006 indicated that 
calendula was the second most prescribed agent, and that the use 
of these agents (including chamomile and arnica) was not linked to 
a high risk of adverse reactions (see Chapter 70, Chamomile).31

According  to  a  report  by  the  Cosmetic  Ingredient  Review 
(CIR)  Expert  Panel  in  2010,  C.  officinalis  ingredients  (extract, 
flower, flower extract, flower oil, and seed oil) are safe for use in 
cosmetic  formulations  for  the  uses  and  concentrations  consid-
ered.  Though  some  of  the  ingredients  may  act  as  mild  ocular 
irritants, they were not found to be sensitizing, photosensitizing, 
or otherwise irritating in animal or clinical testing.32

 ENVIRONMENTAL IMPACT

The  significance  of  the  environmental  impact  from  the 
cultivation  and  commercial  use  of  C.  officinalis  is  not  well 
reported. The herb is known to grow rapidly and for being easy 
to germinate and tend.33

 FORMULATION CONSIDERATIONS

A 2010 in vivo experiment in rats conducted by Vargas et al. indi-
cated  that  hyperbranched  polyglycerol  electrospun  nanofibers 
containing  C.  officinalis  may  be  an  effective  bioactive  wound 
dressing in the clinical setting.34 The researchers noted the chal-
lenges of producing bioactive preparations of the herb due to poor 
solubility and decreased uptake of pharmaceutical ingredients.34

Kassab  et  al.  suggest  that  formulation  adjustments  for  the 
calendula ointment used successfully in the study by Pommier 
et al. in acute radiation dermatitis should be considered given 
that  30  percent  of  the  participants  complained  that  it  was 
difficult to apply.25

With all herbal extracts, the source of the herb greatly affects 
the amount of active constituents in the preparation. Assays that 

C H A P T E R  71  ■   C A L E N D U L A  

273

look at the final product help determine efficacy. Bernatoniene et al. 
describe  the  preparation  of  a  hydrophilic  calendula-containing 
cream in a 2011 published study.35 Calendula can be prepared as 
a tea, oil, cream, serum, or lotion.

 USAGE CONSIDERATIONS

In Germany, calendula is prescribed for dermatitis and eczema as 
well as several non-dermatologic indications, such as upper res-
piratory  conditions,  conjunctival  disorders,  middle  ear  and 
mastoid  ailments,  and  arthropathies.31  Absorption  rates  of  the 
preparation and interactions with other ingredients depend on the 
type of preparation used and the presence of other ingredients.

 SIGNIFICANT BACKGROUND

The German Commission E, European Scientific Co-operative 
on  Phytotherapy,  British  Herbal  Pharmacopoeia,  and  World 
Health Organization monographs acknowledge C. officinalis for 
wound-healing  and  anti-inflammatory  properties.3  Calendula 
has,  indeed,  long  been  used  as  a  topical  agent  for  its  anti-
inflammatory activity. In recent years, the presence of several 
active ingredients, including flavonoids and phenolic acids, has 
fueled research into potential antioxidant activity.

Wound Healing
In 2009, Preethi and Kuttan found that oral administration and 
topical  application  of  C.  officinalis  exhibited  potent  wound- 
healing activity in a rat model. Wound closure was found to be 
90 percent in the extract-treated group and 51.1 percent in the 
control  group  after  eight  days.  Reepithelialization  took  
17.7 days for the control group, but 14 days in animals receiving 
a  20  mg/kg/wt.  dose  and  13  days  for  animals  administered  
100 mg/kg/wt. Compared to control rats, significant increases 
in hydroxyl proline and hexosamine content were recorded in 
the animals treated with calendula.36

The next year, Parente et al. used a rat model to demonstrate 
that the healing activity associated with calendula, particularly 
its constituent triterpenes and steroids, can be partly attributed 
to  the  positive  influence  the  herb  exerts  on  angiogenesis,  as 
indicated by the promotion of neovascularization.13

Photoprotection and Antiaging Activity
Fonseca  et  al.  conducted  an  investigation  in  2010  into  the 
potential of  orally  administered  C.  officinalis extract  to prevent 
ultraviolet (UV) B-induced oxidative stress in the skin of hairless 
mice. They found that doses of 150 and 300 mg/kg maintained 
glutathione  levels  nearly  to  the  level  of  nonexposed  control 
mice.  The  investigators  acknowledged  this  photoprotective 
effect but suggested that more research is necessary to fully elu-
cidate the protective activity delivered to the skin by calendula.11
The next year, the same team studied the possible preventive 
effects of topical C. officinalis extracts against UVB-induced skin 
damage. Using hairless mice, the researchers found that although 
all of the tested formulations were physically and functionally 
stable,  the  gel  formulation  was  the  most  effective  for  topical 
delivery.  The  gel  maintained  diminished  glutathione  levels 
approximating those of nonirradiated mice, but did not alter the 
UVB-enhanced  activities  of  gelatinase-9  or  myeloperoxidase. 
Histologic  examination  revealed  that  the  calendula  gel  attenu-
ated UVB-induced effects that manifest as changes to collagen 
fibrils.  The  authors  attributed  the  observed  photoprotective 

 
274 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

effect from topically applied calendula to the effect of the gel in 
potentially enhancing collagen production in the connective tis-
sue of the hairless mice.37

Using the Cutometer 580 MPA on 21 healthy human volunteers 
over eight weeks earlier in 2011, Akhtar et al. determined that a 
topically applied calendula formulation was effective in rendering 
significant improvements in skin hydration and firmness.38

In 2012, Mishra et al. assessed the effects of a cream containing 
C. officinalis essential oil on the skin of albino rats exposed to UVB. 
In  comparison  to  untreated  controls,  animals  exposed  to  one 
month of daily UVB exposure and treatment with 4 or 5 percent 
calendula  cream  experienced  significant  reductions 
in 
malondialdehyde  levels  and  significant  increases  in  catalase, 
glutathione, superoxide dismutase, ascorbic acid, and total pro-
tein  levels.  The  investigators  concluded  that  topically  applied 
calendula essential oil cream prevents UVB-induced changes in 
cutaneous antioxidant levels.4 Previously, Mishra et al. showed, 
in  vitro,  that  a  calendula  oil  in  cream  formulation  displayed  an 
appreciable sun protection factor (SPF) and has potential to exert 
photoprotective effects in sunscreen creams.33

Anticancer Activity
In 2013, Ali et al. used the two-stage skin carcinogenesis model 
in  mice  to  evaluate  the  chemopreventive  effects  of  the 
methanolic extracts of three medicinal herbs (Trigonella foenum-
graecum, Eclipta alba, and C. officinalis) over 32 weeks. All three 
extracts were effective in suppressing proliferation by boosting 
endogenous  antioxidant  defense,  hindering  nuclear  factor-κB, 
diminishing inflammation, augmenting immunosurveillance of 
the genetically mutated cells, and silencing cell cycle progression 
signals.  The  investigators  noted  that  the  herbal  extracts  also 
engendered the stable cytoplasmic expression of p53-mediated 
apoptosis,  resulting  in  fewer  and  regressed  tumors.39  
C. officinalis is also considered among herbalists and naturopathic 
practitioners  to  be  among  the  herbs  useful  in  supporting  a 
holistic approach to cancer treatment.6

Chronic Venous Leg Ulcer Treatment
Thirty-four patients with venous leg ulcers were clinically exam-
ined by Duran et al. in 2005 after 21 were treated with a topical 
C. offinalis ointment and 13, a control ointment, for three weeks. 
Total surface area of the ulcers declined by 41.71 percent in the 
experimental group, with complete epithelialization achieved in 
seven patients. A reduction of 14.52 percent was recorded in the 
control  group,  with  four  patients  achieving  epithelialization. 
While the investigators viewed their results as preliminary, they 
acknowledged the statistically significant acceleration of wound 
healing in patients using the calendula ointment, suggesting its 
viability in venous ulcer epithelialization.40

In 2012, Kundakovic´ et al. conducted a seven-week prospective 
nonrandomized  pilot  study  of  the  effects  of  Herbadermal® 
ointment, which combines calendula, garlic, and St. John’s wort, 
on  the  epithelialization  and  microbial  flora  of  25  patients  
(15 women, 10 men) with venous ulcers. Epithelialization was 
measured as 99.1 percent after seven weeks, with no significant 
impact on microbial flora identified. The investigators found this 
topical  botanical 
in  delivering 
antierythematous, antiedematous, epithelializing activity.41

formulation  effective 

Other Uses
In  2012,  Saini  et  al.  investigated  the  effects  of  calendula  on 
human  gingival  fibroblast-mediated  collagen  degradation  and 

matrix metalloproteinase (MMP) activity based on the prominent 
role of quercetin among components of the flower. They found 
that  calendula  2  to  3  percent  completely  inhibited  MMP-2 
activity and fibroblast-mediated collagen degradation as did var-
ious doxycycline and quercetin doses, but calendula was more 
effective than the corresponding concentrations of pure querce-
tin, which the researchers ascribed to other key constituents of 
the  herb.  Given  these  findings,  they  speculated  that  calendula 
has the potential to arrest periodontal disease progression.1

 CONCLUSION

There is a long history of traditional medical use of calendula 
and  compelling  anecdotal  evidence  of  its  efficacy  for  certain 
dermatologic  conditions.  As  is  also  the  case  with  most  herbs 
and herbal ingredients in cosmeceuticals, there is a paucity of 
randomized,  double-blind,  placebo-controlled  studies 
establishing  incontrovertible  evidence  of  efficacy.  Products 
containing calendula do appear to be safe but there is potential 
for products of the Compositae family to elicit allergic reactions. 
Additional research is necessary to assess the relative safety of 
these products and to determine if such herbal cocktails, with 
calendula as a leading active ingredient, can impart the same or 
similar  benefits  as  those  reported  from  traditional  use  of  the 
less dilute form of the herb.

REFERENCES

1.  Saini P, Al-Shibani N, Sun J, et al. Effects of Calendula officinalis 

on human gingival fibroblasts. Homeopathy. 2012;101:92.

2.  Anonymous. Final report on the safety assessment of Calendual 
officinalis  extract  and  Calendula  officinalis.  Int  J  Toxicol. 
2001;20(Suppl 2):13.

3.  Arora  D,  Rani  A,  Sharma  A.  A  review  on  phytochemistry  and 
ethnopharmacological  aspects  of  genus  Calendula.  Pharmacogn 
Rev. 2013;7:179.

4.  Mishra AK, Mishra A, Verma A, et al. Effects of calendula essen-
tial oil-based cream on biochemical parameters of skin of albino 
rats against ultraviolet B radiation. Sci Pharm. 2012;80:669.

5.  Pérez-Carreón JI, Cruz-Jiménez G, Licea-Vega JA, et al. Genotoxic 
and anti-genotoxic properties of Calendula officinalis extracts in 
rat  liver  cell  cultures  treated  with  diethylnitrosamine.  Toxicol  In 
Vitro. 2002;16:253.

6.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 
Medicine. Rochester, VT: Healing Arts Press; 2003:458, 488, 491, 
535.

7.  Preethi  KC,  Kuttan  G,  Kuttan  R.  Anti-inflammatory  activity  of 
flower  extract  of  Calendula  officinalis  Linn.  And  its  possible 
mechanism of action. Indian J Exp Biol. 2009;47:113.

8.  Re TA, Mooney D, Antignac E, et al. Application of the threshold 
of  toxicological  concern  approach  for  the  safety  evaluation  of 
calendula flower (Calendula officinalis) petals and extracts used in 
cosmetic  and  personal  care  products.  Food  Chem  Toxicol. 
2009;47:1246.

9.  Foster S. An Illustrated Guide to 101 Medicinal Herbs: Their History, 
Use,  Recommended  Dosages,  and  Cautions.  Loveland,  CO: 
Interweave Press; 1998:44-45.

10.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy:  Modern 

Herbal Medicine. London: Churchill Livingstone; 2000:133.

11.  Fonseca  YM,  Catini  CD,  Vicentini  FT,  et  al.  Protective  effect  of 
Calendula officinalis extract UVB-induced oxidative stress in skin: 
Evaluation of reduced glutathione levels and matrix metallopro-
teinase secretion. J Ethnopharmacol. 2010;127:596.

12.  Basch E, Bent S, Foppa I, et al. Marigold (Calendula officinalis L.): 
An  evidence-based  systematic  review  by  the  Natural  Standard 
Research Collaboration. J Herb Pharmacother. 2006;6:135.

13.  Parente LM, Andrade MA, Brito LA, et al. Angiogenic activity of 

Calendula officinalis flowers L. in rats. Acta Cir Bras. 2011;26:19.

14.  Kalvatchev Z, Walder R, Garzaro D. Anti-HIV activity of extracts 
from  Calendula  officinalis  flowers.  Biomed  Pharmacother. 
1997;51:176.

 
15.  Della Loggia R, Tubaro A, Sosa S, et al. The role of triterpenoids 
in the topical anti-inflammatory activity of Calendula officinalis 
flowers. Planta Med. 1994;60:516.

16.  Akihisa  T,  Yasukawa  K,  Oinuma  H,  et  al.  Triterpene  alcohols 
from  the  flowers  of  compositae  and  their  anti-inflammatory 
effects. Phytochemistry. 1996;43:1255.

17.  Paulsen  E.  Contact  sensitization  from  Compositae-containing 
herbal remedies and cosmetics. Contact Dermatitis. 2002;47:189.
18.  Cordova CA, Siqueira IR, Netto CA, et al. Protective properties of 
butanolic extract of the Calendula officinalis L. (marigold) against 
lipid peroxidation of rat liver microsomes and action as free radi-
cal scavenger. Redox Rep. 2002;7:95.

19.  Chandran  PK,  Kuttan  R.  Effect  of  Calendula  officinalis  flower 
extract on acute phase proteins, antioxidant defense mechanism 
and  granuloma  formation  during  thermal  burns.  J  Clin  Biochem 
Nutr. 2008;43:58.

20.  Kaplan B. Homeopathy: 3. Everyday uses for all the family. Prof 

Care Mother Child. 1994;4:212.

21.  Fuchs  SM,  Schliemann-Willers  S,  Fischer  TW,  et  al.  Protective 
effects  of  different  marigold  (Calendula  officinalis  L.)  and  rose-
mary  cream  preparations  against  sodium-lauryl-sulfate-induced 
irritant contact dermatitis. Skin Pharmacol Physiol. 2005;18:195.
22.  Guala A, Oberle D, Ramos M. Efficacy and safety of two baby 
creams in children with diaper dermatitis: Results of a postmar-
keting surveillance study. J Altern Complement Med. 2007;13:16.
23.  Panahi Y, Sharif MR, Sharif A, et al. A randomized comparative 
trial on the therapeutic efficacy of topical aloe vera and Calendula 
officinalis on diaper dermatitis in children. Scientific WorldJournal. 
2012;2012:810234.

24.  Pommier  P,  Gomez  F,  Sunyach  MP,  et  al.  Phase  III  randomized 
trial  of  Calendula  officinalis  compared  with  trolamine  for  the 
prevention of acute dermatitis during irradiation for breast cancer. 
J Clin Oncol. 2004;22:1447.

25.  Kassab S, Cummings M, Berkovitz S, et al. Homeopathic medi-
cines for adverse effects of cancer treatments. Cochrane Database 
Syst Rev. 2009;2:CD004845.

26.  Kumar S, Juresic E, Barton M, et al. Management of skin toxicity 
during radiation therapy: A review of the evidence. J Med Imaging 
Radiat Oncol. 2010;54:264.

27.  McQuestion M. Evidence-based skin care management in radia-
tion therapy: Clinical update. Semin Oncol Nurs. 2011;27:e1.
28.  Feight D, Baney T, Bruse S, et al. Putting evidence into practice. 

Clin J Oncol Nurs. 2011;15:481.

29.  Wong RK, Bensadoun RJ, Boers-Doets CB, et al. Clinical practice 
guidelines  for  the  prevention  and  treatment  of  acute  and  late 

C H A P T E R  71  ■   C A L E N D U L A  

275

radiation reactions from the MASCC Skin Toxicity Study Group. 
Support Care Cancer. 2013;21:2933.

30.  Reider N, Komericki P, Hausen BM, et al. The seamy side of natu-
ral medicines: Contact sensitization to arnica (Arnica montana L.) 
and  marigold  (Calendula  officinalis  L.).  Contact  Dermatitis. 
2001;45:269.

31.  Jeschke  E,  Ostermann  T,  Lüke  C,  et  al.  Remedies  containing 
Asteraceae  extracts:  A  prospective  observational  study  of  pre-
scribing patterns and adverse drug reactions in German primary 
care. Drug Saf. 2009;32:691.

32.  Andersen  FA,  Bergfeld  WF,  Belsito  DV,  et  al.  Final  report  of  the 
Cosmetic Ingredient Review Expert Panel amended safety assess-
ment  of  Calendula  officinalis-derived  cosmetic  ingredients.  Int  J 
Toxicol. 2010;29:221S.

33.  Mishra A, Mishra A, Chattopadhyay P. Assessment of in vitro sun 
protection factor of Calendula officinalis L. (Asteraceae) essential 
oil formulation. J Young Pharm. 2012;4:17.

34.  Vargas EA, do Vale Baracho NC, de Brito J, et al. Hyperbranched 
polyglycerol electrospun nanofibers for wound dressing applica-
tions. Acta Biomater. 2010;6:1069.

35.  Bernatoniene J, Masteikova R, Davalgiene J, et al. Topical applica-
tion  of  Calendula  officinalis  (L.):  Formulation  and  evaluation  of 
hydrophilic  cream  with  antioxidant  activity.  J  Med  Plants  Res. 
2011;5:868.

36.  Preethi KC, Kuttan R. Wound healing activity of flower extract of 
Calendula officinalis. J Basic Clin Physiol Pharmacol. 2009;20:73.
37.  Fonseca YM, Catini CD, Vicentini FT, et al. Efficacy of marigold 
extract-loaded formulations against UV-induced oxidative stress. 
J Pharm Sci. 2011;100:2182.

38.  Akhtar N, Zaman SU, Khan BA, et al. Calendula extract: Effects 
on  mechanical  parameters  of  human  skin.  Acta  Pol  Pharm. 
2011;68:693.

39.  Ali F, Khan R, Khan AQ, et al. Assessment of augmented immune 
surveillance and tumor cell death by cytoplasmic stabilization of 
p53  as  a  chemopreventive  strategy  of  3  promising  medicinal 
herbs  in  murine  2-stage  skin  carcinogenesis.  Integr  Cancer  Ther. 
2013 Dec 19. [Epub ahead of print]

40.  Duran V, Matic M, Jovanovc´ M, et al. Results of the clinical exam-
ination  of  an  ointment  with  marigold  (Calendula  officinalis) 
extract  in  the  treatment  of  venous  leg  ulcers.  Int  J  Tissue  React. 
2005;27:101.

41.  Kundakovic´  T,  Milenkovic´  M,  Zlatkovic´  S,  et  al.  Treatment  of 
venous ulcers with the herbal-based ointment Herbadermal®: A 
prospective  non-randomized  pilot  study.  Forsch  Komplementmed. 
2012;19:26.

 
276 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   7 2

Edelweiss

Activities:

Anti-inflammatory,  antimicrobial,  antioxidant,  analge-
sic, DNA-protective1

Important Chemical Components:
Polyphenols,  including  quercetin-3-O-b -D-glucoside, 
luteolin-7-O -b -D-glucoside, 
luteolin-3’-O -b -D-
glucoside,  luteolin-4’-O-b -D-glucoside,  apigenin-7-O-
b -D-glucoside,  6-hydroxy-luteolin-7-O-b -D-glucoside, 
luteolin-7,4’-di-O-b -D-glucoside, chrysoeriol-7-O-b -D-
glucoside,  leontopodic  acid  and  3,5-dicaffeolyquinic 
acid;  sesquiterpenes,  such  as  isocomene,  14-acetoxy- 
isocomene,  silphiperfolene  acetate,  silphinene,  and  
bisabolane  derivatives  2;  lignans,  including  leoligin 
[ ( 2 S , 3 R , 4 R ) - 4 - ( 3 , 4 - d i m e t h o x y b e n z y l ) - 2 - ( 3 , 4 -
dimethoxyphenyl)tetrahydrofuran-3-yl]methyl  (2Z)-2-
methylbut-2-enoat; b -sitosterol; coumarins; benzofurans3,4

Origin Classification:

This ingredient is natural. Organic forms exist.

Personal Care Category:

Anti-inflammatory, skin protective, conditioning

Recommended  for  the  following  Baumann  Skin 
Types:

DSNT, DSPT, DSNW, DSPW, OSNT, OSPT, OSNW, and 
OSPW

 SOURCE

Leontopodium  alpinum,  better  known  as  edelweiss  (German  for 
“noble whiteness” and understood as “noble purity”; the scientific 
name “leontopodium” is a Latin adaptation of the Greek leontopó-
dion for “lion’s paw”), is a European mountain flower found in the 
Alps, Pyrenees, and Carpathians, as well as the Balkan Peninsula.5 
Edelweiss is a member of the sunflower (Asteraceae, or less com-
monly known as Compositae) family long used ornamentally and 
honored symbolically in national currency, badges, song (perhaps 
most  famously  in  the  Rodgers  and  Hammerstein  musical  The 
Sound of Music), and other forms of national pride, including as the 
national flower of Switzerland.5 Of medical interest, the plant has 

TABLE 72-1
Pros and Cons of Edelweiss

Pros
Used as an anti-inflammatory agent in folk 

Cons
Few clinical or basic science findings 

medicine

available

Several bioactive constituents identified and 
found to exhibit potent antioxidant and 
anti-inflammatory activity

Activities of the extract depend upon 
plant sourcing and methods of 
extraction used

been used in traditional alpine folk medicine to treat abdominal 
disorders,  angina,  bronchitis,  cancer,  colitis,  diarrhea,  dysentery, 
fever, rheumatoid arthritis, and tonsillitis (Table 72-1).2,6,7

 HISTORY

Folk  medicine  uses  of  edelweiss  were  founded  on  the  anti-
inflammatory qualities of the herb.1,7,8 Diarrhea and dysentery 
were listed as indications in 1582, as was breast cancer, which 
was treated with a compress infused with the boiled extract.1,5,6 
The  use  of  L.  alpinum  in  Polish  traditional  medicine  to  treat 
tumors was reported in the 1960s and cardioprotective benefits 
of  the  herb  were  cited  in  1975.6  Recent  phytochemical  and 
pharmacologic investigations of the aerial and root portions of 
the  plant  have  uncovered  constituents  exhibiting  anti-
inflammatory,  antimicrobial,  and  leukotriene-inhibiting 
properties.2

 CHEMISTRY

In 2006, Schwaiger et al. identified and measured the major phe-
nolic constituents of edelweiss. They compared retention times, 
ultraviolet (UV) and mass spectra of nearly all separated constitu-
ents to commercially available reference compounds or those iso-
lated from the plant using column chromatography. Among the 
constituent  compounds  of  edelweiss  were  found  several  known 
polyphenolic antioxidants, including quercetin-3-O-b -D-glucoside, 
luteolin-7-O-b -D-glucoside, luteolin-3’-O-b -D-glucoside, luteolin-
4’-O-b -D-glucoside,  apigenin-7-O-b -D-glucoside,  6-hydroxy-
luteolin-7-O-b -D-glucoside,  luteolin-7,4’-di-O-b -D-glucoside, 
chrysoeriol-7-O-b -D-glucoside, 
leontopodic  acid,  and 
3,5-dicaffeolyquinic  acid.  A  new  natural  product  [3,4,5-tri-(E)-
caffeoly-D-glucaric  acid]  was  also  discovered  in  the  process  and 
named leontopodic acid B.9 Various secondary active metabolites 
have also been detected, including highly bioactive sesquiterpenes, 
diterpenes, lignans, and benzofurans, as well as the aforemen-
tioned polyphenols.1

Leoligin has been identified as the major lignan, and key active 
component,  found  in  the  roots  of  edelweiss.3,10  In  fact,  it  has 
been shown to act as a safe and effective cholesteryl ester transfer 
protein  agonist,  demonstrating  potential  for  influencing  high-
density  lipoprotetin  metabolism.10  In  addition,  the  isocomene 
and related compounds found in the plant are thought to show 
promise  as  antidementia  agents.2  Overall,  substantial  antioxi-
dant, antibacterial, and anti-inflammatory properties associated 
with edelweiss extracts have been confirmed in several pharma-
cologic studies.11

 ORAL USES

In traditional alpine medicine, edelweiss has been boiled with 
milk  and  honey  to  alleviate  stomach  aches,  in  humans  and 
livestock.4,6 The herb was boiled in wine and mixed with milk 
to  treat  oral  conditions.6  Other  indications  treated  with 
edelweiss tea include bronchitis, diarrhea, and dysentery.4,6

 
In  2006,  Speroni  et  al.  gauged  the  anti-inflammatory  and 
analgesic  effects  of  the  dichloromethane,  methanolic,  and 
carbon dioxide extracts of the aerial parts and roots of edelweiss 
after  oral  administration  to  rats  and  mice.  In  pretreated 
specimens,  histological  examination  revealed  significant 
decreases in carrageenan-induced rat paw inflammation. In the 
rat  paw  edema  assay,  the  most  activity  was  seen  in  the 
lipophilic  extracts  of  the  aerial  plant  parts,  with  swelling 
diminished  by  80  percent  from  the  dichloromethane  extract 
and 72 percent from the carbon dioxide extract. The presence 
in high concentrations of linoleic and linolenic acids, known to 
inhibit the arachidonic acid cascade, in the aerial parts of the 
plant is thought to at least partially account for the greater anti-
inflammatory  effectiveness  from  this  area.  Analgesic  effects 
were more salient in association with treatment from the root 
extracts  as  compared  to  the  aerial  parts,  which  the  authors 
suggested  was  indicative  of  varying  mechanisms  of  action. 
Also, they evaluated the antioxidant properties of some of the 
extracts  to  ascertain  any  correlations  with  the  observed  anti-
inflammatory characteristics. The investigators speculated that 
flavonoid glycosides in the aerial parts contributed to antioxi-
dant  strength,  whereas  terpenes,  lignans,  coumarins,  and 
benzofurans were deemed active root constituents.4

 TOPICAL USES

Edelweiss  has  been  incorporated  into  several  topical 
preparations,  primarily  touted  for  antiaging  activity.  There  is 
little  published  literature  or  clinical  evidence  to  support  such 
inclusion.  The  anti-inflammatory  and  antioxidant  properties 
identified  in  the  aerial  parts  of  the  cultivated  plant  have  been 
recently exploited in various cosmetic formulations, particularly 
sunscreens,  intended  to  provide  cutaneous  protection  against 
UV-induced chronic inflammation, photoaging, and cancer.7,9

In 2004, Dobner et al. conducted a study using L. alpinum that 
offered  dermatologic  implications.  Specifically,  they  examined 
the aerial (i.e., capitula, inflorescence leaves, stems, stem leaves, 
and leaves of the basal rosette)9 parts of edelweiss for their in vivo 
topical  anti-inflammatory  effects  on  croton  oil-induced  ear 
dermatitis  in  mice.  They  found  that  dichloromethane  extract 
dose-dependently  reduced  edema,  with  the  extract  conferring 
greater activity than methanol and 70 percent aqueous methanol 
extracts.  Dichloromethane  extracts  from  the  aerial  parts  of  the 
plant were also found to be more active than dichloromethane root 
extracts. The investigators noted that fatty acids contribute signifi-
cantly to the antiedema effect of the aerial dichloromethane extract 
while the anti-inflammatory activity of the root extract could be 
attributed to bisabolane sesquiterpenes, tricyclic sesquiterpenes, 
coumarins, and lignans.8

 SAFETY ISSUES

There  are  no  reports  of  adverse  side  effects  associated  with  
L. alpinum usage; however, it is a member of the Compositae family 
(see Table 70.2) and therefore may cause allergic contact dermatitis 
in those allergic to ragweed, feverfew, chamomile, and marigold.

 ENVIRONMENTAL IMPACT

L.  alpinum  grows  sparsely  in  several  European  mountain 
ranges.  It  is  a  protected  species  in  various  countries  and,  
in 1886, became the first protected plant in Austria.7,8 Given 
perceived public concerns about the potential overexploitation 

C H A P T E R  72  ■   E D E LW E I S S  

277

of  a  wild  protected  species  for  medicinal  and  cosmetic 
purposes,  Switzerland  created  plantations  of  edelweiss  for 
cultivation  in  2004.7  In  2012,  Daniela  et  al.  found  that  the 
production  of  callus/tissue  cultures  established  at  these 
plantations  may  be  an  ideal  venue  for  the  biotechnological 
production  of  complex  molecules  suitable  for  medical  and 
cosmetic  application.  Specifically,  they  found  that  a  concen-
trated  ethanolic  extract  of  leontopodic  acid-laden  culture 
exhibited  significant  anti-inflammatory  activity  in  primary 
human keratinocytes and endotheliocytes exposed to UVA and 
UVB, lipopolysaccharide, oxidized low-density lipoprotein, and 
various  proinflammatory  cytokines.  The 
investigators 
concluded that edelweiss cell cultures are viable environmen-
tally-  and  species-sensitive  sources  of  anti-inflammatory 
agents potentially suitable for treating chronic inflammatory 
skin and other conditions.7

 FORMULATION CONSIDERATIONS

Various  processes  are  used  to  isolate  the  active  compounds 
from  edelweiss  plants,  and  the  formulation  considerations 
depend upon which processes are used. The soil in which the 
plants are raised, the geographic location, and the climate can 
all affect the type and amount of components in plant extracts; 
therefore,  efficacy  can  vary  depending  on  the  source  of  the 
plants.

 USAGE CONSIDERATIONS

No  interactions  with  other  ingredients  are  known  by  the 
author.

 SIGNIFICANT BACKGROUND

Lignans, polyphenolic plant metabolites derived from phenyl- 
alanine, are thought to exhibit antioxidant, anti-inflammatory, 
antihypertensive, antithrombotic, and lipid-lowering activity.3 
In 2009, Reisinger et al. found that leoligin, the primary lignan 
active in edelweiss, strongly suppressed intimal hyperplasia as 
well as vascular smooth muscle cell proliferation, by inducing 
G1-phase cell cycle arrest, suggesting its viability as a nontoxic, 
nonthrombogenic treatment option for vein graft disease.3

It  is  thought  that  the  constituents  of  edelweiss  that  have 
provided  protection  in  a  harsh  environment,  particularly  its 
exposure to and absorption of UV radiation, may in turn have 
the  potential  to  be  harnessed  to  confer  protection  to  human 
skin.12,13 In addition, the significant polyphenolic and flavonoid 
content in edelweiss is thought to imbue the plant with sub-
stantial  radical-scavenging,  antioxidant,  and  photoprotective 
properties,  with  components  such  as  β-sitosterol,  luteolin-4’-
O-β-D-glucoside, and bisabolane derivatives believed to impart 
soothing effects to its extracts.11,12 The leontopodic acid found 
in  L.  alpinum  is  also  thought  to  deliver  antioxidant  as  well  as 
DNA-protecting  qualities,  and  to  inhibit  elastase,  which  may 
yield an antiaging effect.14

The  white  filamentary  hair  covering  edelweiss  bracts  is 
thought to play an important protective role against dehydration 
as well as cold and UV exposure, absorbing rather than reflecting 
UV radiation.13 Better understanding this UV screening process 
may  lead  to  innovations  in  various  products,  including 
UV-protective sunscreen ingredients in cosmetic formulations.13

 
278 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

In Vitro Studies
In 2003, Dobner et al. evaluated the antimicrobial activity of 
extracts  and  several  individual  components  of  edelweiss. 
Using  agar  diffusion  assays  and  the  microbroth  dilution 
method  to  ascertain  minimum  inhibitory  concentrations, 
they  noted  significant  antimicrobial  activities  displayed 
against  Enterococcus  faecium,  Escherichia  coli,  Pseudomonas  aer-
uginosa,  Staphylococcus  aureus,  Streptococcus  pneumoniae,  and 
Streptococcus pyogenes strains. The researchers concluded that 
their findings buttress the previously observed traditional folk 
medicine uses of edelweiss to treat abdominal and respiratory 
conditions.6

In  2009,  some  of  the  same  investigators,  led  by  Costa, 
assessed the chemopreventive effects of the antioxidant leon-
topodic acid isolated from L. alpinum. After pretreatment with 
leontopodic acid, they evaluated various mycotoxins in two 
different cell lines, aflatoxin B1 on HepG2 cells and deoxyniva-
lenol  on  U937  cells.  Leontopodic  acid  was  demonstrated  to 
have  protected  U937  cells  from  deoxynivalenol-induced  cell 
damage, though it did not protect HepG2 cells from aflatoxin 
B1  toxicity.  The  investigators  also  found  that  the  edelweiss 
isolate  enhanced  glutathione  peroxidase  activity  in  U937;  it 
had  no  such  effect  on  glutathione  S-transferase  activity  in 
HepG2. They concluded that the primary mechanism of the 
potent  antioxidant-associated  chemopreventive  activity 
delivered by leontopodic acid is the elevation of detoxifying 
enzymes,  with  the  edelweiss  constituent  acting  as  a  potent 
antioxidant.15

 CONCLUSION

Edelweiss has been used in traditional medicine and continues 
to  be  used  for  some  health  issues  in  contemporary  times. 
However, there is a conspicuous dearth of research to support 
the  claims  of  effectiveness  for  edelweiss  in  topical  formula-
tions.  For  edelweiss  to  be  established  as  a  genuinely  useful 
ingredient in skin care, like numerous other botanical sources 
of medication, much more research and clinical investigation is 
necessary. The scant data available suggest that such work is 
warranted.

REFERENCES

1.  Safer  S,  Cicek  SS,  Pieri  V,  et  al.  Metabolic  fingerprinting  of 
Leontopodium  species  (Asteraceae)  by  means  of  ¹H  NMR  and 
HPLC-ESI-MS. Phytochemistry. 2011;72:1379.

2.  Hornick A, Schwaiger S, Rollinger JM, et al. Extracts and constitu-
ents of Leontopodium alpinum enhance cholinergic transmission: 
Brain ACh increasing and memory improving properties. Biochem 
Pharmacol. 2008;76:236.

3.  Reisinger U, Schwaiger S, Zeller I, et al. Leoligin, the major lignin 
from  Edelweiss,  inhibits  intimal  hyperplasia  of  venous  bypass 
grafts. Cardiovasc Res. 2009;82:542.

4.  Speroni E, Schwaiger S, Egger P, et al. In vivo efficacy of different 
extracts  of  Edelweiss  (Leontopodium  alpinum  Cass.)  in  animal 
models. J Ethnopharmacol. 2006;105:421.

5.  Safer  S,  Tremetsberger  K,  Guo  YP,  et  al.  Phylogenetic  relation-
ships  in  the  genus  Leontopodium  (Asteraceae:  Gnaphalieae) 
based on AFLP data. Bot J Linn Soc. 2011;165:364.

6.  Dobner MJ, Schwaiger S, Jenewein IH, et al. Antibacterial activity of 
Leontopodium alpinum (Edelweis). J Ethnopharmacol. 2003;89:301.
7.  Daniela L, Alla P, Maurelli R, et al. Anti-inflammatory effects of 
concentrated ethanol extracts of Edelweiss (Leontopodium alpi-
num  Cass.)  callus  cultures  towards  human  keratinocytes  and 
endothelial cells. Mediators Inflamm. 2012;2012:498373.

8.  Dobner MJ, Sosa S, Schwaiger S, et al. Anti-inflammatory activity of 
Leontopodium alpinum and its constitutents. Planta Med. 2004;70:502.
9.  Schwaiger  S,  Seger  C,  Wiesbauer  B,  et  al.  Development  of  an 
HPLC-PAD-MS assay for the identification and quantification of 
major  phenolic  edelweiss  (Leontopodium  alpinum  Cass.)  con-
stituents. Phytochem Anal. 2006;17:291.

10.  Duwensee K, Schwaiger S, Tancevski I, et al. Leoligin, the major 
lignin from Edelweiss, activates cholesteryl ester transfer protein. 
Atherosclerosis. 2011;219:109.

11.  Ganzera M, Greifeneder V, Schwaiger S, et al. Chemical profiling 
of Edelweiss (Leontopodium alpinum Cass.) extracts by micellar 
electrokinetic capillary chromatography. Fitoterapia. 2012;83:1680.
12.  Wenzel AF. Edelweiss (Leontopodium alpinum): Monograph on the 
biological effects of extracts of L. alpinum used in cosmetics, medi-
cal devices and medicinal products. PSST. 17 December, 2012.
13.  Vigneron  JP,  Rassart  M,  Vértesy  Z,  et  al.  Optical  structure  and 
function  of  the  white  filamentary  hair  covering  the  edelweiss 
bracts. Phys Rev E Stat Nonlin Soft Matter Phys. 2005;71:011906.
14.  Schwaiger  S,  Cervellati  R,  Seger  C,  et  al.  Leontopodic  acid  –  A 
novel highly substituted glucaric acid derivative from edelweiss 
(Leontopodium  alpinum  Cass.)  and  its  antioxidative  and  DNA 
protecting properties. Tetrahedron. 2005;61:4621.

15.  Costa S, Schwaiger S, Cervellati R, et al. In vitro evaluation of the 
chemoprotective action mechanisms of leontopodic acid against 
aflatoxin  B1  and  deoxynivalenol-induced  cell  damage.  J  Appl 
Toxicol. 2009;29:7.

 
C H A P T E R   7 3

Lavandula

C H A P T E R  73  ■   L AVA N D U L A  

279

Activities:

Anti-inflammatory,  antimicrobial,  antiseptic,  anticolic, 
antispasmodic, antidepressant, sedative1,2

Important Chemical Components:

Tannins,  coumarins  (e.g.,  coumarin,  umbelliferone), 
flavonoids (e.g., luteolin), triterpenes (e.g., ursolic acid), 
essential  oil  (i.e.,  linalyl  acetate,  linalool,  1,8- 
cineole,  β-ocimene,  limonene,  lavandulyl  acetate, 
terpinen-4-ol,  borneol,  β-caryophyllene,  camphor, 
carvacrol, nerolidol, fenchone, perillyl alcohol)3–8

Origin Classification:

This ingredient is natural. Many organic options exit.

Personal Care Category:

Soothing, sedating, anti-inflammatory, analgesic

Recommended  for  the  following  Baumann  Skin 
Types:

DSNT, DSPT, DSNW, DSPW, OSNT, OSNW, OSPT, and 
OSPW

 SOURCE

Widely  cultivated  in  southern  Europe,  the  United  States,  the 
United Kingdom, and Australia for its essential oil, Lavandula 
angustifolia,  better  known  as  lavender,  is  a  fragrant,  hardy 
perennial  shrub  belonging  to  the  Labiatae  (Lamiaceae),  or  
mint, family.9,10 Native to the Mediterranean region, seeds of 
the  shrub  were  transported  to  England  and  France  through 
migration several hundred years ago. Many species of lavender 
have  been  used  for  therapeutic,  cosmetic,  culinary,  and 
commercial  purposes  for  much  longer,  on  the  order  of 
thousands  of  years.  L.  angustifolia,  also  known  as  English 
lavender, or true lavender, is a commercially important species 
in  the  lucrative  perfume  industry.  Though  all  28  lavender 
species are believed to impart some therapeutic benefits to vary-
ing  degrees,  L.  angustifolia  (previously  known  as  L.  officinalis) 
is  the  species  included  most  often  in  medicinal  formulations 
and is known to exhibit anti-inflammatory qualities.6 L. latifolia, 
L.  stoechas  (known  as  French  lavender  in  Europe  and  Spanish 
lavender in the United States),2 and L. intermedia (a sterile hybrid 
of L. angustifolia and L. latifolia and also known as lavandin) are 
also  popular  for  cosmetic  and  therapeutic  uses.2,7,11,12  Topical 
application of lavender essential oil, extracted by steam distilla-
tion from the freshly cut aerial parts of the plant, is thought to 
alleviate the discomfort characteristic of rheumatism.6 Indeed, 
traditional  uses  of  lavender  oil  include  relaxation,  wound 
healing, and improving circulation to the skin.4,9

 HISTORY

Lavender was used in ancient societies for perfumery as well as 
medical  purposes  (Table  73-1).  Derived  from  the  Latin  word 
lavare  (“to  wash”),  the  plant  was  named  for  its  practical 
antiseptic  and  disinfectant  applications  in  ancient  Arabia, 
Greece, and Rome.9,10 Lavender blossoms, believed to be from 
L. stoechas, were used by ancient Greeks and Romans to scent 
bath water, bathe wounds, and prevent infections at communal 
baths. Its activity as an antiseptic formed the foundation of its 
earliest  traditional  uses.13  Lavender  oil  was  used  in  ancient 
Egypt  in  the  mummification  process.9,10  In  Iranian  medicine,  
L. angustifolia has been used for several centuries to treat inflamma-
tory conditions, with its roots dating back to ancient Persia when 
the  herb  (ostokhoddous  in  Persian)  was  cited  by  the  physician/ 
polymaths  Muhammad  ibn  Zakariya  al-Razi  (Latinized  as 
Rhazes  or  Rasis)  in  his  Continens  circa  900  CE  and,  about  
100  years  later,  Ibn  Sina  (Latinized  as  Avicenna)  in  his  
The  Canon  of  Medicine.9,11,14  It  was  used  to  treat  psychiatric  
conditions in ancient Indian and Tibetan medicine.9 The Ayurvedic 
pharmacopoeia  currently  includes  L.  angustifolia  for  multiple 
indications, including depressive and digestive disorders.9

Traditionally,  lavender  was  hung  in  the  home  to  repel 
mosquitoes,  flies,  fleas,  and  lice,  and  placed  in  linen  closets  to 
repel moths.12 Its disinfectant and fumigant properties were also 
useful for sanitizing floors. Other folk claims made regarding the 
uses of lavender oil include activity as an analgesic, anticonvulsive, 
antidepressant,  antibacterial,  antifungal,  antirheumatic, 
antispasmodic, diuretic, and sedative agent.2,9,14 It was also used 
to treat headaches, particularly those resulting from tension or 
stress.15 In addition, the essential oil distillate was and is used to 
treat wounds, bites, burns (including sunburns), lacerations, and 
even  acne,  psoriasis,  fungal  conditions,  and  herpes.  Despite  a 
long history of various applications, modern scientific research 
into the reputed benefits of lavender has largely been conducted 
only in the last 20 years, though the modern use of lavender in 
aromatherapy  can  be  traced  to  1932,  when  French  perfumer 
René Gattefossé directly applied the essential oil to severe burns 
and published his accounts of healing.9 While many of the biologic 
activities  attributed  to  the  herb  have  not  been  substantiated, 
recent  scientific  and  clinical  findings  appear  to  support  the 
traditional applications of lavender.2

TABLE 73-1
Pros and Cons of Lavandula

Pros
Used for thousands of years for therapeutic 

Cons
Scant clinical evidence of dermatologic 

purposes

efficacy

Wide range of reputed biologic activities

Limited scientific evidence to support 

many of its purported health benefits 

Well regarded for aromatherapy

 
280 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

 CHEMISTRY

The active chemical components that provide lavender with its 
reputed  medicinal  properties  include  tannins,  coumarins, 
flavonoids,  triterpenoids,  and  essential  oil  components, 
themselves  an  intricate  mix  of  mono-  and  sesquiterpenoid 
alcohols, esters, ketones, and oxides.5 Linalool (3,7-dimethylocta-
1,6-dien-3-ol) is the most important phytochemical constituent 
of  the  essential  oil  of  lavender  and  is  considered  its  primary 
active component, though it is present in lower concentration 
than  its  parent  compound  linalyl  acetate  (3,7-dimethyl-
1,6-octadien-3yl  acetate),  another  key  active  substance  in  the 
essential  oil.3,4,16,17  In  animals  and  humans,  lavender  has  been 
shown to exhibit sedative activity upon inhalation.3 Lavender oil 
is believed to be one of the mildest of the known essential oils.4
In 2003, Hajhashemi et al. studied the effects of the hydroal-
coholic  extract,  polyphenolic  fraction,  and  essential  oil  of  
L. angustifolia in formalin- and acetic acid-exposed mice. Results 
from these tests along with a carageenan test in rats buttressed 
the  traditional  uses  of  lavender  for  anti-inflammatory  and 
analgesic indications.14

 ORAL USES

Lavender  essential  oil  should  not  be  taken  internally,  but  the 
dry herb can be consumed as an infusion and is endorsed by 
the German Commission E.6

A 2009 randomized, between-subject, double-blind study to 
measure the effects of orally administered lavender essential oil 
on responses to watching anxiety-provoking film clips revealed 
that lavender exerts an anxiolytic effect in humans under low-
anxiety  conditions,  but  such  effects  many  not  hold  in  high-
anxiety conditions.18

 TOPICAL USES

Lavender is included in a wide variety of skin care products 
including  soaps,  moisturizers,  lotions,  bath  gels,  lip  balms, 
hand  creams,  shampoos,  and  hair  conditioners.19  Current 
data on the uses of lavender bear out many of its traditional 
uses.  Researchers  have  demonstrated  the  sedative  qualities 
of L. angustifolia in humans and animals.3 Positive effects on 
human skin have been demonstrated. Investigators studying 
perineal  pain  among  women  who  had  recently  given  birth 
found an association between use of lavender oil in baths and 
reduced  discomfort.20  Lavender  has  been  reported  to  be  of 
use  in  many  different  areas  of  medicine;  in  fact,  there  is  a 
report  in  the  literature  of  lavender  oil  (among  several  other 
essential oils) being used with moderate success for alopecia 
areata. In a randomized, double-blind, controlled trial lasting 
seven months, 86 patients received daily scalp massage treat-
ments with either essential oil in a mixture of carrier oils or 
carrier  oil  only.  Six  of  41  in  the  control  group  showed 
improvement  whereas  19  of  43  patients  in  the  treatment 
group exhibited significant improvement.21

A 2005 report by Sosa et al. indicated that another lavender 
species,  L.  multifada,  used  in  Moroccan  traditional  medicine, 
has  also  exhibited  topical  anti-inflammatory  activity.  In  this 
study  in  mice,  ethanol  and  aqueous  extracts  from  the  aerial 
parts  of  the  plant  dose-dependently  suppressed  croton  oil-
induced ear edema.22

Head Lice
In 2010, Barker and Altman led a randomized, assessor-blind, 
parallel-group,  comparative  efficacy  trial  in  123  patients  with 
live head lice to evaluate three topical treatments, including a 
“suffocation” product, a formulation containing pyrethrins and 
piperonyl butoxide, and a tea tree oil and lavender oil combina-
tion  (see  Chapter  77,  Tea  Tree  Oil).  The  herbal  combination 
and  the  suffocation  product  were  equally  efficacious,  with  
97.6  percent  in  each  group  presenting  as  free  of  lice  one  day 
after  the  last  treatment,  as  opposed  to  25  percent  in  the 
pyrethins-based product. The investigators suggested that the 
herbal  as  well  as  suffocation  products  appear  to  be  viable 
alternatives to those based on pyrethins.23

Episiotomy/Perineal Pain Treatment
Lavender oil may be prescribed to alleviate the pain associated 
with episiotomy due to its antiseptic and soothing activity. In 
2012,  Sheikhan  et  al.  conducted  a  randomized  controlled 
clinical  trial  with  60  primiparous  women  admitted  for  labor  
in Karaj, Iran. Patients were randomized into a treatment group 
using  lavender  oil  and  a  control  group,  matching  the  standard 
hospital protocol. A statistically significant difference was recorded 
in pain intensity between the groups after four hours and five days 
following  episiotomy,  though  such  differences  were  not  signifi-
cant  at  12  hours  after  surgery.  Five  days  after  episiotomy,  the 
average redness, edema, ecchymosis, drainage, approximation 
(REEDA) score was significantly lower in the lavender group. 
The  investigators  concluded  that  lavender  essential  oil  is  an 
effective  analgesic  agent  for  diminishing  perineal  pain  after 
episiotomy  and  may  be  a  suitable  option  over  povidone-
iodine.24 These results support the findings of a larger clinical 
trial conducted in 120 primiparous women in Iran in 2011 with 
lavender essential oil derived from L. stoechas.25

Prior to the publication of these studies, Jones reviewed the 
evidence on use of lavender oil on perineal trauma, particularly 
in  light  of  increasing  anecdotal  reports  of  effectiveness.  She 
found  negligible  support  for  the  notion  that  lavender  oil 
accelerated healing, but acknowledged the benefits of lavender 
in aromatherapy. Further, she cautioned that women applying 
lavender oil directly to the perineum should use highly diluted 
forms.26

Aphthous Ulceration
In 2012, Altaei conducted laboratory and clinical assessments of 
the efficacy of lavender oil to treat recurrent aphthous ulceration. 
Initially,  rabbits  with  induced  ulcers  were  tested  in  a 
randomized,  double-blind,  placebo-controlled  study,  with 
animals  treated  with  lavender  oil  manifesting  significantly 
diminished  ulcer  size,  accelerated  mucosal  repair,  and  faster 
healing  than  controls.  Lavender  oil  also  demonstrated  broad 
antibacterial  activity  against  all  strains  tested.  In  the  clinical 
study,  115  patients  were  divided  into  topical  lavender  and 
placebo groups. Significant declines in inflammation, ulcer size, 
healing time, and pain were experienced by the subjects treated 
with lavender oil compared to baseline and the placebo group, 
with  no  adverse  effects  noted.27  However,  the  next  year, 
Baccaglini  commented  in  response  to  this  study,  suggesting 
that  the  data  undergirding  topical  lavender  oil  as  a  palliative 
treatment for recurrent aphthous stomatitis (RAS) are actually 
limited,  the  Altaei  animal  data  were  essentially  irrelevant 
because mucosal injuries in rabbits differ from RAS in humans, 
and the human study was beset with multiple design flaws.28

 
Hirsutism
In  2013,  Tirabassi  et  al.  conducted  a  prospective,  open-label, 
placebo-controlled, randomized study with 24 young women 
with mild idiopathic hirsutism to compare the potential efficacy 
of  lavender  and  tea  tree  oils.  Subjects  received  oil  spray 
containing lavender and tea tree oil or placebo twice daily for 
three months in affected areas. Investigators reported a statisti-
cally significant reduction in hair diameter and hirsutism total 
score in the herbal group and no such difference in the placebo 
group. They concluded that the topical application of lavender 
and  tea  tree  oils  is  effective  in  diminishing  mild  idiopathic 
hirsutism (see Chapter 77, Tea Tree Oil).29

 SAFETY ISSUES

There are no reports of significant adverse effects from the use 
of  lavender  for  therapeutic  or  cosmetic  purposes.  Similarly, 
there are no reports of drug interactions with lavender.6 Mild 
contact dermatitis has been identified, though, from the use of 
dried  lavender  flowers  used  in  items  such  as  pillows  and  to 
disinfect ambient air.30 Conversely, researchers have shown, in 
vivo  and  in  vitro,  that  lavender  oil  has  the  capacity  to  mediate 
sudden allergic reactions by inhibiting mast cell degranulation.31 
However, there are caveats and contraindications.

In 2004, Prashar et al. showed that lavender oil was cytotoxic 
to  human  skin  (endothelial  cells  and  fibroblasts)  in  vitro  at  a 
concentration  of  0.25  percent  (v/v).  Individual  assays  revealed 
that the activity of linalool corresponded to that of the whole oil, 
while  linalyl  acetate  cytotoxicity  was  higher,  indicating  that 
linalool may be the active component with linalyl acetate activity 
hampered by an unknown factor in the oil.4

In addition, researchers have shown that linalool and linalyl 
acetate, the primary components of lavender oil, undergo auto-
oxidation  on  air  exposure,  forming  allergenic  oxidation 
products,  with  linalool  acting  as  a  stronger  sensitizing  agent 
implicated  in  allergic  contact  dermatitis.32  The  same 
investigators  subsequently  demonstrated  that  lavender  oil  is 
devoid  of  natural  protection  against  auto-oxidation,  meaning 
that lavender oil exposed to air can lead to the development of 
potent  contact  allergenic  hydroperoxides.33  Nevertheless, 
linalool and linalyl acetate are rarely reported to be the sources 
of contact allergy.4,32 Although the genotoxic profile of lavender 
oil has been deemed difficult to delineate, linalool, in particular, 
is thought to be safe.17 That said, in 2003, the 7th Amendment 
to  the  European  Cosmetic  Directive  mandated  that  cosmetic 
products incorporating any of 26 identified natural ingredients, 
including linalool, be labeled as possibly allergenic.5

Contact allergy to lavender oil is reportedly highest in Japan, 
where its frequency of use has been known to be prevalent.30 It 
is advised that lavender oil and its constituents be used cautiously 
and in dilute forms, particularly in topical application.4 Lavender 
oil  in  ketoprofen  has  also  been  implicated  in  photoallergic 
contact dermatitis.34,35

A small 2007 study with three prepubertal boys presenting with 
gynecomastia is also noteworthy. Henley et al. discerned that the 
patients were healthy otherwise with normal endogenous steroid 
levels. Gynecomastia emerged in each case through the topical use 
of products containing lavender and tea tree oils (see Chapter 77, 
Tea Tree Oil). Discontinuation of the product spurred resolution of 
the condition. The investigators also examined the natural oils in 
human  cell  lines  and  observed  estrogenic  and  antiandrogenic 
properties.  They  concluded  that  chronic  exposure  to  these  oils 
likely accounted for the development of gynecomastia.36

C H A P T E R  73  ■   L AVA N D U L A  

281

 ENVIRONMENTAL IMPACT

Cultivation in hot, dry climates at medium altitudes is necessary 
for  optimal  yields  of  L.  angustifolia  essential  oils,  which  are 
produced  in  relatively  low  quantities.5  Lavender  species  can 
endure  intense  heat,  wind,  and  occasional  frost.5  Most 
commercial supplies are produced in France, where L. angustifolia 
is sometimes intermixed with L. latifolia and L. intermedia.9

 FORMULATION CONSIDERATIONS

In  2006,  Francis  et  al.  found  that  degassing  water  facilitated  
the  dispersion  of  natural,  water-immiscible  oils,  particularly 
lavender, tea tree, and eucalyptus (see Chapter 77, Tea tree Oil). 
The process yields micron-sized droplets without the need for 
additives, with these natural oils in pure water left well suited 
for use in skin care formulations and oral sprays, according to 
the authors.37 Lavender should be packaged in airless pumps to 
prevent oxidation.

 USAGE CONSIDERATIONS

Lavender oil is now primarily used as a carminative, relaxant, 
and sedating agent in aromatherapy, and is one of the more 
popular  of  the  40  major  essential  oils.13,38  Pharmaceutical 
grade  lavender  oil  is  typically  composed  of  0.8  to  3  percent 
volatile oil.9 Both of the main constituents of lavender essential 
oil, linalool and linalyl acetate, are readily absorbed into the 
skin, usually within five minutes of topical application.9

 SIGNIFICANT BACKGROUND

Research  into  the  potential  applications  of  lavender,  particu-
larly  lavender  essential  oil,  in  medicine  and  dermatology, 
specifically, is ongoing but not especially extensive.

Antibacterial Activity
Roller et al. conducted a study in 2009 using four different 
lavender species to compare their antimicrobial efficacy singly 
and  in  combination  on  methicillin-sensitive  and  -resistant 
Staphylococcus  aureus  (MSSA  and  MRSA  ,  respectively).  They 
found  that  lavender  oils  from  L.  angustifolia,  L.  latifolia,  
L.  stoechas,  and  L.  luisieri  suppressed  MSSA  and  MRSA 
growth  by  direct  contact  except  in  the  vapor  phase.  Two 
combinations  (L.  luisieri  and  L.  stoechas;  L.  luisieri  and  
L. angustifolia) of several binary combinations tested resulted 
in  larger  inhibition  zones  than  those  achieved  by  using 
individual oil. The researchers suggested that lavender oils 
might  warrant  more  serious  consideration  for  inclusion  in 
antibacterial formulations.7

Also  that  year,  Warnke  et  al.  found  that  lavender  oil  was 
among  several  essential  oils  shown  in  vitro  to  evince  strong 
efficacy against several common and hospital-acquired bacterial 
and  yeast  isolates  (six  Staphylococcus  strains  including  MRSA, 
four  Streptococcus  strains,  and  three  Candida  strains  including 
Candida  krusei),  suggesting  potential  viability  as  inexpensive 
and  effective  antiseptic  topical  treatment  options  even  for 
antibiotic-resistant  bacterial  strains  and  antimycotic-resistant 
Candida species.39

 
282 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Anticancer Activity
Work is scant in this area, but lavender may have a role to play 
in  acting  against  mutations  and,  more  relevant  to  current 
patients, alleviating some of the related stress.

Evandri et al. performed bacterial reverse mutation assays in 
2005  and  ascertained  that  lavender  oil  displayed  potent  anti-
mutagenic activity, concentration-dependently shrinking mutant 
colonies in the Salmonella typhimurium TA98 strain exposed to the 
direct mutagen 2-nitrofluorene. In addition, lavender oil exhib-
ited moderate antimutagenic properties against the same strain 
exposed  to  the  direct  mutagen  1-nitropyrene.  The  researchers 
concluded that these findings suggest a wide array of potential 
medical applications of lavender oil.13 In vitro investigations into 
prospective anticancer properties of lavender oil have indicated 
that trace compounds, such as perillyl alcohol, do manifest such 
activity, including angiogenesis inhibition.5,40,41

In  2012,  Boehm  et  al.  conducted  a  systematic  review  of 
preclinical and clinical trial evidence on the benefits and safety of 
aromatherapy for cancer patients. Regarding lavender essential 
oil,  they  noted  that  patients  with  estrogen-dependent  tumors 
should exercise caution in using topical lavender because of find-
ings that it has contributed to engendering reversible prepubertal 
gynecomastia  (see  Safety  section).  They  added,  though,  that 
lavender aromatherapy may have a beneficial effect for patients 
by reducing levels of the stress hormone cortisol.38

Aromatherapy
The use of lavender in aromatherapy is supported by anecdotal 
reports  as  well  as  recent  data.  Indeed,  the  essential  oil  of 
lavender  is  reputed  to  confer  sedative,  antispasmodic,  and 
tranquilizing effects and, thus, has become a staple ingredient 
in aromatherapy. Such characteristics have been central, under-
standably, in research regarding mood and cognitive effects. In 
2000,  Saeki  performed  a  randomized,  crossover,  controlled 
study using essential oil of lavender in a hot foot bath, finding 
that small but distinct changes in autonomic activity indicated 
relaxation in subjects.42

In a single-blind, randomized controlled trial of depression in 
80 women, negative responses were reduced in the group treated 
with 80 percent grapeseed oil/20 percent lavender  oil baths as 
opposed to 100 percent grapeseed oil baths for two weeks.43 In a 
placebo-controlled  trial  with  blinded  observer,  lavender  oil 
administered via aroma stream resulted in slight improvement of 
agitated behavior among patients with severe dementia.44

A  study  of  the  olfactory  effects  of  essential  oils  of  lavender 
and  rosemary  on  mood  and  cognitive  performance  offered 
disparate  but  telling  results.  Lavender  was  associated  with  
a  significant  drop  in  performance  of  working  memory  and 
reduced  attention  span,  suggesting  a  sedative  effect.45  The 
rosemary  group  was  much  more  alert  than  the  lavender  and 
control groups. In a subjective evaluation of relative mood, the 
control  group  was  significantly  less  content  than  the  lavender 
and  rosemary  groups.  Mood  enhancement  through  treatment 
with lavender has been seen elsewhere.

In  a  one-month,  double-blind,  randomized  trial,  researchers 
studying depression found that a tincture of L. angustifolia may 
have therapeutic benefits as an adjunct to other treatments for 
moderate depression, thus warranting further investigation.15

In 2008, Xu et al. investigated the pharmaco-physio-psychologic 
effect  of  Ayurvedic  oil-dripping  treatment  [Shirodhara,  which 
combines  the  Sanskrit  words  shiro  (head)  and  dhhara  (flow)] 
using L. angustifolia essential oil in 16 healthy females. Shirodhara 

usually entails using medicated herbal sesame oils. Subjects were 
assigned randomly to robotic arm oil-dripping with either plain 
sesame oil (plain Shirodhara), sesame oil with lavender essential 
oil, or the control supine position. The researchers observed that 
lavender Shirodhara acted as a strong anxiolytic and induced or 
promoted  an  altered  state  of  consciousness,  also  yielding  the 
greatest climb in foot skin temperature of the interventions. The 
well-established relaxing effect of L. angustifolia essential oils was 
thought  to  partially  account  for  these  findings,  as  well  as  the 
pharmacologic  action  of  sesame  oil  or  lavender  essential  oil 
absorbed via the skin or mucosa.46

Although  lavender  aroma  is  reputed  to  exert  a  substantial 
relaxation effect, much of the supportive evidence is anecdotal. 
Howard and Hughes conducted a double-blind, mixed factorial, 
placebo-controlled trial in 96 healthy undergraduate women in 
2008 to gauge the effects of lavender aromatherapy. Participants 
were exposed to lavender, placebo, or no scent while evaluated 
physiologically  following  a  stimulating  cognitive  task.  An 
instructional  procedure,  upon  the  introduction  of  an  aroma, 
manipulated  the  expectations  of  the  participants  regarding  the 
likely effects of the aroma on their ability to relax. The investiga-
tors found that while galvanic skin response was unaffected by 
the  aroma,  the  instructional  prompt  did  influence  relaxation 
patterns,  with  subjects  relaxing  more  when  expecting  to  be 
hindered by the aroma and relaxing less when expecting to be 
calmed by the aroma. The authors concluded that their results 
suggest the potential of expectancy biases, which they claimed 
could be easily manipulated, influencing prior reports of lavender 
aroma facilitating relaxation.47

A more recent study by Grunebaum and colleagues (including 
the  author  of  this  text)  randomized  30  subjects  with  no  prior 
experience  with  cosmetic  facial  injections  to  exposure  to 
lavender  essential  oil  aroma  or  placebo  during  elective  Botox 
injections  to  correct  glabellar  wrinkles. Participants exposed to 
lavender  oil  aroma  experienced  a  significant  decrease  in  heart 
rate after injection compared to their heart rate prior to injection. 
No such differences were seen in patients exposed to placebo. 
The  investigators  found  that  lavender  did  not  influence  pain 
perception,  but  the  lavender  aroma  did  elevate  subjects’  para-
sympathetic activity. They concluded that lavender aromatherapy 
appears  to  have  the  capacity  to  reduce  anxiety  for  those 
undergoing minimally invasive cosmetic procedures.48

In  2011,  Hongratanaworakit  showed  that  the  blended 
essential  oils  of  lavender  and  bergamot  topically  applied  to  
40  healthy  volunteers  synergistically  interacted  to  impart  a 
relaxing  effect.  Specifically,  the  formulation  applied  to  the 
abdomen yielded significant reductions in pulse rate, as well as 
systolic  and  diastolic  blood  pressure,  as  compared  to  those 
taking  placebo,  revealing  diminished  autonomic  arousal  in  the 
treatment group. A comparative reduction in subjective behav- 
ioral  arousal  was  also  noted  between  the  groups.  The  author 
suggested that the lavender/bergamot blend may be suitable in 
the clinical setting for treating anxiety or depression.49

 CONCLUSION

Topical products that contain lavender appear to be safe, with 
mild  allergic  reactions  as  the  most  likely  adverse  responses. 
Research has established a scientific and clinical foundation for 
the traditional uses of lavender. It remains to be seen if double-
blind, randomized, placebo-controlled trials will establish the 
use of lavender for dermatologic purposes. While it is unlikely 
that  commercially  available  topical  formulations  including 

 
lavender  are  harmful,  it  appears  just  as  unlikely  that  such 
products  impart  clinically  significant  benefits.  Linking  a  well-
regarded  plant  known  for  soothing  qualities  to  potentially 
therapeutic  activity  is  an  effective  marketing  strategy  that 
manufacturers  employ  with  lavender  among  several  other 
herbal ingredients.

REFERENCES

1.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy:  Modern 
Herbal Medicine. London: Churchill Livingstone; 2000:29–30.
2.  Cavanagh  HM,  Wilkinson  JM.  Biological  activities  of  lavender 

essential oil. Phytother Res. 2002;16:301.

3.  Lis-Balchin  M,  Hart  S.  Studies  on  the  mode  of  action  of  the 
essential  oil  of  lavender  (Lavandula  angustifolia  P.  Miller). 
Phytother Res. 1999;13:540.

4.  Prashar A, Locke IC, Evans CS. Cytotoxicity of lavender oil and 
its major components to human skin cells. Cell Prolif. 2004;37:221.
5.  Woronuk G, Demissie Z, Rheault M, et al. Biosynthesis and ther-
apeutic properties of Lavandula essential oil constituents. Planta 
Med. 2011;77:7.

6.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 
Medicine. Rochester, VT: Healing Arts Press; 2003:489, 561–2.
7.  Roller  S,  Ernest  N,  Buckle  J.  The  antimicrobial  activity  of  high-
necrodane and other lavender oils on methicillin-sensitive and –
resistant  Staphylococcus  aureus  (MSSA  and  MRSA).  J  Altern 
Complement Med. 2009;15:275.

8.  Ben  Salah  M,  Abderraba  M,  Tarhouni  MR,  et  al.  Effects  of 
ultraviolet  radiation  on  the  kinetics  of  in  vitro  percutaneous 
absorption of lavender oil. Int J Pharm. 2009;382:33.

9.  Denner SS. Lavandula angustifolia Miller: English lavender. Holist 

Nurs Pract. 2009;23:57.

C H A P T E R  73  ■   L AVA N D U L A  

283

24.  Sheikhan F, Jahdi F, Khoei EM, et al. Episiotomy pain relief: Use of 
Lavender oil essence in primiparous Iranian women. Complement 
Ther Clin Pract. 2012;18:66.

25.  Vakilian  K,  Atarha  M,  Bekradi  R,  et  al.  Healing  advantages  of 
lavender essential oil during episiotomy recovery: A clinical trial. 
Complement Ther Clin Pract. 2011;17:50.

26.  Jones C. The efficacy of lavender oil on perineal trauma: A review 

of the evidence. Complement Ther Clin Pract. 2011;17:215.

27.  Altaei  DT.  Topical  lavender  oil  for  the  treatment  of  recurrent 

aphthous ulceration. Am J Dent. 2012;25:39.

28.  Baccaglini L. There is limited evidence that topical lavender oil is 
effective for palliative treatment of recurrent aphthous stomatitis. 
J Evid Based Dent Pract. 2013;13:47.

29.  Tirabassi  G,  Giovannini  L,  Paggi  F,  et  al.  Possible  efficacy  of 
lavender  and  tea  tree  oils  in  the  treatment  of  young  women 
affected  by  mild  idiopathic  hirsutism.  J  Endocrinol  Invest. 
2013;36:50.

30.  Sugiura  M,  Hayakawa  R,  Kato  Y,  et  al.  Results  of  patch  testing 

with lavender oil in Japan. Contact Dermatitis. 2000;43:157.

31.  Kim HM, Cho SH. Lavender oil inhibits immediate-type allergic 

reaction in mice and rats. J Pharm Pharmacol. 1999;51:221.

32.  Sköld M, Hagvall L, Karlberg AT. Autoxidation of linalyl acetate, 
the  main  component  of  lavender  oil,  creates  potent  contact 
allergens. Contact Dermatitis. 2008;58:9.

33.  Hagvall  L,  Sköld  M,  Bråred-Christensson  J,  et  al.  Lavender  oil 
lacks  natural  protection  against  autoxidation,  forming  strong 
contact allergens on air exposure. Contact Dermatitis. 2008;59:143.
34.  Goiriz R, Delgado-Jiménez Y, Sánchez-Pérez J, et al. Photoallergic 
contact dermatitis from lavender oil in topical ketoprofen. Contact 
Dermatitis. 2007;57:381.

35.  Matthieu L, Meuleman L, Van Hecke E, et al. Contact and photo-
contact  allergy  to  ketoprofen.  The  Belgian  experience.  Contact 
Dermatitis. 2004;50:238.

36.  Henley DV, Lipson N, Korach KS, et al. Prepubertal gynecomastia 

linked to lavender and tea tree oils. N Engl J Med. 2007;356:479.

10.  Basch E, Foppa I, Liebowitz R, et al. Lavender (Lavandula angus-

37.  Francis MJ, Gulati N, Pashley RM. The dispersion of natural oils 

tifolia Miller). J Herb Pharmacother. 2004;4:63.

11.  Wu  J.  Treatment  of  rosacea  with  herbal  ingredients.  J  Drugs 

Dermatol. 2006;5:29.

12.  Aburjai  T,  Natsheh  FM.  Plants  used  in  cosmetics.  Phytother  Res. 

2003;17:987.

13.  Evandri  MG,  Battinelli  L,  Daniele  C,  et  al.  The  antimutagenic 
activity  of  Lavandula  angustifolia  (lavender)  essential  oil  in  the 
bacterial reverse mutation assay. Food Chem Toxicol. 2005;43:1381.
14.  Hajhashemi  V,  Ghannadi  A,  Sharif  B.  Anti-inflammatory  and 
analgesic  properties  of  the  leaf  extracts  and  essential  oil  of 
Lavandula angustifolia Mill. J Ethnopharmacol. 2003;89:67.

15.  Akhondzadeh  S,  Kashani  L,  Fotouhi  A,  et  al.  Comparison  of 
Lavandula  angustifolia  Mill.  Tincture  and  imipramine  in  the 
treatment of mild to moderate depression: A double-blind, rand-
omized  trial.  Prog  Neuropsychopharmacol  Biol  Psychiatry. 
2003;27:123.

16.  Bickers D, Calow P, Greim H, et al. A toxicologic and dermato-
logic  assessment  of  linalool  and  related  esters  when  used  as 
fragrance ingredients. Food Chem Toxicol. 2003;41:919.

17.  Di Sotto A, Mazzanti G, Carbone F. Genotoxicity of lavender oil, 
linalyl  acetate,  and  linalool  on  human  lymphocytes  in  vitro. 
Environ Mol Mutagen. 2011;52:69.

18.  Bradley BF, Brown SL, Chu S, et al. Effects of orally administered 
lavender  essential  oil  on  responses  to  anxiety-provoking  film 
clips. Hum Psychopharmacol. 2009;24:319.

19.  Baumann  LS.  Less-known  botanical  cosmeceuticals.  Dermatol 

Ther. 2007;20:330.

20.  Cornwell S, Dale A. Lavender oil and perineal repair. Mod Midwife. 

1995;5:31.

21.  Hay IC, Jamieson M, Ormerod AD. Randomized trial of aroma-
therapy. Successful treatment for alopecia areata. Arch Dermatol. 
1998;134:1349.

22.  Sosa  S,  Altinier  G,  Politi  M,  et  al.  Extracts  and  constituents  of 
Lavandula  multifada  with  topical  anti-inflammatory  activity. 
Phytomedicine. 2005;12:271.

23.  Barker  SC,  Altman  PM.  A  randomized,  assessor  blind,  parallel 
group  comparative  efficacy  trial  of  three  products  for  the 
treatment of head lice in children – Melaleuca oil and lavender oil, 
pyrethrins and piperonyl butoxide, and a “suffocation” product. 
BMC Dermatol. 2010;10:6.

in de-gassed water. J Colloid Interface Sci. 2006;299:673.

38.  Boehm K, Büssing A, Ostermann T. Aromatherapy as an adjuvant 
treatment in cancer care – a descriptive systematic review. Afr J 
Tradit Complement Altern Med. 2012;9:503.

39.  Warnke  PH,  Becker  ST,  Podschun  R,  et  al.  The  battle  against 
multi-resistant strains: Renaissance of antimicrobial essential oils 
as  a  promising  force  to  fight  hospital-acquired  infections.  
J Craniomaxillofac Surg. 2009;37:392.

40.  Zhang  Z,  Chen  H,  Chan  KK,  et  al.  Gas  chromatographic-mass 
spectrometric  analysis  of  perillyl  alcohol  and  metabolites  in 
plasma. J Chromatogr B Biomed Sci Appl. 1999;728:85.

41.  Loutrari  H,  Hatziapostolou  M,  Skouridou  V,  et  al.  Perillyl 
alcohol  is  an  angiogenesis  inhibitor.  J  Pharmacol  Exp  Ther. 
2004;311:568.

42.  Saeki Y. The effect of foot-bath with or without the essential oil 
of  lavender  on  the  autonomic  nervous  system:  A  randomized 
trial. Complement Ther Med. 2000;8:2.

43.  Morris  N.  The  effects  of  lavender  (Lavendula  angustifolium) 
baths on psychological well-being: Two exploratory randomized 
control trials. Complement Ther Med. 2002;10:223.

44.  Holmes  C,  Hopkins  V,  Hensford  C,  et  al.  Lavender  oil  as  a 
treatment  for  agitated  behavior  in  severe  dementia:  A  placebo 
controlled study. Int J Geriatr Psychiatry. 2002;17:305.

45.  Moss  M,  Cook  J,  Wesnes  K,  et  al.  Aromas  of  rosemary  and 
lavender essential oils differentially affect cognition and mood in 
healthy adults. Int J Neurosci. 2003;113:15.

46.  Xu  F,  Uebaba  K,  Ogawa  H,  et  al.  Pharmaco-physio-psychologic 
effect  of  Ayurvedic  oil-dripping  treatment  using  an  essential  oil 
from  Lavandula  angustifolia.  J  Altern  Complement  Med. 
2008;14:947.

47.  Howard S, Hughes BM. Expectancies, not aroma, explain impact 
of  lavender  aromatherapy  on  psychophysiological  indices  of 
relaxation  in  young  healthy  women.  Br  J  Health  Psychol. 
2008;13:603.

48.  Grunebaum LD, Murdock J, Castanedo-Tardan MP, et al. Effects 
of  lavender  olfactory  input  on  cosmetic  procedures.  J  Cosmet 
Dermatol. 2011;10:89.

49.  Hongratanaworakit  T.  Aroma-therapeutic  effects  of  massage 
blended  essential  oils  on  humans.  Nat  Prod  Commun. 
2011;6:1199.

 
284 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   7 4

Horse Chestnut

Activities:

Anti-inflammatory,  antioxidant,  antiedematous, 
vasoconstrictive, venotonic

Important Chemical Components:

Saponins  (particularly  aescin,  found  in  horse  chestnut 
seeds),  hydroxycoumarins  (i.e.,  aesculin,  fraxin,  and  
scopolin,  found  in  the  bark),  flavonoids  (i.e.,  quercetin 
and kampferol, and their glycoside derivatives astragalin, 
isoquercitrin,  and  rutin),  tannins  (i.e.,  leucocyanidin, 
proanthocyanidin  A2),  sterols,  polysaccharides  and  oli-
gosaccharides, and essential oils (e.g., oleic and linoleic 
acids, found in the leaves and flowers)1–4

Origin Classification:

This ingredient is natural. Organic forms exist.

Personal Care Category:

Chronic venous insufficiency, hemorrhoids, edema

Recommended  for  the  following  Baumann  Skin 
Types:

DRNT,  DRNW,  DRPT,  DRPW,  DSNT,  DSNW,  DSPT, 
DSPW,  ORNT,  ORNW,  ORPT,  ORPW,  OSNT,  OSNW, 
OSPT, and OSPW

 SOURCE

There are 15 known species of horse chestnut, which is found 
as both a tree and a shrub in all the temperate regions of Europe, 
Asia,  and  North  America.  Believed  to  have  originated  in  the 
northern  Greece/Balkan  region  of  southeast  Europe,3  the 
European  horse  chestnut,  Aesculus  hippocastanum,  which 
belongs to the Hippocastanaceae family, is the species of horse 
chestnut most often used in medical applications, traditionally 
for bronchitis, dysentery, hemorrhoids, and venous issues.5 It is 
not known whether other species of horse chestnut have been 
thoroughly evaluated for their potential medicinal value. The 
European  horse  chestnut  is  not  related  to  the  more  familiar 
sweet chestnut (Castanea vesca).3 Its common name is believed to 
be based on the appearance of the seeds and the horseshoe-shaped 
mark that remains on the twig after autumnal leaf shedding.3

 HISTORY

Traditional uses of A. hippocastanum are traced to the region of its 
provenance. For instance, A. hippocastanum is one of 227 plants 
identified  in  an  ethnopharmacologic  study  found  to  be  used 
traditionally  for  health  purposes  in  Bosnia  and  Herzegovina.6 
The  species  was  introduced  into  Western  Europe  around  1576 
(Table 74-1).7 As early as that century, nuts of the A. hippocastanum 
tree  were  used  for  medical  applications  ranging  from  

TABLE 74-1
Pros and Cons of Horse Chestnut

Pros
Long history of traditional medical use

Shown in several randomized controlled 
trials to be an effective short-term 
treatment for mild-to-moderate CVI
Effective orally and topically for edema and 

related cutaneous issues 

Con
Appropriateness for broader, particularly 
antiaging, dermatologic indications is 
not well established

persistent  fever,  with  the  first  written  record  appearing  in 
1720,3,8  to  use  on  hemorrhoids  as  early  as  1886,8  and  later 
varicose  veins  in  the  legs,  phlebitis,  and  petechiae.9,10  Early 
traditional  uses  also  included  rheumatism,  leg  cramps, 
gastrointestinal and bladder conditions, and rectal issues.3,10,11 
The bark was used in folk medicine to treat diarrhea and hem-
orrhoids.7 In North America, Native Americans are said to have 
harnessed the toxic qualities of the seeds to stun fish.7 The use 
of  topically  applied  horse  chestnut  in  cosmetic  formulations 
emerged in 1980, with descriptions of applications to the face, 
scalp, oral cavity, body, hands, feet, and legs, as well as for foot 
and bodily hygiene and hemorrhoids.1 Horse chestnut is now 
widely  used  in  the  pharmaceutical  and  cosmetics  industries.2 
Antiaging  or  antiwrinkling  uses  have  also  been  suggested,  as 
Masaki et al. discovered in 1995 that A. hippocastanum extracts 
strongly scavenge active oxygen.12

 CHEMISTRY

Most  of  the  aerial  sections  of  the  European  horse  chestnut 
tree, such as the seeds, leaves, and bark, were traditionally 
utilized  in  medical  treatments.  Modern  horse  chestnut  for-
mulations  are  derived  from  extracts  from  the  seeds,  which 
are  high  in  the  active  component  aescin  (also  spelled  as 
“escin”). In 1960, Lorenz and Marek found that β-aescin was 
the  constituent  of  the  saponin  mixture  in  A.  hippocastanum 
responsible for conferring antiedematous and vasoprotective 
activity.3,13 The selective vascular permeabilization of aescin 
allows  a  higher  sensitivity  (e.g.,  of  calcium  channels)  to 
molecular  ions  leading  to  increased  venous  contractile 
activity.8

The  seeds  contain  hydroxycoumarins,  flavonoids,  tannins, 
sterols,  saponins,  the  antioxidant  proanthocyanidin  A2,  and 
glycosides.  “Aescin”  is  actually  the  collective  name  for  the 
alkylated triterpene glycosides, or saponins, that represent 3 to 
between  6  and  10  percent  of  the  active  constituents  of  the 
seeds.5,10,14 Aescin is present in α and β forms, the latter of which 
is  composed  of  more  than  30  triterpenoid  derivatives  of 
protoaescigenin and barrintogenol C and found in horse chestnut 

 
seed  extract  (HCSE)  pharmaceuticals  used  for  venous 
insufficiency.1,3,8  Saponins  are  strong  anti-inflammatory 
substances with a gentle, soapy texture.

Several  flavonoids  have  been  identified  in  horse  chestnut 
seeds,  with  di-  and  triglycosides  of  quercetin  and  kaempferol 
shown  to  be  dominant  forms.  Kapusta  et  al.  observed  that 
glycosides  of  these  flavonoids  can  be  obtained  from  industrial 
horse chestnut wastewater to be used in cosmetics, nutraceuticals, 
and  food  supplements.2  In  1999,  Wilkinson  and  Brown  noted 
that  an  HCSE  rich  in  quercetin  and  kaempferol  derivatives 
displayed  greater  oxygen-scavenging  capacity  than  65  other 
tested  plant  extracts  as  well  as  antioxidant  potency  exceeding 
that of vitamin E, with cell-protective effects associated with the 
antiaging characteristics of antioxidants.1

The  mechanism  of  action  is  not  fully  understood,  but  it  is 
speculated  that  HCSE  may  work  by  inhibiting  leukocyte 
activation.15  Aescin,  the  major  active  ingredient  of  HCSE,8  is 
believed to inhibit enzymes that attack vein interiors and thus 
fosters  normal,  healthy  tone  in  vein  walls  and  enhances 
circulation.16  Specifically,  aescin  in  HCSE  facilitates  the 
contraction of elastic fibers in capillary walls thereby increasing 
the contractility of the vessels and increasing venous tone.17,18 
Aescin has been found to hinder elastase and hyaluronidase in 
vitro. Both enzymes are involved in the degradation of proteo-
glycans, an important element in the extravascular matrix and 
component  of  endothelium.  Researchers  speculate  that  the 
aescin in horse chestnut alters the equilibrium between proteo-
glycans synthesis and degradation resulting in the prevention 
of  vascular  leakage.5,15  Proanthocyanidin  A2  is  also  said  to 
inhibit  hyaluronidase  activity.1  Interestingly,  extracts  of  
A. hippocastanum were shown to be more effective than aescin 
alone in accounting for the potent venotonic activity associated 
with  the  plant,  suggesting  that  the  suppression  of  other 
enzymes  (i.e.,  collagenase,  elastase,  and  β-glucuronidase)  is 
involved.1,19

Aescin  is  also  associated  with  the  release  of  prostaglandin  
F  2α  (PGF2α)  from  veins,  antagonism  to  5-hydroxytryptamine 
(5-HT,  or  better  known  as  serotonin)  and  histamine,  and 
decreased catabolism of tissue mucopolysaccharides.8

Rutin,  which  is  believed  to  strengthen  fragile  capillaries,  is 
another  active  ingredient  in  horse  chestnut  seeds.  Several 
European  investigators  claim  that  aescin  and  rutin  work 
synergistically  with  other  active  components  to  enhance 
circulation and ease inflammation and discomfort. The leaves of 
the horse chestnut tree purportedly have antioxidant properties 
that may slow skin wrinkling, though such claims have not been 
confirmed  through  controlled  clinical  trials.  The  amassed 
evidence  clearly  shows  that  horse  chestnut  ameliorates 
circulatory vein function.

 ORAL USES

The  oral  administration  of  standardized  HCSE  is  well 
established  as  an  effective  treatment  primarily  for  chronic 
venous  insufficiency  (CVI)  and  edema,  as  well  as  diarrhea, 
fever, hemorrhoids, neuralgia, phlebitis, prostate enlargement, 
rectal  issues,  and  rheumatism.1,11  CVI  is  characterized  by 
edema,  enlarged  veins  near  the  skin  surface,  and  leg  fatigue. 
Indeed,  there  is  copious,  strong  evidence,  as  Ernst  et  al. 
identified  in  a  systematic  review  of  randomized  controlled 
trials (RCTs), for the effectiveness of oral HCSE for treatment 
of  CVI.20  The  same  researchers  previously  conducted  a  com-
prehensive  review  of  placebo-controlled  studies  finding  that 

C H A P T E R  74  ■   H O R S E   C H E S T N U T  

285

HCSE was superior to placebo in all cases.15 They also noted 
reductions  in  lower-leg  volume,  leg  circumference  at  the  calf 
and  ankle,  and  improvement  in  symptoms  such  as  leg  pain, 
pruritus, fatigue, and tension with only mild adverse reactions 
occurring  rarely.  The  same  study  found  equivalence  between 
horse  chestnut  and  O-(β-hydroxyethyl)-rutosides  against  the 
reference medication and equivalence between horse chestnut 
and compression therapy.15

In  a  2012  literature  search  of  six  placebo-controlled  trials 
assessing  leg  pain,  Pittler  and  Ernst  reported  a  significant 
reduction  of  leg  pain  in  the  groups  treated  with  HCSE  as 
compared  to  the  placebo  groups  or  reference  treatments,  with 
only mild and infrequent side effects. They concluded that horse 
chestnut  is  safe  and  effective  for  short-term  CVI  therapy,  but 
more rigorous RCTs are necessary to evaluate overall, long-term 
efficacy.21

In  a  12-week,  randomized,  partially-blinded,  placebo-
controlled parallel study of 240 patients, significant and equiva-
lent  reduction  of  edema  resulted  from  horse  chestnut  and 
compression  therapy  as  compared  to  placebo;  both  effective 
therapies were well tolerated with no adverse side effects.18

Another study, in which 5,000 patients with CVI were treated 
with standardized HCSE, showed improvement or clearing of all 
of the investigated symptoms (i.e., discomfort, fatigue, tension 
and edema in the leg, and pruritus).22

In 2013, Sipos et al., having earlier found that aescin suppresses 
allergic dermatitis in murine models, used a new porcine model 
to further test safe and novel alternatives to glucocorticoids and 
antihistamines.  Orally  administered  pretreatment  of  animals 
with aescin potently and dose-dependently blocked allergic skin 
responses  induced  by  the  compound  48/80.  The  investigators 
concluded that their findings suggest the use of oral aescin as a 
new antiallergic agent.23

In  addition,  A.  hippocastanum,  as  supplemented  orally  in  the 
diet, is considered one of the several botanical extracts that may 
alleviate the symptoms of hemorrhoids and varicose veins.24,25 
The  recommended  dose  for  CVI  in  the  United  States  is  one 
50-mg capsule taken twice daily for 2 to 16 weeks, though 50 to 
75  mg  is  not  uncommon.25,26  The  German  Commission  E 
suggests a total daily dose of 100 mg.14

 TOPICAL USES

There  are  various  uses  for  this  herbal  product  in  traditional 
Chinese medicine (TCM). Known as tien shi li, horse chestnut is 
used as an astringent, an anti-inflammatory, a diuretic, and an 
expectorant  and  for  a  wide  range  of  conditions  including 
circulatory problems and viruses. Western medicine uses HCSE 
as an astringent and an anti-inflammatory. Horse chestnut is a 
common ingredient in lotions, creams, massage oils, and other 
skin  care  products,  often  in  combination  with  other  herbal 
ingredients.  Most  such  topical  products  tout  the  capacity  of 
horse chestnut to combat varicose veins, swelling, and water 
retention, but some of the newer products ascribe antioxidant 
potency  to  horse  chestnut  and  purport  to  combat  wrinkling. 
The  extract  is  also  effective  when  used  in  a  sitz  bath  for  the 
treatment of hemorrhoids. 

The  topical  application  of  standardized  HCSE  balm  with  
2  percent  aescin  supports  healthy  skin,  blood  vessels,  and 
muscles,9,27,28 particularly in the legs and hemorrhoidal plexus.27 
One double-blind, randomized, single-dose study assessing the 
effectiveness  of  a  topically-applied  standardized  HCSE  balm  
(2 percent aescin) for localized swelling and blood accumulation 

 
286 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

showed that the product containing aescin significantly reduced 
tenderness in the affected area as compared to placebo.9 Indeed, 
aescin  has  demonstrated  clinically  significant  activity  in  the 
treatment of hemorrhoids, CVI, and postoperative edema.8

cellulite, backache, and arthritis, but there is no reliable evidence in 
the literature to substantiate these claims. As an ingredient in facial 
creams and shaving products, it is intended for sensitive skin.

 SAFETY ISSUES

The crude form of A. hippocastanum (e.g., bark, leaves, and seeds) 
is  toxic;  only  processed  extracts  should  be  used  for  medicinal 
purposes.7  Horse  chestnut  is  contraindicated  for  patients  who 
have bleeding disorders or who take anticoagulant drugs, such as 
warfarin,  because  the  herb  reduces  blood  coagulation,  or  
clotting.  Nonsteroidal  anti-inflammatory  drugs  (NSAIDs),  par-
ticularly  aspirin,  as  well  as  the  analgesic  acetaminophen/ 
paracetamol  potentially  interact  with  coumarin-containing 
herbal supplements (such as horse chestnut), increasing the risk 
of  bleeding.14,29  Notably,  though,  aesculin,  the  primary 
coumarin present in A. hippocastanum, is found in the bark but 
not  the  seeds.3  Due  to  lack  of  clinical  data,  oral  HCSE  is 
contraindicated  in  pregnant  or  nursing  women.3  An  adverse 
reaction rate of 0.9 to 3.0 percent has been reported in association 
with  the  oral  use  of  HCSE  for  CVI,  with  dizziness,  headache, 
pruritus, and gastrointestinal disturbances more common.5,8

Topical horse chestnut has been associated, in a few instances, 
with  allergic  skin  reactions.  Overall,  though,  horse  chestnut  is 
generally thought to be safe as used in recommended doses. It 
should not be applied to ulcerated or broken skin.10

 ENVIRONMENTAL IMPACT

There is no significant environmental impact of commercial horse 
chestnut production known by the author. In the United States, 
A.  hipposcastanum  is  usually  grown  as  a  shade  tree.7  The  
modern  medical  supply  of  horse  chestnut  is  cultivated  and 
produced primarily in Poland.7

 FORMULATION CONSIDERATIONS

Typically  applied  three  to  four  times  per  day,  topical  HSCE 
formulations  usually  contain  2  percent  aescin  (1–3  percent  is 
recommended).3,30 A wide array of personal care products now 
include  extracts  of  horse  chestnuts,  including  creams  and 
lotions, bath and shower foams, shampoos, and toothpastes.1

 USAGE CONSIDERATIONS

HCSE is used both internally and externally to treat CVI and the 
related conditions such as varicose veins, leg cramps, phlebitis, 
and  hemorrhoids  (varicose  veins  of  the  anus  and  rectum). 
In topical form, horse chestnut is also used for wound healing 
and treating sprains and strains. Topical application of gels or 
creams containing 2 percent aescin, three or four times per day, 
is popular in Europe for eliminating hemorrhoids, skin ulcers, 
and  varicose  veins  and  healing  bruises,  sports  injuries,  and 
similar traumas. It is the most widely prescribed treatment for 
edema with venous insufficiency in Germany, where standard-
ized HCSE has been approved by the Commission E for the treat-
ment of pathological conditions of the veins of the legs, including 
pruritus, edema, nocturnal cramping in the calves, discomfort and 
a sensation of heaviness, as well as varicose and spider veins.4,7

There are some claims that horse chestnut may even be effective 
in the treatment of wrinkles, dark circles under the eyes, hair loss, 

 SIGNIFICANT BACKGROUND

While some have noted the adequacy of horse chestnut in the 
early phases of CVI as a result of its capacity to close venular 
endothelial  gaps,  compression  therapy  remains  indicated  for 
later stages (though horse chestnut may have the potential to 
act  at  later  stages  of  CVI).31  Various  authors  note  that  poor 
compliance  is  associated  with  the  relatively  uncomfortable 
compression  therapy,  rendering  an  oral  and,  perhaps,  topical 
therapy  such  as  horse  chestnut  more  preferable.  The  sooner 
such  therapy  is  initiated,  the  better  the  chance  of  avoiding 
painful compression therapy.

Both  topical  and  systemic  HCSEs  are  popular  in  Europe  for 
the treatment of CVI and varicose veins. The aescin in HCSEs 
clearly  possesses  anti-inflammatory  properties  and  has  been 
demonstrated to ease edema after trauma, especially following 
head and sports injury, and surgery.9,16 A topical aescin prepara-
tion is also popular for use during sporting events in Europe for 
treatment of acute sprains.

Chronic Venous Insufficiency
The  inhibitory  effect  exerted  on  the  catalytic  degradation  of 
capillary  wall  proteoglycans  is  thought  to  account  for  the 
efficacy  associated  with  HCSE  formulations.5  Several  RCTs 
show  that  A.  hippocastanum  is  effective  in  reducing  edema 
associated  with  CVI.32  However,  in  a  2002  four-week  open, 
controlled,  comparative  study  of  HCSE  (Venostasin)  and 
Pycnogenol used to treat 40 patients with CVI, Koch found that 
while  both  medications  were  well  tolerated,  Venostasin  only 
moderately 
improved  symptoms  whereas  Pycnogenol 
significantly  diminished  lower  limb  circumference  as  well  as 
cholesterol and low-density lipoprotein values (see Chapter 49, 
Pycnogenol).33

Aesculaforce®, a fresh plant HCSE, was found in five clinical 
trials (four on CVI, one on varicose veins) as a topical gel, oral 
tincture, or tablet, to decrease objective measures of lower leg 
edema  and,  subjectively,  relieve  patients  of  pruritus,  leg  pain, 
and heaviness associated with CVI and varicose veins. The fresh 
plant  HCSE  formulation  was  safe  and  well  tolerated,  and, 
according to a 2006 review by Suter et al., suitable for patients 
with  mild-to-moderate  venous  insufficiency.5  In  addition,  an 
Australian study that year suggested that the use of HCSE may 
be  more  cost-effective  than  conventional  therapy  for  the 
treatment of venous leg ulcers.34

Rathbun and Kirkpatrick note that multiple RCTs have shown 
that  the  use  of  HCSE  has  achieved  short-term  improvement  
in CVI signs and symptoms, though caution is necessary when 
considering herbal supplements insofar as they are not regulated 
or licensed by the United States Food and Drug Administration.26 
Pittler and Ernst, in their 2012 database review, echoed the con-
clusion  that  HCSE  provides  efficacious  short-term  relief  from 
CVI,  while  calling  for  larger  RCTs  to  verify  the  efficacy  of  the 
herbal treatment.21

Photoprotection and Antiaging Activity
In  1996,  Ramos  et  al.  assessed  liquid  and  dry  extracts  of  A. 
hippocastanum,  Hamamelis  virginiana  (witch  hazel),  Matricaria 
recutita  (chamomile),  Rhamnus  purshiana  (cascara),  and 

 
Cinnamomum zeylanicum (cinnamon) to determine their viability 
as antisolar agents. After incorporation into an octylmethoxycin-
namate synthetic sunscreen, the researchers noted that the solar 
protection factors (SPFs) intensified (see Chapter 70, Chamomile). 
They  concluded  that  inclusion  in  sunscreens  of  such  plant 
extracts,  which  can  also  deliver  emollient  qualities  to  the 
formulation,  may  allow  for  providing  greater  SPF  and,  thus, 
skin protection from UV exposure.35

Noting that contraction forces generated by nonmuscle cells, 
such  as  fibroblasts,  contribute  to  wound  healing  and  vasocon-
striction, Fujimura et al. set out in 2006 to identify plant extracts 
(among 100 of those listed in the Japanese cosmetic ingredients 
codex)  capable  of  creating  such  forces  in  fibroblast-populated 
collagen gels. Finding that an extract of horse chestnut met such 
parameters,  they  conducted  a  nine-week  clinical  trial  with  
40 healthy female volunteers, who applied the 3 percent extract 
gel around the eyes three times daily. At six weeks, significant 
reductions in wrinkle scores for the corners of the eye and lower 
eyelid  were  noted  in  comparison  with  scores  for  the  control 
group, with similar differences seen at nine weeks. The investi-
gators concluded that horse chestnut appears to be a considerable 
antiaging  agent  in  vivo,  though  more  research  is  necessary, 
including comparisons to other agents.36

 CONCLUSION

The use of horse chestnut in chronic venous insufficiency and 
other  venous  disorders  has  some  support  by  randomized 
controlled  trials  due  to  the  effects  of  aescin  on  venous  tone. 
Like  many  other  such  herbs,  the  potential  efficacy  of  its 
inclusion  in  modern  topical  products  remains  questionable, 
though  the  evidence  for  topical  use  for  edema  is  well 
established. Many products targeted for eye puffiness or dark 
circles  under  the  eyes  contain  horse  chestnut  due  to  the 
purported  effects  on  blood  flow  and  circulation  around  the 
eyes.  These  claims  remain  unproven.  Much  more  research 
with topical horse chestnut is needed to support some of the 
more  recent  assertions  regarding  efficacy  in  providing  photo-
protection, treating wrinkles, dark circles under the eyes, spider 
veins, and hair loss (Table 74-1).

REFERENCES

1.  Wilkinson JA, Brown AM. Horse chestnut – Aesculus hippocastanum: 
Potential applications in cosmetic skin-care products. Int J Cosmet Sci. 
1999;21:437.

2.  Kapusta I, Janda B, Szajway B, et al. Flavonoids in horse chestnut 
(Aesculus  hippocastanum)  seeds  and  powdered  waste  water 
byproducts. J Agric Food Chem. 2007;55:8485.

3.  No  authors  listed.  Aesculus  hippocastanum  (Horse  chestnut). 

Monograph. Altern Med Rev. 2009;14:278.

4.  Thornfeldt C. Cosmeceuticals containing herbs: Fact, fiction, and 

future. Dermatol Surg. 2005;31:873.

5.  Suter A, Bommer S, Rechner J. Treatment of patients with venous 
insufficiency  with  fresh  plant  horse  chestnut  seed  extract:  A 
review of 5 clinical studies. Adv Ther. 2006;23:179.

6.  Redzic´  SS. The ecological aspect of ethnobotany and ethnophar-
macology of population in Bosnia and Herzegovina. Coll Antropol. 
2007;31:869.

7.  Foster S. An Illustrated Guide to 101 Medicinal Herbs: Their History, 
Use,  Recommended  Dosages,  and  Cautions.  Loveland,  CO: 
Interweave Press; 1998:116–7.

8.  Sirtori  CR.  Aescin:  Pharmacology,  pharmacokinetics  and  thera-

peutic profile. Pharmacol Res. 2001;44:183.

9.  Calabrese  C,  Preston  P.  Report  of  the  results  of  a  double-blind, 
randomized,  single-dose  trial  of  a  topical  2%  escin  gel  versus 

C H A P T E R  74  ■   H O R S E   C H E S T N U T  

287

placebo  in  the  acute  treatment  of  experimentally-induced 
hematoma in volunteers. Planta Med. 1993;59:394.

10.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy:  Modern 
Herbal Medicine. London: Churchill Livingstone; 2000:448–455.
11.  Grieve  M.  A  Modern  Herbal  (Vol.  II).  New  York:  Dover  

Publications; 1971:192–193.

12.  Masaki  H,  Sakaki  S,  Atsumi  T,  et  al.  Active-oxygen  scavenging 

activity of plant extracts. Biol Pharm Bull. 1995;18:162.

13.  Lorenz D, Marek ML. The active therapeutic principle of horse 
chestnut  (Aesculus  hippocastanum).  Part  I.  Classification  of  the 
active substance. Arzneimittelforschung. 1960;10:263.

14.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

Medicine. Rochester, VT: Healing Arts Press; 2003:524.

15.  Pittler  MH,  Ernst  E.  Horse-chestnut  seed  extract  for  chronic 
venous  insufficiency.  A  criteria-based  systematic  review.  Arch 
Dermatol. 1998;134:1356.

16.  Guillaume M, Padioleau F. Veinotonic effect, vascular protection, 
anti-inflammatory and free radical scavenging properties of horse 
chestnut extract. Arzneimittelforschung. 1994;44:25.

17.  Bisler H, Pfeifer R, Klüken N, et al. Effects of horse-chestnut see 
extract on transcapillary filtration in chronic venous insufficiency. 
Dtsch Med Wochenschr. 1986;111:1321.

18.  Diehm  C,  Trampisch  HJ,  Lange  S,  et  al.  Comparison  of  leg 
compression  stocking  and  oral  horse-chestnut  seed  extract 
therapy  in  patients  with  chronic  venous  insufficiency.  Lancet. 
1996;347:292.

19.  Facino  RM,  Carini  M,  Stefani  R,  et  al.  Anti-elastase  and  anti-
hyaluronidase activities of saponins and sapogenins from Hedera 
helix,  Aesculus  hippocastanum,  and  Ruscus  aculeatus:  Factors 
contributing  to  their  efficacy  in  the  treatment  of  venous 
insufficiency. Arch Pharm (Weinheim). 1995;328:720.

20.  Ernst  E,  Pittler  MH,  Stevinson  C.  Complementary/alternative 
medicine  in  dermatology:  Evidence-assessed  efficacy  of  two 
diseases and two treatments. Am J Clin Dermatol. 2002;3:341.
21.  Pittler  MH,  Ernst  E.  Horse  chestnut  seed  extract  for  chronic 
insufficiency.  Cochrane  Database  Syst  Rev. 

venous 
2012;11:CD003230.

22.  Greeske  K,  Pohlmann  BK.  Horse  chestnut  seed  extract  –  an 
effective  therapy  principle  in  general  practice.  Drug  therapy  of 
chronic venous insufficiency. Fortschr Med. 1996;114:196.

23.  Sipos W, Reutterer B, Frank M, et al. Escin inhibits type I allergic 
dermatitis  in  a  novel  porcine  model.  Int  Arch  Allergy  Immunol. 
2013;161:44.

24.  MacKay  D.  Hemorrhoids  and  varicose  veins:  A  review  of 

treatment options. Altern Med Rev. 2001;6:126.

25.  Dattner AM. From medical herbalism to phytotherapy in derma-

tology: Back to the future. Dermatol Ther. 2003;16:106.

26.  Rathbun SW, Kirkpatrick AC. Treatment of chronic venous insuf-

ficiency. Curr Treat Options Cardiovasc Med. 2007;9:115.

27.  Tozzi E, Scatena M, Castellacci E. Anti-inflammatory local frigo-
therapy  with  a  combination  of  escin,  heparin  and  polyunsatu-
rated phosphatidylcholine (EPL). Clin Ter. 1981;98:517.

28.  Desogus  AI,  D’Alia  G.  Venotropic  therapy:  Results  of  clinical 

experimentation. Clin Ter. 1986;118:339.

29.  Abebe  W.  Herbal  medication:  Potential  for  adverse  interactions 

with analgesic drugs. J Clin Pharm Ther. 2002;27:391.

30.  Hexsel D, Orlandi C, Zechmeister do Prado D. Botanical extracts 
used in the treatment of cellulite. Dermatol Surg. 2005;31:866.
31.  Ottillinger  B,  Greeske  K.  Rational  therapy  of  chronic  venous 
insufficiency—chances and limits of the therapeutic use of horse-
chestnut seeds extract. BMC Cardiovasc Disord. 2001;1:5.

32.  Reuter J, Wölfle U, Korting HC, et al. Which plant for which skin 
disease?  Part  2:  Dermatophytes,  chronic  venous  insufficiency, 
photoprotection,  actinic  keratoses,  vitiligo,  hair  loss,  cosmetic 
indications. J Dtsh Dermatol Ges. 2010;8:866.

33.  Koch R. Comparative study of Venostasin and Pycnogenol in 
insufficiency.  Phytother  Res.  2002;16  

chronic  venous 
(Suppl 1):S1.

34.  Leach MJ, Pincombe J, Foster G. Using horse chestnut seed extract 
in  the  treatment  of  venous  leg  ulcers:  A  cost-benefit  analysis. 
Ostomy Wound Manage. 2006;52:68.

35.  Ramos  MF,  Santos  EP,  Bizarri  CH,  et  al.  Preliminary  studies 
towards utilization of various plant extracts as antisolar agents. 
Int J Cosmet Sci. 1996;18:87.

36.  Fujimura  T,  Tsukahara  K,  Moriwaki  S,  et  al.  A  horse  chestnut 
extract,  which  induces  contraction  forces  in  fibroblasts,  is  a 
potent anti-aging ingredient. J Cosmet Sci. 2006;57:369.

 
288  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

SECTION

I

Antiacne Ingredients

C H A P T E R   7 5

Overview of Acne

Four  main  etiologic  factors  have  been  implicated  in  the  patho-
physiology of acne: sebaceous gland hyperactivity, inflammation, 
abundance  of  Propionibacterium  acnes,  and  dysfunction  of  the 
desquamation  of  the  hair  follicle  (see  Chapter  64,  Anti-
inflammatory  Agents).  These  causal  elements  work  interde-
pendently  and  are  mediated  by  such  important  influences  as 
diet, stress, heredity, and hormonal activity.

 SEBACEOUS GLAND HYPERACTIVITY

Sebum,  composed  of  lipids,  is  continuously  synthesized  by 
the sebaceous glands and secreted to the skin surface through 
the  hair  follicle  pore.  The  sebaceous  glands  are  located  all 
over the body but are largest and most numerous in the face, 
back, chest, and shoulders. These glands become more active 
during puberty because of the increase in androgens, particu-
larly testosterone, which spurs sebum production. Oral drugs 
that  inhibit  sebaceous  gland  activity,  such  as  antiandrogens, 
estrogens, and retinoids, are important treatment modalities 
in  the  successful  control  of  acne.  At  this  time,  there  are  no 
topical  ingredients  that  can  reduce  sebum  secretion,  most 
likely because the sebaceous gland is deep in the hair follicle 
and unreachable by most topical agents.

 FOLLICULAR KERATINIZATION

The keratinocytes that line the hair follicle undergo the matura-
tion process known as keratinization. Once they mature into 
stratum corneum cells, they desquamate into the hair follicle. 
In acne patients, these keratinocytes have a tendency to stick 
together due to the effects of positive and negative charges, the 
actions  of  the  enzyme  transglutaminase,  and  the  viscosity  of 
sebum.  The  clumped  keratinocytes  block  the  pore/follicle, 
creating a blackhead if the pore is open (“open comedone”) or a 
whitehead if it is closed (“closed comedone”). The clogged pore 
is a great nutritional source for P. acnes bacteria.

 THE INFLUENCE OF BACTERIA

P.  acnes  has  been  cited  as  a  key  component  in  the  etiologic 
pathway of acne, a sine qua non feature, because it is typically 
present in higher concentrations in teenagers with acne than in 
controls without acne.1 When P. acnes is present, immune system 
cells are activated to initiate an inflammatory immune response. 
In addition, P. acnes itself releases inflammatory mediators when 

it ingests sebum. This inflammation leads to the red pus-filled 
bump known as a “pimple.” 

Corynebacterium acnes is another bacteria associated with the 
pathophysiologic  pathway  of  acne.  Antibiotic  resistance  to  
P. acnes bacteria is estimated to be as high as 60 percent in some 
patient populations.2 Erythromycin, methicillin, and clindamycin 
are the most common antibiotics to which bacteria have been 
reportedly found to be resistant.3 For this reason, erythromycin 
and clindamycin should no longer be used as monotherapy for 
acne. Benzoyl peroxide (BPO), lauric acid, triclosan, and colloidal 
silver display antibacterial properties that make them attractive 
as antiacne agents that should not lead to bacterial resistance.4–6 
Combining  BPO  with  erythromycin  or  clindamycin  has  been 
proven  to  prevent  the  emergence  of  resistant  strains  of  
P. acnes;3,7,8, therefore, the current clinical acne recommendation 
is  to  include  BPO  in  topical  antiacne  regimens  that  employ 
antibiotics.9 Triclosan is a known allergen, so it is not used for 
acne. Lauric acid and silver are still under investigation, but their 
utility in the treatment of acne is promising.

Acne  is  characterized  by  clogged  pores,  open  and  closed 
comedones, red papules, pustules, and cysts. Treatments include 
anti-inflammatories,  antimicrobials,  exfoliants  to  prevent 
clogged follicles, and retinoids. Blue light is effective to reduce  
P. acnes levels and red light can be used to decrease inflammation. 
Most acne treatments are by prescription. This section will cover 
over-the-counter (OTC) acne ingredients.

The best way to treat acne is through combination therapy using 
an  exfoliant,  an  antimicrobial,  a  retinoid,  and  anti-inflammatory 
ingredients. This section will focus on BPO, as an antimicrobial, 
salicylic  acid,  for  its  dual  role  as  an  exfoliant  and  an  anti-
inflammatory, and retinoids, as the mainstay of acne treatment, 
as well as alternatives such as tea tree oil and silver. Although 
retinoids are usually prescription medications, retinol and other 
retinoids are available over the counter. It is important to realize 
that many ingredients can cause acne (see Table 75-1). One of 
the frequent culprits is isopropyl myristate, which is common in 
skin and hair care products.

The etiologic pathway of acne is convoluted and its treatment 
variable, multistep, and most effective when individualized to 
the patient. An extensive exploration of this most common of 
dermatologic  conditions,  particularly  the  cases  resistant  to 
treatment, will not be pursued in this section. Instead, the focus 
is on basic OTC ingredients for patients with mild-to-moderate 
acne. Note that there are many drugs approved by the United 
States Food and Drug Administration (FDA) for acne, including 
tretinoin, adapalene, and tazarotene, that are beyond the scope 

 
C H A P T E R  75  ■   O V E R V I E W   O F   AC N E  

289

TABLE 75-1
List of Potential Acne-Causing Ingredients Found in Cosmetic Products

Anhydrous Lanolin
Apricot Kernel Oil
Arachidic Acid
Ascorbyl Palmitate
Avocado Oil
Azulene
BHA
Beeswax
Benzaldehyde
Benzoic Acid
b-Carotene
Bubussa Oil
Butyl Stearate
Butylated Hydroxyanisole (BHA)
Butylene Glycol
Cajeput Oil
Calendula
Camphor
Candelilla Wax
Capric Acid
Caprylic Acid
Carbomer 940
Carnuba Wax
Carotene
Carrageenan
Castor Oil
Cetearyl Alcohol
Cetyl Alcohol
Chamomile
Chaulomoogra Oil
Cocoa Butter
Coconut Butter
Coconut Oil
Colloidal Sulfur
Corn Oil
Cotton Seed Oil

Crisco
D & C Red # 3
D & C Red # 4
D & C Red # 6
D & C Red # 7
D & C Red # 9
D & C Red # 17
D & C Red # 19
D & C Red # 21
D & C Red # 27
D & C Red # 30
D & C Red # 33
D & C Red # 36
D & C Red # 40
Decyl Oleate
Dimethicone
Dioctyl Succinate
Disodium Oleamido
PEG 2-Sulfosuccinate
Emulsifying Wax NF
Ethoxylated Lanolin
Ethylhexyl Palmitate
Evening Primrose Oil
Glyceryl Stearate NSE
Glyceryl Stearate SE
Glyceryl Tricapylo/Caprate
Glyceryl-3-Diisostearate
Hexadecyl Alcohol
Hexylene Glycol
Hydrogenated Castor Oil
Hydrogenated Vegetable Oil
Hydroxypropylcellulose
Isocetyl Stearate
Isodecyl Oleate
Isopropyl Isostearate
Isopropyl Myristate

Isopropyl Palmitate
Isostearyl Isostearate
Isostearyl Neopentanoate
Jojoba Oil
Lanolin Alcohol
Lanolin Oil
Lanolin Wax
Laureth 23
Laureth 4
Lithium Stearate
Magnesium Stearate
Menthyl Anthranilate
Mink Oil
Myristic Acid
Myristyl Lactate
Myristyl Myristate
Octyl Palmitate
Octyl Stearate
Oleth-3
Oleth-10
Oleyl Alcohol
Olive Oil
PEG 100 Distearate
PEG 100 Stearate
PEG 150 Distearate
PEG 16 Lanolin
PEG 20 Stearate
PEG 200 Dilaurate
PEG 8 Stearate
PG Caprylate/Caprate
PG Dipelargonate
PG Monostearate
PPG 2 Myristyl Propionate
Palmitic Acid
Peanut Oil
Pentarythrital Tetra Isostearate

PG Dicaprylate/Caprate
PG Dipelargonate
Polyethylene Glycol (PEG 400)
Polyethylene Glycol 300
Polyglyceryl-3-Diisostearate
Potassium Chloride
Propylene Glycol Monostearate
Red Algae
Sandalwood Seed Oil
Sesame Oil
Shark Liver Oil
Simethicone
Sodium Chloride (Salt)
Sodium Laureth Sulfate
Sodium Lauryl Sulfate
Solulan 16
Sorbitan Laurate
Sorbitan Oleate
Soybean Oil
Squalane
Steareth 10
Steareth 2
Steareth 20
Stearic Acid
Stearic Acid Tea
Stearyl Alcohol
Stearyl Heptanoate
Sulfated Castor Oil
Sulfated Jojoba Oil
Stearyl Heptanoate
Talc
Triethanolamine
Vitamin A Palmitate
Wheat Germ Glyceride/Oil
Xylene
Zinc Oxide

of this book because they are prescription products. These acne 
drugs must undergo a formal clinical research process (Phase I to 
Phase III research trials) in order to prove safety and efficacy and 
to  receive  FDA  drug  approval.  After  hundreds  of  millions  of 
dollars  and  at  least  three  years  of  effort,  the  acne  drug  may 
receive  approval  from  the  FDA,  which  dictates  and  strictly 

enforces the manufacturing processes, labeling, and marketing 
claims. OTC medications claimed by manufacturers to improve 
acne do not require FDA drug approval but they must contain 
ingredients  that  have  been  ruled  as  “safe”  and  “effective  for 
acne”  by  the  FDA.  Their  use  is  governed  by  an  official  ruling 
known  as  a  “monograph.”  See  Table  75-2  for  a  set  of 

TABLE 75-2
Summary of Warnings and Directions Required for OTC Acne Medications10

Warnings

Directions

For external use only
When using this product
•	 Skin irritation and dryness is more likely to occur if you use 

another topical acne medication at the same time. If irritation 
occurs, only use one topical acne medication at a time.

•	 Clean the skin thoroughly before applying this product 
•	 Cover the entire affected area with a thin layer one to three times daily 
•	 Because excessive drying of the skin may occur, start with one application daily, then gradually increase to two or 

three times daily if needed or as directed by a doctor 

•	 If bothersome dryness or peeling occurs, reduce application to once a day or every other day.
Products, such as soaps and masks, which are applied and removed, should include appropriate directions in addition to 
the directions set forth above. For example, the second bullet of the standard directions listed above may be revised to 
read “cover the entire affected area with a thin layer and rinse thoroughly one to three times daily.”

In addition to the required directions, all OTC topical acne products marketed under the monograph may contain the  

following optional direction:

“Sensitivity Test for a New User. Apply product sparingly to one or two small affected areas during the first 3 days. If no 

discomfort occurs, follow the directions stated (select one of the following: ‘elsewhere on this label,’ ‘above,’ or ‘below’).” 

 
290 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

TABLE 75-3 
OTC Acne Monograph (21 CFR part 333, subpart D)11

subpart D – topical acne Drug proDucts

Sec. 333.301 Scope
a.  An over-the-counter acne drug product in a form suitable for topical application is 

generally recognized as safe and effective and is not misbranded if it meets each of the 
conditions in this subpart and each general condition established in 330.1 of this chapter
 References in this subpart to regulatory sections of the Code of Federal Regulations are to 
chapter I of title 21 unless otherwise noted 

b. 

Sec. 333.303 Definitions
As used in this subpart:
a. 

 Acne. A disease involving the oil glands and hair follicles of the skin which is manifested by 
blackheads, whiteheads, acne pimples, and acne blemishes
 Acne blemish. A flaw in the skin resulting from acne
 Acne drug product. A drug product used to reduce the number of acne blemishes, acne 
pimples, blackheads, and whiteheads
 Acne pimple. A small, prominent, inflamed elevation of the skin resulting from acne
 Blackhead. A condition of the skin that occurs in acne and is characterized by a black tip
 Whitehead. A condition of the skin that occurs in acne and is characterized by a small, firm, 
whitish elevation of the skin

b. 
c. 

d. 
e. 
f. 

Sec. 333.310 Acne active ingredients
The active ingredient of the product consists of any of the following:
a.  Benzoyl peroxide, 2.5 to 10 percent
b.  Resorcinol, 2 percent, when combined with sulfur in accordance with 333.320(a)
c.  Resorcinol monoacetate, 3 percent, when combined with sulfur in accordance with 333.320(b)
d.  Salicylic acid, 0.5 to 2 percent
e.  Sulfur, 3 to 10 percent
f.  Sulfur, 3 to 8 percent, when combined with resorcinol or resorcinol monoacetate in 

accordance with 333.320

[75 FR 9776, Mar. 4, 2010] 
Sec. 333.320 Permitted combinations of active ingredients
a.  Resorcinol identified in 333.310(b) may be combined with sulfur identified in 333.310(f)
b.  Resorcinol monoacetate identified in 333.310(c) may be combined with sulfur identified  

in 333.310(f)

c. 

d. 

[75 FR 9776, Mar. 4, 2010] 
Sec. 333.350 Labeling of acne drug products
a. 

b. 

 Statement of identity. The labeling of the product contains the established name of the 
drug, if any, and identifies the product as an “acne medication,”  “acne treatment,”  “acne 
medication” (insert dosage form, e.g., “cream,”  “gel,”  “lotion,” or  “ointment”), or  “acne 
treatment” (insert dosage form, e.g.,  “cream,”  “gel,”  “lotion,” or  “ointment”)
 Indications. The labeling of the product states, under the heading “Indications,” the phrase listed 
in paragraph (b)(1) of this section and may contain any of the additional phrases listed in para-
graph (b)(2) of this section. Other truthful and nonmisleading statements, describing only the 
indications for use that have been established and listed in paragraph (b) of this section, may 
also be used, as provided in 330.1(c)(2) of this chapter, subject to the provisions of section 502 
of the Federal Food, Drug, and Cosmetic Act (the act) relating to misbranding and the prohibi-
tion in section 301(d) of the act against the introduction or delivery for introduction into inter-
state commerce of unapproved new drugs in violation of section 505(a) of the act
1.  “For the” (select one of the following: “management” or “treatment”) “of acne”
In addition to the information identified in paragraph (b)(1) of this section, the 
2. 
labeling of the product may contain any one or more of the following statements:
i. 

(Select one of the following: “clears,”  “clears up,”  “clears up most,”  “dries,” “dries up,” 
“dries and clears,”  “helps clear,”  “helps clear up,”  “reduces the number of,” or “reduces 
the severity of”) (select one or more of the following: “acne blemishes,”  “acne pimples,” 
“blackheads,” or “whiteheads”) which may be followed by “and allows skin to heal”

ii.  “Penetrates pores to” (select one of the following: “eliminate most,”  “control,” 
“clear most,” or “reduce the number of”) (select one or more of the following: 
“acne blemishes,”  “acne pimples,”  “blackheads,” or  “whiteheads”)
iii.  “Helps keep skin clear of new” (select one or more of the following: “acne 

blemishes,”  “acne pimples,”  “blackheads,” or  “whiteheads”)

iv.  “Helps prevent new” (select one or more of the following: “acne blemishes,”  “acne 
pimples,”  “blackheads,” or “whiteheads”) which may be followed by “from forming.”
v.  “Helps prevent the development of new” (select one or more of the following: 

“acne blemishes,”  “acne pimples,”  “blackheads,” or  “whiteheads”)

 Warnings. The labeling of the product contains the following warnings under the heading 
“Warnings”:
1. 

 For products containing any ingredients identified in 330.310
i.  The labeling states “For external use only”
ii.  The labeling states “When using this product • skin irritation and dryness is more 
likely to occur if you use another topical acne medication at the same time. If 
irritation occurs, only use one topical acne medication at a time”

2. 

3. 

 For products containing sulfur identified in 333.310(e) and (f)
i.  The labeling states  “Do not use on •  broken skin  •  large areas of the skin”
ii.  The labeling states  “When using this product  •  apply only to areas with acne”
 For products containing any combination identified in 333.320. (i) The labeling states 
“When using this product  •  rinse right away with water if it gets in eyes”
i.  The labeling states  “Stop use and ask a doctor  •  if skin irritation occurs or gets worse”

4.  For products containing benzoyl peroxide identified in 333.310(a)

i.  The labeling states  “Do not use if you • have very sensitive skin • are sensitive 

to benzoyl peroxide”

ii.  The labeling states  “When using this product  • avoid unnecessary sun exposure 
and use a sunscreen  •  avoid contact with the eyes, lips, and mouth  •  avoid con-
tact with hair and dyed fabrics, which may be bleached by this product  •  skin 
irritation may occur, characterized by redness, burning, itching, peeling, or possibly 
swelling. Irritation may be reduced by using the product less frequently or in a 
lower concentration”

iii.  The labeling states “Stop use and ask a doctor if  • irritation becomes severe”
 Directions. The labeling of the product contains the following information under the heading 
“Directions”:
1. 

 For products applied containing any ingredient identified in 333.310. The labeling states 
“ •  clean the skin thoroughly before applying this product  •  cover the entire affected 
area with a thin layer one to three times daily  •  because excessive drying of the skin 
may occur, start with one application daily, then gradually increase to two or three 
times daily if needed or as directed by a doctor  •  if bothersome dryness or peeling 
occurs, reduce application to once a day or every other day”
 For products applied and left on the skin containing benzoyl peroxide identified in 333.310(a)
i.  The labeling states the directions in paragraph (d)(1) of this section
ii.  The labeling states “ •  if going outside, apply sunscreen after using this product. 
If irritation or sensitivity develops, stop use of both products and ask a doctor”
 For products applied and removed from the skin containing any ingredient identified in 
333.310. Products, such as soaps and masks, may be applied and removed and should 
include appropriate directions. All products containing benzoyl peroxide should 
include the directions in paragraph (d)(2)(ii) of this section
 Optional directions. In addition to the required directions in paragraphs (d)(1) and (d)
(2) of this section, the product may contain the following optional labeling: 
“Sensitivity Test for a New User. Apply product sparingly to one or two small affected 
areas during the first 3 days.  If no discomfort occurs, follow the directions stated  
(select one of the following: ‘elsewhere on this label,’  ‘above,’  or  ‘below’)”

2. 

3. 

4. 

[56 FR 41019, Aug. 16, 1991, as amended at 75 FR 9776, Mar. 4, 2010]

FDA  required  warnings  on  the  label  of  OTC  acne  products 
containing  BPO  or  salicylic  acid  as  per  FDA  OTC  regulations 
21  CFR  333,  subpart  D.  Some  ingredients  such  as  BPO  are 
found  in  both  prescription  and  OTC  acne  products 
(see Table 75-3).

REFERENCES

1.  Zaenglein AL, Graber EM. Thiboutot DM. Acne vulgaris and acnei-
form eruptions. In: Goldsmith LA, Katz SI, Gilchrest B, et al. eds.  
Fitzpatrick’s  Dermatology  in  General  Medicine.  8th  ed.  New  York: 
McGraw-Hill; 2012:900.

 
C H A P T E R  75  ■   O V E R V I E W   O F   AC N E  

291

2.  Nishijima  S,  Akamatsu  H,  Akamatsu  M,  et  al.  The  antibiotic 
susceptibility  of  Propionibacterium  acnes  and  Staphylococcus 
epidermidis isolated from acne. J Dermatol. 1994;21:166.

3.  Kircik  LH.  The  role  of  benzoyl  peroxide  in  the  new  treatment 

paradigm for acne. J Drugs Dermatol. 2013;12:s73.

4.  Nakatsuji T, Kao MC, Fang JY, et al. Antimicrobial property of lauric 
acid against Propionibacterium acnes: Its therapeutic potential for 
inflammatory acne vulgaris. J Invest Dermatol. 2009;129:2480.

5.  Domínguez-Delgado CL, Rodríguez-Cruz IM, Escobar-Chávez JJ, 
et al. Preparation and characterization of triclosan nanoparticles 
intended  to  be  used  for  the  treatment  of  acne.  Eur  J  Pharm 
Biopharm. 2011;79:102.

6.  Lansdown AB. Silver. I: Its antibacterial properties and mechanism 

of action. J Wound Care. 2002;11:125.

7.  Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide 
and  erythromycin  alone  and  in  combination  against  antibiotic-
sensitive  and  -resistant  skin  bacteria  from  acne  patients.  Br  J 
Dermatol. 1994;131:331.

8.  Leyden  J,  Levy  S.  The  development  of  antibiotic  resistance  in 

Propionibacterium acnes. Cutis. 2001;67:21.

9.  Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the 
management  of  acne:  An  update  from  the  Global  Alliance  to 
Improve  Outcomes  in  Acne  group.  J  Am  Acad  Dermatol. 
2009;60:S1.

10.  U.S. Department of Health and Human Services, Food and Drug 
Administration,  Center  for  Drug  Evaluation  and  Research 
(CDER). Guidance for Industry Topical Acne Drug Products for 
Over-the-Counter  Human  Use–Revision  of  Labeling  and 
Classification  of  Benzoyl  Peroxide  as  Safe  and  Effective 
Small Entity Compliance Guide. Posted June 2011. http://www 
. f d a . g o v / d o w n l o a d s / D r u g s / G u i d a n c e C o m p l i a n c e 
RegulatoryInformation/Guidances/UCM259744.pdf.  Accessed 
August 11, 2013.

11.  CFR–Code  of  Federal  Regulations  Title  21  –  Food  and  Drugs 
Chapter I, Subchapter D, Drugs for Human Use, Part 333 Topical 
Antimicrobial Drug Products for Over-the-Counter Human Use, 
Subpart  D,  Topical  Acne  Drug  Products,  Food  and  Drug 
Administration.  http://www.accessdata.fda.gov/scripts/cdrh/
cfdocs/cfcfr/CFRSearch.cfm?CFRPart=333&showFR=1&subpart
Node=21:5.0.1.1.12.4. Accessed August 11, 2013.

 
292 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   7 6

Benzoyl Peroxide

Activities:

Anti-inflammatory,  antibacterial,  keratolytic,  wound 
healing

Important Chemical Components:

Benzoyl peroxide, an organic compound in the peroxide 
family, is metabolized to benzoic acid within the skin.

Origin Classification:

Synthesized in the laboratory

Personal Care Category:

Acne therapy

Recommended  for  the  following  Baumann  Skin 
Types:

OSNT,  OSNW,  OSPT,  OSPW  (but  only  by  those  with 
the  Type  1  subtype,  S1,  of  the  four  BST  sensitive  skin 
types).  Should  be  avoided  by  very  dry  types  and  S4  
sensitive skin allergic types because they often have an 
impaired barrier and are irritated by benzoyl peroxide.

 SOURCE

Benzoyl peroxide (BPO) is one of the two most common ingredi-
ents in over-the-counter (OTC) acne treatments.1 It is also found 
in  many  prescription  drug  acne  therapies.  Both  OTC  and 
prescription  versions  have  been  shown  to  be  effective  in  the 
treatment of acne.2 BPO was originally derived from chlorhy-
droxyquinoline, a component of coal tar.3 Currently, BPO is usually 
prepared by treating hydrogen peroxide with benzoyl chloride.

 HISTORY

BPO is used for many purposes including bleaching flour and as 
a catalyst for chemical production of resins.4 There are conflict-
ing  reports  about  the  history  of  the  medical  use  of  BPO  but 
Merker provides a thorough historical review in his 2002 article 
in the International Journal of Dermatology.5 BPO seems to have 
first been used as a topical agent in the management of various 
skin lesions, especially burns, by Loevenhart in 1905.5 The first 
description  of  BPO  in  the  treatment  of  acneiform  eruptions 
dates back to 1934 and, in 1958, Fishman was credited as the 
first  to  suggest  BPO  as  a  viable  treatment  for  acne.6  In  the 
1960s, it was used as a treatment for leg ulcers and decubitus 
ulcers, and its regular use in acne therapy dates back to 1979.1 
But Pace is credited for publishing his results using BPO, identi-
fying it as the main active ingredient in a chlorhydroxyquinoline 
ointment,  for  acne  in  1965,  and  developing  a  commercially 
available product with Werner Stiefel.7,8 This began a flurry of 
patents to improve BPO for use in acne. Richard DeVillez found 
that  BPO  would  dissolve  in  dimethyl  isosorbide  and  remain 

TABLE 76-1
Pros and Cons of Benzoyl Peroxide

Pros
Strong antibacterial activity with no risk of 

Cons
Risk of irritation especially in dry skin types

Produces free radicals that may age skin

bacterial resistance

Works quicker than most acne ingredients
Comedolytic
Inexpensive
Many forms available
Safe
Covered by an FDA monograph

stable  with  increased  skin  penetration.9  Won  and  colleagues 
developed a porous styrene-divinylbenzene polymer structure, 
which is now known as microsponge technology.3,10 In 1980, 
Fulton patented the use of BPO and glycerin to treat acne.11 In 
1983,  Klein  and  Fox  (Dermik  Laboratories)  improved  the 
stability  of  BPO  by  adding  dioctyl  sodium  sulfosuccinate.12  
In 1985, Flynn and colleagues patented the use of the combination 
of BPO and silica to remove excess skin oils found around acne 
lesions,  which  was  launched  in  the  Oxy  acne  product  line.13  
In 1985, Klein filed the first patent for BPO in combination with 
erythromycin, an antibiotic (Benzamycin, Dermik Laboratories).3 
In the last few decades many advances have been achieved in 
the formulations of BPO and there are hundreds of variations 
on  the  market.  The  inclusion  of  BPO  in  an  OTC  product  for 
acne  is  covered  in  the  Food  and  Drug  Administration  (FDA) 
monograph 21 CFR 333, subpart D (Table 76-1).

 CHEMISTRY

The structural formula of BPO is [C6H5C(O)]2O2. It consists of 
two benzoyl groups bridged by a peroxide link (Figure 76-1).

 ORAL USES

BPO is used to whiten teeth but is not used orally for skin care 
reasons.

 TOPICAL USES

BPO is one of the most common ingredients used topically to 
treat  acne.  It  can  be  used  alone  or  combined  with  other 
ingredients,  including  antibiotics  and  retinoids.  When  using 

O

O

O

O

▶

FIGURE 76-1  Chemical structure of benzoyl peroxide.

 
oral  antibiotics,  the  concurrent  use  of  BPO  can  minimize  the 
emergence of bacterial resistance.14,15

BPO is known to penetrate into the skin and absorb unchanged 
into the stratum corneum (SC). In the epidermis or dermis it is 
metabolized  to  benzoic  acid.  It  is  absorbed  as  benzoate  and 
excreted in the urine.15 BPO is not degraded in the liver. Nacht  
et al. demonstrated that in an eight-hour time period, 4.5 percent 
of  BPO  is  absorbed  into  the  skin  when  applied  topically.16  
Yeung et al. showed that BPO had an in vitro flux of 0.6 µg/cm2 
through human skin independent of the drug concentration.17

BPO is safe and effective in the treatment of acne but is toler-
ated better by people with oily skin types as opposed to dry skin 
types.  This  is  due  to  the  fact  that  BPO  can  be  an  irritant  and 
individuals with an impaired skin barrier, such as S4 Baumann 
Skin Types and dry skin types, have impaired barrier function, 
which  allows  increased  BPO  penetration.  BPO  is  also  a  weak 
allergen  but  most  reactions  to  it  are  due  to  its  potential  as  an 
irritant, which more commonly occurs at higher concentrations. 
The  delivery  systems  and  the  vehicles  used  and  the  choice  of 
other ingredients and products in the skin care regimen play an 
important role in BPO sensitivity. Some studies have shown that 
if irritant-type sensitivity develops, BPO can be stopped for four 
days and restarted with less irritation.

Antibacterial Uses
BPO exerts its bactericidal activity by releasing highly reactive 
oxygen able to oxidize proteins in bacterial cell membranes. It 
has  been  shown  to  have  bactericidal  effects  against 
Propionibacterium  acnes  and  Corynebacterium  acnes,  the  bacteria 
known to cause acne.18 It has also been shown to kill Staphylococcus 
capitis,  S.  epidermis,  S.  hominis,  P.  avidum,  P.  granulosum,  and  the 
yeast  Pityrosporum  ovale.19  BPO  does  not  seem  to  leave  any 
residual  subpopulations  of  bacteria;  therefore,  overgrowth  of 
other organisms is not expected to occur with the use of BPO. 
Antibiotic resistance is of great interest in medicine right now, 
including  the  acne  realm  where  P.  acnes  resistance  rates  are 
estimated  to  be  as  high  as  60  percent  in  some  patient 
populations.20  Erythromycin,  methicillin,  and  clindamycin  are 
the most common antibiotics to which bacteria have reportedly 
developed  resistance.21  Combining  BPO  with  erythromycin  or 
clindamycin  has  been  proven  to  prevent  the  emergence  of 
resistant strains of P. acnes;21–23 therefore, the current clinical acne 
recommendation is to include BPO in topical antiacne regimens 
that  utilize  antibiotics.24  In  more  than  45  years  of  use  in  acne 
management, bacterial resistance to BPO has not been reported.25

Keratolytic Activity
BPO  tends  to  clear  acne  lesions  and  comedones  faster  than 
other  acne  therapies.  Its  keratotic  activity  (i.e.,  ability  to 
increase desquamation) may be one reason that the acne lesions 
clear  more  rapidly.  Waller  and  colleagues  performed  a  study 
quantifying  the  amount  of  SC  removed  after  tape  stripping. 
They compared BPO, salicylic acid (SA) 2 percent, and retinoic 
acid  (RA)  0.05  percent.26  After  three  hours,  BPO  was  signifi-
cantly  more  effective  in  disrupting  SC  cohesion  than  SA  and 
RA, but after six hours all three agents showed similar kerato- 
lytic  activity.  The  authors  noted  that  the  ability  of  BPO  to 
disrupt the SC barrier may increase penetration of drugs that 
are  coadministered;  however,  this  would  depend  on  the 
formulation of the BPO.3

Keratolytic  refers  to  the  separation  of  the  SC  keratinocytes 
increased  desquamation  of  the  skin  cells. 

allowing 

C H A P T E R  76  ■   B E N ZOY L   P E R OX I D E  

293

Desquamation is the process of skin cells separating from each 
other and flaking off of the surface of the skin. Exfoliation is the 
process  by  which  a  chemical  or  mechanical  force  is  used  to 
encourage desquamation. Therefore, BPO can be considered an 
exfoliant.

Acne
Many studies have shown that BPO is an effective agent for the 
topical  treatment  of  acne.27  It  seems  to  increase  efficacy  of 
other topically applied antimicrobials. There are several mech-
anisms  by  which  BPO  is  thought  to  improve  acne.  BPO  is  a 
highly lipophilic molecule able to penetrate through the sebum 
and  into  the  pilosebaceous  unit.  Its  bactericidal  activity  has 
been  well  demonstrated.  In  addition,  BP  exhibits  keratolytic 
and anti-inflammatory activity.26

BPO may help increase the efficacy of other antiacne antimi-
crobials  by  preventing  bacterial  resistance  and  by  facilitating 
penetration  into  the  sebum,  keratin,  and  polysaccharides  to 
reach the target bacteria. The predominant organism that causes 
acne,  P.  acnes,  is  capable  of  secreting  biofilm  polysaccharides, 
which hinder antimicrobials from reaching P. acnes.28,29 BPO, by 
virtue  of  its  oxidative  properties,  may  destroy  this  biofilm, 
thereby expediting the delivery of topical antibiotics and other 
agents to the targeted bacteria.

Several  studies  have  demonstrated  that  the  combination  of 
BPO with antimicrobials such as clindamycin is more effective 
than using either  topical BPO or clindamycin alone. One study 
showed that the combination of clindamycin and BPO resulted 
in  a  61  percent  reduction  of  inflammatory  lesions  after  three 
months  as  compared  with  39  percent  and  35  percent,  respec-
tively,  when  the  agents  were  used  alone.30  BPO  is  also  often 
combined with SA.31

BPO  tends  to  more  rapidly  yield  improvement  of  acne  as 
compared to retinoids and other acne therapies.3,32 One study 
showed that after two days of treatment with BPO 5 percent, 
an almost 2 log10 decrease in P. acnes counts was observed.33 In 
2011, a systematic review of the acne study literature revealed 
that that at 2 to 4 weeks, a 5 percent BPO + SA combination was 
most effective at reducing inflammatory and noninflammatory 
acne  lesions.  However,  at  later  time  points  (10–12  weeks), 
5  percent  BPO  +  SA  was  similar  to  BPO  +  clindamycin. 
Therefore,  it  appears  that  BPO  can  engender  a  more  rapid 
improvement of acne, which may contribute to greater compli-
ance.  However,  the  dryness  and  irritation  associated  with  its 
use  may  undermine  compliance.  For  these  reasons,  the 
formulation of BPO and the combinations of other ingredients in 
the  regimen  is  crucial.  Several  studies  have  demonstrated  that 
BPO is effective in cleanser form and may be less irritating.31

 SAFETY ISSUES

Photocarcinogenicity
In 1992, the FDA formed an advisory committee that reviewed 
the  safety  of  BPO  because  there  were  a  few  reports  that 
suggested  that  BPO  would  predispose  mice  to  skin  cancer, 
especially when combined with sun exposure.34–41
The following statement was issued by the FDA:

“During the 1992 Advisory Committee meeting, industry 
representatives  stated  that  published  studies  in  mice 
showed no evidence of benzoyl peroxide being photocar-
cinogenic.  However,  the  Committee  concluded  that  the 

 
294  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

studies  were  insufficient  to  determine  whether  benzoyl 
peroxide  is  carcinogenic.  The  Committee  indicated  that 
the studies were inconclusive because none of the studies 
used  sufficient  numbers  of  mice  and  the  mice  should 
have been observed over their entire lifespan. Therefore, 
the  Committee  unanimously  agreed  that  a  new 
photocarcinogenicity study should be conducted.”34,42

Safety in Pregnancy
Many patients develop acne in pregnancy. Although no specific 
safety  studies  using  BPO  in  pregnant  patients  have  been 
performed, several publications contend that only about 5 percent 
of  topically  applied  BPO  is  absorbed  systemically,  suggesting 
that BPO is a safe option during pregnancy.15,43–45

The FDA advisory committee recommended that:

•	 New  photocarcinogenicity  studies  on  BPO  should  be 

conducted.

•	 Current animal safety data regarding BPO should be conveyed 

in labeling.

•	 Acne  drug  products  containing  BPO  should  stay  on  the 

market while new studies are being performed.

During the period of 1992 to 2011 new safety studies were 
conducted. In 2011 the FDA published a new ruling that changed 
the classification of BPO to Category I and stated:

“We now conclude that benzoyl peroxide, in concentrations 
of  2.5  to  10  percent,  is  GRASE  (GRASE  =  Generally 
Recognized  As  Safe  and  Effective)  for  the  OTC  topical 
treatment of acne. This conclusion is based on safety data 
that  we  received  and  evaluated  since  publication  of  the 
1995  proposed  rule  that  proposed  classifying  benzoyl 
peroxide  as  Category  III.  As  recommended  by  the 
Committee, these new data include studies examining the 
carcinogenic  and  photocarcinogenic  potential  of  benzoyl 
peroxide.  In  addition  to  discussing  these  new  studies  in 
this  section  of  the  document,  we  provide  a  summary  of 
earlier  studies  discussed  in  previous  OTC  acne  drug 
product rulemakings. We believe the combined results of 
the earlier and new studies support the GRASE finding for 
benzoyl  peroxide.”42  (See  Table  76-2  for  additional 
warnings and directions issued by the FDA in 2011 for the 
use of OTC benzoyl peroxide.)

TABLE 76-2
Additional Required Warnings and Directions for OTC Topical Acne 
Products Containing Benzoyl Peroxide or a Combination of Active 
Ingredients (the FDA recommended labeling language for benzoyl 
peroxide in addition to the labeling requirements presented in 
Chapter 80, Overview of Acne, Table 76-2)62

AdditionAl RequiRed diRections
•	 If going outside, apply sunscreen after 
using this product. If irritation or 
sensitivity develops, stop use of both 
products and ask a doctor.

AdditionAl RequiRed WARnings
Do not use if you
•	 have very sensitive skin 
•	 are sensitive to benzoyl peroxide

When using this product
•	 avoid unnecessary sun exposure and use 

a sunscreen

•	 avoid contact with the eyes, lips, and mouth
•	 avoid contact with hair and dyed fabrics, 
which may be bleached by this product
•	 skin irritation may occur, characterized 
by redness, burning, itching, peeling, or 
possibly swelling. Irritation may be 
reduced by using the product less 
frequently or in a lower concentration.

Stop use and ask a doctor if
•	 irritation becomes severe

Irritation
BPO  causes  skin  irritation,  either  as  contact  dermatitis  or 
irritant dermatitis, in approximately 1 percent of patients.46,47 
Agents that increase penetration would increase the suscepti-
bility to irritation while lower strengths of BPO would be less 
likely to cause irritation. Using barrier repair moisturizers may 
decrease incidence of irritation but this has not been studied or 
proven.

Skin Aging
When BPO breaks down into benzoic acid in the skin, benzoy-
loxy, a free radical, forms as an intermediate.48 Benzoyloxy can 
decarboxylate into a phenyl radical.49 It has been shown that 
BPO  depletes  membrane  and  cytosolic  antioxidants.50  These 
free radicals produce oxidative stress, which may cause DNA 
strand  breaks  in  keratinocytes  or  harm  proteins  or  lipids.50–52  
A  study  by  Ibbotson  et  al.  showed  that  topically  applied  BPO 
induced photodamage in mouse skin that resembled that of UVB.48

 ENVIRONMENTAL IMPACT

BPO is used for many different indications including bleaching flour 
used in food and is rated as GRASE by the FDA. It is synthesized in 
laboratories  for  widespread  use  in  the  cosmeceutical  world  and 
should not exert an appreciable impact on the environment.

 FORMULATION CONSIDERATIONS

BPO consists of white crystal agglomerates that are insoluble in 
water but soluble in organic solvents.3,53 BPO is stable at room 
temperature but flammable and explosive when heated greater 
than 100°C. In 1974, Fulton et al. showed that the vehicle for 
BPO delivery is critical. Alcohol gels increase efficacy because 
once the alcohol evaporates, residual BPO is left on the skin.54 
Water-based preparations are less irritating than alcohol-based 
preparations,55 likely because less BPO is deposited on the skin. 
Irritation  potential  may  be  reduced  through  micronizing  the 
BPO particle or making it softer and less abrasive. Urea, glycerin, 
and  the  emollient  dimethicone  also  improve  tolerability. 
Encapsulating the BPO or placing it in a microsponge may slow 
delivery of BPO, reducing the risk of irritation.3

 USAGE CONSIDERATIONS

The use of BPO in acne therapies is associated with a decrease 
in antibiotic resistance.21 Therefore, it is often combined with 
other acne therapies. Because BPO kills bacteria by generating 
reactive  oxygen  species  (ROS)  in  the  sebaceous  follicle,  the 
chemical  compatibility  of  BPO  with  other  agents  should  be 
considered.16  BPO,  as  a  strong  oxidizer,  could  oxidize  other 
agents such as tretinoin and hydroquinone, thus reducing the 
efficacy  of  these  agents.56  One  study  demonstrated  that  BPO 
tends to degrade tretinoin to about 80 percent of initial content 

 
and  this  effect  is  dramatically  increased  in  the  presence  of 
indoor  light.  Adapalene  is  not  degraded  by  BPO  even  in  the 
presence of light.56

When BPO is used in body washes, studies have shown that 
greater efficacy is realized when the product is left on for five 
minutes before rinsing.57,58 The efficacy associated with BPO in 
cleansing  products  equals  that  seen  in  leave-on  products  but 
with less irritation provoked by the cleansers.55, 59

The order of products used is important when BPO is incorpo-
rated in the regimen because it can inactivate other ingredients. 
For example, when applied simultaneously with topical tretinoin, 
BPO can denature the tretinoin and reduce its effectiveness.56

 SIGNIFICANT BACKGROUND

BPO has been used for over 45 years for acne treatment. It is 
available as a prescription medication alone or combined with 
tretinoin, adapalene, or clindamycin. The FDA monograph also 
allows it to be sold without a prescription as long as the label 
includes  the  information  covered  in  the  FDA  monograph.  
BPO is being studied for use in rosacea, seborrheic dermatitis, 
and in other skin diseases, but is currently only approved for 
use in acne. Its use is limited by the fact that it causes irritation 
in  some  skin  types  and  generates  ROS.  Carefully  selecting  a 
treatment  regimen  that  uses  the  proper  ingredients  in  the 
proper sequence can help mitigate these pitfalls of BPO.

 CONCLUSION

BPO has a colorful history in dermatology. It is very effective as 
an acne medication and is one of the few acne medications that 
is  available  both  over  the  counter  and  by  prescription  in  the 
United States. In some other countries, BPO is available only 
by prescription. It is an important medication because it helps 
prevent antibiotic resistance to erythromycin and clindamycin. 
Bacterial  resistance  is  a  serious  problem  in  the  United  States 
and the treatment of acne with erythromycin and clindamycin 
is thought to contribute to this problem. However, the use of 
BPO is limited in dry skin with an impaired barrier because of 
the  risk  of  irritation.  It  reacts  with  other  ingredients  such  as 
tretinoin,  thereby  reducing  tretinoin’s  efficacy.  Most  impor-
tantly, BPO is a source of free radicals to the skin, which may 
contribute  to  glycation,  mitochondrial  damage,  and  skin 
aging.60,61  Combined  use  with  antioxidants  is  suggested  to 
minimize skin damage.

REFERENCES

1.  Bowe WP, Shalita AR. Effective over-the-counter acne treatments. 

Semin Cutan Med Surg. 2008;27:170.

2.  Green  L,  Kircik  LH,  Gwazdauskas  J.  Randomized,  controlled, 
evaluator-blinded studies conducted to compare the efficacy and 
tolerability of 3 over-the-counter acne regimens in subjects with 
mild or moderate acne. J Drugs Dermatol. 2013;12:180.

3.  Tanghetti  EA,  Popp  KF.  A  current  review  of  topical  benzoyl 
peroxide:  New  perspectives  on  formulation  and  utilization. 
Dermatol Clin. 2009;27:17.

4.  Kraus  AL,  Munro  IC,  Orr  JC,  et  al.  Benzoyl  peroxide:  An  inte-
grated human safety assessment for carcinogenicity. Regul Toxicol 
Pharmacol. 1995;21:87.

5.  Merker  PC.  Benzoyl  peroxide:  A  history  of  early  research  and 

researchers. Int J Dermatol. 2002;41:185.

6.  Fishman IM. Benzoyl peroxide in acne: Reply. J Am Acad Dermatol. 

1989;20:518.

7.  Pace WE. A benzoyl peroxide-sulfur cream for acne vulgaris. Can 

Med Assoc J. 1965;93:252.

C H A P T E R  76  ■   B E N ZOY L   P E R OX I D E  

295

8.  Cox RM, Ciufo LR, inventors; Stiefel Laboratories, Inc, assignee. 
Stable  benzoyl  peroxide  composition.  US  patent  3  535  422. 
October 20, 1970.

9.  DeVillez RL, inventor; Board of Regents, The Universityof Texas 
System, assignee. Therapeutic compositions containing benzoyl 
peroxide. US patent 4 923 900. May 8, 1990.

10.  Won  R,  inventor;  Advanced  Polymer  Systems,  Inc,  assignee. 
Method  for  delivery  an  active  ingredient  by  controlled  release 
utilizing  a  novel  delivery  vehicle  which  can  be  prepared  by  a 
process utilizing the active ingredient as a porogen. US patent 4 
690 825. September 1, 1985.

11.  Fulton JE Jr, inventor; AHC Pharmacal, Inc, assignee. Composition 
and  method  for  the  treatment  of  acne.  US  patent  4  189  501. 
February 19, 1980.

12.  Klein RW, Foxx ME, inventors; Dermik Laboratories, Inc, assignee. 
Stable  benzoyl  peroxide  composition.  US  patent  4  387  107.  
June 7, 1983.

13.  Flynn  RG,  Pitkin  CG,  Hileman  GA,  inventors;  Norcliff  Thayer, 
Inc, assignee. Use of fumed silica for treating oily skin and acne. 
US patent 4 536 399. August 20, 1985.

14.  Mays RM, Gordon RA, Wilson JM, et al. New antibiotic therapies 

for acne and rosacea. Dermatol Ther. 2012;25:23.

15.  Pugashetti R, Shinkai K. Treatment of acne vulgaris in pregnant 

patients. Dermatol Ther. 2013;26:302.

16.  Nacht  S,  Yeung  D,  Beasley  JN  Jr,  et  al.  Benzoyl  peroxide: 
Percutaneous  penetration  and  metabolic  disposition.  J  Am  Acad 
Dermatol. 1981;4:31.

17.  Yeung D, Nacht S, Bucks D, et al. Benzoyl peroxide: Percutaneous 
penetration and metabolic disposition. II. Effect of concentration. 
J Am Acad Dermatol. 1983;9:920.

18.  Drucker  CR.  Update  on  topical  antibiotics  in  dermatology. 

Dermatol Ther. 2012;25:6.

19.  Cove JH, Holland KT. The effect of benzoyl peroxide on cutaneous 

micro-organisms in vitro. J Appl Bacteriol. 1983;54:379.

20.  Nishijima  S,  Akamatsu  H,  Akamatsu  M,  et  al.  The  antibiotic 
susceptibility  of  Propionibacterium  acnes  and  Staphylococcus 
epidermidis isolated from acne. J Dermatol. 1994;21:166.

21.  Kircik  LH.  The  role  of  benzoyl  peroxide  in  the  new  treatment 

paradigm for acne. J Drugs Dermatol. 2013;12:s73.

22.  Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide 
and  erythromycin  alone  and  in  combination  against  antibiotic-
sensitive  and  -resistant  skin  bacteria  from  acne  patients.  Br  J 
Dermatol. 1994;131:331.

23.  Leyden  J,  Levy  S.  The  development  of  antibiotic  resistance  in 

Propionibacterium acnes. Cutis. 2001;67:21.

24.  Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the 
management  of  acne:  An  update  from  the  Global  Alliance  to 
Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60:S1.
25.  Gollnick H, Cunliffe W, Berson D, et al. Management of acne: A 
report from a Global Alliance to Improve Outcomes in Acne. J Am 
Acad Dermatol. 2003;49:S1.

26.  Waller JM, Dreher F, Behnam S, et al. ‘Keratolytic’ properties of 
benzoyl peroxide and retinoic acid resemble salicylic acid in man. 
Skin Pharmacol Physiol. 2006;19:283.

27.  Sagransky  M,  Yentzer  BA,  Feldman  SR.  Benzoyl  peroxide:  A 
review of its current use in the treatment of acne vulgaris. Expert 
Opin Pharmacother. 2009;10:2555.

28.  Burkhart CN, Burkhart CG. Genome sequence of Propionibacterium 
acnes  reveals  immunogenic  and  surface-associated  genes  con-
firming existence of the acne biofilm. Int J Dermatol. 2006;45:872.
29.  Burkhart CN, Burkhart CG. Microbiology’s principle of biofilms 
as  a  major  factor  in  the  pathogenesis  of  acne  vulgaris.  Int  J 
Dermatol. 2003;42:925.

30.  Lookingbill DP, Chalker DK, Lindholm JS, et al. Treatment of acne 
with a combination clindamycin/benzoyl peroxide gel compared 
with  clindamycin  gel,  benzoyl  peroxide  gel  and  vehicle  gel: 
Combined results of two double-blind investigations. J Am Acad 
Dermatol. 1997;37:590.

31.  Simpson RC, Grindlay DJ, Williams HC. What’s new in acne? An 
analysis  of  systematic  reviews  and  clinically  significant  trials 
published in 2010–11. Clin Exp Dermatol. 2011;36:840.

32.  do Nascimento LV, Guedes AC, Magalhães GM, et al. Single-blind 
and  comparative  clinical  study  of  the  efficacy  and  safety  of 
benzoyl peroxide 4% gel (BID) and adapalene 0.1% gel (QD) in 
the treatment of acne vulgaris. J Dermatolog Treat. 2003;14:166.
33.  Bojar RA, Cunliffe WJ, Holland KT. The short-term treatment of 
acne vulgaris with benzoyl peroxide: Effects on the surface and 
follicular cutaneous microflora. Br J Dermatol. 1995;132:204.

 
296  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

34.  Food and Drug Administration. Classification of Benzoyl Peroxide 
as  Safe  and  Effective  and  Revision  of  Labeling  to  Drug  Facts 
Format;  Topical  Acne  Drug  Products  for  Over-the-Counter 
Human  Use;  Final  Rule.  Posted  March  4,  2010.  http://www.
regulations.gov/#!documentDetail;D=FDA-1981-N-0114-0001. 
Accessed August 24, 2013.

35.  Hazlewood C, Davies MJ. Benzoyl peroxide-induced damage to 
DNA and its components: Direct evidence for the generation of 
base  adducts,  sugar  radicals,  and  strand  breaks.  Arch  Biochem 
Biophys. 1996;332:79.

36.  Slaga TJ, Klein-Szanto AJ, Triplett LL, et al. Skin tumor-promoting 
activity of benzoyl-peroxide, a widely used free radical-generating 
compound. Science. 1981;213:1023.

37.  Reiners  JJ  Jr,  Nesnow  S,  Slaga  TJ.  Murine  susceptibility  to  two-
stage skin carcinogenesis is influenced by the agent used for pro-
motion. Carcinogenesis. 1984;5:301.

38.  O’Connell JF, Klein-Szanto AJ, DiGiovanni DM, et al. Enhanced 
malignant progression of mouse skin tumors by the free-radical 
generator benzoyl peroxide. Cancer Res. 1986;46:2863.

39.  Iversen  OH.  Carcinogenesis  studies  with  benzoyl  peroxide 

(Panoxyl gel 5%). J Invest Dermatol. 1986;86:442.

40.  Iversen OH. Skin tumorigenesis and carcinogenesis studies with 
7,12-dimethylbenz[a]anthracene,  ultraviolet  light,  benzoyl 
peroxide  (Panoxyl  gel  5%)  and  ointment  gel.  Carcinogenesis. 
1988;9:803.

41.  Athar  M,  Raza  H,  Bickers  DR,  et  al.  Inhibition  of  benzoyl 
peroxide-mediated  tumor  promotion  in  7,12-dimethylbenz[a]
anthracene-initiated skin of Sencar mice by antioxidants nordi-
hydroguaiaretic  acid  and  diallyl  sulfide.  J  Invest  Dermatol. 
1990;94:162.

42.  Food  and  Drug  Administration,  HHS.  Classification  of  benzoyl 
peroxide  as  safe  and  effective  and  revision  of  labeling  to  drug 
facts  format;  topical  acne  drug  products  for  over-the-counter 
human use, final rule. Fed Regist. 2010;75:9767.

43.  Hale EK, Pomeranz MK. Dermatologic agents during pregnancy 
and  lactation:  An  update  and  clinical  review.  Int  J  Dermatol. 
2002;41:197.

44.  Bozzo  P,  Chua-Gocheco  A,  Einarson  A.  Safety  of  skin  care 
products during pregnancy. Can Fam Physician. 2011;57:665.
45.  Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy 

and lactation. Drugs. 2013;73:779.

46.  Greiner  D,  Weber  J,  Kaufmann  R,  et  al.  Benzoyl  peroxide  as  a 
contact allergen in adhesive tape. Contact Dermatitis. 1999;41:233.
47.  Balato N, Lembo G, Cuccurullo FM, et al. Acne and allergic con-

tact dermatitis. Contact Dermatitis. 1996;34:68.

48.  Ibbotson  SH,  Moran  MN,  Nash  JF,  et  al.  The  effects  of  radicals 
compared  with  UVB  as  initiating  species  for  the  induction  of 
chronic cutaneous photodamage. J Invest Dermatol. 1999;112:933.

49.  Binder  RL,  Aardema  MJ,  Thompson  ED.  Benzoyl  peroxide: 
Review  of  experimental  carcinogenesis  and  human  safety  data. 
Prog Clin Biol Res. 1995;391:245.

50.  Valacchi G, Rimbach G, Saliou C, et al. Effect of benzoyl peroxide 
on antioxidant status, NF-kappaB activity and interleukin-1alpha 
gene expression in human keratinocytes. Toxicology. 2001;165:225.
51.  Akman SA, Doroshow JH, Kensler TW. Copper-dependent site-
specific mutagenesis by benzoyl peroxide in the supF gene of the 
mutation reporter plasmid pS189. Carcinogenesis. 1992;13:1783.
52.  Saladino  AJ,  Willey  JC,  Lechner  JF,  et  al.  Effects  of  formaldehyde, 
acetaldehyde, benzoyl peroxide, and hydrogen peroxide on cultured 
normal human bronchial epithelial cells. Cancer Res. 1985;45:2522.
53.  Cotterill JA. Benzoyl peroxide. Acta Derm Venereol Suppl (Stockh). 

1980;Suppl 89:57.

54.  Fulton  JE  Jr,  Farzad-Bakshandeh  A,  Bradley  S.  Studies  on  the 
mechanism of action to topical benzoyl peroxide and vitamin A 
acid in acne vulgaris. J Cutan Pathol. 1974;1:191.

55.  Fakhouri  T,  Yentzer  BA,  Feldman  SR.  Advancement  in  benzoyl 
peroxide-based acne treatment: Methods to increase both efficacy 
and tolerability. J Drugs Dermatol. 2009;8:657.

56.  Martin  B,  Meunier  C,  Montels  D,  et  al.  Chemical  stability  of 
adapalene and tretinoin when combined with benzoyl peroxide 
in presence and in absence of visible light and ultraviolet radiation. 
Br J Dermatol. 1998;139(Suppl 52):8.

57.  Leyden  JJ.  Efficacy  of  benzoyl  peroxide  (5.3%)  emollient  foam 
and benzoyl peroxide (8%) wash in reducing Propionibacterium 
acnes on the back. J Drugs Dermatol. 2010;9:622.

58.  Bikowski  J.  A  review  of  the  safety  and  efficacy  of  benzoyl 
peroxide  (5.3%)  emollient  foam  in  the  management  of  truncal 
acne vulgaris. J Clin Aesthet Dermatol. 2010;3:26.

59.  Burkhart  CG,  Scheinfeld  NS.  Benzoyl  peroxide  skin  washes: 
Basis, logic, effectiveness and tolerance. Skinmed. 2005;4:370.
60.  Babizhayev MA, Deyev AI, Savel’yeva EL, et al. Skin beautifica-
tion with oral non-hydrolized versions of carnosine and carcinine: 
Effective  therapeutic  management  and  cosmetic  skincare 
solutions against oxidative glycation and free-radical production 
as a causal mechanism of diabetic complications and skin aging.  
J Dermatolog Treat. 2012;23:345.

61.  Cadenas  E,  Davies  KJ.  Mitochondrial  free  radical  generation, 
oxidative stress, and aging. Free Radic Biol Med. 2000;29:222.
62.  U.S. Department of Health and Human Services, Food and Drug 
Administration, Center for Drug Evaluation and Research (CDER). 
Guidance for Industry Topical Acne Drug Products for Over-the-
Counter Human Use – Revision of Labeling and Classification of 
Benzoyl  Peroxide  as  Safe  and  Effective  Small  Entity  Compliance 
Guide.  Posted  June  2011.  http://www.fda.gov/downloads/Drugs 
/GuidanceComplianceRegulatoryInformation/Guidances 
/UCM259744.pdf. Accessed August 24, 2013.

 
C H A P T E R   7 7

Tea Tree Oil

C H A P T E R  77  ■   T E A  T R E E   O I L  

297

Activities:

Analgesic,  anti-inflammatory,  antibacterial,  antifungal, 
antimicrobial,  antipruritic,  antiseptic,  insecticidal,  anti-
skin cancer1–4

Important Chemical Components:
Terpinen-4-ol,  γ-terpinene,  α-terpinene,  α-terpineol, 
terpinolene, α-pinene, and cineole are primary constituents. 
Tea tree oil contains more than 100 chemical compounds, 
mainly terpenes and alcohols, including d-limonene.5,6

Origin Classification:

This  ingredient  is  considered  natural.  As  an  ingredient 
used for dermatologic purposes, it is laboratory made.

century, at least, by the Bundjalung indigenous tribe in Australia 
as  an  herbal  medicine  to  treat  upper  respiratory  tract 
infections.1,6 Australian aborigines also use TTO to treat bruises 
and skin infections, and the essential oil is now thought to be a 
suitable alternative option in the acne armamentarium.11 The 
antiseptic and disinfectant properties of TTO were reported by 
Penfold  and  Grant  in  the  1920s,  with  the  finding  that  it 
exhibited 13 times more antiseptic activity than carbolic acid, 
leading to the investigation and usage of the essential oil.12,13 
Further studies in the 1930s established TTO in Australia as an 
effective  topical  antiseptic  and  broad-spectrum  antimicrobial 
agent,  particularly  against  Candida  albicans,  Escherichia  coli, 
Staphylococcus aureus, S. epidermidis, and Propionibacterium acnes.3,12,14 
In fact, the broad-spectrum antibacterial activity of TTO forms the 
basis for its use in acne therapy.4,15

Personal Care Category:

Antiacne, analgesic, antifungal

 CHEMISTRY

Recommended  for  the  following  Baumann  Skin 
Types:

DSNT, DSPT, DSNW, DSPW, OSNT, OSPT, OSNW, and 
OSPW

TTO  is  obtained  through  the  steam  distillation  of  the  leaves 
and terminal branchlets of the M. alternifolia tree.16 Terpinene-
4-ol constitutes up to 60 percent of the oil. Australian standards 
set a minimum content of 30 percent terpinene-4-ol.14

 SOURCE

Melaleuca  alternifolia,  a  member  of  the  Myrtaceae  family  and 
the  source  of  tea  tree  oil  (TTO),  is  a  small  tree  native  to 
Australia.  Although  there  are  three  different  species  of 
coniferous Myrtaceae growing in Australia, New Zealand, and 
Southeast Asia known as tea trees, only the essential oil derived 
from  the  needles  or  leaves  of  the  Australian  M.  alternifolia  is 
used  in  medical  and  cosmetic  products.  Aromatherapists  do 
use the essential oils of all three species, but only M. alternifolia 
has  been  extensively  tested  for  toxicity,  and  its  antimicrobial 
activity evaluated.7 A clear liquid that ranges from colorless to 
faint  yellow  but  with  a  sharp,  camphoraceous  aroma,  TTO 
contains over 100 natural compounds.

Steam distillation is used to extract the oil from the leaves. A 
menthol-like  cooling  sensation  is  yielded  by  the  essential  oil.6  
Its common name is based on the brewing of the leaves for tea 
by early settlers in Australia.8 It is also known by the Maori and 
Samoan expression “ti tree oil.”1,9

Recent data support its use to treat acne vulgaris, seborrheic 
dermatitis, and chronic gingivitis as well as to promote wound 
healing.4 In addition, TTO has been shown to display anti-skin 
cancer activity.4

 HISTORY

An  essential  oil  of  the  M.  alternifolia  tree  or  shrub,  TTO  is 
thought to have been used for thousands of years by Australian 
natives for healing purposes,10 and has been used for nearly a 

 ORAL USES

TTO  is  considered  toxic  when  consumed  orally.  Reported 
adverse effects from consuming TTO include nausea, diarrhea, 
vomiting,  drowsiness,  confusion,  hallucinations,  weakness, 
and coma.6,10,17

 TOPICAL USES

Acne, psoriasis, fungal infections, vaginal infections, tinea, lice, 
rashes, cold sores, cuts, scratches, and various burns are among 
the  indications  for  topical  TTO.  Accordingly,  the  botanical  is 
found in a wide range of over-the-counter (OTC) personal care, 
hair, skin cream, and cosmetic formulations.8,18

Antiacne Activity
In a seminal study of topically applied TTO in 1990, Bassett et al. 
conducted a single-blind, randomized clinical trial in 124 patients 
with  mild-to-moderate  acne  to  assess  efficacy  and  skin 
tolerance. Subjects were treated with either 5 percent TTO gel 
or 5 percent benzoyl peroxide. Both treatments demonstrated 
significant effects in improving acne by lowering the number of 
inflamed lesions, both open and closed comedones. Although 
TTO  oil  took  longer  to  exert  its  effects,  patients  using  TTO 
exhibited fewer side effects. Investigators concluded that using 
a  higher  concentration  of  TTO  might have yielded faster yet 
still effective action.3

In a literature review conducted in 2000, Ernst and Huntley 
analyzed  data  from  six  electronic  databases  to  identify 
randomized  clinical  trials  using  TTO.  They  were  able  to  find 

 
298  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

only four trials. Evidence indicated that the botanical appeared 
to be an effective treatment for acne and fungal infections, with 
any side effects, typically allergic reactions, found to be mild and 
short-lived.19

A 2007 randomized, double-blind clinical trial in 60 patients 
with mild-to-moderate acne revealed the efficacy of 5 percent 
TTO  gel.  Patients,  randomly  assigned  to  one  of  two  groups  
(30 each), were treated with TTO or placebo and followed every 
15 days over a 45-day period. Investigators found that the TTO 
gel was 3.55 times more effective than placebo in reducing total 
acne lesion counts and 5.75 times more effective than placebo in 
lowering the acne severity index. Side effects were similarly mild 
and  tolerable  in  both  groups.15  Topical  application  of  TTO  
three or four times daily is a recommended regimen to treat acne.14

Anticancer Activity
In 2012, Ireland et al. reported that topically applied TTO in 
a  dilute  (10  percent)  dimethyl  sulfoxide  formulation 
quickly  leads  to  a  direct  anticancer  effect  in  subcutaneous 
tumor-bearing  mice.  The  in  vivo  cytotoxicity  of  TTO  was 
linked  to  its  penetration,  according  to  the  researchers.  They 
suggested that future investigations should focus on enhanc-
ing skin penetration to increase in situ terpene concentration.20 
Previously, Greay et al. reported that topically applied TTO 
had  shown  in  vivo  antitumor  activity  in  fully  immune-
competent  subcutaneous  tumor-bearing  mice.21  Also  that 
year,  the  same  team  of  investigators  found  that  TTO  and 
terpinen-4-ol  exhibited  significant  antiproliferative  activity– 
inducing  necrosis  and  cell  cycle  arrest–against  two  murine 
tumor cell lines.22

Antibacterial, Antifungal, and Antiviral Activity
TTO  is  well  known  to  have  displayed  antibacterial  and 
antifungal  activity.2,5  A  2001  in  vitro  study  by  D’Auria  et  al. 
revealed  the  effectiveness  of  lipophilic  TTO  in  blocking  the 
conversion  of  C.  albicans  (and  other  yeasts,  including 
Schizosaccharomyces pombe and Debaryomyces hansenii) from the 
yeast  to  the  pathogenic  mycelial  form.  The  investigators 
concluded  that  such  inhibitory  activity  positions  TTO  as  a 
potentially  suitable  agent  for  treating  fungal  mucosal  and 
cutaneous infections.2 According to a 2000 study by Zhang et al., 
TTO also may have the capacity to attack many of the microbes 
typically associated with otitis externa and otitis media, though 
some ototoxicity is feared.23 Since then, though, the risks have 
been shown to be minimal, with broad-spectrum activity being 
increasingly attributed to the herbal agent.

In  a  2008  case  report,  Millar  and  Moore  documented  their 
successful  treatment  of  a  pediatric  patient  with  warts  on  her 
right middle finger through the once-daily topical application of 
TTO for 12 days. They concluded that this shows the potential 
of TTO to treat warts caused by the human papilloma virus.24

Based on a recent uncontrolled, open-label case series that began 
with 19 patients and ended with 11, Edmondson et al. reported 
that  TTO,  while  it  failed  to  decolonize  methicillin-resistant 
S. aureus (MRSA) (the primary aim of the study), did not inhibit 
wound healing and was associated with a reduction in wound 
size.25  More  recently,  in  a  2013  study  by  Thomsen  et  al.  to 
ascertain  the  antimicrobial  susceptibility  of  Staphylococcus  spp. 
after acclimation to low levels of topical TTO, the investigators 
habituated methicillin-susceptible S. aureus (MSSA), MRSA, and 
coagulase-negative staphylococci (CoNS) to 0.075 percent TTO 
for  three  days.  They  uncovered  no  evidence  that  TTO  

contributes  to  resistance  to  antimicrobial  agents  (i.e.,  fusidic 
acid, mupirocin, chloramphenicol, linezolid, and vancomycin).18

Seborrheic Dermatitis and Other Indications
Seborrheic dermatitis may also be alleviated by TTO.26 In a 2002 
randomized  trial  of  126  patients  with  dandruff  conducted  by 
Satchell  et  al.,  subjects  using  5  percent  TTO  shampoo  experi-
enced  a  41  percent  improvement  whereas  patients  using  a 
placebo showed only an 11 percent improvement in the quadrant 
area  severity  score.27  That  same  year,  Satchell  et  al.  also 
conducted  a  randomized,  controlled,  double-blind,  four-week 
study of 158 patients with interdigital tinea pedis that demon-
strated the efficacy and safety of 25 and 50 percent TTO for the 
treatment of the dermatophyte. An appreciable clinical response 
was noted by the investigators, with 68 percent of the 50 percent 
TTO  group  and  72  percent  of  the  25  percent  TTO  group 
improving, compared to 39 percent in the placebo group.28

In 2010, Barker and Altman conducted a randomized, assessor- 
blind, parallel-group, comparative efficacy trial in 123 subjects to 
evaluate three treatments for head lice in children. A pediculicide 
containing TTO and lavender oil was found to be equally effec-
tive as a head lice “suffocation” product and significantly more 
effective than the product containing pyrethrins and piperonyl 
butoxide (41 of 42 patients were louse-free one day after the last 
treatment  with  tea  tree  and  lavender  oils  compared  to  10  of  
40  patients  using  the  pyrethrins  and  piperonyl  butoxide).29  
In addition, TTO has been used successfully to treat blepharitis 
secondary to ocular demodicosis.30

In 2013, Sakr et al. formulated a multimodal microemulsion 
composed of minoxidil, diclofenac, and TTO and conducted a 
pilot study in 32 women (from 18 to 30 years old) with androge-
netic  alopecia  who  were  randomized  to  apply  1  mL  of  the 
microemulsion,  minoxidil  alone,  or  placebo  twice  daily  for  
32  weeks.  The  combination  treatment  was  associated  with 
significantly  better  mean  hair  counts,  mean  hair  weight,  and 
mean hair thickness. In fact, the stability, safety, and efficacy of 
the  microemulsion  containing  TTO  were  far  superior  to 
minoxidil alone or placebo.31

The combination of TTO and lavender oil was also evaluated 
more  recently  by  Tirabassi  et  al.  in  a  prospective,  open-label, 
placebo-controlled, randomized study in 24 women with mild 
idiopathic hirsutism. Twelve women were randomized to use an 
oil spray containing the botanicals twice daily for three months 
in the affected areas and the remaining 12 women used a placebo 
spray. Statistically significant reductions were noted in hirsutism 
total  score  and  hair  diameter  in  the  group  using  TTO  and 
lavender,  unlike  the  placebo  group.  The  researchers  concluded 
that the topical application of TTO and lavender is a safe and 
practical approach to treating mild idiopathic hirsutism.32

In addition, TTO, through its main active constituent terpinen-

4-ol, may also deliver an antipsoriatic effect.16

 SAFETY ISSUES

In  a  recent  multicenter  Italian  study  on  the  use  of  topical  
botanically-derived  products,  Corazza  et  al.  reported  that  of 
2,661  patients  surveyed,  1,274  (48  percent)  claimed  to  have 
used  such  products  of  whom  139  (11  percent)  experienced 
adverse  cutaneous  reactions.  Propolis,  Compositae  extracts, 
and TTO were the three most frequently cited allergens.33

Terpinen-4-ol,  the  primary  constituent  of  TTO,  has  been 
implicated  in  mild  allergic  contact  reactions,  such  as  allergic 
contact  dermatitis  (ACD)  (see  Table  77-1).  Photooxidation 

 
TABLE 77-1
Pros and Cons of Tea Tree Oil

Pros
Appears to have potential as a versatile agent 

Cons
Implicated in causing mild allergic reactions

in the dermatologic armamentarium
Evidence suggests suitability for the treat-

ment of mild-to-moderate acne

Dearth of randomized, controlled, double-
blind, placebo-controlled clinical trials 
for acne treatment

within a few days to several months of exposure leads to the 
synthesis of peroxides, epoxides, and endoperoxides, such as 
ascaridol  and  1,2,4-trihydroxymethane,  which  are  likely 
responsible  in  cases  of  ACD.34  The  increase  in  use  of  TTO 
over  the  last  15  years  is  expected  to  contribute  to  a  higher 
incidence  of  reports  of  contact  dermatitis  and  eczema, 
according to some authors.35,36

Contact  sensitization  and  ACD  have  been  associated 
with the use of topical TTO, but in low numbers. The most 
recent prevalence rates indicate that 1.4 percent of patients 
referred for patch testing experienced a positive reaction to 
TTO,  which  was  added  to  the  North  American  Contact 
Dermatitis Group screening panel in 1999.6 However, some 
components of TTO may actually alleviate hypersensitivity 
reactions and TTO is considered safe and effective for use 
by most patients.

Studies on mice conducted by Brand et al. in 2002 suggest 
that  some  constituents  of  TTO  may  actually  diminish 
hypersensitivity reactions. In one study, two components of 
topical  TTO,  terpinen-4-ol  and  α-terpineol,  were  found  to 
regulate  the  edema  associated  with  the  efferent  phase  of  a 
contact  hypersensitivity  reaction.37  In  a  separate  study, 
terpninen-4-ol was also found to be effective in controlling 
the  histamine-induced  edema  often  correlated  with  type  I 
allergic reactions.38

Adverse reactions in humans can be mitigated through cor-
rect storage; not using the neat oil; limiting exposure to aged, 
oxidized oil; and using more dilute preparations.1,9,20,39–41 The 
track record for safe usage is approximately 90 years.1 There is 
a report of gynecomastia occurring in three prepubertal boys in 
association with the topical application of lavender and tea tree 
oils. The condition subsided in each patient soon after cessation 
of  product  usage  and  each  patient  had  been  found  to  be 
otherwise  healthy  with  normal  serum  concentrations  of 
endogenous steroids.42

 ENVIRONMENTAL IMPACT

C H A P T E R  77  ■   T E A  T R E E   O I L  

299

 USAGE CONSIDERATIONS

TTO  is  available  in  liquid  and  semisolid  formulations.  TTO 
should be stored in a cool, dark, dry area in a container with 
little air as oil stability can be affected by heat, light, moisture, 
and air exposure.1

 SIGNIFICANT BACKGROUND

With increasing frequency, TTO, usually in concentrations of  
5 to 10 percent, is found as an ingredient in several cosmetic 
products,  including  shampoos,  massage  oils,  skin  and  nail 
creams, as well as household products such as laundry deter-
gents (for eliminating mites).6 TTO has long been regarded as 
an  effective  topical  antiseptic  and  broad-spectrum  antimicro-
bial agent.12 In recent years, a more expansive demographic has 
come  to  use  this  essential  oil  for  a  wide  range  of  indications 
including acne, psoriasis, fungal infections (e.g., oral candidiasis), 
vaginal infections, tinea, lice, rashes, cold sores, cuts, scratches, 
various  burns 
(including  sunburns),  and  for  dental 
applications.1,39,43 It is also being studied for potential effective-
ness against recurrent herpes labialis.44 Given its reputation and 
anecdotal reports of effectiveness, TTO has been incorporated 
into  antifungal  soaps  and  shampoos,  dental  products  (e.g., 
mouthwashes and toothpastes), veterinary products (to protect 
against  fleas  and  ticks),  and  several  household  and  industrial 
disinfectants.  An  antioxidant  application  of  TTO  in  skin  care 
formulations has been proposed, though one study from 2000 
suggests that TTO lacks antioxidant properties.7 Importantly, in 
terms of its antiacne activity, TTO exhibits anti-inflammatory 
properties  by 
lowering  histamine-induced  cutaneous 
inflammation.45

Contradictory Findings
Despite  numerous  favorable  reports  on  its  varied  beneficial 
effects,  the  amount  of  valid  research  showing  the  positive 
effects of TTO on dermatologic conditions is relatively small. 
In one study of complementary and alternative medicine (CAM) 
comparing the effectiveness of Aloe vera gel and TTO in treating 
two  selected  conditions  (atopic  dermatitis  and  chronic  venous 
insufficiency),  neither  product  was  found  to  be  effective.46 
In  a  review  of  four  randomized  clinical  trials,  researchers 
acknowledged that TTO might be effective in treating acne and 
fungal infections, but declared that there is no compelling evi-
dence showing that TTO is truly effective in treating any der-
matologic  condition.19  Since  then,  however,  more  favorable 
findings have emerged. In fact, TTO is thought to have poten-
tial as a standard acne therapy,11 and is included in OTC prod-
ucts designed to treat acne.47

TTO is harvested throughout the year. M. alternifolia are robust, 
sturdy plants native to New South Wales, Australia that recover 
quickly from harvesting and live for up to a decade.

 CONCLUSION

 FORMULATION CONSIDERATIONS

Optimal TTO solubility in the base and optimal TTO delivery 
to targeted skin in proper concentrations are important consid-
erations.12 The presence of preservatives or surfactants may or 
may not amplify the antimicrobial effects of TTO. Australian 
standards require a minimum content of 30 percent terpinene-
4-ol in TTO products.14

Tea tree oil has been recently touted for a wide range of derma-
tologic  conditions  and,  accordingly,  become  an  extremely 
popular  ingredient  in  skin  care  products.  While  anecdotal 
reports  may  hold  some  sway,  it  is  important  to  consider  the 
relative  paucity  of  clinical  evidence  on  tea  tree  oil.  That  is, 
much  more  research,  particularly  randomized,  double-blind, 
controlled  trials,  are  needed  to  establish  the  efficacy  of  prod-
ucts with tea tree oil as the main active ingredient. Nevertheless, 
the evidence, derived mostly from in vitro work, that has emerged 
does  seem  to  support  the  reputed  broad  range  of  activity. 

 
300  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

In particular, the antimicrobial and anti-inflammatory effects of 
the  essential  oil  of  Melaleuca  alternifolia  have  been  well 
established  and  the  data  on  its  use  as  an  acne  adjuvant  are 
particularly promising.

REFERENCES

1.  Carson  CF,  Hammer  KA,  Riley  TV.  Melaleuca  alternifolia  
(Tea  Tree)  oil:  A  review  of  antimicrobial  and  other  medicinal 
properties. Clin Microbiol Rev. 2006;19:50.

2.  D’Auria FD, Laino L, Strippoli V, et al. In vitro activity of tea tree 
oil  against  Candida  albicans  mycelia  conversion  and  other 
pathogenic fungi. J Chemother. 2001;13:377.

3.  Bassett IB, Pannowitz DL, Barnetson RS. A comparative study of 
tea-tree oil versus benzoylperoxide in the treatment of acne. Med 
J Aust. 1990;153:455.

4.  Pazyar N, Yaghoobi R, Bagherani N, et al. A review of applica-
tions of tea tree oil in dermatology. Int J Dermatol. 2013;52:784.
5.  Morelli  V,  Calmet  E,  Jhingade  V.  Alternative  therapies  for  
common dermatologic disorders, part 2. Prim Care. 2010;37:285.

6.  Larson D, Jacob SE. Tea tree oil. Dermatitis. 2012;23:48.
7.  Lis-Balchin M, Hart SL, Deans SG. Pharmacological and antimicrobial 
studies on different tea-tree oils (Melaleuca alternifolia, Leptospermum 
scoparium or Manuka and Kunzea ericoides or Kanuka), originating 
in Australia and New Zealand. Phytother Res. 2000;14:623.

8.  Aburjai T, Natsheh FM. Plants used in cosmetics. Phythother Res. 

2003;17:987.

9.  Carson CF, Riley TV. Safety, efficacy and provenance of tea tree 

(Melaleuca alternifolia) oil. Contact Dermatitis. 2001;45:65.

10.  American  Cancer  Society.  Tea  tree  oil.  http://www.cancer.org 
/Treatment/TreatmentsandSideEffects/Complementaryand 
AlternativeMedicine/HerbsVitaminsandMinerals/tea-tree-oil. 
Accessed October 8, 2013.

11.  Reuter J, Merfort I, Schempp CM. Botanicals in dermatology: An 

evidence-based review. Am J Clin Dermatol. 2010;11:247.

12.  Thomsen  PS,  Jensen  TM,  Hammer  KA,  et  al.  Survey  of  the  
antimicrobial  activity  of  commercially  available  Australian  tea 
tree (Melaleuca alternifolia) essential oil products in vitro. J Altern 
Complement Med. 2011;17:835.

13.  Foster S. An Illustrated Guide to 101 Medicinal Herbs: Their History, 
Use,  Recommended  Dosages,  and  Cautions.  Loveland,  CO: 
Interweave Press; 1998:196-197.

14.  Hoffmann  D.  Medical  herbalism:  The  science  and  practice  of  herbal 

medicine. Rochester, VT: Healing Arts Press; 2003:439.

15.  Enshaieh S, Jooya A, Siadat AH, et al. The efficacy of 5% topical 
tea tree oil gel in mild to moderate acne vulgaris: A randomized, 
double-blind placebo-controlled study. Indian J Dermatol Venereol 
Leprol. 2007;73:22.

16.  Pazyar  N,  Yaghoobi  R.  Tea  tree  oil  as  a  novel  antipsoriasis 

weapon. Skin Pharmacol Physiol. 2012;25:162.

17.  Crawford  GH,  Sciacca  JR,  James  WD.  Tea  tree  oil:  Cutaneous 
effects  of  the  extracted  oil  of  Melaleuca  alternifolia.  Dermatitis. 
2004;15:59.

18.  Thomsen NA, Hammer KA, Riley TV, et al. Effect of habituation 
to tea tree (Melaleuca alternifolia) oil on the subsequent suscepti-
bility of Staphylococcus spp. to antimicrobials, triclosan, tea tree 
oil, terpinen-4-ol and carvacrol. Int J Antimicrob Agents. 2013;41:343.
19.  Ernst  E,  Huntley  A.  Tea  tree  oil:  A  systematic  review  of  rand-
omized  clinical  trials.  Forsch  Komplementarmed  Klass  Naturheilkd. 
2000;7:17.

20.  Ireland  DJ,  Greay  SJ,  Hooper  CM,  et  al.  Topically  applied 
Melaleuca alternifolia (tea tree) oil causes direct anti-cancer cyto-
toxicity  in  subcutaneous  tumour  bearing  mice.  J  Dermatol  Sci. 
2012;67:120.

21.  Greay SJ, Ireland DJ, Kissick HT, et al. Inhibition of established 
subcutaneous  murine  tumour  growth  with  topical  Melaleuca 
alternifolia  (tea  tree)  oil.  Cancer  Chemother  Pharmacol. 
2010;66:1095.

22.  Greay SJ, Ireland DJ, Kissick HT, et al. Induction of necrosis and cell 
cycle  arrest  in  murine  cancer  cell  lines  by  Melaleuca  alternifolia 
(tea  tree)  oil  and  terpinen-4-ol.  Cancer  Chemother  Pharmacol. 
2010;65:877.

23.  Zhang SY, Robertson D. A study of tea tree oil ototoxicity. Audiol 

Neurootol. 2000;5:64.

24.  Millar BC, Moore JE. Successful topical treatment of hand warts 
in  a  paediatric  patient  with  tea  tree  oil  (Melaleuca  alternifolia). 
Complement Ther Clin Pract. 2008;14:225.

25.  Edmondson M, Newall N, Carville K, et al. Uncontrolled, open-
label, pilot study of tea tree (Melaleuca alternifolia) oil solution in 
the decolonisation of methicillin-resistant Staphylococcus aureus 
positive wounds and its influence on wound healing. Int Wound J. 
2011;8:375.

26.  Morelli V, Calmet E, Jhingade V. Alternative therapies for common 

dermatologic disorders, part I. Prim Care. 2010;37:269.

27.  Satchell AC, Saurajen A, Bell C, et al. Treatment of dandruff with 

5% tea tree oil shampoo. J Am Acad Dermatol. 2002;47:852.

28.  Satchell  AC,  Saurajen  A,  Bell  C,  et  al.  Treatment  of  interdigital 
tinea  pedis  with  25%  and  50%  tea  tree  oil  solution:  A  rand-
omized,  placebo-controlled,  blinded  study.  Australas  J  Dermatol. 
2002;43:175.

29.  Barker  SC,  Altman  PM.  A  randomized,  assessor  blind,  parallel 
group  comparative  efficacy  trial  of  three  products  for  the  treat-
ment  of  head  lice  in  children  –  Melaleuca  oil  and  lavender  oil, 
pyrethrins and piperonyl butoxide, and a “suffocation” product. 
BMC Dermatol. 2010;10:6.

30.  Patel KG, Raju VK. Ocular demodicosis. W V Med J. 2013;109:16.
31.  Sakr  FM,  Gado  AM,  Mohammed  HR,  et  al.  Preparation  and 
evaluation  of  a  multimodal  minoxidil  microemulsion  versus 
minoxidil  alone  in  the  treatment  of  androgenetic  alopecia  of 
mixed etiology: A pilot study. Drug Des Devel Ther. 2013;7:413.
32.  Tirabassi  G,  Giovannini  L,  Paggi  F,  et  al.  Possible  efficacy  of 
Lavender  and  Tea  tree  oils  in  the  treatment  of  young  women 
affected  by  mild  idiopathic  hirsutism.  J  Endocrinol  Invest. 
2013;36:50.

33.  Corazza M, Borghi A, Gallo R, et al. Topical botanically derived 
products:  use,  skin  reactions,  and  usefulness  of  patch  tests.  A 
multicentre Italian study. Contact Dermatitis. 2014;70:90.

34.  Hausen BM, Reichling J, Harkenthal M. Degradation products of 
monoterpenes  are  the  sensitizing  agents  in  tea  tree  oil.  
Am J Contact Dermat. 1999;10:68.

35.  Khanna M, Qasem K, Sasseville D. Allergic contact dermatitis to 
tea  tree  oil  with  erythema  multiforme-like  id  reaction.  
Am J Contact Dermat. 2000;11:238.

36.  Knight  TE,  Hausen  BM.  Melaleuca  oil  (tea  tree  oil)  dermatitis.  

J Am Acad Dermatol. 1994;30:423.

37.  Brand  C,  Grimbaldeston  MA,  Gamble  JR,  et  al.  Tea  tree  oil 
reduces  the  swelling  associated  with  the  efferent  phase  of  a 
contact hypersensitivity response. Inflamm Res. 2002;51:236.
38.  Brand C, Townley SL, Finlay-Jones JJ, et al. Tea tree oil reduces 
histamine-induced  oedema  in  murine  ears.  Inflamm  Res. 
2002;51:283.

39.  Hammer KA, Carson CF, Riley TV. Effects of Melaleuca alternifolia 
(tea  tree)  essential  oil  and  the  major  monoterpene  component 
terpinen-4-ol on the development of single- and multistep antibi-
otic resistance and antimicrobial susceptibility. Antimicrob Agents 
Chemother. 2012;56:909.

40.  Hammer KA, Carson CF, Riley TV, et al. A review of the toxicity of 
Melaleuca  alternifolia  (tea  tree)  oil.  Food  Chem  Toxicol.  2006; 
44:616.

41.  Rutherford  T,  Nixon  R,  Tam  M,  et  al.  Allergy  to  tea  tree  oil: 
Retrospective  review  of  41  cases  with  positive  patch  tests  over 
4.5 years. Australas J Dermatol. 2007;48:83.

42.  Henley DV, Lipson N, Korach KS, et al. Prepubertal gynecomastia 

linked to lavender and tea tree oils. N Engl J Med. 2007;356:479.
43.  Baumann  L.  Botanical  ingredients  in  cosmeceuticals.  J  Drugs 

Dermatol. 2007;6:1084.

44.  Carson CF, Ashton L, Dry L, et al. Melaleuca alternifolia (tea tree) 
oil  gel  (6%)  for  the  treatment  of  recurrent  herpes  labialis.  
J Antimicrob Chemother. 2001;48:450.

45.  Koh KJ, Pearce AL, Marshman G, et al. Tea tree oil reduces histamine-

induced skin inflammation. Br J Dermatol. 2002;147:1212.

46.  Ernst  E,  Pittler  MH,  Stevinson  C.  Complementary/alternative 
medicine  in  dermatology:  Evidence-assessed  efficacy  of  two 
diseases and two treatments. Am J Clin Dermatol. 2002;3:341.
47.  Bowe WP, Shalita AR. Effective over-the-counter acne treatments. 

Semin Cutan Med Surg. 2008;27:170.

 
C H A P T E R   7 8

Salicylic Acid

C H A P T E R  78  ■   S A L I C Y L I C   AC I D  

301

Activities:

Anti-inflammatory, pore cleansing

Important Chemical Components:

Also known as 2-hydroxybenzoic acid, the chemical for-
mula of salicylic acid is C6H4(OH)COOH. Its molecular 
formula is C7H6O3.

Origin Classification:

Natural and organic forms are derived from willow bark, 
wintergreen leaves, and sweet birch. Most salicylic acid 
is laboratory made.

Personal Care Category:

Cleansing, antiacne, pore minimizing, exfoliating

Recommended  for  the  following  Baumann  Skin 
Types:

DSNT, DSNW, DSPT, DSPW, OSNT, OSNW, OSPT, and 
OSPW.  Salicylic  acid  may  cause  stinging  in  type  3  (S3) 
sensitive skin (stinging subtype), but it is beneficial for S1 
(acne) and S2 (rosacea) sensitive skin.

 SOURCE

Salicylic acid (SA) is derived primarily from willow bark, but 
has also been extracted from wintergreen leaves, sweet birch, 
myrtle, and meadow sweet flowers.1 Additional natural sources 
of SA include almonds, water chestnuts, peanuts, mushrooms, 
and  various  unripe  fruits  and  vegetables,  including  blackber-
ries,  blueberries,  cantaloupes,  dates,  raisins,  kiwi,  guavas, 
apricots,  broccoli,  green  peppers,  olives,  tomatoes,  as  well  as 
radishes and chicory, among others.2

SA  is  known  to  exhibit  anti-inflammatory  and  comedolytic 
properties,  which  accounts  for  its  inclusion  in  the  dynamic 
antiacne arsenal (Table 78-1). This aromatic acid is also used as a 
denaturant,  hair-conditioning  agent,  and  skin-conditioning 
ingredient in cosmetic formulations.3

TABLE 78-1
Pros and Cons of Salicylic Acid

Pros
Anti-inflammatory
Inexpensive

Covered for acne use by FDA monograph
Long history of traditional anti-inflammatory 

and antipyretic use

Cons
May cause stinging
May thin the stratum corneum, leading to 

increased risk of photodamage

 HISTORY

In antiquity, the willow bark (Salix alba) was considered a medicine 
by the Greek physicians Hippocrates and Dioscorides as well as 
the  Roman  naturalist,  philosopher,  and  author  Pliny  the  Elder.4 
Derivatives of the willow species S. alba were traditionally used as 
an  analgesic  for  head  and  other  aches,  rheumatism,  and  gout;  it 
was also used to treat fever.5–7 Indigenous peoples in North America 
are believed to have used willow species for medical purposes for 
2,000 years, with the Houma employing black willow root as a 
blood  thinner  and  the  Creek  using  willow  root  tea  as  an  anti-
inflammatory and antipyretic.8

The  modern  history  of  SA  is  traced  back  to  1763  when 
England’s  Reverend  Edward  Stone  found  that  willow  bark 
extract  was  effective  in  treating  malarial  fever.4,5,9  In  Italy  in 
1824,  Bartolomeo  Rigatelli  therapeutically  used  an  extract  of 
willow bark and Francesco Fontana characterized the compound, 
labeling  it  “salicina”  (based  on  the  Latin  expression  for  white 
willow,  Salix  alba).9  However,  the  German  chemist  Johann 
Andreas  Buchner  was  given  credit  for  naming  the  active 
ingredient of white willow bark after he isolated salicin in 1826.10 
French pharmacist Henri Leroux isolated a larger amount in 1828 
or 1829.4,10 In 1838, Raffaele Piria, an Italian chemist working in 
Paris, became the first to synthesize SA from salicin,1,4,9,10 as well 
as  name  the  product  “salicylic  acid,”11  and  Hermann  Kolbe  is 
credited  with  using  sodium  phenate  and  carbon  dioxide  to 
generate SA.4 These mid-1800s developments and the discovery 
that  salicylates  were  the  active  constituents  of  willow  species 
paved  the  way  for  the  development  of  acetylsalicylic  acid  
(aspirin),  first  prepared  from  carbolic  acid  in  1853  by  Charles 
Gerhardt, who was unable to identify its structure.4,8,12 With its 
structure discovered, aspirin was first synthesized, from willow 
bark,  in  1897  by  Arthur  Eichengrün,  Felix  Hoffmann,  and 
Heinrich  Dreser  working  at  Friedrich  Bayer  Company,  which 
recorded acetylsalicylic acid under the name “Aspirin” in 1899.4–6,13 
This  acetylated  salicylic  acid  became  the  world’s  first  truly 
blockbuster drug.

The use of SA in the treatment of acne began appearing in 
the  medical  literature  in  the  1960s  and  has  since  become  a 
mainstay  of  topical  acne  therapy,  particularly  in  over- 
the-counter (OTC) products.

Many companies, in the attempt to capitalize upon the popu-
larity  of  α-hydroxy  acids  (AHAs)  such  as  glycolic  acid,  have 
marketed SA as a “β-hydroxy acid” (BHA). However, because SA 
is an aromatic compound, it is actually incorrect to refer to it as a 
β-hydroxy  acid.  Nevertheless,  “β-hydroxy  acid”  or  “BHA”  is  a 
popular component in many OTC cosmetic products.

 CHEMISTRY

SA is the best known simple phenol, with well-established anti-
pyretic and anti-inflammatory activity.14 It is the only member 
of the BHA family, so named because the aromatic carboxylic 
acid  has  a  hydroxy  group  in  the  β  position  (Figure  78-1). 

 
302 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

▶

FIGURE 78-1  Chemical structure of salicylic acid.

This  is  actually  a  misnomer  because  the  carbons  of  aromatic 
compounds are traditionally given Arabic numerals (1, 2, etc.) 
rather  than  the  Greek  letter  designations  typical  for  nonaro-
matic  structures.  As  a  member  of  the  salicylate  family,  like 
aspirin,  SA  contains  anti-inflammatory  capabilities  due  to  its 
effects on the arachidonic acid cascade.15

Product  labels  will  state  the  percentage  of  SA  in  a  formula; 
however, the most important aspect is the amount of available 
free  acid  in  the  formulation.  The  amount  of  free  acid  itself  is 
affected by the following: concentration of the SA (percent SA), 
the pKa of the acid preparation, the pH of the solution (which is 
also affected by the type of vehicle used), and whether or not the 
formula is buffered. Because of this complex interplay of factors, 
it is difficult to compare one brand of SA to another. For example, 
a 20 percent SA peel from one company is not necessarily the 
same strength as a 20 percent SA peel from another company. 
The acid percentage is only a small part of the story. It is neces-
sary  to  consider  the  pH,  the  amount  of  free  acid,  the  additive 
ingredients, and whether or not the peel is buffered in order to 
make a truly useful comparison between different SA brands.

Significance of the pKa
In order to use SA properly, one must understand the pKa as well 
as  how  the  pH  of  a  formula  impacts  its  efficacy.  The  pKa  of  a 
compound measures its capacity to donate protons. The pKa is 
the pH at which the level of free acid equals the level of the salt 
form of the acid. When the pH is lower than the pKa, the free acid 
form, which is responsible for exfoliation of the skin, predominates; 
when the pH is higher than the pKa, the salt form predominates. 
The acid form is the “active form” in the preparation because it 
spurs  exfoliation.  To  create  an  efficacious  peel  that  provokes 
minimal  irritation,  having  the  proper  balance  of  salt  and  acid 
forms is necessary. The pKa for SA is 2.97, whereas it is 3.83 for 
AHAs.16 Because of this significant disparity in pKa, it is difficult to 
formulate a combination product containing both a BHA and an 
AHA that reaches an optimal pH. For example, in a combination 
AHA-BHA product with a pH of 3.5, the AHA acid form but BHA 
salt form would predominate. Consequently, the effects of BHA 
would  be  undermined  or  rendered  suboptimal.  For  this  reason, 
products containing SA alone are preferable to products that con-
tain both AHA and SA.17

Significance of the pH
The higher the pH, the more alkaline or basic the solution is; the 
lower the pH, the more acidic the solution. The irritation engen-
dered by a product is often directly related to how low its pH is, 
with a lower pH causing increased irritation, but greater efficacy.

Buffered Solutions
Some  SA  formulations  are  “buffered,”  which  numerous 
companies  claim  enhances  the  tolerability  of  these  agents.  
A solution is buffered by the addition of a base compound such 

as  sodium  bicarbonate  or  sodium  hydroxide.  This  yields  an 
increased amount of the salt form, less free acid, and a higher pH. 
In addition, buffered solutions are resistant to fluctuations in pH 
upon the addition of a salt or an acid to the preparation. Fewer side 
effects are associated with buffered solutions because of the lower 
pH  and  reduced  amount  of  free  acid,  but  a  decrease  in  efficacy 
may also be seen. These formulations are safer, but less effective.

Forms of Salicylic Acid
SA is found in various forms in cosmetic preparations. The salt 
forms of SA used as preservatives include magnesium salicylate, 
MEA-salicylate  (SA  compounded  with  2-aminoethanol), 
sodium salicylate, and calcium salicylate. The TEA salt of SA is 
used as an ultraviolet (UV) light absorber.3 Ethylhexyl salicylate 
(formerly  known  as  octyl  salicylate)  is  used  as  a  fragrance 
ingredient, sunscreen agent, and UV light absorber and methyl 
salicylate is used as a denaturant and flavoring agent.

 ORAL USES

SA  is  not  used  orally  because  it  induces  gastrointestinal 
irritation. The uses of aspirin and other oral forms of salicylates 
are beyond the scope of this chapter. 

 TOPICAL USES

The penetration of SA into the skin is regulated by the barrier 
function  of  the  skin.  One  study  demonstrated  that  impairing 
the  skin  barrier  with  acetone,  tape  stripping,  or  detergent 
(sodium lauryl sulfate) led to increased penetration of SA. The 
penetration  of  SA  significantly  correlated  with  the  measure-
ments  of  barrier  perturbation  by  transepidermal  water  loss  
(P  =  0.01)  and  erythema  (P  =  0.02)  for  each  individual.18  As  a 
keratolytic agent, SA is used in concentrations of 3 to 6 percent 
to  treat  ichthyoses,  keratosis  pilaris,  palmoplantar  keratosis, 
pityriasis rubra pilaris, and psoriasis.19 It is also used for removal 
of warts and corns in concentrations of 5 to 40 percent.19

Acne
Comedolytics,  such  as  SA  and  AHAs,  are  used  to  loosen  the 
keratinocytes and “unclog” the pores. BHA is more effective in 
reducing the number of comedones than are AHAs.

SA is one of the most effective and frequently used therapies 
for acne. In fact, SA is well established as an effective treatment, 
along with benzoyl peroxide (BPO), and low-dose retinoids, for 
mild  acne.20  It  is  covered  in  the  United  States  Food  and  Drug 
Administration (FDA) monograph for acne for 0.05 to 2 percent 
strengths in OTC products and is considered effective for acne in 
3 percent concentration in prescription medications, as stipulated 
by  the  FDA.21,22  At-home  cleansers,  blemish  treatments  and 
toners, gels, and moisturizers contain SA in addition to at-home 
chemical peels or in-office chemical peels. 

Lee and Kim investigated the efficacy and safety of a 30 percent 
SA peel in 35 Korean patients with facial acne. They found that 
inflammatory as well as noninflammatory lesion counts declined 
proportionately with increased treatment time. The investigators 
also reported that all patients were satisfied with the results and side 
effects were generally tolerable. They concluded that SA peels are 
an effective and safe therapy for Asian patients with facial acne.23

In  2008,  Kessler  et  al.  conducted  a  split-face,  double-blind, 
randomized,  controlled  study  with  20  patients  with  mild-to- 
moderately severe facial acne to compare the efficacy of AHAs 

 
and BHA. The AHA glycolic acid (30 percent) was applied to one 
side and 30 percent SA was applied on the other side every two 
weeks  for  six  treatments  overall.  Both  peels  were  significantly 
and  equally  effective  after  two  treatments,  with  sustained 
effectiveness and fewer side effects associated with SA.24

A 2010 meta-analysis compared studies of BPO, clindamycin, 
BPO  and  SA,  and  BPO/clindamycin  and  found  that  the 
combination  of  BPO  and  SA  was  most  effective  in  acne 
treatment.25 SA plays a role in acne because of its keratolytic 
effects, ability to decrease the number of comedones, and its 
anti-inflammatory characteristics.

In  2011,  Babayeva  et  al.  conducted  a  12-week,  prospective, 
single-blind, randomized, comparative clinical study comparing 
the  efficacy  and  tolerability  of  a  3  percent  alcohol-based  SA 
preparation  combined  with  clindamycin  and  tretinoin  
0.05  percent  cream  combined  with  clindamycin  in  46  patients 
(between  18  and  35  years  old)  with  mild-to-moderate  facial 
acne.  Ultimately,  both  regimens  were  found  to  be  equally 
efficacious  in  lowering  total  lesion,  inflammatory,  and  non-
inflammatory lesion counts. Lesion counts did decline faster in 
the tretinoin group. Neither formulation was found to influence 
stratum corneum (SC) hydration, but skin sebum values did fall 
in the SA group.26 Previously, NilFroushzadeh et al. had shown in 
a single-blinded, randomized clinical trial with 42 female patients 
(between the ages of 15 and 25 years) that a 1 percent clindamycin 
and  2  percent  SA  lotion  used  twice  daily  for  12  weeks  was 
significantly more efficacious than 1 percent clindamycin alone in 
terms  of  total  lesion  count  and  Acne  Severity  Index  score.  No 
significant differences were seen, though, between the clindamyc/
SA  group  and  a  group  treated  once  nightly  with  1  percent 
clindamycin and 0.025 percent tretinoin lotion.27

In an open, baseline-controlled clinical study with 20 patients 
(18 females and 2 males between the ages of 19 and 32 years) with 
mild-to-moderate  facial  acne  conducted  in  2013,  Zheng  et  al. 
assessed  the  safety  and  efficacy  of  an  antioxidant  optimized 
topical SA 1.5 percent cream containing natural skin penetration 
enhancers.  Patients  were  instructed  to  apply  the  formulation 
twice  daily  for  four  weeks.  No  side  effects  were  noted  and  
95  percent  of  the  subjects  improved  (complete  clearing  in  
20  percent,  significant  improvement  in  30  percent,  moderate 
improvement in 15 percent, mild improvement in 30 percent).22
Also that year, Raone et al. conducted a prospective, observa-
tional, multicenter, open-label, postmarketing Phase IV study to 
assess  the  efficacy  and  tolerability  of  a  30  percent  SA,  triethyl 
citrate, and ethyl linoleate peel combined with a home therapy 
with three topical agents (triethyl citrate, ethyl linoleate, and SA 
0.5 percent cream) for the treatment of moderate facial acne. The 
average Global Acne Grading System score fell 49 percent for the 
53 patients as the investigators concluded that the therapy was 
effective and universally well tolerated.28 The authors noted that 
SA peels also enhance the penetration of other topical ingredients 
used to treat acne.28

Although SA has been used steadily for several years to treat 
acne,  the  number  of  well  designed,  controlled  clinical  trials  to 
test its safety and efficacy is relatively small.

C H A P T E R  78  ■   S A L I C Y L I C   AC I D 

303

irritation  of  SA  compared  to  AHA  was  confirmed  in  a  1997 
double-blind consumer-perception study of neurosensory dis-
comfort after three weeks of use. In this study, 20 percent of 
the patients treated with an in-office AHA peel reported subjec-
tive  adverse  reactions  versus  only  4  to  7  percent  of  the  SA 
group.30 The anti-inflammatory effects of SA may also make it 
a useful adjuvant in the treatment of rosacea.17

Antimicrobial
SA  in  5  percent  concentrations  has  shown  activity  against 
Gram-positive  and  Gram-negative  bacteria,  yeast,  and  fungi. 
The pH must be within a range of 2 to 5 to exert this activity.

Pore Minimizing
Comedolytics, such as BHA and AHAs, are used to loosen the 
keratinocytes and “unclog” the pores. BHA is more effective in 
reducing the number of comedones than are AHAs. A study by 
Kligman  demonstrated  that  biopsy  specimens  from  patients 
treated with SA displayed fewer comedones when compared 
to those treated with AHAs. This is due to the fact that AHAs 
are  not  lipid  soluble.30  The  lipophilicity  of  SA  enables  it  to 
penetrate  the  sebaceous  material  in  the  hair  follicle  and 
exfoliate  the  pores.31,32  However,  AHAs,  which  are  water 
soluble, do not have this comedolytic property.33

Photoaging
AHAs  and  BHA  are  naturally-occurring  organic  acids  used  in 
at-home as well as in-office products to assist in exfoliation and 
accelerating  the  cell  cycle.  They  impact  corneocyte  cohesive-
ness  in  the  lower  levels  of  the  SC,34  where  they  alter  its  pH, 
thus affecting the skin.35 The topical application of AHAs and 
BHA in high concentrations causes the detachment of keratino-
cytes  and  epidermolysis;  application  at  lower  concentrations 
diminishes  intercorneocyte  cohesion  directly  above  the 
granular  layer,  promoting  desquamation  and  SC  thinning.35 
The two main effects, then, are accelerating the cell cycle, which 
slows  with  age,  and  augmenting  desquamation,  which  helps 
reduce hyperpigmentation and smoothes the skin surface.

Although glycolic acid is the most commonly used acid in the 
antiaging  armamentarium,  SA  is  frequently  found  in  products 
used to treat photoaged skin. SA functions as an exfoliant and 
accelerates the cell cycle (thus cell renewal) in the same way that 
AHAs have been shown to do. A study examining the antiaging 
benefits  of  topically  applied  SA  up  to  concentrations  of  
30 percent showed fading of pigment spots, decreased surface 
roughness, reduction of fine lines, and improvement of seborrheic 
keratosis.17,36,37 In 1992, Swinehart found that using a buffered 
50  percent  SA  ointment  peel,  after  pretreatment  with  topical 
tretinoin  and  localized  20  percent  trichloroacetic  acid,  on  the 
hands  and  forearms  of  patients  exhibiting  actinically-induced 
pigmentary changes was very effective in eliminating lentigines, 
pigmented keratoses, and actinic damage.37

Anti-inflammatory Uses
Unlike  AHAs,  BHA  affects  the  arachidonic  acid  cascade  and, 
therefore, exhibits anti-inflammatory capabilities. In addition, 
salicylates inhibit nuclear factor-κB and suppress cytokine gene 
expression in activated monocytes and macrophages.29 These 
properties may allow SA peels to be effective while inducing 
less irritation than AHA peels. The lower incidence of perceived 

 SAFETY ISSUES

In February 2000, the Cosmetic Ingredients Review (CIR) Expert 
Panel published an opinion that the use of SA-related substances in 
cosmetics is “safe as used when formulated to avoid irritation and 
when formulated to avoid increased sun sensitivity.”3 It is advised 
that all patients treated with SA-containing products should use a 
broad-spectrum sunscreen as part of their daily skin care regimen.

 
304 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Salicylates are absorbed percutaneously. Around 10 percent of 
applied salicylates can remain in the skin.3 Little acute toxicity 
(LD50 in rats >2 g/kg) via a dermal exposure route is seen for SA, 
methyl salicylate, tridecyl salicylate, and butyloctyl salicylate.

SA is neither phototoxic nor a photosensitizer.3 In fact, SA and 
ethylhexyl  salicylate  act  as  low-level  photoprotective  agents.3 
Because  these  ingredients  are  often  used  as  exfoliating  agents, 
concern has emerged that repeated use may effectively increase 
exposure  of  the  dermis  and  epidermis  to  UV  radiation  by 
reducing SC thickness. Daily use of sun protection is emphasized 
for this reason.

Although SA is relatively safe, its use is associated with risks. 
The most common risk is burning of the skin, which can occur if 
the  skin  is  prepared  too  vigorously,  if  the  patient’s  SC  is  thin 
from exfoliation or concomitant retinoid use, or if the skin barrier 
is impaired as seen with the use of foaming cleansers and soap. 
Toxic levels of salicylates have not been reported in association 
with the concentrations currently used for SA peels.38 However, 
there have been case reports of children with multiple excoriations 
and  elderly  patients  with  ichthyosis  who  developed  salicylism 
after  being  treated  with  topical  products  containing  SA.39 
The  CIR  panel  found  that  an  oral  dose  of  baby  aspirin  
(81 mg) by a 58 kg female would result in a salicylate exposure 
of  1.4  mg/kg/day,  which  would  not  be  expected  to  pose  any 
reproductive  risk.3  They  concluded  that  the  risk  of  using  a 
cosmetic product with SA could result in an exposure of 0.4 to  
0.5 mg/kg/day of SA, which is significantly less than with a baby 
aspirin. To minimize the risk of toxicity, patients that are taking 
aspirin should be cautioned to avoid using topical SA products.

Because  of  the  risk  of  salicylism,  it  is  unwise  to  peel  large 
surface areas of the body in the same office visit. The signs of 
salicylism include nausea, disorientation, and tinnitus. SA use, if 
it  is  improper  or  too  frequent  or  in  high  concentrations,  can 
cause  redness,  itching,  peeling,  increased  skin  sensitivity,  and 
blisters. There are no reported cases of salicylism from SA acne 
products.19 SA is contraindicated in patients who are pregnant, 
breast-feeding, or allergic to aspirin. Nevertheless, safety data are 
lacking for pregnant patients, and SA is considered among the 
safe and effective topical treatments for mild-to-moderate acne 
in this population.40 While animal data do support the practice of 
pregnant  women  avoiding  the  use  of  many  topical  agents, 
including SA,19 the systemic absorption of SA through the skin is 
sufficiently minimal to warrant confidence that topical SA would 
pose no risk to the developing fetus.40,41 SA peels should not be 
used during pregnancy, however.

 ENVIRONMENTAL IMPACT

SA has been synthesized in the laboratory for the last century. 
While numerous plants contain this organic acid, few if any are 
targeted  specifically  for  SA  on  a  large-scale,  industrial  basis; 
therefore, the likely environmental impact is minimal.

 FORMULATION CONSIDERATIONS

SA-containing  formulations  are  available  in  OTC  at-home 
products  that  have  lower  concentrations  of  acids  (usually  
0.5–2 percent),21 and medical strength to be used in the derma-
tologist’s office (usually 20–35 percent). The CIR panel report 
did not establish a limit on concentration of SA or identify the 
minimum  pH  of  formulations  containing  SA.3  SA  seems  to 
absorb well in skin. The absorption of 5 percent SA in human 
skin was measured and it was found that vehicles containing 

an aqueous base allowed more penetration of SA into human 
skin  as  compared  to  a  Vaseline  base.3  The  effects  of  pH  on 
penetration  were  measured  and  a  pH  of  2  was  found  to  be 
associated with the highest level of penetration. Studies suggest 
that  the  SC  is  the  largest  barrier  of  penetration  to  SA. 
Application  of  large  amounts  of  SA  to  the  body  of  psoriatic 
patients does result in increased serum levels of SA and urinary 
excretion of SA. The amount of SA absorbed depends on the 
pH,  the  vehicle,  and  the  condition  of  the  skin’s  permeability 
barrier  (i.e.,  SC).3  Ethanol-containing  vehicles  were  linked  to 
the  highest  penetration  followed  by  aqueous  vehicles  while 
lipohilic vehicles displayed the least penetration.

 USAGE CONSIDERATIONS

SA is popular as an in-office chemical peeling method because 
of its efficacy and ease of use. It is unique among peeling agents 
insofar as it forms a white precipitate once the peel is complete. 
Any area that has been inadequately peeled can be easily iden-
tified and treated by applying the SA solution in the areas that 
were  missed.  In  addition,  timing  and  neutralizing  the  peel  is 
unnecessary. Once the vehicle becomes volatile, which occurs 
in approximately two minutes, there is very little penetration 
of the active agent; this makes timing and neutralizing the peel 
unnecessary. Therefore, SA is much easier to use on areas that 
are difficult to easily rinse such as the back and the arms.

SA peels may exert a whitening effect in patients with darker 
skin types. In a 2006 study by Ahn and Kim of 24 Asian women 
with acne who were treated with biweekly facial peeling with 
30  percent  SA  in  absolute  ethanol  for  three  months,  subjects 
exhibited some skin lightening.31 However, such peels can also 
result  in  postinflammatory  hyperpigmentation.  Practitioners 
should explain to patients with darker skin types the risks of skin 
lightening or darkening from using SA peels. The key is to use a 
peel that is strong enough to exert the desired effect but not strong 
enough to induce inflammation. If in doubt, start with a lower-
strength peel and titrate to stronger peels in later treatments.

SA reportedly enhances percutaneous penetration of vitamin A 
and  triamcinolone  acetonide  but  not  hydrocortisone,  methyl 
nicotinate, or cyclosporine.3 Studies have shown that it does not 
increase sensitivity to other agents and in fact may reduce the 
erythema seen with sensitizing agents.3

 SIGNIFICANT BACKGROUND

In a literature review including Ovid, MEDLINE, EMBASE, and 
Cochrane  Database  Library  searches,  Gamble  et  al.  found 
multiple controlled trials showing BPO, topical antibiotics, and 
topical retinoids used in combination as the therapies offering 
optimal  efficacy  and  safety  for  mild-to-moderate  acne,  but 
acknowledged SA as one of several alternatives not extensively 
studied that have proven efficacious and safe when combined 
with traditional treatment options.42 SA is often the treatment 
of choice for patients that find a topical retinoid too irritating.43
There is no one therapeutic option that addresses each of the 
etiologic  factors  in  acne  vulgaris.  Only  SA,  BPO,  and  steroids 
treat lesions already visible on the skin.

 CONCLUSION

Salicylic  acid  is  a  versatile  component  in  the  antiacne  arma-
mentarium. Importantly, it is safe and reduces inflammation. It 
is also inexpensive. Because it has a low pH, salicylic acid may 

 
provoke  stinging,  particularly  in  individuals  with  S3  sensitive 
skin. More research is necessary to ascertain the role of salicylic 
acid in other inflammatory skin diseases, but its use as a topical 
therapy,  particularly  in  combination,  for  mild-to-moderate 
acne is well researched and substantiated.

REFERENCES

1.  Mahdi  JG,  Mahdi  AJ,  Mahdi  AJ,  et  al.  The  historical  analysis  of 
aspirin discovery, its relation to the willow tree and antiproliferative 
and anticancer potential. Cell Prolif. 2006;39:147.

2.  Duthie GG, Wood AD. Natural saliyclates: Foods, functions and 

disease prevention. Food Funct. 2011;2:515.

3.  Cosmetic  Ingredient  Review  Expert  Panel.  Safety  assessment  of 
Salicylic  Acid,  Butyloctyl  Salicylate,  Calcium  Salicylate,  C12-15 
Alkyl Salicylate, Capryloyl Salicylic Acid, Hexyldodecyl Salicylate, 
Isocetyl Salicylate, Isodecyl Salicylate, Magnesium Salicylate, MEA-
Salicylate,  Ethylhexyl  Salicylate,  Potassium  Salicylate,  Methyl 
Salicylate,  Myristyl  Salicylate,  Sodium  Salicylate,  TEA-Salicylate, 
and Tridecyl Salicylate. Int J Toxicol. 2003;22(Suppl 3):1.

4.  Lafont  O.  From  the  willow  to  aspirin.  Rev  Hist  Pharm  (Paris). 

2007;55:209.

5.  Pasero  G,  Marson  P.  A  short  history  of  anti-rheumatic  therapy.  

II. Aspirin. Reumatismo. 2010;62:148.

6.  Rishton GM. Natural products as a robust source of new drugs 
and drug leads: Past successes and present day issues. Am J Cardiol. 
2008;101:43D.

7.  Hoffmann D. Medical Herbalism: The Science and Practice of Herbal 

Medicine. Rochester, VT: Healing Arts Press; 2003:579.

8.  Foster S. 101 Medicinal Herbs: An Illustrated Guide. Loveland, CO: 

Interweave Press; 1998:210–211.

9.  Marson  P,  Pasero  G.  The  Italian  contributions  to  the  history  of 

salicylates. Reumatismo. 2006;58:66.

C H A P T E R  78  ■   S A L I C Y L I C   AC I D  

305

22.  Zheng Y, Wang M, Chen H, et al. Clinical evidence on the efficacy 
and safety of an antioxidant optimized 1.5% salicylic acid (SA) 
cream in the treatment of facial acne: An open, baseline-controlled 
clinical study. Skin Res Technol. 2013;19:125.

23.  Lee  HS,  Kim  IH.  Salicylic  acid  peels  for  the  treatment  of  acne 

vulgaris in Asian patients. Dermatol Surg. 2003;29:1196.

24.  Kessler E, Flanagan K, Chia C, et al. Comparison of alpha- and 
beta-hydroxy acid chemical peels in the treatment of mild to 
moderately  severe  facial  acne  vulgaris.  Dermatol  Surg. 
2008;34:45.

25.  Seidler  EM,  Kimball  AB.  Meta-analysis  comparing  efficacy  of 
benzoyl  peroxide,  clindamycin,  benzoyl  peroxide  with  salicylic 
acid,  and  combination  benzoyl  peroxide/clindamycin  in  acne.  
J Am Acad Dermatol. 2010;63:52.

26.  Babayeva  L,  Akarsu  S,  Fetil  E,  et  al.  Comparison  of  tretinoin 
0.05% cream and 3% alcohol-based salicylic acid preparation in 
the  treatment  of  acne  vulgaris.  J  Eur  Acad  Dermatol  Venereol. 
2011;25:328.

27.  NilFroushzadeh MA, Siadat AH, Baradaran EH, et al. Clindamycin 
lotion alone versus combination lotion of clindamycin phosphate 
plus  tretinoin  versus  combination  lotion  of  clindamycin 
phosphate plus salicylic acid in the topical treatment of mild to 
moderate  acne  vulgaris:  A  randomized  control  trial.  Indian  J 
Dermatol Venereol Leprol. 2009;75:279.

28.  Raone B, Veraldi S, Raboni R, et al. Salicylic acid peel incorporating 
triethyl citrate and ethyl linoleate in the treatment of moderate 
acne: A new therapeutic approach. Dermatol Surg. 2013;39:1243.

29.  Stevenson MA, Zhao MJ, Asea A, et al. Salicylic acid and aspirin 
inhibit the activity of RSK2 kinase and repress RSK2-dependent 
transcription of cyclic AMP response element binding protein- 
and NF-kappaB-responsive genes. J Immunol. 1999;163:5608.
30.  Kligman AM. A comparative evaluation of a novel low-strength 
salicylic  acid  cream  and  glycolic  acid  products  on  human  skin. 
Cosmet Dermatol. 1997;10:S11.

31.  Ahn HH, Kim IH. Whitening effect of salicylic acid peels in Asian 

10.  Jeffreys D. Aspirin: The remarkable story of a wonder drug. New York: 

patients. Dermatol Surg. 2006;32:372.

Bloomsbury; 2005:38–40.

32.  Bowe WP, Shalita AR. Effective over-the-counter acne treatments. 

11.  Fuster  V,  Sweeny  JM.  Aspirin:  A  historical  and  contemporary 

Semin Cutan Med Surg. 2008;27:170.

therapeutic overview. Circulation. 2011;123:768.

33.  Davies  M,  Marks  R.  Studies  on  the  effect  of  salicylic  acid  on 

12.  Rainsford  KD.  Anti-inflammatory  drugs  in  the  21st  century. 

normal skin. Br J Dermatol. 1976;95:187.

Subcell Biochem. 2007;42:3.

34.  Van  Scott  EJ,  Yu  RJ.  Hyperkeratinization,  corneocyte  cohesion, 

13.  Schmidt  B,  Ribnicky  DM,  Poulev  A,  et  al.  A  natural  history  of 

and alpha hydroxy acids. J Am Acad Dermatol. 1984;11:867.

botanical therapeutics. Metabolism. 2008;57:S3.

14.  Mills  S,  Bone  K.  Principles  and  Practice  of  Phytotherapy:  Modern 

Herbal Medicine. London: Churchill Livingstone; 2000:23–25, 61.

15.  Weirich EG, Longauer JK, Kirkwood AH. Dermatopharmacology 
of salicylic acid. III. Topical contra-inflammatory effect of salicylic 
acid  and  other  drugs  in  animal  experiments.  Dermatologica. 
1976;152:87.

16.  Clark CP 3rd. Alpha hydroxyl acids in skin care. Clin Plast Surg. 

1996;23:49.

17.  Baumann L, Saghari S. Chemical peels. In: Baumann L, Saghari S, 
Weisberg  E,  eds.  Cosmetic  Dermatology:  Principles  and  Practice.  
2nd ed. New York: McGraw-Hill; 2009:148–162.

18.  Benfeldt  E,  Serup  J,  Menné  T.  Effect  of  barrier  perturbation  on 
cutaneous salicylic acid penetration in human skin: In vivo phar-
macokinetics using microdialysis and non-invasive quantification 
of barrier function. Br J Dermatol. 1999;140:739.

19.  Akhavan A, Bershad S. Topical acne drugs: Review of clinical prop-
erties, systemic exposure, and safety. Am J Clin Dermatol. 2003;4:473.
20.  Whitney KM, Ditre CM. Management strategies for acne vulgaris. 

Clin Cosmet Investig Dermatol. 2011;4:41.

21.  Kaminsky A. Less common methods to treat acne. Dermatology. 

2003;206:68.

35.  Berardesca  E,  Distante  F,  Vignoli  GP,  et  al.  Alpha  hydroxyacids 
modulate  stratum  corneum  barrier  function.  Br  J  Dermatol. 
1997;137:934.

36.  Kligman D, Kligman AM. Salicylic acid peels for the treatment of 

photoaging. Dermatol Surg. 1998;24:325.

37.  Swinehart  JM.  Salicylic  acid  ointment  peeling  of  the  hands  and 
forearms. Effective nonsurgical removal of pigmented lesions and 
actinic damage. J Dermatol Surg Oncol. 1992;18:495.

38.  Rubin  MG.  Salicylic  acid  peels.  In:  Manual  of  Chemical  Peels: 
Superficial  and  Medium  Depth.  Philadelphia,  PA:  Lippincott 
Williams & Wilkins; 1995:19–20.

39.  Brubacher  JR,  Hoffman  RS.  Salicylism  from  topical  salicylates: 

Review of the literature. J Toxicol Clin Toxicol. 1996;34:431.

40.  Pugashetti R, Shinkai K. Treatment of acne vulgaris in pregnant 

patients. Dermatol Ther. 2013;26:302.

41.  Bozzo  P,  Chua-Gocheco  A,  Einarson  A.  Safety  of  skin  care 
products during pregnancy. Can Fam Physician. 2011;57:665.
42.  Gamble  R,  Dunn  J,  Dawson  A,  et  al.  Topical  antimicrobial 
treatment of acne vulgaris: An evidence-based review. Am J Clin 
Dermatol. 2012;13:141.

43.  Strauss JS, Krowchuk DP, Leyden JJ, et al. Guidelines of care for 
acne vulgaris management. J Am Acad Dermatol. 2007;56:651.

 
306 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   7 9

Retinol, Retinyl Esters, and Retinoic Acid

Activities:

Anti-inflammatory

Important Chemical Components:

Retinol: A form of vitamin A also known as (2E,4E,6E,8E)-
3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-
2,4,6,8-tetraen-1-ol. Its molecular formula is C20H30O.
Retinoic  acid:  A  metabolite  of  vitamin  A  also  known  as 
all-trans  retinoic  acid  and  (2E,4E,6E,8E)-3,7-dimethyl-9-
(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoic 
acid. Its molecular formula is C20H28O2.
Retinyl  palmitate:  Also  known  as  retinol  palmitate, 
vitamin A palmitate and [(2E,4E,6E,8E)-3,7-Dimethyl-9-
(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenyl] 
hexadecanoate. Its molecular formula is C36H60O2.

Origin Classification:

Retinol  occurs  in  nature  as  vitamin  A,  but  the  retinol 
found in personal care products is laboratory made.

Personal Care Category:

Antiacne, photoprotection

BST Treatable with this Ingredient:

DRPW,  DRNW,  DSNT,  DSPT,  DSNW,  DSPW,  ORNW, 
ORPW, OSNT, OSNW, OSPT, and OSPW. These are the 
preferred ingredients for subtype S1 sensitive skin (acne).

 SOURCE

All  of  the  natural  and  synthetic  derivatives  of  vitamin  A  are 
included  in  a  family  of  compounds  known  as  the  retinoids. 
Many  prescription  retinoids,  including  tretinoin,  adapalene, 
and tazarotene, have been approved by the United States Food 
and Drug Administration (FDA) for use in treating acne. While 
retinol is not FDA approved for use in acne and is not included 
in  the  FDA  monograph  ingredients  that  can  be  used  for  the 
disorder it certainly exerts antiacne effects. Although vitamin A 
is  naturally  occurring  and  is  found  in  foods  that  contain 
carotenoids  such  as  carrots,  the  retinols  used  in  over-the-
counter (OTC) skin care products are laboratory made. Putting 
carrots, carrot extract, or β-carotene on the skin would not be suf-
ficient because of the lack of skin penetration of the ingredients. 
For  this  reason,  effective  skin  care  products  use  retinoic  acid 
(tretinoin),  retinol,  adapalene,  or  tazarotene  as  the  form  of 
retinoid.  Some  skin  care  products  use  retinyl  esters  such  as 
retinyl palmitate (RP), but the efficacy is questionable because 
penetration  rates  are  minimal.  Carotenoids,  a  large  family  of 
secondary  metabolic  products  that  provide  pigment  to  the 
many  fruits  and  vegetables  in  which  they  are  found,  are 
precursors  to  vitamin  A.  Although  some  carotenoids  
(such as β-carotene, lycopene, lutein, astaxanthin, and zeaxanthin) 

are known to confer antioxidant activity and photoprotective 
effects,1,2 a discussion of these compounds is beyond the scope 
of this text.

 HISTORY

In 1937, the Nobel Prize was awarded to Karrer et al. for deter-
mining  the  structure  of  retinol.3  Retinol  was  successfully 
synthesized in 1943 and soon thereafter became commercially 
available. Since that time, the number of retinoid formulations 
has proliferated, now numbering over 2,500 products including 
prescription  and  nonprescription  preparations. Prescription 
topical  retinoids,  including  tretinoin  (Retin  A),  tazarotene 
(Tazorac), and adapalene (Differin), have been widely used for 
decades to treat moderate acne based on their efficacy in reducing 
comedogenesis,4,5  and  normalizing  keratinization.6–9  The  two 
most common retinoids found in OTC products are retinol and 
RP. Due to their “cosmetic” status under FDA regulations, retinol 
and  RP  are  commonly  listed  as  “inactive”  ingredients  in  OTC 
skin care products. Although early reviews of retinol deemed the 
ingredient ineffective, it was later determined that this was due 
to  the  molecule’s  photoinstability  (Table  79-1).  With  light 
exposure,  retinol  degrades  to  a  biologically  inactive  molecule. 
This  breakdown  can  be  avoided  with  the  addition  of  an 
antioxidant or incorporation into a vehicle that resists oxidation. 
Retinol is now known to induce the same effects on the retinoic 
acid receptor as tretinoin and prescription retinoids.

 CHEMISTRY

Vitamin A is found in several forms that convert to each other 
through the actions of various enzymes (see Figure 79-1).

Retinoids
Initially, a “retinoid” was defined as a compound the structure 
and action of which resembled the parent compound retinol. 
Through the last several decades, chemists have made extensive 
modifications  to  the  naturally-occurring  molecule  that  have 
resulted  in  the  development  of  many  forms  of  retinoids.  
The vitamin A or “retinoid” family now includes retinyl esters, 
retinol, tretinoin (retinoic acid), adapalene, tazarotene, and oral 
isotretinoin (Accutane) in addition to four carotenoids including 
β-carotene.

TABLE 79-1
Pros and Cons of Retinol

Pros
Many brand options
Strong scientific justification for use
Has effects on wrinkles as well as acne

Cons
Can cause redness and flaking
Stability affected by other ingredients
Unstable when exposed to light
Insufficient number of studies on retinol
Retinyl esters are not well absorbed

 
C H A P T E R  79  ■   R E T I N O L ,  R E T I N Y L   E S T E R S ,  A N D   R E T I N O I C   AC I D 

307

Retinyl ester 

Retinal 
FiGURe 79-1  Conversion flow of retinoids.

Retinol 

▶

Retinoic acid

The retinoids exhibit many important biologic activities, which 
include  regulating  growth  and  differentiation  in  epithelial  cells, 
inhibiting tumor promotion during experimental carcinogenesis, 
diminishing  malignant  cell  growth,  reducing  inflammation,  and 
bolstering the immune system.10 At the molecular level, retinoids 
confer such effects by regulating gene transcription and influenc-
ing  cellular  differentiation  and  proliferation.  Retinoids  can  act 
directly,  by  inducing  transcription  from  genes  with  promoter 
regions that contain retinoid response elements, or indirectly, by 
blocking the transcription of particular genes.11

Retinoid  ReceptoRs  Retinoid-binding  proteins  were 
discovered in the 1970s.12 In 1987, the identification of retinoic 
acid  receptors  paved  the  way  to  understanding  that  tretinoin 
functions  as  a  hormone.13,14  Much  research  has  since  been 
conducted  to  ascertain  the  mechanisms  of  these  binding 
proteins  and  receptors.  The  biologic  effects  of  retinoic  acid 
are now known to be mediated by various biological systems: 
binding proteins such as cellular retinoic acid-binding proteins  
I  and  II  (CRABP  I  and  II);  cellular  retinol-binding  protein 
(CRBP)15;  and  nuclear  receptors  divided  into  two  categories, 
retinoic  acid  receptors  (RARs)  and  retinoid  X  receptors 
(RXRs).16 All of these nuclear receptors belong to a large family 
called  nuclear  hormone  superfamily  receptors,  of  which  the 
receptors for vitamin D, estradiol, glucocorticoids, and thyroid 
hormone are members.17

RARs  heterodimerize  specifically  with  RXRs  in  order  to 
interact with their retinoic acid response elements (RAREs) and 
mediate  classic  retinoid  activity  and  toxicity.  RXRs  are  more 
promiscuous,  heterodimerizing  with  multiple  members  of  the 
steroid receptor superfamily, including peroxisome proliferator-
activated  receptors  (PPARs),  vitamin  D  receptors,  thyroid 
hormone receptors, and several orphan receptors, such as liver  
X receptors (LXRs), pregnane X receptors (PXRs), and farnesoid 
X receptors (FXRs).18 More research is needed to elucidate the 
interaction of retinoid agents with other hormones.

 ORAL USES

Retinoids are used orally in the form of isotretinoin (Accutane). 
A discussion of oral compounds is beyond the scope of this text.

 TOPICAL USES

Many studies have looked at the efficacy of retinoids in treating 
acne  and  have  resulted  in  FDA  approval  of  many  tretinoin-, 
adapalene-,  and  tazarotene-containing  acne  medications.  The 
discussions  in  this  book  are  limited  to  the  OTC  ingredients 
retinol  and  RP  and  their  use  in  acne.  There  are  no  published 
studies examining the efficacy of retinol and RP in acne; how-
ever, they are frequently used in dermatology practices for this 
indication. The discussion will concentrate on the reasons why 
it  is  believed  that  retinol  may  play  a  role  in  the  treatment  of 
acne, although its efficacy has not been proven. RP is not likely 
to have a role in acne therapy because of its limited absorption. 
However, new types of retinoids are being synthesized, which 
should lead to more options in the near future. RP is the main 
retinyl  ester  occurring  in  the  diet,  stored  in  the  body,  and 
incorporated in topical preparations.19

Retinoids  by  definition  all  bind  an  RAR,  leading  to  a 
predictable response. The primary distinguishing characteristics 
among retinoid types are the amount of absorption of the mol-
ecule, on which enzymes act to convert it to retinoic acid, and 
the amount of irritation caused. In 1997, Duell et al. showed 
that unoccluded retinol is more effective at penetrating human 
skin in vivo than RP or retinoic acid.20 In this study, retinol at  
0.25  percent  was  found  to  induce  the  cellular  and  molecular 
changes observed with the application of 0.025 percent retinoic 
acid,  without  the  irritation  usually  seen  with  retinoic  acid. 
Conversely,  RP  is  considered  a  storage  form  of  vitamin  A, 
accounting for approximately 70 percent of the total vitamin A 
present in human skin.19,21 RP requires cutaneous cleavage of 
its  ester  bond  in  order  to  be  transformed  into  retinol,  which 
then  requires  conversion  into  retinoic  acid in order to impart 
benefits when topically applied.

Mechanism in Acne

comedolytic  Retinoids help remove comedones (blackheads 
and  whiteheads)  through  desquamation,22  affecting  cell 
adhesion, and regulating keratinization.23 Using retinoids helps 
prevent  and  treat  comedones.  The  comedolytic  properties  of 
retinoids are similar to those associated with benzoyl peroxide 
and  salicylic  acid.24  Retinoids  should  be  considered  a  first-
line  therapy  for  acne  because  the  elimination  of  keratinocyte 
accretion  in  the  hair  follicle  facilitates  the  penetration  of 
antibiotics and other acne medications. Comedolytic properties 
are also important because improvement in comedones helps 
the patient see progress faster and increases compliance with 
acne  therapy.  Receding  of  the  papules  and  pustules  of  acne 
can take 8 to 12 weeks, while comedones may start to subside 
within days of initial treatment.

eFFects  on  toll-liKe  ReceptoR  2  The  transmembrane 
proteins  known  as  Toll-like  receptors  (TLRs)  are  thought  to 
play a key role in the pathogenesis of acne. TLR-2 is activated 
by  ligands,  such  as  bacterial  components,  and  modulates  the 
expression of various immune response genes involved in acne 
development.25  Evidence  suggests  that  Propionibacterium  acnes, 
the  bacteria  implicated  in  acne  etiology,  can  induce  TLR-2 
expression  through  secreted  proinflammatory  compounds. 
Retinoids  downregulate  TLR-2  expression,  resulting  in  acne 
symptom improvement.26 The mechanism of action of TLR-2 
in acne development is not known but one study showed that 
TLR-2 activation yielded increases in interleukin (IL)-1α.27

eFFects on inFlammatoRy cytoKines  In 2005, Kang et al. 
demonstrated  that  transcription  factors  nuclear  factor-κB  and 
activator  protein-1  are  activated  in  acne  lesions,  ultimately 
resulting  in  increased  expression  of  inflammatory  cytokines 
and matrix metalloproteinases (MMPs).28,29 Others have since 
shown that several inflammatory cytokines are involved in acne. 
For example, IL-1α, induced by TLR-2, is known to influence 
comedone development.30 In 2013, Agak et al. reported that IL-
17 is induced by P. acnes but suppressed by retinoids.31

Proinflammatory  cytokine  production  promoted  by  P.  acnes 
has  been  shown  to  decline  with  the  addition  of  retinoids  to 
culture  media.26  MMPs  have  recently  gained  attention  for 
playing a role in acne pathogenesis. Notably, investigators have 
observed significant increases in MMP-1, MMP-3, and MMP-9 in 
lesional skin in comparison to donor-matched normal skin.28,32 
The scarring associated with many cases of moderate-to-severe 

 
308  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

acne may be attributable, in part, to the overexpression of these 
MMPs. Retinoids may target this MMP expression as part of its 
therapeutic mechanism of action.

EffEcts  on  sEbum  Production  Patients  with  cystic 
acne, or those who are unresponsive to all other regimens, can 
be  treated  with  oral  retinoids  such  as  isotretinoin.  This  oral 
medication has been shown to alter sebaceous gland function, 
and a marked decrease in sebum production occurs within two 
weeks of the start of therapy.33 Topical retinoids have not yet 
been shown to affect sebaceous gland function. This is likely 
due  to  the  fact  that  sebaceous  glands  are  located  at  a  level 
in  the  hair  follicle  beyond  which  topical  retinoids  have  been 
demonstrated to penetrate.

 SAFETY ISSUES

In 2010, a controversial report by the Environmental Working 
Group (EWG) warned of possible photocarcinogenicity associ-
ated with RP-containing sunscreens. This warning was based 
in  part  on  a  2006  report  by  Xia  et  al.  that  demonstrated  that 
ultraviolet (UV) A and UVB exposure led to the formation of 
photodecomposition  products,  synthesis  of  reactive  oxygen 
species (ROS), and lipid peroxidation induction.34 Reacting to 
the EWG report, Wang et al. acknowledged that of the eight in 
vitro  studies  published  by  the  FDA  from  2002  to  2009,  four 
revealed  that  RP  generated  ROS  after  UVA  exposure.34–39 
However,  Wang  contended  that  the  National  Toxicology 
Program (NTP) study on which the EWG based its report failed 
to prove that the combination of RP and UV results in photo-
carcinogenesis  and,  in  fact,  was  rife  with  reasons  for  skepti-
cism.35,36  The  EWG  offered  its  own  counter  arguments  and 
stood  by  its  report.  This  heated  debate  was  covered  by  the 
Journal of the American Academy of Dermatology.35 It is important 
to note that the RP studies did not consider RP products that 
contain  sun  protection  factor  (SPF)  protection;  therefore,  it  is 
not known if these effects could be mitigated by concomitant 
use of SPF.

 ENVIRONMENTAL IMPACT

There  is  no  environmental  impact  of  commercial  topical 
retinoid formulation manufacture known by the author.

increase in TEWL is believed to be linked to a perturbation of 
the  stratum  corneum  (SC)  water  barrier  function.41,42 
Although  retinoids  augment  cell  proliferation,  this  yields  a 
short-term decline in ceramide biosynthesis. This reduction 
in  the  production  of  ceramides,  a  key  constituent  of  the 
water  barrier  of  the  SC,  may  partly  account  for  the  xerosis 
observed with retinoid use.43

Typically  within  four  days  of  starting  retinoid  therapy,  the 
side  effects  commonly  associated  with  these  agents  become 
apparent. These side effects can usually be alleviated by directing 
the patient to apply small amounts of the retinoid at less frequent 
intervals.  Applying  the  retinoid  along  with  a  barrier  repair 
moisturizer  (see  Chapter  19,  Barrier  Repair  Ingredients),  or  on 
top of a moisturizer or oil-containing product reduces retinoid 
absorption  and  eases  side  effects.  At  the  beginning  of  retinoid 
therapy, it is advisable to suggest that a patient use the product 
once and wait four days to gauge any skin irritation. If excessive 
redness,  flaking,  or  stinging  occurs,  then  the  retinol  product 
should be used every three to four days for the first two weeks. 
The  patient  can  then  begin  to  apply  the  retinoid  every  other 
night for two weeks. After tolerating the retinoid for two weeks 
every  other  night,  the  patient  can  switch  to  nightly  use.  The 
lowest available dose should be started initially. Once the patient 
is nightly applying the retinol on a consistent basis, the strength 
of  the  agent  used  can  be  increased.  The  irritation  seen  with 
retinoids  at  the  beginning  of  therapy  is  the  reason  for  poor 
patient compliance with this ingredient. Consequently, patients 
should  be  given  clear  instructions  on  how  to  begin  product 
usage.  It  is  important  to  remember  that  the  entire  skin  care  
regimen  and  order  of  products  applied  greatly  affects  the 
tolerability and efficacy of retinoids.

Retinoids  possess  neither  phototoxic  nor  photosensitizing 
activity; therefore, they can be used even by people getting sun 
exposure.  Retinoids  should  not  be  used  by  women  who  are 
pregnant or breastfeeding.

 SIGNIFICANT BACKGROUND

An  increasing  compilation  of  clinical  data  suggests  that  the 
topical application of retinoids can mitigate and even somewhat 
reverse  mild-to-moderate  symptoms  of  photoaging.44–47  
[Please see Chapter 83, Retinoids (Retinol), for a discussion of 
such effects delivered by topical retinoids.] This is an important 
area of continuing clinical study of these agents. Oral retinoids 
are already being used to treat photodamage.

 FORMULATION CONSIDERATIONS

Types of OTC Retinoids

Retinol-containing  products  must  be  manufactured  and 
packaged in special low-light conditions to ensure stability, as 
retinol is degraded immediately upon exposure to light. Other 
ingredients such as benzoyl peroxide can affect the stability of 
retinoids,  especially  upon  exposure  to  light.40  Some  products 
include selected antioxidants added to maintain stability. Most 
OTC products contain 0.04 to 0.1 percent retinol.

 USAGE CONSIDERATIONS

Skin  irritation,  desquamation,  and  redness  are  the  most 
frequent side effects associated with topical retinoid use. Dry 
skin,  likely  due  to  an  increase  in  transepidermal  water  loss 
(TEWL)  characteristic  of  topical  retinoid  use,  is  also  a 
common  complaint  of  patients  treated  with  retinoids.  The 

rEtinol  Retinol  is  a  fat-soluble  diterpenoid  that  belongs  to 
the  vitamin  A  or  “retinoid”  family  of  molecules  (Figure  79-2). 
Retinol  is  synthesized  from  the  breakdown  of  β-carotene.  
It is a prodrug that can be converted to all-trans retinoic acid in 
the skin. This change to retinoic acid within the keratinocytes 
is essential for retinol to be active.48 Although it is a precursor 
to  retinoic  acid,  retinol  is  classified  as  a  cosmetic  rather  than 
a drug; therefore, it is used in numerous OTC formulations.49 
Further,  because  cosmetic  companies  cannot  claim  that  their 
retinol products exert a biologic action, retinol is listed on many 
cosmetic products as an “inactive ingredient.” There is no FDA 
monograph  for  retinol  supporting  claims  that  it  ameliorates 
acne  or  photodamaged  skin.  This  regulatory  loophole  has 
only  enhanced  the  views  of  some,  based  on  the  instability 
and  fleeting  shelf  life  of  early  forms  of  retinol,  that  retinol 

 
C H A P T E R  79  ■   R E T I N O L ,  R E T I N Y L   E S T E R S ,  A N D   R E T I N O I C   AC I D  

CH3

CH3

CH3

O

CH3

CH3

CH3

CH3

CH3

CH3

CH3

CH3

CH3

O

R

OH

COOH

CH3

CH3

CH3

CH3

CH3

CH3

Retinyl ester

Retinol

Retinoic acid

CH3

CH3

Retinoic acid

▶

fiGURE 79-2  Chemical formulas for retinol and other retinoids.

309

CH2OH

exhibits  minimal,  if  any,  biologic  activity.  Notably,  though, 
retinol-containing  products  may  have  only  minute  amounts 
of retinol, may be manufactured and packaged incorrectly, or 
may be formulated with ingredients that undermine stability. 
As a result, not all retinol-containing products are efficacious. 
Nevertheless,  retinol  has  been  shown  to  display  significant 
biologic action and efficacy at the proper doses. Retinol must 
be  distinguished  from  retinoid  esters  such  as  RP  and  retinyl 
linoleate.  Many  companies  claim  that  their  product  contains 
“retinol” when, in fact, the product contains these esters, which 
are  less  effective  than,  and  do  not  penetrate  into  the  skin  as 
well as, retinol.

RETinoL   EsTERs  RP  is  a  storage  form  of  retinol  and 
the  main  form  of  vitamin  A  found  naturally  in  the  skin  
(Figure  79-2).21  It  was  also  the  subject  of  a  controversial 
EWG  report  in  the  summer  of  2010  that  warned  of 
possible  photocarcinogenicity  associated  with  RP-containing 
sunscreens (see the Safety Issues section above). In 2005, Yan 
et  al.  investigated  the  phototoxicity  of  RP,  anhydroretinol 
(AR),  and  5,6-epoxyretinyl  palmitate  (5,6-epoxy-RP)  in 
human skin Jurkat T-cells with and without light irradiation. 
Little  damage  occurred  from  irradiation  of  cells  in  the 
absence of a retinoid, but the presence of RP, 5,6-epoxy-RP 
or AR (50, 100, 150, and 200 µM) led to DNA fragmentation, 
with  apoptosis  occurring  at  retinoid  concentrations  of 
at  least  100  µM.  The  researchers  concluded  that  DNA 
damage  and  cytotoxicity  are  engendered  by  RP  and  its 
photodecomposition products in conjunction with exposure 
to UVA and visible light. In addition, they found that UVA 
irradiation  of  these  retinoid  products  yielded  free  radicals 
that promote DNA strand cleavage.21

Based on the observation that exogenous RP builds up from 
topically applied cosmetic and skin care formulations, Yan et al., 
in 2006, studied the time course for the accumulation and disap-
pearance of RP and retinol in the stratified layers of female SKH-1 
mice  skin  singly  or  repeatedly  dosed  with  topical  creams 
containing  0.5  or  2  percent  RP.  The  investigators  noted  that 
within 24 hours of application, RP quickly diffused into the SC 
and epidermal skin layers. RP and retinol levels were highest in 
the  epidermis,  lowest  in  the  dermis,  highest  in  the  epidermis, 
lowest in the dermis, and intermediate in the SC. In separated 
skin layers and intact skin, RP and retinol levels decreased over 
time, but RP levels were higher than controls for 18 days. The 
researchers concluded that topically applied RP altered the nor-
mal physiological levels of RP and retinol in mouse skin.50

 CONCLUSION

Prescription  retinoids  have  convincingly  been  shown  to  be 
effective  for  acne  treatment.  Although  retinol  has  not  been 
studied in acne, it is reasonable to assume that it will exhibit 
similar  effects  because  it  is  converted  to  retinoic  acid  in  the 
skin. Retinol is unstable, so not all formulations are efficacious. 
It is impossible to ascertain by reading the label which products 

are  manufactured  and  packaged  properly;  therefore,  using 
reputable  brands  is  the  best  approach.  Retinol  products  are 
most efficacious when used at night, when degradation by light 
is minimal. With respect to the controversy swirling around RP, 
the  author  advises  patients  to  avoid  daytime  use  of  products 
with  RP  unless  they  use  a  concomitant  SPF.  The  order  of 
ingredients placed on the skin is important when retinoids are 
used  because  other  ingredients  can  affect  the  absorption  and 
stability of retinoids.

REFERENCES

1.  Eichler O, Sies H, Stahl W. Divergent optimum levels of lycopene, 
beta-carotene  and  lutein  protecting  against  UVB  irradiatioin  in 
human fibroblasts. Photochem Photobiol. 2002;75:503.

2.  Dinkova-Kostova AT. Phytochemicals as protectors against ultra-
violet  radiation:  Versatility  of  effects  and  mechanisms.  Planta 
Med. 2008;74:1548.

3.  Karrer P, Morf R, Schopp K. Zur kenntnis des vitamin-a aus fis-

chtranin. Helv Chim Acta. 1931;14:1036.

4.  Thielitz A, Abdel-Naser MB, Fluhr JW, et al. Topical retinoids in 
acne  –  An  evidence-based  overview.  Dtsch  Dermatol  Ges. 
2008;6:1023.

5.  Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the 
management  of  acne:  An  update  from  the  Global  Alliance  to 
Improve  Outcomes  in  Acne  group.  J  Am  Acad  Dermatol. 
2009;60:S1.

6.  Alexis AF. Clinical considerations on the use of concomitant ther-
apy in the treatment of acne. J Dermatolog Treat. 2008;19:199.
7.  Amichai B, Shemer A, Grunwald MH. Low-dose isotretinoin in 
the treatment of acne vulgaris. J Am Acad Dermatol. 2006;54:644.
8.  Akhavan  A,  Bershad  S.  Topical  acne  drugs:  Review  of  clinical 
properties,  systemic  exposure,  and  safety.  Am  J  Clin  Dermatol. 
2003;4:473.

9.  Fluhr JW, Vienne MP, Lauze C, et al. Tolerance profile of retinol, 
retinaldehyde and retinoic acid under maximized and long-term 
clinical conditions. Dermatology. 1999;199(Suppl 1):57.

10.  Keller KL, Fenske NA. Uses of vitamins A, C, and E and related 
compounds  in  dermatology:  A  review.  J  Am  Acad  Dermatol. 
1998;39:611.

11.  Chandraratna  RA.  Tazarotene  –  First  of  a  new  generation  of 
receptor-selective retinoids. Br J Dermatol. 1996;135(Suppl 49):18.
12.  Chytil F, Ong D. Cellular retinoid-binding proteins. In: Sporn MB, 
Roberts  A,  Goodman  D,  eds.  The  Retinoids.  Vol.  2.  Orlando: 
Academic Press; 1984:89–123.

13.  Giguere V, Ong ES, Segui P, et al. Identification of a receptor for 

the morphogen retinoic acid. Nature. 1987;330:624.

14.  Petkovich  M,  Brand  NJ,  Krust  A,  et  al.  A  human  retinoic  acid 
receptor which belongs to the family of nuclear receptors. Nature. 
1987;330:444.

15.  Kligman L, Kligman AM. Photoaging – Retinoids, alpha hydroxy 
acids, and antioxidants. In: Gabard B, Elsner P, Surber C, Treffel P, 
eds.  Dermatopharmacology  of  Topical  Preparations.  New  York: 
Springer; 2000:383.

16.  Pfahl M. The molecular mechanism of retinoid action. Retinoids 

today and tomorrow. Retinoids Dermatol. 1996;44:2.

17.  Petkovich  M.  Regulation  of  gene  expression  by  vitamin  A:  The 
role of nuclear retinoic acid receptors. Annu Rev Nutr. 1992;12:443.
18.  Lippman SM, Lotan R. Advances in the development of retinoids 

as chemopreventive agents. J Nutr. 2000;130:479S.

19.  Fu,  PP,  Xia  Q,  Boudreau  MD,  et  al.  Physiological  role  of  retinyl 

palmitate in the skin. Vitam Horm. 2007;75:223.

20.  Duell  EA,  Kang  S,  Voorhees  JJ.  Unoccluded  retinol  penetrates 
human skin in vivo more effectively than unoccluded retinyl pal-
mitate or retinoic acid. J Invest Dermatol. 1997;109:301.

 
310 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

21.  Yan J, Xia Q, Cherng SH, et al. Photo-induced DNA damage and 
photocytotoxicity  of  retinyl  palmitate  and  its  photodecomposi-
tion products. Toxicol Ind Health. 2005;21:167.

22.  Bikowski JB. Mechanisms of the comedolytic and anti-inflammatory 

properties of topical retinoids. J Drugs Dermatol. 2005;4:41.
23.  Varani J, Nickoloff BJ, Dixit VM, et al. All-trans retinoic acid stim-
ulates growth of adult human keratinocytes cultured in growth 
factor-deficient medium, inhibits production of thrombospondin 
and  fibronectin,  and  reduces  adhesion.  J  Invest  Dermatol. 
1989;93:449.

24.  Waller JM, Dreher F, Behnam S, et al. ‘Keratolytic’ properties of 
benzoyl peroxide and retinoic acid resemble salicylic acid in man. 
Skin Pharmacol Physiol. 2006;19:283.

25.  Heymann  WR.  Toll-like  receptors  in  acne  vulgaris.  J  Am  Acad 

Dermatol. 2006;55:691.

26.  Liu PT, Krutzik SR, Kim J, et al. Cutting edge: All-trans retinoic 
acid  down-regulates  TLR2  expression  and  function.  J  Immunol. 
2005;174:2467.

27.  Selway JL, Kurczab T, Kealey T, et al. Toll-like receptor 2 activa-
tion  and  comedogenesis:  Implications  for  the  pathogenesis  of 
acne. BMC Dermatol. 2013;13:10.

28.  Kang S, Cho S, Chung JH, et al. Inflammation and extracellular 
matrix  degradation  mediated  by  activated  transcription  factors 
nuclear  factor-kappaB  and  activator  protein-1  in  inflammatory 
acne lesions in vivo. Am J Pathol. 2005;166:1691.

29.  Emanuele  E,  Bertona  M,  Altabas  K,  et  al.  Anti-inflammatory 
effects of a topical preparation containing nicotinamide, retinol, 
and 7-dehydrocholesterol in patients with acne: A gene expres-
sion study. Clin Cosmet Investig Dermatol. 2012;5:33.

30.  Downie MM, Sanders DA, Kealey T. Modelling the remission of 
individual acne lesions in vitro. Br J Dermatol. 2002;147:869.
31.  Agak GW, Qin M, Nobe J, et al. Propionibacterium acnes induces 
an IL-17 response in acne vulgaris that is regulated by vitamin A 
and vitamin D. J Invest Dermatol. 2013 Aug 7. [Epub ahead of print]
32.  Trivedi  NR,  Gilliland  KL,  Zhao  W,  et  al.  Gene  array  expression 
profiling  in  acne  lesions  reveals  marked  upregulation  of  genes 
involved in inflammation and matrix remodeling. J Invest Dermatol. 
2006;126:1071.

33.  Farrell LN, Strauss JS, Stranieri AM. The treatment of severe cystic 
acne  with  13-cis-retinoic  acid.  Evaluation  of  sebum  production 
and  the  clinical  response  in  a  multiple-dose  trial.  J  Am  Acad 
Dermatol. 1980;3:602.

34.  Xia Q, Yin JJ, Wamer WG, et al. Photoirradiation of retinyl palmi-
tate in ethanol with ultraviolet light – Formation of photodecom-
position  products,  reactive  oxygen  species,  and  lipid  peroxides. 
Int J Environ Res Public Health. 2006;3:185.

35.  Wang  SQ,  Dusza  SW,  Lim  HW.  Safety  of  retinyl  palmitate  in 
sunscreens: A critical analysis. J Am Acad Dermatol. 2010;63:903.
36.  Burnett ME, Wang SQ. Current sunscreen controversies: A critical 

review. Photodermatol Photoimmunol Photomed. 2011;27:58.

37.  Yin  JJ,  Xia  Q,  Fu  PP.  UVA  photoirradiation  of  anhydroretinol  – 
Formation  of  singlet  oxygen  and  superoxide.  Toxicol  Ind  Health. 
2007;23:625.

38.  Xia Q, Yin JJ, Cherng SH, et al. UVA photoirradiation of retinyl 
palmitate – Formation of singlet oxygen and superoxide, and their 
role in induction of lipid peroxidation. Toxicol Lett. 2006;163:30.
39.  Cherng SH, Xia Q, Blankenship LR, et al. Photodecomposition of 
retinyl  palmitate  in  ethanol  by  UVA  light-formation  of  photode-
composition products, reactive oxygen species, and lipid peroxides. 
Chem Res Toxicol. 2005;18:129.

40.  Martin B, Meunier C, Montels D, et al. Chemical stability of ada-
palene  and  tretinoin  when  combined  with  benzoyl  peroxide  in 
presence and in absence of visible light and ultraviolet radiation. 
Br J Dermatol. 1998;139(Suppl 52):8.

41.  Tagami H, Tadaki T, Obata M, et al. Functional assessment of 
the stratum corneum under the influence of oral aromatic reti-
noid (etretinate) in guinea-pigs and humans. Comparison with 
topical  retinoic  acid  treatment.  Br  J  Dermatol.  1992;  
127:470.

42.  Effendy I, Kwangsukstith C, Lee LY, et al. Functional changes in 
human  stratum  corneum  induced  by  topical  glycolic  acid: 
Comparison  with  all-trans  retinoic  acid.  Acta  Derm  Venereol. 
1995;75:455.

43.  Griffiths CE, Voorhees JJ. Human in vivo pharmacology of topical 

retinoids. Arch Dermatol Res. 1994;287:53.

44.  Rawlings  AV,  Stephens  TJ,  Herndon  JH,  et  al.  The  effect  of  a  
vitamin A palmitate and antioxidant-containing oil-based mois-
turizer  on  photodamaged  skin  of  several  body  sites.  J  Cosmet 
Dermatol. 2013;12:25.

45.  Tucker-Samaras  S,  Zedayko  T,  Cole  C,  et  al.  A  stabilized  0.1% 
retinol facial moisturizer improves the appearance of photodam-
aged  skin  in  an  eight-week,  double-blind,  vehicle-controlled 
study. J Drugs Dermatol. 2009;8:932.

46.  Kikuchi K, Suetake T, Kumasaka N, et al. Improvement of photo-
aged facial skin in middle-aged Japanese females by topical reti-
nol (vitamin A alcohol): A vehicle-controlled, double-blind study. 
J Dermatolog Treat. 2009;20:276.

47.  Antoniou  C,  Kosmadaki  MG,  Stratigos  AJ,  et  al.  Photoaging: 
Prevention and topical treatments. Am J Clin Dermatol. 2010;11:95.
48.  Kurlandsky SB, Xiao JH, Duell EA, et al. Biological activity of all-
trans  retinol  requires  metabolic  conversion  to  all-trans  retinoic 
acid  and  is  mediated  through  activation  of  nuclear  retinoid 
receptors in human keratinocytes. J Biol Chem. 1994;269:32821.
49.  Baumann  L,  Saghari  S.  Retinoids.  In:  Baumann  L,  Saghari  S, 
Weisberg E. eds. Cosmetic Dermatology: Principles and Practice. 2nd ed. 
New York: McGraw-Hill; 2009:256–62.

50.  Yan J, Wamer WG, Howard PC, et al. Levels of retinyl palmitate 
and  retinol  in  the  stratum  corneum,  epidermis,  and  dermis  of 
female  SKH-1  mice  topically  treated  with  retinyl  palmitate. 
Toxicol Ind Health. 2006;22:181.

 
C H A P T E R   8 0

Silver

C H A P T E R  80  ■   S I LV E R  

311

Activities:

Anti-inflammatory,  antibacterial,  antifungal,  antiviral, 
wound healing, antitumorigenic

TABLE 80-1
Pros and Cons of Silver

Pros
Strong antibacterial activity with minimal 

Cons
Theoretical risk of contact dermatitis

Important Chemical Components:
Silver ion Ag+

Origin Classification:

Natural element

Personal Care Category:

Acne therapy, antimicrobial

Recommended  for  the  following  Baumann  Skin 
Types:

DSNT, DSPT, DSNW, DSPW, OSNT, OSNW, OSPT, and 
OSPW.  This  is  the  treatment  of  choice  for  dry  acne-
prone skin.

 SOURCE

Silver is a naturally occurring chemical element on our planet 
(with  the  chemical  symbol  Ag).  It  is  obtained  by  mining. 
Nanoparticles are produced in the laboratory and are designed 
to  be  a  particular  size  and  shape.  Silver  salts  are  formed  by 
combining silver with other agents. This can occur spontane-
ously or in the laboratory setting.

 HISTORY

The  medicinal  use  of  silver  dates  back  at  least  to  the  time  of 
ancient Greek historian Herodotus, who lived in the 5th century 
BCE and stated that when the King of Persia went to war, he 
would  take  boiled  water  stored  in  flagons  of  silver  to  treat 
wounds.1,2  But  the  awareness  of  metallic  silver  dates  back 
further to 4,000 BCE.2 The Phoenicians were known to store 
water  and  other  liquids  in  silver  vats  to  prevent  them  from 
spoiling. Although the metallic silver in the vats was not soluble 
in water and therefore would not have antimicrobial properties, 
the beneficial properties noted by the Romans and Phoenicians 
can  be  explained  by  the  fact  that  leeching  of  silver  ions  into 
water occurred when the water was stored for long periods of 
time.3  Silver  nitrate  was  cited  in  a  Roman  pharmacopeia 
published  in  69  BCE  (Table  80-1).2  Over  three  hundred  years 
earlier,  Hippocrates,  the  father  of  medicine,  documented  the 
beneficial  healing and disease-modifying properties of silver.4 
Avicenna is reported to have used silver as a blood purifier circa 
980  CE  and  Paracelsus  used  silver  systemically,  and  topically 
applied silver nitrate to wounds in the early 1500s, a practice 
that has continued into modern times.2

In 1869, Raulin observed that the fungus Aspergillus niger could 
not grow in silver vessels.5 The Swiss botanist von Nägeli was 

risk of bacterial resistance

Works quicker than most acne ingredients
No risk of irritation especially in dry skin types
Inexpensive
Anti-inflammatory
Long history of use
Does not impair barrier
Can be used before and after procedures, 

including facials

Antifungal and antiviral activity

Not FDA approved for acne
Not covered by an FDA monograph
More clinical studies needed
Not FDA approved for nail and foot fungus
Oral use associated with argyria

studying  silver  when  he  devised  the  term  “oligodynamic”  to 
describe any metal that exhibits bactericidal properties at minute 
concentrations (oligos, small + dynamis, power). Silver nitrate was 
introduced by Credé in 1884 for the prevention of ophthalmia 
neonatorum,  an  infection  in  the  eyes  of  newborn  babies  also 
known as gonorrheal ophthalmia.2,6

In  1901,  Philadelphia  doctor  Albert  Barnes  and  German 
chemist Hermann Hille developed Argyrol, a mild vacuum-dried 
silver  nitrate  precipitate  of  the  protein  vitellin  (derived  from 
wheat),  which  they  marketed  in  1902  to  treat  gonorrhea  and 
gonorrheal  neonatal  blindness.  Argyrol  contained  up  to  
30 percent silver and was also indicated for catarrhal conjunctivitis 
and  follicular  conjunctivitis  in  addition  to  ophthalmia 
neonatorum.7 Barnes convinced Hille not to patent the product, 
but  vigorously  defended  it  against  imitators.  They  marketed 
directly  to  physicians.  Barnes  bought  out  Hille  and  was  a 
millionaire by 1907. He sold the enterprise in 1928, subsequently 
amassing  a  world  famous  art  collection,  including  works  by, 
among  others,  Cézanne,  Matisse,  Picasso,  Modigliani,  Renoir, 
van  Gogh,  Degas,  Seurat,  and  Rousseau,  now  housed  in  the 
Barnes Foundation in Philadelphia.7 Not long after Barnes sold 
his  business,  antibiotics  were  discovered  and  displaced  the  
silver-based Argyrol.

In the early 1900s, people often deposited silver dollars in milk 
bottles  to  prolong  the  milk’s  freshness.  Before  the  advent  of 
penicillin,  clinicians  placed  silver  wafers  on  contaminated 
wounds during World War I to help prevent infection. In fact, 
before antibiotics were introduced, silver was the most impor-
tant  antimicrobial  agent  and  a  major  component  in  wound 
healing.2  Moyer  is  credited  with  resurrecting  interest  in  silver  
(in the form of silver nitrate) in the 1960s,8 but newer delivery 
technologies  fuel  the  more  recent  interest  in  the  medical 
applications of the element.

Indeed,  silver  compounds,  in  metallic,  nanocrystalline,  and 
ionic  preparations,  have  exhibited  broad  antibacterial  activity 
and  have  garnered  recent  interest  for  topical  antiseptic  use  in 
wound  dressings.9  Nanocrystalline  silver  dressings  were  intro-
duced  commercially  as  antimicrobial  dressings  in  1998.10  

 
312  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Today silver is used in dressings, catheters, cleansers, ophthalmic 
ointments,  and  many  other  medical  products.  It  is  so  popular 
that  it  has  been  estimated  that  15  metric  tons  of  silver  were 
incorporated into medical products worldwide in 2010 alone.11 
Silver is also being used in personal care products, textiles, and 
water purification devices.

 CHEMISTRY

Silver  is  element  number  47  on  the  periodic  table  and  is 
designated  as  Ag,  which  comes  from  the  Latin  word  argentum 
(árgyros in Greek), derived from the Indo-European root “arg-,” 
meaning “shining,” “white,” or “gray.” It has the highest electrical 
conductivity  of  all  metals  and  is  classified  as  a  noble  metal. 
Noble metals resist corrosion and oxidation in moist environ-
ments and are usually valuable due to their limited amounts. 
Other  noble  metals  include  ruthenium,  rhodium,  palladium, 
osmium, iridium, platinum, and gold. Silver is stable in pure air 
and  water,  but  tarnishes  when  it  is  exposed  to  air  or  water 
containing ozone or hydrogen sulfide.

Metallic  silver  is  insoluble  in  water;  however,  it  is  highly 
reactive and easily converts to salt forms such as Ag+, Ag2+, Ag3+, 
and Ag0. These salt forms render silver compounds such as silver 
nitrate (AgNO3) and silver chloride (AgCl) soluble in water. Silver 
is  present  in  these  four  oxidation  states.  Ag0  and  Ag+  are  the 
most abundant. The most common oxidation state of silver is +1 
of  which  AgNO3  is  an  example.  Less  common  are  the  +2 
compounds (e.g., silver(II) fluoride, AgF2), and the even less common 
+3  and  +4  compounds.12  Single-charged  silver  Ag+  is  the  most 
biologically active form. In the environment, silver is often naturally 
complexed with sulfide, sulfate, bicarbonate, or chlorides.13

There are several designations used when describing the type 

of silver used in topical skin formulations:

1.  Colloidal  silver:  This  term  describes  a  suspension  of  silver 

particles in an aqueous base.

2.  Nanosilver:  Ag  nanoparticles  can  be  produced  in  various 
sizes and shapes.3 Nanoparticles range from 1 to 100 nm in 
at least one dimension.

Silver  exhibits  many  activities  that  account  for  its  various 
effects on infectious organisms. Silver ions are known to react 
with nucleophilic amino acid residues in proteins, and attach to 
membrane or enzyme proteins leading to protein denaturation. 
Silver is also known to inhibit a number of oxidative enzymes 
such as yeast alcohol dehydrogenase, the uptake of succinate 
by membrane vesicles, and the respiratory chain of bacteria, as 
well as causing metabolite efflux, interfering with DNA replica-
tion,  and  affecting  the  NaC-translocating  NADH:  ubiquinone 
oxidoreductase system.14,15

 ORAL USES

Several  online  businesses  enthusiastically  promote  oral 
colloidal silver products as supplements and for prevention and 
treatment  of  many  diseases.  The  US  Food  and  Drug 
Administration  (FDA)  stated  in  Sec.  310.548  of  a  2012  ruling 
that “there is a lack of adequate data to establish general recog-
nition  of  the  safety  and  effectiveness  of  colloidal  silver 
ingredients or silver salts for over-the-counter (OTC) use in the 
treatment  or  prevention  of  any  disease.”16  This  ruling  was  in 
response to the indiscriminate use of oral silver products, some 
of  which  led  to  toxicity  such  as  argyria.17  Oral  use  of  silver-
containing products is not advised until well-designed research 
trials demonstrate safety and efficacy.

 TOPICAL USES

There  are  many  silver-containing  topical  formulations  on  the 
market, some containing silver ions and some with nanoparticles. 
The topical absorption of silver into the skin depends on several 
factors  including  the  vehicle  used,  concentration,  charge, 
particle  size,  particle  shape,  whether  it  is  a  silver  salt  or  a 
nanoparticle, and the coating (in the case of nanoparticles). As 
expected,  smaller  nanometer  particles  (15 nm  in  rat  skin  and  
6  nm  in  human  skin)  penetrate  better  than  larger  particles 
(102 nm and 198 nm, respectively).18

Colloidal  silver  is  the  most  common  preparation  found  in 
OTC  silver-containing  preparations,  and  the  efficacy  varies 
based on the vehicle, concentration of silver in parts per million, 
the pH, and the length of time of exposure. Nanosilver behaves 
very  differently  than  colloidal  silver  preparations  because  the 
small  size  yields  different  characteristics,  primarily  due  to  its 
high  surface-area-to-volume  ratio.  This  renders  the  molecules 
more reactive in some cases. The most common form of silver 
used topically is silver sulfadiazine 1 percent cream, which has a 
long record of successful use as a safe and effective treatment to 
reduce  Pseudomonas  infection  in  wounds.  Silver  sulfadiazine  1 
percent cream contains a sulfa antibiotic, so it cannot be used by 
individuals allergic to sulfa-containing medications. It is impor-
tant  to  note  that  sulfa  and  sulphur  are  different  compounds. 
Sulfur smells like rotten eggs and is often found in acne medica-
tions. Sulfa is found in the antibiotic known as Bactrim and an 
allergy to it can be life threatening.

Antibacterial Uses
Many  healthcare  products  contain  silver,  including  silver-
coated  catheters,  wound  dressings,  and  pre-procedure 
cleansers.15  Silver  has  been  shown  to  deliver  antimicrobial 
effects  against  bacteria,  viruses,  and  fungi  and  to  inhibit  the 
formation  of  bacterial  biofilms.15,19  Despite  the  long-standing 
and increasing use of silver ions and nanoparticles, its antibac-
terial  mode  of  action  remains  unclear  but  most  data  suggest 
that  the  bactericidal  effect  is  due  to  damage  to  the  bacterial 
membrane.  Silver  exerts  its  bactericidal  activity  by  acting  on 
the  bacteria  at  several  levels  including  the  cell  membrane, 
enzymes,  uncoupling  of  the  respiratory  chain  from  oxidative 
phosphorylation,11  actions  on  DNA,  and  induction  of  proton 
leakage through the bacterial membrane, resulting in complete 
de-energization and, ultimately, cell death.20

Antibiotic resistance is of great interest in public health and 
medicine  right  now,  including  the  acne  realm  where 
Propionibacterium acnes resistance rates are estimated to be as high 
as  60  percent  in  some  patient  populations.21  Erythromycin, 
methicillin, and clindamycin are the most common antibiotics to 
which  bacteria  have  reportedly  developed  resistance.22 
Combining  benzoyl  peroxide  (BPO)  with  erythromycin  
or  clindamycin  has  been  proven  to  prevent  the  emergence  of 
resistant strains of P. acnes;22–25 therefore, the current clinical acne 
recommendation is to include BPO in topical antiacne regimens 
that  utilize  antibiotics  (see  Chapter  76,  Benzoyl  Peroxide).25 
However, BPO kills bacteria by producing free radicals, which 
may increase skin aging and inflammation, so another option to 
prevent antibiotic-resistant P. acnes is needed. Silver may be the 
solution  to  antibacterial  resistance  in  acne  patients.  Although 
silver-resistant  bacteria  have  been  reported  since  1975,26–36  
lack  of  standardized  methodology  for  assessing  bacterial 
susceptibility  to  Ag+,  small  sample  sizes,  and  differing  overall 
methodologies make it difficult to draw firm conclusions about 
the true incidence of antibiotic resistance to silver.37–39

 
Examples  of  silver-resistant  bacterial  strains  that  have  been 
isolated  include  Escherichia  coli,  Enterobacter  cloacae,  Klebsiella 
pneumoniae, Acinetobacter  baumannii, Salmonella  typhimurium,  and 
Pseudomonas  stutzeri,  but  resistant  P.  acnes  has  not  been 
reported.15,26,36,40 Unlike antibiotics, resistance to antiseptics such 
as silver is rare and sporadic. However, it is important to note 
that bacteria have been exposed to subinhibitory levels of silver 
for over four billion years and no widespread resistance has been 
evident  to  date,  whereas  widespread  antibiotic  resistance  has 
developed within the last 60 years.

Anti-inflammatory Uses
Noble  metals,  including  silver,  have  been  shown  for  years  to 
have anti-inflammatory capabilities.41–45 These effects seem to 
be  mediated  by  the  impact  that  silver  exerts  on  the  cytokine 
system. Silver nanoparticles suppress the activity of interleukin 
(IL)-6 and tumor necrosis factor (TNF)-α, IL-12, and IL-1β. The 
effects on the cytokine system account for why silver has been 
demonstrated to relieve rheumatoid arthritis symptoms.10

A  study  by  Nadworny  demonstrated  that  nanocrystalline 
silver  treatments  decreased  dinitrochlorobenzene  (DNCB)-
induced erythema and edema, increased apoptosis (programmed 
cell death) in dermal cells, and decreased matrix metalloprotein-
ase  (MMP)  and  proinflammatory  cytokine  expression.10  She 
postulated  that  the  decreased  TNF-α  seen  in  the  silver-treated 
animals resulted from the elimination of inflammatory cells by 
apoptosis. In 2005, Bhol and Schechter showed that nanocrystal-
line silver inhibited allergic contact dermatitis in mice, suppressed 
the  expression  of  TNF-α  and  IL-12,  and  induced  apoptosis  of 
inflammatory cells.46 The previous year, Bhol et al. used DNCB 
to induce allergic contact dermatitis in a guinea pig model and 
found that topical nanocrystalline silver cream was comparably 
effective  as  topical  steroids  and  immunosuppressants  in  dose-
dependently reducing erythema.47

Anticancer Activity
Silver complexes containing various types of ligands such as 
carboxylic acids, amino acids, nitrogen, phosphorus, or sulfur 
donor ligands have shown significant antiproliferative effects. 
Although  the  mechanism  is  not  known,  it  is  thought  to  be 
due in part to the interactions of silver with DNA and pro-
teins.48  Silver  causes  apoptosis  when  combined  with  other 
agents  (ligands).  These  silver-ligand  complexes  have  been 
shown to exert greater cytotoxicity than the chemotherapeu-
tic agent cisplatin on certain cancer cells. Studies using silver 
complexes have revealed efficacy in the treatment of breast 
cancer.48

Wound Healing
Silver  sulfadiazine  cream  (Silvadeen™)  was  the  earliest 
commercially  available  silver-containing  preparation  to  treat 
wounds.  It  was  developed  in  the  1960s  for  the  treatment  of 
burns. It is known that P. acnes, the bacteria that causes acne 
and  forms  biofilms,  is  a  major  cause  of  wound  infections, 
especially after shoulder surgery, and could play a role in the 
development  of  granulomas  and  skin  infections  (due  to 
biofilms)  seen  after  dermal  filler  injections.19  For  this  reason, 
silver-containing  cleansers  such  as  Theraworx™  are  used  to 
cleanse  skin  prior  to  surgery  and  other  invasive  procedures 
such as urinary catheterization without the skin barrier damage 
caused  by  other  pre-surgical  cleansing  products  such  as 
chlorhexidine or Hibiclens™. Pre-procedure skin cleansers such 

C H A P T E R  80  ■   S I LV E R  

313

as GCP Skincare have been developed to cleanse skin prior to 
dermal filler injections (e.g., Juvéderm, Voluma, and Restylane), 
chemical  peels,  botulinum  toxin  (i.e.,  Botox  and  Dysport) 
injections,  facials,  and  other  cosmetic  procedures.  The  other 
pre-procedure cleansing options, chlorhexidine and Hibiclens, 
are contraindicated for use on the face. In addition, chlorhex-
idine  and  Hibiclens  cannot  be  used  before  chemical  peels 
because  they  impair  the  skin  barrier,49  which  could  lead  to 
increased  depth  of  the  chemical  peel  resulting  in  burning, 
postinflammatory  hyperpigmentation,  and  possible  scarring. 
These  colloidal  silver-containing  cleansers  are  safe  to  use  on 
wounded  skin,  including  after  surgery,  laser  treatments,  and 
chemical  peels.  In  addition  to  silver-containing  cleansers,  a 
recent trend toward the use of wound cover dressings that con-
tain  silver  has  resulted  in  a  large  selection  of  commercially 
available  foam,  film,  hydrocolloid,  gauze,  and  dressings  with 
hydrofiber technology impregnated with silver.15

Burns
AgNO3 has been used in burns but the reduction of AG+ to Ag0 
that occurs leaves the wound blackened. For this reason, silver 
sulfadiazine,  a  topical  antibiotic  cream  used  for  decades  to 
prevent secondary skin infections in wounds, is a more popular 
option  and  the  wound  healing  ointment  of  choice  of  many 
medical  professionals.  Another  formulation  marketed  as 
Silvazine in the United States is a topical cream that contains  
1  percent  silver  sulfadiazine  plus  0.2  percent  chlorhexidine 
digluconate in a water-immiscible cream base. It also exhibits 
antibacterial activity but the chlorhexidine can impair the skin 
barrier  and  cause  an  allergic  reaction,  so  silver  sulfadiazine 
alone is preferable.49

There  are  numerous  studies  in  the  literature  showing  the 
efficacy  of  silver-impregnated  dressings  for  wounds.  In  some 
cases, direct current electricity was used to accelerate the release 
of Ag+ from the bandage into the damaged tissue.50,51

In  addition  to  colloidal  silver  and  silver-impregnated 
dressings, nanoparticle silver in various forms has been used 
to treat burns. Treatment of murine infected burns with silver 
nanoparticles has increased the rate of healing and decreased 
scarring  in  comparison  with  silver  sulfadiazine.52  This  was 
accompanied  by  increased  expression  of  IL-10,  vascular 
endothelial growth factor, and interferon-γ, with reduced IL-6 
expression.  The  literature  includes  more  studies  of  silver 
products in burns and wounds that are beyond the scope of 
this chapter.

Acne
Acne is caused by the presence of the bacteria P. acnes, which 
leads to an inflammatory response in the skin. Silver functions 
as  a  bactericidal  and  anti-inflammatory  agent,  without  the 
production of free radicals seen with BPO. For this reason it is 
a  good  option  for  acne  treatment.  Silver  is  not  approved  by 
the FDA for use in acne, and has not been proven safe or effi-
cacious for this condition. (Acne medications with the excep-
tion  of  salicylic  acid  and  BPO  must  undergo  a  formal  FDA 
drug  approval  process.)  Despite  the  fact  that  formal  acne 
studies have not been performed, silver sulfadiazine has been 
used  “off-label”  for  this  purpose  for  years.  The  use  of  silver 
sulfadiazine for acne is limited by the risk of sulfa allergy and 
the thick white pasty consistency of the preparation. Silver-
containing  cleansers  and  textiles  are  other  options  for  acne 
treatment.

 
314 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Textiles
Textiles  coated  with  silver  have  been  shown  to  reduce  skin 
bacteria counts. Silver is incorporated into textiles by integrating 
silver nanoparticles into the polymer used to form yarn or by 
coating the yarn with silver.53 Some textiles have every strand 
coated while others coat every 5th or 6th strand. There does 
not  seem  to  be  a  difference  in  efficacy  between  the  textiles 
with  every  strand  coated  versus  every  5th  strand  coated; 
however, the textiles with every 5th strand coated are softer. 
The  loss  of  silver  during  washing  varies  between  textile 
technologies.  Fabrics  that  lose  a  negligible  amount  of  silver 
during washings and that are comfortable are preferable. These 
textiles  can  be  used  to  manufacture  pillowcases,  face  masks, 
and  shirts  to  treat  acne.  Textiles  containing  silver  have  been 
used  in  other  skin  disorders  such  as  atopic  dermatitis  but  no 
formal studies in acne have been conducted.

Atopic Dermatitis
One study in patients with atopic dermatitis showed that silver-
coated  textiles  were  able  to  reduce  Staphylococcus  aureus  density 
significantly  after  two  days  of  wearing,  lasting  until  the  end  of 
treatment (day 7) and even one week after removal of the textiles.54 
The  silver-coated  textiles,  compared  to  cotton,  were  able  to 
improve objective and subjective symptoms of atopic dermatitis 
significantly within two weeks without measurable side effects. 
One  technology  known  as  Padycare®  incorporates  silver  into 
micromesh material (82 percent polyamide, 18 percent lycra) for 
clothing  and  bedding.55  Textiles  have  the  added  benefit  of 
preventing  scratching  and  providing  protection  from  irritating 
substances and allergens. The amount of silver lost from textiles 
during washing can vary from 100 percent loss after four washings 
to less than one percent loss.56 Concerns have been raised about 
the silver leaking from the textiles into the water supply, killing 
beneficial bacteria used to treat the water.

 SAFETY ISSUES

Humans are exposed to silver on a daily basis, most commonly 
by ingestion in the diet via water and food.13 Other sources of 
silver  are  inhalation  of  silver  dust,  contact  with  jewelry, 
acupuncture needles, dental amalgams, cleaning products, and 
creams used to treat burns.13 Silver in any form is not carcino-
genic  and  is  not  thought  to  be  toxic  to  the  immune, 
cardiovascular, nervous, or reproductive systems.13

Colloidal silver preparations are much less likely to penetrate 
into the skin because of the large size of the silver ion. Recent 
concern about the safety of nanoparticles has emerged because 
of the ability of nanoparticles to enter the skin and possibly the 
circulatory system. Silver nanoparticles usually consist of 20 to 
15,000 silver atoms and are smaller than the required 100 nm or 
less to be called a “nanoparticle.”13 Of more than 800 consumer 
products  that  contain  nanomaterial,  30  percent  are  claimed  to 
contain silver particles.13 Studies have shown that nanosilver can 
penetrate  into  the  skin,  but  this  ability  depends  on  the  size, 
shape,  and  vehicle  used  as  well  as  the  length  of  exposure.  In 
2009, it was demonstrated for the first time that silver applied as 
nanoparticles  coated  with  polyvinylpirrolidone  was  able  to 
permeate  skin  and  enter  the  stratum  corneum  and  upper 
epidermis. The silver nanoparticle absorption through intact and 
damaged skin was very low but detectable.57 In 2013, topically 
applied  nanocrystalline  silver  dressings  were  applied  to  intact 
human skin destined to be removed via surgery to determine if 

the silver ions were absorbed into skin and subsequently into the 
circulation. The skin was surgically excised and then analyzed 
by tissue mass spectrometry, light microscopy, scanning electron 
microscopy  (SEM),  and  X-ray  diffusion  spectrography  (XRD). 
Silver  clusters  as  large  as  750  nm  could  be  discerned  in  the 
dermis. Pre- and post-dressing serum silver levels were compared 
and  there  was  no  rise  in  silver  in  serum  samples.  This  study 
shows  that  nanoparticles  of  silver  can  be  absorbed  into  the 
dermis but do not enter the circulatory system.58

Silver does not pose the toxic threat to humans that other heavy 
metals do. It is taken up in the intestine and passed through the 
blood, liver, and bone marrow, and, ultimately, is excreted in urine.

Argyria
Argyria  is  typically  an  irreversible  blue-gray  coloring  of  the 
skin, eyes, and mucous membranes caused by deposits of silver 
granules in regions around hair follicles and sweat ducts.59 The 
condition is rare and the vast majority of cases are due to oral 
exposure to silver. Argyria occurs when silver is absorbed into 
the circulatory system and precipitates in the dermis, usually in 
the  form  of  silver  sulfide.  Although  this  condition  does  not 
harm  an  individual’s  health,  it  is  disfiguring  and  usually 
permanent.  This  condition  is  one  of  the  reasons  the  FDA 
prohibited  the  use  of  oral  silver  to  treat  medical  conditions. 
There are a few reports in the literature of lasers being used to 
treat the blue-gray color characteristic of argyria.

 ENVIRONMENTAL IMPACT

Silver  naturally  occurs  in  our  environment,  but  rarely. 
Concentrations  can  be  elevated  by  activities  such  as  coal 
combustion,  manufacturing  of  electronic  goods,  and  disposal 
of photographic supplies. It is released into the air and water 
naturally  by  rain  and  rock  erosion.  The  general  population  is 
exposed to silver in drinking water and food. Dietary intake of 
silver is estimated at 70 to 90 µg per day.13

It has been shown that nanosilver in textiles washes out and 
enters the water supply. However, silver has been used for years 
in  water  treatment  plants  and  is  often  used  in  washing 
machines.13 Farmers are concerned that the antimicrobial effects 
of nanosilver will affect beneficial bacteria in the soil.60 A review 
by Wijnhoven et al. discussed the environmental impact of silver 
and  concluded  that  because  there  are  many  different  forms  of 
silver it is difficult to accurately predict the effects on the envi-
ronment  and  to  know  which  forms  of  silver  are  the  safest.13 
Nanosilver may have various effects because of its size, shape, 
and  different  properties.  Little  is  known  about  the  effects  of 
nanosilver on the environment and if it should prompt increased 
concern compared to naturally occurring silver ions.

 FORMULATION CONSIDERATIONS

Silver  metal  easily  dissolves  in  nitric  acid  yielding  AgNO3,  an 
inorganic,  transparent,  photosensitive,  crystalline  solid  that  is 
readily water soluble.61,62 Colloidal silver formulations are usually 
comprised of silver ions suspended in an aqueous solution.

Given  the  propensity  of  silver  to  complex  with  so  many 
molecules, it is obviously important to consider what interactions 
may occur between silver and other cosmeceutical ingredients. 
Silver reacts with proteins and amino acids and, therefore, would 
not be a good option to combine with peptides, growth factors, 
or stem cell ingredients.

 
Silver sulfadiazine is highly insoluble in water, which accounts 
for  its  thick  white  pasty  consistency  when  formulated  into  a 
topical cream.63

 USAGE CONSIDERATIONS

Silver reacts strongly with proteins. This should be taken into 
account when applying along with growth factor-, collagen-, or 
peptide-containing  ingredients  and  the  regimens  should  be 
adjusted to minimize contact between these ingredients.

 SIGNIFICANT BACKGROUND

The  antifungal  effects  of  spherical  silver  nanoparticles  
(nano-Ag)  on  fungal  pathogens  of  the  skin  have  been  investi-
gated.  Nano-Ag  showed  potent  activity  against  strains  of 
Trichophyton mentagrophytes and  Candida species. The activity of 
nano-Ag was comparable to that of amphotericin B, but superior 
to that of fluconazole.64 Silver has also been shown to have strong 
antiviral effects. Studies have not been conducted but it is likely 
that topical silver formulations can play a role in the treatment of 
nail fungus, foot fungus, and herpes simplex viral infections.

 CONCLUSION

Silver has been used as a medicinal therapy for centuries but is 
not  currently  FDA  approved  to  treat  any  medical  conditions 
including  acne.  Its  antimicrobial  and  anti-inflammatory 
activities, its gentleness to the skin barrier, and its usability on 
the face make it popular for pre- and post-procedure application, 
especially  in  relation  to  dermal  fillers,  botulinum  toxin 
injections,  and  chemical  peels.  It  is  used  off-label  for  many 
purposes but safety and efficacy trials are lacking. Silver may be 
a  good  adjuvant  for  acne  therapy  because  of  the  low  risk  of 
bacterial resistance, the lack of irritation, and the preservation 
of the skin barrier as contrasted to other acne medications such 
as retinoids, antibiotics, and BPO. However, further studies are 
necessary.

REFERENCES

1.  Blakeney  EH,  ed.  The  History  of  Herodotus  [Rawlinson  G,  trans.]. 

London: Dent & Sons, 1945:188.

2.  Alexander  JW.  History  of  the  medical  use  of  silver.  Surg  Infect 

(Larchmt). 2009;10:289.

3.  Jones VE. Nanocrystalline Silver: Use in wound care. In: Slevin M, ed. 
Current  Advances  in  the  Medical  Application  of  Nanotechnology. 
Manchester, UK: Bentham Books, 2012:25–31.

4.  Salcido RS. Silver: An old wine in a new bottle. Adv Skin Wound 

Care. 2006;19:472.

5.  Raulin J. Sci Nat. 1869;11:93. Berk (3) Abstr 1.
6.  Novak  JM.  Current  status  of  Credé  prophylaxis.  Am  J  Optom 

Physiol Opt. 1984;61:340.

7.  Hodson TJ, Gillies WE. Argyrol, argyrosis and the acquisition of 

art. Aust N Z J Ophthalmol. 1985;13:391.

8.  Moyer  CA,  Brentano  L,  Gravens  DL,  et  al.  Treatment  of  large 
human burns with 0.5 percent silver nitrate solution. Arch Surg. 
1965;90:812.

9.  Lipsky  BA,  Hoey  C.  Topical  antimicrobial  therapy  for  treating 

chronic wounds. Clin Infect Dis. 2009;49:1541.

10.  Nadworny PL, Wang J, Tredget EE, et al. Anti-inflammatory activ-
ity of nanocrystalline silver in a porcine contact dermatitis model. 
Nanomedicine. 2008;4:241.

11.  Randall CP, Oyama LB, Bostock JM, et al. The silver cation (Ag+): 
Antistaphylococcal activity, mode of action and resistance studies. 
J Antimicrob Chemother. 2013;68:131.

C H A P T E R  80  ■   S I LV E R  

315

12.  Riedel S, Kaupp M. The highest oxidation states of the transition 

metal elements. Coord Chem Rev. 2009;253:606.

13.  Wijnhoven SWP, Peijnenburg WJGM, Herberts CA, et al. Nano-
silver – A review of available data and knowledge gaps in human 
and environmental risk assessment. Nanotoxicology. 2009;3:109.
14.  Hostýnek JJ, Hinz RS, Lorence CR, et al. Metals and the skin. Crit 

Rev Toxicol. 1993;23:171.

15.  Percival SL, Bowler PG, Russell D. Bacterial resistance to silver in 

wound care. J Hosp Infect. 2005;60:1.

16.  U.S. Food and Drug Administration. Code of Federal Regulations 
Title  21,  Subchapter  D  –  Drugs  for  Human  Use.  http://www 
.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm? 
fr=310.548. Accessed October 19, 2013.

17.  Fung  MC,  Bowen  DL.  Silver  products  for  medical  indications: 

Risk-benefit assessment. J Toxicol Clin Toxicol. 1996;34:119.

18.  Labouta HI, Schneider M. Interaction of inorganic nanoparticles 
with  the  skin  barrier:  Current  status  and  critical  review. 
Nanomedicine. 2013;9:39.

19.  Percival SL, Bowler PG, Dolman J. Antimicrobial activity of silver-
containing dressings on wound microorganisms using an in vitro 
biofilm model. Int Wound J. 2007;4:186.

20.  Dibrov P, Dzioba J, Gosink KK, et al. Chemiosmotic mechanism 
of  antimicrobial  activity  of  Ag(+)  in  Vibrio  cholerae.  Antimicrob 
Agents Chemother. 2002;46:2668.

21.  Nishijima  S,  Akamatsu  H,  Akamatsu  M,  et  al.  The  antibiotic  
susceptibility  of  Propionibacterium  acnes  and  Staphylococcus 
epidermidis isolated from acne. J Dermatol. 1996;21:166.

22.  Kircik  LH.  The  role  of  benzoyl  peroxide  in  the  new  treatment 

paradigm for acne. J Drugs Dermatol. 2013;12:s73.

23.  Eady EA, Farmery MR, Ross JI, et al. Effects of benzoyl peroxide 
and  erythromycin  alone  and  in  combination  against  antibiotic-
sensitive  and  -resistant  skin  bacteria  from  acne  patients.  Br  J 
Dermatol. 1994;131:331.

24.  Leyden  J,  Levy  S.  The  development  of  antibiotic  resistance  in 

Propionibacterium acnes. Cutis. 2001;67:21.

25.  Thiboutot D, Gollnick H, Bettoli V, et al. New insights into the 
management  of  acne:  An  update  from  the  Global  Alliance  to 
Improve Outcomes in Acne group. J Am Acad Dermatol. 2009;60:S1.
26.  McHugh  GL,  Moellering  RC,  Hopkins  CC,  et  al.  Salmonella  
typhimurium  resistance  to  silver  nitrate,  chloramphenicol,  and 
ampicillin. Lancet. 1975;1:235.

27.  Annear  DI,  Mee  BJ,  Bailey  M.  Instability  and  linkage  of  silver 
resistance,  lactose  fermentation,  and  colony  structure  in 
Enterobacter cloacae from burn wounds. J Clin Pathol. 1976;29:441.
28.  Hendry AT, Stewart IO. Silver-resistant Enterobacteriaceae from 

hospital patients. Can J Microbiol. 1979;25:915.

29.  Bridges K, Kidson A, Lowbury EJ, et al. Gentamicin- and silver-
resistant pseudomonas in a burns unit. Br Med J. 1979;1:446.
30.  Belly RT, Kydd GC. Silver resistance in microorganisms. Dev Ind 

Microbiol. 1982;23:567.

31.  Haefeli C, Franklin C, Hardy K. Plasmid-determined silver resist-
ance  in  Pseudomonas  stutzeri  isolated  from  a  silver  mine.  
J Bacteriol. 1984;158:389.

32.  Kaur  P,  Saxena  M,  Vadehra  DV.  Plasmid  mediated  resistance  to 
silver ions in Escherichia coli. Indian J Med Res. 1985;82:122.
33.  Kaur  P,  Vadehra  DV.  Mechanism  of  resistance  to  silver  ions  in 
Klebsiella pneumoniae. Antimicrob Agents Chemother. 1986;29:165.
34.  Starodub  ME,  Trevors  JT.  Mobilization  of  Escherichia  coli  R1  
silver-resistance plasmid pJT1 by Tn5-Mob into Escherichia coli 
C600. Biol Met. 1990;3:24.

35.  Deshpande LM, Chopade BA. Plasmid mediated silver resistance 

in Acinetobacter baumannii. Biometals. 1994;7:49.

36.  Silver  S.  Bacterial  silver  resistance:  Molecular  biology  and  uses 
and  misuses  of  silver  compounds.  FEMS  Microbiol  Rev. 
2003;27:341.

37.  Ip M, Lui SL, Chau SS, et al. The prevalence of resistance to silver 

in a burns unit. J Hosp Infect. 2006;63:342.

38.  Maple PA, Hamilton-Miller JM, Brumfitt W. Comparison of the 
in-vitro activities of the topical antimicrobials azelaic acid, nitro-
furazone, silver sulphadiazine and mupirocin against methicillin-
resistant  Staphylococcus  aureus.  J  Antimicrob  Chemother. 
1992;29:661.

39.  Ug A, Ceylan O. Occurrence of resistance to antibiotics, metals, 
and plasmids in clinical strains of Staphylococcus spp. Arch Med 
Res. 2003;34:130.

40.  Silver S, Phung le T, Silver G. Silver as biocides in burn and wound 
dressings  and  bacterial  resistance  to  silver  compounds.  J  Ind 
Microbiol Biotechnol. 2006;33:627.

 
316 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

41.  Mizushima  Y,  Okumura  H,  Kasukawa  R.  Effects  of  gold  and  
platinum  on  necrotizing  factor,  skin  sensitizing  antibody,  and 
complement. Jpn J Pharmacol. 1965;15:131.

42.  Suzuki S, Okubo M, Kaise S, et al. Gold sodium thiomalate selec-
tivity inhibits interleukin-5-mediated eosinophil survival. J Allergy 
Clin Immunol. 1995;96:251.

43.  Eisler R. Chrysotherapy: A synoptic review. Inflamm Res. 2003;52:487.
44.  Abraham GE, Himmel PB. Management of rheumatoid arthritis: 
Rationale  for  the  use  of  colloidal  metallic  gold.  J  Nutr  Env  Med. 
1997;7:295.

45.  Handel  ML,  Nguyen  LQ,  Lehmann  TP.  Inhibition  of  transcription 
factors by anti-inflammatory and anti-rheumatic drugs: Can variabil-
ity in response be overcome? Clin Exp Pharmacol Physiol. 2000;27:139.
46.  Bhol  KC,  Schechter  PJ.  Topical  nanocrystalline  silver  cream  
suppresses  inflammatory  cytokines  and  induces  apoptosis  of 
inflammatory cells in a murine model of allergic contact dermatitis. 
Br J Dermatol. 2005;152:1235.

47.  Bhol KC, Alroy J, Schechter PJ. Anti-inflammatory effect of topical 
nanocrystalline  silver  cream  on  allergic  contact  dermatitis  in  a 
guinea pig model. Clin Exp Dermatol. 2004;29:282.

48.  Banti  CN,  Hadjikakou  SK.  Anti-proliferative  and  anti-tumor 

activity of silver(I) compounds. Metallomics. 2013;5:569.

49.  Silvestri  DL,  McEnery-Stonelake  M.  Chlorhexidine:  Uses  and 

adverse reactions. Dermatitis. 2013;24:112.

50.  Matylevich  NP,  Chu  CS,  McManus  AT,  et  al.  Direct  current 
reduces plasma protein extravasation after partial-thickness burn 
injury in rats. J Trauma. 1996;41:424.

51.  Chu CS, Matylevich NP, McManus AT, et al. Accelerated healing 
with  a  mesh  autograft/allodermal  composite  skin  graft  treated 
with  silver  nylon  dressings  with  and  without  direct  current  in 
rats. J Trauma. 2000;49:115.

52.  Tian J, Wong KK, Ho CM, et al. Topical delivery of silver nanopar-
ticles promotes wound healing. ChemMedChem. 2007;2:129.

53.  Lansdown  ABG.  Silver  in  Healthcare:  Its  Antimicrobial  Efficacy  and 
Safety  in  Use.  Anderson  D,  ed.  London:  Royal  Society  of 
Chemistry, 2010:159.

54.  Gauger A. Silver-coated textiles in the therapy of atopic eczema. 

Curr Probl Dermatol. 2006;33:152.

55.  Gauger A, Fischer S, Mempel M, et al. Efficacy and functionality 
of silver-coated textiles in patients with atopic eczema. J Eur Acad 
Dermat`ol Venereol. 2006;20:534.

56.  Benn  TM,  Westerhoff  P.  Nanoparticle  silver  released  into  water 
from  commercially  available  sock  fabrics.  Environ  Sci  Technol. 
2008;42:4133.

57.  Larese FF, D’Agostin F, Crosera M, et al. Human skin penetration 
of  silver  nanoparticles  through  intact  and  damaged  skin. 
Toxicology. 2009;255:33.

58.  George R, Merten S, Wang TT, et al. In vivo analysis of dermal and 
systemic absorption of silver nanoparticles through healthy human 
skin. Australas J Dermatol. 2013 Sep 5. [Epub ahead of print]

59.  Bouts  BA.  Images  in  clinical  medicine.  Argyria.  N  Engl  J  Med. 

1999;340:1554.

60.  Murata T, Kanao-Koshikawa M, Takamatsu T. Effects of Pb, Cu, 
Sb, In and Ag contamination on the proliferation of soil bacterial 
colonies, soil dehydrogenase activity, and phospholipid fatty acid 
profiles  of  soil  microbial  communities.  Water  Air  Soil  Pollut. 
2005;164:103.

61.  Asaad  K,  Mashhadi  S.  Topical  application  of  silver  nitrate.  Int  J 

Low Extrem Wounds. 2013;12:324.

62.  Klasen HJ. A historical review of the use of silver in the treatment 
of burns. II. Renewed interest for silver. Burns. 2000;26:131.
63.  Clement  JL,  Jarrett  PS.  Antibacterial  silver.  Metal  Based  Drugs. 

1994;1:467.

64.  Kim  KJ,  Sung  WS,  Moon  SK,  et  al.  Antifungal  effect  of  silver 
nanoparticles  on  dermatophytes.  J  Microbiol  Biotechnol. 
2008;18:1482.

 
C H A P T E R  81  ■   O V E R V I E W   O F   AG I N G 

317

SECTION

J

Antiaging Ingredients

C H A P T E R   8 1

Overview of Aging

 CLINICAL SIGNS OF AGING

There  are  two  main  processes  of  skin  aging,  intrinsic  and 
extrinsic.1 Intrinsic aging is controlled by genes. The genes that 
contribute to skin aging have not yet been elucidated although 
some  are  thought  to  play  a  role  in  aging.  Extrinsic  aging  is 
caused  by  external  factors  such  as  smoking,  excessive  use  of 
alcohol, poor nutrition, and sun exposure, which in many cases 
can  be  reduced  with  effort.  It  is  believed  that  as  much  as  
80  percent  of  facial  aging  can  be  ascribed  to  sun  exposure 
(extrinsic aging).2 It is also speculated that some factors impli-
cated  in  extrinsic  cutaneous  aging  may  impact  the  intrinsic 
aging process.3

Extrinsic  aging  accounts  for  most  facial  aging.  Extrinsically 
aged skin appears predominantly in exposed areas such as the 
face, chest, and extensor surfaces of the arms. It is a result of the 
cumulative effects of a lifetime of exposure to ultraviolet radia-
tion (UVR) and other insults such as pollution. Clinical findings 
of photoaged skin include fragility, thinning, wrinkles, dryness, 
rough  texture,  poor  light  reflection,  sallowness,  pigmented 
lesions  such  as  lentigines  (dark  patches),  sagging,  diminished 
elasticity, and decreased hysteresis (ability to resume shape after 
deformation).

 SCIENCE OF AGING SKIN

The clinical signs of aged skin are primarily thought to be caused 
by  a  loss  of  or  dysfunction  in  collagen,  elastin,  and/or  the 
glycosaminoglycans hyaluronic acid (HA). The goal of antiaging 
skin care products is to prevent the loss of collagen, elastin, and 
HA as well as increase the production of collagen and HA. At 
this  time,  no  procedures  or  products  have  been  developed  to 
increase  the  production  of  functional  elastin.  Matrix  metallo-
proteinases (MMPs), glycation, dysfunction of organelles such 
as  mitochondria  and  lysosomes,  telomere  shortening,  sirtuin 
expression, stem cell function, accumulation of senescent cells, 
and DNA damage also play a role in skin aging.

Matrix Metalloproteinases
The mechanism of action of UVR induction of collagen damage 
has been well characterized in the last decade. It is now known 
that UVR exposure dramatically upregulates the production of 
enzymes  known  as  MMPs.  This  occurs  by  the  following 
mechanism: UV exposure causes an increase in the amount of 

the  transcription  factor  c-Jun;  c-Fos  is  abundant  without  UV 
exposure. When UV exposure occurs, these two transcription 
factors, c-Jun and c-Fos, combine to produce activator protein 
(AP)-1, which activates the MMP genes resulting in production 
of MMPs including collagenase, gelatinase, and stromelysin. It 
has  been  demonstrated  in  humans  that  MMPs,  specifically 
collagenase  and  gelatinase,  are  induced  within  hours  of  UVB 
exposure.4 Fisher et al. showed that multiple exposures to UVB 
yield  a  sustained  induction  of  MMPs.5  Because  collagenase 
degrades collagen, long-term increases in collagenase and other 
MMPs likely result in the disorganized and clumped collagen 
seen in photoaged skin.

Collagen
Collagen gives skin its strength and support – it is the scaffolding 
of  the  skin.  Fibroblasts  (the  primary  type  of  skin  cells  in  the 
dermis)  synthesize  collagen  in  a  process  that  requires  the 
presence of ascorbic acid (vitamin C). The addition of vitamin C 
induces fibroblasts to produce more collagen. Thus, fibroblasts 
can  be  spurred  by  topical  skin  care  products  that  contain 
vitamin  C  to  generate  new  collagen.  When  UV  light  hits  the 
skin,  it  leads  to  skin  aging  in  several  ways  but  the  exposure 
exerts  specific  effects  on  collagen  that  include:  1)  decreased 
expression  of  collagen  genes,  and  2)  increased  levels  of  the 
MMP  enzyme  collagenase.  Retinoids  help  prevent  the  loss  of 
collagen by inhibiting the formation of collagenase and blocking 
the downregulation of collagen gene expression.

Elastin
Elastin confers elasticity (ability to bounce back or rebound) to 
the  skin.  After  puberty,  fibroblasts  cannot  produce  functional 
elastin.  Elastase  is  the  enzyme  known  to  break  down  elastin. 
Sunscreens and antioxidants help prevent the loss of elastin, but 
there are no known ways to increase elastin levels in the skin.

Hyaluronic Acid
HA avidly binds water, affecting skin hydration, volume, and 
plumpness.  It  also  influences  cellular  mobilization  and 
communication. HA has become a popular injectable substance 
(e.g., Belotero, Juvéderm, Restylane, and Voluma) that is used 
to plump aged skin by increasing the levels of this key dermal 
component in the skin.6 In addition, HA is a topical additive to 
many skin care products because of its humectant properties. 

 
318 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Its ability to penetrate into the skin depends on its size and the 
formulation of the product.

affect the mitochondria.10 The role of mitochondria, lasers, and 
lights in skin appearance is under active investigation and, ide-
ally, breakthroughs may be seen relatively soon.

Glycation
Glycation  is  caused  by  the  Maillard  reaction  (see  Chapter  2, 
Basic  Cosmetic  Chemistry).  When  glycation  occurs,  sugar 
molecules attach to proteins, thus initiating a series of chemical 
reactions and creating “crosslinked” proteins. These crosslinked 
proteins, called advanced glycation endproducts (AGEs) emerge 
in  collagen  fibers.  The  formation  of  the  crosslinks  that  bind 
collagen  fibers  to  each  other  may  render  the  skin  stiffer. 
Glycosylated collagen is thought to play a role in the appear-
ance  of  aged  skin.7  Elastin  can  also  be  affected  by  glycation. 
Photoaged  skin  is  characterized  by  the  impaired  ability  to 
rebound  and  when  seen  under  a  microscope  exhibits  elastin 
that is abnormally clumped together. This is known as elastosis. 
Recent research has found that these clumps are likely caused 
by glycation, since the adhering elastin is stiff and devoid of its 
usual springiness. Therefore, glycation most likely plays a role 
in the damage seen in the collagen and elastin of aged skin.

Mitochondria
Every human cell contains mitochondria inside the cytoplasm, 
ranging  in  number  based  on  tissue  and  cell  type.  These 
organelles play a crucial role because they are responsible for 
the energy production that drives all cellular processes. Diseases 
of  the  mitochondria  are  devastating  and  dysfunction  of  the 
mitochondria  is  believed  to  play  an  important  role  in  aging.8 
The  mitochondria  produce  energy  by  converting  adenosine 
diphosphate  (ADP)  to  adenosine  triphosphate  (ATP).  This 
complicated process occurs in the intricate inner membranes of 
the mitochondria.

During the process of forming ATP, which is called oxidative 
phosphorylation,  the  mitochondria  use  oxygen  as  a  carrier  for 
electrons  and  the  flow  of  electrons  generates  energy  that  is 
stored  in  ATP.  The  electrons  are  then  bound  to  oxygen  and 
carried off, usually as water. Oxygen is consumed in this process. 
Energy  production  in  the  mitochondria  results  in  an  excess 
number  of  electrons,  many  of  which  are  bound  to  oxygen  to 
form water. The electrons are innocuous when bound to oxygen 
in even numbers. However, some of the electrons slip out and 
singly  bind  oxygen,  leading  to  a  superoxide  compound  also 
known as a free radical. These free radicals cause damage to the 
mitochondrial  membranes,  mitochondrial  DNA,  and  low- 
density  lipoprotein  cholesterol,  which  is  a  component  of  cell 
membranes.  Mitochondrial  DNA  code  for  proteins  present  in 
the  membranes  of  the  mitochondria  that  are  necessary  for 
energy production. Mutations of mitochondrial DNA engender 
disorder  in  the  energy  production  process  and  can  lead  to  an 
increased  number  of  free  radicals.  The  cycle  is  perpetuated  as 
these free radicals cause more mitochondrial DNA mutations.

Mitochondrial  damage  must  be  prevented  in  order  to  slow 
aging but not much is known about how to accomplish this. For 
the last five to eight years dermatologists who perform copious 
light and laser procedures have begun to suspect that the wave-
lengths of light may have effects on the skin that transcend what 
is presently understood. The currently accepted mechanisms of 
action  of  lasers  and  light-emitting  diodes  do  not  adequately 
explain how skin appearance is ameliorated in these procedures. 
Scientists have begun to suspect that the light exerts effects on 
mitochondria.9  Certain  wavelengths  may  stimulate  mitochon-
dria to work more effectively while UV light may deleteriously 

Lysosomes
Lysosomes are intracellular organelles that function to degrade 
or recycle cellular waste products into basic components that 
can be used as raw materials to form new cellular products. In 
addition, lysosomes, which are composed of various enzymes, 
break  down  toxic  waste  into  less  harmful  substances.  Each 
enzyme within a lysosome has a specific function. In order for 
a lysosome to do its job of ridding cells of waste it needs the 
following: 1) the correct enzymes; 2) the ideal pH (or acidity) 
for  that  enzyme  to  work  (different  enzymes  operate  more 
efficiently  under  different  pH  environments);  and  3)  energy 
produced  by  the  mitochondria  known  as  ATP.  The  lysosome 
membrane  contains  a  pump  that  requires  energy  (ATP)  to 
propel hydrogen ions into the lysosome to maintain its acidity.
Dysfunction  of  the  lysosome,  which  allows  cellular  waste 
products to accumulate inside the cell, leads to several disorders, 
called  lysosomal  storage  diseases  (e.g.,  Tay–Sachs  disease  and 
Gaucher’s disease). Lysosomes are not able to degrade all cellular 
waste;  what  remains  from  lysosomal  digestion  is  called 
lipofuscin. The accumulation of lipofuscin is seen in aged cells.11 
Under a microscope and with proper staining, lipofuscin appears 
fluorescent  and  is  thus  easily  visualized.  Studies  have  shown 
that  oxidative  stress  by  free  radicals  leads  to  an  increase  in 
lipofuscin.  Accumulation  of  lipofuscin  hampers  the  ability  of 
lysozymes  to  work  effectively,  altering  acidity  and  disrupting 
the  supply  of  enzymes.12  In  other  words,  the  amassing  of 
lipofuscin  cellular  waste  contributes  to  cutaneous  aging. 
Treatments to prevent this form of aging would have to achieve 
one of the following: 1) enhance lysosomal function, 2) increase 
breakdown of lipofuscin and cellular waste, 3) reduce free radical 
formation, or 4) enhance lysosomal function.

Medical discoveries often occur first in areas of severe disease 
because  these  advances  are  most  needed  and  may  receive  the 
most attention and funding. Gaucher’s disease, which is a severe 
disorder caused by a lack of a lysosomal enzyme, is successfully 
treated  with  intravenous  infusion  of  the  missing  enzyme.13 
Genetic treatments are being developed for Tay–Sachs disease. 
At this time, there are no published data on skin aging or skin 
appearance and the role of lipofuscin. Although it is likely that 
skin  with  increased  lipofuscin  appears  older,  this  research  has 
not been conducted. It is not yet known if there are any particular 
enzyme  deficiencies  that  lead  to  increased  or  accelerated  skin 
aging.

Telomere Shortening
Telomeres  are  repetitive  nucleotide  sequences  that  compose 
the  terminal  portions  of  mammalian  chromosomes.  Their 
presence  at  the  ends  of  chromosomes  prevents  deterioration  or 
fusion  with  nearby  chromosomes.  However,  the  enzyme  DNA 
polymerase cannot replicate the final base pairs of the chromosome 
curing cellular and chromosomal division. Consequently, these 
terminal sequences are continuously lost on replication, which 
results in the shortening of the chromosome. Since telomeres 
shorten  with  age,  their  erosion  has  become  an  important 
measure of cellular aging, a veritable internal clock.14 Apoptosis, 
or cell death, is triggered when telomeres become “too short,” 
thus precluding further replication. It is important to note that 
UV exposure contributes to telomere shortening and signaling 

 
through  the  tumor-suppressor  protein  p53  after  telomere 
disruption,  which  is  typically  observed  in  skin  aging  and 
photodamage.15 Therefore, telomeres are thought to play a role 
in extrinsic as well as intrinsic aging.16

Telomeres are also thought to play a role in cancer. A recent 
paper suggests that the photoaging and melanogenesis provoked 
by  UV  exposure  is  linked  to  telomere-based  DNA  damage 
signaling that may actually represent a cancer-avoidance protec-
tive  response.17  The  enzyme  telomerase,  which  stabilizes  or 
lengthens telomeres, is expressed in approximately 90 percent of 
all tumors but is absent in many tissues.14 The epidermis is one 
of  the  few  regenerative  tissues  to  express  telomerase.18 
Telomerase is believed to act against excessive telomere loss in 
human epidermis throughout the lifelong regeneration process.19 
There are several products that claim to help lengthen or preserve 
telomeres,  but  such  claims  are  not  well  substantiated  in  
the author’s opinion. The exact role and importance of telomere 
length in skin aging is not known.

Sirtuins
Sirtuins  (SIRTs)  are  a  family  of  NAD+  dependent  protein 
deacetylases  that  regulate  the  biologic  functions  of  proteins. 
There are seven known types of SIRTs found in humans, with 
SIRT1, the most extensively studied, known to guard against 
cellular oxidative stress and DNA damage. SIRTs are involved 
in the cutaneous response to UV and are believed to play a role 
in  aging.20  Interest  in  SIRTs  first  emerged  when  researchers 
noticed that calorie-restricted rodents lived longer than animals 
whose calories were not restricted.21 SIRTs were found to have 
been  upregulated  in  these  calorie-restricted  rodents,  and  that 
certain  types  of  mice  that  overexpressed  SIRT6  had  signifi-
cantly  extended  life  spans.21,22  Another  study  showed  that 
brain-specific  overexpression  of  SIRT1  was  also  shown  to 
extend the life span.23 In 2003, investigators learned that small 
molecules  could  be  used  to  activate  SIRT  expression.24  This 
generated  a  search  for  molecules  that  would  influence  SIRTs 
expression.  Suddenly,  cosmetic  companies  began  launching 
products  that  “stimulate  sirtuins  expression.”  Unfortunately, 
not  enough  is  yet  known  about  SIRTs  and  their  influence  on 
the  aging  process  to  warrant  such  inflated  skin  care  product 
claims.  However,  it  will  be  interesting  to  watch  as  SIRTs 
research develops.

C H A P T E R  81  ■   O V E R V I E W   O F   AG I N G 

319

Senescent Cells
Aged cells that lose their ability to divide and respond to envi-
ronmental  changes  are  known  as  senescent  cells.  Cellular 
senescence is important because it is the way the body naturally 
rids  itself  of  dysfunctional  or  damaged  cells—they  stop 
functioning  and  become  senescent.  Cancer  is  a  disease  that 
occurs  when  cells  lose  the  ability  to  become  senescent  and 
continue  dividing  and  reproducing  even  though  they  are 
damaged. The accumulation of senescent cells is characteristic 
of aged skin, and it is believed that the presence of senescent 
cells leads to cutaneous aging.26 Inflammation has been believed 
for several years to play a role in aging, but the mechanism of 
action  has  not  been  elucidated.  New  research  demonstrates 
how inflammation contributes to an increase in senescent cells, 
and this may provide a clue as to how inflammation promotes 
aging.27 It is likely that the accumulation of these nonfunctioning 
senescent  cells  can  damage  surrounding  “healthy”  cells. 
Senescent cells likely gather around fibroblasts and other skin 
cells rendering them stiffer and unable to function properly. It 
is possible that senescent cells may secrete proteins and other 
substances that are deleterious to surrounding cells.

DNA Damage
It is well known that UV radiation leads to DNA damage by 
formation of thymine dimers. Thymine dimers develop when 
nucleic acid base pairs bind together causing a disruption of the 
DNA.  Damage  to  DNA  is  known  to  lead  to  skin  cancer  but 
likely plays a role in skin aging. The exact role of DNA damage 
in skin aging is not known because the genes that cause skin 
aging have not been identified.

 PREVENTION OF AGING

Sunscreen  prevents  aging  by  minimizing  UV  damage  and 
blocking  or  decreasing  the  formation  of  free  radicals  and 
inflammation.  HA  may  protect  collagen  from  degradation 
through the activity of interleukin (IL)-1.28 Antioxidants, such 
as  tocopherol  (vitamin  E)  and  ascorbic  acid,  protect  collagen 
and elastin from glycation and damage by free radicals, which 
are  known  to  promote  aging.29  Retinoids  decrease  the 
breakdown of collagen by lowering MMP levels and increasing 
collagen synthesis.

Stem Cells
Stem cells have the potential to transform into other types of 
cells.  They  are  distinguished  from  other  cell  types  by  two 
important  characteristics.  First,  they  are  unspecialized  cells 
capable of dividing and forming new “daughter” cells. Second, 
under certain physiologic or experimental conditions, stem cells 
can  be  induced  to  become  specific  types  of  cells  with  special 
functions. Stem cells certainly play an important role in medi-
cine and have been used to repair brain, heart, and pancreatic 
cells among other uses. However, stem cells must be cultured in 
particular conditions and would not survive in a skin care prod-
uct on a shelf. Stem cells are being used in chronic wounds, but 
they are grown in controlled laboratory conditions and do not 
sit on a shelf in uncontrolled conditions.25 In addition, the stem 
cells  in  skin  care  products  are  derived  from  apples  and  other 
nonmammalian sources. There is no reason to believe that these 
formulations will be efficacious in human skin.

Antioxidants
The free radical theory of aging, proposed by Harman in 1956, 
is  one  of  the  most  widely  accepted  theories  to  explain  the 
cause of aging.30,31 Free radicals are compounds formed when 
oxygen  molecules  combine  with  other  molecules  yielding  an 
odd  number  of  electrons.  An  oxygen  molecule  with  paired 
electrons is stable; however, oxygen with an unpaired electron 
is  “reactive”  because  it  seeks  and  seizes  electrons  from  vital 
components  leaving  them  damaged.32  DNA,  cytoskeletal 
elements, cellular proteins, and cellular membranes may all be 
adversely affected by activated oxygen species (see Chapter 2, 
Basic Cosmetic Chemistry).33,34

Antioxidants give oxygen the missing electron it craves and thus 
neutralize free radicals, rendering them harmless. By neutralizing 
free radicals, antioxidants are able to mitigate cutaneous damage as 
well  as  the  effects  of  aging,  “preventing  aging”  in  a  sense  
(see Chapter 46, Antioxidants, for a lengthier discussion).

 
320 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

Free radicals may also increase glycation by more rapidly con-
verting AGE precursors into pernicious AGEs. Although antioxi-
dants are beneficial for many reasons, they do not seem to aid in 
abrogating the glycation process. This is due to the fact that once 
the Schiff base is formed, it is unstable. The use of antioxidants 
may  block  one  pathway,  but  the  Schiff  base  can  move  down 
another pathway that still results in the development of harmful 
free  radicals  (see  Chapter  2,  Basic  Cosmetic  Chemistry,  for 
details on the Schiff base).

Peptides
Peptides are short chains of amino acids, which are the building 
blocks of proteins. In typical cellular settings, peptides commu-
nicate  between  DNA  and  the  cellular  network.  It  is  thought, 
then,  that  peptides  can  be  used  to  direct  cells  to  maintain 
youthful behavior, yielding a stable, non-aging manifestation. 
However, while peptides play several important roles in skin, one 
of the functions of the skin is to prevent penetration of peptides 
and proteins. Consequently, most topically applied peptides fail to 
penetrate into the skin. Some products appear to exert antiaging 
activity,  but  most  evidence  of  effectiveness  comes  from  in  vitro 
studies, however, or small in vivo investigations.

The four main types of peptides used in topical or cosmeceuti-
cal products include signal peptides, enzyme-inhibitor peptides, 
neurotransmitter-inhibitor  peptides  (or  neuropeptides),  and 
carrier  peptides.35  Insulin  is  an  example  of  a  peptide  that  has 
useful activity (regulating blood sugar), but it must be injected to 
penetrate the skin barrier, as topical vehicles such as creams or 
patches, have failed to achieve absorption. In addition to limited 
skin penetration, peptides are difficult to formulate in skin care 
products  because  they  are  reactive  and  tend  to  interfere  with 
other product ingredients, thus reducing their shelf life. For these 
reasons, topical peptide-containing creams will likely be shown 
to have limited utility in treating skin aging until the penetration 
technology  is  improved.  Popular  peptide  ingredients  seen  in 
antiaging  skin  care  include  palmitoyl  pentapeptide  (Matrixyl) 
and acetyl hexapeptide-3 (Argireline). A full discussion of pep-
tides is beyond the scope of this text.

Retinoids
In  the  1970s,  female  patients  that  were  being  treated  with 
tretinoin for acne noticed that their wrinkles improved.36 This 
observation was followed by a clinical trial that showed that 
patients treated with tretinoin displayed improvement of pho-
todamaged skin.37 A plethora of clinical trials have confirmed 
such early observations and now it is well known that retinoids 
are  the  most  efficacious  ingredients  to  treat  photodamaged 
skin.38 For this reason, an entire chapter is dedicated to the use 
of  retinoids  in  antiaging  skin  care  products  [see  Chapter  83, 
Retinoids  (Retinol)].  The  acne  section  also  contains  a  chapter 
on the use of retinoids in acne (see Chapter 79, Retinol, Retinyl 
Esters, and Retinoic Acid).

 CONCLUSION

In summary, skin aging is a complex process. Although many 
of the mechanisms such as the production of MMPs have been 
deciphered, much remains to be uncovered regarding the role 
of  genes,  telomeres,  and  organelles,  such  as  mitochondria,  in 
the aging process. Although many companies tout products that 
claim to affect “genes associated with skin aging,” these state-
ments are greatly inflated. The genes that are being referred to in 

these boasts are usually the collagen and HA genes. There are 
several  processes  beyond  collagen  and  HA  gene  biochemistry 
that lead to cutaneous aging that have not been characterized or 
are poorly understood. However, we will likely learn much more 
about the skin aging process in the near future. In the meantime, 
a daily regimen consisting of sunscreen, antioxidants, and reti-
noids at night is scientifically justified.

REFERENCES

1.  Baumann  L,  Saghari  S.  Photoaging.  In:  Baumann  L,  Saghari  S, 
Weisberg E, eds. Cosmetic Dermatology: Principles and Practice. 2nd ed. 
New York: McGraw-Hill, 2009:34–35.

2.  Uitto  J.  Understanding  premature  skin  aging.  N  Engl  J  Med. 

1997;337:1463.

3.  Farage  MA,  Miller  KW,  Elsner  P,  et  al.  Intrinsic  and  extrinsic  

factors in skin ageing: A review. Int J Cosmet Sci. 2008;30:87.

4.  Fisher  GJ,  Datta  SC,  Talwar  HS,  et  al.  Molecular  basis  of  
sun-induced premature skin ageing and retinoid antagonism. Nature. 
1996;379:335.

5.  Fisher GJ, Wang ZQ, Datta SC, et al. Pathophysiology of prema-
ture  skin  aging  induced  by  ultraviolet  light.  N  Engl  J  Med. 
1997;337:1419.

6.  Baumann L, Blyumin M, Saghari S. Dermal fillers. In: Baumann L, 
Saghari  S,  Weisberg  E,  eds.  Cosmetic  Dermatology:  Principles  and 
Practice. 2nd ed. New York: McGraw-Hill, 2009:195–200.

7.  Pageon H, Bakala H, Monnier VM, et al. Collagen glycation trig-
gers the formation of aged skin in vitro. Eur J Dermatol. 2007;17:12.
8.  Beal  MF.  Mitochondria  take  center  stage  in  aging  and  neurode-

generation. Ann Neurol. 2005;58:495.

9.  Karu  TI,  Pyatibrat  LV,  Kolyakov  SF,  et  al.  Absorption  measure-
ments of cell monolayers relevant to mechanisms of laser photo-
therapy: Reduction or oxidation of cytochrome c oxidase under 
laser radiation at 632.8 nm. Photomed Laser Surg. 2008;26:593.
10.  Krutmann J, Schroeder P. Role of mitochondria in photoaging of 
human skin: The defective powerhouse model. J Investig Dermatol 
Symp Proc. 2009;14:44.

11.  Jung  T,  Bader  N,  Grune  T.  Lipofuscin:  Formation,  distribution, 
and metabolic consequences. Ann N Y Acad Sci. 2007;1119:97.
12.  Terman A, Kurz T, Navratil M, et al. Mitochondrial turnover and 
aging of long-lived postmitotic cells: The mitochondrial-lysosomal 
axis theory of aging. Antioxid Redox Signal. 2010;12:503.

13.  Barton  NW,  Brady  RO,  Dambrosia  JM,  et  al.  Replacement  
therapy for inherited enzyme deficiency – Macrophage-targeted 
glucocerebrosidase  for  Gaucher’s  disease.  N  Engl  J  Med. 
1991;324:1464.

14.  Boukamp P. Ageing mechanisms: The role of telomere loss. Clin 

Exp Dermatol. 2001;26:562.

15.  Kosmadaki  MG,  Gilchrest  BA.  The  role  of  telomeres  in  skin 

aging/photoaging. Micron. 2004;35:155.

16.  Saghari  S,  Baumann  L.  Wrinkled  skin.  In:  Baumann  L,  Saghari  S, 
Weisberg E, eds. Cosmetic Dermatology: Principles and Practice, 2nd ed. 
New York: McGraw-Hill, 2009:145–147.

17.  Gilchrest  BA,  Eller  MS,  Yaar  M.  Telomere-mediated  effects  on 
melanogenesis  and  skin  aging.  J  Investig  Dermatol  Symp  Proc. 
2009;14:25.

18.  Boukamp  P.  Skin  aging:  A  role  for  telomerase  and  telomere 

dynamics? Curr Mol Med. 2005;5:171.

19.  Krunic  D,  Moshir  S,  Greulich-Bode  KM,  et  al.  Tissue  context-
activated  telomerase  in  human  epidermis  correlates  with  little 
age-dependent telomere loss. Biochim Biophys Acta. 2009;1792:297.
20.  Benavente CA, Schnell SA, Jacobson EL. Effects of niacin restric-
tion  on  sirtuin  and  PARP  responses  to  photodamage  in  human 
skin. PLoS One. 2012;7:e42276.

21.  Guarente L. Calorie restriction and sirtuins revisited. Genes Dev. 

2013;27:2072.

22.  Kanfi  Y,  Naiman  S,  Amir  G,  et  al.  The  sirtuin  SIRT6  regulates 

lifespan in male mice. Nature. 2012;483:218.

23.  Satoh A, Brace CS, Ben-Josef G, et al. SIRT1 promotes the central 
adaptive  response  to  diet  restriction  through  activation  of  the 
dorsomedial  and  lateral  nuclei  of  the  hypothalamus.  J  Neurosci. 
2010;30:10220.

24.  Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activa-
tors of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 
2003;425:191.

 
25.  Dabiri  G,  Heiner  D,  Falanga  V.  The  emerging  use  of  bone  
marrow-derived  mesenchymal  stem  cells  in  the  treatment  of 
human chronic wounds. Expert Opin Emerg Drugs. 2013;18:405.
26.  Dimri GP, Lee X, Basile G, et al. A biomarker that identifies senes-
cent  human  cells  in  culture  and  in  aging  skin  in  vivo.  Proc  Natl 
Acad Sci U S A. 1995;92:9363.

27.  Yang  HH,  Kim  C,  Jung  B,  et  al.  Involvement  of  IGF  binding  
protein  5  in  prostaglandin  E(2)-induced  cellular  senescence  in 
human fibroblasts. Biogerontology. 2011;12:239.

28.  Nawrat P, Surazyn´ski A, Karna E, et al. The effect of hyaluronic 
acid  on  interleukin-1-induced  deregulation  of  collagen  metabo-
lism  in  cultured  human  skin  fibroblasts.  Pharmacol  Res. 
2005;51:473.

29.  Pillai  S,  Oresajo  C,  Hayward  J.  Ultraviolet  radiation  and  skin 
aging:  Roles  of  reactive  oxygen  species,  inflammation  and  pro-
tease  activation,  and  strategies  for  prevention  of  inflammation-
induced  matrix  degradation  –  A  review.  Int  J  Cosmet  Sci. 
2005;27:17.

30.  Harman D. Aging: A theory based on free radical and radiation 

chemistry. J Gerontol. 1956;11:298.

C H A P T E R  81  ■   O V E R V I E W   O F   AG I N G  

321

31.  Pelle E, Maes D, Padulo GA, et al. An in vitro model to test rela-
tive antioxidant potential: Ultraviolet-induced lipid peroxidation 
in liposomes. Arch Biochem Biophys. 1990;283:234.

32.  Werninghaus K. The role of antioxidants in reducing photodamage. 
In: Gilchrest B ed. Photodamage. London: Blackwell Science Inc., 
1995:249.

33.  Greenstock  CL.  Free  Radicals,  Aging,  and  Degenerative  Diseases. 

New York: Alan R. Liss, Inc., 1986.

34.  Rikans  LE,  Hornbrook  KR.  Lipid  peroxidation,  antioxidant  pro-

tection and aging. Biochim Biophys Acta. 1997;1362:116.

35.  Gorouhi F, Maibach HI. Role of topical peptides in preventing or 

treating aged skin. Int J Cosmet Sci. 2009;31:327.

36.  Kligman L, Kligman AM. Photoaging – Retinoids, alpha hydroxy 
acids, and antioxidants, In: Gabard B, Elsner P, Surber C, Treffel P, 
eds.  Dermatopharmacology  of  Topical  Preparations.  New  York: 
Springer, 2000:383.

37.  Kligman  AM,  Grove  GL,  Hirose  R,  et  al.  Topical  tretinoin  for 

photoaged skin. J Am Acad Dermatol. 1986;15:836.

38.  Baumann  L,  Saghari  S.  Retinoids.  In:  Baumann  L,  Saghari  S, 
Weisberg E, eds. Cosmetic Dermatology: Principles and Practice. 2nd ed. 
New York: McGraw-Hill, 2009:256–262.

 
322  

C O S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   8 2

Hydroxy Acids

Activities:

Anti-inflammatory, exfoliating, antiacne, depigmenting, 
moisturizing

Important Chemical Components:

Mostly carbon, hydrogen, and oxygen
Molecular formulas:
Citric acid: C6H8O7
Gluconolactone C6H10O6
Glycolic acid: C2H4O3
Lactic acid: C3H6O3
Malic acid: C4H6O5
Mandelic acid: C8H8O3
Phytic acid: C6H18O24P6
Salicylic acid: C7H6O3
Tartaric acid: C4H6O6

Origin Classification:

Acids  are  all  found  in  natural  sources,  but  are  synthe-
sized  in  the  laboratory  for  use  in  chemical  peels  and 
other products.

Personal Care Category:

Antiaging, exfoliant, brightening, antiacne, moisturizer

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW, DRPW, DSNW, DSPW, ORNW, ORPW, OSNW, 
and OSPW. Hydroxy acids are used in all Baumann Skin 
Types  but  the  choice  of  hydroxy  acid  depends  on  the 
individual  skin  type.  All  of  the  acids  discussed  in  this 
chapter  are  useful  in  wrinkle-prone  skin  types.  Acids 
used for acne indications are discussed in the acne sec-
tion of this text.

 SOURCE

Found  in  plants  but  also  manufactured  in  the  laboratory, 
α-hydroxy  acids  (AHAs),  polyhydroxy  acids  (PHAs),  and 
β-hydroxy acid (BHA) are naturally-occurring organic acids that 
induce exfoliation and accelerate the cell cycle. The plant source 
depends on the type of hydroxy acid. There are several types of 
AHAs: citric acid from citrus fruits; glycolic acid from sugar cane, 
grapes, sugar beets, and Virginia creeper leaves; malic acid from 
fruits  such  as  cherries  and  apples;  mandelic  acid  from  bitter 
almond;  lactic  acid  from  dairy  as  well  as  fermented  vegetables 
and fruit; phytic acid from rice; and tartaric acid from grapes.1

PHAs,  also  known  as  polyhydroxy  bionic  acids  (PHBAs), 
include  gluconolactone  and  lactobionic  acid.2  They  were  devel-
oped  to  deliver  the  antiaging  efficacy  of  AHAs  without  the 
irritation  or  increased  vulnerability  to  ultraviolet  (UV)  radiation 
due to their antioxidant effects (Table 82-1).

TABLE 82-1
Pros and Cons of Hydroxy Acids

Pros
Many studies demonstrating efficacy
Low cost
SA exhibits anti-inflammatory and  

antiacne activity 

Cons
May cause stinging
Increased sun sensitivity (AHAs)
May interact with other ingredients  

and products

PHAs have antioxidant capability

Knowledge of chemistry is necessary for 

proper use

Humectant

BHA, also known as salicylic acid (SA), is found in willow bark, 
almonds,  water  chestnuts,  peanuts,  and  some  fruits  and 
vegetables. There is only one type of BHA, as compared to the 
several types of AHA and PHA. BHA can also be produced in the 
laboratory  from  phenylalanine  or  by  hydrolysis  of  aspirin 
(acetylsalicylic acid) or oil of wintergreen (methyl salicylate).

 HISTORY

Cleopatra  was  said  to  have  routinely  bathed  in  sour  milk.3  
If  this  is  true,  it  is  the  first  known  use  of  a  hydroxy  acid  
(lactic acid) to improve the skin’s appearance. Fermented grape 
skins, rife with tartartic acid, were collected from the bottoms 
of wine barrels by women in ancient Rome and used topically 
to enhance beauty.3 More recently, books (and movies) such as 
Gone  with  the  Wind  have  referred  to  the  use  of  buttermilk  to 
remove  “sun  spots.”  AHAs,  especially  lactic  acid,  were  first 
used  in  dermatology  to  treat  dry  skin,  psoriasis,  and  other 
conditions.  Lactic  and  glycolic  acids  have  been  used 
therapeutically since the 1970s.4 In the 1990s, Van Scott and his 
group noticed that glycolic acid improved photodamaged skin. 
In 1992, Van Scott and Yu filed a patent on the use of glycolic 
acid  for  treating  wrinkles  and  subsequently  formed  the 
company NeoStrata.5 AHAs became one of the most popular 
antiaging skin ingredients and enjoyed widespread acceptance 
until  the  United  States  Food  and  Drug  Administration  (FDA) 
began questioning their safety with concomitant sun exposure. 
The FDA ultimately mandated that AHA product labels contain 
a sun safety label. This FDA scrutiny, along with the desire to 
develop a less irritating hydroxy acid, provided the impetus for 
Drs. Van Scott and Yu to later develop PHAs. The most popular 
PHA marketed today is gluconolactone.6

The  Greek  physician  Hippocrates  described  using  willow 
bark in childbirth for pain in the late 4th century BCE.7,8 It was 
not until the 19th century that SA was isolated from the bark of 
the willow tree by the German chemist Johann Andreas Buchner 
in  1828.9  The  active  extract  was  called  salicin,  after  the  Latin 
name  for  the  white  willow  (Salix  alba).  (For  a  more  detailed 
history on the use of salicylic acid in medicine, see Chapter 78, 
Salicylic Acid.) In the late 1990s, people began to incorrectly refer 
to  SA  as  a  BHA,  most  likely  to  associate  it  with  the  popular 
AHAs that were penetrating the antiaging skin care market at the 

 
C H A P T E R  82  ■   H Y D R OX Y   AC I D S  

323

influence on epidermal keratinization by speeding the cell cycle 
and  decreasing  corneocyte  cohesiveness,  leading  to  increased 
desquamation.13–15 The topical application of AHAs and BHA 
in  high  concentrations  results  in  the  detachment  of  keratino-
cytes (skin cells) and epidermolysis, which can cause erosions 
and  blisters.  Application  at  lower  concentrations  attenuates 
intercorneocyte  cohesion  directly  above  the  granular  layer, 
advancing desquamation and thinning of the stratum corneum 
(SC) but not the epidermis.15 Two major effects emerge: accel-
eration  of  the  cell  cycle  (which  is  slowed  in  aged  skin)  and 
increased desquamation, which yields improved skin tone and 
light  reflection  (radiance)  as  well  as  a  smoother  skin  surface. 
AHAs confer a moisturizing effect and are beneficial in dry skin 
because  they  function  as  humectants,  assisting  the  skin  in 
holding onto water. They also enhance desquamation thereby 
normalizing  the  SC  by  eliminating  the  clinging  keratinocytes 
that leave the skin looking rough and scaled. Once desquama-
tion  is  enhanced,  the  skin  is  more  flexible  and  better  able  to 
reflect light. Phytic acid was among several bioactive constitu-
ents  in  rice  bran  incorporated  into  topical  formulations 
containing niosomes recently found to be effective in imparting 
antiaging  benefits  in  30  human  volunteers.16  In  addition  to 
photodamage,  hydroxy  acids  have  been  used  to  treat  a  wide 
range  of  cutaneous  conditions,  including  actinic  keratosis, 
melasma,  ichthyosis,  psoriasis,  warts,  hyperpigmentation, 
acne, and rosacea.

Glycolic Acid
In  1996,  Ditre  demonstrated  that  topically  applying  AHAs 
generated significant changes histologically, with a 25 percent 
increase in skin thickness, increased acid mucopolysaccharides 
in  the  dermis,  enhanced  elastic  fiber  quality,  and  augmented 
collagen density.17 Two years later, Kim et al. showed in vitro 
that glycolic acid treatments increased fibroblast proliferation 
and collagen synthesis.18 A significant decline in wrinkle score 
and an increase in the amount of collagen synthesized in mice 
treated with glycolic acid was subsequently reported by Moon 
et  al.19  In  2001,  Bernstein  et  al.  found  that  topically  applied 
glycolic acid enhanced collagen gene expression in skin biopsy 
specimens,  and  increased  epidermal  and  dermal  hyaluronic 
acid  immunohistochemical  staining  between  glycolic  acid-
treated and vehicle-treated skin.20 Okano et al. further explored 
these findings two years later, and demonstrated that glycolic 
acid  placed  in  cell  cultures  directly  accelerated  collagen 
production by fibroblasts, and increased interleukin-1α release 
from keratinocytes thereby affecting matrix degradation.21

Lactic Acid
Antiaging  benefits  similar  to  those  imparted  by  glycolic  acid 
have  also  been  associated  with  lactic  acid,  which  has  been 
hypothesized  to  be  part  of  the  natural  moisturizing  factor  of 
the  skin  that  plays  a  role  in  hydration  (see  Chapter  7, 
Moisturizing  Agents).22  Several  studies  in  the  1980s  on  the 
activity  of  buffered  12  percent  ammonium  lactate  lotion 
documented its moisturizing ability.23 One study demonstrated 
an increase in skin firmness and thickness as well as improve-
ment in skin texture and moisturization using 5 and 12 percent 
lactic acid. These effects were seen only in the epidermis, with 
no  dermal  changes  in  firmness  or  thickness  noted.24  In  2006, 
Yamamoto  et  al.  found  that  longer  treatment  intervals,  once 
daily for six weeks, with glycolic and lactic acids led to improve-
ments in epidermal as well as dermal constituents, suggesting 

FIGURE 82-1  Salicylic Acid. Chemical structure of salicylic acid, with 

▶
its hydroxy group in the β position.

time. BHA products are not required to contain the “sun safety” 
label that AHAs are directed to display.

 CHEMISTRY

All  AHAs  have  a  terminal  carboxyl  group  with  one  or  two 
hydroxyl  groups  on  the  second  or  α-carbon  and  a  variable 
length  carbon  chain.  The  two  shortest  carbon  chain  acids, 
glycolic (2-hydroxyethanoic) and lactic (2-hydroxypropanoic), 
are the most commonly used in dermatology.10

SA is improperly called a BHA because the aromatic carbox-
ylic  acid  has  a  hydroxyl  group  in  the  β  position  (Figure  82-1). 
This designation is a misnomer insofar as the carbons of aromatic 
compounds  are  traditionally  given  Arabic  numerals  (1,  2,  etc.) 
rather than the Greek letter designations typical for the nonaro-
matic structures. However, the term BHA is commonly used.

PHAs, such as lactobionic acid, are carboxylic acids with two 
or more hydroxyl groups attached to carbon atoms or an alicyclic 
chain. It is essential that at least one hydroxyl group be attached 
to  the  α  position.  Attaching  a  sugar  molecule  to  the  PHA 
structure yields a polysaccharide known as bionic acid.

Hydroxy acid solutions contain free acid forms and salt forms 
that  exist  in  equilibrium  based  on  the  pH  of  the  solution.  
The  most  important  aspect  of  hydroxy  acid  strength  is  the 
amount of available free acid. The amount of free acid itself is 
affected by the following: the concentration of hydroxy acid, the 
pKa of the hydroxy acid, and the pH of the solution (which is 
also influenced by the type of vehicle used), and whether or not 
the peel is buffered. For a detailed discussion of pH and pKa, see 
Chapter 2, Basic Cosmetic Chemistry. It is difficult to know the 
strength  of  a  hydroxy  acid-containing  product  by  reading  the 
label because these important details are not listed. The exfolia-
tive, toxic, and abrasive action as well as absorption into the skin 
of hydroxy acid products increase with higher concentration and 
lower pH.1,11

 ORAL USES

Although hydroxy acids are available in food, their oral use has 
no known role in the treatment of skin conditions at this time.

 TOPICAL USES

Multiple  studies  have  demonstrated  success  using  AHA  and 
BHA products in the treatment of photoaging by ameliorating 
fine  lines,  ephelides  (freckles),  lentigines,  mottled  pigmenta-
tion,  and  surface  roughness.  Actinic  and  seborrheic  keratoses 
have  also  been  effectively  treated  with  AHAs  and  BHA.12 
Topical preparations that contain hydroxy acids exert profound 

 
324 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

the  suitability  of  the  primary  AHAs  in  ameliorating 
photodamaged skin.4

Rendl  et  al.  investigated  the  effects  of  lactic  acid-containing 
creams on the secretion of cytokines by keratinocytes in human 
reconstructed epidermis, finding that topically applied lactic acid 
modulated  the  secretion  of  vascular  endothelial  growth  factor 
(VEGF) by keratinocytes.25 Interestingly, lactic acid is one of the 
few  ingredients  available  in  the  United  States  in  the  same 
strength  in  prescription  and  over-the-counter  (OTC)  form. 
LacHydrin™  is  approved  by  the  FDA  as  a  drug  for  use  in  dry 
skin,  but  not  for  photoaged  skin.  OTC  products  that  contain 
lactic acid to treat photoaged skin are readily available, however.

BHA
In  1992,  Swinehart  demonstrated  that  50  percent  SA  was 
effective  in  treating  patients  with  actinically-induced 
pigmentary changes on the hands and forearms.26 These effects 
are  likely  due  to  increased  exfoliation  and  a  quickened  cell 
cycle,  similar  to  the  effects  observed  with  AHAs.  However, 
unlike  AHAs,  BHA  alters  the  arachidonic  acid  cascade  and, 
therefore,  exhibits  anti-inflammatory  capabilities.  For  this 
reason, SA is often used in the treatment of acne (see Chapter 78, 
Salicylic  Acid).  Notably,  BHA  has  a  tendency  to  dry  the  skin 
and, therefore, is not the best choice for individuals with dry 
skin types.

Polyhydroxy Acids
PHAs,  found  naturally  in  humans  and  other  natural  sources,  
are characterized as milder and less irritating than AHAs, but 
are related to AHAs insofar as they have a hydroxyl group on 
the  α-carbon  and  share  some  biochemical  properties.27  The 
lactonic structure of gluconolactone, one of the most popular 
PHAs,  allows  it  to  conceal  its  acidic  nature,  and  renders  it 
suitable  for  sensitive  skin.28  Some  PHAs  exhibit  antioxidant 
activity due to their ability to chelate metal. Protective antioxi-
dant constituents of PHAs likely account for the fact that these 
compounds do not increase the number of sunburn cells after 
UV  exposure.  One  of  the  most  popular  PHAs  in  skin  care 
products  is  gluconolactone.  In  2004,  Bernstein  et  al.  exposed 
fibroblast  cultures  culled  from  the  skin  of  transgenic  mice  to 
UVB and demonstrated that glycolic acid-treated skin evinced a 
significant increase in sunburn cells, whereas gluconolactone-
treated  skin  did  not.27  The  investigators  attributed  the 
protective  mechanism  of  gluconolactone  to  its  ability  to 
function  as  a  metal-chelating  agent  and  its  potency  in 
scavenging free radicals.

Uneven Skin Tone and Dyspigmentation
Researchers have not yet completely elucidated how hydroxy 
acids  improve  unwanted  pigmentation  engendered  by  sun 
exposure  but  it  appears  that  these  compounds  exert  separate 
effects  on  the  keratinocytes  and  the  melanocytes.  In  the 
epidermis,  the  principal  effect  is  diminished  superficial 
keratinocyte (corneocyte) cohesion leading to desquamation of 
the pigmented keratinocytes with the intention that the newly 
formed keratinocytes will contain less pigment.29 It also helps 
to  increase  the  keratinocyte  turnover  rate  (accelerating  and 
shortening  the  cell  cycle).  By  speeding  up  the  keratinocyte 
transition from birth to desquamation known as the cell cycle, 
this decreases the amount of time that the melanocyte has to 
produce melanin (pigment) and transfer it to the keratinocytes 
(see  Chapter  32,  Overview  of  the  Pigmentation  Process).  

In addition, hydroxy acids may directly inhibit the formation 
of melanin by blocking tyrosinase. Support for this was seen in 
a  study  that  showed  that  in  melanoma  cells,  AHAs  directly 
inhibited  tyrosinase  activity  leading  to  decreased  melanin 
formation.30 A new superficial chemical peel (Theraderm®) that 
combines AHAs, vitamin C and oxygen was shown by Kim in 
2013 to be safe and effective for the treatment of melasma in  
25  Korean  patients  (Fitzpatrick  skin  types  IV  and  V),  with 
significant improvement of hyperpigmentation observed.31

Comparison Studies
In 2008, Oresajo et al. compared the efficacy and clinical toler-
ance of a glycolic acid peel (20–50 percent) to a 5 to 10 percent 
capryloyl salicylic acid, a then-new SA-derived peel, in a split-
face  study  in  50  women  between  35  and  60  years  old  with 
hyperpigmented skin as well as fine lines and wrinkles. Forty-
four participants completed the study, with 41 percent of the 
capryloyl  salicylic  acid  group  and  30  percent  of  the  glycolic 
group  experiencing  significant  improvement  in  fine  lines  and 
wrinkles  compared  to  baseline.  Significant reduction in hyper-
pigmentation compared to baseline was observed in 46 percent of 
the subjects treated with capryloyl salicylic acid and 34 percent 
of those treated with glycolic acid. There were no statistically 
significant differences between the groups, though the investi-
gators  cited  the  apparent  superiority  of  the  new  product, 
which, in five to 10 percent concentrations, they found to be 
generally safe and as effective as 20 to 50 percent glycolic acid 
in treating signs of photoaging.32

The next year, Kornhauser et al. assessed whether topically 
applied hydroxy acids, specifically glycolic and salicylic, alter 
the short-term effects of solar simulated radiation in the skin 
of  14  human  subjects.  Participants  were  treated  in  three  of 
four areas on the mid-back daily Monday through Friday for 
3.5  weeks  with  10  percent  glycolic  acid,  2  percent  SA,  or 
vehicle,  with  the  fourth  area  receiving  no  treatment.  Each 
site was exposed to solar simulated radiation after the final 
treatment  and  shave  biopsies  on  each  site  were  collected. 
The  researchers  found  that  sensitivity  to  solar  simulated 
radiation, as measured by increased erythema, DNA damage, 
and  sunburn  cell  formation,  was  amplified  by  glycolic  acid 
and unaffected by SA.33

In  2010,  Abdel-Daim  et  al.  evaluated  the  photo-
chemopreventive effect of 35 percent glycolic acid dissolved in 
distilled water, 30 percent SA in ethanol, and 10 or 35 percent 
trichloroacetic acid in distilled water on the UV-exposed skin of 
hairless mice. Tumor formation in the treated area, and beyond, 
was  reduced  by  all  of  the  peeling  agents,  with  retention  of 
p53-positive abnormal cells and mRNA expression of cyclooxy- 
genase-2  diminished  in  treated  skin.  Serum  prostaglandin  E2 
was  also  lowered.  The  investigators  concluded  that  use  of 
these  agents  could  confer  a  chemopreventive  effect  by  elimi-
nating photodamaged cells.34

 SAFETY ISSUES

α-Hydroxy Acids
AHAs increase desquamation, which may leave the epidermis 
more vulnerable to UV radiation by thinning the SC. Lai et al. 
demonstrated that combining glycolic acid with UVB exposure 
inhibited cell proliferation and induced apoptosis (cell death). 
The  mechanisms  of  apoptosis  induced  by  co-treatment  of 

 
glycolic  acid  and  UVB  are  likely  related  to  cell  cycle  arrest.35 
Another study showed that use of AHA on UV-exposed skin 
led  to  an  increase  in  sunburn  cells  and  a  lower  minimal 
erythema dose (MED) upon UVB exposure.36 This sensitivity 
to  UV  resolved  after  one  week  of  stopping  the  glycolic  acid 
products.  Although  one  study  revealed  that  glycolic  acid 
imparted  a  photoprotective  effect,37  all  subsequent  studies 
have  indicated  increased  photosensitivity  following  the 
application of AHAs.36,38,39 Concern about the safety of AHA 
use in cosmetic products led to a safety evaluation of AHAs by 
the  Cosmetic  Ingredient  Review  (CIR).  The  FDA  committee 
reviewed the data and issued a guidance (an interim step prior 
to a regulation) calling for labels of AHA-containing cosmetic 
products  (see  FDA  Labeling  Guidelines).  Although  this  FDA 
guidance led consumers to wonder if AHAs “thin the skin,” the 
reverse is actually true. Guinea pigs treated with glycolic acid 
had  approximately  a  twofold  increase  in  epidermal  thickness 
and  almost  double  the  number  of  nucleated  cell  layers  as 
compared  with  the  control  group.40  In  addition,  AHAs  have 
been shown to counteract the epidermal thinning that occurs 
with  prolonged  topical  steroid  use.41  These  studies  illustrate 
that although the SC is thinned by AHAs, the overall epidermis 
is thicker. OTC products are limited to a maximum 10 percent 
AHA concentration by the FDA.42

In  2011,  Okuda  et  al.  evaluated  in  vitro  the  potential  skin 
penetration  of  lactic  and  malic  acids  in  rinse-off  personal  care 
products,  and  compared  them  to  rinse-off  and  leave-on  expo-
sures  to  10  percent  glycolic  acid,  finding  that  there  is  nominal 
penetration  of  AHAs.  They  concluded  that  UV-induced  skin 
effects  of  rinse-off  shampoos  and  conditioners  that  contain 
AHAs are negligible.11

BHA
When  ingested,  SA  exerts  a  possible  ototoxic  effect.43  It  can 
induce  transient  hearing  loss  in  zinc-deficient  individuals.  
For this reason, high percentages of SA (20–30 percent) should 
not  be  applied  to  the  entire  body  in  one  session.  Instead, 
different  segments  of  the  body  should  be  treated  at  different 
times. This is more applicable to the use of in-office peels and 
not to the OTC preparations that usually contain only 0.5 to  
3 percent SA.

There  are  no  studies  specifically  addressing  the  safety  of 
topical SA in pregnancy and most dermatologists advise against 
using it on large areas of the body or in high percentages when 
pregnant. This caution is due to the risks known to be associated 
with  oral  salicylates  such  as  aspirin.  Oral  SA  has  not  been 
associated with an increase in malformations if used during the 
first  trimester,  but  use  in  late  pregnancy  has  been  linked  to 
bleeding, especially intracranial bleeding.44 The risks of aspirin 
use late in pregnancy are probably not relevant when considering 
topical exposure to SA because of the low systemic levels of SA 
when  used  topically.  Topical  SA  is  common  in  many  OTC 
dermatologic agents, and the lack of adverse reports suggests a 
low  teratogenic  potential.45  Nevertheless,  caution  during 
pregnancy is recommended.

SA overdose can lead to salicylate intoxication, the clinical 
presentation of which is typically in a state of metabolic acido-
sis  accompanied  by  compensatory  respiratory  alkalosis.46  A  
16  percentmorbidity  rate  and  a  1  percent  mortality  rate  have 
been observed in patients presenting with an acute overdose.46 
Topical  products  should  be  used  sparingly  if  used  simultane-
ously with oral aspirin to avoid increased levels of salicylates in 
the body.

C H A P T E R  82  ■   H Y D R OX Y   AC I D S  

325

Polyhydroxy Acids
PHAs such as gluconolactone and glucoheptonolactone do not 
cause  sunburn  cell  formation  and,  in  fact,  may  provide  some 
protection from UV radiation.27,47

FDA Labeling Guidelines
The  purpose  of  the  FDA  labeling  “guidance  document”  is  to 
serve as a nonbinding informational resource to help manufac-
turers  to  ensure  that  their  labeling  for  cosmetic  products 
containing AHAs as ingredients is not false or misleading and 
to  educate  consumers  about  the  potential  for  increased  skin 
sensitivity  to  the  sun  from  using  topically  applied  AHA-
containing  cosmetics.48  The  FDA  recommends  that  the 
following  “Sunburn  Alert”  labeling  statement  appear  promi-
nently on cosmetic products containing AHAs:

Sunburn Alert: This product contains an alpha hydroxy acid 
(AHA) that may increase your skin’s sensitivity to the sun 
and particularly the possibility of sunburn. Use a sunscreen, 
wear  protective  clothing,  and  limit  sun  exposure  while 
using this product and for a week afterwards.48

In  addition,  the  FDA  provided  guidance  to  manufacturers 
with Use Conditions for the Sunburn Alert.48 The alert should be 
used in the following situations:

1.  “The product contains an AHA as an ingredient (other than as an 

incidental ingredient as defined in 21 CFR 701.3(l)).

FDA recommends ‘Sunburn Alert’ labeling for cosmetic prod-
ucts containing an AHA as an ingredient. FDA does not recom-
mend ‘Sunburn Alert’ labeling for cosmetic products containing 
an AHA only as an incidental ingredient, as defined in 21 CFR 
701.3(l).

2.  The product is intended for topical application to the skin or mucous 
membrane that are exposed to the sun or for application to areas of 
the body that may result in unintentional application to the skin or 
mucous membrane that are exposed to the sun. The product may be 
a  “leave  on”  product  that  is  intended  to  remain  on  the  skin  or 
mucous membrane or it may be a “discontinuous use” product that 
is intended to be left on the skin for a short period of time (less than 
an hour) followed by thorough rinsing.

FDA  recommends  “Sunburn  Alert”  labeling  for  cosmetic 
products that are intended for topical application to the skin or 
mucous membrane that are exposed to the sun. FDA also recom-
mends “Sunburn Alert” labeling for cosmetic products that are 
intended for application to areas of the body that may result in 
unintentional  topical  application  to  the  skin  or  mucous 
membrane that are exposed to the sun. This guidance does not 
apply to cosmetic products that contain an AHA as an ingredient 
and that are intended for application to non-sun exposed areas of 
the body.

3.  The product contains an AHA as an ingredient and does not also 

contain a sunscreen for sun protection.

This guidance does not apply to drug-cosmetic products that 
contain an AHA as an ingredient and also are labeled to contain 
a sunscreen for sun protection. FDA intends to address labeling 
for such products in a future document.”48

In summary, although BHA, PHAs, exfoliating scrubs, rotating 
facial brushes, microdermabrasion and other agents that increase 
desquamation may also thin the SC, only AHAs are required to 
display this “sunburn alert” on the label. However, it is prudent 
to recommend  to  patients and  clients to use a daily sunscreen 
and an antioxidant when using these agents. PHAs often have 

 
326 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

antioxidant properties that give them a benefit over other des-
quamating ingredients.49

 ENVIRONMENTAL IMPACT

Hydroxy acids have been synthesized in the laboratory for the 
last century. While numerous plants contain these organic acids, 
few  if  any  are  targeted  specifically  on  a  large-scale  industrial 
basis; therefore, the likely environmental impact is minimal.

 FORMULATION CONSIDERATIONS

Hydroxy acid formulations are acidic and have varying acidity 
constants (pKa); therefore, the pH of the formulation, formula-
tion  type,  combination  of  ingredients,  and  order  of  product 
application are especially important. For example, some ingre-
dients perform poorly in an acidic environment and, therefore, 
should  not  be  used  just  after  or  at  the  same  time  as  another 
hydroxy acid-containing product.

In order to use hydroxy acids properly, one must understand 
how the pKa and pH affect the amount of the acid form and the 
salt form of the hydroxy acid available in the product. The acid 
form  is  the  “active  form”  in  the  product  because  it  causes 
exfoliation,  while  the  salt  form  often  causes  irritation.  It  is 
necessary to have the proper balance of the salt and acid forms to 
produce  an  efficacious  preparation  with  minimal  irritation  (see 
Chapter  2,  Basic  Cosmetic  Chemistry).  The  pKa  is  the  pH  at 
which the free acid level is the same as the level of the salt form of 
the  acid.  When  the  pH  is  less  than  the  pKa,  the  free  acid  form 
predominates;  when  the  pH  is  greater  than  the  pKa,  the  salt  
form predominates. The pKa for AHAs is 3.83; for SA, 2.97.12,43 
Because the pKa of BHA differs from that of the AHA family, it is 
difficult to formulate a product combining BHA and an AHA that 
reaches  an  optimal  pH.  For  example,  in  a  combination  AHA/
BHA product with a pH of 3.5, the AHA acid form would pre-
dominate  while  the  BHA  salt  form  would  predominate.  This 
would render the effects of BHA suboptimal. The pKa for PHAs 
varies depending on the type of hydroxy acid in the preparation.
Some  hydroxy  acid  formulations  are  “buffered”  to  increase 
their tolerability to the skin. Buffering results when a base, such 
as  sodium  bicarbonate  or  sodium  hydroxide,  is  added  to  the 
solution. This raises the level of the salt form, which yields less 
free acid and a higher pH. Buffered solutions resist pH changes 
when  a  salt  or  an  acid  is  added  to  the  preparation.  Fewer  side 
effects are associated with these solutions due to the lower pH 
and reduced free acid, but there may also be a decrease in efficacy.

 USAGE CONSIDERATIONS

Knowing the pKa and pH of hydroxy acid formulations is criti-
cal when designing a skin care regimen for a patient. In addition, 
their  Baumann  Skin  Type  (see  Chapter  1,  The  Importance  of 
Skin Type: The Baumann Skin Type System) should be taken 
into  consideration.  S3  stinging  types  often  cannot  consider  a 
hydroxy  acid  product  with  a  substantial  level  of  free  acid 
because  they  would  not  be  able  to  tolerate  the  resultant 
stinging.50 The “lactic acid stinging test” was previously used to 
identify  such  stinging  skin  types.51  In  a  study  with  30  young 
adult student volunteers, Frosch and Kligman applied 5 percent 
lactic  acid  to  the  nasolabial  fold  and  cheek  in  each  subject.52 
Approximately 20 percent of the participants reported experi-
encing  an  unpleasant  sensation.  However,  not  all  S3  stinging 

skin types test positive to the lactic acid stinging test, implying 
that  the  response  is  due  to  more  than  just  the  low  pH.  
A fuller explanation is thus far elusive. At this time, it is correct 
to say that individuals whose Baumann Skin Type tests indicate 
they have an S3 skin type are more likely to sting from hydroxy 
acids than those revealed to have a resistant type skin.

Although  hydroxy  acids  tend  to  thin  the  SC,  it  appears 
that they do not impair the barrier or facilitate the penetra-
tion of other ingredients, unless the ingredient penetration 
is  affected  by  pH  changes.  In  1999,  Hood  et  al.  evaluated 
the barrier integrity of hairless guinea pigs after treatment 
with  5  and  10  percent  glycolic  acid  at  a  pH  of  3.40  They 
found  no  increase  in  skin  penetration  of  exogenously 
applied  hydroquinone,  musk  xylol,  and  3H  water  when 
compared  to  controls.  In  fact,  evidence  suggests  that 
hydroxy  acids,  particularly  PHAs,  can  improve  the  skin 
barrier function.15

The pH and effects on the skin barrier may increase or decrease 
absorption of other ingredients and should be considered when 
designing  a  skin  care  regimen.  In  addition,  the  low  pH  of  the 
hydroxy  acid  may  influence  the  efficacy  of  other  skin  care 
ingredients in the formulation or skin care regimen. The antioxi-
dant  properties  of  PHAs  may  help  prevent  oxidation  of  labile 
ingredients. For example, gluconolactone may prevent the oxida-
tion of hydroquinone and other rapidly oxidized ingredients.49

 SIGNIFICANT BACKGROUND

Topical preparations that contain AHAs have long been known 
to  exert  significant  influence  on  epidermal  keratinization  and 
have been used since the 1970s to treat dry skin conditions.13 
The cosmetic effects of hydroxy acids include normalization of 
SC  exfoliation  resulting  in  increased  plasticization  and 
decreased formation of dry scales on the skin surface. Hydroxy 
acids function by degrading desmosomes and allowing desqua-
mation to proceed. They also modify corneocyte cohesiveness 
at the basement levels of the SC, where they affect its pH, and 
enhance desquamation.14,15 An SC that has been thinned in this 
fashion is left more pliable and compact, giving the skin a more 
youthful appearance. This increased flexibility rendered by the 
use of AHAs has been shown to persist even in low-humidity 
situations.53  A  thinner,  more  compact  SC  is  also  desirable 
because  it  better  reflects  light,  making  the  skin  appear  more 
luminous.15

AHAs and PHAs possess strong humectant properties and are 
frequently added to moisturizers. Humectants draw water into 
the  skin,  provoking  a  slight  swelling  of  the  SC  that  gives  the 
perception of smoother skin with fewer wrinkles. SA is lipophilic 
and  breaks  down  occlusive  lipids  on  the  skin  surface  and  can 
lead to dryness. Therefore, SA is an appropriate treatment option 
for  individuals  with  oily  skin  whereas  AHAs  and  PHAs  are 
suitable for dry skin.

 CONCLUSION

Hydroxy acids join sunscreens, retinoids, and ascorbic acid as 
the  most  effective  antiaging  agents.  To  increase  safety  and 
efficacy, hydroxy acids should always be used in conjunction 
with  sunscreens.  Long-term  use  of  hydroxy  acids  has  been 
proven  to  enhance  skin  appearance  by  improving  fine  lines, 
increasing  skin  radiance,  evening  skin  tone,  and  augmenting 
epidermal  thickness.  Use  of  hydroxy  acids  thins  the  SC  and 
may not be tolerated by individuals with S3 type sensitive skin.

 
REFERENCES

1.  Babilas  P,  Knie  U,  Abels  C.  Cosmetic  and  dermatologic  use  of 

alpha hydroxyl acids. J Dtsch Dermatol Ges. 2012;10:488.

2.  Green BA, Briden E. PHAs and bionic acids: Next generation of 
hydroxy  acids.  In:  Draelos  ZD,  ed.  Cosmeceuticals.  2nd  ed. 
Amsterdam: Elsevier Inc; 2009:209–215.

3.  Clark E, Scerri L. Superficial and medium-depth chemical peels. 

Clin Dermatol. 2008;26:209.

4.  Yamamoto  Y,  Uede  K,  Yonei  N,  et  al.  Effects  of  alpha-hydroxy 
acids on the human skin of Japanese subjects: The rationale for 
chemical peeling. J Dermatol. 2006;33:16.

5.  U.S. Patent number 5385938.
6.  Kornhauser A, Coelho SG, Hearing VJ. Applications of hydroxy 
acids: Classification, mechanisms, and photoactivity. Clin Cosmet 
Investig Dermatol. 2010;3:135.

7.  Klessig DF, Malamy J. The salicylic acid signal in plants. Plant Mol 

Biol. 1994;26:1439.

8.  Raskin  I.  Role  of  salicylic  acid  in  plants.  Annu  Rev  Plant  Physiol 

Plant Mol Biol. 1992;43:439.

9.  Fischer J, Ganellin CR, Ganesan A, et al. Acetylsalicylic acid (aspirin). 
In: Fischer J, Ganellin CR, eds. Analogue-based  Drug Discovery  II. 
Weinheim: Wiley; 2010:33.

10.  Baumann L, Allemann IB. Depigmenting agents. In: Baumann L, 
Saghari  S,  Weisberg  E,  eds.  Cosmetic  Dermatology:  Principles  and 
Practice. 2nd ed. New York: McGraw-Hill; 2009:287.

11.  Okuda M, Donahue DA, Kaufman LE, et al. Negligible penetra-
tion of incidental amounts of alpha-hydroxy acid from rinse-off 
personal care products in human skin using an in vitro static dif-
fusion cell model. Toxicol In Vitro. 2011;25:2041.

12.  Baumann L, Saghari S. Chemical peels. In: Baumann L, Saghari S, 
Weisberg E, eds. Cosmetic Dermatology: Principles and Practice. 2nd ed. 
New York: McGraw-Hill; 2009:148–162.

13.  Van Scott EJ, Yu RJ. Control of keratinization with alpha-hydroxy 
acids and related compounds. I. Topical treatment of ichthyotic 
disorders. Arch Dermatol. 1974;110:586.

14.  Van  Scott  EJ,  Yu  RJ.  Hyperkeratinization,  corneocyte  cohesion, 

and alpha hydroxy acids. J Am Acad Dermatol. 1984;11:867.
15.  Berardesca E, Distante F, Vignoli GP, et al. Alpha hydroxyacids mod-
ulate stratum corneum barrier function. Br J Dermatol. 1997;137:934.
16.  Manosroi A, Chutoprapat R, Abe M, et al. Anti-aging efficacy of 
topical  formulations  containing  niosomes  entrapped  with  rice 
bran bioactive compounds. Pharm Biol. 2012;50:208.

17.  Ditre CM, Griffin TD, Murphy GF, et al. Effects of alpha-hydroxy 
acids  on  photoaged  skin:  A  pilot  clinical,  histologic,  and  ultras-
tructural study. J Am Acad Dermatol. 1996;34:187.

18.  Kim SJ, Park JH, Kim DH, et al. Increased in vivo collagen synthe-
sis and in vitro cell proliferative effect of glycolic acid. Dermatol 
Surg. 1998;24:1054.

19.  Moon SE, Park SB, Ahn HT, et al. The effect of glycolic acid on 
photoaged albino hairless mouse skin. Dermatol Surg. 1999;25:179.
20.  Bernstein  EF,  Lee  J,  Brown  DB,  et  al.  Glycolic  acid  treatment 
increases type I collagen mRNA and hyaluronic acid content of 
human skin. Dermatol Surg. 2001;27:429.

21.  Okano Y, Abe Y, Masaki H, et al. Biological effects of glycolic acid 
on dermal matrix metabolism mediated by dermal fibroblasts and 
epidermal keratinocytes. Exp Dermatol. 2003;12(Suppl 2):57.
22.  Middleton  J.  Sodium  lactate  as  a  moisturizer.  Cosmet  Toiletries. 

1978;93:85.

23.  Wehr  R,  Krochmal  L,  Bagatell  F,  et  al.  A  controlled  two-center 
study of lactate 12 percent lotion and a petrolatum-based creme 
in patients with xerosis. Cutis. 1986;37:205.

24.  Smith  WP.  Epidermal  and  dermal  effects  of  topical  lactic  acid.  

J Am Acad Dermatol. 1996;35:388.

25.  Rendl M, Mayer C, Weninger W, et al. Topically applied lactic acid 
increases  spontaneous  secretion  of  vascular  endothelial  growth 
factor by human reconstructed epidermis. Br J Dermatol. 2001;145:3.
26.  Swinehart  JM.  Salicylic  acid  ointment  peeling  of  the  hands  and 
forearms. Effective nonsurgical removal of pigmented lesions and 
actinic damage. J Dermatol Surg Oncol. 1992;18:495.

27.  Bernstein EF, Brown DB, Schwartz MD, et al. The polyhydroxy 
acid gluconolactone protects against ultraviolet radiation in an in 
vitro model of cutaneous photoaging. Dermatol Surg. 2004;30:189.
28.  Rona  C,  Vailati  F,  Berardesca  E.  The  cosmetic  treatment  of 

wrinkles. J Cosmet Dermatol. 2004 Jan;3(1):26–34.

C H A P T E R  82  ■   H Y D R OX Y   AC I D S  

327

29.  Slavin JW. Considerations in alpha hydroxy acid peels. Clin Plast 

Surg. 1998;25:45.

30.  Usuki A, Ohashi A, Sato H, et al. The inhibitory effect of glycolic 
acid and lactic acid on melanin synthesis in melanoma cells. Exp 
Dermatol. 2003;12(Suppl 2):43.

31.  Kim  WS.  Efficacy  and  safety  of  a  new  superficial  chemical  peel 
using  alpha-hydroxy  acid,  vitamin  C  and  oxygen  for  melasma.  
J Cosmet Laser Ther. 2013;15:21.

32.  Oresajo C, Yatskayer M, Hansenne I. Clinical tolerance and effi-
cacy of capryloyl salicylic acid peel compared to a glycolic acid 
peel  in  subjects  with  fine  lines/wrinkles  and  hyperpigmented 
skin. J Cosmet Dermatol. 2008;7:259.

33.  Kornhauser A, Wei RR, Yamaguchi Y, et al. The effects of topically 
applied  glycolic  acid  and  salicylic  acid  on  ultraviolet  radiation-
induced erythema, DNA damage and sunburn cell formation in 
human skin. J Dermatol Sci. 2009;55:10.

34.  Abdel-Daim  M,  Funasaka  Y,  Kamo  T,  et  al.  Effect  of  chemical 

peeling on photocarcinogenesis. J Dermatol. 2010;37:864.

35.  Lai WW, Hsiao YP, Chung JG, et al. Synergistic phototoxic effects 
of  glycolic  acid  in  a  human  keratinocyte  cell  line  (HaCaT).  
 J Dermatol Sci. 2011;64:191.

36.  Kaidbey  K,  Sutherland  B,  Bennett  P,  et  al.  Topical  glycolic  acid 
enhances  photodamage  by  ultraviolet  light.  Photodermatol 
Photoimmunol Photomed. 2003;19:21.

37.  Perricone NV, Dinardo JC. Photoprotective and antiinflammatory 

effects of topical glycolic acid. Dermatol Surg. 1996;22:435.

38.  Tsai  TF,  Bowman  PH,  Jee  SH,  et  al.  Effects  of  glycolic  acid  on 
light-induced pigmentation in Asian and caucasian subjects. J Am 
Acad Dermatol. 2000;43:238.

39.  Draelos ZD. Therapeutic moisturizers. Dermatol Clin. 2000;18:597.
40.  Hood HL, Kraeling ME, Robl MG, et al. The effects of an alpha 
hydroxy acid (glycolic acid) on hairless guinea pig skin permeabil-
ity. Food Chem Toxicol. 1999;37:1105.

41.  Lavker RM, Kaidbey K, Leyden JJ. Effects of topical ammonium 
lactate on cutaneous atrophy from a potent topical corticosteroid. 
J Am Acad Dermatol. 1992;26:535.

42.  Thomas  JR,  Dixon  TK,  Bhattacharyya  TK.  Effects  of  topical  on 
the aging skin process. Facial Plast Surg Clin North Am. 2013;21:55.
43.  Clark CP 3rd. Alpha hydroxy acids in skin care. Clin Plast Surg. 

1996;23:49.

44.  Draelos  Z.  Hydroxy  acids  for  the  treatment  of  aging  skin.  

 J Geriatric Dermatol. 1997;5:236.

45.  Zhai H, Hannon W, Hahn GS, et al. Strontium nitrate suppresses 
chemically-induced  sensory  irritation  in  humans.  Contact 
Dermatitis. 2000;42:98.

46.  Kreplick LW. Salicylate toxicity in emergency medicine. eMedicine 
Journal. 2001;2(6), June 7. http://www.emedicine.com. Accessed 
February 18, 2014.

47.  Green BA, Wildnauer RH, Edison BL. Polyhydroxy acids (PHAs) 
provide conditioning effects to skin without increasing sensitivity 
to UV light. American Academy of Dermatology poster exhibit, 
New  Orleans,  LA,  February  22–27,  2002.  http://www 
.neostratapro.com/images/neostratapro/en_us/local/landing 
/2002_phas_uv_light.pdf. Accessed January 14, 2014.

48.  U.S.  Food  and  Drug  Administration  Guidance  for  Industry: 
Labeling  for  Topically  Applied  Cosmetics  Containing  Alpha 
Hydroxy Acids as Ingredients, January 10, 2005. http://www.fda 
.gov/Cosmetics/GuidanceComplianceRegulatoryInformation 
/GuidanceDocuments/ucm090816.htm.  Accessed  January  15, 
2014.

49.  Green  B.  After  30  years…  the  future  of  hydroxyacids.  J  Cosmet 

Dermatol. 2005;4:44.

50.  Baumann L. Sensitive skin. In: Baumann L, Saghari S, Weisberg E, 
eds. Cosmetic Dermatology: Principles and Practice. 2nd ed. New York: 
McGraw-Hill; 2009:95–96.

51.  Baumann L, Castanedo-Tardan MP. Bioengineering of the skin. In: 
Baumann  L,  Saghari  S,  Weisberg  E,  eds.  Cosmetic  Dermatology: 
Principles  and  Practice.  2nd  ed.  New  York:  McGraw-Hill;  2009: 
335–96.

52.  Frosch  PJ,  Kligman  AM.  A  method  for  appraising  the  stinging 
capacity  of  topically  applied  substances.  J  Soc  Cosmet  Chem. 
1977;28:197.

53.  Takahashi M, Machida Y. The influence of hydroxyacids on the 
rheological properties of the stratum corneum. J Soc Cosmet Chem. 
1985;36:177.

 
328 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

C H A P T E R   8 3

Retinoids (Retinol)

Activities:

Antiaging, antiacne, depigmenting

Important Chemical Components:

Natural retinoids: The major naturally-occurring retinoids 
are  tretinoin  (all-trans  retinoic  acid,  also  known  simply 
as retinoic acid), the stereoisomers of tretinoin [isotreti-
noin  (13-cis-retinoic  acid)  and  alitretinoin  (9-cis-retinoic 
acid)],  retinol,  retinaldehyde,  and  retinol  esters  (retinyl 
acetate, retinyl palmitate, retinyl propionate).
Synthetic retinoids: The retinoids that have been designed 
in  the  laboratory  to  increase  stability  are  tazarotene 
(molecular formula: C21H21NO2S), adapalene (molecular 
formula:  C28H28O3),  and  retinyl  retinoate  (an  ester  of 
retinoic acid and all-trans retinol).

Origin Classification:

Retinoids  are  natural  and  synthetic  derivatives  of 
vitamin A (also known as all-trans retinol). As ingredients 
in skin therapy, these products are laboratory made.

Personal Care Category:

Antiaging, antiacne

Recommended  for  the  following  Baumann  Skin 
Types:

DRNW,  DRPT,  DRPW,  DSNW,  DSPT,  DSPW,  ORNW, 
ORPW, ORPT, OSPW, OSNW, and OSPT

 SOURCE

Vitamin A is found naturally in the skin and other parts of the 
body  and  is  obtained  through  the  diet  from  carotenoid-
containing  foods,  such  as  sweet  potatoes,  carrots,  dark  green 
leafy  vegetables,  tomatoes,  squash,  apricots,  cantaloupe,  red 
pepper, and tropical fruits (e.g., mangoes and papayas).1,2 Like 
β-carotene,  lutein,  lycopene,  and  other  carotenoids,  retinoids 
are  derived  from  vitamin  A  (all-trans  retinol).  The  retinoid 
family includes natural (e.g., tretinoin, isotretinoin, alitretinoin, 
retinol,  and  retinaldehyde)  and  synthetic  (e.g.,  tazarotene, 
adapalene,  and  retinyl  retinoate)  forms.  Retinol  and  retinyl 
esters  represent  99  percent  of  cutaneous  retinoids  naturally 
present in the skin.3 The retinoids used in prescription products 
and  over-the-counter  (OTC)  skin  care  formulations  are 
synthesized in laboratories.

Retinoids have demonstrated salutary benefits in the treatment 
of  various  cutanous  conditions,  including  acne,  psoriasis, 
ichthyosis,  and  photoaging.  In  fact,  retinoid  efficacy  has  been 
reported in more than 125 distinct dermatologic disorders.4 Two 
prescription  retinoids,  tretinoin  (retinoic  acid)  and  tazarotene, 
have  been  approved  by  the  United  States  Food  and  Drug 
Administration  (FDA)  for  use  in  the  treatment  of  photoaging, 

TABLE 83-1
Pros and Cons of Retinoids

Pros
Variety of products
Excellent research on efficacy, with significant 
evidence from randomized controlled trials

Irritation lessens with time

Cons
Unstable
Difficult to formulate

Many products do not work because of 

packaging and stability issues

Treats acne and skin pigmentation as well as 

Causes irritation especially in S2 rosacea 

wrinkles

Protects skin from sun damage

types

Prevalent myth, actually based on in vitro 
and animal studies,3 that retinoids make 
skin more photosensitive
Should be used at night only

although isotretinoin (the 13-cis isomer of tretinoin), and several 
synthetic  retinoids  are  deployed  for  therapeutic  applications 
(Table  83-1).3  In  addition,  retinol,  though  it  has  not  been 
approved by the FDA to treat photoaging or included among the 
FDA  monograph  ingredients  for  that  purpose,  is  known  to 
impart  antiaging  activity.  The  retinoids  used  in  effective  skin 
care products include retinoic acid (tretinoin), retinol, retinalde-
hyde,  adapalene,  or  tazarotene.  Retinyl  esters  such  as  retinyl 
palmitate  (RP)  are  used  in  several  OTC  formulations,  but  the 
efficacy is questionable because penetration rates are minimal.

 HISTORY

Vitamin A was recognized in 1928 by Green and Mellanby as 
having  anti-infective  properties.3,5  The  structure  of  retinol 
was ascertained just three years later by Karrer et al.6 In 1937, 
Karrer was a corecipient of the Nobel Prize in Chemistry for 
this  and  related  work.  In  1943,  the  first  study  to  document 
the  use  of  vitamin  A  for  the  treatment  of  acne  was  pub-
lished.7  Tretinoin  was  first  used  in  dermatologic  therapy  in 
1959  by  Stüttgen.7–9  In  1969,  Kligman  et  al.  reported  that 
topically applied tretinoin was efficacious in the treatment of acne 
vulgaris.8,10

The apparent ameliorative effects of retinoids on aged skin 
were  recognized  serendipitously  by  Kligman  et  al.  in  the  
mid-1980s  in  examinations  of  female  acne  patients  who 
reported  that  their  skin  felt  smoother  and  less  wrinkled  after 
treatment.11 A small subsequent clinical trial revealed that daily 
topical application of 0.05 percent tretinoin to the forearm and 
face  diminished  ultraviolet  (UV)-induced  epidermal  atrophy, 
dysplasia, keratosis, and dyspigmentation compared to vehicle 
control.12  These  observations  have  since  been  duplicated  in 
numerous studies. 

A metabolic precursor to tretinoin, retinol is often incorporated 
in OTC “antiwrinkle” creams. There is currently no FDA-approved 
monograph for the use of retinol in cosmetics and personal care 
products; however, one may be developed in the future.

 
 Chemistry

Vitamin A is found in various forms, with multiple precursors 
to retinoic acid.

Retinoids
Over the last several decades, myriad synthetic retinoids have 
been developed, with the vitamin A or “retinoid” family now 
including retinyl esters (such as RP), retinol, tretinoin (retinoic 
acid), adapalene, tazarotene, and oral isotretinoin (Accutane) in 
addition to four carotenoids such as β-carotene.

Retinoids  regulate  growth  and  differentiation  in  epithelial 
cells  and  suppress  tumor  promotion  during  experimental 
carcinogenesis, thus hampering malignant cell growth, quelling 
inflammation,  and  supporting  the  immune  system.13  This  is 
accomplished  at  the  molecular  level  through  the  regulation  of 
gene transcription and influencing cellular differentiation as well 
as proliferation. Retinoids act directly by initiating transcription 
from genes with promoter regions containing retinoid response 
elements or indirectly by precluding the transcription of particu-
lar genes.14

The  use  of  topical  retinoids  has  been  shown  clinically  and 
histologically  to  be  effective  in  reversing  some  of  the  physical 
alterations and cutaneous manifestations induced in humans by 
excessive  sun  exposure.  Irritant  reactions,  such  as  xerosis, 
erythema,  and  scaling,  tend  to  be  the  worst  of  any  adverse 
responses  to  retinoid  compounds  (i.e.,  tretinoin,  isotretinoin, 
retinaldehyde,  and  tazarotene).8  This  irritation  is  dose  related 
and resolves with continued use (tachyphylaxis).

Retinaldehyde, retinol, and retinyl esters, all natural retinoic acid 
precursors, are the retinoids used in cosmeceuticals.3,15 Retinol is 
the most efficacious and the most irritating of the forms of retinol 
available  without  a  prescription.  Though  less  irritating,  retinyl 
esters and retinaldehyde typically have less clinical efficacy, due to 
decreased  penetration.  Retinaldehyde,  which  exhibits  slightly 
more efficacy than retinyl esters, is generally well tolerated, and 
appears to renew epidermal cells, blunt the effects of photoaging, 
and limit oxidative stress and bacterial flora on the skin.3

Lipophilic  retinoids  such  as  retinol,  tretinoin,  adapalene,  and 
tazarotene  easily  penetrate  the  epidermis.3  Some  protocols  have 
suggested  short  contact  time  such  as  15  minutes  with  retinoid 
products to decrease the amount of absorption. This ease of pene-
tration of retinoids is unique among antiaging products; most prod-
ucts cannot penetrate into the skin, greatly reducing their efficacy. 
(Retinoid esters such as RP are an exception, and do not penetrate 
well due to their chemical structure.) All retinoids, by definition, 
bind the retinoic acid receptor and therefore should improve pho-
toaged  skin;  however,  only  tretinoin  (Renova)  and  tazarotene 
(Avage) are approved by the FDA to treat photoaged skin. 

Retinoid Receptors
Although  retinoids  have  been  extensively  studied  for  several 
years,  much  remains  to  be  elucidated  regarding  the  mecha-
nisms  of  action  of  these  compounds.  In  the  1970s,  retinoid-
binding  proteins  were  discovered  and,  in  1987,  retinoic  acid 
receptors were identified, leading to the insight that tretinoin 
functions  as  a  hormone.16–18  The  biologic  effects  of  retinoic 
acid are mediated by binding proteins such as cellular retinoic 
acid-binding proteins (CRAB) I and II; cellular retinol-binding 
protein (CRBP); and the nuclear receptors retinoic acid recep-
tors (RARs) and retinoid X receptors (RXRs), both sets of which 
consist of α, β, and γ isotypes.11,19,20 RARs heterodimerize with 

C H A P T E R  83  ■   R E T I N O I D S   ( R E T I N O L ) 

329

RXRs  in  order  to  interact  with  their  retinoic  acid  response 
elements  (RAREs),  with  RXR-α  and  RAR-γ  heterodimers 
serving  as  the  primary  cutaneous  retinoid  receptors  in 
humans.20 (See Chapter 79, Retinol, Retinyl Esters, and Retinoic 
Acid, for more information on retinoid receptors.)

Adapalene and tazarotene bear no structural resemblance to 
natural  retinoids  but  are  categorized  as  retinoids  because  they 
activate  retinoic  acid  receptors  and  share  several  functional 
traits.20  Adapalene  is  marketed  as  Differin  and  EpiDuo. 
Tazarotene,  marketed  as  Tazorac  and  Avage,  is  selective  for 
RAR-β and RAR-γ and is FDA approved to treat psoriasis, acne, 
and photoaging.21,22

 OrAL  Uses

Isotretinoin  (Accutane)  is  used  orally  to  treat  acne.  Oral 
retinoids are rarely used for photoaging because of the risk of 
teratogenicity. One study showed that a dose of 10 to 20 mg 
three times a week for two months led to improvement of skin 
aging  signs  such  as  wrinkles.23  A  discussion  of  oral  retinoid 
compounds is beyond the scope of this text.

 tOPiCAL Uses

In the author’s opinion, retinoids are the most important ingre-
dients to treat and prevent skin aging. Their use is backed up by 
multiple studies. Retinoids elicit their effects at the molecular 
level  by  regulating  gene  transcription  and  affecting  activities 
such  as  cellular  differentiation  and  proliferation.  All-trans 
retinoic  acid  (tretinoin)  has  been  shown  in  various  studies  to 
decrease wrinkles and is the most frequently studied retinoid 
for photoaging treatment.12,20 Much work has been performed 
to characterize this mechanism.24–27 In general, retinoids treat 
and prevent photoaging by inhibiting the breakdown and loss 
of  collagen  and  stimulating  skin  cells  (fibroblasts)  to  increase 
collagen synthesis.27–30

The use of retinoids to prevent or treat the cutaneous signs of 
photoaging  has  been  investigated  in  several  studies.  The  first 
clinical trials demonstrating clinical improvement of photoaged 
skin using tretinoin were published in 1986 and 1988.12,31 The 
findings by Kligman et al. and Weiss et al. have since been dupli-
cated numerous times. In one randomized, single-center study 
performed by Griffiths et al. in 1995, 100 subjects were divided 
into two tretinoin treatment groups (0.1 and 0.025 percent) and 
a  vehicle  cream  group.32  Statistically  significant  improvements 
were seen in both tretinoin groups compared with vehicle. 

A  cascade  of  histologic  changes  have  been  associated  with 
retinoid use, including the abrogation of cellular atypia, increased 
compacting of the stratum corneum (SC), diminished clumping 
of melanin in basal cells, and polarity correction of keratinocytes, 
with  more  orderly  differentiation  as  cells  move  upward.  The 
ultrastructural  changes  induced  by  retinoid  use  include  hyper-
proliferation  of  keratinocytes  (e.g.,  larger  nuclei,  increased 
ribosomes,  etc.)  and  melanosome  size  reduction.  The  topical 
application  of  tretinoin  0.1  percent  to  photodamaged  skin  has 
been shown to prevent the breakdown of collagen and promote 
collagen synthesis, partially restoring collagen type I levels and 
increasing anchoring fibrils (collagen type VII).33

Although tretinoin and tazarotene are FDA approved to treat 
photoaged skin, which means that the efficacy of these retinoids 
is proven, retinol has not undergone the FDA approval process. 
Retinol  is  considered  a  cosmetic  ingredient.  Nevertheless,  a 
number of studies have demonstrated its efficacy in treating aged 

 
330 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

skin  but  no  company  has  made  the  large  monetary  investment 
and time commitment required to seek FDA approval. In spite of 
the lack of FDA approval to treat photoaged skin, several studies 
support the use of retinol to treat aged skin. Many of these were 
performed by the same team responsible for the original work on 
the FDA-approved forms of retinoic acid: John Voorhees, Chair of 
Dermatology  at  the  University  of  Michigan,  and  Sewon  Kang, 
Chair  of  Dermatology  at  Johns  Hopkins  School  of  Medicine. 
These studies are published in reputable peer-reviewed journals 
such as the Journal of Investigative Dermatology.34–38 For this reason, 
the author believes that using OTC retinol can achieve the same 
results as using a prescription retinoid. 

Retinol  has  been  shown  to  penetrate  skin  better  than  retinoic 
acid.37 One study demonstrated that retinol improves the appear-
ance of wrinkles in sun-protected areas.39 Biopsies of treated skin 
show that retinol does induce cellular and molecular changes simi-
lar to those observed with the application of 0.025 percent retinoic 
acid.37  A  separate  study  showed  that  1.6  percent  retinol  induced 
significant epidermal thickening and other skin changes similar to 
those produced by retinoic acid but without measurable irritation.38 
An  elegant  and  frequently  quoted  randomized,  double-blind, 
vehicle-controlled, left and right arm comparison study by Kafi et al. 
in 2007 showed that skin treated with 0.4 percent retinol showed 
increased glycosaminoglycans and collagen in biopsies as compared 
to those treated with vehicle.39 Visual scales also showed improve-
ment of skin wrinkling in the retinol-treated group. Another study 
by Tucker-Samaras et el. showed that 0.1 percent stabilized retinol 
improved photoaged skin as compared to vehicle.40

Retinol and RP are the two most frequently used retinoids in 
OTC products. They are typically listed as excipient or “inactive” 
ingredients  based  on  their  status  as  “cosmetic”  ingredients 
according  to  the  FDA.  Retinol  is  now  well  known  for  its 
photoinstability, but using it at night, along with the addition of 
an antioxidant to the regimen or formulation, circumvents this 
problem.  Significantly,  retinol  is  now  recognized  for  exerting 
similar effects on the retinoic acid receptor as tretinoin. 

Retinyl Palmitate
RP,  a  storage  and  ester  form  of  retinol  and  the  main  type  of 
vitamin  A  present  naturally  in  the  skin,41  has  steadily  gained 
popularity over the last two decades and is incorporated into 
more  than  600  skin  care  products,  including  cosmetics, 
sunscreens,  as  well  as  FDA-approved  OTC  and  prescription 
drugs.42 However, Xia et al., who had earlier demonstrated that 
irradiation  of  RP  with  UVA  yields  photodecomposition 
products,  synthesis  of  reactive  oxygen  species,  and  lipid 
peroxidation  induction,  obtained  similar  findings  identifying 
RP as a photosensitizer after irradiation with UVB.43 Four years 
later,  the  Environmental  Working  Group  (EWG)  issued  a 
consumer warning about the potential photocarcinogenicity of 
RP-containing  sunscreens.  The  EWG’s  methodology  and 
conclusions,  which  the  organization  stood  by,  were  roundly 
criticized in a debate that wound up in the pages of the Journal 
of the American Academy of Dermatology.44 While current evidence 
is  inconclusive,  the  weight  of  extant  evidence  and  clinical 
experience suggests that RP does not easily penetrate into the 
skin.  Retinol  rather  than  RP,  even  though  it  is  easier  to 
formulate,22 is thus the recommended choice.

Retinyl Retinoate
In 2011, Kim et al. conducted a 12-week, randomized, double-
blind,  controlled  trial  to  investigate  the  efficacy  of  retinyl 
retinoate, a new synthetic hybrid of retinoic acid and retinol, in 

treating the periorbital wrinkles of 11 Korean women over the 
age  of  30.  The  researchers  observed  a  statistically  significant 
reduction in facial wrinkles in all 11 participants. Compared to 
0.075 percent retinol cream, 0.06 percent retinyl retinoate treat-
ment over three months resulted in diminished wrinkle depth 
and size. In addition, the test cream outperformed retinol by 22 
percent  in  terms  of  visual  wrinkle  improvement  and  the 
maximum roughness improvement rate. The authors concluded 
that retinyl retinoate reduced facial wrinkles while exhibiting 
greater photostability and provoking less irritation than earlier 
generations of retinoids.45

A year earlier, several of the same team performed two similar 
clinical studies, with a total of 46 Korean women with periorbital 
wrinkles.  Twenty-four  subjects  applied  0.06  percent  retinyl 
retinoate  to  one  side  of  the  face  twice  daily  and  a  placebo 
ointment  to  the  other  side  for  12  weeks  in  the  first  study. 
Twenty-two patients in the second study, conducted over eight 
weeks, applied 0.06 percent retinyl retinoate twice daily to one 
side  of  the  face  and  0.075  percent  retinol  to  the  other  side. 
Assessments  by  investigators  and  subjects  indicated  greater 
improvements in wrinkles on skin treated with retinyl retinoate 
compared to placebo or retinol, with no reported side effects. In 
addition,  average  roughness  was  significantly  diminished  by 
retinyl retinoate based on skin replica analysis. The investigators 
concluded that twice-daily application of retinyl retinoate was 
significantly more effective in treating periorbital wrinkles than 
placebo or retinol.46

 SAFETY ISSUES

Erythema,  skin  irritation,  and  desquamation  are  the  most 
common adverse side effects of topical retinoids. The type and 
dose  of  retinoid  influences  such  reactions,  which  typically 
occur within two to four days of beginning topical treatment.47 
When  retinoid  products  were  first  commercialized,  many 
believed that the redness and inflammation were a prerequisite 
for improvement of aged skin. It has now been established that 
benefits can be derived from using retinoids without incurring 
irritation. Indeed, the attenuating effects on photoaging can be 
separated  from  the  irritation  reliably  produced  by  retinoids. 
Griffiths  et  al.  showed  this  in  1995  in  their  double-blind, 
vehicle-controlled experiment with two different strengths of 
tretinoin  (0.1  and  0.025  percent)  used  to  treat  photoaging. 
Although the formulations were equally efficacious, the degree 
of  irritation  varied  substantially  between  the  two  treatment 
groups, with the 0.1 percent tretinoin-treated group displaying 
almost  a  threefold  greater  incidence  of  irritation  than  those 
treated with the 0.025 percent preparation.32 New ingredients 
are  being  investigated  to  block  the  irritation  of  retinoids 
without affecting the efficacy.

Erythema, flushing, and facial stinging – common side effects 
of topical retinoids – can be reduced by applying the retinoid on 
top of a moisturizer to limit penetration and by decreasing the 
amount  and  frequency  of  application  until  the  retinoid  can  be 
tolerated  as  tachyphylaxis  occurs.  Care  should  be  taken  when 
designing  the  skin  care  regimen  to  include  anti-inflammatory 
ingredients and reduce ingredients that increase skin penetration 
when retinoid treatments are being initiated.

It  is  well  established  that  teratogenicity  is  a  significant  risk 
associated  with  the  use  of  oral  retinoids.  Long  debated  is  the 
advisability of topical retinoid use by women of childbearing age 
due  to  the  potential  risk  of  systemic  absorption.  As  a  general 
rule,  great  care  should  be  taken  when  prescribing  retinoids  

 
(even OTC retinol) to women of childbearing age, although 
no  studies  have  convincingly  demonstrated  harm  from  use 
during pregnancy. A 1993 study by Jick et al. demonstrated no 
significant rise in the fetal malformation rate in 215 women 
treated  with  topical  tretinoin  during  the  first  trimester  of 
pregnancy,  as  compared  with  430  age-matched  nonexposed 
women.48

The  topical  application  of  tretinoin  has  been  thought  by 
many  to  augment  photosensitivity  because  its  daily  use 
engenders  thinning  of  the  SC,  rendering  it  more  compact. 
Such concern arose partly as a result of admonitions to early 
tretinoin  users  to  apply  the  product  only  at  night.  This 
warning  was  based  solely  on  the  poor  stability  of  tretinoin 
upon  UV  light  exposure.  Retinoids  are  now  known  not  to 
have  photosensitizing  or  phototoxic  properties,  and  may 
actually protect the skin from the deleterious sequelae of UV 
exposure.27

 ENVIRONmENTAL ImPACT

There  is  no  environmental  impact  of  commercial  topical 
retinoid formulation manufacture known by the author.

 FORmULATION CONSIDERATIONS

It  is  important  to  understand  that  not  all  retinol-containing 
products are equal. Retinol is very unstable and loses biologic 
activity  on  exposure  to  UV  light,  air,  heat,  water,  and  lipid 
peroxidation.46  When  it  is  formulated  and  packaged  retinol 
must  remain  in  an  airless  system  with  no  exposure  to  light. 
Proper packaging of retinol is in an aluminum tube with a small 
mouth  or  an  airless  pump.  Retinol  must  be  manufactured, 
formulated, and packaged properly to avoid oxidation and loss 
of potency. Also, the amount of retinol in the product must be 
high  enough  to  be  effective.  New  stabilized  forms  of  retinol 
have been shown to exhibit greatly increased efficacy in aging 
skin.49 Nanoparticles have displayed potential in enhancing the 
efficacy, stability, and tolerability of retinoid agents, particularly 
those  more  prone  to  elicit  irritant  reactions  such  as  tretinoin 
and tazarotene.50

In  2011,  Ourique  et  al.  showed  that  nanoencapsulation  of 
tretinoin  with  lipid-core  polymeric  nanocapsules  yielded 
improved photostability, with hydrogels containing nanoencap-
sulated tretinoin manifesting a half-life seven times longer than 
the nonencapsulated tretinoin after eight hours of UVA irradia-
tion. Their experiments also revealed that nanoencapsulation led 
to  extended  retention  of  the  drug  on  the  skin  surface  and 
decreased skin permeation.51

 USAGE CONSIDERATIONS

The side effects commonly seen in patients on retinoid therapy 
can usually be alleviated by directing the patient to apply small 
amounts of the retinoid at less frequent intervals. The lowest 
available dose should be started initially. For individuals with 
sensitive skin, topical retinol can be used every third night for 
the first two weeks. If no redness or irritation results, the reti-
noid  can  be  increased  to  every  other  night  for  two  weeks. 
Eventually  most  patients  can  tolerate  nightly  use.  Once  the 
patient is consistently applying the retinol nightly, the strength 
of  the  retinol  can  be  increased.  Once  the  maximal  retinol 
strength is reached, the patient can be seamlessly switched to a 
prescription retinoid if desired.

C H A P T E R  83  ■   R E T I N O I D S   ( R E T I N O L )  

331

A  1997  study  by  Olsen  et  al.  suggested  that  after  a  48-week 
regimen of once-daily 0.05 percent tretinoin emollient cream, the 
benefits of tretinoin could be sustained by at least three applications 
each week for an additional 24 weeks. The investigators found that 
once-weekly treatment was insufficient for maintaining the previ-
ously  seen  clinical  improvement.  In  addition,  they  noted  that 
discontinuation of therapy for 24 weeks led to the abrogation of 
the earlier benefits derived from the tretinoin regimen.52

 SIGNIFICANT BACKGROUND

Although tretinoin has long been approved for the treatment of 
photoaging,  evidence  suggests  that  it  also  plays  a  role  in  the 
prevention of cutaneous aging. The inhibitory effects of retinoids 
on harmful matrix metalloproteinases (MMPs) are thought to 
be  responsible  for  this  potential  benefit.  UVB  exposure 
dramatically  upregulates  MMP  synthesis.  Activation  of  the 
genes  of  these  collagen-degrading  enzymes  leads  to  the 
production  of  collagenase,  gelatinase,  and  stromelysin,  all  of 
which have been shown to fully degrade cutaneous collagen.53 
Fisher  et  al.  showed  in  1996  that  topical  tretinoin  application 
suppresses the induction of all three of these detrimental MMPs.27
In  addition  to  elevating  MMP  levels,  UV  exposure  has  also 
been  demonstrated  to  reduce  collagen  production.  In  2000, 
Fisher et al. showed that expression of collagen types I and III 
was markedly diminished within 24 hours after one UV expo-
sure. They found that pretreating the skin with tretinoin miti-
gated such a decline in procollagen production.54 Consequently, 
the  consistent  pretreatment  of  skin  with  topical  retinoids  is 
thought to likely contribute to the prevention as well as treat-
ment of photodamage.55

Significantly, the use of topical retinoids (especially tretinoin, 
isotretinoin, and tazarotene) is the only therapeutic option estab-
lished through randomized clinical trials to improve the clinical 
appearance  of  photoaged  skin.  In  addition,  to  elaborate  on  the 
above, topically applied retinoids show indications of being able 
to prevent photoaging and possibly altering the course, and blunting 
the  effects,  of  intrinsically  aging  skin.56  It  is  important  to  note 
that, to date, the cogent evidence in support of topical retinoids 
for photoaging correlates to mild-to-moderate photodamage.20

Stabilized, Low-irritancy Retinol
Tucker-Samaras  et  al.  conducted  an  eight-week,  double-blind, 
split-face,  randomized  clinical  study  in  2009  to  evaluate  the 
effects of once-daily application of stabilized 0.1 percent retinol-
containing  moisturizer  in  36  subjects  with  moderate  facial 
photodamage. The vehicle was used in 28 control subjects. With 
some  improvement  evident  and  significant  at  week  4,  after 
eight  weeks,  the  retinol  moisturizers  were  found  to  be 
significantly more efficacious than the vehicle in reducing overall 
signs  of  photodamage,  specifically  improving  elasticity  and 
firmness and diminishing lines and wrinkles. The investigators 
concluded  that  a  stabilized  retinol  formulation  was  safe  and 
effective in enhancing the appearance of photoaged facial skin.40
Also that year, Kikuchi et al. conducted a randomized, blinded, 
vehicle-controlled  study  to  assess  the  efficacy  of  once-nightly 
applied 0.075 percent retinol cream in treating mild photoaging 
in 57 middle-aged Japanese females. Fifty-four of 57 participants 
completed  the  26-week  study,  with  three  withdrawing  due  to 
irritation.  Signs  of  photoaging  (fine  and  deep  wrinkling)  were 
significantly reduced on the retinol-treated side of the face versus 
control [27 on retinol (50 percent) vs. 13 (24 percent) for fine wrin-
kling and, for deep wrinkling, 15 (28 percent) vs. 1 (2 percent)]. 

 
332 

CO S M E C E U T I C A L S   A N D   CO S M E T I C   I N G R E D I E N T S

The investigators also led a 13-week study using a 0.04 percent 
retinol cream, with less salient improvements in fine wrinkling 
revealed  but  minimal  irritation  elicited.  They  concluded  that 
retinol  creams,  particularly  the  0.04  percent  formulation,  are 
appropriate  for  daily  use,  even  by  those  with  sensitive  skin, 
because of low irritancy.57

Retinoids in Combination
In a 2010 literature review of combination treatments for pho-
toaging, Tierney and Hanke identified 10 studies documenting 
histologic  evidence  that  several  combination  approaches, 
including the use of topical retinoids, yielded cutaneous repair 
of  photodamaged  skin.58  Retinoids  should  be  combined  with 
daily  sunscreen,  antioxidants,  and  other  treatment  solutions 
depending on the patient’s skin type.

 CONCLUSION

Retinoid therapy is appropriate for all patients that are wrinkle- 
prone types within the BSTS. OTC retinol appears to be just as 
effective as prescription retinoids in conferring improvement to 
photoaged  skin,  but  with  less  irritation.  The  author  recom-
mends  combining  retinol  with  an  antioxidant  and  a  daily 
sunscreen  for  optimal  benefit.  Patients  should  be  carefully 
instructed on the use of retinoids and taught to slowly increase 
the  frequency,  amount  used,  and  strength  to  avoid  excessive 
irritation.  They  should  be  educated  that  retinoids  do  not 
increase  sun  sensitivity  and  can  help  protect  them  from  the 
ravages of UV exposure. Care should be taken to recommend a 
retinol that has a stable formulation and proper packaging. The 
product  should  be  discarded  after  six  months  because  retinol 
loses its activity, especially after being opened. RP is less effec-
tive than other retinoids and its safety is a controversial issue; 
for this reason the author recommends avoiding retinyl palmi-
tate and other retinyl esters.

REFERENCES

1.  Schweiggert  RM,  Kopec  RE,  Villalobos-Gutierrez  MG,  et  al. 
Carotenoids  are  more  bioavailable  from  papaya  than  from 
tomato  and  carrot  in  humans:  A  randomised  cross-over  study.  
Br J Nutr. 2014;111:490.

2.  Khan  NC,  West  CE,  de  Pee  S,  et  al.  The  contribution  of  plant 
foods to the vitamin A supply of lactating women in Vietnam: A 
randomized controlled trial. Am J Clin Nutr. 2007;85:1112.

3.  Sorg  O,  Antille  C,  Kaya  G,  et  al.  Retinoids  in  cosmeceuticals. 

Dermatol Ther. 2006;19:289.

4.  Kligman  AM.  The  growing  importance  of  topical  retinoids  in 
clinical  dermatology:  A  retrospective  and  prospective  analysis.  
 J Am Acad Dermatol. 1998;39:S2.

5.  Green HN, Mellanby E. Vitamin A as anti-infective agent. Br Med 

J. 1928;II:691.

6.  Karrer  P,  Morf  R,  Schopp  K.  Zur  kenntnis  des  vitamin-a  aus 

fischtranin. Helv Chim Acta. 1931;14:1036.

7.  Darlenski R, Surber C, Fluhr JW. Topical retinoids in the manage-
ment  of  photodamaged  skin:  From  theory  to  evidence-based 
practical approach. Br J Dermatol. 2010;163:1157.

8.  Stratigos AJ, Katsambas AD. The role of topical retinoids in the 

treatment of photoaging. Drugs. 2005;65:1061.

9.  Torras H. Retinoids in aging. Clin Dermatol. 1996;14:207.

10.  Kligman  AM,  Fulton  JE  Jr,  Plewig  G.  Topical  vitamin  A  acid  in 

acne vulgaris. Arch Dermatol. 1969;99:469.

11.  Kligman  L,  Kligman  AM.  Photoaging  -  Retinoids,  alpha  hydroxy 
acids, and antioxidants. In: Gabard B, Elsner P, Surber C, Treffel P, eds. 
Dermatopharmacology  of  Topical  Preparations.  New  York:  Springer; 
2000:383.

12.  Kligman  AM,  Grove  GL,  Hirose  R,  et  al.  Topical  tretinoin  for 

photoaged skin. J Am Acad Dermatol. 1986;15:836.

13.  Keller KL, Fenske NA. Uses of vitamins A, C, and E and related 
compounds  in  dermatology:  A  review.  J  Am  Acad  Dermatol. 
1998;39:611.

14.  Chandraratna  RA.  Tazarotene  –  first  of  a  new  generation  of 
receptor-selective retinoids. Br J Dermatol. 1996;135(Suppl 49):18.
15.  Serri R, Iorizzo M. Cosmeceuticals: Focus on topical retinoids in 

photoaging. Clin Dermatol. 2008;26:633.

16.  Chytil F, Ong D. Cellular retinoid-binding proteins. In: Sporn MB, 
Roberts  A,  Goodman  D,  eds.  The  Retinoids.  Vol.  2.  Orlando: 
Academic Press; 1984:89–123.

17.  Giguere V, Ong ES, Segui P, et al. Identification of a receptor for 

the morphogen retinoic acid. Nature. 1987;330:624.

18.  Petkovich  M,  Brand  NJ,  Krust  A,  et  al.  A  human  retinoic  acid 
receptor which belongs to the family of nuclear receptors. Nature. 
1987;330:444.

19.  Pfahl M. The molecular mechanism of retinoid action. Retinoids 

today and tomorrow. Retinoids Dermatol. 1996;44:2.

20.  Antoniou  C,  Kosmadaki  MG,  Stratigos  AJ,  et  al.  Photoaging: 
Prevention and topical treatments. Am J Clin Dermatol. 2010;11:95.
21.  Ogden  S,  Samuel  M,  Griffiths  CE.  A  review  of  tazarotene  in 
the  treatment  of  photodamaged  skin.  Clin  Interv  Aging. 
2008;3:71.

22.  Stefanaki  C,  Stratigos  A,  Katsambas  A.  Topical  retinoids  in  the 

treatment of photoaging. J Cosmet Dermatol. 2005;4:130.

23.  Hernandez-Perez E, Khawaja HA, Alvarez TY. Oral isotretinoin 
as  part  of  the  treatment  of  cutaneous  aging.  Dermatol  Surg. 
2000;26:649.

24.  Lever L, Kumar P, Marks R. Topical retinoic acid for treatment of 

solar damage. Br J Dermatol. 1990;122:91.

25.  Leyden JJ, Grove GL, Grove MJ, et al. Treatment of photodam-
aged  facial  skin  with  topical  tretinoin.  J  Am  Acad  Dermatol. 
1989;21:638.

26.  Weinstein  GD,  Nigra  TP,  Pochi  PE,  et  al.  Topical  tretinoin  for 
treatment  of  photodamaged  skin.  A  multicenter  study.  
Arch Dermatol. 1991;127:659.

27.  Fisher  GJ,  Datta  SC,  Talwar  HS,  et  al.  Molecular  basis  of  sun-
induced premature skin ageing and retinoid antagonism. Nature. 
1996;379:335.

28.  Chaqour B, Bellon G, Seite S, et al. All-trans-retinoic acid enhances 
collagen gene expression in irradiated and non-irradiated hairless 
mouse skin. J Photochem Photobiol B. 1997;37:52.

29.  Griffiths CE, Russman AN, Majmudar G, et al. Restoration of col-
lagen formation in photodamaged human skin by tretinoin (reti-
noic acid). N Engl J Med. 1993;329:530.

30.  Schwartz  E,  Cruickshank  FA,  Mezick  JA,  et  al.  Topical  all-trans 
retinoic  acid  stimulates  collagen  synthesis  in  vivo.  J  Invest 
Dermatol. 1991;96:975.

31.  Weiss JS, Ellis CN, Headington JT, et al. Topical tretinoin improves 
photoaged skin: A double-blind vehicle-controlled study. JAMA. 
1988;259:527.

32.  Griffiths CE, Kang S, Ellis CN, et al. Two concentrations of topical 
tretinoin (retinoic acid) cause similar improvement of photoaging 
but  different  degrees  of  irritation.  A  double-blind,  vehicle- 
controlled  comparison  of  0.1%  and  0.025%  tretinoin  creams. 
Arch Dermatol. 1995;131:1037.

33.  Woodley  DT,  Zelickson  AS,  Briggaman  RA,  et  al.  Treatment  of 
photoaged skin with topical tretinoin increases epidermal-dermal 
anchoring fibrils. A preliminary report. JAMA. 1990;263:3057.
34.  Fisher GJ, Reddy AP, Datta SC, et al. All-trans retinoic acid induces 
cellular  retinol-binding  protein  in  human  skin  in  vivo.  J  Invest 
Dermatol. 1995;105:80.

35.  Duell EA, Kang S, Voorhees JJ. Retinoic acid isomers applied to 
human skin in vivo each induce a 4-hydroxylase that inactivates 
only trans retinoic acid. J Invest Dermatol. 1996;106:316.

36.  Duell EA, Derguini F, Kang S, et al. Extraction of human epidermis 
treated  with  retinol  yields  retro-retinoids  in  addition  to  free 
retinol and retinyl esters. J Invest Dermatol. 1996;107:178.

37.  Duell  EA,  Kang  S,  Voorhees  JJ.  Unoccluded  retinol  penetrates 
human skin in vivo more effectively than unoccluded retinyl pal-
mitate or retinoic acid. J Invest Dermatol. 1997;109:301.

38.  Kang S, Duell EA, Fisher GJ, et al. Application of retinol to human 
skin in vivo induces epidermal hyperplasia and cellular retinoid 
binding proteins characteristic of retinoic acid but without meas-
urable  retinoic  acid  levels  or  irritation.  J  Invest  Dermatol. 
1995;105:549.

39.  Kafi R, Kwak HS, Schumacher WE, et al. Improvement of natu-
rally  aged  skin  with  vitamin  A  (retinol).  Arch  Dermatol. 
2007;143:606.

 
40.  Tucker-Samaras  S,  Zedayko  T,  Cole  C,  et  al.  A  stabilized  0.1% 
retinol facial moisturizer improves the appearance of photodam-
aged  skin  in  an  eight-week,  double-blind,  vehicle-controlled 
study. J Drugs Dermatol. 2009;8:932.

41.  Yan J, Xia Q, Cherng SH, et al. Photo-induced DNA damage and 
photocytotoxicity  of  retinyl  palmitate  and  its  photodecomposi-
tion products. Toxicol Ind Health. 2005;21:167.

42.  Burnett ME, Wang SQ. Current sunscreen controversies: A critical 

review. Photodermatol Photoimmunol Photomed. 2011;27:58.

43.  Xia Q, Yin JJ, Wamer WG, et al. Photoirradiation of retinyl palmi-
tate in ethanol with ultraviolet light – Formation of photodecom-
position  products,  reactive  oxygen  species,  and  lipid  peroxides. 
Int J Environ Res Public Health. 2006;3:185.

44.  Wang  SQ,  Dusza  SW,  Lim  HW.  Safety  of  retinyl  palmitate  in 
sunscreens: A critical analysis. J Am Acad Dermatol. 2010;63:903.
45.  Kim  H,  Koh  J,  Baek  J,  et  al.  Retinyl  retinoate,  a  novel  hybrid 
vitamin  derivative,  improves  photoaged  skin:  A  double-blind, 
randomized-controlled trial. Skin Res Technol. 2011;17:380.

46.  Kim H, Kim N, Jung S, et al. Improvement in skin wrinkles from 
the use of photostable retinyl retinoate: A randomized controlled 
trial. Br J Dermatol. 2010;162:497.

47.  Baumann  L,  Saghari  S.  Retinoids.  In:  Baumann  L,  Saghari  S, 
Weisberg E, eds. Cosmetic Dermatology: Principles and Practice. 2nd ed. 
New York: McGraw-Hill; 2009:256–262.

48.  Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and con-

genital disorders. Lancet. 1993;341:1181.

49.  Kligman LH, Gans EH. Re-emergence of topical retinol in derma-

tology. J Dermatol Treat. 2000;11:47.

C H A P T E R  83  ■   R E T I N O I D S   ( R E T I N O L )  

333

50.  Mukherjee S, Date A, Patravale V, et al. Retinoids in the treatment 
of  skin  aging:  An  overview  of  clinical  efficacy  and  safety.  
Clin Interv Aging. 2006;1:327.

51.  Ourique AF, Melero A, de Bona da Silva C, et al. Improved photo-
stability and reduced skin permeation of tretinoin: Development 
of a semisolid nanomedicine. Eur J Pharm Biopharm. 2011;79:95.
52.  Olsen  EA,  Katz  HI,  Levine  N,  et  al.  Sustained  improvement  in 
photodamaged skin with reduced tretinoin emollient cream treat-
ment  regimen:  Effect  of  once-weekly  and  three-times-weekly 
applications. J Am Acad Dermatol. 1997;37:227.

53.  Fisher GJ, Wang ZQ, Datta SC, et al. Pathophysiology of prema-
ture  skin  aging  induced  by  ultraviolet  light.  N  Engl  J  Med. 
1997;337:1419.

54.  Fisher GJ, Datta S, Wang Z, et al. c-Jun-dependent inhibition of 
cutaneous procollagen transcription following ultraviolet irradia-
tion is reversed by all-trans retinoic acid. J Clin Invest. 2000;106:663.
55.  Fisher GJ, Talwar HS, Lin J, et al. Molecular mechanisms of pho-
toaging in human skin in vivo and their prevention by all-trans 
retinoic acid. Photochem Photobiol. 1999;69:154.

56.  Singh  M,  Griffiths  CE.  The  use  of  retinoids  in  the  treatment  of 

photoaging. Dermatol Ther. 2006;19:297.

57.  Kikuchi K, Suetake T, Kumasaka N, et al. Improvement of photo-
aged  facial  skin  in  middle-aged  Japanese  females  by  topical  
retinol  (vitamin  A  alcohol):  A  vehicle-controlled,  double-blind 
study. J Dermatolog Treat. 2009;20:276.

58.  Tierney  EP,  Hanke  CW.  Recent  advances  in  combination  treat-
ments  for  photoaging:  Review  of  the  literature.  Dermatol  Surg. 
2010;36:829.

 
This page intentionally left blank 

Index

Note: An “f” or “t” following a page number denotes a figure or table, respectively.

1,8-cineole, 26 
2-O-α-glucopyranosyl-l-ascorbic acid  

(AA-2G), 179, 206

3,4-dihydroxycinnamic acid, 166 
4HPR, 241
5-O-caffeoyl-quinic acid, 196
9-hydroxy-2-decenoic acid (9-HDA), 204
9-oxo-2-decenoic acid (9-ODA), 204
10-hydroxy-2-decenoic acid (10-HDA),  

205, 210

A
A. hippocastanum, 284
A. hypogaea, 153
A. mellifera, 203
A. oxyphylla, 201
A. rhealba, 254, 255
A. sativa, 253
A. spinosa, 25
A. turkestanica, 88–90
A. vera. See Aloe vera
AA. See Arachidonic acid (AA)
AA-2G, 179, 206
Abreva, 157
Accutane, 329
Acetyglucoside, 130
Acid dissociation constant (pKa), 5
Acne, 288–316

acne-causing ingredients, 289t
bacteria, 288–290
BPO, 292–296
follicular keratinization, 288
green tea, 138–139
jojoba oil, 32, 33
licorice extract, 245
mineral oil, 35
niacinamide, 126
OTC acne monograph, 290t
resveratrol, 153
retinol, retinyl esters, and retinoic acid, 

306–310

salicylic acid, 301–305
sebaceous gland activity, 288
silver, 311–316
skin type, 3
tea tree oil, 297–300
warnings/directions on OTC 

medications, 289t

Acne cosmetica, 35
Active naturals, 9
Active soy, 131
Acyclovir, 157, 220
AD. See Atopic dermatitis (AD)
Adapalene, 306, 329
Advanced glycation endproducts (AGEs), 6, 6f
Advertising. See Cosmeceutical marketing 

claims

Aescin, 285
Aesculaforce, 286
Aesculus hippocastanum, 284
Aflatoxins, 23–24
Age and skin barrier, 54
AGEs. See Advanced glycation endproducts 

Amphoteric surfactants, 19
Anatomy, 16, 16f
Androgenetic alopecia

green tea, 140
melatonin, 218
tea tree oil, 298

(AGEs)

Aging, 317–321. See also Skin aging
Aglycone, 130
AHA. See α-hydroxy acid (AHA)
Ajuga turkestanica, 88–90
ALA. See α-linolenic acid (ALA)
Alexander the Great, 229
“allergen-free,” 11
Allergic contact dermatitis, 82
Allergic rhinitis, 111
Aloe barbadensis, 229, 230
Aloe-coated examination gloves, 232
Aloe latex, 230
Aloe vera, 229–237

aloe-coated examination gloves, 232
anti-inflammatory activity, 234
antimicrobial activity, 234–235
anticancer activity, 234
antioxidant activity, 234
atopic dermatitis, 232
chemistry, 230
combination therapy, 39, 232–233
environmental impact, 233
formulation considerations, 233
history, 229–230
lichen planus, 232
oral uses, 230
photoprotection, 235
pros/cons, 229t
psoriasis, 231
radiotherapy, 232
safety issues, 233
source, 229
topical uses, 230–233
usage considerations, 233–234
wound healing, 231–232
xerosis, 232
Aloesin, 95–96
Alopecia

green tea, 140
melatonin, 218
tea tree oil, 298

α-hydroxy acids (AHAs), 5, 73, 324–325
α-linolenic acid (ALA), 160, 161
Alpinia oxyphylla, 201
Alzheimer’s disease, 215
Amadori product, 6
Aminipropyl dimethicone, 52
Amla, 108
Amodimethicone, 52
Amodimethicone hydroxystearate, 52

Anionic surfactants, 19
Anogenital warts, 139
Anthocyanins, 135t, 136t
Antiacne ingredients, 288–316. See also Acne
Anti-inflammatory agents, 227–287.  
See also Inflammation/anti-inflammatory 
activity

Aloe vera, 229–237
calendula, 271–275
chamomile, 265–270
colloidal oatmeal, 253–256
edelweiss, 276–278
feverfew, 238–243
horse chestnut, 284–287
lavandula, 279–283
licorice extract, 244–252
turmeric, 257–264

Antiaging activity. See also Photoaging;  

Skin aging

appearance claim, 13
ascorbic acid, 179
calendula, 273–274
coenzyme Q10, 191
emblica extract, 109–110
horse chestnut, 286–287
hyaluronic acid, 79
resveratrol, 156
soy, 131

Antibacterial activity

benzoyl peroxide (BPO), 293
feverfew, 240–241
lavandula, 281
licorice extract, 249
peppermint, 225
Rosa damascena, 146–147
silver, 312–313
tea tree oil, 298

Anticarcinogenic activity. See Cancer
Antifungal activity
olive oil, 39
tea tree oil, 298
Antimicrobial activity
Aloe vera, 234–235
green tea, 139–140
honey/propolis/royal jelly, 208–209
resveratrol, 156–157
salicylic acid, 303
tamanu oil, 45–46

Antioxidant activity. See also Antioxidants

Aloe vera, 234
arbutin, 98

335

3 3 6 

I N D E X

Antioxidant activity (continued )

ascorbic acid, 179
coffeeberry, 196
colloidal oatmeal, 256
cucumber, 121
emblica extract, 109–110
ginger, 199–200
honey/propolis/royal jelly, 208
idebenone, 215
licorice extract, 248–249
melatonin, 218
peppermint, 224
Rosa damascena, 146
tocopherol (vitamin E), 185–186
turmeric, 260–261

Antioxidants, 61, 92, 135–175. See also 

Antioxidant activity

caffeic acid, 166–170
classification, 135–136, 135t, 136t
fat-soluble/water-soluble, 135
ferulic acid, 171–175
flaxseed oil, 160–162
green tea, 137–144
network, 190–191
phloretin, 163–165
pycnogenol, 148–151
resveratrol, 152–159
Rosa damascena, 145–147
skin aging, 319–320

Antiviral activity

chamomile, 269
tea tree oil, 298

Antiwrinkling effects. See Wrinkles
Apaf-1, 201
Aphthous stomatitis, 147
Aphthous ulceration, 280
Apis mellifera, 203
Apolipoprotein E (ApoE), 64
APP. See β-amyloid precursor protein 

(APP)

Appearance claims, 13–14
“. . . appearance of wrinkles,” 13
Apples, 163, 164
AQP-3, 87, 89, 196
Aquaporin (AQP), 87, 89
Arachidonic acid (AA)
fatty acid, as, 55
fish oils, 38
inflammation, 227
olive oil, 38

Arachis hypogaea, 153
Arbutin, 97–99

antioxidant activity, 98
chemistry, 97
environmental impact, 98
formulation considerations, 98
history, 97
oral uses, 97
pros/cons, 97t
safety issues, 97
source, 97
synthetic, 98–99
topical uses, 97
usage considerations, 98

Argan fruit kernels, 25
Argan oil, 25–27
Argania spinosa, 25
Argireline, 320
Argyria, 314
Argyrol, 311
Aristotle, 204

Aromatherapy, 282
Ascorbate, 177
Ascorbic acid, 176-181. See also Vitamin C

Ka and pKa, 5
Maillard reaction, 6
pH, 5

antioxidant and antiaging  

activity, 178
chemistry, 177
environmental impact, 178
formulation considerations, 178
history, 176–177
oral uses, 177
pros/cons, 176t
safety issues, 178
source, 176
topical uses, 177–178
usage considerations, 178

l-ascorbic acid, 178, 179
Ascorbyl palmitate, 177–179
Aspergillum, 23, 24
Aspirin, 301. See also Salicylic  

acid (SA)

Asteraceae (compositae) family,  

239, 265, 267t
Atopic dermatitis (AD)

Aloe vera, 232
ceramides, 59
chamomile, 266–267
colloidal oatmeal, 255
green tea, 140
hyaluronic acid, 79
licorice extract, 245–246
silver, 314
tocopherol (vitamin E), 183

Atopiclair, 78
Avage, 329
Avena sativa, 253
Avicenna, 204, 279, 311

B
B. officinalis, 28
B. papyrifera, 115
B[a]P, 201, 261
“Bad” cholesterol, 65
Barnes, Albert, 311
Barrier disruption, 55
Barrier repair ingredients, 54–91

age and skin barrier, 54
Ajuga turkestanica, 88–90
aquaporin, 87, 89
barrier disruption, 55
ceramides, 57–63
cholesterol, 64–67
endogenously synthesized lipids,  

54–55

exogenously applied lipids, 54
fatty acids, 55
glycerin, 74–76
goal, 54
humectants, 73
hyaluronic acid (HA), 77–80
lanolin, 68–69
natural moisturizing factor (NMF), 91
overview, 54
stearic acid, 70–72
urea, 84–86
vitamin B5, 81–83

Basal cell carcinoma (BCC), 16
Basal layer, 16
Basic cosmetic chemistry, 5–7

cosmetic ingredient nomenclature, 5
free radicals, 6–7
glycation, 6

Baumann, Leslie, 1
Baumann skin type (BST), 1, 1f, 2f
Baumann skin type indicator (BSTI),  

1, 4

Baumann skin type system (BSTS),  

1–4

BSTI questionnaire, 4
color dot system, 1, 2f
combining D/O and S/R parameters, 3
combining P/N and W/T parameters, 4
parameters, 1
skin elasticity (W vs. T), 4
skin hydration (D vs. O), 1–2
skin pigmentation (P vs. N), 3–4
skin sensitivity (S vs. R), 3

BBI. See Bowman-Birk inhibitor (BBI)
BCC. See Basal cell carcinoma (BCC)
BDDE, 77
Beach caulophyllum, 46
Bearberry, 97
Bee glue, 204
Bee products. See Honey/propolis/ 

royal jelly

Beginning Cosmetic Chemistry (Schueller/

Romanowski), 5
Behenoxy dimethicone, 52
Belotero, 77
Benzo[a]pyrene (B[a]P), 201, 261
Benzoyl peroxide (BPO), 292–296

acne, 293
antibacterial uses, 293
chemical structure, 292f
chemistry, 292
environmental impact, 294
formulation considerations, 294
irritation, 294
keratolytic activity, 293
oral uses, 292
photocarcinogenicity, 293–294
pregnancy, 294
pros/cons, 292t
safety issues, 293–294
significant background, 295
skin aging, 294
source, 292
topical uses, 292–293
usage considerations, 294–295
warnings/directions on OTC products, 

294t
Bepanthol, 82
Berzelius, Jöns Jacob, 51
β-amyloid precursor protein (APP), 125
β-hydroxy acid (BHA), 5. See also  

Salicylic acid (SA)

BHA. See also Salicylic acid (SA)
Bifidobacterium, 131
Bionect, 78
Bionic acid, 323
α-bisabolol, 266, 268
Bishop, Katherine, 182
Black mulberry, 114–115
Boerhaave, Herman, 84
Borage, 28
Borage seed oil, 28–30

chemistry, 28
environmental impact, 29
formulation considerations, 29
history, 28

 
 
 
 
Borage seed oil (continued )

oral uses, 28–29
safety issues, 29
significant background, 29–30
source, 28
topical uses, 29
usage considerations, 29

Borago officinalis, 28
“botanical,” 12
Bowman-Birk inhibitor (BBI),  

129, 131, 132
Boxus chinensis, 31
BPO. See Benzoyl peroxide (BPO)
Breast cancer, 85
“brightening,” 13
Broussonetia papyrifera, 115
BST. See Baumann skin type (BST)
BSTI. See Baumann skin type indicator 

(BSTI)

BSTS. See Baumann skin type system 

(BSTS)

Bucher, Johann Andreas, 301, 322
Burns, 45, 313
1,4-butanediol diglycidyl ether  

(BDDE), 77
4-n-butylresorcinol, 99
Buyer beware (caveat emptor), 14

C
C. arabica, 194
C. inophyllum, 44
C. longa, 257
C. officinalis, 271
C. sativus, 120
C. tinctorius, 41
C24-C28 alkyl methicone, 52
C30-C45 alkyl dimethicone, 52
C30-C45 alkyl methicone, 52
C-ESTA Face Serum, 179
C-glucosyl chromone, 230
Caffeic acid, 166–170

animal studies, 167–168
anticarcinogenic activity, 169
CAPE, 168
chemistry, 166
environmental impact, 167
formulation considerations, 167
history, 166
oral uses, 166
photoprotection, 168–169
pros/cons, 166t
safety issues, 167
source, 166
topical uses, 166
usage considerations, 167
in vitro studies, 167

Caffeic acid phenethyl ester (CAPE), 168
Calcium salicylate, 303
Calendula officinalis, 271
Calendula

antiaging, 273–274
anticancer activity, 274
chemistry, 271–272
chronic venous leg ulcer treatment, 274
diaper dermatitis, 272
environmental impact, 273
formulation considerations, 273
history, 271
oral uses, 272
periodontitis, 274
photoprotection, 273–274

pros/cons, 271t
radiation dermatitis, 272
safety issues, 272–273
source, 271
topical uses, 272
usage considerations, 273
wound healing, 273
Calhoun, George, 182
Calocoumarin-A, 46
Calophyllic acid, 44
Calophyllolide, 44, 45
Calophyllum inophyllum, 44
Caloxanthone, 46
Camellia oleifera, 20
Camomile. See Chamomile
Camphene, 240
Camphor, 26, 240
Cancer

Aloe vera, 234
BCC, 16
benzoyl peroxide (BPO), 293–294
caffeic acid, 169
calendula, 274
chamomile, 268–269
coenzyme Q10, 191
cucumber, 121
emblica extract, 110
ferulic acid, 173, 174
feverfew, 241
ginger, 200–201
honey/propolis/royal jelly, 209
lavandula, 282
licorice extract, 249
melatonin, 218
mulberry extract, 115
olive oil, 39
peppermint, 224–225
phloretin, 165
resveratrol, 155
SCC, 16
silver, 313
soy, 131
tea tree oil, 298
tocopherol (vitamin E), 184
turmeric, 261–262
urea, 85

Canker sores, 147
Canophyllic acid, 45
CAPE

caffeic acid phenethyl ester  

(CAPE), 168

honey/propolis/royal jelly, 209
propolis constituent, 209

Caper bush, 166
Capparis spinosa, 166
Carmol 40, 84
Carthamus tinctorius, 41
Cataract surgery, 191
Catechins, 135t, 136t
Cationic surfactants, 19
Caveat emptor (buyer beware), 14
Cellex-C, 179
Celsus, 204
Ceramide 1-phosphate, 60
Ceramides, 55, 57–63

atopic dermatitis, 59
ceramide synthesis, 57
chemical structure, 58f
chemistry, 58
collagen, and, 60–61
dry non-atopic skin, 59

I N D E X  

  3 3 7

environmental impact, 60
formulation considerations, 60
history, 57
how to generate, 57
inflammation, 59–60
keratinocyte differentiation, 59
oral uses, 58
pros/cons, 58t
safety issues, 60
significant background, 60
source, 57
steroids, and, 59
topical uses, 58–60
usage considerations, 60

Cetearyl methicone, 52
Cetyl methicone, 52
Cetylacetic acid, 70
Chamamelum nobile, 265
Chamazulene, 266
Chamomile, 265–270

anti-inflammatory activity, 267
anticancer activity,  

268–269

antiviral activity, 269
atopic dermatitis,  

266–267
bisabolol, 268
chemistry, 266
environmental impact, 268
formulation considerations, 268
history, 265–266
oral mucositis, 269
oral uses, 266
pros/cons, 265t
safety issues, 267–268
source, 265
topical uses, 266–267
usage considerations, 268
wound healing, 267

Chan, Margaret, 207
Chemistry. See Basic cosmetic chemistry
Chesebrough, Robert A., 34, 48
Chinese mulberry, 114
Chloasma, 92
Chlorogenic acid, 194
Chol-OOHs, 66
Cholesterol, 55, 64–67
argan oil, 25, 26
barrier repair, 65
chemistry, 65t
diet, 64
endogenous synthesis, 64, 65f
environmental impact, 66
formulation considerations, 66
history, 64–65
keratinization, 65–66
oral uses, 65
photoaging, 66
pros/cons, 65t
safety issues, 66
source, 64
topical uses, 65–66
usage considerations, 66
Cholesterol hydroperoxides  

(Chol-OOHs), 66
Cholesterol sulfate, 64, 66
Chronic venous insufficiency (CVI),  

285, 286

Chronic venous leg ulcer, 274
Cinnamic acid, 136
Citric acid, 322

 
 
 
3 3 8 

I N D E X

Clay jojoba facial masks, 32
“cleanliness,” 13
Cleansing agents, 19–20

amphoteric surfactants, 19
anionic surfactants, 19
cationic surfactants, 19
cleanser choice, 20
irritancy, 19
natural ingredients in cleansers, 20
newer classes of cleansers, 19–20
nonionic surfactants, 19

Cleome icosandra, 146
Cleopatra, 229, 322
Clerodane diterpenes, 88
“clinically proven,” 12, 14
“clinically tested,” 12
CO. See Colloidal oatmeal (CO)
Coenzyme Q10, 188–193
antiaging activity, 191
chemistry, 188–189
combination therapy, 190
environmental impact, 190
formulation considerations, 190
gingivitis, 191
history, 188t
network antioxidants, 190–191
oral uses, 189
pros/cons, 188t
retinopathy, 191–192
safety issues, 190
skin cancer, 191
topical uses, 189–190
usage considerations, 190

Coffea arabica, 194
Coffeeberry, 31, 194–197

antioxidant activity, 196
chemistry, 194
environmental impact, 195
formulation considerations, 195
history, 194
oral uses, 194–195
pros/cons, 194t
safety issues, 195
skin care research, 196
source, 194
topical uses, 195
usage considerations, 195

Collagen, 17, 60–61, 317
Collagen production, 206
Colloidal oatmeal (CO), 253–256

antioxidant activity, 256
atopic dermatitis, 255
avenanthramides, 254
chemistry, 253–254
environmental impact, 255
formulation considerations, 255
history, 253
human studies, 255
oral uses, 254
pros/cons, 253t
safety issues, 255
source, 253
topical uses, 254–255
usage considerations, 255

Colloidal silver, 312. See also Silver
Colony collapse disorder, 207
Color dot system, 1, 2f
Columbus, Christopher, 229
Combination bars (combars), 20
Combination skin, 2
Comedogenicity patch testing, 14

Comedolytics, 303
Comfrey, 267
Common marigold, 271
Compositae (Asteraceae) family, 239, 265, 

267t

Contact dermatitis
feverfew, 239
honey/propolis/royal jelly, 206, 209
HQ, 101, 101f
tocopherol (vitamin E), 184
vitamin B5, 82

CoQ10. See Coenzyme Q10
CoQ10-NLC, 189, 190
Corynebacterium acnes, 288
Cosmeceutical marketing claims,  

11–15

advertising omissions, 11
appearance claims, 13–14
caveat emptor (buyer beware), 14
FTC guidelines, 14
monographs, 12
organic or natural, 11–12. See also 

Organic products
proprietary data, 12–13
testing and approval, 12

Cosmetic chemistry. See Basic cosmetic 

chemistry

Cosmetic Dermatology: Principles and Practice 
(Baumann et al.), 16, 21, 94, 227
Cosmetic ingredient nomenclature, 5
COSMOS, 8
Coumarin derivatives, 45
Cucumber, 120–122

antioxidant, anticancer, antiwrinkle 

activity, 121
chemistry, 120
environmental impact, 121
formulation considerations, 121
history, 120
oral uses, 120
pros/cons, 120t
safety issues, 121
skin whitening, 121
source, 120
topical uses, 120–121
usage considerations, 121

Cucumis sativus, 120
Curcuma longa, 257
Curcumin. See Turmeric
Cutaneous inflammation, 82
CV-2619. See Idebenone
CVI. See Chronic venous insufficiency 

(CVI)

Cyclooxygenase pathway, 227
Cyperus scariosus, 146
Cytokines, 57, 60, 66

D
D (dry), 1–2
Daidzein, 129, 130, 130f, 131
Damask Rose, 145
Dandruff, 206
DAPK1. See Death-associated protein 

kinase 1 (DAPK1)

Dark circles under the eyes, 92
Death-associated protein kinase 1 

(DAPK1), 153
“deep cleaning,” 13
Deer nut, 31
Dehydro-l-ascorbic acid (DHAA), 177
Dental caries, 140

Deoxyarbutin, 98
Depression, 282
“dermatologist approved,” 12
“dermatologist recommended,” 12
“dermatologist tested,” 12
Dermis, 16. See also Epidermis and dermis
Desquamation, 16, 16f
Dexamethasone, 57
Dexeryl, 85
Dexpanthenol. See Vitamin B5
DGLA. See Dihomo-γ-linolenic acid 

(DGLA)

DHAA. See Dehydro-l-ascorbic acid 

(DHAA)

Diabetes

safflower oil, 41
urea, 86

Diaper dermatitis
calendula, 272
vitamin B5, 82

Diclofenac, 73
Differin, 306, 329
Dihomo-γ-linolenic acid (DGLA), 28–29
Dihydrochalcone, 136t
Dihydronaringenin, 163
Dimethicone and silicones, 51–53

chemical structure of dimethicone, 51f
chemistry, 51
combination treatments, 52
environmental impact, 52
formulation considerations, 52
history, 51
oral uses, 51
pros/cons, 51t
safety issues, 52
silicones, listed, 52
source, 51
topical uses, 51–52
usage considerations, 52

Dimethoxysilyl, 52
Dimethylaminoparthenolide (DMAPT), 

239

7,12-dimethylbenz(a) anthracene  

(DMBA)
Aloe vera, 234
caffeic acid, 168
emblica extract, 109, 110
ferulic acid, 174
honey/propolis/royal jelly, 209 
licorice extract, 245
turmeric, 261

2,4-dinitrofluorobenzene (DNFB), 219
Dioscorides, 204, 230, 238, 244, 257, 265, 301
Dissociation constant (Ka), 5
DMAPT. See Dimethylaminoparthenolide 

(DMAPT)

DMBA. See 7,12-dimethylbenz(a) 

anthracene (DMBA)

DNA damage, 319
DNFB. See 2,4-dinitrofluorobenzene  

(DNFB)
Docosanol, 157
Dreser, Heinrich, 301
DRNT, 1f, 2f
DRNW, 1f, 2f
DRPT, 1f, 2f
DRPW, 1f, 2f
Dry, itchy scalp, 249
Dry skin, 2
DSNT, 1f, 2f
DSNW, 1f, 2f

 
 
 
 
DSPT, 1f, 2f
DSPW, 1f, 2f
Dyschromia, 92
Dyspigmentation, 324

E
E. guineensis, 184
E. officinalis, 108
ECG, 137
Eczema

skin type, 3
urea, 85

Edelweiss, 276–278
Edible oils, 23
EFAD. See Essential fatty acid deficiency 

(EFAD)

EFAs. See Essential fatty acids (EFAs)
EGC, 137
EGCG, 137–142
Eichengrün, Arthur, 301
El Basry, 204
El Mad Joussy, 204
Elaies guineensis, 184
Elastin, 17, 317
Eluage antiwrinkle concentrate, 79
Eluage cream, 79
Emblica extract, 108–112

antioxidant/antiaging activity, 109–110
chemistry, 108–109
chemopreventive activity, 110
environmental impact, 109
formulation considerations, 109
history, 108
oral uses, 109
photoprotection, 110
pros/cons, 108t
safety issues, 109
skin whitening, 109
source, 108
topical uses, 109
traditional medical systems, 108
triphala, 110–111
usage considerations, 109
in vitro studies, 111
Emblica officinalis, 108
Emblicanin, 108
Emblicanin B, 108
Emollients, 21, 22f
Endogenously synthesized lipids, 54–55
Endorsements and testimonials, 14
Enediol, 177
English chamomile, 265
Epicatechin, 164
EpiCeram, 60
Epidermal melanin unit, 125, 125f
Epidermis and dermis, 16–18

anatomy, 16, 16f
collagen, 17
elastin, 17
fibroblasts, 17
HA, 17
ingredients that penetrate into dermis, 

17–18

keratinocytes, 16
reference book, 16

EpiDuo, 329
Episiotomy, 280
Equol, 130f
Erythema

ascorbic acid, 178
resveratrol, 153

Essential fatty acid deficiency  

Friedreich’s ataxia. See Essential fatty acid 

I N D E X  

  3 3 9

(EFAD), 41

Essential fatty acids (EFAs), 23
Essential oils, 24
Estrogen, 17
Ethylenediaminopropyl  
dimethicone, 52
Ethylhexyl salicylate, 303
Eumelanin, 93
Evans, Herbert, 182
Exogenous ochronosis, 101
Exogenously applied lipids, 54
Extra virgin olive oil, 38

F
Fat-soluble antioxidants, 135
Fatty acids, 23, 55
Fenretinide, 241
Ferulic acid, 171–175
animal studies, 174
chemistry, 171, 172f
environmental impact, 173
formulation considerations, 173
history, 171
human studies, 174
oral uses, 171
pros/cons, 171t
safety issues, 172–173
skin cancer, 173, 174
source, 171
topical uses, 172
usage considerations, 173
vanillin, 171, 172f
in vitro studies, 173

Feverfew, 238–243

“active natural,” 9
antibacterial activity,  

240–241

chemistry, 238–239
environmental impact, 240
formulation considerations, 240
history, 238
oral uses, 239
parthenolide, 241
photoaging, 241
pros/cons, 238t
safety issues, 239–240
skin cancer, 241
source, 238
topical uses, 239
usage considerations, 240

Fibrillin, 17
Fibroblasts, 17
“firming,” 13
Fish oils, 23, 29
Flavanals (catehins), 135t, 136t
Flavanoid aglycones, 209
Flavanones, 135t, 136t
Flavones, 135t, 136t
Flavonoids, 129, 135t, 136, 136t
Flavonols, 135t, 136t
Flax, 160
Flaxseed oil, 160–162
Fontana, Francesco, 301
Formononetin, 130f, 245
Formosan apple, 164
“fragrance free,” 11
Free radical theory of aging, 319
Free radicals, 6–7, 220, 320
French paradox, 152

deficiency (EFAD)

G
G. glabra, 245
G. inflata, 245
G. uralensis, 245
GAG. See Glycosaminoglycan (GAG) 
Galen, 204, 265
γ-linolenic acid (GLA), 28
Garden marigold, 271
Gattefossé, René, 279
GC. See Glucosylceramides (GC)
GCG, 137
Generic store brands, 14
Genistein, 129, 130, 130f, 131
Gerhardt, Charles, 301
German chamomile, 265
Ginger, 198–202

anticarcinogenic activity, 200–201
antioxidant and anti-inflammatory 

activity, 199–200
chemistry, 198–199
environmental impact, 199
formulation considerations, 199
hair care, 199
history, 198
knee osteoarthritis, 199
oral uses, 199
photoprotection, 200
pros/cons, 198t
skin lightening, 201
source, 198
topical uses, 199
usage considerations, 199
wound healing, 201
[6]-gingerol, 200, 201
Gingivitis, 191
GLA. See γ-linolenic acid (GLA)
Glabrene, 247
Glabridin, 247, 248
Glucoheptonolactone, 325
Gluconolactone, 324, 325
Glucosamine supplementation, 17
Glucoside, 130
Glucosylceramides (GC), 57
Glutathione, 177
Glycation, 6, 318
Glycerin, 21, 73, 74–76
animal studies, 75
chemistry, 74
environmental impact, 75
formulation considerations, 75
history, 74
human studies, 75–76
hydroxyl groups, 74f
oral uses, 75
pros/cons, 74t
safety issues, 75
source, 74
topical uses, 75
usage considerations, 75
in vitro studies, 75

Glycerine, 74. See also Glycerin
Glycerol, 74. See also Glycerin
Glycitein, 131
Glycolic acid, 322, 323
Glycosaminoglycan (GAG), 77
Glycyrrhetinic acid, 244, 248, 250
18β-glycyrrhetinic acid, 248–250
Glycyrrhiza glabra, 245

 
 
 
3 4 0 

I N D E X

Glycyrrhiza inflata, 245
Glycyrrhiza uralensis, 245
Glycyrrhizic acid, 245
Glycyrrhizin, 245, 248–250
Goat nut, 31
Goldbloom, 271
Gole Mohammadi, 145
Granular layer, 16, 16f
Grape seed proanthocyanidin extract 

(GSPE), 154

Gray box bush, 31
Green coffee oil, 196
Green tea, 137–144
acne, 138–139
animal studies, 141
anogenital warts, 139
chemistry, 138
combination therapy, 140
environmental impact, 140
formulation considerations, 140
history, 137–138
human studies, 141–142
oral uses, 138
other antimicrobial uses, 139–140
photoprotection, 141
pros/cons, 137t
safety issues, 140
source, 137
topical uses, 138–140
usage considerations, 140
in vitro studies, 141

Green tea extract formulation (Veregen), 

138, 139

Hirsutism

lavandula, 281
tea tree oil, 298

HIV, 140, 250
HMG-CoA reductase, 64, 66
Hoffman, Felix, 301
Holligold/holigold, 271
Homer, 28
Honey/propolis/royal jelly, 203–212
anticarcinogenic activity, 209
antimicrobial and anti-inflammatory 

activity, 208–209

antioxidant activity, 208
chemistry, 204–205
collagen production, 206
colony collapse disorder, 207
dandruff, 206
environmental impact, 207
formulation considerations, 207
history, 203–204
honeybee, 203, 204f
oral uses, 205
photoprotection, 209–210
pros/cons, 205t
pruritus, 209
safety issues, 206–207
seborrheic dermatitis, 206
skin whitening, 210
source, 203
topical uses, 205–206
usage considerations, 207
wound healing, 205–206
xerosis, 209

Green tea polyphenols (GTPs), 138, 141
GSPE. See Grape seed proanthocyanidin 

Honeybee, 203, 204f
“Hormone of darkness,” 217.  

extract (GSPE)

GTPs. See Green tea polyphenols (GTPs)
“Guides Concerning the Use of 

Endorsements and Testimonials in 
Advertising,” 14

Gynecomastia, 281

H
HA. See Hyaluronic acid (HA)
Hair care, 199
Halia Bara, 199
Hamamelis, 82
Hand, foot, and mouth disease, 250
Hand eczema, 85
Handbalsam, 82
Haworth, Walter Norman, 176–177
HCSE. See Horse chestnut
Head lice

lavandula, 280
tea tree oil, 298
Heavy mineral oil, 34
Henseleit, Kurt, 84
Hepatitis C, 241
Herniarin, 268
Herodotus, 311
Herpes simplex virus (HSV)

chamomile, 269
green tea, 139
peppermint, 225
resveratrol, 157
Hexapeptide-3, 320
Hexuronic acid, 176
Hexyl methicone, 52
HIG-82, 239
Hille, Hermann, 311
Hippocrates, 148, 176, 204, 265, 301, 311, 322

See also Melatonin

Horse chestnut, 284–287

antiaging activity, 286–287
chemistry, 284–285
chronic venous insufficiency, 285, 286
environmental impact, 286
formulation considerations, 286
history, 284
oral uses, 285
photoprotection, 286–287
pros/cons, 284t
safety issues, 286
source, 284
topical uses, 285–286
usage considerations, 286
HQ. See Hydroquinone (HQ)
HRIPT. See Human repeated insult patch 

testing (HRIPT)

HSV. See Herpes simplex virus (HSV)
Human immunodeficiency virus (HIV)

green tea, 140
licorice extract, 250

Human repeated insult patch testing  

(HRIPT), 11
Humectants, 73
Hungarian chamomile, 265
Hyaluronan, 77
Hyaluronic acid (HA), 77–80

anti-inflammatory activity, 79
antiaging activity, 79
chemistry, 77–78
combination therapy, 79
environmental impact, 78
fibroblasts, 17
formulation considerations, 78

history, 77t
humectant properties, 78
oral uses, 78
pros/cons, 77t
safety issues, 78
skin aging, 317–318
source, 77
topical uses, 78
topically delivered/injectable, 79
usage considerations, 78
wound healing, 78

Hydroquinone (HQ), 100–104

alternatives, 103
chemistry, 100
combination therapies, 102–103
contact dermatitis, 101, 101f
environmental impact, 101–102
formulation considerations, 102
history, 100
HQ/glycolic formulation, 106
HQ/retinol combination, 103
oral uses, 100–101
pros/cons, 100t
safety issues, 101
source, 100
topical issues, 101
Tri-Luma, 102
usage considerations, 102

Hydroxy acids, 322–327

α-hydroxy acids (AHAs), 324–325
BHA, 324. See also Salicylic acid (SA)
chemistry, 323
comparison studies, 324
dyspigmentation, 324
environmental impact, 326
FDA labeling guidelines, 325
formulation considerations, 326
glycolic acid, 323
history, 322–323
lactic acid, 323–324
oral uses, 323
polyhydroxy acids (PHAs), 324, 325
pros/cons, 322t
safety issues, 324–326
significant background, 326
source, 322
topical uses, 323–324
uneven skin tone, 324
usage considerations, 326

Hydroxycinnamic acid, 136t, 171
Hydroxydecine cream, 209
Hydroxydecyl ubiquinone. See Idebenone
Hydroxypropyldimethicone, 52
Hydroxytyrosol, 39
Hylatopic, 78
Hyperkeratotic skin conditions, 84
Hyperpigmentation, 247
Hypoallergenicity, 11

I
Ichthyosis

cholesterol, 66
urea, 84

Idebenone, 213–216

antioxidant activity, 215
chemistry, 213
environmental impact, 214
formulation considerations, 214
history, 213
neuroprotective activity, 215

 
 
 
 
Idebenone (continued )

oral uses, 213
pros/cons, 213t
safety issues, 214
source, 213
topical uses, 213–214
usage considerations, 214

IFN α-2b, 190
Imiquimod, 17, 57
INCI nomenclature, 5
Indian gooseberry, 108
Inducible nitric oxide synthase 

 (iNOS), 219

Infantile seborrheic dermatitis, 249. See also 

Seborrheic dermatitis

Inflammation/anti-inflammatory activity, 
227–228. See also Anti-inflammatory 
agents

aging, 227–228
Aloe vera, 234
aloesin, 96
ceramides, 59–60
chamomile, 267
ginger, 199–200
honey/propolis/royal jelly,  

208–209

hyaluronic acid, 79
safflower oil, 42
salicylic acid, 303
silver, 313
soy, 131
tamanu oil, 45
turmeric, 260–261

iNOS, 219
Insulin, 320
Interferon (IFN), 190
International nomenclature of cosmetic 

ingredients (INCI), 5

Iridoid glycosides, 88
Irritancy, 19
Irritant contact dermatitis, 82
Irritant diaper dermatitis, 82
Isoflavones, 129, 130, 130f, 135t, 136t
Isoliquiritigenin, 247
Isotretinoin, 329

J
Jai, 253
Jan Marini Skin Research, 179
Javi, 253
Jojoba oil, 31–33, 61
animal studies, 32
chemistry, 31
environmental impact, 32
formulation considerations, 32
history, 31
human studies, 32
oral uses, 31
pros/cons, 31t
safety issues, 32
source, 31
topical uses, 31–32
usage considerations, 32
in vitro studies, 32

Juvéderm, 17, 77

K
Ka, 5
K6PC-4, 59
K6PC-5, 59

K6PC-9, 59
K6PC-9p, 59
K101, 85, 86
K112PC-5, 59
Kang, Sewon, 330
Kerasal, 84
Keratinization, 65–66, 288
Keratinocyte differentiation, 59
Keratinocytes, 16
Keratolytic activity (BPO), 293
Kligman, Albert, 11
Kligman formula, 102
Knee osteoarthritis, 199
Ko-jo-kon, 152
Kojic acid, 105–107
Kojyl-APPA, 106
Kolbe, Hermann, 301
Krebs, Hans A., 84

L
L. alpinum, 276
L. angustifolia, 279
L. usitatissimum, 160
LA. See Linoleic acid (LA)
Lac-Hydrin, 84
Lactic acid, 323–324
Lactobionic acid, 323
Lamellar bodies, 54
Lanolin, 68–69
Lauric acid, 288
Lavandula, 279–283

antibacterial activity, 281
anticancer activity, 282
aphthous ulceration, 280
aromatherapy, 282
chemistry, 280
depression, 282
environmental impact, 281
episiotomy, 280
formulation considerations, 281
head lice, 280
hirsutism, 281
history, 279
oral uses, 280
perineal pain, 280
pros/cons, 279t
safety issues, 281
source, 279
topical uses, 280–281
usage considerations, 281

Lavandula angustifolia, 279
Lavender. See Lavandula
LDL. See Low-density lipoprotein (LDL)
LDL receptors, 64
Lemon balm, 166
Leoligin, 276
Leontopodic acid, 277
Leontopodium alpinum, 276
Leroux, Henri, 301
Leukomelanoderma en confetti, 101
Levomenol, 266
Lichen planus, 232
Licochalcone A, 245, 246, 249
Licochalcone B, 249
Licochalcone C, 249
Licochalcone D, 249
Licochalcone E, 246
Licorice extract, 244–252

acne, 245
anti-HIV activity, 250

I N D E X  

  3 4 1

antibacterial activity, 249
anticarcinogenic activity, 249
antioxidant activity, 248–249
atopic dermatitis, 245–246
chemistry, 245
dry, itchy scalp, 249
environmental impact, 248
formulation considerations, 248
G. glabra, 245
G. inflata, 245
G. uralensis, 245
hand, foot, and mouth disease, 250
history, 244–245
hyperpigmentation, 247
infantile seborrheic dermatitis, 249
oral uses, 245
other biologic activity, 250
photoprotection, 249
pros/cons, 244t
psoriasis, 247
rosacea, 247
safety issues, 248
sensitive skin, 247
source, 244
topical uses, 245–247
usage considerations, 248

“lifting,” 13
Light mineral oil, 34
“lightening,” 13–14
Lignans, 136t, 277
Lignin, 123
Lignin peroxidases, 123–124
Linoleic acid (LA), 23, 41
Linseed, 160
Linum usitatissimum, 160
Lipid contents (tamanu oil), 45t
Lipid rafts, 64
Lipophilic retinoids, 329
Lipoxygenase pathway, 227
Liquid paraffin, 34
Liquid petrolatum, 34. See also Mineral oil
Liquiritigenin, 250
Liquiritin, 247
Liver X receptors (LXR), 66
Long chain saturated fatty acids, 21
Lovastatin, 65
Low-density lipoprotein (LDL), 25, 26
Low-density lipoprotein (LDL)  

receptors, 64

LXR. See Liver X receptors (LXR)
Lysosomes, 318

M
M. alba, 113–116
M. alternifolia, 297
M. australis, 114
M. indica, 115
M. nigra, 114–115
M. notabilis, 115
M. papyrifera, 115
M. piperita, 225
M. recutita, 265
Magnesium-l-ascorbyl-2-phosphate, 118
Magnesium lactate, 230
Magnesium salicylate, 303
Maillard, Louis Camille, 6
Maillard reaction, 6
Malonylglucoside, 130
Malus doumeri, 164
Mandelic acid, 322

 
 
 
3 4 2 

I N D E X

Manuka honey, 207
Maravilla, 271
Marigold, 271
Marketing claims. See Cosmeceutical 

marketing claims

Marybud, 271
Masferrer, Pardo, 85
MASI. See Melasma area and severity 

index (MASI)
Mask of pregnancy, 92
Matricaria recutita, 265
Matrix metalloproteinase (MMP), 110, 111

caffeic acid, 167
coenzyme Q10, 189, 191
coffeeberry, 196
ferulic acid, 173, 174
idebenone, 214
phloretin, 164
resveratrol, 153
retinoids (retinol), 331
retinol-containing products, 307, 331
skin aging, 317

Matrixyl, 320
Mayweed, 265
MEA-salicylate, 303
Meadowsweet, 267
Medihoney, 207
Melaleuca alternifolia, 297
Melanin production, 93–94
Melanocyte, 92
Melanogenesis
aloesin, 96
arbutin, 99
niacinamide, 127
turmeric, 259
Melanoma, 225
Melanosome, 92
Melanozyme, 123
Melasma, 92
arbutin, 99
mulberry extract, 115–116
soy, 132
vitamin C, 117–118

Melasma area and severity index (MASI)

hyaluronic acid, 79
mulberry extract, 79

Melatonin, 217–222

androgenetic alopecia, 218
animal studies, 219
anticancer activity, 218
antioxidant activity, 218
chemistry, 217
environmental impact, 220
formulation considerations, 220
history, 217
human studies, 219–220
oral uses, 217
postmenopausal women, 220–221
pros/cons, 218t
safety issues, 220
source, 217
topical uses, 217–220
usage considerations, 220
in vitro studies, 218–219

Melatonin receptors, 221
Melissa officinalis, 166
Menopause, 42
Menpentol Leche, 233
Mentha piperita, 225
Menthol, 223–226. See also Peppermint

Methicillin-resistant Staphylococcus aureus 

(MRSA)

honey/propolis/royal jelly, 208
tea tree oil, 298
turmeric, 260

Methicone, 52
Methoxykynuramine, 221
Mineral oil, 34–36

acne cosmetica, 35
chemistry, 34
environmental impact, 35
formulation considerations, 35
history, 34
light/heavy, 34
occlusive, 22
oral uses, 34
petrolatum, compared, 48
pros/cons, 34t
safety issues, 35
significant background, 35
source, 34
topical uses, 34–35
usage considerations, 35

Mineral oil mist, 34
Misleading or false claims, 14. See also 

Cosmeceutical marketing claims

Miso, 129
Mitchell, Peter, 188
Mitochondria, 318
MLE cream, 59
MMP. See Matrix metalloproteinase (MMP)
Moisturizing agents, 21–53

argan oil, 25–27
borage seed oil, 28–30
dimethicone, 51–53
emollients, 21, 22f
jojoba oil, 31–33
mineral oil, 34–36
occlusives, 22
oils, 23–24
olive oil, 37–40
overview, 21
petrolatum, 48–50
safflower oil, 41–43
silicones, 51–53
soy, 131
tamanu oil, 44–47

Monographs, 12
Moraceae, 113
Morus alba, 113–116
Morus australis, 114
Morus indica, 115
Morus nigra, 114–115
Morus notabilis, 115
Morus papyrifera, 115
Mouthwash

chamomile, 269
R. damascena, 147
turmeric, 259

MRSA. See Methicillin-resistant 
Staphylococcus aureus (MRSA)

Mulberroside A, 114
Mulberry extract, 113–116
antioxidant effects, 114
black mulberry, 114–115
cancer, 115
chemistry, 113–114
Chinese mulberry, 114
environmental impact, 115
formulation considerations, 115

history, 113
melasma, 115–116
Morus notabilis, 115
oral uses, 114
paper mulberry, 115
pros/cons, 113t
safety issues, 115
shimaguwa, 114
source, 113
topical uses, 114–115
usage considerations, 115
white mulberry, 114

Multilamellar emulsion (MLE), 59
Murky information void, 15. See also 
Cosmeceutical marketing claims

N
N (non-pigmented), 3–4
N-acetyl-5-methoxytryptamine, 217
N-acetyl-l-hydroxyproline, 57
Na True, 8
Nanosilver, 312
Naringenin chalcone, 163
National Organic Program (NOP), 8
National Sanitation Foundation (NSF 

International), 9
“Natural” ingredients, 9, 12
Natural moisturizing factor (NMF), 91
Natural Products Association (NPA), 9
“naturally derived,” 12
Nefertiti, 229
NeoStrata, 322
Nerve growth factor (NGF), 215
Network antioxidants, 190–191
Neuroprotective activity, 215
NF-κB. See Nuclear factor–κB (NF–κB)
NGF. See Nerve growth factor (NGF)
Niacinamide, 126–128
Nicotinamide, 57, 126
Nivcrisol-D, 208–209
NMF. See Natural moisturizing factor (NMF)
Nomenclature variation (EU vs. US), 5
Noncomedogenic, 14
Nonfermented soy foods, 129
Nonionic surfactants, 19
NOP. See National Organic Program (NOP)
Normal skin, 2
NPA’s “Natural Seal,” 9
Nrf2/ARE pathway, 240
NSF International, 9
Nuclear factor-κB (NF-κB), 238

colloidal oatmeal, 254
feverfew, 239, 241
licorice extract, 246
turmeric, 258, 261

NWU Institutional Repository website, 85

O
O (oily), 1–2
OASIS, 9
Oatmeal. See Colloidal oatmeal (CO)
Oatmeal extract, 5
Oatstraw, 253
Occlusives, 22
Octadecanoic acid, 70
Octyl salicylate, 303
ODC. See Ornithine decarboxylase (ODC)
Oil palm fruit, 184
Oils, 23–24

edible vs. mineral, 23–24
fatty acids, 23

 
 
 
 
Oils (continued )
safety, 24
triglycerides, 23
tumorigenesis, 24

Oily skin, 2
Olea europaea, 37
Oleic acid, 23
Oligomeric proanthocyanidins (OPCs), 

148, 151

Oligosaccharides, 131
Olive oil, 37–40

Paraffin oil, 34
Paraffinum liquidum, 34
PAs. See Pyrrolizidine alkaloids (PAs)
Pauling, Linus, 118
PC-95, 59
PC-SPES, 245
PCOs. See Procyanidol oligomers (PCOs)
PD-Feverfew, 240
PEDYPHAR, 82
Peer review, 13
Peppermint, 223–226

antifungal activity, 39
cancer, 39
chemistry, 37
combination therapy, 39
environmental impact, 38
extra virgin, 38
formulation considerations, 38
history, 37
oral uses, 37–38
pros/cons, 37t
safety issues, 38
source, 37
topical uses, 38
usage considerations, 38–39

Omani propolis, 209
OPCs. See Oligomeric proanthocyanidins 

(OPCs)

ORAC. See Oxygen radical absorbance 

capacity assay (ORAC)

Oral mucositis, 269
Organic products, 8–10
active naturals, 9
baseline criteria for certification, 8
certifying bodies, 8–9
companies that make natural products, 10
future of organics, 10
historical overview, 8
“natural” ingredients, 9, 12
organic certification, 8, 11–12
organic topical products, 9
pitfalls/limitations, 9
precautionary principle, 9–10
Ornithine decarboxylase (ODC)

ginger, 200
turmeric, 261

ORNT, 1f, 2f
ORNW, 1f, 2f
ORPT, 1f, 2f
ORPW, 1f, 2f
OSNT, 1f, 2f
OSNW, 1f, 2f
OSPT, 1f, 2f
OSPW, 1f, 2f
Oxygen radical absorbance capacity assay 

(ORAC), 195

Oxyradicals, 66

P
P (pigmented), 3–4
P. acnes, 288
P. chrysosporium, 123
P. cuspidatum, 152
P. pinaster, 148
Palmitoyl-EGCG, 139
Palmitoyl pentapeptide, 320
Pantothenic acid. See Vitamin B5
Pantothenic acid deficiency, 83
Paper mulberry, 115
PAR-2, 125

antibacterial activity, 225
anticancer activity, 224–225
antioxidant activity, 224
chemistry, 223
environmental impact, 224
formulation considerations, 224
history, 223
melanoma, 225
oral uses, 223–224
pros/cons, 223t
pruritus, 225
safety issues, 224
source, 223
topical uses, 224
TRPM8, 225
usage considerations, 224

Peptides, 320
Perineal pain, 280
Perio-Q gel, 190
Periodontitis

calendula, 274
coenzyme Q10, 190

Perlane, 77
Peroxisome proliferator-activated receptors 

(PPARs), 64, 66

Personal Care Products Council, 5
Petrolatum, 48–50
chemistry, 48
environmental impact, 35, 49
formulation considerations, 49
history, 48
mineral oil, compared, 48
oral uses, 48
pros/cons, 48t
safety issues, 49
significant background, 49
source, 48
topical uses, 49
usage considerations, 49

Petrolatum liquid, 34
Petroleum jelly, 48
Petroleum oil, 34
pH, 5
Phanerochaete chrysosporium, 123
PHAs. See Polyhydroxy acids (PHAs)
PHBAs, 322. See also Polyhydroxy acids 

(PHAs)

Phenoxyethanol, 9, 11
Pheomelanin, 93
Phloretin, 163–165

anticancer activity, 165
chemistry, 163
environmental impact, 163
formulation considerations, 164
history, 163
oral uses, 163
other applications, 165
pros/cons, 164t
safety issues, 163

I N D E X  

  3 4 3

source, 163
topical uses, 163
usage considerations, 164
in vitro studies, 164

Phloretol, 163
Phloridzin, 163
Photoaging. See also Antiaging activity

cholesterol, 66
emblica extract, 110
feverfew, 241
niacinamide, 128
salicylic acid, 303
skin elasticity, 4
turmeric, 261–262

Photoprotection
Aloe vera, 235
caffeic acid, 168–169
calendula, 273–274
emblica extract, 110
ginger, 200
green tea, 141
honey/propolis/royal jelly, 209–210
horse chestnut, 286–287
licorice extract, 249
resveratrol, 156
tamanu oil, 45
tocopherol (vitamin E), 185–186

Phyllanthus emblica, 108
Phytoalexins, 136t
Phytoedysteroids, 88
Phytosterols, 61
Pigmentation, 3–4, 42
Pigmentation process, 92
Pignut, 31
Pine bark extract, 150
Pinnell, Sheldon, 118, 177
Pinus maritima, 148
Pinus pinaster, 148
PIPA. See Postinflammatory pigment 

alteration (PIPA)

Piria, Raffaele, 301
pKa, 5
Plantago major, 166
Pliny the Elder, 28, 301
“plumping,” 14
PNA. See Polynuclear aromatic (PNA)
Polawax, 207
Polygonum cuspidatum, 152
Polyhydroxy acids (PHAs), 323–325
Polyhydroxy bionic acids (PHBAs), 322.  

See also Polyhydroxy acids (PHAs)

Polynuclear aromatic (PNA), 49
Polyphenols, 92, 135, 135t, 136t
Polyphenon E, 139
“pore reducing,” 14
Postinflammatory hyperpigmentation, 92
Postinflammatory pigment alteration 

(PIPA), 92, 118

Pot marigold, 271
PPARs. See Peroxisome proliferator-
activated receptors (PPARs)

Pregnancy (BPO), 294
Proanthocyanidin A2, 285
Proanthocyanidins, 135t, 136t, 148
Procyanidol oligomers (PCOs), 148
Product endorsements and testimonials, 14
Product monograph, 12
Propionibacterium acnes, 288
Propolis, 203. See also Honey/propolis/

royal jelly

 
 
 
3 4 4 

I N D E X

Proprietary data, 12–13
Propylene glycol, 55, 73
Protease-activated receptor-2 (PAR-2), 125
Proteoglycans, 77
Provitamin B5. See Vitamin B5
Pruritus

honey/propolis/royal jelly, 209
licorice extract, 249
peppermint, 225

Pseudoceramides, 58, 58t, 60
Psoriasis

Aloe vera, 231
green tea, 140
licorice extract, 247
tea tree oil, 298
turmeric, 260
urea, 84

Pycnogenol, 148–151
animal studies, 150
chemistry, 148
chronic venous insufficiency, 286
environmental impact, 150
formulation considerations, 150
history, 148
oral uses, 148–149
pros/cons, 149t
source, 148
topical uses, 149
usage considerations, 150
in vitro studies, 150

Pyrrolizidine alkaloids (PAs), 29

Q
Q10H2, 189
QSA-10. See Idebenone
Quillaja saponaria, 20
Quinine nut, 31

R
R (resistant), 3
R. damascena, 145–147
Radiation dermatitis, 82, 272
Radiotherapy, 232
Rafts, 60
RAS. See Recurrent aphthous stomatitis (RAS)
Rasis, 279
Reactive oxygen species, 6
Recurrent aphthous stomatitis (RAS), 280
Renova, 329
Resistant skin, 3
Restylane, 17, 77
“results not typical” disclaimer, 14
Resveratrol, 152–159

acne, 153
animal studies, 155–156
antiaging activity, 156
antimicrobial and antiviral activity, 156–157
chemistry, 153
environmental impact, 154
erythema, 153
formulation considerations, 154
history, 152
isoforms, 153
oral uses, 153
photoprotection, 156
pros/cons, 152t
safety issues, 154
skin lightening, 153
source, 152

topical uses, 153
usage considerations, 154
in vitro studies, 154–155

Retin A, 306
Retinaldehyde, 329
Retinoic acid receptors (RARs), 307, 329
Retinoid receptors, 307, 329
Retinoid X receptors (RXRs), 64, 307
Retinoids, 17, 306–307, 320, 329, 332
Retinol, 306t, 308–309, 330, 331–332
Retinol-containing products, 306–310,  

328–333

antiacne activity, 307–308
retinoid receptors, 307, 329
retinoids, 306–307, 329, 332
retinol, 306t, 308–309, 330, 331–332
retinol esters, 309
retinyl palmitate, 330
retinyl retinoate, 330

Retinol esters, 309
Retinopathy, 191–192
Retinyl palmitate (RP), 330
Retinyl retinoate, 330
RevaléSkin, 195
Revamil, 208
Rhazes, 204
Rigatelli, Bartolomeo, 301
Rodale, J. I., 8
Roman chamomile, 265
Rosa damascena, 145–147

antibacterial activity, 146–147
antioxidant activity, 146
anxiolytic activity, 147
chemistry, 145
environmental impact, 146
formulation considerations, 146
history, 145
oral uses, 146
other activities, 147
pros/cons, 145t
safety issues, 146
source, 145
topical uses, 146
usage considerations, 146

Rosacea

aloesin, 96
argan oil, 27
ascorbic acid, 178
licorice extract, 247
niacinamide, 126
skin type, 3

Roscoe, William, 198
Rose of Castile, 145
Rose oil, 147
Rosemary, 166
Rosmarinus officinalis, 166
Rouelle, Hilaire, 84
Royal jelly, 203. See also Honey/propolis/ 

royal jelly

RP. See Retinyl palmitate (RP)
Ruddles, 271
Rutin, 285

S
S (sensitive), 3
S. aureus, 225
S. chinensis, 31
SA. See Salicylic acid (SA)
Safflower, 41

Safflower oil, 41–43
chemistry, 41
diabetes, 41
environmental impact, 42
formulation considerations, 42
history, 41
inflammation, 42
menopause, 42
oral uses, 41
pigmentation, 42
pros/cons, 41t
safety issues, 42
significant background, 42
source, 41
topical uses, 42
tumorigenesis, 42
usage considerations, 42

Salicylic acid (SA), 301–305, 322, 324

acne, 302–303
anti-inflammatory uses, 303
antimicrobial activity, 303
buffered solutions, 302
chemical structure, 302f, 323f
chemistry, 301–302, 322
environmental impact, 304
forms of SA, 302
formulation considerations, 304
history, 301
oral uses, 302
pH, 302
photoaging, 303
pKa, 302
pore minimizing, 303
pros/cons, 301t
safety issues, 303–304, 325
significant background, 304
source, 301
topical uses, 302–303
usage considerations, 304

Salicylism, 304
Sapindus mukorossi, 20
Saponins, 20
Saturated fatty acids, 55
SC. See Stratum corneum (SC)
Scars, 45
SCC. See Squamous cell carcinoma (SCC)
Scheele, Carl Wilhelm, 74
Schiff base, 6, 6f
Score numbering

dry and oily skin types, 1–2
pigmented skin types, 3–4
resistant skin, 3
sensitive skin types, 3

Scurvy, 176
Seasonal skin, 2
Seborrheic dermatitis

honey/propolis/royal jelly, 206
licorice extract, 249
melatonin, 218
tea tree oil, 298

Sebum, 2
Senescent cells, 319
Sensitive skin, 3
Sensitive skin subtypes, 3
Sesquiterpene lactones, 239
Shen Nung, 137
Shimaguwa, 114
Shirodhara, 282
Short-chain fatty acids, 55

 
 
 
 
Silicones, 51–53
Silver, 311–316
acne, 313
anti-inflammatory activity, 313
antibacterial activity, 312–313
anticancer activity, 313
argyria, 314
atopic dermatitis, 314
burns, 313
chemistry, 311t
colloidal silver/nanosilver, 312
environmental impact, 314
formulation considerations, 314–315
history, 311–312
oral uses, 312
pros/cons, 311t
safety issues, 314
significant background, 315
source, 311
textiles, 314
topical uses, 312–314
usage considerations, 315
wound healing, 313
Simmondsia chinensis, 31
Sinecatechins, 139
SIRTs, 319
SIRT1, 319
Sirtuins (SIRTs), 319
Skin aging, 6, 317–321. See also Antiaging 

activity

antioxidants, 319–320
collagen, 317
DNA damage, 319
elastin, 317
free radical theory of aging, 319
glycation, 318
hyaluronic acid, 317–318
intrinsic/extrinsic aging, 317
lysosomes, 318
matrix metalloproteinases, 317
mitochondria, 318
peptides, 320
prevention of aging, 319–320
retinoids, 320
senescent cells, 319
sirtuins, 319
stem cells, 319
“Sunburn Alert” labeling, 325
telomere shortening, 318–319

Skin barrier, 53
Skin barrier perturbation, 53. See also 

Barrier repair ingredients

Skin cancer. See Cancer
Skin color, 92
Skin elasticity, 4
Skin hydration, 1–2
Skin lightening, 92–134. See also Skin 

whitening
aloesin, 95–96
arbutin, 97–99
cucumber, 120–122
emblica extract, 108–112
ginger, 201
hydroquinone, 100–104
kojic acid, 105–107
lignin peroxidases, 123–124
melanin production, 93–94
mulberry extract, 113–116
niacinamide, 126–128

PAR-2, 125
pigmentation process, 92
resveratrol, 153
soy, 129–134
tocopherol (vitamin E), 184
vitamin C, 117–119
Skin pigmentation, 3–4
Skin science, 16–18. See also Epidermis and 

dermis
Skin sensitivity, 3
Skin type, 1–4. See also Baumann Skin Type 

System (BSTS)
Skin Type Solution, The, 1
Skin Type Solutions with Dr. Leslie Baumann 

(TV), 1

Skin whitening. See also Skin lightening

cucumber, 121
emblica extract, 109
honey/propolis/royal jelly, 210

Skinceuticals, 118, 177
SLES, 19. See also Sodium lauryl  

sulfate (SLS)

SLS. See Sodium lauryl sulfate (SLS)
“smoothing,” 14
Society of Cosmetic Chemists, 7
Sodium hyaluronate, 73
Sodium lauryl ether sulfate (SLES), 19. See 
also Sodium lauryl sulfate (SLS)

Sodium lauryl sulfate (SLS)

anionic agent, 19
glycerin, 74
vitamin B5, 82

Sodium salicylate, 303
SoftSkin A. vera gel-coated glove, 233
Solar lentigos, 92
Sorbitol, 73
Soy, 129–134

animal studies, 132
anti-inflammatory activity, 131
antiaging activity, 131
anticarcinogenic activity, 131
chemistry, 129–130
clinical studies, 132
depigmenting activity, 131
environmental impact, 132
formulation considerations, 132
history, 129
moisturizing activity, 131
oral uses, 130
pros/cons, 129t
safety issues, 132
source, 129
topical uses, 130
usage considerations, 132

Soy ice cream, 129
Soy isoflavones, 129, 130, 130f
Soy sauce, 129
Soybean cake, 129
Soybean trypsin inhibitor (STI), 129, 131, 132
Soymilk, 129
SPF, 13
Sphingolipids, 57
Spinous layer, 16, 16f
Squamous cell carcinoma (SCC), 16
Squamous cells, 16
SREBPs. See Sterol regulatory element-

binding proteins (SREBPs)

Staphylococcus aureus, 225
Starflower, 28

I N D E X  

  3 4 5

Stearamidopropyl dimethicone, 52
Stearic acid, 70–72
Stearic oil, 23
Stearophanic acid, 70
Stearoxy dimethicone, 52
Stearyl dimethicone, 52
Stearyl methicone, 52
Stem cells, 319
Steroid sulfatase deficiency, 66
Steroids and ceramides, 59
Sterol regulatory element-binding proteins 

(SREBPs), 55, 64

STI. See Soybean trypsin inhibitor (STI)
Stilbenes, 136t
Stingers, 178
Stone, Edward, 301
Stratum corneum (SC), 16, 16f 

Aloe vera, 232
benzoyl peroxide, 293
ceramides, 57, 58
cholesterol, 64
coenzyme Q10, 189
glycerin, 75, 76
humectants, 73
hydroxy acids, 323, 326
lanolin, 68
melatonin, 217
niacinamide, 126, 127
petrolatum, 49
phloretin, 164
resveratrol, 154
retinoids, 329
salicylic acid, 303
stearic acid, 70, 71
tocopherol, 183
vitamin B5, 81, 82

Stretch marks, 118
Sugars, 73
SULT2B1b, 64, 66
Sun exposure, 317. See also Photoprotection
“Sunburn Alert” labeling, 325
Superfatted soaps, 19
Surfactants, 20
“sustainable,” 10
Sweet false chamomile, 265
Syndet bars, 20
Synthetic ceramides, 58, 58t, 60
Synthetic oils, 23
Szent-Györgyi, Albert, 118, 176, 177

T
T (tight), 4
T. kirilowii, 121
T. parthenium, 238
T-zone skin, 2
Tachyphylaxis, 102
Taiwanese apple, 164
Tamanu oil, 44–47

anti-inflammatory activity, 45
antimicrobial activity, 45–46
chemistry, 44
environmental impact, 46
formulation considerations, 46
history, 44
lipid contents, 45t
moisturizing activity, 46
oral uses, 44
photoprotection, 45
pros/cons, 45t

 
 
 
3 4 6 

I N D E X

Tamanu oil (continued )
safety issues, 46
scars, 45
significant background, 46
source, 44
topical uses, 44–45
usage considerations, 46
wounds and burns, 45
Tanacetum parthenium, 238
Tannins, 136t
Tazarotene, 306, 329
Tazorac, 306, 329
Tea polyphenols, 96
Tea tree oil (TTO), 267, 297–300
androgenetic alopecia, 298
antiacne activity, 297–298
antibacterial, antifungal, and antiviral 

activity, 298

anticancer activity, 298
chemistry, 297
contradictory findings, 299
environmental impact, 299
formulation considerations, 299
head lice, 298
history, 297
mild idiopathic hirsutism, 298
oral uses, 297
pros/cons, 299t
psoriasis, 298
safety issues, 298–299
seborrheic dermatitis, 298
source, 297
topical uses, 297–298
usage considerations, 299

Telangiectasias, 140
Telomere shortening, 318–319
Terminology

advertising claims, 11–14
INCI nomenclature, 5

Terpinen-4-ol, 298
Testimonials, 14
Testing and approval, 12
12-O-tetradecanoylphorbol-13-acetate (TPA)

ascorbic acid, 177
caffeic acid, 167, 168
emblica extract, 110
ferulic acid, 174
ginger, 200
licorice extract, 245
olive oil, 38
phloretin, 165
resveratrol, 155
turmeric, 261

TEWL. See Transepidermal water loss (TEWL)
Textiles, 314
Theraderm, 324
Tien shi li, 285
Tissue inhibitors of MMP-1 (TIMP-1),  

110, 111

TLR-2, 307
Tocopherol (vitamin E), 182–187

animal studies, 185
antioxidant activity and photoprotection, 

185–186

chemistry, 182–183
environmental impact, 184
formulation considerations, 184–185
history, 182
oral uses, 183
pros/cons, 182t

safety issues, 184
skin cancer protection, 184
skin lightening, 184
source, 182
topical uses, 183–184
usage considerations, 185
wound healing, 184
α-tocopherol, 182, 183
α-tocopherol-acetate, 185
α-tocopherol-linoleate, 185
γ-tocopherol, 183
Tocotrienols, 182, 183
Tofu, 129
Toll-like receptor 2 (TLR-2), 307
Topical ceramide-dominant creams, 61
Topical lactic acid, 57
Topical retinoids, 17
Total soy, 131
TPA. See 12-O-tetradecanoylphorbol-13-

acetate (TPA)

TPA-induced tumor progression, 178
Tranilast, 254 
trans-chrysanthenyl acetate, 241
Transepidermal water loss (TEWL), 54 

borage seed oil, 29
ceramides, 57
cholesterol, 65
defined, 54
dimethicone and silicones, 51
dry skin, 2
flaxseed oil, 160, 161
nonpolar lipids, 64
retinoids, 308
urea, 84
vitamin B5, 81, 82

Transient receptor potential melastatin 

subfamily 8 (TRPM8), 225

Transparent soaps, 20
Tretinoin, 17, 306, 329
Tri-Luma, 102
Trichosanthes kirilowii, 121
Triclosan, 288
Triglycerides
glycerin, 74
oils, 23

trans-3,5,4’-trihydroxystilbene, 152
Triphala, 110–111
Tropoelastin, 17
TRPM8, 225
True chamomile, 265
TTO. See Tea tree oil (TTO)
Tumorigenesis, 24, 42
Turmeric, 257–264

anti-inflammatory activity, 260–261
antioxidant activity, 260–261
chemistry, 258
environmental impact, 259
formulation considerations, 259
history, 257–258
oral uses, 258
photoaging, 261–262
pros/cons, 257t
psoriasis, 260
safety issues, 258–259
skin cancer, 261–262
source, 257
topical uses, 258
usage considerations, 259
wound healing, 259–260
Tutankhamun (King Tut), 203

Tyrosinase inhibitors, 94
Tyrosine, 93f, 94

U
U-Kera E, 85
Ubidecarenone, 188
Ubiquinol, 189
Ubiquinone, 188
Uneven skin tone, 324
Unsaturated fatty acids, 55
“unscented,” 11
Urea, 73, 84–86
Urea cycle, 84
Ureadin line of products, 85, 86
Uronic acid, 77
“USDA Organic” seal, 8
UV exposure. See Photoprotection

V
V. vinifera, 152, 153
Vancomycin-resistant Enterococcus  

(VRE), 208
vanillin, 171, 172f
Vasco de Gama, 176
Vascular endothelial growth factor (VEGF), 

154, 155

Vaseline Petroleum Jelly, 48
Vegetable oils, 23
VEGF. See Vascular endothelial growth 

factor (VEGF)

Venostasin, 286
Venous insufficiency, 285, 286
Venous leg ulcer, 274
Veregen, 138, 139
Vinyldimethicone, 52
Virgin argan oil, 25
Viscosity, 22
Vitamin A, 306, 328. See also Retinol-

containing products

Vitamin B5, 81–83
chemistry, 81
combination therapy, 82
environmental impact, 83
formulation considerations, 83
history, 81
human studies, 82
oral uses, 81
pros/cons, 81t
safety issues, 82
significant background, 83
source, 81
topical uses, 81
usage considerations, 83
Vitamin C, 117–119. See also  

Ascorbic acid
chemistry, 117
environmental impact, 118
formulation considerations, 118
history, 117
melasma, 117–118
oral uses, 117
PIPA, 118
pros/cons, 118t
safety issues, 118
source, 117
stretch marks, 118
topical uses, 117–118
usage considerations, 118

Vitamin C and the Common Cold (Pauling), 118
Vitamin E. See Tocopherol (vitamin E)

 
 
 
 
Vitamins

ascorbic acid, 176–181. See also Vitamin C
vitamin E, 182–187
Vitis vinifera, 152, 153
Voluma, 77
“volumizing,” 14
Voorhees, John, 330
VRE. See Vancomycin-resistant Enterococcus 

(VRE)

W
W (wrinkled), 4
Warts, 139
Water-soluble antioxidants, 135
Water vapor permeability (emollients), 22f
White mineral oil, 34
White mulberry, 114
White oil, 34
Wild chamomile, 265
Wild hazel, 31
Wild oats, 253
Willow bark, 267

Witch hazel, 82
Wöhler, Friedrich, 84
Wound healing

Aloe vera, 231–232
calendula, 273
chamomile, 267
ginger, 201
honey/propolis/royal jelly, 205–206
hyaluronic acid, 78
resveratrol, 154
silver, 313
tamanu oil, 45
tocopherol (vitamin E), 184
turmeric, 259–260

Wrinkles

appearance claim, 13
coffeeberry, 196
cucumber, 121
green tea, 142
kojic acid, 106
niacinamide, 128

www.skintypesolution.com, 4

I N D E X  

  3 4 7

X
X-linked ichthyosis, 66
Xerosis

Aloe vera, 232
coffeeberry, 196
glycerin, 74
honey/propolis/royal jelly, 209
urea, 84
Xgel, 234
Xylometazoline, 82

Y
Yeisai, 137
Yucca schidigera, 20

Z
Z. officinalis, 198
Zinc oxide, 82
Zingiber officinalis, 198
Zingiber zerumbet, 201
Zovirax, 157

 
 
 
